ObjId,DocumentType,DocId,DocketId,Title,Food,Tobacco
09000064816b083a,Other,FDA-2013-N-0590-0002,FDA-2013-N-0590,"memo to ddm re. on implementation of the food and drug administration food safety modernization act amendments to the reportable food registry provisions of the federal food, drug, and cosmetic act",1,0
0900006481681990,Proposed Rule,FDA-2013-N-0590-0001,FDA-2013-N-0590,"implementation of the food and drug administration food safety
modernization act amendments to the reportable food registry provisions of the federal food, drug, and cosmetic act",1,0
090000648174fb4f,Proposed Rule,FDA-2013-N-0590-0003,FDA-2013-N-0590,"implementation of the food and drug administration food safety
modernization act amendments to the reportable food registry provisions of the federal food, drug, and cosmetic act; reopening of comment period",1,0
0900006482581c20,Notice,FDA-2017-N-1393-0001,FDA-2017-N-1393,government-owned inventions; availability for licensing,0,0
090000648214c3fa,Supporting & Related Material,FDA-2011-F-0171-0279,FDA-2011-F-0171,reference 3 - fda fria july 2016 final re food labeling; calorie labeling of articles of food in vending machines; extension of compliance date,1,0
0900006482178a99,Notice,FDA-2011-F-0171-0280,FDA-2011-F-0171,"calorie labeling of articles of food in vending machines: guidance for
industry; small entity compliance guide; availability",1,0
0900006481951d17,Supporting & Related Material,FDA-2011-F-0171-0200,FDA-2011-F-0171,"reference - 6 “2012 census of the industry,” vending times, 2012; 52(12) re food labeling; calorie labeling of articles of food in vending machines",1,0
090000648217ac1b,Other,FDA-2011-F-0171-0283,FDA-2011-F-0171,calorie labeling of articles of food in vending machines: guidance for industry; draft guidance,1,0
0900006480c1cfbc,Proposed Rule,FDA-2011-F-0171-0001,FDA-2011-F-0171,food labeling: calorie labeling of articles of food in vending machines,1,0
0900006480fac182,Other,FDA-2011-F-0171-0251,FDA-2011-F-0171,"fda/oc/op to division of dockets management - omb review, executive order 12866, food labeling; calorie labeling of articles of food in vending machines, proposed rule published 4/6/2011 - memorandum",1,0
09000064819516e4,Supporting & Related Material,FDA-2011-F-0171-0193,FDA-2011-F-0171,"reference 1- fda/cfsan, “food labeling: calorie labeling of articles of food in vending machines, regulatory impact analysis,” 2014 re food labeling; calorie labeling of articles of food in vending machines",1,0
09000064819516e5,Supporting & Related Material,FDA-2011-F-0171-0194,FDA-2011-F-0171,"reference 2- fda/cfsan, “food labeling: calorie labeling of articles of food in vending machines nprm, preliminary regulatory impact analysis,”  re food labeling; calorie labeling of articles of food in vending machines",1,0
09000064819516e7,Supporting & Related Material,FDA-2011-F-0171-0196,FDA-2011-F-0171,"reference 4 - memo to file. correspondence with eric dell of the national automatic merchandising association. april 13, 2013 re food labeling; calorie labeling of articles of food in vending machines",1,0
0900006481951d18,Supporting & Related Material,FDA-2011-F-0171-0198,FDA-2011-F-0171,"reference 7- ""2012 state of the vending industry report, 2013,” automatic merchandiser re food labeling; calorie labeling of articles of food in vending machines",1,0
0900006481951d19,Supporting & Related Material,FDA-2011-F-0171-0199,FDA-2011-F-0171,reference 8 - national automatic merchandising association. comments of: the national automatic merchandising association. docket no. fda-2010-n-0298. 2010 re food labeling; calorie labeling of articles of food in vending machines,1,0
0900006481973980,Supporting & Related Material,FDA-2011-F-0171-0207,FDA-2011-F-0171,"tab c final rule impact analysis, final regulatory action as cleared by oira re food labeling; calorie labeling of articles of food in vending machines (final rule); publication date: december 1, 2014",1,0
0900006480c19867,Supporting & Related Material,FDA-2011-F-0171-0005,FDA-2011-F-0171,"reference 2 -  ""food and drug administration, food labeling guide"" - [food labeling; food labeling; calorie labeling of articles of food in vending machines; proposed rule] re fda-2011-f-0171-0001",1,0
0900006480c19ccc,Supporting & Related Material,FDA-2011-F-0171-0011,FDA-2011-F-0171,"reference list - [preliminary regulatory impact analysis, march 2011, food labeling; food labeling; calorie labeling of articles of food in vending machines; proposed rule, re fda-2011-f-0171-0001]",1,0
0900006480c1a0ec,Supporting & Related Material,FDA-2011-F-0171-0020,FDA-2011-F-0171,"reference 39 - ""u.s. census bureau, statistical abstract of the united states: 2011"" - [preliminary regulatory impact analysis, march 2011, food labeling; food labeling; calorie labeling of articles of food in vending machines; proposed rule, re fda-2011-f-0171-0001]",1,0
090000648214c3f7,Supporting & Related Material,FDA-2011-F-0171-0276,FDA-2011-F-0171,"reference 1 - letter from karin f. r. moore from gma march 2016 re food labeling; calorie labeling of articles of food in vending machines;
extension of compliance date",1,0
090000648217a73b,Other,FDA-2011-F-0171-0282,FDA-2011-F-0171,guidance for industry calorie labeling of articles of food in vending machines - small entity compliance guide,1,0
090000648197397f,Supporting & Related Material,FDA-2011-F-0171-0206,FDA-2011-F-0171,"tab b final rule impact analysis (fria) substantive changes between the draft submitted to oira for review and the regulatory action subsequently cleared by oira re food labeling; calorie labeling of articles of food in vending machines (final rule); publication date: december 1, 2014",1,0
090000648214c3f9,Supporting & Related Material,FDA-2011-F-0171-0278,FDA-2011-F-0171,"reference 2a - attachment to letter from karin moore of gma june 2016 re food labeling; calorie labeling of articles of food in vending machines;
extension of compliance date",1,0
0900006482178bd6,Notice,FDA-2011-F-0171-0281,FDA-2011-F-0171,"calorie labeling of articles of food in vending machines; draft guidance for
industry; availability",1,0
0900006480c19866,Supporting & Related Material,FDA-2011-F-0171-0004,FDA-2011-F-0171,"reference 1 -  ""merriam webster collegiate dictionary, tenth edition, 1993"" - [food labeling; food labeling; calorie labeling of articles of food in vending machines; proposed rule] re fda-2011-f-0171-0001",1,0
0900006480c19865,Supporting & Related Material,FDA-2011-F-0171-0003,FDA-2011-F-0171,"reference list - ""vending machine labeling"" - [food labeling; food labeling; calorie labeling of articles of food in vending machines; proposed rule] re fda-2011-f-0171-0001",1,0
0900006480c19881,Supporting & Related Material,FDA-2011-F-0171-0009,FDA-2011-F-0171,"reference 28 - ""eastern research group, inc., evaluation of recordkeeping costs for food manufacturers, final report” "" - [food labeling; food labeling; calorie labeling of articles of food in vending machines; proposed rule] re fda-2011-f-0171-0001",1,0
0900006480c19ccb,Supporting & Related Material,FDA-2011-F-0171-0010,FDA-2011-F-0171,"preliminary regulatory impact analysis, march 2011, food labeling; food labeling; calorie labeling of articles of food in vending machines; proposed rule, re fda-2011-f-0171-0001",1,0
0900006480c1a0c8,Supporting & Related Material,FDA-2011-F-0171-0013,FDA-2011-F-0171,"reference 3 - ""u.s. small business administration, table of small business size standards matched to north american industry classification system codes,” effective november 5, 2010"" - [preliminary regulatory impact analysis, march 2011, food labeling; food labeling; calorie labeling of articles of food in vending machines; proposed rule, re fda-2011-f-0171-0001]",1,0
0900006481fdeb39,Supporting & Related Material,FDA-2012-N-1210-0900,FDA-2012-N-1210,reference index for revision of the nutrition and supplement facts labels final rule re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fded9a,Supporting & Related Material,FDA-2012-N-1210-0953,FDA-2012-N-1210,reference 17 lifestyle interventions to reduce cardiovascular risk re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdeda1,Supporting & Related Material,FDA-2012-N-1210-0946,FDA-2012-N-1210,"reference 24 iom dri for energy, chapter 5 re food labeling: revision of the nutrition and supplement facts labels",1,0
0900006481fdeda2,Supporting & Related Material,FDA-2012-N-1210-0945,FDA-2012-N-1210,reference 25 iom dris - guiding principles for nutrition re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdee0a,Supporting & Related Material,FDA-2012-N-1210-0979,FDA-2012-N-1210,reference 47 association between omega-3 fatty a re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdee0b,Supporting & Related Material,FDA-2012-N-1210-0978,FDA-2012-N-1210,reference 48 seafood omega-3 intake and risk of coronary he re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdee0e,Supporting & Related Material,FDA-2012-N-1210-0975,FDA-2012-N-1210,reference 51 long-chain omega-3 fatty acids eic re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdee0f,Supporting & Related Material,FDA-2012-N-1210-0974,FDA-2012-N-1210,reference 52 scientific opinion labelling reference intake re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdee11,Supporting & Related Material,FDA-2012-N-1210-0972,FDA-2012-N-1210,"reference 54 dietary cholesterol from eggs increases the ratio of total cholesterol to high-density lipoprotein cholesterol in humans, a meta-analysis re food labeling: revision of the nutrition and supplement facts labels",1,0
0900006481fdee63,Supporting & Related Material,FDA-2012-N-1210-1028,FDA-2012-N-1210,reference 110 expert memo no1_5_11_16 re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdf075,Supporting & Related Material,FDA-2012-N-1210-1148,FDA-2012-N-1210,reference 162 anthropometric reference data for c re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdf07e,Supporting & Related Material,FDA-2012-N-1210-1140,FDA-2012-N-1210,reference 170 fda 2004 and 2005 health and diet survey re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdf131,Supporting & Related Material,FDA-2012-N-1210-0882,FDA-2012-N-1210,reference 016-02 reformulation cost model re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdf135,Supporting & Related Material,FDA-2012-N-1210-0878,FDA-2012-N-1210,reference 016-06 out of control: visceral influences on behavior re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdf13a,Supporting & Related Material,FDA-2012-N-1210-0926,FDA-2012-N-1210,"reference 16-11 do dietary intakes affect search for nutrient information
on food labels? re food labeling: revision of the nutrition and supplement facts labels",1,0
0900006481fdf141,Supporting & Related Material,FDA-2012-N-1210-0919,FDA-2012-N-1210,"reference 16-18 attention capture and transfer in advertising: brand, pictorial, and text-size effects re food labeling: revision of the nutrition and supplement facts labels",1,0
0900006481fdf18d,Supporting & Related Material,FDA-2012-N-1210-0911,FDA-2012-N-1210,reference 16-26 health with special feature on socioeconomic status and health re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdf190,Supporting & Related Material,FDA-2012-N-1210-0908,FDA-2012-N-1210,reference 16-29 status of nutrition labeling re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdf5ba,Supporting & Related Material,FDA-2012-N-1210-1099,FDA-2012-N-1210,reference 155 ileal and faecal protein digesti re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdf6b2,Supporting & Related Material,FDA-2012-N-1210-1157,FDA-2012-N-1210,reference 208-the requirement of magnesium by the normal adu re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdf6b6,Supporting & Related Material,FDA-2012-N-1210-1153,FDA-2012-N-1210,"reference 212-magnesium, nature's physiologic calcium blocke re food labeling: revision of the nutrition and supplement facts labels",1,0
0900006481fdf6b8,Supporting & Related Material,FDA-2012-N-1210-1207,FDA-2012-N-1210,reference 214-dorup-1993-correlation between magnesium and p re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdf6c0,Supporting & Related Material,FDA-2012-N-1210-1199,FDA-2012-N-1210,reference 222-usda_labeling re food labeling: revision of the nutrition and supplement facts labels,1,0
0900006481fdf6f3,Supporting & Related Material,FDA-2012-N-1210-1183,FDA-2012-N-1210,"reference 238-iom_dri for folate, chapter 8 re food labeling: revision of the nutrition and supplement facts labels",1,0
0900006481fdf6f4,Supporting & Related Material,FDA-2012-N-1210-1182,FDA-2012-N-1210,"reference 239-the calcium quandary, how consumers use nutrit re food labeling: revision of the nutrition and supplement facts labels",1,0
090000648172d7b5,Supporting & Related Material,FDA-1995-N-0063-0140,FDA-1995-N-0063,reference 52 summary of findings,0,0
090000648172d7c4,Supporting & Related Material,FDA-1995-N-0063-0145,FDA-1995-N-0063,reference 57 jensen and jensen invited review specialty lipids for infant nutrition i. milks and formulas,0,0
090000648172d766,Supporting & Related Material,FDA-1995-N-0063-0114,FDA-1995-N-0063,reference 26 no material submitted,0,0
090000648172d769,Supporting & Related Material,FDA-1995-N-0063-0117,FDA-1995-N-0063,reference 29 ronald f tetzlaff gmp documentation requirements for automated systems part 1,0,0
090000648172d770,Supporting & Related Material,FDA-1995-N-0063-0121,FDA-1995-N-0063,reference 33 salmonella ealing inspections associated with consumption of infant dired milk,0,0
090000648172d7a2,Supporting & Related Material,FDA-1995-N-0063-0125,FDA-1995-N-0063,reference 37 farber and peterkin listeria monocytogenes a food borne pathogen,1,0
090000648172d7aa,Supporting & Related Material,FDA-1995-N-0063-0133,FDA-1995-N-0063,reference 45 jackson et al control of salmonellosis and similar foodborne infections,0,0
090000648056cbdb,Supporting & Related Material,FDA-1995-N-0063-0007,FDA-1995-N-0063,background material from unknown submitter,0,0
090000648056cbe4,Supporting & Related Material,FDA-1995-N-0063-0008,FDA-1995-N-0063,background material from unknown submitter,0,0
090000648172d767,Supporting & Related Material,FDA-1995-N-0063-0115,FDA-1995-N-0063,reference 27 ieee standard glossary of software engineering terminology,0,0
090000648172d76e,Supporting & Related Material,FDA-1995-N-0063-0119,FDA-1995-N-0063,"reference 31 ronald f tetzlaff gmp documentation requirements for automated systems part 3, fda inspections of computerized laboratory systems",0,0
090000648172de15,Supporting & Related Material,FDA-1995-N-0063-0155,FDA-1995-N-0063,reference 69 shenai et al nutritional balance studies in very low-birth- weight infants: role of soy formula,0,0
090000648172de16,Supporting & Related Material,FDA-1995-N-0063-0156,FDA-1995-N-0063,reference 70 lindroth et al rickets in very low birthweight infants,0,0
090000648174e748,Supporting & Related Material,FDA-1995-N-0063-0169,FDA-1995-N-0063,reference 81 minton et al bone mineral content in term and preterm appropriate-for-gestational-age infants,0,0
090000648174e74f,Supporting & Related Material,FDA-1995-N-0063-0176,FDA-1995-N-0063,"reference 88 memorandum of telephone conversation between ed puro, fda, and mary hudtloff dated march 15, 1994",0,0
09000064817368eb,Supporting & Related Material,FDA-1995-N-0063-0051,FDA-1995-N-0063,"reference 1 - fda. current good manufacturing practices, quality control procedures, quality factors, notification requirements, and records and reports, for infant formula. regulatory impact analysis for final rule - current good manufacturing practices, quality control procedures, quality factors, notification requirements, and records and reports, for infant formula",0,0
090000648172d7c5,Supporting & Related Material,FDA-1995-N-0063-0159,FDA-1995-N-0063,reference 58 ziegler et al cow milk feeding in infancy: further observations on blood loss from the gastrointestinal tract,0,0
090000648172d7c7,Supporting & Related Material,FDA-1995-N-0063-0147,FDA-1995-N-0063,reference 60 infant formula act of 1980 report by the committee on labor and human resources united states senate,0,0
090000648056cb0f,Notice,FDA-1995-N-0063-0041,FDA-1995-N-0063,agency information collection activities: proposed collection; extension,0,0
090000648056cb1b,Other,FDA-1995-N-0063-0045,FDA-1995-N-0063,request for extension of comment period from international formula council,0,0
090000648056cb75,Supporting & Related Material,FDA-1995-N-0063-0096,FDA-1995-N-0063,attachment on basis and context  of sample growth trial protocol comment from international formula council,0,0
090000648056cb73,Supporting & Related Material,FDA-1995-N-0063-0095,FDA-1995-N-0063,attachment g guidelines concerning notification and testing of  infant formulas comment from international formula council,0,0
090000648056cc22,Supporting & Related Material,FDA-1995-N-0063-0107,FDA-1995-N-0063,appendix a3 comment from international formula council,0,0
090000648056cbd5,Supporting & Related Material,FDA-1995-N-0063-0005,FDA-1995-N-0063,background material from unknown submitter,0,0
090000648172de12,Supporting & Related Material,FDA-1995-N-0063-0160,FDA-1995-N-0063,reference 66 koletzko et al intestinal milk - bolus obstruction in formula-fed premature infants given high doses of calcium,0,0
0900006481822218,Notice,FDA-2008-N-0334-0012,FDA-2008-N-0334,"postmarketing safety reports for human drug and biological products;
electronic submission requirements; correction",0,0
0900006482c21dfe,Notice,FDA-2008-N-0334-0016,FDA-2008-N-0334,agency information collection activities; proposed collection; comment request; postmarketing safety reports for human drug and biological products: electronic submission requirements,0,0
09000064817358ac,Other,FDA-2008-N-0334-0010,FDA-2008-N-0334,guidance for industry providing submissions in electronic format - postmarketing safety reports-postmarketing safety reports for human drug and biological products; electronic submission requirements,0,0
090000648186336a,Rule,FDA-2008-N-0334-0014,FDA-2008-N-0334,"postmarketing safety reports for human drug and biological products;
electronic submission requirements; corrections",0,0
09000064817358ae,Supporting & Related Material,FDA-2008-N-0334-0011,FDA-2008-N-0334,reference 1 postmarketing safety reports for human drug and biological products; electronic submission requirements; final rule - administrative practices and procedures; drugs; labeling; medical devices; reporting and recordkeeping requirements; confidential business information; over-the-counter drugs; biologics,0,0
09000064818633f4,Rule,FDA-2008-N-0334-0013,FDA-2008-N-0334,"postmarketing safety reports for human drug and biological products;
electronic submission requirements; correction",0,0
0900006481734bb1,Rule,FDA-2008-N-0334-0009,FDA-2008-N-0334,"postmarketing safety reports for human drug and biological products;
electronic submission requirements",0,0
0900006482f06070,Notice,FDA-2008-N-0334-0017,FDA-2008-N-0334,"agency information collection activities; submission for office of
management and budget review; comment request; postmarketing
safety reports for human drug and biological products: electronic
submission requirements",0,0
0900006481b04f02,Rule,FDA-2008-N-0334-0015,FDA-2008-N-0334,"postmarketing safety reports for human drug and biological products;
electronic submission requirements; delay of compliance date; safety
reporting portal of electronic submission of postmarketing safety
reports for human drugs and nonvaccine biological products",0,0
0900006480a0f0ed,Proposed Rule,FDA-2008-N-0334-0001,FDA-2008-N-0334,postmarketing safety reports for human drug and biological products; electronic submission requirements,0,0
0900006481fac540,Proposed Rule,FDA-2011-F-0172-0613,FDA-2011-F-0172,"a labeling guide for restaurants and retail establishments selling away-
from-home foods—part ii (menu labeling requirements in accordance
with the patient protection affordable care act of 2010); guidance for
industry; availability",0,0
090000648290aa13,Supporting & Related Material,FDA-2011-F-0172-1762,FDA-2011-F-0172,article c flexibility in font size re: comment from publix,0,0
09000064826abbd7,Other,FDA-2011-F-0172-0725,FDA-2011-F-0172,final regulatory impact analysis on food labeling; nutrition labeling of standard menu items in restaurants and similar retail food establishments; extension of compliance date and request for comments,1,0
0900006482963502,Supporting & Related Material,FDA-2011-F-0172-2281,FDA-2011-F-0172,reference letter from p. larkin of nga concerning pending  nutrition r 2017-1614...,0,0
090000648323dcc8,Rule,FDA-2011-F-0172-2905,FDA-2011-F-0172,menu labeling: supplemental guidance for industry; availability,0,0
09000064827b3d3d,Other,FDA-2011-F-0172-1175,FDA-2011-F-0172,letter menu extension to nra dtd 6-28-2017,0,0
0900006480c1aa11,Supporting & Related Material,FDA-2011-F-0172-0049,FDA-2011-F-0172,"reference 67 - ""u.s. census bureau, sectors 44-45: sub: single unit & multiunit firms for the u.s:2007"" - [preliminary regulatory impact analysis, march 2011, food labeling:nutrition labeling of standard menu items in restaurants and similar retail food establishments notice of proposed rulemaking re fda-2011-f-0172-0001]",1,0
0900006480c1aa4a,Supporting & Related Material,FDA-2011-F-0172-0055,FDA-2011-F-0172,"reference 75 - ""bureau of transportation statistics, appendix d – modal profiles, rail profile"" - [preliminary regulatory impact analysis, march 2011, food labeling:nutrition labeling of standard menu items in restaurants and similar retail food establishments notice of proposed rulemaking re fda-2011-f-0172-0001]",1,0
0900006480c197bf,Supporting & Related Material,FDA-2011-F-0172-0024,FDA-2011-F-0172,"reference list - [preliminary regulatory impact analysis, march 2011, food labeling:nutrition labeling of standard menu items in restaurants and similar retail food establishments notice of proposed rulemaking re fda-2011-f-0172-0001]",1,0
0900006480c1a599,Supporting & Related Material,FDA-2011-F-0172-0017,FDA-2011-F-0172,"reference 35 - ""ogden, et al., prevalence of overweight, obesity, and extreme obesity among adults: united states, trends 1976–1980 through 2007–2008"" - [food labeling: nutrition labeling of standard menu items in restaurants and similar retail re fda-2011-f-0172-0001]",1,0
0900006480c1a5a4,Supporting & Related Material,FDA-2011-F-0172-0018,FDA-2011-F-0172,"reference 44 - ""usda, ers, table 1: food and alcoholic beverages: total expenditures,  food cpi and expenditures: food expenditure tables"" - [food labeling: nutrition labeling of standard menu items in restaurants and similar retail re fda-2011-f-0172-0001]",1,0
0900006480c1a5aa,Supporting & Related Material,FDA-2011-F-0172-0022,FDA-2011-F-0172,"reference 50 - ""npd group, fda report, recount restaurant census, spring 2010"" - [food labeling: nutrition labeling of standard menu items in restaurants and similar retail re fda-2011-f-0172-0001]",1,0
0900006480c1a9b5,Supporting & Related Material,FDA-2011-F-0172-0025,FDA-2011-F-0172,"reference 2 - ""us census bureau, county business patterns, united states naics 722 2000-2008"" - [preliminary regulatory impact analysis, march 2011, food labeling:nutrition labeling of standard menu items in restaurants and similar retail food establishments notice of proposed rulemaking re fda-2011-f-0172-0001]",1,0
0900006480c1a9c7,Supporting & Related Material,FDA-2011-F-0172-0027,FDA-2011-F-0172,"reference 20 - ""u.s. department of health and human services and u.s. department of agriculture, 2010 dietary guidelines for americans"" - [preliminary regulatory impact analysis, march 2011, food labeling:nutrition labeling of standard menu items in restaurants and similar retail food establishments notice of proposed rulemaking re fda-2011-f-0172-0001]",1,0
0900006480c1a9f3,Supporting & Related Material,FDA-2011-F-0172-0039,FDA-2011-F-0172,"reference 37 - ""technomic inc., fda report"" - [preliminary regulatory impact analysis, march 2011, food labeling:nutrition labeling of standard menu items in restaurants and similar retail food establishments notice of proposed rulemaking re fda-2011-f-0172-0001]",1,0
0900006482441831,Supporting & Related Material,FDA-2011-F-0172-0620,FDA-2011-F-0172,"food labeling:nutrition labeling of standard menu items in restaurants and similar retail food establishments final regulatory impact analysis
fda–2011–f–0172",1,0
0900006482590936,Rule,FDA-2011-F-0172-0621,FDA-2011-F-0172,"food labeling; nutrition labeling of standard menu items in 
restaurants and similar retail food establishments; extension of 
compliance date; request for comments",1,0
09000064824412de,Rule,FDA-2011-F-0172-0619,FDA-2011-F-0172,food labeling: nutrition labeling of standard menu items in restaurants and similar retail food establishments; extension of compliance date,1,0
0900006482963506,Supporting & Related Material,FDA-2011-F-0172-2285,FDA-2011-F-0172,reference ltr to sec price re 040717 menu labling,0,0
090000648197401a,Other,FDA-2011-F-0172-0547,FDA-2011-F-0172,"omb executive order 12866 regulatory planning and review re food labeling; nutrition labeling of standard menu items in restaurants and similar retail food establishments (final rule); publication date: december 1, 2014",1,0
0900006480c1cf20,Proposed Rule,FDA-2011-F-0172-0001,FDA-2011-F-0172,food labeling: nutrition labeling of standard menu items in restaurants and similar retail food establishments,1,0
090000648197401f,Supporting & Related Material,FDA-2011-F-0172-0551,FDA-2011-F-0172,"tab a menu (fria), draft regulatory action as submitted to the office of management and budget's (omb) office of information and regulatory affairs (oira) for review re omb executive order 12866 regulatory planning and review re food labeling; nutrition labeling of standard menu items in restaurants and similar retail food establishments (final rule); publication date: december 1, 2014",1,0
0900006481974020,Supporting & Related Material,FDA-2011-F-0172-0552,FDA-2011-F-0172,"tab b menu final rule impact analysis (fria) substantive changes between the draft submitted to oira for review and the regulatory action subsequently cleared by oira re omb executive order 12866 regulatory planning and review re food labeling; nutrition labeling of standard menu items in restaurants and similar retail food establishments (final rule); publication date: december 1, 2014",1,0
090000648195229f,Supporting & Related Material,FDA-2011-F-0172-0537,FDA-2011-F-0172,"reference 39- fda, ""regulatory procedures manual,"" chapter 4. re food labeling; nutrition labeling of standard menu items in restaurants and similar retail food establishments.",1,0
09000064819522a0,Supporting & Related Material,FDA-2011-F-0172-0538,FDA-2011-F-0172,"reference 40 - fda, ""regulatory procedures manual,"" chapter 6, section 5. re food labeling; nutrition labeling of standard menu items in restaurants and similar retail food establishments.",1,0
0900006480aabaa3,Other,FDA-2008-N-0115-0003,FDA-2008-N-0115,"omb review, executive order 12866 published 2/19/2010 - [reporting information regarding falsification of data] - reference",0,0
090000648378011d,Proposed Rule,FDA-2008-N-0115-0050,FDA-2008-N-0115,use of materials derived from cattle in medical products intended for use in humans and drugs intended for use in ruminants; reporting information regarding falsification of data,0,0
0900006480aa8374,Proposed Rule,FDA-2008-N-0115-0001,FDA-2008-N-0115,reporting information regarding falsification of data,0,0
09000064805d46ca,Supporting & Related Material,FDA-1997-D-0494-0001,FDA-1997-D-0494,see fda-1997-d-0494-0002,0,0
0900006480900aec,Notice,FDA-1997-D-0494-0002,FDA-1997-D-0494,guidance for fda and industry: direct final rule procedures,0,0
0900006480900ab4,Other,FDA-1997-D-0494-0003,FDA-1997-D-0494,guidance for fda industry direct final rule procedures; guidance document,0,0
0900006480ead32d,Supporting & Related Material,FDA-2010-N-0568-0266,FDA-2010-N-0568,"reference 38 - ""farber, et at, ""secondhand tobacco smoke in children with asthma: sources of and parental perceptions about exposure in children and parental readiness to change"" - [required warnings for cigarette packages and advertisements; final rule]",0,1
0900006480eb4ab6,Supporting & Related Material,FDA-2010-N-0568-0693,FDA-2010-N-0568,"reference 66 - ""fiore, m.c., jaen c.r., baker t.r, et al., treating tobacco use and dependence: 2008 update, rockville, md: u.s. department of health and human services, public health service"" - [required warnings for cigarette packages and advertisements; final rule]",0,1
0900006480eb61e0,Supporting & Related Material,FDA-2010-N-0568-0735,FDA-2010-N-0568,"reference 167 - ""u.s. department of the treasury, daily treasury long-term rate data, daily treasury real long- term rates"" - [required warnings for cigarette packages and advertisements; final rule]",0,0
0900006480eb5d6a,Supporting & Related Material,FDA-2010-N-0568-0708,FDA-2010-N-0568,"reference 128 - ""national center for health statistics (u.s. department of health and human services), national health interview survey: questionnaires, datasets and related documentation, 1997 to the present"" - [required warnings for cigarette packages and advertisements; final rule]",0,0
0900006480eb5da1,Supporting & Related Material,FDA-2010-N-0568-0712,FDA-2010-N-0568,"reference 136 - ""arias, e., united states life tables, 2006, national vital statistics reports, 58(21); june 28, 2010"" - [required warnings for cigarette packages and advertisements; final rule]",0,0
0900006480eb5dc7,Supporting & Related Material,FDA-2010-N-0568-0714,FDA-2010-N-0568,"reference 142 - ""u.s. department ofcommerce, census bureau 2008, national cancer institute and centers for disease control and prevention co-sponsored tobacco use supplement to the current population survey 2006-2007"" - [required warnings for cigarette packages and advertisements; final rule]",0,1
0900006480b87423,Proposed Rule,FDA-2010-N-0568-0001,FDA-2010-N-0568,required warnings for cigarette packages and advertisements,0,0
0900006480eb555a,Supporting & Related Material,FDA-2010-N-0568-0697,FDA-2010-N-0568,"reference 89 - ""u.s. department of health and human services, ending the tobacco epidemic: a tobacco control strategic action plan for the u.s. department of health and human services, nov. 10, 2010"" - [required warnings for cigarette packages and advertisements; final rule]",0,1
0900006480e9ea5d,Supporting & Related Material,FDA-2010-N-0568-0261,FDA-2010-N-0568,"reference 17 - ""u.s. department of health and human services, the health consequences of involuntary exposure to tobacco smoke,  a report of the surgeon general; 2006"" - [required warnings for cigarette packages and advertisements; final rule]",0,1
0900006480bb0be7,Notice,FDA-2010-N-0568-0006,FDA-2010-N-0568,required warnings for cigarette packages and advertisements; research report,0,0
0900006480bad0e1,Supporting & Related Material,FDA-2010-N-0568-0008,FDA-2010-N-0568,"(1) experimental study of graphic cigarette warning labels, final results report, december 2010 - [required warnings for cigarette packages and advertisements; research report] re fda-2010-n-0568-0006",0,0
0900006480eb555d,Supporting & Related Material,FDA-2010-N-0568-0700,FDA-2010-N-0568,"reference 92 - ""ntla research preview, digital nation: expanding internet usage, u.s. department of commerce: national telecommunications and information administration, february 2011"" - [required warnings for cigarette packages and advertisements; final rule]",0,0
0900006480eb556c,Supporting & Related Material,FDA-2010-N-0568-0702,FDA-2010-N-0568,"reference 102 - ""u.s. census bureau, language use and english-speaking ability: 2000,"" october 2003"" - [required warnings for cigarette packages and advertisements; final rule]",0,0
0900006480eb61de,Supporting & Related Material,FDA-2010-N-0568-0733,FDA-2010-N-0568,"reference 165- ""tax foundation, state sales, gasoline, cigarette and alcohol tax rates by state, 2000-2010"" - [required warnings for cigarette packages and advertisements; final rule]",0,0
0900006480eb61e3,Supporting & Related Material,FDA-2010-N-0568-0738,FDA-2010-N-0568,"reference 170 - ""u.s department of agriculture, foreign agricultural service, global agricultural trade system"" - [required warnings for cigarette packages and advertisements; final rule]",0,0
0900006480eb63b6,Supporting & Related Material,FDA-2010-N-0568-0744,FDA-2010-N-0568,"reference 178 - ""jamison, n., et al., federal and state cigarette excise taxes--united states, 1995-2009, morbidity and mortality weekly report"" - [required warnings for cigarette packages and advertisements; final rule]",0,0
0900006480eb63b7,Supporting & Related Material,FDA-2010-N-0568-0745,FDA-2010-N-0568,"reference 179 - ""u.s. census bureau population division, table co-est2001-12-00--time series of intercensal state population estimates: april 1, 1990 to april 1, 2000, april 11, 2002,"" - [required warnings for cigarette packages and advertisements; final rule]",0,0
0900006480bad0e0,Supporting & Related Material,FDA-2010-N-0568-0007,FDA-2010-N-0568,list of documents for the notice of availability and request for comments - [required warnings for cigarette packages and advertisements; research report] re fda-2010-n-0568-0006,0,0
0900006480eb5da9,Supporting & Related Material,FDA-2010-N-0568-0713,FDA-2010-N-0568,"reference 140 - ""u.s. department of labor, bureau of labor statistics. consumer price index detailed report"" - [required warnings for cigarette packages and advertisements; final rule]",0,0
0900006480eb5dd4,Supporting & Related Material,FDA-2010-N-0568-0716,FDA-2010-N-0568,"reference 145 - ""national fire protection association, news release, july 16, 2004."" - [required warnings for cigarette packages and advertisements; final rule]",0,0
0900006480eb619c,Supporting & Related Material,FDA-2010-N-0568-0721,FDA-2010-N-0568,"reference 151 - ""u.s. census bureau, nonemployer statistics, u.s., all industries, 2008, retail trade, accommodation and food services"" - [required warnings for cigarette packages and advertisements; final rule]",1,0
0900006480eb61bd,Supporting & Related Material,FDA-2010-N-0568-0729,FDA-2010-N-0568,"reference 160 - ""u.s. census bureau, american factfinder, 2006 annual survey of manufacturers,"" 2008"" - [required warnings for cigarette packages and advertisements; final rule]",0,0
0900006480e9996b,Supporting & Related Material,FDA-2010-N-0568-0257,FDA-2010-N-0568,"reference 6 - ""centers for disease control and prevention, ""tobacco use among middle and high school students--united states, 2000-2009"" - [required warnings for cigarette packages and advertisements; final rule]",0,1
0900006480eb3f88,Supporting & Related Material,FDA-2010-N-0568-0691,FDA-2010-N-0568,"reference 64 - ""u.s. food and drug administration, cigarette required warnings, june 2011""  - [required warnings for cigarette packages and advertisements; final rule]",1,0
0900006480e9996e,Supporting & Related Material,FDA-2010-N-0568-0258,FDA-2010-N-0568,"reference 7 - ""substance abuse and mental health services administration, ""results from the 2008 national survey on drug use and health: national findings"" - [required warnings for cigarette packages and advertisements; final rule]",0,0
0900006482a3ef61,Other,FDA-1992-S-0039-0064,FDA-1992-S-0039,cber memo to the division of dockets management,0,0
090000648052882e,Notice,FDA-1992-S-0039-0001,FDA-1992-S-0039,electronic submissions; establishment of public docket,0,0
0900006480528898,Supporting & Related Material,FDA-1992-S-0039-0019,FDA-1992-S-0039,"cder, cfr 314(50) new drug applications memo 6 - memorandum",0,0
09000064805288b7,Supporting & Related Material,FDA-1992-S-0039-0027,FDA-1992-S-0039,"cvm, cfr 11.2(b)(2) final disposition of memo 11 - memorandum",0,0
09000064805288bb,Supporting & Related Material,FDA-1992-S-0039-0028,FDA-1992-S-0039,cder to the division of docket postmarketing expedited safety reports – “15-day alert reports memo 12 - memorandum,0,0
0900006481e620b5,Other,FDA-1992-S-0039-0062,FDA-1992-S-0039,"letter from epic pharma, llc to fda re: information request product quality reference #206770",0,0
09000064828d4c21,Supporting & Related Material,FDA-1992-S-0039-0063,FDA-1992-S-0039,fda/cvm memo to the division of dockets management using the,0,0
09000064814a18df,Supporting & Related Material,FDA-1992-S-0039-0060,FDA-1992-S-0039,"fda/cdrh memo to the division of dockets management submission of device information (di) record to the global unique device identification database (gudid), in compliance with the unique device identification rule - memorandum",0,0
0900006480552d61,Supporting & Related Material,FDA-1992-S-0039-0054,FDA-1992-S-0039,fda center fo devices and radiological health to the division of dockets management - memorandum,0,0
090000648052890d,Other,FDA-1992-S-0039-0050,FDA-1992-S-0039,cber blood establishment registration - memo 25,0,0
090000648052892a,Supporting & Related Material,FDA-1992-S-0039-0010,FDA-1992-S-0039,cder to the division of dockets management orphan-drug designation requests memo 33 - memorandum,0,0
09000064805288a0,Supporting & Related Material,FDA-1992-S-0039-0022,FDA-1992-S-0039,"cber, biologics license applications (bla)product license applications (pla) establishment license applications (ela) new drug applications - memo 8 - supplement",0,0
09000064805288d1,Other,FDA-1992-S-0039-0040,FDA-1992-S-0039,cber advertisements and promotional labeling - memo 20,0,0
09000064805288d4,Other,FDA-1992-S-0039-0041,FDA-1992-S-0039,cber advertisements and promotional labeling - memo 20,0,0
0900006480f43469,Supporting & Related Material,FDA-1992-S-0039-0058,FDA-1992-S-0039,fda/cvm memo to the division of dockets management using the esubmitter tool instead of adobe acrobat pdf smartforms - memorandum,0,0
0900006480528922,Supporting & Related Material,FDA-1992-S-0039-0003,FDA-1992-S-0039,cder investigational new drug applications  new drug applications abbreviated newdrug applications master files annual reports promotional material memo 27 - memorandum,0,0
09000064805288a4,Other,FDA-1992-S-0039-0023,FDA-1992-S-0039,"cber, cfr 601.2, 314.50 biologics marketing applications - memo 9",0,0
09000064805288dc,Other,FDA-1992-S-0039-0043,FDA-1992-S-0039,cber investigational nda - memo 21,0,0
090000648052889b,Supporting & Related Material,FDA-1992-S-0039-0020,FDA-1992-S-0039,"cder to the division of dockets management, withdrawal of case report forms, memo 2 and case report tabulations memo 3 - memorandum",0,0
09000064805288c8,Supporting & Related Material,FDA-1992-S-0039-0038,FDA-1992-S-0039,cder advertisements and promotional labeling memo 18 - memorandum,0,0
090000648066936b,Supporting & Related Material,FDA-1992-S-0039-0055,FDA-1992-S-0039,"fda center for drug evaluation and research, et al to the division of dockets management - memorandum",0,0
09000064805288ac,Supporting & Related Material,FDA-1992-S-0039-0025,FDA-1992-S-0039,"cvm, cfr 11.2(b)(2) final disposition of memo 10",0,0
09000064805288bd,Supporting & Related Material,FDA-1992-S-0039-0029,FDA-1992-S-0039,cvm cfr 11.2(b) (2) guidance for indudstry memo 13 - memorandum,0,0
09000064805288e7,Supporting & Related Material,FDA-1992-S-0039-0046,FDA-1992-S-0039,cder abbreviated new drug applications memo 24 - memorandum re fda-1992-s-0039-0047,0,0
090000648052891c,Other,FDA-1992-S-0039-0051,FDA-1992-S-0039,cber blood establishment registration - memo 26,0,0
090000648294f0f0,Other,FDA-2017-D-4359-0002,FDA-2017-D-4359,"guidance for industry 68 on small entites compliance guide for protein blenders, feed manufacturers, and distributors",0,0
090000648294f0ee,Other,FDA-2017-D-4359-0001,FDA-2017-D-4359,guidance for industry on small entitles compliance guide for renderers,0,0
090000648294f0f2,Other,FDA-2017-D-4359-0003,FDA-2017-D-4359,guidance for industry on small entities compliance guide for feeders of ruminant animals with on-farm feed mixing operations,0,0
090000648294fa11,Other,FDA-2017-D-4359-0005,FDA-2017-D-4359,guidance for industry on questions and answers bse feed regulation,0,0
090000648294fa0f,Other,FDA-2017-D-4359-0004,FDA-2017-D-4359,guidance for industry on small entities compliance guide for feeders of ruminant animals without on-farm feed mixing operations,0,0
090000648094efb0,Other,FDA-2002-N-0031-0154,FDA-2002-N-0031,form letter sample #10 - [multiple submitters=4] - form letter comment (c507),0,0
090000648094ec3e,Other,FDA-2002-N-0031-0148,FDA-2002-N-0031,form letter sample #4 - [multiple submitters=7] - form letter comment (emc45),0,0
090000648053331a,Supporting & Related Material,FDA-2002-N-0031-0128,FDA-2002-N-0031,findings of no significant impact,0,0
0900006480533338,Supporting & Related Material,FDA-2002-N-0031-0129,FDA-2002-N-0031,environmental assessment,0,0
09000064805239b5,Supporting & Related Material,FDA-2002-N-0031-0111,FDA-2002-N-0031,substances prohibited from use in animal food or feed - references,1,0
09000064805239d2,Supporting & Related Material,FDA-2002-N-0031-0112,FDA-2002-N-0031,reference 1 - opinion of the scientific steering committee on the human exposure risk (her) via food with respect to bse,1,0
09000064805239f4,Supporting & Related Material,FDA-2002-N-0031-0114,FDA-2002-N-0031,"reference 3 - an estimate of the prevalence of bse in the united states, usda",0,0
0900006480523b2e,Supporting & Related Material,FDA-2002-N-0031-0121,FDA-2002-N-0031,reference 14 - oig report no. 50601-10-kc - audit report,0,0
090000648048a5ef,Other,FDA-2002-N-0031-0094,FDA-2002-N-0031,the honorable paul e. kanjorski to the food and drug administration - letter,1,0
090000648048a62a,Other,FDA-2002-N-0031-0100,FDA-2002-N-0031,the honorable p. sarbanes to the food and drug administration - letter,1,0
0900006480523b1d,Supporting & Related Material,FDA-2002-N-0031-0118,FDA-2002-N-0031,"reference 9 - ""opinion on the safety of ruminant blood with respect to tse risks",0,0
0900006480523b37,Supporting & Related Material,FDA-2002-N-0031-0120,FDA-2002-N-0031,"reference 16 - ""economic impacts of fda regulatory changes due to risk of bovine spongiform encephalopathy""",0,0
0900006480523baf,Supporting & Related Material,FDA-2002-N-0031-0124,FDA-2002-N-0031,"reference 23 - ""an economic chronology of bovine spongiform encephalopathy in north america""",0,0
0900006480523bcb,Supporting & Related Material,FDA-2002-N-0031-0126,FDA-2002-N-0031,"reference 26 - ""economic impacts of proposed changes to livestock feed regulations""",0,0
0900006480523bf8,Supporting & Related Material,FDA-2002-N-0031-0127,FDA-2002-N-0031,"reference 28 - national agricultural statistics service, usda",0,0
09000064804896b9,Notice,FDA-2002-N-0031-0002,FDA-2002-N-0031,substances prohibited from use in animal food or feed; animal proteins prohibited in ruminant feed; correction,1,0
090000648094bc24,Proposed Rule,FDA-2002-N-0031-0132,FDA-2002-N-0031,substances prohibited from use in animal food or feed; final rule: proposed delay of effective date,1,0
090000648094f00a,Other,FDA-2002-N-0031-0156,FDA-2002-N-0031,form letter sample #12 - [multiple submitters=3] - form letter comment (c531),0,0
090000648048a4b5,Other,FDA-2002-N-0031-0063,FDA-2002-N-0031,the honorable jim bunning to the food and drug administration - letter,1,0
090000648048a608,Other,FDA-2002-N-0031-0099,FDA-2002-N-0031,the honorable barbara a. mikulski to the food and drug administration - letter,1,0
090000648048a52f,Supporting & Related Material,FDA-2002-N-0031-0072,FDA-2002-N-0031,facsimile sheet - [the honorable john e. peterson - comment],0,0
090000648048a633,Other,FDA-2002-N-0031-0102,FDA-2002-N-0031,nate berry to the food and drug administration - letter,1,0
0900006480523b71,Supporting & Related Material,FDA-2002-N-0031-0123,FDA-2002-N-0031,"reference 19 - united kingdom, department for environment, food and rural affairs, 2007",1,0
090000648094eaa8,Other,FDA-2002-N-0031-0146,FDA-2002-N-0031,form letter sample#2 - [multiple submitters=13] - form letter comment (c52),0,0
090000648094ee6a,Other,FDA-2002-N-0031-0151,FDA-2002-N-0031,form letter sample #7 - [multiple submitters=10] - form letter comment (c92),0,0
0900006481304148,Proposed Rule,FDA-2012-N-0920-0001,FDA-2012-N-0920,"tobacco products, user fees, requirements for the submission of data needed to calculate user fees for domestic manufacturers and importers of tobacco products",0,1
0900006481fbd96d,Rule,FDA-2012-N-0920-0016,FDA-2012-N-0920,"requirements for the submission of data needed to calculate user fees
for domestic manufacturers and importers of cigars and pipe tobacco",0,1
0900006481fbea5b,Supporting & Related Material,FDA-2012-N-0920-0019,FDA-2012-N-0920,reference 2 form fda 3825 re requirements for the submission of data needed to calculate user fees for domestic manufacturers and importers of cigars and pipe tobacco,0,1
0900006481fbea5a,Supporting & Related Material,FDA-2012-N-0920-0018,FDA-2012-N-0920,"reference 1 regulatory impact analysis re requirements for the submission of data needed to calculate user fees for domestic manufacturers and importers of cigars and pipe tobacco re requirements for the submission of data needed to calculate user fees
for domestic manufacturers and importers of cigars and pipe tobacco",0,1
090000648179c7c3,Supporting & Related Material,FDA-2012-N-0920-0014,FDA-2012-N-0920,"reference 1 fda-3852 re tobacco products, user fees, requirements for the submission of data needed to calculate user fees for domestic manufacturers and importers of tobacco products",0,1
090000648132f28b,Other,FDA-2012-N-0920-0002,FDA-2012-N-0920,"omb review, executive order 12866, tobacco products, user fees, requirements for the submission of data needed to calculate user fees for domestic manufacturers and importers of tobacco products (may 31, 2013) - memorandum",0,1
0900006481fbe15c,Supporting & Related Material,FDA-2012-N-0920-0017,FDA-2012-N-0920,user fee rule references,0,0
090000648179c80d,Supporting & Related Material,FDA-2012-N-0920-0015,FDA-2012-N-0920,"reference 2 - regulatory impact analysis re tobacco products, user fees, requirements for the submission of data needed to calculate user fees for domestic manufacturers and importers of tobacco products",0,1
090000648179ccd9,Rule,FDA-2012-N-0920-0013,FDA-2012-N-0920,"tobacco products, user fees, requirements for the submission of
data needed to calculate user fees for domestic manufacturers and
importers of tobacco products",0,1
09000064804a0a95,Supporting & Related Material,FDA-2002-N-0323-0110,FDA-2002-N-0323,see: fda-2002-n-0323-0164,0,0
09000064804a090d,Notice,FDA-2002-N-0323-0026,FDA-2002-N-0323,"interim final regulations implementing title iii, subtitle a, of the public health security and bioterrorism preparedness and response act of 2002 section 305: registration of food facilities and section 307: prior notice of imported food shipments; notice of public meeting",1,0
09000064804a0963,Other,FDA-2002-N-0323-0045,FDA-2002-N-0323,"memphis, tn bt downsite 10/28/2003",0,0
09000064804a089b,Other,FDA-2002-N-0323-0006,FDA-2002-N-0323,fda and formatta corporation,0,0
09000064804a0996,Other,FDA-2002-N-0323-0069,FDA-2002-N-0323,new york district registration list from 10/28 downlink,0,0
09000064804a0994,Other,FDA-2002-N-0323-0068,FDA-2002-N-0323,list that attended the 10/28/03 satellite downlink in cincinnati district,0,0
09000064804a098b,Other,FDA-2002-N-0323-0063,FDA-2002-N-0323,"bt downlink list of attendees in baton rouge, la",0,0
09000064804a0981,Other,FDA-2002-N-0323-0058,FDA-2002-N-0323,"list of attendees for 10/28th conference in portland, oregon",0,0
09000064804a0a9d,Other,FDA-2002-N-0323-0115,FDA-2002-N-0323,new fda bioterrorism act registration and prior notice interim final rules,0,0
09000064804a0989,Other,FDA-2002-N-0323-0062,FDA-2002-N-0323,"bt downlink list of attendees in baton rouge, la",0,0
09000064804a0986,Other,FDA-2002-N-0323-0061,FDA-2002-N-0323,"bt downlink list of attendees in baton rouge, la",0,0
09000064804a099c,Other,FDA-2002-N-0323-0073,FDA-2002-N-0323,list for bt downlink held in washington,0,0
09000064804a0b31,Other,FDA-2002-N-0323-0156,FDA-2002-N-0323,"meeting held in fresno california on march 4, 2004",0,0
09000064804a097f,Other,FDA-2002-N-0323-0057,FDA-2002-N-0323,list of wisconsin dowlink,0,0
09000064804a0959,Other,FDA-2002-N-0323-0039,FDA-2002-N-0323,participant list for the houston bt downlink,0,0
09000064821f9c22,Notice,FDA-2002-N-0323-0248,FDA-2002-N-0323,agency information collection activities; announcement of office of  management and budget approvals,0,0
09000064820adbef,Supporting & Related Material,FDA-2002-N-0323-0240,FDA-2002-N-0323,reference 6 guidance for industry questions and answers regarding food facility registration (sixth edition) re amendments to registration of food facilities,1,0
09000064820adc7c,Supporting & Related Material,FDA-2002-N-0323-0242,FDA-2002-N-0323,"reference 8 specification of the unique facility identifier (ufi) system for drug establishment registration, guidance for industry re amendments to registration of food facilities",1,0
09000064820adc7e,Supporting & Related Material,FDA-2002-N-0323-0244,FDA-2002-N-0323,reference 10 gao memo government is analyzing alternatives for contractor identification numbers re amendments to registration of food facilities,1,0
0900006481a975de,Supporting & Related Material,FDA-2002-N-0323-0175,FDA-2002-N-0323,"reference 4-2 u.s. department of labor, bureau of labor statistics, consumer price index (cpi) history tables. cpi- all urban consumers- series id cuur0000sa0 re amendments to registration of food facilities",1,0
0900006481a975e0,Supporting & Related Material,FDA-2002-N-0323-0177,FDA-2002-N-0323,"reference 4-4 u.s. department of labor, bureau of labor statistics, national compensation survey: occupation wages in the united states, 2000 re amendments to registration of food facilities",1,0
0900006481a975e1,Supporting & Related Material,FDA-2002-N-0323-0178,FDA-2002-N-0323,"09 reference 4-5 - fda center for food safety and applied nutrition -division of field programs and guidance, “guidance for industry: necessity of the use of food product categories in food facility registrations and updates to food product categories.” re amendments to registration of food facilities",1,0
0900006481a970fb,Supporting & Related Material,FDA-2002-N-0323-0172,FDA-2002-N-0323,"reference 3 guidance for industry: necessity of the use of food product categories in food facility registrations and updates to food product categories,"" re amendments to registration of food facilities",1,0
09000064804a045b,Notice,FDA-2002-N-0323-0002,FDA-2002-N-0323,fda,0,0
09000064804a045e,Notice,FDA-2002-N-0323-0003,FDA-2002-N-0323,registration of food facilities under the public health security and bioterrorism preparedness and response act of 2002; notice of proposed rulemaking,1,0
0900006481f0eacb,Supporting & Related Material,FDA-2016-N-0543-0007,FDA-2016-N-0543,reference 5 - a fda track re food and drug administration review and action on over-the-counter time and extent applications,1,0
09000064823b9aa7,Rule,FDA-2016-N-0543-0013,FDA-2016-N-0543,food and drug administration review and action on over-the-counter time and extent applications,1,0
0900006481f0eac9,Supporting & Related Material,FDA-2016-N-0543-0005,FDA-2016-N-0543,reference 3 2009 gao report on federal rulemaking re food and drug administration review and action on over-the-counter time and extent applications,1,0
0900006481f0eaca,Supporting & Related Material,FDA-2016-N-0543-0006,FDA-2016-N-0543,reference 4 content and format of sunscreen data submissions draft guidance re food and drug administration review and action on over-the-counter time and extent applications,1,0
0900006481f2331f,Proposed Rule,FDA-2016-N-0543-0001,FDA-2016-N-0543,food and drug administration review and action on over-the-counter time and extent applications,1,0
0900006481f0eac8,Supporting & Related Material,FDA-2016-N-0543-0004,FDA-2016-N-0543,reference 2 ofr guide to the rulemaking process re food and drug administration review and action on over-the-counter time and extent applications,1,0
0900006481f0eacc,Supporting & Related Material,FDA-2016-N-0543-0008,FDA-2016-N-0543,reference 5b sunscreen innovation act (sia) website re food and drug administration review and action on over-the-counter time and extent applications,1,0
0900006481f24068,Supporting & Related Material,FDA-2016-N-0543-0002,FDA-2016-N-0543,references list for food and drug administration review and action on over-the-counter time and extent applications,1,0
09000064823ba8d7,Supporting & Related Material,FDA-2016-N-0543-0014,FDA-2016-N-0543,nonprescription sunscreen drug products  format and content of data submissions guidance for industry,0,0
0900006481f0eac7,Supporting & Related Material,FDA-2016-N-0543-0003,FDA-2016-N-0543,reference 1 tea guidance re food and drug administration review and action on over-the-counter time and extent applications,1,0
0900006481f0eacd,Supporting & Related Material,FDA-2016-N-0543-0009,FDA-2016-N-0543,reference 5c - rulemaking history for otc time and extent applications re food and drug administration review and action on over-the-counter time and extent applications,1,0
090000648062ec5d,Notice,FDA-2008-N-0297-0001,FDA-2008-N-0297,status of certain additional over-the-counter drug category ii active ingredients,0,0
090000648070dcb3,Supporting & Related Material,FDA-2008-N-0297-0007,FDA-2008-N-0297,"buchanan ingersoll  rooney, pc [re fda-2008-n-0297-0010]",0,0
0900006480a5cd06,Proposed Rule,FDA-2009-N-0025-0001,FDA-2009-N-0025,animal food labeling; declaration of certifiable color additives,1,0
0900006481a8572a,Notice,FDA-2009-N-0025-0008,FDA-2009-N-0025,"agency information collection activities; proposed collection;
comment request; animal food labeling; declaration of certifiable 
color additives",1,0
0900006481b5dc20,Notice,FDA-2009-N-0025-0009,FDA-2009-N-0025,"agency information collection activities; submission for office of
management and budget review; comment request; animal food
labeling; declaration of certifiable color additives",1,0
0900006484a5e2e5,Notice,FDA-2009-N-0025-0015,FDA-2009-N-0025,"agency information collection activities; proposed collection; comment request; animal food
labeling; declaration of certified and non-certified color additives",1,0
0900006484bdf2db,Notice,FDA-2009-N-0025-0038,FDA-2009-N-0025,"agency information collection activities; submission for office of management and budget review; 
comment request; animal food labeling; declaration of certified and non-certified color additives",1,0
0900006484db6edd,Notice,FDA-2009-N-0025-0039,FDA-2009-N-0025,agency information collection activities; announcement of office of management and budget approvals,0,0
0900006481c88529,Notice,FDA-2009-N-0025-0010,FDA-2009-N-0025,"agency information collection activities; announcement of office of
management and budget approval; animal food labeling; declaration of certifiable color additives",1,0
0900006480f6e620,Rule,FDA-2009-N-0025-0007,FDA-2009-N-0025,animal food labeling; declaration of certifiable color additives,1,0
0900006483478ab4,Notice,FDA-2009-N-0025-0013,FDA-2009-N-0025,"agency information collection activities; submission for office of
management and budget review; comment request; animal food
labeling; declaration of certifiable color additives",1,0
090000648378024c,Notice,FDA-2009-N-0025-0014,FDA-2009-N-0025,agency information collection activities; announcement of office of management and budget approvals,0,0
0900006482f45a02,Notice,FDA-2009-N-0025-0011,FDA-2009-N-0025,"agency information collection activities; proposed collection;
comment request; animal food labeling; declaration of certifiable
color additives",1,0
0900006483478999,Notice,FDA-2012-N-0447-0112,FDA-2012-N-0447,"antimicrobial animal drug sales and distribution reporting; small entity
compliance guide; availability",0,0
0900006481fc35b3,Rule,FDA-2012-N-0447-0108,FDA-2012-N-0447,antimicrobial animal drug sales and distribution reporting,0,0
0900006481fc3b77,Supporting & Related Material,FDA-2012-N-0447-0109,FDA-2012-N-0447,congresswoman slaughter's letter to fda,0,0
0900006481fc3bca,Supporting & Related Material,FDA-2012-N-0447-0110,FDA-2012-N-0447,antimicrobial animal drug sales and distribution reporting final regulatory impact analysis,0,0
0900006481128b32,Proposed Rule,FDA-2012-N-0447-0006,FDA-2012-N-0447,antimicrobial animal drug sales and distribution reporting: extension of comment period,0,0
09000064810b436c,Proposed Rule,FDA-2012-N-0447-0001,FDA-2012-N-0447,antimicrobial animal drug sales and distribution reporting,0,0
0900006481b9c266,Supporting & Related Material,FDA-2012-N-0447-0069,FDA-2012-N-0447,fda pria antimicrobial animal drug sales and distribution reporting,0,0
090000648209c0b3,Notice,FDA-2012-N-0447-0111,FDA-2012-N-0447,"agency information collection activities; announcement of office 
of management and budget approvals",0,0
0900006481aeb0af,Proposed Rule,FDA-2012-N-0447-0066,FDA-2012-N-0447,antimicrobial animal drug sales and distribution reporting,0,0
090000648346cca1,Other,FDA-2012-N-0447-0113,FDA-2012-N-0447,antimicrobial animal drug sales and distribution reporting; guidance for industry; small entity compliance guide #252,0,0
090000648143b90d,Proposed Rule,FDA-2012-N-0447-0028,FDA-2012-N-0447,antimicrobial animal drug sales and distribution annual summary report data tables,0,0
0900006482f4ca35,Rule,FDA-2013-N-0080-0015,FDA-2013-N-0080,human subject protection; acceptance of data from clinical investigations for medical devices,0,0
09000064816addac,Other,FDA-2013-N-0080-0014,FDA-2013-N-0080,"minutes of meeting between fda and advamed, marh 3, 2014",0,0
090000648342fb0e,Notice,FDA-2013-N-0080-0016,FDA-2013-N-0080,"agency information collection activities; announcement of office of
management and budget approvals",0,0
0900006481206965,Proposed Rule,FDA-2013-N-0080-0001,FDA-2013-N-0080,human subject protection: acceptance of data from clinical studies for medical devices,0,0
09000064843fe841,Other,FDA-2013-N-0080-0017,FDA-2013-N-0080,"acceptance of clinical data to support medical device applications and submissions frequently asked questions; guidance for industry and
food and drug administration staff",1,0
09000064804c2749,Proposed Rule,FDA-2000-N-0108-0007,FDA-2000-N-0108,safety reporting requirements for human drug and biological products; extension of comment period,0,0
09000064804c2954,Supporting & Related Material,FDA-2000-N-0108-0013,FDA-2000-N-0108,"tab b - ""omb review march 14, 2003, executive order 12866, changes in the regulatory action made by oira"" - (safety reporting requirements for human drug and biological products), re fda-2000-n-0108-0006 - reference (pages 377-464)",0,0
09000064804c2967,Supporting & Related Material,FDA-2000-N-0108-0018,FDA-2000-N-0108,"tab a - ""omb review march 14, 2003, executive order 12866, substantive changes between the draft submitted to oira and action subsequently announced"" - (safety reporting requirements for human drug and biological products), re fda-2000-n-0108-0006 - reference (pages 308-406)",0,0
0900006480b627c7,Supporting & Related Material,FDA-2000-N-0108-0074,FDA-2000-N-0108,"reference 4.  occupational employment and wage estimates  may 2008  [investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans, final rule]",0,0
09000064804c26bc,Supporting & Related Material,FDA-2000-N-0108-0027,FDA-2000-N-0108,"reference 25 - ""eastern research group, inc., “cost of implementing meddra terminology for pharmaceutical and biologics companies,”2000"" - [safety reporting requirements for human drug and biological products; npr1] re fda-2000-n-0108-0006",0,0
09000064804c26ba,Supporting & Related Material,FDA-2000-N-0108-0021,FDA-2000-N-0108,"reference list - ""v.g. references"" - [safety reporting requirements for human drug and biological products; npr1] re fda-2000-n-0108-0006",0,0
09000064804c26f7,Supporting & Related Material,FDA-2000-N-0108-0002,FDA-2000-N-0108,see fda-2000-n-0108-0006,0,0
09000064804c26fb,Proposed Rule,FDA-2000-N-0108-0003,FDA-2000-N-0108,see fda-2000-n-0108-0006,0,0
0900006480b63055,Rule,FDA-2000-N-0108-0071,FDA-2000-N-0108,final rule re investigational new drug safety reporting requirements for human drug and biological products: safety reporting requirements for bioavailability and bioequivalence studies in humans,0,0
09000064804c26d1,Supporting & Related Material,FDA-2000-N-0108-0026,FDA-2000-N-0108,"reference 17 - ""general accounting office, adverse drug events the magnitude of health risk is uncertain because of limited incidence data, gao/hehs-00-21, january, 2000"" - [safety reporting requirements for human drug and biological products; npr1] re fda-2000-n-0108-0006",0,0
09000064804c26ed,Supporting & Related Material,FDA-2000-N-0108-0022,FDA-2000-N-0108,"reference 10 - ""institute of medicine, edited by kohn et al., to err is human: building a safer health system, national academy press, 1999 "" - [safety reporting requirements for human drug and biological products; npr1] re fda-2000-n-0108-0006",0,0
09000064804c26f1,Supporting & Related Material,FDA-2000-N-0108-0023,FDA-2000-N-0108,"reference 12 - ""department of health and human services, office of the inspector general, review of the food and drug administration’s handling of adverse drug reaction reports, report no. a-15-98-50001, 1999"" - [safety reporting requirements for human drug and biological products; npr1] re fda-2000-n-0108-0006",1,0
09000064804c26fd,Supporting & Related Material,FDA-2000-N-0108-0004,FDA-2000-N-0108,see fda-2000-n-0108-0006,0,0
0900006480b627cb,Supporting & Related Material,FDA-2000-N-0108-0075,FDA-2000-N-0108,"reference 5.  u.s. department of commerce, bureau of the census, economic census, manufacturing industry series  [investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans, final rule]",0,0
09000064804c2946,Supporting & Related Material,FDA-2000-N-0108-0008,FDA-2000-N-0108,"tab b - ""omb review march 14, 2003, executive order 12866, changes in the regulatory action made by oira"" - (safety reporting requirements for human drug and biological products), re fda-2000-n-0108-0006 - reference (pages 79-174)",0,0
09000064804c2951,Supporting & Related Material,FDA-2000-N-0108-0012,FDA-2000-N-0108,"tab a - ""omb review march 14, 2003, executive order 12866, substantive changes between the draft submitted to oira and action subsequently announced"" - (safety reporting requirements for human drug and biological products), re fda-2000-n-0108-0006 - reference (pages 200-307)",0,0
09000064804c26ad,Supporting & Related Material,FDA-2000-N-0108-0025,FDA-2000-N-0108,"reference 15  - ""agency for health care policy and research, “national medical expenditure survey: annual expenses and sources of payment for health care services, research findings 14,” p.7, 1995"" - [safety reporting requirements for human drug and biological products; npr1] re fda-2000-n-0108-0006",0,0
09000064804c26f5,Supporting & Related Material,FDA-2000-N-0108-0024,FDA-2000-N-0108,"reference 14 -""statistical abstract of the united states: the national data book, p.137-138, 1999"" - [safety reporting requirements for human drug and biological products; npr1] re fda-2000-n-0108-0006",0,0
09000064804c265e,Proposed Rule,FDA-2000-N-0108-0001,FDA-2000-N-0108,notice of proposed rulemaking re safety reporting requirements for human drug and biological products see fda-2000-n-0108-0006,0,0
09000064804c2961,Supporting & Related Material,FDA-2000-N-0108-0016,FDA-2000-N-0108,"tab b - ""omb review march 14, 2003, executive order 12866, changes in the regulatory action made by oira"" - (safety reporting requirements for human drug and biological products), re fda-2000-n-0108-0006 - reference (pages 175-277)",0,0
09000064804c2964,Supporting & Related Material,FDA-2000-N-0108-0017,FDA-2000-N-0108,"tab b - ""omb review march 14, 2003, executive order 12866, changes in the regulatory action made by oira"" - (safety reporting requirements for human drug and biological products), re fda-2000-n-0108-0006 - reference (pages 278-376)",0,0
0900006480b62574,Supporting & Related Material,FDA-2000-N-0108-0073,FDA-2000-N-0108,"reference 1.  ""detailed guidance on the collection, verification and presentation of adverse reaction reports arising from clinical trials on medicinal products for human use"" [investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans, final rule]",0,0
09000064804c294a,Supporting & Related Material,FDA-2000-N-0108-0009,FDA-2000-N-0108,"reference regulations policy management staff to the docket, omb review march 14, 2003, executive order 12866"" - (safety reporting requirements for human drug and biological products), re fda-2000-n-0108-0006",0,0
0900006480b62025,Supporting & Related Material,FDA-2000-N-0108-0072,FDA-2000-N-0108,"list of references re investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans, final rule",0,0
09000064804c294e,Supporting & Related Material,FDA-2000-N-0108-0011,FDA-2000-N-0108,"tab a - ""omb review march 14, 2003, executive order 12866, substantive changes between the draft submitted to oira and action subsequently announced"" - (safety reporting requirements for human drug and biological products), re fda-2000-n-0108-0006 - reference (pages 100-199)",0,0
0900006480bf6619,Other,FDA-2009-P-0298-0008,FDA-2009-P-0298,"fda/cfsan response to ovos natural health, inc. (ullman, shapiro & ullman, llp) - petition denial",0,0
09000064809e3560,Other,FDA-2009-P-0298-0001,FDA-2009-P-0298,"ovos natural health, inc. (ullman, shapiro & ullman, llp) - citizen petition",0,0
0900006480ebc94f,Other,FDA-2009-P-0298-0009,FDA-2009-P-0298,council for responsible nutrition (crn) - letter,0,0
0900006480a69fe6,Other,FDA-2009-P-0298-0007,FDA-2009-P-0298,"fda/cfsan interim response to ovos natural health, inc. (ullman, shapiro & ullman, llp) - letter",0,0
09000064809ebbaf,Other,FDA-2009-P-0298-0003,FDA-2009-P-0298,"acknowledgement letter to ullman, shapiro & ullman, llp - correction",0,0
09000064809e3561,Other,FDA-2009-P-0298-0002,FDA-2009-P-0298,"acknowledgement letter to ovos natural health, inc. (ullman, shapiro & ullman, llp)",0,0
09000064821f9e0f,Notice,FDA-2014-N-0189-83201,FDA-2014-N-0189,agency information collection activities; announcement of office of  management and budget approvals,0,0
0900006481ff9d65,Supporting & Related Material,FDA-2014-N-0189-83195,FDA-2014-N-0189,tab c 2014-850 deeming final rule as cleared by omb,0,0
0900006481fbf51a,Supporting & Related Material,FDA-2014-N-0189-83021,FDA-2014-N-0189,"reference 113 intentions to smoke cigarettes among re deeming tobacco products to be subject to the federal food, drug, and
cosmetic act, as amended by the family smoking prevention and
tobacco control act; restrictions on the sale and distribution of tobacco
products and required warning statements for tobacco product",1,1
0900006481fbf539,Supporting & Related Material,FDA-2014-N-0189-83052,FDA-2014-N-0189,"reference 144 acute effects of electronic and tobacco cigarette re deeming tobacco products to be subject to the federal food, drug, and
cosmetic act, as amended by the family smoking prevention and
tobacco control act; restrictions on the sale and distribution of tobacco
products and required warning statements for tobacco product",1,1
0900006481fbf5bd,Supporting & Related Material,FDA-2014-N-0189-83082,FDA-2014-N-0189,"reference 178 electronic nicotine delivery systems international tobacco re deeming tobacco products to be subject to the federal food, drug, and cosmetic act, as amended by the family smoking prevention and tobacco control act; restrictions on the sale and distribution of tobacco
products and required warning statements for tobacco product",1,1
0900006481fbf644,Supporting & Related Material,FDA-2014-N-0189-83088,FDA-2014-N-0189,"reference 184 electronic cigarettes for smoking cessation a re deeming tobacco products to be subject to the federal food, drug, and
cosmetic act, as amended by the family smoking prevention and
tobacco control act; restrictions on the sale and distribution of tobacco
products and required warning statements for tobacco product",1,1
0900006481fbf647,Supporting & Related Material,FDA-2014-N-0189-83091,FDA-2014-N-0189,"reference 187 e-cigarettes and smoking cessation evidence re deeming tobacco products to be subject to the federal food, drug, and
cosmetic act, as amended by the family smoking prevention and
tobacco control act; restrictions on the sale and distribution of tobacco
products and required warning statements for tobacco product",1,1
0900006481fbf3fa,Supporting & Related Material,FDA-2014-N-0189-82978,FDA-2014-N-0189,"reference 73 alcohol and tobacco tax and trade bureau re deeming tobacco products to be subject to the food, drug, and cosmetic act, as amended by the family smoking prevention and tobacco control act; regulations on the sale and distribution of tobacco products and required warning statements for tobacco products",1,1
0900006481fbf3fb,Supporting & Related Material,FDA-2014-N-0189-82979,FDA-2014-N-0189,"reference 73a  dec 2013 dept of treasury statistical report - tobacco re deeming tobacco products to be subject to the food, drug, and cosmetic act, as amended by the family smoking prevention and tobacco control act; regulations on the sale and distribution of tobacco products and required warning statements for tobacco products",1,1
0900006481fbf4bd,Supporting & Related Material,FDA-2014-N-0189-83063,FDA-2014-N-0189,"reference 159 characterization of chemicals released to the env re deeming tobacco products to be subject to the federal food, drug, and
cosmetic act, as amended by the family smoking prevention and
tobacco control act; restrictions on the sale and distribution of tobacco
products and required warning statements for tobacco product",1,1
0900006481fbf4d1,Supporting & Related Material,FDA-2014-N-0189-83072,FDA-2014-N-0189,"reference 168 2012 annual report of the american association of poison re deeming tobacco products to be subject to the federal food, drug, and
cosmetic act, as amended by the family smoking prevention and
tobacco control act; restrictions on the sale and distribution of tobacco
products and required warning statements for tobacco product",1,1
0900006481fbf515,Supporting & Related Material,FDA-2014-N-0189-83016,FDA-2014-N-0189,"reference 108 electronic cigarette use among middle and hs students re deeming tobacco products to be subject to the federal food, drug, and cosmetic act, as amended by the family smoking prevention and tobacco control act; restrictions on the sale and distribution of tobacco products and required warning statements for tobacco products",1,1
0900006481fbf516,Supporting & Related Material,FDA-2014-N-0189-83017,FDA-2014-N-0189,"reference 109 characteristics perceived side effects and benefits of electronic cigarette use re deeming tobacco products to be subject to the federal food, drug, and cosmetic act, as amended by the family smoking prevention and tobacco control act; restrictions on the sale and distribution of tobacco products and required warning statements for tobacco products",1,1
0900006481fbf65c,Supporting & Related Material,FDA-2014-N-0189-83112,FDA-2014-N-0189,"reference 208 the adolescent brain and age related behavioral manifestations re deeming tobacco products to be subject to the federal food, drug, and cosmetic act, as amended by the family smoking prevention and tobacco control act; restrictions on the sale and distribution of tobacco products and required warning statements for tobacco product",1,1
0900006481fbf661,Supporting & Related Material,FDA-2014-N-0189-83117,FDA-2014-N-0189,"reference 213 curbing the epidemic governments and the economics of tobacco control re deeming tobacco products to be subject to the federal food, drug, and cosmetic act, as amended by the family smoking prevention and tobacco control act; restrictions on the sale and distribution of tobacco products and required warning statements for tobacco product",1,1
0900006481fbf666,Supporting & Related Material,FDA-2014-N-0189-83122,FDA-2014-N-0189,"reference 218 tobacco specific nitrosamines re deeming tobacco products to be subject to the federal food, drug, and
cosmetic act, as amended by the family smoking prevention and
tobacco control act; restrictions on the sale and distribution of tobacco
products and required warning statements for tobacco product",1,1
0900006481fbf691,Supporting & Related Material,FDA-2014-N-0189-83127,FDA-2014-N-0189,"reference 224 hookah use among us college students re deeming tobacco products to be subject to the federal food, drug, and
cosmetic act, as amended by the family smoking prevention and
tobacco control act; restrictions on the sale and distribution of tobacco
products and required warning statements for tobacco product",1,1
0900006481fbf693,Supporting & Related Material,FDA-2014-N-0189-83129,FDA-2014-N-0189,"reference 226 waterpipe smoking the role of humectants in the relesase of toxic carbonyls re deeming tobacco products to be subject to the federal food, drug, and cosmetic act, as amended by the family smoking prevention and tobacco control act; restrictions on the sale and distribution of tobacco products and required warning statements for tobacco product",1,1
0900006481fbf695,Supporting & Related Material,FDA-2014-N-0189-83131,FDA-2014-N-0189,"reference 228 change in carbon monoxide exposure among waterpipe bar patrons re deeming tobacco products to be subject to the federal food, drug, and cosmetic act, as amended by the family smoking prevention and tobacco control act; restrictions on the sale and distribution of tobacco products and required warning statements for tobacco product",1,1
0900006481fbf696,Supporting & Related Material,FDA-2014-N-0189-83132,FDA-2014-N-0189,"reference 229 polycyclic aromatic hydrocarbons, carbon monoxide tar and nicotine re deeming tobacco products to be subject to the federal food, drug, and cosmetic act, as amended by the family smoking prevention and tobacco control act; restrictions on the sale and distribution of tobacco products and required warning statements for tobacco product",1,1
0900006481fbf69c,Supporting & Related Material,FDA-2014-N-0189-83138,FDA-2014-N-0189,"reference 235 in vitro cytotoxicity and mutagencity of mainstream waterpipe smoke re deeming tobacco products to be subject to the federal food, drug, and cosmetic act, as amended by the family smoking prevention and tobacco control act; restrictions on the sale and distribution of tobacco products and required warning statements for tobacco product",1,1
0900006481fbf039,Supporting & Related Material,FDA-2014-N-0189-82934,FDA-2014-N-0189,"reference 24 electronic cigarette use among adults re deeming tobacco products to be subject to the food, drug, and cosmetic act, as amended by the family smoking prevention and tobacco control act; regulations on the sale and distribution of tobacco products and required warning statements for tobacco products",1,1
0900006481fbf03a,Supporting & Related Material,FDA-2014-N-0189-82933,FDA-2014-N-0189,"reference 25 prevalence and correlates of waterpipe tobacco smoking by college students in nc re deeming tobacco products to be subject to the food, drug, and cosmetic act, as amended by the family smoking prevention and tobacco control act; regulations on the sale and distribution of tobacco products and required warning statements for tobacco products",1,1
0900006481fbf03f,Supporting & Related Material,FDA-2014-N-0189-82928,FDA-2014-N-0189,"reference 30 growing up tobacco free preventing nicotine addiction re deeming tobacco products to be subject to the food, drug, and cosmetic act, as amended by the family smoking prevention and tobacco control act; regulations on the sale and distribution of tobacco products and required warning statements for tobacco products",1,1
0900006481fbf042,Supporting & Related Material,FDA-2014-N-0189-82925,FDA-2014-N-0189,"reference 33 deposition of cigar smoke particles in the lung re deeming tobacco products to be subject to the food, drug, and cosmetic act, as amended by the family smoking prevention and tobacco control act; regulations on the sale and distribution of tobacco products and required warning statements for tobacco products",1,1
0900006480478037,Other,FDA-1989-P-0124-0001,FDA-1989-P-0124,"sonnenreich & reccograndi, p.c. - citizen petition",0,0
090000648047804b,Other,FDA-1989-P-0124-0007,FDA-1989-P-0124,"sonnenreich & roccograndi, pc to fda/cder february 23, 1993 - letter",0,0
0900006480478047,Other,FDA-1989-P-0124-0005,FDA-1989-P-0124,"fda/cder interim response to sonnenreich & roccograndi, pc",0,0
0900006481119c33,Other,FDA-1989-P-0124-0002,FDA-1989-P-0124,"acknowledgement letter to sonnenreich & roccograndi, pc",0,0
090000648047804d,Other,FDA-1989-P-0124-0008,FDA-1989-P-0124,"sonnenreich & roccograndi, pc to fda/cder march 25 1993 - letter",0,0
0900006481113d00,Other,FDA-1989-P-0124-0011,FDA-1989-P-0124,fda/cder to division of dockets management - memorandum,0,0
09000064811130f8,Other,FDA-1989-P-0124-0010,FDA-1989-P-0124,fda/cder to sonnenreich roccograndi and woo pc - letter,0,0
0900006480478045,Other,FDA-1989-P-0124-0004,FDA-1989-P-0124,fda/cder to health industry manufacturers association (hima) - letter,0,0
0900006480478049,Other,FDA-1989-P-0124-0006,FDA-1989-P-0124,"sonnenreich & roccograndi, pc to fda/cder january 2 1993 - letter",0,0
090000648047804f,Other,FDA-1989-P-0124-0009,FDA-1989-P-0124,"fda/cder to sonnenreich, roccograndi, & woo, pc",0,0
0900006481e6a698,Other,FDA-2015-D-4848-0002,FDA-2015-D-4848,draft guidance for industry and fda staff human factors studies and related clinical study considerations in combination product design and development,0,0
0900006481e49f90,Notice,FDA-2015-D-4848-0001,FDA-2015-D-4848,"human factors studies and related clinical study considerations in
combination product design and development; draft guidance for
industry and food and drug administration staff; availability",1,0
0900006481f93448,Supporting & Related Material,FDA-2014-N-1021-0557,FDA-2014-N-1021,"attachment a-6 janssen g, et al (2015) ineffective degradation of immunogenic gluten epitopes by currently available digestive enzyme supplements. plos one, jun 1;10(6):e0128065. doi: 10.1371 journal.pone.0128065 re: comment from craft brew alliance",0,0
0900006481e13eda,Other,FDA-2014-N-1021-0073,FDA-2014-N-1021,request for extension from beer institute,0,0
0900006481e620b0,Other,FDA-2014-N-1021-0232,FDA-2014-N-1021,request to extend comment period from celiac support association (csa),0,0
0900006481e5d9e4,Other,FDA-2014-N-1021-0231,FDA-2014-N-1021,"request to extend comment period from new belgium brewing company, inc.",0,0
0900006481d38c33,Supporting & Related Material,FDA-2014-N-1021-0003,FDA-2014-N-1021,reference 1.  ciclitira - clinical testing of gliadin re food labeling; gluten-free labeling of fermented or hydrolyzed foods,1,0
0900006481d3929c,Supporting & Related Material,FDA-2014-N-1021-0009,FDA-2014-N-1021,"reference 7.  köhler, et al., immunochemical determination of partially hydrolyzed gluten re food labeling; gluten-free labeling of fermented or hydrolyzed foods",1,0
09000064847f996f,Rule,FDA-2014-N-1021-0560,FDA-2014-N-1021,food labeling; gluten-free labeling of fermented or hydrolyzed foods,1,0
09000064847fe93e,Supporting & Related Material,FDA-2014-N-1021-0564,FDA-2014-N-1021,reference 10 using mass spectrometry to detect hydrolysed gluten in beer that isresponsible for false negatives by elisa re: food labeling; gluten-free labeling of fermented or hydrolyzed foods,1,0
0900006481d38ea2,Supporting & Related Material,FDA-2014-N-1021-0002,FDA-2014-N-1021,references index re food labeling; gluten-free labeling of fermented or hydrolyzed foods,1,0
0900006481d39621,Supporting & Related Material,FDA-2014-N-1021-0010,FDA-2014-N-1021,reference 8.  codex - foods for special dietary use standard 118-1979 re food labeling; gluten-free labeling of fermented or hydrolyzed foods,1,0
0900006481d39623,Supporting & Related Material,FDA-2014-N-1021-0011,FDA-2014-N-1021,reference 9.  garber - elisa methods used to detect gluten in foods re food labeling; gluten-free labeling of fermented or hydrolyzed foods,1,0
0900006481d39704,Supporting & Related Material,FDA-2014-N-1021-0014,FDA-2014-N-1021,reference 12. fellows - chapter 14- evaporation and distillation in food processing and technology re food labeling; gluten-free labeling of fermented or hydrolyzed foods,1,0
0900006481d3979b,Supporting & Related Material,FDA-2014-N-1021-0018,FDA-2014-N-1021,reference 16. fda - pria of gluten-free labeling of fermented or hydrolyzed foods re food labeling; gluten-free labeling of fermented or hydrolyzed foods,1,0
0900006481d38c93,Supporting & Related Material,FDA-2014-N-1021-0005,FDA-2014-N-1021,reference 3.  food essentials - product label database re food labeling; gluten-free labeling of fermented or hydrolyzed foods,1,0
0900006481d3956a,Supporting & Related Material,FDA-2014-N-1021-0006,FDA-2014-N-1021,reference 4.  belitz - enzyme immunoassay in food chemistry re food labeling; gluten-free labeling of fermented or hydrolyzed foods,1,0
0900006481d3956d,Supporting & Related Material,FDA-2014-N-1021-0007,FDA-2014-N-1021,reference 5.  ciccocioppo - immune recognition of gluten in coeliac disease re food labeling; gluten-free labeling of fermented or hydrolyzed foods,1,0
090000648485d18e,Supporting & Related Material,FDA-2014-N-1021-0575,FDA-2014-N-1021,fda tab b - gluten f-h - ria (omb redline compare 2-7-20 to 7-16-20) re fda - gluten f-h memo to dms,0,0
090000648485d18d,Supporting & Related Material,FDA-2014-N-1021-0574,FDA-2014-N-1021,fda tab b - gluten f-h - final rule (omb redline compare 2-7-20 to 7-16-20) re fda - gluten f-h memo to dms,0,0
09000064847fe8e7,Supporting & Related Material,FDA-2014-N-1021-0568,FDA-2014-N-1021,reference 16 2010 nationwide survey of food industry safety practices re: food labeling; gluten-free labeling of fermented or hydrolyzed foods,1,0
0900006481f93339,Supporting & Related Material,FDA-2014-N-1021-0556,FDA-2014-N-1021,exhibit 1 sample omission labeling re: comment from craft brew alliance,0,0
0900006481e6bc04,Other,FDA-2014-N-1021-0254,FDA-2014-N-1021,request for extension from charles bamforth,0,0
0900006481e2e464,Other,FDA-2014-N-1021-0149,FDA-2014-N-1021,request for extension from brewers association,0,0
09000064847fe93d,Supporting & Related Material,FDA-2014-N-1021-0563,FDA-2014-N-1021,"reference 9 effects of a proline endopeptidase on the detection and
quantitation of gluten by antibody-based methods during the
fermentation of a model sorghum beer re: food labeling; gluten-free labeling of fermented or hydrolyzed foods",1,0
09000064847fea2f,Supporting & Related Material,FDA-2014-N-1021-0566,FDA-2014-N-1021,reference 12 improving wheat to remove coeliac epitopes but retain functionality re: food labeling; gluten-free labeling of fermented or hydrolyzed foods,1,0
090000648485d18c,Supporting & Related Material,FDA-2014-N-1021-0573,FDA-2014-N-1021,fda tab a - gluten f-h - ria (2-7-20 to omb) re fda - gluten f-h memo to dms,0,0
090000648111a7db,Other,FDA-1995-P-0043-0006,FDA-1995-P-0043,fda/cder to division of dockets management - memorandum,0,0
0900006480561371,Other,FDA-1995-P-0043-0004,FDA-1995-P-0043,"fda/cder to sonnenreich roccograndi & woo p.c., october 5, 1995 - letter",0,0
090000648056133f,Other,FDA-1995-P-0043-0001,FDA-1995-P-0043,"acknowledgement letter to sonnenreich, roccograndi & woo",0,0
090000648111a7d9,Other,FDA-1995-P-0043-0005,FDA-1995-P-0043,fda/cder to sonnenreich roccograndi and woo pc - letter re fda-1995-p-0043-0002,0,0
0900006480561361,Other,FDA-1995-P-0043-0002,FDA-1995-P-0043,"sonnenreich, roccograndi & woo, p.c. - citizen petition",0,0
090000648056136f,Other,FDA-1995-P-0043-0003,FDA-1995-P-0043,"fda/cder to sonnenreich roccograndi & woo p.c., june 21, 1995 - letter",0,0
09000064813823a9,Proposed Rule,FDA-2011-N-0146-0024,FDA-2011-N-0146,accreditation of third-party auditors/certification bodies to conduct food safety audits and to issue certifications,1,0
090000648152c733,Other,FDA-2011-N-0146-0112,FDA-2011-N-0146,record of outreach sessions from fda/cfsan,0,0
090000648152c5de,Other,FDA-2011-N-0146-0104,FDA-2011-N-0146,record of outreach sessions from fda/cfsan,0,0
09000064824074c7,Rule,FDA-2011-N-0146-0241,FDA-2011-N-0146,amendments to accreditation of third-party certification bodies to conduct food safety audits and to issue certifications to provide for user fee program,1,0
0900006481453f5b,Other,FDA-2011-N-0146-0038,FDA-2011-N-0146,"omb review of proposed rule re executive order 12866 accreditation of third-party auditors/certification bodies to conduct food safety audits and to issue certifications (proposed rule); july 29, 2013 - memorandum",1,0
0900006482408b4f,Supporting & Related Material,FDA-2011-N-0146-0242,FDA-2011-N-0146,list of references re amendments to accreditation of third-party certification bodies to conduct food safety audits and to issue certifications to provide for user fee program,1,0
0900006482408b52,Supporting & Related Material,FDA-2011-N-0146-0245,FDA-2011-N-0146,reference 03 regulatory impact analysis for third-party final rule re amendments to accreditation of third-party certification bodies to conduct food safety audits and to issue certifications to provide for user fee program,1,0
0900006481d5be76,Supporting & Related Material,FDA-2011-N-0146-0204,FDA-2011-N-0146,"reference 8: international organization for standardization, iso 19011:2011 guidelines for auditing management systems,” re accreditation of third-party certification bodies to conduct food safety audits and to issue certifications",1,0
0900006481d5be77,Supporting & Related Material,FDA-2011-N-0146-0205,FDA-2011-N-0146,"reference 10: international organization for standardization/international electrotechnical commission, “iso/iec 17020:2012 conformity assessment--requirements for the operation of various types of bodies performing inspection,” re accreditation of third-party certification bodies to conduct food safety audits and to issue certifications",1,0
0900006481d5bf1a,Supporting & Related Material,FDA-2011-N-0146-0206,FDA-2011-N-0146,"reference 11: global food safety initiative, “enhancing food safety through third-party certification,” march 2011 re accreditation of third-party certification bodies to conduct food safety audits and to issue certifications",1,0
0900006481d5bf1c,Supporting & Related Material,FDA-2011-N-0146-0208,FDA-2011-N-0146,"reference 13: international accreditation forum, “iaf endorsed normative documents, issue 4 (iaf pr 4:2007),” re accreditation of third-party certification bodies to conduct food safety audits and to issue certifications",1,0
0900006481d5bf1d,Supporting & Related Material,FDA-2011-N-0146-0209,FDA-2011-N-0146,"reference 14: codex alimentarius commission, “principles for food import and export inspection and certification (cac/gl 20-1995)” re accreditation of third-party certification bodies to conduct food safety audits and to issue certifications",1,0
0900006481b9da54,Notice,FDA-2011-N-0146-0179,FDA-2011-N-0146,third-party auditor/certification body accreditation for food safety audits: model accreditation standards; draft guidance for industry and food and drug administration staff; availability,1,0
0900006481ba7aa4,Supporting & Related Material,FDA-2011-N-0146-0182,FDA-2011-N-0146,list of references re user fee program to provide for accreditation of third-party auditors/certification bodies to conduct food safety audits and to issue certifications,1,0
0900006481ba7aa6,Supporting & Related Material,FDA-2011-N-0146-0184,FDA-2011-N-0146,reference 2  mduf small business guidance re user fee program to provide for accreditation of third-party auditors/certification bodies to conduct food safety audits and to issue certifications,1,0
0900006481ba7aa7,Supporting & Related Material,FDA-2011-N-0146-0185,FDA-2011-N-0146,reference 3 user fee waivers guidance re user fee program to provide for accreditation of third-party auditors/certification bodies to conduct food safety audits and to issue certifications,1,0
09000064823e6ef0,Notice,FDA-2011-N-0146-0239,FDA-2011-N-0146,third-party certification body accreditation for food safety audits:  model accreditation standards; guidance for industry and food and drug administration staff; availability,1,0
0900006481d76139,Rule,FDA-2011-N-0146-0198,FDA-2011-N-0146,accreditation of third-party certification bodies to conduct food safety audits and to issue certifications,1,0
090000648152db2a,Other,FDA-2011-N-0146-0173,FDA-2011-N-0146,transcript from fda/cfsan,0,0
090000648152c676,Other,FDA-2011-N-0146-0106,FDA-2011-N-0146,record of outreach sessions from fda/cfsan,0,0
090000648152cc1f,Other,FDA-2011-N-0146-0132,FDA-2011-N-0146,record of outreach sessions from fda/cfsan,0,0
0900006482408b50,Supporting & Related Material,FDA-2011-N-0146-0243,FDA-2011-N-0146,reference 01 iso iec 17011-2004_copyright re amendments to accreditation of third-party certification bodies to conduct food safety audits and to issue certifications to provide for user fee program,1,0
0900006482408b51,Supporting & Related Material,FDA-2011-N-0146-0244,FDA-2011-N-0146,reference 02 preliminary regulatory impact analysis for third-party proposed rule re amendments to accreditation of third-party certification bodies to conduct food safety audits and to issue certifications to provide for user fee program,1,0
0900006481b9dfd9,Other,FDA-2011-N-0146-0180,FDA-2011-N-0146,third-party auditor/certification body accreditation for food safety audits: model accreditation standards; draft guidance for industry and food and drug administration staff,1,0
090000648148bc0e,Proposed Rule,FDA-2011-N-0146-0039,FDA-2011-N-0146,accreditation of third-party auditors/certification bodies to conduct food safety audits and to issue certifications; extension of comment periods,1,0
0900006480c08cba,Notice,FDA-2010-N-0122-0003,FDA-2010-N-0122,"agency information collection activities; proposals, submissions, and approvals: focus groups about drug products as used by the food and drug administration",1,0
0900006480ac4803,Notice,FDA-2010-N-0122-0001,FDA-2010-N-0122,"agency information collection activities; proposals, submissions, and approvals: focus groups about drug products, as used by the food and drug administration",1,0
0900006480b15f89,Notice,FDA-2010-N-0122-0002,FDA-2010-N-0122,"agency information collection activities; proposals, submissions, and approvals: focus groups about drug products, as used by the food and drug administration",1,0
09000064824a31a6,Supporting & Related Material,FDA-2013-P-0735-0012,FDA-2013-P-0735,06 reference 4-fed register pdufa patient-focused drug development - request for comments,0,0
090000648132d33d,Other,FDA-2013-P-0735-0001,FDA-2013-P-0735,acknowledgement letter to mario morais,0,0
0900006481832502,Other,FDA-2013-P-0735-0003,FDA-2013-P-0735,petition response from fda/cdrh to mario morais,0,0
090000648132d1e2,Other,FDA-2013-P-0735-0002,FDA-2013-P-0735,citizen petition from mario morais,0,0
090000648187a97b,Other,FDA-2013-P-0735-0004,FDA-2013-P-0735,appeal from mario morais,0,0
09000064824a31a1,Supporting & Related Material,FDA-2013-P-0735-0008,FDA-2013-P-0735,01 reference  1-safety communications _ chronic cerebrospinal venous insufficiency treatment in multiple sclerosis patients_ fda safety communication - copy,0,0
09000064824a31a2,Supporting & Related Material,FDA-2013-P-0735-0009,FDA-2013-P-0735,02 guidance for industry 1-expanded access to investigational drugs for treatment use — questions and answers - copy,0,0
09000064824a31a0,Supporting & Related Material,FDA-2013-P-0735-0007,FDA-2013-P-0735,reference list for 0735,0,0
09000064824a25ed,Other,FDA-2013-P-0735-0006,FDA-2013-P-0735,fda response to joint appeal in fda-2012-p-0119 and fda-2013-p-0735,0,0
090000648187a97d,Other,FDA-2013-P-0735-0005,FDA-2013-P-0735,redacted appeal from mario morais,0,0
090000648250c0fb,Other,FDA-2013-P-0735-0016,FDA-2013-P-0735,mario morais email march 15 2017,0,0
09000064824a31a3,Supporting & Related Material,FDA-2013-P-0735-0010,FDA-2013-P-0735,03 guidance for industry 2-individual patient expanded access applications_ form fda 3926 - copy,0,0
09000064824a31a5,Supporting & Related Material,FDA-2013-P-0735-0013,FDA-2013-P-0735,05 reference 3-pdufa _ enhancing benefit-risk assessment in regulatory decision-making - copy,0,0
09000064824a31a7,Supporting & Related Material,FDA-2013-P-0735-0011,FDA-2013-P-0735,07 reference 5-prescription drug user fee act (pdufa) _ patient-focused drug development_ disease area meetings planned for fiscal years 2013-2017 - copy,0,0
09000064824a31a8,Supporting & Related Material,FDA-2013-P-0735-0015,FDA-2013-P-0735,08 reference 6-pdufa reauthorization performance goals and procedures fy18-22,0,0
09000064824a31a4,Supporting & Related Material,FDA-2013-P-0735-0014,FDA-2013-P-0735,04 - reference 2-pdufa _ the voice of the patient_ a series of reports from fda's patient-focused drug development initiative - copy,0,0
0900006481856a04,Other,FDA-2014-P-0748-0006,FDA-2014-P-0748,citizen petition approval letter from fda/cvm to piedmont animal health,0,0
09000064817282ac,Supporting & Related Material,FDA-2014-P-0748-0004,FDA-2014-P-0748,reference 1 proposed revised labeling citizen petition from piedmont animal health,0,0
0900006481728104,Other,FDA-2014-P-0748-0001,FDA-2014-P-0748,citizen petition from piedmont animal health,0,0
0900006481728108,Other,FDA-2014-P-0748-0002,FDA-2014-P-0748,acknowledgement letter from fda ddm to piedmont animal health,0,0
090000648174dd39,Other,FDA-2014-P-0748-0005,FDA-2014-P-0748,amendment from piedmont animal health,0,0
09000064817282ab,Supporting & Related Material,FDA-2014-P-0748-0003,FDA-2014-P-0748,reference 1 current labeling citizen petition from piedmont animal health,0,0
0900006480475d50,Notice,FDA-1988-N-0019-0001,FDA-1988-N-0019,fda,0,0
0900006481527db3,Proposed Rule,FDA-1988-N-0019-0028,FDA-1988-N-0019,semiannual regulatory agenda,0,0
09000064807410a4,Notice,FDA-2005-N-0345-0002,FDA-2005-N-0345,"distribution of certain drug products by registered blood establishments and comprehensive hemophilia diagnostic treatment centers that qualify as health care entities; prescription drug marketing act of 1987; prescription drug amendments of 1992; policies, requirements and administrative procedures",0,0
0900006481527db7,Proposed Rule,FDA-2005-N-0345-0006,FDA-2005-N-0345,semiannual regulatory agenda,0,0
0900006480449864,Proposed Rule,FDA-2005-N-0345-0001,FDA-2005-N-0345,"distribution of blood derivatives by registered blood establishments that qualify as health care entities; prescription drug marketing act of 1987; prescription drug amendments of 1992; policies, requirements and administrative procedures; proposed rule",0,0
0900006481527db8,Proposed Rule,FDA-1992-N-0407-0001,FDA-1992-N-0407,semiannual regulatory agenda,0,0
0900006481f94d20,Rule,FDA-2011-N-0143-0388,FDA-2011-N-0143,foreign supplier verification programs for importers of food for humans and animals; technical amendment,1,0
0900006481d7fc9e,Supporting & Related Material,FDA-2011-N-0143-0373,FDA-2011-N-0143,reference 5 - model for local federal_state planning and coordination of field operations and training re foreign supplier verification programs for importers of food for humans and animals,1,0
0900006481d7fca1,Supporting & Related Material,FDA-2011-N-0143-0374,FDA-2011-N-0143,reference 6 - guidelines for food import control systems re foreign supplier verification programs for importers of food for humans and animals,1,0
0900006481d7fced,Supporting & Related Material,FDA-2011-N-0143-0375,FDA-2011-N-0143,reference 7 - haccp system and guidelines for its application re foreign supplier verification programs for importers of food for humans and animals,1,0
0900006481d7fec8,Supporting & Related Material,FDA-2011-N-0143-0377,FDA-2011-N-0143,reference 9 - general standard for the labelling of prepackaged food re foreign supplier verification programs for importers of food for humans and animals,1,0
0900006481d7ff97,Supporting & Related Material,FDA-2011-N-0143-0383,FDA-2011-N-0143,reference 16 - information for foreign governments  frequently asked questions on systems recognition re foreign supplier verification programs for importers of food for humans and animals,1,0
0900006481d7ff9c,Supporting & Related Material,FDA-2011-N-0143-0385,FDA-2011-N-0143,reference 18 - wto ministerial conference implementaion-related issues and concerns re foreign supplier verification programs for importers of food for humans and animals,1,0
0900006481d801a1,Supporting & Related Material,FDA-2011-N-0143-0381,FDA-2011-N-0143,reference 14 - reportable food registry guidance for industry re foreign supplier verification programs for importers of food for humans and animals,1,0
090000648152dbed,Other,FDA-2011-N-0143-0240,FDA-2011-N-0143,record of outreach session from fda/cfsan,0,0
0900006481525692,Supporting & Related Material,FDA-2011-N-0143-0255,FDA-2011-N-0143,record of outreach sessions on fda proposed rules ift members webinar august 14 2013 re form fda 3876,0,0
090000648152daa4,Other,FDA-2011-N-0143-0234,FDA-2011-N-0143,record of outreach session from fda/cfsan,0,0
0900006482e6458d,Proposed Rule,FDA-2011-N-0143-0400,FDA-2011-N-0143,"foreign supplier verification programs for importers of food for humans and animals: what you need to know about the food and drug
administration regulation; small entity compliance guide; availability",1,0
09000064814411b7,Other,FDA-2011-N-0143-0036,FDA-2011-N-0143,"omb review of proposed rule re executive order 12866, foreign supplier verification programs for importers of food for humans and animals, july 29, 2013 - memorandum",1,0
09000064818cdcbc,Supporting & Related Material,FDA-2011-N-0143-0253,FDA-2011-N-0143,"tab c final regulatory action as cleared by omb  (suppl nprm) omb executive order 12866 regulatory planning and review re foreign supplier verification programs for importers of food for humans and animals (supplemental proposed rule); publication date: september 29, 2014 see fda-2011-n-0143-0248",1,0
09000064818cdcbd,Supporting & Related Material,FDA-2011-N-0143-0254,FDA-2011-N-0143,"tab c finall regulatoy action as cleared by omb  (suppl pria) omb executive order 12866 regulatory planning and review re foreign supplier verification programs for importers of food for humans and animals (supplemental proposed rule); publication date: september 29, 2014 see fda-2011-n-0143-0248",1,0
090000648143cc64,Other,FDA-2011-N-0143-0029,FDA-2011-N-0143,testimony from pew charitable trusts,0,0
0900006482550a24,Supporting & Related Material,FDA-2011-N-0143-0391,FDA-2011-N-0143,list of references re the food and drug administration food safety modernization act; extension and clarification of compliance dates for certain provisions of four implementing rules,1,0
0900006482550a25,Supporting & Related Material,FDA-2011-N-0143-0392,FDA-2011-N-0143,reference 1 gma industry impacts from disclosure and written assurance requirements re the food and drug administration food safety modernization act; extension and clarification of compliance dates for certain provisions of four implementing rules,1,0
0900006482550a26,Supporting & Related Material,FDA-2011-N-0143-0393,FDA-2011-N-0143,reference 2 united fresh produce association letter april 19 2016 re the food and drug administration food safety modernization act; extension and clarification of compliance dates for certain provisions of four implementing rules,1,0
0900006482550a29,Supporting & Related Material,FDA-2011-N-0143-0396,FDA-2011-N-0143,reference 5 part 117 fsma final rulemaking for cgmp and hapc for human food ria re the food and drug administration food safety modernization act; extension and clarification of compliance dates for certain provisions of four implementing rules,1,0
09000064814a2afc,Other,FDA-2011-N-0143-0244,FDA-2011-N-0143,transcript from fda food safety  modernization act imports rules  september 19 2013 day one,1,0
09000064818f824b,Proposed Rule,FDA-2011-N-0143-0259,FDA-2011-N-0143,food and drug administration food safety modernization act: meetings on rule revisions,1,0
0900006481898ff6,Proposed Rule,FDA-2011-N-0143-0247,FDA-2011-N-0143,foreign supplier verification programs for importers of food for humans and animals,1,0
0900006483007e46,Other,FDA-2011-N-0143-0402,FDA-2011-N-0143,"compliance with providing an acceptable unique facility identifier for
the foreign supplier verification programs regulation: guidance for
industry",0,0
090000648188d030,Other,FDA-2011-N-0143-0246,FDA-2011-N-0143,"comparison redlined version of the codified sections published on july 29, 2013 and september 29, 2014",0,0
09000064807072de,Other,FDA-2008-P-0511-0001,FDA-2008-P-0511,"citizen petition from claxton bakery et al (bell, boyd & lloyd llp)",0,0
090000648070735f,Other,FDA-2008-P-0511-0002,FDA-2008-P-0511,"acknowledgment letter from fda ddm to bell, boyd & lloyd llp",0,0
0900006482e1fcb2,Other,FDA-2008-P-0511-0003,FDA-2008-P-0511,"letter from fda csfan to k&l gates (formerly bell, boyd & lloyd llp)",0,0
0900006480c0eca4,Proposed Rule,FDA-2011-N-0029-0001,FDA-2011-N-0029,medical devices ovarian adnexal mass assessment score test system; labeling; black box restrictions,0,0
09000064811626df,Supporting & Related Material,FDA-2011-N-0090-0218,FDA-2011-N-0090,gs1 us - comment,0,0
09000064811626e2,Supporting & Related Material,FDA-2011-N-0090-0219,FDA-2011-N-0090,gs1 us - comment,0,0
0900006481082634,Proposed Rule,FDA-2011-N-0090-0001,FDA-2011-N-0090,unique device identification system,0,0
090000648115ee5a,Other,FDA-2011-N-0090-0107,FDA-2011-N-0090,gs1® and the gs1 us™ - supplement re fda-2011-n-0090-0080,0,0
09000064811df0d0,Supporting & Related Material,FDA-2011-N-0090-0273,FDA-2011-N-0090,alphatec spine - supplement,0,0
09000064811196ad,Proposed Rule,FDA-2011-N-0090-0019,FDA-2011-N-0090,agency information collection activities; proposed collection; unique device identification system; extension of comment period,0,0
09000064811626e4,Supporting & Related Material,FDA-2011-N-0090-0220,FDA-2011-N-0090,gs1 us - comment,0,0
0900006481ea0935,Rule,FDA-2011-N-0090-0276,FDA-2011-N-0090,unique device identification system; editorial provisions; technical  amendment,0,0
09000064814340dc,Rule,FDA-2011-N-0090-0274,FDA-2011-N-0090,unique device identification system,0,0
09000064810871a6,Other,FDA-2011-N-0090-0022,FDA-2011-N-0090,national council for prescription drug programs (ncpdp) to fda\cdrh -  letter,0,0
090000648108723e,Other,FDA-2011-N-0090-0023,FDA-2011-N-0090,advancing patient safety coalition to office of management and budget  -  letter,0,0
090000648145cdfb,Other,FDA-2011-N-0090-0275,FDA-2011-N-0090,fda/oc to dockets management - memorandum,0,0
090000648116ca95,Proposed Rule,FDA-2011-N-0090-0222,FDA-2011-N-0090,unique device identification system; amendment,0,0
09000064810a3278,Other,FDA-2011-N-0090-0002,FDA-2011-N-0090,"unique device identification system - omb review, executive order 12866  july 10,2012 - reference",0,0
090000648186845f,Notice,FDA-2014-D-1182-0001,FDA-2014-D-1182,"unique device identification system: small entity compliance guide;
guidance for industry; availability",0,0
090000648186916c,Other,FDA-2014-D-1182-0002,FDA-2014-D-1182,small entity compliance guide: unique device identification system; availability,0,0
0900006481babb41,Other,FDA-2015-N-2713-0001,FDA-2015-N-2713,dear applicant letter from fda center for drug evaluation and research re cyclosporine ophthalmic emulsion anda applicant,0,0
0900006481854cf7,Other,FDA-2014-P-0404-0004,FDA-2014-P-0404,"response from fda/cder partial approval and denial letter to teva pharmaceutical industries, ltd (teva respiratory, llc)",0,0
09000064816a1ee3,Other,FDA-2014-P-0404-0002,FDA-2014-P-0404,acknowledgement letter from fda/ddm to teva pharmaceutical industries ltd (teva respiratory llc),0,0
090000648169f67b,Other,FDA-2014-P-0404-0001,FDA-2014-P-0404,"citizen petition from teva pharmaceutical industries, ltd (teva respiratory, llc)",0,0
090000648171fbc5,Supporting & Related Material,FDA-2013-N-0500-0078,FDA-2013-N-0500,"attachment 3 revised virilon package insert with changes highlighted supplement from star pharmaceuticals, inc.",0,0
090000648171fd33,Other,FDA-2013-N-0500-0075,FDA-2013-N-0500,"supplement from star pharmaceuticals, inc.",0,0
09000064839949a4,Supporting & Related Material,FDA-2013-N-0500-0143,FDA-2013-N-0500,"03- reference 02- u.s. department of health and human services, food and drug administration, “fiscal year 2019 justification of estimates for appropriations committees",1,0
09000064814bc8a9,Other,FDA-2013-N-0500-0005,FDA-2013-N-0500,"omb review proposed rule re executive order 12866, supplemental applications proposing labeling changes for approved drugs and biological products 11-13-2013 - memorandum",0,0
09000064814c6d0a,Other,FDA-2013-N-0500-0010,FDA-2013-N-0500,request for extension from biotechnology industry organization (bio) and pharmaceutical research and manufacturers of america (phrma),0,0
09000064814c5e12,Other,FDA-2013-N-0500-0009,FDA-2013-N-0500,request for extension from mylan,0,0
0900006481ab9bdf,Other,FDA-2013-N-0500-0111,FDA-2013-N-0500,agenda for march 27 2015 supplemental applications proposing labeling changes for approved drugs and biological products public meeting,0,0
0900006481a078f5,Proposed Rule,FDA-2013-N-0500-0081,FDA-2013-N-0500,"supplemental applications proposing labeling changes for approved drugs and biological products; public meeting; request for comments;
reopening of the comment period",0,0
0900006481a0854b,Supporting & Related Material,FDA-2013-N-0500-0082,FDA-2013-N-0500,"reference 1 - joint gpha phrma letter to dr hamburg re supplemental applications proposing labeling changes for approved drugs and biological products; public meeting; request for comments;
reopening of the comment period",0,0
0900006481f8f7d2,Supporting & Related Material,FDA-2013-N-0500-0139,FDA-2013-N-0500,"attachment 1 record of comments from march 13, 2014 re: supplemental comment from washington legal foundation",0,0
090000648149a218,Other,FDA-2013-N-0500-0004,FDA-2013-N-0500,generic pharmaceutical association (gpha) - request for extension of comment period,0,0
09000064814c4f5c,Other,FDA-2013-N-0500-0008,FDA-2013-N-0500,request for extension from academy of managed care pharmacy (amcp) et al,0,0
09000064814ca396,Other,FDA-2013-N-0500-0011,FDA-2013-N-0500,request for extension from perrigo,0,0
090000648147a982,Proposed Rule,FDA-2013-N-0500-0001,FDA-2013-N-0500,supplemental applications proposing labeling changes for approved drugs and biological products,0,0
090000648171fbc4,Supporting & Related Material,FDA-2013-N-0500-0077,FDA-2013-N-0500,"attachment 2 revised virilon package insert re supplement from star pharmaceuticals, inc.",0,0
090000648171fad3,Supporting & Related Material,FDA-2013-N-0500-0076,FDA-2013-N-0500,"attachment 1 virilon drug listing re supplement from star pharmaceuticals, inc.",0,0
09000064839949a2,Supporting & Related Material,FDA-2013-N-0500-0141,FDA-2013-N-0500,01-list of references withdrawal of proposed rule on supplemental applications proposing labeling changes for approved drugs and biological products,0,0
090000648148e9e1,Other,FDA-2013-N-0500-0002,FDA-2013-N-0500,"omb review proposed rule re executive order 12866, supplemental applications proposing labeling changes for approved drugs and biological products 11-13-2013 - memorandum",0,0
0900006481a8b7a5,Supporting & Related Material,FDA-2013-N-0500-0105,FDA-2013-N-0500,"briefs submitted in teva pharmaceuticals usa, inc. v. superior court of orange county",0,0
0900006481aba131,Other,FDA-2013-N-0500-0112,FDA-2013-N-0500,transcript of march 27 2015 supplemental applications proposing labeling changes for approved drugs and biological products public meeting,0,0
0900006481abfea0,Other,FDA-2013-N-0500-0136,FDA-2013-N-0500,slide presentations from the march 27 2015 supplemental applications proposing labeling changes for approved drugs and biological products public meeting redacted,0,0
09000064814debad,Proposed Rule,FDA-2013-N-0500-0006,FDA-2013-N-0500,supplemental applications proposing labeling changes for approved drugs and biological products; correction and extension of comment period,0,0
09000064839936bc,Proposed Rule,FDA-2013-N-0500-0140,FDA-2013-N-0500,"withdrawal of proposed rule on supplemental applications proposing
labeling changes for approved drugs and biological products",0,0
09000064839949a3,Supporting & Related Material,FDA-2013-N-0500-0142,FDA-2013-N-0500,"02- reference 01- draft guidance for industry, “updating anda labeling after the marketing application for the reference listed drug has been withdrawn,”",0,0
09000064814b4789,Other,FDA-2013-N-0500-0007,FDA-2013-N-0500,request for extension from perrigo,0,0
0900006481ecead0,Supporting & Related Material,FDA-2004-N-0188-0067,FDA-2004-N-0188,reference 1 bse - a decade on - part i re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecec4b,Supporting & Related Material,FDA-2004-N-0188-0079,FDA-2004-N-0188,reference 15 article 11.4.14 bovine spongiform encephalopathy re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecec59,Supporting & Related Material,FDA-2004-N-0188-0090,FDA-2004-N-0188,"reference 23 bse infectivity in jejunum, ileum and ileocaecal junction of incubating cattle re use of materials derived from cattle in human food and cosmetics",1,0
09000064804708da,Supporting & Related Material,FDA-2004-N-0188-0032,FDA-2004-N-0188,see fda-2004-n-0188-0050,0,0
09000064804702ff,Other,FDA-2004-N-0188-0004,FDA-2004-N-0188,bse stakeholders conference calls,0,0
0900006480a4c757,Supporting & Related Material,FDA-2004-N-0188-0050,FDA-2004-N-0188,fda/regulations policy and management staff (rpms) to the division of dockets management - e.o. 12866 review - [use of materials derived from cattle in human food and cosmetics - interim final rules and request for comments ] - reference 2 [see fda-2004-n-0188-0023],1,0
0900006481ecef4b,Supporting & Related Material,FDA-2004-N-0188-0073,FDA-2004-N-0188,reference 7 article 11.4.1 bovine spongiform encephalopathy re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecead3,Supporting & Related Material,FDA-2004-N-0188-0070,FDA-2004-N-0188,reference 4 confirmed variant creutzfeldt-jakob disease (variant cjd) case in texas re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecec4c,Supporting & Related Material,FDA-2004-N-0188-0083,FDA-2004-N-0188,reference 16 bse ongoing surveillance plan final 71406 re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecec52,Supporting & Related Material,FDA-2004-N-0188-0088,FDA-2004-N-0188,reference 21 prevalence bse (bovine spongiform encephalopathy) re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecec5a,Supporting & Related Material,FDA-2004-N-0188-0091,FDA-2004-N-0188,reference 24 detection of disease-specific prp in the distal ileum of cattle exposed orally to the agent of bovine spongiform encephalopathy re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecec5e,Supporting & Related Material,FDA-2004-N-0188-0099,FDA-2004-N-0188,reference 28 vcjd surveillance data - cjd international surveillance network re use of materials derived from cattle in human food and cosmetics,1,0
09000064804708d9,Supporting & Related Material,FDA-2004-N-0188-0031,FDA-2004-N-0188,see fda-2004-n-0188-0050,0,0
0900006481ecef4c,Supporting & Related Material,FDA-2004-N-0188-0074,FDA-2004-N-0188,reference 8 inactivation of the bse agent by the heat and pressure process for manufacturing gelatine re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecef4e,Supporting & Related Material,FDA-2004-N-0188-0076,FDA-2004-N-0188,reference 9 article 11.4.15 bovine spongiform encephalopathy re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecef49,Supporting & Related Material,FDA-2004-N-0188-0071,FDA-2004-N-0188,reference 5 variant cjd cases worldwide re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecef4a,Supporting & Related Material,FDA-2004-N-0188-0072,FDA-2004-N-0188,reference 6 recognition of bse risk status of member countries -d12483 re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecead2,Supporting & Related Material,FDA-2004-N-0188-0069,FDA-2004-N-0188,reference 3 a novel progressive spongiform encephalopathy in cattle re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecec5b,Supporting & Related Material,FDA-2004-N-0188-0092,FDA-2004-N-0188,reference 25 scientific opinion on bse risk in bovine intestines and mesentery efsa panel on biological hazards (biohaz) re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecec5f,Supporting & Related Material,FDA-2004-N-0188-0095,FDA-2004-N-0188,reference 29 vcjd key facts re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecec61,Supporting & Related Material,FDA-2004-N-0188-0097,FDA-2004-N-0188,reference 31 report of the oie scientific commission for animal diseases re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ece21a,Rule,FDA-2004-N-0188-0065,FDA-2004-N-0188,use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecec4a,Supporting & Related Material,FDA-2004-N-0188-0078,FDA-2004-N-0188,reference 14 long-term subclinical carrier state precedes scrapie replication and adaptation in a resistant species: analogies to bovine spongiform encephalopathy and variant creutzfeldt-jakob disease in humans re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecec5c,Supporting & Related Material,FDA-2004-N-0188-0093,FDA-2004-N-0188,reference 26 gmia gelatin handbook 2012 re use of materials derived from cattle in human food and cosmetics,1,0
0900006481ecef50,Supporting & Related Material,FDA-2004-N-0188-0080,FDA-2004-N-0188,referemce 11 the sourcing and processing of gelatin to reduce the potential risk posed by bovine spongiform encephalopathy (bse) in fda-regulated products for human use re use of materials derived from cattle in human food and cosmetics,1,0
09000064804843c8,Supporting & Related Material,FDA-2003-N-0103-0017,FDA-2003-N-0103,background,0,0
09000064804843c5,Supporting & Related Material,FDA-2003-N-0103-0014,FDA-2003-N-0103,background,0,0
09000064804843c4,Supporting & Related Material,FDA-2003-N-0103-0013,FDA-2003-N-0103,background,0,0
09000064804843c2,Supporting & Related Material,FDA-2003-N-0103-0011,FDA-2003-N-0103,guidance,0,0
09000064804843d1,Supporting & Related Material,FDA-2003-N-0103-0026,FDA-2003-N-0103,background,0,0
09000064804843cc,Supporting & Related Material,FDA-2003-N-0103-0021,FDA-2003-N-0103,background,0,0
09000064804843cb,Supporting & Related Material,FDA-2003-N-0103-0020,FDA-2003-N-0103,background,0,0
09000064804843e6,Supporting & Related Material,FDA-2003-N-0103-0035,FDA-2003-N-0103,background,0,0
0900006480484409,Supporting & Related Material,FDA-2003-N-0103-0048,FDA-2003-N-0103,background,0,0
0900006480484406,Supporting & Related Material,FDA-2003-N-0103-0047,FDA-2003-N-0103,background,0,0
09000064804843f5,Supporting & Related Material,FDA-2003-N-0103-0041,FDA-2003-N-0103,background,0,0
0900006480484436,Other,FDA-2003-N-0103-0059,FDA-2003-N-0103,task force final report july 2003,0,0
0900006480484430,Other,FDA-2003-N-0103-0057,FDA-2003-N-0103,task force final report july 2003,0,0
0900006480484424,Other,FDA-2003-N-0103-0054,FDA-2003-N-0103,task force final report july 2003,0,0
0900006480484428,Other,FDA-2003-N-0103-0055,FDA-2003-N-0103,task force final report july 2003,0,0
09000064804843e9,Supporting & Related Material,FDA-2003-N-0103-0036,FDA-2003-N-0103,background,0,0
09000064804843c3,Notice,FDA-2003-N-0103-0012,FDA-2003-N-0103,number not used,0,0
09000064804843b8,Supporting & Related Material,FDA-2003-N-0103-0007,FDA-2003-N-0103,guidance,0,0
09000064804843c6,Supporting & Related Material,FDA-2003-N-0103-0015,FDA-2003-N-0103,background,0,0
09000064804843c9,Supporting & Related Material,FDA-2003-N-0103-0018,FDA-2003-N-0103,background,0,0
09000064804843bf,Supporting & Related Material,FDA-2003-N-0103-0009,FDA-2003-N-0103,guidance,0,0
09000064804843bb,Supporting & Related Material,FDA-2003-N-0103-0008,FDA-2003-N-0103,guidance,0,0
09000064804843d0,Supporting & Related Material,FDA-2003-N-0103-0025,FDA-2003-N-0103,background,0,0
09000064804843cf,Supporting & Related Material,FDA-2003-N-0103-0024,FDA-2003-N-0103,background,0,0
09000064804843e4,Supporting & Related Material,FDA-2003-N-0103-0034,FDA-2003-N-0103,background,0,0
090000648042b1cb,Supporting & Related Material,FDA-2007-D-0258-0002,FDA-2007-D-0258,guidance,0,0
090000648042b1ca,Notice,FDA-2007-D-0258-0001,FDA-2007-D-0258,fda,0,0
09000064805994b4,Proposed Rule,FDA-1978-N-1254-0001,FDA-1978-N-1254,bioresearch monitoring program,0,0
09000064805994d2,Notice,FDA-1978-N-1254-0002,FDA-1978-N-1254,withdrawal of certain pre-1986 proposed rules; opportunity for public comment,0,0
09000064805994d6,Notice,FDA-1978-N-1254-0003,FDA-1978-N-1254,withdrawal of certain pre-1986 proposed rules; final action,0,0
0900006480599f66,Other,FDA-1995-P-0355-0001,FDA-1995-P-0355,citizen petition from washington legal foundation,0,0
09000064824aa669,Other,FDA-1995-P-0355-0002,FDA-1995-P-0355,acknowledgment letter from fda ddm to washington legal foundation,0,0
0900006480599f67,Other,FDA-1995-P-0355-0003,FDA-1995-P-0355,petition denial letter from fda oc to washington,0,0
0900006480599f68,Other,FDA-1995-P-0355-0004,FDA-1995-P-0355,letter from fda oc to washington legal foundation,0,0
0900006481507600,Other,FDA-2013-D-1622-0002,FDA-2013-D-1622,"draft guidance for industry: submitting food canning establishment registration form and food process filing forms to the food
and drug administration in electronic or paper format",1,0
0900006481505eae,Notice,FDA-2013-D-1622-0001,FDA-2013-D-1622,"draft guidance for industry: submitting food canning establishment registration form and food process filing forms to the food
and drug administration in electronic or paper format; availability",1,0
0900006481cbbb85,Other,FDA-2013-D-1622-0008,FDA-2013-D-1622,"submitting form fda 2541 (food canning establishment registration) and forms fda 2541d, fda 2541e, fda 2541f, and fda 2541g (food process filing forms) to fda in electronic or paper format: guidance for industry",1,0
0900006481cba00c,Notice,FDA-2013-D-1622-0007,FDA-2013-D-1622,"submitting food canning establishment registration form and
food process filing forms to the food and drug administration in electronic or paper format: guidance for industry; availability",1,0
090000648118f830,Other,FDA-1995-S-0036-0135,FDA-1995-S-0036,"resuscitation outcomes consortium (roc) re ind 110280, british columbia, canada public disclosure material report 63 - report",0,0
0900006480e373e5,Other,FDA-1995-S-0036-0112,FDA-1995-S-0036,"advanced circulatory systems, inc., to the division of dockets management re: ide g080169, resqpro clinical trial, community consultation plan - report 41",0,0
0900006481113f5e,Other,FDA-1995-S-0036-0126,FDA-1995-S-0036,resuscitation outcomes consortium (roc) british columbia public disclosure materials re ind 110699 report 54 - report,0,0
0900006481159613,Other,FDA-1995-S-0036-0129,FDA-1995-S-0036,"university of texas health science center at houston, site university of southern california los angeles, public disclosure material report 58 - report",0,0
0900006481cefe33,Other,FDA-1995-S-0036-0167,FDA-1995-S-0036,public disclosure report from resuscitation outcomes consortium (roc)  dallas site re ind 119858 - report 86,0,0
09000064822299f5,Other,FDA-1995-S-0036-0170,FDA-1995-S-0036,"public disclosure material from resuscitation outcomes consortium (roc) hennepin county medical center, minneapolis site re ind 119858 report 89",0,0
0900006481cefe31,Other,FDA-1995-S-0036-0165,FDA-1995-S-0036,public disclosure report from resuscitation outcomes consortium (roc)  milwaukee site re ind 119858 - report 84,0,0
0900006481cefe2e,Other,FDA-1995-S-0036-0162,FDA-1995-S-0036,public disclosure report from resuscitation outcomes consortium (roc) alabama site re ind 119858 - report 81,0,0
09000064823bc263,Other,FDA-1995-S-0036-0176,FDA-1995-S-0036,"esett, neurological emergencies treatment trials (nett) & pecarn networks public disclosure docket report ind# 119,756",0,0
09000064823bc294,Other,FDA-1995-S-0036-0177,FDA-1995-S-0036,"esett, neurological emergencies treatment trials (nett) network summary report of public disclosures ind# 119,756",0,0
0900006482337a8c,Other,FDA-1995-S-0036-0171,FDA-1995-S-0036,"annual report from protect iii emory university school of medicine public disclosure ind 104,188 report 91",0,0
0900006482337ad9,Other,FDA-1995-S-0036-0173,FDA-1995-S-0036,"resuscitation outcomes consortium (roc) milwaukee site, public disclosure for emergency research study of cardiac arrest, report 93",0,0
09000064818679be,Other,FDA-1995-S-0036-0143,FDA-1995-S-0036,correspondence from baroness lady sonia mcmorris query,0,0
09000064818679bd,Other,FDA-1995-S-0036-0142,FDA-1995-S-0036,"neuren pharmaceuticals ltd, ind 111724, site wayne state university
detroit receiving and sinai-grace hospitals and the queen's medical center, honolulu, hi exception from informed consent requirements for emergency research  report 68",0,0
09000064818679c1,Other,FDA-1995-S-0036-0148,FDA-1995-S-0036,"eunice kennedy shriver national institute of child health and human development, ind 79,010, lorazepam, sites listed in abstract, public disclosure material report 69",0,0
0900006481868114,Other,FDA-1995-S-0036-0152,FDA-1995-S-0036,"ben taub general hospital and baylor college of medicine, ind 100681, effects of erythropoietin on cerebral vascular dysfunction and anemia in traumatic brain injury, public disclosure material report 71",0,0
0900006483d2bc1d,Other,FDA-1995-S-0036-0178,FDA-1995-S-0036,"public disclosure report from kelly hoy, diffusion pharmaceuticals inc",0,0
09000064818679c0,Other,FDA-1995-S-0036-0145,FDA-1995-S-0036,correspondence from baroness lady sonia mcmorris query follow-up to query,0,0
09000064818679c3,Other,FDA-1995-S-0036-0146,FDA-1995-S-0036,correspondence from baroness lady sonia mcmorris query follow-up,0,0
090000648186ae53,Other,FDA-1995-S-0036-0147,FDA-1995-S-0036,correspondence from baroness lady sonia mcmorris query follow-up request,0,0
090000648108a994,Other,FDA-1995-S-0036-0122,FDA-1995-S-0036,"resuscitation outcomes consortium (roc) re ind 110699, milwaukee public disclosure material report 50 - report",0,0
0900006482228931,Other,FDA-1995-S-0036-0168,FDA-1995-S-0036,"public disclosure report from penn medicine, hospital of the university of pennsylvania re ind 110314 report 87",0,0
0900006481ab145c,Other,FDA-1995-S-0036-0161,FDA-1995-S-0036,public disclosure report from resuscitation outcomes consortium houston site re tranexamic acid report 80,0,0
0900006480b1a4c4,Other,FDA-1995-S-0036-0110,FDA-1995-S-0036,"report 39 - ""immediate trial  for public disclosure, saint paul minnesota area, ind 70,376,""",0,0
0900006481159612,Other,FDA-1995-S-0036-0128,FDA-1995-S-0036,resuscitation outcomes consortium (roc) pittsburgh public disclosure materials report 57 - report,0,0
0900006481b94e74,Notice,FDA-2014-N-0411-0002,FDA-2014-N-0411,"cooperative agreement for research, education, and outreach in support of the food and drug administration food safety modernization act",1,0
09000064816d165c,Notice,FDA-2014-N-0411-0001,FDA-2014-N-0411,"cooperative agreement to support the illinois institute of technology’s
national center for food safety and technology",1,0
090000648157676a,Notice,FDA-2014-N-0006-0001,FDA-2014-N-0006,"report on the performance of drug and biologics firms in conducting
postmarketing requirements and commitments; availability",0,0
0900006483e11c81,Notice,FDA-2019-N-0006-0001,FDA-2019-N-0006,advisory committees; filing of closed meeting reports,0,0
090000648046324b,Other,FDA-2006-N-0485-0001,FDA-2006-N-0485,independent evaluation of fda's first cycle review performance retrospective analysis final report,0,0
0900006480463238,Notice,FDA-2006-N-0485-0002,FDA-2006-N-0485,fda,0,0
0900006480471148,Other,FDA-2004-P-0215-0017,FDA-2004-P-0215,"hill dermaceuticals, inc. - amendment",0,0
0900006480471169,Other,FDA-2004-P-0215-0007,FDA-2004-P-0215,"fda division of dockets management to hill dermaceuticals, inc. - letter",0,0
0900006480471146,Other,FDA-2004-P-0215-0009,FDA-2004-P-0215,"hill dermaceuticals, inc. to the division of dockets management - letter",0,0
0900006480471165,Other,FDA-2004-P-0215-0012,FDA-2004-P-0215,"hill dermaceuticals, inc. - supplement",0,0
0900006480471159,Other,FDA-2004-P-0215-0010,FDA-2004-P-0215,"hill dermaceuticals, inc. - supplement",0,0
0900006480471158,Supporting & Related Material,FDA-2004-P-0215-0026,FDA-2004-P-0215,"affidavit of ralph harkins, ph.d. - [hill dermaceuticals inc. - supplement] re fda-2004-p-0215-0010",0,0
090000648047114b,Supporting & Related Material,FDA-2004-P-0215-0034,FDA-2004-P-0215,"appendix e - ""summary of contact urticaria (by howard i. maibach, md)"" - [hill dermaceuticals, inc. - supplement]",0,0
0900006480471168,Other,FDA-2004-P-0215-0006,FDA-2004-P-0215,"fda/ddm to hill dermaceuticals, inc.",0,0
090000648047114e,Supporting & Related Material,FDA-2004-P-0215-0036,FDA-2004-P-0215,"appendix g - ""contact urticaria syndrome"" - (cover page)  [hill dermaceuticals, inc. - supplement]",0,0
0900006480471160,Supporting & Related Material,FDA-2004-P-0215-0020,FDA-2004-P-0215,attachment a - [hill dermaceuticals inc. - supplement] re fda-2004-p-0215-0010,0,0
090000648047113d,Other,FDA-2004-P-0215-0001,FDA-2004-P-0215,"acknowledgement letter to hill dermaceuticals, inc.",0,0
0900006480471170,Other,FDA-2004-P-0215-0019,FDA-2004-P-0215,"hill dermaceuticals, inc. - amendment",0,0
090000648047116f,Supporting & Related Material,FDA-2004-P-0215-0029,FDA-2004-P-0215,derma-smoothe/fs[scalp oil] - product description - [hill dermaceuticals inc. - amendment] re fda-2004-p-0215-0019,0,0
0900006480471161,Other,FDA-2004-P-0215-0011,FDA-2004-P-0215,hill dermaceuticals inc. - supplement,0,0
0900006480471157,Supporting & Related Material,FDA-2004-P-0215-0025,FDA-2004-P-0215,affidavit of howard i. maibach. m.d - [hill dermaceuticals inc. - supplement] re fda-2004-p-0215-0010,0,0
090000648047116b,Other,FDA-2004-P-0215-0013,FDA-2004-P-0215,"hill dermaceuticals, inc. to the division of dockets management - letter",0,0
090000648047115f,Supporting & Related Material,FDA-2004-P-0215-0021,FDA-2004-P-0215,attachment b - [hill dermaceuticals inc. - supplement] re fda-2004-p-0215-0010,0,0
0900006480471167,Other,FDA-2004-P-0215-0005,FDA-2004-P-0215,"fda/cder to hill dermaceuticals, inc. - letter",0,0
090000648047114c,Supporting & Related Material,FDA-2004-P-0215-0035,FDA-2004-P-0215,"appendix f - ""reference list: bibliography of howard i. maibach, m.d."" - [hill dermaceuticals, inc. - supplement] re  fda-2004-p-0215-0037 (part 1 of 2)",0,0
0900006480471155,Supporting & Related Material,FDA-2004-P-0215-0024,FDA-2004-P-0215,"bibliography of howard i. maibach, m.d. - [hill dermaceuticals inc. - supplement] re fda-2004-p-0215-0010",0,0
0900006480471154,Supporting & Related Material,FDA-2004-P-0215-0022,FDA-2004-P-0215,attachment c - [hill dermaceuticals inc. - supplement] re fda-2004-p-0215-0010,0,0
0900006480471149,Supporting & Related Material,FDA-2004-P-0215-0033,FDA-2004-P-0215,"appendix d - ""data presented to the advisory committee powerpoint presentation"" - [hill dermaceuticals, inc. - supplement] refda-2004-p-0215-0037",0,0
090000648047114d,Supporting & Related Material,FDA-2004-P-0215-0030,FDA-2004-P-0215,"appendix a - ""dr. howard i. maibach letter on bioequivalence and safety issues pertaining to generic versions of derma-smoothe/fso"" - [hill dermaceuticals, inc. - supplement] re fda-2004-p-0215-0037",0,0
0900006480471144,Other,FDA-2004-P-0215-0004,FDA-2004-P-0215,see fda-2004-p-0215-0007,0,0
0900006480471142,Supporting & Related Material,FDA-2004-P-0215-0002,FDA-2004-P-0215,see fda-2004-p-0215-0001,0,0
090000648058b295,Other,FDA-1998-N-0155-0007,FDA-1998-N-0155,joint commission on accreditation of healthcare organizations - testimony,0,0
090000648058b280,Notice,FDA-1998-N-0155-0002,FDA-1998-N-0155,fda - notice of hearing,0,0
090000648058b259,Other,FDA-1998-N-0155-0003,FDA-1998-N-0155,samsah to fda - memo,0,0
090000648058b2b4,Other,FDA-1998-N-0155-0013,FDA-1998-N-0155,"laarc, matrix institute on addictions - testimony",0,0
090000648058b29b,Supporting & Related Material,FDA-1998-N-0155-0015,FDA-1998-N-0155,sign-in list - [joint commission on accreditation of healthcare organizations-testimony],0,0
090000648058b2a3,Other,FDA-1998-N-0155-0009,FDA-1998-N-0155,american methadone treatment association - testimony,0,0
090000648058b30b,Other,FDA-1998-N-0155-0014,FDA-1998-N-0155,transcript - 11-1-99 public hearing on methadone-laam proposed rule (pages 1 - 100),0,0
090000648058b2a4,Other,FDA-1998-N-0155-0010,FDA-1998-N-0155,"college on problems of drug dependence, inc. - testimony",0,0
090000648058b2b2,Other,FDA-1998-N-0155-0012,FDA-1998-N-0155,medical college of virginia - testimony,0,0
090000648058b294,Supporting & Related Material,FDA-1998-N-0155-0004,FDA-1998-N-0155,agenda for public hearing on methadone/laam proposed rule - list,0,0
090000648058b2a1,Other,FDA-1998-N-0155-0008,FDA-1998-N-0155,research triangle institute - letter,0,0
090000648058b224,Proposed Rule,FDA-1998-N-0155-0001,FDA-1998-N-0155,narcotic drugs in maintenance and detoxification treatment of narcotic,0,0
090000648058b293,Other,FDA-1998-N-0155-0006,FDA-1998-N-0155,samsha - testimony,0,0
090000648058b25e,Supporting & Related Material,FDA-1998-N-0155-0005,FDA-1998-N-0155,omb review - reference (1a),0,0
090000648058b2a5,Other,FDA-1998-N-0155-0011,FDA-1998-N-0155,"nat assn of state alcohol and drug abuse director's, inc. - testimony",0,0
0900006481ed6d6f,Other,FDA-2005-P-0191-0006,FDA-2005-P-0191,citizen petition partial approval and denial response from fda cder to pine grove behavioral health & addiction services,0,0
0900006480440e27,Other,FDA-2005-P-0191-0001,FDA-2005-P-0191,hfa-305 to pine grove behavioral health & addiction services,0,0
0900006480440e2a,Other,FDA-2005-P-0191-0004,FDA-2005-P-0191,citizen petition from pine grove behavioral health & addiction services,0,0
0900006480440e2f,Other,FDA-2005-P-0191-0003,FDA-2005-P-0191,fda/cder to pine grove recovery center,0,0
0900006480440e2e,Other,FDA-2005-P-0191-0002,FDA-2005-P-0191,hfa-305 to pine grove behavioral health & addiction services,0,0
0900006480484621,Notice,FDA-2003-N-0105-0001,FDA-2003-N-0105,fda,0,0
09000064804876d8,Notice,FDA-2002-D-0010-0001,FDA-2002-D-0010,fda,0,0
090000648048771d,Notice,FDA-2002-D-0010-0002,FDA-2002-D-0010,fda,0,0
090000648048771f,Supporting & Related Material,FDA-2002-D-0010-0003,FDA-2002-D-0010,notifying fda of fatalities related to blood collection or transfusion,0,0
0900006480487721,Supporting & Related Material,FDA-2002-D-0010-0004,FDA-2002-D-0010,guidance,0,0
0900006484dcc28b,Other,FDA-2002-D-0010-0005,FDA-2002-D-0010,notifying-fda-of-fatalities-related-to-blood-collection-or-transfusion - l2 update - aug 2021 final,0,0
0900006481e65c6c,Other,FDA-2016-P-0541-0002,FDA-2016-P-0541,"acknowledgement letter from fda ddm to gordon johnston regulatory consultants, llc",0,0
0900006481e65ff7,Other,FDA-2016-P-0541-0001,FDA-2016-P-0541,"citizen petition from gordon johnston regulatory consultants, llc",0,0
0900006481e66137,Supporting & Related Material,FDA-2016-P-0541-0003,FDA-2016-P-0541,"attachment a electronic orange book listing for sodium chloride 0.45% re citizen petition from gordon johnston regulatory consultants, llc",0,0
0900006482195e50,Other,FDA-2016-P-0541-0004,FDA-2016-P-0541,"petition approval letter from fda cder to gordon johnston regulatory consultants, llc",0,0
09000064804dfe07,Notice,FDA-2001-D-0163-0001,FDA-2001-D-0163,fda,0,0
09000064804dfe68,Supporting & Related Material,FDA-2001-D-0163-0002,FDA-2001-D-0163,corrected final guidance,0,0
090000648050733d,Notice,FDA-1996-D-0405-0001,FDA-1996-D-0405,exports: certificates and other assurance that products meet fda requirements; availability,0,0
0900006484bfad1a,Supporting & Related Material,FDA-1996-D-0405-0002,FDA-1996-D-0405,compliance policy guide section 110.100 certification for exports re: exports: certificates and other assurance that products meet fda requirements; availability,0,0
0900006484e23a7d,Notice,FDA-1996-D-0405-0010,FDA-1996-D-0405,compliance policy guide sec. 110.100; withdrawal of guidance,0,0
0900006481e65830,Other,FDA-2016-P-0540-0001,FDA-2016-P-0540,"citizen petition from gordon johnston regulatory consultants, llc",0,0
0900006481e65e6f,Other,FDA-2016-P-0540-0002,FDA-2016-P-0540,"acknowledgement letter from fda ddm to gordon johnston regulatory consultants, llc",0,0
0900006481e65ec5,Supporting & Related Material,FDA-2016-P-0540-0003,FDA-2016-P-0540,"attachment a electronic orange book listing for sodium chloride 3% re citizen petition from gordon johnston regulatory consultants, llc",0,0
0900006482195e42,Other,FDA-2016-P-0540-0004,FDA-2016-P-0540,"petition approval letter from fda cder to gordon johnston regulatory consultants, llc",0,0
0900006481edf359,Other,FDA-2016-P-1085-0002,FDA-2016-P-1085,acknowledgement letter from fda ddm to frontage laboratories inc,0,0
0900006484e0c23b,Other,FDA-2016-P-1085-0004,FDA-2016-P-1085,agency response from fda cder to beijing health life pharm tech co ltd,0,0
0900006481edf35b,Supporting & Related Material,FDA-2016-P-1085-0003,FDA-2016-P-1085,attachment a product inserts re citizen petiton from frontage laboratories,0,0
0900006481edf1d5,Other,FDA-2016-P-1085-0001,FDA-2016-P-1085,"citizen petition from frontage laboratories, inc.",0,0
0900006480ed4122,Other,FDA-2010-P-0491-0156,FDA-2010-P-0491,"the honorable charles e. grassley, et al., to the commissioner for food and drugs - letter",1,0
0900006480b506a0,Supporting & Related Material,FDA-2010-P-0491-0058,FDA-2010-P-0491,"appendix a (6) - ""jones, dietary sweeteners containing fructose: overview of a workshop on the state of the science"" - [corn refiners association - citizen petition] re fda-2010-p-0491-0001",0,0
0900006480b50d75,Supporting & Related Material,FDA-2010-P-0491-2158,FDA-2010-P-0491,"appendix c  (7 ) jessica m. scott, a sticky subject, richmond.com [corn refiners association - citizen petition] re fda-2010-p-0491-0001",0,0
0900006480b50d90,Supporting & Related Material,FDA-2010-P-0491-2171,FDA-2010-P-0491,"appendix c (21) dangers of sweetener fructose, the capital-hometownannapolis.com  [corn refiners association - citizen petition] re fda-2010-p-0491-0001",0,0
0900006480b50db7,Supporting & Related Material,FDA-2010-P-0491-2167,FDA-2010-P-0491,"appendix  c  (17) phil lempert, is this the end ofhigh fructose com syrup?,  supermarket guru   [corn refiners association - citizen petition] re fda-2010-p-0491-0001",0,0
0900006480f89deb,Other,FDA-2010-P-0491-1064,FDA-2010-P-0491,sugar association (wenable llp) - supplement,0,0
0900006480bfc8d2,Supporting & Related Material,FDA-2010-P-0491-0085,FDA-2010-P-0491,"tab 23 - ""report of the dietary guidelines advisory committee on the dietary guidelines for americans, 2010"" - [the sugar association (venable, llp) - comment] re: fda-2010-p-0491-0082",0,0
0900006480b50664,Supporting & Related Material,FDA-2010-P-0491-0002,FDA-2010-P-0491,"appendix a - ""list of references"" - [corn refiners association - citizen petition] re fda-2010-p-0491-0001",0,0
0900006480c260bb,Supporting & Related Material,FDA-2010-P-0491-0094,FDA-2010-P-0491,withdrawn public submission,0,0
0900006480b5100d,Supporting & Related Material,FDA-2010-P-0491-2179,FDA-2010-P-0491,appendix c (31) book revised to account for rise in sugar love [corn refiners association - citizen petition] re fda-2010-p-0491-0001,0,0
0900006480b51012,Supporting & Related Material,FDA-2010-P-0491-2182,FDA-2010-P-0491,"appendix c (34) sophia ahmad, your health: become a label reader,  desmoinesregister.com [the corn refiners association citizen petition]",0,0
0900006480b51013,Supporting & Related Material,FDA-2010-P-0491-2183,FDA-2010-P-0491,"appendix c (35) don colburn & joe rojas-burke, the skinny on big bellies,  oregonlive.com  [the corn refiners association citizen petition]",0,0
0900006480b51081,Supporting & Related Material,FDA-2010-P-0491-2187,FDA-2010-P-0491,"appendix c (39) the you docs: gut trouble? the sneaky culprit, seattle post-intelligencer  [the corn refiners association citizen petition]",0,0
0900006480b51104,Supporting & Related Material,FDA-2010-P-0491-2189,FDA-2010-P-0491,"appendix c (43) gailon totheroh, fructose:' sugar-coated danger, cbn.com  [the corn refiners association citizen petition]",0,0
0900006480b50d77,Supporting & Related Material,FDA-2010-P-0491-2160,FDA-2010-P-0491,"appendix c  (9) merri rosenberg, in the schools; refilling lunch trays: less junk, more veggies, the new york times [corn refiners association - citizen petition] re fda-2010-p-0491-0001",0,0
0900006480b50d78,Supporting & Related Material,FDA-2010-P-0491-2161,FDA-2010-P-0491,"appendix c  (10 ) janet helm., link between obesity, high fructose com syrup?,  southbendtribune.com [corn refiners association - citizen petition] re fda-2010-p-0491-0001",0,0
0900006480b50d7a,Supporting & Related Material,FDA-2010-P-0491-2163,FDA-2010-P-0491,"appendix c  (12) gabriella boston, eating small; the french connection to food and weight, the washington times [corn refiners association - citizen petition] re fda-2010-p-0491-0001",1,0
0900006480b50d7b,Supporting & Related Material,FDA-2010-P-0491-2164,FDA-2010-P-0491,"appendix c  (13) transcripts, healthwatch; elisa zied, author of""so what can i eat,"" discusses nutrition for teenage girls, cbs the early show [corn refiners association - citizen petition] re fda-2010-p-0491-0001",0,0
0900006480b50d8d,Supporting & Related Material,FDA-2010-P-0491-2168,FDA-2010-P-0491,"appendix c (18) nicholas d. kristoff, hazardous to your health, the new york times  [corn refiners association - citizen petition] re fda-2010-p-0491-0001",0,0
0900006480b50d8e,Supporting & Related Material,FDA-2010-P-0491-2169,FDA-2010-P-0491,"appendix c (19) study links soft drinks with obesity, consumeraffairs.com  [corn refiners association - citizen petition] re fda-2010-p-0491-0001",0,0
0900006480ed13cc,Other,FDA-2010-P-0491-0155,FDA-2010-P-0491,"fda/oc office of legislation to the honorable tom hankin, may 24, 2011 - answer",0,0
0900006480b50662,Other,FDA-2010-P-0491-0001,FDA-2010-P-0491,corn refiners association - citizen petition,0,0
090000648102314a,Other,FDA-2010-P-0491-2181,FDA-2010-P-0491,fda/cfsan response to corn refiners association - petition denial letter,0,0
0900006480c22255,Other,FDA-2010-P-0491-0088,FDA-2010-P-0491,fda/cfsan interim response to corn refiners association,0,0
0900006480ed412a,Other,FDA-2010-P-0491-0157,FDA-2010-P-0491,"fda/oc office of legislation to the honorable charles e. grassley, et al, august 1, 2011 - answer",0,0
090000648042db08,Other,FDA-2007-D-0424-0005,FDA-2007-D-0424,fda/op,0,0
09000064806aed12,Notice,FDA-2007-D-0424-0006,FDA-2007-D-0424,"guidance for the public, fda advisory committee members, and fda staff on procedures for determining conflict of interest and eligibility for participation in fda advisory committees; availability",0,0
090000648042daf5,Supporting & Related Material,FDA-2007-D-0424-0002,FDA-2007-D-0424,draft guidance,0,0
090000648042daf6,Supporting & Related Material,FDA-2007-D-0424-0003,FDA-2007-D-0424,draft guidance,0,0
09000064806af196,Other,FDA-2007-D-0424-0007,FDA-2007-D-0424,"guidance for the public, fda advisory committee members, and fda staff on procedures for determining conflict of interest and eligibility for participation in fda advisory committees",0,0
090000648042daf1,Notice,FDA-2007-D-0424-0001,FDA-2007-D-0424,fda,0,0
0900006480499798,Notice,FDA-2003-D-0378-0001,FDA-2003-D-0378,fda,0,0
09000064804997f3,Supporting & Related Material,FDA-2003-D-0378-0002,FDA-2003-D-0378,guideline,0,0
09000064809edb4d,Other,FDA-2009-P-0321-0002,FDA-2009-P-0321,"acknowledgement letter to ferdic, incorporated",0,0
09000064809edb4a,Other,FDA-2009-P-0321-0001,FDA-2009-P-0321,"ferdic, incorporated - citizen petition",0,0
090000648048162a,Other,FDA-2003-D-0033-0003,FDA-2003-D-0033,guidance for industry and food and drug administration staff: food and drug administration and industry actions on premarket notification submissions: effect on food and drug administration review clock and performance assessment,1,0
090000648116e889,Notice,FDA-2003-D-0033-0004,FDA-2003-D-0033,guidance for industry and food and drug administration staff: food and drug administration and industry actions on premarket notification submissions: effect on food and drug administration review clock and performance assessment; availability see fda-2003-d_0033-0001,1,0
0900006480481625,Notice,FDA-2003-D-0033-0001,FDA-2003-D-0033,guidance for industry and food and drug administration staff: food and drug administration and industry actions on premarket notification submissions: effect on food and drug administration review clock and performance assessment; availability,1,0
0900006480481629,Supporting & Related Material,FDA-2003-D-0033-0002,FDA-2003-D-0033,see fda-2003-d-0033-0003,0,0
09000064823c8959,Other,FDA-2016-P-1398-0003,FDA-2016-P-1398,interim response letter from cdrh to dr. hooman noorchashm - redacated,0,0
09000064849d263b,Other,FDA-2016-P-1398-0004,FDA-2016-P-1398,citizen petition response to dr. hooman noorchashm,0,0
0900006482001383,Other,FDA-2016-P-1398-0001,FDA-2016-P-1398,citizen petition from dr. hooman noorchashm,0,0
0900006482001385,Other,FDA-2016-P-1398-0002,FDA-2016-P-1398,acknowledgement letter from fda ddm to dr. hooman noorchashm,0,0
0900006484acfd31,Other,FDA-2021-P-0427-0002,FDA-2021-P-0427,acknowledgment letter from fda dms to pet schooled,0,0
0900006484acfd2d,Other,FDA-2021-P-0427-0001,FDA-2021-P-0427,citizen petition from pet schooled,0,0
0900006484986177,Other,FDA-2019-D-4739-0017,FDA-2019-D-4739,requesting fda feedback on combination products guidance for industry and fda staff,0,0
09000064842503f0,Other,FDA-2019-D-4739-0002,FDA-2019-D-4739,requesting food and drug administration feedback on combination products; draft guidance for industry and food and drug administration staff,1,0
0900006484985b24,Notice,FDA-2019-D-4739-0016,FDA-2019-D-4739,"requesting fda feedback on combination products; guidance for
industry and fda staff; availability",0,0
090000648424ff26,Notice,FDA-2019-D-4739-0001,FDA-2019-D-4739,requesting food and drug administration feedback on combination products; draft guidance for industry and food and drug administration staff; availability,1,0
09000064805529eb,Other,FDA-2007-P-0418-0005,FDA-2007-P-0418,fda/center for drug evaluation and research - final response letter,0,0
090000648042da5d,Other,FDA-2007-P-0418-0001,FDA-2007-P-0418,fda/ddm to cobalt laboratories inc. and cobalt pharmaceuticals inc.,0,0
090000648042da5e,Other,FDA-2007-P-0418-0003,FDA-2007-P-0418,"cobalt laboratories, inc. and cobalt pharmaceuticals, inc. - citizen petition",0,0
090000648042da64,Other,FDA-2007-P-0418-0002,FDA-2007-P-0418,fda/ddm to cobalt laboratories inc. and cobalt pharmaceuticlas inc,0,0
090000648042da65,Other,FDA-2007-P-0418-0004,FDA-2007-P-0418,cobalt laboratories inc. and cobalt pharmaceuticlas inc - petition for stay of action,0,0
09000064804efcc2,Other,FDA-2001-P-0524-0003,FDA-2001-P-0524,"fda/cder interim response to lawrence d. bernhardt & arnold liebman (milberg, weiss, bershad, hynes, and lerach llp) - letter",0,0
09000064804efcc7,Other,FDA-2001-P-0524-0008,FDA-2001-P-0524,"between fda/cder hfd110 and milberg, weiss, bershad hynes, & lerach llp april 17 2001 re minutes of april 4 2001 - memorandum of telephone conversation",0,0
09000064804efcc0,Other,FDA-2001-P-0524-0002,FDA-2001-P-0524,"acknowledgement letter to (milberg, weiss, bershad hynes, and lerach llp)",0,0
09000064804efcc5,Other,FDA-2001-P-0524-0006,FDA-2001-P-0524,between fda/cder hfd110 and pfizer march 6 2001 re minutes of february 28 2001 - memorandum of telephone conversation,0,0
09000064804efcc6,Other,FDA-2001-P-0524-0007,FDA-2001-P-0524,between fda/cder hfd110 and pfizer march 20 2001 re minutes of march 16 2001 - memorandum of telephone conversation,0,0
09000064804efcc4,Other,FDA-2001-P-0524-0005,FDA-2001-P-0524,between fda/cder hfd110 and milberg weiss bershad hynes & lerach llp - memorandum of telephone conversation,0,0
09000064804efcba,Other,FDA-2001-P-0524-0001,FDA-2001-P-0524,"lawrence d. bernhardt & arnold liebman (milberg, weiss, bershad, hynes, and lerach llp) - citizen petition",0,0
090000648105ffbb,Other,FDA-2001-P-0524-0010,FDA-2001-P-0524,"fda/cder to the division of dockets management re involuntarily closure of lawrence d bernhardt and arnold liebman (salvatore j. graziano, esq. of milberg, llp) june 22, 2012 - memorandum",0,0
09000064804efcc8,Other,FDA-2001-P-0524-0009,FDA-2001-P-0524,between fda/cder hfd110 and pfizer april 17 2001 re minutes of april 3 2001 - memorandum of telephone conversation,0,0
0900006484a930dd,Notice,FDA-2021-N-0262-0001,FDA-2021-N-0262,food and drug administration science forum 2021; public workshop,1,0
09000064804e2531,Other,FDA-2001-P-0190-0001,FDA-2001-P-0190,fda/ddm to washington legal foundation,0,0
09000064804e2582,Other,FDA-2001-P-0190-0002,FDA-2001-P-0190,fda/oc to washington legal foundation,0,0
090000648070f519,Rule,FDA-2008-N-0423-0002,FDA-2008-N-0423,fda regulations; technical amendment; correction,0,0
09000064806d80ba,Notice,FDA-2008-N-0423-0001,FDA-2008-N-0423,fda regulations; technical amendment,0,0
0900006482416a9e,Other,FDA-2015-D-4361-0008,FDA-2015-D-4361,gifts to fda-evaluation and acceptance-final guidance with updated reference for the public and fda personnel,0,0
0900006482414334,Notice,FDA-2015-D-4361-0005,FDA-2015-D-4361,gifts to the food and drug administration: evaluation and acceptance; guidance for the public and food and drug administration; availability,1,0
0900006482079351,Other,FDA-2015-D-4361-0002,FDA-2015-D-4361,gifts to fda: evaluation and acceptance: draft guidance for the public and fda staff draft guidance,0,0
090000648241485e,Other,FDA-2015-D-4361-0006,FDA-2015-D-4361,gifts to fda: evaluation and acceptance: draft guidance for the public and fda staff,0,0
09000064820786ba,Notice,FDA-2015-D-4361-0001,FDA-2015-D-4361,gifts to the food and drug administration: evaluation and acceptance: draft guidance for the public and food and drug administration staff; availability,1,0
0900006482416647,Other,FDA-2015-D-4361-0007,FDA-2015-D-4361,gifts to fda-evaluation and acceptance-final guidance for the public and...,0,0
090000648208001c,Other,FDA-2015-D-4361-0003,FDA-2015-D-4361,gifts to fda: evaluation and acceptance: draft guidance for the public and fda staff,0,0
0900006482c3799b,Notice,FDA-2017-N-6129-0001,FDA-2017-N-6129,assessment of food and drug administration hiring and retention; public meeting; request for comments,1,0
0900006481e91e0b,Other,FDA-2016-N-0586-0003,FDA-2016-N-0586,u. s department of health and human services tribal consultation policy,0,0
0900006481e91e06,Other,FDA-2016-N-0586-0002,FDA-2016-N-0586,u.s. department of health and human services food and drug administration tribal consultation policy (draft),1,0
0900006481e8f960,Notice,FDA-2016-N-0586-0001,FDA-2016-N-0586,"draft food and drug administration tribal consultation policy; availability;
request for comments",1,0
090000648244bfec,Notice,FDA-2016-N-0586-0010,FDA-2016-N-0586,food and drug administration tribal consultation policy; availability,1,0
0900006481fb4c08,Supporting & Related Material,FDA-2016-N-0586-0004,FDA-2016-N-0586,transcript from the all tribes call 04-21-16  nwx-fda oc,0,0
090000648244c995,Other,FDA-2016-N-0586-0011,FDA-2016-N-0586,fda tribal consultation policy (final)_508ed_1,0,0
0900006480481746,Notice,FDA-2003-N-0041-0004,FDA-2003-N-0041,fda,0,0
0900006480481747,Supporting & Related Material,FDA-2003-N-0041-0005,FDA-2003-N-0041,supporting statement,0,0
0900006480481736,Notice,FDA-2003-N-0041-0002,FDA-2003-N-0041,fda,0,0
0900006480481748,Notice,FDA-2003-N-0041-0006,FDA-2003-N-0041,fda,0,0
090000648048171f,Notice,FDA-2003-N-0041-0001,FDA-2003-N-0041,fda,0,0
0900006480481745,Other,FDA-2003-N-0041-0003,FDA-2003-N-0041,hfz-510 to dockets management branch,0,0
0900006481f56d85,Other,FDA-2016-P-1128-0001,FDA-2016-P-1128,citizen petition from melissa schilling,0,0
0900006481f57020,Other,FDA-2016-P-1128-0002,FDA-2016-P-1128,acknowledgement letter from fda ddm to melissa schilling,0,0
09000064804d0de7,Other,FDA-2000-N-0143-0007,FDA-2000-N-0143,answer from fda/cder to honorable rosa l. delauro,0,0
09000064804d0dc5,Proposed Rule,FDA-2000-N-0143-0001,FDA-2000-N-0143,notice of proposed rule from fda/cder,0,0
09000064804d0dec,Notice,FDA-2000-N-0143-0002,FDA-2000-N-0143,notice of final rule from fda/cder,0,0
0900006480ac9fd4,Supporting & Related Material,FDA-2009-N-0582-0007,FDA-2009-N-0582,"reference 12 - ""ims health, total u.s. promotional spend by type, 2008"" - background",0,0
0900006480ac9fd9,Supporting & Related Material,FDA-2009-N-0582-0008,FDA-2009-N-0582,"reference 13 - ""ims health, integrated promotional services™, year 2008, data extracted on september 2009"" - background",0,0
0900006480ac9ffb,Supporting & Related Material,FDA-2009-N-0582-0009,FDA-2009-N-0582,"reference 15 - ""office of management and budget, circular a-4, setember 17, 2003"" - background",0,0
0900006480aca060,Supporting & Related Material,FDA-2009-N-0582-0013,FDA-2009-N-0582,"reference 19 - ""scientific literature on direct to consumer advertising of precription pharmaceuticals, 2004-2008; eastern research group, inc., literature review"" - background",0,0
0900006480ac9f70,Supporting & Related Material,FDA-2009-N-0582-0003,FDA-2009-N-0582,"reference 1 - ""fda guidance for industry, ""consumer-directed broadcast advertisements,"" - background",0,0
0900006480fa7047,Proposed Rule,FDA-2009-N-0582-0040,FDA-2009-N-0582,"direct-to-consumer prescription drug advertisements; presentation of the major statement in television and radio advertisements in a clear, conspicuous, and neutral manner; notice of availability of study data",0,0
0900006480ae15c4,Other,FDA-2009-N-0582-0017,FDA-2009-N-0582,"omb changes, executive order 12866 (e.o.)[direct-to-consumer prescription drug advertisements: presentation of the major statement in television and radio advertisements in a clear, conspicuous, and neutral manner ] - reference",0,0
0900006480aca825,Proposed Rule,FDA-2009-N-0582-0001,FDA-2009-N-0582,"direct-to-consumer prescription drug advertisements: presentation of the major statement in television and radio advertisements in a clear, conspicuous, and neutral manner",0,0
0900006480aca03c,Supporting & Related Material,FDA-2009-N-0582-0010,FDA-2009-N-0582,"reference 16 - ""prescription drugs: fda oversight of direct-to-consumer advertising has limitations, gao"" - background",0,0
0900006480aca149,Supporting & Related Material,FDA-2009-N-0582-0002,FDA-2009-N-0582,ddmac references -  [note for monday 3/29/2010 - post this document first but after the fr document and please insert the title of the fr notice here],0,0
0900006480ac9f89,Supporting & Related Material,FDA-2009-N-0582-0006,FDA-2009-N-0582,"reference 4 - ""fda draft guidance for industry, ""presenting risk information in prescription drug and medical device promotion,"" - background",0,0
0900006480aca044,Supporting & Related Material,FDA-2009-N-0582-0012,FDA-2009-N-0582,"reference 18 - ""patient and physician attitudes and behaviors associated with dtc promotion of prescription drugs--summary of fda survey research results, final report, november 19, 2004"" - background",0,0
0900006480ac9f86,Supporting & Related Material,FDA-2009-N-0582-0004,FDA-2009-N-0582,"reference 2 - ""cch trade regulation reporter, paragraph 7569.09 ""clear and conspicous disclosure,"" ocober 21, 1970 - background",0,0
0900006480ac9f87,Supporting & Related Material,FDA-2009-N-0582-0005,FDA-2009-N-0582,"reference 3 - ""see h. rept. no. 102-839, august 11, 1992"" - background",0,0
0900006480aca040,Supporting & Related Material,FDA-2009-N-0582-0011,FDA-2009-N-0582,"reference 17 - ""phrma guiding priniciples; direct to consumer advertisements about prescription medicines, revised december 2008"" - background",0,0
0900006480fdf3d2,Proposed Rule,FDA-2009-N-0582-0055,FDA-2009-N-0582,"direct-to-consumer prescription drug advertisements; presentation of the major statement in television and radio advertisements in a clear, conspicuous, and neutral manner; reopening of the comment period",0,0
0900006480a23f8b,Other,FDA-2008-N-0163-0290,FDA-2008-N-0163,acknowledgement letter to swankin & turner,0,0
0900006480537ef9,Proposed Rule,FDA-2008-N-0163-0001,FDA-2008-N-0163,dental devices: classification of encapsulated amalgam alloy and dental mercury and reclassification of dental mercury; issuance of special controls for amalgam alloy; reopening of comment period,0,0
0900006481220d56,Other,FDA-2008-N-0163-0304,FDA-2008-N-0163,"moms against mercury, et al. - supplement",0,0
0900006480a23fa2,Supporting & Related Material,FDA-2008-N-0163-0297,FDA-2008-N-0163,"reference 1 - mundy, new fda chief must divest several stock, fund holdings - [citizens for health, et al (swankin & turner) - petition for reconsideration]",0,0
09000064805f1545,Supporting & Related Material,FDA-2008-N-0163-0269,FDA-2008-N-0163,reference 3 - [fda-2008-n-0163-0004] fda update/review of potential adverse health risks associated with exposure to mercury in dental amalgam,0,0
090000648175888c,Other,FDA-2008-N-0163-0305,FDA-2008-N-0163,"letter from titus hills reynolds love dickman & mccalmon re conversion to citizen petition of the september 3, 2009 petition for reconsideration",0,0
09000064809ff65c,Supporting & Related Material,FDA-2008-N-0163-0253,FDA-2008-N-0163,"reference 4 - ""update statement by the u. s. public health service on the safety of dental amalgam"" - [dental devices: classification of encapsulated amalgam alloy and dental mercury and reclassification of dental mercury; issuance of special controls for amalgam alloy; final rule]",0,0
09000064809ff68e,Supporting & Related Material,FDA-2008-N-0163-0258,FDA-2008-N-0163,"reference 13 - ""life science research office report: the potential health effects of dental amalgam, july 2004"" - [dental devices: classification of encapsulated amalgam alloy and dental mercury and reclassification of dental mercury; issuance of special controls for amalgam alloy; final rule]",0,0
09000064809ff691,Supporting & Related Material,FDA-2008-N-0163-0259,FDA-2008-N-0163,"reference 14 - ""toxicological profile for mercury "" - [dental devices: classification of encapsulated amalgam alloy and dental mercury and reclassification of dental mercury; issuance of special controls for amalgam alloy; final rule]",0,0
0900006480a24910,Supporting & Related Material,FDA-2008-N-0163-0303,FDA-2008-N-0163,"reference 2 - richardson, et al, mercury vapour (hgº): continuing toxicological uncertainties, and establishing a canadian reference exposure level - [mom's against mercury, et al. - petition for reconsideration]",0,0
0900006480a244fa,Supporting & Related Material,FDA-2008-N-0163-0300,FDA-2008-N-0163,"reference 4 - henry schein inc. q2 2009 earnings call transcript - [citizens for health, et al. - petition for reconsideration]",0,0
0900006480b002a6,Rule,FDA-2008-N-0163-0294,FDA-2008-N-0163,"dental devices: classification of dental amalgam, reclassification of dental mercury, designation of special controls for dental amalgam, mercury, and amalgam alloy; technical amendment",0,0
09000064809ff76b,Supporting & Related Material,FDA-2008-N-0163-0260,FDA-2008-N-0163,"reference 15a - ""integrated risk information system (iris) screening-level literature review"" - [dental devices: classification of encapsulated amalgam alloy and dental mercury and reclassification of dental mercury; issuance of special controls for amalgam alloy; final rule]",0,0
09000064809ff76e,Supporting & Related Material,FDA-2008-N-0163-0261,FDA-2008-N-0163,"reference 15b - ""measurement of hand tremor induced by industrial exposure to metallic mercury"" - [dental devices: classification of encapsulated amalgam alloy and dental mercury and reclassification of dental mercury; issuance of special controls for amalgam alloy; final rule]",0,0
0900006480a003c2,Supporting & Related Material,FDA-2008-N-0163-0267,FDA-2008-N-0163,"reference 86 - ""estimated pregnancy rates by outcome for the united states, 1990-2004, national vital statistics reports, cdc, april 14, 2008 "" - [dental devices: classification of encapsulated amalgam alloy and dental mercury and reclassification of dental mercury; issuance of special controls for amalgam alloy; final rule]",0,0
0900006480a003c8,Supporting & Related Material,FDA-2008-N-0163-0268,FDA-2008-N-0163,"reference 88 - ""preliminary estimates: labeling and related testing costs for medical glove manufacturers, eastern research group memorandum, january 18, 1999"" - [dental devices: classification of encapsulated amalgam alloy and dental mercury and reclassification of dental mercury; issuance of special controls for amalgam alloy; final rule]",0,0
0900006480a24613,Supporting & Related Material,FDA-2008-N-0163-0280,FDA-2008-N-0163,"reference 13 - mundy, fda chief eyes device group - [citizens for health, et al. - petition for reconsideration]",0,0
0900006480a24784,Supporting & Related Material,FDA-2008-N-0163-0288,FDA-2008-N-0163,"reference 21 - dickinson, fda amalgam science called 'absurd' in new experts attack, august 5, 2009 - [citizens for health, et al. - petition for reconsideration]",0,0
09000064809ff68b,Supporting & Related Material,FDA-2008-N-0163-0257,FDA-2008-N-0163,"reference 12 - ""dental amalgam and alternative restorative materials: an update report to the environment health policy committee, september 1997"" - [dental devices: classification of encapsulated amalgam alloy and dental mercury and reclassification of dental mercury; issuance of special controls for amalgam alloy; final rule]",0,0
09000064809ffa77,Supporting & Related Material,FDA-2008-N-0163-0262,FDA-2008-N-0163,"reference 52 - u.s. environmental protection agency (epa) - ""integrated risk information system (iris) screening-level literature review--mercuric chloride, 2002"" - [dental devices: classification of encapsulated amalgam alloy and dental mercury and reclassification of dental mercury; issuance of special controls for amalgam alloy; final rule]",0,0
0900006480a2452b,Supporting & Related Material,FDA-2008-N-0163-0273,FDA-2008-N-0163,"reference 5 - consumers for dental choice fda, june 9, 2009 re: concerns about mercury amalgam regulation and your henry schein board membership - [citizens for health, et al. - petition for reconsideration]",0,0
0900006480a24534,Supporting & Related Material,FDA-2008-N-0163-0275,FDA-2008-N-0163,"reference 7 - consumers for dental choice acting fda chief counsel, july 9, 2009 - [citizens for health, et al. - petition for reconsideration]",0,0
0900006480a2460e,Supporting & Related Material,FDA-2008-N-0163-0278,FDA-2008-N-0163,"reference 10 - landers, american medical news, jan. 14, 2008, questioning kids - [citizens for health, et al. - petition for reconsideration]",0,0
0900006480a24611,Supporting & Related Material,FDA-2008-N-0163-0279,FDA-2008-N-0163,"reference 11 - janis, baltimore city paper, feb. 8, 2006, q+a, dr. joshua sharfstein - [citizens for health, et al. - petition for reconsideration]",0,0
0900006480a24614,Supporting & Related Material,FDA-2008-N-0163-0281,FDA-2008-N-0163,"reference 14 - dickinson, a 'shocking' decision - bias seen in dental amalgams rule  - [citizens for health, et al. - petition for reconsideration]",0,0
0900006482d3c6c6,Supporting & Related Material,FDA-2017-P-6918-0007,FDA-2017-P-6918,reference 2 - standardizing terms for clinical pharmacogenetic test results re citizen petition from st. jude children's research hospital,0,0
0900006482d3c6c7,Supporting & Related Material,FDA-2017-P-6918-0006,FDA-2017-P-6918,reference 3 - clinical practice guideline: tonsillectomy in children re citizen petition from st. jude children's research hospital,0,0
0900006482d3c6c8,Supporting & Related Material,FDA-2017-P-6918-0005,FDA-2017-P-6918,reference 4 - recurrent hypoxemia in young children with obstructive sleep apnea is associated with reduced opioid requirement for analgesia re citizen petition from st. jude children's research hospital,0,0
0900006482d3c9a0,Supporting & Related Material,FDA-2017-P-6918-0015,FDA-2017-P-6918,table 1 cases of toxicity in children after receiving codeine re citizen petition from st. jude children's research hospital re citizen petition from st. jude children's research hospital,0,0
0900006482d3c998,Supporting & Related Material,FDA-2017-P-6918-0003,FDA-2017-P-6918,reference 8 - clinical pharmacogenetics implementation consortium guideline for cytochrome p450 2d6 genotype and codeine therapy re citizen petition from st. jude children's research hospital,0,0
0900006482d3c99e,Supporting & Related Material,FDA-2017-P-6918-0009,FDA-2017-P-6918,reference 17 - systematic evaluation of commercial pharmacogenetic testing in psychiatry re citizen petition from st. jude children's research hospital,0,0
0900006482d3c99f,Supporting & Related Material,FDA-2017-P-6918-0016,FDA-2017-P-6918,reference 18 - pharmacogenetics for safe codeine use in sickle cell disease re citizen petition from st. jude children's research hospital,0,0
0900006482d3c99b,Supporting & Related Material,FDA-2017-P-6918-0012,FDA-2017-P-6918,reference 10 - pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to cyp2d6 duplication re citizen petition from st. jude children's research hospital,0,0
0900006482d3c6c1,Other,FDA-2017-P-6918-0001,FDA-2017-P-6918,citizen petition from st. jude children's research hospital,0,0
0900006482d3c6c5,Supporting & Related Material,FDA-2017-P-6918-0008,FDA-2017-P-6918,reference list re citizen petition from st. jude children's research hospital,0,0
0900006482d3c999,Supporting & Related Material,FDA-2017-P-6918-0014,FDA-2017-P-6918,reference 8(suppl) - clinical pharmacogenetics implementation consortium guideline for cytochrome p450 2d6 genotype and codeine therapy re citizen petition from st. jude children's research hospital,0,0
0900006482d3c99c,Supporting & Related Material,FDA-2017-P-6918-0011,FDA-2017-P-6918,reference 11 - preemptive clinical pharmacogenetics implementation current programs in five united states medical centers re citizen petition from st. jude children's research hospital,0,0
0900006482d3c99d,Supporting & Related Material,FDA-2017-P-6918-0010,FDA-2017-P-6918,reference 15 - challenges in ordering and interpreting pharmacogenomic tests in clinical practice re citizen petition from st. jude children's research hospital,0,0
0900006482d3c6c3,Other,FDA-2017-P-6918-0002,FDA-2017-P-6918,acknowledgment letter from fda ddm to st. jude children’s research hospital,0,0
0900006482d3c997,Supporting & Related Material,FDA-2017-P-6918-0004,FDA-2017-P-6918,reference 6 - bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation re citizen petition from st. jude children's research hospital,0,0
0900006482d3c99a,Supporting & Related Material,FDA-2017-P-6918-0013,FDA-2017-P-6918,reference 9 - codeine use among children in the united states_a nationally representative study from 1996 to 2013 re citizen petition from st. jude children's research hospital,0,0
0900006483f2093e,Other,FDA-2017-D-5712-0002,FDA-2017-D-5712,fda and industry actions on de novo classification requests: effect on fda review clock and goals; guidance for industry and food and drug administration staff,1,0
0900006484dbaf21,Other,FDA-2017-D-5712-0003,FDA-2017-D-5712,fda and industry actions on de novo classification requests: effect on fda review clock and goals; guidance for industry and food and drug administration staff,1,0
0900006482b92175,Other,FDA-2017-D-5712-0001,FDA-2017-D-5712,guidance for industry on fda and industry actions on de novo classification requests effect on fda review clock and goals,0,0
090000648207861c,Notice,FDA-2016-D-1399-0001,FDA-2016-D-1399,"procedures for evaluating appearance issues and granting  authorizations for participation in food and drug administration advisory committees; draft guidance for the public, food and drug administration advisory committee members, and food and drug administration staff; availability",1,0
090000648225ad97,Notice,FDA-2016-D-1399-0003,FDA-2016-D-1399,"procedures for evaluating appearance issues and granting  authorizations for participation in food and drug administration  advisory committees; draft guidance for the public, food and drug administration advisory committee members, and food and drug administration staff; availability; extension of comment period",1,0
090000648207942c,Other,FDA-2016-D-1399-0002,FDA-2016-D-1399,"procedures for evaluating appearance issues and granting authorizations for participation in fda advisory committees; guidance for the public, fda advisory committee members, and fda staff; draft guidance",0,0
0900006482131cd2,Other,FDA-2016-D-1853-0002,FDA-2016-D-1853,unique device identification system: form and content of the unique device identifier (udi); draft guidance for industry and food and drug administration staff,1,0
0900006484bd5e43,Notice,FDA-2016-D-1853-0029,FDA-2016-D-1853,unique device identification system: form and content of the unique device identifier; guidance for industry and food and drug administration staff; availability,1,0
0900006484bd83cc,Other,FDA-2016-D-1853-0030,FDA-2016-D-1853,unique device identification system: form and content of the unique device identifier (udi); guidance for industry and food and drug administration staff,1,0
09000064822183e6,Notice,FDA-2016-D-1853-0012,FDA-2016-D-1853,"agency information collection activities; proposed collection; 
comment request; unique device identification system",0,0
09000064821222de,Notice,FDA-2016-D-1853-0001,FDA-2016-D-1853,"unique device identification system: form and content of the unique
device identifier; draft guidance for industry and food and drug
administration staff; availability and request for comments",1,0
0900006482611b63,Notice,FDA-2016-D-1853-0026,FDA-2016-D-1853,"agency information collection activities; announcement of office of
management and budget approvals",0,0
09000064804dfc8f,Notice,FDA-2001-D-0162-0001,FDA-2001-D-0162,fda,0,0
0900006482d56c24,Notice,FDA-2017-N-6395-0001,FDA-2017-N-6395,request for nominations of members for the clinical trials transformation initiative/food and drug administration patient  engagement collaborative,1,0
0900006484c0a30f,Notice,FDA-2017-N-6395-0002,FDA-2017-N-6395,"request for applications for new members of the clinical trials 
transformation initiative/food and drug administration patient 
engagement collaborative",1,0
09000064804f5fb5,Other,FDA-1999-N-4096-0002,FDA-1999-N-4096,cdrh teleconference for fda stakeholders on 4/28/99  - agenda,0,0
09000064804f5fc0,Other,FDA-1999-N-4096-0007,FDA-1999-N-4096,paul g king consulting - comment,0,0
09000064804f5fb7,Other,FDA-1999-N-4096-0003,FDA-1999-N-4096,cryogen inc - testimony,0,0
09000064804f5fb8,Other,FDA-1999-N-4096-0004,FDA-1999-N-4096,chemically associated neurological disorders - testimony,0,0
09000064804f5fb4,Other,FDA-1999-N-4096-0001,FDA-1999-N-4096,cdrh teleconference for fda stakeholders on 4/28/99  - transcript,0,0
09000064804f5fb9,Other,FDA-1999-N-4096-0005,FDA-1999-N-4096,health industries manufacturers association (hima)  - testimony,0,0
09000064837ae186,Other,FDA-2018-P-1880-0005,FDA-2018-P-1880,response letter from fda cder to louis morris aledort md,0,0
0900006483266230,Other,FDA-2018-P-1880-0002,FDA-2018-P-1880,"acknowledgment letter from fda ddm to louis morris aledort, md",0,0
09000064832654b0,Other,FDA-2018-P-1880-0001,FDA-2018-P-1880,citizens petition from louis morris aledort md,0,0
0900006484e66067,Notice,FDA_FRDOC_0001-11009,FDA_FRDOC_0001,notice to public of website location of center for devices and radiological health fiscal year 2022 proposed guidance development,0,0
0900006481703679,Supporting & Related Material,FDA-2008-N-0176-0020,FDA-2008-N-0176,"reference 6-tables 1-5, 1-9, 1-10, 1-14, 1-20, 1-24, 2-8, 2-9, 2-22, 2-23, 2-46 & 2-47 from u. s. pet ownership & demographics sourcebook 2012 edition, reproduced by permission of the america - defining small numbers of animals for minor use designation; periodic reassessment",0,0
090000648170367a,Supporting & Related Material,FDA-2008-N-0176-0014,FDA-2008-N-0176,list of references,0,0
090000648170367b,Supporting & Related Material,FDA-2008-N-0176-0015,FDA-2008-N-0176,"reference 1- sheep and goats – sheep and lamb inventory by class, national agricultural statistics service (nass), united states department of agriculture (usda), february 1, 2013-defining small numbers of animals for minor use designation; periodic reassessment",0,0
090000648170375e,Supporting & Related Material,FDA-2008-N-0176-0017,FDA-2008-N-0176,"reference 3- brakke consulting, inc., “update of population estimates, disease incidence rates, drug development costs and treatment costs for companion animals,” september 6, 2013 - defining small numbers of animals for minor use designation; periodic reassessment",0,0
090000648170375f,Supporting & Related Material,FDA-2008-N-0176-0018,FDA-2008-N-0176,"reference 4- figures 8, 15, & 27 from u. s. pet ownership & demographics sourcebook 2002 edition, reproduced by permission of the american veterinary medical association - defining small numbers of animals for minor use designation; periodic reassessment",0,0
09000064809fbaec,Supporting & Related Material,FDA-2008-N-0176-0010,FDA-2008-N-0176,"reference list and reference 1 - ""brakke consulting, inc., ‘‘disease incidence rates, drug development and treatment costs,’’ september 2005"" - [defining small number of animals for minor use designation]",0,0
09000064803f6f8d,Supporting & Related Material,FDA-2008-N-0176-0002,FDA-2008-N-0176,defining small number of animals for minor use designation - references,0,0
0900006481703760,Supporting & Related Material,FDA-2008-N-0176-0019,FDA-2008-N-0176,"reference 5- tables 1-5, 1-10, & 1-20 from u. s. pet ownership & demographics sourcebook 2007 edition, reproduced by permission of the american veterinary medical association - defining small numbers of animals for minor use designation; periodic reassessment",0,0
0900006480a12f05,Rule,FDA-2008-N-0176-0009,FDA-2008-N-0176,"defining ""small number of animals"" for minor use designation",0,0
090000648170367c,Supporting & Related Material,FDA-2008-N-0176-0016,FDA-2008-N-0176,"reference 2- brakke consulting, inc., “disease incidence rates, drug
development and treatment costs,” september, 2005 - defining small numbers of animals for minor use designation; periodic reassessment",0,0
09000064803fc39d,Proposed Rule,FDA-2008-N-0176-0001,FDA-2008-N-0176,defining small number of animals for minor use designation,0,0
09000064809fbaee,Supporting & Related Material,FDA-2008-N-0176-0012,FDA-2008-N-0176,"reference 3 - ""american veterinary medical association, ‘‘u.s. pet ownership & demographics sourcebook,’’ 2002"" - [defining small number of animals for minor use designation]",0,0
09000064809fbaed,Supporting & Related Material,FDA-2008-N-0176-0011,FDA-2008-N-0176,"reference 2 - ""brakke consulting, inc., pharmaceutical pricing for companion animal products, december 1, 2008"" - [defining small number of animals for minor use designation]",0,0
0900006481702f42,Notice,FDA-2008-N-0176-0013,FDA-2008-N-0176,"defining small numbers of animals for minor use designation; periodic
reassessment",0,0
0900006481fd113b,Proposed Rule,FDA-2016-D-1164-0001,FDA-2016-D-1164,qualified facility attestation using form fda 3942a (for human food) or form fda 3942b (for animal food); draft guidance for industry; availability; agency information collection activities; proposed collection; comment request,1,0
09000064839957e8,Other,FDA-2016-D-1164-0010,FDA-2016-D-1164,form fda 3942a from hillside creamery,0,0
09000064837008bf,Other,FDA-2016-D-1164-0008,FDA-2016-D-1164,"determination of status as a qualified facility under part 117: current good manufacturing practice, hazard analysis, and risk-based preventive controls for human food and part 507: current good manufacturing practice, hazard analysis, and risk-based preventive controls for food for animals; guidance for industry",1,0
09000064837801b3,Notice,FDA-2016-D-1164-0009,FDA-2016-D-1164,agency information collection activities; announcement of office of management and budget approvals,0,0
09000064833ed951,Notice,FDA-2016-D-1164-0005,FDA-2016-D-1164,"agency information collection activities; proposals, submissions, and approvals: qualified facility attestation",0,0
09000064839ac383,Other,FDA-2016-D-1164-0011,FDA-2016-D-1164,form fda 3942a from natural ice fruits inc,0,0
0900006481fd0b06,Other,FDA-2016-D-1164-0002,FDA-2016-D-1164,guidance for qualified facility attestation using form fda 3942a (for human food) and form fda 3942b (for animal food) draft guidance for industry,1,0
09000064836fe3e4,Notice,FDA-2016-D-1164-0007,FDA-2016-D-1164,"determination of status as a qualified facility under part 117: current good manufacturing practice, hazard analysis, and risk-based preventive controls for human food and part 507: current good manufacturing practice, hazard analysis, and risk-based preventive controls for food for animals; guidance for industry",1,0
0900006484a71bd3,Other,FDA-2021-P-0305-0001,FDA-2021-P-0305,citizen petition from donavan melton,0,0
0900006484c03bd7,Other,FDA-2021-P-0305-0003,FDA-2021-P-0305,final response to  donavan melton from fda cvm,0,0
0900006484a71bd6,Other,FDA-2021-P-0305-0002,FDA-2021-P-0305,acknowledgment letter from fda dms to donavan melton,0,0
090000648203f737,Supporting & Related Material,FDA-2013-N-0125-0018,FDA-2013-N-0125,reference 1 frequently asked questions guidance re use of symbols in labeling,0,0
090000648203f738,Supporting & Related Material,FDA-2013-N-0125-0019,FDA-2013-N-0125,reference 2 national technology transfer  act re use of symbols in labeling,0,0
090000648203df63,Supporting & Related Material,FDA-2013-N-0125-0017,FDA-2013-N-0125,index list of references re use of symbols in labeling,0,0
09000064820f48bd,Supporting & Related Material,FDA-2013-N-0125-0023,FDA-2013-N-0125,reference 6 final regulatory impact analysis re use of certain symbols in labeling,0,0
090000648203d414,Rule,FDA-2013-N-0125-0016,FDA-2013-N-0125,use of symbols in labeling,0,0
090000648203f739,Supporting & Related Material,FDA-2013-N-0125-0020,FDA-2013-N-0125,reference 3 circular a119 re use of symbols in labeling,0,0
090000648203f73a,Supporting & Related Material,FDA-2013-N-0125-0021,FDA-2013-N-0125,reference 4 ivd symbols guidance re use of symbols in labeling,0,0
0900006484635b8a,Other,FDA-2013-N-0125-0025,FDA-2013-N-0125,guidance for industry alternative to certain prescription device labeling requirements,0,0
090000648129c6c1,Proposed Rule,FDA-2013-N-0125-0001,FDA-2013-N-0125,use of certain symbols in labeling,0,0
090000648203f73b,Supporting & Related Material,FDA-2013-N-0125-0022,FDA-2013-N-0125,06 reference 5 alternative to prescription device labeling guidance re use of symbols in labeling,0,0
09000064824264d3,Notice,FDA-2013-N-0125-0024,FDA-2013-N-0125,"agency information collection activities; proposals, submissions, and approvals: announcement of office of management and budget approvals",0,0
09000064849f870c,Other,FDA-2021-P-0084-0001,FDA-2021-P-0084,citizen petition from peggy lillis foundation for c. diff education & advocacy,0,0
09000064849f870f,Other,FDA-2021-P-0084-0002,FDA-2021-P-0084,acknowledgement letter from fda dms to peggy lillis foundation for c. diff education & advocacy,0,0
0900006484bdfa80,Other,FDA-2021-P-0084-0005,FDA-2021-P-0084,interim response letter from fda cber to peggy lillis foundation for c. diff education & advocacy,0,0
0900006481fbdc65,Other,FDA-2015-P-1279-0021,FDA-2015-P-1279,acknowledgement letter from fda ddm to cigar rights of america,0,0
0900006481fbaa04,Other,FDA-2015-P-1279-0013,FDA-2015-P-1279,citizen petition final response from fda ctp to cigar rights of america,0,0
0900006481fbae1d,Other,FDA-2015-P-1279-0016,FDA-2015-P-1279,citizen petition final response from fda ctp to cigar rights of america,0,0
0900006481cef120,Other,FDA-2015-P-1279-0008,FDA-2015-P-1279,citizen petition from cigar rights of america,0,0
0900006481fadea8,Other,FDA-2015-P-1279-0018,FDA-2015-P-1279,citizen petition from cigar rights of america,0,0
0900006481aac5ef,Other,FDA-2015-P-1279-0002,FDA-2015-P-1279,acknowledgement letter from fda ddm to cigar rights of america,0,0
0900006481f866c2,Other,FDA-2015-P-1279-0012,FDA-2015-P-1279,acknowledgement letter from fda ddm to cigar rights of america,0,0
0900006481aac52a,Other,FDA-2015-P-1279-0001,FDA-2015-P-1279,citizen petition from cigar rights of america,0,0
0900006481ad2702,Other,FDA-2015-P-1279-0004,FDA-2015-P-1279,second acknowledgement letter from fda ddm to cigar rights of america,0,0
0900006481ad2700,Other,FDA-2015-P-1279-0003,FDA-2015-P-1279,citizen petition from cigar rights of america regarding hphc (petition 2),0,0
0900006481cef2b5,Other,FDA-2015-P-1279-0009,FDA-2015-P-1279,acknowledgement letter from fda ddm to cigar rights of america,0,0
0900006481faf43a,Supporting & Related Material,FDA-2015-P-1279-0022,FDA-2015-P-1279,appendix: coggins report on health effects of cigar smoking,0,0
0900006482354c53,Other,FDA-2015-P-1279-0023,FDA-2015-P-1279,final response from fda cder to cigar rights of america,0,0
0900006481f86124,Other,FDA-2015-P-1279-0011,FDA-2015-P-1279,citizen petition 5 from cigar rights of america,0,0
0900006481fbae17,Other,FDA-2015-P-1279-0015,FDA-2015-P-1279,citizen petition final response from fda ctp to cigar rights of america,0,0
0900006481bcc3f5,Other,FDA-2015-P-1279-0006,FDA-2015-P-1279,acknowledgment letter from fda ddm to cigar rights of america,0,0
0900006481fae367,Other,FDA-2015-P-1279-0019,FDA-2015-P-1279,acknowledgement letter from fda ddm to cigar rights of america,0,0
0900006481f82d09,Other,FDA-2015-P-1279-0010,FDA-2015-P-1279,interim response from fda ctp to cigar rights of america - tentative - signed,0,0
0900006481fbaec2,Other,FDA-2015-P-1279-0017,FDA-2015-P-1279,citizen petition final response from fda ctp to cigar rights of america,0,0
0900006481bcc3f2,Other,FDA-2015-P-1279-0005,FDA-2015-P-1279,citizen petition from cigar rights of america,0,0
0900006481fbdc60,Other,FDA-2015-P-1279-0020,FDA-2015-P-1279,citizen petition from cigar rights of america,0,0
0900006481fbaa07,Other,FDA-2015-P-1279-0014,FDA-2015-P-1279,citizen petition final response from fda ctp to cigar rights of america,0,0
0900006481c7a70e,Other,FDA-2015-P-1279-0007,FDA-2015-P-1279,interim response letter from fda ctp to cigar rights of america,0,0
0900006484a9d360,Other,FDA-2021-P-0350-0002,FDA-2021-P-0350,acknowledgement letter from fda dms  to donavan melton,0,0
0900006484a9d1dd,Other,FDA-2021-P-0350-0001,FDA-2021-P-0350,citizen petition from donavan melton,0,0
0900006484c03bdc,Other,FDA-2021-P-0350-0003,FDA-2021-P-0350,final response to  donavan melton from fda cvm,0,0
0900006484db14eb,Other,FDA-2021-P-1048-0001,FDA-2021-P-1048,citizen petition from pet schooled,0,0
0900006484db1932,Other,FDA-2021-P-1048-0002,FDA-2021-P-1048,acknowledgment letter from fda dms to pet schooled,0,0
09000064849796b2,Other,FDA-2020-P-2237-0002,FDA-2020-P-2237,acknowledgment letter from fda dms to dr. s. albert edwards,0,0
0900006484c2caa4,Other,FDA-2020-P-2237-0004,FDA-2020-P-2237,response to citizen petition from fda oc to dr. s. albert edwards,0,0
0900006484ba90d1,Other,FDA-2020-P-2237-0003,FDA-2020-P-2237,interim response letter from fda cber to dr. s. albert edwards,0,0
09000064849796b1,Other,FDA-2020-P-2237-0001,FDA-2020-P-2237,citizen petition from dr. s. albert edwards,0,0
09000064804a59ca,Notice,FDA-1999-D-0009-0001,FDA-1999-D-0009,"guidance for industry on the disclosure of materials provided to advisory
committees in connection with open advisory committee meetings convened by the center for drug evaluation and research beginning on january 1, 2000; availability",0,0
09000064804a59d0,Notice,FDA-1999-D-0009-0002,FDA-1999-D-0009,"draft guidance for industry on disclosing information provided to advisory committees in connection with open advisory committee meetings related to the testing or approval of new drugs and convened by the center for drug evaluation and research, beginning on january 1, 2000; availability",0,0
09000064804a59cf,Other,FDA-1999-D-0009-0004,FDA-1999-D-0009,"draft guidance for industry disclosure of materials provided to advisory committees in connection with open advisory committee meetings convened by the center for drug evaluation and research beginning on january 1, 2000",0,0
09000064804a59ce,Other,FDA-1999-D-0009-0003,FDA-1999-D-0009,"guidance for industry disclosure of materials provided to advisory committees in connection with open advisory committee meetings convened by the center for drug evaluation and research beginning on january 1, 2000",0,0
09000064804ed710,Notice,FDA-2000-N-1088-0002,FDA-2000-N-1088,codex alimentarius: meeting of the codex committee on general principles; organization for economic cooperation and development: meeting of the ad hoc group on food safety,1,0
09000064804ed707,Notice,FDA-2000-N-1088-0001,FDA-2000-N-1088,"codex alimentarius: meeting of the codex committee on general principles, organization for economic cooperation and development: meeting of the ad hoc group on food safety",1,0
09000064807d2748,Other,FDA-2008-P-0630-0001,FDA-2008-P-0630,the prescription project of community catalyst - citizen petition,0,0
0900006480f67983,Other,FDA-2008-P-0630-0003,FDA-2008-P-0630,interim response to the prescription project of community catalyst - letter,0,0
09000064807d277c,Other,FDA-2008-P-0630-0002,FDA-2008-P-0630,acknowledgement letter to the prescription project of community catalyst,0,0
0900006481394eec,Notice,FDA-2013-N-0779-0001,FDA-2013-N-0779,retrospective review of draft guidance documents issued before 2010; withdrawal of guidances,0,0
090000648049e6c6,Supporting & Related Material,FDA-2002-N-0279-0016,FDA-2002-N-0279,"tab 4 - [reference (fda to lord, bissell & brook on behalf of apotex, inc. citizen petition)] - background material",0,0
090000648049e6c9,Supporting & Related Material,FDA-2002-N-0279-0024,FDA-2002-N-0279,"tab 14 - [reference (congressional budget office ""how increased competition from generic drugs has affected prices and returns in the pharmaceutical industry"" (july 1998))] - background material",0,0
090000648049e6cc,Supporting & Related Material,FDA-2002-N-0279-0027,FDA-2002-N-0279,tab 20 - [reference (drug expenditure tables)] - background material,0,0
090000648049e7bb,Notice,FDA-2002-N-0279-0011,FDA-2002-N-0279,fda [technical amendment] - notice of final rule,0,0
090000648049e6bf,Supporting & Related Material,FDA-2002-N-0279-0020,FDA-2002-N-0279,"tab 8 - [reference ""congressional house"" (page h 6916 thru h 6921 (9/13/1982))] - background material",0,0
090000648049e6bd,Supporting & Related Material,FDA-2002-N-0279-0012,FDA-2002-N-0279,reference listing - [tab 1 thru 19 reference title list] - background material,0,0
090000648049e6bc,Supporting & Related Material,FDA-2002-N-0279-0013,FDA-2002-N-0279,"tab 1 - [reference ""ftc citizen petiton""] - background material",0,0
090000648049e6c7,Supporting & Related Material,FDA-2002-N-0279-0017,FDA-2002-N-0279,"tab 5 - [reference (guidance for industry ""q7a good manufacturing practice guidance for active pharmaceutical ingredients"")] - background material",0,0
090000648049e7b6,Supporting & Related Material,FDA-2002-N-0279-0009,FDA-2002-N-0279,tab a - omb review (6/18/2000) [final rule page 1 thru 99] - reference,0,0
090000648049e7ae,Supporting & Related Material,FDA-2002-N-0279-0006,FDA-2002-N-0279,tab b - [omb review ([notice of final rule page 99 thru 121 and fda3542a) (6/18/2003)] - reference,0,0
090000648049e6cd,Supporting & Related Material,FDA-2002-N-0279-0019,FDA-2002-N-0279,"tab 7 - [reference andrx pharmaceuticals, inc. v. biovail corporation international and tommy thompson, secretary dhhs] - background material",0,0
090000648049e6cb,Supporting & Related Material,FDA-2002-N-0279-0026,FDA-2002-N-0279,"tab 19 - [reference ""national health care expenditures projections: 2001-2011"" (centers for medicare & medicaid services - office of the actuary)] - background material",0,0
090000648049e7a5,Notice,FDA-2002-N-0279-0002,FDA-2002-N-0279,fda - notice of final rule,0,0
090000648049e7b9,Supporting & Related Material,FDA-2002-N-0279-0010,FDA-2002-N-0279,cover page - omb review (6/18/2003)  - reference,0,0
090000648049e7b1,Supporting & Related Material,FDA-2002-N-0279-0007,FDA-2002-N-0279,tab b - [omb review ([notice of final rule page 1 thru 98)  (6/18/2003)] - reference,0,0
090000648049e7ac,Supporting & Related Material,FDA-2002-N-0279-0005,FDA-2002-N-0279,omb information collection - supporting statement,0,0
090000648049e6c3,Supporting & Related Material,FDA-2002-N-0279-0022,FDA-2002-N-0279,"tab 10 - [reference ""the patent term restoration act of 1983""] (page 48, 56 and 57  lewis a. engman comment)] - background material",0,0
090000648049e6ba,Notice,FDA-2002-N-0279-0001,FDA-2002-N-0279,fda - notice of proposed rule-making,0,0
090000648049e6c4,Supporting & Related Material,FDA-2002-N-0279-0015,FDA-2002-N-0279,tab 3 - [reference (fda to biovail laboratories inc.)]  - background material,0,0
090000648049e6c8,Supporting & Related Material,FDA-2002-N-0279-0018,FDA-2002-N-0279,"tab 6 - [reference (fda to beers, korn, arnold & porter, mcnichol, scheineson, frisch, smith (petiton denial))] - background material",0,0
090000648049e6ca,Supporting & Related Material,FDA-2002-N-0279-0025,FDA-2002-N-0279,"tab 16 - [reference  ""the pediatric exclusivity provision - january 2001 status report to congress"" [dhhs/fda]] - background material",0,0
090000648049e7aa,Supporting & Related Material,FDA-2002-N-0279-0004,FDA-2002-N-0279,omb information collection - supporting statement,0,0
090000648049e7a9,Notice,FDA-2002-N-0279-0003,FDA-2002-N-0279,fda - notice of approval,0,0
090000648049e6c1,Supporting & Related Material,FDA-2002-N-0279-0021,FDA-2002-N-0279,"tab 9 - [reference ""congressional house"" (page h 6922 thru h 6924 (9/13/1982))] - background material",0,0
090000648049e6c0,Supporting & Related Material,FDA-2002-N-0279-0014,FDA-2002-N-0279,"tab 2 - [reference ""generic drug entry prior to patent expiration"" (an ftc study (july 2002))] - background material",0,0
090000648049c9a4,Other,FDA-2002-N-0265-0055,FDA-2002-N-0265,fdc reports - electronic request for appearance,0,0
090000648049c92b,Other,FDA-2002-N-0265-0032,FDA-2002-N-0265,"flowmedica, inc. - electronic request for appearance",0,0
090000648049c96d,Other,FDA-2002-N-0265-0039,FDA-2002-N-0265,inhale therapeutic systems - electronic request for appearance,0,0
090000648049c90c,Other,FDA-2002-N-0265-0023,FDA-2002-N-0265,tom steinke research company - electronic request for appearance,0,0
090000648049c8e0,Other,FDA-2002-N-0265-0004,FDA-2002-N-0265,parexel international corporation - electronic request for appearance,0,0
090000648049c925,Other,FDA-2002-N-0265-0029,FDA-2002-N-0265,"vivus, inc. - electronic request for appearance",0,0
090000648049c992,Other,FDA-2002-N-0265-0046,FDA-2002-N-0265,johnson & johnson pharmaceutical r&d - electronic request for appearance,0,0
090000648049c973,Other,FDA-2002-N-0265-0042,FDA-2002-N-0265,"wyeth pharmaceuticals, inc. - electronic request for appearance",0,0
090000648049c9c1,Other,FDA-2002-N-0265-0057,FDA-2002-N-0265,"coley pharmaceutical group, inc. - electronic request for appearance",0,0
090000648049c9e4,Other,FDA-2002-N-0265-0063,FDA-2002-N-0265,alpine group - electronic request for appearance,0,0
090000648049c9a0,Other,FDA-2002-N-0265-0053,FDA-2002-N-0265,hogan & hartson llp - electronic request for appearance,0,0
090000648049c9c7,Other,FDA-2002-N-0265-0060,FDA-2002-N-0265,carnegie mellon university - electronic request for appearance,0,0
090000648049ca11,Other,FDA-2002-N-0265-0074,FDA-2002-N-0265,ethicon endo-surgery - electronic request for appearance,0,0
090000648049c99a,Other,FDA-2002-N-0265-0049,FDA-2002-N-0265,"alquest, inc. - electronic request for appearance",0,0
090000648049c99b,Other,FDA-2002-N-0265-0050,FDA-2002-N-0265,wyeth pharmaceuticals - electronic request for appearance,0,0
090000648049c922,Other,FDA-2002-N-0265-0027,FDA-2002-N-0265,embsi - electronic request for appearance,0,0
090000648049c8de,Other,FDA-2002-N-0265-0003,FDA-2002-N-0265,"medtronic, inc. - electronic request for appearance",0,0
090000648049c8ff,Other,FDA-2002-N-0265-0016,FDA-2002-N-0265,patton boggs llp - electronic request for appearance,0,0
090000648049c8fd,Other,FDA-2002-N-0265-0015,FDA-2002-N-0265,merck research laboratories - electronic request for appearance,0,0
090000648049c934,Other,FDA-2002-N-0265-0037,FDA-2002-N-0265,"medtronic, inc. - electronic request for appearance",0,0
090000648049c9e6,Other,FDA-2002-N-0265-0064,FDA-2002-N-0265,abbott laboratories - electronic request for appearance,0,0
090000648049c9c5,Other,FDA-2002-N-0265-0059,FDA-2002-N-0265,american medical systems - electronic request for appearance,0,0
090000648049c99e,Other,FDA-2002-N-0265-0052,FDA-2002-N-0265,biomerix - electronic request for appearance,0,0
090000648049c9ee,Other,FDA-2002-N-0265-0068,FDA-2002-N-0265,iomai corporation - electronic request for appearance,0,0
090000648049c9ea,Other,FDA-2002-N-0265-0066,FDA-2002-N-0265,bonscience - electronic request for appearance,0,0
090000648049cbdd,Notice,FDA-2002-D-0266-0005,FDA-2002-D-0266,fda,0,0
090000648049cb29,Notice,FDA-2002-D-0266-0001,FDA-2002-D-0266,fda,0,0
090000648049cbdc,Supporting & Related Material,FDA-2002-D-0266-0004,FDA-2002-D-0266,guidance,0,0
090000648049cbd8,Supporting & Related Material,FDA-2002-D-0266-0002,FDA-2002-D-0266,guidance,0,0
090000648049cbda,Supporting & Related Material,FDA-2002-D-0266-0003,FDA-2002-D-0266,guidance,0,0
090000648044cc1a,Notice,FDA-2005-N-0396-0001,FDA-2005-N-0396,fda,0,0
090000648044cc23,Notice,FDA-2005-N-0396-0002,FDA-2005-N-0396,fda,0,0
090000648044cc24,Notice,FDA-2005-N-0396-0003,FDA-2005-N-0396,fda,0,0
090000648044cc29,Notice,FDA-2005-N-0396-0004,FDA-2005-N-0396,fda,0,0
09000064804b49f5,Notice,FDA-2001-D-0012-0001,FDA-2001-D-0012,fda,0,0
09000064804b4a3f,Notice,FDA-2001-D-0012-0002,FDA-2001-D-0012,fda,0,0
090000648056e80f,Notice,FDA-1998-N-0050-0017,FDA-1998-N-0050,quarterly list of guidance documents at the food and drug administration; notice,1,0
090000648056e820,Notice,FDA-1998-N-0050-0005,FDA-1998-N-0050,annual comprehensive list of guidance documents at the food and drug administration; notice,1,0
090000648056e809,Notice,FDA-1998-N-0050-0011,FDA-1998-N-0050,quarterly list of guidance documents at the food and drug administration; notice,1,0
090000648056e80a,Notice,FDA-1998-N-0050-0012,FDA-1998-N-0050,quarterly list of guidance documents at the food and drug administration; notice,1,0
090000648056e80b,Other,FDA-1998-N-0050-0013,FDA-1998-N-0050,"letter from the weinberg group, inc to fda ddm",0,0
090000648457a7fb,Other,FDA-1998-N-0050-0022,FDA-1998-N-0050,cpg sec. 540.375 canned salmon - adulteration involving decomposition withdrawn 3-22-2010,0,0
0900006480b2c09d,Notice,FDA-1998-N-0050-0007,FDA-1998-N-0050,comprehensive list of guidance documents at food and drug administration; notice,1,0
090000648056e80c,Notice,FDA-1998-N-0050-0014,FDA-1998-N-0050,annual comprehensive list of guidance documents at the food and drug administration; notice,1,0
090000648056e813,Notice,FDA-1998-N-0050-0002,FDA-1998-N-0050,annual comprehensive list of guidance documents at the food and drug administration,1,0
0900006480ac4727,Notice,FDA-1998-N-0050-0006,FDA-1998-N-0050,compliance policy guide section 540-375 canned salmon-adulteration involving decomposition; withdrawal of guidance,0,0
090000648056e817,Notice,FDA-1998-N-0050-0003,FDA-1998-N-0050,annual comprehensive list of guidance documents at the food and drug administration; notice,1,0
090000648056e81c,Notice,FDA-1998-N-0050-0004,FDA-1998-N-0050,annual comprehensive list of guidance documents at the food and drug administration; correction,1,0
090000648056e807,Notice,FDA-1998-N-0050-0009,FDA-1998-N-0050,comprehensive list of current guidance documents at the food and drug administration; notice,1,0
090000648056e80d,Notice,FDA-1998-N-0050-0015,FDA-1998-N-0050,update of guidance documents at the food and drug administration; notice,1,0
090000648056e810,Notice,FDA-1998-N-0050-0018,FDA-1998-N-0050,quarterly list of guidance documents at the food and drug administration; notice,1,0
090000648056e808,Notice,FDA-1998-N-0050-0010,FDA-1998-N-0050,comprehensive list of current guidance documents at the food and drug administration; correction,1,0
090000648056e7f4,Notice,FDA-1998-N-0050-0001,FDA-1998-N-0050,annual comprehensive list of guidance documents at the food and drug administration; notice,1,0
09000064846bd37f,Other,FDA-2020-D-1444-0001,FDA-2020-D-1444,drug safety information - fda's communication to the public,0,0
09000064804efd60,Other,FDA-2000-N-1247-0001,FDA-2000-N-1247,fda concept paper: drug products that present demonstrable difficulties - report,0,0
09000064805b3a4e,Supporting & Related Material,FDA-1985-D-0012-0003,FDA-1985-D-0012,guidance,0,0
09000064805b3a4d,Notice,FDA-1985-D-0012-0002,FDA-1985-D-0012,fda,0,0
09000064805b3a4a,Notice,FDA-1985-D-0012-0001,FDA-1985-D-0012,fda,0,0
09000064805b3a4f,Supporting & Related Material,FDA-1985-D-0012-0004,FDA-1985-D-0012,guidance,0,0
090000648056e4f5,Supporting & Related Material,FDA-1998-D-0039-0002,FDA-1998-D-0039,guidance,0,0
090000648056e4fd,Notice,FDA-1998-D-0039-0003,FDA-1998-D-0039,fda,0,0
090000648056e4ed,Notice,FDA-1998-D-0039-0001,FDA-1998-D-0039,fda,0,0
0900006480b214bb,Supporting & Related Material,FDA-2009-N-0247-0256,FDA-2009-N-0247,blue cross blue shield association (bcbsa) re fda-2009-n-0247-0222,0,0
0900006480bc6d30,Notice,FDA-2009-N-0247-0260,FDA-2009-N-0247,fda transparency initiative: improving transparency to regulated industry,0,0
09000064809e7abb,Other,FDA-2009-N-0247-0070,FDA-2009-N-0247,"public meeting fda transparency task force, june 24, 2009 - transcript",0,0
09000064809e5664,Supporting & Related Material,FDA-2009-N-0247-0056,FDA-2009-N-0247,see fda-2009-n-0247-0094,0,0
0900006480fab1d4,Notice,FDA-2009-N-0247-0301,FDA-2009-N-0247,transparency initiative: exploratory program to increase access to compliance and enforcement data,0,0
09000064809e5699,Other,FDA-2009-N-0247-0066,FDA-2009-N-0247,"medical device safety institute - ""fda transparency:suggestions for improving public health (w.maisel)"" - [public meeting fda transparency task force, june 24, 2009] - testimony",0,0
09000064809e563c,Other,FDA-2009-N-0247-0054,FDA-2009-N-0247,"breast cancer fund - ""testimony for the fda transparency task force (e.napalo)"" - [public meeting fda transparency task force, june 24, 2009] - testimony",0,0
09000064809e5639,Other,FDA-2009-N-0247-0053,FDA-2009-N-0247,"idsn (international document solutions network) - ""technology improves food safety communication (b.kelser)"" - [public meeting fda transparency task force, june 24, 2009] - testimony",1,0
09000064809e5666,Other,FDA-2009-N-0247-0071,FDA-2009-N-0247,"milford medical laboratory (s.lee) - [public meeting fda transparency task force, june 24, 2009] - testimony",0,0
0900006480a51ccd,Supporting & Related Material,FDA-2009-N-0247-0158,FDA-2009-N-0247,"final versions - three hypothetical case studies, presentation date november 3, 2009 (food and drug administration transparency task force; public meeting;request for comments) - reference",1,0
0900006480f8b7c2,Notice,FDA-2009-N-0247-0300,FDA-2009-N-0247,report on good guidance practices improving efficiency and transparency; availability,0,0
09000064816c39bd,Notice,FDA-2009-N-0247-0310,FDA-2009-N-0247,"food and drug administration transparency initiative: increasing
public access to the food and drug administration’s compliance and
enforcement data; availability",1,0
0900006480f4b7a6,Other,FDA-2009-N-0247-0282,FDA-2009-N-0247,food and drug administration transparency initiative: draft proposals for public comment to increase transparency by promoting greater access to the agency’s compliance and enforcement data - report,1,0
09000064809e5b20,Other,FDA-2009-N-0247-0064,FDA-2009-N-0247,"the senior citizens league ""statement of s.benton"" [public meeting fda transparency task force, june 24, 2009] - testimony",0,0
09000064809e5b15,Other,FDA-2009-N-0247-0061,FDA-2009-N-0247,"bray patrick-lake - ""enhancing transparency via patient advocacy in fda regulated clinical research trials"" [public meeting fda transparency task force, june 24, 2009] - testimony",0,0
09000064809e5b11,Other,FDA-2009-N-0247-0060,FDA-2009-N-0247,"medical device manufacturers association (mdma) - ""recommendations to promote predictability and transparency (m.leahy)"" - [public meeting fda transparency task force, june 24, 2009] - testimony",0,0
09000064809e630b,Other,FDA-2009-N-0247-0067,FDA-2009-N-0247,"the tatia oden french memorial foundation - "" recommendations to the transparency task force (k.oden)"" - [public meeting fda transparency task force, june 24, 2009] - testimony",0,0
09000064809e630d,Other,FDA-2009-N-0247-0068,FDA-2009-N-0247,"david lim, ph.d. rac - ""transparencey 101""-  [public meeting fda transparency task force, june 24, 2009] - testimony",0,0
0900006480a0367a,Other,FDA-2009-N-0247-0124,FDA-2009-N-0247,american association for health freedom (aahf) to the division of dockets management - [multiple submitters=801] - letter,0,0
0900006480abb6c5,Other,FDA-2009-N-0247-0183,FDA-2009-N-0247,summary of listening sessions with industry - reference,0,0
09000064809e5b0d,Other,FDA-2009-N-0247-0059,FDA-2009-N-0247,"genetic alliance - ""transforming health through genetics promoting an environment of openness (k.zonno)"" [public meeting fda transparency task force, june 24, 2009] - testimony",0,0
09000064809e563e,Other,FDA-2009-N-0247-0051,FDA-2009-N-0247,"microsoft® - ""enabling transparent goverance with gov 2.0 (c.brubaker)""  [public meeting fda transparency task force, june 24, 2009] - testimony",0,0
0900006480a0c1f1,Notice,FDA-2009-N-0247-0128,FDA-2009-N-0247,food and drug administration transparency task force; reopening comment period,1,0
0900006480a3ba54,Notice,FDA-2009-N-0247-0136,FDA-2009-N-0247,food and drug administration transparency task force; public meeting; request for comments,1,0
09000064809c3c29,Notice,FDA-2009-N-0247-0001,FDA-2009-N-0247,food and drug administration transparency task force; public meeting,1,0
0900006480a517a4,Notice,FDA-2009-N-0526-0001,FDA-2009-N-0526,safe use initiative; availability of information,0,0
0900006484c3d0c8,Other,FDA-2021-P-0882-0001,FDA-2021-P-0882,citizen petition from chelsea kent,0,0
0900006484c3dada,Other,FDA-2021-P-0882-0002,FDA-2021-P-0882,acknowledgement letter from fda dms to chelsea kent,0,0
0900006484c3dae3,Other,FDA-2021-P-0884-0002,FDA-2021-P-0884,acknowledgement letter from fda dms to ronald brock,0,0
0900006484c3dec4,Other,FDA-2021-P-0884-0001,FDA-2021-P-0884,citizen petition from ronald brock,0,0
0900006484c3dae1,Other,FDA-2021-P-0883-0001,FDA-2021-P-0883,citizen petition from wanda brock,0,0
0900006484c3dec1,Other,FDA-2021-P-0883-0002,FDA-2021-P-0883,acknowledgement letter from fda dms to wanda brock,0,0
0900006484c6c5aa,Other,FDA-2021-P-0912-0002,FDA-2021-P-0912,acknowledgment letter from fda dms to harry duty,0,0
0900006484c6c1d8,Other,FDA-2021-P-0912-0001,FDA-2021-P-0912,citizen petition from harry duty,0,0
0900006484dcafe8,Other,FDA-2021-P-1126-0001,FDA-2021-P-1126,citizen petition from harry duty,0,0
0900006484dcb3d2,Other,FDA-2021-P-1126-0002,FDA-2021-P-1126,acknowledgment letter from fda dms to harry duty,0,0
0900006483d7dcb2,Supporting & Related Material,FDA-2019-P-1236-0005,FDA-2019-P-1236,risk-based licensing of biosimilars re memorandum of meeting - listening meeting with dr. sarfaraz niazi regarding biosimilars,0,0
0900006483ae80ed,Other,FDA-2019-P-1236-0002,FDA-2019-P-1236,acknowledgment letter from fda ddm to sarfaraz niazi,0,0
0900006483ae11e2,Other,FDA-2019-P-1236-0001,FDA-2019-P-1236,citizen petition from sarfaraz k. niazi,0,0
0900006483d7dcaf,Other,FDA-2019-P-1236-0004,FDA-2019-P-1236,memorandum of meeting - listening meeting with dr. sarfaraz niazi regarding biosimilars,0,0
0900006483f86af3,Other,FDA-2019-P-1236-0006,FDA-2019-P-1236,interim response letter from fda cder to sarfaraz niazi,0,0
0900006483bf2bd6,Other,FDA-2019-P-1236-0003,FDA-2019-P-1236,testimony from sarfaraz niazi,0,0
090000648248bee8,Other,FDA-2017-P-0428-0001,FDA-2017-P-0428,citizen petition from mucodel pharma llc,0,0
090000648248c2ff,Other,FDA-2017-P-0428-0002,FDA-2017-P-0428,acknowledgment letter from fda ddm to mucodel pharma llc,0,0
09000064824b85e1,Other,FDA-2017-P-0428-0003,FDA-2017-P-0428,memorandum requesting closure of fda-p-2017-0428,0,0
0900006484b47a5b,Supporting & Related Material,FDA-2021-P-0521-0004,FDA-2021-P-0521,references 09 to 16 re citizen petition from linda wastila,0,0
0900006484b47bb7,Supporting & Related Material,FDA-2021-P-0521-0008,FDA-2021-P-0521,references 19 to 23 re citizen petition from linda wastila,0,0
0900006484b5d34f,Other,FDA-2021-P-0521-0072,FDA-2021-P-0521,press release from anonymous,0,0
0900006484b5c50b,Other,FDA-2021-P-0521-0069,FDA-2021-P-0521,press release from anonymous,0,0
0900006484bdf9bd,Other,FDA-2021-P-0521-1533,FDA-2021-P-0521,amended citizen petition for e coalition advocating for adequately  licensed medicines,0,0
0900006484b47a56,Other,FDA-2021-P-0521-0001,FDA-2021-P-0521,citizen petition from linda wastila,0,0
0900006484b47bbc,Supporting & Related Material,FDA-2021-P-0521-0009,FDA-2021-P-0521,references 37 to 47 re citizen petition from linda wastila,0,0
0900006484b47a58,Other,FDA-2021-P-0521-0002,FDA-2021-P-0521,acknowledgment letter from fda dms to linda wastila,0,0
0900006484c0b1d2,Other,FDA-2021-P-0521-1560,FDA-2021-P-0521,withdrawal letter from linda wastila et. al,0,0
0900006484b58f29,Other,FDA-2021-P-0521-0020,FDA-2021-P-0521,press release from petitioner,0,0
0900006484b47a5a,Supporting & Related Material,FDA-2021-P-0521-0003,FDA-2021-P-0521,references 01 to 08 re citizen petition from linda wastila,0,0
0900006484b47a5c,Supporting & Related Material,FDA-2021-P-0521-0007,FDA-2021-P-0521,references 17 to 18 re citizen petition from linda wastila,0,0
0900006484b47bba,Supporting & Related Material,FDA-2021-P-0521-0005,FDA-2021-P-0521,references 24 to 32 re citizen petition from linda wastila,0,0
0900006484b47bbb,Supporting & Related Material,FDA-2021-P-0521-0006,FDA-2021-P-0521,references 33 to 36 re citizen petition from linda wastila,0,0
0900006480633542,Other,FDA-2007-P-0184-0003,FDA-2007-P-0184,judy slome cohain - supplement,0,0
09000064806c06a7,Other,FDA-2007-P-0184-0005,FDA-2007-P-0184,fda response to judy slome cohain - citizen petition denial,0,0
09000064806a9660,Other,FDA-2007-P-0184-0004,FDA-2007-P-0184,judy slome cohain - supplement,0,0
090000648042a728,Other,FDA-2007-P-0184-0001,FDA-2007-P-0184,acknowledgement letter to judy slome cohain,0,0
090000648042a72b,Other,FDA-2007-P-0184-0002,FDA-2007-P-0184,judy slome cohain - citizen petition,0,0
0900006484dc2081,Other,FDA-2021-P-1090-0002,FDA-2021-P-1090,acknowledgment letter from fda dms to pet schooled,0,0
0900006484dc24dc,Other,FDA-2021-P-1090-0001,FDA-2021-P-1090,citizen petition from pet schooled,0,0
0900006484c944b7,Other,FDA-2021-P-0927-0001,FDA-2021-P-0927,citizen petition from donavan melton,0,0
0900006484c95375,Other,FDA-2021-P-0927-0002,FDA-2021-P-0927,acknowledgment letter from fda dms to donavan melton,0,0
0900006482afddc3,Other,FDA-2017-D-3716-0002,FDA-2017-D-3716,low-acid foods packaged in hermetically sealed containers (lacf) regulation and the fda food safety modernization act: guidance for industry,1,0
0900006482afddc4,Other,FDA-2017-D-3716-0003,FDA-2017-D-3716,"seafood haccp and the fda food safety modernization act: guidance for
industry",1,0
0900006482afddc2,Other,FDA-2017-D-3716-0001,FDA-2017-D-3716,juice haccp and the fda food safety modernization act guidance,1,0
0900006481c40270,Other,FDA-2015-P-1404-0004,FDA-2015-P-1404,supplement from allergan,0,0
0900006481ab97c2,Other,FDA-2015-P-1404-0002,FDA-2015-P-1404,"acknowledgement letter from fda ddm to physical pharmaceutica, llc",0,0
0900006481e66e2d,Other,FDA-2015-P-1404-0007,FDA-2015-P-1404,"citizen petition denial response letter from fda cder to (allergan, inc.) and physical pharmaceutica, llc",0,0
0900006481ab97be,Other,FDA-2015-P-1404-0001,FDA-2015-P-1404,"citizen petition from physical pharmaceutica, llc",0,0
0900006484c1c40a,Other,FDA-2021-P-0850-0001,FDA-2021-P-0850,citizen petition from donavan melton,0,0
0900006484c1c411,Other,FDA-2021-P-0850-0002,FDA-2021-P-0850,acknowledgement letter from fda dms to donavan melton,0,0
09000064836b0ed1,Supporting & Related Material,FDA-2018-P-3372-0006,FDA-2018-P-3372,"attachment 4 biofeedback treatment for headache disorders:
a comprehensive efficacy review re: citizen petition from ohio state university",0,0
09000064836b0ed2,Supporting & Related Material,FDA-2018-P-3372-0007,FDA-2018-P-3372,"attachment 5 evidence-based guideline update: pharmacologic
treatment for episodic migraine prevention in adults re: citizen petition from ohio state university",0,0
09000064836b0ecc,Other,FDA-2018-P-3372-0002,FDA-2018-P-3372,acknowledgement letter from fda ddm to ohio state university,0,0
0900006484ab1d70,Other,FDA-2018-P-3372-0008,FDA-2018-P-3372,final response from fda cdrh to ohio state university,0,0
09000064836b0ece,Supporting & Related Material,FDA-2018-P-3372-0003,FDA-2018-P-3372,attachment 1 cochran library virtual reality for stroke rehabilitation (review) re: citizen petition from ohio state university,0,0
09000064836b0ecf,Supporting & Related Material,FDA-2018-P-3372-0004,FDA-2018-P-3372,attachment 2 cochrane library  virtual reality for stroke rehabilitation (review) re: citizen petition from ohio state university,0,0
09000064836b0ed0,Supporting & Related Material,FDA-2018-P-3372-0005,FDA-2018-P-3372,"attachment 3 virtual reality therapy for adults post-stroke: a
systematic review and meta-analysis exploring virtual
environments and commercial games in therapy re: citizen petition from ohio state university",0,0
09000064836b03f4,Other,FDA-2018-P-3372-0001,FDA-2018-P-3372,citizen petition from ohio state university,0,0
090000648048975d,Other,FDA-2003-P-0175-0001,FDA-2003-P-0175,"hf-22 to olsson, frank and weeda, pc",0,0
0900006481013ec6,Notice,FDA-2012-N-0471-0001,FDA-2012-N-0471,agency information collection activities; proposed collection; comment request; user fee cover sheet; form fda 3397,0,0
090000648114ada8,Notice,FDA-2012-N-0471-0002,FDA-2012-N-0471,"agency information collection activities; proposals, submissions, and approvals: prescription drug user fee cover sheet",0,0
0900006481aa6828,Notice,FDA-2012-N-0471-0004,FDA-2012-N-0471,"agency information collection activities: proposed collection;
comment request; user fee cover sheet; form fda 3397",0,0
0900006481cd46f5,Notice,FDA-2012-N-0471-0005,FDA-2012-N-0471,"agency information collection activities; submission for office 
of management and budget review; comment request; user fee cover sheet; form fda 3397",0,0
09000064813a8677,Notice,FDA-2012-N-0471-0003,FDA-2012-N-0471,agency information collection activities; announcement of office of management and budget approval; prescription drug user fee cover sheet; form fda 3397,0,0
0900006480444c25,Other,FDA-2005-N-0281-0013,FDA-2005-N-0281,"december 8, 2005 transcript",0,0
0900006480444c22,Other,FDA-2005-N-0281-0010,FDA-2005-N-0281,"december 7, 2005 transcript",0,0
0900006480444bec,Other,FDA-2005-N-0281-0005,FDA-2005-N-0281,embassy of france / economic department,0,0
0900006480444b44,Notice,FDA-2005-N-0281-0001,FDA-2005-N-0281,fda,0,0
0900006480444b85,Other,FDA-2005-N-0281-0002,FDA-2005-N-0281,"mettler, erik",0,0
0900006480444c24,Other,FDA-2005-N-0281-0012,FDA-2005-N-0281,"december 8, 2005 transcript",0,0
0900006480444bc0,Other,FDA-2005-N-0281-0004,FDA-2005-N-0281,"gallagher, maryann",0,0
0900006480444c01,Other,FDA-2005-N-0281-0007,FDA-2005-N-0281,"agenda for december 7-8, 2005 hearing",0,0
0900006480444c23,Other,FDA-2005-N-0281-0011,FDA-2005-N-0281,"december 7, 2005 transcript",0,0
0900006480444c17,Other,FDA-2005-N-0281-0009,FDA-2005-N-0281,list of attendees for 12/7-8/2005 public meeting,0,0
0900006480444b8f,Other,FDA-2005-N-0281-0003,FDA-2005-N-0281,"frank, lesley",0,0
0900006480444c00,Other,FDA-2005-N-0281-0006,FDA-2005-N-0281,"agenda for december 7-8, 2005 hearing",0,0
0900006480444c02,Other,FDA-2005-N-0281-0008,FDA-2005-N-0281,"director, center for drugs evaluation and research, fda",0,0
09000064804b7e85,Notice,FDA-2000-N-0079-0001,FDA-2000-N-0079,fda,0,0
09000064804e742d,Other,FDA-2001-P-0321-0001,FDA-2001-P-0321,washington legal foundation - citizen petition,0,0
09000064804e7433,Other,FDA-2001-P-0321-0003,FDA-2001-P-0321,fda/associate commissioner for policy response to the washington legal foundation - petition denial,0,0
09000064804e7432,Other,FDA-2001-P-0321-0002,FDA-2001-P-0321,acknowledgement letter to the washington legal foundation,0,0
09000064804d2a37,Other,FDA-2000-P-0183-0001,FDA-2000-P-0183,hfc-1 to robert cohen,0,0
0900006480526fc1,Notice,FDA-1992-D-0021-0001,FDA-1992-D-0021,fda,0,0
0900006480b09be6,Other,FDA-2010-N-0233-0023,FDA-2010-N-0233,meeting attendees - list,0,0
0900006480b09be3,Other,FDA-2010-N-0233-0022,FDA-2010-N-0233,transcript,0,0
0900006480aea319,Notice,FDA-2010-N-0233-0001,FDA-2010-N-0233,the national institutes of health and food and drug administration joint leadership council; stakeholders,1,0
0900006482cd4273,Notice,FDA-2017-N-6475-0001,FDA-2017-N-6475,"food and drug administration fiscal year 2017 performance review board
members",1,0
09000064816bd871,Other,FDA-2014-P-0497-0001,FDA-2014-P-0497,citizen petition from ken surprenant,0,0
090000648213be67,Other,FDA-2014-P-0497-0009,FDA-2014-P-0497,partial approval final response,0,0
09000064818a859f,Other,FDA-2014-P-0497-0003,FDA-2014-P-0497,interim response from fda/cder to ken surprenant,0,0
09000064816be10a,Other,FDA-2014-P-0497-0002,FDA-2014-P-0497,acknowledgement letter from fda ddm to ken surprenant,0,0
090000648043f7eb,Notice,FDA-2005-N-0098-0001,FDA-2005-N-0098,fda,0,0
0900006480739101,Notice,FDA-2005-N-0098-0004,FDA-2005-N-0098,agency informationcollection activities; announcement of office of management and budget approval; survey of current manufacturing practices in the food industry,1,0
090000648043f807,Notice,FDA-2005-N-0098-0002,FDA-2005-N-0098,fda,0,0
090000648043f808,Notice,FDA-2005-N-0098-0003,FDA-2005-N-0098,fda,0,0
09000064804a5a1f,Notice,FDA-1999-D-0012-0006,FDA-1999-D-0012,enforcement policy: electronic records; electronic signatures--compliance policy guide; guidance for fda personnel - notice of correction,0,0
09000064804a5a23,Notice,FDA-1999-D-0012-0004,FDA-1999-D-0012,fda,0,0
09000064804a5a1e,Notice,FDA-1999-D-0012-0005,FDA-1999-D-0012,enforcement policy: electronic records; electronic signatures--compliance policy guide; guidance for fda personnel - notice of availability,0,0
09000064804a5a20,Supporting & Related Material,FDA-1999-D-0012-0007,FDA-1999-D-0012,"draft guidance for industry: part 11, electronic records; electronic signatures--scope and application - [draft guidance for industry on ""part 11, electronic records, electronic signatures--scope and application;"" availability of draft guidance and withdrawal of draft part 11 guidance documents and a compliance policy guide]",0,0
09000064804a5a21,Notice,FDA-1999-D-0012-0002,FDA-1999-D-0012,fda,0,0
09000064804a5a1d,Notice,FDA-1999-D-0012-0001,FDA-1999-D-0012,fda,0,0
09000064804a5a22,Notice,FDA-1999-D-0012-0003,FDA-1999-D-0012,fda,0,0
09000064807e8734,Other,FDA-2008-N-0523-0005,FDA-2008-N-0523,plasma protein therapeutics association (ppta) - request for extension comment due date,0,0
09000064807d5bdd,Other,FDA-2008-N-0523-0004,FDA-2008-N-0523,american dental association (ada) - council's statement [re fda-2008-n-0523-0003],0,0
090000648075c348,Notice,FDA-2008-N-0523-0001,FDA-2008-N-0523,fda-regulated products that contain bisphenol-a; request for information,0,0
0900006484db48cb,Other,FDA-2021-N-0859-0028,FDA-2021-N-0859,fda virtual listening session on the oversight of pet food - agenda,1,0
0900006484db94dc,Other,FDA-2021-N-0859-0038,FDA-2021-N-0859,fda virtual listening session on the oversight of pet food- pet food contaminants,1,0
0900006484db9943,Other,FDA-2021-N-0859-0040,FDA-2021-N-0859,fda virtual listening session on the oversight of pet food- center -slides for fda sa center copper canine dog food for video final video removed,1,0
0900006484db9d15,Other,FDA-2021-N-0859-0042,FDA-2021-N-0859,fda virtual listening session on the oversight of pet food- connors - fda presentation slides dec 17sep21,1,0
0900006484db48cd,Other,FDA-2021-N-0859-0029,FDA-2021-N-0859,fda virtual listening session on the oversight of pet food - cvm presentation - 9-24-21,1,0
0900006484db4d21,Other,FDA-2021-N-0859-0030,FDA-2021-N-0859,fda virtual listening session on the oversight of pet food - transcript - 9-24-21,1,0
0900006484db9d17,Other,FDA-2021-N-0859-0043,FDA-2021-N-0859,fda virtual listening session on the oversight of pet food- thixton - fda presentation sept 2021,1,0
0900006484db9d19,Other,FDA-2021-N-0859-0044,FDA-2021-N-0859,fda virtual listening session on the oversight of pet food-  castonguay - dietassociateddcmedalliance_the-impact-of-dcm-related-fda-messaging,1,0
0900006484c4320b,Other,FDA-2021-N-0859-0001,FDA-2021-N-0859,listening session announcement,0,0
0900006484db9941,Other,FDA-2021-N-0859-0039,FDA-2021-N-0859,fda virtual listening session on the oversight of pet food-greenacre - fda ferret diet,1,0
0900006484db9945,Other,FDA-2021-N-0859-0041,FDA-2021-N-0859,fda virtual listening session on the oversight of pet food- smedley - fda's role in ingredient definition development,1,0
0900006482b74fbb,Notice,FDA-2017-N-4952-0001,FDA-2017-N-4952,"food and drug administration clinical trial requirements, regulations, compliance, and good clinical practice; public workshop",1,0
090000648259fb21,Notice,FDA-2017-D-2497-0001,FDA-2017-D-2497,draft revisions to the food and drug administration blueprint for prescriber education for extended-release and long-acting opioids; availability,1,0
0900006482e789bf,Other,FDA-2017-D-2497-0683,FDA-2017-D-2497,opioid analgesic rems education blueprint,0,0
0900006481578a5a,Other,FDA-2012-D-0530-0025,FDA-2012-D-0530,"requests for feedback on medical device submissions: the pre-
submission program and meetings with food and drug administration
staff; guidance for industry and food and drug administration staff",1,0
090000648146a1b7,Notice,FDA-2012-D-0530-0022,FDA-2012-D-0530,agency information collection activities; submission for office of management and budget review; comment request; guidance on medical devices: the pre-submission program and meetings with fda staff,0,0
090000648118589b,Notice,FDA-2012-D-0530-0019,FDA-2012-D-0530,"agency information collection activities; proposals, submissions, and approvals: guidance on medical devices; pre-submission program and meetings with fda staff",0,0
090000648151ce06,Notice,FDA-2012-D-0530-0023,FDA-2012-D-0530,"agency information collection ctivities; announcement of office of
management and budget approval; equests for feedback on medical
device submissions",0,0
0900006483e3c11b,Notice,FDA-2012-D-0530-0032,FDA-2012-D-0530,agency information collection activities; proposed collection; comment request; q-submission program for medical devices,0,0
09000064826680d8,Notice,FDA-2012-D-0530-0030,FDA-2012-D-0530,"agency information collection activities; announcement of office of
management and budget approvals",0,0
09000064821349fc,Notice,FDA-2012-D-0530-0028,FDA-2012-D-0530,agency information collection activities; proposed collection; comment request; pre-submission program for medical devices,0,0
0900006484161392,Notice,FDA-2012-D-0530-0033,FDA-2012-D-0530,agency information collection activities; submission for office of management and budget review; comment request; q-submission program for medical devices,0,0
0900006481094e0c,Other,FDA-2012-D-0530-0002,FDA-2012-D-0530,draft guidance for industry and food and drug administration staff medical devices the pre-submission program and meetings with fda staff,1,0
0900006481576953,Notice,FDA-2012-D-0530-0024,FDA-2012-D-0530,"requests for feedback on medical device submissions: the pre-
submission program and meetings with food and drug administration
staff; guidance for industry and food and drug administration staff;
availability",1,0
09000064810934d0,Notice,FDA-2012-D-0530-0001,FDA-2012-D-0530,draft guidance for industry and food and drug administration staff; medical devices: the pre-submission program and meetings with fda staff; availability,1,0
09000064811aa8e8,Notice,FDA-2012-D-0530-0021,FDA-2012-D-0530,agency information collection activities; submission for office of management and budge review; comment request; guidance on medical devices; pre-submission program and meetings with fda staff; withdrawal,0,0
090000648232063e,Notice,FDA-2012-D-0530-0029,FDA-2012-D-0530,"agency information collection activities; submission for office of
management and budget review; comment request; pre-submission
program for medical devices",0,0
0900006482b95aad,Other,FDA-2012-D-0530-0031,FDA-2012-D-0530,guidance for industry on requests for feedback on medical device submissions the pre-submission program and meetings with food and drug administration staff,1,0
0900006481e84b42,Other,FDA-2012-D-0530-0027,FDA-2012-D-0530,requests for feedback on medical device submissions: the pre-submission program and meetings with food and drug administration staff guidance for industry and food and drug administration staff,1,0
090000648430cf52,Notice,FDA-2012-D-0530-0035,FDA-2012-D-0530,"agency information collection activities; announcement of office of
management and budget approvals",0,0
0900006481e837da,Notice,FDA-2012-D-0530-0026,FDA-2012-D-0530,"request for expressions of interest from coverage organizations;
coverage organizations interested in providing input regarding private
payer coverage to medical device sponsors who request their
participation in a pre-submission meeting with the food and drug
administration",1,0
09000064849823d2,Other,FDA-2019-D-3904-0001,FDA-2019-D-3904,compliance policy guide cpg sec. 110.650 weekly entry filing guidance for industry and fda staff,0,0
09000064844ab694,Notice,FDA-2017-N-0366-0008,FDA-2017-N-0366,"agency information collection activities; submission for office of
management and budget review; comment request; advisory
committee nomination applications",0,0
090000648473bb59,Notice,FDA-2017-N-0366-0009,FDA-2017-N-0366,"agency information collection activities; proposals, submissions, and approvals",0,0
09000064824ad378,Notice,FDA-2017-N-0366-0001,FDA-2017-N-0366,agency information collection activities: proposed collection; comment request; collection of nominations for candidates to serve on the food and drug administration's advisory committees,1,0
0900006484275aef,Notice,FDA-2017-N-0366-0005,FDA-2017-N-0366,agency information collection activities; proposed collection; comment request; advisory committee nomination applications,0,0
0900006482600398,Notice,FDA-2017-N-0366-0003,FDA-2017-N-0366,agency information collection activities; submission for office of management and budget review; comment request; advisory committee nomination applications,0,0
0900006482a9e338,Notice,FDA-2017-N-0366-0004,FDA-2017-N-0366,"agency information collection activities; announcement of office of
management and budget approvals",0,0
09000064825c5090,Notice,FDA-2017-N-1067-0001,FDA-2017-N-1067,"request for comments on food and drug administration 
accreditation scheme for conformity assessment pilot program",1,0
09000064820816a5,Supporting & Related Material,FDA-2016-N-1487-0005,FDA-2016-N-1487,"reference 3 fda draft guidance for industry: implementation of the ""deemed to be a license"" provision re submission of fda import data in the automated commercial environment",0,0
09000064821636fe,Other,FDA-2016-N-1487-0008,FDA-2016-N-1487,request for extension from american association of exporters and importers,0,0
09000064820816a2,Supporting & Related Material,FDA-2016-N-1487-0002,FDA-2016-N-1487,e.o. 13659 re submission of fda import data in the automated commercial environment,0,0
09000064820816a3,Supporting & Related Material,FDA-2016-N-1487-0003,FDA-2016-N-1487,reference 1 automated commercial system and abi catair re submission of fda import data in the automated commercial environment,0,0
09000064820816a4,Supporting & Related Material,FDA-2016-N-1487-0004,FDA-2016-N-1487,reference 2 fda guidance for industry: submitting form fda 2541 re submission of fda import data in the automated commercial environment,0,0
0900006482080496,Proposed Rule,FDA-2016-N-1487-0001,FDA-2016-N-1487,submission of food and drug administration import data in the automated commercial environment,1,0
0900006484a92f39,Rule,FDA-2016-N-1487-0024,FDA-2016-N-1487,electronic import entries; technical amendments,0,0
090000648208ccb9,Supporting & Related Material,FDA-2016-N-1487-0006,FDA-2016-N-1487,reference 4 re submission of fda import data in the automated commercial environment,0,0
09000064823c749b,Supporting & Related Material,FDA-2016-N-1487-0023,FDA-2016-N-1487,"reference 1 final regulatory flexibility analysis, and final unfunded mandates reform act analysis for submission of food and drug administration import data in the automated commercial environment",1,0
09000064823c5ff3,Rule,FDA-2016-N-1487-0022,FDA-2016-N-1487,submission of food and drug administration import data in the  automated commercial environment,1,0
090000648218d4a4,Other,FDA-2016-N-1487-0014,FDA-2016-N-1487,fda response to request for extension from american association of exporters and importers,0,0
090000648050da5e,Other,FDA-1986-P-0015-0001,FDA-1986-P-0015,hfa-305 to pharmaceutical manufacturers assn.,0,0
09000064825ebcfc,Supporting & Related Material,FDA-2017-P-3202-0003,FDA-2017-P-3202,attachment 1 orange book: approved drug products with therapeutic equivalence evaluations,0,0
09000064825ebcfa,Other,FDA-2017-P-3202-0002,FDA-2017-P-3202,acknowledgment letter from fda ddm to foley & lardner llp,0,0
0900006482b2f8df,Other,FDA-2017-P-3202-0004,FDA-2017-P-3202,withdrawal letter from foley & lardner llp,0,0
09000064825ebb42,Other,FDA-2017-P-3202-0001,FDA-2017-P-3202,citizen petition from foley & lardner llp,0,0
09000064804295f2,Notice,FDA-2007-N-0039-0001,FDA-2007-N-0039,fda,0,0
0900006483cdd6ed,Other,FDA-2018-P-4661-0004,FDA-2018-P-4661,"letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
090000648395abc1,Other,FDA-2018-P-4661-0001,FDA-2018-P-4661,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
090000648395b816,Other,FDA-2018-P-4661-0002,FDA-2018-P-4661,"acknowledgment letter from fda ddm to hyman,  phelps, & mcnamara pc",0,0
09000064840a9595,Other,FDA-2018-P-4661-0005,FDA-2018-P-4661,"letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
090000648395bd2f,Supporting & Related Material,FDA-2018-P-4661-0003,FDA-2018-P-4661,"exhibit 1 prescription drug product list from orange book re: citizen petition from hyman, phelps, and mcnamara pc",0,0
0900006484db19d6,Other,FDA-2021-P-1049-0002,FDA-2021-P-1049,acknowledgment letter from fda dms to pet schooled,0,0
0900006484db19b9,Other,FDA-2021-P-1049-0001,FDA-2021-P-1049,citizen petition from pet schooled,0,0
09000064835c3bbb,Other,FDA-2018-P-2997-0003,FDA-2018-P-2997,citizen petition from new civil liberties alliance,0,0
09000064835af2cf,Other,FDA-2018-P-2997-0002,FDA-2018-P-2997,acknowledgment letter from fda ddm to new civil liberties alliance,0,0
0900006483a4dd59,Other,FDA-2018-P-2997-0006,FDA-2018-P-2997,interim response from fda op to new civil liberties alliance,0,0
09000064835af2cb,Other,FDA-2018-P-2997-0001,FDA-2018-P-2997,citizen petition from new civil liberties alliance,0,0
09000064825eafd0,Other,FDA-2017-P-3201-0001,FDA-2017-P-3201,citizen petition from foley & lardner llp,0,0
09000064825ebb3c,Other,FDA-2017-P-3201-0002,FDA-2017-P-3201,acknowledgment letter from fda ddm to  foley & lardner llp,0,0
0900006482b2f77e,Other,FDA-2017-P-3201-0004,FDA-2017-P-3201,withdrawal letter from foley & lardner llp,0,0
09000064825eb986,Supporting & Related Material,FDA-2017-P-3201-0003,FDA-2017-P-3201,attachment 1 orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from foley & lardner llp,0,0
0900006484c63c28,Other,FDA-2021-P-0909-0002,FDA-2021-P-0909,acknowledgement letter from fda dms to donavan melton,0,0
0900006484c63c26,Other,FDA-2021-P-0909-0001,FDA-2021-P-0909,citizen petition from donavan melton,0,0
0900006481224a02,Other,FDA-2013-P-0280-0001,FDA-2013-P-0280,"r.j. reynolds tobacco company, american snuff company, santa fe natural tobacco company, inc. (rai services company) - citizen petition",0,1
0900006481224a49,Other,FDA-2013-P-0280-0002,FDA-2013-P-0280,"acknowledgement letter to r.j. reynolds tobacco company, american snuff company, santa fe natural tobacco company, inc. (rai services company)",0,1
090000648136111a,Other,FDA-2013-P-0280-0003,FDA-2013-P-0280,"fda/oc to r.j. reynolds tobacco company, american snuff company, santa fe natural tobacco company, inc. (rai services company) - petition approval",0,1
090000648048bb7b,Notice,FDA-2003-N-0207-0001,FDA-2003-N-0207,fda,0,0
090000648048bbb6,Notice,FDA-2003-N-0207-0002,FDA-2003-N-0207,fda,0,0
090000648048bbdd,Supporting & Related Material,FDA-2003-N-0207-0004,FDA-2003-N-0207,supporting statement,0,0
090000648048bbdb,Notice,FDA-2003-N-0207-0003,FDA-2003-N-0207,fda,0,0
0900006481aaebfb,Supporting & Related Material,FDA-2015-P-1296-0006,FDA-2015-P-1296,attachment 6 fda inspection report re citizen petition from leclairryan pc,0,0
0900006481aaebfc,Supporting & Related Material,FDA-2015-P-1296-0007,FDA-2015-P-1296,attachment 7 letter from fda to florida board of pharmacy re citizen petition from leclairryan pc,0,0
0900006481aaec00,Supporting & Related Material,FDA-2015-P-1296-0010,FDA-2015-P-1296,attachment 11 drugs marketed by anazao health re citizen petition from leclairryan pc,0,0
0900006481aaec05,Supporting & Related Material,FDA-2015-P-1296-0012,FDA-2015-P-1296,attachment 15 fda guidance for staff and industry compliance policy guides manual re citizen petition from leclairryan pc,0,0
0900006481aaec0a,Supporting & Related Material,FDA-2015-P-1296-0015,FDA-2015-P-1296,"attachment 20 memorandum of understanding between the u.s. nuclear regulatory commission and the u.s. department of health and human services, fda, federal register notice, march 31, 2015 re citizen petition from leclairryan pc",0,0
0900006481aaebfa,Supporting & Related Material,FDA-2015-P-1296-0005,FDA-2015-P-1296,attachment 5 unapproved prescription drugs drugs marketed in the united states that do not have required fda approval re citizen petition from leclairryan pc,0,0
0900006481aaebfd,Supporting & Related Material,FDA-2015-P-1296-0008,FDA-2015-P-1296,"attachment 8 fda warning letter to international isotopes, inc. re citizen petition from leclairryan pc",0,0
0900006481aaec0b,Supporting & Related Material,FDA-2015-P-1296-0016,FDA-2015-P-1296,attachment 21 nuclear pharmacy guideline criteria for determining when to register as a drug establishment re citizen petition from leclairryan pc,0,0
0900006481aaec0c,Supporting & Related Material,FDA-2015-P-1296-0017,FDA-2015-P-1296,attachment 22 letter from fda to florida board of pharmacy re citizen petition from leclairryan pc,0,0
0900006481aaeeeb,Supporting & Related Material,FDA-2015-P-1296-0002,FDA-2015-P-1296,attachment 1 compounded drugs re citizen petition from leclairryan pc,0,0
0900006481aaeeec,Supporting & Related Material,FDA-2015-P-1296-0003,FDA-2015-P-1296,attachment 2 letter from corar to fda regarding proposed compliance policy guide on radiopharmaceutical compounding re citizen petition from leclairryan pc,0,0
0900006481adbd4a,Other,FDA-2015-P-1296-0019,FDA-2015-P-1296,letter from leclairryan pc jubilant draximage to fda ddm,0,0
0900006481aaec09,Supporting & Related Material,FDA-2015-P-1296-0014,FDA-2015-P-1296,"attachment 19 regulations for in vivo readiopharmaceuticals used for diagnosis and monitoring, federal register notice dated  may 17, 1999 re citizen petition from leclairryan pc",0,0
09000064823ba54c,Other,FDA-2015-P-1296-0024,FDA-2015-P-1296,letter from robinson and cole to fda ddm,0,0
0900006481aaea28,Other,FDA-2015-P-1296-0001,FDA-2015-P-1296,citizen petition from leclairryan pc jubilant draximage,0,0
0900006481aaec01,Supporting & Related Material,FDA-2015-P-1296-0011,FDA-2015-P-1296,attachment 12  letter from fda cder to lantheus medical imaging re citizen petition from leclairryan pc,0,0
0900006481aaeeed,Supporting & Related Material,FDA-2015-P-1296-0004,FDA-2015-P-1296,attachment 3 national association of nuclear pharmacies position statement on appropriate compounding re citizen petition from leclairryan pc,0,0
0900006481aaea91,Other,FDA-2015-P-1296-0018,FDA-2015-P-1296,"acknowledgement letter from fda ddm to leclairryan, pc",0,0
0900006481cca42c,Other,FDA-2015-P-1296-0022,FDA-2015-P-1296,"interim response letter from fda cder to leclairryan, pc",0,0
0900006481aaebfe,Supporting & Related Material,FDA-2015-P-1296-0009,FDA-2015-P-1296,attachment 9 fda letter and establishment inspection report re citizen petition from leclairryan pc,0,0
0900006481aaec08,Supporting & Related Material,FDA-2015-P-1296-0013,FDA-2015-P-1296,attachment 18 anazao health ad citizen petition from leclairryan pc,0,0
0900006482bec8ae,Other,FDA-2015-P-1296-0025,FDA-2015-P-1296,response letter from fda to jubilant draximage,0,0
09000064837408da,Notice,FDA-2018-D-0787-0001,FDA-2018-D-0787,"civil money penalties relating to the clinicaltrials.gov data bank; draft
guidance for food and drug administration staff, responsible parties, and submitters of certain applications and submissions to the food and drug administration; availability",1,0
0900006483741e84,Other,FDA-2018-D-0787-0002,FDA-2018-D-0787,"civil money penalties relating to the clinicaltrials.gov data bank; guidance for fda staff, responsible parties, and submitters of certain applications and submissions to fda; draft guidance",0,0
0900006484807b92,Other,FDA-2018-D-0787-0067,FDA-2018-D-0787,"civil money penalties relating to the clinicaltrials.gov data bank;  guidance for responsible parties, submitters of certain applications and submissions to the food and drug administration, and food and drug administration staff",1,0
0900006484807e88,Notice,FDA-2018-D-0787-0066,FDA-2018-D-0787,"civil money penalties relating to the clinicaltrials.gov data bank;  guidance for responsible parties, submitters of certain applications and submissions to the food and drug administration, and food and drug administration staff; availability",1,0
0900006480e32bcb,Notice,FDA-2010-D-0153-0003,FDA-2010-D-0153,"agency information collection activities; proposals, submissions, and approvals: procedures for requests for information under the federal food, drug, and cosmetic act",1,0
0900006480ae353c,Other,FDA-2010-D-0153-0002,FDA-2010-D-0153,"draft guidance for industry and food and drug administration staff: procedures for section 513(g) requests for information under the federal food, drug, and cosmetic act; guidance document",1,0
0900006480fea98a,Notice,FDA-2010-D-0153-0004,FDA-2010-D-0153,"guidance for industry and staff; procedures for section 513(g) requests for information under the federal food, drug, and cosmetic act: availability",1,0
0900006480feaa00,Other,FDA-2010-D-0153-0005,FDA-2010-D-0153,"guidance for industry and staff; procedures for section 513(g) requests for information under the federal food, drug, and cosmetic act",1,0
090000648421eba6,Other,FDA-2010-D-0153-0006,FDA-2010-D-0153,guidance on fda and industry procedures for section 513(g) requests for info under fd&c act (2019),0,0
0900006480ae3a4d,Notice,FDA-2010-D-0153-0001,FDA-2010-D-0153,"draft guidance for industry and food and drug administration staff: procedures for section 513(g) requests for information under the federal food, drug, and cosmetic act",1,0
090000648424119a,Other,FDA-2010-D-0153-0007,FDA-2010-D-0153,"fda and industry procedures for section 513(g) requests for information under the federal food, drug, and cosmetic act; guidance for industry and food and drug administration staff",1,0
090000648215c3d7,Notice,FDA-2016-N-0566-0002,FDA-2016-N-0566,"agency information collection activities; submission for office of management and budget review; comment request; survey of alumni 
commissioner's fellowship program fellows",0,0
0900006481e83d1d,Notice,FDA-2016-N-0566-0001,FDA-2016-N-0566,agency information collection activities; proposed collection; comment request; outcomes evaluation survey for graduates of the food and drug administration commissioner’s fellowship program,1,0
09000064819e127e,Notice,FDA-2012-N-0194-0005,FDA-2012-N-0194,"agency information collection activities; proposed collection;
comment request; biosimilars user fee cover sheet; form fda 3792",0,0
0900006480fd5d39,Notice,FDA-2012-N-0194-0001,FDA-2012-N-0194,"agency information collection activities; proposals, submissions, and approvals: biosimilars user fee cover sheet",0,0
090000648104fb38,Notice,FDA-2012-N-0194-0004,FDA-2012-N-0194,"agency information collection activities; proposals, submissions, and approvals: biosimilars user fee cover sheet",0,0
0900006481e4a0e2,Notice,FDA-2012-N-0194-0007,FDA-2012-N-0194,"agency information collection activities; announcement of office of
management and budget approval; biosimilar user fee cover sheet;  form
fda 3792",0,0
0900006481b17b76,Notice,FDA-2012-N-0194-0006,FDA-2012-N-0194,"agency information collection activities; submission for office of
management and budget review; comment request; biosimilars user
fee cover sheet; form fda 3792",0,0
0900006481817faa,Notice,FDA-2014-N-1069-0001,FDA-2014-N-1069,"agency information collection activities; proposed collection;
comment request; blood establishment registration and
product listing",0,0
09000064830dd30c,Notice,FDA-2014-N-1069-0005,FDA-2014-N-1069,"agency information collection activities; submission for office of
management and budget review; comment request; blood  establishment registration and product listing, form fda 2830",0,0
0900006483582378,Notice,FDA-2014-N-1069-0007,FDA-2014-N-1069,"agency information collection activities; announcement of office of
management and budget approvals",0,0
0900006481b1cc3e,Notice,FDA-2014-N-1069-0003,FDA-2014-N-1069,"agency information collection activities; announcement of office of
management and budget approval; blood establishment registration and product listing, form fda 2830",0,0
09000064819e628b,Notice,FDA-2014-N-1069-0002,FDA-2014-N-1069,"agency information collection activities; submission for office of
management and budget review; comment request; blood
establishment registration and product listing",0,0
0900006482d728a4,Notice,FDA-2014-N-1069-0004,FDA-2014-N-1069,"agency information collection activities; proposed collection; comment request; blood establishment registration and product listing, form fda 2830",0,0
0900006481f5d523,Notice,FDA-2015-N-0797-0036,FDA-2015-N-0797,"agency information collection activities; announcement of office of
management and budget approvals",0,0
0900006481fb6feb,Proposed Rule,FDA-2015-N-0797-0037,FDA-2015-N-0797,"the food and drug administration food safety modernization act: focus
on strategic implementation of prevention-oriented import safety  programs; public meetings",1,0
0900006481a5cfc1,Notice,FDA-2015-N-0797-0001,FDA-2015-N-0797,"the food and drug administration food safety modernization act: focus
on implementation strategy for prevention-oriented food safety
standards; public meeting and establishment of docket",1,0
0900006481e8a4f4,Notice,FDA-2015-N-0797-0035,FDA-2015-N-0797,"the food and drug administration food safety modernization act:
prevention-oriented import system regulations and implementation;
public meeting",1,0
0900006484a60d80,Other,FDA-2021-P-0272-0002,FDA-2021-P-0272,acknowledgment letter from fda dms to north carolina masks llc,0,0
0900006484a60d14,Other,FDA-2021-P-0272-0001,FDA-2021-P-0272,citizen petition from north carolina masks llc,0,0
0900006480449386,Supporting & Related Material,FDA-2005-N-0341-0004,FDA-2005-N-0341,supporting statement,0,0
0900006480449346,Notice,FDA-2005-N-0341-0001,FDA-2005-N-0341,fda,0,0
0900006480449374,Notice,FDA-2005-N-0341-0002,FDA-2005-N-0341,fda,0,0
0900006480449384,Supporting & Related Material,FDA-2005-N-0341-0003,FDA-2005-N-0341,supporting statement,0,0
0900006480449388,Notice,FDA-2005-N-0341-0005,FDA-2005-N-0341,fda,0,0
090000648048eac1,Notice,FDA-2002-N-0102-0003,FDA-2002-N-0102,fda,0,0
090000648048eab8,Notice,FDA-2002-N-0102-0002,FDA-2002-N-0102,fda,0,0
090000648048ea72,Notice,FDA-2002-N-0102-0001,FDA-2002-N-0102,fda,0,0
0900006480a7f223,Other,FDA-2010-V-0018-0003,FDA-2010-V-0018,fda/cdrh to ge healthcare - approval for variance,0,0
0900006480a78fca,Other,FDA-2010-V-0018-0001,FDA-2010-V-0018,ge healthcare services - application for variance,0,0
0900006481158ba7,Other,FDA-2010-V-0018-0004,FDA-2010-V-0018,ge healthcare - request for extension,0,0
0900006482cd8a1a,Other,FDA-2010-V-0018-0005,FDA-2010-V-0018,ge healthcare - request for extension approval,0,0
0900006480a78ff4,Other,FDA-2010-V-0018-0002,FDA-2010-V-0018,acknowledgement letter to ge healthcare services,0,0
0900006482234230,Notice,FDA-2016-D-2730-0001,FDA-2016-D-2730,"food and drug administration’s application of statutory factors in
determining when a risk evaluation and mitigation strategy is necessary; draft guidance for industry; availability",1,0
0900006483b6917d,Notice,FDA-2016-D-2730-0009,FDA-2016-D-2730,risk evaluation and mitigation strategy: the food and drug administration’s application of statutory factors in determining when a risk evaluation and mitigation strategy is necessary; guidance for industry; availability,1,0
0900006483b69efa,Other,FDA-2016-D-2730-0010,FDA-2016-D-2730,rems: fda's application of statutory factors in determining when a rems is necessary guidance for industry,0,0
0900006482226a98,Other,FDA-2016-D-2730-0002,FDA-2016-D-2730,draft guidance for industry on fda's application of statutory factors in determining when a rems is necessary,0,0
0900006480f89877,Notice,FDA-2011-D-0790-0004,FDA-2011-D-0790,"draft guidance for industry, clinical investigators, institutional review boards, and staff; availability: decisions for investigational device exemption clinical investigations",0,0
0900006480f69c13,Notice,FDA-2011-D-0790-0001,FDA-2011-D-0790,"draft guidance for industry, clinical investigators, institutional review boards, and staff; availability: decisions for investigational device exemption clinical investigations",0,0
0900006480f69b65,Other,FDA-2011-D-0790-0002,FDA-2011-D-0790,"draft guidance for industry, clinical investigators, institutional review boards, and food and drug administration staff, fda decisions for investigational device exemption clinical investigations",1,0
0900006481830756,Other,FDA-2011-D-0790-0036,FDA-2011-D-0790,guidance for sponsors clinical investigators institutional review boards and food and drug administration staff,1,0
090000648182f7fb,Notice,FDA-2011-D-0790-0035,FDA-2011-D-0790,"food and drug administration decisions for investigational device
exemption clinical investigations: guidance for sponsors, clinical
investigators, institutional review boards, and food and drug
administration staff; availability",1,0
090000648131ff08,Notice,FDA-2011-D-0790-0018,FDA-2011-D-0790,food and drug administration decisions for investigational device exemption clinical investigations; draft guidance for industry and food and drug administration staff; availability,1,0
0900006481320322,Other,FDA-2011-D-0790-0019,FDA-2011-D-0790,content of premarket submissions for management of cybersecurity in medical devices; draft guidance for industry and food and drug administration staff,1,0
0900006481319c52,Other,FDA-2013-P-0695-0002,FDA-2013-P-0695,acknowledgement letter to steven a zecola,0,0
0900006481319be2,Other,FDA-2013-P-0695-0001,FDA-2013-P-0695,steven a. zecola - citizen petition,0,0
09000064814a5f5b,Other,FDA-2013-P-0695-0003,FDA-2013-P-0695,fda/cder interim response to steven a zecola - letter,0,0
09000064817ea191,Other,FDA-2013-P-0695-0004,FDA-2013-P-0695,citizen petition denial response from fda cder to steven a. zecola,0,0
090000648188c8c6,Notice,FDA-2014-N-1287-0001,FDA-2014-N-1287,"announcement of requirements and registration for the 2014 food and
drug administration food safety challenge",1,0
090000648379096a,Other,FDA-2018-P-1876-0004,FDA-2018-P-1876,additional commmunication from dr. niazi 01 oct-2018,0,0
09000064836af0e4,Other,FDA-2018-P-1876-0003,FDA-2018-P-1876,letter re biosimilars from dr. s. niazi,0,0
0900006483d7dc3e,Other,FDA-2018-P-1876-0008,FDA-2018-P-1876,memorandum of meeting - listening meeting with dr. sarfaraz niazi regarding biosilmilars,0,0
0900006483d7dc3f,Supporting & Related Material,FDA-2018-P-1876-0009,FDA-2018-P-1876,risk-based licensing of biosimilars re memorandum of meeting - listening meeting with dr. sarfaraz niazi regarding biosilmilars,0,0
0900006483264231,Other,FDA-2018-P-1876-0002,FDA-2018-P-1876,acknowledgment letter from fda ddm to uic college of pharmacy,0,0
0900006483796c3b,Other,FDA-2018-P-1876-0005,FDA-2018-P-1876,fda summary_august 15 2018 mtg with sarfaraz niazi,0,0
090000648326422a,Other,FDA-2018-P-1876-0001,FDA-2018-P-1876,citizen petition from uic college of pharmacy,0,0
09000064838e18e1,Other,FDA-2018-P-1876-0007,FDA-2018-P-1876,letter from fda cder to sarfaraz k. niazi,0,0
09000064838d7dbc,Other,FDA-2018-P-1876-0006,FDA-2018-P-1876,"letter from sarfaraz k. niazi, uic",0,0
0900006483d7dd6f,Other,FDA-2018-P-1876-0010,FDA-2018-P-1876,testimony from sarfaraz niazi,0,0
09000064845544fe,Other,FDA-2020-D-1336-0001,FDA-2020-D-1336,guidance for industry and fda staff dental cements - premarket,0,0
090000648410ba23,Other,FDA-2019-P-5069-0002,FDA-2019-P-5069,acknowledgment letter from fda dms to ontario ginseng growers association,0,0
090000648410c5fa,Supporting & Related Material,FDA-2019-P-5069-0003,FDA-2019-P-5069,attachment 1 re: citizen petition from ontario ginseng growers association,0,0
0900006484749e81,Other,FDA-2019-P-5069-0005,FDA-2019-P-5069,final response letter from fda cfsan to ms. rebecca coates,0,0
090000648448cb4f,Other,FDA-2019-P-5069-0004,FDA-2019-P-5069,interim response letter from fda cfsan to ontario ginseng growers association,0,0
090000648410ba22,Other,FDA-2019-P-5069-0001,FDA-2019-P-5069,citizen petition from ontario ginseng growers association,0,0
090000648049faf9,Notice,FDA-2002-N-0311-0002,FDA-2002-N-0311,fda,0,0
090000648049fafd,Notice,FDA-2002-N-0311-0003,FDA-2002-N-0311,fda,0,0
090000648049faab,Notice,FDA-2002-N-0311-0001,FDA-2002-N-0311,fda,0,0
09000064804963c5,Other,FDA-2003-P-0338-0001,FDA-2003-P-0338,"hfd-005 to frommer lawrence &amp; haug, llp",0,0
0900006480496459,Other,FDA-2003-P-0338-0002,FDA-2003-P-0338,hfd-1 to frommer lawrence &amp; haug llp,0,0
09000064804c599c,Notice,FDA-1999-N-0758-0003,FDA-1999-N-0758,agency information collection activities; announcement of omb approval; fda safety alert/public health advisory readership survey,0,0
09000064804c5985,Notice,FDA-1999-N-0758-0001,FDA-1999-N-0758,agency information collection activities: proposed collection; comment request; fda safety alert/ public health advisory readership survey,0,0
09000064804c5997,Notice,FDA-1999-N-0758-0002,FDA-1999-N-0758,agency information collection activities; submission for omb review; comment request; fda safety alert/public health advisory readership survey,0,0
09000064825f5e64,Supporting & Related Material,FDA-1999-N-0758-0004,FDA-1999-N-0758,sample document of fda safety alert/public health advisory readership survey,0,0
09000064813ba8e3,Other,FDA-1996-P-0056-0001,FDA-1996-P-0056,"fda/cvm to luitpold pharmaceuticals, inc. - letter",0,0
09000064806bf381,Notice,FDA-2008-N-0439-0001,FDA-2008-N-0439,"agency information collection activities; proposed collection; comment request; blood establishment registration and product listing, form fda 2830",0,0
09000064807defa6,Notice,FDA-2008-N-0439-0002,FDA-2008-N-0439,"agency information collection activities; submission for office of management and budget review; comment request; blood establishment registration and product listing, form fda 2830",0,0
090000648222d97d,Notice,FDA-2016-N-2648-0001,FDA-2016-N-2648,"announcement of requirements and registration for the 2016 food and
drug administration naloxone app competition",1,0
0900006480f87cba,Notice,FDA-2011-N-0508-0002,FDA-2011-N-0508,"agency information collection activities; proposals, submissions, and approvals: blood establishment registration and product listing",0,0
0900006480fe7888,Notice,FDA-2011-N-0508-0003,FDA-2011-N-0508,"agency information collection activities; proposals, submissions, and approvals: blood establishment registration and product listing, form fda 2830",0,0
0900006480ed9e3e,Notice,FDA-2011-N-0508-0001,FDA-2011-N-0508,"agency information collection activities; proposals, submissions, and approvals: blood establishment registration and product listing",0,0
0900006481c29f72,Notice,FDA-2015-N-2817-0001,FDA-2015-N-2817,medical devices; export certificates; food and drug administration export reform and enhancement act of 1996; certification fees,1,0
090000648266b120,Other,FDA-2017-P-3330-0003,FDA-2017-P-3330,acknowledgement letter from fda ddm_redacted,0,0
0900006482c99dfb,Other,FDA-2017-P-3330-0005,FDA-2017-P-3330,interim response from fda,0,0
09000064843084fe,Other,FDA-2017-P-3330-0006,FDA-2017-P-3330,dental laser cp final response,0,0
0900006482617d8e,Other,FDA-2017-P-3330-0002,FDA-2017-P-3330,acknowledgement letter from fda ddm,0,0
0900006482617d8c,Other,FDA-2017-P-3330-0001,FDA-2017-P-3330,citizen petition regarding pma k151763,0,0
090000648450bca9,Notice,FDA-2019-N-5799-0003,FDA-2019-N-5799,"modernizing the food and drug administration’s data strategy; public
meeting; extension of comment period",1,0
09000064844c936b,Other,FDA-2019-N-5799-0002,FDA-2019-N-5799,"request for extension from regeneron pharmaceuticals, inc.",0,0
090000648427bfca,Notice,FDA-2019-N-5799-0001,FDA-2019-N-5799,modernizing the food and drug administration’s data strategy; public meeting; request for comments,1,0
0900006484825f8b,Other,FDA-2019-N-5799-0042,FDA-2019-N-5799,letter from symmetric health solutions to fda oc,0,0
0900006480b08e16,Notice,FDA-2006-D-0298-0014,FDA-2006-D-0298,see fda 2006-d-0298-0001,0,0
0900006480b0967a,Supporting & Related Material,FDA-2006-D-0298-0019,FDA-2006-D-0298,"exhibit 2b - ""whole grain half truths"" - [kellogg company - comment]",0,0
0900006480ec0939,Other,FDA-2006-D-0298-0027,FDA-2006-D-0298,aacc international task force - correction re fda-2006-d-0298-0026,0,0
0900006480458e57,Other,FDA-2006-D-0298-0005,FDA-2006-D-0298,draft guidance for industry and fda staff: whole grain label statements,0,0
0900006480b095b4,Supporting & Related Material,FDA-2006-D-0298-0018,FDA-2006-D-0298,"exhibit 2a - ""use of whole grain claims: 2005 to april 2010"" - [kellogg company - comment]",0,0
0900006480458e35,Supporting & Related Material,FDA-2006-D-0298-0002,FDA-2006-D-0298,background information,0,0
0900006480458e3f,Supporting & Related Material,FDA-2006-D-0298-0004,FDA-2006-D-0298,background information,0,0
0900006480458e3d,Supporting & Related Material,FDA-2006-D-0298-0003,FDA-2006-D-0298,background information,0,0
0900006480b08d9c,Notice,FDA-2006-D-0298-0013,FDA-2006-D-0298,n,0,0
0900006480458e10,Notice,FDA-2006-D-0298-0001,FDA-2006-D-0298,draft guidance for industry and fda staff whole grains label statement availability,0,0
0900006480458e59,Supporting & Related Material,FDA-2006-D-0298-0006,FDA-2006-D-0298,guidance,0,0
0900006480b095b2,Supporting & Related Material,FDA-2006-D-0298-0016,FDA-2006-D-0298,"exhibit 1a - ""a survey of consumers whole grain & fiber consumption behaviors, and the perception of whole grainfoods as a source od dietary fiber"" - [kellogg company - comment]",0,0
0900006480b095b3,Supporting & Related Material,FDA-2006-D-0298-0017,FDA-2006-D-0298,"exhibit 1b - ""the american: ""whole"" lot of fiber confusion"" - [kellogg company - comment]",0,0
0900006480b0967b,Supporting & Related Material,FDA-2006-D-0298-0020,FDA-2006-D-0298,"exhibit 3 - ""review of the whole grain council's 2009""whole grain research summary"" prepared for the kellogg company 11/12/09 fulgoni, vl. 3rd"" - [kellogg company - comment]",0,0
0900006480486d78,Supporting & Related Material,FDA-2003-D-0147-0002,FDA-2003-D-0147,guidance,0,0
0900006480486d3d,Notice,FDA-2003-D-0147-0001,FDA-2003-D-0147,fda,0,0
090000648044914e,Supporting & Related Material,FDA-2005-D-0339-0003,FDA-2005-D-0339,guidance,0,0
0900006480449112,Notice,FDA-2005-D-0339-0001,FDA-2005-D-0339,fda,0,0
09000064804491a0,Notice,FDA-2005-D-0339-0006,FDA-2005-D-0339,fda,0,0
0900006480fd2752,Notice,FDA-2005-D-0339-0022,FDA-2005-D-0339,"draft guidance; drug safety information, fda's communication to the public: availability",0,0
090000648044919e,Supporting & Related Material,FDA-2005-D-0339-0004,FDA-2005-D-0339,guidance,0,0
0900006480fd2bfc,Other,FDA-2005-D-0339-0023,FDA-2005-D-0339,"guidance; drug safety information, fda's communication to the public",0,0
090000648044914d,Supporting & Related Material,FDA-2005-D-0339-0002,FDA-2005-D-0339,guidance,0,0
090000648044919f,Supporting & Related Material,FDA-2005-D-0339-0005,FDA-2005-D-0339,guidance,0,0
0900006480447b09,Other,FDA-2005-P-0315-0005,FDA-2005-P-0315,pfizer global research and development - citizen petition,0,0
0900006480447b17,Other,FDA-2005-P-0315-0002,FDA-2005-P-0315,acknowledgement letter to pfizer inc.,0,0
0900006480447b1b,Other,FDA-2005-P-0315-0003,FDA-2005-P-0315,fda/cder to pfizer global research and development,0,0
0900006480447b20,Other,FDA-2005-P-0315-0006,FDA-2005-P-0315,pfizer - amendment,0,0
0900006480447aeb,Other,FDA-2005-P-0315-0001,FDA-2005-P-0315,hfa-305 to pfizer inc.,0,0
0900006480f78eec,Other,FDA-2005-P-0315-0004,FDA-2005-P-0315,fda/cder  to pfizer global research and development - petition denial,0,0
090000648049a36b,Notice,FDA-2003-N-0384-0002,FDA-2003-N-0384,fda,0,0
090000648049a32f,Notice,FDA-2003-N-0384-0001,FDA-2003-N-0384,fda,0,0
09000064825e9728,Supporting & Related Material,FDA-2017-P-3196-0020,FDA-2017-P-3196,"reference 17 faq fisheries and aquaculture report no, 978 re citizen petition from philip spiller et. al.",0,0
09000064825e972e,Supporting & Related Material,FDA-2017-P-3196-0026,FDA-2017-P-3196,reference 23 fda strategic plan for risk communication as updated in 2012 re citizen petition from philip spiller et. al.,0,0
09000064825e9747,Supporting & Related Material,FDA-2017-P-3196-0048,FDA-2017-P-3196,reference 44 fetal methylmercury poisoning re citizen petition from philip spiller et. al.,0,0
09000064825e974d,Supporting & Related Material,FDA-2017-P-3196-0054,FDA-2017-P-3196,reference 50 associations of maternal fish intake during pregnancy re citizen petition from philip spiller et. al.,0,0
09000064825e975a,Supporting & Related Material,FDA-2017-P-3196-0063,FDA-2017-P-3196,reference 59 letter from michael taylor to dr john kaneko re citizen petition from philip spiller et. al.,0,0
09000064825e9bcb,Supporting & Related Material,FDA-2017-P-3196-0018,FDA-2017-P-3196,reference 15 epa study mercury levels in women of childbearing age drop 34 re citizen petition from philip spiller et. al.,0,0
09000064837b7fe5,Other,FDA-2017-P-3196-0074,FDA-2017-P-3196,reconsideration denial cp response to philip spiller,0,0
0900006482c74b46,Other,FDA-2017-P-3196-0072,FDA-2017-P-3196,citizen petition for reconsideration from  philip spiller et. al.,0,0
09000064825e972f,Supporting & Related Material,FDA-2017-P-3196-0027,FDA-2017-P-3196,reference 24 new advice pregnant women and young re citizen petition from philip spiller et. al.,0,0
09000064825e9742,Supporting & Related Material,FDA-2017-P-3196-0045,FDA-2017-P-3196,reference 41 prenatal exposure to mercury and infant re citizen petition from philip spiller et. al.,0,0
09000064825e9745,Supporting & Related Material,FDA-2017-P-3196-0046,FDA-2017-P-3196,reference 42 prenatal exposure to mercury and re citizen petition from philip spiller et. al.,0,0
09000064825e974b,Supporting & Related Material,FDA-2017-P-3196-0052,FDA-2017-P-3196,"reference 48 maternal fish consumption , hair mercury , and infant cognition re citizen petition from philip spiller et. al.",0,0
09000064825e9754,Supporting & Related Material,FDA-2017-P-3196-0057,FDA-2017-P-3196,reference 53 workshop on dha as a required nutrient overview re citizen petition from philip spiller et. al.,0,0
09000064825e9ba8,Supporting & Related Material,FDA-2017-P-3196-0005,FDA-2017-P-3196,reference 2 suggested servings from each food group re citizen petition from philip spiller et. al.,1,0
09000064825e9baa,Supporting & Related Material,FDA-2017-P-3196-0007,FDA-2017-P-3196,reference 4 a qualitative study of fish consumption during pregnancy re citizen petition from philip spiller et. al.,0,0
09000064825e9bc3,Supporting & Related Material,FDA-2017-P-3196-0010,FDA-2017-P-3196,reference 7 a quantitative analysis o f prenatal intake of n-3 re citizen petition from philip spiller et. al.,0,0
09000064825e9bc6,Supporting & Related Material,FDA-2017-P-3196-0013,FDA-2017-P-3196,reference 10 fish intake during pregnancy re citizen petition from philip spiller et. al.,0,0
09000064825e9bc7,Supporting & Related Material,FDA-2017-P-3196-0014,FDA-2017-P-3196,reference 11 report of the dietary re citizen petition from philip spiller et. al.,0,0
09000064825e9bc9,Supporting & Related Material,FDA-2017-P-3196-0016,FDA-2017-P-3196,reference 13 reference dose rfd description and use in re citizen petition from philip spiller et. al.,0,0
09000064825e9c24,Supporting & Related Material,FDA-2017-P-3196-0030,FDA-2017-P-3196,reference 27 fish what pregnant women and parents should know re citizen petition from philip spiller et. al.,0,0
09000064825e9c26,Supporting & Related Material,FDA-2017-P-3196-0032,FDA-2017-P-3196,reference 29 quantitative approach for incorporating methymercury risks and omega-3 re citizen petition from philip spiller et. al.,0,0
09000064825e9c27,Supporting & Related Material,FDA-2017-P-3196-0033,FDA-2017-P-3196,"reference 30 goyer, r.a. (2000) letter to levitt, j. not submitted to the docket re citizen petition from philip spiller et. al.",0,0
09000064825e9ba4,Other,FDA-2017-P-3196-0002,FDA-2017-P-3196,acknowledgment letter from fda ddm to philip spiller et. al.,0,0
09000064825e96e0,Other,FDA-2017-P-3196-0001,FDA-2017-P-3196,citizen petition from philip spiller et. al.,0,0
09000064825e972a,Supporting & Related Material,FDA-2017-P-3196-0022,FDA-2017-P-3196,reference 19 fda fish consumption advice to pregnant women issued in 2001 re citizen petition from philip spiller et. al.,0,0
09000064832a4ddd,Supporting & Related Material,FDA-2018-P-1966-0003,FDA-2018-P-1966,"attachment 3 celebrex pi- re suitability petition from mcneely, hare & war, llp.",0,0
09000064832a4dde,Supporting & Related Material,FDA-2018-P-1966-0004,FDA-2018-P-1966,"attachment 2 highlights of proposed pi- re suitability petition from mcneely, hare & war, llp.",0,0
09000064832a4722,Other,FDA-2018-P-1966-0001,FDA-2018-P-1966,"suitability petition from mcneely, hare & war, llp.",0,0
09000064832a521c,Other,FDA-2018-P-1966-0002,FDA-2018-P-1966,"acknowledgment letter from fda ddm to mcneely, hare & war, llp.",0,0
09000064832a4ddf,Supporting & Related Material,FDA-2018-P-1966-0005,FDA-2018-P-1966,"attachment 1 orange book listing- re suitability petition from mcneely, hare & war, llp.",0,0
09000064832b108b,Supporting & Related Material,FDA-2018-P-1980-0003,FDA-2018-P-1980,attachment 1- excerpts from fda’s orange book re: citizen petition from foley& lardner llp,0,0
09000064832b0b39,Other,FDA-2018-P-1980-0001,FDA-2018-P-1980,citizen petition  from foley & lardner llp,0,0
09000064839ac1f2,Other,FDA-2018-P-1980-0005,FDA-2018-P-1980,"letter from fda cder to akorn pharmaceuticals, mylan pharmaceuticals, inc., gland pharma limited, foley & lardner llp",0,0
09000064838e0b6c,Other,FDA-2018-P-1980-0004,FDA-2018-P-1980,letter from fda cder to foley & lardner llp,0,0
09000064832b0f3d,Other,FDA-2018-P-1980-0002,FDA-2018-P-1980,acknowledgment letter from fda ddm to foley & lardner llp,0,0
090000648175ee75,Other,FDA-2014-P-0861-0002,FDA-2014-P-0861,acknowledgement letter from fda ddm to clinipace worldwide,0,0
09000064818270ee,Other,FDA-2014-P-0861-0005,FDA-2014-P-0861,citizen petition response from fda cder to clinipace worldwide,0,0
090000648175ee7a,Supporting & Related Material,FDA-2014-P-0861-0004,FDA-2014-P-0861,attachment 2 orange book relevant section citizen petition from clinipace worldwide,0,0
090000648175e888,Other,FDA-2014-P-0861-0001,FDA-2014-P-0861,citizen petition from clinipace worldwide,0,0
090000648175ee79,Supporting & Related Material,FDA-2014-P-0861-0003,FDA-2014-P-0861,attachment 1 orange book supplement citizen petition from clinipace worldwide,0,0
090000648268d631,Other,FDA-2017-P-3484-0001,FDA-2017-P-3484,citizen petition from glasshouse pharmaceuticals limited canada,0,0
090000648268e53b,Other,FDA-2017-P-3484-0002,FDA-2017-P-3484,acknowledgement letter from fda ddm to glasshouse pharmaceuticals limited canada,0,0
0900006482cc69e0,Other,FDA-2017-P-3484-0003,FDA-2017-P-3484,interim response letter from fda cder to glasshouse pharmaceuticals limited canada,0,0
090000648314769f,Other,FDA-2017-P-3484-0004,FDA-2017-P-3484,petition approval letter from fda cder,0,0
0900006480b4fc45,Supporting & Related Material,FDA-2010-P-0489-0006,FDA-2010-P-0489,"attachment 5 - ""copy of citizen petition to ansell limited, one of the leading manufacturers of powdered and powder-free surgical gloves..., july 15, 2010"" - [richard f. edlich, m.d., ph.d. - citizen petition] re fda-2010-p-0489-0001",0,0
0900006480b4fbe2,Supporting & Related Material,FDA-2010-P-0489-0003,FDA-2010-P-0489,"attachment 2 - ""fda/cdrh march 9, 2009, interim response to citizen petition dated september 24, 2008""  - [richard f. edlich, m.d., ph.d. - citizen petition] re fda-2010-p-0489-0001",0,0
0900006480b4fbe7,Supporting & Related Material,FDA-2010-P-0489-0005,FDA-2010-P-0489,"attachment 4 - ""copy of citizen petition to revise the device classification of cornstarch powdered examination and surgical gloves and powder, dusting, surgical, june 30, 2010 - [richard f. edlich, m.d., ph.d. - citizen petition] re fda-2010-p-0489-0001",0,0
0900006480b4fc47,Other,FDA-2010-P-0489-0007,FDA-2010-P-0489,"acknowledgement letter to richard f. edlich, md, phd",0,0
0900006480b4f2b1,Other,FDA-2010-P-0489-0001,FDA-2010-P-0489,"richard f. edlich, m.d., ph.d. - citizen petition",0,0
0900006480b4fbe0,Supporting & Related Material,FDA-2010-P-0489-0002,FDA-2010-P-0489,"attachment 1 - ""copy of citizen petition to ban cornstarch powder on medical gloves maltese cross birefringence, september 24, 2008 - [richard f. edlich, m.d., ph.d. - citizen petition] re fda-2010-p-0489-0001",0,0
0900006480b4fbe4,Supporting & Related Material,FDA-2010-P-0489-0004,FDA-2010-P-0489,"attachment 3 - ""copy of citizen petition to remove the consumer report""medical glove powder report"" from the fda website, january 19, 2010 - [richard f. edlich, m.d., ph.d. - citizen petition] re fda-2010-p-0489-0001",0,0
0900006483093645,Other,FDA-2010-P-0489-0024,FDA-2010-P-0489,memo and combined responses to dr edlich citizen petitions_redacted,0,0
0900006484dc2c15,Other,FDA-2021-P-1098-0001,FDA-2021-P-1098,citizen petition from pet schooled,0,0
0900006484dc2c17,Other,FDA-2021-P-1098-0002,FDA-2021-P-1098,acknowledgment letter from fda dms to pet schooled,0,0
09000064847f49e4,Notice,FDA-2014-N-1027-0009,FDA-2014-N-1027,"agency information collection activities; proposals, submissions, and approvals: infant formula recall regulations",0,0
0900006481999d89,Notice,FDA-2014-N-1027-0003,FDA-2014-N-1027,agency information collection activities; announcement of office of management and budget approval infant formula recall regulations,0,0
09000064844f5593,Notice,FDA-2014-N-1027-0008,FDA-2014-N-1027,agency information collection activities; proposed collection; comment request; infant formula recall regulations,0,0
0900006482c60655,Notice,FDA-2014-N-1027-0006,FDA-2014-N-1027,"agency information collection activities; submission for office of
management and budget review; comment request; infant formula
recall regulations",0,0
090000648303ec1d,Notice,FDA-2014-N-1027-0007,FDA-2014-N-1027,"agency information collection activities; announcement of office of
management and budget approvals",0,0
09000064818e8278,Notice,FDA-2014-N-1027-0002,FDA-2014-N-1027,"agency information collection activities; submission for office of
management and budget review; comment request; infant formula
recall regulations",0,0
090000648180bb14,Notice,FDA-2014-N-1027-0001,FDA-2014-N-1027,"agency information collection activities; proposed collection;
comment request; infant formula recall regulations",0,0
09000064826dbb94,Notice,FDA-2014-N-1027-0004,FDA-2014-N-1027,agency information collection activities; proposed collection; comment request; infant formula recall regulations,0,0
0900006484a3c81d,Notice,FDA-2014-N-1027-0010,FDA-2014-N-1027,agency information collection activities; announcement of office of management and budget approvals,0,0
0900006480add0fe,Notice,FDA-2002-D-0094-0007,FDA-2002-D-0094,"draft guidance for the public, food and drug administration advisory committee members, and fda staff: public availability of advisory committee members financial interest information and waivers; availability",1,0
0900006480fd2859,Notice,FDA-2002-D-0094-0031,FDA-2002-D-0094,"guidance for the public, advisory committee members, and staff;  advisory committee members' financial interest information and waivers: availability",0,0
09000064806aed88,Notice,FDA-2002-D-0094-0004,FDA-2002-D-0094,"guidance for the public, fda advisory committee members, and fda staff: public availability of advisory committee members' financial interest information and waivers; availability",0,0
0900006481691d05,Other,FDA-2002-D-0094-0034,FDA-2002-D-0094,"guidance for the public, food and drug administration advisory
committee members, and food and drug administration staff: public
availability of advisory committee members’ financial interest
information and waivers",1,0
09000064806af63a,Other,FDA-2002-D-0094-0005,FDA-2002-D-0094,"guidance for the public, fda advisory committee members, and fda staff:  public availability of advisory committee members' financial interest information and waivers, august 2008",0,0
0900006480fd2db6,Other,FDA-2002-D-0094-0032,FDA-2002-D-0094,"guidance for the public, advisory committee members, and staff;  advisory committee members' financial interest information and waivers",0,0
0900006480b6d38d,Supporting & Related Material,FDA-2002-D-0094-0022,FDA-2002-D-0094,"appendix a - "" rjreynolds letter to fda, june 30, 2010"" - [r.j. reynolds tobacco company - comment] re fda-2002-d-0094-0018",0,1
0900006480add437,Other,FDA-2002-D-0094-0008,FDA-2002-D-0094,"guidance for the public, food and drug administration advisory committee members, and fda staff: public availability of advisory committee members financial interest information and waivers; draft guidance",1,0
090000648048e44e,Notice,FDA-2002-D-0094-0001,FDA-2002-D-0094,draft guidance on disclosure of conflicts of interest for special government employees participating in fda product specific advisory committees; availability,0,0
090000648048e47c,Other,FDA-2002-D-0094-0006,FDA-2002-D-0094,"draft guidance on disclosure of conflicts of interest for special gqvernment employees participating in fda product specific advisory committees, january 2002",0,0
090000648048e4a2,Other,FDA-2002-D-0094-0002,FDA-2002-D-0094,"guidance for the public, fda advisory committee members, and fda staff: public availability of advisory committee members' financial interest information and waivers, october 2007",0,0
09000064816912ef,Notice,FDA-2002-D-0094-0033,FDA-2002-D-0094,"guidance for the public, food and drug administration advisory
committee members, and food and drug administration staff: public
availability of advisory committee members’ financial interest
information and waivers; availability",1,0
090000648048e4a5,Notice,FDA-2002-D-0094-0003,FDA-2002-D-0094,"draft guidance for the public, food and drug administration advisory committee members, and food and drug administration staff: public availability of advisory committee members financial interest information and waivers; availability",1,0
0900006480b82f6d,Supporting & Related Material,FDA-2002-D-0094-0023,FDA-2002-D-0094,"appendix c - ""fdaac august 30, 2010"" - [r.j. reynolds tobacco company - comment] re fda-2002-d-0094-0018",0,1
090000648048b832,Notice,FDA-2003-D-0201-0001,FDA-2003-D-0201,fda,0,0
09000064804b807c,Notice,FDA-2001-D-0060-0001,FDA-2001-D-0060,fda,0,0
09000064843baa63,Other,FDA-2015-P-1674-0007,FDA-2015-P-1674,withdrawal of citizen petition from globus medical inc,0,0
0900006481adc1b3,Supporting & Related Material,FDA-2015-P-1674-0004,FDA-2015-P-1674,attachment c unique device identification system final rule re citizen petition from globus medical inc,0,0
0900006481adc19a,Supporting & Related Material,FDA-2015-P-1674-0002,FDA-2015-P-1674,attachment a fda guidance for industry bar code label requirements questions and answers re citizen petition from globus medical inc,0,0
0900006481adc19b,Supporting & Related Material,FDA-2015-P-1674-0003,FDA-2015-P-1674,attachment b - bar code label requirement for human drug products and biological products final rule re citizen petition from globus medical inc,0,0
0900006481adbc9a,Other,FDA-2015-P-1674-0001,FDA-2015-P-1674,citizen petition from globus medical inc,0,0
0900006481adc182,Other,FDA-2015-P-1674-0005,FDA-2015-P-1674,"acknowledgement letter from fda ddm to globus medical, inc.",0,0
0900006481d4dde1,Other,FDA-2015-P-1674-0006,FDA-2015-P-1674,"interim response letter from fda cdrh to globus medical, inc.",0,0
090000648446ced7,Other,FDA-2019-P-2074-0004,FDA-2019-P-2074,final response from fda cder to encube ethicals private limited,0,0
090000648412624d,Other,FDA-2019-P-2074-0003,FDA-2019-P-2074,interim response from fda cder to encube ethicals private limited,0,0
0900006483c1df0b,Other,FDA-2019-P-2074-0002,FDA-2019-P-2074,acknowledgment letter from fda ddm to encube ethicals private limited,0,0
0900006483c1cf9b,Other,FDA-2019-P-2074-0001,FDA-2019-P-2074,citizen petition from encube ethicals private limited,0,0
09000064843ef00b,Other,FDA-2019-P-4261-0003,FDA-2019-P-4261,"interim response letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
0900006483f44ee0,Other,FDA-2019-P-4261-0001,FDA-2019-P-4261,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
09000064845fd284,Other,FDA-2019-P-4261-0004,FDA-2019-P-4261,"approval letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
0900006483f44ee1,Other,FDA-2019-P-4261-0002,FDA-2019-P-4261,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
0900006481ee4819,Other,FDA-2016-P-1090-0001,FDA-2016-P-1090,"acknowledgement letter from fda ddm to lachman consultant services, inc.",0,0
0900006481ee4816,Supporting & Related Material,FDA-2016-P-1090-0003,FDA-2016-P-1090,"attachment 2 support for co-prescribing naloxone alongside opioids re citizen petition from lachman consultant services, inc. (adapt pharma ltd.)",0,0
0900006481ee49fc,Other,FDA-2016-P-1090-0004,FDA-2016-P-1090,"citizen petition from lachman consultant services, inc. (adapt pharma ltd.)",0,0
090000648479d285,Other,FDA-2016-P-1090-0022,FDA-2016-P-1090,"letter from fda cder to lachman consultant services, inc.",0,0
090000648223fd50,Other,FDA-2016-P-1090-0020,FDA-2016-P-1090,"interim response to lachman consulting services, inc. from fda cder",0,0
0900006481ee49fd,Supporting & Related Material,FDA-2016-P-1090-0002,FDA-2016-P-1090,"attachment 1 narcan nasal spray indication and important safety  information re citizen petition from lachman consultant services, inc. (adapt pharma ltd.)",0,0
090000648169a421,Notice,FDA-2014-D-0261-0001,FDA-2014-D-0261,"the meaning of ‘‘spouse’’ and ‘‘family’’ in the food and drug
administration’s regulations after the supreme court’s ruling in united
states v. windsor—questions and answers: guidance for industry,
consumers, and food and drug administration staff; availability",1,0
090000648169aef8,Other,FDA-2014-D-0261-0002,FDA-2014-D-0261,"the meaning of ‘‘spouse’’ and ‘‘family’’ in the food and drug
administration’s regulations after the supreme court’s ruling in united
states v. windsor—questions and answers: guidance for industry,
consumers, and food and drug administration staff",1,0
0900006484de2a28,Supporting & Related Material,FDA-2021-P-1144-0005,FDA-2021-P-1144,appendix c third example of methodology for establishing interim proposed action levels described in attorneys general petition to fda re: citizen petition from state of new york office of the attorney general,0,0
0900006484de2a26,Supporting & Related Material,FDA-2021-P-1144-0003,FDA-2021-P-1144,appendix a appendix a – first example of methodology for establishing interim proposed action levels described in attorneys general petition to fda re: citizen petition from state of new york office of the attorney general,0,0
0900006484de32ed,Other,FDA-2021-P-1144-0002,FDA-2021-P-1144,acknowledgment letter from fda dms to state of new york office of the attorney general,0,0
0900006484de3228,Other,FDA-2021-P-1144-0001,FDA-2021-P-1144,citizen petition from state of new york office of the attorney general,0,0
0900006484de2a27,Supporting & Related Material,FDA-2021-P-1144-0004,FDA-2021-P-1144,appendix b second example of methodology for establishing interim proposed action levels described in attorneys general petition to fda re: citizen petition from state of new york office of the attorney general,0,0
0900006484de2a29,Supporting & Related Material,FDA-2021-P-1144-0006,FDA-2021-P-1144,"appendix d results of nysoag infant rice cereal inorganic arsenic sampling (4 manufacturers, 7 products, 21 total samples)re: citizen petition from state of new york office of the attorney general",0,0
09000064803a22f3,Notice,FDA-2008-P-0059-0001,FDA-2008-P-0059,"determination that seroquel (quetiapine fumarate) tablets, 150 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
09000064803a4720,Other,FDA-2008-P-0059-0002,FDA-2008-P-0059,"response letter to lachman consultant services, inc - letter",0,0
090000648117e684,Other,FDA-2012-D-0080-0005,FDA-2012-D-0080,guidance on oversight of positron emission tomography drug products - questions and answers,0,0
090000648117e3df,Notice,FDA-2012-D-0080-0004,FDA-2012-D-0080,guidance on oversight of positron emission tomography drug products - questions and answers,0,0
0900006480fc30a5,Notice,FDA-2012-D-0080-0001,FDA-2012-D-0080,draft guidance; availability: oversight of positron emission tomography drug products,0,0
0900006480fc3894,Other,FDA-2012-D-0080-0002,FDA-2012-D-0080,draft guidance; oversight of positron emission tomography drug products,0,0
0900006483435981,Other,FDA-2018-P-0343-0003,FDA-2018-P-0343,petition response letter from fda cder to fish & richardson pc,0,0
0900006482e544f3,Other,FDA-2018-P-0343-0002,FDA-2018-P-0343,acknowledgment letter from fda ddm to fish & richardson pc,0,0
0900006482e544ec,Other,FDA-2018-P-0343-0001,FDA-2018-P-0343,citizen petition from fish & richardson pc,0,0
090000648126db16,Notice,FDA-2013-N-0345-0001,FDA-2013-N-0345,food and drug administration/national institutes of health/national science foundation public workshop on computer methods for medical devices,1,0
0900006481c61c16,Proposed Rule,FDA-2015-N-0540-7641,FDA-2015-N-0540,"homeopathic product regulation: evaluating the food and drug
administration’s regulatory framework after a quarter-century;
reopening of the comment period",1,0
0900006481aaa3e7,Other,FDA-2015-N-0540-0486,FDA-2015-N-0540,"testimony from nancy peplinsky, holistic moms network",0,0
0900006481aaa2e6,Other,FDA-2015-N-0540-0474,FDA-2015-N-0540,presentation from paramesh banerji life sciences llc,0,0
0900006481aaa308,Other,FDA-2015-N-0540-0475,FDA-2015-N-0540,presentation from the american institute of homeopathy,0,0
0900006481aaa012,Other,FDA-2015-N-0540-0479,FDA-2015-N-0540,"testimony from amy rothenberg, american association of naturopathic physicians",0,0
0900006481aaa014,Other,FDA-2015-N-0540-0481,FDA-2015-N-0540,presentation from luana colloca md phd,0,0
0900006481aabe06,Other,FDA-2015-N-0540-0639,FDA-2015-N-0540,presentation from the homoeopathic pharmacopoeia convention of the united states,0,0
0900006481aaa010,Other,FDA-2015-N-0540-0478,FDA-2015-N-0540,presentation from alvin lorman,0,0
0900006481b0e9ff,Other,FDA-2015-N-0540-2177,FDA-2015-N-0540,"testimony of alyssa wostrel, integrative health policy consortium",0,0
0900006481b0ea02,Other,FDA-2015-N-0540-2179,FDA-2015-N-0540,"transcript of the homeopathic product regulation: evaluating the food and drug administration's regulatory framework after a quarter century part 15 public hearing day 2 april 21, 2015",1,0
0900006481c18831,Other,FDA-2015-N-0540-4429,FDA-2015-N-0540,"presentation from edward p. krenzelok, rocky mountain poison and drug center",0,0
0900006481aaa2e0,Other,FDA-2015-N-0540-0472,FDA-2015-N-0540,presentation from peter fisher,0,0
0900006481aabb05,Other,FDA-2015-N-0540-0640,FDA-2015-N-0540,"testimony from will woodlee, ahpa",0,0
0900006481aaf1f8,Other,FDA-2015-N-0540-0995,FDA-2015-N-0540,"testimony from terry cotter, terra-medica inc",0,0
0900006481ab2814,Other,FDA-2015-N-0540-1302,FDA-2015-N-0540,"testimony from youngran chung, md",0,0
0900006481aa9f74,Other,FDA-2015-N-0540-0471,FDA-2015-N-0540,testimony from the homeopathic academy of naturopathic physicians,0,0
0900006481aaa150,Other,FDA-2015-N-0540-0467,FDA-2015-N-0540,"presentation from gary kracoff, johnson compounding and wellness center",0,0
0900006481aaa14c,Other,FDA-2015-N-0540-0466,FDA-2015-N-0540,testimony from yale martin,0,0
0900006481aaa016,Other,FDA-2015-N-0540-0482,FDA-2015-N-0540,"testimony from alison teitelbaum, national center for homeopathy",0,0
0900006481aaf2a0,Other,FDA-2015-N-0540-0998,FDA-2015-N-0540,presentation from american association of homeopathic pharmacists,0,0
0900006481aaf2a1,Other,FDA-2015-N-0540-0999,FDA-2015-N-0540,presentation from emerson healthcare group,0,0
0900006481ab20ea,Other,FDA-2015-N-0540-1293,FDA-2015-N-0540,"testimony from robert dumont, raby institute for integrative medicine at northwestern, llc",0,0
0900006481ab6695,Other,FDA-2015-N-0540-1501,FDA-2015-N-0540,presentation from materia medica holding,0,0
0900006481b291fb,Proposed Rule,FDA-2015-N-0540-2724,FDA-2015-N-0540,"homeopathic product regulation: evaluating the food and drug
administration’s regulatory framework after a quarter-century;
extension of comment period",1,0
0900006481aabb0a,Other,FDA-2015-N-0540-0641,FDA-2015-N-0540,testimony from adriane fugh-berman md,0,0
09000064837ab57c,Supporting & Related Material,FDA-2018-P-3825-0003,FDA-2018-P-3825,pei wei clean label study report final report,0,0
09000064837ab574,Other,FDA-2018-P-3825-0002,FDA-2018-P-3825,"acknowledgment letter from fda to pei wei asian diner, llc.",0,0
09000064837ab3f7,Other,FDA-2018-P-3825-0001,FDA-2018-P-3825,"citizen petition from pei wei asian diner, llc.",0,0
0900006483becaeb,Other,FDA-2018-P-3825-0004,FDA-2018-P-3825,"180 day interim response letter from fda cfsan to pei wei asian diner, llc",0,0
090000648056e98e,Supporting & Related Material,FDA-1998-D-0052-0005,FDA-1998-D-0052,guidance,0,0
090000648056e961,Notice,FDA-1998-D-0052-0001,FDA-1998-D-0052,fda,0,0
090000648056e979,Notice,FDA-1998-D-0052-0002,FDA-1998-D-0052,fda,0,0
090000648056e98c,Notice,FDA-1998-D-0052-0003,FDA-1998-D-0052,fda,0,0
090000648056e98d,Supporting & Related Material,FDA-1998-D-0052-0004,FDA-1998-D-0052,guidance,0,0
090000648052823a,Other,FDA-1992-P-0030-0001,FDA-1992-P-0030,helen k. harris,0,0
09000064805232ba,Other,FDA-2008-P-0255-0002,FDA-2008-P-0255,acknowledgement letter to k.s. trading company,0,0
090000648052328c,Other,FDA-2008-P-0255-0001,FDA-2008-P-0255,k.s. trading company - petition for stay of action,0,0
0900006480a3ed9c,Other,FDA-2009-P-0500-0001,FDA-2009-P-0500,"ferdic, incorporated - citizen petition",0,0
0900006480a3ed9d,Other,FDA-2009-P-0500-0002,FDA-2009-P-0500,"acknowledgement letter to ferdic, incorporated",0,0
09000064813ee373,Other,FDA-2009-P-0500-0003,FDA-2009-P-0500,"fda/office of policy response to ferdic, inc. - petition denial",0,0
090000648464315d,Other,FDA-2020-D-1398-0001,FDA-2020-D-1398,guidance for industry; fda approval of new animal drugs for minor uses and for minor species; #61,0,0
0900006481607d97,Other,FDA-2014-P-0283-0001,FDA-2014-P-0283,citizen petition from leroy l. hamilton,0,0
09000064817168f0,Other,FDA-2014-P-0283-0003,FDA-2014-P-0283,citizen petition denial response from fda cdrh to leroy leslie hamilton,0,0
0900006481607d9b,Other,FDA-2014-P-0283-0002,FDA-2014-P-0283,acknowledgement letter from fda/ddm to leroy l. hamilton,0,0
0900006480483def,Notice,FDA-2003-N-0100-0003,FDA-2003-N-0100,agency information collection activities; announcement of omb approval; medical device user fee cover sheet; form fda 360,0,0
0900006480483dea,Notice,FDA-2003-N-0100-0002,FDA-2003-N-0100,agency information collection activities; submission for omb review; comment request; medical device user fee cover sheet; form fda 3601,0,0
0900006480483da1,Notice,FDA-2003-N-0100-0001,FDA-2003-N-0100,agency information collection activities; proposed collection; comment request; medical device user fee cover sheet; form fda 3601,0,0
0900006480483ded,Supporting & Related Material,FDA-2003-N-0100-0005,FDA-2003-N-0100,supporting statement re medical device user fee cover sheet - form fda 3601 omb control 0910-0511,0,0
09000064804736ff,Notice,FDA-2004-D-0371-0004,FDA-2004-D-0371,fda,0,0
09000064804736fe,Supporting & Related Material,FDA-2004-D-0371-0003,FDA-2004-D-0371,guideline,0,0
09000064804736ec,Notice,FDA-2004-D-0371-0001,FDA-2004-D-0371,fda,0,0
09000064804736ed,Supporting & Related Material,FDA-2004-D-0371-0002,FDA-2004-D-0371,guidance,0,0
0900006480481418,Notice,FDA-2003-N-0027-0003,FDA-2003-N-0027,fda,0,0
0900006480481411,Notice,FDA-2003-N-0027-0001,FDA-2003-N-0027,fda,0,0
0900006480481414,Notice,FDA-2003-N-0027-0002,FDA-2003-N-0027,fda,0,0
0900006480bb387e,Notice,FDA-2005-D-0072-0005,FDA-2005-D-0072,"guidance for public, fda advisory committee members, and fda staff; availability: the open public hearing at fda advisory committee meetings;availability",0,0
090000648043f30b,Other,FDA-2005-D-0072-0002,FDA-2005-D-0072,guidance on the open public hearing; food and drug administration advisory committee meetings; draft guidance,1,0
090000648043f30a,Notice,FDA-2005-D-0072-0001,FDA-2005-D-0072,draft guidance on the open public hearing; food and drug administration advisory committee meetings; availability,1,0
0900006480bb3e0d,Other,FDA-2005-D-0072-0006,FDA-2005-D-0072,"guidance for the public, fda advisory committee members, and fda staff: the open public hearing at fda advisory committee meeting; final guidance",0,0
0900006481f5cca0,Notice,FDA-2012-N-0536-0006,FDA-2012-N-0536,"agency information collection activities; submission for office of
management and budget review; comment request; medical device
user fee cover sheet, form fda 3601",0,0
09000064846e88f5,Notice,FDA-2012-N-0536-0012,FDA-2012-N-0536,"agency information collection activities; proposed collection;
comment request; medical device user fee cover sheet, form fda 3601
and device facility user fee cover sheet, form fda 3601a",0,0
0900006481037d8e,Notice,FDA-2012-N-0536-0001,FDA-2012-N-0536,"agency information collection activities; proposals, submissions, and approvals: medical device user fee cover sheet",0,0
0900006483d98f1c,Notice,FDA-2012-N-0536-0010,FDA-2012-N-0536,"agency information collection activities; submission for office of management and budget review; comment request; medical device user fee cover sheet, form fda 3601",0,0
090000648138cdc9,Notice,FDA-2012-N-0536-0004,FDA-2012-N-0536,"agency information collection activities; announcement of office of management and budget approval; medical device user fee cover sheet, form fda 3601",0,0
0900006481cdc9e1,Notice,FDA-2012-N-0536-0005,FDA-2012-N-0536,"agency information collection activities; proposed collection;
comment request; medical device user fee cover sheet, form fda 3601",0,0
0900006484d4a040,Notice,FDA-2012-N-0536-0015,FDA-2012-N-0536,"agency information collection activities; submission for office of management and budget review; comment request; medical device user fee cover sheet, form fda 3601 and device facility user fee cover sheet, form fda 3601a",0,0
09000064821f9725,Notice,FDA-2012-N-0536-0007,FDA-2012-N-0536,agency information collection activities; announcement of office of  management and budget approvals,0,0
09000064840beec8,Notice,FDA-2012-N-0536-0011,FDA-2012-N-0536,"agency information collection activities; announcement of office of
management and budget approvals",0,0
09000064811e88b8,Notice,FDA-2012-N-0536-0003,FDA-2012-N-0536,"agency information collection activities; submission for office of management and budget review; comment request; medical device user fee cover sheet, form fda 3601",0,0
09000064839cc098,Notice,FDA-2012-N-0536-0008,FDA-2012-N-0536,"agency information collection activities; proposed collection; comment request; medical device user fee cover sheet, form fda 3601",0,0
09000064849672c9,Other,FDA-2020-P-2213-0001,FDA-2020-P-2213,citizen petition from kenneth e. surprenant,0,0
0900006484969130,Supporting & Related Material,FDA-2020-P-2213-0003,FDA-2020-P-2213,attachments a - l - re: citizen petition from kenneth e. surprenant,0,0
09000064849677cb,Other,FDA-2020-P-2213-0002,FDA-2020-P-2213,acknowledgment letter from fda dms to kenneth e. surprenant,0,0
0900006484b07dc8,Other,FDA-2020-P-2213-0031,FDA-2020-P-2213,interim response letter from fda cder to kenneth e. surprenant,0,0
0900006484969131,Supporting & Related Material,FDA-2020-P-2213-0004,FDA-2020-P-2213,attachments m-z  re: citizen petition from kenneth e. surprenant,0,0
0900006480c25e9d,Notice,FDA-2011-N-0251-0001,FDA-2011-N-0251,"food safety modernization act, focus on preventive controls for facilities; notice of public meeting",1,0
0900006480c3c137,Supporting & Related Material,FDA-2011-N-0251-0004,FDA-2011-N-0251,see fda-2011-n-0251-0008,0,0
0900006480e32c3d,Notice,FDA-2011-N-0366-0001,FDA-2011-N-0366,"fda food safety modernization act, focus on inspections and compliance",1,0
09000064818a7e52,Other,FDA-2011-D-0357-0002,FDA-2011-D-0357,"draft guidance for industry, food and drug administration staff, and clinical laboratories; fda notification and medical device reporting for laboratory developed tests (ldts)",1,0
09000064818a6838,Notice,FDA-2011-D-0357-0001,FDA-2011-D-0357,"food and drug administration notification and medical device reporting for laboratory developed tests; draft guidance for industry,
food and drug administration staff, and clinical laboratories; availability",1,0
09000064819425ac,Notice,FDA-2011-D-0357-0003,FDA-2011-D-0357,"framework for regulatory oversight of laboratory developed tests; public
workshop; request for comments",0,0
0900006484745b3c,Notice,FDA-2020-N-1500-0001,FDA-2020-N-1500,"food and drug administration hiring and retention interim assessment;
public meeting; request for comments",1,0
090000648046e8a7,Notice,FDA-2004-N-0049-0001,FDA-2004-N-0049,fda,0,0
090000648046e8aa,Notice,FDA-2004-N-0049-0004,FDA-2004-N-0049,fda,0,0
090000648046e8a8,Supporting & Related Material,FDA-2004-N-0049-0002,FDA-2004-N-0049,supporting statement,0,0
090000648046e8a9,Supporting & Related Material,FDA-2004-N-0049-0003,FDA-2004-N-0049,supporting statement,0,0
0900006481757759,Supporting & Related Material,FDA-2014-P-0831-0004,FDA-2014-P-0831,attachment b fda guidance for industry citizen petition from orthofix inc.,0,0
0900006481757758,Supporting & Related Material,FDA-2014-P-0831-0003,FDA-2014-P-0831,attachment a list of instrumentation citizen petition from orthofix inc.,0,0
090000648175775c,Supporting & Related Material,FDA-2014-P-0831-0006,FDA-2014-P-0831,attachment d bar code labeling requirement citizen petition from orthofix inc.,0,0
0900006481d1c0fc,Other,FDA-2014-P-0831-0008,FDA-2014-P-0831,supplement from orthofix inc.,0,0
0900006481cf4505,Other,FDA-2014-P-0831-0009,FDA-2014-P-0831,amendment from orthofix inc.,0,0
090000648197f38e,Other,FDA-2014-P-0831-0007,FDA-2014-P-0831,interim response letter from fda cdrh to orthofix inc,0,0
09000064817576b3,Other,FDA-2014-P-0831-0002,FDA-2014-P-0831,acknowledgement letter from fda ddm to orthofix inc.,0,0
09000064817576b1,Other,FDA-2014-P-0831-0001,FDA-2014-P-0831,citizen petition from orthofix inc.,0,0
090000648175775a,Supporting & Related Material,FDA-2014-P-0831-0005,FDA-2014-P-0831,attachment c unique device id system citizen petition from orthofix inc.,0,0
0900006483d9c6f8,Other,FDA-2014-P-0831-0010,FDA-2014-P-0831,withdrawal of citizen petition letter from orthofix to fda ddm,0,0
090000648367bd32,Supporting & Related Material,FDA-2018-P-3325-0012,FDA-2018-P-3325,tab 10_pfizer report 2 re citizen petition from pfizer inc,0,0
090000648367bd37,Supporting & Related Material,FDA-2018-P-3325-0017,FDA-2018-P-3325,tab 15_woodcock letter re citizen petition from pfizer inc,0,0
090000648367baca,Supporting & Related Material,FDA-2018-P-3325-0005,FDA-2018-P-3325,tab 3_manson et al re citizen petition from pfizer inc,0,0
090000648367bd30,Supporting & Related Material,FDA-2018-P-3325-0010,FDA-2018-P-3325,tab 8_levy et al re citizen petition from pfizer inc,0,0
090000648367bd36,Supporting & Related Material,FDA-2018-P-3325-0016,FDA-2018-P-3325,tab 14_bhavnani et al re citizen petition from pfizer inc,0,0
0900006483a0ceee,Other,FDA-2018-P-3325-0018,FDA-2018-P-3325,citizen petition denial response  from fda cder to  pfizer inc,0,0
090000648367bac8,Supporting & Related Material,FDA-2018-P-3325-0003,FDA-2018-P-3325,tab 1_1997 woodcock memo re citizen petition from pfizer inc,0,0
090000648367b8d0,Other,FDA-2018-P-3325-0002,FDA-2018-P-3325,acknowledgment letter from fda ddm to pfizer inc,0,0
090000648367b8cd,Other,FDA-2018-P-3325-0001,FDA-2018-P-3325,citizen petition from pfizer inc,0,0
090000648367bacb,Supporting & Related Material,FDA-2018-P-3325-0006,FDA-2018-P-3325,tab 4_gurney et al re citizen petition from pfizer inc,0,0
090000648367bd34,Supporting & Related Material,FDA-2018-P-3325-0014,FDA-2018-P-3325,tab 12_pfizer report 4 re citizen petition from pfizer inc,0,0
090000648367bacc,Supporting & Related Material,FDA-2018-P-3325-0007,FDA-2018-P-3325,tab 5_lacey et al re citizen petition from pfizer inc,0,0
090000648367bd35,Supporting & Related Material,FDA-2018-P-3325-0015,FDA-2018-P-3325,tab 13_pfizer report 5 re citizen petition from pfizer inc,0,0
090000648367bacd,Supporting & Related Material,FDA-2018-P-3325-0008,FDA-2018-P-3325,tab 6_fda letter to usp re citizen petition from pfizer inc,0,0
090000648367bd2f,Supporting & Related Material,FDA-2018-P-3325-0009,FDA-2018-P-3325,tab 7_2000 draft guidance re citizen petition from pfizer inc,0,0
090000648367bd33,Supporting & Related Material,FDA-2018-P-3325-0013,FDA-2018-P-3325,tab 11_pfizer report 3 re citizen petition from pfizer inc,0,0
090000648367bac9,Supporting & Related Material,FDA-2018-P-3325-0004,FDA-2018-P-3325,tab 2_anderson et al re citizen petition from pfizer inc,0,0
090000648367bd31,Supporting & Related Material,FDA-2018-P-3325-0011,FDA-2018-P-3325,tab 9_pfizer report 1 re citizen petition from pfizer inc,0,0
09000064836efb08,Other,FDA-2018-P-1197-0003,FDA-2018-P-1197,interim response from fda cder to exela pharma sciences,0,0
090000648302b1df,Other,FDA-2018-P-1197-0002,FDA-2018-P-1197,acknowledgment letter from fda ddm to exela pharma sciences,0,0
090000648302b1dd,Other,FDA-2018-P-1197-0001,FDA-2018-P-1197,citizen petition from exela pharma sciences,0,0
0900006481249279,Other,FDA-2012-N-1153-0011,FDA-2012-N-1153,national sustainable agriculture coalition (nsac) - request for extension,0,0
0900006481258f14,Notice,FDA-2012-N-1153-0002,FDA-2012-N-1153,improvement of tracking and tracing of food; establishment of pilot projects and congressional report,1,0
0900006481218171,Notice,FDA-2012-N-1153-0001,FDA-2012-N-1153,improvement of tracking and tracing of food; establishment of pilot projects and congressional report,1,0
090000648494b7cb,Other,FDA-2020-P-1369-0003,FDA-2020-P-1369,"interim response letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
09000064845b7087,Other,FDA-2020-P-1369-0002,FDA-2020-P-1369,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
09000064845b7086,Other,FDA-2020-P-1369-0001,FDA-2020-P-1369,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484c2475f,Other,FDA-2021-P-0476-0002,FDA-2021-P-0476,acknowledgment letter from fda dms to marianne english,0,0
0900006484c2475d,Other,FDA-2021-P-0476-0001,FDA-2021-P-0476,citizen petition from marianne english,0,0
0900006484c8da6f,Other,FDA-2021-P-0924-0001,FDA-2021-P-0924,citizen petition from nancy tanner,0,0
0900006484c8daba,Other,FDA-2021-P-0924-0002,FDA-2021-P-0924,acknowledgment letter from fda dms to nancy tanner,0,0
090000648053d428,Notice,FDA-2008-N-0222-0001,FDA-2008-N-0222,agency information collection activities; submission for office of management and budget review; comment request; orphan drugs; common european medicines agency/food and drug administration application form for orphan medicinal product designation (form fda 3671),1,0
0900006480bcfb66,Notice,FDA-2011-N-0015-0001,FDA-2011-N-0015,"agency information collection activities; proposals, submissions, and approvals form for orphan medicinal product designation (form fda 3671)",0,0
0900006480f6bb8e,Notice,FDA-2011-N-0015-0003,FDA-2011-N-0015,"agency information collection activities; proposals, submissions, and approvals: application form for orphan medicinal product designation",0,0
09000064830e0589,Notice,FDA-2011-N-0015-0006,FDA-2011-N-0015,"agency information collection activities; proposals, submissions, and approvals",0,0
090000648322b662,Notice,FDA-2011-N-0015-0007,FDA-2011-N-0015,"agency information collection activities; announcement of office of
management and budget approvals; correction",0,0
0900006480c79eda,Notice,FDA-2011-N-0015-0002,FDA-2011-N-0015,"agency information collection activities; proposals, submissions, and approvals: orphan drugs; common ema/fda application formfor orphan medicinal product designation",0,0
09000064826ece9f,Notice,FDA-2011-N-0015-0004,FDA-2011-N-0015,agency information collection activities; proposed collection; comment request; orphan drugs; common european medicines agency/food and drug administration application form for orphan drug medicinal product designation,1,0
0900006482cfd0ff,Notice,FDA-2011-N-0015-0005,FDA-2011-N-0015,"agency information collection activities; submission for office of
management and budget review; comment request; orphan products
development; food and drug administration orphan drug designation request form and the common european medicines agency/
food and drug administration form for orphan medicinal product
designation",1,0
090000648216209e,Other,FDA-2016-P-2467-0001,FDA-2016-P-2467,citizen petition from actavis llc,0,0
090000648216209f,Other,FDA-2016-P-2467-0002,FDA-2016-P-2467,acknowledgement letter from fda ddm to actavis llc,0,0
09000064826c7114,Other,FDA-2016-P-2467-0003,FDA-2016-P-2467,withdrawal letter from actavis llc to fda,0,0
09000064845e677c,Other,FDA-2020-D-1378-0001,FDA-2020-D-1378,"guidance for industry, fda staff, and third parties; inspection by accredited persons under the medical device user fee and modernization act of 2002 and the fda amendments act of 2007; accreditation criteria",0,0
0900006483d6738a,Other,FDA-2019-P-3266-0002,FDA-2019-P-3266,"acknowledgment letter from fda ddm to medical research collaborative, llc",0,0
09000064842b394a,Other,FDA-2019-P-3266-0014,FDA-2019-P-3266,interim response letter to  medical research collaborative llc,0,0
0900006483d672b4,Other,FDA-2019-P-3266-0001,FDA-2019-P-3266,citizen petition from medical research collaborative llc,0,0
0900006484a6fb3c,Supporting & Related Material,FDA-2021-P-0301-0013,FDA-2021-P-0301,reference 10 re citizen petition from adrienne samuels,0,0
0900006484a6fb5d,Supporting & Related Material,FDA-2021-P-0301-0017,FDA-2021-P-0301,reference 14 re citizen petition from adrienne samuels,0,0
0900006484a6fb26,Supporting & Related Material,FDA-2021-P-0301-0004,FDA-2021-P-0301,reference 1 re citizen petition from adrienne samuels,0,0
0900006484a6fb37,Supporting & Related Material,FDA-2021-P-0301-0009,FDA-2021-P-0301,reference 6 re citizen petition from adrienne samuels,0,0
0900006484a6fb25,Supporting & Related Material,FDA-2021-P-0301-0003,FDA-2021-P-0301,cover letter for citizen petition from adrienne samuels,0,0
0900006484a6fb27,Supporting & Related Material,FDA-2021-P-0301-0005,FDA-2021-P-0301,reference 2 re citizen petition from adrienne samuels,0,0
0900006484a6fb28,Supporting & Related Material,FDA-2021-P-0301-0006,FDA-2021-P-0301,reference 3 re citizen petition from adrienne samuels,0,0
0900006484a6fb3e,Supporting & Related Material,FDA-2021-P-0301-0015,FDA-2021-P-0301,reference 12 re citizen petition from adrienne samuels,0,0
0900006484a6fb35,Supporting & Related Material,FDA-2021-P-0301-0007,FDA-2021-P-0301,reference 4 re citizen petition from adrienne samuels,0,0
0900006484a6fb3a,Supporting & Related Material,FDA-2021-P-0301-0011,FDA-2021-P-0301,reference 8 re citizen petition from adrienne samuels,0,0
0900006484a6fb3d,Supporting & Related Material,FDA-2021-P-0301-0014,FDA-2021-P-0301,reference 11 re citizen petition from adrienne samuels,0,0
0900006484a6fb3b,Supporting & Related Material,FDA-2021-P-0301-0012,FDA-2021-P-0301,reference 9 re citizen petition from adrienne samuels,0,0
0900006484a6fb5f,Supporting & Related Material,FDA-2021-P-0301-0019,FDA-2021-P-0301,reference 16 re citizen petition from adrienne samuels,0,0
0900006484a6fb5e,Supporting & Related Material,FDA-2021-P-0301-0018,FDA-2021-P-0301,reference 15 re citizen petition from adrienne samuels,0,0
0900006484a6fb0b,Other,FDA-2021-P-0301-0001,FDA-2021-P-0301,citizen petition from adrienne samuels,0,0
0900006484d57afc,Other,FDA-2021-P-0301-0022,FDA-2021-P-0301,180 letter from fda cfsan to adrienne samuels,0,0
0900006484a6fb36,Supporting & Related Material,FDA-2021-P-0301-0008,FDA-2021-P-0301,reference 5 re citizen petition from adrienne samuels,0,0
0900006484a6fb22,Other,FDA-2021-P-0301-0002,FDA-2021-P-0301,acknowledgment letter from fda dms to adrienne samuels,0,0
0900006484a6fb39,Supporting & Related Material,FDA-2021-P-0301-0010,FDA-2021-P-0301,reference 7 re citizen petition from adrienne samuels,0,0
0900006484a6fb5c,Supporting & Related Material,FDA-2021-P-0301-0016,FDA-2021-P-0301,reference 13 re citizen petition from adrienne samuels,0,0
09000064834ca81a,Other,FDA-2018-N-1558-0002,FDA-2018-N-1558,request for extension from animal health institute,0,0
09000064836373a5,Notice,FDA-2018-N-1558-0008,FDA-2018-N-1558,food and drug administration’s evaluation of approaches to demonstrate effectiveness of heart worm preventatives for dogs; extension of comment period,1,0
09000064832d8bb3,Notice,FDA-2018-N-1558-0001,FDA-2018-N-1558,food and drug administration’s evaluation of approaches to  demonstrate effectiveness of heartworm preventatives for dogs; request for comments,1,0
09000064834d2fd0,Other,FDA-2018-N-1558-0003,FDA-2018-N-1558,request for extension from animal health institute,0,0
0900006481807bd5,Other,FDA-2011-D-0215-0038,FDA-2011-D-0215,in vitro companion diagnostic devices; guidance for industry and food and drug administration staff,1,0
0900006481807376,Notice,FDA-2011-D-0215-0037,FDA-2011-D-0215,"in vitro companion diagnostic devices; guidance for industry and
fda staff; availability",0,0
0900006480ee570e,Notice,FDA-2011-D-0215-0003,FDA-2011-D-0215,draft guidance for industry and staff; availability: in vitro companion diagnostic devices,0,0
0900006480ec350b,Other,FDA-2011-D-0215-0002,FDA-2011-D-0215,draft guidance for industry and food and drug administration staff in vitro compaion diagnostic devices,1,0
0900006480ec1bf8,Notice,FDA-2011-D-0215-0001,FDA-2011-D-0215,draft guidance for industry and fda staff; availability in vitro companion diagnostic devices,0,0
0900006482f6513d,Supporting & Related Material,FDA-2018-P-0876-0005,FDA-2018-P-0876,"attachment 3 re citizen petition from hyman, phelps _ mcnamara, p_c-1",0,0
0900006482f65024,Supporting & Related Material,FDA-2018-P-0876-0004,FDA-2018-P-0876,"attachment 2 re citizen petition from hyman, phelps _ mcnamara, p_c-1",0,0
0900006482f649f9,Other,FDA-2018-P-0876-0001,FDA-2018-P-0876,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006482f649fb,Other,FDA-2018-P-0876-0002,FDA-2018-P-0876,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara p.c.",0,0
0900006482f65023,Supporting & Related Material,FDA-2018-P-0876-0003,FDA-2018-P-0876,"attachment 1 re citizen petition from hyman, phelps _ mcnamara, p_c-1",0,0
0900006482cc3c66,Supporting & Related Material,FDA-2017-N-6529-0002,FDA-2017-N-6529,list of references re the food and drug administration’s approach to evaluating nicotine replacement therapies; public hearing; request for comments,1,0
0900006482cc3c67,Supporting & Related Material,FDA-2017-N-6529-0003,FDA-2017-N-6529,reference 1 quitting smoking among adults - united states 2000-2015 re the food and drug administration’s approach to evaluating nicotine replacement therapies; public hearing; request for comments,1,0
0900006482cc0a02,Proposed Rule,FDA-2017-N-6529-0001,FDA-2017-N-6529,"the food and drug administration’s approach to evaluating nicotine
replacement therapies; public hearing; request for comments",1,0
0900006482cc3c68,Supporting & Related Material,FDA-2017-N-6529-0004,FDA-2017-N-6529,reference 2 nicotine replacement therapty for long term smoking cessation a meta-analysis (1) re the food and drug administration’s approach to evaluating nicotine replacement therapies; public hearing; request for comments,1,0
0900006482cc3c69,Supporting & Related Material,FDA-2017-N-6529-0005,FDA-2017-N-6529,reference 3 meta-analysis on efficacy of nicotine replacement therapies in smoking cessation re the food and drug administration’s approach to evaluating nicotine replacement therapies; public hearing; request for comments,1,0
0900006484864851,Other,FDA-2020-D-1937-0001,FDA-2020-D-1937,guidance for industry: frequently asked questions about fda's regulation of infant formula,0,0
090000648486484b,Other,FDA-2020-D-1930-0001,FDA-2020-D-1930,guidance for industry and fda: dear manufacturer letter regarding sugar free claims,0,0
090000648208827c,Other,FDA-2015-D-1839-0005,FDA-2015-D-1839,fda’s policy on declaring small amounts of nutrients and dietary ingredients on nutrition labels: guidance for industry,0,0
090000648208061e,Notice,FDA-2015-D-1839-0004,FDA-2015-D-1839,guidance: policy on declaring small amounts of nutrients and dietary ingredients on nutrition labels,0,0
0900006481bb0c28,Proposed Rule,FDA-2015-D-1839-0001,FDA-2015-D-1839,the food and drug administration’s policy on declaring small amounts of nutrients and dietary ingredients on nutrition labels; draft guidance for industry; availability,1,0
0900006481bb1fb9,Other,FDA-2015-D-1839-0002,FDA-2015-D-1839,fda’s policy on declaring small amounts of nutrients and dietary ingredients on nutrition labels draft guidance,0,0
0900006482e2a276,Other,FDA-2017-P-4409-0006,FDA-2017-P-4409,"interim response letter from fda cder to hyman, phelps & mcnamara, pc",0,0
0900006484a15d24,Other,FDA-2017-P-4409-0007,FDA-2017-P-4409,"response letter from fda cder to hyman, phelps & mcnamara, pc",0,0
0900006482963dcd,Other,FDA-2017-P-4409-0002,FDA-2017-P-4409,"acknowledgement letter from fda ddm to hyman, phelps & mcnamara, pc",0,0
0900006482963dcb,Other,FDA-2017-P-4409-0001,FDA-2017-P-4409,"citizen petition from hyman, phelps & mcnamara, pc",0,0
0900006482bcf132,Other,FDA-2017-P-4409-0004,FDA-2017-P-4409,response  from  synergy pharmaceuticals to cder,0,0
0900006481e131e7,Supporting & Related Material,FDA-2016-P-0147-0005,FDA-2016-P-0147,"attachment 3 consumer study of drained weight re citizen petition from bumble bee foods, llc, et al.",0,0
0900006482c8d940,Other,FDA-2016-P-0147-0007,FDA-2016-P-0147,"interim response from fda cfsan to bumble bee foods, llc",0,0
0900006481e131e5,Supporting & Related Material,FDA-2016-P-0147-0003,FDA-2016-P-0147,"attachment 1 existing standard of identity for 'canned tuna' re citizen petition from bumble bee foods, llc, et al.",0,0
0900006481e131e8,Supporting & Related Material,FDA-2016-P-0147-0006,FDA-2016-P-0147,"attachment 4 aoac official method 968.30 re citizen petition from bumble bee foods, llc, et al.",0,0
0900006481e131e6,Supporting & Related Material,FDA-2016-P-0147-0004,FDA-2016-P-0147,"attachment 2 proposed amended standard of identity for 'canned tuna' re citizen petition from bumble bee foods, llc, et al.",0,0
0900006481e12d81,Other,FDA-2016-P-0147-0002,FDA-2016-P-0147,"acknowledgement letter from fda ddm to bumble bee foods, llc",0,0
0900006481e09695,Other,FDA-2016-P-0147-0001,FDA-2016-P-0147,"citizen petition from bumble bee foods, llc, et al.",0,0
0900006484b34ace,Other,FDA-2021-P-0497-0002,FDA-2021-P-0497,acknowledgment letter from fda dms to valisure llc,0,0
0900006484b34acc,Other,FDA-2021-P-0497-0001,FDA-2021-P-0497,citizen petition from valisure llc,0,0
0900006484b34b5a,Supporting & Related Material,FDA-2021-P-0497-0004,FDA-2021-P-0497,attachment b - acc resolution - chemical variability in pharmaceutical products re citizen petition from valisure llc,0,0
0900006484e719ab,Other,FDA-2021-P-0497-0005,FDA-2021-P-0497,interim response letter from fda cder to valisure llc,0,0
0900006484b34ad1,Supporting & Related Material,FDA-2021-P-0497-0003,FDA-2021-P-0497,attachment a - table 5  product description of various batches of sunscreen for which benzene was not detected through initial analysis of at least one sample from each batch re citizen petition from valisure llc,0,0
090000648054bf90,Other,FDA-2006-P-0150-0004,FDA-2006-P-0150,"lachman consultant services, inc. - amendment to citizen petition",0,0
090000648045050e,Other,FDA-2006-P-0150-0001,FDA-2006-P-0150,"acknowledgement letter to lachman consultant services, inc.",0,0
0900006480450517,Other,FDA-2006-P-0150-0003,FDA-2006-P-0150,"lachman consultant services, inc. - citizen petition",0,0
0900006480450518,Supporting & Related Material,FDA-2006-P-0150-0002,FDA-2006-P-0150,see: fda-2006-p-0150-0001,0,0
0900006480bb6370,Other,FDA-2006-P-0150-0005,FDA-2006-P-0150,"fda/cder to lachman consultant services, inc. - petition approval",0,0
0900006480a800a8,Other,FDA-2010-P-0045-0001,FDA-2010-P-0045,"richard f. edlich, m.d., ph.d., et al - citizen petition",0,0
0900006483093531,Other,FDA-2010-P-0045-0038,FDA-2010-P-0045,memo and combined responses to dr edlich citizen petitions_redacted,0,0
0900006480a800ac,Supporting & Related Material,FDA-2010-P-0045-0002,FDA-2010-P-0045,"reference 1 - ""for consumers, medical glove powder report of the food and drug administration"" - [richard f. edlich, m.d., ph.d., et al - citizen petition]",1,0
0900006480a804b8,Other,FDA-2010-P-0045-0003,FDA-2010-P-0045,"acknowledgement letter to richard f. edlich, m.d., ph.d., et al",0,0
0900006483478bc3,Proposed Rule,FDA-2018-N-2309-0001,FDA-2018-N-2309,the food and drug administration predictive toxicology roadmap and its implementation; public hearing; request for comments,1,0
0900006483988d4b,Other,FDA-2018-D-4267-0002,FDA-2018-D-4267,"draft guidance for industry, biomarker qualification evidentiary framework",0,0
090000648398820d,Notice,FDA-2018-D-4267-0001,FDA-2018-D-4267,"biomarker qualification: evidentiary framework; draft guidance for
industry and food and drug administration staff; availability",1,0
0900006481905189,Notice,FDA-2014-N-1575-0001,FDA-2014-N-1575,"best practices for communication between the food and drug
administration and investigational new drug sponsors during drug
development; request for comments",1,0
09000064815fb451,Notice,FDA-2014-N-0225-0001,FDA-2014-N-0225,announcement of center for biologics evaluation and research’s move to the food and drug administration’s white oak campus,1,0
0900006483b7b1c8,Other,FDA-2018-N-4751-0030,FDA-2018-N-4751,request for extension from medical imaging & technology alliance (mita),0,0
09000064839fff9c,Other,FDA-2018-N-4751-0002,FDA-2018-N-4751,instructions for submitting comments - fda-2018-n-4751,0,0
09000064839ffaca,Other,FDA-2018-N-4751-0001,FDA-2018-N-4751,modernizing the food and drug administration's 510(k) program request for comments,1,0
09000064832ed3fe,Other,FDA-2018-P-2025-0002,FDA-2018-P-2025,acknowledgement letter from fda ddm to center for biological diversity,0,0
09000064833126ce,Other,FDA-2018-P-2025-0003,FDA-2018-P-2025,acknowledgement letter from fda ddm to the center for biological diversity - correction,0,0
09000064838f5e71,Other,FDA-2018-P-2025-0013,FDA-2018-P-2025,interim response from fda/cder to center for biological diversity,0,0
09000064832ed3f9,Other,FDA-2018-P-2025-0001,FDA-2018-P-2025,citizen petition from center for biological diversity,0,0
0900006483d0e49f,Other,FDA-2019-P-2869-0001,FDA-2019-P-2869,"citizen petition from valisure, llc.",0,0
0900006483d0e922,Supporting & Related Material,FDA-2019-P-2869-0004,FDA-2019-P-2869,"attachment b - acc resolution - chemical variability in pharmaceutical products re: citizen petition from valisure, llc",0,0
09000064842659d0,Other,FDA-2019-P-2869-0006,FDA-2019-P-2869,"interim response letter from fda cder to valisure, llc",0,0
0900006483d0e9be,Other,FDA-2019-P-2869-0002,FDA-2019-P-2869,"acknowledgment letter from fda ddm to valisure, llc",0,0
0900006483d0e921,Supporting & Related Material,FDA-2019-P-2869-0003,FDA-2019-P-2869,"attachment a - who and iarc classification of dmf 061119 re: citizen petition from  valisure, llc",0,0
090000648457de9f,Other,FDA-2020-D-1353-0001,FDA-2020-D-1353,"draft guidance for industry; regulatory submissions to ofas, part ix fda references",0,0
0900006484704a4c,Other,FDA-2019-P-4448-0004,FDA-2019-P-4448,interim response letter from fda cfsan to samuel a gonzalez,0,0
0900006483fbd297,Other,FDA-2019-P-4448-0001,FDA-2019-P-4448,citizen petition from samuel a. gonzalez,0,0
0900006483fbd298,Other,FDA-2019-P-4448-0002,FDA-2019-P-4448,acknowledgment letter from fda dms to samuel a. gonzalez,0,0
0900006484121492,Supporting & Related Material,FDA-2019-P-5191-0010,FDA-2019-P-5191,appendix 8 - making a commitment to evoo quality and achieving a consumer focus re: citizen petition from american olive oil producers association,0,0
09000064841240ba,Supporting & Related Material,FDA-2019-P-5191-0008,FDA-2019-P-5191,appendix 5 oocc quality database 2014-15 to 2018-19 re: citizen petition from american olive oil producers association,0,0
090000648412146f,Supporting & Related Material,FDA-2019-P-5191-0009,FDA-2019-P-5191,appendix 7 - informe analisis campañas 2017-2018 y 2018-2019 re: citizen petition from american olive oil producers association,0,0
09000064849f2e3b,Other,FDA-2019-P-5191-0017,FDA-2019-P-5191,interim response letter from fda cfsan,0,0
0900006484121493,Supporting & Related Material,FDA-2019-P-5191-0011,FDA-2019-P-5191,appendix 9 olive oil chemistry in argentina re: citizen petition from american olive oil producers association,0,0
090000648497d915,Other,FDA-2019-P-5191-0016,FDA-2019-P-5191,letter from cfsan to the meriam hospital,0,0
090000648412146d,Supporting & Related Material,FDA-2019-P-5191-0005,FDA-2019-P-5191,appendix 3 testing project 2015-2019 us market data (v2) re: citizen petition from american olive oil producers association,0,0
090000648412146e,Supporting & Related Material,FDA-2019-P-5191-0006,FDA-2019-P-5191,appendix 6 theoretical and practical aspects of the determination of pyropheophythins and isomeric diacylglycerols re: citizen petition from american olive oil producers association,0,0
0900006484121494,Supporting & Related Material,FDA-2019-P-5191-0012,FDA-2019-P-5191,appendix 10 southern hemisphere olive oil re: citizen petition from american olive oil producers association,0,0
09000064841240b9,Supporting & Related Material,FDA-2019-P-5191-0007,FDA-2019-P-5191,appendix 4 australian oils database re: citizen petition from american olive oil producers association,0,0
0900006484120fdb,Other,FDA-2019-P-5191-0001,FDA-2019-P-5191,citizen petition from american olive oil producers association,0,0
0900006484121469,Other,FDA-2019-P-5191-0002,FDA-2019-P-5191,acknowledgment letter from dms to american olive oil producers association,0,0
090000648412146b,Supporting & Related Material,FDA-2019-P-5191-0003,FDA-2019-P-5191,appendix 1 proposed regulations re: citizen petition from american olive oil producers association,0,0
0900006484121495,Supporting & Related Material,FDA-2019-P-5191-0013,FDA-2019-P-5191,appendix 11 presentation minor components to determine oil authenticity-2 re: citizen petition from american olive oil producers association,0,0
09000064846d5e31,Other,FDA-2019-P-5191-0015,FDA-2019-P-5191,amended citizen petition for standards of identity for olive oil and olive-pomace oil and apendix 1 from american olive oil producers association,0,0
090000648412146c,Supporting & Related Material,FDA-2019-P-5191-0004,FDA-2019-P-5191,appendix 2 technical support document re: citizen petition from american olive oil producers association,0,0
090000648100a472,Other,FDA-1989-D-0191-0002,FDA-1989-D-0191,fda guide to acceptance market names for food fish sold in interstate commerce; guidance,1,0
0900006480479290,Notice,FDA-1989-D-0191-0001,FDA-1989-D-0191,fda guide to acceptance market names for food fish sold in interstate commerce; availability,1,0
09000064808094f2,Other,FDA-2008-P-0380-0004,FDA-2008-P-0380,fda/cder interim response to national association of chain drug stores - letter,0,0
0900006480651815,Other,FDA-2008-P-0380-0001,FDA-2008-P-0380,"national consumers league, et al - citizen petition",0,0
09000064812c413d,Other,FDA-2008-P-0380-0008,FDA-2008-P-0380,"national consumers league, et al (olson, frank, weeda) - withdrawal of petition",0,0
090000648065ae0d,Other,FDA-2008-P-0380-0002,FDA-2008-P-0380,acknowledgement letter  to national consumers league,0,0
0900006480810eae,Other,FDA-2008-P-0380-0006,FDA-2008-P-0380,memo to the file,0,0
090000648239c58b,Other,FDA-2016-P-3823-0002,FDA-2016-P-3823,acknowledgment letter from fda ddm to jennifer a. osler,0,0
090000648239c589,Other,FDA-2016-P-3823-0001,FDA-2016-P-3823,citizen petition from jennifer a. osler,0,0
090000648380e931,Other,FDA-2016-P-3823-0003,FDA-2016-P-3823,agency response letter from fda cfsan to jennifer a. osler,0,0
09000064820052bb,Other,FDA-2016-P-0618-0004,FDA-2016-P-0618,letter from emily connor,0,0
09000064820066a3,Other,FDA-2016-P-0618-0003,FDA-2016-P-0618,interim response letter from fda cfsan to emily connor,0,0
0900006481e7649a,Other,FDA-2016-P-0618-0001,FDA-2016-P-0618,citizen petition from emily connor,0,0
0900006481e766e6,Other,FDA-2016-P-0618-0002,FDA-2016-P-0618,acknowledgement letter from fda ddm to emily connor,0,0
0900006484324f91,Notice,FDA-2019-N-6050-0001,FDA-2019-N-6050,food and drug administration/federal trade commission workshop on a competitive marketplace for biosimilars; public workshop; request for comments,1,0
0900006484459679,Other,FDA-2019-N-6050-0002,FDA-2019-N-6050,fda ftc public workshop slides,0,0
090000648466456d,Other,FDA-2019-D-1163-0001,FDA-2019-D-1163,release of ora laboratory analytical results to the responsible party:  guidance for food and drug administration staff,1,0
090000648390cf2c,Other,FDA-2017-D-5928-0008,FDA-2017-D-5928,post-complete response letter meetings between fda and anda applicants under gdufa guidance for industry,0,0
0900006483939624,Notice,FDA-2017-D-5928-0007,FDA-2017-D-5928,"post-complete response letter meetings between the food and drug
administration and abbreviated new drug application applicants under
generic drug user fee amendments; guidance for industry; availability",1,0
0900006482bcd99e,Notice,FDA-2017-D-5928-0001,FDA-2017-D-5928,"post-complete response letter meetings between the food and drug 
administration and abbreviated new drug application applicants under 
the generic drug user fee act; draft guidance for industry; availability",1,0
0900006482bcddde,Other,FDA-2017-D-5928-0002,FDA-2017-D-5928,guidance for industry on response letter meetings between fda and anda applicants under gdufa,0,0
0900006484b2edd2,Other,FDA-2021-P-0495-0002,FDA-2021-P-0495,acknowledgment letter from fda dms to hyman phelps mcnamara pc,0,0
0900006484b2edd5,Supporting & Related Material,FDA-2021-P-0495-0003,FDA-2021-P-0495,attachment 1- prescription drug product list  re suitability petition from hyman phelps mcnamara p.c.,0,0
0900006484b2edd6,Supporting & Related Material,FDA-2021-P-0495-0004,FDA-2021-P-0495,attachment 2- highlights of prescribing information for zanaflex re suitability petition from hyman phelps mcnamara p.c.,0,0
0900006484b2ea55,Other,FDA-2021-P-0495-0001,FDA-2021-P-0495,suitability petition from hyman phelps mcnamara p.c.,0,0
0900006484b2ee3d,Supporting & Related Material,FDA-2021-P-0495-0005,FDA-2021-P-0495,attachment 3 - tizanidine hydrochloride capsules - tizanidine hydrochloride capsule re suitability petition from hyman phelps mcnamara p.c.,0,0
09000064849e89f4,Notice,FDA-2014-N-1031-0004,FDA-2014-N-1031,"agency information collection activities; proposals, submissions, and approvals: recall regulations",0,0
0900006484b63c15,Notice,FDA-2014-N-1031-0006,FDA-2014-N-1031,"agency information collection 
activities; announcement of office of 
management and budget approvals",0,0
0900006481ae0264,Notice,FDA-2014-N-1031-0003,FDA-2014-N-1031,"agency information collection activities; announcement of office of
management and budget approval; fda recall regulations",0,0
09000064819fe9fd,Notice,FDA-2014-N-1031-0002,FDA-2014-N-1031,"agency information collection activities; submission for office of
management and budget review; comment request; food and drug
administration recall regulations",1,0
0900006484aa1304,Notice,FDA-2014-N-1031-0005,FDA-2014-N-1031,"agency information collection activities; proposals, submissions, and approvals: food and drug administration recall regulations",1,0
09000064817fdc07,Notice,FDA-2014-N-1031-0001,FDA-2014-N-1031,"agency information collection activities; proposed collection;
comment request; food and drug administration recall regulations",1,0
09000064824c02e7,Supporting & Related Material,FDA-2017-P-0867-0049,FDA-2017-P-0867,attachment 47 - kim2016  re citizen petition from public citizen,0,0
09000064824c02f7,Supporting & Related Material,FDA-2017-P-0867-0058,FDA-2017-P-0867,attachment 56 - meybohm2013-hes-doseclaim  re citizen petition from public citizen,0,0
09000064824c02f8,Supporting & Related Material,FDA-2017-P-0867-0059,FDA-2017-P-0867,attachment 57 - muller2015-posthocofperner2012  re citizen petition from public citizen,0,0
09000064824c02fc,Supporting & Related Material,FDA-2017-P-0867-0063,FDA-2017-P-0867,attachment 61 - myburgh2012_chest-suppappendix  re citizen petition from public citizen,0,0
09000064824c0300,Supporting & Related Material,FDA-2017-P-0867-0067,FDA-2017-P-0867,attachment 65 - myburgh2012_chest-table2corrected2016  re citizen petition from public citizen,0,0
09000064824c0301,Supporting & Related Material,FDA-2017-P-0867-0068,FDA-2017-P-0867,attachment 66 - ozturk2015-coronarysurgery  re citizen petition from public citizen,0,0
09000064824c0305,Supporting & Related Material,FDA-2017-P-0867-0072,FDA-2017-P-0867,attachment 70 - patel2013-meta-analysis hes sepsis-supp  re citizen petition from public citizen,0,0
09000064824c0307,Supporting & Related Material,FDA-2017-P-0867-0074,FDA-2017-P-0867,attachment 72 - perel_cochrane 2013  re citizen petition from public citizen,0,0
09000064824c0309,Supporting & Related Material,FDA-2017-P-0867-0076,FDA-2017-P-0867,attachment 74 - rioux2009  re citizen petition from public citizen,0,0
09000064824c0310,Supporting & Related Material,FDA-2017-P-0867-0083,FDA-2017-P-0867,attachment 81 - van der linden2013- postmark comm children hes vs alb  re citizen petition from public citizen,0,0
09000064824c0311,Supporting & Related Material,FDA-2017-P-0867-0084,FDA-2017-P-0867,attachment 82 - urology surgery  re citizen petition from public citizen,0,0
09000064824c031a,Supporting & Related Material,FDA-2017-P-0867-0093,FDA-2017-P-0867,attachment 91 - wiedermann2014-systreview  re citizen petition from public citizen,0,0
09000064824c00ea,Supporting & Related Material,FDA-2017-P-0867-0003,FDA-2017-P-0867,attachment 1 - alexander1975-plasmaexpanders re citizen petition from public citizen,0,0
09000064824c00ed,Supporting & Related Material,FDA-2017-P-0867-0006,FDA-2017-P-0867,attachment 4 - alexander1975-plasmaexpanders-1 re citizen petition from public citizen,0,0
09000064824c00ef,Supporting & Related Material,FDA-2017-P-0867-0008,FDA-2017-P-0867,attachment 6 - allen_2014_traumaptxs  re citizen petition from public citizen,0,0
09000064824c00f6,Supporting & Related Material,FDA-2017-P-0867-0011,FDA-2017-P-0867,attachment 9 - allison1999-randomized trial of hydroxyethyl starch versus gelatine for trauma resuscitation  re citizen petition from public citizen,0,0
09000064824c00fa,Supporting & Related Material,FDA-2017-P-0867-0015,FDA-2017-P-0867,attachment 13 - brunkhorst2008  re citizen petition from public citizen,0,0
09000064824c00ff,Supporting & Related Material,FDA-2017-P-0867-0020,FDA-2017-P-0867,attachment 18 - ema assessment report_reversal of ban  re citizen petition from public citizen,0,0
09000064824c02d1,Supporting & Related Material,FDA-2017-P-0867-0029,FDA-2017-P-0867,attachment 27 - fda voluven med review  re citizen petition from public citizen,0,0
09000064824c02d2,Supporting & Related Material,FDA-2017-P-0867-0030,FDA-2017-P-0867,attachment 28 - gattas2013-v39-p558  re citizen petition from public citizen,0,0
09000064824c02d9,Supporting & Related Material,FDA-2017-P-0867-0035,FDA-2017-P-0867,attachment 33 - finfer2010-surveyicus  re citizen petition from public citizen,0,0
09000064824c02da,Supporting & Related Material,FDA-2017-P-0867-0036,FDA-2017-P-0867,attachment 34 - haase2013-meta-analysissepsis-supp2  re citizen petition from public citizen,0,0
09000064824c02de,Supporting & Related Material,FDA-2017-P-0867-0040,FDA-2017-P-0867,attachment 38 - hartog_natanson_coreviewbmj2014  re citizen petition from public citizen,0,0
09000064824c02e0,Supporting & Related Material,FDA-2017-P-0867-0042,FDA-2017-P-0867,attachment 40 - haynes 2004  re citizen petition from public citizen,0,0
09000064824c02e2,Supporting & Related Material,FDA-2017-P-0867-0044,FDA-2017-P-0867,attachment 42 - hextend - 2014-11  re citizen petition from public citizen,0,0
090000648048b8b1,Supporting & Related Material,FDA-2003-D-0203-0002,FDA-2003-D-0203,guidance,0,0
090000648048b8ac,Notice,FDA-2003-D-0203-0001,FDA-2003-D-0203,fda,0,0
090000648048b8b2,Supporting & Related Material,FDA-2003-D-0203-0003,FDA-2003-D-0203,guidance,0,0
090000648049879e,Supporting & Related Material,FDA-2003-D-0367-0005,FDA-2003-D-0367,guidance,0,0
090000648049879b,Notice,FDA-2003-D-0367-0004,FDA-2003-D-0367,fda,0,0
0900006480498779,Supporting & Related Material,FDA-2003-D-0367-0002,FDA-2003-D-0367,guidance,0,0
0900006480498740,Notice,FDA-2003-D-0367-0001,FDA-2003-D-0367,fda,0,0
0900006480498786,Supporting & Related Material,FDA-2003-D-0367-0003,FDA-2003-D-0367,guidance,0,0
09000064804994a5,Notice,FDA-2003-D-0376-0001,FDA-2003-D-0376,fda,0,0
09000064804994dd,Supporting & Related Material,FDA-2003-D-0376-0002,FDA-2003-D-0376,guideline,0,0
090000648046eb38,Other,FDA-2004-N-0058-0002,FDA-2004-N-0058,draft drug-diagnostic co-development concept paper,0,0
090000648046eb30,Notice,FDA-2004-N-0058-0001,FDA-2004-N-0058,fda,0,0
090000648457a822,Other,FDA-2004-D-0124-0006,FDA-2004-D-0124,"saline, silicone gel, and alternative breast implants  guidance for industry and fda staff",0,0
090000648046fc25,Supporting & Related Material,FDA-2004-D-0124-0003,FDA-2004-D-0124,guidance,0,0
090000648046fc8c,Supporting & Related Material,FDA-2004-D-0124-0005,FDA-2004-D-0124,guidance,0,0
090000648046fc8b,Notice,FDA-2004-D-0124-0004,FDA-2004-D-0124,fda,0,0
090000648046fc24,Supporting & Related Material,FDA-2004-D-0124-0002,FDA-2004-D-0124,guidance,0,0
090000648046fc18,Notice,FDA-2004-D-0124-0001,FDA-2004-D-0124,fda,0,0
090000648045648a,Supporting & Related Material,FDA-2006-D-0232-0002,FDA-2006-D-0232,guidance,0,0
09000064804564ac,Notice,FDA-2006-D-0232-0003,FDA-2006-D-0232,fda,0,0
09000064804564ad,Supporting & Related Material,FDA-2006-D-0232-0004,FDA-2006-D-0232,guidance,0,0
0900006480456466,Notice,FDA-2006-D-0232-0001,FDA-2006-D-0232,fda,0,0
09000064804b501a,Supporting & Related Material,FDA-2001-N-0017-0005,FDA-2001-N-0017,"omb information collection supporting statement re general licensing provisions; biologics license application, changes to an approved application, labeling; and revocation and suspension 0910-0338",0,0
09000064804b501d,Notice,FDA-2001-N-0017-0004,FDA-2001-N-0017,"agency information collection activities; submission for omb review; comment request; general licensing provisions: biologics license application, changes to an approved application, labeling forms fda 356h and 2567; and revocation and suspension",0,0
09000064804b4fc7,Notice,FDA-2001-N-0017-0001,FDA-2001-N-0017,"agency information collection activities; proposed collection; comment request; general licensing provisions: biologics license application, changes to an approved application, labeling forms fda 356h and 2567; and revocation and suspension",0,0
09000064804b5017,Notice,FDA-2001-N-0017-0002,FDA-2001-N-0017,"agency information collection activities; submission for omb review; comment request; general licensing provisions: biologics license application, changes to an approved application, labeling forms fda 356h and 2567; and revocation and suspension",0,0
09000064806af2a4,Other,FDA-2008-D-0417-0002,FDA-2008-D-0417,guidance for the public and fda staff on convening advisory committee meetings - draft guidance,0,0
09000064806aed1d,Notice,FDA-2008-D-0417-0001,FDA-2008-D-0417,draft guidance for the public and the food and drug administration staff on convening advisory committee meetings; availability,1,0
0900006480b644b8,Notice,FDA-2010-N-0506-0001,FDA-2010-N-0506,office of the commissioner; request for comments: food and drug administration fiscal year 2011-2015 strategic priorities document; requests for comments,1,0
0900006480b95eb8,Other,FDA-2010-N-0506-0035,FDA-2010-N-0506,jerome r. schindler food regulatory consultant - letter re fda-2010-n-0506-0034,1,0
0900006480b072f9,Other,FDA-2010-P-0322-0001,FDA-2010-P-0322,amgen inc. - citizen petition,0,0
0900006480b072fa,Other,FDA-2010-P-0322-0002,FDA-2010-P-0322,acknowledgement letter to amgen inc.,0,0
0900006480b51a1e,Other,FDA-2010-P-0322-0003,FDA-2010-P-0322,"amgen, inc. - withdrawal",0,0
0900006484dc2c2d,Other,FDA-2021-P-1099-0002,FDA-2021-P-1099,acknowledgment letter from fda dms to pet schooled,0,0
0900006484dc28b7,Other,FDA-2021-P-1099-0001,FDA-2021-P-1099,citizen petition from pet schooled,0,0
0900006483792a60,Supporting & Related Material,FDA-2018-P-3770-0004,FDA-2018-P-3770,exhibit 2 proposed package insert for levocarnitine injection re citizen petition from luitpold pharmaceuticals inc,0,0
090000648379280a,Other,FDA-2018-P-3770-0001,FDA-2018-P-3770,citizen petition from luitpold pharmaceuticals inc,0,0
0900006484921274,Other,FDA-2018-P-3770-0007,FDA-2018-P-3770,letter from fda cder to luitpold pharmaceuticals inc.,0,0
0900006483792a5f,Supporting & Related Material,FDA-2018-P-3770-0003,FDA-2018-P-3770,exhibit 1 package insert for leadiant biosciences re citizen petition from luitpold pharmaceuticals inc,0,0
090000648379722a,Other,FDA-2018-P-3770-0006,FDA-2018-P-3770,corrected acknowledgment letter from fda ddm to luitpold pharmaceuticals inc,0,0
090000648379280c,Other,FDA-2018-P-3770-0002,FDA-2018-P-3770,acknowledgment letter from fda ddm to luitpold pharmaceuticals inc,0,0
0900006483792a61,Supporting & Related Material,FDA-2018-P-3770-0005,FDA-2018-P-3770,exhibit 3 side by side comparison re citizen petition from luitpold pharmaceuticals inc,0,0
09000064838c243a,Other,FDA-2018-P-3545-0005,FDA-2018-P-3545,letter from arnall golden gregory llp to fda ddm,0,0
090000648425436d,Other,FDA-2018-P-3545-0008,FDA-2018-P-3545,withdrawal from arnall golden gregory llp,0,0
0900006483c11f5a,Other,FDA-2018-P-3545-0007,FDA-2018-P-3545,letter from arnall golden greory llp to fda ddm,0,0
0900006483723670,Other,FDA-2018-P-3545-0002,FDA-2018-P-3545,"acknowledgment letter from fda ddm to arnall golden gregory, llp",0,0
0900006483b01dc9,Other,FDA-2018-P-3545-0006,FDA-2018-P-3545,"letter from fda cder to arnall golden gregory, llp",0,0
09000064837235fa,Other,FDA-2018-P-3545-0001,FDA-2018-P-3545,"citizen petition from arnall golden gregory, llp",0,0
0900006483723673,Supporting & Related Material,FDA-2018-P-3545-0004,FDA-2018-P-3545,"attachment b re citizen petition from arnall golden gregory, llp",0,0
0900006483723672,Supporting & Related Material,FDA-2018-P-3545-0003,FDA-2018-P-3545,"attachment a re citizen petition from arnall golden gregory, llp",0,0
0900006481e6622a,Other,FDA-2016-P-0542-0002,FDA-2016-P-0542,"acknowledgement letter from fda ddm to gordon johnston regulatory consultants, llc",0,0
0900006481e6622e,Supporting & Related Material,FDA-2016-P-0542-0003,FDA-2016-P-0542,"attachment a electronic orange book listing for calcium chloride; potassium chloride; sodium chloride; sodium lactate re citizen petition from gordon johnston regulatory consultants, llc",0,0
0900006482195e52,Other,FDA-2016-P-0542-0004,FDA-2016-P-0542,"petition approval letter from fda cder to gordon johnston regulatory consultants, llc",0,0
0900006481e66579,Other,FDA-2016-P-0542-0001,FDA-2016-P-0542,"citizen petition from gordon johnston regulatory consultants, llc",0,0
090000648447bea9,Supporting & Related Material,FDA-2020-P-1236-0003,FDA-2020-P-1236,attachment 1 re: citizen petition from foley & lardner llp,0,0
090000648447b542,Other,FDA-2020-P-1236-0002,FDA-2020-P-1236,acknowledgment letter from fda dms to foley & lardner llp,0,0
090000648447b48f,Other,FDA-2020-P-1236-0001,FDA-2020-P-1236,citizen petition from foley & lardner llp,0,0
090000648488ff89,Other,FDA-2020-P-1236-0004,FDA-2020-P-1236,denial letter from fda cder to foley & lardner llp,0,0
09000064840f11fe,Other,FDA-2018-P-2962-16596,FDA-2018-P-2962,petition response letter from fda cder to americans for homeopathy choice,0,0
0900006483996110,Supporting & Related Material,FDA-2018-P-2962-1922,FDA-2018-P-2962,homeopathys role in addressing the over-medication epidemic afhc re:citizen petition from americans for homeopathy choice,0,0
09000064838bc56b,Supporting & Related Material,FDA-2018-P-2962-0827,FDA-2018-P-2962,homeopathy in reducing pain medications afhc fda paper re:citizen petition from americans for homeopathy choice,0,0
09000064838bc57f,Supporting & Related Material,FDA-2018-P-2962-0828,FDA-2018-P-2962,antibiotics afhc fda paper re;citizen petition from americans for homeopathy choice,0,0
090000648358625a,Other,FDA-2018-P-2962-0002,FDA-2018-P-2962,acknowledgment letter from fda ddm to americans for homeopathy choice,0,0
0900006483995cc3,Supporting & Related Material,FDA-2018-P-2962-1924,FDA-2018-P-2962,the use of homeopathy in european hospitals- afhc re:citizen petition from americans for homeopathy choice,0,0
0900006483a69b53,Other,FDA-2018-P-2962-16090,FDA-2018-P-2962,letter from fda cder to americans for homeopathy choice,0,0
0900006483582faa,Other,FDA-2018-P-2962-0001,FDA-2018-P-2962,citizen petition from americans for homeopathy choice,0,0
0900006483995cc4,Supporting & Related Material,FDA-2018-P-2962-1923,FDA-2018-P-2962,homeopathys role in addressing the healthcare costs - afhc re:citizen petition from americans for homeopathy choice,0,0
0900006483c8eef4,Other,FDA-2018-P-2962-16529,FDA-2018-P-2962,memorandum of meeting - afhc meeting with fda cder,0,0
09000064821533b7,Other,FDA-2016-P-0656-0004,FDA-2016-P-0656,interim response,0,0
09000064843ee819,Other,FDA-2016-P-0656-0005,FDA-2016-P-0656,citizen petition denial response letter from fda cder to steven a. zecola,0,0
0900006481e8071a,Other,FDA-2016-P-0656-0002,FDA-2016-P-0656,acknowledgement letter from fda ddm to steven zecola,0,0
0900006481e80716,Other,FDA-2016-P-0656-0001,FDA-2016-P-0656,citizen petition from steven zecola,0,0
0900006484cac78d,Other,FDA-2021-P-0950-0001,FDA-2021-P-0950,citizen petition from donna duty,0,0
0900006484cace14,Other,FDA-2021-P-0950-0002,FDA-2021-P-0950,acknowledgment letter from fda dms to donna duty,0,0
0900006482ef93ad,Other,FDA-2018-P-0599-0002,FDA-2018-P-0599,"acknowledgment letter from fda ddm to national pediculosis association, inc",0,0
0900006483779102,Other,FDA-2018-P-0599-0018,FDA-2018-P-0599,interim response from fda oc to national pediculosis association,0,0
0900006482ef93ab,Other,FDA-2018-P-0599-0001,FDA-2018-P-0599,"citizen petition from national pediculosis association, inc",0,0
09000064842bb398,Other,FDA-2018-P-0599-0020,FDA-2018-P-0599,final response from fda oc to national pediculosis association,0,0
0900006481a7a987,Other,FDA-2013-P-1378-0004,FDA-2013-P-1378,supplement from william schwemer,0,0
090000648172cf5e,Other,FDA-2013-P-1378-0003,FDA-2013-P-1378,citizen petition interim response from fda cder to  william l. schwemer,0,0
0900006481486a0b,Other,FDA-2013-P-1378-0002,FDA-2013-P-1378,acknowledgement letter to william l. schwemer,0,0
0900006484605e35,Other,FDA-2013-P-1378-0005,FDA-2013-P-1378,denial letter from fda cder  to william l. schwemer,0,0
090000648148697d,Other,FDA-2013-P-1378-0001,FDA-2013-P-1378,william l. schwemer - citizen petition,0,0
0900006484a3874c,Other,FDA-2021-P-0191-0002,FDA-2021-P-0191,acknowledgment letter from fda dms to foley & lardner llp,0,0
0900006484c03d8f,Other,FDA-2021-P-0191-0005,FDA-2021-P-0191,petition response to foley & lardner llp from fda cder,0,0
0900006484a38743,Other,FDA-2021-P-0191-0001,FDA-2021-P-0191,citizen petition from foley & lardner llp,0,0
0900006484a38750,Supporting & Related Material,FDA-2021-P-0191-0003,FDA-2021-P-0191,attachment re citizen petition from foley & lardner llp,0,0
0900006484befc3e,Notice,FDA-2021-P-0191-0004,FDA-2021-P-0191,"determination that stromectol (ivermectin) tablets, 6 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006484cac0e1,Other,FDA-2021-P-0949-0002,FDA-2021-P-0949,acknowledgment letter from fda dms to harry duty,0,0
0900006484cac06b,Other,FDA-2021-P-0949-0001,FDA-2021-P-0949,citizen petition from harry duty,0,0
0900006484dacd95,Other,FDA-2021-P-1044-0002,FDA-2021-P-1044,acknowledgment letter from fda dms to dr. laurie coger,0,0
0900006484dab8f7,Other,FDA-2021-P-1044-0001,FDA-2021-P-1044,citizen petition from dr. laurie coger,0,0
0900006484dfd49d,Other,FDA-2021-P-1178-0001,FDA-2021-P-1178,citizen petition from pet schooled,0,0
0900006484dfd49f,Other,FDA-2021-P-1178-0002,FDA-2021-P-1178,acknowledgment letter from fda dms to pet schooled,0,0
09000064843b6afe,Other,FDA-2020-P-0947-0001,FDA-2020-P-0947,"citizen petition from hyman, phelps and mcnamara, p.c.",0,0
0900006484816f41,Other,FDA-2020-P-0947-0003,FDA-2020-P-0947,"interim response from fda cder to hyman, phelps &mcnamara, p.c.",0,0
09000064843b6827,Other,FDA-2020-P-0947-0002,FDA-2020-P-0947,"acknowledgment letter from fda dms to hyman, phelps and mcnamara, p.c.",0,0
0900006484865b86,Other,FDA-2020-P-0947-0004,FDA-2020-P-0947,"letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
0900006483e6dc27,Other,FDA-2019-P-3903-0002,FDA-2019-P-3903,"acknowledgment letter from fda dms to hyman, phelps & mcnamara p.c.",0,0
0900006483e6dc26,Other,FDA-2019-P-3903-0001,FDA-2019-P-3903,"citizen petition from hyman, phelps & mcnamara p.c.",0,0
09000064847c538b,Other,FDA-2019-P-3903-0004,FDA-2019-P-3903,"approval letter from fda cder to hyman, phelps & mcnamara p c",0,0
0900006484363105,Other,FDA-2019-P-3903-0003,FDA-2019-P-3903,"interim response letter from fda cder to hyman, phelps & mcnamara p c",0,0
0900006484bf3afe,Other,FDA-2021-P-0700-0002,FDA-2021-P-0700,acknowledgement letter from fda dms to eric nault,0,0
0900006484bf3543,Other,FDA-2021-P-0700-0001,FDA-2021-P-0700,citizen petition from eric nault,0,0
0900006484ad442e,Other,FDA-2021-P-0436-0002,FDA-2021-P-0436,acknowledgment letter from fda dms to pet schooled,0,0
0900006484dfdec4,Other,FDA-2021-P-0436-0003,FDA-2021-P-0436,response letter from fda cvm to pet schooled,0,0
0900006484ad4539,Other,FDA-2021-P-0436-0001,FDA-2021-P-0436,citizen petition from pet schooled,0,0
0900006481f7cc81,Other,FDA-2016-P-1171-0002,FDA-2016-P-1171,"acknowledgement letter from fda ddm to  breast cancer fund, center for food safety, center for environmental health, center for science in the public interest, consumer federation of america, earthjustice environmental defense fund, improving kids’ environment (ike), learning disabilities association of america, natural resources defense council",1,0
090000648238c887,Other,FDA-2016-P-1171-0004,FDA-2016-P-1171,interim response letter from fda cfsan to breast cancer fund,0,0
0900006481f7ca25,Other,FDA-2016-P-1171-0001,FDA-2016-P-1171,"citizen petition from breast cancer fund, center for food safety, center for environmental health, center for science in the public interest, consumer federation of america, earthjustice, environmental defense fund, improving kids’ environment (ike), learning disabilities association of america, natural resources defense council",1,0
0900006481f7cc83,Supporting & Related Material,FDA-2016-P-1171-0003,FDA-2016-P-1171,"attachment 1 – natural resources defense council, et al to dr. nennis keefe  re citizen petition requesting that fda remove its prior sanction of five ortho-phthalates and ban eight ortho-phthalates",0,0
09000064832de824,Other,FDA-2014-P-1256-0004,FDA-2014-P-1256,response letter from fda cder to public citizen's health research group,0,0
09000064817e6157,Other,FDA-2014-P-1256-0001,FDA-2014-P-1256,citizen petition from public citizen,0,0
0900006481e4518d,Other,FDA-2014-P-1256-0003,FDA-2014-P-1256,interim response letter from fda cder to public citizen's health research group,0,0
090000648185aee6,Other,FDA-2014-P-1256-0002,FDA-2014-P-1256,acknowledgement letter from fda ddm to public citizen,0,0
0900006481b0a63e,Other,FDA-2015-P-1903-0002,FDA-2015-P-1903,"acknowledgement letter from fda ddm to matawan pharmaceuticals, llc",0,0
0900006481b0a162,Other,FDA-2015-P-1903-0001,FDA-2015-P-1903,"citizen petition from matawan pharmaceuticals, llc",0,0
0900006481c3bc5a,Other,FDA-2015-P-3139-0001,FDA-2015-P-3139,citizen petition from kimberly kideckel,0,0
0900006482374277,Other,FDA-2015-P-3139-0003,FDA-2015-P-3139,interim response letter from cfsan to kimberly kideckel,0,0
0900006483b695c9,Other,FDA-2015-P-3139-0004,FDA-2015-P-3139,letter from fda cfsan to kimberly kideckel,0,0
0900006481c3cdb2,Other,FDA-2015-P-3139-0002,FDA-2015-P-3139,acknowledgement letter from fda ddm to kimberly kideckel,0,0
090000648346cd26,Other,FDA-2018-P-2506-0002,FDA-2018-P-2506,acknowledgment letter from fda ddm to k&l gates llp,0,0
090000648346c846,Other,FDA-2018-P-2506-0001,FDA-2018-P-2506,citizen petition from k&l gates llp,0,0
09000064838cf132,Other,FDA-2018-P-2506-0004,FDA-2018-P-2506,letter from fda cder to k&l gates llp re citizen petition,0,0
09000064838bb374,Notice,FDA-2018-P-2506-0003,FDA-2018-P-2506,"determination that axiron (testosterone) transdermal metered
solution, 30 milligrams/1.5 milliliter actuation, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483603a26,Supporting & Related Material,FDA-2018-P-3139-0003,FDA-2018-P-3139,"attachment 1 re citizen petition from hyman, phelps & mcnamara, p c",0,0
0900006483603a28,Supporting & Related Material,FDA-2018-P-3139-0005,FDA-2018-P-3139,"attachment 3 re citizen petition from hyman, phelps & mcnamara, p c",0,0
09000064836039fd,Other,FDA-2018-P-3139-0001,FDA-2018-P-3139,"citizen petition from hyman, phelps & mcnamara, p c",0,0
09000064836039ff,Other,FDA-2018-P-3139-0002,FDA-2018-P-3139,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara",0,0
0900006483603a27,Supporting & Related Material,FDA-2018-P-3139-0004,FDA-2018-P-3139,"attachment 2 re citizen petition from hyman, phelps & mcnamara, p c",0,0
09000064846b5c82,Other,FDA-2020-D-1434-0001,FDA-2020-D-1434,cpg sec. 130.300  fda access to results of quality assurance program audits and inspections,0,0
0900006484a469be,Other,FDA-2018-P-0884-0005,FDA-2018-P-0884,response letter from fda cder to buchanan ingersoll & rooney pc ( on behalf of synergy pharmaceuticals  inc.),0,0
0900006482f68335,Other,FDA-2018-P-0884-0002,FDA-2018-P-0884,acknowledgment letter from fda ddm to buchanan ingersoll & rooney pc ( on behalf of synergy pharmaceuticals  inc.),0,0
0900006483642f4d,Other,FDA-2018-P-0884-0004,FDA-2018-P-0884,interim response letter from fda cder to buchanan ingersoll & rooney pc,0,0
0900006482f68292,Other,FDA-2018-P-0884-0001,FDA-2018-P-0884,citizen petition from buchanan ingersoll & rooney pc ( on behalf of synergy pharmaceuticals  inc.),0,0
0900006484a2ca76,Other,FDA-2020-P-2225-0012,FDA-2020-P-2225,reply from siri & glimstad llp,0,0
0900006484974012,Other,FDA-2020-P-2225-0001,FDA-2020-P-2225,citizen petition from siri & glimstad llp on behalf of dr sin hang lee,0,0
090000648499c481,Other,FDA-2020-P-2225-0008,FDA-2020-P-2225,soa denial letter from fda cber  to siri & glimstad llp,0,0
09000064849740da,Supporting & Related Material,FDA-2020-P-2225-0003,FDA-2020-P-2225,all resources re citizen petition from siri & glimstad llp on behalf of dr sin hang lee,0,0
0900006484974013,Other,FDA-2020-P-2225-0002,FDA-2020-P-2225,acknowledgment letter from fda dms to siri & glimstad llp on behalf of dr sin hang lee,0,0
090000648497923f,Other,FDA-2020-P-2225-0004,FDA-2020-P-2225,stay of action petition from siri & glimstad llp on behalf of dr sin hang lee,0,0
0900006484a9aa03,Supporting & Related Material,FDA-2018-P-3354-0025,FDA-2018-P-3354,references from international contrast ultrasound society (icus) part 6 of 7,0,0
0900006484a9a90e,Supporting & Related Material,FDA-2018-P-3354-0022,FDA-2018-P-3354,references from international contrast ultrasound society (icus) part 3 of 7,0,0
09000064836a76ee,Supporting & Related Material,FDA-2018-P-3354-0003,FDA-2018-P-3354,attachment re citizen petition from international contrast ultrasound society,0,0
0900006484a9a8f2,Supporting & Related Material,FDA-2018-P-3354-0021,FDA-2018-P-3354,references from international contrast ultrasound society (icus) part 2 of 7,0,0
0900006484a9a9c9,Supporting & Related Material,FDA-2018-P-3354-0024,FDA-2018-P-3354,references from international contrast ultrasound society (icus) part 5 of 7,0,0
09000064836a76ec,Other,FDA-2018-P-3354-0002,FDA-2018-P-3354,acknowledgment letter from fda ddm to international contrast ultrasound society,0,0
0900006484a9a980,Supporting & Related Material,FDA-2018-P-3354-0023,FDA-2018-P-3354,references from international contrast ultrasound society (icus) part 4 of 7,0,0
0900006484a9a837,Supporting & Related Material,FDA-2018-P-3354-0020,FDA-2018-P-3354,references from international contrast ultrasound society (icus) part 1 of 7,0,0
0900006484a9aace,Supporting & Related Material,FDA-2018-P-3354-0026,FDA-2018-P-3354,references from international contrast ultrasound society (icus) part 7 of 7,0,0
0900006484862c7c,Other,FDA-2018-P-3354-0018,FDA-2018-P-3354,citizen petition from international contrast ultrasound society,0,0
09000064836a76d1,Other,FDA-2018-P-3354-0001,FDA-2018-P-3354,citizen petition from international contrast ultrasound society,0,0
090000648486323e,Other,FDA-2018-P-3354-0019,FDA-2018-P-3354,acknowledgment letter from fda dms to international contrast ultrasound society,0,0
0900006483b134d4,Other,FDA-2018-P-3354-0017,FDA-2018-P-3354,"letter from fda cder to rush university medical center, mid-america heart institute/saint luke's health system, university of michigan health system, university of southern california",0,0
0900006484b35c8b,Supporting & Related Material,FDA-2021-P-0510-0003,FDA-2021-P-0510,"attachment 1 - atacand - prescription drug product list re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484b384f1,Other,FDA-2021-P-0510-0002,FDA-2021-P-0510,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
0900006484b384ef,Other,FDA-2021-P-0510-0001,FDA-2021-P-0510,"suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484b35c8c,Supporting & Related Material,FDA-2021-P-0510-0004,FDA-2021-P-0510,"attachment 2 - atacand pi - atacand- candes artan cilexetil tablet re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484b35c8d,Supporting & Related Material,FDA-2021-P-0510-0005,FDA-2021-P-0510,"attachment 3 - candesartan cilexetil pi - highlights of prescribing information re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
090000648049a9bb,Other,FDA-2002-P-0245-0007,FDA-2002-P-0245,acknowledgment letter from fda ddm to lachman consultant services,0,0
090000648049a9c6,Other,FDA-2002-P-0245-0003,FDA-2002-P-0245,"final response from fda cder to lachman consultant services, inc.",0,0
090000648049a96d,Other,FDA-2002-P-0245-0001,FDA-2002-P-0245,"interim response from fda cder to lachman consultant services, inc.",0,0
090000648049a9a8,Other,FDA-2002-P-0245-0005,FDA-2002-P-0245,"citizen petition from lachman consultant services, inc. shipping label",0,0
090000648049a9b6,Other,FDA-2002-P-0245-0006,FDA-2002-P-0245,"citizen petition from lachman consultant services, inc.",0,0
090000648049a9c3,Notice,FDA-2002-P-0245-0002,FDA-2002-P-0245,fda determination that wydase (hyaluronidase) inj. was not withdrawn for safety or effectiveness reasons 68 fr 62810,0,0
0900006481f94776,Other,FDA-1993-P-0060-0003,FDA-1993-P-0060,letter from cvm to ddm to close docket,0,0
0900006481f94774,Other,FDA-1993-P-0060-0002,FDA-1993-P-0060,letter from cvm to united animal owners association,0,0
09000064804fc7a6,Other,FDA-1993-P-0060-0001,FDA-1993-P-0060,fda/cvm interim response to united animal owners association - letter,0,0
0900006480b10748,Other,FDA-2010-N-0218-0021,FDA-2010-N-0218,"ernest dummann, national mps society - testimony",0,0
0900006480b03705,Other,FDA-2010-N-0218-0009,FDA-2010-N-0218,oc/fda - agenda,0,0
0900006480b1079e,Other,FDA-2010-N-0218-0025,FDA-2010-N-0218,"art kessler, dystonia medical research foundation - testimony",0,0
0900006480b10710,Other,FDA-2010-N-0218-0016,FDA-2010-N-0218,"tracy vanhoutan, batten disease support and research association (bdsra) - testimony",0,0
0900006480b107ad,Other,FDA-2010-N-0218-0028,FDA-2010-N-0218,"amy waterhouse, biomarin pharmaceutical inc. - testimony",0,0
0900006480b1fa30,Other,FDA-2010-N-0218-0035,FDA-2010-N-0218,fda/rare disease review group - roster,0,0
0900006480b10738,Other,FDA-2010-N-0218-0019,FDA-2010-N-0218,"emil d. kakkis, m.d., ph.d., kakkis everylife foundation - testimony",0,0
0900006480b1072d,Other,FDA-2010-N-0218-0017,FDA-2010-N-0218,"mary gustafson, ppta - testimony",0,0
0900006480b107d0,Other,FDA-2010-N-0218-0029,FDA-2010-N-0218,"miriam o'day, alpha-1 foundation - testimony",0,0
0900006480b1070a,Other,FDA-2010-N-0218-0013,FDA-2010-N-0218,"diane edquist dorman, nord - testimony",0,0
0900006480b1070c,Other,FDA-2010-N-0218-0014,FDA-2010-N-0218,"john l. p. (seamus) thompson, phd et al, columbia university - testimony",0,0
0900006480ae4437,Notice,FDA-2010-N-0218-0001,FDA-2010-N-0218,"considerations regarding food and drug administration review and regulation of articles, for the treatment of rare diseases; public hearing",1,0
0900006480b10750,Other,FDA-2010-N-0218-0024,FDA-2010-N-0218,"chris hempel, addi & cassi fund - testimony",0,0
0900006480b1074c,Other,FDA-2010-N-0218-0022,FDA-2010-N-0218,"sharon f. terry, ma, genetic alliance - testimony",0,0
0900006480b107a3,Other,FDA-2010-N-0218-0027,FDA-2010-N-0218,"ferdinand massari, md, shire human genetic therapies - testimony",0,0
0900006480b1070e,Other,FDA-2010-N-0218-0015,FDA-2010-N-0218,"teresa hickman, mdjunction.com - testimony",0,0
0900006480b1f9ce,Other,FDA-2010-N-0218-0034,FDA-2010-N-0218,fda - transcript,0,0
0900006480b0310c,Other,FDA-2010-N-0218-0007,FDA-2010-N-0218,oc/fda - agenda,0,0
0900006480b10733,Other,FDA-2010-N-0218-0018,FDA-2010-N-0218,"jonathan jacoby, r.a.r.e. - testimony",0,0
0900006480b107a1,Other,FDA-2010-N-0218-0026,FDA-2010-N-0218,"susan alpert, advamed - testimony",0,0
0900006480b1074e,Other,FDA-2010-N-0218-0023,FDA-2010-N-0218,"mark weinberg, m.d., lundbeck, inc - testimony",0,0
0900006480b10746,Other,FDA-2010-N-0218-0020,FDA-2010-N-0218,"dayton t. reardan, phd. rac - testimony",0,0
09000064811a0d33,Other,FDA-2011-P-0768-0007,FDA-2011-P-0768,"acknowledgement letter to physicians for integrity in medical research, inc.",0,0
090000648115f177,Other,FDA-2011-P-0768-0005,FDA-2011-P-0768,"fda/cder to physicians for integrity in medical research, inc. - denial",0,0
09000064811a0d03,Other,FDA-2011-P-0768-0006,FDA-2011-P-0768,"physicians for integrity in medical research, inc. - petition for reconsideration",0,0
0900006480f5a19e,Other,FDA-2011-P-0768-0002,FDA-2011-P-0768,"acknowledgement letter to physicians for integrity in medical research, inc.",0,0
0900006480f5a19c,Other,FDA-2011-P-0768-0001,FDA-2011-P-0768,"physicians for integrity in medical research, inc. - citizen petition",0,0
0900006480ff3387,Other,FDA-2011-P-0768-0003,FDA-2011-P-0768,"fda/cder to physicians for integrity in medical research, inc. - letter",0,0
090000648124f7fe,Other,FDA-2011-P-0768-0009,FDA-2011-P-0768,"physicians for integrity in medical research, inc. response to fda/cder - letter",0,0
0900006481360c6b,Other,FDA-2011-P-0768-0010,FDA-2011-P-0768,"fda/cder to physicians for integrity in medical research, inc. - denial of reconsideration petition",0,0
09000064830e8c05,Other,FDA-2018-P-1448-0002,FDA-2018-P-1448,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara on behalf of collegium pharmaceutical, inc",0,0
09000064830e8633,Other,FDA-2018-P-1448-0001,FDA-2018-P-1448,"citizen petition from hyman, phelps & mcnamara, pc on behalf of collegium pharmaceutical, inc",0,0
09000064836b458b,Other,FDA-2018-P-1448-0004,FDA-2018-P-1448,"letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
090000648342ddad,Supporting & Related Material,FDA-2018-P-2362-0005,FDA-2018-P-2362,"attachment 3 - proposed labeling re: citizen petition from lachman consultant services, inc.",0,0
090000648342dda8,Supporting & Related Material,FDA-2018-P-2362-0003,FDA-2018-P-2362,"attachment 1-orange book details re: citizen petition from lachman consultant services, inc.",0,0
090000648342d88d,Other,FDA-2018-P-2362-0002,FDA-2018-P-2362,acknowledgement letter from fda ddm to lachman consultant services,0,0
090000648342d990,Other,FDA-2018-P-2362-0001,FDA-2018-P-2362,"citizen petition from lachman consultant services, inc.",0,0
090000648342ddab,Supporting & Related Material,FDA-2018-P-2362-0004,FDA-2018-P-2362,"attachment 2-approved labeling for the rld, votrient (pazopanib) tablets re: citizen petition from lachman consultant services, inc.",0,0
0900006481f57013,Notice,FDA-2013-N-0519-0003,FDA-2013-N-0519,"agency information collection activities; proposals, submissions, and approvals: guidance for industry on how to submit information in electronic format to the center for veterinary medicine using the fda electronic submission gateway",0,0
0900006482407453,Notice,FDA-2013-N-0519-0006,FDA-2013-N-0519,"agency information collection activities; announcement of office of
management and budget approvals",0,0
09000064813d23c6,Notice,FDA-2013-N-0519-0002,FDA-2013-N-0519,"agency information collection activities; proposals, submissions, and approvals: guidance for industry no. 108 on how to submit information in electronic format to the center for veterinary medicine, etc.",0,0
09000064812e7501,Notice,FDA-2013-N-0519-0001,FDA-2013-N-0519,agency information collection activities; proposed collection; comment request; guidance for industry on how to submit information in electronic format to center for veterinary medicine using the food and drug administration’s electronic submission gateway,1,0
09000064822911d9,Notice,FDA-2013-N-0519-0005,FDA-2013-N-0519,"agency information collection activities; submission for office of
management and budget review; comment request; guidance for
industry on how to submit information in electronic format to the
center for veterinary medicine using the food and drug administration
electronic submission gateway",1,0
0900006482d5085f,Other,FDA-2014-P-0862-0004,FDA-2014-P-0862,final response from cder to the alliance for natural health usa,0,0
090000648175f69b,Other,FDA-2014-P-0862-0001,FDA-2014-P-0862,citizen petition from the alliance for natural health usa,0,0
090000648175f69d,Other,FDA-2014-P-0862-0002,FDA-2014-P-0862,acknowledgement letter from fda ddm to the alliance for natural health usa,0,0
0900006481986da3,Other,FDA-2014-P-0862-0003,FDA-2014-P-0862,interim response from cder to the alliance for natural health usa,0,0
0900006481167317,Notice,FDA-2012-N-0911-0001,FDA-2012-N-0911,privacy act; systems of records,0,0
0900006481fc9f0b,Other,FDA-2014-P-0856-0011,FDA-2014-P-0856,final response petition denial fda-2014-p-0856,0,0
0900006481af2964,Other,FDA-2014-P-0856-0008,FDA-2014-P-0856,memorandum from fda cder dated 4-23-2015,0,0
0900006481af2966,Other,FDA-2014-P-0856-0010,FDA-2014-P-0856,fda conference call april 2015 presentation redacted,0,0
090000648175d779,Other,FDA-2014-P-0856-0002,FDA-2014-P-0856,acknowledgement letter from fda ddm to the southern network on adverse reactions (sonar),0,0
0900006481981de8,Other,FDA-2014-P-0856-0007,FDA-2014-P-0856,interim response from cder to sonar,0,0
0900006481af2965,Other,FDA-2014-P-0856-0009,FDA-2014-P-0856,fda conference call april 2015 presentation,0,0
090000648175d777,Other,FDA-2014-P-0856-0001,FDA-2014-P-0856,citizen petition from the southern network on adverse reactions,0,0
09000064812394ce,Other,FDA-2013-P-0335-0002,FDA-2013-P-0335,acknowledgement letter to foley & lardner llp,0,0
090000648133c1a9,Other,FDA-2013-P-0335-0003,FDA-2013-P-0335,foley & lardner llp - withdrawal of petition,0,0
0900006481239487,Other,FDA-2013-P-0335-0001,FDA-2013-P-0335,foley & lardner llp - citizen petition,0,0
0900006481a426c3,Notice,FDA-2015-D-0198-0004,FDA-2015-D-0198,"current good manufacturing practice requirements for combination
products; draft guidance for industry and food and drug administration
staff; extension of comment period",1,0
09000064819e13e4,Notice,FDA-2015-D-0198-0001,FDA-2015-D-0198,"current good manufacturing practice requirements for combination
products; draft guidance for industry and food and drug administration
staff; availability",1,0
090000648245ba0b,Other,FDA-2015-D-0198-0028,FDA-2015-D-0198,guidance for industry and fda staff: current good manufacturing practice requirements for combination products final guidance,0,0
09000064819e1c14,Other,FDA-2015-D-0198-0002,FDA-2015-D-0198,"current good manufacturing practice requirements for combination
products; draft guidance for industry and food and drug administration
staff",1,0
090000648245af31,Notice,FDA-2015-D-0198-0027,FDA-2015-D-0198,"current good manufacturing practice requirements for combination
products; guidance for industry and food and drug administration staff;
availability",1,0
0900006481a3b4a1,Other,FDA-2015-D-0198-0005,FDA-2015-D-0198,request for extension from parenteral drug association,0,0
0900006481a02c53,Other,FDA-2015-D-0198-0003,FDA-2015-D-0198,request for an extension from combination products coalition cpc,0,0
0900006482158c55,Supporting & Related Material,FDA-2016-N-1678-0002,FDA-2016-N-1678,reference 01 - fvm sp 2016-2025 re the food and drug administration foods and veterinary medicine program’s strategic plan for fiscal years 2016–2025,1,0
09000064820ad167,Notice,FDA-2016-N-1678-0001,FDA-2016-N-1678,"the food and drug administration foods and veterinary medicine
program’s strategic plan for fiscal years 2016–2025",1,0
0900006482158c56,Supporting & Related Material,FDA-2016-N-1678-0003,FDA-2016-N-1678,reference 02 - partnership for food protection strategic plan re the food and drug administration foods and veterinary medicine program’s strategic plan for fiscal years 2016–2025,1,0
09000064849200f4,Supporting & Related Material,FDA-2020-P-2096-0003,FDA-2020-P-2096,cover letter from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484a577a1,Other,FDA-2020-P-2096-0009,FDA-2020-P-2096,denial of citizen petition for siri & glimstad llp,0,0
0900006484973e70,Supporting & Related Material,FDA-2020-P-2096-0008,FDA-2020-P-2096,footnotes 2 through 37 re citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
090000648491ff67,Other,FDA-2020-P-2096-0002,FDA-2020-P-2096,acknowledgment letter from fda dms to siri & glimstad llp on behalf of informed consent action network,0,0
09000064849200f5,Other,FDA-2020-P-2096-0001,FDA-2020-P-2096,citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484a8899a,Other,FDA-2020-P-2096-0011,FDA-2020-P-2096,acknowledgment letter from fda dms to  siri & glimstad llp on behalf of informed consent action network,0,0
0900006484a88935,Other,FDA-2020-P-2096-0010,FDA-2020-P-2096,petition for reconsideration from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484921475,Supporting & Related Material,FDA-2020-P-2096-0004,FDA-2020-P-2096,footnotes 2 through 37 re citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484bfdd1b,Other,FDA-2021-P-0761-0002,FDA-2021-P-0761,acknowledgment letter from fda dms to international maple syrup institute,0,0
0900006484bfdd19,Other,FDA-2021-P-0761-0001,FDA-2021-P-0761,citizen petition from international maple syrup institute,0,0
0900006480ec7053,Other,FDA-2005-P-0136-0003,FDA-2005-P-0136,"fda/oc commissioner for policy, planning and budget response to public citizen - petition denial",0,0
090000648043fe3e,Other,FDA-2005-P-0136-0002,FDA-2005-P-0136,hfa-305 to public citizen's health research group,0,0
090000648043fe3b,Other,FDA-2005-P-0136-0001,FDA-2005-P-0136,hfa-305 to public citizen's health research group,0,0
0900006480b0a919,Other,FDA-2007-D-0076-0004,FDA-2007-D-0076,guidance for industry and food and drug administration staff: in vitro diagnostic studies; frequently asked questions,1,0
09000064804298a4,Supporting & Related Material,FDA-2007-D-0076-0002,FDA-2007-D-0076,fda/cdrh/cber,0,0
090000648042989f,Notice,FDA-2007-D-0076-0001,FDA-2007-D-0076,fda,0,0
0900006480b0a038,Notice,FDA-2007-D-0076-0003,FDA-2007-D-0076,guidance for industry and food and drug administration staff: in vitro diagnostic studies; frequently asked questions; availability,1,0
09000064804565b8,Notice,FDA-2006-D-0233-0004,FDA-2006-D-0233,fda,0,0
09000064804565c3,Notice,FDA-2006-D-0233-0006,FDA-2006-D-0233,fda,0,0
0900006480456723,Other,FDA-2006-D-0233-0008,FDA-2006-D-0233,transcript of the 2/8/07 public meeting,0,0
090000648045656b,Supporting & Related Material,FDA-2006-D-0233-0002,FDA-2006-D-0233,guidance,0,0
0900006480456727,Other,FDA-2006-D-0233-0010,FDA-2006-D-0233,fda and 21st century medicine coalition,0,0
0900006480456740,Other,FDA-2006-D-0233-0013,FDA-2006-D-0233,fda to personalized medicine coalition,0,0
0900006480456754,Other,FDA-2006-D-0233-0015,FDA-2006-D-0233,fda,0,0
0900006480456574,Supporting & Related Material,FDA-2006-D-0233-0003,FDA-2006-D-0233,guidance,0,0
090000648045651d,Notice,FDA-2006-D-0233-0001,FDA-2006-D-0233,fda,0,0
09000064804565b9,Notice,FDA-2006-D-0233-0005,FDA-2006-D-0233,fda,0,0
0900006480456734,Notice,FDA-2006-D-0233-0011,FDA-2006-D-0233,fda,0,0
0900006480456736,Supporting & Related Material,FDA-2006-D-0233-0012,FDA-2006-D-0233,guidance,0,0
0900006480456752,Other,FDA-2006-D-0233-0014,FDA-2006-D-0233,fda,0,0
0900006480456738,Other,FDA-2006-D-0233-0019,FDA-2006-D-0233,21st century medicine - request for extension of comment due date,0,0
09000064804567f8,Notice,FDA-2006-D-0233-0017,FDA-2006-D-0233,fda,0,0
0900006480456722,Other,FDA-2006-D-0233-0007,FDA-2006-D-0233,transcript of the 2/8/07 public meeting,0,0
090000648045673c,Other,FDA-2006-D-0233-0020,FDA-2006-D-0233,"nanogen, inc - request for extension comment due date",0,0
09000064804565b0,Other,FDA-2006-D-0233-0018,FDA-2006-D-0233,"aureon laboratories, inc. - request extension of comment due date",0,0
0900006480456757,Other,FDA-2006-D-0233-0016,FDA-2006-D-0233,fda,0,0
0900006480456725,Other,FDA-2006-D-0233-0009,FDA-2006-D-0233,transcript of the 2/8/07 public meeting,0,0
0900006484e03fb8,Supporting & Related Material,FDA-2021-P-1180-0003,FDA-2021-P-1180,"attachment 1 re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484e03fb9,Supporting & Related Material,FDA-2021-P-1180-0004,FDA-2021-P-1180,"attachment 2 re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484e03f89,Supporting & Related Material,FDA-2021-P-1180-0005,FDA-2021-P-1180,"attachment 3 re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484e02648,Other,FDA-2021-P-1180-0002,FDA-2021-P-1180,acknowledgment letter from fda dms to hyman phelps and mcnamara p.c.,0,0
0900006484e01d26,Other,FDA-2021-P-1180-0001,FDA-2021-P-1180,"suitability petition from hyman, phelps & mcnamara, p.c.",0,0
090000648179b470,Other,FDA-2012-P-1160-0004,FDA-2012-P-1160,citizen petition denial response from fda cder to steven a. zecola,0,0
09000064812bbe64,Other,FDA-2012-P-1160-0003,FDA-2012-P-1160,fda/cder interim response to steven a. zecola - letter,0,0
0900006481171dfe,Other,FDA-2012-P-1160-0002,FDA-2012-P-1160,acknowledgement letter to steven a. zecola,0,0
0900006481171dfc,Other,FDA-2012-P-1160-0001,FDA-2012-P-1160,steven a. zecola - citizen petition,0,0
0900006482f6501b,Supporting & Related Material,FDA-2018-P-0878-0004,FDA-2018-P-0878,"attachment 2 re citizen petition from hyman, phelps & mcnamara, p.c",0,0
0900006482f64bb0,Supporting & Related Material,FDA-2018-P-0878-0005,FDA-2018-P-0878,"attachment 1 orange book re citizen petition from hyman, phelps & mcnamara, p.c",0,0
0900006482f64ba7,Other,FDA-2018-P-0878-0002,FDA-2018-P-0878,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara",0,0
0900006482f64ee7,Other,FDA-2018-P-0878-0001,FDA-2018-P-0878,"citizen petition from hyman, phelps & mcnamara, p.c",0,0
0900006482f6501c,Supporting & Related Material,FDA-2018-P-0878-0003,FDA-2018-P-0878,"attachment 3 re citizen petition from hyman, phelps & mcnamara, p.c",0,0
0900006481a185e1,Other,FDA-2015-P-0613-0001,FDA-2015-P-0613,"citizen petition from qilu pharma, inc.",0,0
0900006481a185e3,Other,FDA-2015-P-0613-0002,FDA-2015-P-0613,"acknowledgement letter from fda ddm to qilu pharma, inc.",0,0
0900006481c30b27,Other,FDA-2015-P-0613-0003,FDA-2015-P-0613,"interim response letter from fda cder to qilu pharmaceutical co., ltd.",0,0
0900006481fd177a,Other,FDA-2015-P-0613-0004,FDA-2015-P-0613,final petition response partial approval partial denial,0,0
0900006481b2d702,Other,FDA-2015-P-2142-0004,FDA-2015-P-2142,acknowledgement letter from fda ddm to public citizen,0,0
0900006481b2d7d8,Supporting & Related Material,FDA-2015-P-2142-0002,FDA-2015-P-2142,appendix a proposed indication for tasimelteon as stated in fda reviews and memos re citizen petition from public citizen,0,0
09000064842f8fc6,Other,FDA-2015-P-2142-0006,FDA-2015-P-2142,response letter from fda cder to public citizen,0,0
0900006481d8b21a,Other,FDA-2015-P-2142-0005,FDA-2015-P-2142,interim response letter from fda cder to public citizen,0,0
0900006481b2e4b8,Supporting & Related Material,FDA-2015-P-2142-0003,FDA-2015-P-2142,appendix b proposed label changes re citizen petition from public citizen,0,0
0900006481b2d700,Other,FDA-2015-P-2142-0001,FDA-2015-P-2142,citizen petition from public citizen,0,0
0900006481fe88de,Other,FDA-2016-P-1314-0001,FDA-2016-P-1314,citizen petition from center for responsible science (crs),0,0
0900006481fe969e,Supporting & Related Material,FDA-2016-P-1314-0003,FDA-2016-P-1314,attachment 1 skin and eye irritation testing for topically applied products: questions and answers draft guidance for industry re citizen petition from center for responsible science (crs),0,0
09000064823547de,Other,FDA-2016-P-1314-0004,FDA-2016-P-1314,interim response from fda cder to center for responsible science,0,0
0900006481fe969c,Other,FDA-2016-P-1314-0002,FDA-2016-P-1314,acknowledgement letter from fda ddm to  center for responsible science (crs),0,0
0900006484a39012,Other,FDA-2021-N-0175-0001,FDA-2021-N-0175,virtual public meeting: fda rare disease day 2021,0,0
0900006484b35c14,Other,FDA-2021-P-0509-0001,FDA-2021-P-0509,"suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484b35c8a,Supporting & Related Material,FDA-2021-P-0509-0005,FDA-2021-P-0509,"attachment 3 - diclofenac potassium pi - diclofenac potassium tablets, usp 25 mg, 50 mg and 75 mg re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484b35c88,Supporting & Related Material,FDA-2021-P-0509-0003,FDA-2021-P-0509,"attachment 1 - cataflam - discontinued drug product list re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484b35c89,Supporting & Related Material,FDA-2021-P-0509-0004,FDA-2021-P-0509,"attachment 2 - cataflam pi (diclofenac potassium immediate-release tablets) re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484b35c16,Other,FDA-2021-P-0509-0002,FDA-2021-P-0509,"acknowledgement letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
0900006484c96090,Supporting & Related Material,FDA-2021-P-0928-0003,FDA-2021-P-0928,"attachment 1 re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484c971e8,Supporting & Related Material,FDA-2021-P-0928-0005,FDA-2021-P-0928,"attachment 2 re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484c96432,Other,FDA-2021-P-0928-0001,FDA-2021-P-0928,"suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484c96d08,Other,FDA-2021-P-0928-0002,FDA-2021-P-0928,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
0900006484c96092,Supporting & Related Material,FDA-2021-P-0928-0004,FDA-2021-P-0928,"attachment 3 re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484285be9,Supporting & Related Material,FDA-2020-P-0158-0003,FDA-2020-P-0158,attachments 1-10 re: citizen petition from sidley austin llp on behalf of vifor pharma,0,0
0900006484285be3,Other,FDA-2020-P-0158-0001,FDA-2020-P-0158,citizen petition from sidley austin llp on behalf of vifor pharma,0,0
09000064842862c7,Other,FDA-2020-P-0158-0002,FDA-2020-P-0158,"acknowledgment letter from fda dms to sidley austin, llp on behalf of vifor pharma",0,0
0900006484285beb,Supporting & Related Material,FDA-2020-P-0158-0005,FDA-2020-P-0158,attachments 21-27 re: citizen petition from sidley austin llp on behalf of vifor pharma,0,0
0900006484285bea,Supporting & Related Material,FDA-2020-P-0158-0004,FDA-2020-P-0158,attachments 11-20 re: citizen petition from sidley austin llp on behalf of vifor pharma,0,0
0900006484286114,Supporting & Related Material,FDA-2020-P-0158-0006,FDA-2020-P-0158,attachments 28-32 re: citizen petition from sidley austin llp on behalf of vifor pharma,0,0
0900006481e88ebd,Other,FDA-2016-P-0713-0002,FDA-2016-P-0713,acknowledgement letter from fda ddm to pernix therapeutics,0,0
0900006481e88eb9,Other,FDA-2016-P-0713-0001,FDA-2016-P-0713,citizen petition from pernix therapeutics,0,0
090000648211dc50,Other,FDA-2016-P-0713-0003,FDA-2016-P-0713,citizen petition denial letter to pernix therapeutics,0,0
0900006481755911,Other,FDA-2014-P-0825-0001,FDA-2014-P-0825,citizen petition from orthofix inc.,0,0
09000064817559a5,Supporting & Related Material,FDA-2014-P-0825-0005,FDA-2014-P-0825,attachment d bar code label requirement citizen petition from orthofix inc.,0,0
0900006481d1c0f9,Other,FDA-2014-P-0825-0007,FDA-2014-P-0825,supplement from orthofix inc.,0,0
090000648197f2df,Other,FDA-2014-P-0825-0006,FDA-2014-P-0825,interim response letter from fda/cdrh to orthofix inc,0,0
0900006483d9cd8c,Other,FDA-2014-P-0825-0009,FDA-2014-P-0825,withdrawal of citizen petition letter from orthofix to fda ddm,0,0
090000648175591e,Other,FDA-2014-P-0825-0002,FDA-2014-P-0825,acknowledgement letter from fda ddm to orthofix inc.,0,0
09000064817559a3,Supporting & Related Material,FDA-2014-P-0825-0004,FDA-2014-P-0825,attachment b fda guidance for industry citizen petition from orthofix inc.,0,0
0900006481755924,Supporting & Related Material,FDA-2014-P-0825-0003,FDA-2014-P-0825,attachment a list of implants citizen petition from orthofix inc.,0,0
0900006481cf4287,Other,FDA-2014-P-0825-0008,FDA-2014-P-0825,"amendment from orthofix, inc.",0,0
0900006484485cc3,Other,FDA-2020-P-1247-0002,FDA-2020-P-1247,"acknowledgment letter from fda dms to belcher pharmaceuticals, llc",0,0
09000064844861c7,Supporting & Related Material,FDA-2020-P-1247-0003,FDA-2020-P-1247,"attachment 1 tacrolimus_cap_50708_rv12-12 be guidances re citizen petition from belcher pharmaceuticals, llc",0,0
0900006484485cc2,Other,FDA-2020-P-1247-0001,FDA-2020-P-1247,"citizen petition from belcher pharmaceuticals, llc",0,0
09000064848745fe,Other,FDA-2020-P-1247-0005,FDA-2020-P-1247,"interim response letter from fda cder to belcher pharmaceuticals, llc",0,0
0900006483262ddd,Rule,FDA-2018-D-1378-0001,FDA-2018-D-1378,the food and drug administration food safety modernization act; extension and clarification of compliance dates for certain provisions of four implementing rules: what you need to know about the food and drug administration regulation; small entity compliance guide; availibility,1,0
09000064832695b0,Other,FDA-2018-D-1378-0002,FDA-2018-D-1378,the fda food safety modernization act; extension and clarification of compliance dates for certain provisions of four implementing rules: what you need to know about the fda regulation: guidance for industry - small entity compliance guide,1,0
09000064845e6be2,Other,FDA-2020-D-1379-0001,FDA-2020-D-1379,"guidance for  industry, fda staff, and fda-acredited third parties; manufacturer’s notification of the intent to use an accredited person under the accredited persons inspection program authorized by section 228 of the food and drug administration amendments act of
2007 (fdaaa",1,0
09000064831abb50,Supporting & Related Material,FDA-2018-P-1593-0013,FDA-2018-P-1593,djousse et al_ 2016-1 egg consumption and risk of type 2 diabetes: a meta-analysis of prospective studies re citizen petition from pete and gerry’s organics llc,0,0
09000064831ac42d,Supporting & Related Material,FDA-2018-P-1593-0026,FDA-2018-P-1593,o'neil et al_ 2012_supplement re citizen petition from pete and gerry’s organics llc,0,0
09000064831ac42e,Supporting & Related Material,FDA-2018-P-1593-0027,FDA-2018-P-1593,richard et al_ 2017 re citizen petition from pete and gerry’s organics llc,0,0
09000064831ac432,Supporting & Related Material,FDA-2018-P-1593-0031,FDA-2018-P-1593,speeches by fda officials _ reducing the burden of chronic disease re citizen petition from pete and gerry’s organics llc,0,0
09000064831ac4a1,Supporting & Related Material,FDA-2018-P-1593-0037,FDA-2018-P-1593,"usda_national nutrient database for standard reference_ 01123, egg, whole, raw, fresh_2018 re citizen petition from pete and gerry’s organics llc",0,0
09000064831ac4a2,Supporting & Related Material,FDA-2018-P-1593-0038,FDA-2018-P-1593,use of the term _healthy_ in the labeling of human food products_request for information and comments-1 re citizen petition from pete and gerry’s organics llc,1,0
09000064831ac4a5,Supporting & Related Material,FDA-2018-P-1593-0041,FDA-2018-P-1593,wallace and fulgoni 2017 usual choline intakes are associated with egg and protein food consumption in the united statesre citizen petition from pete and gerry’s organics llc,1,0
09000064831ab9ec,Supporting & Related Material,FDA-2018-P-1593-0003,FDA-2018-P-1593,"alexander et al_ 2016 meta-analysis of egg consumption and risk of
coronary heart disease and stroke re citizen petition from pete and gerry’s organics llc",0,0
09000064831ab0d0,Other,FDA-2018-P-1593-0002,FDA-2018-P-1593,acknowledgment letter from fda ddm to pete and gerry's organics llc,0,0
09000064831ab0cc,Other,FDA-2018-P-1593-0001,FDA-2018-P-1593,citizen petition from pete and gerry's organics llc,0,0
09000064831abb48,Supporting & Related Material,FDA-2018-P-1593-0007,FDA-2018-P-1593,"blesso and fernandez 2018 dietary cholesterol, serum lipids, and heart disease: are eggs working for or against you? re citizen petition from pete and gerry’s organics llc",0,0
09000064831abc89,Supporting & Related Material,FDA-2018-P-1593-0021,FDA-2018-P-1593,iom food and nutrition board 1998 re citizen petition from pete and gerry’s organics llc,1,0
09000064831ac2e7,Supporting & Related Material,FDA-2018-P-1593-0014,FDA-2018-P-1593,eckel et al_ 2013_erratum 2014 re citizen petition from pete and gerry’s organics llc,0,0
09000064831ac2ec,Supporting & Related Material,FDA-2018-P-1593-0019,FDA-2018-P-1593,fda_labeling and nutrition _ changes to the nutrition facts label re citizen petition from pete and gerry’s organics llc,0,0
09000064831ac434,Supporting & Related Material,FDA-2018-P-1593-0033,FDA-2018-P-1593,"the australian heart foundation, eggs re citizen petition from pete and gerry’s organics llc",0,0
09000064831ac436,Supporting & Related Material,FDA-2018-P-1593-0035,FDA-2018-P-1593,"tian et al_ 2017_compressed dietary protein consumption and the risk of type 2 diabetes: a systematic review and meta-analysis of
cohort studies re citizen petition from pete and gerry’s organics llc",0,0
09000064831ac2e9,Supporting & Related Material,FDA-2018-P-1593-0016,FDA-2018-P-1593,egg nutrition center_nutrients in eggs 2018 re citizen petition from pete and gerry’s organics llc,0,0
09000064831ac430,Supporting & Related Material,FDA-2018-P-1593-0029,FDA-2018-P-1593,scientific report of the 2015 dietary guidelines advisory committee 2015_appendix-e-3_7 re citizen petition from pete and gerry’s organics llc,0,0
09000064831ac433,Supporting & Related Material,FDA-2018-P-1593-0032,FDA-2018-P-1593,"tamez et al_ 2016 egg consumption and risk of incident type 2 diabetes:
a dose–response meta-analysis of prospective cohort studies re citizen petition from pete and gerry’s organics llc",0,0
09000064831ac435,Supporting & Related Material,FDA-2018-P-1593-0034,FDA-2018-P-1593,"the new zealand heart foundation, eggs and the heart 2017 re citizen petition from pete and gerry’s organics llc",0,0
09000064831ac4a3,Supporting & Related Material,FDA-2018-P-1593-0039,FDA-2018-P-1593,"van horn et al_ 2016 recommended dietary pattern to achieve adherence to the american heart association/american college
of cardiology (aha/acc) guidelinesre citizen petition from pete and gerry’s organics llc",0,0
09000064831abb49,Supporting & Related Material,FDA-2018-P-1593-0008,FDA-2018-P-1593,"british heart foundation, healthy eating re citizen petition from pete and gerry’s organics llc",0,0
09000064831abb4d,Supporting & Related Material,FDA-2018-P-1593-0010,FDA-2018-P-1593,dietary guidelines for americans 2010 re citizen petition from pete and gerry’s organics llc,0,0
09000064831abb4e,Supporting & Related Material,FDA-2018-P-1593-0011,FDA-2018-P-1593,dietary guidelines for americans 2015-2020-ilovepdf-compressed re citizen petition from pete and gerry’s organics llc,0,0
09000064831abb4f,Supporting & Related Material,FDA-2018-P-1593-0012,FDA-2018-P-1593,djousse et al_ 2016 egg consumption and risk of type 2 diabetes: a meta-analysis of prospective studies re citizen petition from pete and gerry’s organics llc,0,0
0900006483638781,Other,FDA-2018-P-3222-0002,FDA-2018-P-3222,acknowledgment letter from fda ddm to foley & lardner llp,0,0
09000064836385c0,Other,FDA-2018-P-3222-0001,FDA-2018-P-3222,citizen petition from foley & lardner llp,0,0
09000064839b46fb,Other,FDA-2018-P-3222-0003,FDA-2018-P-3222,citizen petition withdrawal letter from foley & lardner llp,0,0
090000648435335d,Supporting & Related Material,FDA-2020-P-0745-0003,FDA-2020-P-0745,appendix 1 re citizen petition from fox rothschild llp,0,0
0900006484353359,Other,FDA-2020-P-0745-0001,FDA-2020-P-0745,citizen petition from fox rothschild llp,0,0
090000648435335a,Other,FDA-2020-P-0745-0002,FDA-2020-P-0745,acknowledgment letter from fda dms to fox rothschild llp,0,0
09000064845fd281,Other,FDA-2020-P-0745-0004,FDA-2020-P-0745,approval letter from fda cder to fox rothschild llp,0,0
0900006482a52426,Other,FDA-2017-P-5027-0002,FDA-2017-P-5027,acknowledgement letter from fda ddm to wilson disease association,0,0
0900006482a5242e,Supporting & Related Material,FDA-2017-P-5027-0009,FDA-2017-P-5027,tab 7_schilsky costly choices for treating wilson's disease re citizen petition from wilson disease association,0,0
0900006482a52429,Supporting & Related Material,FDA-2017-P-5027-0004,FDA-2017-P-5027,tab 2_fda approval information for nda 019194 re citizen petition from wilson disease association,0,0
0900006482a5242d,Supporting & Related Material,FDA-2017-P-5027-0008,FDA-2017-P-5027,tab 6_ogd annual report 2016 re citizen petition from wilson disease association,0,0
0900006482f2df3c,Other,FDA-2017-P-5027-0010,FDA-2017-P-5027,response letter from fda cder to wilson disease association,0,0
0900006482a5242a,Supporting & Related Material,FDA-2017-P-5027-0005,FDA-2017-P-5027,tab 3_syprine prescribing information re citizen petition from wilson disease association,0,0
0900006482a5242b,Supporting & Related Material,FDA-2017-P-5027-0006,FDA-2017-P-5027,tab_4 senate special committee on aging_drug pricing report re citizen petition from wilson disease association,0,0
0900006482a5242c,Supporting & Related Material,FDA-2017-P-5027-0007,FDA-2017-P-5027,tab 5_orange book information for nda 019194 re citizen petition from wilson disease association,0,0
0900006482a52428,Supporting & Related Material,FDA-2017-P-5027-0003,FDA-2017-P-5027,tab 1_kadmon press releases re citizen petition from wilson disease association,0,0
0900006482a52c84,Other,FDA-2017-P-5027-0001,FDA-2017-P-5027,citizen petition from wilson disease association,0,0
0900006483a521ed,Other,FDA-2019-P-0622-0002,FDA-2019-P-0622,acknowledgment letter,0,0
0900006483c36c00,Other,FDA-2019-P-0622-0004,FDA-2019-P-0622,response letter re citizen petition from fda oc,0,0
0900006483a521eb,Other,FDA-2019-P-0622-0001,FDA-2019-P-0622,citizen petition,0,0
0900006484961504,Supporting & Related Material,FDA-2020-P-2193-0005,FDA-2020-P-2193,"exhibits 11-20 a phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of roxadustat in the
maintenance treatment of anemia in end stage renal disease
subjects on stable dialysis re: citizen petition from epstein, becker and green, p.c.",0,0
0900006484961502,Supporting & Related Material,FDA-2020-P-2193-0003,FDA-2020-P-2193,"exhibits 1-09 chronic kidney disease in the united states, 2019 re: citizen petition from epstein, becker and green, p.c.",0,0
0900006484961500,Other,FDA-2020-P-2193-0002,FDA-2020-P-2193,"acknowledgment letter from fda dms to epstein, becker and green, p.c.",0,0
0900006484af40b3,Other,FDA-2020-P-2193-0007,FDA-2020-P-2193,"interim response from fda cder to epstein becker and green, p.c.",0,0
0900006484961503,Supporting & Related Material,FDA-2020-P-2193-0004,FDA-2020-P-2193,"exhibit 10 a phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of roxadustat in the maintenance treatment of anemia in end stage renal disease patients on stable dialysis re: citizen petition from epstein, becker and green, p.c.",0,0
0900006484960dc9,Other,FDA-2020-P-2193-0001,FDA-2020-P-2193,"citizen petition from epstein, becker and green, p.c.",0,0
090000648083e92f,Other,FDA-2009-P-0038-0002,FDA-2009-P-0038,acknowlegdement letter to covington & burling llp,0,0
0900006480920098,Other,FDA-2009-P-0038-0006,FDA-2009-P-0038,"fda/cder response to mayne pharma international pty ltd., and warner chilcott  company, inc. - petition denial",0,0
090000648083e8c2,Other,FDA-2009-P-0038-0001,FDA-2009-P-0038,"mayne pharma international pty ltd., and warner chilcott (us), llc, warner chilcott laboratories ireland, ltd., and warner chilcott company, inc.  (covington & burling, llp) - citizen petition",0,0
0900006484aa38c8,Other,FDA-2021-P-0374-0001,FDA-2021-P-0374,citizen petition from pet schooled,0,0
0900006484dbfdc1,Other,FDA-2021-P-0374-0003,FDA-2021-P-0374,final response to pet schooled from fda cvm,0,0
0900006484aa38dc,Other,FDA-2021-P-0374-0002,FDA-2021-P-0374,acknowledgment letter to pet schooled from fda dms,0,0
0900006483e33573,Other,FDA-2019-P-3800-0001,FDA-2019-P-3800,"citizen petition from hyman, phelps & mcnamara p.c.",0,0
090000648423d3cc,Other,FDA-2019-P-3800-0003,FDA-2019-P-3800,"petition response letter from fda cder to hyman, phelps & mcnamara pc",0,0
0900006483e3417c,Other,FDA-2019-P-3800-0002,FDA-2019-P-3800,"acknowledgment letter from fda dms to hyman, phelps & mcnamara p.c.",0,0
09000064843f9ace,Notice,FDA-2019-N-3768-0009,FDA-2019-N-3768,best practices in drug and biological product postmarket safety surveillance for food and drug administration staff; draft document; reopening of comment period,1,0
09000064845c0ad0,Other,FDA-2019-N-3768-0011,FDA-2019-N-3768,best practices in drug and biological product postmarket safety surveillance for fda staff - draft,0,0
0900006484127411,Notice,FDA-2019-N-3768-0001,FDA-2019-N-3768,best practices in drug and biological product postmarket safety surveillance for food and drug administration staff; draft document; availability; establishment of public docket; request for comments,1,0
090000648420ddba,Other,FDA-2019-N-3768-0004,FDA-2019-N-3768,request for extension from pharmaceutical research and manufacturers of america (phrma),0,0
0900006482f7bbf3,Other,FDA-2017-P-5396-1001,FDA-2017-P-5396,interim response from fda to physicians for responsible opioid prescribing,0,0
0900006482b0317a,Other,FDA-2017-P-5396-0002,FDA-2017-P-5396,acknowledgement letter from fda ddm to physicians for responsible opioid prescribing,0,0
0900006482b02c71,Other,FDA-2017-P-5396-0001,FDA-2017-P-5396,citizen petition from physicians for responsible opioid prescribing,0,0
09000064812b1c2a,Notice,FDA-2013-N-0294-0001,FDA-2013-N-0294,submission of new drug application/abbreviated new drug application field alert reports: automated form pilot program,0,0
0900006482198b58,Supporting & Related Material,FDA-2014-P-0687-0009,FDA-2014-P-0687,epfx 2004 user manual,0,0
0900006482198b5a,Supporting & Related Material,FDA-2014-P-0687-0011,FDA-2014-P-0687,epfx youtube video,0,0
0900006481714cad,Supporting & Related Material,FDA-2014-P-0687-0006,FDA-2014-P-0687,exhibit d fda registration approval citizen petition from margaret moline,0,0
0900006481ab47af,Other,FDA-2014-P-0687-0007,FDA-2014-P-0687,interim response letter from fda cdrh to margaret moline,0,0
0900006481714cab,Supporting & Related Material,FDA-2014-P-0687-0004,FDA-2014-P-0687,exhibit b fda information requests citizen petition from margaret moline,0,0
0900006482198b59,Supporting & Related Material,FDA-2014-P-0687-0010,FDA-2014-P-0687,epfx 2008 user manual,0,0
0900006482198ac6,Other,FDA-2014-P-0687-0008,FDA-2014-P-0687,letter from fda cdrh  to margaret moline,0,0
090000648170d0f1,Other,FDA-2014-P-0687-0001,FDA-2014-P-0687,citizen petition from margaret moline,0,0
0900006481714cac,Supporting & Related Material,FDA-2014-P-0687-0005,FDA-2014-P-0687,exhibit c device studies citizen petition from margaret moline,0,0
0900006481714caa,Supporting & Related Material,FDA-2014-P-0687-0003,FDA-2014-P-0687,exhibit a fda import alerts citizen petition from margaret moline,0,0
090000648171212e,Other,FDA-2014-P-0687-0002,FDA-2014-P-0687,acknowledgement letter from fda ddm to margaret moline,0,0
0900006482d01f46,Notice,FDA-2017-N-5925-0011,FDA-2017-N-5925,21st century cures act: announcing the establishment of the susceptibility test interpretive criteria website,0,0
0900006482c21694,Notice,FDA-2017-N-5925-0001,FDA-2017-N-5925,"standard development organizations whose susceptibility test interpretive criteria standards may be recognized by the food and drug 
administration; request for information",1,0
0900006483c2d8ac,Notice,FDA-2017-N-5925-0016,FDA-2017-N-5925,21st century cures act: annual compilation of notices of updates from the susceptibility test interpretive criteria web page; request for comments,0,0
0900006482f7a3ab,Notice,FDA-2017-N-5925-0012,FDA-2017-N-5925,"susceptibility test interpretive criteria recognized and listed on the
susceptibility test interpretive web page; reopening of a public docket;
request for comments",0,0
0900006484925e34,Notice,FDA-2017-N-5925-0026,FDA-2017-N-5925,21st century cures act: annual compilation of notices of updates from the susceptibility test interpretive criteria web page; request for comments,0,0
09000064843b7f11,Other,FDA-2020-P-0945-0002,FDA-2020-P-0945,acknowledgment letter from dms to  dr. ernest c. chisena and dr. jahangir s. rastegar,0,0
090000648478754c,Other,FDA-2020-P-0945-0012,FDA-2020-P-0945,interim response letter from fda cdrh to dr. ernest c. chisena and dr. jahangir s. rastegar,0,0
09000064843b7057,Supporting & Related Material,FDA-2020-P-0945-0008,FDA-2020-P-0945,reference 5 - ultrasound for fracture healing: current evidence  re: citizen petition from dr. ernest c. chisena and dr. jahangir s. rastegar,0,0
09000064843b6dfa,Other,FDA-2020-P-0945-0001,FDA-2020-P-0945,citizen petition from dr. ernest c. chisena and dr. jahangir s. rastegar,0,0
09000064843b7054,Supporting & Related Material,FDA-2020-P-0945-0005,FDA-2020-P-0945,reference 2 - local soft tissue compression enhances fracture healing in a rabbit fibula  re: citizen petition from dr. ernest c. chisena and dr. jahangir s. rastegar,0,0
09000064843b7056,Supporting & Related Material,FDA-2020-P-0945-0007,FDA-2020-P-0945,"reference 4 - low intensity pulsed ultrasonography for fractures:
systematic review of randomised controlled trials  re: citizen petition from dr. ernest c. chisena and dr. jahangir s. rastegar",0,0
090000648449849c,Supporting & Related Material,FDA-2020-P-0945-0010,FDA-2020-P-0945,references 7 - comparative evaluation of the angiogenic potential of hypoxia preconditioned blood-derived secretomes and platelet-rich re: citizen petition from dr. ernest c. chisena and dr. jahangir s. rastegar,0,0
09000064843b7053,Supporting & Related Material,FDA-2020-P-0945-0004,FDA-2020-P-0945,"reference 1- acceleration of tibial fracture-healing by non-invasive, low intensity pulsed ultrasound heckman j.d., et al jbjs 76-a, no 1  january  1994 -  re: citizen petition from dr. ernest c. chisena and dr. jahangir s. rastegar",0,0
09000064843b7055,Supporting & Related Material,FDA-2020-P-0945-0006,FDA-2020-P-0945,reference 3 - re-evaluation of low intensity pulsed ultrasound in treatment of tibial fractures (trust): randomized clinical trial  re: citizen petition from dr. ernest c. chisena and dr. jahangir s. rastegar,0,0
09000064846dfaf3,Supporting & Related Material,FDA-2020-P-0945-0011,FDA-2020-P-0945,enclosure 1997 letter,0,0
09000064843b7015,Supporting & Related Material,FDA-2020-P-0945-0003,FDA-2020-P-0945,"attachment  a -  bulletin of joint disease - a specialized orthosis for suppressing bony destruction from multiple myeloma and to
enhance healing of a pathologic fracture in an appendicular lesion re: citizen petition from dr. ernest c. chisena and dr. jahangir s. rastegar",0,0
09000064843ba662,Supporting & Related Material,FDA-2020-P-0945-0009,FDA-2020-P-0945,reference 6 - low intensity pulsed ultrasound for bone healing: systematic review of randomized controlled trials  re: citizen petition from dr. ernest c. chisena and dr. jahangir s. rastegar,0,0
090000648478754e,Other,FDA-2020-P-0945-0013,FDA-2020-P-0945,interim response letter from fda cdrh to dr. ernest c. chisena and dr. jahangir s. rastegar - redacted,0,0
0900006484a1ea02,Supporting & Related Material,FDA-2021-P-0157-0008,FDA-2021-P-0157,exhibit e- email correspondence from fda ctp to fresh farms e-liquid re citizen's petition and stay petition,0,0
0900006484a1ea39,Other,FDA-2021-P-0157-0003,FDA-2021-P-0157,"acknowledgement letter from fda dms to keller and heckman llp on behalf of fresh farms e-liquid, llc",0,0
0900006484a1cbb2,Other,FDA-2021-P-0157-0001,FDA-2021-P-0157,citizen's petition from keller and heckman llp on behalf of fresh farms e-liquid llc,0,0
0900006484a1cc50,Other,FDA-2021-P-0157-0002,FDA-2021-P-0157,stay of action petition from keller and heckman llp on behalf of fresh farms e-liquid llc,0,0
0900006484a1e9cd,Supporting & Related Material,FDA-2021-P-0157-0007,FDA-2021-P-0157,exhibit d- email correspondence from azim chowdhury re citizen's petition and stay petition,0,0
0900006484c210f9,Other,FDA-2021-P-0157-0010,FDA-2021-P-0157,letter from fda ctp to keller and heckman llp,0,0
0900006484a1e651,Supporting & Related Material,FDA-2021-P-0157-0004,FDA-2021-P-0157,exhibit a- refuse to accept letter re citizen's petition and stay petition from keller and heckman llp on behalf of fresh farms e-liquid llc,0,0
0900006484a1e6ab,Supporting & Related Material,FDA-2021-P-0157-0006,FDA-2021-P-0157,exhibit c- declaration of monica schick re citizen's petition and stay petition,0,0
0900006484a859b5,Other,FDA-2021-P-0157-0009,FDA-2021-P-0157,"fresh farms e-liquid, llc amended petition for stay of action regarding  refuse- to- accept letter",0,0
0900006484a1e6a7,Supporting & Related Material,FDA-2021-P-0157-0005,FDA-2021-P-0157,exhibit b- declaration of anthony devincentis re citizen's petition and stay petition,0,0
0900006480450459,Other,FDA-2006-P-0143-0004,FDA-2006-P-0143,public citizen request to center for medicare & medicaid services (cms) - letter,0,0
0900006483669348,Other,FDA-2006-P-0143-0006,FDA-2006-P-0143,interim response from fda cdrh to public citizen,0,0
09000064846b2f43,Other,FDA-2006-P-0143-0007,FDA-2006-P-0143,denial of petition from fda cdrh to public citizen's health research group,0,0
0900006480450475,Other,FDA-2006-P-0143-0005,FDA-2006-P-0143,public citizen - supplement,0,0
0900006480450455,Other,FDA-2006-P-0143-0002,FDA-2006-P-0143,acknowledgment letter from fda ddm to public citizen,0,0
090000648045044e,Other,FDA-2006-P-0143-0003,FDA-2006-P-0143,public citizen - citizen petition,0,0
0900006480450444,Other,FDA-2006-P-0143-0001,FDA-2006-P-0143,fda ddm to public citizen,0,0
09000064804767f0,Supporting & Related Material,FDA-2004-D-0499-0006,FDA-2004-D-0499,guidance,0,0
09000064804767f1,Notice,FDA-2004-D-0499-0007,FDA-2004-D-0499,fda,0,0
0900006480476709,Notice,FDA-2004-D-0499-0001,FDA-2004-D-0499,fda,0,0
0900006480476713,Supporting & Related Material,FDA-2004-D-0499-0002,FDA-2004-D-0499,guidance,0,0
0900006480ade142,Other,FDA-2010-P-0223-0007,FDA-2010-P-0223,acknowledgement letter to genzyme corporation (covington & burling llp),0,0
0900006480b77de8,Other,FDA-2010-P-0223-0010,FDA-2010-P-0223,fda/cder to covington & burling llp (genzyme corporation) - petition approval,0,0
0900006480ade141,Other,FDA-2010-P-0223-0001,FDA-2010-P-0223,genzyme corporation (covington & burling llp) - citizen petition,0,0
0900006480ade147,Supporting & Related Material,FDA-2010-P-0223-0004,FDA-2010-P-0223,"exhibit b (exhibit a) - ""united states patent no. 2,602,116""  - [genzyme corporation (covington & burling llp) - citizen petition]",0,0
0900006480ade143,Supporting & Related Material,FDA-2010-P-0223-0002,FDA-2010-P-0223,"exhibit a - ""cobrek's first notice letter"" - [genzyme corporation (covington & burling llp) - citizen petition]",0,0
0900006480ade1fc,Supporting & Related Material,FDA-2010-P-0223-0008,FDA-2010-P-0223,"exhibit b (exhibit c) - ""cobrek's second notice letter""  - [genzyme corporation (covington & burling llp) - citizen petition]",0,0
0900006480ade1fb,Supporting & Related Material,FDA-2010-P-0223-0005,FDA-2010-P-0223,"exhibit b (exhibit b) - ""united states patent no. 6,903,083 b2""  - [genzyme corporation (covington & burling llp) - citizen petition]",0,0
0900006480ade1fd,Supporting & Related Material,FDA-2010-P-0223-0006,FDA-2010-P-0223,"exhibit b (exhibit d) - ""genzyme corporation v. cobrek pharmaceuticals, inc., no. 1:10-cv-00112 (n.d. iii.) complaint"" - [genzyme corporation (covington & burling llp) - citizen petition]",0,0
0900006480ade145,Supporting & Related Material,FDA-2010-P-0223-0003,FDA-2010-P-0223,"exhibit b - ""bone care international llc et al. v. pentech pharmaceuticals, inc., 08-cv-1083(n.d. iii.) complaint"" - [genzyme corporation (covington & burling llp) - citizen petition]",0,0
0900006484dacd3b,Supporting & Related Material,FDA-2021-P-1045-0003,FDA-2021-P-1045,exhibit a re: citizen petition from siri and glimstad llp on behalf of informed consent action network,0,0
0900006484dacd38,Other,FDA-2021-P-1045-0002,FDA-2021-P-1045,acknowledgment letter from fda dms to siri and glimstad llp on behalf of informed consent action network,0,0
0900006484dd630f,Other,FDA-2021-P-1045-0004,FDA-2021-P-1045,petition response letter from fda cder to siri & glimstad llp,0,0
0900006484dacd00,Other,FDA-2021-P-1045-0001,FDA-2021-P-1045,citizen petition from siri and glimstad llp on behalf of informed consent action network,0,0
0900006484d56737,Notice,FDA-2021-N-0929-0001,FDA-2021-N-0929,food and drug administration new era of smarter food safety summit on e-commerce; public meeting; request for comments,1,0
0900006482af58ca,Other,FDA-2017-P-5335-0001,FDA-2017-P-5335,citizen petition from anda consultants,0,0
0900006482af68ce,Supporting & Related Material,FDA-2017-P-5335-0004,FDA-2017-P-5335,attachment 2 - drugs@fda prescribing information for nexiclon xr tablets,0,0
0900006482af58cc,Other,FDA-2017-P-5335-0002,FDA-2017-P-5335,acknowledgement letter from fda ddm to anda consultants,0,0
0900006482af68cd,Supporting & Related Material,FDA-2017-P-5335-0003,FDA-2017-P-5335,attachment 1 - orange bood drug products listing re,0,0
0900006482bb809f,Other,FDA-2017-P-6101-0001,FDA-2017-P-6101,citizen petition from strides pharma inc.,0,0
0900006483094cae,Other,FDA-2017-P-6101-0004,FDA-2017-P-6101,interim response letter from fda cder to strides pharma inc.,0,0
090000648367eeaf,Other,FDA-2017-P-6101-0005,FDA-2017-P-6101,agency response letter from fda cder to strides pharma inc.,0,0
0900006482bb8745,Supporting & Related Material,FDA-2017-P-6101-0003,FDA-2017-P-6101,annexure i - the declaration report for product (a074655) unavailability in the us market re citizen petition from strides pharma inc.,0,0
0900006482bb80a1,Other,FDA-2017-P-6101-0002,FDA-2017-P-6101,acknowledgement letter from fda ddm to strides pharma inc.,0,0
09000064821a4ee7,Supporting & Related Material,FDA-2016-P-2558-0004,FDA-2016-P-2558,exhibit 2  choosing wisely antibiotics for pink eye re citizen petition from similasan corporation,0,0
09000064821a4ee9,Supporting & Related Material,FDA-2016-P-2558-0006,FDA-2016-P-2558,exhibit 4 cdc pink eye usually mild and easy to treat re citizen petition from similasan corporation,0,0
09000064821a51c0,Supporting & Related Material,FDA-2016-P-2558-0012,FDA-2016-P-2558,exhibit 10 remco p. rietveld et al re citizen petition from similasan corporation,0,0
09000064821a51c1,Supporting & Related Material,FDA-2016-P-2558-0013,FDA-2016-P-2558,exhibit 11 fda antibiotic resistance re citizen petition from similasan corporation,0,0
09000064821a51c2,Supporting & Related Material,FDA-2016-P-2558-0014,FDA-2016-P-2558,exhibit 12 fda combating antibiotic resistance re citizen petition from similasan corporation,0,0
09000064821a51c4,Supporting & Related Material,FDA-2016-P-2558-0016,FDA-2016-P-2558,exhibit 14 trp pink eye relief re citizen petition from similasan corporation,0,0
09000064821a4ee4,Other,FDA-2016-P-2558-0001,FDA-2016-P-2558,citizen petition from similasan corporation,0,0
09000064821ab135,Other,FDA-2016-P-2558-0002,FDA-2016-P-2558,acknowledgment letter from fda ddm to similasan corporation,0,0
09000064821a4eea,Supporting & Related Material,FDA-2016-P-2558-0007,FDA-2016-P-2558,exhibit 5 webmd pink eye re citizen petition from similasan corporation,0,0
09000064824d13ba,Other,FDA-2016-P-2558-0018,FDA-2016-P-2558,interim response letter from cder to similasan corporation,0,0
09000064821a4ee6,Supporting & Related Material,FDA-2016-P-2558-0003,FDA-2016-P-2558,exhibit 1 hazel a everitt et al re citizen petition from similasan corporation,0,0
09000064821a4ee8,Supporting & Related Material,FDA-2016-P-2558-0005,FDA-2016-P-2558,exhibit 3 cdc conjunctivitis treatment re citizen petition from similasan corporation,0,0
09000064821a51bd,Supporting & Related Material,FDA-2016-P-2558-0009,FDA-2016-P-2558,exhibit 7 joanna jefferis et al re citizen petition from similasan corporation,0,0
09000064821a51be,Supporting & Related Material,FDA-2016-P-2558-0010,FDA-2016-P-2558,exhibit 8 google pink eye re citizen petition from similasan corporation,0,0
09000064821a4eeb,Supporting & Related Material,FDA-2016-P-2558-0008,FDA-2016-P-2558,exhibit 6  azari & barney re citizen petition from similasan corporation,0,0
09000064821a51c3,Supporting & Related Material,FDA-2016-P-2558-0015,FDA-2016-P-2558,exhibit 13 shirley dang re citizen petition from similasan corporation,0,0
09000064821a51bf,Supporting & Related Material,FDA-2016-P-2558-0011,FDA-2016-P-2558,exhibit 9 peter w. rose et al re citizen petition from similasan corporation,0,0
09000064821b8b43,Supporting & Related Material,FDA-2016-P-2558-0017,FDA-2016-P-2558,exhibit 15 kari lee visscher et al re citizen petition from similasan corporation,0,0
0900006482cfe790,Other,FDA-2017-P-6649-0004,FDA-2017-P-6649,withdrawal from greenberg traurig llp,0,0
0900006482cbc0d4,Other,FDA-2017-P-6649-0002,FDA-2017-P-6649,"acknowledgment letter from fda ddm to greenberg traurig, llp ( on behalf of bracco diagnostics inc. )",0,0
0900006482cbc01f,Other,FDA-2017-P-6649-0001,FDA-2017-P-6649,citizen petition from greenberg traurig llp ( on behalf of bracco diagnostics inc),0,0
0900006482cbdbc4,Other,FDA-2017-P-6649-0003,FDA-2017-P-6649,response in opposition to citizen petition fda-2017-p-1297,0,0
0900006480fecb83,Notice,FDA-2011-N-0439-0004,FDA-2011-N-0439,"agency information collection activities; proposals, submissions, and approvals: food and drug administration recall regulations",1,0
0900006480eb644a,Notice,FDA-2011-N-0439-0001,FDA-2011-N-0439,"agency information collection activities; proposals, submissions, and approvals: fda recall regulations",0,0
0900006480f7209a,Notice,FDA-2011-N-0439-0003,FDA-2011-N-0439,"agency information collection activities; proposals, submissions, and approvals: recall regulations",0,0
090000648197ba94,Notice,FDA-2014-N-1697-0002,FDA-2014-N-1697,"privacy act of 1974; report of a new system of records; food and 
drug administration commissioning of state and local officials; 
correction",1,0
090000648196402c,Notice,FDA-2014-N-1697-0001,FDA-2014-N-1697,"privacy act of 1974; report of a new system of records; food and 
drug administration commissioning of state and local officials",1,0
0900006481966730,Supporting & Related Material,FDA-2014-P-2140-0004,FDA-2014-P-2140,attachment 2 citizen petition from lachman consultat services inc.,0,0
0900006481966731,Supporting & Related Material,FDA-2014-P-2140-0005,FDA-2014-P-2140,attachment 3 citizen petition from lachman consultat services inc.,0,0
090000648196672e,Supporting & Related Material,FDA-2014-P-2140-0003,FDA-2014-P-2140,attachment 1 citizen petition from lachman consultat services inc.,0,0
09000064819669ac,Other,FDA-2014-P-2140-0002,FDA-2014-P-2140,"acknowledgement letter from fda ddm to lachman consultant services, inc.",0,0
090000648196672b,Other,FDA-2014-P-2140-0001,FDA-2014-P-2140,"citizen petition from lachman consulting services, inc.",0,0
0900006481966732,Supporting & Related Material,FDA-2014-P-2140-0006,FDA-2014-P-2140,attachment 4 citizen petition from lachman consultat services inc.,0,0
0900006484873c71,Supporting & Related Material,FDA-2020-P-2005-0005,FDA-2020-P-2005,"attachment 1 orange book: approved drug products
with therapeutic equivalence evaluations re: suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484873c02,Other,FDA-2020-P-2005-0002,FDA-2020-P-2005,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
0900006484873c01,Other,FDA-2020-P-2005-0001,FDA-2020-P-2005,"suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484873c72,Supporting & Related Material,FDA-2020-P-2005-0004,FDA-2020-P-2005,"attachment 2 highlights of prescribing information k-tab (potassium chloride) extended-release tablets re: suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484873c73,Supporting & Related Material,FDA-2020-P-2005-0003,FDA-2020-P-2005,"attachment 3 highlights of prescribing information potassium chloride extended-release tablets re: suitability petition from hyman, phelps & mcnamara, p.c.",0,0
09000064846f92ba,Other,FDA-2020-P-1423-0039,FDA-2020-P-1423,soi correction letter to citizen petition from north american olive oil association,0,0
09000064846ad90b,Supporting & Related Material,FDA-2020-P-1423-0003,FDA-2020-P-1423,appendix 1 proposed regulation re citizen petition from north american olive oil association,0,0
09000064846ad925,Supporting & Related Material,FDA-2020-P-1423-0012,FDA-2020-P-1423,appendix 5 ioc standard november 2019 re citizen petition from north american olive oil association,0,0
09000064846ad93a,Supporting & Related Material,FDA-2020-P-1423-0021,FDA-2020-P-1423,appendix 11b oct 2019-”7-stigmastenol decisional tree in refined oo re citizen petition from north american olive oil association,0,0
09000064846ad557,Supporting & Related Material,FDA-2020-P-1423-0028,FDA-2020-P-1423,appendix 15 oct 2015 - k270 and decision trees proposals re citizen petition from north american olive oil association,0,0
09000064846ad55b,Supporting & Related Material,FDA-2020-P-1423-0032,FDA-2020-P-1423,appendix 16b scientific papers on faees re citizen petition from north american olive oil association,0,0
09000064846ad558,Supporting & Related Material,FDA-2020-P-1423-0029,FDA-2020-P-1423,appendix 15a ioc report presentation k270 re citizen petition from north american olive oil association,0,0
09000064846ad939,Supporting & Related Material,FDA-2020-P-1423-0020,FDA-2020-P-1423,appendix 11a oct 2011-study delta 7-stigmastenol +campesterol re citizen petition from north american olive oil association,0,0
09000064846ad927,Supporting & Related Material,FDA-2020-P-1423-0014,FDA-2020-P-1423,appendix 7 naooa consumer study march 2020 - read-only re citizen petition from north american olive oil association,0,0
09000064846ad93e,Supporting & Related Material,FDA-2020-P-1423-0025,FDA-2020-P-1423,"appendix 12b oct 2012 annex 2 alkyl esters, waxes and stigmastadiene re citizen petition from north american olive oil association",0,0
09000064846ad92d,Supporting & Related Material,FDA-2020-P-1423-0018,FDA-2020-P-1423,appendix 10 oct 2006 linolenic acid limit re citizen petition from north american olive oil association,0,0
09000064846ad564,Supporting & Related Material,FDA-2020-P-1423-0038,FDA-2020-P-1423,appendix 18-olive oil blend labels and amazon com comments re citizen petition from north american olive oil association,0,0
09000064846ad559,Supporting & Related Material,FDA-2020-P-1423-0030,FDA-2020-P-1423,appendix 16 fatty acid methyl and ethyl esters as well as wax esters re citizen petition from north american olive oil association,0,0
09000064846ad55f,Supporting & Related Material,FDA-2020-P-1423-0034,FDA-2020-P-1423,appendix 16d gomez coca et al 2016 re citizen petition from north american olive oil association,0,0
09000064846ad563,Supporting & Related Material,FDA-2020-P-1423-0037,FDA-2020-P-1423,appendix 17a li and wang shelf life 2018 re citizen petition from north american olive oil association,0,0
09000064846ad539,Supporting & Related Material,FDA-2020-P-1423-0010,FDA-2020-P-1423,appendix 3b naooa withdrawal of 2012 petition re citizen petition from north american olive oil association,0,0
09000064846ad55a,Supporting & Related Material,FDA-2020-P-1423-0031,FDA-2020-P-1423,appendix 16a di serio food chem 2017 re citizen petition from north american olive oil association,1,0
09000064846ad55c,Supporting & Related Material,FDA-2020-P-1423-0033,FDA-2020-P-1423,appendix 16c april 2008 detection of admixures of deodorised oo with evoo re citizen petition from north american olive oil association,0,0
09000064846ad536,Supporting & Related Material,FDA-2020-P-1423-0007,FDA-2020-P-1423,appendix 2c codex redline re citizen petition from north american olive oil association,0,0
09000064846ad929,Supporting & Related Material,FDA-2020-P-1423-0016,FDA-2020-P-1423,"appendix 9 april 2016 heptadecanoic, heptadecenoic, eicosenoic acids content re citizen petition from north american olive oil association",0,0
09000064846ad535,Supporting & Related Material,FDA-2020-P-1423-0006,FDA-2020-P-1423,appendix 2b ccfo proposed revisions to codex standard november 2018 re citizen petition from north american olive oil association,0,0
09000064846ad905,Other,FDA-2020-P-1423-0002,FDA-2020-P-1423,acknowledgment letter from fda dms to north american olive oil association,0,0
090000648497d917,Other,FDA-2020-P-1423-0057,FDA-2020-P-1423,letter from cfsan to the meriam hospital,0,0
09000064846ad555,Supporting & Related Material,FDA-2020-P-1423-0026,FDA-2020-P-1423,appendix 13 oct 2012 reduction of stigmastadiene limit annex 6 re citizen petition from north american olive oil association,0,0
09000064846ad93c,Supporting & Related Material,FDA-2020-P-1423-0023,FDA-2020-P-1423,appendix 12 oct 2012 reduction of wax limit annex 7 re citizen petition from north american olive oil association,0,0
09000064804a255a,Notice,FDA-2003-N-0448-0002,FDA-2003-N-0448,fda,0,0
09000064804a2555,Notice,FDA-2003-N-0448-0001,FDA-2003-N-0448,fda,0,0
09000064804a255b,Notice,FDA-2003-N-0448-0003,FDA-2003-N-0448,fda,0,0
09000064804943ae,Supporting & Related Material,FDA-2003-D-0305-0003,FDA-2003-D-0305,guidance,0,0
0900006480494337,Notice,FDA-2003-D-0305-0001,FDA-2003-D-0305,fda,0,0
09000064804943b3,Notice,FDA-2003-D-0305-0005,FDA-2003-D-0305,fda,0,0
090000648049437e,Supporting & Related Material,FDA-2003-D-0305-0002,FDA-2003-D-0305,guideline,0,0
09000064804943b1,Supporting & Related Material,FDA-2003-D-0305-0004,FDA-2003-D-0305,guidance,0,0
090000648045143a,Other,FDA-2006-P-0206-0001,FDA-2006-P-0206,hfa-305  to the sugar association,0,0
0900006480451488,Other,FDA-2006-P-0206-0002,FDA-2006-P-0206,hfa-305  to the sugar association,0,0
09000064804514ca,Other,FDA-2006-P-0206-0007,FDA-2006-P-0206,"fda/cfsan to the sugar association, inc.",0,0
09000064804e780c,Other,FDA-2001-N-0348-0004,FDA-2001-N-0348,"supporting statement omb 910-0032 new animal drug applications, form fda 356v and supporting regulations",0,0
09000064804e780b,Notice,FDA-2001-N-0348-0002,FDA-2001-N-0348,"agency information collection activities; submission for omb review; comment request;  new animal drug application, form fda 356 v",0,0
09000064804e780a,Notice,FDA-2001-N-0348-0001,FDA-2001-N-0348,"agency information collection activities; proposed collection; comment request; new animal drug application, form fda 356 v, 21 cfr part 514",0,0
09000064804e780d,Notice,FDA-2001-N-0348-0003,FDA-2001-N-0348,"agency information collection activities; announcement of omb approval; new animal drug application, form fda 356  v",0,0
0900006484a87f06,Supporting & Related Material,FDA-2021-P-0338-0013,FDA-2021-P-0338,attachment c h205-h229 re citizen petition from valisure,0,0
0900006484a87e89,Supporting & Related Material,FDA-2021-P-0338-0002,FDA-2021-P-0338,attachment a - valisure citizen petition on hand sanitizer products re citizen petition from valisure,0,0
0900006484a87f03,Supporting & Related Material,FDA-2021-P-0338-0012,FDA-2021-P-0338,attachment c h178-h204 re citizen petition from valisure,0,0
0900006484a87e91,Supporting & Related Material,FDA-2021-P-0338-0007,FDA-2021-P-0338,attachment c h077-h091 re citizen petition from valisure,0,0
0900006484a87f02,Supporting & Related Material,FDA-2021-P-0338-0011,FDA-2021-P-0338,attachment c h153-h177 re citizen petition from valisure,0,0
0900006484a87f53,Supporting & Related Material,FDA-2021-P-0338-0015,FDA-2021-P-0338,attachment c h258-h267 re citizen petition from valisure,0,0
0900006484a87bde,Other,FDA-2021-P-0338-0001,FDA-2021-P-0338,citizen petition from valisure llc,0,0
0900006484a87e8c,Supporting & Related Material,FDA-2021-P-0338-0004,FDA-2021-P-0338,attachment c h001-h025 re citizen petition from valisure,0,0
0900006484a87e8f,Supporting & Related Material,FDA-2021-P-0338-0006,FDA-2021-P-0338,attachment c h052-h076 re citizen petition from valisure,0,0
0900006484a87f01,Supporting & Related Material,FDA-2021-P-0338-0010,FDA-2021-P-0338,attachment c h128-h152 re citizen petition from valisure,0,0
0900006484a87be0,Other,FDA-2021-P-0338-0016,FDA-2021-P-0338,acknowledgment letter from fda dms to valisure llc,0,0
0900006484a87e8e,Supporting & Related Material,FDA-2021-P-0338-0005,FDA-2021-P-0338,attachment c h026-h051 re citizen petition from valisure,0,0
0900006484d93faf,Other,FDA-2021-P-0338-0018,FDA-2021-P-0338,"interim response letter from fda cder to valisure, llc",0,0
0900006484a87e8a,Supporting & Related Material,FDA-2021-P-0338-0003,FDA-2021-P-0338,attachment b - acc resolution - chemical variability in pharmaceutical products re citizen petition from valisure,0,0
0900006484a87efd,Supporting & Related Material,FDA-2021-P-0338-0008,FDA-2021-P-0338,attachment c h092-h102 re citizen petition from valisure,0,0
0900006484a87efe,Supporting & Related Material,FDA-2021-P-0338-0009,FDA-2021-P-0338,attachment c h103-h127 re citizen petition from valisure,0,0
0900006484a87f4e,Supporting & Related Material,FDA-2021-P-0338-0014,FDA-2021-P-0338,attachment c h230-h257 re citizen petition from valisure,0,0
0900006480e303cd,Supporting & Related Material,FDA-2011-N-0134-0015,FDA-2011-N-0134,see fda-2011-n-0134-0010,0,0
0900006480c0723d,Notice,FDA-2011-N-0134-0001,FDA-2011-N-0134,fda food safety modernization act: title iii--a new paradigm for importers; public meeting,1,0
0900006480f09138,Notice,FDA-2011-N-0607-0001,FDA-2011-N-0607,public database of products with orphan-drug designations: replacing non-informative code names with descriptive identifiers,0,0
09000064824e16d5,Other,FDA-2017-P-1252-0002,FDA-2017-P-1252,acknowledgement letter from fda ddm to xiromed llc on behalf of lifepharma fze,0,0
0900006483670954,Other,FDA-2017-P-1252-0004,FDA-2017-P-1252,response letter from fda cder to  vkt pharma private limeted and xiromed llc,0,0
0900006482aba1ee,Other,FDA-2017-P-1252-0003,FDA-2017-P-1252,interim response letter from fda cder to xiromed llc,0,0
09000064824e16d3,Other,FDA-2017-P-1252-0001,FDA-2017-P-1252,"citizen petition from xiromed, llc on behalf of lifepharma fze",0,0
0900006481e78581,Notice,FDA-2014-N-1698-0056,FDA-2014-N-1698,"food and drug administration activities for patient participation in
medical product discussions; report on stakeholder views; availability",1,0
0900006481912c75,Notice,FDA-2014-N-1698-0001,FDA-2014-N-1698,"food and drug administration activities for patient participation in
medical product discussions; establishment of a public docket",1,0
0900006481ee871c,Supporting & Related Material,FDA-2014-P-0814-0018,FDA-2014-P-0814,"exhibit 20 o'riordan, m. after patient's death, study shows hcv drug cardiotoxic in 14 of 34 treated patients source: www.medscape.com/viewarticle/832251_print september 24, 2014 re: amendment from center for responsible science",0,0
0900006481ee839d,Supporting & Related Material,FDA-2014-P-0814-0009,FDA-2014-P-0814,exhibit 5 online news articles from different organizations re: amendment from center for responsible science,0,0
0900006481ee871a,Supporting & Related Material,FDA-2014-P-0814-0016,FDA-2014-P-0814,"exhibit 18 lerman, r. fda halts trial of cancer drug by seattle's cti biopharma after patients die, source http://www.seattletimes.com/business/fda-halts-cti-biopharma-drug-trial-for-detrimental-effect-on-survival/ february 10, 2016 re: amendment from center for responsible science",0,0
0900006481752b03,Other,FDA-2014-P-0814-0001,FDA-2014-P-0814,citizen petition from the center for responsible science,0,0
0900006481752b05,Other,FDA-2014-P-0814-0002,FDA-2014-P-0814,acknowledgement letter from fda ddm to the center for responsible science,0,0
0900006481ee83a1,Supporting & Related Material,FDA-2014-P-0814-0012,FDA-2014-P-0814,"exhibit 9 the pharmaletter, ansm continues investigations into bial clinical trial death, march 10, 2016 re: amendment from center for responsible science",0,0
0900006481979bbc,Other,FDA-2014-P-0814-0007,FDA-2014-P-0814,interim response from fda cder to the center for responsible science,0,0
09000064818adec0,Other,FDA-2014-P-0814-0006,FDA-2014-P-0814,amendment from the center for responsible science,0,0
0900006481ee8651,Other,FDA-2014-P-0814-0008,FDA-2014-P-0814,amendment from the center for responsible science,0,0
0900006481ee83a2,Supporting & Related Material,FDA-2014-P-0814-0013,FDA-2014-P-0814,"exhibit 10 minutes of the temporary specialist scientific committee (tssc) meeting on ""faah (fatty add amide hydrolase) inhibitors"" of 15 february 2016. re: amendment from center for responsible science",0,0
0900006481ee871b,Supporting & Related Material,FDA-2014-P-0814-0017,FDA-2014-P-0814,"exhibit 19 lougheed, k. hepatitis c drug trial halted after patient death august 24, 2012 re: amendment from center for responsible science",0,0
0900006481ee8445,Supporting & Related Material,FDA-2014-P-0814-0020,FDA-2014-P-0814,"exhibit 22 hogan, a. failure to report a stat investigation december 13, 2015 re: amendment from center for responsible science",0,0
0900006481ee839f,Supporting & Related Material,FDA-2014-P-0814-0011,FDA-2014-P-0814,"exhibit 7 the guardian man who died in french drug trial had 'unprecedented' reaction, say experts. march 2016 re: amendment from center for responsible science",0,0
0900006481ee83a3,Supporting & Related Material,FDA-2014-P-0814-0014,FDA-2014-P-0814,"exhibit 11 brennan ema will assess ansm review of botched clinical trial in france, january 19, 2016 re: amendment from center for responsible science",0,0
0900006482552ffb,Other,FDA-2014-P-0814-0021,FDA-2014-P-0814,letter from cder to center for responsible science,0,0
0900006481752b07,Supporting & Related Material,FDA-2014-P-0814-0003,FDA-2014-P-0814,exhibit 1 declaration of john tessmer citizen petition from the center for responsible science,0,0
0900006481752b09,Supporting & Related Material,FDA-2014-P-0814-0005,FDA-2014-P-0814,exhibit 3-55 attached literature citizen petition from the center for responsible science,0,0
0900006481ee839e,Supporting & Related Material,FDA-2014-P-0814-0010,FDA-2014-P-0814,"exhibit 6 business insider, feb 5, 2016 authorities are rapping up their investigation of a deadly drug trial that left one dead and several others in hospital re: amendment from center for responsible science",0,0
0900006481ee83d2,Supporting & Related Material,FDA-2014-P-0814-0015,FDA-2014-P-0814,"exhibit 14 scientific bloggging science 2.0 blood test predicts cytokine storm drug reaction in humans march 9, 2015 re: amendment from center for responsible science",0,0
0900006481ee8444,Supporting & Related Material,FDA-2014-P-0814-0019,FDA-2014-P-0814,"exhibit 21 earley, lau and uhlig haphazard reporting of deaths in clinical trials: a review of cases of clinicaltrials.gov records and matched publications-a cross-sectional study bmj open access re: amendment from center for responsible science",0,0
0900006481752b08,Supporting & Related Material,FDA-2014-P-0814-0004,FDA-2014-P-0814,exhibit 2 declaration of hal garcia-smith citizen petition from the center for responsible science,0,0
0900006481a8b599,Supporting & Related Material,FDA-2015-P-1094-0017,FDA-2015-P-1094,"exhibit h, guidance for industry regulation of genetically engineered animals containing heritable recombinant dna constructs, citizen petition from food and water watch",1,0
0900006481a8b5a1,Supporting & Related Material,FDA-2015-P-1094-0024,FDA-2015-P-1094,"exhibit l, 21 uscs § 321, citizen petition from food and water watch",1,0
0900006481a8b5a4,Supporting & Related Material,FDA-2015-P-1094-0027,FDA-2015-P-1094,"exhibit mm, 78 fr 43093, citizen petition from food and water watch",1,0
0900006481a8b5b1,Supporting & Related Material,FDA-2015-P-1094-0039,FDA-2015-P-1094,"exhibit y, veterinary medicine advisory committee meeting aquadvantage salmon, citizen petition from food and water watch",1,0
0900006481a8b323,Other,FDA-2015-P-1094-0001,FDA-2015-P-1094,citizen petition from food and water watch,1,0
0900006481a8b327,Other,FDA-2015-P-1094-0002,FDA-2015-P-1094,acknowledgement letter from fda ddm to food and water watch,1,0
0900006481a8b591,Supporting & Related Material,FDA-2015-P-1094-0009,FDA-2015-P-1094,"exhibit d, 21 cfr 170.30, citizen petition from food and water watch",1,0
0900006481a8b596,Supporting & Related Material,FDA-2015-P-1094-0014,FDA-2015-P-1094,"exhibit ff, phenotypic characterization, d. prather dvm, citizen petition from food and water watch",1,0
0900006481a8b5a6,Supporting & Related Material,FDA-2015-P-1094-0029,FDA-2015-P-1094,"exhibit o, background document: public hearing on the labeling of food made from the aquadvantage salmon, citizen petition from food and water watch",1,0
0900006481a8b5b2,Supporting & Related Material,FDA-2015-P-1094-0040,FDA-2015-P-1094,"exhibit z, idetification of a brazil-nut allergen in transgenic soybeans, citizen petition from food and water watch",1,0
0900006481a8b5a9,Supporting & Related Material,FDA-2015-P-1094-0032,FDA-2015-P-1094,"exhibit r, 21 uscs § 334, citizen petition from food and water watch",1,0
0900006481a8b5b0,Supporting & Related Material,FDA-2015-P-1094-0038,FDA-2015-P-1094,"exhibit x, potential public health impacts of the use of recombinant bovine somatotropin in dairy production, citizen petition from food and water watch",1,0
0900006481a8b58c,Supporting & Related Material,FDA-2015-P-1094-0004,FDA-2015-P-1094,"exhibit aa, j. agric. food chern. 2005, 53, 9023-9030, citizen petition from food and water watch",1,0
0900006481a8b58e,Supporting & Related Material,FDA-2015-P-1094-0006,FDA-2015-P-1094,"exhibit bb, 21 cfr 171.1, citizen petition from food and water watch",1,0
0900006481a8b329,Supporting & Related Material,FDA-2015-P-1094-0003,FDA-2015-P-1094,"exhibit a, veterinary medicine advisory committee briefing, citizen petition from food and water watch",1,0
0900006481a8b58f,Supporting & Related Material,FDA-2015-P-1094-0007,FDA-2015-P-1094,"exhibit c, 21 cfr 10.115, citizen petition from food and water watch",1,0
0900006481a8b590,Supporting & Related Material,FDA-2015-P-1094-0008,FDA-2015-P-1094,"exhibit cc, agriculture: a glossary of terms, programs, and laws, 2005 edition, citizen petition from food and water watch",1,0
0900006481a8b5aa,Supporting & Related Material,FDA-2015-P-1094-0033,FDA-2015-P-1094,"exhibit s, role of the insulin-like growth factor family in cancer development and progression, citizen petition from food and water watch",1,0
0900006481a8b598,Supporting & Related Material,FDA-2015-P-1094-0016,FDA-2015-P-1094,"exhibit gg, comment from elizabeth colantuoni, citizen petition from food and water watch",1,0
0900006481a8b5a7,Supporting & Related Material,FDA-2015-P-1094-0030,FDA-2015-P-1094,"exhibit p, 21 uscs § 342, citizen petition from food and water watch",1,0
0900006481a8b58d,Supporting & Related Material,FDA-2015-P-1094-0005,FDA-2015-P-1094,"exhibit b, aquadvantage® fish growth chart, citizen petition from food and water watch",1,0
0900006481a8b593,Supporting & Related Material,FDA-2015-P-1094-0011,FDA-2015-P-1094,"exhibit e, 21 cfr 170.38, citizen petition from food and water watch",1,0
0900006481a8b5ae,Supporting & Related Material,FDA-2015-P-1094-0036,FDA-2015-P-1094,"exhibit v, gastrointestinal absorption of recombinant human insulin-like growth factor-1 in rats, citizen petition from food and water watch",1,0
0900006481a8b59e,Supporting & Related Material,FDA-2015-P-1094-0021,FDA-2015-P-1094,"exhibit jj, environmental and indirect human health risk assessment of the aquadvantage® salmon, citizen petition from food and water watch",1,0
0900006481a8b59a,Supporting & Related Material,FDA-2015-P-1094-0018,FDA-2015-P-1094,"exhibit hh, letter from cfsan to food and water watch, citizen petition from food and water watch",1,0
090000648483908e,Supporting & Related Material,FDA-2020-P-1831-0007,FDA-2020-P-1831,reference 05- teperino - (hh partial agonism drives warburg-like metabolism in muscle and brown fat) re citizen petition from meenal kheterpal,0,0
0900006484839089,Supporting & Related Material,FDA-2020-P-1831-0006,FDA-2020-P-1831,reference 04- jacobsen_jama derm - systematic review and pooled analysis) re citizen petition from meenal kheterpal,0,0
0900006484839eeb,Supporting & Related Material,FDA-2020-P-1831-0013,FDA-2020-P-1831,reference 11 - (variations of serum ck and prevalance of persistent hyperck) re citizen petition from meenal kheterpal,0,0
0900006484839ee6,Supporting & Related Material,FDA-2020-P-1831-0010,FDA-2020-P-1831,reference 08 -  (correlation of alpha smooth muscle actin in bcc) re citizen petition from meenal kheterpal,0,0
090000648483a6bd,Supporting & Related Material,FDA-2020-P-1831-0028,FDA-2020-P-1831,reference 26 - lilleng neuromusc disorders 2011 re citizen petition from meenal kheterpal,0,0
090000648483a782,Supporting & Related Material,FDA-2020-P-1831-0037,FDA-2020-P-1831,reference 28 - thompson 2006 horm res re citizen petition from meenal kheterpal,0,0
090000648483a101,Supporting & Related Material,FDA-2020-P-1831-0021,FDA-2020-P-1831,reference 19 - dummer bjd 2019 re citizen petition from meenal kheterpal,0,0
0900006484839cf9,Supporting & Related Material,FDA-2020-P-1831-0018,FDA-2020-P-1831,reference 16 - sekulic bmc cancer 2017 re citizen petition from meenal kheterpal,0,0
090000648483a6bc,Supporting & Related Material,FDA-2020-P-1831-0027,FDA-2020-P-1831,reference 25 - lev 1999 clinica chimica act re citizen petition from meenal kheterpal,0,0
090000648483493e,Other,FDA-2020-P-1831-0002,FDA-2020-P-1831,acknowledgment letter fda dms to meenal kheterpal,0,0
090000648483a0be,Supporting & Related Material,FDA-2020-P-1831-0024,FDA-2020-P-1831,reference 22 - bohlmeyer rheum dis clin north am 1994 re citizen petition from meenal kheterpal,0,0
0900006484839eea,Supporting & Related Material,FDA-2020-P-1831-0012,FDA-2020-P-1831,reference 10 - (lab guide to diagnosing myositis) re citizen petition from meenal kheterpal,0,0
0900006484839eec,Supporting & Related Material,FDA-2020-P-1831-0014,FDA-2020-P-1831,reference 12 - brewster 2006 circulation re citizen petition from meenal kheterpal,0,0
090000648483a783,Supporting & Related Material,FDA-2020-P-1831-0030,FDA-2020-P-1831,reference 29 - amelink 1990 acta physiologca re citizen petition from meenal kheterpal,0,0
0900006484838f88,Supporting & Related Material,FDA-2020-P-1831-0004,FDA-2020-P-1831,reference 02- odomzo pi new with sun re: citizen petition from meenal kheterpal,0,0
0900006484839eee,Supporting & Related Material,FDA-2020-P-1831-0016,FDA-2020-P-1831,reference 14 - totsuka j appl physiol 2002 re citizen petition from meenal kheterpal,0,0
090000648483a100,Supporting & Related Material,FDA-2020-P-1831-0020,FDA-2020-P-1831,reference 18 - migden lancet oncol 2015 re citizen petition from meenal kheterpal,0,0
090000648483a789,Supporting & Related Material,FDA-2020-P-1831-0033,FDA-2020-P-1831,reference 32 - duyff j neurol neurosurg psychiatry 2000 re citizen petition from meenal kheterpal,0,0
090000648483a781,Supporting & Related Material,FDA-2020-P-1831-0029,FDA-2020-P-1831,reference 27 - kyriakides euro j neurol 2010 re citizen petition from meenal kheterpal,0,0
0900006484839090,Supporting & Related Material,FDA-2020-P-1831-0008,FDA-2020-P-1831,reference 06- xiao (hedgehog signaling regulates e-cadherin expression) re citizen petition from meenal kheterpal,0,0
0900006484a57751,Other,FDA-2020-P-1831-0038,FDA-2020-P-1831,interim response for the hedgehog inhibitor,0,0
0900006484835d2b,Supporting & Related Material,FDA-2020-P-1831-0003,FDA-2020-P-1831,reference 01- erivedge (vismodegib) capsules re: citizen petition from meenal kheterpal,0,0
0900006484839088,Supporting & Related Material,FDA-2020-P-1831-0005,FDA-2020-P-1831,reference 03- daurismo (glasdegib) re: citizen petition from meenal kheterpal,0,0
0900006484839eed,Supporting & Related Material,FDA-2020-P-1831-0015,FDA-2020-P-1831,reference 13 - sayers med sci sports exerc 2003 re citizen petition from meenal kheterpal,0,0
0900006484839eef,Supporting & Related Material,FDA-2020-P-1831-0017,FDA-2020-P-1831,reference 15 - sekulic new eng j med 2012 re citizen petition from meenal kheterpal,0,0
0900006484bc8cf7,Other,FDA-2021-P-0653-0001,FDA-2021-P-0653,citizen petition from environmental defense fund,0,0
0900006484bc935e,Other,FDA-2021-P-0653-0002,FDA-2021-P-0653,acknowledgment letter from fda dms to environmental defense fund,0,0
0900006484bd7015,Supporting & Related Material,FDA-2021-P-0677-0003,FDA-2021-P-0677,"attachment 1 (diltiazem hcl er capsules anda sp) prescription drug product list  re: citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484bd7017,Supporting & Related Material,FDA-2021-P-0677-0005,FDA-2021-P-0677,"attachment 3 (diltiazem hcl er capsules anda sp) diltiazem hydrochloride extended-release capsules re: citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484bd7a4a,Other,FDA-2021-P-0677-0001,FDA-2021-P-0677,"suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484bd7a4c,Other,FDA-2021-P-0677-0002,FDA-2021-P-0677,"acknowledgement letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
0900006484bd7016,Supporting & Related Material,FDA-2021-P-0677-0004,FDA-2021-P-0677,"attachment 2 (diltiazem hcl er capsules anda sp) cardizem cd- diltiazem hydrochloride capsule, coated, extended release bausch health us llc. re: citizen petition from hyman, phelps & mcnamara, p.c.",0,0
090000648391d086,Other,FDA-2018-P-4591-0001,FDA-2018-P-4591,citizen petition from international maple syrup institute,0,0
090000648404daca,Other,FDA-2018-P-4591-0003,FDA-2018-P-4591,interim response letter from fda cfsan to international maple syrup institute,0,0
090000648391d088,Other,FDA-2018-P-4591-0002,FDA-2018-P-4591,acknowledgment letter from fda ddm to international maple syrup institute,0,0
0900006480472821,Notice,FDA-2004-D-0286-0001,FDA-2004-D-0286,fda,0,0
0900006480472822,Supporting & Related Material,FDA-2004-D-0286-0002,FDA-2004-D-0286,"fda review of vaccine labeling requirements for warnings, use instructions, and precautionary information",0,0
0900006480681e56,Supporting & Related Material,FDA-2008-P-0049-0009,FDA-2008-P-0049,exhibit d (3) [fda-2008-p-0049-0006.1] - so you sow [invoice] - comment,0,0
0900006480838fca,Other,FDA-2008-P-0049-0013,FDA-2008-P-0049,"swanson health products, inc. - supplement petition",0,0
09000064803a2c0e,Supporting & Related Material,FDA-2008-P-0049-0003,FDA-2008-P-0049,exhibit 1 - [fda-2008-p-0049-0001],0,0
0900006480681ec2,Supporting & Related Material,FDA-2008-P-0049-0007,FDA-2008-P-0049,exhibit d(1) [fda-2008-p-0049-0006.1] - so you sow - [invioce] - comment,0,0
09000064808393de,Supporting & Related Material,FDA-2008-P-0049-0015,FDA-2008-P-0049,"exhibit b - ""state of california department of justice"" - [swanson health products, inc. - supplement petition]",0,0
09000064808391e3,Supporting & Related Material,FDA-2008-P-0049-0014,FDA-2008-P-0049,"exhibit a - ""superior court of the state of california county of alameda"" - [swanson health products, inc. - supplement petition]",0,0
09000064803a0fba,Other,FDA-2008-P-0049-0001,FDA-2008-P-0049,"swanson health products, inc. - citizen petition",0,0
0900006480681eb6,Supporting & Related Material,FDA-2008-P-0049-0008,FDA-2008-P-0049,exhibit d(2) [fda-2008-p-0049-0006.1] - so you sow [invoice] - comment,0,0
09000064803a0ffe,Other,FDA-2008-P-0049-0002,FDA-2008-P-0049,"acknowledgement letter to sedgewick, detert, moran & arnold llp [swanson health products, inc.]",0,0
09000064819a9719,Other,FDA-2015-P-0059-0002,FDA-2015-P-0059,supplement from cspi,0,0
09000064819a9717,Other,FDA-2015-P-0059-0003,FDA-2015-P-0059,citizen petition from the center for science in the public interest (cspi),0,0
090000648318fdb3,Other,FDA-2015-P-0059-0013,FDA-2015-P-0059,denial response letter from fda cfsan to center for science in the public interest,0,0
0900006481b38ce3,Other,FDA-2015-P-0059-0004,FDA-2015-P-0059,interim response letter from fda cfsan to cspi,0,0
0900006481f93ba2,Other,FDA-2015-P-0059-0011,FDA-2015-P-0059,supplement from center for science in the public interest (cspi),0,0
0900006481badf23,Other,FDA-2015-P-0059-0006,FDA-2015-P-0059,letter from center for science in the public interest to fda cfsan,0,0
0900006481bae1c0,Supporting & Related Material,FDA-2015-P-0059-0007,FDA-2015-P-0059,"attachment 1 law banning the sale of powdered caffeine in ohio, passed in june 2015 re letter from center for science in the public interest to fda cfsan",0,0
0900006481bae1c1,Supporting & Related Material,FDA-2015-P-0059-0008,FDA-2015-P-0059,"attachment 2 law banning the sale of powdered caffeine to minors in illinois, passed in july 2015 re letter from center for science in the public interest to fda cfsan",0,0
09000064819a971b,Other,FDA-2015-P-0059-0001,FDA-2015-P-0059,acknowledgement letter from fda ddm to cspi,0,0
0900006481b75ed3,Other,FDA-2014-P-2035-0014,FDA-2014-P-2035,"interim response letter from fda cfsan to dr. carla davis, texas children's hospital",0,0
090000648322b058,Other,FDA-2014-P-2035-0292,FDA-2014-P-2035,supplement from center for science in the public interest (cspi),0,0
09000064833f76b7,Other,FDA-2014-P-2035-0296,FDA-2014-P-2035,04.16.2018 cspi and fare memorandum of meeting,0,0
0900006481945409,Other,FDA-2014-P-2035-0002,FDA-2014-P-2035,acknowledgement letter from fda ddm to dr. carla davis,0,0
0900006481945892,Other,FDA-2014-P-2035-0001,FDA-2014-P-2035,"citizen petition from dr. carla m. davis, et al.",0,0
0900006484e03f23,Other,FDA-2021-P-1181-0002,FDA-2021-P-1181,acknowledgment letter from fda dms to pet schooled,0,0
0900006484e03f21,Other,FDA-2021-P-1181-0001,FDA-2021-P-1181,citizen petition from pet schooled,0,0
0900006481ecaba7,Supporting & Related Material,FDA-2016-P-0974-0003,FDA-2016-P-0974,attachment a electronic orange book tolvaptan tablet; oral 15mg 30mg samsca otsuka america pharm re citizen petition from gordon johnston regulatory consultants llc,0,0
090000648214c5e4,Notice,FDA-2016-P-0974-0005,FDA-2016-P-0974,"determination that samsca (tolvaptan) tablets, 60 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006481ecaba8,Supporting & Related Material,FDA-2016-P-0974-0004,FDA-2016-P-0974,attachment b electronic orange book for tolvaptan 60 mg samsca otsuka america pharm re citizen petition from gordon johnston regulatory consultants llc,0,0
0900006481ec9df8,Other,FDA-2016-P-0974-0002,FDA-2016-P-0974,"acknowledgement letter from fda ddm to gordon johnston regulatory consultants, llc",0,0
0900006481ec8ff4,Other,FDA-2016-P-0974-0001,FDA-2016-P-0974,citizen petition from gordon johnston regulatory consultants llc,0,0
0900006483411229,Other,FDA-2017-P-3832-0004,FDA-2017-P-3832,fda-2017-p-3832 - npa response letter,0,0
09000064826f02fa,Other,FDA-2017-P-3832-0001,FDA-2017-P-3832,"citizen petition for reconsideration from porzio, bromberg & newman pc (natural products association)",0,0
09000064826f03e3,Other,FDA-2017-P-3832-0002,FDA-2017-P-3832,"acknowledgement letter from fda ddm to porzio, bromberg & newman, pc (natural products association)",0,0
0900006482d3fb14,Other,FDA-2017-P-3832-0003,FDA-2017-P-3832,"interim response from fda to porzio, bromberg & newman, p.c.",0,0
0900006484dd10a8,Other,FDA-2021-P-1141-0002,FDA-2021-P-1141,acknowledgment letter from fda dms to harry duty,0,0
0900006484dd10b9,Other,FDA-2021-P-1141-0001,FDA-2021-P-1141,citizen petition from harry duty,0,0
0900006483d68217,Other,FDA-2019-P-3265-0002,FDA-2019-P-3265,"acknowledgment letter from fda ddm to medical research collaborative, llc",0,0
0900006483d6729f,Other,FDA-2019-P-3265-0001,FDA-2019-P-3265,citizen petition from medical research collaborative llc,0,0
09000064841b9ebe,Other,FDA-2019-P-3265-0003,FDA-2019-P-3265,"letter from fda cder to medical research collaborative, llc",0,0
0900006483410777,Other,FDA-2016-P-1674-0008,FDA-2016-P-1674,fda-2016-p-1674 tatelyle granting response,0,0
090000648204be6b,Supporting & Related Material,FDA-2016-P-1674-0003,FDA-2016-P-1674,attachment 1 summary of beneficial physiological effects june 15 2016 re citizen petition from tate & lyle ingredients americas llc,0,0
09000064820486c7,Other,FDA-2016-P-1674-0002,FDA-2016-P-1674,acknowledgement letter from fda ddm to tate & lyle ingredients americas llc,0,0
090000648204829d,Other,FDA-2016-P-1674-0001,FDA-2016-P-1674,citizen petition from tate & lyle ingredients americas llc,0,0
09000064822f1c2a,Other,FDA-2016-P-1674-0005,FDA-2016-P-1674,letter from general mills supporting tate & lyle's petition,0,0
090000648204be6c,Supporting & Related Material,FDA-2016-P-1674-0004,FDA-2016-P-1674,attachment 3 citizen petition b references june 15 2016 re citizen petition from tate & lyle ingredients americas llc,0,0
0900006482548ee1,Other,FDA-2016-P-1674-0007,FDA-2016-P-1674,interim response letter from cfsan to tate & lyle ingredients americas llc,0,0
0900006482286036,Other,FDA-2016-P-3070-0002,FDA-2016-P-3070,acknowledgement letter from fda ddm to dupont nutrition & health,0,0
090000648252ec87,Other,FDA-2016-P-3070-0010,FDA-2016-P-3070,interim response letter from cfsan to dupont nutrition & health,0,0
090000648228603c,Supporting & Related Material,FDA-2016-P-3070-0005,FDA-2016-P-3070,appendix table 2a - postprandial glucose control - human clinical studies with soy fiber re citizen petition from dupont nutrition & health,0,0
090000648228603b,Supporting & Related Material,FDA-2016-P-3070-0004,FDA-2016-P-3070,appendix table 1b - laxation - human clinical studies with soy fiber - institutionalized subjects re citizen petition from dupont nutrition & health,0,0
090000648228603a,Supporting & Related Material,FDA-2016-P-3070-0003,FDA-2016-P-3070,appendix table 1a - laxation - human clinical studies with soy fiber - healthy re citizen petition from dupont nutrition & health,0,0
090000648228603d,Supporting & Related Material,FDA-2016-P-3070-0006,FDA-2016-P-3070,appendix table 2b - postprandial glucose control - human clinical studies with soy fiber (diabetic) re citizen petition from dupont nutrition & health,0,0
090000648228603e,Supporting & Related Material,FDA-2016-P-3070-0007,FDA-2016-P-3070,appendix table 3 - cholesterol reduction - human clinical studies with soy fiber re citizen petition from dupont nutrition & health,0,0
0900006482285e13,Other,FDA-2016-P-3070-0001,FDA-2016-P-3070,citizen's petition from dupont nutrition & health,0,0
0900006483410f07,Other,FDA-2016-P-3070-0011,FDA-2016-P-3070,fda-2016-p-3070-dupont nutrition and health granting response,0,0
0900006482060aa9,Notice,FDA-2016-D-1280-0001,FDA-2016-D-1280,"international conference on harmonisation: electronic transmission of international conference on harmonisation; electronic transmission of postmarket individual case safety reports for drugs and biologics, excluding vaccines; availability of fda regional implementation specifications for ich e2b(r3) reporting to the food and drug administration adverse event reporting system",1,0
0900006484da73e7,Other,FDA-2021-P-1040-0002,FDA-2021-P-1040,acknowledgment letter from fda dms to petschooled,0,0
0900006484da75c6,Other,FDA-2021-P-1040-0001,FDA-2021-P-1040,citizen petition from pet schooled,0,0
0900006482500c0e,Other,FDA-2016-P-2533-0003,FDA-2016-P-2533,interim response letter from cvm to american feed industry association,0,0
090000648219f0f7,Other,FDA-2016-P-2533-0002,FDA-2016-P-2533,acknowledgment letter from fda ddm american feed industry association and national grain and feed association,0,0
090000648219e1f3,Other,FDA-2016-P-2533-0001,FDA-2016-P-2533,citizen petition from american feed industry association and national grain and feed association,0,0
0900006480ed9b2b,Other,FDA-2011-D-0579-0001,FDA-2011-D-0579,guidance for industry; availability of fda’s esubmitter program for regulatory submissions from licensed blood establishments,0,0
090000648171f410,Supporting & Related Material,FDA-2014-P-0724-0006,FDA-2014-P-0724,exhibit 4 conformer classification citizen petition from barbara spohn-lillo,0,0
090000648171f411,Supporting & Related Material,FDA-2014-P-0724-0007,FDA-2014-P-0724,exhibit 5 misc. definitions citizen petition from barbara spohn-lillo,0,0
09000064821bf430,Other,FDA-2014-P-0724-0014,FDA-2014-P-0724,citizen petition denial from cdrh,0,0
090000648171f413,Supporting & Related Material,FDA-2014-P-0724-0009,FDA-2014-P-0724,exhibit 7 misc. definitions citizen petition from barbara spohn-lillo,0,0
0900006481910e7b,Supporting & Related Material,FDA-2014-P-0724-0012,FDA-2014-P-0724,exhibit 5c fda case report citizen petition from barbara spohn-lillo,0,0
090000648171f1e1,Supporting & Related Material,FDA-2014-P-0724-0003,FDA-2014-P-0724,exhibit 1 petitioner's certification citizen petition from barbara spohn-lillo,0,0
0900006481b03f3a,Other,FDA-2014-P-0724-0013,FDA-2014-P-0724,interim response letter from fda cdrh to rocky mountain anaplastology inc.,0,0
090000648171f40f,Supporting & Related Material,FDA-2014-P-0724-0005,FDA-2014-P-0724,exhibit 3 artificial eye classification citizen petition from barbara spohn-lillo,0,0
090000648171f414,Supporting & Related Material,FDA-2014-P-0724-0010,FDA-2014-P-0724,exhibit 8 fda prosthesis vs. implant citizen petition from barbara spohn-lillo,0,0
0900006481910e81,Other,FDA-2014-P-0724-0002,FDA-2014-P-0724,acknowledgement letter from fda ddm to barbara spohn-lillo november 2014,0,0
0900006481910e5b,Supporting & Related Material,FDA-2014-P-0724-0011,FDA-2014-P-0724,exhibit 5b fda prosthesis vs. implant citizen petition from barbara spohn-lillo,0,0
090000648171f40e,Supporting & Related Material,FDA-2014-P-0724-0004,FDA-2014-P-0724,exhibit 2 supporting precedent citizen petition from barbara spohn-lillo,0,0
0900006481910e31,Other,FDA-2014-P-0724-0001,FDA-2014-P-0724,citizen petition from barbara spohn-lillo,0,0
090000648171f412,Supporting & Related Material,FDA-2014-P-0724-0008,FDA-2014-P-0724,exhibit 6 scleral shell definition citizen petition from barbara spohn-lillo,0,0
0900006481922a01,Other,FDA-2014-P-1883-0001,FDA-2014-P-1883,citizen petition from lannett holdings inc.,0,0
0900006481922a09,Other,FDA-2014-P-1883-0002,FDA-2014-P-1883,acknowledgement letter from fda ddm to lannett holdings inc.,0,0
09000064819b10b3,Other,FDA-2014-P-1883-0006,FDA-2014-P-1883,response letter from fda cder to lannett holdings inc.,0,0
0900006481922a07,Supporting & Related Material,FDA-2014-P-1883-0004,FDA-2014-P-1883,exhibit 2 drug product list citzen petition from lannett holdings inc.,0,0
0900006481922a06,Supporting & Related Material,FDA-2014-P-1883-0003,FDA-2014-P-1883,exhibit 1 orange book information citzen petition from lannett holdings inc.,0,0
0900006481922a08,Supporting & Related Material,FDA-2014-P-1883-0005,FDA-2014-P-1883,exhibit 3 medicare part d information citzen petition from lannett holdings inc.,0,0
0900006481763f61,Other,FDA-2014-P-0878-0001,FDA-2014-P-0878,citizen petition from amarin pharma inc.,0,0
0900006481763f63,Other,FDA-2014-P-0878-0002,FDA-2014-P-0878,acknowledgement letter from fda ddm to amarin pharma inc.,0,0
0900006481949658,Other,FDA-2014-P-0878-0006,FDA-2014-P-0878,"denial petition response letter from fda cder  to amarin pharma, inc.",0,0
090000648235df5e,Proposed Rule,FDA-2016-D-2841-0001,FDA-2016-D-2841,"describing a hazard that needs control in documents accompanying 
the food, as required by four rules implementing the fda food safety 
modernization act: guidance for industry; availability",1,0
0900006482357f82,Supporting & Related Material,FDA-2016-D-2841-0003,FDA-2016-D-2841,"reference 1 - grocery manufacturers association 21 cfr 117.136 industry impacts from disclosure and written assurance requirements re describing a hazard that needs control in documents accompanying the food, as required by four rules implementing the fda food safety modernization act: guidance for industry; availability",1,0
0900006482357e58,Other,FDA-2016-D-2841-0002,FDA-2016-D-2841,"draft guidance for draft guidance for describing a hazard that needs control in documents accompanying the food, as required by four rules implementing the fda food safety modernization act",1,0
0900006482470618,Notice,FDA-2017-N-0086-0001,FDA-2017-N-0086,"suggestions, recommendations, and comments for topics that may be 
considered by the food and drug administration combination product 
policy council; establishment of a docket",1,0
090000648253d819,Other,FDA-2017-P-2131-0002,FDA-2017-P-2131,acknowledgment letter from fda ddm to menn law firm ltd,0,0
090000648253db62,Other,FDA-2017-P-2131-0001,FDA-2017-P-2131,citizen petition from menn law firm ltd,0,0
0900006482a8cc80,Other,FDA-2017-P-2131-0003,FDA-2017-P-2131,citizen petition withdrawal letter,0,0
09000064841e7fa5,Other,FDA-2019-P-3855-0026,FDA-2019-P-3855,"amendment to citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e531e0,Other,FDA-2019-P-3855-0001,FDA-2019-P-3855,"citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006484289a14,Other,FDA-2019-P-3855-0027,FDA-2019-P-3855,petition response letter from fda cder to latham watkins llp,0,0
0900006483e55590,Other,FDA-2019-P-3855-0002,FDA-2019-P-3855,"acknowledgment letter from fda dms to latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e5322c,Supporting & Related Material,FDA-2019-P-3855-0014,FDA-2019-P-3855,"exhibit 012 - aug  20, 2013 pre-ind meeting request - written responses-  re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e53234,Supporting & Related Material,FDA-2019-P-3855-0016,FDA-2019-P-3855,"exhibit 014 - may 7, 2019 lannett form 10-q- re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e531e4,Supporting & Related Material,FDA-2019-P-3855-0003,FDA-2019-P-3855,"exhibit 001 - june 15, 2015 meeting preliminary comments from fda to genus- re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e53237,Supporting & Related Material,FDA-2019-P-3855-0019,FDA-2019-P-3855,"exhibit 017 - jan 6, 2019 lannett (lci) q2 2019 - results earnings call transcript - re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e53228,Supporting & Related Material,FDA-2019-P-3855-0010,FDA-2019-P-3855,"exhibit 008 - feb 1, 2019 citizen petition from k l gates on behalf of genus-  re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e53236,Supporting & Related Material,FDA-2019-P-3855-0018,FDA-2019-P-3855,"exhibit 016 - aug 20, 2018 special investor conference call, verbatim report of webcast by lannett - re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e53238,Supporting & Related Material,FDA-2019-P-3855-0020,FDA-2019-P-3855,"exhibit 018 - july 1, 2019 response to citizen petition from fda to k l gates on behalf of genus - re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e53224,Supporting & Related Material,FDA-2019-P-3855-0006,FDA-2019-P-3855,"exhibit 004 - nov_ 7, 2018 lannett (lci) q1 2019 results - earnings call transcript- re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e531e5,Supporting & Related Material,FDA-2019-P-3855-0004,FDA-2019-P-3855,"exhibit 002 - july 10, 2015 response to preliminary comments from genus to fda-  re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e5322d,Supporting & Related Material,FDA-2019-P-3855-0015,FDA-2019-P-3855,"exhibit 013 - unapproved labeling for lannett's cocaine hydrochloride product - re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e53235,Supporting & Related Material,FDA-2019-P-3855-0017,FDA-2019-P-3855,"exhibit 015 - nov 8, 2018 lannett form 10-q - re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e531e6,Supporting & Related Material,FDA-2019-P-3855-0005,FDA-2019-P-3855,"exhibit 003 - july 15, 2015 meeting minutes from fda to genus-  re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e5323a,Supporting & Related Material,FDA-2019-P-3855-0022,FDA-2019-P-3855,"exhibit 020 - june 24, 2004 response to citizen petition from fda to genpharm - re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e53225,Supporting & Related Material,FDA-2019-P-3855-0007,FDA-2019-P-3855,"exhibit 005 - dec_ 1, 2017 press release, lannett co-  re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e5322a,Supporting & Related Material,FDA-2019-P-3855-0012,FDA-2019-P-3855,"exhibit 010 - feb 24, 2012 citizen petition from lannettet -  re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e53229,Supporting & Related Material,FDA-2019-P-3855-0011,FDA-2019-P-3855,"exhibit 009 - july 3, 2019 press release, lannett co-  re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e5322b,Supporting & Related Material,FDA-2019-P-3855-0013,FDA-2019-P-3855,"exhibit 011 - nov 12, 2015 response to citizen petition from fda to lannett- re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
09000064841d8190,Other,FDA-2019-P-3855-0025,FDA-2019-P-3855,"amendment to citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e53226,Supporting & Related Material,FDA-2019-P-3855-0008,FDA-2019-P-3855,"exhibit 006 - nct02500836- clinical trials -  re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e53227,Supporting & Related Material,FDA-2019-P-3855-0009,FDA-2019-P-3855,"exhibit 007 - nct01746940- clinical trials -  re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
0900006483e53239,Supporting & Related Material,FDA-2019-P-3855-0021,FDA-2019-P-3855,"exhibit 019 - may 25, 2011 response to citizen petition from fda to mutual - re: citizen petition from latham & watkins, llp on behalf of genus lifesciences, inc",0,0
09000064848d3167,Other,FDA-2019-P-5440-0003,FDA-2019-P-5440,interim response letter from fda cder to diane kramer,0,0
0900006484176411,Other,FDA-2019-P-5440-0001,FDA-2019-P-5440,citizen petition from diane kramer,0,0
0900006484a34ada,Other,FDA-2019-P-5440-0004,FDA-2019-P-5440,response letter from fda cder to diane kramer,0,0
0900006484176412,Other,FDA-2019-P-5440-0002,FDA-2019-P-5440,acknowledgement letter from fda dms to diane kramer,0,0
0900006484be4b08,Other,FDA-2019-D-1997-0002,FDA-2019-D-1997,"fda oversight of food products covered by systems recognition arrangements: 
guidance for food and drug administration staff draft guidance",1,0
0900006484be41db,Notice,FDA-2019-D-1997-0001,FDA-2019-D-1997,food and drug administration oversight of food products covered by systems recognition arrangements; draft guidance for food and drug administration staff; availability,1,0
09000064824e9e20,Other,FDA-1998-P-0257-0005,FDA-1998-P-0257,nisin citizen petition response letter,0,0
090000648253dc0b,Other,FDA-1998-P-0257-0006,FDA-1998-P-0257,2017-03-02 nisin citizen petition response letter,0,0
0900006480594b7b,Other,FDA-1998-P-0257-0002,FDA-1998-P-0257,acknowledgement letter from fda ddm to stephaine brown,0,0
0900006480594b6a,Other,FDA-1998-P-0257-0001,FDA-1998-P-0257,citizen petition from stephanie heather brown,0,0
0900006480594b7e,Other,FDA-1998-P-0257-0003,FDA-1998-P-0257,interim letter from cfsan to stephanie heather brown,0,0
09000064824c6b63,Supporting & Related Material,FDA-1998-P-0257-0004,FDA-1998-P-0257,exibit 1 re cititzen petition from stephaine brown,0,0
0900006484a87a8f,Other,FDA-2021-P-0337-0002,FDA-2021-P-0337,acknowledgment letter from fda dms to siri and glimstad llp on behalf of informed consent action network,0,0
0900006484a87a8d,Other,FDA-2021-P-0337-0001,FDA-2021-P-0337,citizen petition from siri and glimstad llp on behalf of informed consent action network,0,0
0900006484d9ce93,Other,FDA-2021-P-0337-0004,FDA-2021-P-0337,"interim response from fda cber to siri & glimstad, llp",0,0
0900006484a87a91,Supporting & Related Material,FDA-2021-P-0337-0003,FDA-2021-P-0337,cover letter from siri and glimstad llp on behalf of informed consent action network,0,0
09000064835d813f,Other,FDA-2018-P-3076-0001,FDA-2018-P-3076,citizen petition from dr. joseph purita,0,0
09000064835d82cf,Other,FDA-2018-P-3076-0002,FDA-2018-P-3076,acknowledgment letter from fda ddm to dr. joseph purita,0,0
0900006483a3152a,Other,FDA-2018-P-3076-0003,FDA-2018-P-3076,interim response letter from fda cder to dr. joseph purita,0,0
0900006483df5d6c,Other,FDA-2018-P-3076-0004,FDA-2018-P-3076,response letter from fda cder to dr. joseph purita,0,0
0900006480f4d339,Other,FDA-2011-D-0721-0002,FDA-2011-D-0721,guidance for industry implementation of the fee provisions of section 107 of the fda food safety modernization act,1,0
0900006480f4d3c5,Notice,FDA-2011-D-0721-0001,FDA-2011-D-0721,guidance for industry on implementation of the fee provisions of the fda food safety modernization act; availability,1,0
090000648290df41,Supporting & Related Material,FDA-2017-P-4145-0004,FDA-2017-P-4145,"attachment 2 draft insert labeling proposed for azacitidine for injection re citizen petition from mylan pharmaceuticals, inc",0,0
090000648290dc10,Other,FDA-2017-P-4145-0001,FDA-2017-P-4145,"citizen petition from mylan pharmaceuticals, inc",0,0
090000648290dc12,Other,FDA-2017-P-4145-0002,FDA-2017-P-4145,acknowledgement letter from fda ddm to mylan pharmaceuticals inc,0,0
090000648290df42,Supporting & Related Material,FDA-2017-P-4145-0005,FDA-2017-P-4145,"attachment 3 labeling for reference listed drug vidaza re citizen petition from mylan pharmaceuticals, inc",0,0
090000648290df40,Supporting & Related Material,FDA-2017-P-4145-0003,FDA-2017-P-4145,"attachment 1 approved drug products with therapeutic equivalence evaluations re citizen petition from mylan pharmaceuticals, inc",0,0
09000064810109e1,Supporting & Related Material,FDA-2012-D-0140-0008,FDA-2012-D-0140,see fda-2012-d-0140-0006,0,0
0900006480fc306a,Notice,FDA-2012-D-0140-0001,FDA-2012-D-0140,draft guidance for industry on notification to food and drug administration of issues that may result in a prescription drug shortage; availability,1,0
0900006480fc3d57,Other,FDA-2012-D-0140-0002,FDA-2012-D-0140,notification to fda of issues that may result in a prescription drug or biological product shortage,0,0
0900006481d93908,Other,FDA-2015-A-4705-0001,FDA-2015-A-4705,"advisory opinion petition from luedeka neely group, p.c. on behalf of consorzio del formaggio parmigiano-reggiano",0,0
0900006481d93bc4,Other,FDA-2015-A-4705-0002,FDA-2015-A-4705,"acknowledgement letter from fda ddm to luedeka neely group, p.c. on behalf of consorzio del formaggio parmigiano-reggiano",0,0
09000064825833c8,Other,FDA-2015-A-4705-0003,FDA-2015-A-4705,fda-2015-a-4705 withdrawal of petition,0,0
09000064815b0f68,Notice,FDA-2013-D-1600-0001,FDA-2013-D-1600,"draft guidance for industry and tobacco retailers; enforcement policy
for certain (provisional) tobacco products that the food and drug
administration finds not substantially equivalent; availability",1,1
0900006481c6c25e,Notice,FDA-2013-D-1600-0007,FDA-2013-D-1600,"enforcement policy for certain (provisional) tobacco products that
the food and drug administration finds not substantially equivalent;
guidance for industry and tobacco retailers; availability",1,1
0900006481c6cf3b,Other,FDA-2013-D-1600-0008,FDA-2013-D-1600,enforcement policy for certain (provisional) tobacco products that fda finds not substantially equivalent; guidance for industry and tobacco retailers,0,1
09000064815b2337,Other,FDA-2013-D-1600-0002,FDA-2013-D-1600,"draft guidance for industry and tobacco retailers; enforcement policy
for certain (provisional) tobacco products that the food and drug
administration finds not substantially equivalent",1,1
0900006481953f5c,Notice,FDA-2013-D-0295-0010,FDA-2013-D-0295,"guidance for industry on scale-up post-approval changes:
manufacturing equipment addendum; availability",0,0
0900006481251f6d,Other,FDA-2013-D-0295-0002,FDA-2013-D-0295,"draft guidance for industry; scale-up and post-approval changes, manufacturing equipment addendum",0,0
0900006481252361,Notice,FDA-2013-D-0295-0001,FDA-2013-D-0295,"draft guidance for industry; availability: scale-up and post-approval changes, manufacturing equipment addendum",0,0
0900006481954f47,Other,FDA-2013-D-0295-0011,FDA-2013-D-0295,"guidance for industry on scale-up post-approval changes:
manufacturing equipment addendum",0,0
0900006484145cee,Other,FDA-2019-P-2239-0008,FDA-2019-P-2239,interim response letter from fda to bioneutra north america inc,0,0
0900006483c4568b,Supporting & Related Material,FDA-2019-P-2239-0003,FDA-2019-P-2239,appendix a -  re citizen petition from bioneutra north america inc,0,0
0900006483c4568c,Supporting & Related Material,FDA-2019-P-2239-0004,FDA-2019-P-2239,appendix a - fda re citizen petition from bioneutra north america inc,0,0
0900006483c45614,Other,FDA-2019-P-2239-0001,FDA-2019-P-2239,citizen petition from bioneutra north america inc,0,0
0900006483c45689,Other,FDA-2019-P-2239-0002,FDA-2019-P-2239,acknowledgement letter from fda ddm to bioneutra north america inc,0,0
0900006484291e7a,Other,FDA-2019-P-2239-0009,FDA-2019-P-2239,final response letter from fda to bioneutra north america inc,0,0
0900006482af743c,Other,FDA-2017-P-1298-0091,FDA-2017-P-1298,interim response letter from fda cfsan to the good food institute,1,0
090000648445b23c,Other,FDA-2017-P-1298-0302,FDA-2017-P-1298,supplement from the good food institute,1,0
09000064824e6abe,Other,FDA-2017-P-1298-0001,FDA-2017-P-1298,citizen petition from the good food institute,1,0
09000064824e6b25,Supporting & Related Material,FDA-2017-P-1298-0004,FDA-2017-P-1298,attachment b orders from federal court cases - gitson and ang re citizen petition from the good food institute,1,0
09000064824e6ac0,Other,FDA-2017-P-1298-0002,FDA-2017-P-1298,acknowledgement letter from fda ddm to the good food institute,1,0
0900006482aed82e,Other,FDA-2017-P-1298-0064,FDA-2017-P-1298,supplement from the good food institute,1,0
09000064824e6b24,Supporting & Related Material,FDA-2017-P-1298-0003,FDA-2017-P-1298,"attachment a soyfoods association of north america, summary of consumer research re citizen petition from the good food institute",1,0
090000648243acf7,Supporting & Related Material,FDA-2016-P-4388-0003,FDA-2016-P-4388,"baker, a pharmacological review 2007 re. citizen petition from s. varghese",0,0
090000648243acf8,Supporting & Related Material,FDA-2016-P-4388-0004,FDA-2016-P-4388,citizen petition reference list re. citizen petition from s. varghese,0,0
09000064826f191b,Other,FDA-2016-P-4388-0009,FDA-2016-P-4388,interim response letter from fda cder to dr. s. varghese,0,0
0900006482b249b2,Other,FDA-2016-P-4388-0010,FDA-2016-P-4388,chpa response to citizen petition loperamide otc to rx 090517 final,0,0
090000648243acf9,Supporting & Related Material,FDA-2016-P-4388-0005,FDA-2016-P-4388,loperamide abuse and dependence 2015 re. citizen petition from s. varghese,0,0
090000648243acfa,Supporting & Related Material,FDA-2016-P-4388-0006,FDA-2016-P-4388,"loperamide induced tdp, re. citizen petition from s. varghese",0,0
090000648240c140,Other,FDA-2016-P-4388-0002,FDA-2016-P-4388,acknowledgment letter from fda ddm to dr. s. varghese,0,0
090000648243acfb,Supporting & Related Material,FDA-2016-P-4388-0007,FDA-2016-P-4388,"poor man's methadone, re. citizen petition from s. varghese",0,0
090000648240c13d,Other,FDA-2016-P-4388-0001,FDA-2016-P-4388,citizen petition from dr. s. varghese,0,0
090000648499895d,Other,FDA-2016-P-4388-0013,FDA-2016-P-4388,response letter from fda cder to dr. s. varghese,0,0
09000064849a9a01,Supporting & Related Material,FDA-2020-P-2312-0002,FDA-2020-P-2312,memo from fda dms to phibro,0,0
09000064849a887b,Other,FDA-2020-P-2312-0001,FDA-2020-P-2312,petition from covington & burling llp,0,0
09000064835e8806,Other,FDA-2018-P-0673-0009,FDA-2018-P-0673,interim response from fda cder to justice for jake,0,0
0900006484a3b7c6,Other,FDA-2018-P-0673-0011,FDA-2018-P-0673,response letter from fda cder to justice for jake,0,0
0900006482f1adff,Other,FDA-2018-P-0673-0001,FDA-2018-P-0673,citizen petition from justice for jake,0,0
0900006482f1ae53,Supporting & Related Material,FDA-2018-P-0673-0003,FDA-2018-P-0673,"attachment one, 239 signed form letters re citizen petition from justice for jake",0,0
0900006482f1ae01,Other,FDA-2018-P-0673-0002,FDA-2018-P-0673,acknowledgment letter from fda ddm to justice for jake,0,0
0900006484be90d7,Other,FDA-2021-P-0714-0002,FDA-2021-P-0714,acknowledgment letter from fda dms to lassman law + policy,0,0
0900006484be90da,Supporting & Related Material,FDA-2021-P-0714-0003,FDA-2021-P-0714,exhibits re citizen petition from lassman law + policy,0,0
0900006484be90d5,Other,FDA-2021-P-0714-0001,FDA-2021-P-0714,citizen petition from lassman law + policy,0,0
090000648436075f,Supporting & Related Material,FDA-2020-P-0763-0003,FDA-2020-P-0763,doubts about the efficacy of tolvaptan for polycystic kidney disease re citizen petition from clark anderson,0,0
0900006484c02749,Other,FDA-2020-P-0763-0005,FDA-2020-P-0763,response letter from fda cder to clark anderson,0,0
09000064847e402a,Other,FDA-2020-P-0763-0004,FDA-2020-P-0763,interim response from fda cder to clark anderson,0,0
090000648435c5b7,Other,FDA-2020-P-0763-0002,FDA-2020-P-0763,acknowledgment letter from fda dms to clark anderson,0,0
090000648435c1d7,Other,FDA-2020-P-0763-0001,FDA-2020-P-0763,citizen petition from clark anderson,0,0
0900006484aa7666,Other,FDA-2021-P-0389-0001,FDA-2021-P-0389,citizen petition from idrs labs private limited,0,0
0900006484ca5f9e,Other,FDA-2021-P-0389-0003,FDA-2021-P-0389,response letter from fda cder to idrs labs private limited,0,0
0900006484aa7668,Other,FDA-2021-P-0389-0002,FDA-2021-P-0389,acknowledgement letter from fda dms to idrs labs private limited,0,0
0900006482054403,Other,FDA-2005-P-0198-0003,FDA-2005-P-0198,petition closure memorandum from fda cfsan,0,0
09000064804410e5,Other,FDA-2005-P-0198-0002,FDA-2005-P-0198,interim response letter from fda cfsan to perricone juices,0,0
09000064804410c3,Other,FDA-2005-P-0198-0001,FDA-2005-P-0198,acknowledgment letter from fda ddm to perricone juices,0,0
09000064809b8f1e,Notice,FDA-2008-D-0253-0001,FDA-2008-D-0253,draft guidance for industry on presenting risk information in prescription drug and medical device promotion; availability,0,0
09000064809b8fbb,Other,FDA-2008-D-0253-0002,FDA-2008-D-0253,presenting risk information in prescription drug and medical device promotion,0,0
0900006482f0221b,Other,FDA-2018-P-0625-0002,FDA-2018-P-0625,acknowledgment letter from fda ddm to made in the usa foundation,0,0
0900006482f0221f,Supporting & Related Material,FDA-2018-P-0625-0005,FDA-2018-P-0625,exhibit 3 re citizen petition from made in the usa foundation-2,0,0
0900006482f0221e,Supporting & Related Material,FDA-2018-P-0625-0004,FDA-2018-P-0625,exhibit 2 re citizen petition from made in the usa foundation-2,0,0
09000064835e5aca,Other,FDA-2018-P-0625-0007,FDA-2018-P-0625,interim response from fda cder to made in the usa foundation,0,0
0900006482f02219,Other,FDA-2018-P-0625-0001,FDA-2018-P-0625,citizen petition from made in the usa foundation,0,0
0900006482f0221d,Supporting & Related Material,FDA-2018-P-0625-0003,FDA-2018-P-0625,exhibit 1 re citizen petition from made in the usa foundation,0,0
0900006483dd0f53,Other,FDA-2018-P-0625-0008,FDA-2018-P-0625,letter from fda cder to made in the usa foundation,0,0
0900006483e655e2,Other,FDA-2019-P-3886-0002,FDA-2019-P-3886,acknowledgment letter from fda dms to turner scientific,0,0
0900006483e65647,Supporting & Related Material,FDA-2019-P-3886-0003,FDA-2019-P-3886,attachment 1 guidance document submission - ototoxicity - nonclinical evaluation during drug development re citizen petition from turner scientific,0,0
0900006483eadcce,Other,FDA-2019-P-3886-0004,FDA-2019-P-3886,citizen petition withdrawal request from turner scientific llc to fda dms,0,0
0900006483e655e1,Other,FDA-2019-P-3886-0001,FDA-2019-P-3886,citizen petition from turner scientific,0,0
09000064813b64a7,Other,FDA-2013-P-0425-0003,FDA-2013-P-0425,"fda/cder to rhodes technologies (kleinfeld, kaplan and becker, llp) - denial of petition",0,0
09000064812921cf,Other,FDA-2013-P-0425-0002,FDA-2013-P-0425,"acknowledgement letter to rhodes technologies (kleinfeld, kaplan and becker, llp)",0,0
0900006481292188,Other,FDA-2013-P-0425-0001,FDA-2013-P-0425,"rhodes technologies (kleinfeld, kaplan and becker, llp) - citizen petition",0,0
0900006483a73d13,Supporting & Related Material,FDA-2019-P-0726-0004,FDA-2019-P-0726,attachment 2 insert- fxt 60mg-alvogen re suitability citizen petition from sunny pharmtech inc,0,0
0900006483a73d14,Supporting & Related Material,FDA-2019-P-0726-0005,FDA-2019-P-0726,attachment 3 draft labeling text-0212bm re suitability citizen  petition from sunny pharmtech inc,0,0
0900006483a73d15,Supporting & Related Material,FDA-2019-P-0726-0006,FDA-2019-P-0726,attachment 4 annotated comparison with listed drug-0212-bm re suitability citizen petition from sunny pharmtech inc,0,0
0900006483a73a87,Other,FDA-2019-P-0726-0001,FDA-2019-P-0726,suitability citizen petition from sunny pharmtech inc,0,0
0900006483a73a89,Other,FDA-2019-P-0726-0002,FDA-2019-P-0726,acknowledgment letter from fda ddm to sunny pharmtech inc,0,0
0900006483a73d12,Supporting & Related Material,FDA-2019-P-0726-0003,FDA-2019-P-0726,attachment 1 orange book approved drug products with therapeutic equivalence evaluations re suitability citizen  petition from sunny pharmtech inc,0,0
0900006482e530d5,Supporting & Related Material,FDA-2018-P-0339-0004,FDA-2018-P-0339,"attachment 2 labeling for listed drug, treanda cephalon, inc. re: citizen petition from hahn loeser & parks llp",0,0
0900006482e530d6,Supporting & Related Material,FDA-2018-P-0339-0005,FDA-2018-P-0339,attachment 3 draft insert labeling proposed for bendamustine hydrochloride for injection (200 mg) re: citizen petition from hahn loeser & parks llp,0,0
0900006482e4f7a1,Other,FDA-2018-P-0339-0001,FDA-2018-P-0339,citizen petition from hahn loeser and parks llp,0,0
0900006482e530d4,Supporting & Related Material,FDA-2018-P-0339-0003,FDA-2018-P-0339,"attachment 1 approved drug products with therapeutic equivalence evaluations, november 13, 2017 accessed.  re: citizen petition from  hahn loeser & parks llp",0,0
09000064837ec68a,Other,FDA-2018-P-0339-0006,FDA-2018-P-0339,letter from hahn loeser & parks llp to fda cder-ogd,0,0
0900006482e4f7a5,Other,FDA-2018-P-0339-0002,FDA-2018-P-0339,acknowledgment letter from fda ddm hahn loeser & parks llp,0,0
090000648183b320,Notice,FDA-2013-N-0745-0053,FDA-2013-N-0745,"reopening of docket and request for comments on the food and drug
administration safety and innovation act action plan",1,0
09000064815f6b9f,Proposed Rule,FDA-2013-N-0745-0022,FDA-2013-N-0745,"action plan for the collection, analysis, and availability of demographic subgroup data in applications for approval of food and drug administration-regulated medical products; notice of public
hearing; request for comments",1,0
09000064813bf052,Notice,FDA-2013-N-0745-0001,FDA-2013-N-0745,request for comments on the food and drug administration safety and innovation act section 907 report,1,0
0900006482b0317c,Other,FDA-2015-P-0578-0005,FDA-2015-P-0578,letter from fda to public citizen's health research group,0,0
0900006481a12b71,Other,FDA-2015-P-0578-0001,FDA-2015-P-0578,citizen petition from public citizen's health research group,0,0
0900006481e04f0b,Other,FDA-2015-P-0578-0004,FDA-2015-P-0578,interim response from fda cder to public citizen's health research group,0,0
0900006481a14d83,Other,FDA-2015-P-0578-0002,FDA-2015-P-0578,acknowledgement letter from fda ddm to public citizen's health research group,0,0
0900006481a12b74,Supporting & Related Material,FDA-2015-P-0578-0003,FDA-2015-P-0578,background material from public citizen citizen petition from public citizen's health research group,0,0
0900006482cf38d4,Other,FDA-2017-N-6313-0002,FDA-2017-N-6313,prescription drug user fee act vi commitment to assess current practices of the food and drug administration and sponsors in communicating during investigational new drug development; establishment of a public docket; request for comments,1,0
0900006482cf28d9,Notice,FDA-2017-N-6313-0001,FDA-2017-N-6313,"prescription drug user fee act vi commitment to assess current  practices of the food and drug administration and sponsors in
communicating during investigational new drug development; establishment of a public docket; request for comments",1,0
0900006482548a0e,Other,FDA-2017-P-2230-0002,FDA-2017-P-2230,"acknowledgment letter from fda ddm to kleinfeld, kaplan and becker, llp  (purdue pharma l.p.)",0,0
0900006482548946,Other,FDA-2017-P-2230-0001,FDA-2017-P-2230,"citizen petition from kleinfeld, kaplan and becker, llp  (purdue pharma l.p.)",0,0
0900006482b15e2c,Other,FDA-2017-P-2230-0005,FDA-2017-P-2230,"citizen petition response letter from fda cder to kleinfeld, kaplan and becker, llp",0,0
0900006481756b2b,Other,FDA-2014-P-0830-0002,FDA-2014-P-0830,"acknowledgement letter from fda ddm to merz north america (buchanan, ingersoll and rooney pc)",0,0
090000648235806c,Other,FDA-2014-P-0830-0006,FDA-2014-P-0830,"denial letter from fda cder to merz north america (buchanan, ingersoll and rooney pc)",0,0
09000064819f250c,Other,FDA-2014-P-0830-0004,FDA-2014-P-0830,interim response,0,0
0900006481756b28,Other,FDA-2014-P-0830-0001,FDA-2014-P-0830,"citizen petition from merz north america (buchanan, ingersoll and rooney pc)",0,0
09000064836b2b36,Other,FDA-2018-P-3355-0003,FDA-2018-P-3355,citizen petition from oregon pain guidance,0,0
0900006483ab67ae,Other,FDA-2018-P-3355-0017,FDA-2018-P-3355,interim response from fda cder,0,0
09000064836a7fbf,Other,FDA-2018-P-3355-0002,FDA-2018-P-3355,acknowledgment letter from fda ddm to oregon pain guidance,0,0
09000064836a816f,Other,FDA-2018-P-3355-0001,FDA-2018-P-3355,citizen petition from oregon pain guidance,0,0
09000064836b2beb,Supporting & Related Material,FDA-2018-P-3355-0004,FDA-2018-P-3355,attachments re citizen petition from oregon pain guidance,0,0
09000064836e1b92,Other,FDA-2018-P-3355-0005,FDA-2018-P-3355,acknowledgment letter from fda ddm to oregon pain guidance,0,0
09000064848f91dd,Other,FDA-2020-P-2067-0001,FDA-2020-P-2067,"suitability petition from hyman, phelps & mcnamara, pc",0,0
09000064848f91e2,Supporting & Related Material,FDA-2020-P-2067-0004,FDA-2020-P-2067,"attachment 2 re suitability petition from hyman, phelps & mcnamara, pc",0,0
09000064848f91de,Other,FDA-2020-P-2067-0002,FDA-2020-P-2067,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, pc",0,0
09000064848f91e3,Supporting & Related Material,FDA-2020-P-2067-0005,FDA-2020-P-2067,"attachment 3 re suitability petition from hyman, phelps & mcnamara, pc",0,0
09000064848f91e1,Supporting & Related Material,FDA-2020-P-2067-0003,FDA-2020-P-2067,"attachment 1 re suitability petition from hyman, phelps & mcnamara, pc",0,0
09000064846f6807,Other,FDA-2020-P-1582-0002,FDA-2020-P-1582,acknowledgment letter from fda dms to council for responsible nutrition,0,0
09000064849717c4,Other,FDA-2020-P-1582-0004,FDA-2020-P-1582,180 day interim response letter to the council for response nutrition from fda cfsan,0,0
09000064846f66ef,Other,FDA-2020-P-1582-0001,FDA-2020-P-1582,citizen petition from the council for responsible nutrition,0,0
0900006482f64093,Supporting & Related Material,FDA-2018-P-0870-0003,FDA-2018-P-0870,"attachment 1 orange book: approved drug products with therapeutic equivalence evaluations re: citizen petition from  lachman consultant services, inc.",0,0
0900006482f64095,Supporting & Related Material,FDA-2018-P-0870-0005,FDA-2018-P-0870,"attachment 3-potassium chloride extended release tablet proposed geriatric and overdosage labeling re:  citizen petition from lachman consultant services, inc.",0,0
09000064849224ac,Other,FDA-2018-P-0870-0006,FDA-2018-P-0870,"letter from lachman consultant services, inc.",0,0
0900006482f63aee,Other,FDA-2018-P-0870-0001,FDA-2018-P-0870,"citizen petition from lachman consultant services, inc.",0,0
0900006482f64091,Other,FDA-2018-P-0870-0002,FDA-2018-P-0870,"acknowledgment letter from fda ddm to lachman consultant services, inc.",0,0
0900006482f64094,Supporting & Related Material,FDA-2018-P-0870-0004,FDA-2018-P-0870,"attachment 2- prescription drug product list re: citizen petition from lachman consultant services, inc.",0,0
0900006483e2d63e,Notice,FDA-2019-N-3453-0001,FDA-2019-N-3453,promoting effective drug development programs: opportunities and priorities for the food and drug administration’s office of new drugs,1,0
0900006483b69f9f,Other,FDA-2019-P-1640-0002,FDA-2019-P-1640,"acknowledgment letter from fda ddm to top health ingredients, inc",0,0
0900006483b69fa4,Supporting & Related Material,FDA-2019-P-1640-0004,FDA-2019-P-1640,"appendix 2 re citizen petition from top health ingredients, inc",0,0
0900006484109bf5,Other,FDA-2019-P-1640-0008,FDA-2019-P-1640,"interim response letter from fda cfsan to top health ingredients, inc",0,0
09000064842ea5b1,Other,FDA-2019-P-1640-0011,FDA-2019-P-1640,"letter from fda cfsan to top health ingredients, inc.",0,0
0900006484291eca,Other,FDA-2019-P-1640-0010,FDA-2019-P-1640,"final response letter from fda cfsan to top health ingredients, inc",0,0
0900006483b69fa3,Supporting & Related Material,FDA-2019-P-1640-0003,FDA-2019-P-1640,"appendix 1 re citizen petition from top health ingredients, inc",0,0
0900006483b69f92,Other,FDA-2019-P-1640-0001,FDA-2019-P-1640,"citizen petition from top health ingredients, inc.",0,0
09000064849a9202,Other,FDA-2020-P-2313-0002,FDA-2020-P-2313,petition for stay of action from covington & burling llp,0,0
09000064849a9a02,Supporting & Related Material,FDA-2020-P-2313-0001,FDA-2020-P-2313,memo from fda dms to phibro,0,0
0900006484ad87e3,Supporting & Related Material,FDA-2021-P-0438-0003,FDA-2021-P-0438,attachment 1-  national toxicology program technical report re: citizen petition from joe dinardo,0,0
0900006484ad87e4,Supporting & Related Material,FDA-2021-P-0438-0004,FDA-2021-P-0438,attachment 2- per and polyfluoroalkyl substances (pfas)  fda re: citizen petition from joe dinardo,0,0
0900006484ad56b5,Other,FDA-2021-P-0438-0002,FDA-2021-P-0438,acknowledgment  letter from fda dms  to  joe dinardo,0,0
0900006484ad55fe,Other,FDA-2021-P-0438-0001,FDA-2021-P-0438,citizen petition from joe dinardo,0,0
0900006484ad87e6,Supporting & Related Material,FDA-2021-P-0438-0006,FDA-2021-P-0438,attachment 4 safer chemicals healthy families. mcdonalds re: citizen petition from joe dinardo,0,0
0900006484ad87e7,Supporting & Related Material,FDA-2021-P-0438-0007,FDA-2021-P-0438,attachment 5- detroit metrotimes. some michigan cows  re: citizen petition from joe dinardo,0,0
0900006484ad87e5,Supporting & Related Material,FDA-2021-P-0438-0005,FDA-2021-P-0438,attachment 3- fda.gov- testing food for pfas and assessing dietary exposure re: citizen petition from joe dinardo,1,0
09000064849bae17,Other,FDA-2020-P-2322-0002,FDA-2020-P-2322,acknowledgment letter from fda dms to covington & burling llp on behalf of pharmaceutical research and manufacturers of america,0,0
09000064849bae16,Other,FDA-2020-P-2322-0001,FDA-2020-P-2322,citizen petition from covington & burling llp on behalf of pharmaceutical research and manufacturers of america,0,0
0900006484bac316,Other,FDA-2020-P-2322-0003,FDA-2020-P-2322,interim response to covington & burling llp from fda cder,0,0
090000648048b7c7,Supporting & Related Material,FDA-2003-D-0198-0002,FDA-2003-D-0198,guidance,0,0
090000648048b7c2,Notice,FDA-2003-D-0198-0001,FDA-2003-D-0198,fda,0,0
0900006482b9515d,Other,FDA-2003-D-0198-0003,FDA-2003-D-0198,user fees and refunds for premarket notification submissions (510(k)s) :  guidance for industry and food and drug administration staff,1,0
090000648044a08f,Notice,FDA-2005-N-0351-0002,FDA-2005-N-0351,fda,0,0
090000648044a0c4,Notice,FDA-2005-N-0351-0001,FDA-2005-N-0351,fda,0,0
09000064804816fa,Notice,FDA-2003-N-0039-0003,FDA-2003-N-0039,fda,0,0
09000064804816fc,Notice,FDA-2003-N-0039-0004,FDA-2003-N-0039,fda,0,0
09000064804816f8,Notice,FDA-2003-N-0039-0001,FDA-2003-N-0039,fda,0,0
09000064804816f9,Notice,FDA-2003-N-0039-0002,FDA-2003-N-0039,fda,0,0
09000064804816fe,Supporting & Related Material,FDA-2003-N-0039-0006,FDA-2003-N-0039,supporting statement,0,0
09000064804816fd,Supporting & Related Material,FDA-2003-N-0039-0005,FDA-2003-N-0039,supporting statement,0,0
090000648046fb73,Notice,FDA-2004-D-0120-0001,FDA-2004-D-0120,fda,0,0
0900006480b3e098,Notice,FDA-2010-N-0445-0001,FDA-2010-N-0445,request for applications: supplemental funding under the emergency response laboratory network microbiological cooperative agreement program,0,0
0900006484dcf02d,Other,FDA-2020-D-1380-0004,FDA-2020-D-1380,regulatory requirements for hearing aid devices and personal sound amplification products draft guidance for industry and food and drug administration staff,1,0
0900006484dd6df9,Other,FDA-2020-D-1380-0005,FDA-2020-D-1380,regulatory requirements for hearing aid devices and personal sound amplification products; draft guidance for industry and food and drug administration staff,1,0
09000064845e6c3e,Other,FDA-2020-D-1380-0001,FDA-2020-D-1380,guidance for industry and fda staff; regulatory requirements for hearing aid devices and personal sound amplification products,0,0
0900006484dce4ff,Notice,FDA-2020-D-1380-0003,FDA-2020-D-1380,regulatory requirements for hearing aid devices and personal sound amplification products; draft guidance for industry and food and drug administration staff; availability,1,0
0900006484936fce,Supporting & Related Material,FDA-2020-P-2132-0003,FDA-2020-P-2132,"attachment 1:  drug shortage detail oral suspension re citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484981cf4,Other,FDA-2020-P-2132-0004,FDA-2020-P-2132,"withdrawal from hyman, phelps & mcnamara, p.c.",0,0
0900006484936ab3,Other,FDA-2020-P-2132-0002,FDA-2020-P-2132,"acknowledgement letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
0900006484936aad,Other,FDA-2020-P-2132-0001,FDA-2020-P-2132,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
09000064827c2b7f,Other,FDA-2017-P-0663-0003,FDA-2017-P-0663,"petition denial letter from fda cder to mucodel pharma, llc",0,0
09000064824a56a9,Other,FDA-2017-P-0663-0001,FDA-2017-P-0663,"citizen petition from mucodel pharma, llc",0,0
09000064824a579a,Other,FDA-2017-P-0663-0002,FDA-2017-P-0663,"acknowledgment letter from fda ddm to mucodel pharma, llc",0,0
09000064824d2340,Other,FDA-2017-P-1104-0002,FDA-2017-P-1104,"acknowledgment letter from fda ddm to gator pharmaceuticals, inc.",0,0
09000064840780d6,Other,FDA-2017-P-1104-0008,FDA-2017-P-1104,dismissal of citizen petition  from fda cder to gator pharmaceuticals inc,0,0
0900006482a63cd5,Other,FDA-2017-P-1104-0007,FDA-2017-P-1104,"interim response letter from cder to gator pharmaceuticals, inc.",0,0
09000064824d1d3f,Supporting & Related Material,FDA-2017-P-1104-0003,FDA-2017-P-1104,"attachment 1 colprep kit- sodium sulfate, potassium sulfate, and magnesium sulfate for oral solution powder, for solution re citizen petition from gator pharmaceuticals, inc.",0,0
09000064824d1d3d,Other,FDA-2017-P-1104-0001,FDA-2017-P-1104,"citizen petition from gator pharmaceuticals, inc.",0,0
09000064824d1d40,Supporting & Related Material,FDA-2017-P-1104-0004,FDA-2017-P-1104,"attachment 2 suprep bowel prep- sodium suhate, potassium suhate, magnesium suhate solution, concentrate re citizen petition from gator pharmaceuticals, inc.",0,0
0900006481dcf113,Other,FDA-2014-P-0594-0012,FDA-2014-P-0594,"withdrawal from hyman, phelps & mcnamara, p.c.",0,0
090000648190ddd0,Other,FDA-2014-P-0594-0010,FDA-2014-P-0594,interim response letter from fda/cder to hyman phelps mcnamara p.c.,0,0
090000648170efe2,Supporting & Related Material,FDA-2014-P-0594-0005,FDA-2014-P-0594,exhibit 1 letter from fda cder to ranbaxy inc supplement from teva pharmaceuticals usa inc goodwin procter llp,0,0
09000064816e42cd,Other,FDA-2014-P-0594-0001,FDA-2014-P-0594,citizen petition from hyman phelps mcnamara p.c.,0,0
09000064816e5151,Other,FDA-2014-P-0594-0002,FDA-2014-P-0594,acknowledgement letter from fda ddm to hyman phelps mcnamara pc,0,0
090000648170efe1,Supporting & Related Material,FDA-2014-P-0594-0004,FDA-2014-P-0594,exhibit a letter from teva pharmaceuticals usa inc supplement from teva pharmaceuticals usa inc goodwin procter llp,0,0
09000064816fc98e,Other,FDA-2014-P-0594-0003,FDA-2014-P-0594,"supplement from teva pharmaceuticals usa, inc. goodwin procter llp",0,0
09000064818c2423,Supporting & Related Material,FDA-2014-P-1615-0002,FDA-2014-P-1615,exhibit tabs 1 through 13,0,0
0900006481a14fa0,Other,FDA-2014-P-1615-0004,FDA-2014-P-1615,petition denial response letter,0,0
09000064818bbf25,Other,FDA-2014-P-1615-0001,FDA-2014-P-1615,citizen petition from spectrum pharmaceuticals inc,0,0
09000064818c2425,Other,FDA-2014-P-1615-0003,FDA-2014-P-1615,acknowledgment letter from fda ddm to spectrum pharmaceuticals inc,0,0
0900006482538af9,Supporting & Related Material,FDA-2017-P-2043-0003,FDA-2017-P-2043,"attachment 1 status of inv 45244 - re citizen petition from yiling pharmaceutical, ltd",0,0
0900006482538a12,Other,FDA-2017-P-2043-0002,FDA-2017-P-2043,"acknowledgment lette from fda ddm to yiling pharmaceutical, ltd",0,0
0900006482b847c0,Other,FDA-2017-P-2043-0005,FDA-2017-P-2043,"interim response letter to yiling pharmaceutical, ltd",0,0
0900006482be0d27,Other,FDA-2017-P-2043-0006,FDA-2017-P-2043,response letter from fda to yiling pharmaceuticals,0,0
0900006482538448,Other,FDA-2017-P-2043-0001,FDA-2017-P-2043,"citizen petition from yiling pharmaceutical, ltd",0,0
0900006482538afa,Supporting & Related Material,FDA-2017-P-2043-0004,FDA-2017-P-2043,"attachment 2 re-quote re citizen petition from yiling pharmaceutical, ltd",0,0
0900006482214e24,Supporting & Related Material,FDA-2016-P-2781-0003,FDA-2016-P-2781,"exhibit a nanotherapies for the treatment of ocular diseases re citizen petition from alcon pharmaceuticals, ltd. novartis pharmaceuticals corporation",0,0
0900006482214e22,Other,FDA-2016-P-2781-0002,FDA-2016-P-2781,"acknowledgement letter from fda ddm to alcon pharmaceuticals, ltd.",0,0
0900006482214e25,Supporting & Related Material,FDA-2016-P-2781-0004,FDA-2016-P-2781,"exhibit b generic medications in ophthalmology re citizen petition from alcon pharmaceuticals, ltd. novartis pharmaceuticals corporation",0,0
0900006482214e27,Supporting & Related Material,FDA-2016-P-2781-0005,FDA-2016-P-2781,"exhibit c drug delivery to the ocular posterior segment using lipid emulsion via eye drop administration: effect of emulsion formulations and surface modification re citizen petition from alcon pharmaceuticals, ltd. novartis pharmaceuticals corporation",0,0
0900006482214643,Other,FDA-2016-P-2781-0001,FDA-2016-P-2781,"citizen petition from alcon pharmaceuticals, ltd. novartis pharmaceuticals corporation",0,0
09000064824ba546,Other,FDA-2016-P-2781-0006,FDA-2016-P-2781,citizen petition partial approval and denial response from fda cder to  novartis pharmaceuticals corporation,0,0
0900006481f84dcf,Supporting & Related Material,FDA-2016-P-1180-0007,FDA-2016-P-1180,appendix 4 nondigestible oligosaccharides re advantafiber fda citizen petition,0,0
0900006481f84dff,Supporting & Related Material,FDA-2016-P-1180-0018,FDA-2016-P-1180,appendix 15 the capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans re advantafiber fda citizen petition,0,0
0900006481f84d1e,Supporting & Related Material,FDA-2016-P-1180-0005,FDA-2016-P-1180,appendix 2 will isomalto-oligosaccharides a well-established functional food in asia break through the european and american market re advantafiber fda citizen petition,1,0
0900006481f84dd5,Supporting & Related Material,FDA-2016-P-1180-0013,FDA-2016-P-1180,appendix 10 effects of isomaltooligosaccharides with different degrees of polymerization on human fecal bifidobacteria re advantafiber fda citizen petition,0,0
0900006481f84dd7,Supporting & Related Material,FDA-2016-P-1180-0015,FDA-2016-P-1180,appendix 12 dose-response test of isomaltooligosaccharides for increasing fecal bifidobacteria re advantafiber fda citizen petition,0,0
0900006481f84dfe,Supporting & Related Material,FDA-2016-P-1180-0017,FDA-2016-P-1180,appendix 14 study on the regulative effect of isomalto-oligosaccharides on human intestinal flora re advantafiber fda citizen petition,0,0
0900006481f84e06,Supporting & Related Material,FDA-2016-P-1180-0025,FDA-2016-P-1180,"appendix 22 an in vitro study of the effect of probiotics, prebiotics and synbiotics on the elderly faecal microbiota re advantafiber fda citizen petition",0,0
09000064823e9b98,Supporting & Related Material,FDA-2016-P-1180-0033,FDA-2016-P-1180,appendix 2 qiang - health benefits carbohydrate polymers re appendix table of contents re advantafiber (top health inc.) fda citizen petition submission in response to fda guidance final,0,0
09000064823e9b9a,Supporting & Related Material,FDA-2016-P-1180-0035,FDA-2016-P-1180,appendix 4 gloria - harmful effects of chronic long term constpn re appendix table of contents re advantafiber (top health inc.) fda citizen petition submission in response to fda guidance final,0,0
0900006481f84d1d,Supporting & Related Material,FDA-2016-P-1180-0004,FDA-2016-P-1180,appendix 1 nondigestible oligo- and polysaccharides dietary fiber re advantafiber fda citizen petition,0,0
0900006481f84dd0,Supporting & Related Material,FDA-2016-P-1180-0008,FDA-2016-P-1180,appendix 5 the definition of dietary fiber re advantafiber fda citizen petition,0,0
0900006481f84dd1,Supporting & Related Material,FDA-2016-P-1180-0009,FDA-2016-P-1180,appendix 6 long-term supplementation of isomalto-oligosaccharides improved colonic microflora profile re advantafiber fda citizen petition,0,0
0900006482af5748,Other,FDA-2016-P-1180-0044,FDA-2016-P-1180,"supplement to citizens petition from top health ingredients, inc.",0,0
09000064823e9b9f,Supporting & Related Material,FDA-2016-P-1180-0040,FDA-2016-P-1180,appendix 9 - kaneko 1993 eng translation jrnl of home ec japan re appendix table of contents re advantafiber (top health inc.) fda citizen petition submission in response to fda guidance final,0,0
09000064834109e2,Other,FDA-2016-P-1180-0046,FDA-2016-P-1180,letter from fda cfsan to top health ingredients inc.,0,0
09000064823e94a8,Supporting & Related Material,FDA-2016-P-1180-0032,FDA-2016-P-1180,appendix 1 schmidt - prevalence of_constipation_in_the_general_adult re appendix table of contents re advantafiber (top health inc.) fda citizen petition submission in response to fda guidance final,0,0
09000064823e94a7,Supporting & Related Material,FDA-2016-P-1180-0031,FDA-2016-P-1180,appendix table of contents re advantafiber (top health inc.) fda citizen petition submission in response to fda guidance final,0,0
090000648234522b,Other,FDA-2016-P-1180-0029,FDA-2016-P-1180,interim response letter from cfsan to top health ingredients inc,0,0
0900006481f847b4,Other,FDA-2016-P-1180-0001,FDA-2016-P-1180,citizen petition from top health ingredients inc,0,0
0900006481f84dce,Supporting & Related Material,FDA-2016-P-1180-0006,FDA-2016-P-1180,appendix 3 health benefits of non-digestible oligosaccharidesre advantafiber fda citizen petition,0,0
0900006481f84e00,Supporting & Related Material,FDA-2016-P-1180-0019,FDA-2016-P-1180,appendix 16 the effect of  a commercial high-fibre diet and an iso-malto-oligosaccharide-supplemented diet on post prandial glucose concentrations in dogs re advantafiber fda citizen petition,0,0
0900006481f84e04,Supporting & Related Material,FDA-2016-P-1180-0023,FDA-2016-P-1180,appendix 20 effect of prebiotic oligosaccharides on growth of lactobacillus strains used as a probiotic for chickens re advantafiber fda citizen petition,0,0
0900006481f84e05,Supporting & Related Material,FDA-2016-P-1180-0024,FDA-2016-P-1180,"appendix 21 carbohydrate preference, acid tolerance and bile tolerance in five strains of befidobacterium re advantafiber fda citizen petition",0,0
0900006481f84e29,Supporting & Related Material,FDA-2016-P-1180-0026,FDA-2016-P-1180,"appendix 23 panose, a new prebiotic candidate re advantafiber fda citizen petition",0,0
0900006481f84d1c,Supporting & Related Material,FDA-2016-P-1180-0003,FDA-2016-P-1180,appendix table of contents re advantafiber fda citizen petition,0,0
0900006484a5b471,Other,FDA-2019-P-1678-0004,FDA-2019-P-1678,"withdrawal from hyman, phelps & mcnamara, p.c. on behalf exela pharma sciences, llc",0,0
0900006483b723a8,Other,FDA-2019-P-1678-0002,FDA-2019-P-1678,"acknowledgment letter from fda ddm to exela pharma sciences, llc.",0,0
0900006483fe291b,Other,FDA-2019-P-1678-0003,FDA-2019-P-1678,"interim response letter from fda cder to exela pharma sciences, llc",0,0
0900006483b7253f,Other,FDA-2019-P-1678-0001,FDA-2019-P-1678,"citizen petition from exela pharma sciences, llc.",0,0
0900006482449613,Notice,FDA-2016-N-4232-0001,FDA-2016-N-4232,"battery safety concerns in electronic nicotine delivery systems; public
workshop; establishment of a public docket; request for comments",0,0
09000064825d591d,Other,FDA-2016-N-4232-0035,FDA-2016-N-4232,testimony from american academy of pediatrics,0,0
0900006482592a4d,Other,FDA-2017-P-2836-0002,FDA-2017-P-2836,acknowledgment letter from fda ddm to vkt pharma private limited,0,0
09000064836709ec,Other,FDA-2017-P-2836-0004,FDA-2017-P-2836,response letter from fda cder to  vkt pharma private limeted and xiromed llc,0,0
0900006482c0d2f1,Other,FDA-2017-P-2836-0003,FDA-2017-P-2836,interim response letter from fda cder to vkt pharma private limited,0,0
0900006482592a46,Other,FDA-2017-P-2836-0001,FDA-2017-P-2836,citizen petition from vkt pharma private limited,0,0
0900006481c66539,Other,FDA-2015-P-0711-0004,FDA-2015-P-0711,interim response letter from fda cber to larry garner,0,0
0900006481dcbfa5,Other,FDA-2015-P-0711-0005,FDA-2015-P-0711,citizen petition partial approval and denial response from fda cber to larry m. garner,0,0
0900006481a2e7f8,Other,FDA-2015-P-0711-0001,FDA-2015-P-0711,citizen petition from l. garner,0,0
0900006481a2e7fb,Other,FDA-2015-P-0711-0002,FDA-2015-P-0711,acknowledgment letter from fda ddm to larry garner,0,0
090000648423c428,Other,FDA-2019-P-4101-0003,FDA-2019-P-4101,petition response letter from fda cder to iqvia rds inc,0,0
0900006483ee2f1d,Other,FDA-2019-P-4101-0002,FDA-2019-P-4101,acknowledgment letter from fda dms to iqvia rds inc.,0,0
0900006483ee2f1c,Other,FDA-2019-P-4101-0001,FDA-2019-P-4101,citizen petition from iqvia rds inc.,0,0
0900006480bb8002,Other,FDA-2010-P-0641-0001,FDA-2010-P-0641,washington action for safe water - citizen petition,0,0
090000648252c3fa,Other,FDA-2017-P-1911-0002,FDA-2017-P-1911,"acknowledgment letter from fda ddm to kleinfeld, kaplan and becker, llp  (purdue pharma l.p.)",0,0
090000648252bfb9,Other,FDA-2017-P-1911-0001,FDA-2017-P-1911,"citizen petition from kleinfeld, kaplan and becker, llp  (purdue pharma l.p.)",0,0
0900006482547d99,Other,FDA-2017-P-1911-0003,FDA-2017-P-1911,"withdrawal letter from kleinfeld, kaplan & becker llp (purdue pharma l.p.)",0,0
09000064846bd381,Other,FDA-2020-D-1445-0001,FDA-2020-D-1445,"guidance for industry and fda; letter to industry, state and local food regulators and inspectors regarding  web-based alert training",1,0
0900006482ef8d71,Supporting & Related Material,FDA-2018-P-0597-0003,FDA-2018-P-0597,attachment1- pew letter to house approps jun_2017(1),0,0
0900006482ef8d2d,Other,FDA-2018-P-0597-0001,FDA-2018-P-0597,citizen petition from the alliance for natural health usa,0,0
0900006482ef8d6e,Other,FDA-2018-P-0597-0002,FDA-2018-P-0597,acknowledgment letter from fda ddm to alliance for natural health usa,0,0
0900006483553734,Other,FDA-2018-P-0597-0004,FDA-2018-P-0597,interim response from fda cder re fda-2018-p-0597,0,0
0900006483d5d7d2,Other,FDA-2018-P-0597-0008,FDA-2018-P-0597,letter from fda cder to alliance for natural health usa,0,0
0900006484976f03,Other,FDA-2020-P-2234-0002,FDA-2020-P-2234,"acknowledgment letter from fda dms to ray law firm, pllc",0,0
0900006484976dac,Other,FDA-2020-P-2234-0001,FDA-2020-P-2234,"suitability petition from ray law firm, pllc",0,0
0900006484a3b795,Other,FDA-2020-P-2234-0003,FDA-2020-P-2234,"final suitability petition approval letter from fda cvm to ray law firm, pllc",0,0
0900006481fc11da,Supporting & Related Material,FDA-2016-P-1251-0004,FDA-2016-P-1251,"attachment 2 approved labeling for the rld, busulfex (busulfan) injection 6 mg/ml in 60 mg/10ml approved re citizen petition from lachman consultant services, inc.",0,0
0900006481fc11db,Supporting & Related Material,FDA-2016-P-1251-0005,FDA-2016-P-1251,"attachment 3 proposed prescribing information for busulfan injection, 6 mg/ml in 30 mg/5 ml strength re citizen petition from lachman consultant services, inc.",0,0
0900006481fc0e7f,Other,FDA-2016-P-1251-0001,FDA-2016-P-1251,"citizen petition from lachman consultant services, inc.",0,0
0900006481fc11d9,Supporting & Related Material,FDA-2016-P-1251-0003,FDA-2016-P-1251,"attachment 1 approved drug products with therapeutic equivalence evaluations, electronic orange book accessed may 6, 2016 re citizen petition from lachman consultant services, inc.",0,0
0900006481fc11d7,Other,FDA-2016-P-1251-0002,FDA-2016-P-1251,"acknowledgement letter from fda ddm to lachman consultant services, inc.",0,0
0900006484b64ea1,Other,FDA-2016-P-1251-0006,FDA-2016-P-1251,"agency response from fda cder to lachman consultant services, inc.",0,0
090000648046e914,Notice,FDA-2004-N-0054-0009,FDA-2004-N-0054,fda,0,0
090000648046e8f7,Supporting & Related Material,FDA-2004-N-0054-0002,FDA-2004-N-0054,background,0,0
090000648046e8f4,Notice,FDA-2004-N-0054-0001,FDA-2004-N-0054,fda,0,0
090000648046e8f8,Supporting & Related Material,FDA-2004-N-0054-0003,FDA-2004-N-0054,background,0,0
090000648046e912,Supporting & Related Material,FDA-2004-N-0054-0007,FDA-2004-N-0054,supporting statement,0,0
090000648046e910,Notice,FDA-2004-N-0054-0005,FDA-2004-N-0054,fda,0,0
090000648046e913,Notice,FDA-2004-N-0054-0008,FDA-2004-N-0054,fda,0,0
090000648046e911,Supporting & Related Material,FDA-2004-N-0054-0006,FDA-2004-N-0054,supporting statement,0,0
09000064804990be,Notice,FDA-2003-D-0373-0001,FDA-2003-D-0373,fda,0,0
09000064804990fe,Supporting & Related Material,FDA-2003-D-0373-0002,FDA-2003-D-0373,guidance,0,0
0900006480472efd,Notice,FDA-2004-N-0310-0002,FDA-2004-N-0310,fda,0,0
0900006480472f02,Supporting & Related Material,FDA-2004-N-0310-0005,FDA-2004-N-0310,supporting statement,0,0
0900006480472ef5,Notice,FDA-2004-N-0310-0001,FDA-2004-N-0310,fda,0,0
0900006480472f03,Notice,FDA-2004-N-0310-0006,FDA-2004-N-0310,fda,0,0
0900006480472f01,Supporting & Related Material,FDA-2004-N-0310-0004,FDA-2004-N-0310,supporting statement,0,0
0900006480472f00,Supporting & Related Material,FDA-2004-N-0310-0003,FDA-2004-N-0310,supporting statement,0,0
09000064809f010c,Notice,FDA-2009-N-0284-0001,FDA-2009-N-0284,"meetings: food and drug administration regulation and licensure of whole blood and blood components, including source plasma",1,0
0900006483915990,Notice,FDA-2018-N-4131-0001,FDA-2018-N-4131,"agency information collection activities; proposed collection; comment request; food and drug administration adverse event reports;
electronic submissions",1,0
0900006483e06883,Notice,FDA-2018-N-4131-0007,FDA-2018-N-4131,agency information collection activities; announcement of office of management and budget approvals,0,0
0900006483cd0bd5,Notice,FDA-2018-N-4131-0004,FDA-2018-N-4131,"agency information collection activities; submission for office of
management and budget review; comment request; food and drug
administration adverse event reports; electronic submissions",1,0
0900006482291406,Rule,FDA-2016-P-1026-0006,FDA-2016-P-1026,"medical devices; exemption from premarket notification: method,
metallic reduction, glucose (urinary, nonquantitative) test system in a
reagent tablet format",0,0
090000648204fcd6,Notice,FDA-2016-P-1026-0003,FDA-2016-P-1026,"medical devices; exemption from premarket notification: method, metallic reduction, glucose (urinary, non-quantitative) test system in a reagent tablet format; republication",0,0
0900006481ed6723,Other,FDA-2016-P-1026-0002,FDA-2016-P-1026,"acknowledgement letter from fda ddm to germaine laboratories, inc.",0,0
0900006482295b63,Supporting & Related Material,FDA-2016-P-1026-0007,FDA-2016-P-1026,reference 1 - guidance - procedures for class ii device exemptions from premarket notification 1998,0,0
090000648204943e,Supporting & Related Material,FDA-2016-P-1026-0004,FDA-2016-P-1026,reference 1 - guidance for industry and cdrh staff on procedures for class ii device exemptions from premarket notification,0,0
0900006481ed61cd,Other,FDA-2016-P-1026-0001,FDA-2016-P-1026,"citizen petition from germaine laboratories, inc.",0,0
09000064821fad0d,Other,FDA-2016-P-1026-0005,FDA-2016-P-1026,letter from cdrh to germaine laboratories inc,0,0
0900006482ef8d48,Other,FDA-2018-P-0598-0002,FDA-2018-P-0598,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara",0,0
0900006482ef8d4a,Supporting & Related Material,FDA-2018-P-0598-0003,FDA-2018-P-0598,"tab 1 - iso 27427, anaesthetic and respiratory equipment _ nebulizing systems and components (2010) re citizen petition from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
0900006482ef913c,Supporting & Related Material,FDA-2018-P-0598-0007,FDA-2018-P-0598,"tab 5 - dean hess et al_, medication nebulizer performance effects of diluent volume, nebulizer flow, and nebulizer brand, 110 che re citizen petition from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
0900006482ef9142,Supporting & Related Material,FDA-2018-P-0598-0012,FDA-2018-P-0598,"tab 10 - lawrence x_ yu, quality by design for orally inhaled drug products, pqri workshop on demonstrating bioequivalence of loca re citizen petition from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
0900006482ef913a,Supporting & Related Material,FDA-2018-P-0598-0005,FDA-2018-P-0598,"tab 3 - andrew m_ wilson et al_, importance of drug-device interaction in determining systemic effects of inhaled corticosteroids re citizen petition from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
0900006482ef9140,Supporting & Related Material,FDA-2018-P-0598-0010,FDA-2018-P-0598,"tab 8 - christopher ocallaghan peter w_ barry the science of nebulised drug delivery 52 suppl 2 thorax s31 s36 (1997) re citizen petition from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
0900006482ef913b,Supporting & Related Material,FDA-2018-P-0598-0006,FDA-2018-P-0598,"tab 4 - ah kendrick et al_, selecting and using nebulizer equipment re citizen petition from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
0900006482ef913f,Supporting & Related Material,FDA-2018-P-0598-0009,FDA-2018-P-0598,"tab 7 - jg hardy et al_, lung deposition from four nebulizers, 87 respir med 461 (1993) re citizen petition from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
0900006482ef913e,Supporting & Related Material,FDA-2018-P-0598-0008,FDA-2018-P-0598,"tab 6 - d_ todd loffert et al_, a comparison of commercial jet nebulizers, 106 chest 1788 (1994) re citizen petition from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
09000064834b6ea1,Other,FDA-2018-P-0598-0014,FDA-2018-P-0598,petition denial letter from fda cder to kurt karst 07-06-2018,0,0
0900006482ef8d46,Other,FDA-2018-P-0598-0001,FDA-2018-P-0598,"citizen petition from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
0900006482ef8d69,Supporting & Related Material,FDA-2018-P-0598-0013,FDA-2018-P-0598,"tab 11 - wallace p_ adams et al_, demonstrating bioequivalence of locally acting orally inhaled drug products, 23 j aerosol med pu re citizen petition from hyman, phelps & mcnamara, pc",0,0
0900006482ef9141,Supporting & Related Material,FDA-2018-P-0598-0011,FDA-2018-P-0598,"tab 9 - t_ gessler et al_, ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension, 17 eur respir j 14, 16 re citizen petition from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
0900006482ef9139,Supporting & Related Material,FDA-2018-P-0598-0004,FDA-2018-P-0598,"tab 2 - food and drug administration respiratory drug delivery devices a cdrh perspective (nov_ 2 2010) re citizen petition from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",1,0
09000064830e239d,Other,FDA-2018-P-1441-0002,FDA-2018-P-1441,acknowledgment letter from fda ddm to patients for access to advanced hemophilia therapy,0,0
090000648379e6c4,Other,FDA-2018-P-1441-0009,FDA-2018-P-1441,response letter from fda cder to mr. antell and mr. dattoli,0,0
09000064830e1b85,Other,FDA-2018-P-1441-0001,FDA-2018-P-1441,citizen petition from patients for access to advanced hemophilia therapy,0,0
090000648151d50f,Other,FDA-2014-P-0112-0002,FDA-2014-P-0112,acknowledgement letter from fda ddm to nadachair,0,0
0900006483b5a4e9,Other,FDA-2014-P-0112-0003,FDA-2014-P-0112,letter from fda cdrh to nadachair,0,0
090000648151ccc4,Other,FDA-2014-P-0112-0001,FDA-2014-P-0112,citizen petition from nadachair,0,0
0900006482505d56,Notice,FDA-2017-N-0455-0001,FDA-2017-N-0455,enhancing patient engagement efforts across the food and drug administration; establishment of a public docket; request for comments,1,0
09000064847d12f9,Other,FDA-2020-P-1728-0001,FDA-2020-P-1728,citizen petition from tenshi kaizen private limited,0,0
09000064847d0fe1,Supporting & Related Material,FDA-2020-P-1728-0003,FDA-2020-P-1728,attachment 4 re: citizen petition from tenshi kaizen private limited,0,0
09000064847d0fde,Supporting & Related Material,FDA-2020-P-1728-0006,FDA-2020-P-1728,attachment 1 re: citizen petition from tenshi kaizen private limited,0,0
09000064847d0fe0,Supporting & Related Material,FDA-2020-P-1728-0004,FDA-2020-P-1728,attachment 3 re: citizen petition from tenshi kaizen private limited,0,0
09000064847d0fdf,Supporting & Related Material,FDA-2020-P-1728-0005,FDA-2020-P-1728,attachment 2 re: citizen petition from tenshi kaizen private limited,0,0
09000064847d0fdc,Other,FDA-2020-P-1728-0002,FDA-2020-P-1728,acknowledgment letter from fda dms to tenshi kaizen private limited,0,0
0900006482b94e1d,Other,FDA-2017-D-5739-0002,FDA-2017-D-5739,formal meetings between fda and anda applicants of complex products under gdufa guidance for industry; draft guidance,0,0
09000064849761b3,Other,FDA-2017-D-5739-0008,FDA-2017-D-5739,"formal meetings between the food and drug administration and
abbreviated new drug application applicants of complex products under generic drug user fee amendments; guidance for industry",1,0
0900006484985c2a,Notice,FDA-2017-D-5739-0009,FDA-2017-D-5739,"formal meetings between the food and drug administration and
abbreviated new drug application applicants of complex products under generic drug user fee amendments; guidance for industry; availability; correction",1,0
0900006482b9370d,Notice,FDA-2017-D-5739-0001,FDA-2017-D-5739,"formal meetings between the food and drug administration and
abbreviated new drug application applicants of complex products under generic drug user fee act; draft guidance for industry;  availability",1,0
0900006484975d73,Notice,FDA-2017-D-5739-0007,FDA-2017-D-5739,"formal meetings between the food and drug administration and
abbreviated new drug application applicants of complex products under generic drug user fee amendments; guidance for industry; availability",1,0
0900006484986175,Other,FDA-2017-D-5739-0010,FDA-2017-D-5739,formal meetings between fda and anda applicants of complex products under gdufa guidance for industry,0,0
0900006483fabf25,Other,FDA-2019-D-3679-0002,FDA-2019-D-3679,interacting with the fda on complex innovative trial designs for drugs and biological products draft guidance for industry,0,0
09000064849a443c,Notice,FDA-2019-D-3679-0014,FDA-2019-D-3679,interacting with the food and drug administration on complex innovative trial designs for drugs and biological products; guidance for industry; availability,1,0
09000064849a5c00,Other,FDA-2019-D-3679-0015,FDA-2019-D-3679,interacting with the fda on complex innovative trial designs for drugs and biological products; guidance for industry,0,0
0900006483fab277,Notice,FDA-2019-D-3679-0001,FDA-2019-D-3679,interacting with the food and drug administration on complex innovative clinical trial designs for drugs and biological products; draft guidance for industry; availability,1,0
0900006482d58cb9,Other,FDA-2017-P-6968-0002,FDA-2017-P-6968,"acknowledgment letter from fda ddm to ceva animal health, llc",0,0
0900006483018aaa,Other,FDA-2017-P-6968-0005,FDA-2017-P-6968,"response letter from fda to ceva animal health, llc",0,0
0900006482f08015,Other,FDA-2017-P-6968-0004,FDA-2017-P-6968,"amendment from ceva animal health, llc",0,0
0900006482d58e60,Other,FDA-2017-P-6968-0001,FDA-2017-P-6968,"suitability petition from ceva animal health, llc",0,0
0900006482d58cbb,Supporting & Related Material,FDA-2017-P-6968-0003,FDA-2017-P-6968,"appendices for suitability petition from ceva animal health, llc",0,0
090000648207e576,Supporting & Related Material,FDA-2016-P-1852-0009,FDA-2016-P-1852,milk and milk products: microbiology of cream and butter,0,0
090000648207e5b5,Supporting & Related Material,FDA-2016-P-1852-0016,FDA-2016-P-1852,microbiological quality and safety issues in cheesemaking,0,0
090000648207e5d7,Supporting & Related Material,FDA-2016-P-1852-0052,FDA-2016-P-1852,"a review of the microbiological hazards of dairy products made from
raw milk",0,0
090000648207e5db,Supporting & Related Material,FDA-2016-P-1852-0056,FDA-2016-P-1852,understanding potential intervention measures to reduce the risk of foodborne illness from consumption of cheese manufactured from unpasteurized milk,0,0
0900006482081b61,Other,FDA-2016-P-1852-0002,FDA-2016-P-1852,acknowledgement letter from fda ddm to farm-to-consumer legal defense fund,0,0
090000648207e433,Supporting & Related Material,FDA-2016-P-1852-0026,FDA-2016-P-1852,"microbiology of cream, butter, ice cream and related products",0,0
090000648207e436,Supporting & Related Material,FDA-2016-P-1852-0029,FDA-2016-P-1852,factors influencing bacterial growth in butter,0,0
090000648207e44d,Supporting & Related Material,FDA-2016-P-1852-0034,FDA-2016-P-1852,"prevalence of listeria monocytogenes and other listeria species in butter from united kingdom production, retail, and catering premises",0,0
090000648207e486,Supporting & Related Material,FDA-2016-P-1852-0050,FDA-2016-P-1852,"2013 report to the natural resources, agriculture & environment interim committee and the health & human services interim committees",0,0
090000648207e571,Supporting & Related Material,FDA-2016-P-1852-0004,FDA-2016-P-1852,"milk for manufacturing purposes and its production and processing
recommended requirements",0,0
090000648207e575,Supporting & Related Material,FDA-2016-P-1852-0008,FDA-2016-P-1852,queso fresco: cheese with a reputation,0,0
090000648207e577,Supporting & Related Material,FDA-2016-P-1852-0010,FDA-2016-P-1852,§ 11380. required health warning on labels of raw milk and raw milk products,0,0
090000648207e42f,Supporting & Related Material,FDA-2016-P-1852-0022,FDA-2016-P-1852,quantitative assessment of relative risk to public health from food borne listeria monocytogenes among selected categories of ready-to-eat foods,1,0
090000648207e437,Supporting & Related Material,FDA-2016-P-1852-0030,FDA-2016-P-1852,idapa 02.04.13.007 007. definitions,0,0
090000648207e451,Supporting & Related Material,FDA-2016-P-1852-0038,FDA-2016-P-1852,exposure of listeria monocytogenes within an epidemic caused by butter in finland,0,0
090000648207e482,Supporting & Related Material,FDA-2016-P-1852-0046,FDA-2016-P-1852,molecular approaches to analysing the microbial composition of raw milk and raw milk cheese,0,0
090000648207e485,Supporting & Related Material,FDA-2016-P-1852-0049,FDA-2016-P-1852,"ut admin code r70330. raw milk for retail. june 1, 2016",0,0
09000064843c8d4f,Other,FDA-2016-P-1852-0061,FDA-2016-P-1852,citizen petition denial response letter from fda cfsan to to pete kennedy - mark mcafee,0,0
090000648242a392,Other,FDA-2016-P-1852-0059,FDA-2016-P-1852,interim response letter from cfsan to organic pastures dairy company & organic pastures dairy company,0,0
090000648207e574,Supporting & Related Material,FDA-2016-P-1852-0007,FDA-2016-P-1852,"sale of milk, milk products, raw milk and raw milk..., az st § 3-606",0,0
090000648207e5b1,Supporting & Related Material,FDA-2016-P-1852-0012,FDA-2016-P-1852,"the human milk microbiome changes over lactation and is shaped by
maternal weight and mode of delivery",0,0
090000648207e5b9,Supporting & Related Material,FDA-2016-P-1852-0019,FDA-2016-P-1852,"food and drug administration (fda), u.s. department of health and human services. (2011). section i: definitions. grade “a” pasteurized milk ordinance (pp. 6-7). rev. 2011.",1,0
090000648207e5ba,Supporting & Related Material,FDA-2016-P-1852-0020,FDA-2016-P-1852,quantitative assessment of relative risk to public health from foodborne listeria monocytogenes among selected categories of ready-to-eat foods,0,0
090000648207e5d5,Supporting & Related Material,FDA-2016-P-1852-0051,FDA-2016-P-1852,microbiota of human breast tissue,0,0
090000648207e5b2,Supporting & Related Material,FDA-2016-P-1852-0013,FDA-2016-P-1852,impact of microbial ecology of meat and poultry products on predictions from exposure assessment scenarios for refrigerated storage,0,0
0900006483d47844,Supporting & Related Material,FDA-2019-P-3109-0004,FDA-2019-P-3109,"appendix 2. draft labels of the proposed generic soft chew: label for small dogs and puppies (6-25 lbs.) and medium to large dogs (25.1-200 lbs.) re citizen petition from noble pharma, llc",0,0
0900006483d47994,Other,FDA-2019-P-3109-0002,FDA-2019-P-3109,"acknowledgment letter from fda ddm to noble pharma, llc",0,0
0900006483d476e8,Other,FDA-2019-P-3109-0001,FDA-2019-P-3109,"citizen petition from noble pharma, llc",0,0
0900006483d47795,Supporting & Related Material,FDA-2019-P-3109-0003,FDA-2019-P-3109,"appendix 1. pioneer product labels for small dogs and puppies (6-25 lbs.) and medium to large (25.1-200 lbs.) dogs re citizen petition from noble pharma, llc",0,0
0900006483f08086,Other,FDA-2019-P-3109-0006,FDA-2019-P-3109,"approval letter from fda cvm to noble pharma, llc",0,0
0900006483be9a70,Notice,FDA-2019-N-1468-0001,FDA-2019-N-1468,"characterizing the food and drug administration’s approach to benefit-
risk assessment throughout the medical product life cycle; public
meeting; request for comments",1,0
0900006483c912d7,Supporting & Related Material,FDA-2019-P-2407-0003,FDA-2019-P-2407,attachment 1 declaration of rubicon re citizen petition from kratz & barry llp on behalf of rubicon research private limited,0,0
0900006483c91512,Other,FDA-2019-P-2407-0001,FDA-2019-P-2407,citizen petition from kratz & barry llp on behalf of rubicon research private limited,0,0
0900006483c91518,Other,FDA-2019-P-2407-0002,FDA-2019-P-2407,acknowledgment letter from fda ddm to kratz & barry llp,0,0
0900006483c912d8,Supporting & Related Material,FDA-2019-P-2407-0004,FDA-2019-P-2407,attachment 2 declaration of george j. barry iii re citizen petition from kratz & barry llp on behalf of rubicon research private limited,0,0
09000064841bfc80,Other,FDA-2019-P-2407-0005,FDA-2019-P-2407,letter from fda cder to kratz & barry llp and yiling pharmaceutical ltd.,0,0
090000648190d1af,Notice,FDA-2014-N-1072-0002,FDA-2014-N-1072,"agency information collection activities; proposals, submissions, and approvals: application for participation in the food and drug administration commissioner's fellowship program",1,0
09000064830e0b16,Notice,FDA-2014-N-1072-0007,FDA-2014-N-1072,"agency information collection activities; proposals, submissions, and approvals",0,0
090000648380ac38,Notice,FDA-2014-N-1072-0008,FDA-2014-N-1072,agency information collection activities; proposed collection; comment request; application for participation in food and drug administration fellowship and traineeship programs,1,0
090000648432061c,Notice,FDA-2014-N-1072-0010,FDA-2014-N-1072,"agency information collection activities; submission for office of
management and budget review; comment request; application for
participation in food and drug administration fellowship and
traineeship programs",1,0
09000064826f5b96,Notice,FDA-2014-N-1072-0003,FDA-2014-N-1072,agency information collection activities; proposed collection; comment request; application for participation in food and drug administration fellowship programs,1,0
09000064849a75bd,Notice,FDA-2014-N-1072-0011,FDA-2014-N-1072,"agency information collection
activities; submission for office of
management and budget review; comment request; application for participation in food and drug administration fellowship and traineeship programs",1,0
09000064817fdb35,Notice,FDA-2014-N-1072-0001,FDA-2014-N-1072,"agency information collection activities; proposed collection;
comment request; application for participation in the food and drug
administration commissioner’s fellowship program",1,0
0900006482cf739c,Notice,FDA-2014-N-1072-0005,FDA-2014-N-1072,"agency information collection activities; submission for office of management and budget review; comment request; application for 
participation in food and drug administration fellowship programs",1,0
090000648322b860,Notice,FDA-2014-N-1072-0006,FDA-2014-N-1072,"agency information collection activities; announcement of office of
management and budget approvals; correction",0,0
0900006484a7ec7d,Notice,FDA-2014-N-1072-0012,FDA-2014-N-1072,agency information collection activities; announcement of office of management and budget approvals,0,0
0900006484a37db7,Notice,FDA-2020-N-2030-0002,FDA-2020-N-2030,agency information collection activities; submission for office of management and budget review; comment request; application for food and drug administration approval to market a new drug,1,0
0900006484960494,Notice,FDA-2020-N-2030-0001,FDA-2020-N-2030,agency information collection activities; proposed collection; comment request; application for food and drug administration approval to market a new drug,1,0
0900006484ae14ab,Notice,FDA-2020-N-2030-0003,FDA-2020-N-2030,agency information collection activities; announcement of office of management and budget approvals,0,0
0900006484b1a994,Notice,FDA-2021-N-0431-0001,FDA-2021-N-0431,food and drug administration public meeting on financial efficiency of human drug user fee programs; public meeting; request for comments,1,0
0900006482f7cca2,Other,FDA-2018-P-0945-0001,FDA-2018-P-0945,citizen petition from scott beach,0,0
09000064842cba2b,Supporting & Related Material,FDA-2018-P-0945-0026,FDA-2018-P-0945,beach cp - footnote 4 re agency response letter from fda cber to scott beach,0,0
09000064842cba56,Supporting & Related Material,FDA-2018-P-0945-0018,FDA-2018-P-0945,beach cp - footnote 12 re agency response letter from fda cber to scott beach,0,0
09000064842cba5b,Supporting & Related Material,FDA-2018-P-0945-0039,FDA-2018-P-0945,beach cp - footnote 19 re agency response letter from fda cber to scott beach,0,0
0900006483631c26,Other,FDA-2018-P-0945-0010,FDA-2018-P-0945,interim response letter from fda cber to scott beach,0,0
09000064842cb40a,Other,FDA-2018-P-0945-0012,FDA-2018-P-0945,agency response letter from fda cber to scott beach,0,0
09000064842cb4f7,Supporting & Related Material,FDA-2018-P-0945-0034,FDA-2018-P-0945,beach cp - footnote 31 re agency response letter from fda cber to scott beach,0,0
09000064842cb4f9,Supporting & Related Material,FDA-2018-P-0945-0032,FDA-2018-P-0945,beach cp - footnote 34 re agency response letter from fda cber to scott beach,0,0
09000064842cb4fc,Supporting & Related Material,FDA-2018-P-0945-0029,FDA-2018-P-0945,beach cp footnote 17 re agency response letter from fda cber to scott beach,0,0
09000064842cb4fe,Supporting & Related Material,FDA-2018-P-0945-0027,FDA-2018-P-0945,beach cp- footnote 29 re agency response letter from fda cber to scott beach,0,0
09000064842cba2a,Supporting & Related Material,FDA-2018-P-0945-0014,FDA-2018-P-0945,beach cp - footnote 2 re agency response letter from fda cber to scott beach,0,0
09000064842cba2c,Supporting & Related Material,FDA-2018-P-0945-0025,FDA-2018-P-0945,beach cp - footnote 5 re agency response letter from fda cber to scott beach,0,0
09000064842cba30,Supporting & Related Material,FDA-2018-P-0945-0021,FDA-2018-P-0945,beach cp - footnote 9 re agency response letter from fda cber to scott beach,0,0
09000064842cba5c,Supporting & Related Material,FDA-2018-P-0945-0038,FDA-2018-P-0945,beach cp - footnote 20 re agency response letter from fda cber to scott beach,0,0
09000064842cb4fd,Supporting & Related Material,FDA-2018-P-0945-0028,FDA-2018-P-0945,beach cp- footnote 24 re agency response letter from fda cber to scott beach,0,0
09000064842cba57,Supporting & Related Material,FDA-2018-P-0945-0017,FDA-2018-P-0945,beach cp - footnote 13 re agency response letter from fda cber to scott beach,0,0
09000064842cba2f,Supporting & Related Material,FDA-2018-P-0945-0022,FDA-2018-P-0945,beach cp - footnote 8 re agency response letter from fda cber to scott beach,0,0
09000064842cb4fb,Supporting & Related Material,FDA-2018-P-0945-0030,FDA-2018-P-0945,beach cp - footnote 39 re agency response letter from fda cber to scott beach,0,0
09000064842cba55,Supporting & Related Material,FDA-2018-P-0945-0019,FDA-2018-P-0945,beach cp - footnote 11 re agency response letter from fda cber to scott beach,0,0
09000064842cba5a,Supporting & Related Material,FDA-2018-P-0945-0040,FDA-2018-P-0945,beach cp - footnote 16 re agency response letter from fda cber to scott beach,0,0
0900006482f7cca4,Other,FDA-2018-P-0945-0002,FDA-2018-P-0945,acknowledgment letter from fda ddm to scott beach,0,0
09000064842cb4f8,Supporting & Related Material,FDA-2018-P-0945-0033,FDA-2018-P-0945,beach cp - footnote 33 re agency response letter from fda cber to scott beach,0,0
09000064842cba58,Supporting & Related Material,FDA-2018-P-0945-0016,FDA-2018-P-0945,beach cp - footnote 14 re agency response letter from fda cber to scott beach,0,0
09000064842cba5e,Supporting & Related Material,FDA-2018-P-0945-0036,FDA-2018-P-0945,beach cp - footnote 23 re agency response letter from fda cber to scott beach,0,0
09000064842cba5d,Supporting & Related Material,FDA-2018-P-0945-0037,FDA-2018-P-0945,beach cp - footnote 21 re agency response letter from fda cber to scott beach,0,0
09000064803b01dc,Notice,FDA-2008-N-0077-0001,FDA-2008-N-0077,agency information collection activities; proposed collection; comment request; medwatch: the food and drug administration medical products reporting program,1,0
0900006480a0e0b6,Notice,FDA-2008-N-0077-0006,FDA-2008-N-0077,agency information collection activities; announcement of office of management and budget approval; medwatch: food and drug administration medical products reporting program,1,0
0900006480720344,Notice,FDA-2008-N-0077-0005,FDA-2008-N-0077,agency information collection activities; submission for office of management and budget review; comment request; medwatch: food and drug administration medical products reporting program,1,0
0900006480a68b1b,Other,FDA-2006-P-0518-0005,FDA-2006-P-0518,"george washington university medical center to fda, december 3, 2009 - letter re fda-2006-p-0518-0001",0,0
0900006480463a6c,Other,FDA-2006-P-0518-0004,FDA-2006-P-0518,national jewish medical and research center to fda - letter,0,0
0900006480463a67,Other,FDA-2006-P-0518-0001,FDA-2006-P-0518,the george washington university medical center  - citizen petiion,0,0
0900006480463a6a,Other,FDA-2006-P-0518-0003,FDA-2006-P-0518,fda interim response to george washington university -  letter,0,0
0900006480463a56,Other,FDA-2006-P-0518-0002,FDA-2006-P-0518,acknowledgement letter  to the george washington university medical center,0,0
0900006484b5157d,Other,FDA-2021-P-0529-0002,FDA-2021-P-0529,acknowledgment letter from fda dms to siri  & glimstad llp on behalf of informed consent action network,0,0
0900006484b604b1,Supporting & Related Material,FDA-2021-P-0529-0005,FDA-2021-P-0529,combined fns part 3 of 7 re citizen petition from siri  & glimstad llp on behalf of informed consent action network,0,0
0900006484b604b2,Supporting & Related Material,FDA-2021-P-0529-0009,FDA-2021-P-0529,combined fns part 7 of 7 re re citizen petition from siri  & glimstad llp on behalf of informed consent action network,0,0
0900006484b5179c,Supporting & Related Material,FDA-2021-P-0529-0008,FDA-2021-P-0529,combined fns part 6 of 7 re citizen petition from siri  & glimstad llp on behalf of informed consent action network,0,0
0900006484b51584,Supporting & Related Material,FDA-2021-P-0529-0006,FDA-2021-P-0529,combined fns part 4 of 7 re citizen petition from siri  & glimstad llp on behalf of informed consent action network,0,0
0900006484b5157f,Supporting & Related Material,FDA-2021-P-0529-0257,FDA-2021-P-0529,combined fns part 1 of 7 re citizen petition from siri  & glimstad llp on behalf of informed consent action network,0,0
0900006484b51b03,Other,FDA-2021-P-0529-0001,FDA-2021-P-0529,citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484b51580,Supporting & Related Material,FDA-2021-P-0529-0004,FDA-2021-P-0529,combined fns part 2 of 7 re citizen petition from siri  & glimstad llp on behalf of informed consent action network,0,0
0900006484b51bda,Supporting & Related Material,FDA-2021-P-0529-0007,FDA-2021-P-0529,combined fns part 5 of 7 re citizen petition from siri  & glimstad llp on behalf of informed consent action network,0,0
0900006484bdf677,Other,FDA-2021-P-0529-1053,FDA-2021-P-0529,petition for stay of action from siri & glimstad llp (on behalf of informed consent action network),0,0
0900006484c9d6a7,Other,FDA-2021-P-0529-1077,FDA-2021-P-0529,response letter to citizen petition from fda cber to siri & glimstad llp,0,0
0900006484be012a,Other,FDA-2021-P-0529-1054,FDA-2021-P-0529,acknowledgment letter from fda dms to siri & glimstad llp (on behalf of informed consent action network),0,0
0900006484b604b0,Supporting & Related Material,FDA-2021-P-0529-0003,FDA-2021-P-0529,combined fns part 1 of 7 re citizen petition from siri  & glimstad llp on behalf of informed consent action network,0,0
0900006483c4b908,Other,FDA-2019-D-1263-0002,FDA-2019-D-1263,"submitting documents using real-world data and real-world evidence
to fda for drugs and biologics; guidance for industry; draft guidance",0,0
0900006483c4aeb5,Notice,FDA-2019-D-1263-0001,FDA-2019-D-1263,"submitting documents using real-world data and real-world evidence
to the food and drug administration for drugs and biologics; draft guidance for industry; availability",1,0
0900006484dc7319,Other,FDA-2021-P-1114-0001,FDA-2021-P-1114,citizen petition from lewis katz school of medicine of temple university,0,0
0900006484dc731d,Other,FDA-2021-P-1114-0002,FDA-2021-P-1114,acknowledgment letter from fda dms to lewis katz school of medicine of temple university,0,0
09000064846c8516,Other,FDA-2016-P-2532-0004,FDA-2016-P-2532,30 day response letter from fda cfsan  to dr. cundiff,0,0
09000064825df8be,Other,FDA-2016-P-2532-0003,FDA-2016-P-2532,response letter from fda to david k. cundiff,0,0
090000648219f0fd,Other,FDA-2016-P-2532-0002,FDA-2016-P-2532,acknowledgment letter from fda ddm david k. cundiff,0,0
090000648219e1f5,Other,FDA-2016-P-2532-0001,FDA-2016-P-2532,citizen petition from david k. cundiff,0,0
0900006483b8bb74,Other,FDA-2014-P-0823-0013,FDA-2014-P-0823,agency response letter from fda cder to richard d. burk,0,0
0900006481752bc0,Other,FDA-2014-P-0823-0001,FDA-2014-P-0823,citizen petition from richard d. burk,0,0
09000064828cd79d,Other,FDA-2014-P-0823-0009,FDA-2014-P-0823,letter from richard d. burk to fda cder,0,0
0900006481948b54,Other,FDA-2014-P-0823-0003,FDA-2014-P-0823,letter from richard burk,0,0
0900006482033f82,Other,FDA-2014-P-0823-0006,FDA-2014-P-0823,letter from richard d. burk to fda cder,0,0
0900006482cc69f0,Other,FDA-2014-P-0823-0011,FDA-2014-P-0823,letter from richard d. burk to fda ddm,0,0
0900006482912544,Other,FDA-2014-P-0823-0010,FDA-2014-P-0823,letter from richard d. burk to fda cder,0,0
09000064831affdc,Other,FDA-2014-P-0823-0012,FDA-2014-P-0823,letter from richard d. burk to fda cder,0,0
090000648175334a,Other,FDA-2014-P-0823-0002,FDA-2014-P-0823,acknowledgement letter from fda ddm to richard d. burk,0,0
0900006481e4cafa,Other,FDA-2014-P-0823-0004,FDA-2014-P-0823,interim response letter from fda cder to richard d. burk,0,0
0900006481edc3b8,Other,FDA-2014-P-0823-0005,FDA-2014-P-0823,letter from richard d. burk to fda cder,0,0
0900006481a1e058,Other,FDA-2015-P-0633-0001,FDA-2015-P-0633,citizen petition from jonathan smith,0,0
0900006482d48e64,Other,FDA-2015-P-0633-0020,FDA-2015-P-0633,final response letter from fda to jonathan smith,0,0
0900006481c35409,Other,FDA-2015-P-0633-0003,FDA-2015-P-0633,interim response from fda cder to university of kentucky college of medicine,0,0
0900006481a1e3e1,Other,FDA-2015-P-0633-0002,FDA-2015-P-0633,"acknowledgement letter from fda ddm to jonathan smith, m.d.",0,0
0900006483398895,Notice,FDA-2018-N-0529-0031,FDA-2018-N-0529,draft concept paper: illicit trade in tobacco products after implementation of a food and drug administration product standard; extension of comment period,1,1
090000648301d52e,Supporting & Related Material,FDA-2018-N-0529-0002,FDA-2018-N-0529,508-illicit trade in tobacco products after implementation of an fda pro...,0,1
090000648301be26,Notice,FDA-2018-N-0529-0001,FDA-2018-N-0529,draft concept paper: illicit trade in tobacco products after implementation of a food and drug administration product standard; availability; request for comments,1,1
09000064830e0568,Other,FDA-2018-N-0529-0023,FDA-2018-N-0529,request for extension from altria client services llc,0,0
090000648379e78f,Other,FDA-2018-P-3806-0002,FDA-2018-P-3806,acknowledgment letter from fda ddm to greg grillo,0,0
0900006483b588b0,Other,FDA-2018-P-3806-0003,FDA-2018-P-3806,letter from fda cder to greg grillo,0,0
090000648379e789,Other,FDA-2018-P-3806-0001,FDA-2018-P-3806,citizen petition from greg grillo,0,0
0900006484954f8f,Other,FDA-2018-P-3806-0004,FDA-2018-P-3806,response letter from fda cder to greg grillo,0,0
0900006484a08072,Other,FDA-2021-P-0124-0002,FDA-2021-P-0124,"acknowledgement letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
0900006484a08074,Supporting & Related Material,FDA-2021-P-0124-0003,FDA-2021-P-0124,"attachment 1 re suitability petition from hyman, phelps & mcnamara p.c.",0,0
0900006484a08294,Supporting & Related Material,FDA-2021-P-0124-0006,FDA-2021-P-0124,"attachment 4 re suitability petition from hyman, phelps & mcnamara p.c.",0,0
0900006484a08070,Other,FDA-2021-P-0124-0001,FDA-2021-P-0124,"suitability petition from hyman, phelps & mcnamara p.c.",0,0
0900006484a08293,Supporting & Related Material,FDA-2021-P-0124-0004,FDA-2021-P-0124,"attachment 2 re suitability petition from hyman, phelps & mcnamara p.c.",0,0
0900006484a08295,Supporting & Related Material,FDA-2021-P-0124-0005,FDA-2021-P-0124,"attachment 3 re suitability petition from hyman, phelps & mcnamara p.c.",0,0
0900006484a145cf,Supporting & Related Material,FDA-2021-P-0137-0005,FDA-2021-P-0137,"attachment 3 re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484a1454d,Other,FDA-2021-P-0137-0002,FDA-2021-P-0137,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
0900006484a14552,Supporting & Related Material,FDA-2021-P-0137-0003,FDA-2021-P-0137,"attachment 1 re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484a145ce,Supporting & Related Material,FDA-2021-P-0137-0004,FDA-2021-P-0137,"attachment 2 re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484a1454b,Other,FDA-2021-P-0137-0001,FDA-2021-P-0137,"suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484a5b473,Other,FDA-2018-P-4769-0004,FDA-2018-P-4769,"withdrawal from hyman, phelps & mcnamara, p.c.",0,0
0900006483d11b5c,Other,FDA-2018-P-4769-0003,FDA-2018-P-4769,"letter from fda cder to exela pharma sciences, llc",0,0
090000648399e454,Other,FDA-2018-P-4769-0001,FDA-2018-P-4769,"citizen petition  from exela pharma sciences, llc.",0,0
090000648399e9b8,Other,FDA-2018-P-4769-0002,FDA-2018-P-4769,"acknowledgment letter from fda ddm to exela pharma sciences, llc",0,0
090000648320c32f,Other,FDA-2017-P-4335-0003,FDA-2017-P-4335,interim response from fda cdrh to william bonificio,0,0
0900006482941359,Other,FDA-2017-P-4335-0002,FDA-2017-P-4335,acknowledgement letter from fda ddm to william bonificio,0,0
0900006482940f49,Other,FDA-2017-P-4335-0001,FDA-2017-P-4335,citizen petition from william bonificio,0,0
0900006484b3ab07,Other,FDA-2017-P-4335-0004,FDA-2017-P-4335,response letter from fda cdrh to william bonificio,0,0
090000648045040e,Other,FDA-2005-P-0434-0002,FDA-2005-P-0434,hfa-305 to ms. elizabeth m. trevino,0,0
09000064804503ea,Other,FDA-2005-P-0434-0001,FDA-2005-P-0434,hfa-305 to ms. elizabeth m. trevino,0,0
0900006482073c10,Other,FDA-2005-P-0434-0003,FDA-2005-P-0434,petition closure memorandum from fda cfsan,0,0
0900006480a6b578,Other,FDA-2003-P-0127-0004,FDA-2003-P-0127,"the weinberg group, inc.  - petition withdrawal re fda-2003-p-0127-0003",0,0
0900006480486267,Other,FDA-2003-P-0127-0003,FDA-2003-P-0127,"the weinberg group, inc. - citizen petition",0,0
0900006480486265,Other,FDA-2003-P-0127-0001,FDA-2003-P-0127,"acknowledgement letter to the weinberg group, inc.",0,0
0900006480486268,Other,FDA-2003-P-0127-0002,FDA-2003-P-0127,"fda/cder response to the weinberg group inc., february 3, 2004 - letter",0,0
090000648046fb07,Supporting & Related Material,FDA-2004-D-0118-0005,FDA-2004-D-0118,guidance,0,0
090000648046fb09,Notice,FDA-2004-D-0118-0007,FDA-2004-D-0118,fda,0,0
090000648046fb08,Supporting & Related Material,FDA-2004-D-0118-0006,FDA-2004-D-0118,guidance,0,0
090000648046faff,Notice,FDA-2004-D-0118-0001,FDA-2004-D-0118,fda,0,0
090000648046fb05,Supporting & Related Material,FDA-2004-D-0118-0003,FDA-2004-D-0118,guideline,0,0
090000648046fb02,Supporting & Related Material,FDA-2004-D-0118-0002,FDA-2004-D-0118,guideline,0,0
090000648046fb06,Supporting & Related Material,FDA-2004-D-0118-0004,FDA-2004-D-0118,guideline,0,0
090000648044d23f,Notice,FDA-2005-N-0401-0001,FDA-2005-N-0401,fda,0,0
090000648044d269,Notice,FDA-2005-N-0401-0002,FDA-2005-N-0401,fda,0,0
090000648044d26b,Supporting & Related Material,FDA-2005-N-0401-0003,FDA-2005-N-0401,supporting statement,0,0
090000648044d270,Notice,FDA-2005-N-0401-0005,FDA-2005-N-0401,fda,0,0
090000648044d26d,Supporting & Related Material,FDA-2005-N-0401-0004,FDA-2005-N-0401,supporting statement,0,0
09000064804562e3,Notice,FDA-2006-D-0229-0001,FDA-2006-D-0229,fda,0,0
09000064804562e4,Supporting & Related Material,FDA-2006-D-0229-0002,FDA-2006-D-0229,guidance,0,0
0900006480bbe739,Other,FDA-2010-P-0396-0003,FDA-2010-P-0396,"cephalon, inc - supplement",0,0
0900006480b21361,Other,FDA-2010-P-0396-0002,FDA-2010-P-0396,"acknowledgement letter to cephalon, inc",0,0
0900006480bc9e86,Other,FDA-2010-P-0396-0004,FDA-2010-P-0396,"fda/cder to fish & richardson, p.c., (cephalon , inc.) - petition denial",0,0
0900006480b21223,Other,FDA-2010-P-0396-0001,FDA-2010-P-0396,"cephalon, inc. - citizen petition",0,0
0900006482a8cb69,Other,FDA-2017-P-5080-0001,FDA-2017-P-5080,citizen petition from quagen pharmaceuticals llc,0,0
0900006482a8d28e,Other,FDA-2017-P-5080-0002,FDA-2017-P-5080,acknowledgement letter from fda ddm to quagen pharmaceuticals llc,0,0
090000648499e486,Other,FDA-2017-P-5080-0004,FDA-2017-P-5080,withdrawal from quagen pharmaceuticals llc,0,0
0900006482f31492,Other,FDA-2017-P-5080-0003,FDA-2017-P-5080,interim response letter from fda cder to quagen pharmaceuticals llc,0,0
0900006480fe6e4a,Other,FDA-2012-P-0317-0001,FDA-2012-P-0317,abbott laboratories (covington & burling llp) -  citizen petition,0,0
09000064821533b9,Other,FDA-2012-P-0317-0009,FDA-2012-P-0317,abbvie meeting minutes,0,0
090000648225d84a,Other,FDA-2012-P-0317-0010,FDA-2012-P-0317,citizen petition denial response from fda cder to covington & burling llp (abbott laboratories),0,0
0900006480fe7a80,Other,FDA-2012-P-0317-0002,FDA-2012-P-0317,acknowledgement letter to abbott laboratories (covington & burling llp),0,0
090000648114ac14,Other,FDA-2012-P-0317-0005,FDA-2012-P-0317,interim response to abbott laboratories (covington & burling llp) - letter,0,0
090000648446403b,Other,FDA-2020-P-1181-0001,FDA-2020-P-1181,"petition for stay of action from todd & weld, llp",0,0
09000064848579c7,Other,FDA-2020-P-1181-0003,FDA-2020-P-1181,"letter from fda cdrh to todd & weld, llp",0,0
090000648446403c,Other,FDA-2020-P-1181-0002,FDA-2020-P-1181,"acknowledgment letter from fda dms to todd & weld, llp",0,0
090000648433d00f,Other,FDA-2019-P-3803-0003,FDA-2019-P-3803,"interim response letter from fda cder to hyman, phelps & mcnamara p c",0,0
090000648498557f,Other,FDA-2019-P-3803-0004,FDA-2019-P-3803,withdrawal from hyman phelps & mcnamara,0,0
0900006483e34bf0,Other,FDA-2019-P-3803-0001,FDA-2019-P-3803,"citizen petition from hyman, phelps & mcnamara p.c",0,0
0900006483e34bf1,Other,FDA-2019-P-3803-0002,FDA-2019-P-3803,"acknowledgment letter from fda dms to hyman, phelps & mcnamara p.c.",0,0
0900006484bd1c5d,Other,FDA-2020-P-2357-0004,FDA-2020-P-2357,180 day interim response letter from fda cfsan to keller and heckman llp,0,0
09000064849ce2e5,Other,FDA-2020-P-2357-0001,FDA-2020-P-2357,"citizen petition from keller and heckman llp on behalf of nexira, alland & robert and importers service corporation",0,0
09000064849ce2e6,Other,FDA-2020-P-2357-0002,FDA-2020-P-2357,"acknowledgment letter from fda dms to keller and heckman llp n behalf of nexira, alland & robert, and importers service corporation",0,0
09000064849ce2e9,Supporting & Related Material,FDA-2020-P-2357-0003,FDA-2020-P-2357,"appendix i uebelhack re citizen petition from keller and heckman llp on behalf of nexira, alland & robert and importers service corporation",0,0
0900006481cfd30a,Other,FDA-2015-P-3991-0002,FDA-2015-P-3991,acknowledgement letter from fda ddm to the take back america campaign,0,0
0900006481cfd30f,Supporting & Related Material,FDA-2015-P-3991-0003,FDA-2015-P-3991,end notes re citizen petition from the take back america campaign,0,0
0900006481dbfc7d,Other,FDA-2015-P-3991-0009,FDA-2015-P-3991,"supplement from fred mayer, ppsi",0,0
0900006481fba4dd,Other,FDA-2015-P-3991-0010,FDA-2015-P-3991,"citizen petition interim response from fda op to roger morgan, frederick mayer, ron allen, scott chipman",0,0
0900006481cfbfd5,Other,FDA-2015-P-3991-0001,FDA-2015-P-3991,citizen petition from the take back america campaign,0,0
0900006481d5cd54,Other,FDA-2015-P-3991-0005,FDA-2015-P-3991,supplement from ppsi,0,0
0900006481d5cd5a,Supporting & Related Material,FDA-2015-P-3991-0006,FDA-2015-P-3991,citizen petition from take back america campaign re supplement from ppsi,0,0
0900006481d5cd5b,Supporting & Related Material,FDA-2015-P-3991-0007,FDA-2015-P-3991,public policy statement from the american society of addiction medicine re supplement from ppsi,0,0
0900006481d5cd5c,Supporting & Related Material,FDA-2015-P-3991-0008,FDA-2015-P-3991,letter from ppsi to fda re supplement from ppsi,0,0
0900006481cfd637,Supporting & Related Material,FDA-2015-P-3991-0004,FDA-2015-P-3991,day dreamers and marinol re citizen petition from the take back america campaign,0,0
09000064824e1346,Other,FDA-2017-P-1251-0002,FDA-2017-P-1251,acknowledgement letter from fda ddm to american feed industry association and national grain and feed association,0,0
09000064824e1344,Other,FDA-2017-P-1251-0001,FDA-2017-P-1251,citizen petition from american feed industry association and national grain and feed association,0,0
0900006482a9f8c8,Other,FDA-2017-P-1251-0003,FDA-2017-P-1251,tentative response from fda cvm to ngfa,0,0
09000064820a577c,Other,FDA-2016-P-0214-0007,FDA-2016-P-0214,interim response from cber to rosalind advisors inc,0,0
0900006481e1a1fa,Other,FDA-2016-P-0214-0002,FDA-2016-P-0214,"acknowledgement letter from fda ddm to rosalind advisors, inc.",0,0
09000064821b8643,Other,FDA-2016-P-0214-0008,FDA-2016-P-0214,denial response from fda cber to public citizen,0,0
0900006481e1a1f9,Other,FDA-2016-P-0214-0001,FDA-2016-P-0214,"citizen petition from rosalind advisors, inc.",0,0
0900006484dc0101,Other,FDA-2021-P-0378-0003,FDA-2021-P-0378,interim response letter from fda cder to public citizen’s health research group,0,0
0900006484aa49c6,Other,FDA-2021-P-0378-0002,FDA-2021-P-0378,acknowledgement letter from fda dms to public citizen’s health research group,0,0
0900006484aa49c4,Other,FDA-2021-P-0378-0001,FDA-2021-P-0378,citizen petition from public citizen’s health research group,0,0
0900006484dc3cfa,Other,FDA-2021-P-1102-0001,FDA-2021-P-1102,citizen petition from pet schooled,0,0
0900006484dc3ee3,Other,FDA-2021-P-1102-0002,FDA-2021-P-1102,acknowledgment letter from fda dms to pet schooled,0,0
090000648299cde7,Other,FDA-2015-P-3391-0006,FDA-2015-P-3391,"denial letter from cfsan to ashley franz (patricia syverson, bonnett fairbourn friedmant & balint, pc)",0,0
0900006481c7c2c9,Other,FDA-2015-P-3391-0002,FDA-2015-P-3391,"acknowledgement letter from fda ddm to patricia syverson, bonnett fairbourn friedmant & balint, pc",0,0
0900006481c7cdc5,Supporting & Related Material,FDA-2015-P-3391-0003,FDA-2015-P-3391,"attachment a images of product label re citizen petition from ashley franz (patricia syverson, bonnett fairbourn friedmant & balint, pc)",0,0
0900006481c7cdc6,Supporting & Related Material,FDA-2015-P-3391-0004,FDA-2015-P-3391,"attachment b order granting motion from the united states district court southern district of california re citizen petition from  ashley franz (patricia syverson, bonnett fairbourn friedmant & balint, pc)",0,0
0900006481c7c167,Other,FDA-2015-P-3391-0001,FDA-2015-P-3391,"citizen petition from ashley franz (patricia syverson, bonnett fairbourn friedmant & balint, pc)",0,0
0900006483b68912,Other,FDA-2019-P-1364-0005,FDA-2019-P-1364,withdrawal from public citizen,0,0
0900006483b134a9,Other,FDA-2019-P-1364-0003,FDA-2019-P-1364,acknowledgment letter from fda ddm to public citizen's health research group,0,0
0900006483b13310,Other,FDA-2019-P-1364-0001,FDA-2019-P-1364,citizen petition from public citizen's health research group,0,0
0900006483b13efe,Other,FDA-2019-P-1364-0002,FDA-2019-P-1364,cover letter petition  from public citizen's health research group,0,0
0900006483b13ef8,Supporting & Related Material,FDA-2019-P-1364-0004,FDA-2019-P-1364,"attachment 1 - new opioid analgesic approvals and outpatient utilization of opioid analgesics in the united states, 1997 through 2015 re:  citizen petition from public citizen’s health research group",0,0
0900006482538d3c,Supporting & Related Material,FDA-2017-P-2044-0003,FDA-2017-P-2044,"attachment a - understanding the epidemic _ drug overdose _ cdc injury center-1 re citizen petition from nirsum pharmaceuticals, llc",0,0
0900006482538d3f,Supporting & Related Material,FDA-2017-P-2044-0006,FDA-2017-P-2044,"attachment d drug approvals and databases _ june 2015_ additions and deletions to the drug product list re citizen petition from nirsum pharmaceuticals, llc",0,0
090000648258019b,Other,FDA-2017-P-2044-0013,FDA-2017-P-2044,report from nikej shah,0,0
0900006482c4111a,Other,FDA-2017-P-2044-0017,FDA-2017-P-2044,"final determination response to nirsum pharmaceuticals, inc",0,0
0900006482c3e67f,Notice,FDA-2017-P-2044-0016,FDA-2017-P-2044,"determination that revex (nalmefene hydrochloride injection), 0.1 milligram base/milliliter and 1.0 milligram base/milliliter, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006482538d56,Supporting & Related Material,FDA-2017-P-2044-0012,FDA-2017-P-2044,"attachment j - selincro epar re citizen petition from nirsum pharmaceuticals, llc",0,0
0900006482538d55,Supporting & Related Material,FDA-2017-P-2044-0011,FDA-2017-P-2044,"attachment i - essence 2  re citizen petition from nirsum pharmaceuticals, llc",0,0
0900006482538d3d,Supporting & Related Material,FDA-2017-P-2044-0004,FDA-2017-P-2044,"attachment b - revex orange book re citizen petition from nirsum pharmaceuticals, llc",0,0
0900006482538d52,Supporting & Related Material,FDA-2017-P-2044-0008,FDA-2017-P-2044,"attachment f - revex label updated april 2006 re citizen petition from nirsum pharmaceuticals, llc",0,0
0900006482538d54,Supporting & Related Material,FDA-2017-P-2044-0010,FDA-2017-P-2044,"attachment h - essence 1 re citizen petition from nirsum pharmaceuticals, llc",0,0
09000064825875a6,Other,FDA-2017-P-2044-0014,FDA-2017-P-2044,report from nikej shah,0,0
0900006482538d3e,Supporting & Related Material,FDA-2017-P-2044-0005,FDA-2017-P-2044,"attachment c - drug approvals and databases _ june 2008_ additions and deletions to the drug product list re citizen petition from nirsum pharmaceuticals, llc",0,0
0900006482538d53,Supporting & Related Material,FDA-2017-P-2044-0009,FDA-2017-P-2044,"attachment g - essence 1 - 2 subgroup analysis re citizen petition from nirsum pharmaceuticals, llc",0,0
0900006482538d51,Supporting & Related Material,FDA-2017-P-2044-0007,FDA-2017-P-2044,"attachment e - fda snda letter 2006 re citizen petition from nirsum pharmaceuticals, llc",0,0
0900006482538845,Other,FDA-2017-P-2044-0001,FDA-2017-P-2044,"citizen petition from nirsum pharmaceuticals, llc",0,0
0900006482538bad,Other,FDA-2017-P-2044-0002,FDA-2017-P-2044,"acknowledgment letter from fda ddm to nirsum pharmaceuticals, llc",0,0
090000648253da36,Supporting & Related Material,FDA-2017-P-2128-0004,FDA-2017-P-2128,exhibit iii - proposed label re citizen petition from jubilant generics limited,0,0
090000648253da34,Supporting & Related Material,FDA-2017-P-2128-0005,FDA-2017-P-2128,exhibit i - orange book re citizen petition from jubilant generics limited,0,0
090000648253da35,Supporting & Related Material,FDA-2017-P-2128-0003,FDA-2017-P-2128,exhibit ii - fluoxetine tabs 60 mg rld label re citizen petition from jubilant generics limited,0,0
090000648253dcaa,Other,FDA-2017-P-2128-0002,FDA-2017-P-2128,acknowledgment letter from fda ddm to jubilant generics limited,0,0
090000648253da32,Other,FDA-2017-P-2128-0001,FDA-2017-P-2128,citizen petition from jubilant generics limited,0,0
0900006482db3e96,Supporting & Related Material,FDA-2018-P-0098-0005,FDA-2018-P-0098,"attachment 3 labeling for zonegran® re citizen petition from lachman consultant services, inc.",0,0
0900006482db3e95,Supporting & Related Material,FDA-2018-P-0098-0004,FDA-2018-P-0098,"attachment 2 draft insert labeling proposed for zonisamide capsules re citizen petition from lachman consultant services, inc.",0,0
0900006482db3e94,Supporting & Related Material,FDA-2018-P-0098-0003,FDA-2018-P-0098,"attachment 1 relevant copy of the page from the current edition of the electronic approved drug products with therapeutic equivalence evaluations, accessed january 8, 2018 re citizen petition from lachman consultant services, inc.",0,0
0900006482db3e90,Other,FDA-2018-P-0098-0001,FDA-2018-P-0098,"citizen petition from lachman consultant services, inc.",0,0
0900006482dcef25,Other,FDA-2018-P-0098-0002,FDA-2018-P-0098,"acknowledgment letter from fda ddm  to lachman consultant services, inc.",0,0
09000064810c7496,Notice,FDA-2011-N-0608-0010,FDA-2011-N-0608,"agency information collection activities; proposals, submissions, and approvals: medwatch, food and drug administration medical products reporting program",1,0
0900006480f14d60,Notice,FDA-2011-N-0608-0001,FDA-2011-N-0608,"agency information collection activities; proposals, submissions, and approvals: medwatch - medical products reporting program",0,0
0900006480f7d55c,Notice,FDA-2011-N-0608-0009,FDA-2011-N-0608,"agency information collection activities; proposals, submissions, and approvals: medwatch; medical products reporting program",0,0
0900006483516f51,Other,FDA-2018-P-1740-0005,FDA-2018-P-1740,amended citizen petition from provetica animal health llc,0,0
090000648360175b,Other,FDA-2018-P-1740-0006,FDA-2018-P-1740,suitability response letter from fda cvm to provetica animal health llc,0,0
090000648322860d,Supporting & Related Material,FDA-2018-P-1740-0004,FDA-2018-P-1740,"appendix 2-proposed product label (draft) - generic deracoxib chewable tablets, provetica animal health llc",0,0
0900006483228932,Other,FDA-2018-P-1740-0002,FDA-2018-P-1740,acknowledgment letter from fda ddm to provetica animal health llc,0,0
090000648322860c,Supporting & Related Material,FDA-2018-P-1740-0003,FDA-2018-P-1740,"appendix 1- pioneer product label - deramaxx™ (deracoxib) chewable tablets, elanco us inc., nada 141-203",0,0
09000064832283ff,Other,FDA-2018-P-1740-0001,FDA-2018-P-1740,citizen petition from provetica animal health llc,0,0
090000648313c16e,Other,FDA-2015-A-5109-0003,FDA-2015-A-5109,petition denial letter from fda cfsan,0,0
0900006481ddfb0d,Other,FDA-2015-A-5109-0001,FDA-2015-A-5109,"advisory opinion request from wallace, jordan, ratliff & brandt, llc",0,0
0900006481ddfb0f,Other,FDA-2015-A-5109-0002,FDA-2015-A-5109,"acknowledgement letter from fda ddm to wallace, jordan, ratliff & brandt, llc",0,0
0900006481d92cbe,Other,FDA-2015-D-4380-0002,FDA-2015-D-4380,"best practices for communication between ind sponsors and fda
during drug development guidance for industry and review staff",0,0
0900006481d9267b,Notice,FDA-2015-D-4380-0001,FDA-2015-D-4380,"best practices for communication between investigational new drug
sponsors and food and drug administration during drug development; draft guidance for industry and review staff; availability",1,0
09000064816d0a96,Other,FDA-2014-P-0534-0002,FDA-2014-P-0534,acknowledgement letter from fda ddm to neurelis inc. (pacific link consulting),0,0
09000064816e91a7,Other,FDA-2014-P-0534-0004,FDA-2014-P-0534,withdrawal from pacific-link consulting,0,0
09000064816cfdcd,Other,FDA-2014-P-0534-0001,FDA-2014-P-0534,citizen petition from neurelis inc. (pacific link consulting),0,0
09000064816f2f0c,Other,FDA-2014-P-0534-0003,FDA-2014-P-0534,withdrawal letter from pacific link consulting,0,0
09000064843c64cf,Other,FDA-2020-P-0983-0001,FDA-2020-P-0983,citizen petition from grbiosystems inc.,0,0
09000064843c64d0,Other,FDA-2020-P-0983-0002,FDA-2020-P-0983,acknowledgment letter from fda dms to grbiosystems inc.,0,0
090000648484500b,Other,FDA-2020-P-0983-0003,FDA-2020-P-0983,interim response letter from fda cder to grbiosystems inc,0,0
090000648377a1e9,Notice,FDA-2018-D-1752-0001,FDA-2018-D-1752,"public availability of lists of retail consignees to effectuate certain
human and animal food recalls; draft guidance for industry and food and drug administration staff; availability",1,0
090000648377c2d6,Other,FDA-2018-D-1752-0002,FDA-2018-D-1752,public availability of lists of retail consignees to effectuate certain human and animal food recalls guidance for industry and fda staff,1,0
090000648497085c,Other,FDA-2018-D-1752-0029,FDA-2018-D-1752,"public availability of lists of retail consignees to effectuate certain
human and animal food recalls; guidance for industry and food and
drug administration staff; availability",1,0
0900006484970634,Notice,FDA-2018-D-1752-0028,FDA-2018-D-1752,"public availability of lists of retail consignees to effectuate certain
human and animal food recalls; guidance for industry and food and
drug administration staff; availability",1,0
090000648377d7ae,Other,FDA-2018-P-3672-0001,FDA-2018-P-3672,suitability petition from zoetis inc.,0,0
090000648377d867,Other,FDA-2018-P-3672-0002,FDA-2018-P-3672,acknowledgment letter from fda ddm to zoetis lnc.,0,0
09000064839bef4a,Other,FDA-2018-P-3672-0005,FDA-2018-P-3672,suitability petition approval letter from fda cvm to  from zoetis inc.,0,0
090000648377d86b,Supporting & Related Material,FDA-2018-P-3672-0003,FDA-2018-P-3672,"attachment 1. pioneer product label - nicarb• (nicarbazin) 25% type a medicated article, nada 009-476, phibro animal health corporation re: suitability petition from zoetis inc.",0,0
090000648377d86c,Supporting & Related Material,FDA-2018-P-3672-0004,FDA-2018-P-3672,"attachment 2. proposed generic product label (draft) - generic ""nkarbazin 25% type a medicated article,""zoetls inc re: suitability petition from zoetis inc.",0,0
0900006482b650a9,Supporting & Related Material,FDA-2017-P-5787-0007,FDA-2017-P-5787,reference 5 andersson_cloned human and rat steroid 5α-reductases (pnas 1990) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b658b5,Supporting & Related Material,FDA-2017-P-5787-0011,FDA-2017-P-5787,"reference 9 antiandrogen drugs definition (free online medical dictionary, thesaurus and encyclopedia 2013) re citizen petition post- finasteride syndrome foundation",0,0
0900006482b658b6,Supporting & Related Material,FDA-2017-P-5787-0012,FDA-2017-P-5787,reference 10 aumuller_localization of 5ar isoenzymes in human tissue (acta anat 1996) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b658d7,Supporting & Related Material,FDA-2017-P-5787-0028,FDA-2017-P-5787,reference 26 castelli_regional distribution of 5ar2 in rat brain (psychoneuroendocrin 2013) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b658d9,Supporting & Related Material,FDA-2017-P-5787-0030,FDA-2017-P-5787,reference 28 castro-magana_finasteride and human testicular steroidogenesis (j androl 1996) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b659f2,Supporting & Related Material,FDA-2017-P-5787-0054,FDA-2017-P-5787,reference 52 geller_castration-like effects of finasteride on prostate (j cell biochem 1992) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b65a1e,Supporting & Related Material,FDA-2017-P-5787-0069,FDA-2017-P-5787,reference 67 imperato-mcginley_5ar deficiency and pseudohermaphrotism (science 1974) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b65a20,Supporting & Related Material,FDA-2017-P-5787-0071,FDA-2017-P-5787,reference 69 imperato-mcginley_c19 and c21 metabolites w finasteride and 5ar2 deficiency (jcem 1990) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b65a8d,Supporting & Related Material,FDA-2017-P-5787-0093,FDA-2017-P-5787,reference 91 labrie_serum steroid precursors and androgen metabolites (j clin endocrinol metab 1997) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b65ba9,Supporting & Related Material,FDA-2017-P-5787-0199,FDA-2017-P-5787,reference 197 whiting_finasteride 1 mg in mphl age 41-60 (eur j dermotol 2003) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b65bac,Supporting & Related Material,FDA-2017-P-5787-0202,FDA-2017-P-5787,reference 200 yamana_type 3 5ar inhibition by finasteride and dutasteride (horm mol clin invest 2010) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b65d4e,Supporting & Related Material,FDA-2017-P-5787-0057,FDA-2017-P-5787,reference 55 glina_finasteride and infertility (rev hosp clin 2004) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b65d51,Supporting & Related Material,FDA-2017-P-5787-0060,FDA-2017-P-5787,"reference 58 gormley_treating aga with 5-alpha reductase inhibitors_u.s. patent # 5,547,957 (20-aug-1996) re citizen petition post- finasteride syndrome foundation",0,0
0900006482b65aa8,Supporting & Related Material,FDA-2017-P-5787-0098,FDA-2017-P-5787,reference 96 lugg_dht and no penile erection in the the rat (endocrin 1995) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b65aab,Supporting & Related Material,FDA-2017-P-5787-0101,FDA-2017-P-5787,reference 99 mantzoros_dht and male sexual behavior (bmj 1995) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b65ac9,Supporting & Related Material,FDA-2017-P-5787-0111,FDA-2017-P-5787,reference 109 medwatch fda form 3500_pfss#4 continued (26-may-2017) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b65afa,Supporting & Related Material,FDA-2017-P-5787-0127,FDA-2017-P-5787,reference 125 moore_finasteride and uncertainty in establishing harm (jama derm 2015) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b65b00,Supporting & Related Material,FDA-2017-P-5787-0131,FDA-2017-P-5787,reference 129 o'donnell_t-dependent spermatogenesis in rats and 5ari (j androl 1999) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b65b03,Supporting & Related Material,FDA-2017-P-5787-0134,FDA-2017-P-5787,reference 132 park_androgens and nos mrna in rat corpus cavernosum (bju int 1999) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b65b27,Supporting & Related Material,FDA-2017-P-5787-0145,FDA-2017-P-5787,reference 143 propecia full prescribing info (31-jan-2014) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b65b2e,Supporting & Related Material,FDA-2017-P-5787-0152,FDA-2017-P-5787,"reference 150 rittmaster_adiol-g in liver, skin and prostate (jcem 1993) re citizen petition post- finasteride syndrome foundation",0,0
0900006482b65b73,Supporting & Related Material,FDA-2017-P-5787-0178,FDA-2017-P-5787,reference 176 suzuki_pk and binding of finasteride to 5ar1 and 5ar2 (drug metab pharmacokin 2010),0,0
0900006482b65b74,Supporting & Related Material,FDA-2017-P-5787-0179,FDA-2017-P-5787,reference 177 tay_finasteride in adenoca of prostate (ann onc 2004) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b65b75,Supporting & Related Material,FDA-2017-P-5787-0180,FDA-2017-P-5787,reference 178 the pharma letter_fda c'tee raises concerns over merck's propecia (11-19-97) re citizen petition post- finasteride syndrome foundation,0,0
0900006482b65b76,Supporting & Related Material,FDA-2017-P-5787-0181,FDA-2017-P-5787,reference 179 the pharma letter_propecia approved in us for mpb (1-12-98) re citizen petition post- finasteride syndrome foundation,0,0
09000064842c8ffc,Notice,FDA-2019-N-5646-0001,FDA-2019-N-5646,"food and drug administration rare disease day 2020: supporting the future of rare disease product development; public meeting; request
for comments",1,0
090000648447b8be,Supporting & Related Material,FDA-2020-P-1238-0003,FDA-2020-P-1238,"exhibits re petition for stay of action from cigar association of america, inc.",0,0
0900006484472a76,Other,FDA-2020-P-1238-0001,FDA-2020-P-1238,"petition for stay of action from cigar association of america, inc.",0,0
090000648447b8bc,Other,FDA-2020-P-1238-0002,FDA-2020-P-1238,"acknowledgment letter from fda dms to cigar association of america, inc.",0,0
09000064849f2b38,Supporting & Related Material,FDA-2021-P-0074-0005,FDA-2021-P-0074,"attachment 3 re suitability petition from hyman, phelps & mcnamara pc",0,0
09000064849f2ea5,Supporting & Related Material,FDA-2021-P-0074-0003,FDA-2021-P-0074,"attachment 1 re suitability petition from hyman, phelps & mcnamara pc",0,0
09000064849f2ea6,Supporting & Related Material,FDA-2021-P-0074-0004,FDA-2021-P-0074,"attachment 2 re suitability petition from hyman, phelps & mcnamara pc",0,0
09000064849f2ea4,Other,FDA-2021-P-0074-0002,FDA-2021-P-0074,"acknowledgement letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
09000064849f2ea3,Other,FDA-2021-P-0074-0001,FDA-2021-P-0074,"suitability petition from hyman, phelps & mcnamara, p.c.",0,0
09000064838bd33f,Other,FDA-2018-P-4306-0001,FDA-2018-P-4306,citizen petition from jill h. osborne,0,0
0900006483c3e5c3,Other,FDA-2018-P-4306-0037,FDA-2018-P-4306,interim response from fda cder  re citizen petition,0,0
0900006484b306c8,Other,FDA-2018-P-4306-0050,FDA-2018-P-4306,response letter from fda cder to jill h. osborne,0,0
09000064838bdb53,Other,FDA-2018-P-4306-0002,FDA-2018-P-4306,acknowledgment letter from fda ddm to jill h. osborne,0,0
090000648045c689,Supporting & Related Material,FDA-2006-N-0308-0003,FDA-2006-N-0308,supporting statement,0,0
090000648045c68f,Supporting & Related Material,FDA-2006-N-0308-0006,FDA-2006-N-0308,supporting statement,0,0
090000648045c682,Notice,FDA-2006-N-0308-0002,FDA-2006-N-0308,fda,0,0
090000648045c68b,Supporting & Related Material,FDA-2006-N-0308-0004,FDA-2006-N-0308,supporting statement,0,0
090000648045c68d,Supporting & Related Material,FDA-2006-N-0308-0005,FDA-2006-N-0308,supporting statement,0,0
090000648045c667,Notice,FDA-2006-N-0308-0001,FDA-2006-N-0308,fda,0,0
090000648045c691,Notice,FDA-2006-N-0308-0007,FDA-2006-N-0308,fda,0,0
09000064809c8b1d,Notice,FDA-2009-N-0251-0001,FDA-2009-N-0251,"agency information collection activities; proposals, submissions, and approvals",0,0
0900006480a59071,Notice,FDA-2009-N-0251-0003,FDA-2009-N-0251,agency information collection activities; submission for office of management and budget review; comment request; user fee cover sheet; form fda 3397,0,0
090000648080b358,Other,FDA-2009-P-0663-0002,FDA-2009-P-0663,"acknowledgment letter from fda ddm to pharmaforce, inc.",0,0
090000648080b337,Other,FDA-2009-P-0663-0001,FDA-2009-P-0663,"citizen petition from pharmaforce, inc.",0,0
090000648097fcef,Other,FDA-2009-P-0663-0003,FDA-2009-P-0663,"withdrawal letter from pharmaforce, inc.",0,0
0900006484a924b0,Other,FDA-2021-P-0344-0002,FDA-2021-P-0344,acknowledgment letter from fda dms to zydus pharmaceuticals usa inc,0,0
0900006484a924ae,Other,FDA-2021-P-0344-0001,FDA-2021-P-0344,suitability petition from zydus pharmaceuticals usa inc,0,0
0900006484a924d0,Supporting & Related Material,FDA-2021-P-0344-0004,FDA-2021-P-0344,attachment 2 approved labeling for indocin indomethacin suppositories nda re suitability petition from zydus pharmaceuticals usa inc,0,0
0900006484a924cf,Supporting & Related Material,FDA-2021-P-0344-0003,FDA-2021-P-0344,attachment 1 orange book pages of rld indocin indomethacin suppositories re suitability petition from zydus pharmaceuticals usa inc,0,0
0900006484d67902,Notice,FDA-2018-N-3037-0004,FDA-2018-N-3037,"agency information collection activities; proposed collection; comment request; generic clearance for quantitative testing for the development of food and drug
administration communications",1,0
09000064839cbd39,Notice,FDA-2018-N-3037-0002,FDA-2018-N-3037,"agency information collection activities; submission for office of
management and budget review; comment request; generic clearance
for quantitative testing for the development of food and drug
administration communications",1,0
0900006483694ae5,Notice,FDA-2018-N-3037-0001,FDA-2018-N-3037,agency information collection activities; proposed collection; comment request; generic clearance for quantitative testing for the development of fda communications,0,0
0900006483c131a7,Notice,FDA-2018-N-3037-0003,FDA-2018-N-3037,"agency information collection activities; announcement of office of
management and budget approvals",0,0
0900006484dbe791,Supporting & Related Material,FDA-2021-P-1085-0004,FDA-2021-P-1085,"envelope re suitability petition from ray law firm, pllc",0,0
0900006484dbe7db,Supporting & Related Material,FDA-2021-P-1085-0003,FDA-2021-P-1085,"attachment 1 re suitability petition from ray law firm, pllc",0,0
0900006484dbe7d9,Other,FDA-2021-P-1085-0002,FDA-2021-P-1085,"acknowledgment letter from fda dms to ray law firm, pllc",0,0
0900006484dbe6c3,Other,FDA-2021-P-1085-0001,FDA-2021-P-1085,"suitability petition from ray law firm, pllc",0,0
09000064843d0508,Other,FDA-2020-P-1003-0001,FDA-2020-P-1003,"citizen petition from john j. coleman,  m.a., m.s., ph.d.",0,0
09000064843d0302,Other,FDA-2020-P-1003-0002,FDA-2020-P-1003,"acknowledgment letter from fda dms to john j. coleman,  m.a., m.s., ph.d.",0,0
090000648471012f,Other,FDA-2020-P-1003-0003,FDA-2020-P-1003,interim response letter from fda cdrh to john j. coleman,0,0
090000648216dfea,Supporting & Related Material,FDA-2016-P-2478-0013,FDA-2016-P-2478,"tab 11 - wallace p. adams et al., demonstrating bioequivalence of locally acting orally inhaled drug products, 23 j aerosol med pulm drug deliv 1 (2010) re citizen petition from hogan lovells us llp (united therapeutics corporation (ut)",0,0
090000648216e28f,Supporting & Related Material,FDA-2016-P-2478-0003,FDA-2016-P-2478,"tab 1 - iso 27427, anaesthetic and respiratory equipment – nebulizing systems and components (2010) re citizen petition from hogan lovells us llp (united therapeutics corporation (ut)",0,0
090000648216e292,Supporting & Related Material,FDA-2016-P-2478-0006,FDA-2016-P-2478,"tab 4 - ah kendrick et al., selecting and using nebulizer equipment, 52 suppl 2 thorax s92 (1997) re citizen petition from hogan lovells us llp (united therapeutics corporation (ut)",0,0
090000648216e291,Supporting & Related Material,FDA-2016-P-2478-0005,FDA-2016-P-2478,"tab 3 - andrew m. wilson et al., importance of drug-device interaction in determining systemic effects of inhaled corticosteroids, 353 lancet 2128 (1999) re citizen petition from hogan lovells us llp (united therapeutics corporation (ut)",0,0
090000648216e294,Supporting & Related Material,FDA-2016-P-2478-0008,FDA-2016-P-2478,"tab 6 - d. todd loffert et al., a comparison of commercial jet nebulizers, 106 chest 1788 (1994) re citizen petition from hogan lovells us llp (united therapeutics corporation (ut)",0,0
090000648216e28b,Other,FDA-2016-P-2478-0002,FDA-2016-P-2478,acknowledgement lette from fda ddm to hogan lovells us llp,0,0
090000648216dfe6,Supporting & Related Material,FDA-2016-P-2478-0009,FDA-2016-P-2478,"tab 7  - jg hardy et al., lung deposition from four nebulizers, 87 respir med 461 (1993) re citizen petition from hogan lovells us llp (united therapeutics corporation (ut)",0,0
090000648216dfe8,Supporting & Related Material,FDA-2016-P-2478-0011,FDA-2016-P-2478,"tab 9 -  t. gessler et al., ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension, 17 eur respir j 14, 16-17 (2001) re citizen petition from hogan lovells us llp (united therapeutics corporation (ut)",0,0
090000648216e1a8,Other,FDA-2016-P-2478-0001,FDA-2016-P-2478,citizen petition from hogan lovells us llp (united therapeutics corporation (ut),0,0
090000648216e290,Supporting & Related Material,FDA-2016-P-2478-0004,FDA-2016-P-2478,"tab 2 - food and drug administration, respiratory drug delivery devices – a cdrh perspective (nov. 2, 2010) re citizen petition from hogan lovells us llp (united therapeutics corporation (ut)",1,0
090000648216e293,Supporting & Related Material,FDA-2016-P-2478-0007,FDA-2016-P-2478,"tab 5 - dean hess et al., medication nebulizer performance: effects of diluent volume, nebulizer flow, and nebulizer brand, 110 chest 498 (1996) re citizen petition from hogan lovells us llp (united therapeutics corporation (ut)",0,0
090000648216dfe7,Supporting & Related Material,FDA-2016-P-2478-0010,FDA-2016-P-2478,"tab 8 - christopher o’callaghan & peter w. barry, the science of nebulised drug delivery, 52 suppl 2 thorax s31, s36 (1997) re citizen petition from hogan lovells us llp (united therapeutics corporation (ut)",0,0
090000648216dfe9,Supporting & Related Material,FDA-2016-P-2478-0012,FDA-2016-P-2478,"tab 10 - lawrence x. yu, quality by design for orally inhaled drug products, pqri workshop on demonstrating bioequivalence of locally acting orally inhaled drug products (mar. 9-11, 2009) re citizen petition from hogan lovells us llp (united therapeutics corporation (ut)",0,0
090000648244de3f,Other,FDA-2016-P-2478-0014,FDA-2016-P-2478,petition denial letter from fda cder to hogan lovells us llp,0,0
090000648253fbbf,Supporting & Related Material,FDA-2017-P-2162-0006,FDA-2017-P-2162,"tab 4 - ah kendrick et al., selecting and using nebulizer equipment, 52 suppl 2 thorax s92 (1997) re citizen petition from hyman, phelps & mcnamara, p.c. (united therapeutics corp)",0,0
090000648253fbc2,Supporting & Related Material,FDA-2017-P-2162-0009,FDA-2017-P-2162,"tab 7 - jg hardy et al., lung deposition from four nebulizers, 87 respir med 461 (1993) re citizen petition from hyman, phelps & mcnamara, p.c. (united therapeutics corp)",0,0
090000648253fbc3,Supporting & Related Material,FDA-2017-P-2162-0010,FDA-2017-P-2162,"tab 8 - christopher o’callaghan & peter w. barry, the science of nebulised drug delivery, 52 suppl 2 thorax s31, s36 (1997) re citizen petition from hyman, phelps & mcnamara, p.c. (united therapeutics corp)",0,0
090000648253fbbe,Supporting & Related Material,FDA-2017-P-2162-0005,FDA-2017-P-2162,"tab 3 - andrew m. wilson et al., importance of drug-device interaction in determining systemic effects of inhaled corticosteroids, 353 lancet 2128 (1999) re citizen petition from hyman, phelps & mcnamara, p.c. (united therapeutics corp)",0,0
0900006482b02489,Other,FDA-2017-P-2162-0014,FDA-2017-P-2162,"letter from fda to hyman, phelps & mcnamara",0,0
090000648253fbab,Supporting & Related Material,FDA-2017-P-2162-0003,FDA-2017-P-2162,"tab 1 - iso 27427, anaesthetic and respiratory equipment – nebulizing systems and components (2010) re citizen petition from hyman, phelps & mcnamara, p.c. (united therapeutics corp)",0,0
090000648253fbc0,Supporting & Related Material,FDA-2017-P-2162-0007,FDA-2017-P-2162,"tab 5 - dean hess et al., medication nebulizer performance: effects of diluent volume, nebulizer flow, and nebulizer brand, 110 chest 498 (1996) re citizen petition from hyman, phelps & mcnamara, p.c. (united therapeutics corp)",0,0
090000648253fbc6,Supporting & Related Material,FDA-2017-P-2162-0013,FDA-2017-P-2162,"tab 11- wallace p. adams et al., demonstrating bioequivalence of locally acting orally inhaled drug products, 23 j aerosol med pulm drug deliv 1 (2010) re citizen petition from hyman, phelps & mcnamara, p.c. (united therapeutics corp)",0,0
090000648253fbbd,Supporting & Related Material,FDA-2017-P-2162-0004,FDA-2017-P-2162,"tab 2 - food and drug administration, respiratory drug delivery devices – a cdrh perspective (nov. 2, 2010) re citizen petition from hyman, phelps & mcnamara, p.c. (united therapeutics corp)",1,0
090000648253fbc1,Supporting & Related Material,FDA-2017-P-2162-0008,FDA-2017-P-2162,"tab 6 - d. todd loffert et al., a comparison of commercial jet nebulizers, 106 chest 1788 (1994) re citizen petition from hyman, phelps & mcnamara, p.c. (united therapeutics corp)",0,0
090000648253fbc4,Supporting & Related Material,FDA-2017-P-2162-0011,FDA-2017-P-2162,"tab 9 - t. gessler et al., ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension, 17 eur respir j 14, 16-17 (2001) re citizen petition from hyman, phelps & mcnamara, p.c. (united therapeutics corp)",0,0
090000648253fbc5,Supporting & Related Material,FDA-2017-P-2162-0012,FDA-2017-P-2162,"tab 10 - lawrence x. yu, quality by design for orally inhaled drug products, pqri workshop on demonstrating bioequivalence of locally acting orally inhaled drug products (mar. 9-11, 2009) re citizen petition from hyman, phelps & mcnamara, p.c. (united therapeutics corp)",0,0
090000648253fba7,Other,FDA-2017-P-2162-0001,FDA-2017-P-2162,"citizen petition from hyman, phelps & mcnamara, p.c. (united therapeutics corp)",0,0
090000648253fba9,Other,FDA-2017-P-2162-0002,FDA-2017-P-2162,"acknowledgment letter from fda ddm to  hyman, phelps & mcnamara, p.c.",0,0
0900006480f54e1e,Notice,FDA-2011-N-0529-0012,FDA-2011-N-0529,burden of fda food safety modernization act fee amounts on small business,1,0
0900006480ed1f09,Notice,FDA-2011-N-0529-0001,FDA-2011-N-0529,burden of food and drug administration food safety modernization act fee amounts on small business,1,0
0900006481705d7c,Supporting & Related Material,FDA-2014-P-0654-0004,FDA-2014-P-0654,reference 2 attachment 2 citizen petition from edwards lifesciences llc,0,0
0900006481735f75,Other,FDA-2014-P-0654-0008,FDA-2014-P-0654,supplement from edwards lifesciences llc,0,0
090000648170561f,Other,FDA-2014-P-0654-0002,FDA-2014-P-0654,acknowledgement letter from fda ddm to edwards lifesciences llc,0,0
0900006481705d7d,Supporting & Related Material,FDA-2014-P-0654-0005,FDA-2014-P-0654,reference 3 attachment 3 citizen petition from edwards lifesciences llc,0,0
0900006481918149,Other,FDA-2014-P-0654-0009,FDA-2014-P-0654,request for reconsideration from edwards lifesciences llc,0,0
090000648170561c,Other,FDA-2014-P-0654-0001,FDA-2014-P-0654,citizen petition from  edwards lifesciences llc,0,0
0900006481705d7b,Supporting & Related Material,FDA-2014-P-0654-0003,FDA-2014-P-0654,reference 1 attachment 1 citizen petition from edwards lifesciences llc,0,0
0900006481705d7e,Supporting & Related Material,FDA-2014-P-0654-0006,FDA-2014-P-0654,reference 4 attachment 4 citizen petition from edwards lifesciences llc,0,0
0900006481a6d3b6,Supporting & Related Material,FDA-2015-P-0989-0003,FDA-2015-P-0989,tab 1 fda foia 2015_713 citizen petition from organic pastures,0,0
0900006481a6d459,Supporting & Related Material,FDA-2015-P-0989-0009,FDA-2015-P-0989,tab 7 653 f.supp.1229 citizen petition from organic pastures,0,0
0900006481a6d460,Supporting & Related Material,FDA-2015-P-0989-0015,FDA-2015-P-0989,tab 13 definitions citizen petition from organic pastures,0,0
0900006481a6d3b8,Supporting & Related Material,FDA-2015-P-0989-0005,FDA-2015-P-0989,tab 3 cadph foia response citizen petition from organic pastures,0,0
0900006481a6d45b,Supporting & Related Material,FDA-2015-P-0989-0011,FDA-2015-P-0989,tab 9 cdfa foia request citizen petition from organic pastures,0,0
0900006481a6d3b7,Supporting & Related Material,FDA-2015-P-0989-0004,FDA-2015-P-0989,tab 2 fda foia appeal citizen petition from organic pastures,0,0
0900006481a6d458,Supporting & Related Material,FDA-2015-P-0989-0008,FDA-2015-P-0989,tab 6 ca foia response citizen petition from organic pastures,0,0
0900006481a6d3b4,Other,FDA-2015-P-0989-0002,FDA-2015-P-0989,acknowledgement letter from fda ddm to organic pastures dairy company,0,0
0900006481a6d457,Supporting & Related Material,FDA-2015-P-0989-0007,FDA-2015-P-0989,tab 5 fda foia ack letter citizen petition from organic pastures,0,0
0900006481a6d45d,Supporting & Related Material,FDA-2015-P-0989-0012,FDA-2015-P-0989,tab 10 pmo definitions citizen petition from organic pastures,0,0
0900006481a6d45e,Supporting & Related Material,FDA-2015-P-0989-0013,FDA-2015-P-0989,tab 11 21cfr1240.61 citizen petition from organic pastures,0,0
0900006481a6d5b7,Supporting & Related Material,FDA-2015-P-0989-0016,FDA-2015-P-0989,tab 14 fda food safety document citizen petition from organic pastures,1,0
0900006481a6d5b9,Supporting & Related Material,FDA-2015-P-0989-0018,FDA-2015-P-0989,tab 16 cdc foia request citizen petition from organic pastures,0,0
0900006481a6d3b2,Other,FDA-2015-P-0989-0001,FDA-2015-P-0989,citizen petition from organic pastures dairy company,0,0
0900006481a6d3b9,Supporting & Related Material,FDA-2015-P-0989-0006,FDA-2015-P-0989,tab 4 fda foia request citizen petition from organic pastures,0,0
0900006481a6d45a,Supporting & Related Material,FDA-2015-P-0989-0010,FDA-2015-P-0989,tab 8 ca foia response citizen petition from organic pastures,0,0
0900006481a6d45f,Supporting & Related Material,FDA-2015-P-0989-0014,FDA-2015-P-0989,tab 12 ncsl document citizen petition from organic pastures,0,0
0900006481a6d5b8,Supporting & Related Material,FDA-2015-P-0989-0017,FDA-2015-P-0989,tab 15 psychrotrophs in dairy products citizen petition from organic pastures,0,0
090000648200404a,Notice,FDA-2016-D-1159-0001,FDA-2016-D-1159,"food and drug administration categorization of investigational device exemption devices to assist the centers for medicare and medicaid
services with coverage decisions; draft guidance for sponsors, clinical
investigators, industry, institutional review boards, and food and drug
administration staff; availability",1,0
0900006482ce1245,Other,FDA-2016-D-1159-0007,FDA-2016-D-1159,"fda categorization of investigational device exemption (ide) devices to assist the centers for medicare and medicaid services (cms) with  coverage decisions guidance for sponsors, clinical investigators, industry, institutional review boards, and food and drug administration staff",1,0
0900006482014c42,Other,FDA-2016-D-1159-0002,FDA-2016-D-1159,"fda categorization of investigational device exemption (ide) devices to assist the centers for medicare and medicaid services (cms) with coverage decisions draft guidance for sponsors, clinical investigators, industry, institutional review boards and food and drug administration staff",1,0
0900006482cdbd97,Notice,FDA-2016-D-1159-0006,FDA-2016-D-1159,"food and drug administration categorization of investigational device exemption devices to assist the centers for medicare and medicaid
services with coverage decisions; guidance for sponsors, clinical
investigators, industry, institutional review boards, and food and drug
administration staff; availability",1,0
0900006483badd00,Other,FDA-2019-P-1818-0002,FDA-2019-P-1818,acknowledgment letter from fda ddm to public citizen health research group,0,0
0900006483badd40,Supporting & Related Material,FDA-2019-P-1818-0005,FDA-2019-P-1818,attachment 3 rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics. re : citizen petition from public citizen health research group,0,0
0900006483bad73e,Other,FDA-2019-P-1818-0001,FDA-2019-P-1818,citizen petition from public citizen health research group,0,0
0900006483badd38,Supporting & Related Material,FDA-2019-P-1818-0003,FDA-2019-P-1818,attachment 1 fda required rems safety information re: citizen petition from public citizen health research group,0,0
0900006484089569,Other,FDA-2019-P-1818-0007,FDA-2019-P-1818,interim response from fda cder to public citizen's health research group,0,0
0900006483badd3a,Supporting & Related Material,FDA-2019-P-1818-0004,FDA-2019-P-1818,attachment 2 duration of treatment in postmenopausal osteoporosis: how long to treat and what are the consequences of cessation of treatment? re: citizen petition from public citizen health research group,0,0
09000064844c68e2,Other,FDA-2019-P-1818-0008,FDA-2019-P-1818,agency response letter from fda cder to public citizen's health research group,0,0
0900006482b9bff8,Other,FDA-2017-P-6027-0001,FDA-2017-P-6027,"citizen petition from axinn, veltrop & harkrider llp",0,0
0900006482b9c29f,Supporting & Related Material,FDA-2017-P-6027-0004,FDA-2017-P-6027,"attachment - 2 anda 071293 approved labeling - re citizen petition from axinn, veltrop & harkrider llp",0,0
0900006482b9c317,Supporting & Related Material,FDA-2017-P-6027-0005,FDA-2017-P-6027,"attachment - 3 proposed draft labeling re citizen petition from axinn, veltrop & harkrider llp",0,0
0900006482b9c05f,Supporting & Related Material,FDA-2017-P-6027-0003,FDA-2017-P-6027,"attachment -1 fda orange book - re citizen petition from axinn, veltrop & harkrider llp",0,0
0900006482b9c664,Other,FDA-2017-P-6027-0002,FDA-2017-P-6027,"acknowledgment letter from fda ddm to axinn, veltrop & harkrider llp",0,0
0900006483bf6be0,Other,FDA-2018-D-2074-0002,FDA-2018-D-2074,"initiation of voluntary recalls under 21 cfr part 7, subpart c guidance for industry and fda staff draft guidance",0,0
0900006483be94d9,Proposed Rule,FDA-2018-D-2074-0001,FDA-2018-D-2074,initiation of voluntary recalls draft guidance for industry and food and drug administration staff; availability,1,0
09000064848531ab,Other,FDA-2020-P-1871-0002,FDA-2020-P-1871,acknowledgment letter from fda dms to siri & glimstad llp on behalf of informed consent action network,0,0
0900006484973f36,Supporting & Related Material,FDA-2020-P-1871-0018,FDA-2020-P-1871,attachment 1 re: citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484852c30,Other,FDA-2020-P-1871-0001,FDA-2020-P-1871,citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
09000064849683a5,Other,FDA-2020-P-1871-0017,FDA-2020-P-1871,withdrawal letter from siri & glimstad,0,0
09000064848532df,Supporting & Related Material,FDA-2020-P-1871-0003,FDA-2020-P-1871,attachment 1 re: citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006483246793,Other,FDA-2017-P-6479-0004,FDA-2017-P-6479,interim response from fda cder to teligent pharma inc,0,0
0900006482c6c1aa,Other,FDA-2017-P-6479-0001,FDA-2017-P-6479,"citizen petition from teligent pharma, inc.",0,0
0900006482c6c6d3,Supporting & Related Material,FDA-2017-P-6479-0003,FDA-2017-P-6479,"orange book listing for nicardipine hydrochloride injection accessed on november 13, 2017 re citizen petition from teligent pharma, inc.",0,0
0900006482c6c507,Other,FDA-2017-P-6479-0002,FDA-2017-P-6479,acknowledgement letter from fda ddm to teligent pharma inc.,0,0
0900006484864037,Other,FDA-2017-P-6479-0005,FDA-2017-P-6479,"letter from lachman consultants services inc. and teligent pharma, inc. and hyman, phelps & mcnamara, p.c.",0,0
09000064849c1209,Other,FDA-2020-P-2008-0006,FDA-2020-P-2008,interim response letter from fda cdrh to philips respironics,0,0
090000648487682a,Other,FDA-2020-P-2008-0002,FDA-2020-P-2008,acknowledgment letter from fda dms to philips respironics,0,0
0900006484876bc3,Supporting & Related Material,FDA-2020-P-2008-0003,FDA-2020-P-2008,attachment c re: citizen petition from philips respironics,0,0
0900006484876984,Other,FDA-2020-P-2008-0001,FDA-2020-P-2008,citizen petition from philips respironics,0,0
0900006484876bc2,Supporting & Related Material,FDA-2020-P-2008-0004,FDA-2020-P-2008,attachment b re: citizen petition from philips respironics,0,0
0900006484876bc1,Supporting & Related Material,FDA-2020-P-2008-0005,FDA-2020-P-2008,attachment a re: citizen petition from philips respironics,0,0
09000064843513ae,Supporting & Related Material,FDA-2020-P-0734-0018,FDA-2020-P-0734,appendix 16 nrfit single use epidural catheter feeder example images re citizen petition from gbuk group ltd,0,0
09000064843513a4,Supporting & Related Material,FDA-2020-P-0734-0008,FDA-2020-P-0734,appendix 6 nrfit single use blunt drawing up filter needle example labels re citizen petition from gbuk group ltd,0,0
09000064843513a8,Supporting & Related Material,FDA-2020-P-0734-0012,FDA-2020-P-0734,appendix 10 nrfit single use tuohy borst adaptor example labels bns re citizen petition from gbuk group ltd,0,0
090000648435137b,Supporting & Related Material,FDA-2020-P-0734-0004,FDA-2020-P-0734,appendix 2 nrfit singel use slip syringe example labels re citizen petition from gbuk group ltd,0,0
09000064843513a6,Supporting & Related Material,FDA-2020-P-0734-0010,FDA-2020-P-0734,appendix 8 nrfit single use bacterial disc filter example labels re citizen petition from gbuk group ltd,0,0
090000648435137a,Supporting & Related Material,FDA-2020-P-0734-0003,FDA-2020-P-0734,appendix 1 nrfit single use lock syringe example labels re citizen petition from gbuk group ltd,0,0
09000064843513a5,Supporting & Related Material,FDA-2020-P-0734-0009,FDA-2020-P-0734,appendix 7 nrfit single use blunt drawing up needle example labels re citizen petition from gbuk group ltd,0,0
09000064843513a7,Supporting & Related Material,FDA-2020-P-0734-0011,FDA-2020-P-0734,appendix 9 nrfit single use epidural flat filter example labels re citizen petition from gbuk group ltd,0,0
090000648435137c,Supporting & Related Material,FDA-2020-P-0734-0005,FDA-2020-P-0734,appendix 3 nrfit single use loss of resistance syringe example labels re citizen petition from gbuk group ltd,0,0
09000064843513a9,Supporting & Related Material,FDA-2020-P-0734-0013,FDA-2020-P-0734,appendix 11 nrfit single use needle hub cap example labels re citizen petition from gbuk group ltd,0,0
09000064843513ac,Supporting & Related Material,FDA-2020-P-0734-0016,FDA-2020-P-0734,appendix 14 nrfit single use lock syringe example images re citizen petition from gbuk group ltd,0,0
09000064843513a3,Supporting & Related Material,FDA-2020-P-0734-0007,FDA-2020-P-0734,appendix 5 nrfit single use drawing up filter straw example labels re citizen petition from gbuk group ltd,0,0
09000064843513aa,Supporting & Related Material,FDA-2020-P-0734-0014,FDA-2020-P-0734,appendix 12 nrfit single use syringe to syringe adaptor example labels re citizen petition from gbuk group ltd,0,0
09000064843513ad,Supporting & Related Material,FDA-2020-P-0734-0017,FDA-2020-P-0734,appendix 15 nrfit single use needle hub cap example images re citizen petition from gbuk group ltd,0,0
09000064843513af,Supporting & Related Material,FDA-2020-P-0734-0019,FDA-2020-P-0734,appendix 17 nrfit single use blunt drawing up filter needle example images re citizen petition from gbuk group ltd,0,0
0900006484351377,Other,FDA-2020-P-0734-0002,FDA-2020-P-0734,acknowledgment letter from fda dms to gbuk group ltd,0,0
0900006484787408,Other,FDA-2020-P-0734-0020,FDA-2020-P-0734,interim response letter from fda cdrh to gbuk group ltd,0,0
090000648435137d,Supporting & Related Material,FDA-2020-P-0734-0006,FDA-2020-P-0734,appendix 4 nrfit single use syringe cap example labels re citizen petition from gbuk group ltd,0,0
09000064843513ab,Supporting & Related Material,FDA-2020-P-0734-0015,FDA-2020-P-0734,appendix 13 nrfit singel use epidural catheter feeder example labels bns re citizen petition from gbuk group ltd,0,0
0900006484351376,Other,FDA-2020-P-0734-0001,FDA-2020-P-0734,citizen petition from gbuk group ltd,0,0
0900006483741ce7,Other,FDA-2018-P-1013-0004,FDA-2018-P-1013,interim response from fda cber,0,0
0900006482fa416e,Other,FDA-2018-P-1013-0001,FDA-2018-P-1013,citizen petition from akin gump strauss hauer & feld llp on behalf of verax biomedical incorporated,0,0
0900006482fa431b,Other,FDA-2018-P-1013-0002,FDA-2018-P-1013,acknowledgment letter from fda ddm to akin gump strauss hauer & feld llp on behalf of verax biomedical incorporated,0,0
0900006482fa431d,Supporting & Related Material,FDA-2018-P-1013-0003,FDA-2018-P-1013,attachment 1 re citizen petition from akin gump strauss hauer & feld llp on behalf of verax biomedical incorporated,0,0
090000648048ea18,Supporting & Related Material,FDA-2003-D-0242-0004,FDA-2003-D-0242,guidance,0,0
090000648048ea08,Supporting & Related Material,FDA-2003-D-0242-0002,FDA-2003-D-0242,guideline,0,0
090000648048e9da,Notice,FDA-2003-D-0242-0001,FDA-2003-D-0242,fda,0,0
090000648048ea16,Supporting & Related Material,FDA-2003-D-0242-0003,FDA-2003-D-0242,guideline,0,0
090000648048ea1a,Supporting & Related Material,FDA-2003-D-0242-0005,FDA-2003-D-0242,guidance,0,0
090000648048ea1c,Notice,FDA-2003-D-0242-0006,FDA-2003-D-0242,fda,0,0
09000064804402e8,Supporting & Related Material,FDA-2005-D-0158-0003,FDA-2005-D-0158,guidance,0,0
09000064804402e6,Supporting & Related Material,FDA-2005-D-0158-0002,FDA-2005-D-0158,guidance,0,0
09000064804402e9,Supporting & Related Material,FDA-2005-D-0158-0004,FDA-2005-D-0158,guidance,0,0
09000064804402e4,Notice,FDA-2005-D-0158-0001,FDA-2005-D-0158,fda,0,0
0900006480440ea2,Other,FDA-2005-G-0193-0002,FDA-2005-G-0193,guidance for industry and fda staff - class ii special controls guidance document: low energy ultrasound wound cleaner,0,0
0900006480440e70,Notice,FDA-2005-G-0193-0001,FDA-2005-G-0193,guidance for industry and food and drug administration staff; class ii special controls guidance document: low energy ultrasound wound cleaner; availability,1,0
090000648067d46d,Supporting & Related Material,FDA-2007-P-0017-0006,FDA-2007-P-0017,mutual pharmaceutical co . - copyrighted material,0,0
090000648069ea0a,Other,FDA-2007-P-0017-0007,FDA-2007-P-0017,fda center for drug evaluation and research to william b. schultz zuckerman spaeder llp - petition denial,0,0
0900006480630398,Other,FDA-2007-P-0017-0002,FDA-2007-P-0017,mutual pharmaceutical company - citizen petition,0,0
0900006480429396,Other,FDA-2007-P-0017-0001,FDA-2007-P-0017,acknowledgement letter to zuckerman spaeder llp,0,0
0900006480630394,Supporting & Related Material,FDA-2007-P-0017-0003,FDA-2007-P-0017,mutual pharmaceutical co . tab a: skelaxin (active ingredient metaxalone) proposed revised packaging insert,0,0
0900006480630396,Supporting & Related Material,FDA-2007-P-0017-0004,FDA-2007-P-0017,mutual pharmaceutical co . - tab b: in vitro assessment of reaction phenotyping (enzyme identification) for human cytochrome p450 enzymes,0,0
0900006480630393,Supporting & Related Material,FDA-2007-P-0017-0005,FDA-2007-P-0017,mutual pharmaceutical co . - tab c: a list of the drugs and foods that are recognized to inhibit or induce the p450 enzymes,0,0
0900006480b51dc1,Notice,FDA-2010-N-0308-0001,FDA-2010-N-0308,parallel review of medical products,0,0
0900006480f5cb51,Notice,FDA-2010-N-0308-0044,FDA-2010-N-0308,pilot program for parallel review of medical products: correction,0,0
0900006480f501bb,Notice,FDA-2010-N-0308-0043,FDA-2010-N-0308,pilot program for parallel review of medical products,0,0
09000064823432a7,Notice,FDA-2010-N-0308-0047,FDA-2010-N-0308,program for parallel review of medical devices,0,0
090000648234481d,Supporting & Related Material,FDA-2010-N-0308-0048,FDA-2010-N-0308,"reference 1 - requests for feedback on medical device submissions:
the pre-submission program and meetings with food and drug administration staff guidance for industry and food and drug administration staff",1,0
09000064814c8a96,Notice,FDA-2010-N-0308-0045,FDA-2010-N-0308,see fda-2010-n-0308-0046,0,0
09000064814c8999,Notice,FDA-2010-N-0308-0046,FDA-2010-N-0308,pilot program for parallel review of medical products; extension of the duration of the program,0,0
0900006480bf730f,Other,FDA-2010-P-0545-0006,FDA-2010-P-0545,"fda/cder to ucb, inc. - petition denial",0,0
0900006480b7198f,Supporting & Related Material,FDA-2010-P-0545-0003,FDA-2010-P-0545,"exhibit a - curriculum vitae, stanley m. fineman, m.d. mba - [u.c.b, inc. - citizen petition]",0,0
0900006480b71989,Other,FDA-2010-P-0545-0001,FDA-2010-P-0545,"ucb, inc. - citizen petition",0,0
0900006480b719b8,Other,FDA-2010-P-0545-0004,FDA-2010-P-0545,"acknowledgement letter to ucb, inc.",0,0
0900006480b7198e,Supporting & Related Material,FDA-2010-P-0545-0002,FDA-2010-P-0545,"appendix a - declaration of stanley m. fineman, m.d. mba - [u.c.b, inc. - citizen petition]",0,0
090000648432c195,Other,FDA-2020-P-0624-0002,FDA-2020-P-0624,"acknowledgment letter from fda dms to reguliance, llc on behalf of medichem, s.a.",0,0
0900006484d60e26,Supporting & Related Material,FDA-2020-P-0624-0006,FDA-2020-P-0624,"response to information request re citizen petition from reguliance, llc on behalf of medichem, s.a.",0,0
090000648432c19a,Supporting & Related Material,FDA-2020-P-0624-0005,FDA-2020-P-0624,"attachment 3 - medichem rufinamide tablets labeling re citizen petition from reguliance, llc on behalf of medichem, s.a.",0,0
090000648432c198,Supporting & Related Material,FDA-2020-P-0624-0003,FDA-2020-P-0624,"attachment 1 - banzel_orange book re citizen petition from reguliance, llc on behalf of medichem, s.a.",0,0
090000648432c199,Supporting & Related Material,FDA-2020-P-0624-0004,FDA-2020-P-0624,"attachment 2  - banzel_labeling 11_2019 re citizen petition from reguliance, llc on behalf of medichem, s.a.",0,0
090000648432c185,Other,FDA-2020-P-0624-0001,FDA-2020-P-0624,"citizen petition from reguliance, llc on behalf of medichem, s.a.",0,0
0900006483d80544,Supporting & Related Material,FDA-2019-P-3347-0003,FDA-2019-P-3347,"appendix a maude database for product code ink: may 30, 2014-may 30, 2019 re citizen petition from stryker",0,0
0900006483d7e9e9,Other,FDA-2019-P-3347-0002,FDA-2019-P-3347,acknowledgment letter from fda ddm to stryker,0,0
0900006483f6e65a,Notice,FDA-2019-P-3347-0004,FDA-2019-P-3347,medical devices; exemption from premarket notification: class ii; powered wheeled stretcher; request for comments,0,0
0900006483d7e444,Other,FDA-2019-P-3347-0001,FDA-2019-P-3347,citizen petition from stryker,0,0
0900006484276af7,Other,FDA-2019-P-3347-0005,FDA-2019-P-3347,petition response letter from fda cdrh to stryker medical,0,0
090000648429e1b6,Rule,FDA-2019-P-3347-0006,FDA-2019-P-3347,medical devices; exemption from premarket notification; class ii devices; powered wheeled stretcher,0,0
090000648155a284,Other,FDA-2010-P-0613-0004,FDA-2010-P-0613,"citizen petition denial response from fda cder to watson pharmaceuticals, inc.",0,0
0900006480baa535,Other,FDA-2010-P-0613-0002,FDA-2010-P-0613,"acknowledgement letter to watson laboratories, inc.",0,0
0900006480baa531,Other,FDA-2010-P-0613-0001,FDA-2010-P-0613,"watson laboratories, inc. - citizen petition",0,0
0900006480baa534,Supporting & Related Material,FDA-2010-P-0613-0003,FDA-2010-P-0613,"attachment a - androderm labeling [watson laboratories, inc. citizen petition]",0,0
09000064804420b6,Other,FDA-2006-D-0031-0006,FDA-2006-D-0031,"frequently asked questions about medical devices:  guidance for irbs, clinical investigators, and sponsors",0,0
09000064817ae075,Other,FDA-2006-D-0031-0008,FDA-2006-D-0031,"draft informed consent information sheet: guidance for institutional
review boards, clinical investigators, and sponsors",0,0
09000064817ad90f,Notice,FDA-2006-D-0031-0007,FDA-2006-D-0031,"draft informed consent information sheet: guidance for institutional
review boards, clinical investigators, and sponsors; availability",0,0
09000064804420b4,Supporting & Related Material,FDA-2006-D-0031-0004,FDA-2006-D-0031,waiver of irb requirements for drug and biological products stuides,0,0
0900006481892941,Notice,FDA-2006-D-0031-0125,FDA-2006-D-0031,"draft informed consent information sheet: guidance for institutional
review boards, clinical investigators, and sponsors; reopening of the
comment period",0,0
09000064804420b2,Supporting & Related Material,FDA-2006-D-0031-0003,FDA-2006-D-0031,fda institutional review board inspections,0,0
090000648184359d,Other,FDA-2006-D-0031-0023,FDA-2006-D-0031,request for extension of the comment period from biotechnology industry organization (bio),0,0
09000064804420b0,Supporting & Related Material,FDA-2006-D-0031-0002,FDA-2006-D-0031,"information sheet guidance for irbs,clinical investigators, and sponsors",0,0
09000064804420ae,Notice,FDA-2006-D-0031-0001,FDA-2006-D-0031,fda,0,0
09000064804420b5,Other,FDA-2006-D-0031-0005,FDA-2006-D-0031,"significant risk and nonsignificant risk medical device studies:  guidance for irbs, clinical investigators, and sponsors",0,0
09000064823bc9df,Other,FDA-2016-P-4047-0002,FDA-2016-P-4047,acknowledgment letter from fda ddm to mayne pharma lnternational pty ltd,0,0
09000064825e9e63,Other,FDA-2016-P-4047-0003,FDA-2016-P-4047,interim response letter from cder to mayne pharma lnternational pty ltd,0,0
09000064823bc4c4,Other,FDA-2016-P-4047-0001,FDA-2016-P-4047,citizen petitions from mayne pharma lnternational pty ltd,0,0
09000064830569f6,Other,FDA-2016-P-4047-0005,FDA-2016-P-4047,final response letter from cder to mayne pharma lnternational pty ltd,0,0
0900006482324a05,Supporting & Related Material,FDA-2016-P-3465-0003,FDA-2016-P-3465,exhibit 1 letter from inwood pharmacy to novitium pharma llc re citizen petition from novitium pharma llc,0,0
0900006482324a06,Supporting & Related Material,FDA-2016-P-3465-0004,FDA-2016-P-3465,exhibit 2 controlled correspondence from fda cder to novitium pharma llc re citizen petition from novitium pharma llc,0,0
0900006482324a01,Other,FDA-2016-P-3465-0001,FDA-2016-P-3465,citizen petition from novitium pharma llc,0,0
0900006482538463,Other,FDA-2016-P-3465-0005,FDA-2016-P-3465,withdrawal from novitium pharma llc,0,0
0900006482324a03,Other,FDA-2016-P-3465-0002,FDA-2016-P-3465,acknowledgement letter from fda ddm to novitium pharma llc,0,0
09000064832d8716,Other,FDA-2018-P-1185-0006,FDA-2018-P-1185,amended suitability petition from provetica animal health l. l. c.,0,0
0900006483416db9,Other,FDA-2018-P-1185-0007,FDA-2018-P-1185,petition response letter from fda cvm to provetica animal health llc,0,0
09000064830270b2,Other,FDA-2018-P-1185-0001,FDA-2018-P-1185,suitability petition from provetica animal health llc,0,0
090000648319a6ba,Other,FDA-2018-P-1185-0005,FDA-2018-P-1185,amended suitability petition from provetica animal health llc,0,0
09000064830271d0,Other,FDA-2018-P-1185-0002,FDA-2018-P-1185,acknowledgment letter from fda ddm to provetica animal health llc,0,0
090000648302734d,Supporting & Related Material,FDA-2018-P-1185-0003,FDA-2018-P-1185,appendix 1- pioneer product label - heartgard plus re: suitability petition from provetica animal health llc,0,0
0900006483027653,Supporting & Related Material,FDA-2018-P-1185-0004,FDA-2018-P-1185,appendix 2 - proposed product label (draft) generic re: suitability petition from provetica animal health llc,0,0
0900006481e7c2a7,Other,FDA-2014-D-1318-0126,FDA-2014-D-1318,"testimony from daniel fisher, md, phd",0,0
0900006481dd91f1,Other,FDA-2014-D-1318-0002,FDA-2014-D-1318,"electroconvulsive therapy (ect) devices for class ii intended uses draft guidance for industry, clinicians and food and drug administration staff",1,0
0900006481dd7b15,Notice,FDA-2014-D-1318-0001,FDA-2014-D-1318,"electroconvulsive therapy devices for class ii intended uses: draft guidance for industry, clinicians, and fda staff; availability",0,0
09000064813af1e8,Other,FDA-2013-P-0148-0004,FDA-2013-P-0148,fda/cder interim response to crowell & moring llp - letter,0,0
090000648159d2bd,Other,FDA-2013-P-0148-0006,FDA-2013-P-0148,citizen petition denial response from fda/cder to crowell & moring llp,0,0
09000064811ef1b7,Other,FDA-2013-P-0148-0002,FDA-2013-P-0148,acknowledgement letter to crowell & moring llp,0,0
09000064811ed89f,Other,FDA-2013-P-0148-0001,FDA-2013-P-0148,crowell & moring llp - citizen petition,0,0
09000064818be8c6,Other,FDA-2014-P-1611-0001,FDA-2014-P-1611,citizen petition from southern network on adverse reactions sonar,0,0
09000064818bfd3d,Other,FDA-2014-P-1611-0002,FDA-2014-P-1611,acknowledgement letter from fda ddm to southern network on adverse reactions (sonar),0,0
09000064834cd23b,Other,FDA-2014-P-1611-0005,FDA-2014-P-1611,partial approval and partial denial response from fda cder to the southern network on adverse reactions regarding levaquin,0,0
0900006481fccb6e,Supporting & Related Material,FDA-2014-P-1611-0004,FDA-2014-P-1611,"exhibit 1 bennett et al, fluoroquinolone-related neiropshychiatric and mitochondrial toxicity re citizen petition from sonar",0,0
0900006481a34041,Other,FDA-2014-P-1611-0003,FDA-2014-P-1611,interim response from cder to the southern network on adverse reactions,0,0
090000648260659a,Supporting & Related Material,FDA-2017-P-3251-0021,FDA-2017-P-3251,exhibit t to cerdelga due diligence petition patent 1 cerdelga re citizen petition from petitioner,0,0
09000064826065a1,Supporting & Related Material,FDA-2017-P-3251-0024,FDA-2017-P-3251,exhibit w to cerdelga due diligence petition clinical trial 1 re citizen petition from petitioner,0,0
0900006482607045,Supporting & Related Material,FDA-2017-P-3251-0010,FDA-2017-P-3251,exhibit i to cerdelga due diligence petition article 2009 re costa rica(1) re citizen petition from petitioner,0,0
0900006482606511,Supporting & Related Material,FDA-2017-P-3251-0007,FDA-2017-P-3251,exhibit f to cerdelga due diligence petition article wsj 2005 re citizen petition from petitioner,0,0
0900006482606515,Supporting & Related Material,FDA-2017-P-3251-0013,FDA-2017-P-3251,exhibit l to cerdelga due diligence petition article 1991 nyt re citizen petition from petitioner,0,0
090000648260659b,Supporting & Related Material,FDA-2017-P-3251-0026,FDA-2017-P-3251,exhibit t to cerdelga due diligence petition patent 2 for cerdelga re citizen petition from petitioner,0,0
09000064826065a2,Supporting & Related Material,FDA-2017-P-3251-0022,FDA-2017-P-3251,exhibit u to cerdelga due diligence petition patent assignment 1 re citizen petition from petitioner,0,0
09000064829dff6c,Other,FDA-2017-P-3251-0031,FDA-2017-P-3251,denial letter from cder to petitioner,0,0
09000064826059ba,Supporting & Related Material,FDA-2017-P-3251-0004,FDA-2017-P-3251,exhibit b to cerdelga due diligence petition fda okays genzyme pill for gaucher disease - the boston globe(1) re citizen petition from petitioner,0,0
0900006482606512,Supporting & Related Material,FDA-2017-P-3251-0006,FDA-2017-P-3251,"exhibit e to cerdelga due diligence petition new genzyme pill to treat rare gaucher disease will cost us patients $310,250 a year re citizen petition from petitioner",0,0
0900006482606599,Supporting & Related Material,FDA-2017-P-3251-0020,FDA-2017-P-3251,exhibit s to cerdelga due diligence petition orange book patent listings for cerdelga re citizen petition from petitioner,0,0
09000064826059bc,Supporting & Related Material,FDA-2017-P-3251-0008,FDA-2017-P-3251,"exhibit g to cerdelga due diligence petition when a drug costs $300,000 - the new york times re citizen petition from petitioner",0,0
0900006482606518,Supporting & Related Material,FDA-2017-P-3251-0016,FDA-2017-P-3251,exhibit o to cerdelga due diligence petition u-michigan signs royalty agreement for gaucher disease drug _ university of michigan re citizen petition from petitioner,0,0
090000648260651a,Supporting & Related Material,FDA-2017-P-3251-0018,FDA-2017-P-3251,exhibit q  to cerdelga due diligence petition article 3 re citizen petition from petitioner,0,0
09000064825ffe12,Other,FDA-2017-P-3251-0001,FDA-2017-P-3251,citizen petition from petitioner,0,0
0900006482601a74,Other,FDA-2017-P-3251-0002,FDA-2017-P-3251,acknowledgment letter from fda ddm to petitioner,0,0
0900006482606513,Supporting & Related Material,FDA-2017-P-3251-0009,FDA-2017-P-3251,exhibit h to cerdelga due diligence petition explanation of benefits 1(1) re citizen petition from petitioner,0,0
0900006482606516,Supporting & Related Material,FDA-2017-P-3251-0014,FDA-2017-P-3251,exhibit m to cerdelga due diligence petition approval dates for cerezyme re citizen petition from petitioner,0,0
0900006482606517,Supporting & Related Material,FDA-2017-P-3251-0015,FDA-2017-P-3251,exhibit n to cerdelga due diligence petition more contamination troubles for genzyme - the boston globe re citizen petition from petitioner,0,0
090000648260659c,Supporting & Related Material,FDA-2017-P-3251-0011,FDA-2017-P-3251,exhibit j to cerdelga due diligence petition orphan drug bounty comes at steep price - shots - health news - npr re citizen petition from petitioner,0,0
090000648260659d,Supporting & Related Material,FDA-2017-P-3251-0027,FDA-2017-P-3251,exhibit t to cerdelga due diligence petition patent 3 for cerdelga re citizen petition from petitioner,0,0
090000648260659e,Supporting & Related Material,FDA-2017-P-3251-0023,FDA-2017-P-3251,exhibit v to cerdelga due diligence petition clinical trials listing re citizen petition from petitioner,0,0
090000648260659f,Supporting & Related Material,FDA-2017-P-3251-0025,FDA-2017-P-3251,exhibit x to cerdelga due diligence petition clinical trial 2 re citizen petition from petitioner,0,0
09000064826059b9,Supporting & Related Material,FDA-2017-P-3251-0003,FDA-2017-P-3251,exhibit a cerdelga due diligence petition fda approves u-m invented drug for gaucher disease _ university of michigan news(4) re citizen petition from petitioner,0,0
09000064826059bb,Supporting & Related Material,FDA-2017-P-3251-0005,FDA-2017-P-3251,"exhibit d to cerdelga due diligence petition cerdelga, 25 years in the making _ biotech primer(2) re citizen petition from petitioner",0,0
09000064837c0eed,Other,FDA-2018-P-3861-0002,FDA-2018-P-3861,acknowledgment letter from fda ddm to innogenix llc,0,0
09000064837c0f5b,Supporting & Related Material,FDA-2018-P-3861-0006,FDA-2018-P-3861,attachment 4 draft package insert labeling for metronidazole tablets re citizen petition from innogenix llc,0,0
09000064837c0f59,Supporting & Related Material,FDA-2018-P-3861-0004,FDA-2018-P-3861,attachment 2 current package insert labeling for flagyl tablets re citizen petition from innogenix llc,0,0
09000064837c0f5a,Supporting & Related Material,FDA-2018-P-3861-0005,FDA-2018-P-3861,attachment 3 cdc growth charts re citizen petition from innogenix llc,0,0
09000064837c0f58,Supporting & Related Material,FDA-2018-P-3861-0003,FDA-2018-P-3861,attachment 1 approved drug products with therapeutic equivalence evaluations re citizen petition from innogenix llc,0,0
09000064837c0eeb,Other,FDA-2018-P-3861-0001,FDA-2018-P-3861,citizen petition from innogenix llc,0,0
090000648391ceb3,Other,FDA-2018-P-4590-0002,FDA-2018-P-4590,"acknowledgment letter from fda ddm to ascend laboratories, llc",0,0
0900006483cb9c2a,Other,FDA-2018-P-4590-0005,FDA-2018-P-4590,"letter from fda cder to ascend laboratories, llc",0,0
090000648391ceb1,Other,FDA-2018-P-4590-0001,FDA-2018-P-4590,"citizen petition from ascend laboratories, llc",0,0
090000648408937d,Other,FDA-2019-P-3311-0004,FDA-2019-P-3311,"denial response letter from fda cder to rc outsourcing, llc",0,0
090000648408928b,Other,FDA-2019-P-3311-0003,FDA-2019-P-3311,denial for citizen petition from fda cder to rc outsourcing llc,0,0
0900006483d75e5f,Other,FDA-2019-P-3311-0001,FDA-2019-P-3311,"citizen petition from rc outsourcing, llc.",0,0
0900006483d75f77,Other,FDA-2019-P-3311-0002,FDA-2019-P-3311,"acknowledgment letter from fda ddm to rc outsourcing, llc",0,0
0900006484651679,Other,FDA-2020-D-1407-0001,FDA-2020-D-1407,"devices used to process human cells, tissues, and cellular and tissue-based products hct ps guidance for industry and fda staff",0,0
0900006481a17d83,Supporting & Related Material,FDA-2015-P-0596-0003,FDA-2015-P-0596,attachment 1,0,0
0900006481a17d84,Supporting & Related Material,FDA-2015-P-0596-0004,FDA-2015-P-0596,attachment 2,0,0
0900006481a17d7e,Other,FDA-2015-P-0596-0001,FDA-2015-P-0596,citizen petition request from lachman consultant services inc,0,0
09000064847396bc,Other,FDA-2015-P-0596-0006,FDA-2015-P-0596,"letter from fda cder to lachman consultant services, inc.",0,0
0900006481a17d81,Other,FDA-2015-P-0596-0002,FDA-2015-P-0596,acknowledgement letter from fda ddm to lachman consultant services inc,0,0
0900006481a17d85,Supporting & Related Material,FDA-2015-P-0596-0005,FDA-2015-P-0596,attachment 3,0,0
09000064833f76b9,Other,FDA-2018-P-2073-0003,FDA-2018-P-2073,interim response letter from fda cdrh to lms direct research foundation,0,0
09000064849d22af,Other,FDA-2018-P-2073-0005,FDA-2018-P-2073,citizen petition response to lms direct research foundation,0,0
090000648331224d,Other,FDA-2018-P-2073-0001,FDA-2018-P-2073,citizen petition from lms direct research foundation,0,0
090000648331224e,Other,FDA-2018-P-2073-0002,FDA-2018-P-2073,acknowledgment letter from fda ddm to lms direct research foundation,0,0
09000064849ec500,Supporting & Related Material,FDA-2021-P-0036-0003,FDA-2021-P-0036,"attachment 1 re suitability petition from hyman, phelps & mcnamara pc",0,0
09000064849ec653,Supporting & Related Material,FDA-2021-P-0036-0004,FDA-2021-P-0036,"attachment 2 re suitability petition from hyman, phelps & mcnamara pc",0,0
09000064849ebcfd,Other,FDA-2021-P-0036-0002,FDA-2021-P-0036,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, pc",0,0
09000064849ebcfc,Other,FDA-2021-P-0036-0001,FDA-2021-P-0036,"suitability petition from hyman, phelps & mcnamara, pc",0,0
09000064849ec654,Supporting & Related Material,FDA-2021-P-0036-0005,FDA-2021-P-0036,"attachment 3 re suitability petition from hyman, phelps & mcnamara pc",0,0
0900006484a08a92,Supporting & Related Material,FDA-2021-P-0125-0004,FDA-2021-P-0125,"attachment 2 re suitability petition from hyman, phelps & mcnamara p.c.",0,0
0900006484a08a90,Supporting & Related Material,FDA-2021-P-0125-0003,FDA-2021-P-0125,"attachment 1 re suitability petition from hyman, phelps & mcnamara p.c.",0,0
0900006484a08a93,Supporting & Related Material,FDA-2021-P-0125-0005,FDA-2021-P-0125,"attachment 3 re suitability petition from hyman, phelps & mcnamara p.c.",0,0
0900006484a08a8c,Other,FDA-2021-P-0125-0002,FDA-2021-P-0125,"acknowledgment letter from fda dms to hyman, phelps & mcnamara p.c.",0,0
0900006484a08a8a,Other,FDA-2021-P-0125-0001,FDA-2021-P-0125,"suitability petition from hyman, phelps & mcnamara p.c.",0,0
090000648375a2a9,Other,FDA-2018-P-3599-0002,FDA-2018-P-3599,acknowledgment letter from fda ddm to auromedics pharma llc,0,0
0900006484bfa9b4,Other,FDA-2018-P-3599-0004,FDA-2018-P-3599,citizen petition approval letter from fda cder to auromedics pharma llc,0,0
0900006483759c25,Other,FDA-2018-P-3599-0001,FDA-2018-P-3599,citizen petition from auromedics pharma llc,0,0
0900006483b083f7,Other,FDA-2018-P-3599-0003,FDA-2018-P-3599,letter from fda cder to auromedics pharma llc,0,0
0900006480483355,Notice,FDA-2003-D-0091-0001,FDA-2003-D-0091,fda,0,0
0900006480483384,Supporting & Related Material,FDA-2003-D-0091-0002,FDA-2003-D-0091,guidance,0,0
0900006480473724,Supporting & Related Material,FDA-2004-D-0373-0004,FDA-2004-D-0373,background material,0,0
0900006480473722,Supporting & Related Material,FDA-2004-D-0373-0002,FDA-2004-D-0373,background material,0,0
0900006480473723,Supporting & Related Material,FDA-2004-D-0373-0003,FDA-2004-D-0373,background material,0,0
0900006480473721,Notice,FDA-2004-D-0373-0001,FDA-2004-D-0373,fda,0,0
09000064804504f7,Supporting & Related Material,FDA-2006-P-0149-0002,FDA-2006-P-0149,see fda 2006-p-0149-0001,0,0
09000064804504f5,Other,FDA-2006-P-0149-0001,FDA-2006-P-0149,acknowledgement letter (ack1) to washington legal foundation (wlf),0,0
09000064804504f8,Supporting & Related Material,FDA-2006-P-0149-0003,FDA-2006-P-0149,see fda-2006-p-0149-0001,0,0
09000064804504fa,Other,FDA-2006-P-0149-0004,FDA-2006-P-0149,washington legal foundation (wlf) - citizen petition,0,0
09000064817f26c9,Other,FDA-2006-P-0149-0010,FDA-2006-P-0149,citizen petition denial response from fda cdrh to washington legal foundation,0,0
090000648044928d,Supporting & Related Material,FDA-2005-D-0340-0004,FDA-2005-D-0340,guidance,0,0
090000648044927b,Supporting & Related Material,FDA-2005-D-0340-0002,FDA-2005-D-0340,guidance,0,0
0900006480449242,Notice,FDA-2005-D-0340-0001,FDA-2005-D-0340,fda,0,0
090000648044928a,Supporting & Related Material,FDA-2005-D-0340-0003,FDA-2005-D-0340,guidance,0,0
090000648048772c,Supporting & Related Material,FDA-2003-N-0155-0004,FDA-2003-N-0155,supporting statement,0,0
090000648048772f,Supporting & Related Material,FDA-2003-N-0155-0005,FDA-2003-N-0155,supporting statement,0,0
09000064804876f0,Notice,FDA-2003-N-0155-0001,FDA-2003-N-0155,fda,0,0
0900006480487731,Notice,FDA-2003-N-0155-0006,FDA-2003-N-0155,fda,0,0
0900006480487717,Notice,FDA-2003-N-0155-0002,FDA-2003-N-0155,fda,0,0
0900006480487729,Notice,FDA-2003-N-0155-0003,FDA-2003-N-0155,fda,0,0
09000064804736ca,Supporting & Related Material,FDA-2004-D-0368-0002,FDA-2004-D-0368,guidance,0,0
09000064804736c9,Notice,FDA-2004-D-0368-0001,FDA-2004-D-0368,fda,0,0
09000064804736cb,Supporting & Related Material,FDA-2004-D-0368-0003,FDA-2004-D-0368,guidance,0,0
0900006480a86ae0,Other,FDA-2009-P-0364-0008,FDA-2009-P-0364,"fda/cder to graceway pharmaceuticals, llc - petition denial",0,0
09000064809ff00e,Supporting & Related Material,FDA-2009-P-0364-0003,FDA-2009-P-0364,"tab a - ""reconsideration of the approval of anda 77-524; spear pharmaceuticals fluorouracil cream, usp 5%, for the treatment of actinic keratosis (ak) and superficial basal cell carcinoma (sbcc),"" fda/cder memorandum dated may 30, 2008 - [graceway pharmaceuticals, llc - citizen petition] re: fda-2009-p-0364-0001",0,0
09000064809ff087,Supporting & Related Material,FDA-2009-P-0364-0005,FDA-2009-P-0364,"tab p - ""valeant pharmaceuticals international citizen petition 2004p-0557: request that fda refrain from approving andas for generic versions of efudex cream,"" fda/cder memorandum dated december 3, 2007 - [graceway pharmaceuticals, llc - citizen petition] re: fda-2009-p-0364-0001",0,0
09000064809ff0f5,Supporting & Related Material,FDA-2009-P-0364-0007,FDA-2009-P-0364,"tab bb - ""the development and use of topical bioavailability data: a regulatory view,"" fda/cder powerpoint presentation - [graceway pharmaceuticals, llc - citizen petition] re: fda-2009-p-0364-0001",0,0
09000064809fee1a,Other,FDA-2009-P-0364-0001,FDA-2009-P-0364,"graceway pharmaceuticals, llc - citizen petition",0,0
09000064809ff04b,Supporting & Related Material,FDA-2009-P-0364-0004,FDA-2009-P-0364,"tab c - ""fda/cder response to graceway pharmaceutical, llc"" - [graceway pharmaceuticals, llc - citizen petition] re: fda-2009-p-0364-0001",0,0
09000064809ff0fa,Other,FDA-2009-P-0364-0002,FDA-2009-P-0364,"acknowledgement letter to graceway pharmaceutical, llp",0,0
09000064809ff0d7,Supporting & Related Material,FDA-2009-P-0364-0006,FDA-2009-P-0364,"tab aa - ""fda/cder approval package for 3m pharmaceuticals - aldara 5% cream (imiquimod) (application number nda 20-723/s016)"" - [graceway pharmaceuticals, llc - citizen petition] re: fda-2009-p-0364-0001",0,0
0900006484b08d4f,Other,FDA-2021-P-0460-0002,FDA-2021-P-0460,acknowledgment letter from fda dms to scientific advisory board on behalf of children's health defense,0,0
0900006484b08da5,Supporting & Related Material,FDA-2021-P-0460-0003,FDA-2021-P-0460,appendix vol 1 of 5 footnotes 1 13 re citizen petition from scientific advisory board on behalf of children's health defense,0,0
0900006484b08da9,Supporting & Related Material,FDA-2021-P-0460-0007,FDA-2021-P-0460,appendix vol 5 of 5 footnotes 69 73 re citizen petition from scientific advisory board on behalf of children's health defense,0,0
0900006484b08da6,Supporting & Related Material,FDA-2021-P-0460-0004,FDA-2021-P-0460,appendix vol 2 of 5 footnotes 14 29 re citizen petition from scientific advisory board on behalf of children's health defense,0,0
0900006484b08da8,Supporting & Related Material,FDA-2021-P-0460-0006,FDA-2021-P-0460,appendix vol 4 of 5 footnotes 48 68 re citizen petition from scientific advisory board on behalf of children's health defense,0,0
0900006484b08d4d,Other,FDA-2021-P-0460-0001,FDA-2021-P-0460,citizen petition from scientific advisory board on behalf of children's health defense,0,0
0900006484c9deb9,Other,FDA-2021-P-0460-30085,FDA-2021-P-0460,response letter to citizen petition from fda cber to children’s health defense,0,0
0900006484b08da7,Supporting & Related Material,FDA-2021-P-0460-0005,FDA-2021-P-0460,appendix vol 3 of 5 footnotes 30 47 re citizen petition from scientific advisory board on behalf of children's health defense,0,0
0900006482cfe8f2,Other,FDA-2015-P-5081-0080,FDA-2015-P-5081,final response letter from fda to meghan o' hara,0,0
0900006481dd9c0e,Other,FDA-2015-P-5081-0002,FDA-2015-P-5081,acknowledgement letter from fda ddm to o'hara et al.,0,0
0900006481dd9c0b,Other,FDA-2015-P-5081-0001,FDA-2015-P-5081,"citizen petiton from o'hara, vogel, bazlen, craig, denning, willson, weir and larock",0,0
090000648205557f,Other,FDA-2015-P-5081-0021,FDA-2015-P-5081,interim response fda-2015-p-5081,0,0
090000648499d847,Other,FDA-2020-P-2299-0001,FDA-2020-P-2299,citizen petition from zydus pharmaceuticals usa inc,0,0
090000648499d84b,Supporting & Related Material,FDA-2020-P-2299-0003,FDA-2020-P-2299,annexure 1 orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from zydus pharmaceuticals usa inc,0,0
0900006484a91f36,Other,FDA-2020-P-2299-0004,FDA-2020-P-2299,withdrawal citizen petition from zydus pharmaceuticals usa inc,0,0
090000648499d848,Other,FDA-2020-P-2299-0002,FDA-2020-P-2299,acknowledgment letter from fda dms to zydus pharmaceuticals usa inc,0,0
0900006484c0b10d,Supporting & Related Material,FDA-2021-P-0786-0006,FDA-2021-P-0786,references 19 to 23 re citizen petition from coalition advocating for adequately licensed medicines (caalm),0,0
0900006484c0b10e,Supporting & Related Material,FDA-2021-P-0786-0007,FDA-2021-P-0786,references 24 to 32 re citizen petition from coalition advocating for adequately licensed medicines (caalm),0,0
0900006484c0b12d,Supporting & Related Material,FDA-2021-P-0786-0008,FDA-2021-P-0786,references 33 to 36 re citizen petition from coalition advocating for adequately licensed medicines (caalm),0,0
0900006484c0b12e,Supporting & Related Material,FDA-2021-P-0786-0009,FDA-2021-P-0786,references 37 to 47 re citizen petition from coalition advocating for adequately licensed medicines (caalm),0,0
0900006484c0acc8,Other,FDA-2021-P-0786-0002,FDA-2021-P-0786,acknowledgment letter from fda dms to coalition advocating for adequately licensed medicines (caalm),0,0
0900006484c0b10a,Supporting & Related Material,FDA-2021-P-0786-0004,FDA-2021-P-0786,references 09 to 16 re citizen petition from coalition advocating for adequately licensed medicines (caalm),0,0
0900006484c0b10b,Supporting & Related Material,FDA-2021-P-0786-0005,FDA-2021-P-0786,references 17 to 18 re citizen petition from coalition advocating for adequately licensed medicines (caalm),0,0
0900006484c0acc6,Other,FDA-2021-P-0786-0001,FDA-2021-P-0786,citizen petition from coalition advocating for adequately licensed medicines (caalm),0,0
0900006484c9e06a,Other,FDA-2021-P-0786-1557,FDA-2021-P-0786,response letter to citizen petition from fda cber to coalition advocating for adequately licensed medicines (caalm),0,0
0900006484c0b109,Supporting & Related Material,FDA-2021-P-0786-0003,FDA-2021-P-0786,references 01 to 08 re citizen petition from coalition advocating for adequately licensed medicines (caalm),0,0
09000064846c9701,Supporting & Related Material,FDA-2020-P-1478-0006,FDA-2020-P-1478,appendix iv  - re: citizen petition from the sugar association,0,0
09000064846c9703,Supporting & Related Material,FDA-2020-P-1478-0008,FDA-2020-P-1478,appendix vi  - re: citizen petition from the sugar association,0,0
09000064846c9705,Supporting & Related Material,FDA-2020-P-1478-0010,FDA-2020-P-1478,appendix viii - re: citizen petition from the sugar association,0,0
09000064846c96fe,Supporting & Related Material,FDA-2020-P-1478-0003,FDA-2020-P-1478,appendix i - glossary of terms - re: citizen petition from the sugar association,0,0
09000064846c9702,Supporting & Related Material,FDA-2020-P-1478-0007,FDA-2020-P-1478,appendix v  - re: citizen petition from the sugar association,0,0
09000064846c96ff,Supporting & Related Material,FDA-2020-P-1478-0004,FDA-2020-P-1478,appendix ii - re: citizen petition from the sugar association,0,0
09000064846c9700,Supporting & Related Material,FDA-2020-P-1478-0005,FDA-2020-P-1478,appendix iii - re: citizen petition from the sugar association,0,0
09000064846c9704,Supporting & Related Material,FDA-2020-P-1478-0009,FDA-2020-P-1478,appendix vii - re: citizen petition from the sugar association,0,0
09000064846c9717,Supporting & Related Material,FDA-2020-P-1478-0012,FDA-2020-P-1478,appendix x - re: citizen petition from the sugar association,0,0
09000064846c9706,Supporting & Related Material,FDA-2020-P-1478-0011,FDA-2020-P-1478,appendix ix - re: citizen petition from the sugar association,0,0
09000064846cae23,Other,FDA-2020-P-1478-0002,FDA-2020-P-1478,acknowledgment letter from fda dms to the sugar association,0,0
0900006484999969,Other,FDA-2020-P-1478-0048,FDA-2020-P-1478,interim response letter from fda cfsan to the sugar association,0,0
09000064846c8470,Other,FDA-2020-P-1478-0001,FDA-2020-P-1478,citizen petition from the sugar association,0,0
0900006480afe1bb,Other,FDA-1995-N-0259-0004,FDA-1995-N-0259,national association of convenience stores - letter,0,0
0900006480ecc7f8,Supporting & Related Material,FDA-1995-N-0259-0005,FDA-1995-N-0259,"fda/oc regulations policy and management staff, omb review - memorandum re regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents (final rule) fda-1995-n-0259-0002",0,1
0900006480ac184d,Rule,FDA-1995-N-0259-0002,FDA-1995-N-0259,regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents,0,1
0900006480572ba7,Proposed Rule,FDA-1995-N-0259-0001,FDA-1995-N-0259,regulations restricting the sale & distribution of cigarettes & smokeless tobacco products to protect children & adolescents,0,1
0900006480ac015e,Supporting & Related Material,FDA-1995-N-0259-0003,FDA-1995-N-0259,"reference 1 - ""samhsa results from the 2008 national survey on drug use and health"" - [ regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents; reissuance of final rule]",0,1
0900006480ae8bc6,Other,FDA-2010-D-0189-0002,FDA-2010-D-0189,guidance for industry and fda staff: enforcement policy concerning certain regulations restricting the sale and distribution of cigarettes and smokeless tobacco,0,1
0900006480ae8af4,Notice,FDA-2010-D-0189-0001,FDA-2010-D-0189,guidance for industry and food and drug administration staff: enforcement policy concerning regulations restricting sale and distribution of cigarettes and smokeless tobacco,1,1
0900006480ac1897,Proposed Rule,FDA-2010-N-0136-0001,FDA-2010-N-0136,implementation of the family smoking prevention and tobacco control act; request for comments,0,1
09000064813dc732,Rule,FDA-2010-N-0136-0037,FDA-2010-N-0136,general enforcement regulations,0,0
0900006480abf873,Supporting & Related Material,FDA-2010-N-0136-0010,FDA-2010-N-0136,"reference - ""national cancer institute control monograph series"" -  [implementation of the family smoking prevention and tobacco control act; request for comments] re fda-2010-n-0136-0001",0,1
0900006480aef9ea,Proposed Rule,FDA-2010-N-0136-0013,FDA-2010-N-0136,implementation of the family smoking prevention and tobacco control act; extension of comment period,0,1
0900006480f17e16,Other,FDA-2010-N-0136-0035,FDA-2010-N-0136,"omb review, executive order 12866, request for comment on implementation of the family smoking prevention and tobacco control act; anprm march 19, 2010",0,1
0900006480ae3b34,Other,FDA-2010-N-0136-0011,FDA-2010-N-0136,"lorillard tobacco company (covington & burling, llp) - request for extension of comment due date",0,1
09000064823c8f0a,Supporting & Related Material,FDA-2016-P-4093-0006,FDA-2016-P-4093,tab d -- gender difference in antidiuretic response to desmopressin re citizen petition from ferring pharmaceuticals inc,0,0
09000064823c8f0f,Supporting & Related Material,FDA-2016-P-4093-0011,FDA-2016-P-4093,"tab i -- memorandum of meeting minutes (september 8, 2015) (relevant excerpts) re citizen petition from ferring pharmaceuticals inc.",0,0
09000064823c8f15,Supporting & Related Material,FDA-2016-P-4093-0014,FDA-2016-P-4093,"tab l -- memorandum of meeting minutes (june 5, 2013) (relevant excerpts) re citizen petition from ferring pharmaceuticals inc.",0,0
09000064823c8f0b,Supporting & Related Material,FDA-2016-P-4093-0007,FDA-2016-P-4093,"tab e -- april 22, 2010 complete response letter re citizen petition from ferring pharmaceuticals inc",0,0
09000064823c8f10,Supporting & Related Material,FDA-2016-P-4093-0012,FDA-2016-P-4093,"tab j -- fda briefing material ser120 (october 19, 2016) re citizen petition from ferring pharmaceuticals inc.",0,0
09000064823c8f11,Supporting & Related Material,FDA-2016-P-4093-0013,FDA-2016-P-4093,"tab k -- fda briefing material nocdurna (january 12, 2015) re citizen petition from ferring pharmaceuticals inc.",0,0
09000064823c8f09,Supporting & Related Material,FDA-2016-P-4093-0005,FDA-2016-P-4093,tab c -- sex differences in vasopressin v2 receptor expression and vasopressin-induced antidiuresis re citizen petition from ferring pharmaceuticals inc,0,0
09000064823c8f0d,Supporting & Related Material,FDA-2016-P-4093-0009,FDA-2016-P-4093,"tab g -- ferring briefing material nocdurna (january 12, 2015) (relevant excerpts) re citizen petition from ferring pharmaceuticals inc.",0,0
09000064823c8f18,Supporting & Related Material,FDA-2016-P-4093-0017,FDA-2016-P-4093,tab o -- low-dose desmopressin combined with serum sodium monitoring re citizen petition from ferring pharmaceuticals inc,0,0
09000064823c8f1a,Supporting & Related Material,FDA-2016-P-4093-0019,FDA-2016-P-4093,tab q -- gender difference in efficacy and dose re citizen petition from ferring pharmaceuticals inc,0,0
09000064823c9420,Other,FDA-2016-P-4093-0002,FDA-2016-P-4093,acknowledgement letter from fda ddm to ferring pharmaceuticals inc,0,0
09000064824eac35,Other,FDA-2016-P-4093-0021,FDA-2016-P-4093,citizen petition denial letter from fda cder to ferring pharmaceuticals inc,0,0
09000064823c8f08,Supporting & Related Material,FDA-2016-P-4093-0004,FDA-2016-P-4093,tab b -- the evaluation and treatment of nocturia re citizen petition from ferring pharmaceuticals inc,0,0
09000064823c8f0c,Supporting & Related Material,FDA-2016-P-4093-0008,FDA-2016-P-4093,"tab f -- january 30, 2013 complete response letter re citizen petition from ferring pharmaceuticals inc.",0,0
09000064823c8f16,Supporting & Related Material,FDA-2016-P-4093-0015,FDA-2016-P-4093,"tab m -- memorandum of meeting minutes (june 18, 2007) (relevant excerpts) re citizen petition from ferring pharmaceuticals inc.",0,0
09000064823c8f19,Supporting & Related Material,FDA-2016-P-4093-0018,FDA-2016-P-4093,tab p -- desmopressin in elderly patients with nocturia re citizen petition from ferring pharmaceuticals inc,0,0
09000064823c8f1b,Supporting & Related Material,FDA-2016-P-4093-0020,FDA-2016-P-4093,"tab r -- summary minutes emdac (january 12, 2015) re citizen petition from ferring pharmaceuticals inc.",0,0
09000064823c941e,Other,FDA-2016-P-4093-0001,FDA-2016-P-4093,citizen petition from ferring pharmaceuticals inc,0,0
09000064823c9422,Supporting & Related Material,FDA-2016-P-4093-0003,FDA-2016-P-4093,tab a -- the effect of nocturia on sleep quality and daytime function in patients with lower urinary tract symptoms a cross sectional study re citizen petition from ferring pharmaceuticals inc,0,0
09000064823c8f0e,Supporting & Related Material,FDA-2016-P-4093-0010,FDA-2016-P-4093,"tab h -- january 30, 2015 complete response letter re citizen petition from ferring pharmaceuticals inc.",0,0
09000064823c8f17,Supporting & Related Material,FDA-2016-P-4093-0016,FDA-2016-P-4093,tab n -- desmopressin treatment in nocturia re citizen petition from ferring pharmaceuticals inc,0,0
0900006482b7c59d,Other,FDA-2017-P-5921-0001,FDA-2017-P-5921,citizen petition from arent fox llp,0,0
0900006482b7c3f5,Other,FDA-2017-P-5921-0002,FDA-2017-P-5921,acknowledgement letter from fda ddm to arent fox llp,0,0
0900006482fa61aa,Other,FDA-2017-P-5921-0003,FDA-2017-P-5921,citizens petition withdrawal from arent fox llp,0,0
090000648228fbed,Other,FDA-2016-P-3112-0002,FDA-2016-P-3112,acknowledgment letter from fda ddm to mario morais,0,0
090000648249f0c0,Other,FDA-2016-P-3112-0003,FDA-2016-P-3112,interim response letter from fda oc to mr. mario morais,0,0
090000648228fbeb,Other,FDA-2016-P-3112-0001,FDA-2016-P-3112,citizen petition from mario morais,0,0
09000064824ab05a,Other,FDA-2016-P-3112-0009,FDA-2016-P-3112,petitioner response to fda petition denial,0,0
09000064824a14a5,Other,FDA-2016-P-3112-0004,FDA-2016-P-3112,petition denial letter fda-2016-p-3112,0,0
09000064824a1b07,Supporting & Related Material,FDA-2016-P-3112-0005,FDA-2016-P-3112,reference list for 3112,0,0
09000064824a1b08,Supporting & Related Material,FDA-2016-P-3112-0006,FDA-2016-P-3112,"reference 1 september 15 2012 email from buckles, d",0,0
09000064824a1b09,Supporting & Related Material,FDA-2016-P-3112-0007,FDA-2016-P-3112,reference 2 biovail corp v us food and drug admin,1,0
09000064843385ac,Other,FDA-2019-P-3937-0003,FDA-2019-P-3937,"interim response letter from fda cder to teva pharmaceuticals usa, inc",0,0
0900006483e7d3a9,Other,FDA-2019-P-3937-0001,FDA-2019-P-3937,"citizen petition from teva pharmaceuticals usa, inc.",0,0
0900006483e7d3ab,Other,FDA-2019-P-3937-0002,FDA-2019-P-3937,"acknowledgment letter from fda dms to teva pharmaceuticals usa, inc",0,0
0900006482454fc4,Supporting & Related Material,FDA-2017-P-0137-0004,FDA-2017-P-0137,"reference 2 detailed ims, moving annual total (mat) data re citizen petition from macleods pharmaceuticals limited",0,0
0900006482852346,Other,FDA-2017-P-0137-0005,FDA-2017-P-0137,interim response letter to macleods pharmaceuticals limited from fda cder,0,0
0900006482454f8d,Other,FDA-2017-P-0137-0002,FDA-2017-P-0137,acknowledgement letter from fda ddm to macleods pharmaceuticals limited,0,0
0900006482454f8b,Other,FDA-2017-P-0137-0001,FDA-2017-P-0137,citizen petition from macleods pharmaceuticals limited,0,0
0900006482454fc3,Supporting & Related Material,FDA-2017-P-0137-0003,FDA-2017-P-0137,reference 1 current orange book search results re citizen petition from macleods pharmaceuticals limited,0,0
0900006483646694,Other,FDA-2017-P-0137-0006,FDA-2017-P-0137,withdrawal of citizen petition  from macleods pharmaceuticals limited,0,0
0900006481fec4e0,Supporting & Related Material,FDA-2016-P-1319-0003,FDA-2016-P-1319,attachment 1 nda # 21-572 detail record from the current electronic edition of the orange book re citizen petition from florek & endres pllc,0,0
0900006481fec369,Supporting & Related Material,FDA-2016-P-1319-0004,FDA-2016-P-1319,"attachment 2 cubicin® (daptomycin for injection), 500 mg/vial package insert (rld labeling) re citizen petition from florek & endres pllc",0,0
0900006481fec368,Supporting & Related Material,FDA-2016-P-1319-0005,FDA-2016-P-1319,"attachment 3 u.s. centers for disease control and prevention, national center for health statistics, body measurements, available at http://www.cdc.gov/nchs/fastats/body-measurements.htm (last updated nov. 2, 2012) re citizen petition from florek & endres pllc",0,0
0900006481fec364,Other,FDA-2016-P-1319-0001,FDA-2016-P-1319,citizen petition from florek & endres pllc,0,0
0900006481fec366,Other,FDA-2016-P-1319-0002,FDA-2016-P-1319,acknowledgement letter from fda ddm to  florek & endres pllc,0,0
090000648378c7e8,Other,FDA-2018-P-3742-0002,FDA-2018-P-3742,acknowledgment letter from fda ddm to pharmacmechanics,0,0
09000064837914f8,Other,FDA-2018-P-3742-0003,FDA-2018-P-3742,acknowledgment letter from fda ddm to pharmacmechanics,0,0
090000648378c7b1,Other,FDA-2018-P-3742-0001,FDA-2018-P-3742,citizen petition from pharmacmechanics,0,0
0900006483b52c55,Other,FDA-2018-P-3742-0004,FDA-2018-P-3742,letter from fda cder to pharmacomechanics,0,0
09000064811d148a,Notice,FDA-2012-D-1240-0001,FDA-2012-D-1240,draft guidances for industry and staff; availability: submissions for postapproval modifications to a combination product approved undercertain marketing applications,0,0
09000064811d1b7e,Other,FDA-2012-D-1240-0002,FDA-2012-D-1240,draft guidances for industry and staff; submissions for postapproval modifications to a combination product approved undercertain marketing applications,0,0
0900006483b05d37,Other,FDA-2019-P-1318-0001,FDA-2019-P-1318,citizen petition from lachman consultants,0,0
0900006483b06087,Supporting & Related Material,FDA-2019-P-1318-0003,FDA-2019-P-1318,attachment 1 orange book listing for abraxane (paclitaxel) for injectable suspension accessed 11/22/16 re: citizen petition from lachman consultants.,0,0
0900006483b06089,Supporting & Related Material,FDA-2019-P-1318-0004,FDA-2019-P-1318,attachment 2 reference listed drug prescribing information for abraxane (paclitaxel) for injectable suspension re: citizen petition from lachman consultants,0,0
0900006483b06355,Other,FDA-2019-P-1318-0002,FDA-2019-P-1318,acknowledgment letter from fda ddm to lachman consultants.,0,0
0900006483b0608a,Supporting & Related Material,FDA-2019-P-1318-0005,FDA-2019-P-1318,"attachment 3 proposed prescribing information for paclitaxel for injectable suspension, 100 mg/vial and 200 mg/vial re: citizen petition from lachman consultants.",0,0
09000064818c2bc8,Supporting & Related Material,FDA-2014-P-1622-0003,FDA-2014-P-1622,exhibit 1,0,0
09000064818c28cf,Other,FDA-2014-P-1622-0002,FDA-2014-P-1622,acknowledgement letter from fda ddm to genesee health system,0,0
0900006481cb1a7c,Other,FDA-2014-P-1622-0013,FDA-2014-P-1622,withdrawal of citizen petition from ghs genesee health system,0,0
09000064818c2bc9,Supporting & Related Material,FDA-2014-P-1622-0004,FDA-2014-P-1622,exhibit 2,0,0
09000064818c2bcb,Supporting & Related Material,FDA-2014-P-1622-0006,FDA-2014-P-1622,exhibit 4,0,0
09000064818c2bcc,Supporting & Related Material,FDA-2014-P-1622-0007,FDA-2014-P-1622,exhibit 5,0,0
09000064818c2bcd,Supporting & Related Material,FDA-2014-P-1622-0008,FDA-2014-P-1622,exhibit 6,0,0
09000064818c2c34,Supporting & Related Material,FDA-2014-P-1622-0009,FDA-2014-P-1622,exhibit 7,0,0
0900006481a3a47f,Other,FDA-2014-P-1622-0012,FDA-2014-P-1622,interim response from cder to genesee health system,0,0
09000064818c2230,Other,FDA-2014-P-1622-0001,FDA-2014-P-1622,citizen petition from genesee health system,0,0
09000064818c2bca,Supporting & Related Material,FDA-2014-P-1622-0005,FDA-2014-P-1622,exhibit 3,0,0
09000064818c2c35,Supporting & Related Material,FDA-2014-P-1622-0011,FDA-2014-P-1622,exhibit 8,0,0
09000064818c2c36,Supporting & Related Material,FDA-2014-P-1622-0010,FDA-2014-P-1622,exhibit 9,0,0
0900006481b2f54f,Other,FDA-2015-P-2149-0001,FDA-2015-P-2149,citizen petition from the natural solutions foundation,0,0
0900006481b3081c,Other,FDA-2015-P-2149-0002,FDA-2015-P-2149,acknowledgement letter from fda ddm to the natural solutions foundation,0,0
0900006481d8e76b,Other,FDA-2015-P-2149-0003,FDA-2015-P-2149,citizen petition denial response letter from fda cder to national solutions foundation,0,0
0900006482556d05,Other,FDA-2017-P-2365-0002,FDA-2017-P-2365,acknowledgement letter from fda ddm to senators schumer & gillibrand,0,0
0900006482bc0e21,Other,FDA-2017-P-2365-0005,FDA-2017-P-2365,interim response letter from cfsan to senators schumer & gillibrand,0,0
0900006482d3c0b3,Other,FDA-2017-P-2365-0006,FDA-2017-P-2365,final response letter from fda to the office of senator charles e. schumer,0,0
0900006482556b5f,Other,FDA-2017-P-2365-0001,FDA-2017-P-2365,citizen petition from senators schumer & gillibrand,0,0
0900006484876bc7,Other,FDA-2020-P-2010-0001,FDA-2020-P-2010,citizen petition from philips respironics,0,0
0900006484877182,Supporting & Related Material,FDA-2020-P-2010-0003,FDA-2020-P-2010,attachment d re: citizen petition from philips respironics,0,0
09000064849c1206,Other,FDA-2020-P-2010-0007,FDA-2020-P-2010,interim response letter from fda cdrh to philips respironics,0,0
0900006484877181,Supporting & Related Material,FDA-2020-P-2010-0004,FDA-2020-P-2010,attachment c re: citizen petition from philips respironics,0,0
0900006484876e80,Other,FDA-2020-P-2010-0002,FDA-2020-P-2010,acknowledgment letter from fda dms to philips respironics,0,0
0900006484877180,Supporting & Related Material,FDA-2020-P-2010-0005,FDA-2020-P-2010,attachment b re: citizen petition from philips respironics,0,0
090000648487717f,Supporting & Related Material,FDA-2020-P-2010-0006,FDA-2020-P-2010,attachment a re: citizen petition from philips respironics,0,0
09000064844cfa2c,Supporting & Related Material,FDA-2020-P-1305-0004,FDA-2020-P-1305,attachment 2- emergency-use-authorization jan 2017-of-medical-products re: citizen petition from dr. s. albert edwards,0,0
09000064844cfa2b,Supporting & Related Material,FDA-2020-P-1305-0003,FDA-2020-P-1305,attachment 1 - title 21--food and drugs chapter i--food and drug administration department of health and human services subchapter d--drugs for human use-  re: citizen petition from dr. s. albert edwards,1,0
090000648471c56d,Other,FDA-2020-P-1305-0005,FDA-2020-P-1305,withdrawal from s albert edwards,0,0
09000064844cf5c5,Other,FDA-2020-P-1305-0002,FDA-2020-P-1305,acknowledgment letter from fda dms to dr. s. albert edwards,0,0
09000064844cea63,Other,FDA-2020-P-1305-0001,FDA-2020-P-1305,citizen petition from dr. albert edwards,0,0
090000648237b7b4,Notice,FDA-2016-P-2674-0003,FDA-2016-P-2674,"determination that calan sr (verapamil hydrochloride) extended-
release oral tablet, 180 milligrams, was not withdrawn from sale for
reasons of safety or effectiveness",0,0
09000064821e93b4,Other,FDA-2016-P-2674-0002,FDA-2016-P-2674,"acknowledgment letter from fda ddm to heritage pharma labs, inc.",0,0
09000064823884d9,Other,FDA-2016-P-2674-0004,FDA-2016-P-2674,"fda cder response to heritage pharma labs, inc.",0,0
09000064821e8ef4,Other,FDA-2016-P-2674-0001,FDA-2016-P-2674,"citizen petition from heritage pharma, inc.",0,0
0900006480472e97,Supporting & Related Material,FDA-2004-D-0306-0003,FDA-2004-D-0306,guideline,0,0
0900006480472e94,Notice,FDA-2004-D-0306-0001,FDA-2004-D-0306,fda,0,0
0900006480472e98,Supporting & Related Material,FDA-2004-D-0306-0004,FDA-2004-D-0306,guideline,0,0
0900006480472e9a,Notice,FDA-2004-D-0306-0006,FDA-2004-D-0306,fda,0,0
0900006480472e99,Supporting & Related Material,FDA-2004-D-0306-0005,FDA-2004-D-0306,guideline,0,0
0900006480472e95,Supporting & Related Material,FDA-2004-D-0306-0002,FDA-2004-D-0306,guideline,0,0
090000648042d706,Supporting & Related Material,FDA-2007-N-0381-0004,FDA-2007-N-0381,jeffrey shuren,0,0
090000648042d6f9,Notice,FDA-2007-N-0381-0001,FDA-2007-N-0381,fda,0,0
090000648042d702,Notice,FDA-2007-N-0381-0002,FDA-2007-N-0381,fda,0,0
090000648042d705,Notice,FDA-2007-N-0381-0003,FDA-2007-N-0381,fda,0,0
090000648042d707,Supporting & Related Material,FDA-2007-N-0381-0005,FDA-2007-N-0381,jeffrey shuren,0,0
09000064844beca3,Other,FDA-2019-D-5573-0002,FDA-2019-D-5573,"technical considerations for demonstrating reliability of emergency-use injectors submitted under a bla, nda or anda: guidance for industry and food and drug administration staff draft guidance",1,0
09000064844bee36,Notice,FDA-2019-D-5573-0001,FDA-2019-D-5573,"technical considerations for demonstrating reliability of emergency-use injectors submitted under a biologics license application, new drug application, or abbreviated new drug application; draft guidance for industry and food and drug administration; availability",1,0
09000064824f7fec,Other,FDA-2016-P-3195-0004,FDA-2016-P-3195,"denial letter from cdrh  to wood, herron & evans, l.l.p.",0,0
09000064822a3371,Supporting & Related Material,FDA-2016-P-3195-0003,FDA-2016-P-3195,"exhibit 1 mriaudio product information re citiizen petition from wood, herron & evans, llp",0,0
09000064822a1f29,Other,FDA-2016-P-3195-0001,FDA-2016-P-3195,"citizen petition from wood, herron & evans, llp",0,0
09000064822a27f2,Other,FDA-2016-P-3195-0002,FDA-2016-P-3195,"acknowledgment letter from fda ddm to wood, herron & evans, llp",0,0
0900006483980af7,Notice,FDA-2018-N-4087-0001,FDA-2018-N-4087,the food and drug administration’s proposed current good manufacturing practice policies for outsourcing facilities: considerations regarding access to office stock; public meeting; request for comments,1,0
0900006480f785d0,Other,FDA-2011-P-0575-0003,FDA-2011-P-0575,"fda/cder  to warner chilcott company, llc - petition approval",0,0
0900006480ed39eb,Other,FDA-2011-P-0575-0002,FDA-2011-P-0575,"acknowledgement letter to warner chilcott company, llc",0,0
0900006480ed3940,Other,FDA-2011-P-0575-0001,FDA-2011-P-0575,"warner chilcott company, llc -  citizen petition",0,0
0900006481e6f4ee,Other,FDA-2011-P-0086-0007,FDA-2011-P-0086,supplement from janssen,0,0
0900006480becf96,Supporting & Related Material,FDA-2011-P-0086-0003,FDA-2011-P-0086,"exhibit 3 - ""diagnostic & statistical manual of mental disorders"" - [johnson & johnson pharmaceutical research, llc., (ropes & gray, llp) - citizen petition]",0,0
0900006481e881a5,Other,FDA-2011-P-0086-0008,FDA-2011-P-0086,supplement from janssen research and development,0,0
0900006480becc27,Other,FDA-2011-P-0086-0001,FDA-2011-P-0086,"johnson & johnson pharmaceutical research, llc., (ropes & gray, llp) - citizen petition",0,0
0900006482360a28,Other,FDA-2011-P-0086-0009,FDA-2011-P-0086,"supplement from janssen research & development, llc",0,0
09000064814ba9d1,Other,FDA-2011-P-0086-0006,FDA-2011-P-0086,"janssen research & development, llc. - supplement",0,0
0900006480becc2c,Other,FDA-2011-P-0086-0002,FDA-2011-P-0086,"acknowledgement letter to johnson & johnson pharmaceutical research, llc., (ropes & gray, llp)",0,0
090000648236fae8,Supporting & Related Material,FDA-2016-P-3696-0003,FDA-2016-P-3696,attachment 1 orange book drug products listing re citizen petition from anda consultants,0,0
090000648236fae6,Other,FDA-2016-P-3696-0002,FDA-2016-P-3696,acknowledgment letter from fda ddm to anda consultants,0,0
090000648236e933,Other,FDA-2016-P-3696-0001,FDA-2016-P-3696,citizen petition from anda consultants,0,0
090000648237c52b,Supporting & Related Material,FDA-2016-P-3696-0004,FDA-2016-P-3696,attachment 2 product-specific guidance list no listing for fluorometholone ophthalmic suspension re citizen petition from anda consultants,0,0
09000064824a73ab,Other,FDA-2016-P-3696-0005,FDA-2016-P-3696,"withdrawal notification from mark shaw, anda consultants",0,0
0900006482c60dee,Other,FDA-2017-P-6451-0001,FDA-2017-P-6451,suitability petition from locke lord llp,0,0
0900006482c60fc6,Supporting & Related Material,FDA-2017-P-6451-0004,FDA-2017-P-6451,attachment2_draft insert labeling for proposed micafungin sodium for injection 50-100-150(1) re: suitability petition from locke lord llp,0,0
0900006482c60df0,Other,FDA-2017-P-6451-0002,FDA-2017-P-6451,acknowledgment letter from fda ddm to locke lord llp,0,0
0900006482c60df2,Supporting & Related Material,FDA-2017-P-6451-0003,FDA-2017-P-6451,attachment1_approved drug products with therapeutic equivalent evaluation re: suitability petition from locke lord llp,0,0
0900006482c60fc7,Supporting & Related Material,FDA-2017-P-6451-0005,FDA-2017-P-6451,"attachment3_labeling of the approved product, mycamine® for injection ) re: suitability petition from locke lord llp",0,0
09000064839e38a3,Other,FDA-2019-P-0114-0002,FDA-2019-P-0114,"acknowledgment letter from fda ddm to pfizer innovative health global regulatory affairs, hopira, inc.",0,0
09000064839e37fa,Other,FDA-2019-P-0114-0001,FDA-2019-P-0114,"citizen petition from  pfizer innovative health global regulatory affairs, hopira, inc.",0,0
090000648185aeec,Supporting & Related Material,FDA-2014-P-1281-0003,FDA-2014-P-1281,attachment a re citizen petition from arnall golden fda-214-p-1281-0001 gregory llp,0,0
0900006482af4712,Other,FDA-2014-P-1281-0006,FDA-2014-P-1281,withdrawal  email of citizen petition arnall golden gregory llp’s (agg) to fda,0,0
09000064819ae7bb,Other,FDA-2014-P-1281-0005,FDA-2014-P-1281,interim response letter from fda cder to arnall golden gregory llp,0,0
090000648185aeed,Supporting & Related Material,FDA-2014-P-1281-0004,FDA-2014-P-1281,attachment b re citizen petition from arnall golden fda-2014-p-1281-0001 gregory llp,0,0
0900006481853477,Other,FDA-2014-P-1281-0002,FDA-2014-P-1281,acknowledgement letter from arnall golden gregory llp,0,0
0900006481853475,Other,FDA-2014-P-1281-0001,FDA-2014-P-1281,citizen petition from arnall golden gregory llp,0,0
0900006480f6d42a,Other,FDA-2011-P-0823-0002,FDA-2011-P-0823,acknowledgement letter to astrazeneca pharmaceuticals lp (covington & burling llp),0,0
0900006480f6ccb5,Other,FDA-2011-P-0823-0001,FDA-2011-P-0823,astrazeneca pharmaceuticals lp (covington & burling llp) - citizen petition,0,0
090000648100ae07,Other,FDA-2011-P-0823-0003,FDA-2011-P-0823,"fda/cder response to astrazeneca pharmaceuticals lp dated may 11, 2012 - petition denial",0,0
0900006482433da8,Notice,FDA-2016-N-4342-0001,FDA-2016-N-4342,agency information collection activities; proposed collection; comment request; application for participation in the food and drug administration regulatory science student internship program,1,0
0900006482fbb23b,Other,FDA-2018-P-1040-0002,FDA-2018-P-1040,acknowledgment letter from fda ddm to joshua brooks,0,0
0900006482fbb233,Other,FDA-2018-P-1040-0001,FDA-2018-P-1040,citizen petition from joshua brooks,0,0
0900006483796020,Supporting & Related Material,FDA-2018-P-3786-0005,FDA-2018-P-3786,"attachment 3 re citizen petition from hyman, phelps & mcnamara pc",0,0
0900006483795ff5,Supporting & Related Material,FDA-2018-P-3786-0004,FDA-2018-P-3786,"attachment 2 re citizen petition from hyman, phelps & mcnamara pc",0,0
0900006483795ff2,Other,FDA-2018-P-3786-0002,FDA-2018-P-3786,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara",0,0
0900006483795ff4,Supporting & Related Material,FDA-2018-P-3786-0003,FDA-2018-P-3786,"attachment 1 re citizen petition from hyman, phelps & mcnamara pc",0,0
0900006483795ff0,Other,FDA-2018-P-3786-0001,FDA-2018-P-3786,"citizen petition from hyman, phelps & mcnamara pc",0,0
0900006482bbc248,Other,FDA-2017-P-6108-0002,FDA-2017-P-6108,acknowledgement letter from fda ddm to goodwin procter llp,0,0
09000064831476a1,Other,FDA-2017-P-6108-0003,FDA-2017-P-6108,petition approval letter from fda cder,0,0
0900006482bbc246,Other,FDA-2017-P-6108-0001,FDA-2017-P-6108,citizen petition from goodwin procter llp,0,0
09000064849594b9,Supporting & Related Material,FDA-2020-P-2181-0004,FDA-2020-P-2181,"attachment 2 - micro-k labeling re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
09000064849594b5,Other,FDA-2020-P-2181-0002,FDA-2020-P-2181,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
09000064849594b4,Other,FDA-2020-P-2181-0001,FDA-2020-P-2181,"suitability petition from hyman, phelps & mcnamara, p.c.",0,0
09000064849594ba,Supporting & Related Material,FDA-2020-P-2181-0005,FDA-2020-P-2181,"attachment 3 - proposed micro-k ls labeling re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
09000064849594b8,Supporting & Related Material,FDA-2020-P-2181-0003,FDA-2020-P-2181,"attachment 1 - micro-k ls -orange book: approved drug products with therapeutic equivalence evaluations re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006483a88ce2,Notice,FDA-2018-D-4711-0001,FDA-2018-D-4711,"nonbinding feedback after certain food and drug administration
inspections of device establishments; draft guidance for industry and food and drug administration staff; availability",1,0
09000064844beeed,Notice,FDA-2018-D-4711-0010,FDA-2018-D-4711,nonbinding feedback after certain food and drug administration inspections of device establishments; guidance for industry and food and drug administration staff; availability,1,0
0900006483a8889f,Other,FDA-2018-D-4711-0003,FDA-2018-D-4711,request for extension from advanced medical technology association (advamed),0,0
09000064844c68e5,Other,FDA-2018-D-4711-0011,FDA-2018-D-4711,nonbinding feedback after certain fda inspections of device establishments guidance for industry and food and drug administration staff,1,0
090000648465dec0,Notice,FDA-2018-D-4711-0012,FDA-2018-D-4711,"agency information collection activities; announcement of office of
management and budget approvals",0,0
0900006483a8918c,Other,FDA-2018-D-4711-0002,FDA-2018-D-4711,nonbinding feedback after certain fda inspections of device establishments; draft guidance for industry and food and drug administration staff; draft guidance,1,0
09000064844418b1,Notice,FDA-2018-D-4711-0008,FDA-2018-D-4711,agency information collection activities; submission for office of management and budget review; comment request; nonbinding feedback after certain food and drug administration inspections of device establishments,1,0
090000648435b94d,Other,FDA-2019-P-3907-0003,FDA-2019-P-3907,interim response letter from fda cder to novitium pharma llc,0,0
0900006483e6f50b,Other,FDA-2019-P-3907-0001,FDA-2019-P-3907,citizen petition from novitium pharma llc,0,0
0900006483e6f50c,Other,FDA-2019-P-3907-0002,FDA-2019-P-3907,acknowledgment letter from fda dms to novitium pharma llc,0,0
0900006484a81fa9,Other,FDA-2019-P-3907-0004,FDA-2019-P-3907,withdrawal from novitium pharma llc,0,0
090000648244a4aa,Supporting & Related Material,FDA-2017-P-0052-0007,FDA-2017-P-0052,reference 4 dsrresearch anonymity2015 re citizen petition from donor sibling registry,0,0
090000648361f8aa,Supporting & Related Material,FDA-2017-P-0052-0205,FDA-2017-P-0052,"reference 1 - the genetic basis of complex traits rare variants or common gene, common disease re: response letter from fda cber to donor sibling registry",0,0
090000648361f8a9,Supporting & Related Material,FDA-2017-P-0052-0204,FDA-2017-P-0052,list of references re: response letter from fda cber to donor sibling registry,0,0
090000648361f8ac,Supporting & Related Material,FDA-2017-P-0052-0206,FDA-2017-P-0052,reference 2 - recent advances in the genetics of schizophrenia re: response letter from fda cber to donor sibling registry,0,0
090000648244a4ac,Supporting & Related Material,FDA-2017-P-0052-0009,FDA-2017-P-0052,reference 4 dsrresearchdonorsparents2013 re citizen petition from donor sibling registry,0,0
090000648244a4b0,Supporting & Related Material,FDA-2017-P-0052-0013,FDA-2017-P-0052,reference 4 dsrresearchnon-bio_parent_paper2012 re citizen petition from donor sibling registry,0,0
090000648244a4b1,Supporting & Related Material,FDA-2017-P-0052-0014,FDA-2017-P-0052,reference 4 dsrresearchoffspring_paper2011 re citizen petition from donor sibling registry,0,0
090000648244a4c1,Supporting & Related Material,FDA-2017-P-0052-0018,FDA-2017-P-0052,reference 4 dsrresearchoocyeparents2012 re citizen petition from donor sibling registry,0,0
090000648244de45,Other,FDA-2017-P-0052-0003,FDA-2017-P-0052,signed certification w. kramer,0,0
090000648361f837,Other,FDA-2017-P-0052-0203,FDA-2017-P-0052,response letter from fda cber to donor sibling registry,0,0
090000648244a4a9,Supporting & Related Material,FDA-2017-P-0052-0006,FDA-2017-P-0052,reference 4 dsr research 1700 mothers 2013 re citizen petition from donor sibling registry,0,0
090000648244a4ae,Supporting & Related Material,FDA-2017-P-0052-0011,FDA-2017-P-0052,reference 4 dsrresearchemergingmodelscontact2015 re citizen petition from donor sibling registry,0,0
090000648244a4af,Supporting & Related Material,FDA-2017-P-0052-0012,FDA-2017-P-0052,reference 4 dsrresearchgeneticissuesdonors2013 re citizen petition from donor sibling registry,0,0
090000648244a4bf,Supporting & Related Material,FDA-2017-P-0052-0016,FDA-2017-P-0052,reference 4 dsrresearchoffspringidentity2016 re citizen petition from donor sibling registry,0,0
090000648244a4c2,Supporting & Related Material,FDA-2017-P-0052-0019,FDA-2017-P-0052,reference 4 dsrresearchparents_exeriences2009 re citizen petition from donor sibling registry,0,0
090000648244a4c8,Supporting & Related Material,FDA-2017-P-0052-0025,FDA-2017-P-0052,reference 12 comparativeanalysisof sperm banks re citizen petition from donor sibling registry,0,0
090000648244a4b2,Supporting & Related Material,FDA-2017-P-0052-0015,FDA-2017-P-0052,reference 4 dsrresearchoffspringcontactsiblings2016 re citizen petition from donor sibling registry,0,0
090000648244a4c4,Supporting & Related Material,FDA-2017-P-0052-0021,FDA-2017-P-0052,reference 4 dsrresearchsperm_and_egg_donors_experiences2010 re citizen petition from donor sibling registry,0,0
090000648244a4c5,Supporting & Related Material,FDA-2017-P-0052-0022,FDA-2017-P-0052,reference 4 dsrreseearchoffspring2013 re citizen petition from donor sibling registry,0,0
090000648244a4c6,Supporting & Related Material,FDA-2017-P-0052-0023,FDA-2017-P-0052,reference 4 dsrrsearcheggdonorparents2012 re citizen petition from donor sibling registry,0,0
090000648244a83f,Supporting & Related Material,FDA-2017-P-0052-0026,FDA-2017-P-0052,reference 19 kretchmar cystic fibrosis re citizen petition from donor sibling registry,0,0
090000648254ad57,Supporting & Related Material,FDA-2017-P-0052-0128,FDA-2017-P-0052,attachment 3 2015-2017 huffington post contributions re: comment from wendy kramer,0,0
090000648244a29e,Other,FDA-2017-P-0052-0001,FDA-2017-P-0052,citizen petition from donor sibling registry,0,0
090000648244a2a0,Other,FDA-2017-P-0052-0002,FDA-2017-P-0052,acknowledgement letter from fda ddm to donor sibling registry,0,0
090000648244a2a3,Supporting & Related Material,FDA-2017-P-0052-0004,FDA-2017-P-0052,reference 1 asrm recommendations re citizen petition from donor sibling registry,0,0
0900006484a679f6,Other,FDA-2021-P-0284-0001,FDA-2021-P-0284,citizen petition from donavan melton,0,0
0900006484a67a01,Other,FDA-2021-P-0284-0002,FDA-2021-P-0284,acknowledgment letter from fda dms to donavan melton,0,0
0900006484c03ba1,Other,FDA-2021-P-0284-0003,FDA-2021-P-0284,final response to donavan melton from fda cvm,0,0
0900006480b09408,Notice,FDA-2010-N-0180-0002,FDA-2010-N-0180,"agency information collection activities; proposals, submissions, and approvals: adoption of food and drug administration food code by local, state, and tribal governments",1,0
0900006480ad7226,Notice,FDA-2010-N-0180-0001,FDA-2010-N-0180,"agency information collection activities; proposals, submissions, and approvals: adoption of fda food code by local, state, and tribal governments",1,0
0900006480ba4316,Notice,FDA-2010-N-0180-0003,FDA-2010-N-0180,"agency information collection activities; proposals, submissions, and approvals: adoption of food and drug administration food code by local, state and tribal governments",1,0
090000648435061c,Supporting & Related Material,FDA-2020-P-0725-0005,FDA-2020-P-0725,appendix 3 enfit isosaf nn single use syringe example labels re citizen petition from gbuk group ltd,0,0
09000064843502eb,Supporting & Related Material,FDA-2020-P-0725-0003,FDA-2020-P-0725,appendix 1 enfit isosaf single use syringe example labels re citizen petition from gbuk group ltd,0,0
09000064843502e8,Other,FDA-2020-P-0725-0002,FDA-2020-P-0725,acknowledgment letter from fda dms to gbuk group ltd,0,0
090000648435061b,Supporting & Related Material,FDA-2020-P-0725-0004,FDA-2020-P-0725,appendix 2 enfit isosaf single use syringe ldt example labels re citizen petition from gbuk group ltd,0,0
090000648435061d,Supporting & Related Material,FDA-2020-P-0725-0006,FDA-2020-P-0725,appendix 4 enfit isosaf single use syringe and push fit cap example labels re citizen petition from gbuk group ltd,0,0
0900006484350620,Supporting & Related Material,FDA-2020-P-0725-0009,FDA-2020-P-0725,appendix 7 drawing up devices example labels re citizen petition from gbuk group ltd,0,0
09000064843502e7,Other,FDA-2020-P-0725-0001,FDA-2020-P-0725,citizen petition from gbuk group ltd,0,0
0900006484350621,Supporting & Related Material,FDA-2020-P-0725-0010,FDA-2020-P-0725,appendix 8 example images re citizen petition from gbuk group ltd,0,0
09000064847873e6,Other,FDA-2020-P-0725-0011,FDA-2020-P-0725,interim response letter from fda cdrh to gbuk group ltd,0,0
090000648435061f,Supporting & Related Material,FDA-2020-P-0725-0008,FDA-2020-P-0725,appendix 6 bottle adaptors example labels re citizen petition from gbuk group ltd,0,0
090000648435061e,Supporting & Related Material,FDA-2020-P-0725-0007,FDA-2020-P-0725,appendix 5 syringe cap example labels re citizen petition from gbuk group ltd,0,0
090000648294d5c6,Other,FDA-2017-P-4351-0002,FDA-2017-P-4351,acknowledgment letter from fda ddm to hogan lovells us llp (relypsa inc.),0,0
090000648294d5cb,Supporting & Related Material,FDA-2017-P-4351-0006,FDA-2017-P-4351,exhibit 4 - lesko et al 2017 veltassa ddi reprint re citizen petition from hogan lovells us llp  ( relypsa inc.),0,0
090000648294bcfc,Other,FDA-2017-P-4351-0001,FDA-2017-P-4351,citizen petition from hogan lovells us llp  ( relypsa inc.),0,0
0900006482c3c1de,Other,FDA-2017-P-4351-0008,FDA-2017-P-4351,petition withdrawal letter from relypsa inc.,0,0
090000648294d5c8,Supporting & Related Material,FDA-2017-P-4351-0003,FDA-2017-P-4351,"exhibit 1 - fda press release for veltassaa oct 21, 2015 re citizen petition from hogan lovells us llp  ( relypsa inc.)",0,0
090000648294d5c9,Supporting & Related Material,FDA-2017-P-4351-0004,FDA-2017-P-4351,"exhibit 2 - fda drug safety communication for kayexalate oct 22, 2015 re citizen petition from hogan lovells us llp  ( relypsa inc.)",0,0
090000648294dcb6,Supporting & Related Material,FDA-2017-P-4351-0007,FDA-2017-P-4351,"exhibit 5 - kayexalate prescribing information jan 3, 2011 re citizen petition from hogan lovells us llp  ( relypsa inc.)",0,0
090000648294d5ca,Supporting & Related Material,FDA-2017-P-4351-0005,FDA-2017-P-4351,"exhibit 3 - veltassa prescribing information nov 25, 2016 re citizen petition from hogan lovells us llp  ( relypsa inc.)",0,0
0900006481239e43,Other,FDA-2013-P-0337-0001,FDA-2013-P-0337,"hyman, phelps & mcnamara, pc - petition for stay of action",0,0
090000648124f805,Other,FDA-2013-P-0337-0003,FDA-2013-P-0337,"hyman, phelps & mcnamara, p.c. - withdrawal of petition for stay of action",0,0
0900006481239e98,Other,FDA-2013-P-0337-0002,FDA-2013-P-0337,"acknowledgement letter to hyman, phelps & mcnamara, pc",0,0
0900006481ff6c7c,Supporting & Related Material,FDA-2016-P-1364-0003,FDA-2016-P-1364,"attachment 1 orange book listing for abraxane (paclitaxel) for injectable suspension accessed 05/24/16 re citizen petition from lachman consultant services, inc.",0,0
0900006481ff6cc4,Other,FDA-2016-P-1364-0002,FDA-2016-P-1364,"acknowledgement letter from fda ddm to lachman consultant services, inc.",0,0
0900006481ff6c7a,Other,FDA-2016-P-1364-0001,FDA-2016-P-1364,"citizen petition from lachman consultant services, inc.",0,0
0900006481ff6c9c,Supporting & Related Material,FDA-2016-P-1364-0004,FDA-2016-P-1364,"attachment 2 reference listed drug prescribing information for abraxane (paclitaxel) for injectable suspension) re citizen petition from lachman consultant services, inc.",0,0
0900006481ff6c9d,Supporting & Related Material,FDA-2016-P-1364-0005,FDA-2016-P-1364,"attachment 3 proposed prescribing information for paclitaxel for injectable suspension, 250 mg/vial re citizen petition from lachman consultant services, inc.",0,0
0900006482b77d4b,Other,FDA-2017-P-5909-0002,FDA-2017-P-5909,acknowledgment letter from fda ddm to  goodwin procter llp,0,0
0900006482c9fada,Other,FDA-2017-P-5909-0004,FDA-2017-P-5909,petition response letter,0,0
0900006482c98c5d,Notice,FDA-2017-P-5909-0003,FDA-2017-P-5909,"determination that trintellix (vortioxetine hydrobromide) oral
tablet, eq 15 milligram base, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006482b77278,Other,FDA-2017-P-5909-0001,FDA-2017-P-5909,citizen petition from goodwin procter llp,0,0
090000648253d67a,Supporting & Related Material,FDA-2017-P-2129-0004,FDA-2017-P-2129,exhibit ii - medrol label re,0,0
090000648253dcac,Other,FDA-2017-P-2129-0002,FDA-2017-P-2129,acknowledgment letter from fda ddm to jubilant generics limited,0,0
090000648253d677,Other,FDA-2017-P-2129-0001,FDA-2017-P-2129,citizen petition from jubilant generics limited,0,0
090000648253d67b,Supporting & Related Material,FDA-2017-P-2129-0005,FDA-2017-P-2129,exhibit iii - proposed label re,0,0
090000648253d679,Supporting & Related Material,FDA-2017-P-2129-0003,FDA-2017-P-2129,"exhibit i - orange book: approved drug products with therapeutic
equivalence evaluations",0,0
0900006480b8a278,Other,FDA-2010-P-0580-0003,FDA-2010-P-0580,"acknowledgement letter to bracewell & giuliani, llp",0,0
0900006480b8a154,Supporting & Related Material,FDA-2010-P-0580-0002,FDA-2010-P-0580,"exhibit a - ""fda/cdrh response to medtronic minimed, apirl 7, 2006"" - [bracewell & giuliani, llp - citizen petition]",0,0
0900006480c3f4bd,Other,FDA-2010-P-0580-0004,FDA-2010-P-0580,"fda/center for devices and radiological health - interim repsonse to bracewell & giuliani, llp",0,0
0900006480c3f4c7,Other,FDA-2010-P-0580-0005,FDA-2010-P-0580,"houssiere durant houssiere, llp - letter",0,0
09000064816b6d75,Other,FDA-2010-P-0580-0006,FDA-2010-P-0580,"citizen petition response from fda cdrh to houssiere, durant & houssiere, llp and bracewell & giuliani, llp",0,0
0900006480b8a152,Other,FDA-2010-P-0580-0001,FDA-2010-P-0580,"bracewell & giuliani, llp - citizen petition",0,0
0900006480fbebd5,Other,FDA-2011-D-0674-0002,FDA-2011-D-0674,"draft guidance for industry fda records access authority under section 414 and 704 of the federal food, drug, & cosmetic act",1,0
090000648169ddb1,Rule,FDA-2011-D-0674-0043,FDA-2011-D-0674,"guidance for industry: food and drug administration records access
authority under the federal food, drug, and cosmetic act; availability",1,0
0900006480fbeaae,Notice,FDA-2011-D-0674-0001,FDA-2011-D-0674,"draft guidance for industry;food and drug administration records access authority under federal food, drug, and cosmetic act; availability",1,0
090000648169ddb5,Other,FDA-2011-D-0674-0044,FDA-2011-D-0674,"guidance for industry; fda records access authority under sections 414 and 704 of the federal food, drug, and cosmetic act",1,0
0900006480efc77a,Other,FDA-2011-P-0623-0002,FDA-2011-P-0623,"acknowledgement letter to international premium cigar & pipe retailers association (ipcpr), hyman phelps & mcnamara, p.c.",0,0
0900006480ef8fa8,Other,FDA-2011-P-0623-0001,FDA-2011-P-0623,"international premium cigar & pipe retailers association (ipcpr) hyman, phelps and mcnamara, p.c. -  citizen petition",0,0
0900006481fbaec9,Other,FDA-2011-P-0623-0006,FDA-2011-P-0623,"citizen petition final response from fda ctp to hyman, phelps & mcnamara, p.c.",0,0
0900006480f7bbad,Other,FDA-2011-P-0623-0003,FDA-2011-P-0623,"fda/ctp interim response to international premium cigar & pipe retailers association (ipcpr) hyman, phelps and mcnamara, p.c. - letter",0,0
09000064816a49de,Other,FDA-2014-P-0407-0001,FDA-2014-P-0407,"citizen petition from almatica pharma, inc.",0,0
09000064816b526d,Other,FDA-2014-P-0407-0003,FDA-2014-P-0407,supplement from almatica pharma inc,0,0
0900006481719aa8,Supporting & Related Material,FDA-2014-P-0407-0004,FDA-2014-P-0407,exhibit c naprelan controlled release tablets supplement from almatica pharma inc,0,0
09000064818a7e58,Other,FDA-2014-P-0407-0007,FDA-2014-P-0407,"interim response from fda/cder to almatica pharma, inc.",0,0
0900006481d73efd,Other,FDA-2014-P-0407-0008,FDA-2014-P-0407,"citizen petition denial response letter from fda cder to almatica pharma, inc.",0,0
09000064816a4a46,Other,FDA-2014-P-0407-0002,FDA-2014-P-0407,acknowledgement letter from fda ddm to almatica pharm inc,0,0
0900006481719aaa,Supporting & Related Material,FDA-2014-P-0407-0005,FDA-2014-P-0407,exhibit e fda draft guidance on naproxen sodium supplement from almatica pharma inc,0,0
0900006481719aac,Supporting & Related Material,FDA-2014-P-0407-0006,FDA-2014-P-0407,exhibit k fda guidance document on bioavavailability and bioequivalence studies for orally administered drug products supplement from almatica pharma inc,0,0
09000064816b7603,Other,FDA-2014-P-0461-0002,FDA-2014-P-0461,acknowledgement letter from fda ddm to wiley rein llp,0,0
09000064816b737f,Other,FDA-2014-P-0461-0001,FDA-2014-P-0461,citizen petition from wiley rein llp,0,0
0900006482bc2a0c,Other,FDA-2014-P-0461-0004,FDA-2014-P-0461,withdrawal from wiley rein llp,0,0
09000064816b7ab6,Other,FDA-2014-P-0462-0002,FDA-2014-P-0462,acknowledgement letter from fda ddm to wiley rein llp,0,0
0900006482bc25f7,Other,FDA-2014-P-0462-0005,FDA-2014-P-0462,withdrawal from wiley rein llp,0,0
09000064816b7a74,Other,FDA-2014-P-0462-0001,FDA-2014-P-0462,citizen petition from wiley rein llp,0,0
0900006481ca27bb,Other,FDA-2014-P-0462-0004,FDA-2014-P-0462,letter from wiley rein llp,0,0
090000648170395b,Other,FDA-2014-P-0648-0002,FDA-2014-P-0648,acknowledgement letter from fda ddm to burdock group consultants,0,0
0900006481703960,Supporting & Related Material,FDA-2014-P-0648-0004,FDA-2014-P-0648,reference 1 footnotes citizen petition from burdock group consultants,0,0
09000064817034db,Other,FDA-2014-P-0648-0001,FDA-2014-P-0648,citizen petition from inovobiologic (burdock group consultants),0,0
0900006481703961,Supporting & Related Material,FDA-2014-P-0648-0005,FDA-2014-P-0648,reference 1 references citizen petition from burdock group consultants,0,0
090000648170395f,Supporting & Related Material,FDA-2014-P-0648-0003,FDA-2014-P-0648,reference 1 appendicies citizen petition from burdock group consultants,0,0
0900006481d543f1,Other,FDA-2015-P-4307-0003,FDA-2015-P-4307,acknowledgement letter from fda ddm to guy aliotta,0,0
0900006481d4f18e,Other,FDA-2015-P-4307-0001,FDA-2015-P-4307,citizen petition from guy aliotta,0,0
0900006481d543ed,Supporting & Related Material,FDA-2015-P-4307-0002,FDA-2015-P-4307,multiple signatures to change.org xylitol petition re citizen petition from guy aliotta,0,0
0900006482039828,Other,FDA-2015-P-4307-0004,FDA-2015-P-4307,interim response letter from fda cfsan to guy aliotta,0,0
0900006483fa1b53,Notice,FDA-2019-N-3403-0001,FDA-2019-N-3403,"the food and drug administration solicits input on potential role for
abuse-deterrent formulations of central nervous system stimulants;
establishment of a public docket; request for comments",1,0
0900006484470c61,Other,FDA-2020-D-1057-0001,FDA-2020-D-1057,notifying fda of a permanent discontinuance or interruption in manufacturing under section 506c of the fd&c act guidance for industry,0,0
090000648447e178,Notice,FDA-2020-D-1057-0003,FDA-2020-D-1057,"notifying the food and drug administration of a permanent discontinuance or interruption in manufacturing under section 506c of
the federal food, drug, and cosmetic act; guidance for industry; availability",1,0
09000064844ae92f,Other,FDA-2020-D-1057-0006,FDA-2020-D-1057,bio feedback on fda guidance during covid19 pandemic,0,0
090000648447ed08,Other,FDA-2020-D-1057-0004,FDA-2020-D-1057,notifying fda of a permanent discontinuance or interruption in manufacturing under section 506c of the fd&c act guidance for industry,0,0
0900006483c82a88,Supporting & Related Material,FDA-2019-P-2370-0003,FDA-2019-P-2370,exhibit 1- orange book: approved drug products with therapeutic equivalence equations re: citizen petition from alembic pharmaceuticals limited,0,0
0900006483c829ff,Other,FDA-2019-P-2370-0002,FDA-2019-P-2370,acknowledgment letter from fda ddm to alembic pharmaceuticals limited,0,0
0900006483c8299a,Other,FDA-2019-P-2370-0001,FDA-2019-P-2370,citizen petition from alembic pharmaceuticals limited,0,0
09000064840e96fe,Other,FDA-2019-P-2370-0004,FDA-2019-P-2370,response letter from fda cder to alembic pharmaceuticals limited,0,0
09000064826addc5,Supporting & Related Material,FDA-2017-P-3581-0003,FDA-2017-P-3581,exhibit-1 orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from alembic pharmaceuticals limited,0,0
09000064826addc3,Other,FDA-2017-P-3581-0001,FDA-2017-P-3581,citizen petition from alembic pharmaceuticals limited,0,0
0900006482bf9705,Other,FDA-2017-P-3581-0005,FDA-2017-P-3581,response from fda cder to alembic pharmaceuticals,0,0
0900006482bf72d4,Notice,FDA-2017-P-3581-0004,FDA-2017-P-3581,"determination that elavil (amitriptyline hydrochloride) oral tablets, 10, 25, 50, 75, 100, and 150 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
09000064826ae52f,Other,FDA-2017-P-3581-0002,FDA-2017-P-3581,acknowledgment letter from fda ddm to alembic pharmaceuticals limited,0,0
090000648420224f,Other,FDA-2019-P-2945-0062,FDA-2019-P-2945,fda interim response,0,0
0900006483d23067,Supporting & Related Material,FDA-2019-P-2945-0014,FDA-2019-P-2945,attachment l examples of advertisements for thc/cbd products for pets re citizen petition from jesse j leblanc iii,0,0
0900006483d2307c,Supporting & Related Material,FDA-2019-P-2945-0016,FDA-2019-P-2945,attachment n environmental impact re citizen petition from jesse j leblanc iii,0,0
0900006483d23121,Supporting & Related Material,FDA-2019-P-2945-0004,FDA-2019-P-2945,attachment b flow chart comparing adverse effects of nicotine (tobacco) to thc (marinol) re citizen petition from jesse j leblanc iii,0,1
0900006483d23060,Supporting & Related Material,FDA-2019-P-2945-0009,FDA-2019-P-2945,attachment g canadian public health warnings pages g1 - g3 re citizen petition from jesse j leblanc iii,0,0
0900006483d23068,Supporting & Related Material,FDA-2019-P-2945-0015,FDA-2019-P-2945,attachment m fda laboratory reports on cannabis products (2015 and 2016) pages ml to m7 re citizen petition from jesse j leblanc iii,0,0
0900006483d23124,Supporting & Related Material,FDA-2019-P-2945-0007,FDA-2019-P-2945,"attachment e cannabis advertisement in print: marisol therapeutic gardens, pueblo west, colorado; etc. re citizen petition from jesse j leblanc iii",0,0
0900006483d23061,Supporting & Related Material,FDA-2019-P-2945-0010,FDA-2019-P-2945,attachment h sections of state laws listing health conditions approved to use medical cannabis re citizen petition from jesse j leblanc iii,0,0
0900006483d23128,Supporting & Related Material,FDA-2019-P-2945-0008,FDA-2019-P-2945,"attachment f ""cannabis abuse disorder risk assessment"", by jesse leblanc iii (2018) and charlotte's web calculations re citizen petition from jesse j leblanc iii",0,0
0900006483d22cee,Other,FDA-2019-P-2945-0001,FDA-2019-P-2945,citizen petition from jesse j leblanc iii,0,0
0900006483d23122,Supporting & Related Material,FDA-2019-P-2945-0005,FDA-2019-P-2945,"attachment c fda's consumer updates: ""6-tip offs: don't fall for health fraud"" and ""products claiming ""cure"" for cancer are a cruel deception"" re citizen petition from jesse j leblanc iii",0,0
0900006483d23123,Supporting & Related Material,FDA-2019-P-2945-0006,FDA-2019-P-2945,"attachment d listing of cbd health claims taken from ""hemp health revolution: the a to z benefits of hemp extract"" by sherill sellman, n.d. re citizen petition from jesse j leblanc iii",0,0
0900006483d23120,Supporting & Related Material,FDA-2019-P-2945-0003,FDA-2019-P-2945,attachment a flow chart highlighting adverse effects from epidiolex (cbd) and marinol (thc) re citizen petition from jesse j leblanc iii,0,0
0900006483d23066,Supporting & Related Material,FDA-2019-P-2945-0013,FDA-2019-P-2945,attachment k stories of persons harmed by non-fda approved cannabis drugs re citizen petition from jesse j leblanc iii,0,0
0900006483d22cf0,Other,FDA-2019-P-2945-0002,FDA-2019-P-2945,acknowledgment letter from fda ddm to jesse j leblanc iii,0,0
0900006483d23062,Supporting & Related Material,FDA-2019-P-2945-0011,FDA-2019-P-2945,"attachment i advertising along interstate highway 25, pueblo, colorado; and colorado highway 50 near pueblo west, colorado re citizen petition from jesse j leblanc iii",0,0
0900006483d23065,Supporting & Related Material,FDA-2019-P-2945-0012,FDA-2019-P-2945,"attachment j fda ""warning letter"" to dr. young lee, president advanced
spine and pain llc, march 28. 2019 pages j1 to j6 re citizen petition from jesse j leblanc iii",0,0
0900006483d0b671,Other,FDA-2019-P-2853-0001,FDA-2019-P-2853,citizen petition from fresenius medical care north america,0,0
09000064841ee4c1,Other,FDA-2019-P-2853-0003,FDA-2019-P-2853,interim response letter from fda to fresenius medical care north america,0,0
0900006484870383,Other,FDA-2019-P-2853-0004,FDA-2019-P-2853,final response from fda cder to fresenius medical care north america,0,0
0900006483d0ba13,Other,FDA-2019-P-2853-0002,FDA-2019-P-2853,acknowledgment letter from fda ddm to fresenius medical care north america,0,0
0900006482bea5ef,Supporting & Related Material,FDA-2017-P-6219-0003,FDA-2017-P-6219,"attachment 1 fda orange book page for exalgo® (hydromorphone hcl), extended-release tablets, 32mg re citizen petition from axinn, veltrop & harkrider llp",0,0
0900006482bea5f0,Supporting & Related Material,FDA-2017-P-6219-0004,FDA-2017-P-6219,"attachment 2 copy of approved labeling for exalgo® (hydromorphone hcl), extended-release tablets, 32mg re citizen petition from axinn, veltrop & harkrider llp",0,0
0900006482bea277,Other,FDA-2017-P-6219-0001,FDA-2017-P-6219,"citizen petition from axinn, veltrop & harkrider llp",0,0
0900006482bea5ed,Other,FDA-2017-P-6219-0002,FDA-2017-P-6219,"acknowledgement letter from fda ddm to axinn, veltrop & harkrider llp",0,0
0900006484729915,Other,FDA-2017-P-6219-0006,FDA-2017-P-6219,"withdrawal from axinn, veltrop & harkrider llp",0,0
0900006482bea5f1,Supporting & Related Material,FDA-2017-P-6219-0005,FDA-2017-P-6219,"attachment 3 copy of proposed draft labeling for hydromorphone hcl extended-release tablets, 24 mg re citizen petition from axinn, veltrop & harkrider llp",0,0
0900006483ef086e,Supporting & Related Material,FDA-2019-P-4140-0005,FDA-2019-P-4140,"exhibit 3 - declaration (curriculum vitae) of christopher g. gharibo, m.d. re: citizen petition from persion pharmaceuticals llc",0,0
0900006483ef05ae,Other,FDA-2019-P-4140-0002,FDA-2019-P-4140,acknowledgment letter from fda dms to persion pharmaceuticals llc,0,0
0900006483ef0d8a,Supporting & Related Material,FDA-2019-P-4140-0008,FDA-2019-P-4140,exhibit 6 - nih public access the role of opioid prescription in incident opioid abuse and dependence among individuals with chronic non-cancer pain: the role of opioid prescription re: citizen petition from persion pharmaceuticals llc,0,0
0900006483ef0d8e,Supporting & Related Material,FDA-2019-P-4140-0011,FDA-2019-P-4140,exhibit 9 - highlights of prescribing information (vantrela er) re: citizen petition from persion pharmaceuticals llc,0,0
0900006483ef0145,Other,FDA-2019-P-4140-0001,FDA-2019-P-4140,citizen petition from persion pharmaceuticals llc,0,0
0900006483ef086d,Supporting & Related Material,FDA-2019-P-4140-0004,FDA-2019-P-4140,exhibit 2 - effects of renal impairment and hepatic impairment on the pharmacokinetics of hydrocodone after administration of a novel extended-release hydrocodone tablet formulated with oraguardtm technology re: citizen petition from persion pharmaceuticals,0,0
0900006483ef0d88,Supporting & Related Material,FDA-2019-P-4140-0006,FDA-2019-P-4140,exhibit 4 - declaration of craig antell. d.o. re: citizen petition from persion pharmaceuticals llc,0,0
0900006483ef086c,Supporting & Related Material,FDA-2019-P-4140-0003,FDA-2019-P-4140,exhibit 1 johnson (2007) opioid safety in patients with renal or hepatic dysfunction re: citizen petition from persion pharmaceuticals llc,0,0
09000064842cb5fe,Other,FDA-2019-P-4140-0016,FDA-2019-P-4140,response letter from fda cder to persion pharmaceuticals llc,0,0
0900006483ef0d89,Supporting & Related Material,FDA-2019-P-4140-0007,FDA-2019-P-4140,exhibit 5 - dasgupta et al (2015) cohort study of the impact of high-dose opioid analgesics on overdose mortality re: citizen petition from persion pharmaceuticals llc,0,0
0900006483ef0d8b,Supporting & Related Material,FDA-2019-P-4140-0009,FDA-2019-P-4140,exhibit 7 -  younossi et al (2011) changes in the prevalence of the most common causes of chronic liver diseases in the united states from 1988 to 2008 re: citizen petition from persion pharmaceuticals llc,0,0
0900006483ef0d8c,Supporting & Related Material,FDA-2019-P-4140-0010,FDA-2019-P-4140,exhibit 8 - nih public access pain and opioid use in chronic liver disease re: citizen petition from persion pharmaceuticals llc,0,0
09000064821b9e4f,Other,FDA-2016-P-2568-0001,FDA-2016-P-2568,citizen petition from fresenius kabi usa,0,0
09000064821b9c78,Supporting & Related Material,FDA-2016-P-2568-0003,FDA-2016-P-2568,attachment a product listing from the active section of the orange book re citizen petition from fresenius kabi usa,0,0
09000064821b9c7f,Other,FDA-2016-P-2568-0002,FDA-2016-P-2568,acknowledgment letter from fda ddm to fresenius kabi usa,0,0
090000648484cec6,Other,FDA-2020-P-1864-0001,FDA-2020-P-1864,"citizen petition from kambiz tajkarimi, md",0,0
0900006484b14ca5,Other,FDA-2020-P-1864-0003,FDA-2020-P-1864,interim response letter from fda cdrh to kambiz tajkarimi,0,0
090000648484cf40,Other,FDA-2020-P-1864-0002,FDA-2020-P-1864,acknowledgment letter from fda dms to kambiz tajkarimi,0,0
09000064804993b2,Notice,FDA-2003-D-0375-0006,FDA-2003-D-0375,fda,0,0
09000064804993b4,Supporting & Related Material,FDA-2003-D-0375-0007,FDA-2003-D-0375,guidance,0,0
09000064804992f9,Notice,FDA-2003-D-0375-0001,FDA-2003-D-0375,fda,0,0
090000648049937c,Supporting & Related Material,FDA-2003-D-0375-0002,FDA-2003-D-0375,guidance,0,0
09000064804993b7,Notice,FDA-2003-D-0375-0008,FDA-2003-D-0375,fda,0,0
09000064804993ab,Notice,FDA-2003-D-0375-0003,FDA-2003-D-0375,fda,0,0
09000064804993ad,Supporting & Related Material,FDA-2003-D-0375-0004,FDA-2003-D-0375,supporting statement,0,0
09000064804993b0,Supporting & Related Material,FDA-2003-D-0375-0005,FDA-2003-D-0375,supporting statement,0,0
0900006480474585,Other,FDA-2004-P-0409-0001,FDA-2004-P-0409,"hfa-305 to lachman consultant services, inc.",0,0
0900006480474588,Other,FDA-2004-P-0409-0002,FDA-2004-P-0409,"hfa-305 to lachman consultant services, inc.",0,0
090000648047458b,Other,FDA-2004-P-0409-0003,FDA-2004-P-0409,"hfd-600 to lachman consultant services, inc`",0,0
090000648048f41f,Supporting & Related Material,FDA-2003-N-0249-0003,FDA-2003-N-0249,supporting statement,0,0
090000648048f40e,Notice,FDA-2003-N-0249-0002,FDA-2003-N-0249,fda,0,0
090000648048f3d4,Notice,FDA-2003-N-0249-0001,FDA-2003-N-0249,fda,0,0
090000648048f424,Notice,FDA-2003-N-0249-0005,FDA-2003-N-0249,fda,0,0
090000648048f422,Supporting & Related Material,FDA-2003-N-0249-0004,FDA-2003-N-0249,supporting statement,0,0
09000064805f8421,Notice,FDA-2008-N-0286-0001,FDA-2008-N-0286,agency information collection activities; proposed collection; comment request; survey to evaluate fdas food defense awareness initiative alert,1,0
09000064809375b3,Notice,FDA-2008-N-0286-0003,FDA-2008-N-0286,"agency information collection activities; proposals, submissions, and approvals",0,0
0900006480b03323,Supporting & Related Material,FDA-2010-N-0295-0007,FDA-2010-N-0295,"reference 3 - ""...tobacco use among u.s. racial/ethmic minority groups - african americans, america indians and alaska natives, asian americans and pacific islanders, and hispanics:a report of the surgeon general 1998"" - [web-based public meeting to discuss issues related to the development of an enforcement action plan; request for data, information, and views]",0,1
0900006480b0329f,Supporting & Related Material,FDA-2010-N-0295-0005,FDA-2010-N-0295,"reference 1 - ""centers for disease control and prevention, ""smoking-attributable mortality, years of potential life lost, and productivity losses - united states, 2000-2004,"" morbidity and mortality weekly report"" - [web-based public meeting to discuss issues related to the development of an enforcement action plan; request for data, information, and views]",0,0
0900006480b28548,Other,FDA-2010-N-0295-0016,FDA-2010-N-0295,"overview of section 105: enforcement action plan for advertising and promotion restrictions, asimoneau, june 30, 2010 - [web-based public meeting to discuss issues related to the development of an enforcement action plan; request for data, information, and views] - presentation",0,0
0900006480b2854e,Other,FDA-2010-N-0295-0019,FDA-2010-N-0295,"tobacco enforcement program practices & strategies for enforcement, nmanzanilla, june 30, 2010 - [web-based public meeting to discuss issues related to the development of an enforcement action plan; request for data, information, and views] - presentation",0,1
0900006480b2854c,Other,FDA-2010-N-0295-0018,FDA-2010-N-0295,"south seattle: the south park community experience, shouston, june 30, 2010 - [web-based public meeting to discuss issues related to the development of an enforcement action plan; request for data, information, and views] - presentation",0,0
0900006480b033ad,Supporting & Related Material,FDA-2010-N-0295-0009,FDA-2010-N-0295,"reference 9 - ""id., p. 15"" - [web-based public meeting to discuss issues related to the development of an enforcement action plan; request for data, information, and views]",0,0
0900006480b032a5,Supporting & Related Material,FDA-2010-N-0295-0006,FDA-2010-N-0295,"reference 2 - ""national cancer institute, u.s. department of health & human services, the role of the media in promoting and reducing tobacco use""  - [web-based public meeting to discuss issues related to the development of an enforcement action plan; request for data, information, and views]",0,1
0900006480b2852e,Other,FDA-2010-N-0295-0013,FDA-2010-N-0295,"astho tobacco issues forum, jengel, june 30, 2010 - [web-based public meeting to discuss issues related to the development of an enforcement action plan; request for data, information, and views] - presentation",0,1
0900006480b2852c,Other,FDA-2010-N-0295-0012,FDA-2010-N-0295,"background and overview of the fda center for tobacco products, the family smoking prevention and tobacco control act (the tobacco control act), asimoneau, june 30, 2010 - [web-based public meeting to discuss issues related to the development of an enforcement action plan; request for data, information, and views] - presentation",0,1
0900006480b2843e,Other,FDA-2010-N-0295-0010,FDA-2010-N-0295,"web-based public meeting on issues related to development of enforcement plan, june 30, 2010 - [web-based public meeting to discuss issues related to the development of an enforcement action plan; request for data, information, and views] - transcript",0,0
0900006480b03354,Supporting & Related Material,FDA-2010-N-0295-0008,FDA-2010-N-0295,"reference 8 - ""national cancer institute, u.s. department of health & human services, the role of the media in promoting and reducing tobacco use"" - [web-based public meeting to discuss issues related to the development of an enforcement action plan; request for data, information, and views]",0,1
0900006480b2852a,Other,FDA-2010-N-0295-0011,FDA-2010-N-0295,"marketing of menthol and other cigarettes to youth and to minority youth, chusten, june 30, 2010 - [web-based public meeting to discuss issues related to the development of an enforcement action plan; request for data, information, and views] - presentation",0,0
0900006480b2854a,Other,FDA-2010-N-0295-0017,FDA-2010-N-0295,"promotion and advertising of menthol and other cigarettes to youth, including youth in minority communities, abullock, june 30, 2010 - [web-based public meeting to discuss issues related to the development of an enforcement action plan; request for data, information, and views] - presentation",0,0
0900006480b28530,Other,FDA-2010-N-0295-0014,FDA-2010-N-0295,"follow the signs: big tobacco retail contriacts and practices in urban markets, lwright, june 30, 2010 - [web-based public meeting to discuss issues related to the development of an enforcement action plan; request for data, information, and views] - presentation",0,1
0900006480b28532,Other,FDA-2010-N-0295-0015,FDA-2010-N-0295,"mapping tobacco marketing: who's targeting you?, npope, june 30, 2010 - [web-based public meeting to discuss issues related to the development of an enforcement action plan; request for data, information, and views] - presentation",0,1
0900006480b055e3,Notice,FDA-2010-N-0295-0001,FDA-2010-N-0295,"web-based public meeting to discuss issues related to the development of an enforcement action plan; request for data, information, and views",0,0
0900006484b7f8c5,Other,FDA-2021-P-0558-0002,FDA-2021-P-0558,acknowledgement letter from fda dms to environmental working group and women’s voices for the earth,0,0
0900006484b8000b,Other,FDA-2021-P-0558-0001,FDA-2021-P-0558,citizen petition from environmental working group and women’s voices for the earth,0,0
090000648228e8ae,Supporting & Related Material,FDA-2016-P-2863-0016,FDA-2016-P-2863,"attachment 13 - effect of high performance chicory inulin on constipation re citizen petition from general mills, inc.",0,0
090000648228e8b5,Supporting & Related Material,FDA-2016-P-2863-0017,FDA-2016-P-2863,"attachment 14 - selective stimulation of bifidobacteria in the human colon by oligofructose and inulin re citizen petition from general mills, inc.",0,0
090000648228e994,Supporting & Related Material,FDA-2016-P-2863-0007,FDA-2016-P-2863,"attachment 4 - evans 1992 the normal range and a simple diagram for recording whole gut transit time re citizen petition from general mills, inc.",0,0
090000648228eab2,Supporting & Related Material,FDA-2016-P-2863-0012,FDA-2016-P-2863,"attachment 9 - effect of cereal fruit and vegetable fibers on fecal weight and transit time: a comprehensive review of intervention trials re citizen petition from general mills, inc.",0,0
090000648228eabb,Supporting & Related Material,FDA-2016-P-2863-0013,FDA-2016-P-2863,"attachment 10 - effect of yacon on colonic transit time in healthy volunteers re citizen petition from general mills, inc.",0,0
090000648228eaed,Supporting & Related Material,FDA-2016-P-2863-0014,FDA-2016-P-2863,"attachment 11 - effect of nondig oligosacch on large bowel functions blood lipid concentrations and glucose absorption young healthy males re citizen petition from general mills, inc.",0,0
09000064822922fd,Supporting & Related Material,FDA-2016-P-2863-0033,FDA-2016-P-2863,"attachment 30 - randomized double blind cross over study investigating prebiotic effect of agave fructans in healthy human subjects re citizen petition from general mills, inc.",0,0
0900006482292d5c,Supporting & Related Material,FDA-2016-P-2863-0040,FDA-2016-P-2863,"attachment 37 - jerusalem artichoke and chicory inulin in bakery products affect faecal microbiota of healthy volunteers re citizen petition from general mills, inc.",0,0
0900006482296f21,Supporting & Related Material,FDA-2016-P-2863-0080,FDA-2016-P-2863,"attachment 77 - effect of oligofructose-enriched inulin on bone metabolismin girls with low calcium intakes re citizen petition from general mills, inc.",0,0
0900006482296f22,Supporting & Related Material,FDA-2016-P-2863-0081,FDA-2016-P-2863,"attachment 78 - inulin and oligofructose do not influence the absorption ofcholesterol, or the excretion of cholesterol, ca, mg, zn, fe, orbile acids but increases energy excretion in ileostomy subjects re citizen petition from general mills, inc.",0,0
09000064822958c6,Supporting & Related Material,FDA-2016-P-2863-0063,FDA-2016-P-2863,"attachment 60 - fructooligosaccharides exhibit more rapid fermentation than long-chaininulin in an in vitro fermentation system re citizen petition from general mills, inc.",0,0
0900006482296910,Supporting & Related Material,FDA-2016-P-2863-0068,FDA-2016-P-2863,"attachment 65 - microbiota benefits after inulin and partially hydrolized guar gum supplementation – a randomized clinical trial in constipated women re citizen petition from general mills, inc.",0,0
090000648229693d,Supporting & Related Material,FDA-2016-P-2863-0069,FDA-2016-P-2863,"attachment 66 - dietary fiber mixture in pediatric patients with controlled chronic constipation re citizen petition from general mills, inc.",0,0
0900006482296945,Supporting & Related Material,FDA-2016-P-2863-0073,FDA-2016-P-2863,"attachment 70 - effects of thickened beverages fortified with inulin on beverage acceptance, gastrointestinal function, and bone resorption ininstitutionalized adults re citizen petition from general mills, inc.",0,0
0900006482296f1a,Supporting & Related Material,FDA-2016-P-2863-0074,FDA-2016-P-2863,"attachment 71- inulin as the soluble fiber in liquid enteral nutrition re citizen petition from general mills, inc.",0,0
090000648228ec96,Supporting & Related Material,FDA-2016-P-2863-0024,FDA-2016-P-2863,"attachment 21 - prolonged administration of low dose inulin stimulates the growth of bifidobacteria in humans re citizen petition from general mills, inc.",0,0
090000648228f0e2,Supporting & Related Material,FDA-2016-P-2863-0029,FDA-2016-P-2863,"attachment 26 -effects of chicory inulin in constipated elderly people: a double-blind controlled trial re citizen petition from general mills, inc.",0,0
0900006482294ffb,Supporting & Related Material,FDA-2016-P-2863-0057,FDA-2016-P-2863,"attachment 54 - nondigestible oligosaccharides do not interfere with calcium and nonheme iron absorption in young healthy men re citizen petition from general mills, inc.",0,0
090000648223ffe2,Other,FDA-2016-P-2863-0001,FDA-2016-P-2863,"citizen petition from general mills, inc.",0,0
09000064822924c7,Supporting & Related Material,FDA-2016-P-2863-0037,FDA-2016-P-2863,"attachment 34 - prebiotic effect of fruit and vegetable shots containing jerusalem artichokeinulin: a human intervention study re citizen petition from general mills, inc.",0,0
0900006482292ce4,Supporting & Related Material,FDA-2016-P-2863-0048,FDA-2016-P-2863,"attachment 45 - young adolescents who respond to aninulin -type fructan substantially increase total absorbed calcium and daily calcium accretion to the skeleton re citizen petition from general mills, inc.",0,0
09000064822939b2,Supporting & Related Material,FDA-2016-P-2863-0051,FDA-2016-P-2863,"attachment 48 - non-digestible oligosaccharides and calcium absorptionin girls with adequate calcium intakes re citizen petition from general mills, inc.",0,0
09000064822f32d2,Other,FDA-2016-P-2863-0085,FDA-2016-P-2863,amendment  from general mills,0,0
090000648228ea4f,Supporting & Related Material,FDA-2016-P-2863-0010,FDA-2016-P-2863,"attachment 7 -  comparison of dye and pellet gi transit time during controlled diet differing in protein and fiber levels re citizen petition from general mills, inc.",0,0
090000648228f035,Supporting & Related Material,FDA-2016-P-2863-0027,FDA-2016-P-2863,"attachment 24 -dietary fructo-oligosaccharides in healthy adults do not negatively affectfaecal cytotoxicity: a randomised, double-blind, placebo-controlledcrossover trial re citizen petition from general mills, inc.",0,0
09000064842b1c53,Other,FDA-2020-P-0284-0001,FDA-2020-P-0284,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484864039,Other,FDA-2020-P-0284-0003,FDA-2020-P-0284,"letter from fda cder to lachman consultants services inc. and teligent pharma, inc. and hyman, phelps & mcnamara, p.c.",0,0
09000064842b1c55,Other,FDA-2020-P-0284-0002,FDA-2020-P-0284,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
0900006484dc28f4,Other,FDA-2021-P-1100-0001,FDA-2021-P-1100,citizen petition from pet schooled,0,0
0900006484dc2c5f,Other,FDA-2021-P-1100-0002,FDA-2021-P-1100,acknowledgment letter from fda dms to pet schooled,0,0
090000648491195d,Other,FDA-2019-P-5441-0005,FDA-2019-P-5441,"letter from hyman, phelps & mcnamara, p.c.",0,0
0900006484177e69,Other,FDA-2019-P-5441-0001,FDA-2019-P-5441,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484177e6b,Other,FDA-2019-P-5441-0002,FDA-2019-P-5441,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
0900006484a7633f,Other,FDA-2019-P-5441-0006,FDA-2019-P-5441,"withdrawal from hyman, phelps & mcnamara",0,0
0900006484207392,Other,FDA-2019-P-5441-0003,FDA-2019-P-5441,"supplemental to citizen petition from hyman, phelps & mcnamara, p.c.",0,0
09000064845bebd8,Other,FDA-2019-P-5441-0004,FDA-2019-P-5441,"interim response from fda to hyman, phelps & mcnamara, p.c.",0,0
0900006483aa4cca,Supporting & Related Material,FDA-2019-P-0777-0004,FDA-2019-P-0777,attachment b news release from nmpf re citizen petition from national milk producers federation,0,0
0900006483aa4ccd,Supporting & Related Material,FDA-2019-P-0777-0007,FDA-2019-P-0777,attachment e dmi consumer perceptions: dairy and plant-based milks phase ii re citizen petition from national milk producers federation,0,0
0900006483aa4ccf,Supporting & Related Material,FDA-2019-P-0777-0009,FDA-2019-P-0777,attachment g ndc average daily servings of dairy foods by ethnicity and age group (nhanes 2011-2014) re citizen petition from national milk producers federation,0,0
0900006483aa4ccb,Supporting & Related Material,FDA-2019-P-0777-0005,FDA-2019-P-0777,attachment c nutrient composition of imitation dairy beverages compared to milk re citizen petition from national milk producers federation,0,0
0900006483aa4fa0,Other,FDA-2019-P-0777-0002,FDA-2019-P-0777,acknowledgment letter from fda ddm to national milk producers federation,0,0
090000648404dac4,Other,FDA-2019-P-0777-0024,FDA-2019-P-0777,interim response letter from fda cfsan to national milk producers federation,0,0
0900006483aa4cc9,Supporting & Related Material,FDA-2019-P-0777-0003,FDA-2019-P-0777,attachment a section-by-section analysis of the amendments to section 101.3(e) re citizen petition from national milk producers federation,0,0
0900006483aa4cd2,Supporting & Related Material,FDA-2019-P-0777-0012,FDA-2019-P-0777,appendix copyrighted articles re citizen petition from national milk producers federation - part 1,0,0
0900006483aa4cda,Supporting & Related Material,FDA-2019-P-0777-0013,FDA-2019-P-0777,appendix to who guidelines on food fortification with micronutrients re citizen petition from national milk producers federation - part 2,1,0
0900006483aa4cce,Supporting & Related Material,FDA-2019-P-0777-0008,FDA-2019-P-0777,attachment f ndc contribution of dairy foods to nutrient intakes by americans (march 2015) re citizen petition from national milk producers federation,0,0
0900006483aa4cd0,Supporting & Related Material,FDA-2019-P-0777-0010,FDA-2019-P-0777,attachment h ndc average contribution of dairy foods to calorie and nutrient intakes (nhanes 2011-2014) re citizen petition from national milk producers federation,0,0
0900006483aa4f9e,Other,FDA-2019-P-0777-0001,FDA-2019-P-0777,citizen petition from national milk producers federation,0,0
0900006483aa4cd1,Supporting & Related Material,FDA-2019-P-0777-0011,FDA-2019-P-0777,attachment i ndc nhanes 2011-2014 dairy foods messaging re citizen petition from national milk producers federation,0,0
0900006483aa4ccc,Supporting & Related Material,FDA-2019-P-0777-0006,FDA-2019-P-0777,attachment d ndc consumer perceptions: dairy milk and plant-based milk alternatives re citizen petition from national milk producers federation,0,0
09000064822f54b0,Other,FDA-2016-P-3312-0002,FDA-2016-P-3312,"acknowledgment letter from fda ddm to gilead sciences, inc.",0,0
09000064824a121b,Other,FDA-2016-P-3312-0003,FDA-2016-P-3312,"request to withdraw citizen petition from gilead sciences, inc to fda cder",0,0
09000064822f54ae,Other,FDA-2016-P-3312-0001,FDA-2016-P-3312,"citizen petition from gilead sciences, inc.",0,0
0900006481d843cd,Supporting & Related Material,FDA-2015-P-4564-0009,FDA-2015-P-4564,appendix 1 reference 23 fish and marine omega-3 polyunsatured fatty acid consumption and incidence of type 2 diabetes: a systematic review and meta-analysis re citizen petition from kind llc,0,0
090000648250aad3,Other,FDA-2015-P-4564-0017,FDA-2015-P-4564,interim response letter from cfsan to kind llc,0,0
0900006481d843ff,Supporting & Related Material,FDA-2015-P-4564-0011,FDA-2015-P-4564,appendix 2 - letter of support from sara baer-sinnott et al re citizen petition from kind llc,0,0
0900006481d84401,Supporting & Related Material,FDA-2015-P-4564-0012,FDA-2015-P-4564,"appendix 2 - letter of support from david j.a. jenkins, md, phd, dsc re citizen petition from kind llc",0,0
0900006481d84405,Supporting & Related Material,FDA-2015-P-4564-0015,FDA-2015-P-4564,"appendix 2 - letter of support from walter c. willett, harvard school of public health, department of nutrition re citizen petition from kind llc",0,0
0900006481d81c24,Other,FDA-2015-P-4564-0001,FDA-2015-P-4564,citizen petition from kind llc,0,0
0900006481d84257,Supporting & Related Material,FDA-2015-P-4564-0003,FDA-2015-P-4564,appendix 1- reference list re citizen petition from kind llc,0,0
0900006481d843c7,Supporting & Related Material,FDA-2015-P-4564-0007,FDA-2015-P-4564,appendix 1 reference 18 usda: changes in eating patterns and re citizen petition from kind llc,0,0
0900006481d84403,Supporting & Related Material,FDA-2015-P-4564-0014,FDA-2015-P-4564,"appendix 2 - letter of support from michael roussell, naked nutrition, llc re citizen petition from kind llc",0,0
0900006482575432,Other,FDA-2015-P-4564-0018,FDA-2015-P-4564,supplement from kind llc,0,0
0900006481d84561,Supporting & Related Material,FDA-2015-P-4564-0004,FDA-2015-P-4564,"appendix 1 reference 7 intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes:  systematic review and meta-analysis of observational studies re citizen petition from kind llc",0,0
0900006481d81c8e,Other,FDA-2015-P-4564-0002,FDA-2015-P-4564,acknowledgement letter from fda ddm to kind llc,0,0
0900006481d843cb,Supporting & Related Material,FDA-2015-P-4564-0008,FDA-2015-P-4564,"appendix 1 reference 21 effect of a moderate fat diet with and without avocados on lipoprotein particle number, size and subclasses in overweight and obese adults: a randomized, controlled trial re citizen petition from kind llc",0,0
0900006481d843fe,Supporting & Related Material,FDA-2015-P-4564-0010,FDA-2015-P-4564,appendix 2 - index of letters of support re citizen petition from kind llc,0,0
0900006481d84402,Supporting & Related Material,FDA-2015-P-4564-0013,FDA-2015-P-4564,"appendix 2 - letter of support from dariush mozaffarian, tufts university re citizen petition from kind llc",0,0
0900006481d84334,Supporting & Related Material,FDA-2015-P-4564-0005,FDA-2015-P-4564,appendix 1 reference 8 2013 aha acc guideline on lifestyle management to reduce cardiovascular risk re citizen petition from kind llc,0,0
0900006481d8435f,Supporting & Related Material,FDA-2015-P-4564-0006,FDA-2015-P-4564,"appendix 1 reference 15 relationships among food label use, motivation, and dietary quality re citizen petition from kind llc",1,0
0900006483f2bc44,Other,FDA-2019-P-0913-0009,FDA-2019-P-0913,interim response letter from fda cfsan to independent nutrition inc,0,0
0900006483b01cf4,Supporting & Related Material,FDA-2019-P-0913-0005,FDA-2019-P-0913,attachment 3 re citizen petition from independent nutrition inc,0,0
0900006483b021ca,Supporting & Related Material,FDA-2019-P-0913-0008,FDA-2019-P-0913,attachment 6 re citizen petition from independent nutrition,0,0
0900006483b01cf5,Supporting & Related Material,FDA-2019-P-0913-0006,FDA-2019-P-0913,attachment 4 re citizen petition from independent nutrition inc,0,0
0900006483b01cee,Other,FDA-2019-P-0913-0001,FDA-2019-P-0913,citizen petition from independent nutrition inc,0,0
0900006483b01cf0,Other,FDA-2019-P-0913-0002,FDA-2019-P-0913,acknowledgment letter from fda ddm to independent nutrition inc,0,0
0900006483b01cf3,Supporting & Related Material,FDA-2019-P-0913-0004,FDA-2019-P-0913,attachment 2 re citizen petition from independent nutrition inc,0,0
0900006483b01cf2,Supporting & Related Material,FDA-2019-P-0913-0003,FDA-2019-P-0913,attachment 1 re citizen petition from independent nutrition inc,0,0
0900006483b01cf6,Supporting & Related Material,FDA-2019-P-0913-0007,FDA-2019-P-0913,attachment 5 re citizen petition from independent nutrition inc,0,0
0900006483a96b7c,Other,FDA-2018-P-2408-0022,FDA-2018-P-2408,agency response letter fro fda cder to public citizen,0,0
090000648343ad9c,Supporting & Related Material,FDA-2018-P-2408-0006,FDA-2018-P-2408,attachment 3-phase ii febux_arthritis rheum_2005 re: citizen petition from public citizen,0,0
090000648343ada2,Supporting & Related Material,FDA-2018-P-2408-0011,FDA-2018-P-2408,attachment 9-urate and gout from managed care data_j clin rheumatol_2006 re: citizen petition from public citizen,0,0
090000648343ada7,Supporting & Related Material,FDA-2018-P-2408-0016,FDA-2018-P-2408,attachment 13-collaborative overview of randomised trials_bmj_1994 re: citizen petition from public citizen,0,0
090000648343adab,Supporting & Related Material,FDA-2018-P-2408-0020,FDA-2018-P-2408,attachment 18-cv safety febuxostat vs allopurinol_nejm_2018-with suppl re: citizen petition from public citizen,0,0
090000648343ada0,Supporting & Related Material,FDA-2018-P-2408-0009,FDA-2018-P-2408,attachment 7-acr guidelines for gout_arthritis care _ research_2012 re: citizen petition from public citizen,0,0
090000648343ada1,Supporting & Related Material,FDA-2018-P-2408-0010,FDA-2018-P-2408,attachment 8-rct allopurinol dose escalation_ann rheum dis_2009 re: citizen petition from public citizen,0,0
090000648343ad9a,Supporting & Related Material,FDA-2018-P-2408-0004,FDA-2018-P-2408,attachment 1-trial-febuxostat vs allopurinol for gout_arthritis res ther_2010 re :citizen petition from public citizen,0,0
090000648343ada4,Supporting & Related Material,FDA-2018-P-2408-0013,FDA-2018-P-2408,attachment 11-2016 eular recommendations for management of gout_ann rheum dis_2017 re: citizen petition from public citizen,0,0
090000648343ada9,Supporting & Related Material,FDA-2018-P-2408-0018,FDA-2018-P-2408,attachment 15-cv thrombotic events in celecoxib aptc reference_am j cardiol_2003 re: citizen petition from public citizen,0,0
090000648343adac,Supporting & Related Material,FDA-2018-P-2408-0021,FDA-2018-P-2408,attachment 19-cv risk in older adults on febux_circulation_2018 re: citizen petition from public citizen,0,0
090000648343ada6,Supporting & Related Material,FDA-2018-P-2408-0015,FDA-2018-P-2408,attachment 13-allopurinol high dose_arthritis _ rheumatism_2011 re: citizen petition from public citizen,0,0
090000648343ad9d,Supporting & Related Material,FDA-2018-P-2408-0007,FDA-2018-P-2408,attachment 4-phase ii febux_arthritis rheum_2005 re: citizen petition from public citizen,0,0
090000648343ada8,Supporting & Related Material,FDA-2018-P-2408-0017,FDA-2018-P-2408,attachment 14-ch 395_ gout and other crystal-associated arthropathies_harrisons_2014 re: citizen petition from public citizen,0,0
0900006483439f51,Other,FDA-2018-P-2408-0002,FDA-2018-P-2408,acknowledgement letter fro fda ddm to public citizen,0,0
090000648343ad9b,Supporting & Related Material,FDA-2018-P-2408-0005,FDA-2018-P-2408,attachment 2- long-term extension study_j rheumatol_2009 re: citizen petition from public citizen,0,0
090000648343ad9e,Supporting & Related Material,FDA-2018-P-2408-0008,FDA-2018-P-2408,attachment 5-fact trial-febuxostat vs allopurinol for gout_n engl j med_2005 re: citizen petition from public citizen,0,0
090000648343ada3,Supporting & Related Material,FDA-2018-P-2408-0012,FDA-2018-P-2408,attachment 10-apex trial-effect of fuboxostat vs allopurinol and placebo for gout_arthritis rheum_2008 re: citizen petition from public citizen,0,0
090000648343ad9f,Supporting & Related Material,FDA-2018-P-2408-0003,FDA-2018-P-2408,attachment 6-ch 44 gout_current diagnosis _ treatment rheumatology_2013 re: citizen petition from public citizen,0,0
090000648343ada5,Supporting & Related Material,FDA-2018-P-2408-0014,FDA-2018-P-2408,attachment 12-focus open label trial_rheum_2009 re: citizen petition from public citizen,0,0
090000648343adaa,Supporting & Related Material,FDA-2018-P-2408-0019,FDA-2018-P-2408,attachment 17-febuxostat for gout_cochrane syst rev_2012 re: citizen petition from public citizen,0,0
0900006483439cb6,Other,FDA-2018-P-2408-0001,FDA-2018-P-2408,citizen petition from public citizen,0,0
09000064810cd925,Other,FDA-2012-P-0119-0006,FDA-2012-P-0119,interim response to mario morais letter,0,0
09000064824a25ce,Supporting & Related Material,FDA-2012-P-0119-0016,FDA-2012-P-0119,04 - reference 2-pdufa _ the voice of the patient_ a series of reports from fda's patient-focused drug development initiative,0,0
090000648109970e,Other,FDA-2012-P-0119-0005,FDA-2012-P-0119,"mario morais june 19, 2012 - supplement",0,0
090000648250c03c,Other,FDA-2012-P-0119-0021,FDA-2012-P-0119,mario morais email march 15 2017,0,0
09000064824a25c2,Supporting & Related Material,FDA-2012-P-0119-0014,FDA-2012-P-0119,02 guidance for industry 1-expanded access to investigational drugs for treatment use — questions and answers,0,0
09000064824a25d0,Supporting & Related Material,FDA-2012-P-0119-0018,FDA-2012-P-0119,06 reference 4-fed register pdufa patient-focused drug development - request for comments,0,0
09000064824a25d1,Supporting & Related Material,FDA-2012-P-0119-0019,FDA-2012-P-0119,07 reference 5-prescription drug user fee act (pdufa) _ patient-focused drug development_ disease area meetings planned for fiscal years 2013-2017,0,0
09000064824a25d2,Supporting & Related Material,FDA-2012-P-0119-0020,FDA-2012-P-0119,08 reference 6-pdufa reauthorization performance goals and procedures fy18-22,0,0
0900006481878b58,Other,FDA-2012-P-0119-0010,FDA-2012-P-0119,redacted appeal from mario morais,0,0
09000064810057e2,Other,FDA-2012-P-0119-0003,FDA-2012-P-0119,"mario morais march 17, 2012 - supplement",0,0
09000064824a25d3,Other,FDA-2012-P-0119-0011,FDA-2012-P-0119,fda response to joint appeal in fda-2012-p-0119 and fda-2013-p-0735,0,0
0900006481878b56,Other,FDA-2012-P-0119-0009,FDA-2012-P-0119,appeal from mario morais,0,0
0900006480faf553,Other,FDA-2012-P-0119-0001,FDA-2012-P-0119,mario morais - citizen petition,0,0
09000064811802b7,Other,FDA-2012-P-0119-0007,FDA-2012-P-0119,"mario morais august 14, 2012 - supplement",0,0
09000064824a25c0,Supporting & Related Material,FDA-2012-P-0119-0012,FDA-2012-P-0119,reference list for 0119,0,0
09000064824a25c1,Supporting & Related Material,FDA-2012-P-0119-0013,FDA-2012-P-0119,01 reference  1-safety communications _ chronic cerebrospinal venous insufficiency treatment in multiple sclerosis patients_ fda safety communication,0,0
09000064824a25cd,Supporting & Related Material,FDA-2012-P-0119-0015,FDA-2012-P-0119,03 guidance for industry 2-individual patient expanded access applications_ form fda 3926,0,0
09000064824a25cf,Supporting & Related Material,FDA-2012-P-0119-0017,FDA-2012-P-0119,05 reference 3-pdufa _ enhancing benefit-risk assessment in regulatory decision-making,0,0
0900006481832500,Other,FDA-2012-P-0119-0008,FDA-2012-P-0119,redacted partial approval partial denial response from fda/cdrh to mario morais,0,0
0900006480faf55c,Other,FDA-2012-P-0119-0002,FDA-2012-P-0119,acknowledgement letter to mario morias,0,0
09000064812dfb96,Notice,FDA-2012-N-1131-0002,FDA-2012-N-1131,agency information collection activities; submission for office of management and budget review; comment request; new animal drug applications and supporting regulations and form fda 356v,0,0
090000648116eb64,Notice,FDA-2012-N-1131-0001,FDA-2012-N-1131,"agency information collection activities; proposals, submissions, and approvals: new animal drug applications and supporting regulations",0,0
09000064816b26e3,Other,FDA-2014-P-0446-0001,FDA-2014-P-0446,citizen petition from starkist company (pisani and roll llp),0,0
0900006482b95df7,Other,FDA-2014-P-0446-0003,FDA-2014-P-0446,final response letter from fda to pisani & roll llp,0,0
09000064816b271a,Other,FDA-2014-P-0446-0002,FDA-2014-P-0446,acknowledgement letter from fda ddm to pisani and roll llp,0,0
0900006482ce5ac4,Supporting & Related Material,FDA-2017-P-6751-0006,FDA-2017-P-6751,exhibit 4 a true and correct copy of the “compare to dairy” chart re citizen petition from capstone law apc on behalf of melanie kelley,0,0
0900006482ce5ac1,Supporting & Related Material,FDA-2017-P-6751-0003,FDA-2017-P-6751,exhibit 1 judge o'neill's order re citizen petition from capstone law apc on behalf of melanie kelley,0,0
0900006483425d02,Other,FDA-2017-P-6751-0012,FDA-2017-P-6751,180 day interim response letter from fda cfsan to capstone law apc,0,0
0900006482ce5ac2,Supporting & Related Material,FDA-2017-P-6751-0004,FDA-2017-P-6751,exhibit 2 judge carter's order re citizen petition from capstone law apc on behalf of melanie kelley,0,0
0900006482ce5abf,Other,FDA-2017-P-6751-0002,FDA-2017-P-6751,acknowledgement letter from fda ddm to capstone law apc on behalf of melanie kelley,0,0
0900006482ce5abd,Other,FDA-2017-P-6751-0001,FDA-2017-P-6751,citizen petition from capstone law apc on behalf of melanie kelley,0,0
0900006482ce5ac3,Supporting & Related Material,FDA-2017-P-6751-0005,FDA-2017-P-6751,exhibit 3 front label images of silk unsweetened vanilla almondmilk re citizen petition from capstone law apc on behalf of melanie kelley,0,0
090000648229b435,Other,FDA-2016-D-1270-0010,FDA-2016-D-1270,request for extension from valerie lis,0,0
0900006482095c65,Notice,FDA-2016-D-1270-0001,FDA-2016-D-1270,use of standards in the food and drug administration’s regulatory oversight of next generation sequencing-based in vitro diagnostics used for diagnosing germline diseases; draft guidance for stakeholders and food and drug administration staff; availability,1,0
090000648313a560,Notice,FDA-2016-D-1270-0040,FDA-2016-D-1270,"considerations for design, development, and analytical validation of next generation sequencing-based in vitro diagnostics intended to aid in the diagnosis of suspected germline diseases; guidance for stakeholders and food and drug administration staff; availability",1,0
09000064820ae5cd,Other,FDA-2016-D-1270-0002,FDA-2016-D-1270,use of standards in fda regulatory oversight of next generation sequencing (ngs)-based in vitro diagnostics (ivds) used for diagnosing germline diseases draft guidance for stakeholders and food and drug administration staff,1,0
090000648314ed7e,Other,FDA-2016-D-1270-0041,FDA-2016-D-1270,"considerations for design, development, and analytical validation of next generation sequencing (ngs) - based in vitro diagnostics (ivds) intended to aid in the diagnosis of suspected germline diseases
guidance for stakeholders and food and drug administration staff",1,0
0900006483582583,Other,FDA-2018-P-1283-0005,FDA-2018-P-1283,"petition response letter metaxalone tablets, 640 mg, withdrawal was not due to safety and effectiveness",0,0
090000648305503b,Other,FDA-2018-P-1283-0002,FDA-2018-P-1283,"acknowledgment letter from fda ddm to sovereign pharmaceuticals, llc",0,0
090000648305503d,Supporting & Related Material,FDA-2018-P-1283-0003,FDA-2018-P-1283,attachment 1 orange book re citizen petition from sovereign pharmaceuticals llc,0,0
0900006483567867,Notice,FDA-2018-P-1283-0004,FDA-2018-P-1283,"determination that metaxalone tablets, 640 milligrams, were not
withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483055039,Other,FDA-2018-P-1283-0001,FDA-2018-P-1283,citizen petition from sovereign pharmaceuticals llc,0,0
09000064824fc8a0,Supporting & Related Material,FDA-2017-P-1463-0003,FDA-2017-P-1463,appendix a re citizen petition from tate & lyle ingredients americas llc,0,0
09000064824fc86f,Other,FDA-2017-P-1463-0001,FDA-2017-P-1463,citizen petition from tate & lyle ingredients americas llc,0,0
09000064824fc89d,Other,FDA-2017-P-1463-0002,FDA-2017-P-1463,acknowledgement letter from fda ddm to tate & lyle ingredients americas llc,0,0
0900006483548a07,Supporting & Related Material,FDA-2018-P-2862-0005,FDA-2018-P-2862,"attachment 3 re citizen petition from lupin pharmaceuticals, inc",0,0
0900006483548a08,Supporting & Related Material,FDA-2018-P-2862-0006,FDA-2018-P-2862,"attachment 4 re citizen petition from lupin pharmaceuticals, inc",0,0
0900006483548a06,Supporting & Related Material,FDA-2018-P-2862-0004,FDA-2018-P-2862,"attachment 2 re citizen petition from lupin pharmaceuticals, inc",0,0
09000064839fb109,Other,FDA-2018-P-2862-0007,FDA-2018-P-2862,"interim response from fda cder to  lupin pharmaceuticals, inc",0,0
0900006483548a01,Other,FDA-2018-P-2862-0001,FDA-2018-P-2862,"citizen petition from lupin pharmaceuticals, inc",0,0
0900006483548a05,Supporting & Related Material,FDA-2018-P-2862-0003,FDA-2018-P-2862,"attachment 1 re citizen petition from lupin pharmaceuticals, inc",0,0
0900006483548a03,Other,FDA-2018-P-2862-0002,FDA-2018-P-2862,"acknowledgment letter from fda ddm to lupin pharmaceuticals, inc",0,0
0900006483d44b9b,Other,FDA-2018-P-2862-0008,FDA-2018-P-2862,"letter from fda cder to lupin pharmaceuticals, inc.",0,0
09000064841fc48f,Other,FDA-2019-P-5800-0002,FDA-2019-P-5800,acknowledgment letter from fda dms to akin gump strauss hauer & feld llp on behalf of verax biomedical incorporated,0,0
0900006484985250,Other,FDA-2019-P-5800-0004,FDA-2019-P-5800,partial petition approval and denial from fda cber  to verax,0,0
09000064846aeb79,Other,FDA-2019-P-5800-0003,FDA-2019-P-5800,interim response to verax from fda cber,0,0
09000064841fc7ba,Other,FDA-2019-P-5800-0001,FDA-2019-P-5800,citizen petition from akin gump strauss hauer & feld llp on behalf of verax biomedical incorporated,0,0
09000064846f0156,Other,FDA-2020-P-1562-0001,FDA-2020-P-1562,petition for stay of action from station management consultants inc. d/b/a sunoco,0,0
09000064846f0157,Other,FDA-2020-P-1562-0002,FDA-2020-P-1562,acknowledgment letter from fda dms to station management consultants inc. d/b/a sunoco,0,0
09000064846f1f65,Other,FDA-2020-P-1562-0003,FDA-2020-P-1562,"withdrawal letter from station management consultants, inc. d/b/a sunoco",0,0
0900006481cc9210,Other,FDA-2015-P-2375-0005,FDA-2015-P-2375,interim response letter from fda cdrh to public citizen health research group,0,0
0900006481b6d808,Other,FDA-2015-P-2375-0001,FDA-2015-P-2375,citizen petition from public citizen,0,0
0900006484a10138,Other,FDA-2015-P-2375-0006,FDA-2015-P-2375,public citizen seprafilm final response,0,0
0900006481b6e115,Other,FDA-2015-P-2375-0004,FDA-2015-P-2375,acknowledgement letter from fda ddm to public citizen,0,0
0900006481b6e118,Supporting & Related Material,FDA-2015-P-2375-0002,FDA-2015-P-2375,appendix a seprafilm safety and efficacy data re citizen petition from public citizen,0,0
0900006481b6e119,Supporting & Related Material,FDA-2015-P-2375-0003,FDA-2015-P-2375,appendix b maude death reports involving seprafilm re citizen petition from public citizen,0,0
0900006484b3e93d,Other,FDA-2020-P-2301-0004,FDA-2020-P-2301,"response letter from fda cder to alpha cognition usa, inc.",0,0
09000064849a1fea,Supporting & Related Material,FDA-2020-P-2301-0003,FDA-2020-P-2301,"attachment 1 - screenshot of the electronic orange book search results for galantamine oral tablet re citizen petition from alpha cognition usa, inc",0,0
09000064849a1fe6,Other,FDA-2020-P-2301-0001,FDA-2020-P-2301,"citizen petition from alpha cognition usa, inc",0,0
09000064849a1fe7,Other,FDA-2020-P-2301-0002,FDA-2020-P-2301,"acknowledgment letter from fda dms to alpha cognition usa, inc",0,0
09000064841ed868,Other,FDA-2019-P-5759-0002,FDA-2019-P-5759,acknowledgment letter from fda dms to aavis pharmaceuticals,0,0
09000064841ed886,Supporting & Related Material,FDA-2019-P-5759-0004,FDA-2019-P-5759,annex-ii-prescribing information of canada approved product re citizen petition from aavis pharmaceuticals,0,0
09000064841ed867,Other,FDA-2019-P-5759-0001,FDA-2019-P-5759,citizen petition from aavis pharmaceuticals,0,0
09000064841ed885,Supporting & Related Material,FDA-2019-P-5759-0003,FDA-2019-P-5759,annex-i-list of the approved product re citizen petition from aavis pharmaceuticals,0,0
0900006484ac8918,Other,FDA-2019-P-5759-0007,FDA-2019-P-5759,response to information request from aavis pharmaceuticals,0,0
09000064841ed888,Supporting & Related Material,FDA-2019-P-5759-0006,FDA-2019-P-5759,annex-iv fda draft guidance on acetaminophen; butalbital re citizen petition from aavis pharmaceuticals,0,0
09000064841ed887,Supporting & Related Material,FDA-2019-P-5759-0005,FDA-2019-P-5759,annex-iii-draft prescribing information re citizen petition from aavis pharmaceuticals,0,0
0900006484c2bbfd,Supporting & Related Material,FDA-2021-P-0508-0008,FDA-2021-P-0508,reference 6 dinardo fall from grase re citizen petition from joe dinardo and craig a downs,0,0
0900006484c2bc01,Supporting & Related Material,FDA-2021-P-0508-0012,FDA-2021-P-0508,reference 10 zhong comparison of toxicological effects of oxybenzone avobenzone octocrylene and octinoxate sunscreen re citizen petition from joe dinardo and craig a downs,0,0
0900006484c2bbbf,Supporting & Related Material,FDA-2021-P-0508-0004,FDA-2021-P-0508,reference 2 ntp benzophenone carcinogenicity report re citizen petition from joe dinardo and craig a downs,0,0
0900006484c2bc00,Supporting & Related Material,FDA-2021-P-0508-0011,FDA-2021-P-0508,reference 9 dinardo comments fda 1978 n 0018 1508 attachment 1 re citizen petition from joe dinardo and craig a downs,0,0
0900006484c2c92a,Supporting & Related Material,FDA-2021-P-0508-0016,FDA-2021-P-0508,reference 14 zhang assessment of multiple hormone activities of a uv-filter octocrylene in zebrafish danio rerio re citizen petition from joe dinardo and craig a downs,0,0
0900006484c2c92b,Supporting & Related Material,FDA-2021-P-0508-0017,FDA-2021-P-0508,reference 15 molins delgado a potential new threat to wild life presence of uv filters in bird eggs from a preserved area re citizen petition from joe dinardo and craig a downs,0,0
0900006484c2c929,Supporting & Related Material,FDA-2021-P-0508-0015,FDA-2021-P-0508,reference 13 picot-groz diurnal variations in personal care products in seawater and mussels at three mediterranean coastal re citizen petition from joe dinardo and craig a downs,0,0
0900006484c2bbbe,Supporting & Related Material,FDA-2021-P-0508-0003,FDA-2021-P-0508,reference 1 downs octocrylene to bp march 2021 chemical research in toxicology re citizen petition from joe dinardo and craig a downs,0,0
0900006484c2bbc0,Supporting & Related Material,FDA-2021-P-0508-0005,FDA-2021-P-0508,reference 3 bp federal register food additive regulations synthetic flavoring agents and adjuvants re citizen petition from joe dinardo and craig a downs,1,0
0900006484c2bbc1,Supporting & Related Material,FDA-2021-P-0508-0006,FDA-2021-P-0508,reference 4 matta effect of sunscreen application on plasma concentration of sunscreen active ingredients a randomized clinical trial re citizen petition from joe dinardo and craig a downs,0,0
0900006484c2bbfe,Supporting & Related Material,FDA-2021-P-0508-0009,FDA-2021-P-0508,reference 7 bronaugh in vivo percutaneous absorption of fragrance ingredients in rhesus monkeys and humans re citizen petition from joe dinardo,0,0
0900006484c2c6c3,Other,FDA-2021-P-0508-0002,FDA-2021-P-0508,acknowledgement letter from fda dms to joe dinardo and craig a downs,0,0
0900006484c2bbc3,Supporting & Related Material,FDA-2021-P-0508-0018,FDA-2021-P-0508,reference 16 alonso toxic heritage maternal transfer of pyrethroid insecticides and sunscreen agents in dolphins from b re citizen petition from joe dinardo and craig a downs,0,0
0900006484c2c928,Supporting & Related Material,FDA-2021-P-0508-0014,FDA-2021-P-0508,reference 12 cunha co-occurrence of musk fragrances and uv-filters in seafood and macroalgae collected in european hots re citizen petition from joe dinardo and craig a downs,0,0
0900006484c2bbc4,Supporting & Related Material,FDA-2021-P-0508-0019,FDA-2021-P-0508,reference 17 he toxicological effects of two organic ultraviolet filters and a related commercial sunscreen product re citizen petition from joe dinardo and craig a downs,0,0
0900006484c2c6c1,Other,FDA-2021-P-0508-0001,FDA-2021-P-0508,citizen petition from joe dinardo and craig a downs,0,0
0900006484c2bbc5,Supporting & Related Material,FDA-2021-P-0508-0020,FDA-2021-P-0508,reference 18 stien metabolomics reveal that octocrylene accumulates in pocillopora damicornis tissues as fatty acid con re citizen petition from joe dinardo and craig a downs,0,0
0900006484c2bc02,Supporting & Related Material,FDA-2021-P-0508-0013,FDA-2021-P-0508,reference 11 yan reproductive toxicity and estrogen activity in japanese medaka oryzias latipes exposed to environm re citizen petition from joe dinardo and craig a downs,0,0
0900006484c2bbc2,Supporting & Related Material,FDA-2021-P-0508-0007,FDA-2021-P-0508,reference 5 foubert the presence of benzophenone in sunscreens and cosmetics containing the organic uv filter octocrylen re citizen petition from joe dinardo and craig a downs,0,0
0900006484c2bbff,Supporting & Related Material,FDA-2021-P-0508-0010,FDA-2021-P-0508,reference 8 national drug code directory fda re citizen petition from joe dinardo and craig a downs,0,0
090000648042b3ba,Notice,FDA-2007-N-0272-0001,FDA-2007-N-0272,fda,0,0
090000648042b3bd,Notice,FDA-2007-N-0272-0002,FDA-2007-N-0272,fda,0,0
090000648047023a,Notice,FDA-2004-D-0183-0001,FDA-2004-D-0183,fda,0,0
090000648047023f,Other,FDA-2004-D-0183-0003,FDA-2004-D-0183,"class ii special controls guidance document: immunomagnetic circulating cancer cell selection and enumeration system guidance for industry
and fda staff",0,0
090000648047023e,Supporting & Related Material,FDA-2004-D-0183-0002,FDA-2004-D-0183,guidance,0,0
0900006480470240,Supporting & Related Material,FDA-2004-D-0183-0004,FDA-2004-D-0183,guidance,0,0
090000648044c132,Supporting & Related Material,FDA-2005-D-0384-0002,FDA-2005-D-0384,guidance,0,0
090000648044c165,Supporting & Related Material,FDA-2005-D-0384-0005,FDA-2005-D-0384,guidance,0,0
090000648044c0f7,Notice,FDA-2005-D-0384-0001,FDA-2005-D-0384,fda,0,0
090000648044c169,Notice,FDA-2005-D-0384-0006,FDA-2005-D-0384,fda,0,0
090000648044c163,Notice,FDA-2005-D-0384-0004,FDA-2005-D-0384,fda,0,0
090000648069e961,Other,FDA-2008-D-0406-0002,FDA-2008-D-0406,"information sheet guidance for sponsors, clinical investigators, and  irbs - frequently asked questions-statment of investigator (form fda 1572) - draft guidance",0,0
090000648069e78b,Notice,FDA-2008-D-0406-0001,FDA-2008-D-0406,"draft information sheet guidance for sponsors, clinical investigators, and institutional review boards on frequently asked questions--statement of investigator (form fda 1572); availability",0,0
0900006480afb847,Other,FDA-2008-D-0406-0038,FDA-2008-D-0406,"information sheet guidance for sponsors, clinical investigators, and irbs; frequently asked questions - statement of investigator (form fda 1572)",0,0
0900006480afbba8,Notice,FDA-2008-D-0406-0037,FDA-2008-D-0406,"information sheet guidance for sponsors, clinical investigators, and irbs: frequently asked questionsstatement of investigator (form fda 1572); availability",0,0
0900006484b23af1,Other,FDA-2008-D-0406-0043,FDA-2008-D-0406,information sheet guidance for sponsors clinical investigators and irbs frequently asked questions statement of investigator (form fda 1572) (revision 1); draft guidance,0,0
0900006484b23723,Notice,FDA-2008-D-0406-0042,FDA-2008-D-0406,"frequently asked questions— statement of investigator (form fda 1572) (revision 1); draft information 
sheet guidance for sponsors, clinical investigators, and institutional review boards; availability",0,0
0900006480632db6,Supporting & Related Material,FDA-2008-P-0363-0008,FDA-2008-P-0363,tab 5 - danish cattle federation - [figures on danish cattle] - citizen petition,0,0
0900006480632dd8,Supporting & Related Material,FDA-2008-P-0363-0009,FDA-2008-P-0363,tab 6 - danish veterinary and food administration - [the current status of bse and scrapie in denmark{february 2006}] - citizen petition,1,0
09000064806329d2,Other,FDA-2008-P-0363-0010,FDA-2008-P-0363,acknowlegement letter to nordic cryobank aps,0,0
0900006480632d4a,Supporting & Related Material,FDA-2008-P-0363-0007,FDA-2008-P-0363,tab 3 - access gpo - [bovine spongiform encephalopathy (bse)] - citizen petition,0,0
090000648083ee2c,Other,FDA-2008-P-0363-0012,FDA-2008-P-0363,fda/cber interim response to nordic cryobank aps - letter,0,0
09000064809610dd,Other,FDA-2008-P-0363-0013,FDA-2008-P-0363,fda/cber interim response to nordic cryobank aps - letter,0,0
090000648065015c,Supporting & Related Material,FDA-2008-P-0363-0003,FDA-2008-P-0363,exhibit g - united kingdom bse cases - citizen petition,0,0
0900006480650162,Supporting & Related Material,FDA-2008-P-0363-0004,FDA-2008-P-0363,exhibit h - europe (excluding un) bse cases - citizen petition,0,0
0900006480650146,Supporting & Related Material,FDA-2008-P-0363-0002,FDA-2008-P-0363,exhibit f - percentage of bse cases by country - citizen petition,0,0
090000648065016c,Supporting & Related Material,FDA-2008-P-0363-0005,FDA-2008-P-0363,exhibit i - vcjd occurence [vcjd cases (onset data) - citizen petition,0,0
0900006480650180,Supporting & Related Material,FDA-2008-P-0363-0006,FDA-2008-P-0363,exhibit j - bse comparison [bse cases] - citizen petition,0,0
0900006480b74729,Other,FDA-2008-P-0363-0014,FDA-2008-P-0363,"fda/cber response to nordic cryobank aps, june 17, 2010 - petition denial",0,0
0900006480632971,Other,FDA-2008-P-0363-0001,FDA-2008-P-0363,nordic cryobank aps - citizen petition,0,0
0900006480820bd0,Other,FDA-2008-P-0363-0011,FDA-2008-P-0363,nordic cryobank aps to fda/cber - letter,0,0
09000064817301bd,Notice,FDA-2010-D-0194-0023,FDA-2010-D-0194,"agency information collection activities; announcement of office of
management and budget approval; safety assurance case",0,0
09000064816aadb0,Notice,FDA-2010-D-0194-0022,FDA-2010-D-0194,"agency information collection activities; submission for office of
management and budget review; comment request; draft guidance for
industry and fda staff; total product life cycle: infusion pump—premarket notification submissions",0,0
090000648195509a,Other,FDA-2010-D-0194-0025,FDA-2010-D-0194,infusion pumps total product life cycle; guidance for industry and fda administration staff,0,0
0900006481232915,Notice,FDA-2010-D-0194-0018,FDA-2010-D-0194,"agency information collection activities; proposals, submissions, and approvals: draft guidance for industry and fda staff; total product life cycle, infusion pump - premarket notification submissions",0,0
0900006480b1071d,Other,FDA-2010-D-0194-0002,FDA-2010-D-0194,guidance for industry and fda staff; total product life cycle: infusion pump – premarket notification (510(k)) submissions; draft guidance,0,0
0900006480b10719,Notice,FDA-2010-D-0194-0001,FDA-2010-D-0194,draft guidance for industry and fda staff; total product life cycle: infusion pump – premarket notification (510(k)) submissions; availability,0,0
0900006481953fe6,Notice,FDA-2010-D-0194-0024,FDA-2010-D-0194,"infusion pumps total product life cycle; guidance for industry and food
and drug administration staff; availability",1,0
0900006484d6d19b,Other,FDA-2021-P-0992-0002,FDA-2021-P-0992,acknowledgment letter from fda dms to zoetis inc,0,0
0900006484d6c9bc,Supporting & Related Material,FDA-2021-P-0992-0004,FDA-2021-P-0992,attachment 2 policy letter from dhhs  re: citizen petition from zoetis inc,0,0
0900006484d6c9bb,Supporting & Related Material,FDA-2021-P-0992-0003,FDA-2021-P-0992,"attachment 1 dechra veterinary products, llc re: citizen petition from zoetis inc",0,0
0900006484d6cbf5,Other,FDA-2021-P-0992-0001,FDA-2021-P-0992,citizen petition from zoetis inc,0,0
09000064849faabc,Notice,FDA-2021-Z-0025-0002,FDA-2021-Z-0025,requests for proposals for insulin reimportation and personal prescription drug importation,0,0
0900006484ac7a40,Notice,FDA-2021-Z-0025-0008,FDA-2021-Z-0025,withdrawal of notice regarding the food and drug administration drug review timeline transparency; revocation of statement of policy,1,0
0900006484c0e025,Notice,FDA-2021-Z-0025-0015,FDA-2021-Z-0025,medical devices; class i surgeon’s and patient examination gloves,0,0
0900006484dff4c7,Proposed Rule,FDA-2021-Z-0025-0016,FDA-2021-Z-0025,securing updated and necessary statutory evaluations timely; proposal to withdraw or repeal,0,0
0900006484aa9678,Notice,FDA-2021-Z-0025-0003,FDA-2021-Z-0025,"making permanent regulatory flexibilities provided during the covid–19 public health emergency by 
exempting certain medical devices from premarket notification requirements; withdrawal of proposed exemptions",0,0
09000064849f7f15,Rule,FDA-2021-Z-0025-0001,FDA-2021-Z-0025,securing updated and necessary statutory evaluations timely,0,0
0900006484bdf3c6,Notice,FDA-2021-Z-0025-0014,FDA-2021-Z-0025,requests for proposals for insulin reimportation and personal prescription drug importation; withdrawal,0,0
0900006484aa97fd,Notice,FDA-2021-Z-0025-0004,FDA-2021-Z-0025,medical devices; class i surgeon’s and patient examination glove,0,0
09000064841b6f9d,Supporting & Related Material,FDA-2019-P-5593-0003,FDA-2019-P-5593,"attachment 1 - orange book details re citizen petition from hyman, phelps & mcnamara, p.c.",0,0
09000064841b6f31,Other,FDA-2019-P-5593-0001,FDA-2019-P-5593,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
09000064841b6f9f,Supporting & Related Material,FDA-2019-P-5593-0005,FDA-2019-P-5593,"attachment 3 - proposed labeling re citizen petition from hyman, phelps & mcnamara, p.c.",0,0
09000064841b6f32,Other,FDA-2019-P-5593-0002,FDA-2019-P-5593,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
09000064841b6f9e,Supporting & Related Material,FDA-2019-P-5593-0004,FDA-2019-P-5593,"attachment 2 - ultram label re citizen petition from hyman, phelps & mcnamara, p.c.",0,0
090000648321b0ff,Supporting & Related Material,FDA-2018-P-1698-0006,FDA-2018-P-1698,exhibit 4 - bpca priority list 2017-18 re suitability petition from haynes and boone llp,0,0
090000648321b441,Other,FDA-2018-P-1698-0001,FDA-2018-P-1698,"suitability petition from haynes and boone, llp",0,0
090000648321b443,Other,FDA-2018-P-1698-0002,FDA-2018-P-1698,"acknowledgment letter from fda ddm to haynes and boone, llp",0,0
0900006483222847,Supporting & Related Material,FDA-2018-P-1698-0007,FDA-2018-P-1698,exhibit 5 - confidential - midodrine prevalence report excerpt 4812-9019-5812_1 re suitability petition from haynes and boone,0,0
090000648321b0fe,Supporting & Related Material,FDA-2018-P-1698-0005,FDA-2018-P-1698,exhibit 3 - midodrine-draft-label re suitability petition from haynes and boone llp,0,0
090000648321b446,Supporting & Related Material,FDA-2018-P-1698-0003,FDA-2018-P-1698,exhibit 1 - mylan midodrine hcl tablets ob listing re suitability petition from haynes and boone llp,0,0
090000648321b448,Supporting & Related Material,FDA-2018-P-1698-0004,FDA-2018-P-1698,exhibit 2 - mylan midodrine hcl label re suitability petition from haynes and boone llp,0,0
0900006482a95b4e,Supporting & Related Material,FDA-2017-P-5118-0003,FDA-2017-P-5118,attachment 1 teriyaki marinade neck tab re citizen petition from tricia thompson,0,0
0900006482a95b50,Supporting & Related Material,FDA-2017-P-5118-0005,FDA-2017-P-5118,attachment 3 teriyaki sauce front label re citizen petition from tricia thompson,0,0
0900006482a95b4f,Supporting & Related Material,FDA-2017-P-5118-0004,FDA-2017-P-5118,attachment 2 teriyaki marinade back label re citizen petition from tricia thompson,0,0
0900006482a95efa,Supporting & Related Material,FDA-2017-P-5118-0008,FDA-2017-P-5118,attachment 6 mini rice cakes back label re citizen petition from tricia thompson,0,0
0900006482a95efc,Supporting & Related Material,FDA-2017-P-5118-0010,FDA-2017-P-5118,attachment 8 gluten free watchdog post re citizen petition from tricia thompson,0,0
0900006482a95b4c,Other,FDA-2017-P-5118-0002,FDA-2017-P-5118,acknowledgement letter from fda ddm to tricia thompson,0,0
0900006482a95b4a,Other,FDA-2017-P-5118-0001,FDA-2017-P-5118,citizen petition from tricia thompson,0,0
0900006482d03c8c,Other,FDA-2017-P-5118-1133,FDA-2017-P-5118,supplement from tricia thompson,0,0
0900006482a95efb,Supporting & Related Material,FDA-2017-P-5118-0009,FDA-2017-P-5118,attachment 7 power point slides 1 and 15 from fda webinar re citizen petition from tricia thompson,0,0
0900006482d86292,Other,FDA-2017-P-5118-1172,FDA-2017-P-5118,supplement from tricia thompson,0,0
0900006482f398f2,Other,FDA-2017-P-5118-1369,FDA-2017-P-5118,"interim response letter from fda cfsan to gluten free watchdog, llc",0,0
0900006482a95b51,Supporting & Related Material,FDA-2017-P-5118-0006,FDA-2017-P-5118,attachment 4 teryaki sauce back label re citizen petition from tricia thompson,0,0
0900006482a95ef9,Supporting & Related Material,FDA-2017-P-5118-0007,FDA-2017-P-5118,attachment 5 mini rice cakes front label re citizen petition from tricia thompson,0,0
09000064829c8409,Other,FDA-2017-P-4736-0002,FDA-2017-P-4736,acknowledgement letter from fda ddm to american dental association,0,0
09000064829c819b,Other,FDA-2017-P-4736-0001,FDA-2017-P-4736,citizen petition from american dental association,0,0
0900006482e8765e,Other,FDA-2017-P-4736-0003,FDA-2017-P-4736,interim response from fda cder to the americal dental association,0,0
09000064839fbdde,Other,FDA-2017-P-4736-0004,FDA-2017-P-4736,denial of citizen petition from fda cder to american dental association,0,0
0900006482b9bc9c,Other,FDA-2017-P-6020-0002,FDA-2017-P-6020,"acknowledgment letter from ddm to axinn, veltrop & harkrider llp",0,0
0900006482b9b6f5,Supporting & Related Material,FDA-2017-P-6020-0005,FDA-2017-P-6020,"attachment - 3 proposed draft labeling re citizen petition from axinn, veltrop & harkrider llp",0,0
0900006482b9b32c,Other,FDA-2017-P-6020-0001,FDA-2017-P-6020,"citizen petition from axinn, veltrop & harkrider llp",0,0
0900006482b9b32e,Supporting & Related Material,FDA-2017-P-6020-0003,FDA-2017-P-6020,"attachment -1 fda orange book (nda 202155) re citizen petition from axinn, veltrop & harkrider llp",0,0
0900006482b9b32f,Supporting & Related Material,FDA-2017-P-6020-0004,FDA-2017-P-6020,"attachment - 2 nda 202155 approved labeling re citizen petition from axinn, veltrop & harkrider llp",0,0
0900006481849cd0,Other,FDA-2014-P-1057-0001,FDA-2014-P-1057,citizen petition from pharmacists planning service inc,0,0
0900006481849cd2,Other,FDA-2014-P-1057-0002,FDA-2014-P-1057,second acknowledgement letter from fda ddm to pharmacists planning service inc,0,0
0900006481a84f72,Other,FDA-2014-P-1057-0004,FDA-2014-P-1057,petition denial letter from fda cder to pharmacists planning service inc. ppsi,0,0
0900006481849cd1,Other,FDA-2014-P-1057-0003,FDA-2014-P-1057,acknowledgement letter from fda ddm to pharmacists planning service inc,0,0
0900006481b40d13,Other,FDA-2015-P-2230-0001,FDA-2015-P-2230,citizen petition from hyman phelps and mcnamara pc,0,0
0900006481b40d18,Supporting & Related Material,FDA-2015-P-2230-0004,FDA-2015-P-2230,attachment 2 product labeling for nexium 24 hr re citizen petition from hyman phelps and mcnamara pc,0,0
0900006481d7d82c,Other,FDA-2015-P-2230-0005,FDA-2015-P-2230,"withdrawal from hyman, phelps, & mcnamara, p.c.",0,0
0900006481b40d15,Other,FDA-2015-P-2230-0002,FDA-2015-P-2230,acknowledgement letter from fda ddm to hyman phelps and mcnamara pc,0,0
0900006481b40d17,Supporting & Related Material,FDA-2015-P-2230-0003,FDA-2015-P-2230,attachment 1 orange book listing re citizen petition from hyman phelps and mcnamara pc,0,0
09000064816bd7f8,Other,FDA-2014-P-0496-0001,FDA-2014-P-0496,citizen petition from pharmacists planning service inc,0,0
09000064816bd83c,Other,FDA-2014-P-0496-0002,FDA-2014-P-0496,acknowledgement letter from fda ddm to pharmacists planning service inc,0,0
09000064818ad449,Other,FDA-2014-P-0496-0004,FDA-2014-P-0496,"citizen petition interim response from fda cder to pharmacists planning services, inc. (ppsi)",0,0
0900006481a805f8,Other,FDA-2014-P-0496-0005,FDA-2014-P-0496,petition denial letter from fda cder to pharmacists planning service inc. ppsi,0,0
090000648244fdde,Other,FDA-2017-P-0115-0002,FDA-2017-P-0115,acknowledgement letter from fda ddm to jubilant generics limited,0,0
090000648244fde1,Supporting & Related Material,FDA-2017-P-0115-0003,FDA-2017-P-0115,exhibit i listing drugs@fda re citizen petition from jubilant generics limited,0,0
090000648244fde2,Supporting & Related Material,FDA-2017-P-0115-0004,FDA-2017-P-0115,exhibit ii rld label re citizen petition from jubilant generics limited,0,0
090000648244fddd,Other,FDA-2017-P-0115-0001,FDA-2017-P-0115,citizen petition from jubilant generics limited,0,0
090000648244fbc3,Supporting & Related Material,FDA-2017-P-0115-0006,FDA-2017-P-0115,jubilant citizen petition fda receipt re citizen petition from jubilant generics limited,0,0
090000648244fbc2,Supporting & Related Material,FDA-2017-P-0115-0005,FDA-2017-P-0115,exhibit iii proposed label re citizen petition from jubilant generics limited,0,0
0900006481ba85ab,Other,FDA-2015-P-2678-0001,FDA-2015-P-2678,"citizen petition from brian c. weiner, marlboro gastroenterology pc",0,0
0900006481dbab83,Other,FDA-2015-P-2678-0003,FDA-2015-P-2678,"interim response letter from fda cfsan to brian c. weiner, marlboro gastroenterology pc",0,0
0900006481ba85ac,Other,FDA-2015-P-2678-0002,FDA-2015-P-2678,"acknowledgement letter from fda ddm to brian c. weiner, marlboro gastroenterology pc",0,0
090000648361dc4f,Notice,FDA-2018-N-2701-0001,FDA-2018-N-2701,"agency information collection activities;  submission for office of management and budget review; comment request; food and drug administration food safety, health, and diet survey",1,0
0900006483cd85bf,Other,FDA-2018-P-4851-0009,FDA-2018-P-4851,"letter from fda cder to hetero labs ltd. (hetero usa, inc.)",0,0
0900006483cd5b28,Notice,FDA-2018-P-4851-0008,FDA-2018-P-4851,"determination that lupron (leuprolide acetate) injection, 1 milligram/0.2 milliliter, was not withdrawn from sale for reasons of safety or effectiveness",0,0
09000064839c023c,Supporting & Related Material,FDA-2018-P-4851-0003,FDA-2018-P-4851,attachment 2 re: citizen petition from hetero labs limited,0,0
09000064839c023d,Supporting & Related Material,FDA-2018-P-4851-0004,FDA-2018-P-4851,attachment 3- lachman_consultant_services_inc_citizen_petition re: citizen petition from hetero labs limited,0,0
09000064839c023e,Supporting & Related Material,FDA-2018-P-4851-0005,FDA-2018-P-4851,"attachment 4- response_letter_from_cder_orp_to_lachman_consultant_services,_inc_ re: citizen petition from hetero labs limited",0,0
09000064839c023f,Supporting & Related Material,FDA-2018-P-4851-0006,FDA-2018-P-4851,attachment 5- lupron review document re: citizen petition from hetero labs limited,0,0
09000064839c0781,Other,FDA-2018-P-4851-0007,FDA-2018-P-4851,acknowledgment letter from fda ddm to hetero labs limited,0,0
09000064839c023b,Supporting & Related Material,FDA-2018-P-4851-0002,FDA-2018-P-4851,attachment 1 re: citizen petition from hetero labs limited,0,0
09000064839bfdbd,Other,FDA-2018-P-4851-0001,FDA-2018-P-4851,citizen petition from hetero labs limited,0,0
090000648411b383,Supporting & Related Material,FDA-2019-P-5151-0052,FDA-2019-P-5151,"tab 51 - annual periodic adverse experience report to fda. (april 28, 2006) (excerpt) re citizen petition from glaxosmithkline",0,0
090000648411af72,Supporting & Related Material,FDA-2019-P-5151-0026,FDA-2019-P-5151,tab 24 - ntx/89/001: gr38032f: preliminary study for the reproduction study in rabbits by oral administration during the period of fetal organogenesis (i) (study no. t-881001). (zfn00077091-113) re citizen petition from glaxosmithkline,0,0
090000648411b359,Supporting & Related Material,FDA-2019-P-5151-0003,FDA-2019-P-5151,"tab 1 - zofran tablets label zft 9pi, october 2016  re citizen petition from glaxosmithkline",0,0
090000648411b35e,Supporting & Related Material,FDA-2019-P-5151-0008,FDA-2019-P-5151,tab 6 - american college of obstetricians and gynecologists (acog). practice bulletin no. 189. nausea and vomiting of pregnancy. obstet gynecol 2018;131(1):e15-e30 re citizen petition from glaxosmithkline,0,0
090000648411b363,Supporting & Related Material,FDA-2019-P-5151-0013,FDA-2019-P-5151,tab 11 - draft label with fda comments. (november 2015) (npczofr00003937) re citizen petition from glaxosmithkline,0,0
090000648411b369,Supporting & Related Material,FDA-2019-P-5151-0019,FDA-2019-P-5151,tab 17 - fda pharmacologist review (nda 20-781). (zfn00002134-249) - re citizen petition from glaxosmithkline,0,0
090000648411b36b,Supporting & Related Material,FDA-2019-P-5151-0021,FDA-2019-P-5151,tab 19 - ntx/91/001: reproduction study on gr38032f (sn-307) in rats by intravenous administration during the period of organogenesis (study no. 100424) (zfn00077547) re citizen petition from glaxosmithkline,0,0
090000648411b36c,Supporting & Related Material,FDA-2019-P-5151-0022,FDA-2019-P-5151,tab 20 - ntx/90/009: reproduction study (seg ii) on gr38032f (sn-307) in rabbits by oral route. (study no. 100441) (zfn00077391) re citizen petition from glaxosmithkline,0,0
090000648411b378,Supporting & Related Material,FDA-2019-P-5151-0042,FDA-2019-P-5151,"tab 41 - shimizu m, ota t, kato s, kobayashi y, yamashita y, asano m, mori k, fujimura t. reproduction study (seg ii) of ondansetron hydrochloride in rats by intravenous route. jpn pharmacol ther 1992;20:155-74. (japanese version, gsk translation and plaintiffs’ translation) re citizen petition from glaxosmithkline",0,0
090000648411b379,Supporting & Related Material,FDA-2019-P-5151-0043,FDA-2019-P-5151,"tab 42 - ezaki h, yokoyama s, takahashi n, takamatsu m, tokado y, and takeda k. reproduction study (seg. ii) of ondansetron hydrochloride in rabbits by oral route.  jpn pharmacol ther 1992;20:ss1187-96. (japanese version, gsk translation and plaintiffs’ translation) re citizen petition from glaxosmithkline",0,0
090000648411af73,Supporting & Related Material,FDA-2019-P-5151-0027,FDA-2019-P-5151,tab 25 - ntx/89/002: gr38032f (sn-307): preliminary study for the reproduction study in rabbits by oral administration during the period of fetal organogenesis (ii). (study no. t-881002). (zfn00077114-145) re citizen petition from glaxosmithkline,0,0
090000648411b35c,Supporting & Related Material,FDA-2019-P-5151-0006,FDA-2019-P-5151,tab 4 - 20-007 approval package (zofndaa0095829) re citizen petition from glaxosmithkline,0,0
090000648411b37f,Supporting & Related Material,FDA-2019-P-5151-0049,FDA-2019-P-5151,"tab 48 - kuryshev ya, brown am, wang l, benedict cr, rampe d. interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. j pharmacol experiment ther 2000;295:614-620 re citizen petition from glaxosmithkline",0,0
090000648411b382,Supporting & Related Material,FDA-2019-P-5151-0051,FDA-2019-P-5151,"tab 50 - annual periodic adverse experience report to fda. (april 27, 2005) (excerpt) re citizen petition from glaxosmithkline",0,0
090000648411b38a,Supporting & Related Material,FDA-2019-P-5151-0059,FDA-2019-P-5151,"tab 58 - eurocat guide 1.3, european surveillance of congenital anomalies, instructions for the registration and surveillance of congenital anomalies. (2005) re citizen petition from glaxosmithkline",0,0
0900006484491037,Other,FDA-2019-P-5151-0074,FDA-2019-P-5151,supplement from jennerlaw part 1 of 2,0,0
09000064842f5b7b,Other,FDA-2019-P-5151-0063,FDA-2019-P-5151,memo to docket - 11-8-19 call,0,0
090000648411af75,Supporting & Related Material,FDA-2019-P-5151-0029,FDA-2019-P-5151,"tab 27 - danielsson, b, wikner bn, kallen b. use of ondansetron in pregnancy and congenital malformations in the infant. repro toxicol 2014;50:134-137 re citizen petition from glaxosmithkline",0,0
090000648411b388,Supporting & Related Material,FDA-2019-P-5151-0057,FDA-2019-P-5151,"tab 56 - cdc, metropolitan atlanta congenital defects program (macdp). cdc/bpa 6-digit code for congenital anomalies. (2018) re citizen petition from glaxosmithkline",0,0
090000648411b37c,Supporting & Related Material,FDA-2019-P-5151-0046,FDA-2019-P-5151,"tab 45 - secker rc, et al. reproduction study (seg. iii) of ondansetron hydrochloride in rats by oral route. jpn pharmacol ther (1992); 20:221-236. (japanese version, gsk translation and plaintiffs’ translation) re citizen petition from glaxosmithkline",0,0
090000648411b387,Supporting & Related Material,FDA-2019-P-5151-0056,FDA-2019-P-5151,"tab 55 - cdc, metropolitan atlanta congenital defects program (macdp). birth defects and genetic diseases branch 6-digit code for reportable congenital anomalies (2004) re citizen petition from glaxosmithkline",0,0
090000648411b38b,Supporting & Related Material,FDA-2019-P-5151-0060,FDA-2019-P-5151,"tab 59 - eurocat guide 1.4, european surveillance of congenital anomalies. (2013) re citizen petition from glaxosmithkline",0,0
090000648411af74,Supporting & Related Material,FDA-2019-P-5151-0028,FDA-2019-P-5151,"tab 26 - danielsson b, webster ws, ritchie he. ondansetron and teratogenicity in rats: evidence for a mechanism mediated via embryonic herg blockade. reprod toxicol 2018;81:237-245 re citizen petition from glaxosmithkline",0,0
090000648411b360,Supporting & Related Material,FDA-2019-P-5151-0010,FDA-2019-P-5151,"tab 8 - james p. reichmann citizen petition. (january 4, 2012) re citizen petition from glaxosmithkline",0,0
090000648411b367,Supporting & Related Material,FDA-2019-P-5151-0017,FDA-2019-P-5151,tab 15 - 27-531 annual report. (1993) (zofindac0013783) re citizen petition from glaxosmithkline,0,0
0900006482b11e1c,Other,FDA-2016-P-2675-0006,FDA-2016-P-2675,letter from fda to foley & lardner llp,0,0
09000064821e9d47,Supporting & Related Material,FDA-2016-P-2675-0003,FDA-2016-P-2675,"attachment 1 orange book: approved drug products with therapeutic
equivalence evaluations re citizen petition from foley & lardner llp",0,0
09000064824f0113,Other,FDA-2016-P-2675-0004,FDA-2016-P-2675,interim response from fda cder to foley & lardner llp,0,0
0900006482b0f6c3,Notice,FDA-2016-P-2675-0005,FDA-2016-P-2675,"determination that gynorest (dydrogesterone) oral tablets, 5  milligrams and 10 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
09000064821e9d45,Other,FDA-2016-P-2675-0002,FDA-2016-P-2675,acknowledgment letter from fda ddm to foley & lardner llp,0,0
09000064821e97c2,Other,FDA-2016-P-2675-0001,FDA-2016-P-2675,citizen petition from foley & lardner llp,0,0
090000648430fea4,Other,FDA-2020-P-0512-0001,FDA-2020-P-0512,"citizen petition from hyman, phelps, & mcnamara pc",0,0
090000648430ff25,Other,FDA-2020-P-0512-0002,FDA-2020-P-0512,"acknowledgment letter from fda dms to hyman, phelps, & mcnamara pc",0,0
09000064843161fb,Supporting & Related Material,FDA-2020-P-0512-0004,FDA-2020-P-0512,"attachment 2 - highlights of prescribing information for abraxane re: citizen petition from hyman, phelps, & mcnamara pc",0,0
09000064843161fa,Supporting & Related Material,FDA-2020-P-0512-0003,FDA-2020-P-0512,"attachment 1 - orange book: approved drug products with therapeutic equivalence evaluations re: citizen petition from hyman, phelps, & mcnamara pc",0,0
09000064843161ff,Supporting & Related Material,FDA-2020-P-0512-0005,FDA-2020-P-0512,"attachment 3 - highlights of prescribing information for paclitaxel re: citizen petition from hyman, phelps, & mcnamara pc",0,0
0900006484316200,Supporting & Related Material,FDA-2020-P-0512-0006,FDA-2020-P-0512,"attachment 4 - paclitaxel protein-bound particles for injectable suspension (albumin0bound)  - citizen petition from hyman, phelps, & mcnamara pc",0,0
0900006484b9b4be,Other,FDA-2021-P-0567-0002,FDA-2021-P-0567,acknowledgement letter from fda dms to m a pharmaceutical consulting inc,0,0
0900006484b9b462,Other,FDA-2021-P-0567-0001,FDA-2021-P-0567,suitability petition from m a pharmaceutical consulting inc,0,0
0900006484ba0eba,Supporting & Related Material,FDA-2021-P-0567-0003,FDA-2021-P-0567,attachment 1 approved drug products with therapeutic equivalence evaluations re suitability petition from m a pharmaceutical consulting inc,0,0
0900006484ba0f31,Supporting & Related Material,FDA-2021-P-0567-0004,FDA-2021-P-0567,attachment 2 vesicare ls solifenacin succinate oral suspension re suitability petition from m a pharmaceutical consulting inc,0,0
0900006484ba0f32,Supporting & Related Material,FDA-2021-P-0567-0005,FDA-2021-P-0567,attachment 3 proposed label for solifenacin succinate oral solution re suitability petition from m a pharmaceutical consulting inc,0,0
09000064806aef85,Other,FDA-2008-D-0434-0002,FDA-2008-D-0434,"draft guidance for hde holders, institutional review boards (irbs), clinical investigators, and fda staff - humanitarian device exemption (hde) regulation: questions and answers",0,0
0900006480aa737b,Notice,FDA-2008-D-0434-0011,FDA-2008-D-0434,"agency information collection activities; proposals, submissions, and approvals: guidance for humanitarian device exemption holders, institutional review boards, clinical investigators, and fda staff, etc.",0,0
09000064806aecd9,Notice,FDA-2008-D-0434-0001,FDA-2008-D-0434,"humanitarian device exemption regulation: draft guidance for exemption holders, institutional review boards, clinical investigators, and food and drug administration staff; questions and answers",1,0
0900006480a31abf,Notice,FDA-2008-D-0434-0010,FDA-2008-D-0434,"agency information collection activities; proposals, submissions, and approvals",0,0
0900006480b15515,Notice,FDA-2008-D-0434-0012,FDA-2008-D-0434,"guidance for humanitarian device exemption holders, et al.; availability: humanitarian device exemption regulation; questions and answers",0,0
0900006480b154b6,Other,FDA-2008-D-0434-0013,FDA-2008-D-0434,"guidance for hde holders, institutional review boards (irbs), clinical investigators, and food and drug administration staff - humanitarian device exemption (hde) regulation: questions and answers",1,0
0900006483baeb44,Supporting & Related Material,FDA-2019-P-1783-0003,FDA-2019-P-1783,"attachment 1 - new opioid analgesic approvals and outpatient
utilization of opioid analgesics in the united states,
1997 through 2015 - re: citizen petition from public citizen",0,0
0900006483f1122a,Other,FDA-2019-P-1783-0005,FDA-2019-P-1783,response letter ( denial) from fda cder to public citizen's health research group,0,0
0900006483baee9b,Other,FDA-2019-P-1783-0002,FDA-2019-P-1783,acknowledgment letter from fda ddm to public citizen,0,0
0900006483bae3e2,Other,FDA-2019-P-1783-0001,FDA-2019-P-1783,citizen petition from public citizen,0,0
0900006480fa13a3,Other,FDA-2010-P-0644-0009,FDA-2010-P-0644,interim response to international packaged ice association - letter,0,0
0900006480bbad1a,Supporting & Related Material,FDA-2010-P-0644-0004,FDA-2010-P-0644,"appendix 3 - ""nacs daily community columns foodservice"" -  [international packaged ice association (ipia) - citizen petition]",0,0
0900006480bbad19,Supporting & Related Material,FDA-2010-P-0644-0003,FDA-2010-P-0644,"appendix 2 - ""department of public health and human serices, chapter 110 subchapter 8 drinking water and ice"" -  [international packaged ice association (ipia) - citizen petition]",0,0
0900006480bbad1c,Supporting & Related Material,FDA-2010-P-0644-0006,FDA-2010-P-0644,"appendix 5 - ""department of defense standard practice, sanitation requirements for food establishments"" -  [international packaged ice association (ipia) - citizen petition]",1,0
0900006480bbad17,Other,FDA-2010-P-0644-0001,FDA-2010-P-0644,international packaged ice association (ipia) - citizen petition,0,0
0900006480bbad1b,Supporting & Related Material,FDA-2010-P-0644-0005,FDA-2010-P-0644,"appendix 4 - ""99-manurfacture and storage of ice in puerto rico"" -  [international packaged ice association (ipia) - citizen petition]",0,0
0900006480bbad1d,Supporting & Related Material,FDA-2010-P-0644-0007,FDA-2010-P-0644,"appendix 6 - ""amendment of solicitation/modification of contact...."" -  [international packaged ice association (ipia) - citizen petition]",0,0
090000648148763c,Other,FDA-2010-P-0644-0010,FDA-2010-P-0644,international packaged ice association - supplement,0,0
0900006480bbad18,Supporting & Related Material,FDA-2010-P-0644-0002,FDA-2010-P-0644,"appendix 1 - ""state of florida regulations for packaged ice dealers"" - [international packaged ice association (ipia) - citizen petition]",0,0
0900006480bbad3d,Other,FDA-2010-P-0644-0008,FDA-2010-P-0644,acknowledgement letter to international packaged ice association (ipia),0,0
09000064839baa33,Other,FDA-2018-P-4832-0001,FDA-2018-P-4832,citizen petition from goodwin procter llp (on behalf of amneal pharmaceuticals llc,0,0
09000064839bad14,Other,FDA-2018-P-4832-0002,FDA-2018-P-4832,acknowledgment letter from fda ddm to goodwin procter llp,0,0
0900006483d1e951,Other,FDA-2018-P-4832-0004,FDA-2018-P-4832,interim response letter from fda cder to goodwin procter llp,0,0
09000064811bb825,Other,FDA-2012-P-0747-0003,FDA-2012-P-0747,"interim response to leroy leslie hamilton, ph.d. - letter",0,0
090000648108a992,Other,FDA-2012-P-0747-0002,FDA-2012-P-0747,"acknowledgement letter to leroy leslie hamilton, ph.d.",0,0
090000648121ea1b,Other,FDA-2012-P-0747-0004,FDA-2012-P-0747,"fda/cdrh to leroy leslie hamilton, ph.d. - petition approval",0,0
090000648108a990,Other,FDA-2012-P-0747-0001,FDA-2012-P-0747,"leroy leslie hamilton, ph.d. - citizen petition",0,0
090000648216523f,Notice,FDA-2012-N-0748-0008,FDA-2012-N-0748,"agency information collection activities; proposals, submissions, and approvals",0,0
0900006481cb3234,Notice,FDA-2012-N-0748-0007,FDA-2012-N-0748,"agency information collection activities; proposed collection;
submission for office of management and budget review; guidance for
industry on generic drug user fee cover sheet",0,0
0900006481b152df,Notice,FDA-2012-N-0748-0006,FDA-2012-N-0748,"agency information collection activities; proposed collection;
comment request; guidance for industry on generic drug user fee
cover sheet; form fda 3794",0,0
09000064810b1b31,Notice,FDA-2012-N-0748-0001,FDA-2012-N-0748,agency information collection activities; proposed collection comment request; generic drug user fee cover sheet; form fda 3794,0,0
090000648115f3c7,Notice,FDA-2012-N-0748-0005,FDA-2012-N-0748,"agency information collection activities; proposals, submissions, and approvals: generic drug user fee cover sheet",0,0
090000648221526e,Supporting & Related Material,FDA-2016-P-2782-0004,FDA-2016-P-2782,exhibit 2 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
09000064824ba07b,Other,FDA-2016-P-2782-0031,FDA-2016-P-2782,citizen petition partial approval and denial response from fda cder to novartis pharmaceuticals ophthalmology,0,0
09000064822150e5,Supporting & Related Material,FDA-2016-P-2782-0019,FDA-2016-P-2782,exhibit 17 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
09000064822150ec,Supporting & Related Material,FDA-2016-P-2782-0025,FDA-2016-P-2782,exhibit 23 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
09000064822151b8,Other,FDA-2016-P-2782-0001,FDA-2016-P-2782,"citizen petition from alcon pharmaceuticals, ltd. (novartis pharmaceuticals corporation)",0,0
09000064822150e0,Supporting & Related Material,FDA-2016-P-2782-0014,FDA-2016-P-2782,exhibit 12 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
0900006482215270,Supporting & Related Material,FDA-2016-P-2782-0006,FDA-2016-P-2782,exhibit 4 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
0900006482215271,Supporting & Related Material,FDA-2016-P-2782-0007,FDA-2016-P-2782,exhibit 5 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
0900006482215274,Supporting & Related Material,FDA-2016-P-2782-0010,FDA-2016-P-2782,exhibit 8 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
09000064822150e2,Supporting & Related Material,FDA-2016-P-2782-0016,FDA-2016-P-2782,exhibit 14 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
09000064822150e8,Supporting & Related Material,FDA-2016-P-2782-0022,FDA-2016-P-2782,exhibit 20 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
0900006482215217,Supporting & Related Material,FDA-2016-P-2782-0003,FDA-2016-P-2782,exhibit 1 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
0900006482215272,Supporting & Related Material,FDA-2016-P-2782-0008,FDA-2016-P-2782,exhibit 6 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
0900006482215273,Supporting & Related Material,FDA-2016-P-2782-0009,FDA-2016-P-2782,exhibit 7 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
090000648221526f,Supporting & Related Material,FDA-2016-P-2782-0005,FDA-2016-P-2782,exhibit 3 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
0900006482215276,Supporting & Related Material,FDA-2016-P-2782-0012,FDA-2016-P-2782,exhibit 10 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
09000064822150e4,Supporting & Related Material,FDA-2016-P-2782-0018,FDA-2016-P-2782,exhibit 16 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
09000064822150e6,Supporting & Related Material,FDA-2016-P-2782-0020,FDA-2016-P-2782,exhibit 18 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
09000064822150eb,Supporting & Related Material,FDA-2016-P-2782-0024,FDA-2016-P-2782,exhibit 22 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
09000064822150ed,Supporting & Related Material,FDA-2016-P-2782-0026,FDA-2016-P-2782,exhibit 24 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
09000064822150f0,Supporting & Related Material,FDA-2016-P-2782-0029,FDA-2016-P-2782,exhibit 27 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
09000064822150f1,Supporting & Related Material,FDA-2016-P-2782-0030,FDA-2016-P-2782,exhibit 28 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
09000064822150e3,Supporting & Related Material,FDA-2016-P-2782-0017,FDA-2016-P-2782,exhibit 15 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
09000064822150e7,Supporting & Related Material,FDA-2016-P-2782-0021,FDA-2016-P-2782,exhibit 19 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
09000064822150ee,Supporting & Related Material,FDA-2016-P-2782-0027,FDA-2016-P-2782,exhibit 25 re request the commissioner of fda to require any anda applicant who cites ciprodex as the rld to establish bioequivalence by performing in vivo clinical endpoint studies,0,0
0900006482532adc,Supporting & Related Material,FDA-2017-P-1990-0005,FDA-2017-P-1990,"reference 2 improvement of constipation by a small amount of xylooligosaccharides re citizen petition from aidp, inc",0,0
0900006482532ae0,Supporting & Related Material,FDA-2017-P-1990-0009,FDA-2017-P-1990,"reference 6 effect of xylooligosaccharide intake on severe constipation in pregnant women re citizen petition from aidp, inc",0,0
09000064834111b3,Other,FDA-2017-P-1990-0019,FDA-2017-P-1990,fda-2017-p-1990-aidp - addendum,0,0
0900006483074d38,Supporting & Related Material,FDA-2017-P-1990-0018,FDA-2017-P-1990,a supplemental submission to previous citizen petition fda-2017-p-1990,0,0
0900006482532add,Supporting & Related Material,FDA-2017-P-1990-0006,FDA-2017-P-1990,"reference 3 - translation of reference 2 article - improvement of constipation by a small amount of xylooligosaccharides re citizen petition from aidp, inc",0,0
090000648253274b,Other,FDA-2017-P-1990-0002,FDA-2017-P-1990,"acknowledgement letter from fda ddm to aidp, inc.",0,0
0900006482532ae3,Supporting & Related Material,FDA-2017-P-1990-0012,FDA-2017-P-1990,"reference 9 effects of xylooligosaccharide in type 2 diabetes mellitus re citizen petition from aidp, inc",0,0
0900006482532ae8,Supporting & Related Material,FDA-2017-P-1990-0013,FDA-2017-P-1990,"reference 10 effects of xylooligosaccharide on fecal bifdobacteria, lactic acid and lipid metabolism re citizen petition from aidp, inc",0,0
0900006482532adb,Supporting & Related Material,FDA-2017-P-1990-0004,FDA-2017-P-1990,"reference 1 xylo-oligosaccharides alone or in synbiotic combination re citizen petition from aidp, inc",0,0
09000064839346e9,Other,FDA-2017-P-1990-0021,FDA-2017-P-1990,letter from fda cfsan to aidp inc.,0,0
0900006482bc3323,Other,FDA-2017-P-1990-0016,FDA-2017-P-1990,interim response letter from fda to aidp,0,0
09000064838f1ae8,Other,FDA-2017-P-1990-0020,FDA-2017-P-1990,letter from fda cfsan to aidp inc.,0,0
0900006482532749,Other,FDA-2017-P-1990-0001,FDA-2017-P-1990,"citizen petition from aidp, inc",0,0
0900006482532ada,Supporting & Related Material,FDA-2017-P-1990-0003,FDA-2017-P-1990,"reference list re citizen petition from aidp, inc",0,0
0900006482532ade,Supporting & Related Material,FDA-2017-P-1990-0007,FDA-2017-P-1990,"reference 4 effect of xylooligosaccharide-sugar mixture on defecation re citizen petition from aidp, inc",0,0
0900006482532adf,Supporting & Related Material,FDA-2017-P-1990-0008,FDA-2017-P-1990,"reference 5 trasnlation of reference 4 article -effect of xylooligosaccharide-sugar mixture on defecation re citizen petition from aidp, inc",0,0
0900006482532ae1,Supporting & Related Material,FDA-2017-P-1990-0010,FDA-2017-P-1990,"reference 7 xyloogosaccharides improved intestinal dysfunction re citizen petition from aidp, inc",0,0
0900006482532ae2,Supporting & Related Material,FDA-2017-P-1990-0011,FDA-2017-P-1990,"reference 8 xylooligosaccharide increases bifidobacteria re citizen petition from aidp, inc",0,0
0900006482532ae9,Supporting & Related Material,FDA-2017-P-1990-0014,FDA-2017-P-1990,"reference 11 - translation of reference 10 article - effects of xylooligosaccharide on fecal bifdobacteria, lactic acid and lipid metabolism re citizen petition from aidp, inc",0,0
0900006482532aea,Supporting & Related Material,FDA-2017-P-1990-0015,FDA-2017-P-1990,"reference 12 dietary intake of xylooligosaccharides improves the intestinal microbiota, fecal moisture re citizen petition from aidp, inc",0,0
09000064830745fb,Supporting & Related Material,FDA-2017-P-1990-0017,FDA-2017-P-1990,supplemental submission of publications  -  re request that the fda amend 21 cfr § 101.9 (c)(6)(i) to recognize xylooligosaccharides as a dietary fiber for the purposes of nutrition labeling.,0,0
09000064817030da,Other,FDA-2014-P-0646-0001,FDA-2014-P-0646,citizen petition from kamat pharmatech,0,0
0900006482214fbd,Supporting & Related Material,FDA-2014-P-0646-0010,FDA-2014-P-0646,draft proposed trazodone oral solution prescribing information re supplement from kamat pharmatech,0,0
0900006482d8388b,Other,FDA-2014-P-0646-0011,FDA-2014-P-0646,letter from kamat pharmatech to fda ddm,0,0
090000648199a04b,Supporting & Related Material,FDA-2014-P-0646-0004,FDA-2014-P-0646,citizen petition from kamat pharmatech re letter from kamat pharmatech to fda/ddm,0,0
090000648199a275,Other,FDA-2014-P-0646-0002,FDA-2014-P-0646,letter from kamat pharmatech to fda/ddm,0,0
0900006482214e28,Other,FDA-2014-P-0646-0007,FDA-2014-P-0646,supplement from kamat pharmatech,0,0
09000064817030de,Other,FDA-2014-P-0646-0005,FDA-2014-P-0646,acknowledgement letter from fda ddm to kamat pharmatech,0,0
0900006482214e2a,Supporting & Related Material,FDA-2014-P-0646-0009,FDA-2014-P-0646,trazodone rld prescribing information re supplement from kamat pharmatech,0,0
0900006482214e29,Supporting & Related Material,FDA-2014-P-0646-0008,FDA-2014-P-0646,kamat pharmatech's suitability petition revision,0,0
09000064821ddb39,Other,FDA-2014-P-0646-0006,FDA-2014-P-0646,letter from kamat pharmatech to fda,0,0
090000648199a464,Other,FDA-2014-P-0646-0003,FDA-2014-P-0646,letter from kamat pharmatech to fda/ddm,0,0
09000064817032a0,Other,FDA-2014-P-0647-0002,FDA-2014-P-0647,acknowledgement letter from fda ddm to kamat pharmatech,0,0
09000064819ad0bf,Supporting & Related Material,FDA-2014-P-0647-0004,FDA-2014-P-0647,citizen petition from kamat pharmatech re letter from kamat pharmatech to fda/ddm,0,0
09000064819ad0bd,Other,FDA-2014-P-0647-0003,FDA-2014-P-0647,letter from kamat pharmatech to fda/ddm,0,0
090000648170329e,Other,FDA-2014-P-0647-0001,FDA-2014-P-0647,citizen petition from kamat pharmatech,0,0
0900006481922959,Other,FDA-2014-P-1882-0001,FDA-2014-P-1882,citizen petition from isabella guajardo,0,0
090000648192298a,Other,FDA-2014-P-1882-0002,FDA-2014-P-1882,acknowledgement letter from fda ddm to isabella guajardo,0,0
090000648330e2d6,Other,FDA-2016-P-1246-0007,FDA-2016-P-1246,response letter from fda cder to the working group on women's health and well-being in menopause and the north american menopause society,0,0
0900006481fd70cf,Supporting & Related Material,FDA-2016-P-1246-0004,FDA-2016-P-1246,attachment 1 why the product labeling for low-dose vaginal estrogen should be changed re citizen petition  from the working group on women's health and well-being in menopause and the north american menopause society,0,0
0900006481fae7e8,Other,FDA-2016-P-1246-0002,FDA-2016-P-1246,acknowledgement letter from fda ddm to the working group on women's health and well-being in menopause and the north american menopause society,0,0
0900006481fd70ce,Supporting & Related Material,FDA-2016-P-1246-0003,FDA-2016-P-1246,attachment 2 - 050916 nams petition signatures re citizen petition  from the working group on women's health and well-being in menopause and the north american menopause society,0,0
0900006481faea92,Other,FDA-2016-P-1246-0001,FDA-2016-P-1246,citizen petition  from the working group on women's health and well-being in menopause and the north american menopause society,0,0
0900006482033b07,Other,FDA-2016-P-1246-0005,FDA-2016-P-1246,correction from the north american menopause society,0,0
0900006481cd0f79,Supporting & Related Material,FDA-2015-P-3778-0009,FDA-2015-P-3778,appendix 7  table d‐2 ansi-aami-iec 60601‐1 third edition re citizen petition from orthofix,0,0
0900006481cd11dd,Supporting & Related Material,FDA-2015-P-3778-0007,FDA-2015-P-3778,appendix 5  guidance for industry “alternative to certain prescription device labeling requirements 1-21-2000 re citizen petition from orthofix,0,0
0900006481cd11d4,Other,FDA-2015-P-3778-0002,FDA-2015-P-3778,"acknowledgement letter from fda ddm to orthofix, inc.",0,0
0900006481f7d367,Other,FDA-2015-P-3778-0012,FDA-2015-P-3778,interim response to orthofix,0,0
0900006481cd11db,Supporting & Related Material,FDA-2015-P-3778-0005,FDA-2015-P-3778,appendix 3  fda public workshop presentation “use of symbols on medical device labeling” re citizen petition from orthofix,0,0
0900006482155681,Other,FDA-2015-P-3778-0013,FDA-2015-P-3778,withdrawal from orthofix inc.,0,0
0900006481cd0f78,Supporting & Related Material,FDA-2015-P-3778-0008,FDA-2015-P-3778,appendix 6  astm f2503‐13 standard practice for marking medical devices and other items for safety in the magnetic resonance environment re citizen petition from orthofix,0,0
0900006481f68908,Other,FDA-2015-P-3778-0011,FDA-2015-P-3778,interim response to orthofix,0,0
0900006481cd0f7a,Supporting & Related Material,FDA-2015-P-3778-0010,FDA-2015-P-3778,appendix 8  use of certain symbols in labeling” fda docket fda‐2013‐n‐0125 re citizen petition from orthofix,0,0
0900006481cd11dc,Supporting & Related Material,FDA-2015-P-3778-0006,FDA-2015-P-3778,appendix 4  guidance for industry and fda staff- use of symbols on labels 11-30-2004 re citizen petition from orthofix,0,0
0900006481cd11d9,Supporting & Related Material,FDA-2015-P-3778-0003,FDA-2015-P-3778,"appendix 1 federal register volume 78, number 76 at page 23508‐23513 april 19, 2013 re citizen petition from orthofix",0,0
0900006481cd11da,Supporting & Related Material,FDA-2015-P-3778-0004,FDA-2015-P-3778,appendix 2  iso 15223‐1:2012 re citizen petition from orthofix,0,0
0900006481cd0eda,Other,FDA-2015-P-3778-0001,FDA-2015-P-3778,citizen petition from orthofix,0,0
09000064823048ed,Other,FDA-2016-D-3329-0001,FDA-2016-D-3329,guidance for fda staff compliance policy guide section 101.100 fda considerations for recommending charges under 21 u.s.c. §331(a) or (d) for causing the introduction of violative products into interstate commerce,0,0
0900006483716433,Supporting & Related Material,FDA-2018-P-3535-0003,FDA-2018-P-3535,appendix 1 re petition from norbrook laboratories limited,0,0
0900006483716435,Supporting & Related Material,FDA-2018-P-3535-0005,FDA-2018-P-3535,appendix 3 re petition from norbrook laboratories limited,0,0
0900006483716758,Other,FDA-2018-P-3535-0001,FDA-2018-P-3535,petition from norbrook laboratories limited,0,0
09000064838d245a,Other,FDA-2018-P-3535-0006,FDA-2018-P-3535,amendment to suitability petition fda-2018-p-3535: pimobendan oral solution,0,0
0900006483716434,Supporting & Related Material,FDA-2018-P-3535-0004,FDA-2018-P-3535,appendix 2 re petition from norbrook laboratories limited,0,0
0900006483716431,Other,FDA-2018-P-3535-0002,FDA-2018-P-3535,acknowledgment letter from fda ddm to norbrook laboratories limited,0,0
09000064838d689b,Supporting & Related Material,FDA-2018-P-4340-0005,FDA-2018-P-4340,annex iii fk package insert (tigecycline) re citizen petition from freyr inc.,0,0
09000064838d6d4a,Other,FDA-2018-P-4340-0002,FDA-2018-P-4340,acknowledgment letter from fda ddm to freyr inc.,0,0
09000064838d6411,Other,FDA-2018-P-4340-0001,FDA-2018-P-4340,citizen petition from freyr inc.,0,0
09000064838d6899,Supporting & Related Material,FDA-2018-P-4340-0003,FDA-2018-P-4340,annex i orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from freyr inc.,0,0
09000064838d689a,Supporting & Related Material,FDA-2018-P-4340-0004,FDA-2018-P-4340,annex ii reference listed drug package insert (tygacil) re citizen petition from freyr inc.,0,0
090000648367f6d4,Supporting & Related Material,FDA-2018-P-3327-0006,FDA-2018-P-3327,"attachment 4 re citizen petition from hyman, phelps & mcnamara, pc",0,0
090000648367f6d6,Supporting & Related Material,FDA-2018-P-3327-0008,FDA-2018-P-3327,"attachment 6 re citizen petition from hyman, phelps & mcnamara, pc",0,0
090000648367eeb5,Other,FDA-2018-P-3327-0001,FDA-2018-P-3327,"citizen petition from hyman, phelps & mcnamara, pc",0,0
090000648367f666,Other,FDA-2018-P-3327-0002,FDA-2018-P-3327,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara, p.c.",0,0
090000648367f6d2,Supporting & Related Material,FDA-2018-P-3327-0004,FDA-2018-P-3327,"attachment 2 re citizen petition from hyman, phelps & mcnamara, pc",0,0
090000648367f6d3,Supporting & Related Material,FDA-2018-P-3327-0005,FDA-2018-P-3327,"attachment 3 re citizen petition from hyman, phelps & mcnamara, pc",0,0
090000648367f6d1,Supporting & Related Material,FDA-2018-P-3327-0003,FDA-2018-P-3327,"attachment 1 re citizen petition from hyman, phelps & mcnamara, pc",0,0
090000648367f6d5,Supporting & Related Material,FDA-2018-P-3327-0007,FDA-2018-P-3327,"attachment 5 re citizen petition from hyman, phelps & mcnamara, pc",0,0
090000648367f6d7,Supporting & Related Material,FDA-2018-P-3327-0009,FDA-2018-P-3327,"attachment 7 re citizen petition from hyman, phelps & mcnamara, pc",0,0
09000064849a8125,Other,FDA-2020-P-1506-0009,FDA-2020-P-1506,partial interim response from fda cvm to daniel waltz,0,0
09000064846dc535,Supporting & Related Material,FDA-2020-P-1506-0005,FDA-2020-P-1506,footnotes 19-24 re citizen petition from animal legal defense fund,0,0
09000064846d4bff,Other,FDA-2020-P-1506-0002,FDA-2020-P-1506,acknowledgment letter from animal legal defense fund,0,0
09000064846dc538,Supporting & Related Material,FDA-2020-P-1506-0008,FDA-2020-P-1506,footnotes 69-83 re citizen petition from animal legal defense fund,0,0
09000064846dc536,Supporting & Related Material,FDA-2020-P-1506-0006,FDA-2020-P-1506,footnotes 25-47 re citizen petition from animal legal defense fund,0,0
09000064846dc537,Supporting & Related Material,FDA-2020-P-1506-0007,FDA-2020-P-1506,footnotes 48-68 re citizen petition from animal legal defense fund,0,0
09000064846cf29e,Other,FDA-2020-P-1506-0001,FDA-2020-P-1506,citizen petition from animal legal defense fund,0,0
09000064846dc383,Supporting & Related Material,FDA-2020-P-1506-0004,FDA-2020-P-1506,footnotes 16-19 re citizen petition from animal legal defense fund,0,0
09000064846dc382,Supporting & Related Material,FDA-2020-P-1506-0003,FDA-2020-P-1506,footnotes 4-15 re citizen petition from animal legal defense fund,0,0
09000064839e9fd2,Other,FDA-2019-P-0175-0001,FDA-2019-P-0175,"citizen petition  from fresenius kabi usa, llc",0,0
09000064839e9fcf,Other,FDA-2019-P-0175-0002,FDA-2019-P-0175,"acknowledgment letter from fda ddm to  fresenius kabi usa, llc",0,0
090000648229c201,Supporting & Related Material,FDA-2016-P-3162-0003,FDA-2016-P-3162,attachment 1 orange book drug products listing re citizen petition from anda consultants,0,0
090000648229c1ff,Other,FDA-2016-P-3162-0002,FDA-2016-P-3162,acknowledgement letter from fda ddm to anda consultants,0,0
090000648249369d,Other,FDA-2016-P-3162-0004,FDA-2016-P-3162,withdrawal from anda consultants,0,0
090000648229c1fd,Other,FDA-2016-P-3162-0001,FDA-2016-P-3162,citizen petition from anda consultants,0,0
09000064849f3df1,Supporting & Related Material,FDA-2021-P-0083-0003,FDA-2021-P-0083,"attachment 1 re suitability petition from hyman, phelps & mcnamara pc",0,0
09000064849f3ebd,Supporting & Related Material,FDA-2021-P-0083-0005,FDA-2021-P-0083,"attachment 3 re suitability petition from hyman, phelps & mcnamara pc",0,0
09000064849f3df2,Supporting & Related Material,FDA-2021-P-0083-0004,FDA-2021-P-0083,"attachment 2 re suitability petition from hyman, phelps & mcnamara pc",0,0
09000064849f3ded,Other,FDA-2021-P-0083-0002,FDA-2021-P-0083,"acknowledgment letter from fda dms to hyman, phelps & mcnamara pc",0,0
09000064849f3dec,Other,FDA-2021-P-0083-0001,FDA-2021-P-0083,"suitability petition from hyman, phelps & mcnamara pc",0,0
090000648485ac5f,Other,FDA-2020-P-1881-0002,FDA-2020-P-1881,acknowledgment letter from fda dms to the weinberg group,0,0
0900006484a6b556,Other,FDA-2020-P-1881-0003,FDA-2020-P-1881,interim response from fda cder to the weinberg group a propharma group company,0,0
0900006484a95e90,Other,FDA-2020-P-1881-0005,FDA-2020-P-1881,letter to the weinberg group from fda cder,0,0
090000648485a88c,Other,FDA-2020-P-1881-0001,FDA-2020-P-1881,citizen petition from the weinberg group,0,0
0900006484a93000,Notice,FDA-2020-P-1881-0004,FDA-2020-P-1881,"determination that serentil (mesoridazine besylate) tablets, 10 milligrams, 25 milligrams, 50 milligrams, and 100 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006484a67d67,Other,FDA-2021-P-0268-0003,FDA-2021-P-0268,supplement from foley hoag llp,0,0
0900006484a5fab8,Other,FDA-2021-P-0268-0001,FDA-2021-P-0268,"citizen petition from foley hoag, llp",0,0
0900006484a5fabb,Other,FDA-2021-P-0268-0002,FDA-2021-P-0268,"acknowledgment letter from fda dms to foley hoag, llp",0,0
0900006484cb33aa,Other,FDA-2021-P-0268-0004,FDA-2021-P-0268,"interim response from fda cder to foley hoag, llp",0,0
090000648042b382,Notice,FDA-2007-N-0267-0002,FDA-2007-N-0267,fda,0,0
090000648042b383,Notice,FDA-2007-N-0267-0001,FDA-2007-N-0267,fda,0,0
09000064814413c3,Other,FDA-2004-P-0401-0004,FDA-2004-P-0401,fda/cder to fda/ddm - memorandum,0,0
09000064804744d6,Other,FDA-2004-P-0401-0002,FDA-2004-P-0401,"hfa-305 to andrx pharmaceuticals, inc.",0,0
09000064804744d0,Other,FDA-2004-P-0401-0001,FDA-2004-P-0401,"hfa-305 to andrx pharmaceuticals, inc.",0,0
09000064804744da,Other,FDA-2004-P-0401-0003,FDA-2004-P-0401,"hfd-005 to foley & lardner, llp",0,0
090000648048633c,Other,FDA-2005-P-0517-0618,FDA-2005-P-0517,wyeth (wiley rein & fielding llp) - citizen petition,0,0
090000648048634c,Other,FDA-2005-P-0517-0228,FDA-2005-P-0517,acknowledgement letter to wyeth (wiley rein & fielding llp),0,0
0900006480499293,Other,FDA-2005-P-0517-0306,FDA-2005-P-0517,see fda-2005-p-0517-0028,0,0
0900006480499294,Other,FDA-2005-P-0517-0028,FDA-2005-P-0517,"fda center for drug evaluation and research to wiley, rein, & felding, llp",0,0
09000064804862b2,Supporting & Related Material,FDA-2005-P-0517-0001,FDA-2005-P-0517,acknowledgement letter to wyeth (wiley rein & fielding llp) re fda-2005-p-0517-0228,0,0
0900006480486387,Supporting & Related Material,FDA-2005-P-0517-0646,FDA-2005-P-0517,international academy of compounding pharmacists (iacp) - comment re fda-2005-p-0517-0629,0,0
090000648049c0bd,Other,FDA-2005-P-0517-0649,FDA-2005-P-0517,fda office of regulatory affairs to wyeth (wiley rein & fielding llp) - partial petition approval/denial,0,0
0900006480a421e1,Notice,FDA-2009-N-0483-0001,FDA-2009-N-0483,agency information collection activities; proposed collection; comment request; medical device user fee cover sheet; form fda 3601,0,0
0900006480a7f651,Notice,FDA-2009-N-0483-0002,FDA-2009-N-0483,agency information collection activities; submission for office of management and budget review; comment request; medical device user fee cover sheet-form fda 3601,0,0
0900006480ae71a4,Notice,FDA-2009-N-0483-0003,FDA-2009-N-0483,"agency information collection activities; proposals, submissions, and approvals: medical device user fee cover sheet (form fda 3601)",0,0
0900006480558358,Notice,FDA-1995-P-0003-0001,FDA-1995-P-0003,fda,0,0
0900006480558359,Other,FDA-1995-P-0003-0003,FDA-1995-P-0003,indiana medical device mfg council - citizen petition,0,0
0900006480558364,Notice,FDA-1995-P-0003-0002,FDA-1995-P-0003,fda,0,0
0900006481cde6a0,Supporting & Related Material,FDA-2015-P-3876-0002,FDA-2015-P-3876,press release - epa will propose rule to protect waterways by reducing mercury from dental offices re citizen petition from world alliance for mercury-free dentistry,0,0
0900006481cde6a3,Supporting & Related Material,FDA-2015-P-3876-0003,FDA-2015-P-3876,"letter to the honorable john kerry, secretary of state re citizen petition from world alliance for mercury-free dentistry",0,0
0900006481cde6ce,Supporting & Related Material,FDA-2015-P-3876-0004,FDA-2015-P-3876,state department urged to press fda to curb mercury dental fillings re citizen petition from world alliance for mercury-free dentistry,0,0
0900006481cde6d0,Supporting & Related Material,FDA-2015-P-3876-0006,FDA-2015-P-3876,minamata convention  on mercury (2013) re citizen petition from world alliance for mercury-free dentistry,0,0
0900006481cde6cf,Supporting & Related Material,FDA-2015-P-3876-0005,FDA-2015-P-3876,the real cost of dental mercury re citizen petition from world alliance for mercury-free dentistry,0,0
0900006481cde4c4,Other,FDA-2015-P-3876-0001,FDA-2015-P-3876,citizen petition from world alliance for mercury-free dentistry,0,0
0900006481cde6d2,Supporting & Related Material,FDA-2015-P-3876-0007,FDA-2015-P-3876,"changing patterns in the use, recycling, and material substitution of mercury in the united states (2013) re citizen petition from world alliance for mercury-free dentistry",0,0
0900006481f7825f,Other,FDA-2015-P-3876-0009,FDA-2015-P-3876,interim response to world alliance for mercury-free dentistry,0,0
0900006481cdeba5,Other,FDA-2015-P-3876-0008,FDA-2015-P-3876,acknowledgement letter from fda ddm to world alliance for mercury-free dentistry,0,0
0900006483bdc637,Supporting & Related Material,FDA-2019-P-1911-0004,FDA-2019-P-1911,appendix ii - akeo paper - japanese and english translation re: acknowledgment letter from fda ddm to keller and heckman llp,0,0
0900006483bdc5c9,Other,FDA-2019-P-1911-0001,FDA-2019-P-1911,"citizen petition from keller and heckman llp on behalf of nexira, ingredion and tic gums, alland and robert, importers service corporation",0,0
09000064841096fd,Other,FDA-2019-P-1911-0007,FDA-2019-P-1911,interim response letter from fda cfsan to keller and heckman llp,0,0
0900006483bdc4df,Other,FDA-2019-P-1911-0002,FDA-2019-P-1911,acknowledgment letter from fda ddm to keller and heckman llp,0,0
0900006484325a5e,Other,FDA-2019-P-1911-0008,FDA-2019-P-1911,final response letter from fda cfsan to keller and heckman llp,0,0
0900006483bdc636,Supporting & Related Material,FDA-2019-P-1911-0003,FDA-2019-P-1911,appendix i - manufacturing process of gum acacia re: acknowledgment letter from fda ddm to keller and heckman llp,0,0
0900006483bdc638,Supporting & Related Material,FDA-2019-P-1911-0005,FDA-2019-P-1911,appendix iii - university of minnesota study (2019) re: acknowledgment letter from fda ddm to keller and heckman llp,0,0
0900006483bdc639,Supporting & Related Material,FDA-2019-P-1911-0006,FDA-2019-P-1911,appendix iv - gi labs study (2019)  re: acknowledgment letter from fda ddm to keller and heckman llp,0,0
0900006484dbcb6f,Other,FDA-2021-P-1082-0001,FDA-2021-P-1082,suitability petition from hyman phelps mcnamara p.c.,0,0
0900006484dbd0f0,Other,FDA-2021-P-1082-0002,FDA-2021-P-1082,acknowledgment letter from fda dms to hyman phelps mcnamara pc,0,0
09000064846c79c1,Other,FDA-2019-P-5833-0008,FDA-2019-P-5833,"letter from fda cder to archway apothecary, llc",0,0
0900006484202825,Supporting & Related Material,FDA-2019-P-5833-0005,FDA-2019-P-5833,"attachment 3 - a pilot study investigating changes in the human plasma and urine nad+ metabolome during a 6 hour intravenous infusion of nad re: citizen petition from archway apothecary, llc",0,0
0900006484202826,Supporting & Related Material,FDA-2019-P-5833-0006,FDA-2019-P-5833,"attachment 4 - archway apothecary nad potency test results re: citizen petition from archway apothecary, llc.",0,0
0900006484202823,Supporting & Related Material,FDA-2019-P-5833-0003,FDA-2019-P-5833,"attachment 1- intravenous administration of nicotinamide adenine dinucleotide significantly reduces self report craving ratings associated with opiate and alcohol withdrawal re: citizen petition from archway apothecary, llc",0,0
0900006484202827,Supporting & Related Material,FDA-2019-P-5833-0007,FDA-2019-P-5833,"attachment 5 - beta-nicotinamide adenine dnucleotide (nad) method validation final report re: citizen petition from archway apothecary, llc",0,0
0900006484202221,Other,FDA-2019-P-5833-0001,FDA-2019-P-5833,"citizen petition from archway apothecary, llc",0,0
090000648420281f,Other,FDA-2019-P-5833-0002,FDA-2019-P-5833,"acknowledgment letter from fda dms to archway apothecary, llc",0,0
0900006484202824,Supporting & Related Material,FDA-2019-P-5833-0004,FDA-2019-P-5833,"attachment 2 - therapeutic effect of br+nad on opioid and alcohol withdrawal: implications for clinical populations re: citizen petition from archway apothecary, llc",0,0
090000648294dcbd,Supporting & Related Material,FDA-2017-P-4352-0005,FDA-2017-P-4352,"attachment 5 - cdc guideline for prescribing opioids for chronic pain-4 re citizen petition from  pharmaceutical manufacturing research services, inc.",0,0
090000648294dcbf,Supporting & Related Material,FDA-2017-P-4352-0007,FDA-2017-P-4352,attachment 10 - opioid abuse in chronic pain _ misconceptions and mitigation strategies-3,0,0
090000648294e0b5,Supporting & Related Material,FDA-2017-P-4352-0009,FDA-2017-P-4352,"attachment 12 - cdc, understanding the epidemic-1 re citizen petition from  pharmaceutical manufacturing research services, inc.",0,0
090000648294e0ba,Supporting & Related Material,FDA-2017-P-4352-0014,FDA-2017-P-4352,"attachment 22- nida, overdose death rates re citizen petition from  pharmaceutical manufacturing research services, inc.",0,0
090000648294e0b6,Supporting & Related Material,FDA-2017-P-4352-0010,FDA-2017-P-4352,"attachment 13- cdc, opioid overdose-1 re citizen petition from  pharmaceutical manufacturing research services, inc.",0,0
090000648294e0b7,Supporting & Related Material,FDA-2017-P-4352-0011,FDA-2017-P-4352,"attachment 14 - cdc, opioid data analysis-1 re citizen petition from  pharmaceutical manufacturing research services, inc.",0,0
090000648294e0b9,Supporting & Related Material,FDA-2017-P-4352-0013,FDA-2017-P-4352,"attachment 18 - characteristics of initial prescription episodes and likelihood of long-term opioid use supplemental table re citizen petition from  pharmaceutical manufacturing research services, inc.",0,0
090000648294dcb7,Other,FDA-2017-P-4352-0001,FDA-2017-P-4352,"citizen petition from  pharmaceutical manufacturing research services, inc.",0,0
090000648294dcbe,Supporting & Related Material,FDA-2017-P-4352-0006,FDA-2017-P-4352,"attachment 9 - a proactive response to prescription opioid abuse-3 re citizen petition from  pharmaceutical manufacturing research services, inc.",0,0
090000648294e0b4,Supporting & Related Material,FDA-2017-P-4352-0008,FDA-2017-P-4352,"attachment 11- the promotion and marketing of oxycontin commercial triumph, public health tragedy-1 re citizen petition from  pharmaceutical manufacturing research services, inc.",0,0
0900006482d155a7,Other,FDA-2017-P-4352-0017,FDA-2017-P-4352,petition denial from fda cder to e. thompson,0,0
090000648294dcb9,Other,FDA-2017-P-4352-0002,FDA-2017-P-4352,"acknowledgement letter from fda ddm to  pharmaceutical manufacturing research services, inc.",0,0
090000648294dcbb,Supporting & Related Material,FDA-2017-P-4352-0003,FDA-2017-P-4352,"attachment 3 - assessment of analgesic treatment of chronic pain a public workshop transcripts may 31 2013-2 re citizen petition from  pharmaceutical manufacturing research services, inc.",0,0
090000648294dcbc,Supporting & Related Material,FDA-2017-P-4352-0004,FDA-2017-P-4352,"attachment 4 - reducing the risks of relief _ the cdc opioid-prescribing guideline re citizen petition from  pharmaceutical manufacturing research services, inc.",0,0
090000648294e0b8,Supporting & Related Material,FDA-2017-P-4352-0012,FDA-2017-P-4352,"attachment 17- characteristics of initial prescription episodes and likelihood of long-term opioid use-1 re citizen petition from  pharmaceutical manufacturing research services, inc.",0,0
0900006481b72890,Other,FDA-2015-P-2413-0002,FDA-2015-P-2413,"acknowledgement letter from fda ddm to acura pharmaceuticals, inc.",0,0
0900006481b7283a,Other,FDA-2015-P-2413-0001,FDA-2015-P-2413,"citizen petition from acura pharmaceuticals, inc.",0,0
0900006481d86833,Other,FDA-2015-P-2413-0003,FDA-2015-P-2413,"citizen petition denial response from fda cder to acura pharmaceuticals, inc.",0,0
090000648427fd4c,Other,FDA-2020-P-0129-0002,FDA-2020-P-0129,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p. c.",0,0
090000648427fd4b,Other,FDA-2020-P-0129-0001,FDA-2020-P-0129,"citizen petition from hyman, phelps & mcnamara, p. c.",0,0
090000648494ab9b,Other,FDA-2020-P-0129-0004,FDA-2020-P-0129,"letter from hyman, phelps & mcnamara, pc",0,0
09000064849583ce,Other,FDA-2020-P-0129-0005,FDA-2020-P-0129,"withdrawal from hyman, phelps & mcnamara p.c.",0,0
090000648472a159,Other,FDA-2020-P-0129-0003,FDA-2020-P-0129,"letter from fda cder to hyman, phelps & mcnamara, p. c.",0,0
090000648322c949,Other,FDA-2017-P-6745-0008,FDA-2017-P-6745,supplement from foley hoag llp,0,0
0900006482ce1f74,Supporting & Related Material,FDA-2017-P-6745-0004,FDA-2017-P-6745,exhibit 2 united states patent for method for production of botulinum toxin re citizen petition from foley hoag llp on behalf of medytox inc.,0,0
0900006483a33cac,Other,FDA-2017-P-6745-0010,FDA-2017-P-6745,response letter from fda cder to foley hoag llp,0,0
09000064833225c5,Other,FDA-2017-P-6745-0009,FDA-2017-P-6745,interim response letter from fda cder to foley hoag llp,0,0
0900006482ce20b6,Supporting & Related Material,FDA-2017-P-6745-0006,FDA-2017-P-6745,exhibit 4 notarial certificate from e-hyun law firm and notary office re citizen petition from foley hoag llp on behalf of medytox inc.,0,0
0900006482ce20b7,Supporting & Related Material,FDA-2017-P-6745-0007,FDA-2017-P-6745,"exhibit 5 earnings review report from korea investment & securitties co., ltd. re citizen petition from foley hoag llp on behalf of medytox inc.",0,0
0900006482ce1f71,Other,FDA-2017-P-6745-0002,FDA-2017-P-6745,acknowledgement letter from fda ddm to foley hoag llp,0,0
0900006482ce1f73,Supporting & Related Material,FDA-2017-P-6745-0003,FDA-2017-P-6745,"exhibit 1 declaration of theresa j. smith, m.s. re citizen petition from foley hoag llp on behalf of medytox inc.",0,0
0900006482ce1f75,Supporting & Related Material,FDA-2017-P-6745-0005,FDA-2017-P-6745,exhibit 3 transcript of text from geotext translations re citizen petition from foley hoag llp on behalf of medytox inc.,0,0
0900006482ce1f6f,Other,FDA-2017-P-6745-0001,FDA-2017-P-6745,citizen petition from foley hoag llp on behalf of medytox inc.,0,0
0900006481d7e89a,Supporting & Related Material,FDA-2015-P-4529-0006,FDA-2015-P-4529,exhibit f sumant ramachandra lessons for the united states: biosimilar market development worldwide re: citizen petition from uaw retiree medical benefits trust,0,0
0900006481d7e3dd,Other,FDA-2015-P-4529-0001,FDA-2015-P-4529,citizen petition from uaw retiree medical benefits trust,0,0
0900006481d7e456,Supporting & Related Material,FDA-2015-P-4529-0003,FDA-2015-P-4529,exhibit a  kevin riley citi on the impact of biosimilars and losing $360 billion in revenues re: citizen petition from uaw retiree medical benefits trust,0,0
0900006481d7e89b,Supporting & Related Material,FDA-2015-P-4529-0007,FDA-2015-P-4529,exhibit g mark mccamish effect of naming on competition and innovation re: citizen petition from uaw retiree medical benefits trust,0,0
0900006481d7e89d,Supporting & Related Material,FDA-2015-P-4529-0009,FDA-2015-P-4529,exhibit i transcript from pbs newshour what's keeping less expensive biologic drugs from the u.s. market? re: citizen petition from uaw retiree medical benefits trust,0,0
0900006481fe0138,Other,FDA-2015-P-4529-0011,FDA-2015-P-4529,interim response may 19 2016,0,0
0900006481d7e89c,Supporting & Related Material,FDA-2015-P-4529-0008,FDA-2015-P-4529,exhibit h what you need to know about biosimilar medicinal products re: citizen petition from uaw retiree medical benefits trust,0,0
0900006481d7e459,Supporting & Related Material,FDA-2015-P-4529-0004,FDA-2015-P-4529,exhibit b pfizer to acquire hospira re: citizen petition from uaw retiree medical benefits trust,0,0
0900006481d7e89f,Supporting & Related Material,FDA-2015-P-4529-0010,FDA-2015-P-4529,exhibit k investor statement on board oversight of biosimilar issues re: citizen petition from uaw retiree medical benefits trust,0,0
09000064820aa053,Other,FDA-2015-P-4529-0012,FDA-2015-P-4529,petition denial letter,0,0
0900006481d7e3e4,Other,FDA-2015-P-4529-0002,FDA-2015-P-4529,acknowledgement letter from fda ddm to uaw retiree medical benefits trust,0,0
0900006481d7e45d,Supporting & Related Material,FDA-2015-P-4529-0005,FDA-2015-P-4529,exhibit d fernandez and hurtado biosimilars: company strategies to capture value from the biologics market re: citizen petition from uaw retiree medical benefits trust,0,0
09000064827ded10,Supporting & Related Material,FDA-2017-P-4027-0003,FDA-2017-P-4027,attachment 1 annex i - orange book details - prednisone tablets 1 mg,0,0
09000064827ded0d,Other,FDA-2017-P-4027-0002,FDA-2017-P-4027,acknowledgment letter from fda ddm  to strides pharma inc.,0,0
09000064827de997,Other,FDA-2017-P-4027-0001,FDA-2017-P-4027,citizen petition from strides pharma inc,0,0
0900006482ce317c,Other,FDA-2017-P-4027-0005,FDA-2017-P-4027,relisting notice meticorten,0,0
0900006482cc9ac1,Notice,FDA-2017-P-4027-0004,FDA-2017-P-4027,"determination that meticorten (prednisone) tablets, 1 milligram and 5
milligrams, were not withdrawn from sale for reasons of safety or
effectiveness",0,0
09000064849a0b49,Supporting & Related Material,FDA-2020-P-2296-0011,FDA-2020-P-2296,reference 8. - british national formulary re: citizen petition from parenteral technologies llc,0,0
09000064849a0b54,Supporting & Related Material,FDA-2020-P-2296-0022,FDA-2020-P-2296,reference 19. - do parents give what they intend -otc meds re: citizen petition from parenteral technologies llc,0,0
09000064849a0b4d,Supporting & Related Material,FDA-2020-P-2296-0015,FDA-2020-P-2296,reference 12. - temple comments to fda re: citizen petition from parenteral technologies llc,0,0
0900006484b3cd5f,Other,FDA-2020-P-2296-0025,FDA-2020-P-2296,"interim response letter from fda cder to parenteral technologies, llc",0,0
090000648499cb09,Other,FDA-2020-P-2296-0001,FDA-2020-P-2296,citizen petition from parenteral technologies llc,0,0
09000064849a0b4e,Supporting & Related Material,FDA-2020-P-2296-0016,FDA-2020-P-2296,reference 13. - temple comparison of dosign regimens and report on three legacy studies,0,0
09000064849a0b51,Supporting & Related Material,FDA-2020-P-2296-0019,FDA-2020-P-2296,reference 16. - acute pain underdosing re: citizen petition from parenteral technologies llc,0,0
09000064849a09d1,Supporting & Related Material,FDA-2020-P-2296-0003,FDA-2020-P-2296,references_ pdf_ citizen petition_parenteral technologies re: citizen petition from parenteral technologies llc,0,0
09000064849a0b45,Supporting & Related Material,FDA-2020-P-2296-0007,FDA-2020-P-2296,reference 4. - evaluation of aspirin-acetaminophen combination re: citizen petition from parenteral technologies llc,0,0
09000064849a0b47,Supporting & Related Material,FDA-2020-P-2296-0009,FDA-2020-P-2296,reference 6. - windofer a. vogel re: citizen petition from parenteral technologies llc,0,0
09000064849a0b4b,Supporting & Related Material,FDA-2020-P-2296-0013,FDA-2020-P-2296,reference 10. temple pediatric dosing of acetaminophen re: citizen petition from parenteral technologies llc,0,0
09000064849a0b43,Supporting & Related Material,FDA-2020-P-2296-0005,FDA-2020-P-2296,reference 2. - clincial comparison of three antipyretic agents re: citizen petition from parenteral technologies llc,0,0
09000064849a0b46,Supporting & Related Material,FDA-2020-P-2296-0008,FDA-2020-P-2296,reference 5. - efficacy and safety of acetaminophen vs ibuprofen re: citizen petition from parenteral technologies llc,0,0
09000064849a0b52,Supporting & Related Material,FDA-2020-P-2296-0020,FDA-2020-P-2296,reference 17. - fda briefing information for the june 29-30 2009 joint meeting re: citizen petition from parenteral technologies llc,0,0
09000064849a0b4c,Supporting & Related Material,FDA-2020-P-2296-0014,FDA-2020-P-2296,reference 11. boston fever study - safety of acetaminophen and ibuprofen - lesko re: citizen petition from parenteral technologies llc,0,0
09000064849a0b56,Supporting & Related Material,FDA-2020-P-2296-0024,FDA-2020-P-2296,reference 21. - analysis of liquid medciation dose errors made by parents and caregivers re: citizen petition from parenteral technologies llc,0,0
090000648499cb0c,Other,FDA-2020-P-2296-0002,FDA-2020-P-2296,"acknowledgment letter from fda dms to parenteral technologies, llc",0,0
09000064849a0b4a,Supporting & Related Material,FDA-2020-P-2296-0012,FDA-2020-P-2296,reference 9. clinical pharmacokinetics in infants and children re: citizen petition from parenteral technologies llc,0,0
09000064849a09d2,Supporting & Related Material,FDA-2020-P-2296-0004,FDA-2020-P-2296,reference 1.  - us fda meeting of the nonprescrpition drugs advisory committee re: citizen petition from parenteral technologies llc,0,0
09000064849a0b44,Supporting & Related Material,FDA-2020-P-2296-0006,FDA-2020-P-2296,reference 3. - comparison of the effect of acetaminophen and aspirin re: citizen petition from parenteral technologies llc,0,0
09000064849a0b4f,Supporting & Related Material,FDA-2020-P-2296-0017,FDA-2020-P-2296,reference 14. - liquid medciation errors and dosing tools re: citizen petition from parenteral technologies llc,0,0
09000064849a0b53,Supporting & Related Material,FDA-2020-P-2296-0021,FDA-2020-P-2296,reference 18. - unit of measurement used a parent dosing error re: citizen petition from parenteral technologies llc,0,0
09000064849a0b55,Supporting & Related Material,FDA-2020-P-2296-0023,FDA-2020-P-2296,reference 20. - evaluation of consistency in dosing directions re: citizen petition from parenteral technologies llc,0,0
09000064849a0b48,Supporting & Related Material,FDA-2020-P-2296-0010,FDA-2020-P-2296,reference 7. - pharmacokinetics of acetaminophen in children re: citizen petition from parenteral technologies llc,0,0
09000064849a0b50,Supporting & Related Material,FDA-2020-P-2296-0018,FDA-2020-P-2296,reference 15. - underdosing of acetaminophen re: citizen petition from parenteral technologies llc,0,0
090000648464e010,Other,FDA-2020-P-1403-0002,FDA-2020-P-1403,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
090000648464e00f,Other,FDA-2020-P-1403-0001,FDA-2020-P-1403,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484c6ea72,Other,FDA-2020-P-1403-0005,FDA-2020-P-1403,"citizen petition withdrawal letter from hyman, phelps & mcnamara, p.c.",0,0
0900006480bfdf83,Other,FDA-2011-P-0127-0002,FDA-2011-P-0127,"acknowledgement letter to baxter healthcare corporation, et al (king & spalding llp)",0,0
0900006480e3e5de,Other,FDA-2011-P-0127-0007,FDA-2011-P-0127,"fda/cder to baxter healthcare corporation, et al., (king & spalding llp) - petition partial approval and denial",0,0
0900006480bfdf7e,Other,FDA-2011-P-0127-0001,FDA-2011-P-0127,"baxter healthcare corporation, et al., (king & spalding llp) - citizen petition",0,0
0900006481535e8e,Other,FDA-2013-P-1641-0003,FDA-2013-P-1641,supplement from teva pharmaceutical industries ltd.,0,0
09000064814c4529,Other,FDA-2013-P-1641-0001,FDA-2013-P-1641,citizen petition from teva pharmaceuticals,0,0
09000064815fccf0,Other,FDA-2013-P-1641-0004,FDA-2013-P-1641,"presentation from teva pharmacuetical  re february 25, 2014 type c fda meeting on scientific data on copaxone’s complexity and mode of action in consideration of evidentiary standards for follow on products",0,0
09000064816e2a7e,Other,FDA-2013-P-1641-0009,FDA-2013-P-1641,"citizen petition denial response from fda cder to teva neuroscience, inc.",0,0
09000064814c457d,Other,FDA-2013-P-1641-0002,FDA-2013-P-1641,acknowledgement letter to teva pharmaceuticals,0,0
0900006481661939,Other,FDA-2013-P-1641-0005,FDA-2013-P-1641,"memorandum of meeting minutes february 25, 2014",0,0
0900006481683ff7,Other,FDA-2013-P-1641-0006,FDA-2013-P-1641,supplement from teva pharmaceutical industries ltd.,0,0
0900006481715590,Other,FDA-2014-P-0700-0002,FDA-2014-P-0700,acknowledgement letter from fda ddm to qilu pharma,0,0
09000064817155c7,Supporting & Related Material,FDA-2014-P-0700-0003,FDA-2014-P-0700,"attachment 1 approved package insert for rld citizen petition from qilu pharma, inc. (qilu pharmaceutical co., ltd.)",0,0
09000064817155c8,Supporting & Related Material,FDA-2014-P-0700-0004,FDA-2014-P-0700,"attachment 2 proposed package insert citizen petition from qilu pharma, inc. (qilu pharmaceutical co., ltd.)",0,0
090000648171558b,Other,FDA-2014-P-0700-0001,FDA-2014-P-0700,"citizen petition from qilu pharma, inc. (qilu pharmaceutical co., ltd.)",0,0
09000064818e581c,Supporting & Related Material,FDA-2014-P-1670-0003,FDA-2014-P-1670,attachment 1,0,0
09000064818e581d,Supporting & Related Material,FDA-2014-P-1670-0004,FDA-2014-P-1670,attachment 2,0,0
09000064818e5748,Other,FDA-2014-P-1670-0002,FDA-2014-P-1670,acknowledgement letter from fda ddm to gordon johnston regulatory consultants llc,0,0
09000064818e562a,Other,FDA-2014-P-1670-0001,FDA-2014-P-1670,citizen petition from gordon johnston regulatory consultants llc,0,0
09000064818e581f,Supporting & Related Material,FDA-2014-P-1670-0005,FDA-2014-P-1670,attachment 3,0,0
090000648193885a,Other,FDA-2014-P-1975-0002,FDA-2014-P-1975,"acknowledgement letter from fda ddm to e5 pharma, llc",0,0
09000064819387d4,Other,FDA-2014-P-1975-0001,FDA-2014-P-1975,"citizen petition from e5 pharma, llc",0,0
09000064819387dc,Supporting & Related Material,FDA-2014-P-1975-0004,FDA-2014-P-1975,attachment 2 proposed amendments to pioneer labeling citizen petition from e5 pharma llc,0,0
09000064819c8079,Other,FDA-2014-P-1975-0005,FDA-2014-P-1975,suitability petition approval response letter from fda cvm to e5 pharma llc,0,0
09000064819387d8,Supporting & Related Material,FDA-2014-P-1975-0003,FDA-2014-P-1975,attachment 1pioneer labeling clomicalm tablets citizen petition from e5 pharma llc,0,0
09000064817a0e48,Other,FDA-2014-P-0980-0002,FDA-2014-P-0980,acknowledgement letter to lachman consultant services inc,0,0
09000064817a0c97,Other,FDA-2014-P-0980-0001,FDA-2014-P-0980,citizen petition from lachman consultant services inc,0,0
09000064817a0e4a,Supporting & Related Material,FDA-2014-P-0980-0003,FDA-2014-P-0980,attachment 1 supplement approval letter re citizen petition from lachman consultant services inc,0,0
09000064819a648c,Notice,FDA-2014-P-0980-0004,FDA-2014-P-0980,"determination that reyataz (atazanavir sulfate) capsules, 100 milligrams, were withdrawn from sale for reasons of safety or effectiveness",0,0
0900006481bbc9af,Supporting & Related Material,FDA-2015-P-2830-0003,FDA-2015-P-2830,"attachment 1:  nih ninds the epilsepsies and seizures hope through research re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcbe4,Supporting & Related Material,FDA-2015-P-2830-0007,FDA-2015-P-2830,"attachment 8: us prescribing information oxtellar xr re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcbe9,Supporting & Related Material,FDA-2015-P-2830-0009,FDA-2015-P-2830,"attachment 13: epilepsy foundation sudden unexpected death in epilepsy (sudep) re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcc03,Supporting & Related Material,FDA-2015-P-2830-0019,FDA-2015-P-2830,"attachment 35: fda cder meeting of the advisory committee for pharmaceutical science and clinical pharmacology, briefing information,(4-13-10) re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcbee,Supporting & Related Material,FDA-2015-P-2830-0012,FDA-2015-P-2830,"attachment 16:  fda cder nda 202810 summary review re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bc1228,Other,FDA-2015-P-2830-0002,FDA-2015-P-2830,"acknowledgment letter from fda ddm to supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcbe7,Supporting & Related Material,FDA-2015-P-2830-0008,FDA-2015-P-2830,"attachment 11: epilepsy foundation seizure emergencies re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcc04,Supporting & Related Material,FDA-2015-P-2830-0020,FDA-2015-P-2830,"attachment 36: midha, k. and mckay g. use of partial area under the curve for be assessment of products with complex pk profiles; a view point re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcbef,Supporting & Related Material,FDA-2015-P-2830-0013,FDA-2015-P-2830,"attachment 17:  fda cder nda 202810 medical review re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcbf2,Supporting & Related Material,FDA-2015-P-2830-0014,FDA-2015-P-2830,"attachment 20: transcript from fda cder advisory committee for pharmaceutical science meeting (july 26, 2011) re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbc9ac,Other,FDA-2015-P-2830-0001,FDA-2015-P-2830,"citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcc02,Supporting & Related Material,FDA-2015-P-2830-0018,FDA-2015-P-2830,"attachment 34:  gdufa regulatory science priorities for fiscal year 2015 re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcc05,Supporting & Related Material,FDA-2015-P-2830-0021,FDA-2015-P-2830,"attachment 37 - yu, approaches to demonstrate bioequivalence of narrow therapeutic index drug (2011) re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481e01655,Other,FDA-2015-P-2830-0022,FDA-2015-P-2830,citizen petition denial response from fda cder to ropes and gray llp,0,0
0900006481bbc9b0,Supporting & Related Material,FDA-2015-P-2830-0004,FDA-2015-P-2830,"attachment 2:  cdc epilepsy fast facts re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcbe1,Supporting & Related Material,FDA-2015-P-2830-0005,FDA-2015-P-2830,"attachment 5: cdc epilepsy faq re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcbe3,Supporting & Related Material,FDA-2015-P-2830-0006,FDA-2015-P-2830,"attachment 7 citizen petition from ucb inc re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcbec,Supporting & Related Material,FDA-2015-P-2830-0010,FDA-2015-P-2830,"attachment 14: us prescribing information trileptal re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcbed,Supporting & Related Material,FDA-2015-P-2830-0011,FDA-2015-P-2830,"attachment 15: fda cder nda 20810 clinical pharmacology and biopharmaceutics review(s) re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcbfd,Supporting & Related Material,FDA-2015-P-2830-0015,FDA-2015-P-2830,"attachment 29: mhpra, antiepileptic drugs: new advice on switching between different manufacturers' products for a particular drug re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcbfe,Supporting & Related Material,FDA-2015-P-2830-0016,FDA-2015-P-2830,"attachment 30: danish health medicines authority, bioequivalence and labeling of medicines with regard to generic substitution re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481bbcbff,Supporting & Related Material,FDA-2015-P-2830-0017,FDA-2015-P-2830,"attachment 31: verbeeck, r. and musuamba, f. the revised 2010 ema guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action re citizen petition from supernus pharmaceuticals (ropes and gray, llp)",0,0
0900006481a52ae4,Other,FDA-2015-P-0876-0002,FDA-2015-P-0876,acknowledgment letter from fda ddm to jill escher,0,0
0900006481fc092e,Other,FDA-2015-P-0876-0004,FDA-2015-P-0876,letter from escher fund for autism to fda cder,0,0
090000648267787f,Other,FDA-2015-P-0876-0006,FDA-2015-P-0876,letter from escher fund for autism to fda cder,0,0
0900006481c5563a,Other,FDA-2015-P-0876-0003,FDA-2015-P-0876,interim response letter from fda cder to escher fund for autism,0,0
09000064824c03d7,Other,FDA-2015-P-0876-0005,FDA-2015-P-0876,letter from escher fund for autism to fda cder,0,0
0900006482f06fe3,Other,FDA-2015-P-0876-0007,FDA-2015-P-0876,letter from escher fund for autism to fda ddm,0,0
0900006482f32af4,Other,FDA-2015-P-0876-0008,FDA-2015-P-0876,response letter from fda cder to escher fund for autism,0,0
0900006481a52ae0,Other,FDA-2015-P-0876-0001,FDA-2015-P-0876,citizen petition from the escher fund for autism,0,0
09000064843d420e,Other,FDA-2019-P-4155-0003,FDA-2019-P-4155,"interim response letter from fda cder to teva pharmaceuticals usa, inc",0,0
0900006483f08eda,Other,FDA-2019-P-4155-0002,FDA-2019-P-4155,"acknowledgment letter from fda dms to teva pharmaceuticals usa, inc.",0,0
0900006483f08ed9,Other,FDA-2019-P-4155-0001,FDA-2019-P-4155,"citizen petition from teva pharmaceuticals usa, inc",0,0
0900006482d84da8,Supporting & Related Material,FDA-2017-P-7033-0004,FDA-2017-P-7033,exhibit 2 rld label re citizen petition from jubliant generics limited,0,0
0900006482d84daa,Supporting & Related Material,FDA-2017-P-7033-0006,FDA-2017-P-7033,exhibit 4 oxetol dosage & drug information re citizen petition from jubliant generics limited,0,0
0900006482d84da4,Other,FDA-2017-P-7033-0002,FDA-2017-P-7033,acknowledgment letter from fda ddm to jubilant generics limited,0,0
0900006482d84d79,Other,FDA-2017-P-7033-0001,FDA-2017-P-7033,citizen petition from jubliant generics limited,0,0
0900006482d84da7,Supporting & Related Material,FDA-2017-P-7033-0003,FDA-2017-P-7033,exhibit 1 orange book listing re citizen petition from jubliant generics limited,0,0
0900006482d84da9,Supporting & Related Material,FDA-2017-P-7033-0005,FDA-2017-P-7033,exhibit 3 proposed product draft label re citizen petition from jubliant generics limited,0,0
0900006482bbbda9,Other,FDA-2017-P-2229-0014,FDA-2017-P-2229,interim response letter from cfsan to american bakers association,0,0
0900006482bbbd2b,Other,FDA-2017-P-2229-0013,FDA-2017-P-2229,interim response letter from cfsan to covington & burling llp,0,0
09000064825483e5,Other,FDA-2017-P-2229-0002,FDA-2017-P-2229,"acknowledgment letter from fda ddm to covington & burling, llp and american bakers association",0,0
0900006482547f12,Supporting & Related Material,FDA-2017-P-2229-0004,FDA-2017-P-2229,"appendix b - food labeling: revision of the nutrition and supplement facts labels, docket no. fda-2012-n-1210 re citizen petition from covington & burling, llp and american bakers association",1,0
09000064834111b7,Other,FDA-2017-P-2229-0015,FDA-2017-P-2229,fda-2017-p-2229 - aba letter,0,0
0900006482547f0f,Other,FDA-2017-P-2229-0001,FDA-2017-P-2229,"citizen petition from  american bakers association (covington & burling, llp)",0,0
0900006482547f11,Supporting & Related Material,FDA-2017-P-2229-0003,FDA-2017-P-2229,"appendix a -  the records access provision of the regulation exceeds fda’s statutory authority re citizen petition from covington & burling, llp and american bakers association",0,0
0900006483595a5f,Other,FDA-2018-P-2985-0002,FDA-2018-P-2985,acknowledgement letter from fda ddm to norbrook inc.,0,0
09000064836e9f0d,Other,FDA-2018-P-2985-0006,FDA-2018-P-2985,amendment to citizen petition from norbrook inc.,0,0
090000648383aa21,Other,FDA-2018-P-2985-0007,FDA-2018-P-2985,petition approval letter from fda cvm to norbrook inc.,0,0
09000064835943d9,Other,FDA-2018-P-2985-0001,FDA-2018-P-2985,citizen petition from norbrook inc.,0,0
09000064835993a9,Supporting & Related Material,FDA-2018-P-2985-0003,FDA-2018-P-2985,appendix 1 pioneer labeling for felimazole coated tablets 2.5mg and 5mg re: citizen petition from norbrook inc.,0,0
09000064835993aa,Supporting & Related Material,FDA-2018-P-2985-0004,FDA-2018-P-2985,"appendix 2 label differences between the pioneer, felimazole 2.5mg & 5mg coated tablets re: citizen petition from norbrook inc.",0,0
09000064835993ab,Supporting & Related Material,FDA-2018-P-2985-0005,FDA-2018-P-2985,appendix 3 patent certification statement re: citizen petition from norbrook inc.,0,0
09000064835d8c12,Other,FDA-2018-P-0614-0003,FDA-2018-P-0614,interim response from fda ddm to  geneyork pharmaceuticals group llc,0,0
0900006482eff648,Other,FDA-2018-P-0614-0001,FDA-2018-P-0614,citizen petition from geneyork pharmaceuticals group llc,0,0
09000064847f48c4,Other,FDA-2018-P-0614-0004,FDA-2018-P-0614,letter from fda cder to geneyork pharmaceuticals group llc,0,0
0900006482eff64a,Other,FDA-2018-P-0614-0002,FDA-2018-P-0614,acknowledgment letter from fda ddm to geneyork pharmaceuticals group llc,0,0
0900006481abfc50,Supporting & Related Material,FDA-2015-P-1433-0005,FDA-2015-P-1433,"exhibit 3 reeves et al. scientific standards and the regulation of gm insects, re: citizen petition from michael welber",0,0
09000064821578f5,Other,FDA-2015-P-1433-0081,FDA-2015-P-1433,"petition denial august 5, 2016",0,0
0900006481abf79a,Other,FDA-2015-P-1433-0002,FDA-2015-P-1433,acknowledgement letter from fda ddm to michael welber,0,0
0900006481abfc4f,Supporting & Related Material,FDA-2015-P-1433-0004,FDA-2015-P-1433,"exhibit 2 millerloaiza 2015 expansion of aedes albopictus panama, re: citizen petition from michael welber",0,0
0900006481d1d826,Other,FDA-2015-P-1433-0069,FDA-2015-P-1433,interim response letter from fda cvm to mr. michael welber,0,0
0900006481abf794,Other,FDA-2015-P-1433-0001,FDA-2015-P-1433,citizen petition from michael welber,0,0
0900006481abf79d,Supporting & Related Material,FDA-2015-P-1433-0003,FDA-2015-P-1433,"exhibit 1 genewatch uk mosquitoes and tetracycline, re: citizen petition from michael welber",0,0
0900006482f64378,Supporting & Related Material,FDA-2018-P-0874-0007,FDA-2018-P-0874,appendix 6 re citizen petition from bonumose llc,0,0
090000648318e5b2,Supporting & Related Material,FDA-2018-P-0874-0024,FDA-2018-P-0874,attachment 2 - bonumose_d-tagatose citizen petition appendix 2 part 1 re amended citizen petition from bonumose llc,0,0
090000648318e5b3,Supporting & Related Material,FDA-2018-P-0874-0025,FDA-2018-P-0874,attachment 3 - bonumose_d-tagatose citizen petition appendix 2 part 2 re amended citizen petition from bonumose llc,0,0
090000648318e5b4,Supporting & Related Material,FDA-2018-P-0874-0026,FDA-2018-P-0874,attachment 4 - bonumose_d-tagatose citizen petition appendix 2 part 3 re amended citizen petition from bonumose llc,0,0
090000648318e9fe,Supporting & Related Material,FDA-2018-P-0874-0033,FDA-2018-P-0874,attachment 11 - bonumose_d-tagatose citizen petition appendix 2 part 10 re amended citizen petition from bonumose llc,0,0
090000648318ea02,Supporting & Related Material,FDA-2018-P-0874-0037,FDA-2018-P-0874,attachment 15 - bonumose_d-tagatose citizen petition appendix 2 part 14 re amended citizen petition from bonumose llc,0,0
090000648318ea13,Supporting & Related Material,FDA-2018-P-0874-0040,FDA-2018-P-0874,attachment 18 - bonumose_d-tagatose citizen petition appendix 2 part 17 re amended citizen petition from bonumose llc,0,0
090000648318ea15,Supporting & Related Material,FDA-2018-P-0874-0042,FDA-2018-P-0874,attachment 20 - bonumose_d-tagatose citizen petition appendix 2 part 19 re amended citizen petition from bonumose llc,0,0
0900006482f64379,Supporting & Related Material,FDA-2018-P-0874-0008,FDA-2018-P-0874,appendix 7 re citizen petition from bonumose llc,0,0
0900006482f64380,Supporting & Related Material,FDA-2018-P-0874-0015,FDA-2018-P-0874,appendix 14 re citizen petition from bonumose llc,0,0
0900006482f643b1,Supporting & Related Material,FDA-2018-P-0874-0020,FDA-2018-P-0874,appendix 19 re citizen petition from bonumose llc,0,0
0900006482f64368,Supporting & Related Material,FDA-2018-P-0874-0005,FDA-2018-P-0874,appendix 4 re citizen petition from bonumose llc,0,0
090000648318e0f0,Other,FDA-2018-P-0874-0023,FDA-2018-P-0874,amended citizen petition from bonumose llc,0,0
090000648318e9fc,Supporting & Related Material,FDA-2018-P-0874-0031,FDA-2018-P-0874,attachment 9 - bonumose_d-tagatose citizen petition appendix 2 part 8 re amended citizen petition from bonumose llc,0,0
090000648318e9fd,Supporting & Related Material,FDA-2018-P-0874-0032,FDA-2018-P-0874,attachment 10 - bonumose_d-tagatose citizen petition appendix 2 part 9 re amended citizen petition from bonumose llc,0,0
090000648318ea01,Supporting & Related Material,FDA-2018-P-0874-0036,FDA-2018-P-0874,attachment 14 - bonumose_d-tagatose citizen petition appendix 2 part 13 re amended citizen petition from bonumose llc,0,0
090000648318ea14,Supporting & Related Material,FDA-2018-P-0874-0041,FDA-2018-P-0874,attachment 19 - bonumose_d-tagatose citizen petition appendix 2 part 18 re amended citizen petition from bonumose llc,0,0
0900006482f6437b,Supporting & Related Material,FDA-2018-P-0874-0010,FDA-2018-P-0874,appendix 9 re citizen petition from bonumose llc,0,0
0900006482f6437a,Supporting & Related Material,FDA-2018-P-0874-0009,FDA-2018-P-0874,appendix 8 re citizen petition from bonumose llc,0,0
0900006482f643ac,Supporting & Related Material,FDA-2018-P-0874-0016,FDA-2018-P-0874,appendix 15 re citizen petition from bonumose llc,0,0
0900006482f643af,Supporting & Related Material,FDA-2018-P-0874-0018,FDA-2018-P-0874,appendix 17 re citizen petition from bonumose llc,0,0
0900006482f64361,Other,FDA-2018-P-0874-0001,FDA-2018-P-0874,citizen petition from bonumose llc,0,0
0900006482f6437c,Supporting & Related Material,FDA-2018-P-0874-0011,FDA-2018-P-0874,appendix 10 re citizen petition from bonumose llc,0,0
0900006482f64366,Supporting & Related Material,FDA-2018-P-0874-0003,FDA-2018-P-0874,appendix 2 re citizen petition from bonumose llc,0,0
0900006482f6437d,Supporting & Related Material,FDA-2018-P-0874-0012,FDA-2018-P-0874,appendix 11 re citizen petition from bonumose llc,0,0
090000648219ba07,Other,FDA-2016-P-0770-0004,FDA-2016-P-0770,interim response from fda cder,0,0
090000648219de7b,Other,FDA-2016-P-0770-0005,FDA-2016-P-0770,"citizen petition interim response letter from fda cder to international isotopes, inc.",0,0
0900006481e96e6f,Supporting & Related Material,FDA-2016-P-0770-0002,FDA-2016-P-0770,attachment 1 - electronic orange book listing for xenon xe-133 gas inhalation re citizen petition from international isotopes inc.,0,0
0900006481e96280,Other,FDA-2016-P-0770-0001,FDA-2016-P-0770,citizen petition from international isotopes inc.,0,0
0900006481e96ea2,Other,FDA-2016-P-0770-0003,FDA-2016-P-0770,acknowledgement letter from fda ddm to international isotopes inc.,0,0
09000064841d90b9,Other,FDA-2016-P-0770-0006,FDA-2016-P-0770,"letter from fda cder to international isotopes, inc.",0,0
09000064804719e7,Notice,FDA-2004-D-0244-0005,FDA-2004-D-0244,fda,0,0
09000064804719dc,Supporting & Related Material,FDA-2004-D-0244-0003,FDA-2004-D-0244,guideline,0,0
09000064804719db,Supporting & Related Material,FDA-2004-D-0244-0002,FDA-2004-D-0244,guideline,0,0
09000064804719e6,Supporting & Related Material,FDA-2004-D-0244-0004,FDA-2004-D-0244,guidance,0,0
09000064804719da,Notice,FDA-2004-D-0244-0001,FDA-2004-D-0244,fda,0,0
09000064845d84e3,Other,FDA-2020-D-1375-0001,FDA-2020-D-1375,"guidance for industry: color additive petitions - fda recommendations for submission of chemical and technological data on color additives for food, drugs, cosmetics, or medical devices",1,0
0900006481c700bf,Supporting & Related Material,FDA-2011-P-0646-0023,FDA-2011-P-0646,exhibit 22 - 23 fda material on helping consumers reduce sodium intake and sodium reduction re: amended citizen petition from the city of philadelphia,0,0
0900006481c69313,Supporting & Related Material,FDA-2011-P-0646-0014,FDA-2011-P-0646,exhibit 3 vital statistics report philadelphia 2012 (natality findings and mortality findings) re: amended citizen petition from the city of philadelphia,0,0
0900006481c69310,Supporting & Related Material,FDA-2011-P-0646-0011,FDA-2011-P-0646,"exhibit 2 department of agriculture nutrient intakes from food and beverages: mean amounts consumed per individual, by gender and age 2011-2012 re: amended citizen petition from the city of philadelphia",1,0
09000064814e26bf,Other,FDA-2011-P-0646-0004,FDA-2011-P-0646,supplement from the city of philadelphia department of public health,0,0
0900006481c69314,Supporting & Related Material,FDA-2011-P-0646-0015,FDA-2011-P-0646,exhibit 3 vital statistics report philadelphia 2012 (appendix) re: amended citizen petition from the city of philadelphia,0,0
0900006481c69315,Supporting & Related Material,FDA-2011-P-0646-0016,FDA-2011-P-0646,exhibit 3 vital statistics report philadelphia 2012 (technical notes) re: amended citizen petition from the city of philadelphia,0,0
0900006481cb1cc9,Other,FDA-2011-P-0646-0027,FDA-2011-P-0646,letter from health promotion council to city of philadelphia,0,0
0900006480f12202,Other,FDA-2011-P-0646-0002,FDA-2011-P-0646,"acknowledgement letter to the city of philadelphia, department of public health",0,0
0900006481c700bd,Supporting & Related Material,FDA-2011-P-0646-0021,FDA-2011-P-0646,"exhibit 20 food and nutrition board, institute of medicine, national academies, dietary reference intakes (dris): tolerable upper intake levels re: amended citizen petition from the city of philadelphia",1,0
0900006480f81bf5,Other,FDA-2011-P-0646-0003,FDA-2011-P-0646,"interim response to city of philadephia, department of public health - letter",0,0
0900006481cbdf92,Other,FDA-2011-P-0646-0028,FDA-2011-P-0646,letter from thomas jefferson university college of population health to  city of philadelphia,0,0
0900006481c69312,Supporting & Related Material,FDA-2011-P-0646-0013,FDA-2011-P-0646,exhibit 3 vital statistics report philadelphia 2012 (population findings) re: amended citizen petition from the city of philadelphia,0,0
0900006481c69311,Supporting & Related Material,FDA-2011-P-0646-0012,FDA-2011-P-0646,exhibit 3 vital statistics report philadelphia 2012 re: amended citizen petition from the city of philadelphia,0,0
0900006481c691d8,Other,FDA-2011-P-0646-0008,FDA-2011-P-0646,"amended citizen petition from city of philadelphia, department of public health",0,0
0900006481c69317,Supporting & Related Material,FDA-2011-P-0646-0018,FDA-2011-P-0646,"exhibit 5 philadelphia department of public health, hypertension and heart disease comparison by ten largest counties, 2011 re: amended citizen petition from the city of philadelphia",0,0
0900006480f0e7e9,Other,FDA-2011-P-0646-0001,FDA-2011-P-0646,"city of philadephia, department of public health - citizen petition",0,0
0900006481dd8a66,Other,FDA-2011-P-0646-0031,FDA-2011-P-0646,"interim response letter from fda cfsan to deparment of public health, city of philadelphia",0,0
0900006481c69318,Supporting & Related Material,FDA-2011-P-0646-0019,FDA-2011-P-0646,"exhibit 6 philadelphia department of public health, premature cardiovascular mortality rate per 100,000 re: amended citizen petition from the city of philadelphia",0,0
0900006481c700be,Supporting & Related Material,FDA-2011-P-0646-0022,FDA-2011-P-0646,"exhibit 21 u.s. centers for disease control and prevention, sodium reduction in communities
program (srcp), re: amended citizen petition from the city of philadelphia",0,0
0900006481c700bc,Supporting & Related Material,FDA-2011-P-0646-0020,FDA-2011-P-0646,"exhibit 19 american heart association, government to issue guidelines for lowering sodium in foods re: amended citizen petition from the city of philadelphia",0,0
0900006481c6930e,Supporting & Related Material,FDA-2011-P-0646-0009,FDA-2011-P-0646,attachment 1 list of exhibits re: amended citizen petition from the city of philadelphia,0,0
0900006481c6930f,Supporting & Related Material,FDA-2011-P-0646-0010,FDA-2011-P-0646,"exhibit 1 dhhs, philadelphia city council hearing transcripts, october 9, 2007 re: amended citizen petition from the city of philadelphia",0,0
0900006481c69316,Supporting & Related Material,FDA-2011-P-0646-0017,FDA-2011-P-0646,exhibit 4 public health management corp southeastern pa household health survey (2014-15) re: amended citizen petition from the city of philadelphia,0,0
0900006482cfec92,Other,FDA-2017-P-2659-0005,FDA-2017-P-2659,final response letter from fda to jubilant generics limited,0,0
0900006482bc8171,Other,FDA-2017-P-2659-0004,FDA-2017-P-2659,interim response from fda to jubilant generics,0,0
09000064825801e6,Supporting & Related Material,FDA-2017-P-2659-0003,FDA-2017-P-2659,"attachment 1 orange book: approved drug products with therapeutic
equivalence evaluations re",0,0
09000064825801e0,Other,FDA-2017-P-2659-0001,FDA-2017-P-2659,citizen petition from jubilant generics,0,0
09000064825801e2,Other,FDA-2017-P-2659-0002,FDA-2017-P-2659,acknowledgment letter from fda ddm to jubilant generics,0,0
0900006482cfd5ec,Notice,FDA-2017-P-2659-0006,FDA-2017-P-2659,"determination that noroxin (norfloxacin) tablets, 400 milligrams,
was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483787532,Other,FDA-2018-P-3709-0002,FDA-2018-P-3709,acknowledgment letter from fda ddm to jennifer nelson,0,0
090000648385a5c6,Supporting & Related Material,FDA-2018-P-3709-0005,FDA-2018-P-3709,attachment 2- recall type re: citizen petition from jennifer nelson recall type 10 25 2019,0,0
090000648385a5df,Other,FDA-2018-P-3709-0004,FDA-2018-P-3709,addendum to citizen petition from jennifer nelson,0,0
090000648378790b,Supporting & Related Material,FDA-2018-P-3709-0003,FDA-2018-P-3709,attachment 1- cautery dld maudeexcel re: citizen petition from jennifer nelson,0,0
0900006483b4b800,Other,FDA-2018-P-3709-0011,FDA-2018-P-3709,interim response letter from fda cdrh to jennifer nelson,0,0
0900006483786d77,Other,FDA-2018-P-3709-0001,FDA-2018-P-3709,citizen petition from jennifer nelson,0,0
090000648326a4cd,Other,FDA-2018-N-1794-0001,FDA-2018-N-1794,"fda report on the quality, safety, and effectiveness of servicing of medical devices in accordance with section 710 of the food and drug administration reauthorization act of 2017 (fdara)",1,0
0900006482b9c7fd,Other,FDA-2017-P-6028-0002,FDA-2017-P-6028,"acknowledgment letter from fda ddm to axinn, veltrop & harkrider llp",0,0
0900006482ba35d4,Supporting & Related Material,FDA-2017-P-6028-0007,FDA-2017-P-6028,"attachment 2 anda 076186 approved labeling re citizen petition from axinn, veltrop & harkrider llp",0,0
0900006482b9cdb6,Supporting & Related Material,FDA-2017-P-6028-0004,FDA-2017-P-6028,"attachment - 2 anda 071293 approved labeling - re citizen petition from axinn, veltrop & harkrider llp",0,0
0900006482ba2c9a,Supporting & Related Material,FDA-2017-P-6028-0006,FDA-2017-P-6028,"attachment 1 fda orange book re citizen petition from axinn, veltrop & harkrider llp",0,0
0900006482b9cc47,Supporting & Related Material,FDA-2017-P-6028-0003,FDA-2017-P-6028,"attachment -1 fda orange book  - re citizen petition from axinn, veltrop & harkrider llp",0,0
0900006482b9cdba,Supporting & Related Material,FDA-2017-P-6028-0005,FDA-2017-P-6028,"attachment - 3 proposed draft labeling re citizen petition from axinn, veltrop & harkrider llp",0,0
0900006482ba35d5,Supporting & Related Material,FDA-2017-P-6028-0008,FDA-2017-P-6028,"attachment 3 proposed draft labeling re citizen petition from axinn, veltrop & harkrider llp",0,0
0900006482b9c9b6,Other,FDA-2017-P-6028-0001,FDA-2017-P-6028,"citizen petition from axinn, veltrop & harkrider llp",0,0
0900006483a171ff,Other,FDA-2019-P-0412-0001,FDA-2019-P-0412,citizen petition from summit pharmaceuticals inc,0,0
0900006483a1750e,Supporting & Related Material,FDA-2019-P-0412-0004,FDA-2019-P-0412,appendix 2 re citizen petition from summit pharmaceuticals inc,0,0
0900006483a17201,Other,FDA-2019-P-0412-0002,FDA-2019-P-0412,acknowledgment letter from fda ddm to summit pharmaceuticals inc,0,0
0900006483a1750f,Supporting & Related Material,FDA-2019-P-0412-0005,FDA-2019-P-0412,appendix 3 re citizen petition from summit pharmaceuticals inc,0,0
0900006483a1750d,Supporting & Related Material,FDA-2019-P-0412-0003,FDA-2019-P-0412,appendix 1 re citizen petition from summit pharmaceuticals inc,0,0
09000064837c7d23,Other,FDA-2018-P-3883-0002,FDA-2018-P-3883,acknowledgment letter from fda ddm to foley & lardner llp,0,0
0900006483b65cc4,Other,FDA-2018-P-3883-0005,FDA-2018-P-3883,letter from fda cder to foley & lardner llp,0,0
09000064837c7d20,Other,FDA-2018-P-3883-0001,FDA-2018-P-3883,citizen petition from foley & lardner llp,0,0
0900006483b631ae,Notice,FDA-2018-P-3883-0004,FDA-2018-P-3883,"determination that cortisporin (hydrocortisone/neomycin sulfate/ polymyxin b sulfate) otic solution, 10 milligrams/milliliter hydrocortisone, 3.5 milligrams base/milliliter neomycin sulfate, 10,000 units/milliliter polymyxin b sulfate, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006484954a7a,Other,FDA-2020-P-2004-0003,FDA-2020-P-2004,"withdrawal from lachman consulting services, inc",0,0
0900006484873703,Other,FDA-2020-P-2004-0002,FDA-2020-P-2004,"acknowledgment letter from fda dms to lachman consulting services, inc",0,0
0900006484873702,Other,FDA-2020-P-2004-0001,FDA-2020-P-2004,"citizen petition from lachman consulting services, inc",0,0
0900006481b6dc41,Other,FDA-2015-P-2374-0001,FDA-2015-P-2374,citizen petition from hyman phelps and mcnamara pc,0,0
0900006481b6d75d,Supporting & Related Material,FDA-2015-P-2374-0004,FDA-2015-P-2374,attachment 3 proposed prescribing information for abiraterone acetate tablets re citizen petition from hyman phelps and mcnamara pc,0,0
090000648481b175,Other,FDA-2015-P-2374-0005,FDA-2015-P-2374,withdrawal from hyman phelps and mcnamara pc,0,0
0900006481b6dc44,Other,FDA-2015-P-2374-0002,FDA-2015-P-2374,acknowledgement letter from fda ddm to hyman phelps and mcnamara pc,0,0
0900006481b6d75b,Supporting & Related Material,FDA-2015-P-2374-0003,FDA-2015-P-2374,attachment 1 orange book listing for zytiga tablets re citizen petition from hyman phelps and mcnamara pc,0,0
09000064814a61ed,Notice,FDA-2013-N-0579-0002,FDA-2013-N-0579,"agency information collection activities; submission for office of management and budget review; comment request; biological products: reporting of biological product deviations and human cells, tissues, and cellular and tissue-based product deviations in manufacturing; forms fda 3486 and 3486a",0,0
09000064823935bf,Notice,FDA-2013-N-0579-0005,FDA-2013-N-0579,"agency information collection activities; submission for office of management and budget review; comment request; biological products: reporting of biological product deviations and human cells, tissues, and cellular and tissue-based deviations in manufacturing",0,0
090000648130b88c,Notice,FDA-2013-N-0579-0001,FDA-2013-N-0579,"agency information collection activities; proposed collection; comment request; biological products: reporting of biological product deviations and human cells, tissues, and cellular and tissue-based product deviations in manufacturing; forms fda 3486 and 3486a",0,0
0900006482018b27,Notice,FDA-2013-N-0579-0003,FDA-2013-N-0579,"agency information collection activities; proposed collection; comment request; biological products: reporting of biological product deviations and human cells, tissues, and cellular and tissue-based deviations in manufacturing; forms fda 3486 and 3486a",0,0
090000648424ffef,Notice,FDA-2013-N-0579-0009,FDA-2013-N-0579,"agency information collection activities; submission for office of
management and budget review; comment request; biological
products: reporting of biological product deviations and human cells,
tissues, and cellular and tissue-based deviations in manufacturing",0,0
0900006482611b62,Notice,FDA-2013-N-0579-0006,FDA-2013-N-0579,"agency information collection activities; announcement of office of
management and budget approvals",0,0
090000648444cc69,Notice,FDA-2013-N-0579-0010,FDA-2013-N-0579,"agency information collection activities; announcement of office of
management and budget approvals",0,0
0900006483dd472a,Notice,FDA-2013-N-0579-0007,FDA-2013-N-0579,"agency information collection activities; proposed collection;
comment request; biological products: reporting of biological
product deviations and human cells, tissues, and cellular and tissuebased deviations in manufacturing",0,0
0900006484467b1b,Other,FDA-2020-P-1205-0001,FDA-2020-P-1205,"petition for stay of action from steptoe & johnson llp on behalf of alec bradley cigar distributors, inc., et al.",0,0
0900006484467b1f,Supporting & Related Material,FDA-2020-P-1205-0003,FDA-2020-P-1205,"exhibits part i re steptoe & johnson llp on behalf of alec bradley cigar distributors, inc., et al.",0,0
0900006484467c52,Other,FDA-2020-P-1205-0002,FDA-2020-P-1205,"acknowledgment letter from fda  dms to steptoe & johnson llp on behalf of alec bradley cigar distributors, inc., et al.",0,0
0900006484467b20,Supporting & Related Material,FDA-2020-P-1205-0004,FDA-2020-P-1205,"exhibits part ii re steptoe & johnson llp on behalf of alec bradley cigar distributors, inc., et al.",0,0
0900006483fcf373,Supporting & Related Material,FDA-2019-P-4515-0003,FDA-2019-P-4515,attachment 1 - propranolol hydrochloride tablets re citizen petition from foley & lardner llp,0,0
0900006483fcf371,Other,FDA-2019-P-4515-0002,FDA-2019-P-4515,acknowledgment letter from fda dms to foley & lardner llp,0,0
090000648445739d,Other,FDA-2019-P-4515-0004,FDA-2019-P-4515,interim response from foley & lardner llp to fda cder,0,0
0900006483fcf2d6,Other,FDA-2019-P-4515-0001,FDA-2019-P-4515,citizen petition from foley & lardner llp,0,0
09000064848603f8,Other,FDA-2019-P-4515-0005,FDA-2019-P-4515,letter from fda cder to foley & lardner llp,0,0
09000064824b7709,Other,FDA-2016-P-2497-0005,FDA-2016-P-2497,interim response letter from cdrh to clinical decision support coalition,0,0
09000064821826cf,Other,FDA-2016-P-2497-0001,FDA-2016-P-2497,citizen petition from clinical decision support coalition,0,0
09000064821826d3,Supporting & Related Material,FDA-2016-P-2497-0003,FDA-2016-P-2497,"appendix a case studies involving software that
guides the use of pharmaceuticals re citizen petition from clinical decision support coalition",0,0
09000064821826d1,Other,FDA-2016-P-2497-0002,FDA-2016-P-2497,acknowledgement letter from fda ddm to clinical decision support coalition,0,0
09000064821826d4,Supporting & Related Material,FDA-2016-P-2497-0004,FDA-2016-P-2497,reference documents citizen petition reference documents re citizen petition from clinical decision support coalition,0,0
0900006484057604,Notice,FDA-2018-N-3728-0004,FDA-2018-N-3728,agency information collection activities; submission for office of management and budget review; comment request; collection of conflict of interest information for participation in food and drug administration non-employee fellowship and traineeship programs,1,0
09000064849e8b26,Notice,FDA-2018-N-3728-0008,FDA-2018-N-3728,"agency information collection
activities; proposed collection;
comment request; collection of
information for participation in the
food and drug administration non-
employee fellowship and traineeship
programs",1,0
090000648444cc6e,Notice,FDA-2018-N-3728-0007,FDA-2018-N-3728,"agency information collection activities; announcement of office of
management and budget approvals",0,0
0900006484197fee,Notice,FDA-2018-N-3728-0005,FDA-2018-N-3728,agency information collection activities; proposed collection; comment request; collection of information for participation in the food and drug administration non- employee fellowship and traineeship programs,1,0
0900006483837c42,Notice,FDA-2018-N-3728-0001,FDA-2018-N-3728,agency information collection activities; proposed collection; comment request; collection of conflict of interest information for participation in food and drug administration non-employee fellowship and  traineeship programs,1,0
0900006484bd64dd,Other,FDA-2021-P-0674-0001,FDA-2021-P-0674,"suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484bd6f2c,Supporting & Related Material,FDA-2021-P-0674-0003,FDA-2021-P-0674,"attachment 1 prescription drug product list (topiramate capsules anda sp)  re: citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484bd6fb6,Supporting & Related Material,FDA-2021-P-0674-0004,FDA-2021-P-0674,"attachment 2 (topiramate capsules anda sp) topamax- topiramate tablet, coated re: citizen petition hyman, phelps & mcnamara, p.c.",0,0
0900006484bd6fbb,Supporting & Related Material,FDA-2021-P-0674-0005,FDA-2021-P-0674,"attachment 3 highlights of prescribing information (topiramate capsules anda sp) (1) re: citizen petition hyman, phelps & mcnamara, p.c.",0,0
0900006484bd6d31,Other,FDA-2021-P-0674-0002,FDA-2021-P-0674,"acknowledgement letter fda dms to hyman, phelps & mcnamara, p.c.",0,0
0900006480472e86,Supporting & Related Material,FDA-2004-D-0305-0003,FDA-2004-D-0305,guidance,0,0
0900006480472e82,Supporting & Related Material,FDA-2004-D-0305-0002,FDA-2004-D-0305,guidance,0,0
0900006480472e80,Notice,FDA-2004-D-0305-0001,FDA-2004-D-0305,fda,0,0
090000648042a71d,Other,FDA-2007-P-0183-0004,FDA-2007-P-0183,"purdue pharma l.p., & rhodes technologies - letter",0,0
090000648042a71c,Other,FDA-2007-P-0183-0003,FDA-2007-P-0183,"acknowledgement letter to purdue pharma l.p., & rhodes technologies",0,0
090000648043f8b5,Other,FDA-2007-P-0183-0005,FDA-2007-P-0183,"fda letter to purdue pharma l.p. & rhodes technologies, inc. - petition denial",0,0
090000648050c969,Other,FDA-2007-P-0183-0006,FDA-2007-P-0183,petition for reconsideration - philip c. strassburger,0,0
090000648050c9e2,Other,FDA-2007-P-0183-0007,FDA-2007-P-0183,acknowledgement letter - purdue pharma l.p.,0,0
090000648042a712,Other,FDA-2007-P-0183-0001,FDA-2007-P-0183,"acknowledgement letter to purdue pharma l.p., & rhodes technologies",0,0
090000648042a71a,Other,FDA-2007-P-0183-0002,FDA-2007-P-0183,purdue pharma l.p. and rhodes technologies - petition for stay,0,0
090000648045d30a,Other,FDA-2006-P-0334-0005,FDA-2006-P-0334,center for science in the public interest - citizen petition,0,0
090000648045d301,Supporting & Related Material,FDA-2006-P-0334-0006,FDA-2006-P-0334,center for science in the public interest - appendix ii - comparison of nutritional criteria for several food labeling systems,1,0
090000648045d2e9,Other,FDA-2006-P-0334-0001,FDA-2006-P-0334,fda/ddm to center for science in the public interest,0,0
090000648045d30d,Other,FDA-2006-P-0334-0002,FDA-2006-P-0334,fda/ddm to center for science in the public interest,0,0
090000648045d310,Other,FDA-2006-P-0334-0004,FDA-2006-P-0334,fda/ddm to center for science in the public interest,0,0
090000648045d30c,Supporting & Related Material,FDA-2006-P-0334-0008,FDA-2006-P-0334,center for science in the public interest - appendix i - a list of individuals that have asked that they be listed as supporters of this petition,0,0
090000648045d308,Supporting & Related Material,FDA-2006-P-0334-0007,FDA-2006-P-0334,center for science in the public interest - appendix iii - pdp symbols used by private label programs,0,0
090000648045d30f,Other,FDA-2006-P-0334-0003,FDA-2006-P-0334,fda/ddm to center for science in the public interest,0,0
0900006480b24efc,Other,FDA-2010-P-0377-0003,FDA-2010-P-0377,acknowledgement letter to the great lakes environmental law center and the natural resources defense council,0,0
09000064810ce837,Other,FDA-2010-P-0377-0009,FDA-2010-P-0377,the great lakes environmental law center and the natural resources defense council - letter,0,0
0900006480b17b18,Supporting & Related Material,FDA-2010-P-0377-0002,FDA-2010-P-0377,see fda-2010-p-0377-0003,0,0
090000648120992e,Other,FDA-2010-P-0377-0010,FDA-2010-P-0377,fda/cder to great lakes environmental law center and the natural resources defense council - petition denial,0,0
0900006480b179bf,Other,FDA-2010-P-0377-0001,FDA-2010-P-0377,great lakes environmental law center and the natural resources defense council - citizen petition,0,0
0900006480ee122d,Other,FDA-2010-P-0377-0008,FDA-2010-P-0377,interim response to great lakes environmental law center and the natural resources defense council - letter,0,0
0900006480bca90e,Other,FDA-2010-P-0377-0005,FDA-2010-P-0377,interim response to great lakes environmental law center and the natural resources defense council,0,0
0900006484dbcae0,Supporting & Related Material,FDA-2021-P-1081-0003,FDA-2021-P-1081,"attachment 1 orange book: approved drug products with therapeutic equivalence evaluations re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484dbcae1,Supporting & Related Material,FDA-2021-P-1081-0005,FDA-2021-P-1081,"attachment 3 therapeutic monitoring of vancomycin for serious
methicillin-
resistant staphylococcus aureus infections:
a revised consensus guideline and review by the american
society of health-system pharmacists, the infectious diseases society of america, the pediatric infectious diseases society, and the society of infectious diseases  re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484dbcad1,Supporting & Related Material,FDA-2021-P-1081-0004,FDA-2021-P-1081,"attachment 2 highlights of prescribing information re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484dbcacd,Other,FDA-2021-P-1081-0001,FDA-2021-P-1081,"suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484dbcad2,Supporting & Related Material,FDA-2021-P-1081-0006,FDA-2021-P-1081,"attachment 4 proposed labeling re suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484dbcade,Other,FDA-2021-P-1081-0002,FDA-2021-P-1081,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
09000064831b8f38,Other,FDA-2018-P-0033-0003,FDA-2018-P-0033,"petition response letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
0900006482d926bc,Other,FDA-2018-P-0033-0001,FDA-2018-P-0033,"citizen petition from hyman, phelps & mcnamara",0,0
0900006482d9270c,Other,FDA-2018-P-0033-0002,FDA-2018-P-0033,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara",0,0
09000064812e2f3a,Notice,FDA-2011-D-0057-0020,FDA-2011-D-0057,guidance for industry and food and drug administration staff on best practices for conducting and reporting pharmacoepidemiologic safety studies using electronic healthcare data; availability,1,0
09000064812e3665,Other,FDA-2011-D-0057-0021,FDA-2011-D-0057,guidance for industry and fda staff ;  best practices for conducting and reporting pharmacoepidemiologic safety studies using electronic healthcare data,0,0
0900006480bf039b,Notice,FDA-2011-D-0057-0001,FDA-2011-D-0057,draft guidance for industry and food and drug administration staff; availability: best practices for conducting and reporting pharmacoepidemiologic safety studies using electronic healthcare data sets,1,0
0900006480bf0733,Other,FDA-2011-D-0057-0002,FDA-2011-D-0057,best practices for conducting and reporting pharmacoepidemiologic safety studies using electronic healthcare data sets - draft guidance,0,0
0900006482956e20,Other,FDA-2017-P-4388-0002,FDA-2017-P-4388,"acknowledgment letter from fda ddm to abhai, llc.",0,0
0900006482956e24,Supporting & Related Material,FDA-2017-P-4388-0004,FDA-2017-P-4388,"attachment 2 butalbital, acetaminophen and caffeine- butalbital, acetaminophen, and caffeine tablet par pharmaceutical re suitability petition from abhai, llc",0,0
09000064829567e2,Other,FDA-2017-P-4388-0001,FDA-2017-P-4388,"suitability petition from abhai, llc",0,0
0900006482956e22,Supporting & Related Material,FDA-2017-P-4388-0003,FDA-2017-P-4388,"attachment 1 orange book; approved drug products with therapeutic equivalence evaluations product details for anda 040511 re suitability petition from abhai, llc",0,0
09000064819d21bf,Supporting & Related Material,FDA-2015-P-0181-0004,FDA-2015-P-0181,"exhibits7-17 citizen petition from mylan specialty, l.p.",0,0
0900006481af4ddb,Other,FDA-2015-P-0181-0008,FDA-2015-P-0181,supplement from mylan specialty,0,0
09000064819d21c0,Supporting & Related Material,FDA-2015-P-0181-0005,FDA-2015-P-0181,"exhibits18-22 citizen petition from mylan specialty, l.p.",0,0
0900006481b373c3,Other,FDA-2015-P-0181-0009,FDA-2015-P-0181,citizen petition denial response from fda cder to mylan speciality l.p.,0,0
0900006481ac0beb,Other,FDA-2015-P-0181-0007,FDA-2015-P-0181,"supplement from mylan specialty, lp",0,0
09000064819d21c1,Supporting & Related Material,FDA-2015-P-0181-0006,FDA-2015-P-0181,"exhibits 23-28 citizen petition from mylan specialty, l.p.",0,0
09000064819d1d72,Supporting & Related Material,FDA-2015-P-0181-0003,FDA-2015-P-0181,"exhibits1-6 citizen petition from mylan specialty, l.p.",0,0
09000064819d1d70,Other,FDA-2015-P-0181-0001,FDA-2015-P-0181,"citizen petition from mylan specialty, l.p.",0,0
09000064819d21c2,Other,FDA-2015-P-0181-0002,FDA-2015-P-0181,"acknowledgement letter from fda ddm to mylan specialty, l.p.",0,0
0900006481bb2ded,Supporting & Related Material,FDA-2015-P-2482-0008,FDA-2015-P-2482,"attachment 5 house of representatives 105th congress 1st session report 105-310 re: comment from alkermes, inc.",0,0
0900006481c2b7c2,Other,FDA-2015-P-2482-0013,FDA-2015-P-2482,supplement from otsuka (venable llp),0,0
0900006481cb1cf5,Other,FDA-2015-P-2482-0015,FDA-2015-P-2482,"citizen petition denial response from fda/cder to otsuka pharmaceutical development and commercialization, inc.",0,0
0900006481bb2dee,Supporting & Related Material,FDA-2015-P-2482-0009,FDA-2015-P-2482,"attachment 6 clinical review and evaluation nda 20-450 cerebyx (fosphenytoin) re: comment from alkermes, inc.",0,0
0900006481bb2deb,Supporting & Related Material,FDA-2015-P-2482-0007,FDA-2015-P-2482,"attachment 3 congressional record house re: comment from alkermes, inc.",0,0
0900006481bc610b,Other,FDA-2015-P-2482-0011,FDA-2015-P-2482,supplement from venable llc,0,0
0900006481b83c26,Other,FDA-2015-P-2482-0002,FDA-2015-P-2482,"acknowledgement letter from fda ddm to otsuka pharmaceutical development and commercialization, inc.",0,0
0900006481b83c22,Other,FDA-2015-P-2482-0001,FDA-2015-P-2482,"citizen petition from otsuka pharmaceutical development and commercialization, inc.",0,0
0900006481baf4b5,Supporting & Related Material,FDA-2015-P-2482-0004,FDA-2015-P-2482,supplement from otsuka (venable llp),0,0
0900006481bb2de7,Supporting & Related Material,FDA-2015-P-2482-0005,FDA-2015-P-2482,"attachment 1 us district court veloxis pharmaceuticals vs fda re: comment from alkermes, inc.",0,0
0900006481bb2dea,Supporting & Related Material,FDA-2015-P-2482-0006,FDA-2015-P-2482,"attachment 2 us district court otsuka pharmaceutical co ltd vs sylvia mathews burwell et al re: comment from alkermes, inc.",0,0
0900006481c30e91,Supporting & Related Material,FDA-2015-P-2482-0014,FDA-2015-P-2482,supplement from otsuka (venable llp),0,0
0900006481f114c5,Other,FDA-2016-P-1104-0001,FDA-2016-P-1104,citizen petition from gordon johnston regulatory consultants llc,0,0
090000648235b4c5,Other,FDA-2016-P-1104-0004,FDA-2016-P-1104,letter from cder fda to gordon johnston regulatory consultants llc,0,0
0900006481f14768,Other,FDA-2016-P-1104-0002,FDA-2016-P-1104,acknowledgement letter from fda ddm to gordon johnston regulatory consultants llc,0,0
0900006481f1169b,Supporting & Related Material,FDA-2016-P-1104-0003,FDA-2016-P-1104,attachment a  product listing from the active section of the orange book - re citizen petition from gordon johnston regulatory consultants llc,0,0
09000064827ba615,Other,FDA-2017-P-2164-0005,FDA-2017-P-2164,interim response letter to steptoe & johnson llp dtd 6-29-2017,0,0
09000064825439d7,Supporting & Related Material,FDA-2017-P-2164-0003,FDA-2017-P-2164,"attachment 1 re citizen petition from steptoe & johnson, llp",0,0
09000064825435df,Other,FDA-2017-P-2164-0002,FDA-2017-P-2164,"acknowledgment letter from fda ddm to steptoe & johnson, llp",0,0
09000064825400ca,Other,FDA-2017-P-2164-0001,FDA-2017-P-2164,"citizen petition from steptoe & johnson, llp (national association of convenience stores)",0,0
090000648257f8fa,Other,FDA-2017-P-2660-0001,FDA-2017-P-2660,citizen petition from jubilant generics,0,0
0900006482c1673f,Other,FDA-2017-P-2660-0006,FDA-2017-P-2660,final response from fda cder to jubilant generics,0,0
090000648257fce8,Other,FDA-2017-P-2660-0002,FDA-2017-P-2660,acknowledgment letter from fda ddm to jubilant generics,0,0
0900006482c11632,Notice,FDA-2017-P-2660-0005,FDA-2017-P-2660,"determination that cardene sr (nicardipine hcl) extended-release
capsules, 30 milligrams, 45 milligrams, and 60 milligrams, were not
withdrawn from sale for reasons of safety or effectiveness",0,0
0900006482bf99e5,Other,FDA-2017-P-2660-0004,FDA-2017-P-2660,interim response from fda cder to jubilant generics,0,0
090000648257fcea,Supporting & Related Material,FDA-2017-P-2660-0003,FDA-2017-P-2660,"attachment 1 - orange book: approved drug products with therapeutic
equivalence evaluations re citizen petition from jubilant generics",0,0
09000064817b2bdd,Other,FDA-2014-P-0984-0002,FDA-2014-P-0984,acknowledgement letter to lachman consultant services inc,0,0
09000064817b2bdb,Other,FDA-2014-P-0984-0001,FDA-2014-P-0984,citizen petition from lachman consultant services inc.,0,0
090000648411605a,Other,FDA-2019-P-2982-0004,FDA-2019-P-2982,agency response letter from fda cder to hetero labs limited,0,0
0900006483d2a74e,Other,FDA-2019-P-2982-0002,FDA-2019-P-2982,acknowledgment letter from fda ddm to hetero labs limited,0,0
0900006484113e5f,Notice,FDA-2019-P-2982-0003,FDA-2019-P-2982,"determination that mexitil (mexiletine hydrochloride) capsules, 150 milligrams, 200 milligrams, and 250 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483d2a557,Other,FDA-2019-P-2982-0001,FDA-2019-P-2982,citizen petition from hetero labs limited,0,0
0900006482d3ce66,Other,FDA-2017-P-6922-0002,FDA-2017-P-6922,"acknowledgment letter from fda ddm to haynes and boone, llp",0,0
0900006482d3ce64,Other,FDA-2017-P-6922-0001,FDA-2017-P-6922,"citizen petition from haynes and boone, llp",0,0
0900006482d3ced7,Supporting & Related Material,FDA-2017-P-6922-0006,FDA-2017-P-6922,"exhibit c - lionberger 2008 re citizen petition from haynes and boone, llp",0,0
0900006482d3ced5,Supporting & Related Material,FDA-2017-P-6922-0008,FDA-2017-P-6922,"exhibit a - ssp be guidance_july 2014 re citizen petition from haynes and boone, llp",0,0
090000648327dbcc,Other,FDA-2017-P-6922-0009,FDA-2017-P-6922,petition denial letter from fda cder,0,0
0900006482d3ced8,Supporting & Related Material,FDA-2017-P-6922-0005,FDA-2017-P-6922,"exhibit d - fda draft guidance nasal aerosols and nasal sprays (2003) re citizen petition from haynes and boone, llp",0,0
0900006482d3ced6,Supporting & Related Material,FDA-2017-P-6922-0007,FDA-2017-P-6922,"exhibit b - sucralfate oral suspension guidance october 2017 re citizen petition from haynes and boone, llp",0,0
0900006482d3ced9,Supporting & Related Material,FDA-2017-P-6922-0004,FDA-2017-P-6922,"exhibit e - tabibian 1989 re citizen petition from haynes and boone, llp",0,0
0900006482d3ceda,Supporting & Related Material,FDA-2017-P-6922-0003,FDA-2017-P-6922,"exhibit f - lam 1985 re citizen petition from haynes and boone, llp",0,0
0900006482d738a2,Other,FDA-2017-P-4249-0006,FDA-2017-P-4249,withdrawal from ge healthcare inc,0,0
0900006482923ca8,Supporting & Related Material,FDA-2017-P-4249-0002,FDA-2017-P-4249,attachment 1 orange book product listing dotarem re suitability petition from ge healthcare inc,0,0
0900006482924167,Supporting & Related Material,FDA-2017-P-4249-0004,FDA-2017-P-4249,attachment 2 dotarem approved label re suitability petition from ge healthcare inc,0,0
0900006482923ca3,Other,FDA-2017-P-4249-0001,FDA-2017-P-4249,suitability petition from ge healthcare inc,0,0
0900006482923ca6,Other,FDA-2017-P-4249-0003,FDA-2017-P-4249,acknowledgement letter from fda ddm to ge healthcare inc,0,0
0900006482924168,Supporting & Related Material,FDA-2017-P-4249-0005,FDA-2017-P-4249,attachment 3 draft labeling for the proposed 5ml product re suitability petition from ge healthcare inc,0,0
09000064847d20b8,Other,FDA-2020-P-1730-0002,FDA-2020-P-1730,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, pc",0,0
09000064847d20b7,Other,FDA-2020-P-1730-0001,FDA-2020-P-1730,"suitability petition from hyman, phelps & mcnamara, pc",0,0
09000064847d2994,Supporting & Related Material,FDA-2020-P-1730-0003,FDA-2020-P-1730,"attachment 1 re suitability petition from hyman, phelps & mcnamara, pc",0,0
09000064847d2995,Supporting & Related Material,FDA-2020-P-1730-0004,FDA-2020-P-1730,"attachment 2 re suitability petition from hyman, phelps & mcnamara, pc",0,0
09000064847d2996,Supporting & Related Material,FDA-2020-P-1730-0005,FDA-2020-P-1730,"attachment 3 re suitability petition from hyman, phelps & mcnamara, pc",0,0
0900006484879770,Other,FDA-2019-P-5394-0003,FDA-2019-P-5394,interim response letter from fda cfsan to consumer healthcare products association,0,0
090000648415675b,Other,FDA-2019-P-5394-0001,FDA-2019-P-5394,citizen petition from consumer healthcare products association,0,0
0900006484156ac4,Other,FDA-2019-P-5394-0002,FDA-2019-P-5394,acknowledgment letter from fda dms to consumer healthcare products association,0,0
0900006484949819,Supporting & Related Material,FDA-2020-P-2144-0003,FDA-2020-P-2144,attachment 1 ema/274695/2017; committee for medicinal products for human use (chmp) assessment report on extension of marketing authorisation: brilique (ticagrelor) re citizen petition from robert van osdel,0,0
09000064849431a5,Other,FDA-2020-P-2144-0002,FDA-2020-P-2144,acknowledgment letter from fda dms to robert van osdel,0,0
090000648494981a,Supporting & Related Material,FDA-2020-P-2144-0004,FDA-2020-P-2144,"attachment 2 approved labeling for the rld, brilinta® re citizen petition from robert van osdel",0,0
09000064849431a4,Other,FDA-2020-P-2144-0001,FDA-2020-P-2144,citizen petition from robert van osdel,0,0
090000648494981b,Supporting & Related Material,FDA-2020-P-2144-0005,FDA-2020-P-2144,"attachment 3 draft labeling for the proposed product, ticagrelor orally disintegrating tablet 90 mg re citizen petition from robert van osdel",0,0
0900006484959bb5,Other,FDA-2020-P-2180-0005,FDA-2020-P-2180,citizen petition for stay of action regarding efficacy end points of the phase iii clinical trials of covid-19  vaccines from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484973f39,Supporting & Related Material,FDA-2020-P-2180-0069,FDA-2020-P-2180,all cited materials - footnotes 2 through 29 - re citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
090000648495716c,Supporting & Related Material,FDA-2020-P-2180-0004,FDA-2020-P-2180,all cited materials - footnotes 2 through 29 - re citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484959da5,Supporting & Related Material,FDA-2020-P-2180-0007,FDA-2020-P-2180,all - part 2 footnote 21 through 33 re citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484957166,Supporting & Related Material,FDA-2020-P-2180-0003,FDA-2020-P-2180,cover letter from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484957167,Other,FDA-2020-P-2180-0001,FDA-2020-P-2180,citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484959da0,Supporting & Related Material,FDA-2020-P-2180-0006,FDA-2020-P-2180,all - part 1 footnote 2  through 19 re citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484957168,Other,FDA-2020-P-2180-0002,FDA-2020-P-2180,acknowledgment letter from fda dms to siri & glimstad llp on behalf of informed consent action network,0,0
090000648499c70d,Other,FDA-2020-P-2180-0070,FDA-2020-P-2180,denial letter from fda cber to siri & glimstad llp,0,0
0900006481a6907d,Other,FDA-2015-P-0569-0005,FDA-2015-P-0569,"trade complaint referral, actions against bayer healthcare and essure product",0,0
0900006481a1158e,Other,FDA-2015-P-0569-0001,FDA-2015-P-0569,"citizen petition from koch parafinczuk and wolf, p.a.",0,0
0900006481a11864,Other,FDA-2015-P-0569-0002,FDA-2015-P-0569,"acknowledgement letter from fda ddm to koch parafinczuk & wolf, p.a.",0,0
0900006481a11590,Supporting & Related Material,FDA-2015-P-0569-0003,FDA-2015-P-0569,"exhibits a to f citizen petition from koch parafinczuk and wolf, p.a.",0,0
0900006483bec695,Other,FDA-2019-P-1980-0002,FDA-2019-P-1980,acknowledgment letter from fda ddm to novitium pharma llc,0,0
09000064840c0615,Other,FDA-2019-P-1980-0006,FDA-2019-P-1980,interim response letter from fda cder to novitium pharma llc,0,0
0900006483bebb13,Supporting & Related Material,FDA-2019-P-1980-0003,FDA-2019-P-1980,attachment 1 orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from novitium pharma llc,0,0
0900006483bebb14,Supporting & Related Material,FDA-2019-P-1980-0004,FDA-2019-P-1980,attachment 2 regulatory agent appointment letter from gemini lab llc to fda re citizen petition from novitium pharma llc,0,0
0900006484a81f95,Other,FDA-2019-P-1980-0007,FDA-2019-P-1980,withdrawal from novitium pharma llc,0,0
0900006483bebb15,Supporting & Related Material,FDA-2019-P-1980-0005,FDA-2019-P-1980,attachment 3 letters from fda cder to novitium pharma llc re citizen petition from novitium pharma llc,0,0
0900006483beba19,Other,FDA-2019-P-1980-0001,FDA-2019-P-1980,citizen petition from novitium pharma llc,0,0
0900006484aeb18e,Other,FDA-2021-P-0445-0002,FDA-2021-P-0445,acknowledgment letter from fda dms to janice s. lintz,0,0
0900006484aeb18c,Other,FDA-2021-P-0445-0001,FDA-2021-P-0445,citizen petition from janice s. lintz,0,0
09000064806fe2ad,Other,FDA-2007-A-0100-0005,FDA-2007-A-0100,"wiley rein, llp - withdrawal of advisory opinion request",0,0
0900006480429d87,Other,FDA-2007-A-0100-0003,FDA-2007-A-0100,"fda response to wiley rein, llp - letter",0,0
0900006480429d85,Other,FDA-2007-A-0100-0002,FDA-2007-A-0100,"fda acknowledgement letter to wiley rein, llp",0,0
0900006480429d82,Other,FDA-2007-A-0100-0001,FDA-2007-A-0100,fda/ddm to wileyrein llp,0,0
0900006480429d84,Other,FDA-2007-A-0100-0004,FDA-2007-A-0100,"wiley rein, llp - advisory opinion petition",0,0
090000648043f49b,Supporting & Related Material,FDA-2005-D-0087-0003,FDA-2005-D-0087,guidance,0,0
090000648043f499,Notice,FDA-2005-D-0087-0001,FDA-2005-D-0087,fda,0,0
090000648043f49a,Supporting & Related Material,FDA-2005-D-0087-0002,FDA-2005-D-0087,guidance,0,0
0900006484e29c47,Other,FDA-2021-P-0893-0071,FDA-2021-P-0893,supplement from sidley austin llp part 3 of 4,0,0
0900006484e28d9b,Other,FDA-2021-P-0893-0070,FDA-2021-P-0893,supplement from sidley austin llp part 2 of 4,0,0
0900006484c48b9f,Supporting & Related Material,FDA-2021-P-0893-0027,FDA-2021-P-0893,"tab 24 - drugs; official names, new names, 34 fed. reg. 6043 (apr. 3, 1969) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c48cba,Supporting & Related Material,FDA-2021-P-0893-0008,FDA-2021-P-0893,"tab 5 - mary s. leffell et al., red blood cell transfusions and the risk allosensitization in patients awaiting primary kidney transplantation, 97 transplantation 525 (2014) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c48cbd,Supporting & Related Material,FDA-2021-P-0893-0011,FDA-2021-P-0893,"tab 8 - anne tompkins goetsch et al., observations on the effect of massive doses of iron given intravenously to patients with hypochromic anemia, 1 blood (mar. 1946) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c48cbf,Supporting & Related Material,FDA-2021-P-0893-0013,FDA-2021-P-0893,"tab 10 - elizabeth c. theil et al., similarity of the structure of ferritin and iron dextran (imferon) determined by extended x-ray absorption fine structure analysis, 254 the journal of biological chemistry 8132 (1979) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c48cc8,Supporting & Related Material,FDA-2021-P-0893-0022,FDA-2021-P-0893,"tab 19 - s. rep. no. 87-1744, at 19 (1962) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c48cc9,Supporting & Related Material,FDA-2021-P-0893-0043,FDA-2021-P-0893,"tab 40 - jamie b. vora, milliman, inc. white paper, “evaluation of medical specialty medications: utilization and management opportunities” (apr. 8, 2014) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c4b0c7,Supporting & Related Material,FDA-2021-P-0893-0061,FDA-2021-P-0893,"tab 58 - sree rayavarapu et al., comparative risk assessment of formulation changes in generic drug products: a pharmacology/toxicology perspective, 146 toxicological sciences, 2, 3 (2015) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c45860,Supporting & Related Material,FDA-2021-P-0893-0005,FDA-2021-P-0893,"tab 2 - iain c. macdougall et al., iron sucrose: a wealth of experience in treating iron deficiency, 37 adv ther 1960 (2020) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c48ba0,Supporting & Related Material,FDA-2021-P-0893-0028,FDA-2021-P-0893,"tab 25 - drugs; official names, new names, 34 fed. reg. 12178 (jul. 23, 1969) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c48cbb,Supporting & Related Material,FDA-2021-P-0893-0009,FDA-2021-P-0893,"tab 6 - emma l. o’lone et al., parenteral versus oral iron therapy for adults and children with chronic kidney disease, cochrane database of systematic reviews 2019, issue 2. art. no.: cd007857 re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c48cbe,Supporting & Related Material,FDA-2021-P-0893-0012,FDA-2021-P-0893,"tab 9 - felix funk et al., the new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose, 60 arzneimittelforschung (june 2010) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c48cc1,Supporting & Related Material,FDA-2021-P-0893-0015,FDA-2021-P-0893,"tab 12 - peter geisser & susanna burckhardt, the pharmacokinetics and pharmacodynamics of iron preparations, 3 pharmaceutics 12 (2011) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c49c29,Supporting & Related Material,FDA-2021-P-0893-0031,FDA-2021-P-0893,"tab 28 - drugs; official names, new names, 36 fed. reg. 778 (jan. 16, 1971) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c4af6f,Supporting & Related Material,FDA-2021-P-0893-0058,FDA-2021-P-0893,"tab 55 - gerald j. dal pan et al., postmarketing spontaneous pharmacovigilance systems 178, in brian l. strom et al., pharmacoepidemiology (6th ed. 2020) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c48cc0,Supporting & Related Material,FDA-2021-P-0893-0014,FDA-2021-P-0893,"tab 11 - lawrence x. yu et al., understanding pharmaceutical quality by design, 16 aaps journal 771 (2014) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c49c2c,Supporting & Related Material,FDA-2021-P-0893-0034,FDA-2021-P-0893,"tab 31 - usan, procedure for usan name selection re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c49d75,Supporting & Related Material,FDA-2021-P-0893-0053,FDA-2021-P-0893,"tab 50 - virginie korb-savoldellia, prevalence of computerized physician order entry systems–related medication prescription errors: a systematic review, 111 international journal of medical informatics 112 (2018) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c49d80,Supporting & Related Material,FDA-2021-P-0893-0054,FDA-2021-P-0893,"tab 51 - ka-chun cheung et al., medication errors: the importance of safe dispensing, 67 british journal of clinical pharmacology 676 (2009) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c48a9f,Other,FDA-2021-P-0893-0002,FDA-2021-P-0893,acknowledgment letter from fda dms to sidley austin llp on behalf of  vifor (international) inc switzerland,0,0
0900006484e29c71,Other,FDA-2021-P-0893-0072,FDA-2021-P-0893,supplement from sidley austin llp part 4 of 4,0,0
0900006484c45861,Supporting & Related Material,FDA-2021-P-0893-0006,FDA-2021-P-0893,"tab 3 - angelo karaboyas et al., low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period, 13 clinical kidney journal 425 (2019) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c48cca,Supporting & Related Material,FDA-2021-P-0893-0044,FDA-2021-P-0893,"tab 41 - robert nease et al., “express scripts specialty benefit services: specialty drug trend report” (june 2011) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
0900006484c49c2e,Supporting & Related Material,FDA-2021-P-0893-0036,FDA-2021-P-0893,"tab 33 - the united states pharmacopeia, twentieth revision and the national formulary, fifteenth edition at 421 (official from jul. 1, 1980) re citizen petition from sidley austin llp on behalf of  vifor (international) inc switzerland",0,0
09000064841f726a,Supporting & Related Material,FDA-2019-P-5791-0003,FDA-2019-P-5791,"attachment 1- approved drug products with therapeutic equivalence evaluation, accessed november 22, 2019 (orange book) re citizen petition from guvam pharma llc",0,0
09000064841f726b,Supporting & Related Material,FDA-2019-P-5791-0004,FDA-2019-P-5791,attachment 2- federal register notice that azo gantanol and azo gantrisin were not withdrawn from sale for reason of safety or effectiveness re citizen petition from guvam pharma llc,0,0
09000064841f726c,Supporting & Related Material,FDA-2019-P-5791-0005,FDA-2019-P-5791,attachment 3- nda 21-105 labeling re citizen petition from guvam pharma llc,0,0
09000064841f7115,Other,FDA-2019-P-5791-0001,FDA-2019-P-5791,"citizen petition from guvam pharma, llc",0,0
09000064841f75fa,Other,FDA-2019-P-5791-0002,FDA-2019-P-5791,acknowledgment letter from fda dms to guvam pharma llc,0,0
09000064841f726d,Supporting & Related Material,FDA-2019-P-5791-0006,FDA-2019-P-5791,"attachment 4- draft package insert labeling for phenazopyridire hydrochloride tablets, 50mg, 100mg and 200mg re citizen petition from guvam pharma llc",0,0
09000064832daa54,Other,FDA-2017-P-6692-0040,FDA-2017-P-6692,interim response from fda cder to drug watch int.,0,0
0900006482cca918,Other,FDA-2017-P-6692-0002,FDA-2017-P-6692,"acknowledgment letter from fda ddm to drug watch international, inc.",0,0
0900006482cca916,Other,FDA-2017-P-6692-0001,FDA-2017-P-6692,"citizen petition from drug watch international, inc.",0,0
0900006483d9e026,Other,FDA-2017-P-6692-0102,FDA-2017-P-6692,"letter from fda cder to drug watch international, inc.",0,0
0900006483494a5a,Other,FDA-2017-P-6692-0042,FDA-2017-P-6692,"petition denial letter from fda cder to drug watch international, inc",0,0
09000064835f2499,Other,FDA-2017-P-6692-0043,FDA-2017-P-6692,"citizen petition for reconsideration from drug watch international, inc.",0,0
090000648472225d,Other,FDA-2020-P-1626-0001,FDA-2020-P-1626,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484722028,Other,FDA-2020-P-1626-0002,FDA-2020-P-1626,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, pc.",0,0
0900006484a6602b,Other,FDA-2020-P-1626-0004,FDA-2020-P-1626,"withdrawal of citizen petition from hyman, phelps & mcnamara, p.c.",0,0
09000064849999b3,Other,FDA-2020-P-1626-0003,FDA-2020-P-1626,"interim response letter from fda cder to hyman, phelps & mcnamara, pc",0,0
090000648425e1d0,Other,FDA-2019-P-6099-0001,FDA-2019-P-6099,citizen petition from george m. stone on behalf of patients for access to advanced therapy for hemophilia,0,0
09000064846d6fcc,Other,FDA-2019-P-6099-0004,FDA-2019-P-6099,interim response from fda cber to public citizen,0,0
09000064848af559,Other,FDA-2019-P-6099-0005,FDA-2019-P-6099,final response from fda cber to patients for access to advanced therapy for hemophilia (paath),0,0
090000648425e1d2,Other,FDA-2019-P-6099-0002,FDA-2019-P-6099,acknowledgment letter from fda dms to george m. stone,0,0
09000064844ad201,Other,FDA-2019-P-6099-0003,FDA-2019-P-6099,letter from george m. stone on behalf of patients for access to advanced therapy for hemophilia,0,0
0900006484c48aa3,Other,FDA-2021-P-0894-0002,FDA-2021-P-0894,acknowledgment letter from fda dms to pet schooled,0,0
0900006484c48aa1,Other,FDA-2021-P-0894-0001,FDA-2021-P-0894,citizen petition from pet schooled,0,0
0900006481f39751,Supporting & Related Material,FDA-2016-P-1115-0004,FDA-2016-P-1115,final petition index re citizen petition from mostyn law firm,0,0
0900006481f39907,Supporting & Related Material,FDA-2016-P-1115-0015,FDA-2016-P-1115,"exhibit 11 - bscm06700722854 bsc ran short of marlex in 2011, creating a fire drill inside bsc re citizen petition from mostyn law firm",0,0
0900006481f3990c,Supporting & Related Material,FDA-2016-P-1115-0020,FDA-2016-P-1115,"exhibit 16 - bscm13000000037 marlex background, update slides re citizen petition from mostyn law firm",0,0
0900006481f3990f,Supporting & Related Material,FDA-2016-P-1115-0023,FDA-2016-P-1115,exhibit 19 - bscm13800009800 bsc hid the intended purpose of the marlex because the information might scare away the chinese sellers re citizen petition from mostyn law firm,0,0
0900006481f39910,Supporting & Related Material,FDA-2016-P-1115-0024,FDA-2016-P-1115,exhibit 20 - bscm13800008924 zhao detailed visits to 5 chinese distributors of marlex found on alibaba.com re citizen petition from mostyn law firm,0,0
0900006481f39911,Supporting & Related Material,FDA-2016-P-1115-0025,FDA-2016-P-1115,exhibit 21 - “there’s no end in sight for alibaba’s counterfeit problem” published in fortune magazine at http://fortune.com/2015/05/18/theres-no-end-in-sight-for-alibabas-counterfeit-problem/. re citizen petition from mostyn law firm,0,0
0900006481f39912,Supporting & Related Material,FDA-2016-P-1115-0026,FDA-2016-P-1115,exhibit 22 - bscm13800008343 r&d executive ron ciulla stressed the need for a c of c to defendant mccaslin. defendant mccaslin acknowledged the need and asked if all would be dead without a c of c re citizen petition from mostyn law firm,0,0
0900006481f3991c,Supporting & Related Material,FDA-2016-P-1115-0035,FDA-2016-P-1115,exhibit 31- letters to doctors in response to allegations that bsc is using counterfeit resin re citizen petition from mostyn law firm,0,0
0900006481f3991f,Supporting & Related Material,FDA-2016-P-1115-0038,FDA-2016-P-1115,exhibit 34 - bscm11500006055 mechanical testing protocol re citizen petition from mostyn law firm,0,0
0900006481f39922,Supporting & Related Material,FDA-2016-P-1115-0041,FDA-2016-P-1115,exhibit 37 - bscm07300073860 the limited and flawed testing that was done revealed differences between the single pellet of the counterfeit resin and material purchased from channel prime alliance in 2005 re citizen petition from mostyn law firm,0,0
0900006481f39752,Supporting & Related Material,FDA-2016-P-1115-0005,FDA-2016-P-1115,"exhibit 1 - bscm13500000937 robert mullally asks, ""how did all this resin end up in china if it was made in texas?"" re citizen petition from mostyn law firm",0,0
0900006481f39756,Supporting & Related Material,FDA-2016-P-1115-0009,FDA-2016-P-1115,exhibit 5 - bscm07300068256 cambridge polymer group test results re citizen petition from mostyn law firm,0,0
0900006481f39905,Supporting & Related Material,FDA-2016-P-1115-0013,FDA-2016-P-1115,exhibit 9 - bscm04500000465 2004 marlex hgx-030-01 msds re citizen petition from mostyn law firm,0,0
0900006481f3990d,Supporting & Related Material,FDA-2016-P-1115-0021,FDA-2016-P-1115,"exhibit 17 - bscm11200014917 impending marlex shortage would cost bsc $120,000,000 in annual profits re citizen petition from mostyn law firm",0,0
0900006481f39916,Supporting & Related Material,FDA-2016-P-1115-0030,FDA-2016-P-1115,"exhibit 26 - bscm13500000465 bsc solved its dilemma by declaring that the chinese resin was made by dongguan sunmei plastic raw material co., ltd., a chinese company, to clear chinese customs re citizen petition from mostyn law firm",0,0
0900006481f3991a,Supporting & Related Material,FDA-2016-P-1115-0033,FDA-2016-P-1115,"exhibit 29 - bscm11500006697 the shipper of the 4,400 lbs by air was not ""over-cautious"" re citizen petition from mostyn law firm",0,0
0900006481f3991b,Supporting & Related Material,FDA-2016-P-1115-0034,FDA-2016-P-1115,"exhibit 30 - bscm11500006979 even though bsc’s chance of being audited was low, bsc played it safe and split the resin into 4 separate shipments re citizen petition from mostyn law firm",0,0
0900006481f3991d,Supporting & Related Material,FDA-2016-P-1115-0036,FDA-2016-P-1115,exhibit 32 - bscm11500005941 burrill report - equivalency testing re citizen petition from mostyn law firm,0,0
0900006481f38f9c,Other,FDA-2016-P-1115-0001,FDA-2016-P-1115,citizen petition from mostyn law firm,0,0
0900006481fdcd30,Supporting & Related Material,FDA-2016-P-1115-0047,FDA-2016-P-1115,footnote 29 bscm07700280242,0,0
09000064824541a1,Other,FDA-2016-P-1115-0053,FDA-2016-P-1115,supplement from mostyn law,0,0
0900006481fdcd2f,Supporting & Related Material,FDA-2016-P-1115-0046,FDA-2016-P-1115,82. footnote 34 bscm14700006847 - unsealed by 3.22.16 agreement,0,0
0900006481fdcd31,Supporting & Related Material,FDA-2016-P-1115-0048,FDA-2016-P-1115,footnote 82 bscm07700158425,0,0
0900006481f39755,Supporting & Related Material,FDA-2016-P-1115-0008,FDA-2016-P-1115,exhibit 4 - 1/24/16 order of the honorable judge goodwin re citizen petition from mostyn law firm,0,0
0900006481f39757,Supporting & Related Material,FDA-2016-P-1115-0010,FDA-2016-P-1115,exhibit 6 - http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm204199.htm re citizen petition from mostyn law firm,0,0
0900006481fe9554,Other,FDA-2015-P-4566-0004,FDA-2015-P-4566,interim response from fda cder,0,0
0900006481d83080,Supporting & Related Material,FDA-2015-P-4566-0002,FDA-2015-P-4566,"attachment 1 expert statement of manju t. beier, pharm d. re citizen petition from concordia pharmaceuticals (buchanan ingersoll and rooney pc)",0,0
0900006481d83000,Other,FDA-2015-P-4566-0003,FDA-2015-P-4566,acknowledgement letter from fda ddm to buchanan ingersoll and rooney pc,0,0
0900006482af6158,Other,FDA-2015-P-4566-0005,FDA-2015-P-4566,final response from fda cder to buchanan ingersoll & rooney pc,0,0
0900006481d82c69,Other,FDA-2015-P-4566-0001,FDA-2015-P-4566,citizen petition from concordia pharmaceuticals (buchanan ingersoll and rooney pc),0,0
0900006482092d6d,Supporting & Related Material,FDA-2016-P-1946-0005,FDA-2016-P-1946,"attachment 3 effects of various tampering methods on exposure to oxycodone in healthy subjects re citizen petition from hyman, phelps & mcnamara, pc",0,0
09000064824c86d6,Other,FDA-2016-P-1946-0008,FDA-2016-P-1946,"cp denial letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
0900006482092d6c,Supporting & Related Material,FDA-2016-P-1946-0004,FDA-2016-P-1946,"attachment 2 relative abuse of abuse-deterrent formulations via alternative oral routes re citizen petition from hyman, phelps & mcnamara, pc",0,0
0900006482092caf,Supporting & Related Material,FDA-2016-P-1946-0003,FDA-2016-P-1946,"attachment 1 comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulation with abuse-deterrent properties re citizen petition from hyman, phelps & mcnamara, pc",0,0
0900006482092cad,Other,FDA-2016-P-1946-0001,FDA-2016-P-1946,"citizen petition from hyman, phelps & mcnamara, pc (collegium pharmaceutical, inc. )",0,0
0900006482092e14,Other,FDA-2016-P-1946-0002,FDA-2016-P-1946,"acknowledgement letter from fda ddm to hyman, phelps & mcnamara, pc",0,0
090000648235f3a0,Supporting & Related Material,FDA-2016-P-3620-0004,FDA-2016-P-3620,"appendix b (evidence to support the use of fibersym® rw and fiberrite® rw modified wheat starch as a source of dietary fiber in the united states) re citizen petition from mgp ingredients, inc.",0,0
09000064833f0c39,Other,FDA-2016-P-3620-0014,FDA-2016-P-3620,"memorandum for the record, phone call participant list june 6 2018 call.",0,0
090000648235f39f,Supporting & Related Material,FDA-2016-P-3620-0003,FDA-2016-P-3620,"appendix a (additional evidence in support of other physiological effects beneficial to human health) re citizen petition from mgp ingredients, inc.",0,0
0900006483ae29cc,Other,FDA-2016-P-3620-0018,FDA-2016-P-3620,"addendum from mgp ingredients, inc.",0,0
090000648251565f,Other,FDA-2016-P-3620-0009,FDA-2016-P-3620,"letter from general mills , inc. to fda ddm",0,0
09000064831c5f19,Supporting & Related Material,FDA-2016-P-3620-0012,FDA-2016-P-3620,"m. g. p. ingredients inc. re: citizen petition from mgp ingredients, inc.",0,0
09000064831c6238,Supporting & Related Material,FDA-2016-P-3620-0013,FDA-2016-P-3620,"letter from south dakota state university re: citizen petition from mgp ingredients, inc.",0,0
090000648235f425,Other,FDA-2016-P-3620-0002,FDA-2016-P-3620,"acknowledgment letter from fda ddm to mgp ingredients, inc.",0,0
090000648257b4bf,Other,FDA-2016-P-3620-0010,FDA-2016-P-3620,"interim response letter from cfsan to mgp ingredients, inc.",0,0
090000648235f39d,Other,FDA-2016-P-3620-0001,FDA-2016-P-3620,"citizen petition from mgp ingredients, inc.",0,0
09000064831c5f16,Supporting & Related Material,FDA-2016-P-3620-0011,FDA-2016-P-3620,"addendum to citizen petition re: citizen petition from mgp ingredients, inc.",0,0
0900006483a4e9a1,Other,FDA-2016-P-3620-0017,FDA-2016-P-3620,"addendum from mgp ingredients, inc.",0,0
09000064834109eb,Other,FDA-2016-P-3620-0015,FDA-2016-P-3620,"mgp ingredients, inc addendum",0,0
090000648235f3a1,Supporting & Related Material,FDA-2016-P-3620-0005,FDA-2016-P-3620,"appendix c (technical data sheets for fibersym® rw and fiberrite® rw) re citizen petition from mgp ingredients, inc.",0,0
0900006483b34ca7,Other,FDA-2016-P-3620-0019,FDA-2016-P-3620,"letter from fda cfsan to mgp ingredients, inc.",0,0
09000064838bd406,Other,FDA-2016-P-3620-0016,FDA-2016-P-3620,"addendum from mgp ingredients, inc.",0,0
0900006481ee0545,Other,FDA-2016-P-1088-0002,FDA-2016-P-1088,"acknowledgement letter from fda ddm to abhai llp c/o kvk-tech, inc",0,0
0900006481edffa8,Supporting & Related Material,FDA-2016-P-1088-0004,FDA-2016-P-1088,"attachment 2 package information oxybutynin hydrochloride 2.5 mg and 5 mg tablets re: citizen petition from abhai llc c/o: kvk-tech, inc",0,0
0900006481edffa9,Supporting & Related Material,FDA-2016-P-1088-0005,FDA-2016-P-1088,"attachment 3 label information oxybutynin chloride tablets re: citizen petition from abhai llc c/o: kvk-tech, inc",0,0
09000064848d5ce8,Other,FDA-2016-P-1088-0007,FDA-2016-P-1088,"amendment to suitability petition for oxybutynin chloride tablets, usp 2.5 mg",0,0
0900006481edffaa,Supporting & Related Material,FDA-2016-P-1088-0006,FDA-2016-P-1088,"attachment 4 label information oxybutynin chloride tablets, usp re citizen petition from abhai llc c/o: kvk-tech, inc",0,0
0900006481edffa5,Other,FDA-2016-P-1088-0001,FDA-2016-P-1088,"citizen petition from abhai llc c/o kvk-tech, inc",0,0
0900006481edffa7,Supporting & Related Material,FDA-2016-P-1088-0003,FDA-2016-P-1088,"attachment 1 package leaflet ditropan 2.5 mg and 5 mg tablets re: citizen petition from abhai llc c/o: kvk-tech, inc",0,0
0900006484969987,Other,FDA-2016-P-1088-0008,FDA-2016-P-1088,"agency response letter from fda cder to abhai llp c/o kvk-tech, inc",0,0
0900006480b13840,Other,FDA-2010-P-0359-0001,FDA-2010-P-0359,"goodwin procter, llp - citizen petition",0,0
0900006480bb615d,Other,FDA-2010-P-0359-0003,FDA-2010-P-0359,goodwin procter llp - letter,0,0
0900006480b13a22,Other,FDA-2010-P-0359-0002,FDA-2010-P-0359,acknowledgement letter to goodwin procter llp,0,0
0900006483ed552e,Other,FDA-2010-P-0359-0004,FDA-2010-P-0359,interim response to goodwin procter llp. from cdrh,0,0
0900006482a94fd6,Other,FDA-2017-P-5114-0002,FDA-2017-P-5114,acknowledgement letter from fda ddm to locke lord llp,0,0
0900006482a94fda,Supporting & Related Material,FDA-2017-P-5114-0004,FDA-2017-P-5114,attachment 2 re citizen petition from locke lord llp,0,0
0900006482a94f87,Other,FDA-2017-P-5114-0001,FDA-2017-P-5114,citizen petition from locke lord llp,0,0
0900006482a94fdb,Supporting & Related Material,FDA-2017-P-5114-0005,FDA-2017-P-5114,attachment 3 re citizen petition from locke lord llp,0,0
0900006482c9fadd,Other,FDA-2017-P-5114-0007,FDA-2017-P-5114,petition response letter,0,0
0900006482a94fd9,Supporting & Related Material,FDA-2017-P-5114-0003,FDA-2017-P-5114,attachment 1 re citizen petition from locke lord llp,0,0
0900006482c98c5b,Notice,FDA-2017-P-5114-0006,FDA-2017-P-5114,"determination that trintellix (vortioxetine hydrobromide) oral
tablet, eq 15 milligram base, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006482428120,Other,FDA-2016-P-1106-0004,FDA-2016-P-1106,"letter from fda cder to gordon johnston regulatory consultants, llc",0,0
0900006481f11632,Other,FDA-2016-P-1106-0001,FDA-2016-P-1106,citizen petition from gordon johnston regulatory consultants llc,0,0
0900006481f13d7a,Other,FDA-2016-P-1106-0002,FDA-2016-P-1106,acknowledgement letter from fda ddm to gordon johnston regulatory consultants llc,0,0
0900006481f11698,Supporting & Related Material,FDA-2016-P-1106-0003,FDA-2016-P-1106,attachment a product listing from the active section of the orange book -  re citizen petition from gordon johnston regulatory consultants llc,0,0
090000648301d61d,Other,FDA-2018-P-1174-0002,FDA-2018-P-1174,citizen petition from pharma regulatory consultants llc,0,0
090000648301e145,Supporting & Related Material,FDA-2018-P-1174-0005,FDA-2018-P-1174,"attachment 3- approved labeling for reference- listed drug, revatio ( sildenafil citrate) by pfizer re:  citizen petition from pharma regulatory consultants llc",0,0
090000648301e144,Supporting & Related Material,FDA-2018-P-1174-0004,FDA-2018-P-1174,attachment 2- draft insert labeling for proposed product re: citizen petition from pharma regulatory consultants llc,0,0
090000648301d704,Other,FDA-2018-P-1174-0001,FDA-2018-P-1174,acknowledgment letter from fda ddm to pharma regulatory consultants llc,0,0
090000648301e143,Supporting & Related Material,FDA-2018-P-1174-0003,FDA-2018-P-1174,attachment 1 orange book' approved drug products with therapeutic equivalence evaluations re: citizen petition from pharma regulatory consultants llc,0,0
0900006483aa8261,Supporting & Related Material,FDA-2019-P-0915-0004,FDA-2019-P-0915,"attachment b package insert of lacosamide granules for oral solution re: suitability petition from sunshine lake pharma co., ltd.",0,0
0900006483aa7b08,Other,FDA-2019-P-0915-0001,FDA-2019-P-0915,"suitability petition from sunshine lake pharma co., ltd.",0,0
0900006483aa8260,Supporting & Related Material,FDA-2019-P-0915-0003,FDA-2019-P-0915,"attachment a package insert of reference list drug (vimpat ®) re suitability petition from sunshine lake pharma co., ltd.",0,0
0900006483aa7f22,Other,FDA-2019-P-0915-0002,FDA-2019-P-0915,"acknowledgment letter from fda ddm to sunshine lake pharma co., ltd.",0,0
09000064811762a5,Proposed Rule,FDA-2012-N-1148-0001,FDA-2012-N-1148,actions related to nicotine replacement therapies and smoking-cessation products: report to congress on innovative products and treatments for tobacco dependence; public hearing,0,1
090000648119460a,Supporting & Related Material,FDA-2012-N-1148-0004,FDA-2012-N-1148,testimony regarding nrt and innovative tobacco cessation - testimony,0,1
09000064811a3b89,Proposed Rule,FDA-2012-N-1148-0011,FDA-2012-N-1148,food and drug administration actions related to nicotine replacement therapies and smoking-cessation products; report to congress on innovative products and treatments for tobacco dependence; public hearing; extension of comment period,1,1
0900006481194525,Supporting & Related Material,FDA-2012-N-1148-0005,FDA-2012-N-1148,slides presented at 12/17/12 public hearing,0,0
0900006481f114c8,Other,FDA-2016-P-1105-0001,FDA-2016-P-1105,citizen petition from gordon johnston regulatory consultants llc,0,0
0900006481f13d7c,Other,FDA-2016-P-1105-0002,FDA-2016-P-1105,acknowledgement letter from fda ddm to gordon johnston regulatory consultants llc,0,0
090000648235b7c1,Other,FDA-2016-P-1105-0004,FDA-2016-P-1105,letter from cder fda to gordon johnston regulatory consultants llc,0,0
0900006481f1169a,Supporting & Related Material,FDA-2016-P-1105-0003,FDA-2016-P-1105,attachment a product listing from the active section of the orange book re citizen petition from gordon johnston regulatory consultants llc,0,0
09000064824f45c8,Other,FDA-2017-P-1391-0002,FDA-2017-P-1391,acknowledgement letter from fda ddm to epstein becker & green p.c.,0,0
09000064824f43ec,Other,FDA-2017-P-1391-0001,FDA-2017-P-1391,citizen petition from epstein becker & green p.c.,0,0
0900006481f62e4d,Supporting & Related Material,FDA-2015-P-3794-0004,FDA-2015-P-3794,interim response - savage re citizen petition from lawrence r. savage,0,0
0900006481f5d84e,Other,FDA-2015-P-3794-0003,FDA-2015-P-3794,interim response letter to lawrence savage,0,0
0900006481cd14cb,Other,FDA-2015-P-3794-0001,FDA-2015-P-3794,citizen petition from lawrence r. savage,0,0
0900006481cd177d,Other,FDA-2015-P-3794-0002,FDA-2015-P-3794,acknowledgment letter from fda ddm to lawrence r. savage,0,0
090000648493c511,Supporting & Related Material,FDA-2020-P-2136-0003,FDA-2020-P-2136,"cover letter re citizen petition from siri & glimstad, llp (on behalf of informed consent action network)",0,0
090000648493c50e,Other,FDA-2020-P-2136-0002,FDA-2020-P-2136,"acknowledgment letter from fda dms to siri & glimstad, llp (on behalf of informed consent action network)",0,0
090000648493c512,Supporting & Related Material,FDA-2020-P-2136-0004,FDA-2020-P-2136,"footnotes 2-3 re citizen petition from siri & glimstad, llp (on behalf of informed consent action network)",0,0
090000648493c50d,Other,FDA-2020-P-2136-0001,FDA-2020-P-2136,"citizen petition from siri & glimstad, llp (on behalf of informed consent action network)",0,0
0900006484aabc0a,Other,FDA-2020-P-2136-0005,FDA-2020-P-2136,"interim response from fda cber to siri & glimstad, llp",0,0
0900006483988ec2,Supporting & Related Material,FDA-2018-P-4714-0007,FDA-2018-P-4714,"exhibit 12 copyrighted article isbill, k. (2018) thoughts on sexual health re citizen petition from therapeuticmd, inc.",0,0
090000648398806d,Supporting & Related Material,FDA-2018-P-4714-0003,FDA-2018-P-4714,"exhibits 1-4 copyrighted articles re citizen petition from therapeuticsmd, inc.",0,0
0900006483988bdd,Supporting & Related Material,FDA-2018-P-4714-0009,FDA-2018-P-4714,"exhibit 14 citizen petition partial approval and denial response letter from fda cder to novo nordisk inc. re citizen petition from therapeuticmd, inc.",0,0
0900006483988c8b,Supporting & Related Material,FDA-2018-P-4714-0012,FDA-2018-P-4714,"exhibit 17 copyrighted article chang, raw, lionberger, and yu (2012) generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products re citizen petition from therapeuticsmd, inc.",0,0
0900006483988bde,Supporting & Related Material,FDA-2018-P-4714-0010,FDA-2018-P-4714,"exhibit 15 copyrighted article marques, m. (2014) enzymes in the dissolution testing of gelatin capsules re citizen petition from therpeuticmd, inc. re citizen petition from therapeuticmd, inc.",0,0
09000064839890aa,Supporting & Related Material,FDA-2018-P-4714-0015,FDA-2018-P-4714,"exhibit 20 highlights of prescribing information imvexxy re citizen petition from therapeuticmd, inc.",0,0
090000648398806e,Supporting & Related Material,FDA-2018-P-4714-0004,FDA-2018-P-4714,"exhibit 5 bransaeter and nelson (1955) proteolysis by lactobacillus casei ii. peptidase activity re citizen petition from therapeuticsmd, inc.",0,0
090000648398806f,Supporting & Related Material,FDA-2018-P-4714-0005,FDA-2018-P-4714,"exhibits 6-10 copyrighted articles re citizen petition from therapeuticsmd, inc.",0,0
0900006483988bdc,Supporting & Related Material,FDA-2018-P-4714-0008,FDA-2018-P-4714,"exhibit 13 nda approval letter from fda cder to therapeuticsmd, inc.",0,0
0900006483cffd39,Other,FDA-2018-P-4714-0016,FDA-2018-P-4714,"letter from fda cder to therapeuticsmd, inc.",0,0
090000648398806b,Other,FDA-2018-P-4714-0001,FDA-2018-P-4714,"citizen petition from therapeuticsmd, inc.",0,0
0900006483988070,Supporting & Related Material,FDA-2018-P-4714-0006,FDA-2018-P-4714,"exhibit 11 pickar, amadio, bernick, and mirkin (2016) pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule re citizen petition from therapeuticsmd, inc.",0,0
0900006483988c8c,Supporting & Related Material,FDA-2018-P-4714-0013,FDA-2018-P-4714,"exhibit 18 copyrighted article kingsberg et al (2017) patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, tx-004hr re citizen petition from therapeuticmd, inc.",0,0
09000064839890a9,Supporting & Related Material,FDA-2018-P-4714-0014,FDA-2018-P-4714,"exhibit 19 fda in vitro bioequivalence data for a topical
product: bioequivalence review perspective re citizen petition from therapeuticmd, inc.",0,0
0900006483988c8a,Supporting & Related Material,FDA-2018-P-4714-0011,FDA-2018-P-4714,"exhibit 16 copyrighted article press, nousek-goebl, bur, and greene (1986) estrogen receptor localization in the female genital tract re citizen petition from therapeuticsmd, inc.",0,0
090000648398806c,Other,FDA-2018-P-4714-0002,FDA-2018-P-4714,"acknowledgment letter from fda ddm to therapeuticsmd, inc.",0,0
0900006484a12399,Other,FDA-2021-P-0136-0002,FDA-2021-P-0136,acknowledgment letter from fda dms to principal lassman law +policy,0,0
0900006484a122da,Other,FDA-2021-P-0136-0001,FDA-2021-P-0136,citizen petition from lassman law+policy,0,0
0900006484c0fc86,Other,FDA-2021-P-0136-0003,FDA-2021-P-0136,"interim response to principal, lassman law+policy from fda cder",0,0
09000064806f11a5,Other,FDA-2007-P-0009-0006,FDA-2007-P-0009,fda response to the honorable dianne feinstein [in support of casa/cp1-fda-2007-p-0009-0002] - letter,0,0
0900006480c759f1,Other,FDA-2007-P-0009-0009,FDA-2007-P-0009,interim response to the national center on addiction and substance abuse at columbia university,0,0
09000064806eeeee,Other,FDA-2007-P-0009-0005,FDA-2007-P-0009,the national center on addiction and substance abuse at columbia university to fda commissioner von eschenbach - letter,0,0
09000064804292e5,Other,FDA-2007-P-0009-0002,FDA-2007-P-0009,the national center on addiction and substance abuse at columbia university (casa) - citizen petition,0,0
0900006480bd780f,Other,FDA-2007-P-0009-0007,FDA-2007-P-0009,"national center on addiction and substance abuse (casa) at columbia university to fda/cder, january 31, 2011  - letter",0,0
090000648054899d,Other,FDA-2007-P-0009-0003,FDA-2007-P-0009,center for drug evaluation and research to the national center for addiction and substance abuse at columbia university - letter,0,0
0900006480c014b2,Other,FDA-2007-P-0009-0008,FDA-2007-P-0009,national center on addiction and substance abuse (casa) - supplement,0,0
0900006481334521,Other,FDA-2007-P-0009-0010,FDA-2007-P-0009,fda/cder response to national center on addiction and substance abuse at columbia university - denial of petition,0,0
09000064804292e0,Other,FDA-2007-P-0009-0001,FDA-2007-P-0009,acknowledgement letter to the national center on addiction and substance abuse at columbia university,0,0
0900006480a52aac,Notice,FDA-2009-D-0319-0001,FDA-2009-D-0319,guidance for industry and food and drug administration staff; in vitro diagnostic 2009 h1n1 tests for use in the 2009 h1n1 emergency; availability,1,0
0900006480a5303e,Other,FDA-2009-D-0319-0002,FDA-2009-D-0319,guidance for industry and food and drug administration staff; in vitro diagnostic 2009 h1n1 tests for use in the 2009 h1n1 emergency; availability,1,0
0900006484e357a9,Supporting & Related Material,FDA-2021-P-1209-0004,FDA-2021-P-1209,"attachment - labeling ketorolac  10mg rs re suitability petition from senores pharmaceuticals, inc.",0,0
0900006484e35b43,Supporting & Related Material,FDA-2021-P-1209-0003,FDA-2021-P-1209,"attachment 1 - orange book: approved drug products with therapeutic equivalence evaluations re suitability petition from senores pharmaceuticals, inc.",0,0
0900006484e35b44,Supporting & Related Material,FDA-2021-P-1209-0005,FDA-2021-P-1209,"attachment 3 - draft labeling re suitability petition from senores pharmaceuticals, inc.",0,0
0900006484e357ad,Supporting & Related Material,FDA-2021-P-1209-0007,FDA-2021-P-1209,"attachment - 5 - bio guidance re suitability petition from senores pharmaceuticals, inc.",0,0
0900006484e35b20,Other,FDA-2021-P-1209-0001,FDA-2021-P-1209,"suitability petition from senores pharmaceuticals, inc.",0,0
0900006484e357ac,Supporting & Related Material,FDA-2021-P-1209-0006,FDA-2021-P-1209,"attachment 4 - labeling side by side comparision re suitability petition from senores pharmaceuticals, inc.",0,0
0900006484e357a7,Other,FDA-2021-P-1209-0002,FDA-2021-P-1209,"acknowledgment letter from fda dms to senores pharmaceuticals, inc.",0,0
0900006483e81982,Supporting & Related Material,FDA-2019-P-3946-0009,FDA-2019-P-3946,exhibit 7 - changes in the prevalence of the most common causes of chronic liver diseases in the united states from 1988 to 2008 re citizens petition from persion pharmaceuticals llc,0,0
0900006483e8180b,Supporting & Related Material,FDA-2019-P-3946-0003,FDA-2019-P-3946,exhibit 1 - opioid safety in patients with renal or hepatic dysfunction re citizens petition from persion pharmaceuticals llc,0,0
0900006483e81070,Other,FDA-2019-P-3946-0002,FDA-2019-P-3946,acknowledgment letter from fda dms to persion pharmaceuticals llc,0,0
0900006483e8197f,Supporting & Related Material,FDA-2019-P-3946-0006,FDA-2019-P-3946,"exhibit 4 - declaration of craig antell, d.o. re citizens petition from persion pharmaceuticals llc",0,0
0900006483e8180c,Supporting & Related Material,FDA-2019-P-3946-0004,FDA-2019-P-3946,exhibit 2 - effects of renal impairment and hepatic impairment on the pharmacokinetics of hydrocodone after administration of a novel extended-release hydrocodone tablet formulated with oraguardtm technology re citizens petition from persion pharmaceuticals llc,0,0
0900006483e81983,Supporting & Related Material,FDA-2019-P-3946-0010,FDA-2019-P-3946,exhibit 8 - pain and opioid use in chronic liver disease re citizens petition from persion pharmaceuticals llc,0,0
0900006483e81984,Supporting & Related Material,FDA-2019-P-3946-0011,FDA-2019-P-3946,exhibit 9 - highlights of prescribing information re citizens petition from persion pharmaceuticals llc,0,0
0900006483edb9e9,Other,FDA-2019-P-3946-0012,FDA-2019-P-3946,withdrawal from persion pharmaceuticals llc,0,0
0900006483e81981,Supporting & Related Material,FDA-2019-P-3946-0008,FDA-2019-P-3946,"exhibit 6 - the role of opioid prescription in incident opioid abuse and
dependence among individuals with chronic non-cancer pain:
the role of opioid prescription re citizens petition from persion pharmaceuticals llc",0,0
0900006483e80a6b,Other,FDA-2019-P-3946-0001,FDA-2019-P-3946,citizens petition from persion pharmaceuticals llc,0,0
0900006483e81980,Supporting & Related Material,FDA-2019-P-3946-0007,FDA-2019-P-3946,exhibit 5 - cohort study of the impact of high-dose opiod analgesics on overdose mortality re citizens petition from persion pharmaceuticals llc,0,0
0900006483eefbb5,Other,FDA-2019-P-3946-0013,FDA-2019-P-3946,citizen petition from persion pharmaceuticals llc,0,0
0900006483e8180d,Supporting & Related Material,FDA-2019-P-3946-0005,FDA-2019-P-3946,"exhibit 3 - declaration of christopher g. gharibo, m.d. re citizens petition from persion pharmaceuticals llc",0,0
090000648214dcb7,Supporting & Related Material,FDA-2016-P-2375-0003,FDA-2016-P-2375,attachment 1 orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from akorn specialty generics,0,0
090000648214dcb5,Other,FDA-2016-P-2375-0002,FDA-2016-P-2375,acknowledgement letter from fda ddm to akorn specialty generics,0,0
09000064824992f8,Other,FDA-2016-P-2375-0004,FDA-2016-P-2375,interim response letter from cder to akorn pharmaceuticals,0,0
090000648214dcaf,Other,FDA-2016-P-2375-0001,FDA-2016-P-2375,citizen petition from akorn specialty generics,0,0
09000064839ac1b4,Other,FDA-2016-P-2375-0005,FDA-2016-P-2375,"letter from fda cder to akorn pharmaceuticals, mylan pharmaceuticals, inc., gland pharma limited, foley & lardner llp",0,0
09000064824c39f7,Other,FDA-2017-P-1002-0002,FDA-2017-P-1002,"acknowledgment letter from fda ddm to inrange systems, inc.",0,0
0900006482bc4d77,Other,FDA-2017-P-1002-0003,FDA-2017-P-1002,"denial response from fda cdrh to inrange systems, inc",0,0
09000064824c39f5,Other,FDA-2017-P-1002-0001,FDA-2017-P-1002,"citizen petition from inrange systems, inc.",0,0
090000648324fef3,Other,FDA-2018-P-1808-0001,FDA-2018-P-1808,"citizen petition from lachman consultant services, inc",0,0
090000648324fef8,Supporting & Related Material,FDA-2018-P-1808-0003,FDA-2018-P-1808,"attachment 1 orange book re citizen petition from lachman consultant services, inc",0,0
090000648324fef5,Other,FDA-2018-P-1808-0002,FDA-2018-P-1808,"acknowledgment letter from fda ddm to lachman consultant services, inc",0,0
090000648324fef9,Supporting & Related Material,FDA-2018-P-1808-0004,FDA-2018-P-1808,"attachment 2 proposed labeling re citizen petition from lachman consultant services, inc",0,0
090000648324ff54,Supporting & Related Material,FDA-2018-P-1808-0005,FDA-2018-P-1808,"attachment 3 approved labeling for reference listed drug re citizen petition from lachman consultant services, inc",0,0
0900006482b87979,Other,FDA-2017-P-5967-0002,FDA-2017-P-5967,acknowledgement letter from fda ddm to apotex inc.,0,0
0900006482c9fa7e,Other,FDA-2017-P-5967-0005,FDA-2017-P-5967,final petition response,0,0
0900006482c98464,Notice,FDA-2017-P-5967-0004,FDA-2017-P-5967,"determination that trintellix (vortioxetine hydrobromide) oral
tablet, eq 15 milligram base, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006482b87977,Other,FDA-2017-P-5967-0001,FDA-2017-P-5967,citizen petition from apotex inc.,0,0
0900006482b8797d,Supporting & Related Material,FDA-2017-P-5967-0003,FDA-2017-P-5967,attachment 1 - orange book: approved drug products with therapeutic equivalence  evaluations re citizen petition from apotex inc.,0,0
090000648248674c,Other,FDA-2017-P-0398-0001,FDA-2017-P-0398,citizen petition from florek & endres pllc,0,0
0900006482486750,Supporting & Related Material,FDA-2017-P-0398-0003,FDA-2017-P-0398,attachment 1 nda # 21-217 detail record from the current electronic edition of the orange book re citizen petition from florek & endres pllc,0,0
0900006482486752,Supporting & Related Material,FDA-2017-P-0398-0004,FDA-2017-P-0398,"attachment 2 exalgo® (hydromorphone hcl), extended-release tablets, for oral use package insert (rld labeling) re citizen petition from florek & endres pllc",0,0
0900006482c0602e,Other,FDA-2017-P-0398-0005,FDA-2017-P-0398,withdrawal from florek & endres pllc,0,0
090000648248674e,Other,FDA-2017-P-0398-0002,FDA-2017-P-0398,acknowledgement letter from fda ddm to florek & endress pllc,0,0
090000648190535c,Notice,FDA-2014-N-1009-0002,FDA-2014-N-1009,"agency information collection activities; submission for office of
management and budget review; comment request; information
request regarding ph of smokeless tobacco products",0,1
09000064817d76c9,Notice,FDA-2014-N-1009-0001,FDA-2014-N-1009,"agency information collection activities; proposed collection;
comment request; information request regarding ph of smokeless
tobacco products",0,1
09000064811607d1,Other,FDA-2012-P-1107-0002,FDA-2012-P-1107,acknowledgement letter to fziomed inc. (hogan lovells us llp),0,0
090000648167003e,Other,FDA-2012-P-1107-0028,FDA-2012-P-1107,"letter from fziomed , inc, (nogan lovells us llp) to fda cdrh",0,0
0900006481718955,Other,FDA-2012-P-1107-0038,FDA-2012-P-1107,letter from fda cdrh to fda oc,0,0
090000648171893c,Other,FDA-2012-P-1107-0037,FDA-2012-P-1107,letter from fda cdrh to fda oc,0,0
0900006481717052,Other,FDA-2012-P-1107-0035,FDA-2012-P-1107,letter from fda cdrh to fda ddm and fda oc,0,0
0900006481a54871,Other,FDA-2012-P-1107-0040,FDA-2012-P-1107,"letter from oc to fziomed, inc. (hunton and williams, llp) closing the docket",0,0
0900006481735188,Notice,FDA-2012-P-1107-0039,FDA-2012-P-1107,"oxiplex/sp gel; fziomed, incorporated’s petition for review of
the food and drug administration’s denial of premarket approval; notice
of meeting cancellation",1,0
090000648146356b,Other,FDA-2012-P-1107-0022,FDA-2012-P-1107,fda/oc response to fziomed inc. (hogan lovells us llp) - petition approval,0,0
09000064816700b4,Other,FDA-2012-P-1107-0029,FDA-2012-P-1107,"memorandum from fda cdrh to division of dockets management and administrative team for the office of the commissioner dated march 14, 2014",0,0
09000064819a8a56,Other,FDA-2012-P-1107-0041,FDA-2012-P-1107,withdrawal from hunton & williams,0,0
09000064817168f7,Other,FDA-2012-P-1107-0034,FDA-2012-P-1107,letter from fda cdrh to fda ddm and fda oc,0,0
09000064815a2dce,Other,FDA-2012-P-1107-0024,FDA-2012-P-1107,letter from fda cdrh to hogan lovell us llp and cdrh,0,0
09000064816f9561,Notice,FDA-2012-P-1107-0033,FDA-2012-P-1107,"oxiplex®/sp gel; fziomed, incorporated’s petition for review of
the food and drug administration’s denial of premarket approval; notice
of meeting",1,0
09000064816e9fee,Other,FDA-2012-P-1107-0032,FDA-2012-P-1107,letter from fda/oc to hogan lovells us llp and cdrh,0,0
0900006481718745,Other,FDA-2012-P-1107-0036,FDA-2012-P-1107,letter from fda cdrh to fda oc,0,0
09000064816d9ef2,Other,FDA-2012-P-1107-0031,FDA-2012-P-1107,letter from fda/oc to hogan lovells us llp and cdrh,0,0
0900006481535e8b,Other,FDA-2012-P-1107-0023,FDA-2012-P-1107,memorandum from fda cdrh to ddm,0,0
090000648162f9f1,Other,FDA-2012-P-1107-0026,FDA-2012-P-1107,"letter from fziomed, inc. (hogan lovells us llp)",0,0
0900006481160690,Other,FDA-2012-P-1107-0001,FDA-2012-P-1107,fziomed inc. (hogan lovells us llp) - citizen petition,0,0
09000064816b29e7,Other,FDA-2012-P-1107-0030,FDA-2012-P-1107,cdrh executive summary for the 515(g)(2) panel to review the denial of p070023,0,0
0900006481674ae0,Other,FDA-2012-P-1107-0025,FDA-2012-P-1107,letter from fda cder to hogan lovells us llp and fda cdrh,0,0
0900006481869ed8,Supporting & Related Material,FDA-2014-P-1044-0003,FDA-2014-P-1044,attachment ii current drug shortage bulletin: mercaptopurine tablets re citizen petition from zydus pharmaceuticals inc fda-2014-p-1044-0001,0,0
090000648198fde8,Other,FDA-2014-P-1044-0007,FDA-2014-P-1044,"withdrawal from zydus pharmaceuticals (usa), inc.",0,0
0900006481869ed9,Supporting & Related Material,FDA-2014-P-1044-0004,FDA-2014-P-1044,attachment iii  orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from zydus pharmaceuticals inc fda-2014-p-1044-0001,0,0
0900006481869b15,Supporting & Related Material,FDA-2014-P-1044-0005,FDA-2014-P-1044,shipping label re citizen petition from zydus pharmaceuticals inc,0,0
0900006481869e84,Supporting & Related Material,FDA-2014-P-1044-0002,FDA-2014-P-1044,attachment i cited correspondence re citizen petition from zydus pharmaceuticals inc fda-2014-p-1044-0001,0,0
0900006481869e82,Other,FDA-2014-P-1044-0006,FDA-2014-P-1044,acknowledgement letter from fda ddm to zydus pharmaceuticals inc,0,0
0900006481869e80,Other,FDA-2014-P-1044-0001,FDA-2014-P-1044,citizen petition from zydus pharmaceuticals inc,0,0
0900006481223059,Other,FDA-2013-D-0168-0002,FDA-2013-D-0168,draft guidance for industry and staff; recommendations for labeling medical products to inform users the product or product container is not made with natural rubber latex,0,0
0900006481223626,Notice,FDA-2013-D-0168-0001,FDA-2013-D-0168,draft guidance for industry and staff; availability: recommendations for labeling medical products to inform users the product or product container is not made with natural rubber latex,0,0
0900006481954f4b,Other,FDA-2013-D-0168-0010,FDA-2013-D-0168,"recommendations for labeling medical products to inform users that
the product or product container is not made with natural rubber latex;
guidance for industry and food and drug administration staff.",1,0
0900006481953f62,Notice,FDA-2013-D-0168-0009,FDA-2013-D-0168,"recommendations for labeling medical products to inform users that
the product or product container is not made with natural rubber latex;
guidance for industry and food and drug administration staff; availability.",1,0
0900006482922b8d,Supporting & Related Material,FDA-2017-P-4233-0004,FDA-2017-P-4233,attachment 2 - draft insert labeling for proposed product re citizen petition from lachman consultant services inc,0,0
0900006482922b8e,Supporting & Related Material,FDA-2017-P-4233-0005,FDA-2017-P-4233,"attachment 3 - approved labeling for reference-listed drug, vimpat (lacosamide) tablets re citizien petition from lachman consultant services inc",0,0
0900006482922b8c,Supporting & Related Material,FDA-2017-P-4233-0003,FDA-2017-P-4233,"attachment 1 -  approved drug products with therapeutic equivalence evaluations, electronic orange book listing, accessed 7/12/17 re citizen petition lachman consultant services inc",0,0
0900006482922570,Other,FDA-2017-P-4233-0001,FDA-2017-P-4233,"citizen petition from lachman consultant services, inc.",0,0
0900006482922578,Other,FDA-2017-P-4233-0002,FDA-2017-P-4233,acknowledgement letter from ddm to lachman consultant services inc,0,0
090000648178e162,Supporting & Related Material,FDA-2014-P-0933-0005,FDA-2014-P-0933,exhibit 3 colloid cp citizen petition from teva neuroscience inc.,0,0
090000648178e163,Supporting & Related Material,FDA-2014-P-0933-0006,FDA-2014-P-0933,exhibit 4 fda response to 6th copax petition citizen petition from teva neuroscience inc.,0,0
090000648178e166,Supporting & Related Material,FDA-2014-P-0933-0009,FDA-2014-P-0933,exhibit 7 2008 petition citizen petition from teva neuroscience inc.,0,0
090000648178d253,Supporting & Related Material,FDA-2014-P-0933-0003,FDA-2014-P-0933,exhibit 1 fda june 9 letter citizen petition from teva neuroscience inc.,0,0
090000648178e167,Supporting & Related Material,FDA-2014-P-0933-0010,FDA-2014-P-0933,exhibit 8 2009 petition citizen petition from teva neuroscience inc.,0,0
090000648178e169,Supporting & Related Material,FDA-2014-P-0933-0012,FDA-2014-P-0933,exhibit 10 2012 petition citizen petition from teva neuroscience inc.,0,0
090000648178e16b,Supporting & Related Material,FDA-2014-P-0933-0014,FDA-2014-P-0933,exhibit 12 bakshi paper citizen petition from teva neuroscience inc.,0,0
090000648178d254,Supporting & Related Material,FDA-2014-P-0933-0004,FDA-2014-P-0933,exhibit 2 6thcopax petition citizen petition from teva neuroscience inc.,0,0
090000648178e164,Supporting & Related Material,FDA-2014-P-0933-0007,FDA-2014-P-0933,exhibit 5 towfic article citizen petition from teva neuroscience inc.,0,0
0900006481949949,Other,FDA-2014-P-0933-0021,FDA-2014-P-0933,"denial petition response letter from fda cder to teva neuroscience, inc.,teva pharmaceuticals",0,0
090000648178e165,Supporting & Related Material,FDA-2014-P-0933-0008,FDA-2014-P-0933,exhibit 6 teva slides from type c meeting citizen petition from teva neuroscience inc.,0,0
090000648178e168,Supporting & Related Material,FDA-2014-P-0933-0011,FDA-2014-P-0933,exhibit 9 2010 petition citizen petition from teva neuroscience inc.,0,0
090000648180d4f8,Other,FDA-2014-P-0933-0018,FDA-2014-P-0933,"supplement from teva neuroscience, inc.",0,0
090000648178d251,Other,FDA-2014-P-0933-0002,FDA-2014-P-0933,acknowledgement letter from fda ddm to teva neuroscience inc,0,0
090000648178d24f,Other,FDA-2014-P-0933-0001,FDA-2014-P-0933,citizen petition from teva neuroscience,0,0
09000064817b5bbf,Other,FDA-2014-P-0933-0016,FDA-2014-P-0933,"supplement from teva neuroscience, inc.",0,0
090000648178e16a,Supporting & Related Material,FDA-2014-P-0933-0013,FDA-2014-P-0933,exhibit 11 leber letter citizen petition from teva neuroscience inc.,0,0
090000648343b713,Other,FDA-2018-P-1949-0045,FDA-2018-P-1949,"petition response letter from fda cder to avadel specialty pharmaceuticals, llc",0,0
090000648327fa49,Other,FDA-2018-P-1949-0001,FDA-2018-P-1949,"citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327fa4b,Other,FDA-2018-P-1949-0002,FDA-2018-P-1949,"acknowledgment letter from fda ddm to avadel specialty pharmaceuticals, llc",0,0
090000648327fa70,Supporting & Related Material,FDA-2018-P-1949-0009,FDA-2018-P-1949,"fn 8_stanley 2005 eur urol supp_importance of sleep re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327facf,Supporting & Related Material,FDA-2018-P-1949-0040,FDA-2018-P-1949,"fn 47_20150112-emdac-t1-transcript re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327face,Supporting & Related Material,FDA-2018-P-1949-0039,FDA-2018-P-1949,"fn 46_ad comm minutes 1_12_15 re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327fac6,Supporting & Related Material,FDA-2018-P-1949-0034,FDA-2018-P-1949,"fn 38_nct01262456 clinicaltrials_gov re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327fa89,Supporting & Related Material,FDA-2018-P-1949-0021,FDA-2018-P-1949,"fn 22_cohn 2017_expert rev clin pharmacol re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327fa72,Supporting & Related Material,FDA-2018-P-1949-0011,FDA-2018-P-1949,"fn 10_stewart 1992 j am ger soc_nocturia risk of falls in elderly re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327faa4,Supporting & Related Material,FDA-2018-P-1949-0023,FDA-2018-P-1949,"fn 24_ad comm transcript 1_12_15 re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327facb,Supporting & Related Material,FDA-2018-P-1949-0036,FDA-2018-P-1949,"fn 42_guidance for industry_pro measures 2009 re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327fad0,Supporting & Related Material,FDA-2018-P-1949-0041,FDA-2018-P-1949,"fn 48_nocdurna 2015 complete response letter_redacted re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327fad1,Supporting & Related Material,FDA-2018-P-1949-0042,FDA-2018-P-1949,"fn 49_furness 2011 cochrane oral health group re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327faca,Supporting & Related Material,FDA-2018-P-1949-0035,FDA-2018-P-1949,"fn 41_chapple et al_2006 eur urol re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327facc,Supporting & Related Material,FDA-2018-P-1949-0037,FDA-2018-P-1949,"fn 43_abrams 2018 neurourology urodynamics re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327fa4d,Supporting & Related Material,FDA-2018-P-1949-0003,FDA-2018-P-1949,"fn 2_bosch 2010 prevalence and cause of nocturia re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327fa4e,Supporting & Related Material,FDA-2018-P-1949-0004,FDA-2018-P-1949,"fn 3_markland 2011 j urol_nhanes prevalence of nocturia voids per night re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327fa4f,Supporting & Related Material,FDA-2018-P-1949-0005,FDA-2018-P-1949,"fn 4_wein 2002 bjui re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327fa74,Supporting & Related Material,FDA-2018-P-1949-0013,FDA-2018-P-1949,"fn 12_kobelt 2003 bju intl_vitality utility productivity in nocturia re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327fa75,Supporting & Related Material,FDA-2018-P-1949-0014,FDA-2018-P-1949,"fn 13_tikkinen 2010 eur urol_nocturia frequency bother and qol finland re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327fa84,Supporting & Related Material,FDA-2018-P-1949-0018,FDA-2018-P-1949,"fn 19_fjellestad 1993 clinical endocrinol re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327fac2,Supporting & Related Material,FDA-2018-P-1949-0030,FDA-2018-P-1949,"fn 34_jin 2008 indian j urol_practical mgmt of nocturia re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327facd,Supporting & Related Material,FDA-2018-P-1949-0038,FDA-2018-P-1949,"fn 44_bennett 2018 neurourology urodynamics re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327fad2,Supporting & Related Material,FDA-2018-P-1949-0043,FDA-2018-P-1949,"fn 50_nocdurna sublingual wafers_product information re citizen petition from avadel specialty pharmaceuticals, llc",0,0
090000648327fa6f,Supporting & Related Material,FDA-2018-P-1949-0008,FDA-2018-P-1949,"fn 7_weiss 2009 j urol_prev of np in nocturia re citizen petition from avadel specialty pharmaceuticals, llc",0,0
0900006481b6dc3f,Other,FDA-2015-P-2373-0002,FDA-2015-P-2373,"acknowledgement letter from fda ddm to david k. cundiff, md",0,0
090000648490b114,Other,FDA-2015-P-2373-0008,FDA-2015-P-2373,response letter from fda cder to dr. david k. cundiff,0,0
0900006481dd5a42,Other,FDA-2015-P-2373-0006,FDA-2015-P-2373,interim response letter from fda cder to dr. david k. cundiff,0,0
0900006481b6d5ee,Other,FDA-2015-P-2373-0001,FDA-2015-P-2373,"citizen petition from david k. cundiff, md",0,0
090000648457a555,Other,FDA-2019-P-4424-0004,FDA-2019-P-4424,response letter from fda  cder to hibrow healthcare  llc,0,0
0900006483fac2b1,Other,FDA-2019-P-4424-0001,FDA-2019-P-4424,citizen petition from hibrow healthcare llc,0,0
0900006483fac2b2,Other,FDA-2019-P-4424-0002,FDA-2019-P-4424,acknowledgment letter from fda dms to hibrow healthcare llc,0,0
09000064844bf0e2,Other,FDA-2019-P-4424-0003,FDA-2019-P-4424,interim response letter from fda cder to hibrow healthcare llc,0,0
0900006482d843bf,Other,FDA-2017-P-7032-0001,FDA-2017-P-7032,citizen petition from jubilant generics limited,0,0
0900006482d84aba,Supporting & Related Material,FDA-2017-P-7032-0005,FDA-2017-P-7032,exhibit 3 draft labeling for proposed product re citizen petition from jubilant generics limited,0,0
0900006482d84ab7,Supporting & Related Material,FDA-2017-P-7032-0003,FDA-2017-P-7032,exhibit 1 electronic orange book re citizen petition from jubilant generics limited,0,0
0900006482d843c1,Other,FDA-2017-P-7032-0002,FDA-2017-P-7032,acknowledgment letter from fda ddm to jubilant generics limited,0,0
0900006482d84ab8,Supporting & Related Material,FDA-2017-P-7032-0004,FDA-2017-P-7032,exhibit 2 rld labeling re citizen petition from jubilant generics limited,0,0
0900006484c4a80a,Other,FDA-2017-P-7032-0006,FDA-2017-P-7032,petition approval letter from fda cder to jubilant generics limited,0,0
09000064841edadf,Supporting & Related Material,FDA-2019-P-5760-0005,FDA-2019-P-5760,attachment 3 reference listed drug prescribing information for levetiracetam in sodium chloride injection re: citizen petition from sun pharmaceutical industries limited,0,0
09000064841edad8,Other,FDA-2019-P-5760-0002,FDA-2019-P-5760,acknowledgment letter from fda dms to sun pharmaceutical industries limited,0,0
09000064841edade,Supporting & Related Material,FDA-2019-P-5760-0004,FDA-2019-P-5760,"attachment 2 proposed prescribing information for levetiracetam in sodium chloride injection 2.5 mg/ml, 5 mg/ml, 10 mg/ml and 15 mg/ml re: citizen petition from sun pharmaceutical industries limited",0,0
0900006484bd644b,Other,FDA-2019-P-5760-0006,FDA-2019-P-5760,amendment from sun pharmaceutical industries limited,0,0
09000064841ed95d,Other,FDA-2019-P-5760-0001,FDA-2019-P-5760,citizen petition from sun pharmaceutical industries limited,0,0
09000064841edadd,Supporting & Related Material,FDA-2019-P-5760-0003,FDA-2019-P-5760,attachment 1 approved drug products with therapeutic equivalence evaluation re: citizen petition from sun pharmaceutical industries limited,0,0
09000064844c6c80,Other,FDA-2019-P-1351-1251,FDA-2019-P-1351,letter from law office of alan dumoff,0,0
0900006483b0f6dc,Other,FDA-2019-P-1351-0002,FDA-2019-P-1351,"acknowledgment letter from fda ddm to law office of alan dumoff on behalf of american association of naturopathic physicians, et al",0,0
0900006483b0d4e2,Other,FDA-2019-P-1351-0001,FDA-2019-P-1351,"citizen petition from law office of alan dumoff on behalf of american association of naturopathic physicians, et al",0,0
0900006483f87413,Other,FDA-2019-P-1351-0351,FDA-2019-P-1351,interim response letter from fda cder to law office of alan dumoff on behalf of american association of naturopathic physicians,0,0
09000064804619af,Notice,FDA-2006-N-0425-0002,FDA-2006-N-0425,fda,0,0
0900006480461999,Notice,FDA-2006-N-0425-0001,FDA-2006-N-0425,fda,0,0
0900006480463622,Notice,FDA-2006-N-0491-0001,FDA-2006-N-0491,fda,0,0
090000648046364e,Notice,FDA-2006-N-0491-0002,FDA-2006-N-0491,fda,0,0
0900006480a007e0,Notice,FDA-2009-N-0353-0001,FDA-2009-N-0353,cooperative agreement between the food and drug administration and the dauphin island sea lab,1,0
09000064837dd937,Other,FDA-2018-P-3896-0002,FDA-2018-P-3896,acknowledgment letter from fda ddm chul-hi park ph.d.,0,0
09000064837de290,Supporting & Related Material,FDA-2018-P-3896-0003,FDA-2018-P-3896,attachment 1 pedestrian physics of staple line leaks re: citizen petition from chul-hi park ph.d.,0,0
090000648495db00,Other,FDA-2018-P-3896-0005,FDA-2018-P-3896,interim response from fda cdrh to chul-hi park,0,0
09000064837dad33,Other,FDA-2018-P-3896-0001,FDA-2018-P-3896,citizen petition from chul-hi park ph.d.,0,0
0900006484dc39fa,Other,FDA-2018-P-3896-0006,FDA-2018-P-3896,petition response from fda cdrh to chul-hi park,0,0
0900006484dc9b20,Other,FDA-2021-P-1124-0002,FDA-2021-P-1124,acknowledgment letter from fda dms to pet schooled,0,0
0900006484dc9a35,Other,FDA-2021-P-1124-0001,FDA-2021-P-1124,citizen petition from pet schooled,0,0
0900006481f11635,Other,FDA-2016-P-1107-0001,FDA-2016-P-1107,citizen petition from gordon johnston regulatory consultants llc,0,0
0900006481f11697,Supporting & Related Material,FDA-2016-P-1107-0003,FDA-2016-P-1107,attachment a product listing from the active section of the orange book -  re citizen petition from gordon johnston regulatory consultants llc,0,0
090000648235b994,Other,FDA-2016-P-1107-0004,FDA-2016-P-1107,letter from cder fda to gordon johnston regulatory consultants llc,0,0
0900006481f13d78,Other,FDA-2016-P-1107-0002,FDA-2016-P-1107,acknowledgement letter from fda ddm to gordon johnston regulatory consultants llc,0,0
0900006480be0f3b,Notice,FDA-2011-N-0049-0001,FDA-2011-N-0049,"agency information collection activities; proposals, submissions, and approvals: presubmission conferences, new animal drug applications and supporting regulations, etc.",0,0
0900006480c25e9a,Notice,FDA-2011-N-0049-0002,FDA-2011-N-0049,"agency information collection activities; submission for office  of management  and budget review; comment request; presubmission conferences, new animal drug applications and supporting regulations, and food and drug administation form 356v",1,0
0900006482953f1d,Supporting & Related Material,FDA-2017-P-4372-0001,FDA-2017-P-4372,"attachment 1- biosmetics eye care re citizen petition from aegis regulatory, inc.",0,0
0900006482e19815,Other,FDA-2017-P-4372-0004,FDA-2017-P-4372,petition denial letter from fda cfsan to aegis,0,0
090000648295386b,Other,FDA-2017-P-4372-0002,FDA-2017-P-4372,"citizen petition from aegis regulatory, inc.",0,0
0900006482953e5f,Other,FDA-2017-P-4372-0003,FDA-2017-P-4372,"acknowledgment letter from fda ddm to aegis regulatory, inc.",0,0
0900006482bfe2c4,Other,FDA-2017-P-6248-0001,FDA-2017-P-6248,"citizen petiton from lachman consultant services, inc",0,0
0900006482bfe3b2,Supporting & Related Material,FDA-2017-P-6248-0004,FDA-2017-P-6248,"attachment 2 draft insert labeling for proposed product re citizen petiton from lachman consultant services, inc",0,0
0900006482bfe3b1,Supporting & Related Material,FDA-2017-P-6248-0003,FDA-2017-P-6248,"attachment 1 approved drug products with therapeutic equivalence evaluations re citizen petiton from lachman consultant services, inc",0,0
0900006482bfe3af,Other,FDA-2017-P-6248-0002,FDA-2017-P-6248,"acknowledgement letter from fda ddm to lachman consultant services, inc",0,0
0900006482bfe3b3,Supporting & Related Material,FDA-2017-P-6248-0005,FDA-2017-P-6248,"attachment 3 approved labeling for reference-listed drug, topamax (topiramate) tablets re citizen petiton from lachman consultant services, inc",0,0
090000648172a4bb,Other,FDA-2014-P-0752-0002,FDA-2014-P-0752,"citizen petition from pharmacist's planning service, inc.",0,0
0900006481a805fa,Other,FDA-2014-P-0752-0003,FDA-2014-P-0752,petition denial letter from fda cder to pharmacists planning service inc. ppsi,0,0
090000648172a4c1,Other,FDA-2014-P-0752-0001,FDA-2014-P-0752,"acknowledgement letter from fda ddm to pharmacists planning service, inc.",0,0
0900006482344c9e,Supporting & Related Material,FDA-2014-P-1282-0007,FDA-2014-P-1282,attachment 3 fda-approved labeling for rld (2016) re suitability petition amendment from morgan lewis & bockius llp,0,0
0900006482344e28,Supporting & Related Material,FDA-2014-P-1282-0008,FDA-2014-P-1282,attachment 4 draft labeling for proposed anda product (2016} re suitability petition amendment from morgan lewis & bockius llp,0,0
0900006482344c07,Other,FDA-2014-P-1282-0005,FDA-2014-P-1282,suitability petition amendment from morgan lewis & bockius llp,0,0
0900006481864b3c,Supporting & Related Material,FDA-2014-P-1282-0004,FDA-2014-P-1282,attachment 1 fda approved labeling for reference listed drug,0,0
0900006481864b3b,Supporting & Related Material,FDA-2014-P-1282-0003,FDA-2014-P-1282,attachment 2 draft labeling for proposed anda drug,0,0
0900006481857034,Other,FDA-2014-P-1282-0001,FDA-2014-P-1282,citizen petition from morgan lewis & bockius llp,0,0
0900006482344c99,Supporting & Related Material,FDA-2014-P-1282-0006,FDA-2014-P-1282,attachment 2 draft labeling for proposed anda product (2014) re suitability petition amendment from morgan lewis & bockius llp,0,0
0900006481857036,Other,FDA-2014-P-1282-0002,FDA-2014-P-1282,acknowledgement letter from fda ddm to morgan lewis & bockius llp,0,0
09000064821e0d87,Notice,FDA-2016-P-1037-0004,FDA-2016-P-1037,"determination that prevacid iv (lansoprazole) intravenous injection,
30 milligrams/vial, was not withdrawn from sale for reasons of safety or
effectiveness",0,0
0900006481ed7162,Other,FDA-2016-P-1037-0001,FDA-2016-P-1037,"citizen petition from rose zhao, emprise pharma",0,0
0900006481ed7508,Other,FDA-2016-P-1037-0003,FDA-2016-P-1037,acknowledgement letter from fda ddm to rose zhao,0,0
0900006481ed7d94,Supporting & Related Material,FDA-2016-P-1037-0002,FDA-2016-P-1037,"attachment 1 - orange book: approved drug products with therapeutic equivalence evaluations for prevacid iv re citizen petition from rose zhao, emprise pharma",0,0
0900006481856a09,Supporting & Related Material,FDA-2014-P-1038-0004,FDA-2014-P-1038,"attachment b amphetamine sulfate description  each tablet for oral administration contains 5 mg or 10 mg of amphetamine sulfate re citizen petition from lachman consultant services inc., fda-2014-p-1038-0001",0,0
0900006481856a08,Supporting & Related Material,FDA-2014-P-1038-0003,FDA-2014-P-1038,"attachment a orange book approved drug products with therapeutic equivalence evaluations re citizen petition from lachman consultant services inc., fda-2014-p-1038-0001",0,0
090000648185693a,Other,FDA-2014-P-1038-0002,FDA-2014-P-1038,acknowledgement letter from fda ddm to lachman consultant services inc,0,0
0900006481855c94,Other,FDA-2014-P-1038-0001,FDA-2014-P-1038,citizen petition from lachman consultant services inc,0,0
0900006481856a0a,Supporting & Related Material,FDA-2014-P-1038-0005,FDA-2014-P-1038,"attachment c amphetamine sulfate description  each tablet for oral administration contains 2.5 mg  5 mg 10 mg 15 mg 20 mg or 30 mg of amphetamine sulfate re citizen petition from lachman consultant services inc., fda-2014-p-1038-0001",0,0
090000648424b53f,Other,FDA-2019-P-3082-0004,FDA-2019-P-3082,"interim response letter from fda cder to andarix pharmaceuticals, inc",0,0
0900006483d42e3e,Other,FDA-2019-P-3082-0001,FDA-2019-P-3082,"citizen petition from andarix pharmaceuticals, inc.",0,0
0900006483d42b69,Other,FDA-2019-P-3082-0002,FDA-2019-P-3082,"acknowledgment letter from fda ddm to andarix pharmaceuticals, inc.",0,0
0900006483d44de6,Supporting & Related Material,FDA-2019-P-3082-0003,FDA-2019-P-3082,"appendix 1- electronic orange book listing of neo tect kit re citizen petition from andarix pharmaceuticals, inc.",0,0
09000064843d8726,Notice,FDA-2019-P-3082-0005,FDA-2019-P-3082,determination that neo tect kit (kit for the preparation of technetium tc–99m depreotide injection) was not withdrawn from sale for reasons of safety or effectiveness,0,0
09000064823da94a,Other,FDA-2016-P-4164-0002,FDA-2016-P-4164,"acknowledgment letter from fda ddm to lachman consultant services, inc.",0,0
09000064823daa90,Supporting & Related Material,FDA-2016-P-4164-0005,FDA-2016-P-4164,attachment 3 - carbinoxamine maleate- carbinoxamine maleate tablet re citizen petition from lachman consultant services inc,0,0
09000064823daa8e,Supporting & Related Material,FDA-2016-P-4164-0003,FDA-2016-P-4164,attachment 1 - orange book approved drug products with therapeutic equivalence re citizen petition from lachman consultant services inc,0,0
09000064823daa8f,Supporting & Related Material,FDA-2016-P-4164-0004,FDA-2016-P-4164,attachment 2 - carbinoxamine maleate - carbinoxamine maleate orally disintegrating tablet re citizen petition from lachman consultant services inc,0,0
0900006484841d57,Other,FDA-2016-P-4164-0006,FDA-2016-P-4164,response for information request from lachman consultant services,0,0
09000064823da316,Other,FDA-2016-P-4164-0001,FDA-2016-P-4164,citizen petition from lachman consultant services inc,0,0
0900006481750c88,Supporting & Related Material,FDA-2014-P-0813-0004,FDA-2014-P-0813,"attachment 2 labeling for listed drug, sandoz, citizen petition from lachman consultant services inc.",0,0
0900006481750c89,Supporting & Related Material,FDA-2014-P-0813-0005,FDA-2014-P-0813,"attachment 3 labeling for drug, eagle pharm, citizen petition from lachman consultant services inc.",0,0
090000648484f8c1,Other,FDA-2014-P-0813-0007,FDA-2014-P-0813,"withdrawal from lachman consultant services, inc.",0,0
0900006481750c8a,Supporting & Related Material,FDA-2014-P-0813-0006,FDA-2014-P-0813,"attachment 4 draft insert labeling, citizen petition from lachman consultant services inc.",0,0
0900006481750b20,Other,FDA-2014-P-0813-0001,FDA-2014-P-0813,"citizen petition from lachman consultant services, inc.",0,0
0900006481750c85,Other,FDA-2014-P-0813-0002,FDA-2014-P-0813,"acknowledgement letter from fda ddm to lachman consultant services, inc.",0,0
0900006481750c87,Supporting & Related Material,FDA-2014-P-0813-0003,FDA-2014-P-0813,attachment 1 orange book excerpt citizen petition from lachman consultant services inc.,0,0
0900006482a9619d,Other,FDA-2017-P-5124-0001,FDA-2017-P-5124,"citizen petition from hyman, phelps & mcnamara, pc",0,0
0900006482ef71e5,Other,FDA-2017-P-5124-0004,FDA-2017-P-5124,"final response letter from fda to hyman, phelps & mcnamara, pc",0,0
090000648300e7c9,Rule,FDA-2017-P-5124-0005,FDA-2017-P-5124,medical devices: exemption from premarket notification; class ii devices; over-the-counter denture repair kit,0,0
0900006482c9142c,Notice,FDA-2017-P-5124-0003,FDA-2017-P-5124,medical devices; exemption from premarket notification: over-the-counter denture repair kits,0,0
0900006482a961a1,Other,FDA-2017-P-5124-0002,FDA-2017-P-5124,"acknowledgement letter from fda ddm to hyman, phelps & mcnamara, pc",0,0
090000648297f09f,Other,FDA-2017-P-4500-0001,FDA-2017-P-4500,citizen petition from kent heckenlively,0,0
0900006484486259,Other,FDA-2017-P-4500-1795,FDA-2017-P-4500,interim response heckenlively cp final,0,0
090000648297f601,Supporting & Related Material,FDA-2017-P-4500-0003,FDA-2017-P-4500,exhibit a vaccination moratorium regulation re citizen petition from kent heckenlively,0,0
090000648297f0cb,Other,FDA-2017-P-4500-0002,FDA-2017-P-4500,acknowledgement letter from fda ddm to kent heckenlively,0,0
0900006484b39782,Supporting & Related Material,FDA-2021-P-0513-0003,FDA-2021-P-0513,"attachment 1 - colestid prescription drug list re suitability petition from hyman, phelps & mcnamara p.c.",0,0
0900006484b39785,Supporting & Related Material,FDA-2021-P-0513-0004,FDA-2021-P-0513,"attachment 2 - colestid pi flavored colestid- colestipol hydrochloride granule, for suspension pharmacia and upjohn company llc re suitability petition from hyman, phelps & mcnamara p.c.",0,0
0900006484b39786,Supporting & Related Material,FDA-2021-P-0513-0005,FDA-2021-P-0513,"attachment 3 - colestipol hydrochloride pi colestipol hydrochloride granules for oral suspension re suitability petition from hyman, phelps & mcnamara p.c.",0,0
0900006484b38fcd,Other,FDA-2021-P-0513-0002,FDA-2021-P-0513,"acknowledgment letter from fda dms to hyman, phelps & mcnamara p.c.",0,0
0900006484b38fcb,Other,FDA-2021-P-0513-0001,FDA-2021-P-0513,"suitability petition from hyman, phelps & mcnamara p.c.",0,0
0900006484b4186d,Other,FDA-2020-P-2247-0020,FDA-2020-P-2247,interim response letter from fda cder to boehringer ingelheim usa corporation,0,0
0900006484ab8e22,Supporting & Related Material,FDA-2020-P-2247-0018,FDA-2020-P-2247,summary of 3-17-21 meeting with boehringer ingelheim,0,0
0900006484981e75,Supporting & Related Material,FDA-2020-P-2247-0006,FDA-2020-P-2247,"exhibit 9 re: boehringer ingelheim usa corporation on behalf of boehringer ingelheim pharmaceuticals, inc",0,0
0900006484981e4c,Supporting & Related Material,FDA-2020-P-2247-0013,FDA-2020-P-2247,"exhibit 2 re: boehringer ingelheim usa corporation on behalf of boehringer ingelheim pharmaceuticals, inc",0,0
0900006484981e77,Supporting & Related Material,FDA-2020-P-2247-0004,FDA-2020-P-2247,"exhibit 11 re: boehringer ingelheim usa corporation on behalf of boehringer ingelheim pharmaceuticals, inc",0,0
0900006484981e76,Supporting & Related Material,FDA-2020-P-2247-0005,FDA-2020-P-2247,"exhibit 10 re: boehringer ingelheim usa corporation on behalf of boehringer ingelheim pharmaceuticals, inc",0,0
0900006484981e4d,Supporting & Related Material,FDA-2020-P-2247-0012,FDA-2020-P-2247,"exhibit 3 re: boehringer ingelheim usa corporation on behalf of boehringer ingelheim pharmaceuticals, inc",0,0
0900006484981e74,Supporting & Related Material,FDA-2020-P-2247-0007,FDA-2020-P-2247,"exhibit 8 re: boehringer ingelheim usa corporation on behalf of boehringer ingelheim pharmaceuticals, inc",0,0
0900006484981e4f,Supporting & Related Material,FDA-2020-P-2247-0010,FDA-2020-P-2247,"exhibit 5 re: boehringer ingelheim usa corporation on behalf of boehringer ingelheim pharmaceuticals, inc",0,0
0900006484981e78,Supporting & Related Material,FDA-2020-P-2247-0003,FDA-2020-P-2247,"exhibit 12 re: boehringer ingelheim usa corporation on behalf of boehringer ingelheim pharmaceuticals, inc",0,0
0900006484981e49,Other,FDA-2020-P-2247-0002,FDA-2020-P-2247,"acknowledgment letter from fda dms to boehringer ingelheim usa corporation on behalf of boehringer ingelheim pharmaceuticals, inc",0,0
0900006484982237,Other,FDA-2020-P-2247-0001,FDA-2020-P-2247,"citizen petition from boehringer ingelheim usa corporation on behalf of boehringer ingelheim pharmaceuticals, inc",0,0
0900006484ab8e23,Supporting & Related Material,FDA-2020-P-2247-0019,FDA-2020-P-2247,boehringer ingelheim fda meeting slides,0,0
0900006484981e4b,Supporting & Related Material,FDA-2020-P-2247-0014,FDA-2020-P-2247,"exhibit 1 re: boehringer ingelheim usa corporation on behalf of boehringer ingelheim pharmaceuticals, inc",0,0
0900006484981e4e,Supporting & Related Material,FDA-2020-P-2247-0011,FDA-2020-P-2247,"exhibit 4 re: boehringer ingelheim usa corporation on behalf of boehringer ingelheim pharmaceuticals, inc",0,0
0900006484981e50,Supporting & Related Material,FDA-2020-P-2247-0009,FDA-2020-P-2247,"exhibit 6 re: boehringer ingelheim usa corporation on behalf of boehringer ingelheim pharmaceuticals, inc",0,0
0900006484981e51,Supporting & Related Material,FDA-2020-P-2247-0008,FDA-2020-P-2247,"exhibit 7 re: boehringer ingelheim usa corporation on behalf of boehringer ingelheim pharmaceuticals, inc",0,0
0900006484cb2a60,Other,FDA-2021-P-0953-0001,FDA-2021-P-0953,citizen petition from lisa harper,0,0
0900006484cb2a37,Other,FDA-2021-P-0953-0002,FDA-2021-P-0953,acknowledgment letter from fda dms to lisa harper,0,0
090000648045729b,Notice,FDA-2006-N-0245-0004,FDA-2006-N-0245,fda,0,0
0900006480457292,Supporting & Related Material,FDA-2006-N-0245-0002,FDA-2006-N-0245,supporting statement,0,0
090000648045729a,Supporting & Related Material,FDA-2006-N-0245-0003,FDA-2006-N-0245,supporting statement,0,0
0900006480457276,Notice,FDA-2006-N-0245-0001,FDA-2006-N-0245,fda,0,0
0900006480a5f1d0,Other,FDA-2009-D-0563-0002,FDA-2009-D-0563,"draft guidance for industry and food and drug administration staff; preliminary timetable for the review of applications for modified risk tobacco products under the federal food, drug, and cosmetic act; guidance",1,1
0900006480a5f56b,Notice,FDA-2009-D-0563-0001,FDA-2009-D-0563,"draft guidance for industry and food and drug administration staff; preliminary timetable for the review of applications for modified risk tobacco products under the federal food, drug, and cosmetic act; availability",1,1
0900006484a73c42,Other,FDA-2021-P-0311-0002,FDA-2021-P-0311,acknowledgment letter from fda dms to loeb & loeb llp,0,0
0900006484a73c40,Other,FDA-2021-P-0311-0001,FDA-2021-P-0311,citizen petition from loeb & loeb llp,0,0
0900006484d7c830,Other,FDA-2021-P-0311-0003,FDA-2021-P-0311,interim response from fda cder to james n. czaban and eve costopoulos,0,0
0900006482a32e19,Other,FDA-2017-P-4939-0002,FDA-2017-P-4939,acknowledgement letter from fda ddm to chul-hi park,0,0
09000064833efb10,Other,FDA-2017-P-4939-0005,FDA-2017-P-4939,interim response letter to dr. chul-hi park,0,0
0900006483338191,Other,FDA-2017-P-4939-0004,FDA-2017-P-4939,interim response letter from fda-cdrh to dr. chul-hi park,0,0
0900006484dc39d8,Other,FDA-2017-P-4939-0006,FDA-2017-P-4939,petition response from fda cdrh to chul-hi park,0,0
0900006482a32dc7,Other,FDA-2017-P-4939-0001,FDA-2017-P-4939,citizen petition from chul-hi park,0,0
0900006484e42d22,Supporting & Related Material,FDA-2021-P-1215-0003,FDA-2021-P-1215,attachment 1 - federal register re: citizen petition from alembic pharmaceutical limited,0,0
0900006484e42c90,Other,FDA-2021-P-1215-0002,FDA-2021-P-1215,acknowledgment letter from fda dms to alembic pharmaceutical limited,0,0
0900006484e42d23,Supporting & Related Material,FDA-2021-P-1215-0004,FDA-2021-P-1215,attachment 2 - electronic orange book re: citizen petition from alembic pharmaceutical limited,0,0
0900006484e42036,Other,FDA-2021-P-1215-0001,FDA-2021-P-1215,citizen petition from alembic pharmaceutical limited,0,0
09000064822f358e,Supporting & Related Material,FDA-2016-P-3311-0003,FDA-2016-P-3311,attachment a evidence to support the use of polydextrose as a source of dietary fiber in the united states: evidence summarizing its physiological effects and caloric content re citizen petition from tate & lyle ingredients americas llc  and dupont nutrition & health,0,0
09000064822f358f,Supporting & Related Material,FDA-2016-P-3311-0004,FDA-2016-P-3311,"attachment b - part 1 gastrointestinal effects and energy value of polydextrose in healthy non obese men 1, 2 re citizen petition from tate & lyle ingredients americas llc  and dupont nutrition & health",0,0
09000064822f3592,Supporting & Related Material,FDA-2016-P-3311-0007,FDA-2016-P-3311,attachment b - part 4 impact of dietary polydextrose fiber on the human gut metabolome re citizen petition from tate & lyle ingredients americas llc  and dupont nutrition & health,0,0
09000064822f358c,Other,FDA-2016-P-3311-0001,FDA-2016-P-3311,citizen petition from tate & lyle ingredients americas llc  and dupont nutrition & health,0,0
09000064822f3594,Supporting & Related Material,FDA-2016-P-3311-0009,FDA-2016-P-3311,attachment b - part 6  polydextrose: its impact on short-term food intake and subjective feelings of satiety in males-a randomized controlled cross-over study re citizen petition from tate & lyle ingredients americas llc  and dupont nutrition & health,1,0
0900006482534b14,Other,FDA-2016-P-3311-0012,FDA-2016-P-3311,tate & lyle ingredients americas llc and dupont nutrition & health,0,0
09000064822f3593,Supporting & Related Material,FDA-2016-P-3311-0008,FDA-2016-P-3311,"attachment b - part 5 comparative laxation of psyllium with and without
senna in an ambulatory constipated population re citizen petition from tate & lyle ingredients americas llc  and dupont nutrition & health",0,0
09000064822f43d7,Other,FDA-2016-P-3311-0002,FDA-2016-P-3311,acknowledgment letter from fda ddm to tate & lyle ingredients americas llc  and dupont nutrition & health,0,0
09000064822f3590,Supporting & Related Material,FDA-2016-P-3311-0005,FDA-2016-P-3311,"attachment b - part 2 effect of high cholesterol diet and polydextrose supplementation on the microflora, bacterial enzyme activity, putrefactive products, volatile faty acid re citizen petition from tate & lyle ingredients americas llc  and dupont nutrition & health",0,0
09000064822f3591,Supporting & Related Material,FDA-2016-P-3311-0006,FDA-2016-P-3311,attachment b - part 3 effects of polydextrose on different levels of energy intake.  a systematic review and meta-analysis re citizen petition from tate & lyle ingredients americas llc  and dupont nutrition & health,0,0
0900006483410f0c,Other,FDA-2016-P-3311-0013,FDA-2016-P-3311,fda-2016-p-3311 tatelyle dupont nutrition granting response,0,0
0900006484e03fba,Other,FDA-2021-P-1183-0002,FDA-2021-P-1183,acknowledgment letter from fda dms to pet schooled,0,0
0900006484e03f8a,Other,FDA-2021-P-1183-0001,FDA-2021-P-1183,citizen petition from pet schooled,0,0
09000064849ae940,Notice,FDA-2010-N-0161-0012,FDA-2010-N-0161,agency information collection activities; submission for office of management and budget review; comment request; export of food and drug administration-regulated products: export certificates,1,0
0900006482cae34e,Notice,FDA-2010-N-0161-0007,FDA-2010-N-0161,"agency information collection activities; proposed collection; 
comment request; export of food and drug administration-regulated 
products: export certificates",1,0
090000648192e746,Notice,FDA-2010-N-0161-0003,FDA-2010-N-0161,"agency information collection activities; proposed collection;
comment request; export of food and drug administration regulated
products: export certificates",1,0
09000064849f0cfc,Notice,FDA-2010-N-0161-0013,FDA-2010-N-0161,agency information collection activities; submission for office of management and budget review; comment request; export of food and drug administration-regulated products: export certificates,1,0
0900006484b1b457,Notice,FDA-2010-N-0161-0015,FDA-2010-N-0161,agency information collection activities; announcement of office of management and budget approvals,0,0
0900006480acd1ce,Notice,FDA-2010-N-0161-0001,FDA-2010-N-0161,"agency information collection activities; proposals, submissions, and approvals: export of food and drug administration regulated products; export certificates",1,0
0900006480b67bc8,Notice,FDA-2010-N-0161-0002,FDA-2010-N-0161,"agency information collection activities; proposals, submissions, and approvals: export of food and drug administration regulated products; export certificates",1,0
0900006482f453d7,Notice,FDA-2010-N-0161-0010,FDA-2010-N-0161,"agency information collection activities; submission for office of
management and budget review; comment request; export of food and drug administration-regulated products: export certificates",1,0
09000064819f7e45,Notice,FDA-2010-N-0161-0004,FDA-2010-N-0161,"agency information collection activities; submission for office of
management and budget review; comment request; export of food and drug administration regulated products: export certificates",1,0
090000648337b832,Notice,FDA-2010-N-0161-0011,FDA-2010-N-0161,"agency information collection activities; announcement of office of
management and budget approvals",0,0
0900006481a02519,Notice,FDA-2010-N-0161-0005,FDA-2010-N-0161,"agency information collection activities; submission for office of management and budget review; comment request; export of food and drug administration regulated products: export certificates;
correction",1,0
0900006481b5dc5e,Notice,FDA-2010-N-0161-0006,FDA-2010-N-0161,"agency information collection activities; announcement of office of
management and budget approval; export certificates for food and drug administration regulated products",1,0
09000064824e152e,Supporting & Related Material,FDA-2017-P-1230-0003,FDA-2017-P-1230,attachment 1 orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from regcon solutions,0,0
09000064824e152b,Other,FDA-2017-P-1230-0001,FDA-2017-P-1230,citizen petition from regcon solutions,0,0
09000064824e152d,Other,FDA-2017-P-1230-0002,FDA-2017-P-1230,acknowledgement letter from fda ddm to regcon solutions,0,0
0900006482d441c1,Other,FDA-2017-P-1230-0006,FDA-2017-P-1230,final response from fda cder to regcon solutions,0,0
0900006482a8da9b,Other,FDA-2017-P-1230-0004,FDA-2017-P-1230,interim response from fda cder to regcon solutions,0,0
09000064839ac197,Other,FDA-2016-P-1285-0008,FDA-2016-P-1285,"letter from fda cder to akorn pharmaceuticals, mylan pharmaceuticals, inc., gland pharma limited, foley & lardner llp",0,0
0900006481fd8973,Supporting & Related Material,FDA-2016-P-1285-0003,FDA-2016-P-1285,"attachment 1 approved drug products with therapeutic equivalence evaluation (electronic orange book) accessed may 11, 2016 re citizen petition from mylan pharmaceuticals inc",0,0
0900006481fda244,Other,FDA-2016-P-1285-0002,FDA-2016-P-1285,acknowledgement letter from fda ddm to mylan pharmaceuticals inc,0,0
0900006481fd8971,Other,FDA-2016-P-1285-0001,FDA-2016-P-1285,citizen petition from mylan pharmaceuticals inc,0,0
0900006481fd8975,Supporting & Related Material,FDA-2016-P-1285-0005,FDA-2016-P-1285,"attachment 3 labeling of the approved product, furosemide injection-10 mg/ml by fresenius kabi re citizen petition from mylan pharmaceuticals inc",0,0
0900006481fd8974,Supporting & Related Material,FDA-2016-P-1285-0004,FDA-2016-P-1285,"attachment 2 draft insert labeling proposed for furosemide injection, usp-10 mg/ml re citizen petition from mylan pharmaceuticals inc",0,0
0900006481fd8976,Supporting & Related Material,FDA-2016-P-1285-0006,FDA-2016-P-1285,"attachment 4 labeling of the approved product, furosemide injection-10 mg/ml by hospira re citizen petition from mylan pharmaceuticals inc",0,0
0900006482f3ad3a,Other,FDA-2016-P-1285-0007,FDA-2016-P-1285,interim response letter from fda cder to mylan pharmaceuticals inc,0,0
0900006480f4c517,Notice,FDA-2011-N-0708-0001,FDA-2011-N-0708,"agency information collection activities; proposed collection; comment request; fda form 3728, animal generic drug user fee act cover sheet",0,0
090000648109da1c,Notice,FDA-2011-N-0708-0002,FDA-2011-N-0708,"agency information collection activities; proposals, submissions, and approvals: animal generic drug user fee act cover sheet",0,0
0900006480f65e5a,Other,FDA-2011-P-0355-0020,FDA-2011-P-0355,"mela sciences, inc. - withdrawal of citizen petition",0,0
0900006480c7a537,Supporting & Related Material,FDA-2011-P-0355-0017,FDA-2011-P-0355,"attachment 20 - ""electronic correspondence between eosciences and fda/cdrh, re p090012- melafind, november 23, 2009"" - [mela™ sciences, inc. - citizen petition]  - [mela™ sciences, inc. - citizen petition]",0,0
0900006480c79fd1,Supporting & Related Material,FDA-2011-P-0355-0007,FDA-2011-P-0355,"attachment 9 - ""fda/cdrh letter to electro-optical sciences, inc., october 4, 2006 re melafind"" - [mela™ sciences, inc. - citizen petition]",0,0
0900006480c7a10e,Supporting & Related Material,FDA-2011-P-0355-0010,FDA-2011-P-0355,"attachment 12 - ""fda pma p090012 executive summary, november 18, 2010"" - [mela™ sciences, inc. - citizen petition]",0,0
0900006480c7a534,Supporting & Related Material,FDA-2011-P-0355-0014,FDA-2011-P-0355,"attachment 17 - ""electronic correspondence between eosciences and fda/cdrh, re p090012 corrected filing letter, august 24, 2009"" - [mela™ sciences, inc. - citizen petition]",0,0
0900006480c79fcc,Supporting & Related Material,FDA-2011-P-0355-0003,FDA-2011-P-0355,"attachment 4 - ""105th congress, house of representatives (report 105-307) re medical device regulatory modernization act of 1997"" - [mela™ sciences, inc.  - citizen petition]",0,0
0900006480c79fcf,Supporting & Related Material,FDA-2011-P-0355-0006,FDA-2011-P-0355,"attachment 7 - ""electronic correspondence between eosciences and fda/cdrh, re revised protocol 20061, january 4, 2006"" - [mela™ sciences, inc. - citizen petition]",0,0
0900006480c7a111,Supporting & Related Material,FDA-2011-P-0355-0011,FDA-2011-P-0355,"attachment 13 - ""fda advisory committee, general and plastic surgery devices panel, november 18, 2010"" - [mela™ sciences, inc. - citizen petition]",0,0
0900006480c7a112,Supporting & Related Material,FDA-2011-P-0355-0012,FDA-2011-P-0355,"attachment 14 - ""fda presentation, p090012 melafind® mela sciences, inc., november 18. 2010"" - [mela™ sciences, inc. - citizen petition]",0,0
0900006480f65bee,Other,FDA-2011-P-0355-0021,FDA-2011-P-0355,"fda/cdrh to mela science, inc. - response letter",0,0
0900006480c7a539,Other,FDA-2011-P-0355-0019,FDA-2011-P-0355,"acknowledgement letter to mela sciences, inc.",0,0
0900006480c79fce,Supporting & Related Material,FDA-2011-P-0355-0005,FDA-2011-P-0355,"attachment 6 - electro-optical sciences, inc.™ protocol 20061: evaluation of pigmented skin lesions with melafind® system - [mela™ sciences, inc. - citizen petition]",0,0
0900006480c79fd2,Supporting & Related Material,FDA-2011-P-0355-0008,FDA-2011-P-0355,"attachment 10 - ""fda/cdrh letter to electro-optical sciences, inc., march 10, 2010, re melafind"" - [mela™ sciences, inc. - citizen petition]",0,0
0900006480c79fcb,Supporting & Related Material,FDA-2011-P-0355-0002,FDA-2011-P-0355,"attachment 3 - ""fda/cdrh division of general, restorative and neurological devices  letter to electro-optical sciences, inc., october 29, 2004"" - [mela™ sciences, inc. - citizen petition]",0,0
0900006480c79fcd,Supporting & Related Material,FDA-2011-P-0355-0004,FDA-2011-P-0355,"attachment 5 - melafinf® panel meeting november 24, 2010 - [mela™ sciences, inc. - citizen petition]",0,0
0900006480c7a10d,Supporting & Related Material,FDA-2011-P-0355-0009,FDA-2011-P-0355,"attachment 11 - ""electro-optical sciences, inc., (goodwin procter) letter to fda/cdrh, april 15, 2010 re p090012 melafind...."" - [mela™ sciences, inc. - citizen petition]",0,0
0900006480c7a535,Supporting & Related Material,FDA-2011-P-0355-0015,FDA-2011-P-0355,"attachment 18 - ""electronic correspondence between eosciences and fda/cdrh, re p090012 90-day letter, october 13, 2009"" - [mela™ sciences, inc. - citizen petition]",0,0
0900006480c7a536,Supporting & Related Material,FDA-2011-P-0355-0016,FDA-2011-P-0355,"attachment 19 - ""fda/cdrh letters to electro-optical sciences, inc., august 18, 2009 and july 29, 2009"" - [mela™ sciences, inc. - citizen petition]",0,0
0900006480c7a538,Supporting & Related Material,FDA-2011-P-0355-0018,FDA-2011-P-0355,"attachment 21 - ""fda panel meeting, november, 18, 2010, re fda alters the definition of safety & effectiveness"" - [mela™ sciences, inc. - citizen petition]",0,0
0900006480c75c18,Other,FDA-2011-P-0355-0001,FDA-2011-P-0355,"mela sciences, inc. - citizen petition",0,0
0900006480c7a116,Supporting & Related Material,FDA-2011-P-0355-0013,FDA-2011-P-0355,"attachment 16 - ""original premarket approval application pma# p090012 melafind®, non-invasive imaging device for the early detection of melanoma, electro-optical sciences, inc."" - [mela™ sciences, inc. - citizen petition]",0,0
09000064819090bd,Other,FDA-2014-P-1771-0001,FDA-2014-P-1771,citizen petition from amgen sidley austin llp,0,0
0900006481a68396,Other,FDA-2014-P-1771-0004,FDA-2014-P-1771,citizen petition denial response,0,0
09000064819090c0,Other,FDA-2014-P-1771-0002,FDA-2014-P-1771,acknowledgement letter from fda ddm to sidley austin llp,0,0
0900006481a84f74,Other,FDA-2014-P-1569-0003,FDA-2014-P-1569,petition denial letter from cder to pharmacists planning service inc.,0,0
09000064818b90ee,Other,FDA-2014-P-1569-0001,FDA-2014-P-1569,acknowledgment letter from fda ddm to pharmacists planning service inc,0,0
09000064818b6fc0,Other,FDA-2014-P-1569-0002,FDA-2014-P-1569,citizen petition from pharmacists planning service inc,0,0
090000648261034e,Notice,FDA-2013-N-0578-0006,FDA-2013-N-0578,"agency information collection activities; announcement of office of
management and budget approvals",0,0
0900006483f9b1fd,Notice,FDA-2013-N-0578-0007,FDA-2013-N-0578,"agency information collection activities; proposed collection; comment request; general licensing provisions: biologics license application, changes to an approved application, labeling, revocation and suspension, postmarketing studies status reports, and form fda 356h",0,0
090000648444cc70,Notice,FDA-2013-N-0578-0009,FDA-2013-N-0578,"agency information collection activities; announcement of office of
management and budget approvals",0,0
090000648146a14d,Notice,FDA-2013-N-0578-0002,FDA-2013-N-0578,"review; comment request; general licensing provisions: biologics license application, changes to an approved application, labeling, revocation and suspension, postmarketing studies status reports, and forms fda 356h and 2567",0,0
090000648151cd35,Notice,FDA-2013-N-0578-0003,FDA-2013-N-0578,"agency information collection activities; announcement of office of
management and budget approval; general licensing provisions:
biologics license application, changes to an approved application,
labeling, revocation and suspension, postmarketing studies status reports, and forms fda 356h and 2567",0,0
090000648131aea8,Notice,FDA-2013-N-0578-0001,FDA-2013-N-0578,"agency information collection activities; proposals, submissions, and approvals: general licensing provisions - biologics license application, etc.",0,0
09000064842b64fa,Notice,FDA-2013-N-0578-0008,FDA-2013-N-0578,"agency information collection activities; submission for office of management and budget review; comment request; general licensing provisions: biologics license application, changes to an approved application, labeling, revocation and suspension, postmarketing studies status reports, and form fda 356h",0,0
090000648235ae12,Notice,FDA-2013-N-0578-0005,FDA-2013-N-0578,"agency information collection activities; submission for office of management and budget review; comment request; general licensing 
provisions: biologics license application, changes to an approved 
application, labeling, revocation and suspension, and postmarketing 
studies status reports",0,0
090000648209bee6,Notice,FDA-2013-N-0578-0004,FDA-2013-N-0578,"agency information collection activities; proposed collection; comment request; general licensing provisions: biologics license application, changes to an approved application, labeling, revocation and suspension, postmarketing studies status reports, and form fda 356h",0,0
0900006484253497,Supporting & Related Material,FDA-2019-P-3192-0042,FDA-2019-P-3192,"exhibit 11 re petition for reconsideration from us worldmeds, llc",0,0
09000064842534a6,Supporting & Related Material,FDA-2019-P-3192-0044,FDA-2019-P-3192,"exhibit 13 re petition for reconsideration from us worldmeds, llc",0,0
09000064842534a9,Supporting & Related Material,FDA-2019-P-3192-0047,FDA-2019-P-3192,"exhibit 16 re petition for reconsideration from us worldmeds, llc",0,0
09000064842534ae,Supporting & Related Material,FDA-2019-P-3192-0052,FDA-2019-P-3192,"exhibit 21 re petition for reconsideration from us worldmeds, llc",0,0
0900006484253493,Supporting & Related Material,FDA-2019-P-3192-0038,FDA-2019-P-3192,"exhibit 7 re petition for reconsideration from us worldmeds, llc",0,0
0900006483d570cb,Supporting & Related Material,FDA-2019-P-3192-0009,FDA-2019-P-3192,exhibit 7- apokyn apomorphine hydrochloride injection re citizen petition from us worldmeds,0,0
0900006483d5794c,Supporting & Related Material,FDA-2019-P-3192-0013,FDA-2019-P-3192,exhibit 11- patients’ and caregivers’ experiences of the impact of parkinson’s disease on health status re citizen petition from us worldmeds,0,0
0900006483d577cb,Supporting & Related Material,FDA-2019-P-3192-0026,FDA-2019-P-3192,exhibit 24- injection safety re citizen petition from us worldmeds,0,0
0900006484251530,Supporting & Related Material,FDA-2019-P-3192-0032,FDA-2019-P-3192,"exhibit 1 re petition for reconsideration from us worldmeds, llc",0,0
0900006484253492,Supporting & Related Material,FDA-2019-P-3192-0037,FDA-2019-P-3192,"exhibit 6 re petition for reconsideration from us worldmeds, llc",0,0
09000064842534ad,Supporting & Related Material,FDA-2019-P-3192-0051,FDA-2019-P-3192,"exhibit 20 re petition for reconsideration from us worldmeds, llc",0,0
09000064842534a5,Supporting & Related Material,FDA-2019-P-3192-0043,FDA-2019-P-3192,"exhibit 12 re petition for reconsideration from us worldmeds, llc",0,0
0900006483d57254,Supporting & Related Material,FDA-2019-P-3192-0007,FDA-2019-P-3192,exhibit 5- parkinson's disease and movement disorders: moving forward re citizen petition from us worldmeds,0,0
0900006483d57697,Supporting & Related Material,FDA-2019-P-3192-0021,FDA-2019-P-3192,exhibit 19- center for drug evaluation and research: summary review re citizen petition from us worldmeds,0,0
0900006483d577ca,Supporting & Related Material,FDA-2019-P-3192-0025,FDA-2019-P-3192,exhibit 23- sharing insulin pens: are you putting patients at risk re citizen petition from us worldmeds,0,0
0900006483d57979,Supporting & Related Material,FDA-2019-P-3192-0018,FDA-2019-P-3192,exhibit 16- starting apokyn re citizen petition from us worldmeds,0,0
0900006483d57222,Supporting & Related Material,FDA-2019-P-3192-0006,FDA-2019-P-3192,"exhibit 4- past, present, and future of parkinson's disease: a special essay on the 200th anniversary of the shaking palsy re citizen petition from us worldmeds",0,0
0900006483d57220,Supporting & Related Material,FDA-2019-P-3192-0004,FDA-2019-P-3192,exhibit 2- cognitive decline in parkinson disease re citizen petition from us worldmeds,0,0
0900006483d577cc,Supporting & Related Material,FDA-2019-P-3192-0027,FDA-2019-P-3192,"exhibit 25- fda in brief: to advance efficient development and review of combination products, the fda outlines principles to promote a more predictable premarket review pathway re citizen petition from us worldmeds",0,0
090000648425348f,Supporting & Related Material,FDA-2019-P-3192-0034,FDA-2019-P-3192,"exhibit 3 re petition for reconsideration from us worldmeds, llc",0,0
09000064842534a7,Supporting & Related Material,FDA-2019-P-3192-0045,FDA-2019-P-3192,"exhibit 14 re petition for reconsideration from us worldmeds, llc",0,0
0900006483d570cc,Supporting & Related Material,FDA-2019-P-3192-0010,FDA-2019-P-3192,exhibit 8- the voice of the patient re citizen petition from us worldmeds,0,0
0900006483d57696,Supporting & Related Material,FDA-2019-P-3192-0020,FDA-2019-P-3192,exhibit 18- center for drug evaluation and research: other action letters re citizen petition from us worldmeds,0,0
0900006483d57699,Supporting & Related Material,FDA-2019-P-3192-0023,FDA-2019-P-3192,exhibit 21- complete response re citizen petition from us worldmeds,0,0
0900006483d5794f,Supporting & Related Material,FDA-2019-P-3192-0016,FDA-2019-P-3192,exhibit 14- about apokyn re citizen petition from us worldmeds,0,0
09000064821e830f,Supporting & Related Material,FDA-2016-P-2672-0015,FDA-2016-P-2672,"exhibit 12 letter from charles m. lizza to hon. esther salas, u.s.d.j., ecf no. 312, jazz pharm., inc. v. amneal pharm. llc et al., no. 2:13-cv-391 (filed aug. 12, 2016) re citizen petition from jazz pharmaceuticals inc.",0,0
09000064821e8304,Supporting & Related Material,FDA-2016-P-2672-0008,FDA-2016-P-2672,"exhibit 5 decision instituting (in part) inter partes review, paper no. 10, ranbaxy inc. v. jazz pharm., inc., ipr2016-00024 (p.t.a.b. apr. 12, 2016) re citizen petition from jazz pharmaceuticals inc.",0,0
09000064821e823c,Other,FDA-2016-P-2672-0001,FDA-2016-P-2672,citizen petition from jazz pharmaceuticals inc.,0,0
09000064821e8310,Supporting & Related Material,FDA-2016-P-2672-0016,FDA-2016-P-2672,"exhibit 13 expert report of leslie z. benet, ph.d. re citizen petition from jazz pharmaceuticals inc.",0,0
090000648247f348,Other,FDA-2016-P-2672-0019,FDA-2016-P-2672,"petition approval letter from fda cder to jazz pharmaceuticals, inc.",0,0
09000064821e8948,Other,FDA-2016-P-2672-0002,FDA-2016-P-2672,"acknowledgment letter from fda ddm to jazz pharmaceuticals, inc.",0,0
09000064821e8241,Supporting & Related Material,FDA-2016-P-2672-0003,FDA-2016-P-2672,index of exhibits re citizen petition from jazz pharmaceuticals inc.,0,0
09000064821e8302,Supporting & Related Material,FDA-2016-P-2672-0006,FDA-2016-P-2672,"exhibit 3  petition for inter partes review of u.s. patent no. 8,772,306, paper no. 1, ranbaxy inc. v. jazz pharm., inc., ipr2016-00024 (p.t.a.b. apr. 12, 2016) re citizen petition from jazz pharmaceuticals inc.",0,0
09000064821e8308,Supporting & Related Material,FDA-2016-P-2672-0012,FDA-2016-P-2672,"exhibit 9 decl. of bradford c. frese in supp. of mot. for j. on the pleadings as to u.s. patent no. 8,772,306 under rule 12(c), ecf no. 244-1, jazz pharm., inc. v. amneal pharm. llc et al., no. 2:13-cv-391 (filed mar. 23, 2016) re citizen petition from jazz pharmaceuticals inc.",0,0
09000064821e830e,Supporting & Related Material,FDA-2016-P-2672-0014,FDA-2016-P-2672,"exhibit 11 def. par’s reply to jazz’s opp’n to the mot. for j. on the pleadings as to u.s. patent no. 8,772, 306 under rule 12(c) (redacted), ecf no. 309, jazz pharm., inc., v. amneal pharm. llc et al., no. 2:13-cv-391 (filed july 25, 2016) re citizen petition from jazz pharmaceuticals inc.",0,0
09000064821e8303,Supporting & Related Material,FDA-2016-P-2672-0007,FDA-2016-P-2672,"exhibit 4 eller m et al., evaluation of drug–drug interactions of sodium oxybate with divalproex: results from a pharmacokinetic / pharmacodynamic study. sleep medicine. 2013 december; 14:e302-e303 re citizen petition from jazz pharmaceuticals inc.",0,0
09000064821e8306,Supporting & Related Material,FDA-2016-P-2672-0010,FDA-2016-P-2672,"exhibit 7 letter from michelle bonomi-huvala, par pharm., inc. to jazz pharm., inc., notice of paragraph iv certification, enclosure (aug. 5, 2014) re citizen petition from jazz pharmaceuticals inc.",0,0
09000064821e830d,Supporting & Related Material,FDA-2016-P-2672-0013,FDA-2016-P-2672,"exhibit 10 jazz’s mem. of law in opp’n to par’s mot. for j. on the pleadings as to u.s. patent no. 8,772,306 under rule 12(c) (redacted), ecf no. 308, jazz pharm., inc., v. amneal pharm. llc et al., no. 2:13-cv-391 (filed july 21, 2016) re citizen petition from jazz pharmaceuticals inc.",0,0
09000064821e8300,Supporting & Related Material,FDA-2016-P-2672-0004,FDA-2016-P-2672,"exhibit 1 petition for inter partes review of u.s. patent no. 8,772,306, paper no. 3, par pharm., inc. v. jazz pharm., inc., ipr2016-00002 (p.t.a.b. apr. 12, 2016) re citizen petition from jazz pharmaceuticals inc.",0,0
09000064821e8301,Supporting & Related Material,FDA-2016-P-2672-0005,FDA-2016-P-2672,"exhibit 2 petition for inter partes review of u.s. patent no. 8,772,306, 16, paper no. 1, amneal pharm. llc v. jazz pharm., inc., ipr2016-00546 (p.t.a.b. filed feb. 2, re citizen petition from jazz pharmaceuticals inc.
2016)",0,0
09000064821e8305,Supporting & Related Material,FDA-2016-P-2672-0009,FDA-2016-P-2672,"exhibit 6 decision denying inter partes review, paper no. 11, amneal pharmaceuticals llc . v. jazz pharm., inc., ipr2016-00546 (p.t.a.b. july 28, 2016) re citizen petition from jazz pharmaceuticals inc.",0,0
09000064821e8307,Supporting & Related Material,FDA-2016-P-2672-0011,FDA-2016-P-2672,"exhibit 8 letter from michelle bonomi-huvala, par pharm., inc. to jazz pharm., inc., notice of paragraph iv certification, enclosure (sept. 1, 2015) re citizen petition from jazz pharmaceuticals inc.",0,0
0900006483f5881d,Supporting & Related Material,FDA-2019-P-4281-0006,FDA-2019-P-4281,valisure citizen petition attachment d - acc resolution - chemical variability in pharmaceutical products,0,0
0900006483f58b41,Other,FDA-2019-P-4281-0002,FDA-2019-P-4281,"acknowledgment letter from fda dms to valisure, llc",0,0
0900006483f5881a,Supporting & Related Material,FDA-2019-P-4281-0003,FDA-2019-P-4281,valisure citizen petition attachment a - chemist affidavit - wolfgang hinz,0,0
090000648445107c,Other,FDA-2019-P-4281-0007,FDA-2019-P-4281,"interim response letter from fda cder to valisure, llc",0,0
0900006483f58b40,Other,FDA-2019-P-4281-0001,FDA-2019-P-4281,"citizen petition from valisure, llc",0,0
090000648448039a,Other,FDA-2019-P-4281-0008,FDA-2019-P-4281,"decision from fda cder to valisure, llc",0,0
0900006483f5881b,Supporting & Related Material,FDA-2019-P-4281-0004,FDA-2019-P-4281,valisure citizen petition attachment b - gc-ms ranitidine data report,0,0
0900006483f5881c,Supporting & Related Material,FDA-2019-P-4281-0005,FDA-2019-P-4281,valisure citizen petition attachment c - dr. ernstoff statement,0,0
090000648304e7d2,Other,FDA-2018-P-1263-0001,FDA-2018-P-1263,citizen petition from kratz & barry llp on behalf of rubicon research private limited,0,0
09000064841bf49b,Other,FDA-2018-P-1263-0006,FDA-2018-P-1263,letter from fda cder to kratz & barry llp and yiling pharmaceutical ltd.,0,0
0900006483310837,Other,FDA-2018-P-1263-0004,FDA-2018-P-1263,supplement from rubicon research private limited,0,0
090000648304e7d6,Supporting & Related Material,FDA-2018-P-1263-0003,FDA-2018-P-1263,attachment 1 declaration of rubicon re citizen petition from kratz & barry llp on behalf of rubicon research private limited,0,0
0900006483726844,Other,FDA-2018-P-1263-0005,FDA-2018-P-1263,interim response letter from fda cder to kratz & barry llp,0,0
090000648304e7d4,Other,FDA-2018-P-1263-0002,FDA-2018-P-1263,acknowledgment letter from fda ddm to kratz & barry llp,0,0
090000648047353d,Notice,FDA-2004-D-0353-0001,FDA-2004-D-0353,fda,0,0
0900006480473541,Supporting & Related Material,FDA-2004-D-0353-0002,FDA-2004-D-0353,guidance,0,0
0900006480492902,Supporting & Related Material,FDA-2008-D-0205-0002,FDA-2008-D-0205,"content and review of chemistry, manufacturing, and control (cmc) information for human gene therapy investigational new drug applications (inds); - guidance",0,0
09000064843108d9,Supporting & Related Material,FDA-2008-D-0205-0056,FDA-2008-D-0205,"reference 21 q2b validation of analytical procedures methodology re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
090000648431083d,Supporting & Related Material,FDA-2008-D-0205-0037,FDA-2008-D-0205,"reference 2 national academies report on human genome editing re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
0900006484310843,Supporting & Related Material,FDA-2008-D-0205-0043,FDA-2008-D-0205,"reference 8 q11 development and manufacture of drug substances re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
090000648430fed3,Other,FDA-2008-D-0205-0034,FDA-2008-D-0205,"chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
090000648430fedb,Supporting & Related Material,FDA-2008-D-0205-0036,FDA-2008-D-0205,"reference 1 m4q- the ctd - quality re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
09000064843108da,Supporting & Related Material,FDA-2008-D-0205-0057,FDA-2008-D-0205,"reference 22 quality of biotechnological products stability testing of biotechnological biological products re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
09000064843108dc,Supporting & Related Material,FDA-2008-D-0205-0059,FDA-2008-D-0205,"reference 24 q1e evaluation of stability data re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
090000648431087c,Supporting & Related Material,FDA-2008-D-0205-0050,FDA-2008-D-0205,"reference 15 federal register notice international conference on harmonisation guidance on quality of biotechnological biological products re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
0900006484310880,Supporting & Related Material,FDA-2008-D-0205-0053,FDA-2008-D-0205,"reference 18 potency tests for cellular and gene therapy products re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
0900006484310844,Supporting & Related Material,FDA-2008-D-0205-0044,FDA-2008-D-0205,"reference 9 recommendations for microbial vectors used for gene therapy re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
090000648431087e,Supporting & Related Material,FDA-2008-D-0205-0051,FDA-2008-D-0205,"reference 16 reid y et al authentication of human cell lines by str dna profiling analysis re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
0900006484310879,Supporting & Related Material,FDA-2008-D-0205-0047,FDA-2008-D-0205,"reference 12 characterization and qualification of cell substrates and other biological materials re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
09000064843108dd,Supporting & Related Material,FDA-2008-D-0205-0060,FDA-2008-D-0205,"reference 25 container closure systems for packaging human drugs and biologics re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
090000648430feda,Supporting & Related Material,FDA-2008-D-0205-0035,FDA-2008-D-0205,"reference list cmc re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
090000648431083e,Supporting & Related Material,FDA-2008-D-0205-0038,FDA-2008-D-0205,"reference 3 using the ectd specifications guidance re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
0900006484310881,Supporting & Related Material,FDA-2008-D-0205-0054,FDA-2008-D-0205,"reference 19 points to consider in the characterization of cell lines used to produce biologicals re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
090000648431087a,Supporting & Related Material,FDA-2008-D-0205-0048,FDA-2008-D-0205,"reference 13 points to consider in the manufacture and testing of monoclonal antibody products for human use re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
090000648431087f,Supporting & Related Material,FDA-2008-D-0205-0052,FDA-2008-D-0205,"reference 17 process validation general principles and practices re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
090000648048d039,Supporting & Related Material,FDA-2008-D-0205-0003,FDA-2008-D-0205,"content and review of chemistry, manufacturing, and control (cmc) information for human gene therapy investigational new drug application (inds) - reference list",0,0
09000064835c5dd5,Other,FDA-2008-D-0205-0007,FDA-2008-D-0205,request for extension from biotechnology innovation organization (bio),0,0
09000064843108df,Supporting & Related Material,FDA-2008-D-0205-0062,FDA-2008-D-0205,"reference 27 quality systems approach to pharmaceutical cgmp regulations re chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; guidance for industry; availability",0,0
09000064836b3161,Notice,FDA-2008-D-0205-0008,FDA-2008-D-0205,"draft guidances relating to the development of human gene therapy
products; availability; extension of comment period",0,0
09000064804a3293,Notice,FDA-2008-D-0205-0001,FDA-2008-D-0205,"guidance for food and drug administration reviewers and sponsors: content and review of chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; availability",1,0
09000064834d74a3,Notice,FDA-2008-D-0205-0004,FDA-2008-D-0205,"chemistry, manufacturing, and control information for human gene therapy investigational new drug applications; draft guidance for industry; availability",0,0
090000648043ed63,Other,FDA-2005-P-0053-0001,FDA-2005-P-0053,hfa-305 to buc & beardsley,0,0
090000648043ed73,Other,FDA-2005-P-0053-0002,FDA-2005-P-0053,hfa-305 to buc & beardsley,0,0
090000648043ed7c,Other,FDA-2005-P-0053-0003,FDA-2005-P-0053,hfd-001 to ranbaxy laboratories limited,0,0
090000648484a57f,Supporting & Related Material,FDA-2020-P-1857-0004,FDA-2020-P-1857,footnotes 16-44 re: citizen petition from siri & glimstad llp,0,0
090000648484a019,Other,FDA-2020-P-1857-0001,FDA-2020-P-1857,citizen petition from siri & glimstad llp,0,0
090000648484a01e,Other,FDA-2020-P-1857-0002,FDA-2020-P-1857,acknowledgment letter from fda dms to siri & glimstad llp,0,0
0900006484a607af,Other,FDA-2020-P-1857-0936,FDA-2020-P-1857,"interim response letter siri & glimstad, llp",0,0
090000648484a020,Supporting & Related Material,FDA-2020-P-1857-0003,FDA-2020-P-1857,footnotes 4-14 re: citizen petition from siri & glimstad llp,0,0
0900006482f64adb,Supporting & Related Material,FDA-2018-P-0877-0003,FDA-2018-P-0877,appendix re citizen petition from the food lawyers,1,0
090000648341122f,Other,FDA-2018-P-0877-0005,FDA-2018-P-0877,fda-2018-p-0877 - the food lawyers interim response,1,0
0900006482f64ad9,Other,FDA-2018-P-0877-0002,FDA-2018-P-0877,acknowledgment letter from fda ddm to the food lawyers,1,0
09000064838d09c9,Other,FDA-2018-P-0877-0006,FDA-2018-P-0877,supplement to citizen petition requesting 21 cfr 101.9(c)(6)(i) listing of dietary fibers be amended to include konjac flour,0,0
09000064832649a6,Other,FDA-2018-P-0877-0004,FDA-2018-P-0877,memo of correspondence with the food lawyers on konjac flour citizen petition,1,0
0900006484286704,Other,FDA-2018-P-0877-0010,FDA-2018-P-0877,petition response letter from fda cfsan to the food lawyers,1,0
0900006482f64ad7,Other,FDA-2018-P-0877-0001,FDA-2018-P-0877,citizen petition from the food lawyers,1,0
09000064838d1132,Supporting & Related Material,FDA-2018-P-0877-0007,FDA-2018-P-0877,appendix of scientific papers cited  in supplement to citizen petition requesting cfr 101.9 (c)(6)(i) listing of dietary fibers be amended to include konjac flour,0,0
0900006483d8c118,Other,FDA-2018-P-0877-0009,FDA-2018-P-0877,supplement from the food lawyers,1,0
0900006482ae2824,Other,FDA-2016-P-1108-0005,FDA-2016-P-1108,"response letter from fda to gordon johnston regulatory consultants, llc",0,0
0900006481f11695,Supporting & Related Material,FDA-2016-P-1108-0003,FDA-2016-P-1108,attachment a product listing from the active section of the orange book- re citizen petition from gordon johnston regulatory consultants llc,0,0
0900006481f13d76,Other,FDA-2016-P-1108-0002,FDA-2016-P-1108,acknowledgement letter from fda ddm to gordon johnston regulatory consultants llc,0,0
0900006481f11637,Other,FDA-2016-P-1108-0001,FDA-2016-P-1108,citizen petition from gordon johnston regulatory consultants llc,0,0
0900006482428124,Other,FDA-2016-P-1108-0004,FDA-2016-P-1108,"letter from fda cder to gordon johnston regulatory consultants, llc",0,0
0900006481f93b87,Supporting & Related Material,FDA-2016-P-1213-0004,FDA-2016-P-1213,"attachment 2 draft labeling for the proposed product, goody's migraine re citizen petition from medtech products inc.",0,0
0900006481f93b88,Supporting & Related Material,FDA-2016-P-1213-0005,FDA-2016-P-1213,attachment 3 request for waiver from requirement to submit a pediatric assessment re citizen petition from medtech products inc.,0,0
0900006481f93b89,Other,FDA-2016-P-1213-0002,FDA-2016-P-1213,acknowledgement letter from fda ddm to medtech products inc.,0,0
0900006481f93b86,Supporting & Related Material,FDA-2016-P-1213-0003,FDA-2016-P-1213,"attachment 1 approved labeling for the rld, excedrin (migraine) re citizen petition from medtech products inc.",0,0
0900006481f93b7a,Other,FDA-2016-P-1213-0001,FDA-2016-P-1213,citizen petition from medtech products inc.,0,0
0900006482ef0acd,Other,FDA-2016-P-1213-0006,FDA-2016-P-1213,notice of withdrawal letter from fda to a prestige brands company,0,0
09000064820488d1,Other,FDA-2016-P-1676-0002,FDA-2016-P-1676,"acknowledgement letter from fda ddm to jr rapoza associates, inc.",0,0
0900006482504d6b,Other,FDA-2016-P-1676-0006,FDA-2016-P-1676,"final response letter to jr rapoza associates, inc.",0,0
0900006482401959,Other,FDA-2016-P-1676-0005,FDA-2016-P-1676,"interim response letter to jr rapoza associates, inc.",0,0
09000064820488d3,Supporting & Related Material,FDA-2016-P-1676-0003,FDA-2016-P-1676,"attachment 1 orange book listing re citizen petition from jr rapoza associates, inc.",0,0
09000064820488d4,Supporting & Related Material,FDA-2016-P-1676-0004,FDA-2016-P-1676,"attachment 2 approved drug labeling rld re citizen petition from jr rapoza associates, inc.",0,0
0900006482048712,Other,FDA-2016-P-1676-0001,FDA-2016-P-1676,"citizen petition from jr rapoza associates, inc.",0,0
090000648250c66d,Notice,FDA-2016-P-1676-0007,FDA-2016-P-1676,"determination that cyanocobalamin injection, 1 milligram per milliliter in a 10 milliliter vial, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006481971e3c,Other,FDA-2014-P-2188-0001,FDA-2014-P-2188,citizen petition from acura pharmaceuticals inc,0,0
09000064819728e0,Supporting & Related Material,FDA-2014-P-2188-0011,FDA-2014-P-2188,exibit i,0,0
09000064819728e2,Supporting & Related Material,FDA-2014-P-2188-0013,FDA-2014-P-2188,exibit k,0,0
09000064819728e6,Supporting & Related Material,FDA-2014-P-2188-0017,FDA-2014-P-2188,exibit o,0,0
09000064819728e8,Supporting & Related Material,FDA-2014-P-2188-0019,FDA-2014-P-2188,exibit q,0,0
09000064819728ec,Supporting & Related Material,FDA-2014-P-2188-0023,FDA-2014-P-2188,exibit u,0,0
0900006481a8c0a8,Other,FDA-2014-P-2188-0024,FDA-2014-P-2188,"supplement from acura pharmaceuticals, inc.",0,0
09000064819728dd,Supporting & Related Material,FDA-2014-P-2188-0008,FDA-2014-P-2188,exibit f,0,0
0900006481972ae1,Supporting & Related Material,FDA-2014-P-2188-0007,FDA-2014-P-2188,exibit e,0,0
09000064819728de,Supporting & Related Material,FDA-2014-P-2188-0009,FDA-2014-P-2188,exibit g,0,0
09000064819728e4,Supporting & Related Material,FDA-2014-P-2188-0015,FDA-2014-P-2188,exibit m,0,0
09000064819728e5,Supporting & Related Material,FDA-2014-P-2188-0016,FDA-2014-P-2188,exibit n,0,0
09000064819728e9,Supporting & Related Material,FDA-2014-P-2188-0020,FDA-2014-P-2188,exibit r,0,0
0900006481972add,Supporting & Related Material,FDA-2014-P-2188-0003,FDA-2014-P-2188,exibit a,0,0
0900006481972ae0,Supporting & Related Material,FDA-2014-P-2188-0006,FDA-2014-P-2188,exibit d,0,0
09000064819728ea,Supporting & Related Material,FDA-2014-P-2188-0021,FDA-2014-P-2188,exibit s,0,0
090000648197285a,Other,FDA-2014-P-2188-0002,FDA-2014-P-2188,acknowledgement letter from fda ddm to wiley rein llp,0,0
09000064819728df,Supporting & Related Material,FDA-2014-P-2188-0010,FDA-2014-P-2188,exibit h,0,0
09000064819728e1,Supporting & Related Material,FDA-2014-P-2188-0012,FDA-2014-P-2188,exibit j,0,0
09000064819728e3,Supporting & Related Material,FDA-2014-P-2188-0014,FDA-2014-P-2188,exibit l,0,0
09000064819728eb,Supporting & Related Material,FDA-2014-P-2188-0022,FDA-2014-P-2188,exibit t,0,0
0900006481972ade,Supporting & Related Material,FDA-2014-P-2188-0004,FDA-2014-P-2188,exibit b,0,0
0900006481972adf,Supporting & Related Material,FDA-2014-P-2188-0005,FDA-2014-P-2188,exibit c,0,0
0900006481ad6916,Other,FDA-2014-P-2188-0025,FDA-2014-P-2188,citizen petition denial response letter from fda cder to wiley rein llp,0,0
09000064819728e7,Supporting & Related Material,FDA-2014-P-2188-0018,FDA-2014-P-2188,exibit p,0,0
09000064820aa04f,Other,FDA-2015-P-2000-0012,FDA-2015-P-2000,petition denial letter,0,0
0900006481d7fbde,Other,FDA-2015-P-2000-0010,FDA-2015-P-2000,"interim response letter from fda cder to abbvie, inc.",0,0
0900006481b16af1,Supporting & Related Material,FDA-2015-P-2000-0003,FDA-2015-P-2000,"attachment a labeling information re citizen petition from abbvie, inc",0,0
0900006481b16aef,Other,FDA-2015-P-2000-0002,FDA-2015-P-2000,"acknowledgement letter from fda ddm to abbvie, inc.",0,0
0900006481b16aed,Other,FDA-2015-P-2000-0001,FDA-2015-P-2000,"citizen petition from abbvie, inc",0,0
0900006481c01af0,Other,FDA-2015-P-2000-0007,FDA-2015-P-2000,"supplement from abbvie, inc.",0,0
0900006482c98c5f,Notice,FDA-2017-P-5910-0003,FDA-2017-P-5910,"determination that trintellix (vortioxetine hydrobromide) oral
tablet, eq 15 milligram base, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006482b7736c,Other,FDA-2017-P-5910-0001,FDA-2017-P-5910,citizen petition from cipla limited,0,0
0900006482b77c53,Other,FDA-2017-P-5910-0002,FDA-2017-P-5910,acknowledgement letter from fda ddm to cipla limited,0,0
0900006482c9fa8e,Other,FDA-2017-P-5910-0004,FDA-2017-P-5910,petition response letter,0,0
090000648391d2c7,Other,FDA-2018-D-4587-0001,FDA-2018-D-4587,external guidance document submission from international pharmaceutical excipients council of the americas (ipec-americas),0,0
090000648391d963,Other,FDA-2018-D-4587-0002,FDA-2018-D-4587,acknowledgment letter from fda ddm to  international pharmaceutical excipients council of the americas (ipec-americas),0,0
0900006482dcf7b1,Supporting & Related Material,FDA-2018-P-0130-0003,FDA-2018-P-0130,"attachment 1 relevant copy of the page from the current edition of the electronic approved drug products with therapeutic equivalence evaluations, accessed january 8, 20 18 re citizen petition from lachman consultant services, inc.",0,0
0900006482dcf7b3,Supporting & Related Material,FDA-2018-P-0130-0005,FDA-2018-P-0130,"attachment 3 labeling for zonegran® capsules re citizen petition from lachman consultant services, inc.",0,0
0900006482dcf7af,Other,FDA-2018-P-0130-0001,FDA-2018-P-0130,"citizen petition from lachman consultant services, inc.",0,0
0900006482dcf7b2,Supporting & Related Material,FDA-2018-P-0130-0004,FDA-2018-P-0130,"attachment 2 draft insert labeling proposed for zonisamide tablets re citizen petition from lachman consultant services, inc.",0,0
0900006482dcf7b4,Other,FDA-2018-P-0130-0002,FDA-2018-P-0130,"acknowledgment letter from fda ddm  to lachman consultant services, inc.",0,0
090000648404c00c,Other,FDA-2019-P-4670-0001,FDA-2019-P-4670,citizen petition from lonza inc.,0,0
09000064847dfe00,Supporting & Related Material,FDA-2019-P-4670-0006,FDA-2019-P-4670,"study report  - an acute, randomized, double-blind, controlled, crossover study to investigate the effect of an arabinogalactan product
on glucose and insulin response in adults, study report
bio-1904",0,0
090000648480da0b,Other,FDA-2019-P-4670-0007,FDA-2019-P-4670,report from lonza,0,0
0900006484485d36,Other,FDA-2019-P-4670-0005,FDA-2019-P-4670,interim response letter from fda cfsan to lonza inc,0,0
090000648404c03b,Supporting & Related Material,FDA-2019-P-4670-0004,FDA-2019-P-4670,appendix b full-length copies of all relevant references re citizen petition from lonza inc,0,0
090000648404c00d,Other,FDA-2019-P-4670-0002,FDA-2019-P-4670,acknowledgment letter from fda dms to lonza inc.,0,0
090000648404c010,Supporting & Related Material,FDA-2019-P-4670-0003,FDA-2019-P-4670,appendix a qualitative results from 3 human studies on the effects of arabinogalactan on immune function re citizen petition from lonza inc.,0,0
090000648304398f,Other,FDA-2018-P-1238-0002,FDA-2018-P-1238,"acknowledgment letter from fda ddm  to lachman consultant services, inc.",0,0
0900006483043b70,Supporting & Related Material,FDA-2018-P-1238-0005,FDA-2018-P-1238,"attachment 3 proposed labeling for succinylcholine chloride re: citizen petition from lachman consultant services, inc.",0,0
09000064830439dd,Supporting & Related Material,FDA-2018-P-1238-0003,FDA-2018-P-1238,"attachment 1 approved drug products with therapeutic equivalence evaluations re: citizen petition from lachman consultant services, inc.",0,0
0900006483043b6f,Supporting & Related Material,FDA-2018-P-1238-0004,FDA-2018-P-1238,"attachment 2 rld labeling quelicin- re: citizen petition from lachman consultant services, inc.",0,0
0900006483043849,Other,FDA-2018-P-1238-0001,FDA-2018-P-1238,citizen petition from lachman consultant services inc.,0,0
0900006484487134,Other,FDA-2020-P-1248-0002,FDA-2020-P-1248,acknowledgment letter from fda dms to mark miles,0,0
0900006484486e1a,Other,FDA-2020-P-1248-0001,FDA-2020-P-1248,citizen petition from mark miles,0,0
0900006484874b79,Other,FDA-2020-P-1248-0003,FDA-2020-P-1248,interim response letter from fda cder to mark miles,0,0
090000648480bba7,Other,FDA-2020-P-1052-0004,FDA-2020-P-1052,tentative response from fda ctp to national tobacco reform initiative (ntri),0,1
0900006484409d03,Other,FDA-2020-P-1052-0001,FDA-2020-P-1052,citizen petition from national tobacco reform initiative (ntri),0,1
090000648440bac4,Other,FDA-2020-P-1052-0002,FDA-2020-P-1052,acknowledgment letter from fda dms to national tobacco reform initiative (ntri),0,1
0900006483b78606,Supporting & Related Material,FDA-2019-P-1679-0020,FDA-2019-P-1679,"exhibit 17 recitizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b784b3,Supporting & Related Material,FDA-2019-P-1679-0011,FDA-2019-P-1679,"exhibit 9 re citizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b733b0,Supporting & Related Material,FDA-2019-P-1679-0003,FDA-2019-P-1679,"exhibit 1 re citizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b733ae,Other,FDA-2019-P-1679-0002,FDA-2019-P-1679,"acknowledgment letter from fda ddm to goodwin procter, llp on behalf of braeburn, inc",0,0
0900006483cc0d04,Other,FDA-2019-P-1679-0052,FDA-2019-P-1679,"change of address letter from braeburn, inc.",0,0
0900006484067157,Other,FDA-2019-P-1679-0077,FDA-2019-P-1679,interim response from fda office of orphan products to lassman law + policy,0,0
0900006484087d08,Other,FDA-2019-P-1679-0078,FDA-2019-P-1679,"supplement from braeburn, inc.",0,0
0900006483e9a813,Other,FDA-2019-P-1679-0074,FDA-2019-P-1679,"supplement from braeburn, inc.",0,0
0900006483b733b1,Supporting & Related Material,FDA-2019-P-1679-0004,FDA-2019-P-1679,"exhibit 2 re citizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b73893,Supporting & Related Material,FDA-2019-P-1679-0005,FDA-2019-P-1679,"exhibit 3 re citizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b784b0,Supporting & Related Material,FDA-2019-P-1679-0008,FDA-2019-P-1679,"exhibit 6 re citizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b78601,Supporting & Related Material,FDA-2019-P-1679-0014,FDA-2019-P-1679,"exhibit 12 recitizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b78604,Supporting & Related Material,FDA-2019-P-1679-0018,FDA-2019-P-1679,"exhibit 15 re citizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b78607,Supporting & Related Material,FDA-2019-P-1679-0021,FDA-2019-P-1679,"exhibit 18 recitizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b73894,Supporting & Related Material,FDA-2019-P-1679-0006,FDA-2019-P-1679,"exhibit 4 re citizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b73895,Supporting & Related Material,FDA-2019-P-1679-0007,FDA-2019-P-1679,"exhibit 5 re citizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b78600,Supporting & Related Material,FDA-2019-P-1679-0013,FDA-2019-P-1679,"exhibit 11 re citizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b78605,Supporting & Related Material,FDA-2019-P-1679-0019,FDA-2019-P-1679,"exhibit 16 re citizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b72aef,Other,FDA-2019-P-1679-0001,FDA-2019-P-1679,"citizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483e56804,Other,FDA-2019-P-1679-0073,FDA-2019-P-1679,"supplement from braeburn, inc.",0,0
0900006483b784b1,Supporting & Related Material,FDA-2019-P-1679-0009,FDA-2019-P-1679,"exhibit 7 re citizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b784b2,Supporting & Related Material,FDA-2019-P-1679-0010,FDA-2019-P-1679,"exhibit 8 re citizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b78602,Supporting & Related Material,FDA-2019-P-1679-0016,FDA-2019-P-1679,"exhibit 13 recitizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b784b4,Supporting & Related Material,FDA-2019-P-1679-0012,FDA-2019-P-1679,"exhibit 10 re citizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
0900006483b78603,Supporting & Related Material,FDA-2019-P-1679-0017,FDA-2019-P-1679,"exhibit 14 re citizen petition from goodwin procter,  llp on behalf of braeburn, inc.",0,0
090000648364f8be,Notice,FDA-2005-N-0101-0002,FDA-2005-N-0101,agency information collection activities; proposed collection; comment request; prescription drug user fee cover sheet; form fda 3397,0,0
0900006483a49c2f,Notice,FDA-2005-N-0101-0003,FDA-2005-N-0101,agency information collection activities; submission for office of management and budget review; comment request; prescription drug user fee cover sheet; form fda 3397,0,0
090000648043f8a4,Notice,FDA-2005-N-0101-0001,FDA-2005-N-0101,fda,0,0
0900006483c131a9,Notice,FDA-2005-N-0101-0004,FDA-2005-N-0101,"agency information collection activities; announcement of office of
management and budget approvals",0,0
090000648044b048,Other,FDA-2005-P-0367-0003,FDA-2005-P-0367,interim response letter from fda cder to foley & lardner llp,0,0
090000648044b043,Other,FDA-2005-P-0367-0008,FDA-2005-P-0367,reply letter from foley & lardner llp to fda ddm,0,0
09000064807b06cd,Other,FDA-2005-P-0367-0005,FDA-2005-P-0367,citizen petition partial approval and denial response letter from fda cder to foley & lardner llp,0,0
090000648044b03c,Other,FDA-2005-P-0367-0002,FDA-2005-P-0367,acknowledgment letter from fda ddm to foley & lardner llp,0,0
090000648044aff5,Other,FDA-2005-P-0367-0001,FDA-2005-P-0367,acknowledgment letter from fda ddm to foley & lardner llp,0,0
090000648044b02c,Other,FDA-2005-P-0367-0004,FDA-2005-P-0367,citizen petition from foley & lardner llp,0,0
090000648456acb9,Supporting & Related Material,FDA-2020-P-1344-0004,FDA-2020-P-1344,"attachment 2 federal register notice for docket no. fda–2013–p–0241, aug 5, 2013 [78 fed. reg. 47321] re citizen petition from lachman consultant services, inc.",0,0
090000648456aa34,Other,FDA-2020-P-1344-0001,FDA-2020-P-1344,"citizen petition from lachman consultant services, inc.",0,0
090000648456acba,Supporting & Related Material,FDA-2020-P-1344-0005,FDA-2020-P-1344,"attachment 3 federal register notice for docket no. 01p–0333, mar 1, 2004 [69 fed. reg. 9630] re citizen petition from lachman consultant services, inc.",0,0
090000648456aa37,Other,FDA-2020-P-1344-0002,FDA-2020-P-1344,"acknowledgment letter from fda dms to lachman consultant services, inc.",0,0
090000648456aa39,Supporting & Related Material,FDA-2020-P-1344-0003,FDA-2020-P-1344,"attachment 1 orange book: approved drug products with therapeutic equivalence evaluations listing for cytoxan, nda 012142, accessed 05/05/2020  re citizen petition from lachman consultant services, inc.",0,0
0900006484258f6c,Other,FDA-2019-P-6049-0001,FDA-2019-P-6049,"citizen petition from us worldmeds, llc",0,0
0900006484251fea,Supporting & Related Material,FDA-2019-P-6049-0018,FDA-2019-P-6049,"exhibit 16 re citizen petition from us worldmeds, llc",0,0
0900006484251ffe,Supporting & Related Material,FDA-2019-P-6049-0020,FDA-2019-P-6049,"exhibit 18 re citizen petition from us worldmeds, llc",0,0
0900006484252000,Supporting & Related Material,FDA-2019-P-6049-0022,FDA-2019-P-6049,"exhibit 20 re citizen petition from us worldmeds, llc",0,0
0900006484251cf4,Supporting & Related Material,FDA-2019-P-6049-0004,FDA-2019-P-6049,"exhibit 2 re citizen petition from us worldmeds, llc",0,0
0900006484251fe2,Supporting & Related Material,FDA-2019-P-6049-0010,FDA-2019-P-6049,"exhibit 8 re citizen petition from us worldmeds, llc",0,0
0900006484251fe5,Supporting & Related Material,FDA-2019-P-6049-0013,FDA-2019-P-6049,"exhibit 11 re citizen petition from us worldmeds, llc",0,0
0900006484252001,Supporting & Related Material,FDA-2019-P-6049-0023,FDA-2019-P-6049,"exhibit 21 re citizen petition from us worldmeds, llc",0,0
0900006484252005,Supporting & Related Material,FDA-2019-P-6049-0027,FDA-2019-P-6049,"exhibit 25 re citizen petition from us worldmeds, llc",0,0
0900006484251fe6,Supporting & Related Material,FDA-2019-P-6049-0014,FDA-2019-P-6049,"exhibit 12 re citizen petition from us worldmeds, llc",0,0
0900006484252002,Supporting & Related Material,FDA-2019-P-6049-0024,FDA-2019-P-6049,"exhibit 22 re citizen petition from us worldmeds, llc",0,0
0900006484252006,Supporting & Related Material,FDA-2019-P-6049-0028,FDA-2019-P-6049,"exhibit 26 re citizen petition from us worldmeds, llc",0,0
0900006484251cf8,Supporting & Related Material,FDA-2019-P-6049-0008,FDA-2019-P-6049,"exhibit 6 re citizen petition from us worldmeds, llc",0,0
0900006484252003,Supporting & Related Material,FDA-2019-P-6049-0025,FDA-2019-P-6049,"exhibit 23 re citizen petition from us worldmeds, llc",0,0
0900006484258f70,Other,FDA-2019-P-6049-0002,FDA-2019-P-6049,"acknowledgment letter from fda dms to us worldmeds, llc",0,0
0900006484251cf5,Supporting & Related Material,FDA-2019-P-6049-0005,FDA-2019-P-6049,"exhibit 3 re citizen petition from us worldmeds, llc",0,0
0900006484251fe7,Supporting & Related Material,FDA-2019-P-6049-0015,FDA-2019-P-6049,"exhibit 13 re citizen petition from us worldmeds, llc",0,0
0900006484251ffd,Supporting & Related Material,FDA-2019-P-6049-0019,FDA-2019-P-6049,"exhibit 17 re citizen petition from us worldmeds, llc",0,0
0900006484251fff,Supporting & Related Material,FDA-2019-P-6049-0021,FDA-2019-P-6049,"exhibit 19 re citizen petition from us worldmeds, llc",0,0
0900006484251cf3,Supporting & Related Material,FDA-2019-P-6049-0003,FDA-2019-P-6049,"exhibit 1 re citizen petition from us worldmeds, llc",0,0
0900006484251fe8,Supporting & Related Material,FDA-2019-P-6049-0016,FDA-2019-P-6049,"exhibit 14 re citizen petition from us worldmeds, llc",0,0
0900006484252004,Supporting & Related Material,FDA-2019-P-6049-0026,FDA-2019-P-6049,"exhibit 24 re citizen petition from us worldmeds, llc",0,0
0900006484664570,Other,FDA-2019-P-6049-0030,FDA-2019-P-6049,"response letter from fda cder to us worldmeds, llc",0,0
0900006484251cf7,Supporting & Related Material,FDA-2019-P-6049-0007,FDA-2019-P-6049,"exhibit 5 re citizen petition from us worldmeds, llc",0,0
0900006484251fe1,Supporting & Related Material,FDA-2019-P-6049-0009,FDA-2019-P-6049,"exhibit 7 re citizen petition from us worldmeds, llc",0,0
0900006482e2ffb0,Other,FDA-2013-S-0610-0003,FDA-2013-S-0610,electronic method for specific electronic submissions to fda's dockets management staff,0,0
09000064814cb005,Supporting & Related Material,FDA-2013-S-0610-0001,FDA-2013-S-0610,specific electronic submissions,0,0
09000064814caa73,Supporting & Related Material,FDA-2013-S-0610-0002,FDA-2013-S-0610,instructions from the division of dockets management on how to submit electronic citizen petitions re citizen petition submission; technical amendment,0,0
0900006483fe24a3,Other,FDA-2019-P-1560-0003,FDA-2019-P-1560,"interim response letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
0900006483b593fe,Other,FDA-2019-P-1560-0002,FDA-2019-P-1560,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara on behalf of xellia pharmaceuticals aps and xellia pharmaceuticals usa, llc",0,0
0900006483b58e2c,Other,FDA-2019-P-1560-0001,FDA-2019-P-1560,"citizen petition from hyman, phelps & mcnamara on behalf of xellia pharmaceuticals aps and xellia pharmaceuticals usa, llc.",0,0
090000648195ee4c,Other,FDA-2014-D-1891-0002,FDA-2014-D-1891,draft guidance for industry on how to obtain a letter from fda stating that bioequivalence study protocols contain safety protections comparable to applicable rems for rld,0,0
090000648195e613,Notice,FDA-2014-D-1891-0001,FDA-2014-D-1891,"how to obtain a letter from the food and drug administration stating that bioequivalence study protocols contain safety protections
comparable to applicable risk evaluation and mitigation strategies
for reference listed drugs; draft guidance for industry; availability",1,0
0900006482331232,Other,FDA-2016-P-3482-0001,FDA-2016-P-3482,citizen petition from zydus pharmaceuticals (usa) inc,0,0
0900006482330fb0,Supporting & Related Material,FDA-2016-P-3482-0004,FDA-2016-P-3482,"annex ii copy of drugs@fda listing of subject formulation, lynparza (oiaparib capsules, for oral use, 50 mg). re citizen petition from zydus pharmaceuticals (usa) inc",0,0
0900006482330fb1,Supporting & Related Material,FDA-2016-P-3482-0005,FDA-2016-P-3482,"annex iii  copy of current approved fda labeling for l ynparza (olaparib capsules, for oral use, 50 mg dated 12/2014) re citizen petition from zydus pharmaceuticals (usa) inc",0,0
0900006482331234,Other,FDA-2016-P-3482-0002,FDA-2016-P-3482,acknowledgement letter from fda ddm to zydus pharmaceuticals (usa) inc,0,0
0900006482330faf,Supporting & Related Material,FDA-2016-P-3482-0003,FDA-2016-P-3482,"annex i copy of orange book current through october 2016, listing the subject formulation, l ynparza (olaparib capsules, for oral use, 50 mg). re citizen petition from zydus pharmaceuticals (usa) inc",0,0
09000064824d84a2,Other,FDA-2016-P-3482-0006,FDA-2016-P-3482,citizen petition withdrawal letter from zydus pharmaceuticals inc. to fda cder,0,0
0900006483410571,Other,FDA-2016-P-4275-0057,FDA-2016-P-4275,letter from fda cfsan to bioneutra north america inc - denial response,0,0
09000064825652e9,Other,FDA-2016-P-4275-0054,FDA-2016-P-4275,letter from bioneutra north america inc. to fda ddm,0,0
09000064823ee087,Supporting & Related Material,FDA-2016-P-4275-0045,FDA-2016-P-4275,"appendix c - tamura et al 2016 prevalence and self-recognition of chronic
constipation: results of an internet survey re citizen petition from bioneutra north america inc",0,0
09000064823ee0a4,Supporting & Related Material,FDA-2016-P-4275-0053,FDA-2016-P-4275,"appendix c - yen et al 2011 long-term supplementation of isomalto-oligosaccharides improved colonic microflora profile, bowel function, and blood cholesterol levels in constipated elderly peopleda placebo-controlled, diet-controlled trial re citizen petition from bioneutra north america inc",0,0
09000064823ee136,Supporting & Related Material,FDA-2016-P-4275-0010,FDA-2016-P-4275,"appendix c - cummings et al 1992 fecal weight, colon cancer risk, and dietary intake of nonstarch polysaccharides (dietary fiber) re citizen petition from bioneutra north america inc",0,0
09000064823ee137,Supporting & Related Material,FDA-2016-P-4275-0011,FDA-2016-P-4275,appendix c - cummings et al 2004 passclaim1 – gut health and immunity re citizen petition from bioneutra north america inc,0,0
09000064823ee139,Supporting & Related Material,FDA-2016-P-4275-0013,FDA-2016-P-4275,appendix c - dhingra et al 2012 dietary fibre in foods: a review re citizen petition from bioneutra north america inc,0,0
09000064823ee155,Supporting & Related Material,FDA-2016-P-4275-0016,FDA-2016-P-4275,"appendix c - everhart et al 1989 a longitudinal survey of self-reported
bowel habits in the united states re citizen petition from bioneutra north america inc",0,0
09000064823ee164,Supporting & Related Material,FDA-2016-P-4275-0034,FDA-2016-P-4275,appendix c - mcgill et al 2015 ten-year trends in fiber and whole grain intakes and food sources for the united states population: national health and nutrition examination survey 2001–2010 re citizen petition from bioneutra north america inc,1,0
09000064823edcd8,Supporting & Related Material,FDA-2016-P-4275-0003,FDA-2016-P-4275,appendix a - key research aspects of four human studies on imo and bowel function re citizen petition from bioneutra north america inc,0,0
09000064823ee07d,Supporting & Related Material,FDA-2016-P-4275-0028,FDA-2016-P-4275,appendix c - kaneko et al 1994 effects of isomaltooligosaccharides with different degrees of polymerization on human fecal bifidobacteria re citizen petition from bioneutra north america inc,0,0
09000064823ee07f,Supporting & Related Material,FDA-2016-P-4275-0030,FDA-2016-P-4275,appendix c - kohmoto et al 1991 dose-response test of  isomaltooligosaccharides for increasing fecal bifidobacteria re citizen petition from bioneutra north america inc,0,0
09000064823ee08e,Supporting & Related Material,FDA-2016-P-4275-0051,FDA-2016-P-4275,appendix c - u s fda 2016d re citizen petition from bioneutra north america inc,0,0
0900006482a19e26,Other,FDA-2016-P-4275-0056,FDA-2016-P-4275,letter from bioneutra north america inc to fda cfsan,0,0
09000064823ee133,Supporting & Related Material,FDA-2016-P-4275-0007,FDA-2016-P-4275,"appendix c - chang et al 2012 prevalence of functional gastrointestinal disorders in taiwan: questionnaire-based survey for adults based on
the rome iii criteria re citizen petition from bioneutra north america inc",0,0
09000064823ee134,Supporting & Related Material,FDA-2016-P-4275-0008,FDA-2016-P-4275,appendix c - chen et al 2001 effects of isomalto-oligosaccharides on bowel functions and indicators of nutritional status in constipated elderly men re citizen petition from bioneutra north america inc,0,0
09000064823ee158,Supporting & Related Material,FDA-2016-P-4275-0019,FDA-2016-P-4275,appendix c - harari et al 1996 bowel habit in relation to age and gender re citizen petition from bioneutra north america inc,0,0
09000064823ee165,Supporting & Related Material,FDA-2016-P-4275-0035,FDA-2016-P-4275,appendix c - nishino et al 1981 oligosaccharides in soy sauce re citizen petition from bioneutra north america inc,0,0
09000064823ee167,Supporting & Related Material,FDA-2016-P-4275-0037,FDA-2016-P-4275,"appendix c - pare et al 2001 an epidemiological survey of constipation in
canada: definitions, rates, demographics, and predictors of health care seeking re citizen petition from bioneutra north america inc",0,0
09000064823ee168,Supporting & Related Material,FDA-2016-P-4275-0038,FDA-2016-P-4275,"appendix c - rome foundation 2006 rome iii diagnostic criteria for
functional gastrointestinal disorders re citizen petition from bioneutra north america inc",0,0
090000648275cf5e,Other,FDA-2016-P-4275-0055,FDA-2016-P-4275,cfsan interim response letter  to bioneutra north america inc.,0,0
09000064823ee135,Supporting & Related Material,FDA-2016-P-4275-0009,FDA-2016-P-4275,appendix c - connell et al 1965 variation of bowel habit in two population samples re citizen petition from bioneutra north america inc,0,0
09000064823ee156,Supporting & Related Material,FDA-2016-P-4275-0017,FDA-2016-P-4275,appendix c - fukuda et al 2007 pattern of dietary fiber intake among the japanese general population re citizen petition from bioneutra north america inc,0,0
09000064823ee15b,Supporting & Related Material,FDA-2016-P-4275-0020,FDA-2016-P-4275,appendix c - health canada 2013 list of dietary fibres reviewed and accepted by health canada’s food directorate re citizen petition from bioneutra north america inc,1,0
09000064823ee15d,Supporting & Related Material,FDA-2016-P-4275-0022,FDA-2016-P-4275,appendix c - higgins & johanson 2004 epidemiology of constipation in north america: a systematic review re citizen petition from bioneutra north america inc,0,0
090000648320d894,Other,FDA-2018-P-1678-0001,FDA-2018-P-1678,"citizen petition from  mapi usa, inc",0,0
090000648320e044,Other,FDA-2018-P-1678-0002,FDA-2018-P-1678,"acknowledgment letter from fda ddm to  mapi usa, inc",0,0
090000648320d896,Supporting & Related Material,FDA-2018-P-1678-0003,FDA-2018-P-1678,"appendix 1 - proposed labeling for midazolam injection usp (20 pages) re citizen petition from  mapi usa, inc",0,0
090000648320d897,Supporting & Related Material,FDA-2018-P-1678-0004,FDA-2018-P-1678,"appendix 2 - approved labeling for midazolam injection by hospira - reference standard (41 pages) re citizen petition from  mapi usa, inc",0,0
090000648320d898,Supporting & Related Material,FDA-2018-P-1678-0005,FDA-2018-P-1678,"appendix 3- side-by-side comparison table and justifications of proposed and approved labeling for midazolam injection (47 pages) re citizen petition from  mapi usa, inc",0,0
09000064827a27ad,Other,FDA-2016-P-4591-0003,FDA-2016-P-4591,"petition denial letter from fda cder to   hyman, phelps & mcnamara pc",0,0
090000648243bb33,Other,FDA-2016-P-4591-0001,FDA-2016-P-4591,"citizen petition from hyman, phelps & mcnamara, pc",0,0
090000648243c1c4,Other,FDA-2016-P-4591-0002,FDA-2016-P-4591,"acknowledgement letter from fda ddm to hyman, phelps & mcnamara, p.c.",0,0
0900006481715199,Other,FDA-2014-P-0699-0002,FDA-2014-P-0699,acknowledgement letter from fda ddm to jason williams,0,0
0900006481715143,Other,FDA-2014-P-0699-0001,FDA-2014-P-0699,citizen petition from jason williams,0,0
09000064818cd987,Other,FDA-2014-P-0699-0008,FDA-2014-P-0699,citizen petition denial response letter from fda/cder to jason williams,0,0
0900006481f73c79,Other,FDA-2014-P-0511-0004,FDA-2014-P-0511,gablofen/baclofen petition close out memorandum from cder director,0,0
09000064816bf01d,Other,FDA-2014-P-0511-0001,FDA-2014-P-0511,citizen petition from agila specialties inc.,0,0
09000064818a7e56,Other,FDA-2014-P-0511-0003,FDA-2014-P-0511,interim response from fda/cder to agila specialties inc.,0,0
09000064816bf020,Other,FDA-2014-P-0511-0002,FDA-2014-P-0511,acknowledgement letter from fda ddm to agila specialties inc.,0,0
09000064818be29c,Supporting & Related Material,FDA-2014-P-1603-0004,FDA-2014-P-1603,attachment ii,0,0
09000064818be199,Other,FDA-2014-P-1603-0001,FDA-2014-P-1603,citizen petition from zydus pharmaceuticals usa inc,0,0
09000064818be23f,Other,FDA-2014-P-1603-0002,FDA-2014-P-1603,aknowledgment letter from fda ddm to zydus pharmaceuticals usa inc,0,0
09000064818be29d,Supporting & Related Material,FDA-2014-P-1603-0005,FDA-2014-P-1603,attachment iii,0,0
09000064818be29b,Supporting & Related Material,FDA-2014-P-1603-0003,FDA-2014-P-1603,attachment i,0,0
090000648239a670,Other,FDA-2014-P-0445-0004,FDA-2014-P-0445,denial letter from cdrh to robert lytle,0,0
0900006481723a91,Other,FDA-2014-P-0445-0003,FDA-2014-P-0445,citizen petition interim response from fda cdrh to robert l lytle,0,0
09000064816b1e95,Other,FDA-2014-P-0445-0002,FDA-2014-P-0445,acknowledgement letter from fda ddm to robert l lytle,0,0
09000064816b1e64,Other,FDA-2014-P-0445-0001,FDA-2014-P-0445,citizen petition from robert l. lytle,0,0
09000064816c10fa,Other,FDA-2014-P-0513-0001,FDA-2014-P-0513,citizen petition from university of tx md anderson cancer center,0,0
09000064816c1541,Other,FDA-2014-P-0513-0002,FDA-2014-P-0513,acknowledgement letter from fda ddm to the university of tx md anderson cancer center,0,0
0900006481b65298,Other,FDA-2014-P-0513-0003,FDA-2014-P-0513,citizen petition approval response letter from fda cder to the university of texas md anderson cancer center,0,0
0900006481d83adb,Other,FDA-2015-P-4582-0001,FDA-2015-P-4582,citizen petition from margaret moustafa,0,0
0900006481d83c16,Supporting & Related Material,FDA-2015-P-4582-0007,FDA-2015-P-4582,attachment 6 coralynn b. trewet interstitial lung disease pulmonary fibrosis re: citizen petition from margaret moustafa,0,0
0900006481d83e08,Supporting & Related Material,FDA-2015-P-4582-0004,FDA-2015-P-4582,attachment 2 coralynn b. trewet drug induced pulmonary diseases re: citizen petition from margaret moustafa,0,0
0900006481d83e0b,Supporting & Related Material,FDA-2015-P-4582-0006,FDA-2015-P-4582,attachment 5 kevin r. flaherty nonspecific interstitial pneumonia re: citizen petition from margaret moustafa,0,0
0900006481d83e06,Supporting & Related Material,FDA-2015-P-4582-0003,FDA-2015-P-4582,attachment 1 references re: citizen petition from margaret moustafa,0,0
0900006481d83e03,Other,FDA-2015-P-4582-0002,FDA-2015-P-4582,acknowledgement letter from fda ddm to margaret moustafa,0,0
0900006481fdcca4,Other,FDA-2015-P-4582-0008,FDA-2015-P-4582,interim response may 18 2016,0,0
0900006481d83e0a,Supporting & Related Material,FDA-2015-P-4582-0005,FDA-2015-P-4582,attachment 4 collard and king classification of diffuse lung disease re: citizen petition from margaret moustafa,0,0
09000064843288d9,Other,FDA-2018-P-3281-0013,FDA-2018-P-3281,final response letter from fda cder to pfizer essential health,0,0
0900006483a8808c,Other,FDA-2018-P-3281-0010,FDA-2018-P-3281,letter from fda cder to pfizer essential health,0,0
090000648365d019,Other,FDA-2018-P-3281-0001,FDA-2018-P-3281,citizen petition from pfizer inc,0,0
090000648365d3a3,Other,FDA-2018-P-3281-0002,FDA-2018-P-3281,acknowledgment letter from fda ddm to pfizer inc.,0,0
0900006483adbbbc,Supporting & Related Material,FDA-2019-P-1198-0006,FDA-2019-P-1198,appendix 2 letter of support re citizen petition from kind llc,0,0
0900006483adbd18,Other,FDA-2019-P-1198-0002,FDA-2019-P-1198,"acknowledgment letter from fda ddm to kind, llc",0,0
0900006483adbbb9,Supporting & Related Material,FDA-2019-P-1198-0003,FDA-2019-P-1198,"appendix 1 reference 1 copyrighted article lles, et al (2018) nutrient content claims how they impact perceived healthfulness of fortified snack foods and the moderating effects of nutrition facts labels re citizen petition from kind, llc",0,0
090000648449edb8,Other,FDA-2019-P-1198-0009,FDA-2019-P-1198,interim response letter from fda cfsan to kind llc,0,0
0900006483adb871,Other,FDA-2019-P-1198-0001,FDA-2019-P-1198,citizen petition from kind llc,0,0
0900006483adbbba,Supporting & Related Material,FDA-2019-P-1198-0004,FDA-2019-P-1198,appendix 1 reference 2 copyrighted article kalergis and macdonald (2009)  discretionary food fortification: implications of consumer attitudes re citizen petition from kind llc (1),1,0
0900006483adbbbb,Supporting & Related Material,FDA-2019-P-1198-0005,FDA-2019-P-1198,appendix 1 reference 3 manuscript katz et al the public health case for modernizing the definition of protein quality re citizen petition from kind llc,0,0
0900006482590eef,Supporting & Related Material,FDA-2017-P-2803-0014,FDA-2017-P-2803,exhibit k - pharmacokinetics and pharmacodynamics of pegfilgrastim - yang re citizen petition from apotex,0,0
0900006482590d94,Other,FDA-2017-P-2803-0003,FDA-2017-P-2803,"acknowledgment letter from fda ddm to apotex, inc.",0,0
0900006482b8cebe,Other,FDA-2017-P-2803-0018,FDA-2017-P-2803,"petition response letter from fda cder to apotex, inc.",0,0
0900006482590eeb,Supporting & Related Material,FDA-2017-P-2803-0010,FDA-2017-P-2803,exhibit g - optimizing adjuvant chemotherapy in early-stage breast cancer - perez re citizen petition from apotex,0,0
0900006482592092,Other,FDA-2017-P-2803-0016,FDA-2017-P-2803,"citizen petition from apotex, inc.",0,0
0900006482590eed,Supporting & Related Material,FDA-2017-P-2803-0012,FDA-2017-P-2803,exhibit i - granulocyte-colony stimulating factor administration - tigue re citizen petition from apotex,0,0
090000648259116d,Supporting & Related Material,FDA-2017-P-2803-0004,FDA-2017-P-2803,exhibit a - confirmation of biosimilarity - desai re citizen petition from apotex,0,0
0900006482590ee8,Supporting & Related Material,FDA-2017-P-2803-0007,FDA-2017-P-2803,exhibit d - predicting individual risk of neutropenic complications - lyman ii re citizen petition from apotex,0,0
0900006482590ee9,Supporting & Related Material,FDA-2017-P-2803-0008,FDA-2017-P-2803,exhibit e - risk models for predicting chemotherapy-induced neutropenia - lyman i re citizen petition from apotex,0,0
0900006482590eee,Supporting & Related Material,FDA-2017-P-2803-0013,FDA-2017-P-2803,exhibit j - first and subsequent cycle use of pegfilgrastim - vogel re citizen petition from apotex,0,0
090000648259116c,Supporting & Related Material,FDA-2017-P-2803-0001,FDA-2017-P-2803,"declaration of dr.  scadden re citizen petition from apotex, inc.",0,0
0900006482590eec,Supporting & Related Material,FDA-2017-P-2803-0011,FDA-2017-P-2803,exhibit h - pharmacokinetic pharmacodynamic modeling - roskos re citizen petition from apotex,0,0
0900006482590ef0,Supporting & Related Material,FDA-2017-P-2803-0015,FDA-2017-P-2803,exhibit l - neutrophil dynamics in response to chemotherapy and g-csf - zhuge re citizen petition from apotex,0,0
0900006482590eea,Supporting & Related Material,FDA-2017-P-2803-0009,FDA-2017-P-2803,exhibit f - neutropenia in cancer patients - mayor re citizen petition from apotex,0,0
090000648259116e,Supporting & Related Material,FDA-2017-P-2803-0005,FDA-2017-P-2803,exhibit b - chemotherapy for breast cancer - hassan re citizen petition from apotex,0,0
090000648259116f,Supporting & Related Material,FDA-2017-P-2803-0006,FDA-2017-P-2803,exhibit c - pegylation of therapeutic proteins - jevsevar re citizen petition from apotex,0,0
090000648258f9a5,Other,FDA-2017-P-2803-0002,FDA-2017-P-2803,"citizen petition from apotex, inc.",0,0
0900006482c9fae2,Other,FDA-2017-P-4195-0004,FDA-2017-P-4195,petition response letter,0,0
0900006482c98c5a,Notice,FDA-2017-P-4195-0003,FDA-2017-P-4195,"determination that trintellix (vortioxetine hydrobromide) oral
tablet, eq 15 milligram base, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006482921ba5,Other,FDA-2017-P-4195-0001,FDA-2017-P-4195,"citizen petition from  inc research, llc",0,0
0900006482922b91,Other,FDA-2017-P-4195-0002,FDA-2017-P-4195,"acknowledgment letter from fda ddm to  inc research, llc",0,0
0900006483306d3f,Supporting & Related Material,FDA-2018-P-2050-0003,FDA-2018-P-2050,"references re citizen petition from ss formulations, llc.",0,0
0900006483307315,Other,FDA-2018-P-2050-0002,FDA-2018-P-2050,"acknowledgment letter from fda ddm to ss formulations, llc.",0,0
0900006483306996,Other,FDA-2018-P-2050-0001,FDA-2018-P-2050,"citizen petition from ss formulations, llc.",0,0
09000064838e6dff,Other,FDA-2018-P-2050-0004,FDA-2018-P-2050,"letter from fda cder to ss formulations, llc",0,0
09000064824ffb80,Other,FDA-2017-P-1495-0001,FDA-2017-P-1495,citizen petition from sandoz inc,0,0
09000064825ac89f,Other,FDA-2017-P-1495-0003,FDA-2017-P-1495,withdrawal of cp from sandoz inc,0,0
09000064824ffb82,Other,FDA-2017-P-1495-0002,FDA-2017-P-1495,acknowledgement letter from fda ddm to sandoz inc,0,0
090000648046ecc0,Notice,FDA-2004-N-0066-0001,FDA-2004-N-0066,fda,0,0
090000648046ecc4,Notice,FDA-2004-N-0066-0002,FDA-2004-N-0066,fda,0,0
09000064804737f9,Notice,FDA-2004-N-0378-0002,FDA-2004-N-0378,fda,0,0
09000064804737f7,Notice,FDA-2004-N-0378-0001,FDA-2004-N-0378,fda,0,0
09000064804737fc,Notice,FDA-2004-N-0378-0005,FDA-2004-N-0378,fda,0,0
09000064804737fa,Supporting & Related Material,FDA-2004-N-0378-0003,FDA-2004-N-0378,supporting statement,0,0
09000064804737fb,Supporting & Related Material,FDA-2004-N-0378-0004,FDA-2004-N-0378,supporting statement,0,0
0900006480429ca2,Notice,FDA-2007-N-0088-0001,FDA-2007-N-0088,fda,0,0
09000064804420cd,Supporting & Related Material,FDA-2006-D-0032-0002,FDA-2006-D-0032,draft guidance,0,0
09000064804420c8,Notice,FDA-2006-D-0032-0001,FDA-2006-D-0032,fda,0,0
09000064804420d6,Notice,FDA-2006-D-0032-0005,FDA-2006-D-0032,fda,0,0
09000064804420d7,Other,FDA-2006-D-0032-0006,FDA-2006-D-0032,"guidance for clinical investigators, institutional review boards and sponsors; process for handling referrals to fda under 21 cfr 50.54;  additional safeguards for children in clinical investigations",0,0
09000064804420d8,Supporting & Related Material,FDA-2006-D-0032-0007,FDA-2006-D-0032,guidance,0,0
09000064804420ce,Supporting & Related Material,FDA-2006-D-0032-0003,FDA-2006-D-0032,draft guidance,0,0
09000064804420cf,Supporting & Related Material,FDA-2006-D-0032-0004,FDA-2006-D-0032,draft guidance,0,0
0900006480a71ffd,Other,FDA-2009-P-0602-0002,FDA-2009-P-0602,"acknowledgement letter to kaiser permanente health plan, inc",0,0
0900006480a71ffa,Other,FDA-2009-P-0602-0001,FDA-2009-P-0602,"kaiser permanente health plan, inc. - citizen petition",0,0
0900006480b08e1b,Other,FDA-2009-P-0602-0004,FDA-2009-P-0602,"interim response to kaiser foundation health plan, inc.",0,0
0900006483d61ee6,Other,FDA-2009-P-0602-0005,FDA-2009-P-0602,memorandum of meeting from  fda/cder,0,0
0900006484dda744,Other,FDA-2021-P-1142-0001,FDA-2021-P-1142,"citizen petition from biodelivery sciences international, inc.",0,0
0900006484dda746,Other,FDA-2021-P-1142-0002,FDA-2021-P-1142,"acknowledgment letter from fdm dms to biodelivery sciences international, inc.",0,0
0900006481fc4730,Other,FDA-2015-P-4946-0004,FDA-2015-P-4946,withdrawal from zydus pharmaceuticals (usa) inc.,0,0
0900006481dbed80,Supporting & Related Material,FDA-2015-P-4946-0002,FDA-2015-P-4946,annexure i orange book approved drug products with therapeutic equivalence evaluations re citizen petition from zydus pharmaceuticals (usa) inc.,0,0
0900006481dbed03,Other,FDA-2015-P-4946-0003,FDA-2015-P-4946,acknowledgement letter from fda ddm to zydus pharmaceuticals (usa) inc.,0,0
0900006481dbe8fb,Other,FDA-2015-P-4946-0001,FDA-2015-P-4946,citizen petition from zydus pharmaceuticals (usa) inc.,0,0
09000064820066a6,Other,FDA-2015-P-3739-0003,FDA-2015-P-3739,interim response letter from fda cfsan to bryan kutz,0,0
0900006481ccc985,Other,FDA-2015-P-3739-0002,FDA-2015-P-3739,acknowledgement letter from fda ddm to bryan kutz,0,0
0900006481ccc4c0,Other,FDA-2015-P-3739-0001,FDA-2015-P-3739,citizen petition from bryan kutz,0,0
090000648299c6b9,Supporting & Related Material,FDA-2017-P-4670-0005,FDA-2017-P-4670,attachment 3 - emend merck website product listing re citizen petition from baxter healthcare corporation,0,0
0900006482e77ed5,Other,FDA-2017-P-4670-0008,FDA-2017-P-4670,interim response from fda to baxter healthcare corporation,0,0
090000648299c6b8,Supporting & Related Material,FDA-2017-P-4670-0004,FDA-2017-P-4670,attachment 2 - emend dailymed labels re citizen petition from baxter healthcare corporation,0,0
090000648299b0cb,Other,FDA-2017-P-4670-0001,FDA-2017-P-4670,citizen petition from baxter healthcare corporation,0,0
090000648299c597,Other,FDA-2017-P-4670-0002,FDA-2017-P-4670,acknowledgment letter from fda ddm to baxter healthcare corporation,0,0
090000648299c6ba,Supporting & Related Material,FDA-2017-P-4670-0006,FDA-2017-P-4670,attachment 4 - emend drugsatfda label approved 31 may 2017 nda 022023s015 re citizen petition from baxter healthcare corporation,0,0
090000648299c6bb,Supporting & Related Material,FDA-2017-P-4670-0007,FDA-2017-P-4670,attachment 5 - fresenius kabi drugsatfda label approved 09 june 2016 original anda 206197 re citizen petition from baxter healthcare corporation,0,0
09000064837b55db,Other,FDA-2017-P-4670-0009,FDA-2017-P-4670,petition approval letter from fda cder to baxter healthcare corp,0,0
090000648299c6b7,Supporting & Related Material,FDA-2017-P-4670-0003,FDA-2017-P-4670,attachment 1 - emend (fosaprepitant dimeglumine) orange book listing re citizen petition from baxter healthcare corporation,0,0
0900006484021236,Supporting & Related Material,FDA-2019-P-4645-0004,FDA-2019-P-4645,"attachment 2 - vesicare approved labeling re citizen petition from reguliance llc on behalf of  intas pharmaceuticals, ltd.",0,0
0900006484021245,Supporting & Related Material,FDA-2019-P-4645-0007,FDA-2019-P-4645,"attachment 5 - ogd product-specific guidance re citizen petition from reguliance llc on behalf of  intas pharmaceuticals, ltd.",0,0
0900006484021243,Supporting & Related Material,FDA-2019-P-4645-0005,FDA-2019-P-4645,"attachment 3 - proposed labeling for solifenacin intas odt re citizen petition from reguliance llc on behalf of  intas pharmaceuticals, ltd.",0,0
0900006484021247,Supporting & Related Material,FDA-2019-P-4645-0009,FDA-2019-P-4645,"attachment 7 - comparative in-vitro dissolution studies re citizen petition from reguliance llc on behalf of  intas pharmaceuticals, ltd.",0,0
090000648402119b,Other,FDA-2019-P-4645-0001,FDA-2019-P-4645,"citizen petition from reguliance llc on behalf of  intas pharmaceuticals, ltd.",0,0
0900006484021235,Supporting & Related Material,FDA-2019-P-4645-0003,FDA-2019-P-4645,"attachment 1 - copy of orange book pages for vesicare re citizen petition from reguliance llc on behalf of  intas pharmaceuticals, ltd.",0,0
0900006484021248,Supporting & Related Material,FDA-2019-P-4645-0010,FDA-2019-P-4645,"attachment 8 - prea automatic full waiver_list 8-14-2019 re citizen petition from reguliance llc on behalf of  intas pharmaceuticals, ltd.",0,0
0900006484021246,Supporting & Related Material,FDA-2019-P-4645-0008,FDA-2019-P-4645,"attachment 6 - ogd recommended dissolution method re citizen petition from reguliance llc on behalf of  intas pharmaceuticals, ltd.",0,0
090000648402142d,Other,FDA-2019-P-4645-0002,FDA-2019-P-4645,acknowledgment letter from fda dms to reguliance llc on behalf of intas pharmaceuticals ltd.,0,0
0900006484021244,Supporting & Related Material,FDA-2019-P-4645-0006,FDA-2019-P-4645,"attachment 4 - side-by-side comparison of vesicare and solifenacin labeling re citizen petition from reguliance llc on behalf of  intas pharmaceuticals, ltd.",0,0
0900006481fbb1aa,Other,FDA-2016-P-1250-0002,FDA-2016-P-1250,acknowledgement letter from fda ddm to pts consulting,0,0
09000064827ab0e0,Other,FDA-2016-P-1250-0007,FDA-2016-P-1250,letter from pts consulting  requesting to  withdraw cp,0,0
0900006481fbb1a8,Other,FDA-2016-P-1250-0001,FDA-2016-P-1250,citizen petition from pts consulting,0,0
0900006481fbb1ac,Supporting & Related Material,FDA-2016-P-1250-0003,FDA-2016-P-1250,"attachment 1 - chlorpromazine hydrochloride tables, 100 mg, anda no. 080439, sandoz (discontinued) 36th edition",0,0
0900006481fbb1ad,Supporting & Related Material,FDA-2016-P-1250-0004,FDA-2016-P-1250,"attachment 2 - usl pharma's anda no 084114 for chlorpromazine hydrochloride tables, 100 mg 36th edition",0,0
0900006482369b08,Other,FDA-2016-P-1250-0005,FDA-2016-P-1250,interim response from cder to pts consulting llc,0,0
0900006481f93b76,Supporting & Related Material,FDA-2016-P-1212-0003,FDA-2016-P-1212,"attachment 1 approved labeling for the rld, excedrin (migraine) re citizen petition from medtech products inc.",0,0
0900006481f93b77,Supporting & Related Material,FDA-2016-P-1212-0004,FDA-2016-P-1212,"attachment 2 draft labeling for the proposed product, goody's migraine re citizen petition from medtech products inc.",0,0
0900006481f93b78,Supporting & Related Material,FDA-2016-P-1212-0005,FDA-2016-P-1212,attachment 3 request for waiver from requirement to submit a pediatric assessment re citizen petition from medtech products inc.,0,0
0900006481f93b8b,Other,FDA-2016-P-1212-0002,FDA-2016-P-1212,acknowledgement letter from fda ddm to medtech products inc.,0,0
0900006481f93b74,Other,FDA-2016-P-1212-0001,FDA-2016-P-1212,citizen petition from medtech products inc.,0,0
0900006482eee5b0,Other,FDA-2016-P-1212-0006,FDA-2016-P-1212,notice of withdrawal letter from fda to a prestige brands company,0,0
09000064825de6db,Other,FDA-2016-P-4141-0003,FDA-2016-P-4141,"interim response letter from cder to hyman, phelps & mcnamara, p.c.",0,0
0900006483aea054,Other,FDA-2016-P-4141-0004,FDA-2016-P-4141,"response letter from cder to hyman, phelps & mcnamara, p.c.",0,0
09000064823cd319,Other,FDA-2016-P-4141-0002,FDA-2016-P-4141,"acknowledgment letter from fda ddm to hyman phelps & mcnamara,  p.c.",0,0
09000064823ccc67,Other,FDA-2016-P-4141-0001,FDA-2016-P-4141,"citizen petition from hyman phelps & mcnamara, p.c. (upsher-smith laboratories, inc.)",0,0
0900006483b6b1ef,Other,FDA-2019-P-1643-0002,FDA-2019-P-1643,acknowledgment letter from fda ddm to public citizen's health research group,0,0
0900006483b70296,Other,FDA-2019-P-1643-0003,FDA-2019-P-1643,supplement from public citizen,0,0
0900006483b7f0b4,Other,FDA-2019-P-1643-0004,FDA-2019-P-1643,withdrawal from public citizen,0,0
0900006483b6ad28,Other,FDA-2019-P-1643-0001,FDA-2019-P-1643,citizen petition from public citizen's health research group,0,0
09000064818e4a34,Other,FDA-2014-P-1660-0001,FDA-2014-P-1660,citizen petition from teva pharmaceutical industries ltd teva respiratory llc,0,0
09000064818e4cfb,Other,FDA-2014-P-1660-0002,FDA-2014-P-1660,acknowledgement letter from fda ddm to teva pharmaceuticals,0,0
0900006481af1be0,Other,FDA-2014-P-1660-0003,FDA-2014-P-1660,"fda cder to teva respiratory, llc  citizen petition partial approval and partial denial",0,0
0900006481966d70,Other,FDA-2014-P-2142-0001,FDA-2014-P-2142,citizen petition from zydus pharmaceuticals,0,0
0900006481966868,Other,FDA-2014-P-2142-0002,FDA-2014-P-2142,acknowledgement letter from fda ddm to zydus pharmaceuticals,0,0
0900006481cbd45f,Other,FDA-2014-P-2142-0003,FDA-2014-P-2142,"withdrawal of citizen petition from zydus pharmaceuticals, inc",0,0
09000064812632f3,Notice,FDA-2013-D-0362-0001,FDA-2013-D-0362,draft guidance for industry and food and drug administration staff; glass syringes for delivering drug and biological products: technical information to supplement standardization standard 11040–4; availability,1,0
0900006481264a85,Other,FDA-2013-D-0362-0002,FDA-2013-D-0362,draft guidance for industry and food and drug administration staff; glass syringes for delivering drug and biological products: technical information to supplement standardization standard 11040–4,1,0
09000064824d4c1a,Other,FDA-2017-P-1108-0002,FDA-2017-P-1108,acknowledgement letter from fda ddm to orbicular pharmaceutical technologies,0,0
09000064824d4c18,Other,FDA-2017-P-1108-0001,FDA-2017-P-1108,citizen petition from orbicular pharmaceutical technologies,0,0
0900006482b486e3,Other,FDA-2017-P-1108-0005,FDA-2017-P-1108,"response letter from fda to orbicular pharmaceutical technologies, pvt. ltd",0,0
0900006482a8d92f,Other,FDA-2017-P-1108-0003,FDA-2017-P-1108,interim response letter re citizen petition from orbicular pharmaceutical technologies,0,0
0900006482b3b694,Notice,FDA-2017-P-1108-0004,FDA-2017-P-1108,"determination that timoptic (timolol maleate ophthalmic solution), 0.25 percent and 0.5 percent, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006484420d31,Other,FDA-2020-P-1065-0002,FDA-2020-P-1065,acknowledgment letter from fda dms to b. braun medical inc.,0,0
090000648483c700,Other,FDA-2020-P-1065-0004,FDA-2020-P-1065,letter from fda cder to b. braun medical inc.,0,0
0900006484420d30,Other,FDA-2020-P-1065-0001,FDA-2020-P-1065,citizen petition from b. braun medical inc.,0,0
0900006484420b29,Supporting & Related Material,FDA-2020-P-1065-0003,FDA-2020-P-1065,appendix 1: list of b. braun drug products for which te code designation is requested re citizen petition from b. braun medical inc.,0,0
0900006484704ef7,Other,FDA-2020-P-0678-0005,FDA-2020-P-0678,"petition response letter from fda cder to fresenius kabi usa, llc",0,0
090000648433c777,Other,FDA-2020-P-0678-0001,FDA-2020-P-0678,"citizen petition from fresenius kabi usa, llc.",0,0
09000064847042cd,Notice,FDA-2020-P-0678-0004,FDA-2020-P-0678,"determination that dextrose in plastic container (dextrose)  injectable, 30 grams/100 milliliters, 40 grams/100 milliliters, 60 grams/100 milliliters, and 70 grams/100 milliliters, were not withdrawn from sale for reasons of safety or effectiveness",0,0
090000648433c77b,Supporting & Related Material,FDA-2020-P-0678-0003,FDA-2020-P-0678,"attachment a - current orange book listing of dextrose 70% re citizen petition from fresenius kabi usa, llc.",0,0
090000648433c778,Other,FDA-2020-P-0678-0002,FDA-2020-P-0678,"acknowledgment letter from fda dms to fresenius kabi usa, llc.",0,0
0900006484a46ffd,Supporting & Related Material,FDA-2021-P-0211-0004,FDA-2021-P-0211,attachment 2- nda 018897 rld labeling re: suitability petition from fresenius kabi usa llc,0,0
0900006484a46e21,Other,FDA-2021-P-0211-0001,FDA-2021-P-0211,suitability petition from fresenius kabi usa llc,0,0
0900006484a46fe2,Supporting & Related Material,FDA-2021-P-0211-0003,FDA-2021-P-0211,attachment 1- orange book listing of sodium chloride re: suitability petition from fresenius kabi usa llc,0,0
0900006484a46fda,Other,FDA-2021-P-0211-0002,FDA-2021-P-0211,acknowledgment letter from fda dms to fresenius kabi usa llc,0,0
0900006484a47000,Supporting & Related Material,FDA-2021-P-0211-0005,FDA-2021-P-0211,attachment 3- fresenius kabi proposed labeling sodium chloride pbp pi re: suitability petition from fresenius kabi usa llc,0,0
09000064822360ee,Supporting & Related Material,FDA-2016-P-2737-0006,FDA-2016-P-2737,attachment 3- appendix tabs 19-20-2 re citizen petition from natural resources defense council,0,0
09000064822367c1,Supporting & Related Material,FDA-2016-P-2737-0048,FDA-2016-P-2737,attachment 45 - appendix tabs 99-102 re citizen petition from natural resources defense council,0,0
09000064822367c4,Supporting & Related Material,FDA-2016-P-2737-0051,FDA-2016-P-2737,attachment 48 - appendix tab 103-3 re citizen petition from natural resources defense council,0,0
09000064822367c5,Supporting & Related Material,FDA-2016-P-2737-0052,FDA-2016-P-2737,attachment 49 - appendix tab 103-4 re citizen petition from natural resources defense council,0,0
090000648223679e,Supporting & Related Material,FDA-2016-P-2737-0013,FDA-2016-P-2737,attachment 10 - appendix tabs 76-77 re citizen petition from natural resources defense council,0,0
090000648223679f,Supporting & Related Material,FDA-2016-P-2737-0014,FDA-2016-P-2737,attachment 11 - appendix tab 78-1 re citizen petition from natural resources defense council,0,0
09000064822367a0,Supporting & Related Material,FDA-2016-P-2737-0015,FDA-2016-P-2737,attachment 12 - appendix tab 78-2-3 re citizen petition from natural resources defense council,0,0
09000064822367a3,Supporting & Related Material,FDA-2016-P-2737-0018,FDA-2016-P-2737,attachment 15 - appendix tab 79-2 re citizen petition from natural resources defense council,0,0
09000064822367ab,Supporting & Related Material,FDA-2016-P-2737-0026,FDA-2016-P-2737,attachment 23 - appendix tab 79-10-1 re citizen petition from natural resources defense council,0,0
09000064822367b0,Supporting & Related Material,FDA-2016-P-2737-0031,FDA-2016-P-2737,attachment 28 - appendix tab 79-15-1 re citizen petition from natural resources defense council,0,0
09000064822367bc,Supporting & Related Material,FDA-2016-P-2737-0043,FDA-2016-P-2737,attachment 40 - appendix tab 79-27 re citizen petition from natural resources defense council,0,0
09000064822367c0,Supporting & Related Material,FDA-2016-P-2737-0047,FDA-2016-P-2737,attachment 44 - appendix tabs 80-98 re citizen petition from natural resources defense council,0,0
090000648223679b,Supporting & Related Material,FDA-2016-P-2737-0010,FDA-2016-P-2737,attachment 7- appendix tabs 39-56 re citizen petition from natural resources defense council,0,0
09000064822367a4,Supporting & Related Material,FDA-2016-P-2737-0019,FDA-2016-P-2737,attachment 16 - appendix tab 79-3 re citizen petition from natural resources defense council,0,0
09000064822367a6,Supporting & Related Material,FDA-2016-P-2737-0021,FDA-2016-P-2737,attachment 18 - appendix tab 79-5 re citizen petition from natural resources defense council,0,0
09000064822367af,Supporting & Related Material,FDA-2016-P-2737-0030,FDA-2016-P-2737,attachment 27 - appendix tab 79-14-1 re citizen petition from natural resources defense council,0,0
09000064822367b4,Supporting & Related Material,FDA-2016-P-2737-0035,FDA-2016-P-2737,attachment 32 - appendix tab 79-19 re citizen petition from natural resources defense council,0,0
09000064822360ed,Supporting & Related Material,FDA-2016-P-2737-0005,FDA-2016-P-2737,attachment 2 - appendix tabs 1-18 re citizen petition from natural resources defense council,0,0
09000064822367c2,Supporting & Related Material,FDA-2016-P-2737-0049,FDA-2016-P-2737,attachment 46 - appendix tab 103-1 re citizen petition from natural resources defense council,0,0
09000064822367c8,Supporting & Related Material,FDA-2016-P-2737-0055,FDA-2016-P-2737,attachment 52 - appendix tabs 104-108 re citizen petition from natural resources defense council,0,0
09000064846c0f80,Supporting & Related Material,FDA-2016-P-2737-0142,FDA-2016-P-2737,attachment 7 supplement tabs s22-s25 re supplement to citizen petition from natural resources defense council,0,0
0900006482500c0c,Other,FDA-2016-P-2737-0125,FDA-2016-P-2737,interim response letter from cvm to natural resources defense council,0,0
0900006484a57697,Other,FDA-2016-P-2737-0144,FDA-2016-P-2737,final response letter to natural resources defense council from fda cvm,0,0
09000064822360ef,Supporting & Related Material,FDA-2016-P-2737-0007,FDA-2016-P-2737,attachment 4- appendix tabs 21-25 re citizen petition from natural resources defense council,0,0
09000064822367c6,Supporting & Related Material,FDA-2016-P-2737-0053,FDA-2016-P-2737,attachment 50 - appendix tab 103-5 re citizen petition from natural resources defense council,0,0
09000064849ec65b,Supporting & Related Material,FDA-2021-P-0037-0005,FDA-2021-P-0037,"attahcment 3 re suitability petition from hyman, phelps & mcnamara pc",0,0
09000064849ec656,Other,FDA-2021-P-0037-0002,FDA-2021-P-0037,"acknowledgment letter from fda dms to hyman, phelps & mcnamara pc",0,0
09000064849ec65a,Supporting & Related Material,FDA-2021-P-0037-0004,FDA-2021-P-0037,"attahcment 2 re suitability petition from hyman, phelps & mcnamara pc",0,0
09000064849ec655,Other,FDA-2021-P-0037-0001,FDA-2021-P-0037,"suitability petition from hyman, phelps & mcnamara pc",0,0
09000064849ec659,Supporting & Related Material,FDA-2021-P-0037-0003,FDA-2021-P-0037,"attahcment 1 re suitability petition from hyman, phelps & mcnamara pc",0,0
09000064849ffd52,Other,FDA-2021-P-0037-0006,FDA-2021-P-0037,"withdrawal from hyman, phelps & mcnamara pc",0,0
09000064849deda5,Other,FDA-2021-P-0027-0002,FDA-2021-P-0027,acknowledgment letter from fda dms to pet schooled,0,0
0900006484bd2355,Other,FDA-2021-P-0027-0007,FDA-2021-P-0027,response letter from fda cvm to pet schooled,0,0
09000064849deda4,Other,FDA-2021-P-0027-0001,FDA-2021-P-0027,citizen petition from pet schooled,0,0
090000648048f1e0,Supporting & Related Material,FDA-2008-D-0206-0003,FDA-2008-D-0206,"content and review of chemistry, manufacturing, and control (cmc) information for human somatic cell therapy investigational new drug applications (inds) - reference list",0,0
0900006480493652,Other,FDA-2008-D-0206-0002,FDA-2008-D-0206,"content and review of chemistry, manufacturing, and control (cmc) information for human somatic cell therapy investigational new drug applications (inds):  guidance for fda reviewers and sponsors",0,0
09000064804a3276,Notice,FDA-2008-D-0206-0001,FDA-2008-D-0206,"guidance for food and drug administration reviewers and sponsors: content and review of chemistry, manufacturing, and control information for human somatic cell therapy investigational new drug applications; availability",1,0
09000064804440b1,Notice,FDA-2005-N-0240-0001,FDA-2005-N-0240,fda,0,0
09000064804440ae,Notice,FDA-2005-N-0240-0002,FDA-2005-N-0240,fda,0,0
090000648045c57a,Notice,FDA-2006-N-0306-0001,FDA-2006-N-0306,fda,0,0
090000648045c593,Notice,FDA-2006-N-0306-0002,FDA-2006-N-0306,fda,0,0
0900006480bd6958,Other,FDA-2010-D-0281-0015,FDA-2010-D-0281,"guidance for industry and food and drug administration staff; “‘harmful and potentially harmful constituents’ in tobacco products as used in section 904(e) of the federal food, drug, and cosmetic act”",1,1
0900006480c2de49,Notice,FDA-2010-D-0281-0017,FDA-2010-D-0281,pediatric advisory committee; notice of meeting,0,0
0900006480b4da5e,Other,FDA-2010-D-0281-0013,FDA-2010-D-0281,altria client services - supplement,0,0
0900006480bd6814,Notice,FDA-2010-D-0281-0014,FDA-2010-D-0281,"guidance for industry and food and drug administration staff; availability: harmful and potentially harmful constituents in tobacco products, etc.",1,1
09000064821bd935,Other,FDA-2010-D-0281-0018,FDA-2010-D-0281,"guidance for industry for “harmful and potentially harmful constituents” in tobacco products as used in section 904(e) of the federal food, drug, and cosmetic act (revised)*",1,1
0900006480aff64a,Other,FDA-2010-D-0281-0002,FDA-2010-D-0281,"guidance for industry and fda staff: ""harmful and potenially harmful constituents"" in tobacco products as used in secion 904(e) of the federal food, drug, and cosmetic act",1,1
0900006480aff991,Notice,FDA-2010-D-0281-0001,FDA-2010-D-0281,"draft guidance for industry and food and drug administration staff: ""harmful and potentially harmful constituents in tobacco products as used in section 904(e) of the federal food, drug, and cosmetic act""",1,1
0900006483805a0c,Other,FDA-2018-P-3951-0001,FDA-2018-P-3951,citizen petition from chul-hi park,0,0
0900006483c50bdf,Other,FDA-2018-P-3951-0004,FDA-2018-P-3951,interim response letter from fda cdrh,0,0
0900006483805a0e,Other,FDA-2018-P-3951-0002,FDA-2018-P-3951,acknowledgment letter from fda ddm to chul-hi park,0,0
0900006484dc39fc,Other,FDA-2018-P-3951-0005,FDA-2018-P-3951,petition response from fda cdrh to chul-hi park,0,0
0900006484bc2b57,Notice,FDA-2021-P-0424-0003,FDA-2021-P-0424,"medical devices; exemption from premarket notification: powered patient transport, all other powered patient transport",0,0
0900006484dcec1d,Other,FDA-2021-P-0424-0006,FDA-2021-P-0424,petition response letter from fda cdrh to stryker medical,0,0
0900006484ac839b,Other,FDA-2021-P-0424-0002,FDA-2021-P-0424,acknowledgment letter from fda dms to stryker medical,0,0
0900006484c0a28b,Notice,FDA-2021-P-0424-0005,FDA-2021-P-0424,"medical devices; exemption from premarket notification: powered 
patient transport, all other powered patient transport; extension of 
comment period",0,0
0900006484ac8399,Other,FDA-2021-P-0424-0001,FDA-2021-P-0424,citizen petition from stryker medical,0,0
09000064816058f4,Notice,FDA-2014-N-0237-0001,FDA-2014-N-0237,"report to congress; report on the food and drug administration’s policy
to be proposed regarding premarket notification requirements for
modifications to legally marketed devices; notice to public of web site
location of report to congress",1,0
0900006481172df3,Other,FDA-2012-P-0906-0003,FDA-2012-P-0906,"fda/cder response to lachman consultant services, inc. - petition approval",0,0
09000064810e205a,Other,FDA-2012-P-0906-0001,FDA-2012-P-0906,"lachman consultant services, inc. - citizen petition",0,0
09000064810e20f0,Other,FDA-2012-P-0906-0002,FDA-2012-P-0906,"acknowledgement letter to lachman consultant sevices, inc.",0,0
0900006481cb1458,Other,FDA-2014-P-2301-0004,FDA-2014-P-2301,citizen petition denial response from fda cder to probiomed sa de cv,0,0
0900006481996c83,Other,FDA-2014-P-2301-0002,FDA-2014-P-2301,"acknowledgement letter from fda ddm to probiomed s.a. de c.v., mexico",0,0
0900006481991a9e,Other,FDA-2014-P-2301-0001,FDA-2014-P-2301,citizen petition from probiomed s.a. de c.v. mexico,0,0
0900006481b43220,Other,FDA-2014-P-2301-0003,FDA-2014-P-2301,interim response letter from fda cder to probiomed sa de cv,0,0
0900006481911791,Supporting & Related Material,FDA-2014-P-1802-0003,FDA-2014-P-1802,appendix 1,0,0
0900006481911793,Supporting & Related Material,FDA-2014-P-1802-0004,FDA-2014-P-1802,appendix 2,0,0
09000064819c7fb9,Other,FDA-2014-P-1802-0005,FDA-2014-P-1802,suitability petition approval response letter from fda cvm to e5 pharma llc,0,0
0900006481911711,Other,FDA-2014-P-1802-0002,FDA-2014-P-1802,acknowledgement letter from fda ddm to e5 pharma llc,0,0
090000648191174c,Other,FDA-2014-P-1802-0001,FDA-2014-P-1802,"citizen petition from e5 pharma, llc",0,0
090000648190d3f9,Other,FDA-2014-P-1773-0001,FDA-2014-P-1773,"citizen petition from pharmacists planning service, inc.",0,0
0900006482d5085d,Other,FDA-2014-P-1773-0005,FDA-2014-P-1773,"citizen petition denial response letter from fda cder to pharmacists planning service, inc.",0,0
0900006481cb8490,Other,FDA-2014-P-1773-0004,FDA-2014-P-1773,"citizen petition partial denial response letter from fda cfsan to pharmacists planning service, inc.",0,0
0900006481a30b65,Other,FDA-2014-P-1773-0003,FDA-2014-P-1773,interim response from cder to ppsi,0,0
090000648190d3fb,Other,FDA-2014-P-1773-0002,FDA-2014-P-1773,acknowledgement letter from fda ddm to pharmacits planning sercive inc. (ppsi),0,0
0900006481866f2c,Other,FDA-2014-P-1343-0002,FDA-2014-P-1343,"acknowledgement letter from ddm to american society of interventional pain physicians (asipp) (pain management center of paducah clinical professor, anesthesiology and perioperative medicine university of louisville, kentucky and millennium pain center)",0,0
090000648185f014,Other,FDA-2014-P-1343-0001,FDA-2014-P-1343,"citizen petition from american society of interventional pain physicians (asipp) (pain management center of paducah clinical professor, anesthesiology and perioperative medicine university of louisville, kentucky and millennium pain center)",0,0
0900006481a2b41f,Other,FDA-2014-P-1343-0003,FDA-2014-P-1343,interim response to petition,0,0
0900006481cb1533,Other,FDA-2014-P-1343-0005,FDA-2014-P-1343,citizen petition partial approval and denial response from fda cder to american society of interventional pain physicians,0,0
0900006481edc448,Other,FDA-2015-P-2807-0005,FDA-2015-P-2807,"citizen petition approval response from fda cder to lachman consultant services, inc.",0,0
0900006481bb6c82,Other,FDA-2015-P-2807-0002,FDA-2015-P-2807,acknowledgment letter from fda ddm to  lachman consulting services inc.,0,0
0900006481bb629a,Supporting & Related Material,FDA-2015-P-2807-0003,FDA-2015-P-2807,attachment 1 orange book listing re: citizen petition from lachman consultant services inc.,0,0
0900006481bb9d44,Other,FDA-2015-P-2807-0001,FDA-2015-P-2807,citizen petition from lachman consultant services inc,0,0
0900006481e3752b,Other,FDA-2015-P-2807-0004,FDA-2015-P-2807,"interim response letter from fda cder to lachman consultant services, inc.",0,0
0900006481a02a92,Supporting & Related Material,FDA-2015-P-0464-0007,FDA-2015-P-0464,attach 2,0,0
0900006481a02a96,Supporting & Related Material,FDA-2015-P-0464-0011,FDA-2015-P-0464,attach 6,0,0
0900006481a01fee,Supporting & Related Material,FDA-2015-P-0464-0003,FDA-2015-P-0464,attach 1a - 1g,0,0
0900006481a01ff0,Supporting & Related Material,FDA-2015-P-0464-0005,FDA-2015-P-0464,attach 1n,0,0
0900006481a02a93,Supporting & Related Material,FDA-2015-P-0464-0008,FDA-2015-P-0464,attach 3,0,0
0900006481a02e9e,Supporting & Related Material,FDA-2015-P-0464-0019,FDA-2015-P-0464,attach 14,0,0
0900006481a02a9a,Supporting & Related Material,FDA-2015-P-0464-0015,FDA-2015-P-0464,attach 10,0,0
0900006481a02e9b,Supporting & Related Material,FDA-2015-P-0464-0016,FDA-2015-P-0464,attach 11,0,0
0900006481a02e9f,Supporting & Related Material,FDA-2015-P-0464-0020,FDA-2015-P-0464,attach 15,0,0
0900006481e4c741,Other,FDA-2015-P-0464-0022,FDA-2015-P-0464,interim response letter from fda cder to colgate-palmolive company,0,0
0900006481a01fef,Supporting & Related Material,FDA-2015-P-0464-0004,FDA-2015-P-0464,attach 1h - 1m,0,0
0900006481a02a91,Supporting & Related Material,FDA-2015-P-0464-0006,FDA-2015-P-0464,attach 1o - 1u,0,0
0900006481a02a98,Supporting & Related Material,FDA-2015-P-0464-0013,FDA-2015-P-0464,attach 8,0,0
0900006481a02a99,Supporting & Related Material,FDA-2015-P-0464-0014,FDA-2015-P-0464,attach 9 pdf,0,0
0900006481a02e9d,Supporting & Related Material,FDA-2015-P-0464-0018,FDA-2015-P-0464,attach 13,0,0
0900006481a02a94,Supporting & Related Material,FDA-2015-P-0464-0009,FDA-2015-P-0464,attach 4,0,0
0900006481a02a95,Supporting & Related Material,FDA-2015-P-0464-0010,FDA-2015-P-0464,attach 5,0,0
0900006481a02a97,Supporting & Related Material,FDA-2015-P-0464-0012,FDA-2015-P-0464,attach 7,0,0
0900006481a02e9c,Supporting & Related Material,FDA-2015-P-0464-0017,FDA-2015-P-0464,attach 12 pdf,0,0
0900006481a01fec,Other,FDA-2015-P-0464-0002,FDA-2015-P-0464,acknowledgement letter from fda ddm to colgate palmolive company,0,0
0900006481a01fea,Other,FDA-2015-P-0464-0001,FDA-2015-P-0464,citizen petition from colgate palmolive company,0,0
0900006482d92336,Other,FDA-2018-P-0034-0002,FDA-2018-P-0034,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara",0,0
0900006482d92334,Other,FDA-2018-P-0034-0001,FDA-2018-P-0034,"citizen petition from hyman, phelps & mcnamara",0,0
090000648367eeb3,Other,FDA-2018-P-0034-0005,FDA-2018-P-0034,agency response letter from fda cder to strides pharma inc.,0,0
090000648346d33a,Other,FDA-2018-P-0034-0004,FDA-2018-P-0034,"interim response letter from fda cder to hyman, phelps & mcnamara",0,0
090000648390d53a,Other,FDA-2017-P-6245-0009,FDA-2017-P-6245,interim response letter from fda cfsan to viguard health inc.,0,0
0900006482bfdf10,Other,FDA-2017-P-6245-0002,FDA-2017-P-6245,acknowledgement letter from fda ddm to viguard health inc.,0,0
0900006482bfdaa4,Other,FDA-2017-P-6245-0001,FDA-2017-P-6245,citizen petition from viguard health inc.,0,0
0900006483aebade,Other,FDA-2017-P-6245-0010,FDA-2017-P-6245,withdrawal from viguard health inc.,0,0
0900006482616f51,Other,FDA-2017-P-3329-0001,FDA-2017-P-3329,"citizen petition from hyman, phelps, & mcnamara, p.c.",0,0
0900006482c93384,Other,FDA-2017-P-3329-0003,FDA-2017-P-3329,"interim response from fda to hyman, phelps & mcnamara, p.c.",0,0
0900006482619ed2,Other,FDA-2017-P-3329-0002,FDA-2017-P-3329,"acknowledgement letter from fda ddm to hyman, phelps & mcnamara, p.c.",0,0
0900006483ae9eca,Other,FDA-2017-P-3329-0004,FDA-2017-P-3329,"response from fda cder to hyman, phelps & mcnamara, p.c.",0,0
0900006483ec1c13,Other,FDA-2018-N-4002-0005,FDA-2018-N-4002,"international council for harmonization (ich) e2b (r3) standards - transcript wednesday, july 17, 2019",0,0
09000064838df0b4,Notice,FDA-2018-N-4002-0001,FDA-2018-N-4002,"electronic submission of adverse event reports to the food and drug
administration adverse event reporting system using international
council for harmonisation e2b(r3) standards; public meetings; request
for comments",1,0
0900006483c4e958,Other,FDA-2018-N-4002-0003,FDA-2018-N-4002,meeting transcript - electronic submission of adverse event reports to fda adverse event reporting system (faers) using international council for harmonisation (ich) e2b (r3) standards,0,0
0900006483ade980,Notice,FDA-2018-N-4002-0002,FDA-2018-N-4002,"electronic submission of adverse event reports to the food and drug
administration adverse event reporting system using international
council for harmonisation e2b(r3) standards; public meetings; request
for comments",1,0
09000064847c5ca0,Other,FDA-2018-N-4002-0006,FDA-2018-N-4002,international council for harmonization (ich) e2b(r3) standards - transcript 02/19/2020,0,0
0900006482b81bc8,Other,FDA-2017-P-5946-0001,FDA-2017-P-5946,citizen petition from goodwin procter llp,0,0
0900006482fd697a,Other,FDA-2017-P-5946-0004,FDA-2017-P-5946,response letter from fda to goodwin procter llp,0,0
0900006482b81bca,Other,FDA-2017-P-5946-0002,FDA-2017-P-5946,acknowledgement letter from fda ddm to goodwin procter llp,0,0
0900006482fcf267,Notice,FDA-2017-P-5946-0003,FDA-2017-P-5946,"determination that doryx mpc (doxycycline hyclate), delayed-release tablets, 60 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
09000064846bb3db,Supporting & Related Material,FDA-2020-P-1443-0005,FDA-2020-P-1443,tab 2 re: citizen petition from elanco animal health,0,0
09000064846bb418,Supporting & Related Material,FDA-2020-P-1443-0022,FDA-2020-P-1443,tab 13 re: citizen petition from elanco animal health,0,0
09000064846bb41a,Supporting & Related Material,FDA-2020-P-1443-0020,FDA-2020-P-1443,tab 15 re: citizen petition from elanco animal health,0,0
09000064846bba14,Supporting & Related Material,FDA-2020-P-1443-0018,FDA-2020-P-1443,tab 17 re: citizen petition from elanco animal health,0,0
09000064846bba1e,Supporting & Related Material,FDA-2020-P-1443-0008,FDA-2020-P-1443,tab 27 re: citizen petition from elanco animal health,0,0
09000064846bba16,Supporting & Related Material,FDA-2020-P-1443-0016,FDA-2020-P-1443,tab 19 re: citizen petition from elanco animal health,0,0
09000064846bba1a,Supporting & Related Material,FDA-2020-P-1443-0012,FDA-2020-P-1443,tab 23 re: citizen petition from elanco animal health,0,0
09000064846bb3e0,Supporting & Related Material,FDA-2020-P-1443-0028,FDA-2020-P-1443,tab 7 re: citizen petition from elanco animal health,0,0
09000064846bba19,Supporting & Related Material,FDA-2020-P-1443-0013,FDA-2020-P-1443,tab 22 re: citizen petition from elanco animal health,0,0
09000064846bb3da,Supporting & Related Material,FDA-2020-P-1443-0004,FDA-2020-P-1443,tab 1 re: citizen petition from elanco animal health,0,0
09000064846bb3de,Supporting & Related Material,FDA-2020-P-1443-0030,FDA-2020-P-1443,tab 5 re: citizen petition from elanco animal health,0,0
09000064846bb412,Supporting & Related Material,FDA-2020-P-1443-0027,FDA-2020-P-1443,tab 8 re: citizen petition from elanco animal health,0,0
09000064846bba1b,Supporting & Related Material,FDA-2020-P-1443-0011,FDA-2020-P-1443,tab 24 re: citizen petition from elanco animal health,0,0
09000064846bb3d9,Supporting & Related Material,FDA-2020-P-1443-0003,FDA-2020-P-1443,appendix 1 re: citizen petition from elanco animal health,0,0
09000064846bb3dd,Supporting & Related Material,FDA-2020-P-1443-0007,FDA-2020-P-1443,tab 4 re: citizen petition from elanco animal health,0,0
09000064846bb413,Supporting & Related Material,FDA-2020-P-1443-0026,FDA-2020-P-1443,tab 9 re: citizen petition from elanco animal health,0,0
09000064846bba1c,Supporting & Related Material,FDA-2020-P-1443-0010,FDA-2020-P-1443,tab 25 re: citizen petition from elanco animal health,0,0
09000064846bb41b,Supporting & Related Material,FDA-2020-P-1443-0019,FDA-2020-P-1443,tab 16 re: citizen petition from elanco animal health,0,0
09000064846bb419,Supporting & Related Material,FDA-2020-P-1443-0021,FDA-2020-P-1443,tab 14 re: citizen petition from elanco animal health,0,0
09000064846bb3dc,Supporting & Related Material,FDA-2020-P-1443-0006,FDA-2020-P-1443,tab 3 re: citizen petition from elanco animal health,0,0
09000064846bb414,Supporting & Related Material,FDA-2020-P-1443-0025,FDA-2020-P-1443,tab 10 re: citizen petition from elanco animal health,0,0
09000064846bb417,Supporting & Related Material,FDA-2020-P-1443-0023,FDA-2020-P-1443,tab 12 re: citizen petition from elanco animal health,0,0
09000064846bba15,Supporting & Related Material,FDA-2020-P-1443-0017,FDA-2020-P-1443,tab 18 re: citizen petition from elanco animal health,0,0
09000064846bba18,Supporting & Related Material,FDA-2020-P-1443-0014,FDA-2020-P-1443,tab 21 re: citizen petition from elanco animal health,0,0
09000064846bba1d,Supporting & Related Material,FDA-2020-P-1443-0009,FDA-2020-P-1443,tab 26 re: citizen petition from elanco animal health,0,0
0900006481495921,Notice,FDA-2011-D-0305-0058,FDA-2011-D-0305,distribution of in vitro diagnostic products labeled for research use only or investigational use only: guidance for industry and food and drug administration staff; availability,1,0
0900006480fb95ae,Other,FDA-2011-D-0305-0057,FDA-2011-D-0305,"hyman, phelps & mcnamara, p.c. - supplement comment re fda-2011-d-0305-0050",0,0
0900006480e38c85,Notice,FDA-2011-D-0305-0001,FDA-2011-D-0305,draft guidance for industry and fda staff: commercially distributed in vitro diagnostic products labeled for research use only or investigational use only: frequently asked questions; availability,0,0
0900006480e3906e,Other,FDA-2011-D-0305-0002,FDA-2011-D-0305,commercially distributed in vitro diagnostic products labeled for research use only or investigational use only: frequently asked questions - draft guidance,0,0
09000064821487f4,Other,FDA-2016-P-2344-0001,FDA-2016-P-2344,citizen petition from anda consultants,0,0
09000064821487f7,Other,FDA-2016-P-2344-0002,FDA-2016-P-2344,acknowledgement letter from fda ddm to anda consultants,0,0
0900006480457401,Notice,FDA-2006-N-0249-0002,FDA-2006-N-0249,fda,0,0
090000648045741e,Notice,FDA-2006-N-0249-0001,FDA-2006-N-0249,fda,0,0
0900006480441ad1,Other,FDA-2006-P-0021-0002,FDA-2006-P-0021,see fda-2006-p-0021-0001,0,0
0900006480441a75,Other,FDA-2006-P-0021-0001,FDA-2006-P-0021,acknowledgement letter to kerr corporation,0,0
0900006480441a87,Other,FDA-2006-P-0021-0004,FDA-2006-P-0021,kerr corporation - citizen petition,0,0
0900006480441ad2,Other,FDA-2006-P-0021-0003,FDA-2006-P-0021,fda/cdrh to kerr corporation - letter,0,0
0900006480b15f5a,Notice,FDA-2010-N-0101-0002,FDA-2010-N-0101,"agency information collection activities; proposals, submissions, and approvals: human cells, tissues, and cellular and tissue-based products",0,0
0900006480abaf76,Notice,FDA-2010-N-0101-0001,FDA-2010-N-0101,"agency information collection activities; proposals, submissions, and approvals: human cells, tissues, and cellular and tissue-basedproducts, etc.",0,0
0900006480abe656,Other,FDA-2010-P-0150-0003,FDA-2010-P-0150,acknowledgement letter to the united states pharmacopeial convention (usp),0,0
0900006480abe658,Supporting & Related Material,FDA-2010-P-0150-0002,FDA-2010-P-0150,"appendix a - ""food chemicals codex standards incorported by reference in fda gras regulations"" - [united states pharmacopeial convention (usp) - citizen petition]",1,0
0900006484721cc0,Other,FDA-2010-P-0150-0005,FDA-2010-P-0150,cp withdrawal letter from united states pharmacopeial  (usp),0,0
0900006480b5c4cd,Other,FDA-2010-P-0150-0004,FDA-2010-P-0150,interim response  to united states pharmacopeial convention,0,0
0900006480abe653,Other,FDA-2010-P-0150-0001,FDA-2010-P-0150,united states pharmacopeial convention (usp) - citizen petition,0,0
09000064849d0890,Other,FDA-2020-P-2360-0001,FDA-2020-P-2360,citizen petition from pet schooled the educated community,0,0
09000064849d20b5,Other,FDA-2020-P-2360-0002,FDA-2020-P-2360,acknowledgment letter from fda dms to pet schooled,0,0
0900006484bcd0fc,Other,FDA-2020-P-2360-0068,FDA-2020-P-2360,response letter from fda cvm to pet schooled,0,0
0900006484776f50,Supporting & Related Material,FDA-2020-P-1674-0003,FDA-2020-P-1674,attachment- detailed position paper to support the addition of sickle cell disease to the current list of neglected tropical diseases on the priority review voucher list section 524 of the food drug and cosmetic act re: citizen petition from putting rare diseases patients first!,1,0
09000064849ed8a4,Other,FDA-2020-P-1674-0017,FDA-2020-P-1674,interim response letter from fda cder to putting rare diseases patients first!,0,0
0900006484d8e855,Other,FDA-2020-P-1674-0022,FDA-2020-P-1674,response letter from fda cder to putting rare diseases patients first!®,0,0
0900006484776f4d,Other,FDA-2020-P-1674-0002,FDA-2020-P-1674,acknowledgment letter from fda dms to putting rare diseases patients first!,0,0
090000648476e4bf,Other,FDA-2020-P-1674-0001,FDA-2020-P-1674,citizen petition from putting rare diseases patients first!,0,0
09000064844ad265,Other,FDA-2020-P-1297-0002,FDA-2020-P-1297,acknowledgment letter from fda dms to joe dinardo,0,0
09000064844ad264,Other,FDA-2020-P-1297-0001,FDA-2020-P-1297,citizen petition from joe dinardo,0,0
09000064848fd5cf,Other,FDA-2020-P-1297-0003,FDA-2020-P-1297,letter from fda cder to joe dinardo,0,0
0900006484da7aa1,Other,FDA-2020-P-1297-0004,FDA-2020-P-1297,response letter from fda cder to joe dinardo,0,0
0900006484de4fc1,Other,FDA-2021-P-1147-0001,FDA-2021-P-1147,citizen petition from andrej tokmakov,0,0
0900006484e66663,Other,FDA-2021-P-1147-0020,FDA-2021-P-1147,supplement  information for citizen petition from andrej tokmakov page 2,0,0
0900006484de4b9e,Other,FDA-2021-P-1147-0002,FDA-2021-P-1147,acknowledgment letter from fda dms to andrej tokmakov,0,0
0900006484e66665,Other,FDA-2021-P-1147-0019,FDA-2021-P-1147,supplement  information for citizen petition from andrej tokmakov page 1,0,0
0900006484de5165,Supporting & Related Material,FDA-2021-P-1147-0003,FDA-2021-P-1147,attachment 1 re: citizen petition from andrej tokmakov,0,0
0900006484229cdd,Other,FDA-2019-P-5970-0001,FDA-2019-P-5970,citizen petition from iqvia rds inc,0,0
090000648422a0c6,Other,FDA-2019-P-5970-0002,FDA-2019-P-5970,acknowledgment letter from fda dms to iqvia rds inc,0,0
090000648422a0ca,Supporting & Related Material,FDA-2019-P-5970-0004,FDA-2019-P-5970,attachment 2 information of current and resolved drug shortages and discontinuations reported to fda re citizen petition from iqvia rds inc,0,0
090000648422a0c9,Supporting & Related Material,FDA-2019-P-5970-0003,FDA-2019-P-5970,attachment 1 electronic orange book search results re citizen petition from iqvia rds inc,0,0
090000648430d93c,Other,FDA-2019-P-5970-0005,FDA-2019-P-5970,response letter from fda cder to iqvia rds in,0,0
0900006482d84d72,Supporting & Related Material,FDA-2017-P-7034-0003,FDA-2017-P-7034,exhibit 1 orange book listing re citizen petition from jubilant generics limited,0,0
0900006482d84d74,Supporting & Related Material,FDA-2017-P-7034-0005,FDA-2017-P-7034,exhibit 3 proposed product draft label re citizen petition from jubilant generics limited,0,0
0900006482d84d2a,Other,FDA-2017-P-7034-0001,FDA-2017-P-7034,citizen petition from jubilant generics limited,0,0
0900006482d84d75,Supporting & Related Material,FDA-2017-P-7034-0006,FDA-2017-P-7034,exhibit 4 valtrex tablets 250 mg re citizen petition from jubilant generics limited,0,0
0900006482d84d73,Supporting & Related Material,FDA-2017-P-7034-0004,FDA-2017-P-7034,exhibit 2 rld label re citizen petition from jubilant generics limited,0,0
0900006482d84d2c,Other,FDA-2017-P-7034-0002,FDA-2017-P-7034,acknowledgment letter from fda ddm to jubilant generics limited,0,0
09000064810e98aa,Other,FDA-2012-D-0585-0002,FDA-2012-D-0585,draft guidances for industry: necessity of use of food categories in food facility registrations and updates to food categories,1,0
090000648114e449,Notice,FDA-2012-D-0585-0016,FDA-2012-D-0585,guidance for industry: necessity of use of food product categories in food facility registrations and updates to food product categories; availability,1,0
09000064810dabde,Notice,FDA-2012-D-0585-0001,FDA-2012-D-0585,draft guidances for industry: necessity of use of food categories in food facility registrations and updates to food categories,1,0
090000648114df62,Other,FDA-2012-D-0585-0017,FDA-2012-D-0585,guidance for industry: necessity of use of food product categories in food facility registrations and updates to food product categories,1,0
0900006483d998b9,Supporting & Related Material,FDA-2019-P-3423-0003,FDA-2019-P-3423,attachment 1 - fda electronic orange book printout for baclofen products labeling for ivax/teva baclofen tablets re suitability petition from oxford pharmaceuticals llc,0,0
0900006483d99458,Other,FDA-2019-P-3423-0002,FDA-2019-P-3423,acknowledgment letter from fda ddm to oxford pharmaceuticals llc,0,0
0900006483d9927a,Other,FDA-2019-P-3423-0001,FDA-2019-P-3423,"suitability petition from oxford pharmaceuticals, llc",0,0
09000064816e13dc,Other,FDA-2014-P-0585-0001,FDA-2014-P-0585,citizen petition from a. haggag (capstone law),0,0
09000064819e06e6,Other,FDA-2014-P-0585-0003,FDA-2014-P-0585,interim response letter from fda cfsan to capstone law apc,0,0
09000064816e140d,Other,FDA-2014-P-0585-0002,FDA-2014-P-0585,acknowledgement letter from fda ddm to capstone law apc,0,0
0900006481cafbcb,Other,FDA-2014-P-0585-0004,FDA-2014-P-0585,citizen petition denial response from fda cfsan to captsone law apc,0,0
0900006480f414a1,Other,FDA-2011-P-0709-0001,FDA-2011-P-0709,jennifer kuzdzal - citizen petition,0,0
0900006480f414a5,Other,FDA-2011-P-0709-0002,FDA-2011-P-0709,acknowledgement letter to jennifer kuzdzal,0,0
0900006481e12d7d,Other,FDA-2015-P-1752-0006,FDA-2015-P-1752,withdrawal letter from actavis elizabeth llc,0,0
0900006481db7dc3,Other,FDA-2015-P-1752-0005,FDA-2015-P-1752,withdrawal from wiley rein llp,0,0
0900006481ae5958,Other,FDA-2015-P-1752-0001,FDA-2015-P-1752,citizen petition from wiley rein llp,0,0
0900006481ae595f,Other,FDA-2015-P-1752-0002,FDA-2015-P-1752,acknowledgement letter from fda ddm to wiley rein llp,0,0
0900006481d2aa32,Other,FDA-2015-P-1752-0003,FDA-2015-P-1752,interim response letter from fda cder to wiley rein llp,0,0
0900006483a3a530,Other,FDA-2019-P-0537-0001,FDA-2019-P-0537,citizen petition from kulkarni law firm,0,0
0900006483a3a9f6,Other,FDA-2019-P-0537-0002,FDA-2019-P-0537,acknowledgment letter from fda ddm to kulkarni law firm,0,0
0900006483dd93de,Other,FDA-2019-P-0537-0003,FDA-2019-P-0537,letter from fda cder to the kulkarni law firm,0,0
0900006484387cb5,Other,FDA-2019-P-0537-0004,FDA-2019-P-0537,response letter from fda cder to kulkarni law firm,0,0
0900006482f1de55,Other,FDA-2018-P-0674-0002,FDA-2018-P-0674,acknowledgment letter from fda ddm to medtech products inc,0,0
0900006482f1de57,Supporting & Related Material,FDA-2018-P-0674-0003,FDA-2018-P-0674,"attachment 1 approved labeling for the rld, excedrin® (migraine) re citizen petition from medtech products inc",0,0
0900006482f1bab2,Other,FDA-2018-P-0674-0001,FDA-2018-P-0674,citizen petition from medtech products inc,0,0
0900006482f1de59,Supporting & Related Material,FDA-2018-P-0674-0005,FDA-2018-P-0674,attachment 3 request for waiver from requirement to submit a pediatric assessment re citizen petition from medtech products inc,0,0
0900006482f1de58,Supporting & Related Material,FDA-2018-P-0674-0004,FDA-2018-P-0674,"attachment 2 draft labeling for the proposed product, goody's® migraine re citizen petition from medtech products inc",0,0
0900006484731920,Supporting & Related Material,FDA-2020-P-1641-0003,FDA-2020-P-1641,exhibit 1 copy of current fda-approved label for epidiolex re citizen petition from john j coleman,0,0
0900006484731921,Supporting & Related Material,FDA-2020-P-1641-0004,FDA-2020-P-1641,exhibit 2 copy of june 25 2018 press release by fda announcing approval of epidiolex re citizen petition from john j coleman,0,0
09000064847cede0,Other,FDA-2020-P-1641-0006,FDA-2020-P-1641,response letter from fda cder to john j. coleman,0,0
0900006484731922,Supporting & Related Material,FDA-2020-P-1641-0005,FDA-2020-P-1641,exhibit 3 dea final order placing all fda-approved cbd drugs in schedule v re citizen petition from john j coleman,0,0
090000648473191d,Other,FDA-2020-P-1641-0002,FDA-2020-P-1641,acknowledgment letter from fda dms to john j coleman,0,0
090000648473191c,Other,FDA-2020-P-1641-0001,FDA-2020-P-1641,citizen petition from john j coleman,0,0
0900006481856fce,Supporting & Related Material,FDA-2014-P-1293-0004,FDA-2014-P-1293,"attachment b primakoff, et al., fully effective contraception in male and female guinea pigs immunized with the sperm protein ph-20 re citizen petition from hyman phelps & mcnamara pc fda-2014-p-1293-0001",0,0
0900006481856d9b,Other,FDA-2014-P-1293-0001,FDA-2014-P-1293,citizen petition from hyman phelps & mcnamara pc,0,0
0900006481967f47,Other,FDA-2014-P-1293-0009,FDA-2014-P-1293,withdrawal of citizen petition,0,0
0900006481856d9f,Supporting & Related Material,FDA-2014-P-1293-0003,FDA-2014-P-1293,"attachment a wassermann, et al., recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency re citizen petition from hyman phelps & mcnamara pc fda-2014-p-1293-0001",0,0
0900006481856fd0,Supporting & Related Material,FDA-2014-P-1293-0006,FDA-2014-P-1293,"attachment d hunnicutt, et al., sperm surface protein ph-20 is bifunctional: one activity is a hyaluronidase and a second, distinct activity is required in secondary sperm-zona binding re citizen petition from hyman phelps & mcnamara pc fda-2014-p-1293-0001",0,0
0900006481856fd1,Supporting & Related Material,FDA-2014-P-1293-0007,FDA-2014-P-1293,"attachment e cherr, et. al., the dual functions of gpi-anchored ph-20: hyaluronidase and intracellular signalingre citizen petition from hyman phelps & mcnamara pc fda-2014-p-1293-0001",0,0
0900006481856fcf,Supporting & Related Material,FDA-2014-P-1293-0005,FDA-2014-P-1293,"attachment c coska, et al., purification and microsequencing of hyaluronidase isozymes from human urine re citizen petition from hyman phelps & mcnamara pc fda-2014-p-1293-0001",0,0
0900006481856fd2,Supporting & Related Material,FDA-2014-P-1293-0008,FDA-2014-P-1293,"attachment f hegg, et al., immunogenicity of trastuzumab intravenous and subcutaneous formulations in the phase iii hannah study re citizen petition from hyman phelps & mcnamara pc fda-2014-p-1293-0001",0,0
0900006481856d9d,Other,FDA-2014-P-1293-0002,FDA-2014-P-1293,acknowledgement letter from fda ddm to hyman phelps & mcnamara pc,0,0
09000064816b5dd5,Notice,FDA-2014-N-0386-0001,FDA-2014-N-0386,"agency information collection activities; proposed collection;
comment request; orphan drugs products: common european
medicines agency/food and drug administration application form for
orphan medicinal product designation",1,0
09000064848b4f92,Notice,FDA-2014-N-0386-0003,FDA-2014-N-0386,"agency information collection activities; proposed collection;
comment request; orphan drugs",0,0
0900006484a7eb64,Notice,FDA-2014-N-0386-0007,FDA-2014-N-0386,agency information collection activities; announcement of office of management and budget approvals,0,0
09000064818af03d,Notice,FDA-2014-N-0386-0002,FDA-2014-N-0386,"agency information collection activities; submission for office of
management and budget review; comment request; orphan drugs;
common european medicines agency/ food and drug administration
application form for orphan medicinal product designation",1,0
09000064849c0f39,Notice,FDA-2014-N-0386-0005,FDA-2014-N-0386,agency information collection activities; submission for office of management and budget review; comment request; orphan drugs,0,0
09000064805336f0,Other,FDA-2007-P-0345-0004,FDA-2007-P-0345,fda/cder interim response to hellerehrman llp - letter,0,0
090000648042b940,Other,FDA-2007-P-0345-0001,FDA-2007-P-0345,acknowledgement letter to hellerehrman llp,0,0
09000064807d7e26,Other,FDA-2007-P-0345-0005,FDA-2007-P-0345,fda/cder to cooley godward kronish llp - responce to ctitizen petition,0,0
090000648042b941,Supporting & Related Material,FDA-2007-P-0345-0002,FDA-2007-P-0345,see: fda-2007-p-0345-0001,0,0
090000648042b942,Other,FDA-2007-P-0345-0003,FDA-2007-P-0345,hellerehrman llp - citizen petition,0,0
090000648044027e,Supporting & Related Material,FDA-2005-D-0156-0002,FDA-2005-D-0156,guidance,0,0
0900006480440287,Supporting & Related Material,FDA-2005-D-0156-0004,FDA-2005-D-0156,guidance,0,0
0900006480440268,Notice,FDA-2005-D-0156-0001,FDA-2005-D-0156,fda,0,0
0900006480440288,Notice,FDA-2005-D-0156-0005,FDA-2005-D-0156,fda,0,0
0900006484b612e1,Supporting & Related Material,FDA-2021-P-0545-0003,FDA-2021-P-0545,children health defense brief re citizen petition from theo allen,0,0
0900006484d697b9,Other,FDA-2021-P-0545-0004,FDA-2021-P-0545,withdrawal of citizen petition from theo allen,0,0
0900006484b611b9,Other,FDA-2021-P-0545-0001,FDA-2021-P-0545,citizen petition from theo allen,0,0
0900006484b612de,Other,FDA-2021-P-0545-0002,FDA-2021-P-0545,acknowledgment letter from fda dms to theo allen,0,0
09000064841e21d0,Other,FDA-2019-P-5691-0002,FDA-2019-P-5691,acknowledgment letter from fda dms to foley & lardner llp,0,0
09000064841e015f,Other,FDA-2019-P-5691-0001,FDA-2019-P-5691,"suitability petition from foley & lardner, llp",0,0
09000064841e0162,Supporting & Related Material,FDA-2019-P-5691-0004,FDA-2019-P-5691,"attachment 2 - label re: suitability petition from foley & lardner, llp",0,0
0900006484e389b0,Other,FDA-2019-P-5691-0006,FDA-2019-P-5691,"amendment from foley & lardner, llp",0,0
09000064841e0161,Supporting & Related Material,FDA-2019-P-5691-0003,FDA-2019-P-5691,"attachment 1 - orange book_ approved drug products with therapeutic equivalenc re: suitability petition from foley & lardner, llp",0,0
09000064841e0163,Supporting & Related Material,FDA-2019-P-5691-0005,FDA-2019-P-5691,"attachment 3 - microsoft word - proposed labeling.doc re: suitability petition from foley & lardner, llp",0,0
090000648480d9e0,Other,FDA-2020-P-1771-0002,FDA-2020-P-1771,"acknowledgment letter from fda dms to windels marx lane & mittendorf, llp",0,0
090000648480d038,Other,FDA-2020-P-1771-0001,FDA-2020-P-1771,"citizen petition from windels marx lane & mittendorf, llp",0,0
09000064849662ee,Other,FDA-2020-P-1771-0003,FDA-2020-P-1771,withdrawal from windels marx lane mittendorf llp,0,0
090000648423a331,Other,FDA-2019-P-5997-0001,FDA-2019-P-5997,"citizen petition for center for biological diversity, center for environmental health, farmworkers association of florida, johns hopkins center for a livable future, migrant clinicians network, and u.s. public interest research group",0,0
090000648423c51f,Other,FDA-2019-P-5997-0002,FDA-2019-P-5997,"acknowledgment letter from fda dms to center for biological diversity, center for environmental health, farmworkers association of florida, johns hopkins center for a livable future, migrant clinicians network, and u.s. public interest research group",0,0
0900006482dcf653,Supporting & Related Material,FDA-2018-P-0131-0003,FDA-2018-P-0131,"attachment 1 relevant copy of the page from the current edition of the electronic approved drug products with therapeutic equi valence evaluations, accessed january 8, 20 18 re citizen petition from lachman consultant services, inc.",0,0
0900006482dcf651,Other,FDA-2018-P-0131-0001,FDA-2018-P-0131,"citizen petition from lachman consultant services, inc.",0,0
0900006482dcf655,Supporting & Related Material,FDA-2018-P-0131-0005,FDA-2018-P-0131,"attachment 3 labeling for zonegran® capsules re citizen petition from lachman consultant services, inc.",0,0
0900006482dcf654,Supporting & Related Material,FDA-2018-P-0131-0004,FDA-2018-P-0131,"attachment 2 draft [nsert labeling proposed for zonisamide orally disintegrating tablets re citizen petition from lachman consultant services, inc.",0,0
0900006482dcf656,Other,FDA-2018-P-0131-0002,FDA-2018-P-0131,"acknowledgment letter from fda ddm  to lachman consultant services, inc.",0,0
090000648184cac3,Other,FDA-2014-P-1269-0002,FDA-2014-P-1269,acknowledgement letter from fda ddm to pfizer inc,0,0
0900006481c7999c,Other,FDA-2014-P-1269-0003,FDA-2014-P-1269,citizen petition partial approval and denial response letter from fda cder to pfizer inc.,0,0
090000648182bd41,Other,FDA-2014-P-1269-0001,FDA-2014-P-1269,"citizen petition from pfizer, inc.",0,0
0900006482ac8344,Other,FDA-2017-P-5205-0001,FDA-2017-P-5205,"citizen petition from xiromed, llc on behalf of lifepharma fze",0,0
0900006482f39a76,Other,FDA-2017-P-5205-0003,FDA-2017-P-5205,"interim response letter from fda cder to xiromed, llc",0,0
0900006482ac8346,Other,FDA-2017-P-5205-0002,FDA-2017-P-5205,"acknowledgement letter from fda ddm to xiromed, llc on behalf of lifepharma fze",0,0
090000648383fec7,Other,FDA-2017-P-5205-0004,FDA-2017-P-5205,letter re citizen petition from fda cder-orp to xiromed llc,0,0
090000648379dc86,Other,FDA-2017-P-6214-0004,FDA-2017-P-6214,interim response letter from fda cder to esophageal cancer action network inc.,0,0
0900006482be548e,Other,FDA-2017-P-6214-0001,FDA-2017-P-6214,citizen petition from yabao pharmaceutical co. ltd bj,0,0
09000064831927dc,Other,FDA-2017-P-6214-0003,FDA-2017-P-6214,interim response letter from fda cder to yabao pharmaceutical co. ltd bj,0,0
0900006482be5a74,Other,FDA-2017-P-6214-0002,FDA-2017-P-6214,acknowledgment letter from fda ddm to yabao pharmaceutical co. ltd bj,0,0
090000648259471d,Other,FDA-2017-P-2869-0001,FDA-2017-P-2869,"citizen petition from lachman consultant services, inc.",0,0
0900006482594723,Supporting & Related Material,FDA-2017-P-2869-0005,FDA-2017-P-2869,attachment 3 approved labeling for rld robinul forte tablets by casper re citizen petition from lachman consultants services inc,0,0
0900006482594721,Supporting & Related Material,FDA-2017-P-2869-0003,FDA-2017-P-2869,attachment 1 approved drug products with therapeutic equivalence evaluations re citizen petition from lachman consultants services inc,0,0
0900006482594722,Supporting & Related Material,FDA-2017-P-2869-0004,FDA-2017-P-2869,attachment 2 draft insert labeling for proposed product re citizen petition from lachman consultants services inc,0,0
090000648259471f,Other,FDA-2017-P-2869-0002,FDA-2017-P-2869,"acknowledgement letter from fda ddm to lachman consultant services, inc.",0,0
09000064836cb8a9,Other,FDA-2018-P-3426-0001,FDA-2018-P-3426,"citizen petition from pharmax group, inc",0,0
0900006483ae88ec,Other,FDA-2018-P-3426-0004,FDA-2018-P-3426,"response letter from fda cder to pharmax group, inc",0,0
09000064836cb8ab,Other,FDA-2018-P-3426-0002,FDA-2018-P-3426,"acknowledgment letter from fda ddm to pharmax group, inc",0,0
09000064836cb8ad,Supporting & Related Material,FDA-2018-P-3426-0003,FDA-2018-P-3426,"attachment 1 orange book cyproheptadine approvals sept 6 2018 re citizen petition from pharmax group, inc",0,0
0900006484a91e53,Supporting & Related Material,FDA-2021-P-0342-0004,FDA-2021-P-0342,attachment 2 - niosh list 2016 re suitability petition from cardinal health regulatory sciences,0,0
0900006484a91e54,Supporting & Related Material,FDA-2021-P-0342-0005,FDA-2021-P-0342,attachment 3 - usp 800 faqs re suitability petition from cardinal health regulatory sciences,0,0
0900006484a91e4e,Other,FDA-2021-P-0342-0001,FDA-2021-P-0342,suitability petition from cardinal health regulatory sciences,0,0
0900006484a91eca,Supporting & Related Material,FDA-2021-P-0342-0009,FDA-2021-P-0342,attachment 7 - draft label for the proposed product re suitability petition from cardinal health regulatory sciences,0,0
0900006484a91e52,Supporting & Related Material,FDA-2021-P-0342-0003,FDA-2021-P-0342,attachment 1 - orange book_ approved drug products with therapeutic equivalence evaluations re suitability petition from cardinal health regulatory sciences,0,0
0900006484a91e55,Supporting & Related Material,FDA-2021-P-0342-0006,FDA-2021-P-0342,attachment 4 - letter from fda about model labeling for rld (vfend) re suitability petition from cardinal health regulatory sciences,0,0
0900006484a91ec8,Supporting & Related Material,FDA-2021-P-0342-0007,FDA-2021-P-0342,attachment 5 - rld (vfend) model label carved exclusivity information re suitability petition from cardinal health regulatory sciences,0,0
0900006484a91ec9,Supporting & Related Material,FDA-2021-P-0342-0008,FDA-2021-P-0342,"attachment 6 - rld (vfend) label from drugs@fda (version january, 2021) re suitability petition from cardinal health regulatory sciences",0,0
0900006484a91e50,Other,FDA-2021-P-0342-0002,FDA-2021-P-0342,acknowledgement letter from fda dms to cardinal health regulatory sciences,0,0
09000064848f9147,Other,FDA-2020-P-2066-0001,FDA-2020-P-2066,citizens petition from the america's frontline doctors,0,0
09000064848fa2ec,Other,FDA-2020-P-2066-0002,FDA-2020-P-2066,acknowledgment letter from fda dms to america’s frontline doctors,0,0
0900006484aa05e9,Other,FDA-2020-P-2066-0003,FDA-2020-P-2066,interim response from fda cder to america's frontline doctors c/o free speech foundation,0,0
0900006480473152,Other,FDA-2004-P-0334-0001,FDA-2004-P-0334,hfa-305 to environmental working group,0,0
0900006480473156,Other,FDA-2004-P-0334-0002,FDA-2004-P-0334,fda/cder response to environmental working group - letter,0,0
0900006480473157,Other,FDA-2004-P-0334-0003,FDA-2004-P-0334,fda/cder response to environmental working group - letter,0,0
090000648039ad45,Notice,FDA-2008-N-0027-0001,FDA-2008-N-0027,"agency information collection activities; proposed collection; comment request; medical device user fee amendments of 2007; foreign small business qualification certification, fda form 3602a",0,0
09000064804a3bbd,Notice,FDA-2008-N-0027-0005,FDA-2008-N-0027,"agency information collection activities; submission for office of management and budget review; comment request; medical device user fee amendments of 2007; foreign small business qualification certification, form fda 3602a",0,0
09000064804a3235,Notice,FDA-2008-N-0027-0004,FDA-2008-N-0027,"agency information collection activities; submission for office of management and budget review; comment request; medical device user fee amendments of 2007; foreign small business qualification certification, form fda 3602a",0,0
0900006480949ec2,Other,FDA-2008-P-0444-0003,FDA-2008-P-0444,codonics to fda - letter,0,0
09000064806b21bc,Other,FDA-2008-P-0444-0002,FDA-2008-P-0444,"acknowledgement letter to codonics, inc.",0,0
09000064806b2183,Other,FDA-2008-P-0444-0001,FDA-2008-P-0444,codonics inc. - citizen petition,0,0
0900006480c3dd31,Other,FDA-2008-P-0444-0005,FDA-2008-P-0444,fda/cdrh to codonics inc. - petition denial,0,0
09000064809ed100,Other,FDA-2008-P-0444-0004,FDA-2008-P-0444,"fda/cdrh interim response to codonics, inc. - letter",0,0
090000648092e62c,Other,FDA-2008-P-0529-0007,FDA-2008-P-0529,fda/cder response to teva pharmaceutical industries ltd. - petition denial,0,0
090000648072c7f6,Other,FDA-2008-P-0529-0001,FDA-2008-P-0529,"teva pharmaceutical industries ltd., teva neuroscience inc. - citizen petition",0,0
090000648072c83c,Other,FDA-2008-P-0529-0002,FDA-2008-P-0529,"acknowledgement letter to teva pharmaceutical industries ltd., teva neuroscience inc. (teva)",0,0
09000064808db1c7,Other,FDA-2008-P-0529-0004,FDA-2008-P-0529,ira s. krull [re fda-2008-p-0529-0003.1] - letter,0,0
0900006484d7d3b0,Other,FDA-2021-P-0308-0003,FDA-2021-P-0308,"interim response from fda cder to hyman, phelps& mcnamara, p.c.",0,0
0900006484a71d08,Other,FDA-2021-P-0308-0002,FDA-2021-P-0308,"acknowledgment letter from fda dms to hyman, phelps and mcnamara, p.c. (on behalf of exela pharma sciences, llc)",0,0
0900006484a71d03,Other,FDA-2021-P-0308-0001,FDA-2021-P-0308,"citizen petition from hyman, phelps and mcnamara, p.c. (on behalf of exela pharma sciences, llc)",0,0
090000648314f976,Other,FDA-2018-P-1532-0002,FDA-2018-P-1532,acknowledgment letter from fda ddm to king & spalding llp,0,0
090000648314f978,Supporting & Related Material,FDA-2018-P-1532-0003,FDA-2018-P-1532,attachment 1 approved drug products with therapeutic equivalence evaluations (electronic orange book) for akovaz re petition from king & spalding llp,0,0
0900006484d99c0f,Other,FDA-2018-P-1532-0007,FDA-2018-P-1532,petition denial letter from fda cder to king & spalding llp,0,0
090000648314f979,Supporting & Related Material,FDA-2018-P-1532-0004,FDA-2018-P-1532,attachment 2 reference listed drug prescribing information for akovaz re petition from king & spalding llp,0,0
090000648314f97a,Supporting & Related Material,FDA-2018-P-1532-0005,FDA-2018-P-1532,"attachment 3 draft labeling for proposed ephedrine sulfate injection, usp 50 mg/10 ml re petition from king & spalding llp",0,0
090000648314f7a6,Other,FDA-2018-P-1532-0001,FDA-2018-P-1532,petition from king & spalding llp,0,0
0900006483f959bb,Supporting & Related Material,FDA-2019-P-4362-0003,FDA-2019-P-4362,"attachment 1 39th edition 2019 approved drug product list [discontinued drug product list] re citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006483f957be,Other,FDA-2019-P-4362-0001,FDA-2019-P-4362,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484e24e42,Other,FDA-2019-P-4362-0008,FDA-2019-P-4362,"citizen petition approval letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
09000064844833a0,Other,FDA-2019-P-4362-0007,FDA-2019-P-4362,"letter from hyman, phelps & mcnamara",0,0
0900006483f959bd,Supporting & Related Material,FDA-2019-P-4362-0005,FDA-2019-P-4362,"attachment 3 cefazolin for injection, usp re citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006483f959bc,Supporting & Related Material,FDA-2019-P-4362-0004,FDA-2019-P-4362,"attachment 2 prescribing information ancef® cefazolin for injection re citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006483f959be,Supporting & Related Material,FDA-2019-P-4362-0006,FDA-2019-P-4362,"attachment 4 heuer, et al (2017) journal title re citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006483f957bf,Other,FDA-2019-P-4362-0002,FDA-2019-P-4362,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
0900006482092d72,Supporting & Related Material,FDA-2016-P-1952-0003,FDA-2016-P-1952,"attachment a product listing from the discontinued section of orange book  re citizen petition from fresenius kabi usa, llc",0,0
090000648209366e,Supporting & Related Material,FDA-2016-P-1952-0004,FDA-2016-P-1952,attachment b currently approved andas in the orange book re fresenius kabi citizen petition,0,0
09000064821c4a03,Other,FDA-2016-P-1952-0005,FDA-2016-P-1952,response letter from fda cder to fresenius kabi usa llc,0,0
090000648209366c,Other,FDA-2016-P-1952-0002,FDA-2016-P-1952,acknowledgement letter from fda ddm to fresenius kabi usa llc,0,0
0900006482092d70,Other,FDA-2016-P-1952-0001,FDA-2016-P-1952,"citizen petition from fresenius kabi usa, llc",0,0
09000064832547ab,Other,FDA-2017-P-6211-0012,FDA-2017-P-6211,interim response ltr for fda-2017-p-6211 to hugh c welsh of dsm dtd 4-19-18,0,0
0900006482be57ab,Other,FDA-2017-P-6211-0002,FDA-2017-P-6211,acknowledgement letter from fda ddm to dsm nutritional products llc,0,0
0900006482be53bc,Other,FDA-2017-P-6211-0001,FDA-2017-P-6211,citizen petition from dsm nutritional products llc,0,0
0900006481a3aee6,Other,FDA-2015-P-0762-0002,FDA-2015-P-0762,acknowledgement letter from fda ddm to pharmacists planning service inc.,0,0
0900006481a3ade2,Other,FDA-2015-P-0762-0001,FDA-2015-P-0762,citizen petition from pharmacists planning service inc.,0,0
0900006481ca0a6e,Other,FDA-2015-P-0762-0003,FDA-2015-P-0762,"interim response from fda cfsan to pharmacists planning services, inc",0,0
09000064820290df,Supporting & Related Material,FDA-2016-P-1547-0004,FDA-2016-P-1547,"attachment 2 orange book: approved drug products with
therapeutic equivalence evaluations re citizens petition from baxter healthcare corporation",0,0
090000648202e5c8,Other,FDA-2016-P-1547-0002,FDA-2016-P-1547,acknowledgement letter from fda ddm to baxter healthcare corporation,0,0
09000064823debf3,Other,FDA-2016-P-1547-0005,FDA-2016-P-1547,approval letter from cder fda to baxter healthcare corporation,0,0
09000064820290dc,Other,FDA-2016-P-1547-0001,FDA-2016-P-1547,citizens petition from baxter healthcare corporation,0,0
09000064820290de,Supporting & Related Material,FDA-2016-P-1547-0003,FDA-2016-P-1547,attachment 1 current and resolved drug shortages and discontinuations reported to fda re citizens petition from baxter healthcare corporation,0,0
090000648196be12,Other,FDA-2014-P-2168-0001,FDA-2014-P-2168,citizen petition from lachman consultant services  inc,0,0
090000648196c14f,Supporting & Related Material,FDA-2014-P-2168-0003,FDA-2014-P-2168,attach 1,0,0
090000648196c150,Supporting & Related Material,FDA-2014-P-2168-0004,FDA-2014-P-2168,attach 2,0,0
090000648196c151,Supporting & Related Material,FDA-2014-P-2168-0005,FDA-2014-P-2168,attach 3,0,0
090000648196c149,Other,FDA-2014-P-2168-0002,FDA-2014-P-2168,acknowledgement letter from fda ddm to lachman consultant services inc,0,0
0900006482ef26e3,Other,FDA-2017-P-0176-0003,FDA-2017-P-0176,interim response from fda to american herbal products association,0,0
090000648245cdca,Other,FDA-2017-P-0176-0002,FDA-2017-P-0176,acknowledgement letter from fda ddm to american herbal products association,0,0
090000648245cdc8,Other,FDA-2017-P-0176-0001,FDA-2017-P-0176,citizen petition from american herbal products association,0,0
0900006481abf3a4,Supporting & Related Material,FDA-2015-P-1431-0023,FDA-2015-P-1431,"tab q nccn clinical practice guidelines in oncology non-hodgkins lymphoma version 2 2015 (march 3 2015) (excerpts), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf361,Supporting & Related Material,FDA-2015-P-1431-0004,FDA-2015-P-1431,"tab b approval letter, nda 022249 (march 20, 2008), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf393,Supporting & Related Material,FDA-2015-P-1431-0011,FDA-2015-P-1431,"tab i package insert, nda 50708 (april 27, 2006), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf39e,Supporting & Related Material,FDA-2015-P-1431-0022,FDA-2015-P-1431,"tab u fda petition response regarding xyzal (levocetirizine hydrochloride), docket no fda-2010-p-0545 (feb 24, 2011), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf35e,Other,FDA-2015-P-1431-0002,FDA-2015-P-1431,"acknowledgement letter from fda ddm to teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abea41,Other,FDA-2015-P-1431-0001,FDA-2015-P-1431,"citizen petition from teva pharmaceuticals (cephalon, inc)",0,0
0900006481abf392,Supporting & Related Material,FDA-2015-P-1431-0010,FDA-2015-P-1431,"tab h anda 065461, approval summary 1, labeling_review branch (march 5, 2009), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf396,Supporting & Related Material,FDA-2015-P-1431-0014,FDA-2015-P-1431,"tab l package insert, anda 200882, re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf363,Supporting & Related Material,FDA-2015-P-1431-0006,FDA-2015-P-1431,"tab d nda 022249, package insert (march 15, 2015), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf397,Supporting & Related Material,FDA-2015-P-1431-0015,FDA-2015-P-1431,"tab m pub l no 97-414, 96 stat 2049 (1983), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf39c,Supporting & Related Material,FDA-2015-P-1431-0020,FDA-2015-P-1431,"tab s fda petition response regarding rapamune (sirolimus), docket no 2003p-0518 (sept 20, 2004), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf362,Supporting & Related Material,FDA-2015-P-1431-0005,FDA-2015-P-1431,"tab c approval letter, nda 022303 (oct 31, 2008), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf39a,Supporting & Related Material,FDA-2015-P-1431-0018,FDA-2015-P-1431,"tab p bla 103705, prescribing information (rituxan pi) (august 12, 2014), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf391,Supporting & Related Material,FDA-2015-P-1431-0009,FDA-2015-P-1431,"tab g approval letter, nda 50708 (march 29, 2006), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf395,Supporting & Related Material,FDA-2015-P-1431-0013,FDA-2015-P-1431,"tab k package insert, nda 021689 (december 19, 2014), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf39d,Supporting & Related Material,FDA-2015-P-1431-0021,FDA-2015-P-1431,"tab t fda petition response regarding lyrica (pregabalin), docket no fda-2010-p-0087 (august 3, 2010), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf360,Supporting & Related Material,FDA-2015-P-1431-0003,FDA-2015-P-1431,"tab a clinical review nda 022249 (february 26, 2008), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf394,Supporting & Related Material,FDA-2015-P-1431-0012,FDA-2015-P-1431,"tab j package insert, anda 065461 (august 10, 2009), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf398,Supporting & Related Material,FDA-2015-P-1431-0016,FDA-2015-P-1431,"tab n hr report no 97-840, 97th congress 2nd session (sept 17, 1982), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf399,Supporting & Related Material,FDA-2015-P-1431-0017,FDA-2015-P-1431,"tab o fda petition response regarding colcrys (colchicine), docket no 2012-p-1018 (feb 15, 2013), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf364,Supporting & Related Material,FDA-2015-P-1431-0007,FDA-2015-P-1431,"tab e package insert, nda 22303 (october 31, 2008), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf39b,Supporting & Related Material,FDA-2015-P-1431-0019,FDA-2015-P-1431,"tab r nda 022249 clinical review at 62, re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481abf365,Supporting & Related Material,FDA-2015-P-1431-0008,FDA-2015-P-1431,"tab f clinical review, nda 022303 (july 30, 2008), re citizen petition from teva pharmaceuticals (cephalon, inc.)",0,0
0900006481c94876,Other,FDA-2015-P-1431-0025,FDA-2015-P-1431,fda final response denial letter,0,0
09000064819f6aa4,Supporting & Related Material,FDA-2015-P-0389-0006,FDA-2015-P-0389,annex 4,0,0
09000064819f583a,Other,FDA-2015-P-0389-0001,FDA-2015-P-0389,citizen petition request from orbicular pharmaceutical technologies pvt ltd,0,0
09000064819f6aa3,Supporting & Related Material,FDA-2015-P-0389-0005,FDA-2015-P-0389,annex 3,0,0
09000064819f68b6,Other,FDA-2015-P-0389-0002,FDA-2015-P-0389,acknowledgement letter from fda ddm to orbicular pharmaceutical technologies pvt ltd,0,0
0900006481aed573,Other,FDA-2015-P-0389-0007,FDA-2015-P-0389,withdrawal from orbicular pharmaceutical technologies pvt ltd,0,0
09000064819f68bb,Supporting & Related Material,FDA-2015-P-0389-0004,FDA-2015-P-0389,annex 2,0,0
09000064819f68ba,Supporting & Related Material,FDA-2015-P-0389-0003,FDA-2015-P-0389,annex 1,0,0
0900006481fda552,Supporting & Related Material,FDA-2016-P-1286-0004,FDA-2016-P-1286,"attachment 1 orange book listing for glycopyrrolate injection accessed 05/12/2016 re citizen petition from lachman consultant services, inc.",0,0
0900006481fda556,Other,FDA-2016-P-1286-0002,FDA-2016-P-1286,"acknowledgement letter from fda ddm to  lachman consultant services, inc.",0,0
0900006481fda24b,Supporting & Related Material,FDA-2016-P-1286-0005,FDA-2016-P-1286,"attachment 2 reference listed drug prescribing information for glycopyrrolate injection, 0.2 mg/ml 0.4 mg/2 ml, 1 mg/5 ml, and 4 mg/20 ml re citizen petition from lachman consultant services, inc.",0,0
0900006481fda24a,Supporting & Related Material,FDA-2016-P-1286-0003,FDA-2016-P-1286,"attachment 3 proposed prescribing information for glycopyrrolate injection 0.1 mg/0.5 ml pre-filled syringe (single-dose) re citizen petition from lachman consultant services, inc.",0,0
0900006481fda248,Other,FDA-2016-P-1286-0001,FDA-2016-P-1286,"citizen petition from lachman consultant services, inc.",0,0
090000648487169c,Other,FDA-2016-P-1286-0006,FDA-2016-P-1286,response from lachman consultant services,0,0
0900006484214556,Supporting & Related Material,FDA-2019-P-5922-0003,FDA-2019-P-5922,"exhibit 1- introduction, conclusions, and historical backgroundrelative to e-cigarettes re: citizen petition for respira technologies, inc.",0,0
090000648421455b,Supporting & Related Material,FDA-2019-P-5922-0008,FDA-2019-P-5922,"exhibit 6- e-cigarette use among youth and young adults: a report of the surgeon general re: citizen petition for respira technologies, inc.",0,0
0900006484214580,Supporting & Related Material,FDA-2019-P-5922-0010,FDA-2019-P-5922,"exhibit 8- the public health rationale for recommended restrictions on new tobacco product labeling, advertising, marketing, and promotion re: citizen petition for respira technologies, inc.",0,1
0900006484214559,Supporting & Related Material,FDA-2019-P-5922-0006,FDA-2019-P-5922,"exhibit 4- pathology of vaping-associated lung injury re: citizen petition for respira technologies, inc.",0,0
090000648421455c,Supporting & Related Material,FDA-2019-P-5922-0009,FDA-2019-P-5922,"exhibit 7- letter to norman e. ""ned"" sharpless, m.d. from u.s. senators re: citizen petition for respira technologies, inc.",0,0
0900006484214581,Supporting & Related Material,FDA-2019-P-5922-0011,FDA-2019-P-5922,"exhibit 9- safer technologies program for medical devices draft guidance for industry and food and drug administration staff draft guidance re: citizen petition for respira technologies, inc.",1,0
09000064845617e2,Other,FDA-2019-P-5922-0013,FDA-2019-P-5922,"interim response letter from fda ctp to respira technologies, inc.",0,0
09000064842141f9,Other,FDA-2019-P-5922-0001,FDA-2019-P-5922,"citizen petition from respira technologies, inc.",0,0
0900006484213cca,Other,FDA-2019-P-5922-0002,FDA-2019-P-5922,"acknowledgment letter from fda ddm to respira technologies, inc",0,0
0900006484214557,Supporting & Related Material,FDA-2019-P-5922-0004,FDA-2019-P-5922,"exhibit 2- health effects of e‑cigarette use among u.s. youth and young adults re: citizen petition for respira technologies, inc.",0,0
0900006484214558,Supporting & Related Material,FDA-2019-P-5922-0005,FDA-2019-P-5922,"exhibit 3- understanding the health impact and dangers of smoke and ""vapor"" re citizen petition for respira technologies, inc.",0,0
090000648421455a,Supporting & Related Material,FDA-2019-P-5922-0007,FDA-2019-P-5922,"exhibit 5- survey re: citizen petition for respira technologies, inc.",0,0
090000648302afa8,Other,FDA-2018-P-1195-0001,FDA-2018-P-1195,"citizen petition from hyman, phelps & mcnamara, pc",0,0
090000648361f194,Supporting & Related Material,FDA-2018-P-1195-0005,FDA-2018-P-1195,"attachment 1 - citizen petition supplement  from hyman, phelps & mcnamara, pc",0,0
0900006483d058f1,Other,FDA-2018-P-1195-0009,FDA-2018-P-1195,petition for reconsideration and stay regarding from arnall golden gregory llp,0,0
0900006483d05457,Supporting & Related Material,FDA-2018-P-1195-0010,FDA-2018-P-1195,attachment to petition for reconsideration and stay from arnall golden gregory llp,0,0
09000064836efbfc,Other,FDA-2018-P-1195-0007,FDA-2018-P-1195,"interim response from fda cder to hyman, phelps & mcnamara, pc",0,0
0900006483d86907,Other,FDA-2018-P-1195-0012,FDA-2018-P-1195,"letter from fda cder to arnall golden gregory, llp",0,0
090000648302afde,Other,FDA-2018-P-1195-0002,FDA-2018-P-1195,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara",0,0
0900006483daa962,Other,FDA-2018-P-1195-0015,FDA-2018-P-1195,acknowledgment letter from fda ddm to arnall golden gregory llp,0,0
090000648361f179,Other,FDA-2018-P-1195-0004,FDA-2018-P-1195,"citizen petition supplement  from hyman, phelps & mcnamara, pc",0,0
0900006483c47797,Other,FDA-2018-P-1195-0008,FDA-2018-P-1195,"letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
09000064836efad1,Other,FDA-2018-P-1195-0006,FDA-2018-P-1195,interim response letter from fda cder to kurt karst,0,0
09000064846afe3e,Other,FDA-2018-P-1195-0016,FDA-2018-P-1195,"petition response letter from fda cder to arnall golden gregory, llc",0,0
0900006483d0f6e0,Other,FDA-2018-P-1195-0011,FDA-2018-P-1195,acknowledgment letter from fda ddm to arnall golden gregory llp,0,0
0900006484a1bfeb,Other,FDA-2015-P-4770-0004,FDA-2015-P-4770,"response letter from fda cder to epic pharma, llc",0,0
0900006481d9ef2a,Supporting & Related Material,FDA-2015-P-4770-0003,FDA-2015-P-4770,"attachment 2 orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from epic pharma, llc",0,0
0900006481d9eeb8,Other,FDA-2015-P-4770-0001,FDA-2015-P-4770,"acknowledgement letter from fda ddm to epic pharma, llc",0,0
0900006481d9eebc,Supporting & Related Material,FDA-2015-P-4770-0002,FDA-2015-P-4770,"attachment 1 package insert and proposed package insert re citizen petition from epic pharma, llc",0,0
0900006484c21113,Other,FDA-2021-P-0852-0002,FDA-2021-P-0852,"acknowledgement letter from fda dms to lachman consultant services, inc.",0,0
0900006484c21111,Other,FDA-2021-P-0852-0001,FDA-2021-P-0852,"citizen petition from lachman consultant services, inc.",0,0
090000648099d851,Other,FDA-2009-P-0227-0003,FDA-2009-P-0227,acknowledgement letter to the national center on addiction and substance abuse at columbia university,0,0
090000648099d850,Other,FDA-2009-P-0227-0001,FDA-2009-P-0227,the national center on addiction and substance abuse at columbia university - citizen petition,0,0
0900006480a5bcdc,Other,FDA-2009-P-0227-0005,FDA-2009-P-0227,the national center on addiction and substance abuse at columbia university - letter,0,0
0900006480a56766,Other,FDA-2009-P-0227-0004,FDA-2009-P-0227,fda/cder interim response to the national center on addiction - letter,0,0
090000648099d852,Supporting & Related Material,FDA-2009-P-0227-0002,FDA-2009-P-0227,appendix a: under the counter: the diversion and abuse of controlled prescription drugs in the u.s. (2002) - [the national center on addiction and substance abuse at columbia university - citizen petition],0,0
090000648133451e,Other,FDA-2009-P-0227-0006,FDA-2009-P-0227,fda/cder response to national center on addiction and substance abuse at columbia university - denial of petition,0,0
0900006480a3ba57,Notice,FDA-2009-D-0470-0001,FDA-2009-D-0470,"draft guidance for industry and fda staff; the scope of the prohibition against marketing a tobacco product in combination with another article or product regulated under the federal food, drug, and cosmetic act; availability",1,1
0900006480a3bb34,Other,FDA-2009-D-0470-0002,FDA-2009-D-0470,"draft guidance for industry and fda staff; the scope of the prohibition against marketing a tobacco product in combination with another article or product regulated under the federal food, drug, and cosmetic act",1,1
0900006484a6b5dc,Supporting & Related Material,FDA-2021-P-0293-0003,FDA-2021-P-0293,"exhibits 1-5 re citizen petition from therapeuticsmd, inc.",0,0
0900006484a6b5dd,Supporting & Related Material,FDA-2021-P-0293-0004,FDA-2021-P-0293,"exhibits 6-10 re citizen petition from therapeuticsmd, inc.",0,0
0900006484d628dd,Other,FDA-2021-P-0293-0005,FDA-2021-P-0293,"interim response from fda cder to therapeuticsmd, inc.",0,0
0900006484a6b5d8,Other,FDA-2021-P-0293-0002,FDA-2021-P-0293,"acknowledgment letter from fda dms to citizen petition from therapeuticsmd, inc.",0,0
0900006484a6b3dd,Other,FDA-2021-P-0293-0001,FDA-2021-P-0293,"citizen petition from therapeutics md, inc.",0,0
0900006483a003b1,Other,FDA-2018-P-2901-0003,FDA-2018-P-2901,interim response from fda cder to yiling pharmaceutical ltd,0,0
090000648355d3c5,Other,FDA-2018-P-2901-0002,FDA-2018-P-2901,acknowledgement letter from fda ddm to yiling pharmaceutical ltd,0,0
09000064841bf4cd,Other,FDA-2018-P-2901-0004,FDA-2018-P-2901,letter from fda cder to kratz & barry llp and yiling pharmaceutical ltd.,0,0
090000648355d2e5,Other,FDA-2018-P-2901-0001,FDA-2018-P-2901,citizen petition from yiling pharmaceutical ltd,0,0
0900006483b5993f,Supporting & Related Material,FDA-2019-P-1566-0004,FDA-2019-P-1566,"appendix 2 draft label of the proposed generic soft chewable tablet re citizen petition from noble pharma, llc",0,0
0900006483dabd89,Other,FDA-2019-P-1566-0006,FDA-2019-P-1566,"amendment from noble pharma, llc",0,0
0900006483d43df2,Other,FDA-2019-P-1566-0005,FDA-2019-P-1566,"letter from fda cvm to nobel pharma, llc",0,0
0900006483b593de,Other,FDA-2019-P-1566-0001,FDA-2019-P-1566,"citizen petition from noble pharma, llc",0,0
0900006483b595b8,Other,FDA-2019-P-1566-0002,FDA-2019-P-1566,"acknowledgment letter from fda ddm to noble pharma, llc",0,0
0900006483b5993e,Supporting & Related Material,FDA-2019-P-1566-0003,FDA-2019-P-1566,"appendix 1 pioneer label re citizen petition from noble pharma, llc",0,0
0900006483e035df,Other,FDA-2019-P-1566-0007,FDA-2019-P-1566,request to withdraw amendment,0,0
0900006482c50db7,Other,FDA-2017-P-3405-0003,FDA-2017-P-3405,interim response  from fda cdrh  to  michael boggi,0,0
0900006483598350,Other,FDA-2017-P-3405-0004,FDA-2017-P-3405,letter from fda cdrh to  michael boggi,0,0
090000648266f8dd,Other,FDA-2017-P-3405-0002,FDA-2017-P-3405,acknowledgement letter from fda ddm to michael boggi,0,0
090000648266f8db,Other,FDA-2017-P-3405-0001,FDA-2017-P-3405,citizen petition from michael boggi,0,0
0900006481fbb1a4,Other,FDA-2016-P-1249-0001,FDA-2016-P-1249,"citizen petition from hyman, phelps & mcnamara, p. c.",0,0
0900006481fbb1a6,Other,FDA-2016-P-1249-0002,FDA-2016-P-1249,"hyman, phelps & mcnamara, p. c. from fda ddm to  hyman, phelps & mcnamara, p. c.",0,0
090000648228718c,Other,FDA-2016-P-1249-0004,FDA-2016-P-1249,"citizen petition denial response from fda cder to haner & kuo, pllc",0,0
090000648220c71f,Supporting & Related Material,FDA-2016-P-2736-0022,FDA-2016-P-2736,"appendix c - 2 - copies of references cited in citizen petition on human intervention studies regarding effect of itf on calcium absorption re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c774,Supporting & Related Material,FDA-2016-P-2736-0056,FDA-2016-P-2736,"appendix g - 4 - copies of misc references cited in citizen petition other than copies included in appendices b-e re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c797,Supporting & Related Material,FDA-2016-P-2736-0070,FDA-2016-P-2736,"appendix g - 18 - copies of misc references cited in citizen petition other than copies included in appendices b-e re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c920,Supporting & Related Material,FDA-2016-P-2736-0032,FDA-2016-P-2736,"appendix d - 3 - copies of references cited in citizen petition on human intervention studies regarding effect of itf on blood cholesterol levels re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c921,Supporting & Related Material,FDA-2016-P-2736-0033,FDA-2016-P-2736,"appendix d - 4 - copies of references cited in citizen petition on human intervention studies regarding effect of itf on blood cholesterol levels recitizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c922,Supporting & Related Material,FDA-2016-P-2736-0034,FDA-2016-P-2736,"appendix d - 5 - copies of references cited in citizen petition on human intervention studies regarding effect of itf on blood cholesterol levels re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c924,Supporting & Related Material,FDA-2016-P-2736-0036,FDA-2016-P-2736,"appendix d - 7 - copies of references cited in citizen petition on human intervention studies regarding effect of itf on blood cholesterol levels re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c930,Supporting & Related Material,FDA-2016-P-2736-0039,FDA-2016-P-2736,"appendix d - 10 - copies of references cited in citizen petition on human intervention studies regarding effect of itf on blood cholesterol levels re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c932,Supporting & Related Material,FDA-2016-P-2736-0041,FDA-2016-P-2736,"appendix d - 12 - copies of references cited in citizen petition on human intervention studies regarding effect of itf on blood cholesterol levels re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c0f6,Supporting & Related Material,FDA-2016-P-2736-0015,FDA-2016-P-2736,"appendix b - 12 - copies of references cited in citizen petition on human intervention studies regarding effect of the itf on bowel function re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c60a,Supporting & Related Material,FDA-2016-P-2736-0007,FDA-2016-P-2736,"appendix b - 4 - copies of references cited in citizen petition on human intervention studies regarding effect of the itf on bowel function re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c71c,Supporting & Related Material,FDA-2016-P-2736-0019,FDA-2016-P-2736,"appendix b - 16 - copies of references cited in citizen petition on human intervention studies regarding effect of the itf on bowel function re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c71e,Supporting & Related Material,FDA-2016-P-2736-0021,FDA-2016-P-2736,"appendix c - 1 - copies of references cited in citizen petition on human intervention studies regarding effect of itf on calcium absorption re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c971,Supporting & Related Material,FDA-2016-P-2736-0063,FDA-2016-P-2736,"appendix g - 11 - copies of misc references cited in citizen petition other than copies included in appendices b-e re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c773,Supporting & Related Material,FDA-2016-P-2736-0055,FDA-2016-P-2736,"appendix g - 3 - copies of misc references cited in citizen petition other than copies included in appendices b-e re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c91e,Supporting & Related Material,FDA-2016-P-2736-0030,FDA-2016-P-2736,"appendix d - 1 - copies of references cited in citizen petition on human intervention studies regarding effect of itf on blood cholesterol levels re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c923,Supporting & Related Material,FDA-2016-P-2736-0035,FDA-2016-P-2736,"appendix d - 6 - copies of references cited in citizen petition on human intervention studies regarding effect of itf on blood cholesterol levels re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c935,Supporting & Related Material,FDA-2016-P-2736-0044,FDA-2016-P-2736,"appendix d - 15 - copies of references cited in citizen petition on human intervention studies regarding effect of itf on blood cholesterol levels re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c936,Supporting & Related Material,FDA-2016-P-2736-0045,FDA-2016-P-2736,"appendix d - 16 - copies of references cited in citizen petition on human intervention studies regarding effect of itf on blood cholesterol levels re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c96e,Supporting & Related Material,FDA-2016-P-2736-0060,FDA-2016-P-2736,"appendix g - 8 - copies of misc references cited in citizen petition other than copies included in appendices b-e re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c76d,Supporting & Related Material,FDA-2016-P-2736-0049,FDA-2016-P-2736,"appendix e - 3 - copies of references cited in citizen petition on human intervention studies regarding effect of itf on postprandial glycemic response re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c76f,Supporting & Related Material,FDA-2016-P-2736-0051,FDA-2016-P-2736,"appendix e - 5 - copies of references cited in citizen petition on human intervention studies regarding effect of itf on postprandial glycemic response re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c770,Supporting & Related Material,FDA-2016-P-2736-0052,FDA-2016-P-2736,"appendix f - references cited in citizen petition not included in appendix a re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c602,Other,FDA-2016-P-2736-0001,FDA-2016-P-2736,"citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
090000648220c608,Supporting & Related Material,FDA-2016-P-2736-0005,FDA-2016-P-2736,"appendix b - 2 - copies of references cited in citizen petition on human intervention studies regarding effect of the itf on bowel function re citizen petition from hyman, phelps & mcnamara, p.c. (beneo, cosucra groupe warcoing s.a., and sensus b.v.)",0,0
0900006482e28106,Other,FDA-2018-P-0258-0002,FDA-2018-P-0258,acknowledgment letter from fda ddm to gilman cheese corporation,0,0
0900006483a6444d,Other,FDA-2018-P-0258-0009,FDA-2018-P-0258,letter from fda cfsan to gilman cheese corporation,0,0
0900006482e28103,Other,FDA-2018-P-0258-0001,FDA-2018-P-0258,citizen petition from gilman cheese corporation,0,0
090000648196be15,Other,FDA-2014-P-2169-0001,FDA-2014-P-2169,citizen petition request from lachman consultant services inc,0,0
090000648196bf3d,Supporting & Related Material,FDA-2014-P-2169-0004,FDA-2014-P-2169,attach 2,0,0
090000648196bf3c,Supporting & Related Material,FDA-2014-P-2169-0003,FDA-2014-P-2169,attach 1,0,0
090000648196bf3e,Supporting & Related Material,FDA-2014-P-2169-0005,FDA-2014-P-2169,attach 3,0,0
090000648196c152,Other,FDA-2014-P-2169-0002,FDA-2014-P-2169,aknowledgement letter from fda ddm to lachman consultant services inc,0,0
09000064817772e3,Other,FDA-2014-P-0916-0001,FDA-2014-P-0916,citizen petition from hope pharmaceuticals,0,0
090000648191375d,Other,FDA-2014-P-0916-0006,FDA-2014-P-0916,citizen petition denial letter to craig sherman md of hope pharmaceuticals,0,0
09000064818721ea,Other,FDA-2014-P-0916-0004,FDA-2014-P-0916,supplement from hope pharmaceuticals,0,0
09000064817b2bd9,Supporting & Related Material,FDA-2014-P-0916-0003,FDA-2014-P-0916,withdrawal letter from hope pharmaceuticals re fda-2014-p-0771-0003,0,0
09000064818cdafa,Other,FDA-2014-P-0916-0005,FDA-2014-P-0916,revised supplement from hope pharmaceuticals,0,0
09000064817772ea,Other,FDA-2014-P-0916-0002,FDA-2014-P-0916,acknowledgment letter from fda ddm to hope pharmaceuticals,0,0
0900006481e04099,Other,FDA-2016-P-0135-0002,FDA-2016-P-0135,"acknowledgement letter from fda ddm to hyman, phelps & mcnamara, p.c.",0,0
0900006482277e57,Other,FDA-2016-P-0135-0004,FDA-2016-P-0135,"letter from hyman, phelps & mcnamara, p.c. to fda  withdrawing petition",0,0
090000648209b04f,Other,FDA-2016-P-0135-0003,FDA-2016-P-0135,interim response from fda cder,0,0
090000648227611b,Other,FDA-2016-P-0135-0005,FDA-2016-P-0135,"withdrawal from hyman, phelps & mcnamara, p.c.",0,0
0900006481e03f6d,Other,FDA-2016-P-0135-0001,FDA-2016-P-0135,"citizen petition from hyman, phelps & mcnamara, p.c. - per petitioner, withdrawal of petition",0,0
0900006483959707,Other,FDA-2018-P-4656-0001,FDA-2018-P-4656,citizen petition from animal legal defense fund,0,0
09000064839598ed,Other,FDA-2018-P-4656-0002,FDA-2018-P-4656,acknowledgment letter from fda ddm to animal legal defense fund,0,0
0900006483ca61d2,Other,FDA-2018-P-4656-0006,FDA-2018-P-4656,letter from fda cvm to animal legal defense fund,0,0
0900006483da9110,Other,FDA-2018-P-3640-0008,FDA-2018-P-3640,180 day interim response letter from fda cfsan to information technology and innovation foundation,0,0
090000648377119a,Other,FDA-2018-P-3640-0001,FDA-2018-P-3640,citizen petition from information technology and innovation foundation,0,0
090000648377119d,Other,FDA-2018-P-3640-0002,FDA-2018-P-3640,acknowledgment letter from fda ddm to information technology and innovation foundation,0,0
090000648404db24,Other,FDA-2018-P-3640-0009,FDA-2018-P-3640,interim response letter from fda cfsan to information tech and innovation foundation,0,0
0900006481b93482,Other,FDA-2015-P-2481-0002,FDA-2015-P-2481,acknowledgement letter from fda cdrh to sweetspot diabetes care,0,0
090000648413267c,Other,FDA-2015-P-2481-0004,FDA-2015-P-2481,petition withdrawal letter from dexcom to fda,0,0
0900006482f01034,Other,FDA-2015-P-2481-0003,FDA-2015-P-2481,"contact person transfer letter for sweetspot diabetes care, inc.",0,0
0900006481b9347d,Other,FDA-2015-P-2481-0001,FDA-2015-P-2481,reclassification petition from sweetspot diabetes care,0,0
0900006484066a16,Other,FDA-2017-P-2626-0007,FDA-2017-P-2626,response letter from fda  cfsan emord and associates on behalf of real food consumer coalition,1,0
090000648257b69d,Other,FDA-2017-P-2626-0002,FDA-2017-P-2626,"acknowledgement letter from fda ddm to emord & associates, p. c.",0,0
090000648257b58e,Other,FDA-2017-P-2626-0001,FDA-2017-P-2626,"citizen petition from emord & associates, p. c.",0,0
0900006482bd8106,Other,FDA-2017-P-2626-0003,FDA-2017-P-2626,"interim response letter from fda cfsan to emord & associates, p. c.",0,0
090000648495d4b4,Supporting & Related Material,FDA-2020-P-2187-0003,FDA-2020-P-2187,"attachment 1 - copy of the relevant excerpt from the current electronic edition of the approved drug products with therapeutic equivalence evaluations re suitability petition from lachman consulting services, inc.",0,0
090000648495d4b0,Other,FDA-2020-P-2187-0001,FDA-2020-P-2187,"suitability petition from lachman consulting services, inc.",0,0
09000064849a2dbc,Other,FDA-2020-P-2187-0006,FDA-2020-P-2187,withdrawal from lachman consultant services,0,0
090000648495d4b6,Supporting & Related Material,FDA-2020-P-2187-0005,FDA-2020-P-2187,"attachment 3: draft package insert proposed for vancomycin hydrochloride for oral solution incorporating the proposed additional strength of eq 125 mg (base)/5 ml re suitability petition from lachman consulting services, inc.",0,0
090000648495d4b5,Supporting & Related Material,FDA-2020-P-2187-0004,FDA-2020-P-2187,"attachment 2 - current labeling for vancomycin hydrochloride, for solution, oral eq 250 mg (base)/5 ml by ani pharmaceuticals inc., approved under andaa061667, product number 002, source: dailymed) re suitability petition from lachman consulting services, inc.",0,0
090000648495d4b1,Other,FDA-2020-P-2187-0002,FDA-2020-P-2187,"acknowledgment letter from fda dms to lachman consulting services, inc.",0,0
09000064823167af,Supporting & Related Material,FDA-2016-P-3426-0004,FDA-2016-P-3426,exhibit 2 controlled correspondence from fda cder to novitium pharma llc re citizen petition from novitium pharma llc,0,0
0900006482316a92,Other,FDA-2016-P-3426-0001,FDA-2016-P-3426,citizen petition from novitium pharma llc,0,0
0900006482316a96,Supporting & Related Material,FDA-2016-P-3426-0003,FDA-2016-P-3426,exhibit 1 letter from inwood pharmacy to novitium pharma llc re citizen petition from novitium pharma llc,0,0
090000648251122f,Other,FDA-2016-P-3426-0005,FDA-2016-P-3426,petition response letter from fda cder to novitium pharma llc,0,0
0900006482316a94,Other,FDA-2016-P-3426-0002,FDA-2016-P-3426,acknowledgement letter from fda ddm to novitium pharma llc,0,0
0900006481f93b72,Supporting & Related Material,FDA-2016-P-1211-0004,FDA-2016-P-1211,"attachment 2 draft labeling for the proposed product, goody's migraine re citizen petition from medtech products inc.",0,0
0900006481f93dec,Other,FDA-2016-P-1211-0001,FDA-2016-P-1211,citizen petition from medtech products inc.,0,0
0900006481f93df0,Supporting & Related Material,FDA-2016-P-1211-0003,FDA-2016-P-1211,"attachment 1 approved labeling for the rld, excedrin (migraine) re citizen petition from medtech products inc.",0,0
0900006482eee082,Other,FDA-2016-P-1211-0006,FDA-2016-P-1211,notice of withdrawal letter from fda to a prestige brands company,0,0
0900006481f93b8d,Other,FDA-2016-P-1211-0002,FDA-2016-P-1211,acknowledgement letter from fda ddm to medtech products inc.,0,0
0900006481f93b73,Supporting & Related Material,FDA-2016-P-1211-0005,FDA-2016-P-1211,attachment 3 request for waiver from requirement to submit a pediatric assessment re citizen petition from medtech products inc.,0,0
09000064846d4d46,Supporting & Related Material,FDA-2020-P-1511-0006,FDA-2020-P-1511,attachment 2 nymalize (nimodipine) oral solution re citizens petition from annora pharma private limited,0,0
09000064846d4c08,Supporting & Related Material,FDA-2020-P-1511-0007,FDA-2020-P-1511,attachment 1 orange book nimodipine oral solution re citizens petition from annora pharma private limited,0,0
0900006484a3add5,Other,FDA-2020-P-1511-0011,FDA-2020-P-1511,final response letter from fda cder to annora pharma private limited,0,0
09000064846d4c04,Other,FDA-2020-P-1511-0002,FDA-2020-P-1511,citizens petition from annora pharma private limited,0,0
09000064846d4cb7,Supporting & Related Material,FDA-2020-P-1511-0004,FDA-2020-P-1511,attachment 4 package inser for 3 mg per ml re citizens petition from annora pharma private limited,0,0
0900006484a39793,Notice,FDA-2020-P-1511-0010,FDA-2020-P-1511,"determination that nymalize (nimodipine), oral solution, 3 milligrams/milliliter, was not withdrawn from sale for reasons of safety or effectiveness",0,0
09000064846d4cb8,Supporting & Related Material,FDA-2020-P-1511-0003,FDA-2020-P-1511,attachment 5 package insert for 6 mg per ml (new concentration) re citizens petition from annora pharma private limited,0,0
090000648497e03c,Other,FDA-2020-P-1511-0009,FDA-2020-P-1511,interim response letter from fda cder to annora pharma private limited,0,0
09000064846d4c05,Other,FDA-2020-P-1511-0001,FDA-2020-P-1511,acknowledgment letter from fda dms to annora pharma private limited,0,0
09000064846d4cb6,Supporting & Related Material,FDA-2020-P-1511-0005,FDA-2020-P-1511,attachment 3 notice of formulation change by arbor pharmaceuticals llc re citizens petition from annora pharma private limited,0,0
09000064804758a1,Other,FDA-2004-P-0465-0002,FDA-2004-P-0465,hfa-305 to london and mead,0,0
09000064804758c2,Other,FDA-2004-P-0465-0003,FDA-2004-P-0465,hfd-1 to london & mead,0,0
0900006480475877,Other,FDA-2004-P-0465-0001,FDA-2004-P-0465,hfa-305 to london and mead,0,0
090000648408ff27,Other,FDA-2003-P-0291-0004,FDA-2003-P-0291,response letter from fda cfsan to center for science in the public interest,0,0
0900006480492bd9,Other,FDA-2003-P-0291-0001,FDA-2003-P-0291,fda/ddm to cspi,0,0
0900006480492c43,Other,FDA-2003-P-0291-0003,FDA-2003-P-0291,center for science in the public interest (cspi),0,0
0900006480492c4c,Other,FDA-2003-P-0291-0002,FDA-2003-P-0291,fda/cfsan to center for science in the public interest,0,0
0900006480495f70,Other,FDA-2003-P-0334-0002,FDA-2003-P-0334,"hfa-305 to cape cod, inc.",0,0
0900006480f5524b,Other,FDA-2003-P-0334-0004,FDA-2003-P-0334,"associates of cape cod (acc), inc. - withdrawal",0,0
0900006480495f26,Other,FDA-2003-P-0334-0001,FDA-2003-P-0334,"hfa-305 to cape cod, inc.",0,0
0900006480495f95,Other,FDA-2003-P-0334-0003,FDA-2003-P-0334,"hfm-1 to hyman, phelps &amp; mcnamara, pc",0,0
0900006481fdb470,Supporting & Related Material,FDA-2016-P-1287-0003,FDA-2016-P-1287,"attachment 1  orange book for amphotericin b liposome for injection, accessed 05/12/16 re citizen petition from lachman consultant services, inc.",0,0
0900006484877df5,Other,FDA-2016-P-1287-0006,FDA-2016-P-1287,letter from lachman consultant services,0,0
0900006481fdb4a2,Other,FDA-2016-P-1287-0001,FDA-2016-P-1287,"citizen petition from lachman consultant services, inc.",0,0
0900006484d628d7,Other,FDA-2016-P-1287-0007,FDA-2016-P-1287,"approval letter from fda cder to lachman consultant services, inc.",0,0
0900006481fdb46f,Supporting & Related Material,FDA-2016-P-1287-0004,FDA-2016-P-1287,"attachment 2 reference listed drug prescribing informaiton for ambisome (amphotericin b liposome) for injection, 50 mg/vial by astellas pharmaceuticals re citizen petition from lachman consultant services, inc.",0,0
0900006481fdb4a4,Other,FDA-2016-P-1287-0002,FDA-2016-P-1287,"acknowledgement letter from fda ddm to  lachman consultant services, inc.",0,0
0900006481fdb46e,Supporting & Related Material,FDA-2016-P-1287-0005,FDA-2016-P-1287,"attachment 3 proposed prescribing information for amphotericin b liposome for injection 250 mg/vial re citizen petition from lachman consultant services, inc.",0,0
090000648420dd1d,Other,FDA-2019-P-5887-0002,FDA-2019-P-5887,acknowledgment letter from fda dms to upfield us inc.,0,0
090000648420dd20,Supporting & Related Material,FDA-2019-P-5887-0003,FDA-2019-P-5887,appendix a re citizen petition from upfield us inc. citizen petition from upfield us inc.,0,0
090000648420d4cb,Other,FDA-2019-P-5887-0001,FDA-2019-P-5887,citizen petition from upfield us inc.,0,0
0900006481e44e52,Notice,FDA-2013-N-0662-0003,FDA-2013-N-0662,"agency information collection activities: proposed collection; comment request; applications for food and drug administration approval to market a new drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug
applications certifying that a patent claiming a drug is valid or will not be infringed",1,0
0900006482408286,Notice,FDA-2013-N-0662-0006,FDA-2013-N-0662,"agency information collection activities; announcement of office of
management and budget approvals",0,0
090000648425db89,Notice,FDA-2013-N-0662-0009,FDA-2013-N-0662,"agency information collection activities; announcement of office of
management and budget approvals",0,0
0900006481427764,Notice,FDA-2013-N-0662-0002,FDA-2013-N-0662,agency information collection activities; submission for office of management and budget review; comment request; applications for food and drug administration approval to market a new drug: patent submission and listing requirements,1,0
0900006483ca08dc,Notice,FDA-2013-N-0662-0007,FDA-2013-N-0662,"agency information collection activities; proposed collection; comment request; applications for food and drug administration
approval to market a new drug: patent submission and listing requirements",1,0
0900006483eed742,Notice,FDA-2013-N-0662-0008,FDA-2013-N-0662,"agency information collection activities; submission for office of
management and budget review; comment request; applications for
food and drug administration approval to market a new drug— patent submission and listing requirements",1,0
090000648217555a,Notice,FDA-2013-N-0662-0005,FDA-2013-N-0662,"agency information collection activities; submission for office of
management and budget review; comment request; applications for
food and drug administration approval to market a new drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is valid or will not be infringed",1,0
09000064813282d7,Notice,FDA-2013-N-0662-0001,FDA-2013-N-0662,agency information collection activities: proposed collection; comment request; applications for food and drug administration approval to market a new drug:  patent submission and listing requirements,1,0
0900006484c0254a,Other,FDA-2021-P-0767-0001,FDA-2021-P-0767,citizen petition from buchanan ingersoll and rooney pc on behalf of covis pharma gmbh,0,0
0900006484c0257f,Other,FDA-2021-P-0767-0002,FDA-2021-P-0767,acknowledgment letter from fda dms to buchanan ingersoll and rooney pc on behalf of covis pharma gmbh,0,0
09000064843181b1,Other,FDA-2018-P-1751-0005,FDA-2018-P-1751,response letter from fda  cder regcon solutions llc,0,0
09000064838750e4,Other,FDA-2018-P-1751-0004,FDA-2018-P-1751,"interim response letter from fda cder to regcon solutions, llc.",0,0
090000648322c314,Other,FDA-2018-P-1751-0002,FDA-2018-P-1751,"acknowledgment letter from fda ddm to regcon solutions, llc.",0,0
090000648322c07b,Supporting & Related Material,FDA-2018-P-1751-0003,FDA-2018-P-1751,attachment 1- orange book_ approved drug products with therapeutic equivalence evaluations,0,0
090000648322c079,Other,FDA-2018-P-1751-0001,FDA-2018-P-1751,"citizen petition from regcon solutions, llc.",0,0
0900006481e96f7a,Other,FDA-2016-P-0769-0001,FDA-2016-P-0769,"citizen petition from empire state consumer project, inc.",0,0
0900006481e971a1,Other,FDA-2016-P-0769-0002,FDA-2016-P-0769,"acknowledgement letter from fda ddm to empire state consumer project, inc.",0,0
090000648219de79,Other,FDA-2016-P-0769-0003,FDA-2016-P-0769,"interim response letter from fda cder to empire state consumer project, inc.",0,0
0900006482c2ae3a,Other,FDA-2016-P-0769-0007,FDA-2016-P-0769,final response letter from fda to empire state consumer project inc,0,0
0900006482afbc27,Supporting & Related Material,FDA-2017-P-5370-0005,FDA-2017-P-5370,footnote 4-relative abuse liability of prescription opiods compared to heroin in morphhine-maintained heroin abusers re citizen petition from dennis ryll,0,0
0900006482afbc29,Supporting & Related Material,FDA-2017-P-5370-0007,FDA-2017-P-5370,footnote 6-buprenorphine induces ceiling respiratory depression but not in analgesia-british journal of anesthesia re citizen petition from dennis ryll,0,0
0900006482afbc2a,Supporting & Related Material,FDA-2017-P-5370-0008,FDA-2017-P-5370,footnote 7-buprenorphine infrequently found in fatal overdoses in new york city-drug alcohol dep re citizen petition from dennis ryll,0,0
0900006482afbc2b,Supporting & Related Material,FDA-2017-P-5370-0009,FDA-2017-P-5370,footnote 8-characteristics of initial prescription episodes and liklihood of long term opiod use- united staes 2006-2015-morbidity mortality weekly re citizen petition from dennis ryll,0,0
0900006482afbf55,Other,FDA-2017-P-5370-0001,FDA-2017-P-5370,citizen petition from dennis ryll,0,0
09000064839006c2,Other,FDA-2017-P-5370-0013,FDA-2017-P-5370,withdrawal from dennis ryll,0,0
0900006482afbc26,Supporting & Related Material,FDA-2017-P-5370-0004,FDA-2017-P-5370,footnote 3-twelve reasons for considering buprenorphine as a frontline analgesic re citizen petition from dennis ryll,0,0
0900006482afbf58,Other,FDA-2017-P-5370-0002,FDA-2017-P-5370,acknowledgement letter from fda ddm to dennis l ryll,0,0
0900006482afbc25,Supporting & Related Material,FDA-2017-P-5370-0003,FDA-2017-P-5370,footnote 2-opioid pharmacology and pharmacogenetics draft re citizen petition from dennis ryll,0,0
0900006482afbc2c,Supporting & Related Material,FDA-2017-P-5370-0010,FDA-2017-P-5370,footnote 9-buprenorphine an attractive opiod with underutilized potential in treatment of chronic pain-journal of pain research re citizen petition from dennis ryll,0,0
09000064839080d5,Other,FDA-2017-P-5370-0012,FDA-2017-P-5370,withdrawal letter from dennis ryll,0,0
0900006482f6584f,Other,FDA-2017-P-5370-0011,FDA-2017-P-5370,interim response from fda to dennis ryll,0,0
0900006482afbc28,Supporting & Related Material,FDA-2017-P-5370-0006,FDA-2017-P-5370,footnote 5-a double blind within subject comparison of spontaneous opiod witthdrawl from buprenorphine versus heroin-opioid pharmacology and pharma re citizen petition from dennis ryll,0,0
090000648249399c,Supporting & Related Material,FDA-2017-P-0494-0005,FDA-2017-P-0494,annex 3 re citizen petition from navinta llc,0,0
090000648249399a,Supporting & Related Material,FDA-2017-P-0494-0003,FDA-2017-P-0494,annex 1 re citizen petition from navinta llc,0,0
0900006482493996,Other,FDA-2017-P-0494-0002,FDA-2017-P-0494,acknowledgment letter  from fda ddm to navinta llc,0,0
090000648249399b,Supporting & Related Material,FDA-2017-P-0494-0004,FDA-2017-P-0494,annex 2 re citizen petition from navinta llc,0,0
090000648249360e,Other,FDA-2017-P-0494-0001,FDA-2017-P-0494,citizen petition from navinta llc,0,0
0900006481a34e9d,Other,FDA-2014-P-1353-0003,FDA-2014-P-1353,denial response from fda cfsan to the international formula council,0,0
090000648186a230,Other,FDA-2014-P-1353-0002,FDA-2014-P-1353,acknowledgement letter from fda/ddm to international formula council (ifc),0,0
090000648185fc82,Other,FDA-2014-P-1353-0001,FDA-2014-P-1353,citizen petition from international formula council (ifc),0,0
0900006481919aa3,Other,FDA-2014-P-1844-0001,FDA-2014-P-1844,citizen petition request from lachman consultant services inc,0,0
0900006481919aa9,Supporting & Related Material,FDA-2014-P-1844-0003,FDA-2014-P-1844,attachment 1,0,0
0900006482499761,Other,FDA-2014-P-1844-0005,FDA-2014-P-1844,request to withdraw petition,0,0
0900006481919aaa,Other,FDA-2014-P-1844-0002,FDA-2014-P-1844,acknowledgement letter from fda ddm to terri nataline lachman consultant services  inc,0,0
0900006481adc7f4,Other,FDA-2014-P-1844-0004,FDA-2014-P-1844,"interim response letter from fda cder to lachman consultant services, inc.",0,0
0900006481d85d6a,Other,FDA-2015-P-4601-0001,FDA-2015-P-4601,citizen petition from frier levitt,0,0
0900006481d85d6e,Other,FDA-2015-P-4601-0002,FDA-2015-P-4601,acknowledgement letter from fda ddm to frier levitt,0,0
090000648389da87,Other,FDA-2015-P-4601-0005,FDA-2015-P-4601,letter from fda cder to john e. morrone,0,0
0900006481d85d70,Supporting & Related Material,FDA-2015-P-4601-0003,FDA-2015-P-4601,exhibit a support letter from dr. patricia stafford re: citizen petition from frier levitt,0,0
090000648204b84c,Other,FDA-2015-P-4601-0004,FDA-2015-P-4601,interim response re: fda-2015-p-4601,0,0
09000064819b0218,Supporting & Related Material,FDA-2015-P-0095-0007,FDA-2015-P-0095,"attachment 1 citizen petition from duval and associates (leonhard lang, gmbh)",0,0
09000064819b01f2,Other,FDA-2015-P-0095-0008,FDA-2015-P-0095,"citizen petition from duval and associates (leonhard lang, gmbh)",0,0
09000064819b021d,Supporting & Related Material,FDA-2015-P-0095-0002,FDA-2015-P-0095,"attachment 6 citizen petition from duval and associates (leonhard lang, gmbh)",0,0
09000064819b021a,Supporting & Related Material,FDA-2015-P-0095-0005,FDA-2015-P-0095,"attachment 3 citizen petition from duval and associates (leonhard lang, gmbh)",0,0
09000064819b021b,Supporting & Related Material,FDA-2015-P-0095-0004,FDA-2015-P-0095,"attachment 4 citizen petition from duval and associates (leonhard lang, gmbh)",0,0
09000064819b021c,Supporting & Related Material,FDA-2015-P-0095-0003,FDA-2015-P-0095,"attachment 5 citizen petition from duval and associates (leonhard lang, gmbh)",0,0
09000064819b0219,Supporting & Related Material,FDA-2015-P-0095-0006,FDA-2015-P-0095,"attachment 2 citizen petition from duval and associates (leonhard lang, gmbh)",0,0
09000064819b021e,Other,FDA-2015-P-0095-0001,FDA-2015-P-0095,"acknowledgement letter from fda ddm to duval and associates, p.a.",0,0
0900006481948c11,Supporting & Related Material,FDA-2014-P-2058-0003,FDA-2014-P-2058,"attachment 1 fda orange book listing citizen petition from lachman consultant services, inc.",0,0
0900006481948c13,Supporting & Related Material,FDA-2014-P-2058-0005,FDA-2014-P-2058,"attachment 3 proposed labeling citizen petition from lachman consultant services, inc.",0,0
0900006481948c14,Other,FDA-2014-P-2058-0002,FDA-2014-P-2058,"acknowledgement letter from fda ddm to lachman consultant services, inc.",0,0
0900006481948c0f,Other,FDA-2014-P-2058-0001,FDA-2014-P-2058,"citizen petition from lachman consultant services, inc.",0,0
0900006481948c12,Supporting & Related Material,FDA-2014-P-2058-0004,FDA-2014-P-2058,"attachment 2 product labeling citizen petition from lachman consultant services, inc.",0,0
0900006482a8df20,Other,FDA-2017-P-5082-0002,FDA-2017-P-5082,"acknowledgment letter from fda ddm to chromadex, inc.",0,0
0900006482f35b2f,Other,FDA-2017-P-5082-0014,FDA-2017-P-5082,"interim response letter from fda cfsan to chromadex, inc.",0,0
0900006482a8c848,Supporting & Related Material,FDA-2017-P-5082-0003,FDA-2017-P-5082,"exhibit 1 elysium basis summary report re citizen petition from  chromadex, inc.",0,0
0900006482a8c846,Other,FDA-2017-P-5082-0001,FDA-2017-P-5082,"citizen petition from  chromadex, inc.",0,0
0900006482e15079,Other,FDA-2017-P-5082-0011,FDA-2017-P-5082,"supplement from sheldon bradshaw, king & spalding llp",0,0
0900006482be5372,Other,FDA-2017-P-6208-0002,FDA-2017-P-6208,acknowledgment letter from fda ddm to inc research/inventiv health/inventiv health,0,0
0900006482be5374,Supporting & Related Material,FDA-2017-P-6208-0003,FDA-2017-P-6208,exhibit 1 orange book listing - citizen petition from inc research/inventiv health/inventiv health,0,0
0900006483146f8c,Other,FDA-2017-P-6208-0004,FDA-2017-P-6208,interim response letter,0,0
0900006482be5371,Other,FDA-2017-P-6208-0001,FDA-2017-P-6208,citizen petition from inc research/inventiv health/inventiv health,0,0
0900006484b02546,Other,FDA-2017-P-6208-0005,FDA-2017-P-6208,withdrawal of citizen petition for inc research/inventiv health,0,0
0900006484b5d305,Other,FDA-2017-P-6208-0006,FDA-2017-P-6208,"withdrawal from kinapse, a syneos health company",0,0
0900006480494960,Supporting & Related Material,FDA-2003-D-0309-0002,FDA-2003-D-0309,guidance,0,0
0900006480494923,Notice,FDA-2003-D-0309-0001,FDA-2003-D-0309,fda,0,0
0900006480532c5f,Notice,FDA-2008-D-0229-0001,FDA-2008-D-0229,guidance for industry on the food and drug administration recommendations for sampling and testing yellow corn and dry-milled yellow corn shipments intended for human food use for cry9c protein residues; withdrawal of guidance,1,0
0900006480532c37,Notice,FDA-2008-D-0229-0002,FDA-2008-D-0229,epa white paper regarding starlink[reg]corn dietary exposure and risk; availability,0,0
0900006480a8e976,Notice,FDA-2010-N-0057-0001,FDA-2010-N-0057,"agency information collection activities; proposals, submissions, and approvals",0,0
0900006480aef92c,Notice,FDA-2010-N-0057-0002,FDA-2010-N-0057,"agency information collection activities; proposals, submissions, and approvals: how to submit information in electronic format to center for veterinary medicine using fda electronic submission gateway",0,0
090000648421d9dc,Supporting & Related Material,FDA-2019-P-5943-0006,FDA-2019-P-5943,"attachment 3 - draft pi_redacted re citizen petition from hyman, phelps & mcnamara, p.c.",0,0
090000648421d968,Other,FDA-2019-P-5943-0001,FDA-2019-P-5943,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
090000648421d9d9,Supporting & Related Material,FDA-2019-P-5943-0003,FDA-2019-P-5943,"attachment 1 - orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from hyman, phelps & mcnamara, p.c.",0,0
090000648421d96a,Other,FDA-2019-P-5943-0002,FDA-2019-P-5943,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
090000648421d9da,Supporting & Related Material,FDA-2019-P-5943-0004,FDA-2019-P-5943,"attachment 2 - vibratabs labeling re citizen petition from hyman, phelps & mcnamara, p.c.",0,0
090000648421d9db,Supporting & Related Material,FDA-2019-P-5943-0005,FDA-2019-P-5943,"attachment 3 - draft pi re citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484251331,Supporting & Related Material,FDA-2019-P-6047-0005,FDA-2019-P-6047,"attachment 3 fresenius kabi proposed package insert re suitability petition from fresenius kabi usa, llc",0,0
09000064842516ea,Other,FDA-2019-P-6047-0001,FDA-2019-P-6047,"suitability petition from fresenius kabi usa, llc",0,0
090000648425132f,Supporting & Related Material,FDA-2019-P-6047-0003,FDA-2019-P-6047,"attachment 1 orange book listing of sterile water for irrigation re citizen petition from fresenius kabi usa, llc",0,0
09000064842516eb,Other,FDA-2019-P-6047-0002,FDA-2019-P-6047,"acknowledgment letter from fda dms to fresenius kabi usa, llc",0,0
0900006484251330,Supporting & Related Material,FDA-2019-P-6047-0004,FDA-2019-P-6047,"attachment 2 reference listed drug labeling sterile water for irrigation usp re suitability petition from fresenius kabi usa, llc",0,0
09000064823bccfd,Other,FDA-2016-P-1955-0009,FDA-2016-P-1955,petition denial letter from fda cder to mallinckrodt pharmaceuticals,0,0
0900006482186110,Other,FDA-2016-P-1955-0006,FDA-2016-P-1955,supplement from mallinckrodt pharmaceuticals,0,0
0900006482093671,Other,FDA-2016-P-1955-0002,FDA-2016-P-1955,acknowledgement letter from fda ddm to mallinckrodt pharmaceuticals,0,0
0900006482092dc9,Supporting & Related Material,FDA-2016-P-1955-0003,FDA-2016-P-1955,"exhibit a - transcript of proceedings, anesthesiology and respiratory therapy devices panel of the medical devices advisory committee (nov. 22, 1996) re citizen petition from mallinckrodt pharmaceuticals",0,0
0900006482092dca,Supporting & Related Material,FDA-2016-P-1955-0004,FDA-2016-P-1955,"exhibit b  lavoie, a. et al., life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. am. j. respir. crit. care med. 1996:153;1985-87 re citizen petition from mallinckrodt pharmaceuticals",0,0
0900006482092dcb,Supporting & Related Material,FDA-2016-P-1955-0005,FDA-2016-P-1955,"exhibit c - import alert # 89-04, detention without physical examination of devices from firms that have not met device quality system requirements (march 16, 2016) (excerpt) re citizen petition from mallinckrodt pharmaceuticals",0,0
0900006482092dc8,Other,FDA-2016-P-1955-0001,FDA-2016-P-1955,citizen petition from mallinckrodt pharmaceuticals,0,0
0900006483a34134,Other,FDA-2018-P-3401-0010,FDA-2018-P-3401,"agency response letter from fda cder to novo nordisk, inc.",0,0
0900006483a33c49,Other,FDA-2018-P-3401-0009,FDA-2018-P-3401,"agency response letter from fda cder to novo nordisk, inc.",0,0
09000064836bcb86,Supporting & Related Material,FDA-2018-P-3401-0006,FDA-2018-P-3401,novonordisk_citizenpetition_05september2018_references_part_4_of_6 re: citizen petition from novo nordisk inc,0,0
09000064836bcba8,Supporting & Related Material,FDA-2018-P-3401-0007,FDA-2018-P-3401,novonordisk_citizenpetition_05september2018_references_part_5_of_6-1re: citizen petition from novo nordisk inc,0,0
09000064836bcba9,Supporting & Related Material,FDA-2018-P-3401-0008,FDA-2018-P-3401,novonordisk_citizenpetition_05september2018_references_part_6_of_6 re: citizen petition from novo nordisk inc,0,0
09000064836bca45,Other,FDA-2018-P-3401-0001,FDA-2018-P-3401,citizen petition from novo nordisk inc.,0,0
09000064836bce6d,Other,FDA-2018-P-3401-0002,FDA-2018-P-3401,"acknowledgment letter from fda ddm to novo nordisk, inc.",0,0
09000064836bcb84,Supporting & Related Material,FDA-2018-P-3401-0004,FDA-2018-P-3401,novonordisk_citizenpetition_05september2018_references_part_2_of_6-1 re: citizen petition from novo nordisk inc,0,0
09000064836bcb85,Supporting & Related Material,FDA-2018-P-3401-0005,FDA-2018-P-3401,novonordisk_citizenpetition_05september2018_references_part_3_of_6-1re: citizen petition from novo nordisk inc,0,0
09000064836bcb83,Supporting & Related Material,FDA-2018-P-3401-0003,FDA-2018-P-3401,novonordisk_citizenpetition_05september2018_references_part_1_of_6 re: citizen petition from novo nordisk inc,0,0
09000064839ec6fa,Other,FDA-2018-P-2749-0003,FDA-2018-P-2749,interim response from fda cder to anne a. shirinian-orlando,0,0
090000648351271d,Other,FDA-2018-P-2749-0001,FDA-2018-P-2749,citizen petition from anne a. shirinian-orlando,0,0
0900006483cea079,Other,FDA-2018-P-2749-0004,FDA-2018-P-2749,letter from fda cder to anne a. shirinian-orlando,0,0
090000648351271f,Other,FDA-2018-P-2749-0002,FDA-2018-P-2749,acknowledgment letter from fda ddm to anne a. shirinian-orlando,0,0
09000064818422e5,Notice,FDA-2014-P-0549-0003,FDA-2014-P-0549,"determination that sular (nisoldipine) extended-release
tablets, 10 milligrams, 20 milligrams, 25.5 milligrams, 30 milligrams, and 40 milligrams, were not withdrawn from sale for reasons of safety or
effectiveness",0,0
0900006481844a21,Other,FDA-2014-P-0549-0004,FDA-2014-P-0549,response letter from fda cder to emcure pharmaceuticals inc.,0,0
09000064816d4cab,Other,FDA-2014-P-0549-0001,FDA-2014-P-0549,"citizen petition from emcure pharmaceuticals usa, inc",0,0
09000064816d575b,Other,FDA-2014-P-0549-0002,FDA-2014-P-0549,acknowledgement letter from fda ddm to emcure pharmaceuticals inc.,0,0
09000064816e8840,Other,FDA-2014-P-0603-0002,FDA-2014-P-0603,acknowledgement letter from fda ddm to pacific link consulting,0,0
09000064816e883c,Other,FDA-2014-P-0603-0001,FDA-2014-P-0603,citizen petition from pacific link consulting,0,0
09000064818a85a2,Other,FDA-2014-P-0603-0003,FDA-2014-P-0603,citizen petition denial response from fda cder to pacific link consulting,0,0
09000064817202ba,Supporting & Related Material,FDA-2011-P-0610-0009,FDA-2011-P-0610,attachments a through e perrigo v. fda supplement from abbvie inc. hogan lovells us llp,0,0
090000648119c7f7,Supporting & Related Material,FDA-2011-P-0610-0004,FDA-2011-P-0610,"hogan lovells llp (behalf of abbvie, inc.) - citizen petition supplement",0,0
090000648171fc35,Other,FDA-2011-P-0610-0008,FDA-2011-P-0610,supplement from abbvie inc. hogan lovells us llp,0,0
09000064817da617,Other,FDA-2011-P-0610-0010,FDA-2011-P-0610,petition approval/denial from fda/cder,0,0
0900006480ee6771,Other,FDA-2011-P-0610-0002,FDA-2011-P-0610,"acknowledgement letter to abbott laboratories (mayer brown, llp)",0,0
09000064814bb904,Other,FDA-2011-P-0610-0005,FDA-2011-P-0610,abbvie inc. (hogan lovells) - supplement,0,0
0900006480fea041,Other,FDA-2011-P-0610-0003,FDA-2011-P-0610,"fda/cder letter to mayer brown llp, dated february 16, 2012",0,0
0900006480ee676f,Other,FDA-2011-P-0610-0001,FDA-2011-P-0610,"abbott laboratories (mayer brown, llp) - citizen petition",0,0
0900006482957054,Other,FDA-2017-P-4389-0002,FDA-2017-P-4389,"acknowledgement letter from fda ddm to wildway, llc",0,0
0900006482e311db,Other,FDA-2017-P-4389-0003,FDA-2017-P-4389,interim response letter,0,0
0900006482957052,Other,FDA-2017-P-4389-0001,FDA-2017-P-4389,"citizen petition from wildway , llc",0,0
090000648199e0c8,Other,FDA-2015-P-0014-0001,FDA-2015-P-0014,"citizen petition from edward boshnick, o.d.",0,0
090000648199e0ca,Other,FDA-2015-P-0014-0002,FDA-2015-P-0014,"acknowledgement letter from fda ddm to edward boshnick, o.d.",0,0
0900006481d1b5c8,Other,FDA-2015-P-4131-0003,FDA-2015-P-4131,acknowledgement letter from fda ddm to the university of florida,0,0
0900006481d1b5c0,Other,FDA-2015-P-4131-0001,FDA-2015-P-4131,citizen petition from the university of florida,0,0
0900006481fa80f3,Other,FDA-2015-P-4131-0004,FDA-2015-P-4131,interim response fda-2015-p-4131,0,0
0900006481d1b6e6,Supporting & Related Material,FDA-2015-P-4131-0002,FDA-2015-P-4131,reference list re citizen petition from university of florida,0,0
0900006482548ae0,Supporting & Related Material,FDA-2017-P-2233-0028,FDA-2017-P-2233,"attachment 26 -  lynch, managing phase down of amalgam part i educational and training issues re citizen petition from consumers for dental choice",0,0
09000064825488b3,Supporting & Related Material,FDA-2017-P-2233-0018,FDA-2017-P-2233,"attachment 16 -  european commission, final report, review of the community strategy concerning mercury re citizen petition from consumers for dental choice",0,0
09000064825488ba,Supporting & Related Material,FDA-2017-P-2233-0025,FDA-2017-P-2233,"attachment 23 -  jones, 30-year follow-up of residual effects on nz school dental nurses (2007) re citizen petition from consumers for dental choice",0,0
09000064825488c6,Supporting & Related Material,FDA-2017-P-2233-0043,FDA-2017-P-2233,"attachment 41 -  unep, lessons from countries phasing down dental amalgam use re citizen petition from consumers for dental choice",0,0
0900006482548869,Supporting & Related Material,FDA-2017-P-2233-0005,FDA-2017-P-2233,"attachment 3 - changing patterns in the use, recycling, and material substitution of mercury in the united states re citizen petition from consumers for dental choice",0,0
09000064825488b6,Supporting & Related Material,FDA-2017-P-2233-0021,FDA-2017-P-2233,"attachment 19 -  haj-ali, survey of general dentists regarding posterior restorations, selection criteria, and associated clinical problems re citizen petition from consumers for dental choice",0,0
09000064825488b8,Supporting & Related Material,FDA-2017-P-2233-0023,FDA-2017-P-2233,"attachment 21 -  hendriks, cost benefit analysis of direct posterior restorations (1985) re citizen petition from consumers for dental choice",0,0
09000064825488c0,Supporting & Related Material,FDA-2017-P-2233-0037,FDA-2017-P-2233,"attachment 35 -  riley, components of patient satisfaction with dental restorative visit (2012) re citizen petition from consumers for dental choice",0,0
09000064825488c5,Supporting & Related Material,FDA-2017-P-2233-0042,FDA-2017-P-2233,attachment 40 -  the real cost of dental mercury re citizen petition from consumers for dental choice,0,0
0900006482548ae1,Supporting & Related Material,FDA-2017-P-2233-0029,FDA-2017-P-2233,"attachment 27 -  lynch, minimally-invasive management of dental caries in dental schools re citizen petition from consumers for dental choice",0,0
0900006482548ae2,Supporting & Related Material,FDA-2017-P-2233-0030,FDA-2017-P-2233,"attachment 28 -  mandari, six-year success rates of occlusal amalgam and glass-ionomer restorations placed using minial intervention approaches (20 re citizen petition from consumers for dental choice",0,0
090000648254b121,Supporting & Related Material,FDA-2017-P-2233-0050,FDA-2017-P-2233,"attachment 48 - swedish chemicals agency, mercury phase-out, a study of the experience of swedish companies re citizen petition from consumer for dental choice",0,0
0900006482548ad2,Supporting & Related Material,FDA-2017-P-2233-0006,FDA-2017-P-2233,"attachment 4 -  da mata, cost-effectiveness of art restorations in elderly adults re citizen petition from consumers for dental choice",0,0
0900006482548ad9,Supporting & Related Material,FDA-2017-P-2233-0013,FDA-2017-P-2233,attachment 11 -  environmental costs of mercury pollution re citizen petition from consumers for dental choice,0,0
0900006482548adb,Supporting & Related Material,FDA-2017-P-2233-0015,FDA-2017-P-2233,attachment 13 -  epa will propose rule to protect waterways by reducing mercury from dental offices re citizen petition from consumers for dental choice,0,0
0900006482548ade,Supporting & Related Material,FDA-2017-P-2233-0026,FDA-2017-P-2233,"attachment 24 -  lei yin, associations of blood mercury, inorganic mercury, methyl mercury etc_ (2016) re citizen petition from consumers for dental choice",0,0
0900006482548adf,Supporting & Related Material,FDA-2017-P-2233-0027,FDA-2017-P-2233,attachment 25 -  letter to secretary john kerry (21 september 2015) re citizen petition from consumers for dental choice,0,0
0900006482548ae3,Supporting & Related Material,FDA-2017-P-2233-0031,FDA-2017-P-2233,"attachment 29 -  mickenautsch, comparative cost of art and conventional treatment within a dental school clinic (2009) re citizen petition from consumers for dental choice",0,0
0900006482548af1,Supporting & Related Material,FDA-2017-P-2233-0048,FDA-2017-P-2233,"attachment 46 -  zanata, ten-year survival of art restorations in permanent posterior teeth (2011) re citizen petition from consumers for dental choice",0,0
09000064825488c4,Supporting & Related Material,FDA-2017-P-2233-0041,FDA-2017-P-2233,"attachment 39 -  swedish chemicals agency, dental amalgam, prohibition to use dental amalgam re citizen petition from consumers for dental choice",0,0
0900006482548ad6,Supporting & Related Material,FDA-2017-P-2233-0010,FDA-2017-P-2233,"attachment 8 -  dentsply, annual report per sec form 10-k (31 dec_ 2014) re citizen petition from consumers for dental choice",0,0
0900006482548ad8,Supporting & Related Material,FDA-2017-P-2233-0012,FDA-2017-P-2233,"attachment 10 -  duplinsky _ cicchetti, health status of dentists exposed to mercury from amalgam tooth resotrations (2012) re citizen petition from consumers for dental choice",0,0
0900006482548ada,Supporting & Related Material,FDA-2017-P-2233-0014,FDA-2017-P-2233,attachment 12 -  epa health services industry detailed study -- dental amalgam (2008) re citizen petition from consumers for dental choice,0,0
0900006482548ae7,Supporting & Related Material,FDA-2017-P-2233-0035,FDA-2017-P-2233,"attachment 33 -  opdam, longevity of repaired restorations (copy) re citizen petition from consumers for dental choice",0,0
090000648254b122,Supporting & Related Material,FDA-2017-P-2233-0051,FDA-2017-P-2233,attachment 49 - minamata convention (2013) re citizen petition from consumers for dental choice,0,0
0900006484973ddc,Other,FDA-2020-P-1878-0004,FDA-2020-P-1878,withdrawal from foley & lardner llp,0,0
0900006484864d65,Other,FDA-2020-P-1878-0001,FDA-2020-P-1878,"citizen petition from foley & lardner, llp",0,0
0900006484864d66,Other,FDA-2020-P-1878-0002,FDA-2020-P-1878,acknowledgment letter from fda dms to foley & lardner llp,0,0
0900006484864d69,Supporting & Related Material,FDA-2020-P-1878-0003,FDA-2020-P-1878,"attachment a re citizens petition from foley & lardner, llp",0,0
0900006483269f66,Other,FDA-2018-P-1892-0002,FDA-2018-P-1892,"acknowledgment letter from fda ddm to aurobindo pharma usa, inc",0,0
090000648423c423,Other,FDA-2018-P-1892-0004,FDA-2018-P-1892,"petition response letter from fda cder to aurobindo pharma usa, inc",0,0
0900006483269f61,Other,FDA-2018-P-1892-0001,FDA-2018-P-1892,"citizen petiton from aurobindo pharma usa, inc",0,0
0900006483a0d2f4,Other,FDA-2018-P-1892-0003,FDA-2018-P-1892,"interim response  from fda cder to  aurobindo pharma usa, inc",0,0
0900006484aeb26a,Other,FDA-2020-P-2060-0003,FDA-2020-P-2060,interim response from fda cdrh to penn avenue law & policy,0,0
09000064848ecb69,Other,FDA-2020-P-2060-0001,FDA-2020-P-2060,citizen petition from penn avenue law & policy,0,0
09000064848ed38f,Other,FDA-2020-P-2060-0002,FDA-2020-P-2060,acknowledgment letter from fda dms to penn avenue law & policy,0,0
0900006480487234,Notice,FDA-2003-D-0151-0001,FDA-2003-D-0151,fda,0,0
090000648043f2ff,Notice,FDA-2005-D-0071-0001,FDA-2005-D-0071,fda,0,0
090000648043f301,Supporting & Related Material,FDA-2005-D-0071-0003,FDA-2005-D-0071,guideline,0,0
090000648043f300,Supporting & Related Material,FDA-2005-D-0071-0002,FDA-2005-D-0071,guideline,0,0
090000648149dd68,Other,FDA-2008-P-0486-0004,FDA-2008-P-0486,fda/cder memorandum to file withdrawal of citizens petition,0,0
09000064808ea89b,Other,FDA-2008-P-0486-0003,FDA-2008-P-0486,fda/cder interim response to norman lefkovitz - letter,0,0
09000064806f0fcb,Other,FDA-2008-P-0486-0002,FDA-2008-P-0486,"acknowledgement letter to norman w. lefkovitz, m.d.",0,0
09000064806f0f80,Other,FDA-2008-P-0486-0001,FDA-2008-P-0486,"norman w. lefkovitz, m.d. - citizen petition",0,0
0900006480ae71e4,Notice,FDA-2009-N-0486-0003,FDA-2009-N-0486,"agency information collection activities; proposals, submissions, and approvals: fiscal year 2010 medical device user fee small business qualification and certification",0,0
0900006480a49ad9,Notice,FDA-2009-N-0486-0001,FDA-2009-N-0486,"agency information collection activities; proposals, submissions, and approvals",0,0
0900006480a7f62f,Notice,FDA-2009-N-0486-0002,FDA-2009-N-0486,"agency information collection activities; submission for office of management and budget review; comment request; guidance for industry, fda, and foreign governments: fiscal year 2010 medical device user fee small business qualification and certification",0,0
0900006483abc6f2,Other,FDA-2018-P-3413-0003,FDA-2018-P-3413,letter from fda cder to pharmaceutical r & d and qa consulting services,0,0
0900006484dc3c57,Other,FDA-2018-P-3413-0004,FDA-2018-P-3413,withdrawal letter from pharmaceutical r & d and qa consulting services to fda cder,0,0
09000064836cacf8,Other,FDA-2018-P-3413-0001,FDA-2018-P-3413,citizen petition from pharmaceutical r&d and qa consulting services on behalf of centaur pharmaceuticals private limited,0,0
09000064836cacfa,Other,FDA-2018-P-3413-0002,FDA-2018-P-3413,acknowledgment letter from fda ddm to pharmaceutical r&d and qa consulting services on behalf of centaur pharmaceuticals private limited,0,0
0900006484aa000d,Other,FDA-2021-P-0358-0001,FDA-2021-P-0358,citizen petition from nexus pharmaceuticals inc.,0,0
0900006484aa0182,Other,FDA-2021-P-0358-0002,FDA-2021-P-0358,acknowledgment letter from fda dms to nexus pharmaceuticals inc.,0,0
0900006484dba3bc,Other,FDA-2021-P-0358-0005,FDA-2021-P-0358,"interim response letter from fda cder to nexus pharmaceuticals, inc.",0,0
09000064825310b3,Other,FDA-2016-P-3082-0014,FDA-2016-P-3082,interim response letter from fda cder to  ropes & gray llp (pfizer inc.),0,0
090000648228e03d,Other,FDA-2016-P-3082-0002,FDA-2016-P-3082,acknowledgment letter from fda ddm to  ropes & gray llp (pfizer inc.),0,0
0900006482535a32,Supporting & Related Material,FDA-2016-P-3082-0017,FDA-2016-P-3082,exhibit 2 to supplement to cp from ropes & gray llp (pfizer inc.) to fda cder,0,0
0900006482535a37,Supporting & Related Material,FDA-2016-P-3082-0022,FDA-2016-P-3082,exhibit 7 to supplement to cp from ropes & gray llp (pfizer inc.) to fda cder,0,0
090000648228e78c,Supporting & Related Material,FDA-2016-P-3082-0004,FDA-2016-P-3082,exhibit 2 citizen petition re citizen petition from ropes & gray llp (pfizer inc.),0,0
090000648228e78d,Supporting & Related Material,FDA-2016-P-3082-0005,FDA-2016-P-3082,exhibit 3 citizen petition re citizen petition from ropes & gray llp (pfizer inc.),0,0
0900006482286d0e,Other,FDA-2016-P-3082-0001,FDA-2016-P-3082,citizen petition from ropes & gray llp (pfizer inc.),0,0
09000064826b9ca8,Other,FDA-2016-P-3082-0026,FDA-2016-P-3082,petition approval from fda cder  to ropes & gray llp,0,0
090000648228e78b,Supporting & Related Material,FDA-2016-P-3082-0003,FDA-2016-P-3082,exhibit 1 citizen petition re citizen petition from ropes & gray llp (pfizer inc.),0,0
0900006482531b64,Other,FDA-2016-P-3082-0025,FDA-2016-P-3082,supplement from pfizer inc. (ropes & gray llp),0,0
090000648228e9fd,Supporting & Related Material,FDA-2016-P-3082-0009,FDA-2016-P-3082,"exhibit 7 complaint for declaratory, injunctive, and other relief re citizen petition from ropes & gray llp (pfizer inc.)",0,0
090000648228e9fe,Supporting & Related Material,FDA-2016-P-3082-0010,FDA-2016-P-3082,exhibit 8 memorandum opinion re citizen petition from ropes & gray llp (pfizer inc.),0,0
090000648228e9ff,Supporting & Related Material,FDA-2016-P-3082-0011,FDA-2016-P-3082,exhibit 9 combined response to two petitions re citizen petition from ropes & gray llp (pfizer inc.),0,0
090000648228ea01,Supporting & Related Material,FDA-2016-P-3082-0013,FDA-2016-P-3082,"exhibit 11 memorandum of points and authorities in support of
plaintiff’s motion for reconsideration re citizen petition from ropes & gray llp (pfizer inc.)",0,0
0900006482535b47,Other,FDA-2016-P-3082-0015,FDA-2016-P-3082,supplement to cp from ropes & gray llp (pfizer inc.) to fda cder,0,0
090000648228e9fa,Supporting & Related Material,FDA-2016-P-3082-0006,FDA-2016-P-3082,exhibit 4 combined response  to three citizen petitions re citizen petition from ropes & gray llp (pfizer inc.),0,0
090000648228e9fc,Supporting & Related Material,FDA-2016-P-3082-0008,FDA-2016-P-3082,exhibit 6 response to the citizen petition re citizen petition from ropes & gray llp (pfizer inc.),0,0
090000648228e9fb,Supporting & Related Material,FDA-2016-P-3082-0007,FDA-2016-P-3082,exhibit 5 citizen petition re citizen petition from ropes & gray llp (pfizer inc.),0,0
090000648228ea00,Supporting & Related Material,FDA-2016-P-3082-0012,FDA-2016-P-3082,exhibit 10 memorandum opinion re citizen petition from ropes & gray llp (pfizer inc.),0,0
0900006482535a33,Supporting & Related Material,FDA-2016-P-3082-0018,FDA-2016-P-3082,exhibit 3 to supplement to cp from ropes & gray llp (pfizer inc.) to fda cder,0,0
090000648253590a,Supporting & Related Material,FDA-2016-P-3082-0016,FDA-2016-P-3082,exhibit 1 to supplement to cp from ropes & gray llp (pfizer inc.) to fda cder,0,0
0900006482535a36,Supporting & Related Material,FDA-2016-P-3082-0021,FDA-2016-P-3082,exhibit 6 to supplement to cp from ropes & gray llp (pfizer inc.) to fda cder,0,0
0900006482535a38,Supporting & Related Material,FDA-2016-P-3082-0023,FDA-2016-P-3082,exhibit 8 to supplement to cp from ropes & gray llp (pfizer inc.) to fda cder,0,0
0900006482535a34,Supporting & Related Material,FDA-2016-P-3082-0019,FDA-2016-P-3082,exhibit 4 to supplement to cp from ropes & gray llp (pfizer inc.) to fda cder,0,0
0900006482535a35,Supporting & Related Material,FDA-2016-P-3082-0020,FDA-2016-P-3082,exhibit 5 to supplement to cp from ropes & gray llp (pfizer inc.) to fda cder,0,0
09000064836b2051,Supporting & Related Material,FDA-2017-P-6029-0027,FDA-2017-P-6029,novonordisk_citizenpetition_05september2018_references_part_3_of_6-1re: citizen petition from novo nordisk inc,0,0
09000064836b2052,Supporting & Related Material,FDA-2017-P-6029-0028,FDA-2017-P-6029,novonordisk_citizenpetition_05september2018_references_part_4_of_6 re: citizen petition from novo nordisk inc,0,0
0900006482b9d399,Supporting & Related Material,FDA-2017-P-6029-0003,FDA-2017-P-6029,references list re citizen petition from novo nordisk inc,0,0
0900006482b9d39a,Supporting & Related Material,FDA-2017-P-6029-0004,FDA-2017-P-6029,reference 1 challenges in industrial prodcution re citizen petition from novo nordisk inc,0,0
0900006482b9d39d,Supporting & Related Material,FDA-2017-P-6029-0007,FDA-2017-P-6029,reference 4 strategies for the assessment of protein aggregates re citizen petition from novo nordisk inc,0,0
0900006482b9d3aa,Supporting & Related Material,FDA-2017-P-6029-0013,FDA-2017-P-6029,reference 10 stability of protein pharmaceuticals manning 2010 re citizen petition from novo nordisk inc,0,0
0900006482b9d3ad,Supporting & Related Material,FDA-2017-P-6029-0016,FDA-2017-P-6029,reference 13 observations regarding the immunogenicity sauna 2012 re citizen petition from novo nordisk inc,0,0
09000064836b204f,Supporting & Related Material,FDA-2017-P-6029-0025,FDA-2017-P-6029,novonordisk_citizenpetition_05september2018_references_part_1_of_6 re: citizen petition from novo nordisk inc,0,0
09000064836b2053,Supporting & Related Material,FDA-2017-P-6029-0029,FDA-2017-P-6029,novonordisk_citizenpetition_05september2018_references_part_5_of_6-1 re: citizen petition from novo nordisk inc,0,0
09000064836b2054,Supporting & Related Material,FDA-2017-P-6029-0030,FDA-2017-P-6029,novonordisk_citizenpetition_05september2018_references_part_6_of_6 re: citizen petition from novo nordisk inc,0,0
0900006482b9d39e,Supporting & Related Material,FDA-2017-P-6029-0008,FDA-2017-P-6029,reference 5 european medicines agency 2009 re citizen petition from novo nordisk inc,0,0
0900006482d9e58c,Other,FDA-2017-P-6029-0022,FDA-2017-P-6029,"response letter from fda cder to novo nordisk, inc",0,0
09000064836b1f49,Other,FDA-2017-P-6029-0024,FDA-2017-P-6029,acknowledgment  letter from fda ddm to novo nordisk inc,0,0
0900006482b9d3a7,Supporting & Related Material,FDA-2017-P-6029-0010,FDA-2017-P-6029,reference 7 fda_regulatory considerations for peptide drug products ppt re citizen petition from novo nordisk inc,0,0
0900006482b9d39b,Supporting & Related Material,FDA-2017-P-6029-0005,FDA-2017-P-6029,reference 2 protein aggregation and bioprocessing cromwell 2005 re citizen petition from novo nordisk inc,0,0
0900006482b9d39c,Supporting & Related Material,FDA-2017-P-6029-0006,FDA-2017-P-6029,reference 3 pharmacokinetics re citizen petition from novo nordisk inc,0,0
0900006482b9d3ac,Supporting & Related Material,FDA-2017-P-6029-0015,FDA-2017-P-6029,reference 12 quantitative predictions nielsen 2008 re citizen petition from novo nordisk inc,0,0
0900006482b9d3b0,Supporting & Related Material,FDA-2017-P-6029-0019,FDA-2017-P-6029,reference 16 the molecular basis steensgaard 2008 re citizen petition from novo nordisk inc,0,0
0900006482b9d6e2,Supporting & Related Material,FDA-2017-P-6029-0021,FDA-2017-P-6029,reference 18 the opposite effects of cu zhou 2012 re citizen petition from novo nordisk inc,0,0
09000064836b2050,Supporting & Related Material,FDA-2017-P-6029-0026,FDA-2017-P-6029,novonordisk_citizenpetition_05september2018_references_part_2_of_6-1re: citizen petition from novo nordisk inc,0,0
09000064836b19b7,Other,FDA-2017-P-6029-0023,FDA-2017-P-6029,citizen petition from novo nordisk inc.,0,0
0900006482b9d39f,Supporting & Related Material,FDA-2017-P-6029-0009,FDA-2017-P-6029,reference 6 fda_ salmon calcitonin cp response re citizen petition from novo nordisk inc,0,0
0900006482b9d3a8,Supporting & Related Material,FDA-2017-P-6029-0011,FDA-2017-P-6029,reference 8 characterization of seed nuclei hoppe 2008 re citizen petition from novo nordisk inc,0,0
0900006482b9d3af,Supporting & Related Material,FDA-2017-P-6029-0018,FDA-2017-P-6029,reference 15 statement by janet woodcock 2007 re citizen petition from novo nordisk inc,0,0
0900006482b9d6e1,Supporting & Related Material,FDA-2017-P-6029-0020,FDA-2017-P-6029,reference 17 the fdas assessment woodcock 2007 re citizen petition from novo nordisk inc,0,0
0900006483c1c9ef,Other,FDA-2019-P-2070-0001,FDA-2019-P-2070,"citizen petition from techreg services, inc.",0,0
0900006483c1cae2,Other,FDA-2019-P-2070-0002,FDA-2019-P-2070,"acknowledgment letter from fda ddm to techreg services, inc.",0,0
09000064819c8794,Other,FDA-2014-P-1694-0004,FDA-2014-P-1694,suitability petition denial response letter from fda cvm to parnell corporate services us inc,0,0
09000064818f8811,Other,FDA-2014-P-1694-0001,FDA-2014-P-1694,suitability citizen petition from parnell corporate services us inc,0,0
09000064818f8db0,Other,FDA-2014-P-1694-0002,FDA-2014-P-1694,acknowledgement letter form fda ddm  to parnell corporate services us inc,0,0
09000064818f8db2,Supporting & Related Material,FDA-2014-P-1694-0003,FDA-2014-P-1694,appendix 1,0,0
0900006481a4e50a,Other,FDA-2015-P-0840-0002,FDA-2015-P-0840,acknowledgment letter from fda ddm to dr. richard sherman,0,0
0900006481a4e50e,Supporting & Related Material,FDA-2015-P-0840-0005,FDA-2015-P-0840,"attachment 3  table of phosphate content of selected prescription medications, citizen petition from dr. richard sherman",0,0
0900006481a4e50c,Supporting & Related Material,FDA-2015-P-0840-0003,FDA-2015-P-0840,"attachement 1 ki dearth of data, citizen petition from dr. richard sherman",0,0
0900006481a4e50d,Supporting & Related Material,FDA-2015-P-0840-0004,FDA-2015-P-0840,"attachment 2 phosphorus content in prescrip medications new considerations, citizen petition from dr. richard sherman",0,0
0900006481a4e508,Other,FDA-2015-P-0840-0001,FDA-2015-P-0840,citizen petition from dr. richard sherman,0,0
0900006481c6d887,Other,FDA-2015-P-0840-0023,FDA-2015-P-0840,interim response letter from fda cder to dr. richard sherman,0,0
0900006483618f6b,Other,FDA-2015-P-1201-0014,FDA-2015-P-1201,report from tate & lyle,0,0
0900006481aa26d0,Other,FDA-2015-P-1201-0001,FDA-2015-P-1201,citizen petition from tate & lyle,0,0
0900006481aa22eb,Supporting & Related Material,FDA-2015-P-1201-0003,FDA-2015-P-1201,"appendix a - metabolism study, metabolism studysnopsis report re citizen petition from tate & lyle",0,0
0900006481aa239c,Supporting & Related Material,FDA-2015-P-1201-0005,FDA-2015-P-1201,"appendix c - consumer and health professional research, qualitative consumer group researh, health professional quantitative study, consumer quantitative label test re citizen petition from tate & lyle",0,0
0900006481aa239b,Supporting & Related Material,FDA-2015-P-1201-0004,FDA-2015-P-1201,"appendix b - glycemic studies, glycemic response allulose study1, glycemic response allulose study 2 re citizen petition from tate & lyle",0,0
0900006481aa22e8,Other,FDA-2015-P-1201-0002,FDA-2015-P-1201,acknowledgement letter from fda ddm to tate & lyle,0,0
09000064836473ce,Other,FDA-2015-P-1201-0015,FDA-2015-P-1201,supplement from matsutani chemical industry co. ltd.,0,0
0900006481e997d7,Other,FDA-2015-P-1201-0011,FDA-2015-P-1201,interim response letter from fda cfsan to tate & lyle,0,0
0900006481aa239d,Supporting & Related Material,FDA-2015-P-1201-0006,FDA-2015-P-1201,"appendix d - previously granted labeling exemptions, 61 fed red 3126 (olestra), 61 fed red 42754 (orange roughty) re citizen petition from tate & lyle",0,0
0900006481a85a5a,Supporting & Related Material,FDA-2015-P-1050-0007,FDA-2015-P-1050,"exhibit 5 2010 copax petition, citizen petition from teva pharmaceuticals",0,0
0900006481a85e3f,Supporting & Related Material,FDA-2015-P-1050-0011,FDA-2015-P-1050,"exhibit 7 2013 copax colloid citizen petition, citizen petition from teva pharmaceuticals",0,0
0900006481aa98bf,Other,FDA-2015-P-1050-0012,FDA-2015-P-1050,citizen petition denial letter from cder to teva pharmaceuticals,0,0
0900006481a85a54,Other,FDA-2015-P-1050-0002,FDA-2015-P-1050,acknowledgement letter from fda ddm to teva pharmaceuticals,0,0
0900006481a85a5b,Supporting & Related Material,FDA-2015-P-1050-0010,FDA-2015-P-1050,"exhibit 6 2012 copax petition, citizen petition from teva pharmaceuticals",0,0
0900006481a85a59,Supporting & Related Material,FDA-2015-P-1050-0006,FDA-2015-P-1050,"exhibit 4 2009 copax petition, citizen petition from teva pharmaceuticals",0,0
0900006481a85e40,Supporting & Related Material,FDA-2015-P-1050-0008,FDA-2015-P-1050,"exhibit 8 2013 copax petition, citizen petition from teva pharmaceuticals",0,0
0900006481a85e41,Supporting & Related Material,FDA-2015-P-1050-0009,FDA-2015-P-1050,"exhibit 9 2014 copax petition, citizen petition from teva pharmaceuticals",0,0
0900006481a85a58,Supporting & Related Material,FDA-2015-P-1050-0005,FDA-2015-P-1050,"exhibit 3 2008 petition, citizen petition from teva pharmaceuticals",0,0
0900006481a859af,Other,FDA-2015-P-1050-0001,FDA-2015-P-1050,citizen petition from teva pharmaceuticals,0,0
0900006481a85a56,Supporting & Related Material,FDA-2015-P-1050-0003,FDA-2015-P-1050,exhibit 1 fda june 9 letter citizen petition from teva pharmaceuticals,0,0
0900006481a85a57,Supporting & Related Material,FDA-2015-P-1050-0004,FDA-2015-P-1050,"exhibit 2 fda response to 2014 copax petition, citizen petition from teva pharmaceuticals",0,0
0900006481b3f4ed,Supporting & Related Material,FDA-2015-P-2141-0003,FDA-2015-P-2141,controlled correspondence 188990 re citizen petition from heritage pharma labs inc.,0,0
0900006481d8b2a1,Other,FDA-2015-P-2141-0004,FDA-2015-P-2141,"interim response letter from fda cder to heritage pharma labs, inc.",0,0
0900006481b2ba22,Other,FDA-2015-P-2141-0001,FDA-2015-P-2141,citizen petition from heritage pharma labs inc,0,0
0900006481b2c5a2,Other,FDA-2015-P-2141-0002,FDA-2015-P-2141,acknowledgement letter from fda ddm to heritage pharma labs inc,0,0
0900006481ecbef3,Other,FDA-2015-P-4945-0003,FDA-2015-P-4945,interim response letter from fda cdrh to mr. ryszard rokicki,0,0
0900006481dbe6dc,Other,FDA-2015-P-4945-0001,FDA-2015-P-4945,citizen petition from ryszard rokicki,0,0
0900006481dbe6dd,Other,FDA-2015-P-4945-0002,FDA-2015-P-4945,acknowledgement letter from fda ddm to ryszard rokicki,0,0
090000648327a722,Other,FDA-2015-P-4945-0008,FDA-2015-P-4945,letter from fda cdrh to mr. ryszard rokicki,0,0
09000064819de45f,Supporting & Related Material,FDA-2015-P-0233-0007,FDA-2015-P-0233,attachment 5 skin lightening and beauty in four asian cultures citizen petition from the madison company,0,0
09000064819de461,Supporting & Related Material,FDA-2015-P-0233-0009,FDA-2015-P-0233,attachment 7 wsj women embrace the no makeup look citizen petition from the madison company,0,0
0900006481b818b6,Other,FDA-2015-P-0233-0010,FDA-2015-P-0233,interim response letter from fda cder to the madison company,0,0
09000064819de459,Other,FDA-2015-P-0233-0001,FDA-2015-P-0233,citizen petition from the madison company,0,0
09000064819de45d,Supporting & Related Material,FDA-2015-P-0233-0005,FDA-2015-P-0233,attachment 3 galderma receives fda approval of mirvaso citizen petition from the madison company,0,0
09000064819de45b,Supporting & Related Material,FDA-2015-P-0233-0003,FDA-2015-P-0233,attachment 1 achieving an even skin tone citizen petition from the madison company,0,0
09000064819de460,Supporting & Related Material,FDA-2015-P-0233-0008,FDA-2015-P-0233,attachment 6 top five beauty trends in 2014 euromonitor citizen petition from the madison company,0,0
09000064819de45e,Supporting & Related Material,FDA-2015-P-0233-0006,FDA-2015-P-0233,"attachment 4 grammer k, fink b, matts p visible skin color distribution citizen petition from the madison company",0,0
09000064819de45c,Supporting & Related Material,FDA-2015-P-0233-0004,FDA-2015-P-0233,attachment 2 final tone 2 by p&g citizen petition from the madison company,0,0
09000064819ded84,Other,FDA-2015-P-0233-0002,FDA-2015-P-0233,acknowledgement letter from fda ddm to the madison company,0,0
0900006483908721,Other,FDA-2018-P-4549-0001,FDA-2018-P-4549,"citizen petition from unichem pharmaceuticals (usa), inc.",0,0
09000064845072cd,Other,FDA-2018-P-4549-0009,FDA-2018-P-4549,"response letter from fda cder to unichem pharmaceuticals, inc",0,0
0900006483cc25c8,Other,FDA-2018-P-4549-0007,FDA-2018-P-4549,interim response letter for fda-2018-p-4549,0,0
0900006483908a4e,Supporting & Related Material,FDA-2018-P-4549-0006,FDA-2018-P-4549,"exhibit 4 - ims data from january 2018 through september 2018 for terbinafine tablets, 250 mg re: citizen petition from unichem pharmaceuticals (usa), inc.",0,0
0900006483908a4c,Supporting & Related Material,FDA-2018-P-4549-0004,FDA-2018-P-4549,"exhibit-2  - current and resolved drug shortages and discontinuations reported to fda: reference for discontinuation oflamisil tablets, 250 mgre: citizen petition from unichem pharmaceuticals (usa), inc.",0,0
0900006483908a0e,Supporting & Related Material,FDA-2018-P-4549-0003,FDA-2018-P-4549,"exhibit-1 - screenshot of the electric orange book search results for lamisi!® tablets (rld/rs)  re: citizen petition from unichem pharmaceuticals (usa), inc.",0,0
090000648390e01b,Other,FDA-2018-P-4549-0002,FDA-2018-P-4549,"acknowledgment letter from fda ddm to unichem pharmaceuticals (usa), inc.",0,0
0900006483908a4d,Supporting & Related Material,FDA-2018-P-4549-0005,FDA-2018-P-4549,"exhibit-3 - screenshot of the electronic orange book search results for terbinafine tablets, 250 mg (aurobindo's anda) re: citizen petition from unichem pharmaceuticals (usa), inc.",0,0
09000064824df0f2,Other,FDA-2017-P-1226-0002,FDA-2017-P-1226,"acknowledgement letter from fda ddm to inrange systems, inc",0,0
09000064824df0f0,Other,FDA-2017-P-1226-0001,FDA-2017-P-1226,"citizen petition from inrange systems, inc",0,0
0900006482bc4d7a,Other,FDA-2017-P-1226-0004,FDA-2017-P-1226,denial response from fda cdrh to inrange systems inc,0,0
09000064824df0f4,Supporting & Related Material,FDA-2017-P-1226-0003,FDA-2017-P-1226,"exhibit a live product information re citizen petition from inrange systems, inc",0,0
0900006483269d4e,Other,FDA-2018-P-1891-0002,FDA-2018-P-1891,"acknowledgment letter from fda ddm to puracap pharmaceutical, llc",0,0
09000064832698fd,Other,FDA-2018-P-1891-0001,FDA-2018-P-1891,"citizen petition from puracap pharmaceutical, llc on behalf of epic pharma, llc",0,0
0900006483269d50,Supporting & Related Material,FDA-2018-P-1891-0003,FDA-2018-P-1891,"attachment 1 orange book re citizen petition from puracap pharmaceutical, llc on behalf of epic pharma, llc",0,0
0900006481ca49ca,Other,FDA-2015-P-3410-0002,FDA-2015-P-3410,acknowledgement letter from fda ddm to david cundiff,0,0
0900006481edaf6a,Other,FDA-2015-P-3410-0003,FDA-2015-P-3410,interim response from fda cder to david k. cundiff,0,0
0900006481c9e5fb,Other,FDA-2015-P-3410-0001,FDA-2015-P-3410,citizen petition from david k cundiff,0,0
090000648490b118,Other,FDA-2015-P-3410-0004,FDA-2015-P-3410,response letter from fda cder to dr. david k. cundiff,0,0
09000064844b98b3,Other,FDA-2012-P-0153-0004,FDA-2012-P-0153,citizen petition denial response letter from fda cdrh to intertek,0,0
0900006480fb6e80,Other,FDA-2012-P-0153-0002,FDA-2012-P-0153,acknowledgement letter to intertek,0,0
0900006480fb6333,Other,FDA-2012-P-0153-0001,FDA-2012-P-0153,intertek - citizen petition,0,0
090000648136f1dc,Other,FDA-2012-P-0153-0003,FDA-2012-P-0153,fda cdrh letter to lntertek third party program - interim response,0,0
090000648494c340,Other,FDA-2020-P-2166-0002,FDA-2020-P-2166,"acknowledgment letter from fda dms to emprise pharma, llc on behalf of new time pharmaceutical co ltd",0,0
090000648494d236,Supporting & Related Material,FDA-2020-P-2166-0005,FDA-2020-P-2166,"reference 3 pharmacokinetic properties of a new controlled-release formulation of carvedilol re suitability petition from emprise pharma llc, on behalf of new time pharmaceutical co, ltd",0,0
090000648494d237,Supporting & Related Material,FDA-2020-P-2166-0006,FDA-2020-P-2166,"reference 4 us patent 8101209b2 re suitability petition from emprise pharma llc, on behalf of new time pharmaceutical co, ltd",0,0
090000648494c33f,Other,FDA-2020-P-2166-0001,FDA-2020-P-2166,"suitability petition from emprise pharma llc, on behalf of new time pharmaceutical co, ltd",0,0
090000648494d234,Supporting & Related Material,FDA-2020-P-2166-0003,FDA-2020-P-2166,"reference 1 package insert for coreg re suitability petition from emprise pharma llc, on behalf of new time pharmaceutical co, ltd",0,0
090000648494d238,Supporting & Related Material,FDA-2020-P-2166-0007,FDA-2020-P-2166,"reference 5 us patent 8883207b2 re suitability petition from emprise pharma llc, on behalf of new time pharmaceutical co, ltd",0,0
090000648494d235,Supporting & Related Material,FDA-2020-P-2166-0004,FDA-2020-P-2166,"reference 2 package insert for coreg cr re suitability petition from emprise pharma llc, on behalf of new time pharmaceutical co, ltd",0,0
09000064846e1016,Other,FDA-2020-P-1540-0002,FDA-2020-P-1540,acknowledgment letter from fda dms to alliance for natural health usa,0,0
0900006484a692c0,Other,FDA-2020-P-1540-0003,FDA-2020-P-1540,interim response to alliance for natural health usa from fda cder,0,0
09000064846e0606,Other,FDA-2020-P-1540-0001,FDA-2020-P-1540,citizen petition from alliance for natural health usa,0,0
0900006484a69721,Other,FDA-2020-P-1540-0004,FDA-2020-P-1540,supplement from alliance for natural health usa,0,0
0900006484979278,Other,FDA-2020-P-2236-0002,FDA-2020-P-2236,acknowledgment letter from fda dms to covington & burling llp on behalf of pharmaceutical research and manufacturers of america,0,0
0900006484b2edd0,Other,FDA-2020-P-2236-0003,FDA-2020-P-2236,response letter from fda cder to covington & burling llp,0,0
0900006484979277,Other,FDA-2020-P-2236-0001,FDA-2020-P-2236,"citizen petition from covington & burling, llp on behalf of pharmaceutical research and manufacturers of america",0,0
0900006484552b1d,Supporting & Related Material,FDA-2020-P-1334-0026,FDA-2020-P-1334,"exhibit 8 re citizen petition from therapeutics md, inc.",0,0
0900006484552b2f,Supporting & Related Material,FDA-2020-P-1334-0013,FDA-2020-P-1334,"exhibit 21 re citizen petition from therapeutics md, inc.",0,0
0900006484552a16,Other,FDA-2020-P-1334-0002,FDA-2020-P-1334,"acknowledgment letter from fda dms to therapeutics md, inc.",0,0
0900006484552b2c,Supporting & Related Material,FDA-2020-P-1334-0015,FDA-2020-P-1334,"exhibit 19 re citizen petition from therapeutics md, inc.",0,0
09000064845532d9,Supporting & Related Material,FDA-2020-P-1334-0032,FDA-2020-P-1334,"exhibit 2 re citizen petition from therapeutics md, inc.",0,0
0900006484552b1f,Supporting & Related Material,FDA-2020-P-1334-0024,FDA-2020-P-1334,"exhibit 10 re citizen petition from therapeutics md, inc.",0,0
0900006484552b23,Supporting & Related Material,FDA-2020-P-1334-0020,FDA-2020-P-1334,"exhibit 14 re citizen petition from therapeutics md, inc.",0,0
09000064845533ca,Supporting & Related Material,FDA-2020-P-1334-0027,FDA-2020-P-1334,"exhibit 7 re citizen petition from therapeutics md, inc.",0,0
0900006484552b22,Supporting & Related Material,FDA-2020-P-1334-0021,FDA-2020-P-1334,"exhibit 13 re citizen petition from therapeutics md, inc.",0,0
0900006484552b30,Supporting & Related Material,FDA-2020-P-1334-0012,FDA-2020-P-1334,"exhibit 22 re citizen petition from therapeutics md, inc.",0,0
090000648492ed1d,Other,FDA-2020-P-1334-0034,FDA-2020-P-1334,"interim response from fda cder to therapeuticsmd, inc.",0,0
09000064845514d5,Other,FDA-2020-P-1334-0001,FDA-2020-P-1334,"citizen petition from therapeutics md, inc.",0,0
0900006484552b26,Supporting & Related Material,FDA-2020-P-1334-0017,FDA-2020-P-1334,"exhibit 17 re citizen petition from therapeutics md, inc.",0,0
0900006484553609,Supporting & Related Material,FDA-2020-P-1334-0004,FDA-2020-P-1334,"exhibit 30 re citizen petition from therapeutics md, inc.",0,0
0900006484552b21,Supporting & Related Material,FDA-2020-P-1334-0022,FDA-2020-P-1334,"exhibit 12 re citizen petition from therapeutics md, inc.",0,0
0900006484552b32,Supporting & Related Material,FDA-2020-P-1334-0010,FDA-2020-P-1334,"exhibit 24 re citizen petition from therapeutics md, inc.",0,0
09000064845532da,Supporting & Related Material,FDA-2020-P-1334-0031,FDA-2020-P-1334,"exhibit 3 re citizen petition from therapeutics md, inc.",0,0
0900006484552b31,Supporting & Related Material,FDA-2020-P-1334-0011,FDA-2020-P-1334,"exhibit 23 re citizen petition from therapeutics md, inc.",0,0
09000064845533c9,Supporting & Related Material,FDA-2020-P-1334-0028,FDA-2020-P-1334,"exhibit 6 re citizen petition from therapeutics md, inc.",0,0
0900006484552b2d,Supporting & Related Material,FDA-2020-P-1334-0014,FDA-2020-P-1334,"exhibit 20 re citizen petition from therapeutics md, inc.",0,0
09000064845532db,Supporting & Related Material,FDA-2020-P-1334-0030,FDA-2020-P-1334,"exhibit 4 re citizen petition from therapeutics md, inc.",0,0
0900006484552b20,Supporting & Related Material,FDA-2020-P-1334-0023,FDA-2020-P-1334,"exhibit 11 re citizen petition from therapeutics md, inc.",0,0
0900006484553606,Supporting & Related Material,FDA-2020-P-1334-0007,FDA-2020-P-1334,"exhibit 27 re citizen petition from therapeutics md, inc.",0,0
090000648455360a,Supporting & Related Material,FDA-2020-P-1334-0003,FDA-2020-P-1334,"exhibit 31 re citizen petition from therapeutics md, inc.",0,0
0900006484552b2b,Supporting & Related Material,FDA-2020-P-1334-0016,FDA-2020-P-1334,"exhibit 18 re citizen petition from therapeutics md, inc.",0,0
0900006484b3987c,Other,FDA-2021-P-0514-0002,FDA-2021-P-0514,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
0900006484b394c9,Supporting & Related Material,FDA-2021-P-0514-0005,FDA-2021-P-0514,"attachment 3 naloxone nasal spray pi re suitability petition from hyman, phelps & mcnamara p.c.",0,0
0900006484b39cf8,Supporting & Related Material,FDA-2021-P-0514-0004,FDA-2021-P-0514,"attachment 2 - narcan pi re suitability petition from hyman, phelps & mcnamara p.c.",0,0
0900006484b39879,Other,FDA-2021-P-0514-0001,FDA-2021-P-0514,"suitability petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484b39cf7,Supporting & Related Material,FDA-2021-P-0514-0003,FDA-2021-P-0514,"attachment 1 - narcan re suitability petition from hyman, phelps & mcnamara p.c.",0,0
090000648046e86f,Supporting & Related Material,FDA-2004-D-0046-0003,FDA-2004-D-0046,guideline,0,0
090000648046e86c,Notice,FDA-2004-D-0046-0001,FDA-2004-D-0046,fda,0,0
090000648046e86e,Supporting & Related Material,FDA-2004-D-0046-0002,FDA-2004-D-0046,guideline,0,0
090000648046e870,Supporting & Related Material,FDA-2004-D-0046-0004,FDA-2004-D-0046,guideline,0,0
09000064809cc394,Notice,FDA-2008-N-0572-0003,FDA-2008-N-0572,"agency information collection activities; proposals, submissions, and approvals",0,0
090000648078cbb7,Notice,FDA-2008-N-0572-0001,FDA-2008-N-0572,agency emergency processing under office of management and budget review; implementation of the animal generic drug user fee act of 2008; user fee cover sheet form fda 3728,0,0
0900006480905028,Notice,FDA-2008-N-0572-0002,FDA-2008-N-0572,"agency information collection activities; proposals, submissions, and approvals",0,0
0900006480a4f381,Notice,FDA-2009-N-0360-0002,FDA-2009-N-0360,"agency information collection activities; submission for office of management and budget review; comment request; food and drug administration public health notification readership survey (formerly known as ""safety alert/public health advisory readership survey"")",1,0
0900006480a10ad9,Notice,FDA-2009-N-0360-0001,FDA-2009-N-0360,"agency information collection activities; proposals, submissions, and approvals",0,0
09000064815562f6,Notice,FDA-2009-N-0360-0004,FDA-2009-N-0360,agency information collection activities; proposed collection; comment request; food and drug administration safety communication readership survey,1,0
09000064817ed6b9,Notice,FDA-2009-N-0360-0006,FDA-2009-N-0360,"agency information collection activities; announcement of office of
management and budget approval; fda safety communication
readership survey",0,0
09000064843f99ec,Notice,FDA-2009-N-0360-0010,FDA-2009-N-0360,agency information collection activities; proposed collection; comment request; food and drug administration safety communication readership survey,1,0
09000064844aba16,Notice,FDA-2009-N-0360-0011,FDA-2009-N-0360,"agency information collection activities; proposed collection;
comment request; food and drug administration safety communication readership survey; withdrawal of notice",1,0
0900006482c4b29a,Notice,FDA-2009-N-0360-0009,FDA-2009-N-0360,"agency information collection activities; announcement of office of
management and budget approvals",0,0
09000064816ff439,Notice,FDA-2009-N-0360-0005,FDA-2009-N-0360,"agency information collection activities; submission for office of
management and budget review; comment request; food and drug
administration safety communication readership survey",1,0
09000064825087c3,Notice,FDA-2009-N-0360-0007,FDA-2009-N-0360,agency information collection activities; proposed collection; comment request; food and drug administration safety communication readership survey,1,0
09000064827dddb3,Notice,FDA-2009-N-0360-0008,FDA-2009-N-0360,"agency information collection activities; submission for office of
management and budget review; comment request; food and drug
administration safety communication readership survey",1,0
0900006480bb7067,Notice,FDA-2009-N-0360-0003,FDA-2009-N-0360,"agency information collection activities; proposals, submissions, and approvals: public health notification readership survey",0,0
0900006480f89b62,Other,FDA-2010-P-0360-0007,FDA-2010-P-0360,"hyman, phelps & mcnamara, p.c. - amendment",0,0
0900006480b13bcc,Supporting & Related Material,FDA-2010-P-0360-0003,FDA-2010-P-0360,"attachment 2 - ""novartis gleevec™(imatinib mesylate) capsules"" - [hyman, phelps & mcnamara, p.c. - citizen petition]",0,0
0900006480b13bcb,Supporting & Related Material,FDA-2010-P-0360-0002,FDA-2010-P-0360,"attachment 1 - ""orange book: approved drug products with therapeutic equivalence evaluations"" - [hyman, phelps & mcnamara, p.c. - citizen petition]",0,0
0900006480b13c49,Other,FDA-2010-P-0360-0006,FDA-2010-P-0360,"acknowledgement letter hyman phelps & mcnamara, p.c",0,0
0900006480b13c3a,Supporting & Related Material,FDA-2010-P-0360-0004,FDA-2010-P-0360,"attachment 3 - ""highlights of prescribing information, gleevec"" - [hyman, phelps & mcnamara, p.c. - citizen petition]",0,0
090000648152aa68,Other,FDA-2010-P-0360-0009,FDA-2010-P-0360,"citizen petition approval response from fda cder to hyman, phelps & mcnamara, p.c.",0,0
0900006480b13bca,Other,FDA-2010-P-0360-0001,FDA-2010-P-0360,"hyman, phelps & mcnamara, p.c. - citizen petition",0,0
09000064810bca90,Other,FDA-2010-P-0360-0008,FDA-2010-P-0360,"hyman, phelps & mcnamara, p.c. - amendment",0,0
0900006480b13c48,Supporting & Related Material,FDA-2010-P-0360-0005,FDA-2010-P-0360,"attachment 4 - ""highlights of prescribing information - [hyman, phelps & mcnamara, p.c. - citizen petition]",0,0
0900006480b1b535,Supporting & Related Material,FDA-2010-P-0383-0002,FDA-2010-P-0383,"exhibit a - ""fentanyl fda contact report regarding (product): fentanyl citrate tablets (fentora®0 - april 7, 2008"" - [cephalon, inc., (fish & richardson p.c) - citizen petition]",0,0
0900006480b1b5e6,Supporting & Related Material,FDA-2010-P-0383-0009,FDA-2010-P-0383,"exhibit 4 - ""watson laboratories, inc., process flow diagram of manufacturing process..."" - [cephalon, inc., (fish & richardson p.c) - citizen petition]",0,0
0900006480b1b617,Supporting & Related Material,FDA-2010-P-0383-0011,FDA-2010-P-0383,"exhibit 10 - ""volume c - in the united states district court in and for the district of delaware"" - [cephalon, inc., (fish & richardson p.c) - citizen petition]",0,0
0900006480b1b61e,Other,FDA-2010-P-0383-0013,FDA-2010-P-0383,"acknowledgement letter to cephalon, inc., (fish & richardson p.c)",0,0
0900006480b1b619,Other,FDA-2010-P-0383-0014,FDA-2010-P-0383,"fish & richardson, p.c., to the division of dockets management, re: replacement signature page for declaration appending citizen petition filing for fish & richardson p.c. on behalf of cephalon inc."" - [cephalon, inc., (fish & richardson p.c) - citizen petition] - letter",0,0
0900006480b1b5e5,Supporting & Related Material,FDA-2010-P-0383-0008,FDA-2010-P-0383,"exhibit 3 - ""volume b - in the united states district court in and for the district of delaware, civil action - [cephalon, inc., (fish & richardson p.c) - citizen petition]",0,0
0900006480bc9e85,Other,FDA-2010-P-0383-0017,FDA-2010-P-0383,"fda/cder to fish & richardson, p.c.  (cephalon, inc.) - petition denial",0,0
0900006480b1b61a,Other,FDA-2010-P-0383-0015,FDA-2010-P-0383,"fish & richardson, p.c., to the division of dockets management, re: redacted expert's declaration to append citizen petition filing for fish & richardson p.c. on behalf of cephalon inc."" - [cephalon, inc., (fish & richardson p.c) - citizen petition] - letter",0,0
0900006480b1b5e1,Supporting & Related Material,FDA-2010-P-0383-0004,FDA-2010-P-0383,"exhibit c - ""volume c - in the united states district court in and for the district of delaware, civil action""  - [cephalon, inc., (fish & richardson p.c) - citizen petition]",0,0
0900006480b1b5e3,Supporting & Related Material,FDA-2010-P-0383-0006,FDA-2010-P-0383,"exhibit 1 - ""pharmaceutical development; fentanyl citrate buccal tablets, anda 079075""(redacted) - [cephalon, inc., (fish & richardson p.c) - citizen petition]",0,0
0900006480b1b5e7,Supporting & Related Material,FDA-2010-P-0383-0010,FDA-2010-P-0383,"exhibit 5 - ""fentanyl fda contact report - 4/7/08"" - [cephalon, inc., (fish & richardson p.c) - citizen petition]",0,0
0900006480b1b534,Other,FDA-2010-P-0383-0001,FDA-2010-P-0383,"cephalon, inc., (fish & richardson p.c) - citizen petition",0,0
0900006480b67802,Other,FDA-2010-P-0383-0016,FDA-2010-P-0383,"cephalon, inc. (fish & richardson, p.c.) - supplement",0,0
0900006480b1b5e0,Supporting & Related Material,FDA-2010-P-0383-0003,FDA-2010-P-0383,"exhibit b - ""volume a - in the united states district court in and for the district of delaware, civil action""  - [cephalon, inc., (fish & richardson p.c) - citizen petition]",0,0
0900006480b1b5e2,Supporting & Related Material,FDA-2010-P-0383-0005,FDA-2010-P-0383,"delaration of lon j. mathias, redacted - [cephalon, inc., (fish & richardson p.c) - citizen petition]",0,0
0900006480b1b5e4,Supporting & Related Material,FDA-2010-P-0383-0007,FDA-2010-P-0383,"exhibit 2 -  ""description of manufacturing process and process controls; fentanyl citrate buccal tablets"" - [cephalon, inc., (fish & richardson p.c) - citizen petition]",0,0
0900006480b1b618,Supporting & Related Material,FDA-2010-P-0383-0012,FDA-2010-P-0383,"exhibit 11 - ""figure 546a-13, 2, 6, 8, and 10, fentanyl citrate, sodium starch glycolate, mannitol, potassium bicarbonate, magnesium stearate..."" - [cephalon, inc., (fish & richardson p.c) - citizen petition]",0,0
0900006483d53ee8,Other,FDA-2019-P-0538-0026,FDA-2019-P-0538,letter from fda cder to k&l gates llp,0,0
0900006483a3c01e,Supporting & Related Material,FDA-2019-P-0538-0010,FDA-2019-P-0538,"exhibit 008 - hr rep 98-857(ii) (excerpt) re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3b783,Supporting & Related Material,FDA-2019-P-0538-0006,FDA-2019-P-0538,"exhibit 005 - 130 cong rec 23,764-774re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3b888,Supporting & Related Material,FDA-2019-P-0538-0013,FDA-2019-P-0538,"exhibit 011 - lannett earnings call transcript - q1 2019 re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3b77f,Supporting & Related Material,FDA-2019-P-0538-0002,FDA-2019-P-0538,"exhibit 001 - lannett pr newswire re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3aff6,Other,FDA-2019-P-0538-0001,FDA-2019-P-0538,"citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3b886,Supporting & Related Material,FDA-2019-P-0538-0011,FDA-2019-P-0538,"exhibit 009 - 130 cong rec 24,970-979 re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3b784,Supporting & Related Material,FDA-2019-P-0538-0008,FDA-2019-P-0538,"exhibit 006 - 130 cong rec_ 15,846-853 re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3ba2b,Supporting & Related Material,FDA-2019-P-0538-0020,FDA-2019-P-0538,"exhibit 017 - fda response to ista citizen petition re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3b889,Supporting & Related Material,FDA-2019-P-0538-0015,FDA-2019-P-0538,"exhibit 012 - fda guidance for refuse to file  re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3ba2c,Supporting & Related Material,FDA-2019-P-0538-0021,FDA-2019-P-0538,"exhibit 018 - 54 fed_ reg_ 28,872 (july 10, 1989) re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3b167,Other,FDA-2019-P-0538-0023,FDA-2019-P-0538,"acknowledgment letter from fda ddm to k& l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3b780,Supporting & Related Material,FDA-2019-P-0538-0003,FDA-2019-P-0538,"exhibit 002 - lannett co inc re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3ba2d,Supporting & Related Material,FDA-2019-P-0538-0022,FDA-2019-P-0538,"exhibit 019 - 57 fed_ reg_ 17,950 (apr_ 28, 1992) re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3b887,Supporting & Related Material,FDA-2019-P-0538-0012,FDA-2019-P-0538,"exhibit 010 - 59 fed_ reg_ 50,338 (oct_ 3, 1994) re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3b911,Supporting & Related Material,FDA-2019-P-0538-0017,FDA-2019-P-0538,"exhibit 014 - 62 fed_ reg_ 43,535 (aug_ 14, 1997)re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3ba2a,Supporting & Related Material,FDA-2019-P-0538-0019,FDA-2019-P-0538,"exhibit 016 - ista pharmaceuticals citizen petition re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3b781,Supporting & Related Material,FDA-2019-P-0538-0004,FDA-2019-P-0538,"exhibit 003 - 129 cong rec 19,807-808, 19,844-845 re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3b912,Supporting & Related Material,FDA-2019-P-0538-0018,FDA-2019-P-0538,"exhibit 015 - 66 fed_ reg_ 36,794 (july 13, 2001) re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3b782,Supporting & Related Material,FDA-2019-P-0538-0005,FDA-2019-P-0538,"exhibit 004 - 130 cong rec 24,416-439, 458-465 re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3b88a,Supporting & Related Material,FDA-2019-P-0538-0016,FDA-2019-P-0538,"exhibit 013 - pdufa performance goals 2013-2017 re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006483a3c01d,Supporting & Related Material,FDA-2019-P-0538-0009,FDA-2019-P-0538,"exhibit 007 - h_r_ 3605 (1984) re: citizen petition from  k&l gates llp on behalf of genus lifesciences, inc.",0,0
0900006480f0f02a,Notice,FDA-2011-N-0556-0003,FDA-2011-N-0556,"center for devices and radiological health 510(k) clearance process; recommendations proposed in institute of medicine report: ""medical devices and the public's health, the fda 510(k) clearance process at 35 years,"" public meeting; correction",0,0
0900006480ed1e22,Notice,FDA-2011-N-0556-0001,FDA-2011-N-0556,"institute of medicine report; availability: medical devices and the public's health, the fda 510(k) clearance process at 35 years",0,0
0900006480edf586,Notice,FDA-2011-N-0556-0002,FDA-2011-N-0556,"center for devices and radiological health 510(k) clearance process; recommendations proposed in institute of medicine report: ‘‘medical devices and the public’s health, the fda 510(k) clearance process at 35 years;’’ public meeting",0,0
0900006481a3ade1,Supporting & Related Material,FDA-2015-P-0758-0006,FDA-2015-P-0758,"annexure 4 copy of fda federal register notice., citizen petition from orbicular pharmaceutical technologies",0,0
0900006481a3adde,Supporting & Related Material,FDA-2015-P-0758-0003,FDA-2015-P-0758,"annexure 1 copy of orange book current through september 2013, listing the subject formulation as rld., citizen petition from orbicular pharmaceutical technologies",0,0
0900006481a3addc,Other,FDA-2015-P-0758-0002,FDA-2015-P-0758,acknowledgement letter from fda ddm to orbicular pharmaceutical technologies pvt ltd,0,0
0900006481a3addf,Supporting & Related Material,FDA-2015-P-0758-0004,FDA-2015-P-0758,"annexure 2 copy of orange book current through october 03,2014 & drugs@fda listing of discontinued rld formulation, lumigan® 0.03%., citizen petition from orbicular pharmaceutical technologies",0,0
0900006481a3ade0,Supporting & Related Material,FDA-2015-P-0758-0005,FDA-2015-P-0758,"annexure 3 copy of orange book current through march 10, 2015 & drugs@fda listing of lupin's bimatoprost., citizen petition from orbicular pharmaceutical technologies",0,0
0900006481aed575,Other,FDA-2015-P-0758-0007,FDA-2015-P-0758,withdrawal from orbicular pharmaceutical technologies pvt ltd,0,0
0900006481a3adda,Other,FDA-2015-P-0758-0001,FDA-2015-P-0758,citizen petition from orbicular pharmaceutical technologies pvt ltd,0,0
0900006481d1d822,Other,FDA-2015-P-2120-0011,FDA-2015-P-2120,"citizen petition denial response from fda cder to klienfeld, kaplan and becker, llp (purdue pharma l.p.)",0,0
0900006481b2a436,Supporting & Related Material,FDA-2015-P-2120-0004,FDA-2015-P-2120,"exhibit 2 physicians desk reference, 53rd ed. 1999, label for oxycontin (“oxycontin 1999 label”) re citizen petition from kleinfeld kaplan & becker, llp (kkb)",0,0
0900006481b2a914,Supporting & Related Material,FDA-2015-P-2120-0009,FDA-2015-P-2120,"exhibit 9 comments of purdue phama l.p. docket no. fda-2011-n-0830. june 8, 2015 re citizen petition from kleinfeld kaplan & becker, llp (kkb)",0,0
0900006481b29e8b,Other,FDA-2015-P-2120-0002,FDA-2015-P-2120,"acknowledgement letter from fda ddm to kleinfeld kaplan & becker, llp (kkb)",0,0
0900006481b2a913,Supporting & Related Material,FDA-2015-P-2120-0008,FDA-2015-P-2120,"exhibit 8 physicians desk reference, 53rd ed. 1999, label for roxicodone ir 5 mg (“roxicodone ir 5mg 199 label”) re citizen petition from kleinfeld kaplan & becker, llp (kkb)",0,0
0900006481b2a435,Supporting & Related Material,FDA-2015-P-2120-0003,FDA-2015-P-2120,"exhibit 1 physicians desk reference, 53rd ed. 1999, label for percodan (“percodan 1999 label”) re citizen petition from kleinfeld kaplan & becker, llp (kkb)",0,0
0900006481b2a438,Supporting & Related Material,FDA-2015-P-2120-0005,FDA-2015-P-2120,"exhibit 4 medical officer review, integrated summary of efficacy, oxycodone controlled release, nda 20553, curtis wrights, m.d. and medical officer review, oxycontin study 0402b-cancer pain, curtis wright, m.d. re citizen petition from kleinfeld kaplan & becker, llp (kkb)",0,0
0900006481b2a43a,Supporting & Related Material,FDA-2015-P-2120-0007,FDA-2015-P-2120,"exhibit 6 nda review, nda 20-553, e.d. bashaw, pharmd, with excerpts from appendix to review re citizen petition from kleinfeld kaplan & becker, llp (kkb)",0,0
0900006481b29ce9,Other,FDA-2015-P-2120-0001,FDA-2015-P-2120,"citizen petition from kleinfeld kaplan & becker, llp (kkb)",0,0
0900006481b2a439,Supporting & Related Material,FDA-2015-P-2120-0006,FDA-2015-P-2120,"exhibit 5 exclusivity summary, nda 20553 re citizen petition from kleinfeld kaplan & becker, llp (kkb)",0,0
0900006481bc51d2,Other,FDA-2015-P-2854-0001,FDA-2015-P-2854,citizen petition from olsson frank weeda terman matz pc,0,0
0900006481c1ba07,Supporting & Related Material,FDA-2015-P-2854-0004,FDA-2015-P-2854,attachment 2: david wright affidavit redacted re citizen petition from olsson frank weeda terman matz pc,0,0
0900006481bc5dd7,Other,FDA-2015-P-2854-0002,FDA-2015-P-2854,acknowledgment letter from fda ddm to olsson frank weeda terman matz pc,0,0
0900006481c1b4ce,Supporting & Related Material,FDA-2015-P-2854-0003,FDA-2015-P-2854,attachment 1: andrew lewis affidavit redacted  re citizen petition from olsson frank weeda terman matz pc,0,0
0900006481e33dfe,Other,FDA-2015-P-2854-0006,FDA-2015-P-2854,supplement from provensis (olsson frank weeda terman matz pc),0,0
0900006483b2a104,Other,FDA-2019-D-1372-0004,FDA-2019-D-1372,elemental impurities in human drug products questions and answers proposed draft guidance for industry,0,0
0900006483b1bb56,Other,FDA-2019-D-1372-0003,FDA-2019-D-1372,acknowledgment letter from fda ddm to international pharmaceutical excipients council of the americas (ipec -america),0,0
0900006483b18d60,Other,FDA-2019-D-1372-0001,FDA-2019-D-1372,external guidance document submission from international pharmaceutical excipients council of the americas (ipec -america),0,0
09000064842512ce,Supporting & Related Material,FDA-2019-P-6044-0004,FDA-2019-P-6044,"exhibit 1 safety of epinephrine in higher doses re citizen petition from latham & watkins llp on behalf of par sterile products, llc",0,0
09000064844d3255,Other,FDA-2019-P-6044-0006,FDA-2019-P-6044,agency response letter from fda cder to latham and watkins llp,0,0
09000064842512a2,Other,FDA-2019-P-6044-0002,FDA-2019-P-6044,acknowledgment letter from fda dms to latham & watkins llp,0,0
0900006484252119,Other,FDA-2019-P-6044-0003,FDA-2019-P-6044,acknowledgment letter from fda dms to latham and watkins llp,0,0
090000648425101c,Other,FDA-2019-P-6044-0001,FDA-2019-P-6044,"citizen petition from latham & watkins llp on behalf of par sterile products, llc",0,0
0900006484425d0c,Supporting & Related Material,FDA-2020-P-1072-0003,FDA-2020-P-1072,"attachment 1 - orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from yiling pharmaceutical, ltd",0,0
0900006484721985,Notice,FDA-2020-P-1072-0004,FDA-2020-P-1072,"determination that zovirax (acyclovir) oral capsules, 200 milligrams, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006484721deb,Other,FDA-2020-P-1072-0005,FDA-2020-P-1072,response letter from fda cder to yiling pharmaceutical ltd,0,0
0900006484425d09,Other,FDA-2020-P-1072-0002,FDA-2020-P-1072,"acknowledgment letter from fda dms to yiling pharmaceutical, ltd",0,0
0900006484425d08,Other,FDA-2020-P-1072-0001,FDA-2020-P-1072,"citizen petition from yiling pharmaceutical, ltd",0,0
0900006484dc43ec,Other,FDA-2021-P-1108-0001,FDA-2021-P-1108,"citizen petition from xiromed, llc (xiromed) on behalf of xiromed pharma españa s.l.",0,0
0900006484dc43ff,Other,FDA-2021-P-1108-0002,FDA-2021-P-1108,"acknowledgment letter from fda dms to  xiromed, llc (xiromed) on behalf of xiromed pharma españa s.l.",0,0
0900006484dfb330,Other,FDA-2021-P-1108-0003,FDA-2021-P-1108,withdrawal from xiromed llc,0,0
0900006484e085be,Other,FDA-2021-P-1188-0002,FDA-2021-P-1188,acknowledgment letter from fda dms to arent fox llp,0,0
0900006484e08fd5,Other,FDA-2021-P-1188-0001,FDA-2021-P-1188,citizen petition from arent fox llp,0,0
0900006484e11243,Supporting & Related Material,FDA-2021-P-1188-0003,FDA-2021-P-1188,attachment 1 re: citizen petition from arent fox llp,0,0
0900006481ad2ba7,Other,FDA-2015-P-1590-0003,FDA-2015-P-1590,"acknowledgement letter from fda ddm to qilu pharmaceutical co., ltd.",0,0
0900006481ad2b15,Other,FDA-2015-P-1590-0001,FDA-2015-P-1590,"suitability petition from qilu pharmaceutical co., ltd.",0,0
0900006481ad2d86,Supporting & Related Material,FDA-2015-P-1590-0002,FDA-2015-P-1590,"attachment 2 proposed package labeling for carfilzomib re suitability petition from qilu pharmaceutical co., ltd.",0,0
09000064817221c0,Other,FDA-2014-P-0737-0001,FDA-2014-P-0737,citizen petition from pfizer inc (ropes and gray llp),0,0
09000064818b8f68,Other,FDA-2014-P-0737-0003,FDA-2014-P-0737,citizen petition denial response from fda cder to ropes & gray llp,0,0
0900006481723631,Other,FDA-2014-P-0737-0002,FDA-2014-P-0737,acknowledgement letter from fda ddm to pfizer (ropes and gray llp),0,0
0900006481983f9a,Other,FDA-2014-P-2243-0001,FDA-2014-P-2243,citizen petition request from apotex inc,0,0
0900006481b1e90b,Other,FDA-2014-P-2243-0004,FDA-2014-P-2243,citizen petition approval response from fda cder to apotex corp.,0,0
0900006481985adf,Other,FDA-2014-P-2243-0002,FDA-2014-P-2243,acknowledgement letter from fda ddm to apotex inc,0,0
0900006481985bcc,Supporting & Related Material,FDA-2014-P-2243-0003,FDA-2014-P-2243,attachment,0,0
0900006481ae5712,Supporting & Related Material,FDA-2015-P-1757-0002,FDA-2015-P-1757,"appendix a, 21 cfr part 111 cgmp regulations governing dietary supplements re citizen petition from the organic and natural health association",0,0
0900006481ae598b,Other,FDA-2015-P-1757-0001,FDA-2015-P-1757,citizen petition from the organic and natural health association,0,0
0900006481ae598e,Other,FDA-2015-P-1757-0003,FDA-2015-P-1757,acknowledgement letter from fda ddm to the organic and natural health association,0,0
0900006484115e4d,Other,FDA-2019-P-4832-0008,FDA-2019-P-4832,"withdrawal letter from arent fox llp on behalf of aquestive therapeutics, inc.",0,0
09000064840a813c,Other,FDA-2019-P-4832-0001,FDA-2019-P-4832,"citizen petition from arent fox llp on behalf of aquestive therapeutics, inc",0,0
09000064840a8228,Supporting & Related Material,FDA-2019-P-4832-0007,FDA-2019-P-4832,"exhibit 5- nasal drug delivery: new developments and strategies re: citizen petition from arent fox llp on behalf of aquestive therapeutics, inc",0,0
09000064840a8226,Supporting & Related Material,FDA-2019-P-4832-0005,FDA-2019-P-4832,"exhibit 3- pharmacokinetic study of valtoco™ (nrl-1; diazepam nasal spray) in patients with epilepsy under ictal and inter-ictal conditions – interim report re: citizen petition from arent fox llp on behalf of aquestive therapeutics, inc.",0,0
09000064840a8224,Supporting & Related Material,FDA-2019-P-4832-0003,FDA-2019-P-4832,"exhibit 1- a pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers re: citizen petition from arent fox llp on behalf of aquestive therapeutics, inc",0,0
09000064840a8225,Supporting & Related Material,FDA-2019-P-4832-0004,FDA-2019-P-4832,"exhibit 2- bioavailability and safety of valtoco™ (diazepam intranasal solution) compared to oral and rectal diazepam re: citizen petition from arent fox llp on behalf of aquestive therapeutics, inc",0,0
09000064840a8227,Supporting & Related Material,FDA-2019-P-4832-0006,FDA-2019-P-4832,"exhibit 4- buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability re: citizen petition from arent fox llp on behalf of aquestive therapeutics, inc",0,0
09000064840a82be,Other,FDA-2019-P-4832-0002,FDA-2019-P-4832,"acknowledgement letter from fda dms to arent fox llp on behalf of aquestive therapeutics, inc",0,0
0900006482b12601,Other,FDA-2017-P-5477-0002,FDA-2017-P-5477,"acknowledgement letter from fda ddm to hyman, phelps & mcnamara, pc",0,0
0900006482b125ff,Other,FDA-2017-P-5477-0001,FDA-2017-P-5477,"citizen petition from hyman, phelps & mcnamara on behalf of united therapeutics corporation",0,0
0900006482b1264c,Supporting & Related Material,FDA-2017-P-5477-0003,FDA-2017-P-5477,"tab 1 - iso 27427, anaesthetic and respiratory equipment - nebulizing systems and components (2010) re citizen petition from hyman, phelps & mcnamara on behalf of united therapeutics corporation",0,0
0900006482b12665,Supporting & Related Material,FDA-2017-P-5477-0013,FDA-2017-P-5477,"tab 11 - wallace p_ adams et al_, demonstrating bioequivalence of locally acting orally inhaled drug products, 23 j aerosol med pu re citizen petition from hyman, phelps & mcnamara on behalf of united therapeutics corporation",0,0
0900006482b1264e,Supporting & Related Material,FDA-2017-P-5477-0005,FDA-2017-P-5477,"tab 3 - andrew m_ wilson et al_, importance of drug-device interaction in determining systemic effects of inhaled corticosteroids re citizen petition from hyman, phelps & mcnamara on behalf of united therapeutics corporation",0,0
0900006482b12663,Supporting & Related Material,FDA-2017-P-5477-0011,FDA-2017-P-5477,"tab 9 - t_ gessler et al_, ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension, 17 eur respir j 14, 16 re citizen petition from hyman, phelps & mcnamara on behalf of united therapeutics corporation",0,0
0900006482b1264d,Supporting & Related Material,FDA-2017-P-5477-0004,FDA-2017-P-5477,"tab 2 - food and drug administration respiratory drug delivery devices  a cdrh perspective (nov. 2 2010) re citizen petition from hyman, phelps & mcnamara on behalf of united therapeutics corporation",1,0
0900006482b1264f,Supporting & Related Material,FDA-2017-P-5477-0006,FDA-2017-P-5477,"tab 4 - ah kendrick et al_, selecting and using nebucitizen petition from hyman, phelps & mcnamara on behalf of united therapeutics corporation citizen petition from hyman,",0,0
0900006482b12660,Supporting & Related Material,FDA-2017-P-5477-0008,FDA-2017-P-5477,"tab 6 - d_ todd loffert et al_, a comparison of commercial jet nebulizers, 106 chest 1788 (1994) re citizen petition from hyman, phelps & mcnamara on behalf of united therapeutics corporation",0,0
0900006482ec4def,Other,FDA-2017-P-5477-0014,FDA-2017-P-5477,petition denial letter from fda cder to hyman phelps mcnamara,0,0
0900006482b12650,Supporting & Related Material,FDA-2017-P-5477-0007,FDA-2017-P-5477,"tab 5 - dean hess et al_, medication nebulizer performance effects of diluent volume, nebulizer flow, and nebulizer brand, 110 che re citizen petition from hyman, phelps & mcnamara on behalf of united therapeutics corporation",0,0
0900006482b12661,Supporting & Related Material,FDA-2017-P-5477-0009,FDA-2017-P-5477,"tab 7 - jg hardy et al_, lung deposition from four nebulizers, 87 respir med 461 (1993) re citizen petition from hyman, phelps & mcnamara on behalf of united therapeutics corporation",0,0
0900006482b12662,Supporting & Related Material,FDA-2017-P-5477-0010,FDA-2017-P-5477,"tab 8 - christopher ocallaghan  peter w. barry the science of nebulised drug delivery 52 suppl 2 thorax s31 s36 (1997) re citizen petition from hyman, phelps & mcnamara on behalf of united therapeutics corporation",0,0
0900006482b12664,Supporting & Related Material,FDA-2017-P-5477-0012,FDA-2017-P-5477,"tab 10 - lawrence x_ yu, quality by design for orally inhaled drug products, pqri workshop on demonstrating bioequivalence of loca re citizen petition from hyman, phelps & mcnamara on behalf of united therapeutics corporation",0,0
090000648342cfb3,Supporting & Related Material,FDA-2018-P-2361-0003,FDA-2018-P-2361,attachment1-orange book - triamcinolone acetonide 0.1% re:  citizen petition from bf innovation inc. (on behalf of bright future pharmaceutical laboratories limited),0,0
090000648342cfb4,Supporting & Related Material,FDA-2018-P-2361-0004,FDA-2018-P-2361,attachment 2-fda drug shortages - triamcinolone mylan re: citizen petition from bf innovation inc. (on behalf of bright future pharmaceutical laboratories limited),0,0
090000648342c62f,Other,FDA-2018-P-2361-0001,FDA-2018-P-2361,citizen petition from bf innovation inc. (on behalf of bright future pharmaceutical laboratories limited),0,0
09000064849763d8,Other,FDA-2018-P-2361-0006,FDA-2018-P-2361,withdrawal from bright future pharmaceutical laboratories ltd,0,0
090000648342cf99,Other,FDA-2018-P-2361-0002,FDA-2018-P-2361,acknowledgment letter from fda ddm to bf innovation inc. (on behalf of bright future pharmaceutical laboratories limited),0,0
09000064839949a5,Other,FDA-2018-P-2361-0005,FDA-2018-P-2361,interim response letter from fda cder to bf innovation inc.,0,0
0900006484b33398,Notice,FDA-2020-P-2048-0005,FDA-2020-P-2048,"determination that manganese sulfate, injectable, equivalent 0.1 milligram manganese/milliliter, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006484b3435f,Other,FDA-2020-P-2048-0006,FDA-2020-P-2048,"response letter from fda cder to fresenius kabi usa, llc",0,0
0900006484a9a681,Other,FDA-2020-P-2048-0004,FDA-2020-P-2048,"interim response letter from fda cder to fresenius kabi usa, llc",0,0
09000064848d294b,Other,FDA-2020-P-2048-0002,FDA-2020-P-2048,"acknowledgement letter from fda dms to fresenius kabi usa, llc",0,0
09000064848d294a,Other,FDA-2020-P-2048-0001,FDA-2020-P-2048,"citizen petition from fresenius kabi usa, llc",0,0
09000064848d2798,Supporting & Related Material,FDA-2020-P-2048-0003,FDA-2020-P-2048,"attachment a – current orange book listing of manganese sulfate re citizen petition from fresenius kabi usa, llc",0,0
090000648484545b,Other,FDA-2020-P-1073-0004,FDA-2020-P-1073,"interim response letter from fda cder to david behar, m.d.",0,0
0900006484426ab6,Other,FDA-2020-P-1073-0002,FDA-2020-P-1073,"acknowledgment letter from fda dms to david behar, m.d.",0,0
090000648442667d,Other,FDA-2020-P-1073-0001,FDA-2020-P-1073,"citizen petition from david behar, m.d.",0,0
0900006484426b81,Supporting & Related Material,FDA-2020-P-1073-0003,FDA-2020-P-1073,"cover letter re: citizen petition from david behar, m.d.",0,0
0900006484c195e4,Other,FDA-2020-P-1073-0005,FDA-2020-P-1073,"final response to david behar, m.d. from fda cder",0,0
0900006480487161,Supporting & Related Material,FDA-2003-D-0150-0002,FDA-2003-D-0150,draft guidance,0,0
090000648048711a,Notice,FDA-2003-D-0150-0001,FDA-2003-D-0150,fda,0,0
0900006480445c6a,Notice,FDA-2005-N-0290-0004,FDA-2005-N-0290,fda,0,0
0900006480445c1c,Notice,FDA-2005-N-0290-0001,FDA-2005-N-0290,fda,0,0
0900006480445c64,Notice,FDA-2005-N-0290-0002,FDA-2005-N-0290,fda,0,0
0900006480445c68,Supporting & Related Material,FDA-2005-N-0290-0003,FDA-2005-N-0290,supporting statement,0,0
0900006480552947,Other,FDA-2008-P-0291-0002,FDA-2008-P-0291,acknowledgement letter to prn publishing,0,0
09000064805528d8,Other,FDA-2008-P-0291-0001,FDA-2008-P-0291,prn publishing - citizen petition,0,0
0900006480f92c11,Other,FDA-2008-P-0291-0004,FDA-2008-P-0291,fda/cder to prn publishing - petition denial,0,0
090000648079832c,Other,FDA-2008-P-0291-0003,FDA-2008-P-0291,fda/cder interim response to prn publishing - letter,0,0
0900006480a4222b,Notice,FDA-2009-N-0488-0001,FDA-2009-N-0488,"agency information collection activities; proposed collection; comment request; records and reports concerning experience with approved new animal drugs; adverse event reports on forms fda 1932, 1932a, and 2301",0,0
0900006480a7f553,Notice,FDA-2009-N-0488-0002,FDA-2009-N-0488,"agency information collection activities; submission for office of management and budget review; comment request; records and reports concerning experience with approved new animal drugs; adverse event reports on forms fda 1932, 1932a, and 2301",0,0
0900006482bc4873,Supporting & Related Material,FDA-2017-P-6136-0003,FDA-2017-P-6136,enclosure re citizen petition from foley & lardner llp,0,0
0900006482bc486f,Other,FDA-2017-P-6136-0001,FDA-2017-P-6136,citizen petition from foley & lardner llp,0,0
0900006482bc4871,Other,FDA-2017-P-6136-0002,FDA-2017-P-6136,acknowledgement letter from fda ddm to foley & lardner llp,0,0
09000064830e6d93,Other,FDA-2017-P-6136-0004,FDA-2017-P-6136,interim response from fda cder to foley & lardner llp,0,0
0900006483df6768,Other,FDA-2017-P-6136-0005,FDA-2017-P-6136,denial letter from fda  cder to foley & lardner llp,0,0
0900006483f9c1af,Supporting & Related Material,FDA-2019-P-4386-0003,FDA-2019-P-4386,"references for citizen petition for fresenius kabi usa, llc.",0,0
0900006483f9bcb3,Other,FDA-2019-P-4386-0002,FDA-2019-P-4386,"acknowledgment letter from fda dms to fresenius kabi usa, llc",0,0
0900006483f9bebf,Other,FDA-2019-P-4386-0001,FDA-2019-P-4386,"citizen petition from fresenius kabi usa, llc",0,0
0900006482098346,Other,FDA-2016-P-1963-0002,FDA-2016-P-1963,acknowledgment letter from fda to schafer veterinary consultants llc,0,0
090000648209b051,Supporting & Related Material,FDA-2016-P-1963-0003,FDA-2016-P-1963,attachment 1 pioneer product labeling,0,0
090000648209770d,Other,FDA-2016-P-1963-0001,FDA-2016-P-1963,citizen petition from smartvet holdings inc,0,0
0900006480bfd118,Supporting & Related Material,FDA-2011-P-0120-0007,FDA-2011-P-0120,"index for appendix c: references 118 - 150, volume 4 of 5 - [pronova biopharma norge as (pronova) - citizen petition]",0,0
0900006480bfc88d,Supporting & Related Material,FDA-2011-P-0120-0005,FDA-2011-P-0120,"index for appendix b: references 97 - 117, volume 3 of 5 - [pronova biopharma norge as (pronova) - citizen petition]",0,0
0900006480bfafd8,Supporting & Related Material,FDA-2011-P-0120-0002,FDA-2011-P-0120,"appendix d - index of references 1 - 190, appendix  a-c - [pronova biopharma norge as (pronova) - citizen petition]",0,0
0900006480bfafdc,Supporting & Related Material,FDA-2011-P-0120-0003,FDA-2011-P-0120,"index for appendix a: references 1 - 50, volume 1 of 5 - [pronova biopharma norge as (pronova) - citizen petition]",0,0
0900006480cdc62d,Other,FDA-2011-P-0120-0010,FDA-2011-P-0120,fda/cder to pronova biopharma norge as - petition approval,0,0
0900006480bfd003,Supporting & Related Material,FDA-2011-P-0120-0008,FDA-2011-P-0120,"index for appendix c: references 151 - 190, volume 5 of 5 - [pronova biopharma norge as (pronova) - citizen petition]",0,0
0900006480bfc88e,Supporting & Related Material,FDA-2011-P-0120-0006,FDA-2011-P-0120,"reference 97 - atsdr report, ""toxicological profiles for polychlorinated biphenyls (update)"" (appendix b: references 97 - 117, volume 3 of 5) - [pronova biopharma norge as (pronova) - citizen petition]",0,0
0900006480bfafd4,Other,FDA-2011-P-0120-0001,FDA-2011-P-0120,pronova biopharma norge as (pronova) - citizen petiton,0,0
0900006480bfd493,Other,FDA-2011-P-0120-0009,FDA-2011-P-0120,acknowledgement letter to pronova biopharma norge as,0,0
0900006480bfbb92,Supporting & Related Material,FDA-2011-P-0120-0004,FDA-2011-P-0120,"index for appendix a: references 51 - 96, volume 2 of 5 - [pronova biopharma norge as (pronova) - citizen petition]",0,0
0900006482923084,Other,FDA-2017-P-4245-0002,FDA-2017-P-4245,acknowledgement letter from ddm to eas consulting group llc,0,0
090000648376f6b5,Other,FDA-2017-P-4245-0004,FDA-2017-P-4245,withdrawal from eas consulting group (jubilant generics),0,0
09000064829237db,Other,FDA-2017-P-4245-0001,FDA-2017-P-4245,citizen petition from eas consulting group (jubilant generics),0,0
0900006482e11a33,Other,FDA-2017-P-4245-0003,FDA-2017-P-4245,interim response from fda to jubilant generics,0,0
09000064824a1497,Supporting & Related Material,FDA-2017-P-0508-0027,FDA-2017-P-0508,the world oral health report 2003a,0,0
09000064824a14a4,Supporting & Related Material,FDA-2017-P-0508-0029,FDA-2017-P-0508,"added sugar intake and cardiovascular diseases mortality
among us adults",0,0
09000064824a147f,Supporting & Related Material,FDA-2017-P-0508-0016,FDA-2017-P-0508,obesity and sugar-sweetened beverages in african-american preschool children: a longitudinal study,0,0
09000064824a1491,Supporting & Related Material,FDA-2017-P-0508-0021,FDA-2017-P-0508,a longitudinal analysis of sugar-sweetened beverage intake in infancy and obesity at 6 years,0,0
09000064824a1495,Supporting & Related Material,FDA-2017-P-0508-0025,FDA-2017-P-0508,innate and learned preferences for sweet taste during childhood.,0,0
09000064824a14a3,Supporting & Related Material,FDA-2017-P-0508-0028,FDA-2017-P-0508,sugars intake for adults and children,0,0
09000064824a1461,Supporting & Related Material,FDA-2017-P-0508-0003,FDA-2017-P-0508,the relationship of sugar to population-level diabetes prevalence: an econometric analysis of repeated cross-sectional data,0,0
09000064824a146a,Supporting & Related Material,FDA-2017-P-0508-0009,FDA-2017-P-0508,food shopping behaviors and socioeconomic status influence obesity rates in seattle and in paris,1,0
09000064824a1478,Supporting & Related Material,FDA-2017-P-0508-0010,FDA-2017-P-0508,call to halve target for added sugar,0,0
09000064824a1480,Supporting & Related Material,FDA-2017-P-0508-0017,FDA-2017-P-0508,public health: the toxic truth about sugar,0,0
090000648297758b,Other,FDA-2017-P-0508-0040,FDA-2017-P-0508,"interim response letter from cfsan to union of concerned scientists, center for science and democracy",0,0
09000064824c01f8,Supporting & Related Material,FDA-2017-P-0508-0031,FDA-2017-P-0508,"pure, white and deadly by john yudkin",0,0
09000064824a148e,Supporting & Related Material,FDA-2017-P-0508-0019,FDA-2017-P-0508,review of wic food packages: improving balance and choice: final report,1,0
09000064824a1496,Supporting & Related Material,FDA-2017-P-0508-0026,FDA-2017-P-0508,added sugars and cardiovascular disease risk in children,0,0
0900006482495847,Other,FDA-2017-P-0508-0001,FDA-2017-P-0508,"citizen petition from the union of concerned scientists, center for science and democracy",0,0
09000064824a1490,Supporting & Related Material,FDA-2017-P-0508-0020,FDA-2017-P-0508,sugar on trial: what you really need to know,0,0
09000064824a1494,Supporting & Related Material,FDA-2017-P-0508-0024,FDA-2017-P-0508,dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies,0,0
09000064824a1463,Supporting & Related Material,FDA-2017-P-0508-0005,FDA-2017-P-0508,the children’s food & beverage advertising initiative in action,1,0
09000064824a1479,Supporting & Related Material,FDA-2017-P-0508-0011,FDA-2017-P-0508,evaluating the nutrition quality and marketing of children’s cereals,0,0
09000064824a1465,Supporting & Related Material,FDA-2017-P-0508-0007,FDA-2017-P-0508,sugar-sweetened beverages and weight gain in 2- to 5-year-old children,0,0
09000064824a1467,Supporting & Related Material,FDA-2017-P-0508-0008,FDA-2017-P-0508,dietary guidelines advisory committee 2015,0,0
09000064824a147b,Supporting & Related Material,FDA-2017-P-0508-0013,FDA-2017-P-0508,"obesity in the early childhood years: state of the science and
implementation of promising solutions: workshop in brief",0,0
09000064824958ae,Other,FDA-2017-P-0508-0002,FDA-2017-P-0508,"acknowledgment letter from fda ddm to the union of concerned scientists, center for science and democracy",0,0
09000064824a1462,Supporting & Related Material,FDA-2017-P-0508-0004,FDA-2017-P-0508,"consumption of high-fructose corn syrup in beverages may play a
role in the epidemic of obesity",0,0
09000064824a1464,Supporting & Related Material,FDA-2017-P-0508-0006,FDA-2017-P-0508,the biasing health halos of fast-food restaurant health claims: lower calorie estimates and higher side-dish consumption intentions,1,0
0900006481d85ca2,Other,FDA-2015-P-4600-0002,FDA-2015-P-4600,acknowledgement letter from fda ddm to bayer healthcare pharmaceuticals,0,0
0900006482212543,Other,FDA-2015-P-4600-0003,FDA-2015-P-4600,interim response letter from cder to bayer healthcare llc,0,0
0900006481d85d0b,Other,FDA-2015-P-4600-0001,FDA-2015-P-4600,citizen petition from bayer healthcare llc,0,0
090000648198e714,Supporting & Related Material,FDA-2014-P-2276-0002,FDA-2014-P-2276,"exhibit 1 citizen petition from alan laboratories, inc.",0,0
090000648198e71c,Other,FDA-2014-P-2276-0005,FDA-2014-P-2276,"acknowledgement letter from fda ddm to alan laboratories, inc.",0,0
090000648198e718,Supporting & Related Material,FDA-2014-P-2276-0004,FDA-2014-P-2276,"exhibit 3 citizen petition from alan laboratories, inc.",0,0
0900006481b469c2,Other,FDA-2014-P-2276-0006,FDA-2014-P-2276,"interim response letter from fda cder to alan laboratories, inc.",0,0
090000648198e716,Supporting & Related Material,FDA-2014-P-2276-0003,FDA-2014-P-2276,"exhibit 2 citizen petition from alan laboratories, inc.",0,0
090000648220c555,Other,FDA-2014-P-2276-0007,FDA-2014-P-2276,"letter from fda cder to alan laboratories, inc.",0,0
090000648198e5e9,Other,FDA-2014-P-2276-0001,FDA-2014-P-2276,"citizen petition from alan laboratories, inc.",0,0
0900006482c3b454,Other,FDA-2017-P-6357-0001,FDA-2017-P-6357,citizen petition from diana wierzchos,0,0
0900006482c3be24,Other,FDA-2017-P-6357-0002,FDA-2017-P-6357,acknowledgment letter from fda ddm to  diana wierzchos,0,0
0900006482c3b456,Supporting & Related Material,FDA-2017-P-6357-0003,FDA-2017-P-6357,attachment -1 factory farms destroy communities re  citizen petition from diana wierzchos,0,0
0900006481cfe1f4,Other,FDA-2015-P-1669-0005,FDA-2015-P-1669,interim response from fda cder to regcon solutions,0,0
0900006481adb4be,Other,FDA-2015-P-1669-0004,FDA-2015-P-1669,acknowledgement letter from fda ddm to regcon solutions,0,0
0900006481adba2a,Supporting & Related Material,FDA-2015-P-1669-0003,FDA-2015-P-1669,attachment b shipping label re citizen petition from regcon solutions,0,0
0900006481adba29,Supporting & Related Material,FDA-2015-P-1669-0002,FDA-2015-P-1669,attachment a orange book approved drug products with therapeutic equivalent evaluation for acamprosate re citizen petition from regcon solutions,0,0
0900006481adb33e,Other,FDA-2015-P-1669-0001,FDA-2015-P-1669,citizen petition from regcon solutions,0,0
0900006481fbcd9b,Other,FDA-2015-P-1669-0006,FDA-2015-P-1669,citizen petition petition approval letter 04/12/2016,0,0
0900006482a34fd3,Other,FDA-2017-P-1077-0003,FDA-2017-P-1077,interim response letter from cder to recordati rare diseases inc,0,0
09000064824cb691,Other,FDA-2017-P-1077-0001,FDA-2017-P-1077,citizen-petition from recordati rare diseases inc,0,0
09000064824cb694,Other,FDA-2017-P-1077-0002,FDA-2017-P-1077,acknowledgement letter from fda ddm to recordati rare diseases inc.,0,0
0900006483264f8e,Supporting & Related Material,FDA-2018-P-1877-0003,FDA-2018-P-1877,attachment 1: orange book: approved drug products with therapeutic equivalence evaluations re: citizen petition from laurus labs,0,0
0900006483264ded,Other,FDA-2018-P-1877-0001,FDA-2018-P-1877,citizen petition from laurus labs,0,0
0900006483264f19,Other,FDA-2018-P-1877-0002,FDA-2018-P-1877,acknowledgment letter from fda ddm to laurus labs,0,0
0900006483a3b7df,Other,FDA-2018-P-1877-0007,FDA-2018-P-1877,letter from fda cder to laurus labs limited,0,0
09000064838cf223,Other,FDA-2018-P-1877-0005,FDA-2018-P-1877,letter from fda cder to laurus labs limited re citizen petition,0,0
0900006483a38ba0,Notice,FDA-2018-P-1877-0006,FDA-2018-P-1877,"determination that esbriet (pirfenidone) film coated tablets, 534 milligrams, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483265416,Supporting & Related Material,FDA-2018-P-1877-0004,FDA-2018-P-1877,rld esbriet® package insert updated in drugs@fda re: citizen petition from laurus labs,0,0
090000648484b473,Supporting & Related Material,FDA-2020-P-1859-0004,FDA-2020-P-1859,"attachment 2- hectorol (doxercalciferol) injection, package insert re citizen petition from gland pharma limited",0,0
090000648484b472,Supporting & Related Material,FDA-2020-P-1859-0003,FDA-2020-P-1859,attachment 1-  orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from gland pharma limited,0,0
090000648484b474,Supporting & Related Material,FDA-2020-P-1859-0005,FDA-2020-P-1859,attachment iii  - draft labeling carton container label and package insert for the proposed drug product re citizen petition from gland pharma limited,0,0
090000648484b470,Other,FDA-2020-P-1859-0002,FDA-2020-P-1859,acknowledgment letter from fda dms to gland pharma limited,0,0
090000648484ab9f,Other,FDA-2020-P-1859-0001,FDA-2020-P-1859,suitability petition from gland pharma limited,0,0
0900006484a939be,Supporting & Related Material,FDA-2021-P-0345-0004,FDA-2021-P-0345,"attachment 2 - highlights of prescribing information for ascor re suitability petition from bpi labs, llc",0,0
0900006484a9399b,Supporting & Related Material,FDA-2021-P-0345-0003,FDA-2021-P-0345,"attachment 1 - orange book approved drug products with therapeutic equivalence evaluations re suitability petition from bpi labs, llc",0,0
0900006484a939bf,Supporting & Related Material,FDA-2021-P-0345-0005,FDA-2021-P-0345,"attachment 3 - highlights of prescribing information for ascorbic acid injection re suitability petition from bpi labs, llc",0,0
0900006484a93997,Other,FDA-2021-P-0345-0001,FDA-2021-P-0345,"suitability petition from bpi labs, llc",0,0
0900006484a93999,Other,FDA-2021-P-0345-0002,FDA-2021-P-0345,"acknowledgment letter from fda dms to bpi labs, llc",0,0
090000648494737a,Other,FDA-2020-P-2146-0001,FDA-2020-P-2146,"citizen petition from bf innovation, inc.",0,0
0900006484a9a60e,Other,FDA-2020-P-2146-0003,FDA-2020-P-2146,"response letter from fda cder to bf innovation, inc.",0,0
090000648494747d,Other,FDA-2020-P-2146-0002,FDA-2020-P-2146,"acknowledgment letter from fda dms to  bf innovation, inc.",0,0
0900006484abcac3,Other,FDA-2020-P-0421-0008,FDA-2020-P-0421,response letter from fda cder to cooley's anemia foundation,0,0
09000064842eeb19,Other,FDA-2020-P-0421-0001,FDA-2020-P-0421,citizen petition from cooley's anemia foundation (caf),0,0
09000064842eeb1b,Other,FDA-2020-P-0421-0002,FDA-2020-P-0421,acknowledgment letter to cooley’s anemia foundation,0,0
09000064847961cf,Other,FDA-2020-P-0421-0007,FDA-2020-P-0421,interim response letter from fda cder to cooley's anemia foundation,0,0
090000648427e588,Supporting & Related Material,FDA-2020-P-0102-0003,FDA-2020-P-0102,appendix 1 ivqia data re citizen petition from the ritedose corporation,0,0
090000648427dc95,Other,FDA-2020-P-0102-0002,FDA-2020-P-0102,acknowledgment letter from fda dms to the ritedose corporation,0,0
09000064847488ab,Other,FDA-2020-P-0102-0004,FDA-2020-P-0102,interim response from fda cder to linda valentine,0,0
090000648427a1d2,Other,FDA-2020-P-0102-0001,FDA-2020-P-0102,citizen petition from the ritedose corporation,0,0
0900006484b95c6d,Other,FDA-2020-P-0102-0005,FDA-2020-P-0102,withdrawal from the ritedose corporation,0,0
0900006484a65ebb,Other,FDA-2021-P-0278-0001,FDA-2021-P-0278,citizen petition from b. braun medical inc.,0,0
0900006484a65ee2,Other,FDA-2021-P-0278-0002,FDA-2021-P-0278,acknowledgment letter from fda dms to b. braun medical inc.,0,0
0900006484ca880c,Other,FDA-2021-P-0278-0003,FDA-2021-P-0278,interim response letter from fda cder to b. braun medical inc.,0,0
09000064804816ea,Notice,FDA-2003-D-0038-0003,FDA-2003-D-0038,fda,0,0
09000064804816dc,Notice,FDA-2003-D-0038-0001,FDA-2003-D-0038,fda,0,0
09000064804816e9,Supporting & Related Material,FDA-2003-D-0038-0002,FDA-2003-D-0038,guidance,0,0
0900006480b22d91,Other,FDA-2006-P-0088-0005,FDA-2006-P-0088,michael patterson - citizen petition,0,0
0900006480b22dbd,Other,FDA-2006-P-0088-0006,FDA-2006-P-0088,see fda-2006-p-0088-0005,0,0
09000064804449ba,Supporting & Related Material,FDA-2006-P-0088-0002,FDA-2006-P-0088,see fda-2006-p-0088-0001,0,0
09000064804449bb,Other,FDA-2006-P-0088-0003,FDA-2006-P-0088,fda/cdrh interim response to michael patterson - letter,0,0
09000064804449bc,Other,FDA-2006-P-0088-0004,FDA-2006-P-0088,"fda/cdrh response to michael patterson, ph.d. - petition denial",0,0
09000064804449b7,Other,FDA-2006-P-0088-0001,FDA-2006-P-0088,acknowledgement letter to michael patterson,0,0
0900006480475f71,Other,FDA-2004-P-0479-0002,FDA-2004-P-0479,hfa-305 to aac consulting group,0,0
0900006480475f76,Other,FDA-2004-P-0479-0003,FDA-2004-P-0479,hfd-600 to aac consulting group,0,0
0900006480475f32,Other,FDA-2004-P-0479-0001,FDA-2004-P-0479,hfa-305 to aac consulting group,0,0
09000064809edb49,Other,FDA-2009-P-0320-0002,FDA-2009-P-0320,acknowledgement letter to pharma medica,0,0
09000064809edb48,Other,FDA-2009-P-0320-0001,FDA-2009-P-0320,pharma medica - citizen petition,0,0
0900006480a4679c,Other,FDA-2009-D-0490-0002,FDA-2009-D-0490,"guidance for industry and fda staff - investigatinal new drug applications (inds) for minimally manipulated, unrelated allogenic placental/umbilical cord blood intended for hematopoietic reconstitutino for specified indications - draft guidance",0,0
0900006480ed3837,Notice,FDA-2009-D-0490-0010,FDA-2009-D-0490,"guidance for industry and food and drug administration staff; availability: investigational new drug applications for minimally manipulated, unrelated allogeneic placental-umbilical cord blood, etc.",1,0
090000648132872c,Other,FDA-2009-D-0490-0013,FDA-2009-D-0490,"draft guidance for industry and fda staff:  investigational new drug applications for minimally manipulated, unrelated allogeneic placental/umbilical cord blood intended for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system",0,0
09000064815fb385,Notice,FDA-2009-D-0490-0016,FDA-2009-D-0490,"guidance for industry and food and drug administration staff:
investigational new drug applications for minimally manipulated, unrelated allogeneic placental/umbilical cord blood intended for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system; availability",1,0
0900006481328036,Notice,FDA-2009-D-0490-0012,FDA-2009-D-0490,"draft guidance for industry and fda staff:  investigational new drug applications for minimally manipulated, unrelated allogeneic placental/umbilical cord blood intended for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system; availability",0,0
0900006480a45940,Notice,FDA-2009-D-0490-0001,FDA-2009-D-0490,"draft guidance for industry and food and drug administration staff: investigational new drug applications for minimally manipulated, unrelated allogeneic placental/umbilical cord blood intended for hematopoietic reconstitution for specified indications; availability",1,0
09000064815fc38c,Other,FDA-2009-D-0490-0017,FDA-2009-D-0490,"guidance for industry and fda staff: investigational new drug applications for minimally manipulated, unrelated allogeneic placental/umbilical cord blood intended for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system",0,0
0900006480ed2f10,Other,FDA-2009-D-0490-0011,FDA-2009-D-0490,"guidance for industry and food and drug administration staff; investigational new drug applications (inds) for minimally manipulated, unrelated allogeneic placental-umbilical cord blood intended for hermatopoietic reconstitution for specified indications",1,0
0900006484a71cfb,Other,FDA-2021-P-0307-0001,FDA-2021-P-0307,"citizen petition from covington and burling llp on behalf of the pharmaceutical research and manufacturers of america, ballard spahr llp, on behalf of the partnership for safe medicines, and sidley austin llp, on behalf of the council for affordable health coverage",0,0
0900006484d686d0,Other,FDA-2021-P-0307-0003,FDA-2021-P-0307,"interim response letter from fda cder to covington & burling llp, ballard spahr llp, sidley austin llp",0,0
0900006484a71d36,Other,FDA-2021-P-0307-0002,FDA-2021-P-0307,acknowledgment letter from fda dms to covington and burling llp,0,0
0900006484a85a10,Other,FDA-2020-P-2033-0005,FDA-2020-P-2033,interim response letter from fda dms to kentucky drug quality study,0,0
09000064848adbdd,Other,FDA-2020-P-2033-0002,FDA-2020-P-2033,acknowledgment letter from fda dms to kentucky drug quality study,0,0
09000064848ada3f,Other,FDA-2020-P-2033-0001,FDA-2020-P-2033,citizen petition from university of kentucky drug quality study,0,0
0900006482cb6c2b,Other,FDA-2017-P-6631-0001,FDA-2017-P-6631,"citizen petition from amin talati upadhye llp (natural algae astaxanthin association (""naxa""))",0,0
0900006482cb6c2d,Supporting & Related Material,FDA-2017-P-6631-0004,FDA-2017-P-6631,"exhibit b - about zanthosyn re citizen petition from amin talati upadhye llp (natural algae astaxanthin association (""naxa""))",0,0
0900006482cb6c2e,Supporting & Related Material,FDA-2017-P-6631-0005,FDA-2017-P-6631,"exhibit c- 75-day premarket notification of new dietary tngrcdients re citizen petition from amin talati upadhye llp (natural algae astaxanthin association (""naxa""))",0,0
0900006482cb77b1,Other,FDA-2017-P-6631-0002,FDA-2017-P-6631,"acknowledgement letter from fda ddm to amin talati upadhye llp (natural algae astaxanthin association (""naxa""))",0,0
0900006482cb6c2f,Supporting & Related Material,FDA-2017-P-6631-0006,FDA-2017-P-6631,"exhibit d zanthosyn (30 ct) re citizen petition from amin talati upadhye llp (natural algae astaxanthin association (""naxa""))",0,0
0900006482cb6c30,Supporting & Related Material,FDA-2017-P-6631-0003,FDA-2017-P-6631,"exhit a frequently asked questions - zanthosyn re citizen petition from amin talati upadhye llp (natural algae astaxanthin association (""naxa""))",0,0
09000064825a11c2,Supporting & Related Material,FDA-2017-P-2967-0003,FDA-2017-P-2967,attachment 1 approved drug products with therapeutic equivalence evaluations re citizen petition from lachman consultant services inc,0,0
09000064825a11c3,Supporting & Related Material,FDA-2017-P-2967-0004,FDA-2017-P-2967,attachment 2 draft insert labeling for proposed product re citizen petition from lachman consultant services inc,0,0
09000064825a11c0,Other,FDA-2017-P-2967-0002,FDA-2017-P-2967,"acknowledgement letter from fda ddm to lachman consultant services, inc",0,0
09000064825a11c4,Supporting & Related Material,FDA-2017-P-2967-0005,FDA-2017-P-2967,attachment 3 approved labeling for reference listed drug lipitor tablets by pfizer re citizen petition from lachman consultant services inc,0,0
09000064825a11be,Other,FDA-2017-P-2967-0001,FDA-2017-P-2967,citizen petition from lachman consultant services inc,0,0
090000648129c5e2,Notice,FDA-2012-N-0324-0003,FDA-2012-N-0324,"agency information collection activities; announcement of office of management and budget approval; guidance for industry, fda staff, and foreign governments: fiscal year 2012 medical device user fee small business qualification and certification",0,0
0900006480ff345d,Notice,FDA-2012-N-0324-0001,FDA-2012-N-0324,"agency information collection activities; proposals, submissions, and approvals; guidance for industry, fiscal year 2012 medical device user fee small business qualification and certification",0,0
09000064811e0a07,Notice,FDA-2012-N-0324-0002,FDA-2012-N-0324,"agency information collection activities; proposals, submissions, and approvals: guidance for industry, fda staff, and foreign governments; fy 2012 medical device user fee small business qualification and certification",0,0
0900006482506bdf,Other,FDA-2017-P-1573-0003,FDA-2017-P-1573,acknowledgment letter from fda ddm to hospira inc,0,0
0900006482506e32,Other,FDA-2017-P-1573-0001,FDA-2017-P-1573,citizen petition from hospira inc,0,0
0900006482506ebe,Other,FDA-2017-P-1573-0002,FDA-2017-P-1573,"prior approval supplemental letter from cder to par sterile products, llc",0,0
09000064829e047f,Other,FDA-2017-P-1573-0004,FDA-2017-P-1573,"citizen petition response letter from fda cder to latham & watkins, llp",0,0
0900006482b9372b,Notice,FDA-2017-P-2530-0003,FDA-2017-P-2530,"determination that spectazole (econazole nitrate) topical cream, 1%, was not withdrawn from sale for reasons of safety or effectiveness",0,0
09000064825680ec,Other,FDA-2017-P-2530-0002,FDA-2017-P-2530,"acknowledgement letter from fda ddm to lachman consultant services, inc.",0,0
09000064825680e9,Other,FDA-2017-P-2530-0001,FDA-2017-P-2530,citizen petition from lachman consultants services inc,0,0
0900006482b95f04,Other,FDA-2017-P-2530-0004,FDA-2017-P-2530,"final response letter from fda to lachman consultant services, inc.",0,0
090000648437e0f8,Supporting & Related Material,FDA-2018-P-4143-0022,FDA-2018-P-4143,4 gsj 2018-single center trial,0,0
090000648437e0fd,Supporting & Related Material,FDA-2018-P-4143-0027,FDA-2018-P-4143,9 becker spine 2018,0,0
090000648437e20e,Supporting & Related Material,FDA-2018-P-4143-0034,FDA-2018-P-4143,16 ut 2019,0,0
090000648437e0f9,Supporting & Related Material,FDA-2018-P-4143-0023,FDA-2018-P-4143,5 gsj 2019- late infections literature synthesis,0,0
090000648437e0fc,Supporting & Related Material,FDA-2018-P-4143-0026,FDA-2018-P-4143,8 submitted to srs _ nass 2020 for review,0,0
090000648437e210,Supporting & Related Material,FDA-2018-P-4143-0036,FDA-2018-P-4143,supplement material for docket fda,0,0
090000648437e0f7,Supporting & Related Material,FDA-2018-P-4143-0021,FDA-2018-P-4143,3 gsj 2018- proof of error in reprocessing,0,0
090000648437e209,Supporting & Related Material,FDA-2018-P-4143-0030,FDA-2018-P-4143,12 otw 2020,0,0
090000648437e20c,Supporting & Related Material,FDA-2018-P-4143-0033,FDA-2018-P-4143,15 sni 2019,0,0
090000648437dfa8,Supporting & Related Material,FDA-2018-P-4143-0019,FDA-2018-P-4143,1 css 2018- economic benefits-2,0,0
090000648437e20f,Supporting & Related Material,FDA-2018-P-4143-0035,FDA-2018-P-4143,17 otw 2018,0,0
090000648437e0fb,Supporting & Related Material,FDA-2018-P-4143-0025,FDA-2018-P-4143,7 srs 2019- multicenter trial,0,0
090000648437e0fa,Supporting & Related Material,FDA-2018-P-4143-0024,FDA-2018-P-4143,6 jssr 2018- multicenter trial summary,0,0
090000648437e0fe,Supporting & Related Material,FDA-2018-P-4143-0028,FDA-2018-P-4143,10 becker spine 2019,0,0
090000648437e20a,Supporting & Related Material,FDA-2018-P-4143-0031,FDA-2018-P-4143,13 sni 2018,0,0
090000648437e500,Supporting & Related Material,FDA-2018-P-4143-0029,FDA-2018-P-4143,11 bonezone 2019,0,0
0900006483b79469,Other,FDA-2018-P-4143-0012,FDA-2018-P-4143,letter from fda cdrh to university of toledo,0,0
0900006483874e50,Supporting & Related Material,FDA-2018-P-4143-0003,FDA-2018-P-4143,attachment 1 orthopedics this week re citizen petiton from university of toledo,0,0
0900006483874e22,Other,FDA-2018-P-4143-0002,FDA-2018-P-4143,acknowledgment letter from fda ddm to university of toledo,0,0
090000648437dfa9,Supporting & Related Material,FDA-2018-P-4143-0020,FDA-2018-P-4143,2 gsj 2018- past literature synthesis,0,0
0900006483874e1f,Other,FDA-2018-P-4143-0001,FDA-2018-P-4143,citizen petition from university of toledo,0,0
090000648437e20b,Supporting & Related Material,FDA-2018-P-4143-0032,FDA-2018-P-4143,14 spineuniverse 2019,0,0
0900006483b57291,Notice,FDA-2018-P-2754-0005,FDA-2018-P-2754,"determination that onfi (clobazam) tablets, 5 milligrams, was not
withdrawn from sale for reasons of safety or effectiveness",0,0
09000064839ec94b,Other,FDA-2018-P-2754-0004,FDA-2018-P-2754,interim response from fda cder to ascend laboratories llc,0,0
090000648351b060,Other,FDA-2018-P-2754-0002,FDA-2018-P-2754,acknowledgment letter from fda ddm to  ascend laboratories llc,0,0
0900006483b58f33,Other,FDA-2018-P-2754-0006,FDA-2018-P-2754,letter from fda cder to ascend laboratories,0,0
090000648351b114,Supporting & Related Material,FDA-2018-P-2754-0003,FDA-2018-P-2754,attachment a- orange book: approved drug products with therapeutic equivalence evaluations re: citizen petition from ascend laboratories llc,0,0
0900006483519329,Other,FDA-2018-P-2754-0001,FDA-2018-P-2754,citizen petition from ascend laboratories llc,0,0
0900006483301e65,Supporting & Related Material,FDA-2018-P-1719-0005,FDA-2018-P-1719,attachment 2 - agency letter along with federal register notice - redacted,0,0
09000064832211e0,Supporting & Related Material,FDA-2018-P-1719-0003,FDA-2018-P-1719,"attachment 1 - excerpt from the electronic version of the orange book re citizen petition from sciarra laboratories, inc",0,0
09000064832211de,Other,FDA-2018-P-1719-0002,FDA-2018-P-1719,"acknowledgment letter from fda ddm to sciarra laboratories, inc",0,0
09000064832211e1,Supporting & Related Material,FDA-2018-P-1719-0004,FDA-2018-P-1719,"attachment 2 - agency letter along with federal register notice re citizen petition from sciarra laboratories, inc",0,0
0900006483220cca,Other,FDA-2018-P-1719-0001,FDA-2018-P-1719,"citizen petition from sciarra laboratories, inc",0,0
0900006483864771,Other,FDA-2018-P-1719-0006,FDA-2018-P-1719,"letter from fda cder to sciarra laboratories, inc.",0,0
0900006484986bc4,Other,FDA-2018-P-1719-0007,FDA-2018-P-1719,"withdrawal from sciarra laboratories, inc",0,0
090000648495a47c,Other,FDA-2020-P-1390-0003,FDA-2020-P-1390,180 day interim response letter to varun varad from fda cfsan,0,0
0900006484606f8f,Other,FDA-2020-P-1390-0002,FDA-2020-P-1390,acknowledgment letter from fda dms to varun verada,0,0
0900006484605e85,Other,FDA-2020-P-1390-0001,FDA-2020-P-1390,citizen petition from varun varada,0,0
090000648470ba7e,Supporting & Related Material,FDA-2020-P-1617-0003,FDA-2020-P-1617,attachment 1 - orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from e4 consulting,0,0
090000648470b6e8,Other,FDA-2020-P-1617-0001,FDA-2020-P-1617,citizen petition from e4 consulting,0,0
090000648470b6e9,Other,FDA-2020-P-1617-0002,FDA-2020-P-1617,acknowledgment letter from fda dms to e4 consulting,0,0
09000064849a99fd,Other,FDA-2020-P-1617-0004,FDA-2020-P-1617,interim response letter from fda cder to e4 consulting,0,0
0900006483b69c46,Other,FDA-2019-P-1636-0002,FDA-2019-P-1636,"acknowledgment letter from fda ddm to nexsen pruet, llc",0,0
0900006483b69f14,Supporting & Related Material,FDA-2019-P-1636-0003,FDA-2019-P-1636,"annexure i: copy of orange book current through march 2019, listing the subject formulation neostigminemethylsulfate injection, solution 3 mg/3 ml (1 mg/1ml) nda 203629. re: citizen petition from nexsen pruet, llc",0,0
0900006483b69fea,Supporting & Related Material,FDA-2019-P-1636-0004,FDA-2019-P-1636,"annexure ii: copy of drugs@fda listing subject formulation neostigmine methylsulfate injection, solution3 mg/3 ml (1 mg/1ml) nda 203629. re: citizen petition from nexsen pruet, llc",0,0
09000064848654bb,Other,FDA-2019-P-1636-0007,FDA-2019-P-1636,"letter from fda cder to nexsen pruet, llc",0,0
0900006483fe2646,Other,FDA-2019-P-1636-0006,FDA-2019-P-1636,"interim response letter from fda cder to nexsen pruet, llc",0,0
0900006483b6a24b,Supporting & Related Material,FDA-2019-P-1636-0005,FDA-2019-P-1636,"annuxure iii: copy of current approved fda labeling for neostigmine methylsulfate injection, solution 3mg/3 ml (1 mg/1ml) nda 203629 dated november 20, 2018. re: citizen petition from nexsen pruet, llc",0,0
0900006483b69dbf,Other,FDA-2019-P-1636-0001,FDA-2019-P-1636,"citizen petition from nexsen pruet, llc",0,0
090000648046a8cf,Other,FDA-2004-P-0020-0002,FDA-2004-P-0020,"hfa-305 to ferdic, incorporated",0,0
090000648046a8cc,Other,FDA-2004-P-0020-0001,FDA-2004-P-0020,"hfa-305 to ferdic, incorporated",0,0
090000648043ee1b,Other,FDA-2005-P-0057-0002,FDA-2005-P-0057,"hfa-305 to hyman, phelps & mcnamara, p.c",0,0
090000648043ee1c,Other,FDA-2005-P-0057-0003,FDA-2005-P-0057,"hfa-305 to hyman, phelps & mcnamara, p.c",0,0
090000648302a986,Other,FDA-2005-P-0057-0004,FDA-2005-P-0057,withdraw memo fda-2005-p-0057,0,0
090000648043ee10,Other,FDA-2005-P-0057-0001,FDA-2005-P-0057,"hfa-305 to hyman, phelps & mcnamara, p.c",0,0
0900006480830776,Supporting & Related Material,FDA-2009-P-0023-0011,FDA-2009-P-0023,"tab 17 - fda/cdrh ""siemens sonocur basic-p010039,"" january 19, 2002",0,0
0900006480830b74,Supporting & Related Material,FDA-2009-P-0023-0015,FDA-2009-P-0023,"tab 30 - ""physical medicine devices, 21cfr890.5975, april 1, 2008"" - [electro medical systems corporation - citizen petition]",0,0
0900006480830b8b,Supporting & Related Material,FDA-2009-P-0023-0017,FDA-2009-P-0023,"tab 32 - ""fda/cdrh premarket notification 510(k), november 1, 2008"" - [electro medical systems corporation - citizen petition]",0,0
0900006480830b6b,Supporting & Related Material,FDA-2009-P-0023-0014,FDA-2009-P-0023,"tab 29 - ""physical medicine devices, 21cfr890.5660, april 1, 2008"" - [electro medical systems corporation - citizen petition]",0,0
09000064808305fe,Supporting & Related Material,FDA-2009-P-0023-0003,FDA-2009-P-0023,"tab 5 - ""guidance for industry & for fda reviewers ""guidance for the content of premarket notifications (510(k)s) for extracorporeal shock wave lithotripters indicated for the fragmentation of kidney & ureteral calculi,"" august 9, 2000 - [electro medical systems corporation - citizen petition]",0,0
090000648083063b,Supporting & Related Material,FDA-2009-P-0023-0007,FDA-2009-P-0023,"tab 13 - fd&c act chapter v, sections 513-523  ""drugs & devices""",0,0
0900006480830642,Supporting & Related Material,FDA-2009-P-0023-0008,FDA-2009-P-0023,"tab 14 - cdrh consumer information ""new device approval: ems swiss dolorclast-p050004,"" may 7, 2007",0,0
090000648083075e,Supporting & Related Material,FDA-2009-P-0023-0010,FDA-2009-P-0023,"tab 16-  fda/cdrh ""dornier epos ultra-p-000048,"" january 15, 2002",0,0
090000648083080d,Supporting & Related Material,FDA-2009-P-0023-0012,FDA-2009-P-0023,"tab 18 - ""fda/cdrh orthospec extracorporeal shock wave therapy device-p040026, april 1, 2005"" - [electro medical systems corporation - citizen petition]",0,0
09000064808208b2,Other,FDA-2009-P-0023-0001,FDA-2009-P-0023,electro medical systems corporation - citizen petition,0,0
0900006480820975,Other,FDA-2009-P-0023-0002,FDA-2009-P-0023,acknowledgement letter  to electro medical systems corporation,0,0
0900006480830624,Supporting & Related Material,FDA-2009-P-0023-0004,FDA-2009-P-0023,"tab 10 - ""guidance for the content of premarket notifications ( ) for extracorporeal shock wave..."" - [electro medical systems corporation - citizen petition]",0,0
0900006480830632,Supporting & Related Material,FDA-2009-P-0023-0005,FDA-2009-P-0023,"tab 11 - 21cfr 876.4480 - ""gastroenterology-urology devices,"" april 1, 2008 - [electro medical systems corporation - citizen petition]",0,0
0900006480830646,Supporting & Related Material,FDA-2009-P-0023-0009,FDA-2009-P-0023,"tab 15 - fda/cdrh ""ossatron-p990086"" dated october 12, 2000",0,0
0900006480830b82,Supporting & Related Material,FDA-2009-P-0023-0016,FDA-2009-P-0023,"tab 31- ""food and drug administration, hhs - 21cfr890.9, 1175"" - [electro medical systems corporation - citizen petition]",1,0
0900006480830c19,Supporting & Related Material,FDA-2009-P-0023-0018,FDA-2009-P-0023,"tab 48 - ""fda/cdrh guidance document for the preparation of premarket notification [510(k)] applications for therapeutic massagers & vibrators, july 26, 1995"" - [electro medical systems corporation - citizen petition]",0,0
0900006480830c1e,Supporting & Related Material,FDA-2009-P-0023-0019,FDA-2009-P-0023,"tabs 49 & 50 - ""fda/cdrh 510(k) premarket notification database"" - [electro medical systems corporation - citizen petition]",0,0
0900006480830c27,Supporting & Related Material,FDA-2009-P-0023-0020,FDA-2009-P-0023,"tab 51 - letter to fda/cdrh from electro medical systems, inc., dated january 2, 2008 - [electro medical systems corporation - citizen petition]",0,0
0900006480830636,Supporting & Related Material,FDA-2009-P-0023-0006,FDA-2009-P-0023,"tab 12 - 21cfr 876.5990 - ""gastroenterology-urology devices,"" april 1, 2008",0,0
0900006480830adc,Supporting & Related Material,FDA-2009-P-0023-0013,FDA-2009-P-0023,"tab 19 - fda/cdrh orbasone pain relief system-p040039, august 10, 2005"" - [electro medical systems corporation - citizen petition]",0,0
0900006482af779f,Other,FDA-2017-P-0970-0006,FDA-2017-P-0970,interim response letter from fda cfsan to ricebran technologies,0,0
09000064834111b0,Other,FDA-2017-P-0970-0007,FDA-2017-P-0970,fda-2017-p-0970-ricebran granting response,0,0
09000064824c10f9,Supporting & Related Material,FDA-2017-P-0970-0003,FDA-2017-P-0970,appendix a proprietary laboratory reports re citizen petition from ricebran technologies,0,0
09000064824c1502,Supporting & Related Material,FDA-2017-P-0970-0004,FDA-2017-P-0970,appendix b studies reviewed on the effect of rice bran fiber re citizen petition from ricebran technologies-2,0,0
09000064824c1503,Supporting & Related Material,FDA-2017-P-0970-0005,FDA-2017-P-0970,appendix c studies reviewed on the effect of rice bran fiber re citizen petition from ricebran technologies-3,0,0
09000064824c10f5,Other,FDA-2017-P-0970-0001,FDA-2017-P-0970,citizen petition from ricebran technologies,0,0
09000064824c10f7,Other,FDA-2017-P-0970-0002,FDA-2017-P-0970,acknowledgement letter from fda ddm to ricebran technologies,0,0
090000648379db93,Other,FDA-2017-P-2733-0006,FDA-2017-P-2733,response letter from fda cder to esophageal cancer action network inc.,0,0
0900006482588d4e,Other,FDA-2017-P-2733-0001,FDA-2017-P-2733,citizen petition from esophageal cancer action network inc.,0,0
0900006482588b7d,Other,FDA-2017-P-2733-0002,FDA-2017-P-2733,acknowledgment letter from fda ddm to esophageal cancer action network inc.,0,0
0900006482c0d2f4,Other,FDA-2017-P-2733-0004,FDA-2017-P-2733,interim response letter from fda cder to esophageal cancer action network inc.,0,0
090000648294ff0c,Supporting & Related Material,FDA-2017-P-4360-0009,FDA-2017-P-4360,exhibit b life-threatening effects of discontinuing inhaled nitric oxide in sever respiratory failure re citizen petition from mallinckrodt pharmaceuticals,0,0
090000648294ff0d,Supporting & Related Material,FDA-2017-P-4360-0008,FDA-2017-P-4360,exhibit c detention without physical examination of devices from firms that hae not met dqsr re citizen petition from mallinckrodt pharmaceuticals,0,0
090000648294ff3e,Supporting & Related Material,FDA-2017-P-4360-0004,FDA-2017-P-4360,"exhibit g praxair distribution, inc vs mallinckrodt hospital products ip re citizen petition from mallinckrodt pharmaceuticals",0,0
090000648294ff0b,Supporting & Related Material,FDA-2017-P-4360-0010,FDA-2017-P-4360,"exhibit a transcript of proceedings, anesthesiology and respiratory therapy device panel re citizen petition from mallinckrodt pharmaceuticals",0,0
090000648294ff0e,Supporting & Related Material,FDA-2017-P-4360-0007,FDA-2017-P-4360,"exhibit d praxair distribution, inc v ino therapeutics, llc re citizen petition from mallinckrodt pharmaceuticals",0,0
0900006482d155a8,Other,FDA-2017-P-4360-0014,FDA-2017-P-4360,petition denial letter from fda cder to mallinckrodt pharmaceuticals,0,0
090000648294ff3a,Supporting & Related Material,FDA-2017-P-4360-0006,FDA-2017-P-4360,"exhibit e praxair distribution, inc v ino therapeutics, llc d b a ikaria, inc re citizen petition from mallinckrodt pharmaceuticals",0,0
090000648294ff07,Other,FDA-2017-P-4360-0001,FDA-2017-P-4360,citizen petition from mallinckrodt pharmaceuticals,0,0
090000648294ff09,Other,FDA-2017-P-4360-0002,FDA-2017-P-4360,acknowledgement letter from fda ddm to mallinckrodt pharmaceuticals,0,0
090000648294ff3f,Supporting & Related Material,FDA-2017-P-4360-0003,FDA-2017-P-4360,"exhibit h tissue debate raises fairness, transparency questions for combo re citizen petition from mallinckrodt pharmaceuticals",0,0
0900006482b5c9fc,Other,FDA-2017-P-4360-0012,FDA-2017-P-4360,supplement from mallinckrodt pharmaceuticals,0,0
090000648294ff3d,Supporting & Related Material,FDA-2017-P-4360-0005,FDA-2017-P-4360,"exhibit f declaration of robert t. stone, phd re citizen petition from mallinckrodt pharmaceuticals",0,0
0900006482e29c03,Other,FDA-2018-P-0266-0002,FDA-2018-P-0266,acknowledgment letter from fda ddm to arent fox llp,0,0
0900006483507295,Other,FDA-2018-P-0266-0003,FDA-2018-P-0266,response letter from fda cder to arent fox llp,0,0
0900006482e29ba1,Other,FDA-2018-P-0266-0001,FDA-2018-P-0266,citizen petition from arent fox llp,0,0
0900006481e13fd4,Other,FDA-2016-P-0187-0002,FDA-2016-P-0187,acknowledgement letter from fda ddm to hogan lovells us llp,0,0
0900006481e14158,Other,FDA-2016-P-0187-0001,FDA-2016-P-0187,citizen petition from united therapeutics corporation (hogan lovells us llp),0,0
0900006481e13fd7,Supporting & Related Material,FDA-2016-P-0187-0003,FDA-2016-P-0187,index of exhibits re citizen petition from united therapeutics corporation (hogan lovells us llp),0,0
0900006481e141a5,Supporting & Related Material,FDA-2016-P-0187-0006,FDA-2016-P-0187,tab 3 importance of drug-device interaction in determining systemic effects of inhaled corticosteroids re citizen petition from united therapeutics corporation (hogan lovells us llp),0,0
0900006481e14726,Supporting & Related Material,FDA-2016-P-0187-0010,FDA-2016-P-0187,tab 7 lung deposition from four nebulizers re citizen petition from united therapeutics corporation (hogan lovells us llp),0,0
0900006481e1477a,Supporting & Related Material,FDA-2016-P-0187-0014,FDA-2016-P-0187,tab 11 demonstrating bioequivalence of locally acting orally inhaled drug products re citizen petition from united therapeutics corporation (hogan lovells us llp),0,0
0900006481e1419f,Supporting & Related Material,FDA-2016-P-0187-0004,FDA-2016-P-0187,tab 1 anaesthetic and respiratory equipment - nebulizing systems and components re citizen petition from united therapeutics corporation (hogan lovells us llp),0,0
0900006481e14725,Supporting & Related Material,FDA-2016-P-0187-0009,FDA-2016-P-0187,tab 6 a comparison of commercial jet nebulizers re citizen petition from united therapeutics corporation (hogan lovells us llp),0,0
0900006481e14729,Supporting & Related Material,FDA-2016-P-0187-0013,FDA-2016-P-0187,tab 10 quality by design for orally inhaled drug products re citizen petition from united therapeutics corporation (hogan lovells us llp),0,0
0900006481e14724,Supporting & Related Material,FDA-2016-P-0187-0008,FDA-2016-P-0187,"tab 5 medication nebulizer performance effects of diluent volume, nebulizer flow, and nebulizer brand re citizen petition from united therapeutics corporation (hogan lovells us llp)",0,0
0900006481e141a4,Supporting & Related Material,FDA-2016-P-0187-0005,FDA-2016-P-0187,tab 2 fda respiratory drug delivery devices - a cdrh perspective re citizen petition from united therapeutics corporation (hogan lovells us llp),0,0
090000648203811d,Other,FDA-2016-P-0187-0015,FDA-2016-P-0187,petition denial response june 13 2016,0,0
0900006481e14727,Supporting & Related Material,FDA-2016-P-0187-0011,FDA-2016-P-0187,tab 8 the science of nebulised drug delivery re citizen petition from united therapeutics corporation (hogan lovells us llp),0,0
0900006481e14728,Supporting & Related Material,FDA-2016-P-0187-0012,FDA-2016-P-0187,tab 9 ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension re citizen petition from united therapeutics corporation (hogan lovells us llp),0,0
0900006481e141a6,Supporting & Related Material,FDA-2016-P-0187-0007,FDA-2016-P-0187,tab 4 selecting and using nebuliser equipment re citizen petition from united therapeutics corporation (hogan lovells us llp),0,0
090000648185d613,Other,FDA-2014-P-0328-0003,FDA-2014-P-0328,"interim response from fda/cder to hyman, phelps & mcnamara , p.c.",0,0
090000648167201e,Other,FDA-2014-P-0328-0002,FDA-2014-P-0328,"acknowledgement letter from fda/ddm to hyman, phelps & mcnamara, p.c.",0,0
090000648192b5ae,Other,FDA-2014-P-0328-0004,FDA-2014-P-0328,citizens petition approval letter to robert dormer and gordon johnston,0,0
0900006481671ff0,Other,FDA-2014-P-0328-0001,FDA-2014-P-0328,"citizen petition from hyman, phelps & mcnamara , p.c.",0,0
0900006481c3519a,Other,FDA-2015-P-3085-0002,FDA-2015-P-3085,"acknowledgement letter from fda ddm to mid-atlantic biotherapeutics, inc. [virtual regulatory solutions]",0,0
0900006481c348cd,Other,FDA-2015-P-3085-0001,FDA-2015-P-3085,"citizen petition from mid-atlantic biotherapeutics, inc. [virtual regulatory solutions]",0,0
0900006481cb7611,Other,FDA-2015-P-3085-0003,FDA-2015-P-3085,"withdrawal of citizen petition from mid-atlantic biotherapeutics, inc.",0,0
0900006481d3ab83,Other,FDA-2015-P-4237-0002,FDA-2015-P-4237,acknowledgement letter from fda ddm to gland pharma limited,0,0
0900006481d4230d,Supporting & Related Material,FDA-2015-P-4237-0003,FDA-2015-P-4237,attachment 1 orange book: approved drug products with therapeutic equivalence evaluations (mesnex) re citizen petition from gland pharma limited,0,0
0900006481d42310,Supporting & Related Material,FDA-2015-P-4237-0004,FDA-2015-P-4237,attachment 2 approved labeling (package insert) for mesnex (mesna) injection re: citizen petition from gland pharma limited,0,0
0900006481d42311,Supporting & Related Material,FDA-2015-P-4237-0005,FDA-2015-P-4237,"attachment 3 the draft labeling (package insert) for the proposed mesna injection, 20 mg/ ml (1 g/50 ml), infusion bag re: citizen petition from gland pharma limited",0,0
0900006481d3aaf7,Other,FDA-2015-P-4237-0001,FDA-2015-P-4237,citizen petition from gland pharma limited,0,0
090000648378ae9d,Supporting & Related Material,FDA-2018-P-3730-0004,FDA-2018-P-3730,attachment 2 drugs @ fda re: citizen petition from aizant drug research solutions pvt. ltd,0,0
090000648378abc4,Other,FDA-2018-P-3730-0002,FDA-2018-P-3730,acknowledgment letter from fda ddm to aizant drug research solutions pvt. ltd.,0,0
0900006483a3947c,Notice,FDA-2018-P-3730-0006,FDA-2018-P-3730,"determination that esbriet (pirfenidone) film coated tablets, 534 milligrams, was not withdrawn from sale for reasons of safety or effectiveness",0,0
09000064837888d4,Other,FDA-2018-P-3730-0001,FDA-2018-P-3730,citizen petition from aizant drug research solutions pvt. ltd,0,0
0900006483a3b3c9,Other,FDA-2018-P-3730-0005,FDA-2018-P-3730,letter from fda cder to aziant drug research solutions pvt. ltd.,0,0
090000648378ae9c,Supporting & Related Material,FDA-2018-P-3730-0003,FDA-2018-P-3730,attachment 1 orange book  re: citizen petition from aizant drug research solutions pvt. ltd,0,0
090000648425d320,Notice,FDA-2019-P-3877-0003,FDA-2019-P-3877,"determination that glucophage (metformin hydrochloride) oral tablets, 500 milligrams, 850 milligrams, and 1 gram, and glucophage xr (metformin hydrochloride) oral extended-release tablets, 500 milligrams and 750 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483e6b6a3,Other,FDA-2019-P-3877-0002,FDA-2019-P-3877,acknowledgment letter from fda dms to harman finochem limited,0,0
0900006483e5c0a8,Other,FDA-2019-P-3877-0001,FDA-2019-P-3877,citizen petition from harman finochem limited,0,0
090000648425fa9c,Other,FDA-2019-P-3877-0004,FDA-2019-P-3877,response letter to harman finochem limited updated from fda cder,0,0
090000648487a7a5,Other,FDA-2020-P-2013-0002,FDA-2020-P-2013,"acknowledgment letter from fda dms to lachman consulting services, inc.",0,0
090000648496deaf,Other,FDA-2020-P-2013-0003,FDA-2020-P-2013,withdrawal from lachman consultant services,0,0
090000648487a79f,Other,FDA-2020-P-2013-0001,FDA-2020-P-2013,"citizen petition from lachman consulting services, inc.",0,0
09000064826a5c0c,Supporting & Related Material,FDA-2017-P-3486-0006,FDA-2017-P-3486,"list of references  re citizen petition from biomedecon, llc",0,0
090000648269b7d2,Other,FDA-2017-P-3486-0002,FDA-2017-P-3486,"acknowledgment letter from fda ddm to biomedecon, llc",0,0
09000064826a5c0f,Supporting & Related Material,FDA-2017-P-3486-0003,FDA-2017-P-3486,"appendix  a: product inserts pramipexole, ropinirole, rotigotine re citizen petition from biomedecon, llc",0,0
090000648269b721,Other,FDA-2017-P-3486-0001,FDA-2017-P-3486,"citizen petition from biomedecon, llc",0,0
09000064826a53d1,Supporting & Related Material,FDA-2017-P-3486-0005,FDA-2017-P-3486,"appendix c: presentations. ispor 2016,  amcp 2016
sleep 2017 (poster and oral presentation) re citizen petition from biomedecon, llc",0,0
09000064840e4eea,Other,FDA-2017-P-3486-0016,FDA-2017-P-3486,letter from cder to public citizen,0,0
0900006482cb22ea,Other,FDA-2017-P-3486-0013,FDA-2017-P-3486,"interim response to biomedecon, llc from fda cder",0,0
09000064826a5c10,Supporting & Related Material,FDA-2017-P-3486-0004,FDA-2017-P-3486,"appendix  b: systematic literature review. see attached excel file re citizen petition from biomedecon, llc",0,0
090000648243b8fc,Supporting & Related Material,FDA-2016-P-4587-0006,FDA-2016-P-4587,"exhibit d praxair distribution, inc. v. ino therapeutics, llc,
ipr2015-00884 (patent 8,291,904 b2); ipr2015-00888 (patent
8,776,794 b2); ipr2015-00889 (patent 8,573,209 b2); ipr2015-00891
(patent 8,573,210 b2); ipr2015-00893 (patent 8,776795 b2),
transcript of proceedings may 16, 2016 re citizen petition from mallinckrodt pharmaceuticals",0,0
090000648243b92e,Supporting & Related Material,FDA-2016-P-4587-0009,FDA-2016-P-4587,"exhibit g praxair distribution, inc. vs. mallinckrodt hospital products ip ltd, ipr 2015-00893 (patent: 8,776,795 b2), petitioner’s reply to patent owners response, feb. 24, 2016 re citizen petition from mallinckrodt pharmaceuticals",0,0
090000648243b8f5,Other,FDA-2016-P-4587-0001,FDA-2016-P-4587,citizen petition from mallinckrodt pharmaceuticals,0,0
090000648243b8f7,Other,FDA-2016-P-4587-0002,FDA-2016-P-4587,acknowledgement letter from fda ddm to mallinckrodt pharmaceuticals,0,0
090000648256de63,Other,FDA-2016-P-4587-0012,FDA-2016-P-4587,supplement from mallinckrodt pharmaceuticals,0,0
090000648243b8fd,Supporting & Related Material,FDA-2016-P-4587-0007,FDA-2016-P-4587,"exhibit e praxair distribution, inc. v. ino therapeutics, llc d/b/a ikaria, inc., petition for inter partes review of u.s. patent no. 8,776,795, march 16, 2015 re citizen petition from mallinckrodt pharmaceuticals",0,0
090000648243b92f,Supporting & Related Material,FDA-2016-P-4587-0010,FDA-2016-P-4587,"exhibit h tissue debate raises fairness, transparency questions for combo
products, the gray sheet (4/29/2002) re citizen petition from mallinckrodt pharmaceuticals",0,0
090000648243b8fa,Supporting & Related Material,FDA-2016-P-4587-0004,FDA-2016-P-4587,exhibit b life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. am. j. respir. crit. care med. 1996:153;1985-87 re citizen petition from mallinckrodt pharmaceuticals,0,0
090000648243b8fb,Supporting & Related Material,FDA-2016-P-4587-0005,FDA-2016-P-4587,"exhibit c import alert # 89-04, detention without physical examination of devices from firms that have not met device quality system
requirements (march 16, 2016) (excerpt) re citizen petition from mallinckrodt pharmaceuticals",0,0
090000648243b92d,Supporting & Related Material,FDA-2016-P-4587-0008,FDA-2016-P-4587,"exhibit f declaration of robert t. stone, ph.d., ipr (unassigned, patent: 8,291,904), march 13, 2015 re citizen petition from mallinckrodt pharmaceuticals",0,0
090000648243b8f9,Supporting & Related Material,FDA-2016-P-4587-0003,FDA-2016-P-4587,"exhibit a transcript of proceedings, anesthesiology and respiratory therapy devices panel of the medical devices advisory committee
(nov. 22, 1996) re citizen petition from mallinckrodt pharmaceuticals",0,0
090000648263f08a,Other,FDA-2016-P-4587-0013,FDA-2016-P-4587,fda-2016-p-4587 petition denial letter,0,0
0900006482040779,Other,FDA-2016-P-1650-0002,FDA-2016-P-1650,"acknowledgement letter from fda ddm to lannett company, inc.",0,0
0900006482040777,Other,FDA-2016-P-1650-0001,FDA-2016-P-1650,"citizen petition from lannett company, inc.",0,0
0900006484a69419,Other,FDA-2016-P-1650-0006,FDA-2016-P-1650,"withdrawal from lannett company, inc.",0,0
090000648204077b,Supporting & Related Material,FDA-2016-P-1650-0003,FDA-2016-P-1650,"attachment 1 pdufa exemption information re citizen petition from lannett company, inc.",0,0
090000648240cfb7,Other,FDA-2016-P-1650-0004,FDA-2016-P-1650,interim response letter,0,0
0900006483aa8b52,Other,FDA-2016-P-1650-0005,FDA-2016-P-1650,meeting on user fee issue for approved product,0,0
09000064846fee8a,Supporting & Related Material,FDA-2020-P-1601-0006,FDA-2020-P-1601,appendix 3 re: citizen petition from informed consent action network,0,0
09000064846feec5,Supporting & Related Material,FDA-2020-P-1601-0010,FDA-2020-P-1601,appendix 7 re: citizen petition from informed consent action network,0,0
09000064846feed4,Supporting & Related Material,FDA-2020-P-1601-0020,FDA-2020-P-1601,appendix 17 re: citizen petition from informed consent action network,0,0
09000064846fee84,Other,FDA-2020-P-1601-0002,FDA-2020-P-1601,acknowledgment letter from fda dms to  siri & glimstad llp on behalf of  informed consent action network,0,0
090000648470223d,Supporting & Related Material,FDA-2020-P-1601-0025,FDA-2020-P-1601,cover letter re: petition for administrative stay of action from siri & glimstad llp on behalf of informed consent action network,0,0
09000064846fee86,Supporting & Related Material,FDA-2020-P-1601-0003,FDA-2020-P-1601,cover letter - appendix to citizen petition re: citizen petition from informed consent action network,0,0
09000064846fee89,Supporting & Related Material,FDA-2020-P-1601-0005,FDA-2020-P-1601,appendix 2 re: citizen petition from informed consent action network,0,0
09000064846fee8c,Supporting & Related Material,FDA-2020-P-1601-0008,FDA-2020-P-1601,appendix 5 re: citizen petition from informed consent action network,0,0
09000064846feec9,Supporting & Related Material,FDA-2020-P-1601-0014,FDA-2020-P-1601,appendix 11 re: citizen petition from informed consent action network,0,0
09000064846feecc,Supporting & Related Material,FDA-2020-P-1601-0017,FDA-2020-P-1601,appendix 14 re: citizen petition from informed consent action network,0,0
09000064849301c6,Supporting & Related Material,FDA-2020-P-1601-0043,FDA-2020-P-1601,appendix 1 re: petition for administrative stay of action from informed consent action network,0,0
090000648493135b,Supporting & Related Material,FDA-2020-P-1601-0057,FDA-2020-P-1601,appendix 6 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fed23,Other,FDA-2020-P-1601-0001,FDA-2020-P-1601,citizen petition from siri & glimstad llp on behalf of  informed consent action network,0,0
09000064846fee88,Supporting & Related Material,FDA-2020-P-1601-0004,FDA-2020-P-1601,appendix 1 re: citizen petition from informed consent action network,0,0
09000064846feed3,Supporting & Related Material,FDA-2020-P-1601-0019,FDA-2020-P-1601,appendix 16 re: citizen petition from informed consent action network,0,0
09000064846feeca,Supporting & Related Material,FDA-2020-P-1601-0015,FDA-2020-P-1601,appendix 12 re: citizen petition from informed consent action network,0,0
09000064846feed5,Supporting & Related Material,FDA-2020-P-1601-0021,FDA-2020-P-1601,appendix 18 re: citizen petition from informed consent action network,0,0
090000648470223e,Supporting & Related Material,FDA-2020-P-1601-0026,FDA-2020-P-1601,attachment 1- petition for administrative action to require placebo control group in clinical trials of covid-19 vaccines re: petition for administrative stay of action from siri & glimstad llp on behalf of informed consent action network,0,0
09000064849312e8,Supporting & Related Material,FDA-2020-P-1601-0050,FDA-2020-P-1601,appendix 13 re: petition for administrative stay of action from informed consent action network,0,0
09000064849312e9,Supporting & Related Material,FDA-2020-P-1601-0051,FDA-2020-P-1601,appendix 12 re: petition for administrative stay of action from informed consent action network,0,0
0900006484931357,Supporting & Related Material,FDA-2020-P-1601-0056,FDA-2020-P-1601,appendix 7 re: petition for administrative stay of action from informed consent action network,0,0
09000064849301c7,Supporting & Related Material,FDA-2020-P-1601-0044,FDA-2020-P-1601,appendix 2 re: petition for administrative stay of action from informed consent action network,0,0
090000648499c70b,Other,FDA-2020-P-1601-0069,FDA-2020-P-1601,denial letter from fda cber to siri & glimstad llp,0,0
0900006484701f91,Other,FDA-2020-P-1601-0024,FDA-2020-P-1601,acknowledgment letter from fda dms to informed consent action network,0,0
09000064849301c5,Supporting & Related Material,FDA-2020-P-1601-0042,FDA-2020-P-1601,attachment 1- petition for administrative action to require placebo control group in clinical trials of covid-19 vaccines re: petition for administrative stay of action from siri & glimstad llp on behalf of informed consent action network,0,0
090000648042add9,Notice,FDA-2007-N-0218-0001,FDA-2007-N-0218,fda,0,0
090000648042addd,Notice,FDA-2007-N-0218-0003,FDA-2007-N-0218,fda,0,0
090000648042addc,Notice,FDA-2007-N-0218-0002,FDA-2007-N-0218,fda,0,0
090000648042ade0,Supporting & Related Material,FDA-2007-N-0218-0006,FDA-2007-N-0218,supporting statement,0,0
090000648042addf,Supporting & Related Material,FDA-2007-N-0218-0005,FDA-2007-N-0218,supporting statement,0,0
090000648042adde,Notice,FDA-2007-N-0218-0004,FDA-2007-N-0218,fda,0,0
0900006482cf30e7,Other,FDA-2017-P-6777-0002,FDA-2017-P-6777,"acknowledgement letter from fda ddm to hyman, phelps & mcnamara pc",0,0
09000064833225be,Other,FDA-2017-P-6777-0003,FDA-2017-P-6777,"interim response letter from fda cder to hyman, phelps & mcnamara pc",0,0
0900006484dad41d,Other,FDA-2017-P-6777-0004,FDA-2017-P-6777,"withdrawal from hyman, phelps & mcnamara, p.c.",0,0
0900006482cf2fdd,Other,FDA-2017-P-6777-0001,FDA-2017-P-6777,"citizen petition from hyman, phelps & mcnamara, p.c. (on behalf of xellia pharmaceutical )",0,0
09000064844833a6,Other,FDA-2019-P-4363-0007,FDA-2019-P-4363,"letter from hyman, phelps & mcnamara",0,0
0900006483f958e2,Supporting & Related Material,FDA-2019-P-4363-0004,FDA-2019-P-4363,"attachment 2 re citizen petition from hyman, phelps & mcnamara, p. c.",0,0
0900006483f958e3,Supporting & Related Material,FDA-2019-P-4363-0005,FDA-2019-P-4363,"attachment 3 re citizen petition from hyman, phelps & mcnamara, p. c.",0,0
0900006483f958e1,Supporting & Related Material,FDA-2019-P-4363-0003,FDA-2019-P-4363,"attachment 1 re citizen petition from hyman, phelps & mcnamara, p. c.",0,0
0900006483f958de,Other,FDA-2019-P-4363-0002,FDA-2019-P-4363,acknowledgment letter from fda dms to hyman phelps & mcnamara pc,0,0
0900006483f958dd,Other,FDA-2019-P-4363-0001,FDA-2019-P-4363,"citizen petition from hyman, phelps & mcnamara, p. c.",0,0
0900006483f958e4,Supporting & Related Material,FDA-2019-P-4363-0006,FDA-2019-P-4363,"attachment 4 re citizen petition from hyman, phelps & mcnamara, p. c.",0,0
0900006484e23f62,Other,FDA-2019-P-4363-0008,FDA-2019-P-4363,"citizen petition approval letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
09000064839ecc86,Other,FDA-2019-P-0198-0001,FDA-2019-P-0198,"citizen petition from lachman consultant services, inc.",0,0
09000064839ecf67,Supporting & Related Material,FDA-2019-P-0198-0003,FDA-2019-P-0198,"attachment-1-orange-book re citizen petition from lachman consultant services, inc.",0,0
0900006484165346,Other,FDA-2019-P-0198-0006,FDA-2019-P-0198,"response letter from fda to lachman consultant services, inc",0,0
0900006483d6ddeb,Other,FDA-2019-P-0198-0005,FDA-2019-P-0198,"letter from fda cder to lachman consultant services, inc.",0,0
09000064839ecf68,Supporting & Related Material,FDA-2019-P-0198-0004,FDA-2019-P-0198,"attachment-2-smz-tmp-os-ims-data re citizen petition from lachman consultant services, inc.",0,0
09000064839ecc87,Other,FDA-2019-P-0198-0002,FDA-2019-P-0198,"acknowledgment letter from fda ddm to lachman consultant services, inc.",0,0
0900006480f735ce,Notice,FDA-2011-N-0841-0001,FDA-2011-N-0841,"agency information collection activities; proposals, submissions, and approvals: food safety modernization act; economic hardship fee reduction guidance",1,0
090000648348dcc4,Other,FDA-2018-P-0097-0003,FDA-2018-P-0097,interim response from fda cder,0,0
0900006482db4257,Other,FDA-2018-P-0097-0002,FDA-2018-P-0097,"acknowledgement letter from fda ddm to hyman, phelps & mcnamara pc",0,0
0900006482db339a,Other,FDA-2018-P-0097-0001,FDA-2018-P-0097,"citizen petition from hyman, phelps & mcnamara",0,0
0900006483988972,Other,FDA-2018-P-0097-0004,FDA-2018-P-0097,"withdrawal  of petition from hyman, phelps & mcnamara pc",0,0
0900006482e29cc6,Other,FDA-2018-P-0268-0002,FDA-2018-P-0268,acknowledgment letter from fda ddm to arent fox llp,0,0
09000064835078e8,Other,FDA-2018-P-0268-0003,FDA-2018-P-0268,response letter from fda cder to arent fox llp,0,0
0900006482e29cc4,Other,FDA-2018-P-0268-0001,FDA-2018-P-0268,citizen petition from arent fox llp,0,0
0900006482e29ccb,Other,FDA-2018-P-0269-0002,FDA-2018-P-0269,acknowledgment letter from fda ddm to arent fox llp,0,0
0900006482e29cc8,Other,FDA-2018-P-0269-0001,FDA-2018-P-0269,citizen petition from arent fox llp,0,0
09000064835078ea,Other,FDA-2018-P-0269-0003,FDA-2018-P-0269,response letter from fda cder to arent fox llp,0,0
0900006482eee360,Other,FDA-2018-P-0564-0002,FDA-2018-P-0564,"acknowledgment letter from fda ddm to panera, llc",0,0
09000064836cfaaa,Other,FDA-2018-P-0564-0006,FDA-2018-P-0564,"interim response letter from fda cfsan to panera, llc",0,0
0900006482eee149,Other,FDA-2018-P-0564-0001,FDA-2018-P-0564,citizen petition from panera llc,0,0
0900006482b4ddea,Supporting & Related Material,FDA-2017-P-5799-0003,FDA-2017-P-5799,attachment 1 re citizen petition from granules pharmaceuticals inc,0,0
090000648300c1ec,Other,FDA-2017-P-5799-0004,FDA-2017-P-5799,interim response letter from fda cder to granules pharmaceuticals,0,0
0900006482b4dde8,Other,FDA-2017-P-5799-0002,FDA-2017-P-5799,acknowledgement letter from fda ddm to granules pharmaceuticals inc,0,0
09000064837fefbc,Other,FDA-2017-P-5799-0005,FDA-2017-P-5799,response letter from fda cder to granules pharmaceuticals,0,0
0900006482b4ddd9,Other,FDA-2017-P-5799-0001,FDA-2017-P-5799,citizen petition from granules pharmaceuticals inc,0,0
0900006481843c80,Other,FDA-2014-P-0637-0005,FDA-2014-P-0637,response letter from fda cder to lachman consultant services inc.,0,0
09000064816fd343,Other,FDA-2014-P-0637-0001,FDA-2014-P-0637,"citizen petition from lachman consultant services, inc.",0,0
09000064816fd349,Supporting & Related Material,FDA-2014-P-0637-0002,FDA-2014-P-0637,attachment 1 orange book listing citizen petition from lachman consultant services inc,0,0
09000064816fd347,Other,FDA-2014-P-0637-0003,FDA-2014-P-0637,acknowledgement letter from fda ddm to lachman consultant services inc.,0,0
090000648183b41a,Notice,FDA-2014-P-0637-0004,FDA-2014-P-0637,"determination that fusilev (levoleucovorin calcium), injection, 175 milligrams/17.5 milliliters and 250 milligrams/25 milliliters, were not
withdrawn from sale for reasons of safety or effectiveness",0,0
090000648172d9a8,Other,FDA-2014-P-0771-0001,FDA-2014-P-0771,citizen petition from hope pharmaceuticals,0,0
09000064817b2740,Other,FDA-2014-P-0771-0004,FDA-2014-P-0771,withdrawal letter from hope pharmaceuticals,0,0
09000064817559ac,Other,FDA-2014-P-0771-0003,FDA-2014-P-0771,withdrawal letter from hope pharmaceuticals,0,0
090000648172d9aa,Other,FDA-2014-P-0771-0002,FDA-2014-P-0771,acknowledgement letter from fda ddm to hope pharmaceuticals,0,0
0900006480fd2112,Other,FDA-2011-P-0662-0003,FDA-2011-P-0662,fda/cder to covington & burling llp (astrazeneca pharmaceuticals lp) - petition denial,0,0
0900006480f17198,Other,FDA-2011-P-0662-0001,FDA-2011-P-0662,covington & burling llp (astrazeneca pharmaceuticals lp)  - citizen petition,0,0
0900006480f1719d,Other,FDA-2011-P-0662-0002,FDA-2011-P-0662,acknowledgement letter to covington & burling llp (astrazeneca pharmaceuticals lp),0,0
0900006481872fa9,Other,FDA-2014-P-1383-0001,FDA-2014-P-1383,citizens petition from lachman consultant services inc,0,0
0900006481872fab,Supporting & Related Material,FDA-2014-P-1383-0003,FDA-2014-P-1383,attachment i orange book approved drug products with therapeutic equivalence evaluations,0,0
0900006481873288,Other,FDA-2014-P-1383-0002,FDA-2014-P-1383,acknowledgement letter from fda ddm to lachman consultant services inc,0,0
0900006481873281,Supporting & Related Material,FDA-2014-P-1383-0004,FDA-2014-P-1383,attachment ii highlights of prescribing information,0,0
0900006481873282,Supporting & Related Material,FDA-2014-P-1383-0005,FDA-2014-P-1383,attachment iii highlights of prescribing information,0,0
0900006481873283,Supporting & Related Material,FDA-2014-P-1383-0006,FDA-2014-P-1383,attachment iv highlights of prescribing information,0,0
0900006481b4919a,Other,FDA-2015-P-2247-0002,FDA-2015-P-2247,cover letter re citizen petition from tricia spencer,0,0
0900006481b49196,Other,FDA-2015-P-2247-0003,FDA-2015-P-2247,acknowledgement letter from fda ddm to tricia spencer,0,0
0900006481dba365,Other,FDA-2015-P-2247-0006,FDA-2015-P-2247,interim response letter from fda cfsan to tricia spencer,0,0
0900006481b48dbd,Other,FDA-2015-P-2247-0001,FDA-2015-P-2247,citizen petition from tricia spencer,0,0
09000064838047c6,Other,FDA-2018-P-3949-0002,FDA-2018-P-3949,"acknowledgment letter  from fda ddm to lachman consultant services, inc.",0,0
09000064838049e9,Supporting & Related Material,FDA-2018-P-3949-0003,FDA-2018-P-3949,"attachment 1 orange book re: citizens petition from lachman consultant services, inc.",0,0
09000064838049ea,Supporting & Related Material,FDA-2018-P-3949-0004,FDA-2018-P-3949,"attachment 2 highlights of prescribing information re: citizens petition from lachman consultant services, inc.",0,0
0900006483bb9439,Notice,FDA-2018-P-3949-0006,FDA-2018-P-3949,"determination that trisenox (arsenic trioxide) injection, 1 milligram/milliliter, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483bba430,Other,FDA-2018-P-3949-0007,FDA-2018-P-3949,"letter from fda cder to lachman consultant services, inc.",0,0
0900006483804597,Other,FDA-2018-P-3949-0001,FDA-2018-P-3949,"citizens petition from lachman consultant services, inc.",0,0
0900006483804b1e,Supporting & Related Material,FDA-2018-P-3949-0005,FDA-2018-P-3949,"attachment 3 highlights of prescribing information re: citizen petition from lachman consultant services, inc.",0,0
090000648420cba2,Other,FDA-2019-P-3424-0003,FDA-2019-P-3424,"response letter from fda cder to medical research collaborative, llc",0,0
0900006483d99361,Other,FDA-2019-P-3424-0002,FDA-2019-P-3424,"acknowledgment letter from fda ddm to medical research collaborative, llc",0,0
0900006483d992c3,Other,FDA-2019-P-3424-0001,FDA-2019-P-3424,"citizen petition from medical research collaborative, llc",0,0
0900006482c7bb0e,Supporting & Related Material,FDA-2017-P-6513-0010,FDA-2017-P-6513,reference-file 2 severe intestinal malabsorption associated with re citizen petition from public citizen,0,0
0900006482c7bb12,Supporting & Related Material,FDA-2017-P-6513-0006,FDA-2017-P-6513,reference-file 6 olmesartan associated sprue-like enteropathy and re citizen petition from public citizen,0,0
0900006482e8e423,Other,FDA-2017-P-6513-0012,FDA-2017-P-6513,supplement from public citizen,0,0
090000648406ab20,Other,FDA-2017-P-6513-0016,FDA-2017-P-6513,citizen petition denial letter from fda cder to public citizen,0,0
0900006482c7c927,Other,FDA-2017-P-6513-0002,FDA-2017-P-6513,acknowledgment letter from fda ddm to  public citizen,0,0
0900006482c7bb10,Supporting & Related Material,FDA-2017-P-6513-0008,FDA-2017-P-6513,reference-file 4 chronic diarrhea and weight loss re citizen petition from public citizen,0,0
0900006482c7bb14,Supporting & Related Material,FDA-2017-P-6513-0004,FDA-2017-P-6513,reference-file 8 antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension re citizen petition from public citizen,0,0
0900006482c7bb0f,Supporting & Related Material,FDA-2017-P-6513-0009,FDA-2017-P-6513,reference-file 3 letters to the editor re citizen petition from public citizen,0,0
0900006482c7bb13,Supporting & Related Material,FDA-2017-P-6513-0005,FDA-2017-P-6513,reference-file 7 “triple phase” budesonide capsules for re citizen petition from public citizen,0,0
090000648326326a,Other,FDA-2017-P-6513-0015,FDA-2017-P-6513,interim response from fda cder to public citizen,0,0
0900006482c7bb0d,Supporting & Related Material,FDA-2017-P-6513-0011,FDA-2017-P-6513,reference-file 1 - the comparative efficacy and safety of the angiotensin receptor re citizen petition from public citizen,0,0
0900006482c7bb11,Supporting & Related Material,FDA-2017-P-6513-0007,FDA-2017-P-6513,reference-file 5 a case of severe sprue-like enteropathy associated with re citizen petition from public citizen,0,0
0900006482c7bd5e,Supporting & Related Material,FDA-2017-P-6513-0003,FDA-2017-P-6513,reference-file 9 comparison of efficacy and safety of azilsartan and olmesartan re citizen petition from public citizen,0,0
0900006482c7bb0b,Other,FDA-2017-P-6513-0001,FDA-2017-P-6513,citizen petition from public citizen,0,0
09000064830e75f6,Other,FDA-2017-P-6411-0010,FDA-2017-P-6411,"petition response letter from fda cder to insys therapeutics, inc.",0,0
0900006482c59270,Other,FDA-2017-P-6411-0002,FDA-2017-P-6411,"acknowledgment letter from insys therapeutics, inc.",0,0
0900006482c5926d,Other,FDA-2017-P-6411-0001,FDA-2017-P-6411,"citizen petition from insys therapeutics, inc.",0,0
09000064824b7391,Other,FDA-2017-P-0866-0002,FDA-2017-P-0866,acknowledgment letter from fda ddm to hyman phelps & mcnamara,0,0
0900006483238d48,Other,FDA-2017-P-0866-0004,FDA-2017-P-0866,"response letter from cder to hyman, phelps & mcnamara p.c.",0,0
09000064829d6aee,Other,FDA-2017-P-0866-0003,FDA-2017-P-0866,"interim response letter from cder to hyman, phelps & mcnamara p.c.",0,0
09000064824b70a4,Other,FDA-2017-P-0866-0001,FDA-2017-P-0866,citizen petition from hyman phelps & mcnamara,0,0
09000064826c79eb,Supporting & Related Material,FDA-2017-P-3675-0003,FDA-2017-P-3675,"attachment  1- orange book listing for nalbuphine hydrochloride injection accessed on june 9, 2017",0,0
09000064826c6c8f,Other,FDA-2017-P-3675-0001,FDA-2017-P-3675,"citizen petition from  teligent pharma, inc.",0,0
09000064831471ab,Other,FDA-2017-P-3675-0005,FDA-2017-P-3675,petition denial letter from fda cder to teligent pharma,0,0
09000064826c7565,Other,FDA-2017-P-3675-0002,FDA-2017-P-3675,acknowledgement letter from fda ddm to teligent pharma inc.,0,0
0900006482cc68f9,Other,FDA-2017-P-3675-0004,FDA-2017-P-3675,interim response letter from fda cder to teligent pharma inc.,0,0
090000648378e4dc,Supporting & Related Material,FDA-2018-P-3746-0003,FDA-2018-P-3746,attachment 1 orange book search results re citizen petition from bf innovation inc on behalf of bright future pharmaceutical laboratories limited,0,0
090000648378e81b,Other,FDA-2018-P-3746-0001,FDA-2018-P-3746,citizen petition from bf innovation inc on behalf of bright future pharmaceutical laboratories limited,0,0
090000648378e81f,Other,FDA-2018-P-3746-0002,FDA-2018-P-3746,acknowledgment letter from fda ddm to bf innovation inc on behalf of bright future pharmaceutical laboratories limited,0,0
090000648378e4dd,Supporting & Related Material,FDA-2018-P-3746-0004,FDA-2018-P-3746,attachment 2 fda correspondence control re citizen petition from bf innovation inc on behalf of bright future pharmaceutical laboratories limited,0,0
090000648383fec5,Other,FDA-2018-P-3746-0005,FDA-2018-P-3746,letter re citizen petition from fda cder to bf innovation inc.,0,0
09000064844253ea,Supporting & Related Material,FDA-2020-P-1071-0003,FDA-2020-P-1071,"attachment 1 fda orange book page for ofirmev re suitability petition from hyman, phelps & mcnamara, pc",0,0
09000064844263de,Supporting & Related Material,FDA-2020-P-1071-0005,FDA-2020-P-1071,"attachment 3 proposed prescribing information for acetaminophen injection re suitability petition from hyman, phelps & mcnamara, pc",0,0
09000064844263dd,Supporting & Related Material,FDA-2020-P-1071-0004,FDA-2020-P-1071,"attachment 2 prescribing information for ofirmev re suitability petition from hyman, phelps & mcnamara, pc",0,0
09000064844253e7,Other,FDA-2020-P-1071-0002,FDA-2020-P-1071,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, pc",0,0
09000064844253e6,Other,FDA-2020-P-1071-0001,FDA-2020-P-1071,"suitability petition from hyman, phelps & mcnamara, pc",0,0
0900006483d97936,Other,FDA-2019-P-3156-0004,FDA-2019-P-3156,"withdrawal from medical research collaborative, llc",0,0
0900006483d51857,Other,FDA-2019-P-3156-0001,FDA-2019-P-3156,"citizen petition from medical research collaborative, llc",0,0
0900006483d525cb,Other,FDA-2019-P-3156-0002,FDA-2019-P-3156,"acknowledgment letter from fda ddm to medical research collaborative, llc",0,0
0900006483fcecd6,Other,FDA-2019-P-4507-0001,FDA-2019-P-4507,citizen petition from foley & lardner llp,0,0
09000064840e92fa,Other,FDA-2019-P-4507-0003,FDA-2019-P-4507,withdrawal from foley & lardner llp,0,0
0900006483fcf10d,Other,FDA-2019-P-4507-0002,FDA-2019-P-4507,acknowledgment letter from fda dms to foley & lardner llp,0,0
0900006481ba8cfa,Other,FDA-2013-P-0608-0005,FDA-2013-P-0608,supplement from janssen,0,0
09000064821eb780,Other,FDA-2013-P-0608-0007,FDA-2013-P-0608,"supplement from janssen research and development, llc",0,0
09000064816afeba,Other,FDA-2013-P-0608-0004,FDA-2013-P-0608,"supplement from janssen research & development, llc",0,0
0900006484be923e,Other,FDA-2013-P-0608-0008,FDA-2013-P-0608,"agency response letter from fda cder to janssen research and development, l.l.c. (ropes & gray, llp)",0,0
0900006481e96981,Other,FDA-2013-P-0608-0006,FDA-2013-P-0608,"supplement from janssen research and development, llc",0,0
090000648147ae77,Other,FDA-2013-P-0608-0003,FDA-2013-P-0608,"fda/cder interim response to ropes & gray, llp - letter",0,0
09000064812e43a1,Other,FDA-2013-P-0608-0002,FDA-2013-P-0608,"acknowledgement letter to janssen research and development, l.l.c. (ropes & gray, llp)",0,0
09000064812e3ad5,Other,FDA-2013-P-0608-0001,FDA-2013-P-0608,"janssen research and development, l.l.c. (ropes & gray, llp) - citizen petition",0,0
090000648042d8a5,Other,FDA-2007-P-0401-0001,FDA-2007-P-0401,fda/ddm to public citizen health research group,0,0
090000648042d8b8,Other,FDA-2007-P-0401-0002,FDA-2007-P-0401,public citizen health research group - citizen petition,0,0
0900006480b1cb58,Other,FDA-2007-P-0401-0004,FDA-2007-P-0401,see fda-2007-p-0401-0005,0,0
0900006480b1cb93,Other,FDA-2007-P-0401-0005,FDA-2007-P-0401,fda/cder to  public citizen's  health research group- petition denial,0,0
090000648042d8bc,Other,FDA-2007-P-0401-0003,FDA-2007-P-0401,fda/cder interim response to public citizen's health research group - letter,0,0
0900006480470253,Supporting & Related Material,FDA-2004-D-0184-0007,FDA-2004-D-0184,guidance,0,0
0900006480470250,Supporting & Related Material,FDA-2004-D-0184-0004,FDA-2004-D-0184,supporting statement,0,0
090000648047024f,Notice,FDA-2004-D-0184-0003,FDA-2004-D-0184,fda,0,0
090000648047024b,Notice,FDA-2004-D-0184-0001,FDA-2004-D-0184,fda,0,0
0900006480470251,Supporting & Related Material,FDA-2004-D-0184-0005,FDA-2004-D-0184,supporting statement,0,0
0900006480470252,Notice,FDA-2004-D-0184-0006,FDA-2004-D-0184,fda,0,0
0900006480470254,Notice,FDA-2004-D-0184-0008,FDA-2004-D-0184,fda,0,0
090000648047024c,Supporting & Related Material,FDA-2004-D-0184-0002,FDA-2004-D-0184,guideline,0,0
0900006484d94422,Other,FDA-2021-P-1019-0002,FDA-2021-P-1019,"acknowledgment letter from fda dms to emery pharma on behalf of najafi pharma, inc.",0,0
0900006484d9445a,Supporting & Related Material,FDA-2021-P-1019-0004,FDA-2021-P-1019,"appendix b independent testimonial from ilkcan cokgor, md, neurologist. re citizen petition from emery pharma on behalf of najafi pharma, inc.",0,0
0900006484d9441e,Other,FDA-2021-P-1019-0001,FDA-2021-P-1019,"citizen petition from emery pharma on behalf of najafi pharma, inc.",0,0
0900006484d94457,Supporting & Related Material,FDA-2021-P-1019-0003,FDA-2021-P-1019,"appendix a  recommended dietary allowances (rdas) for vitamin b6 re citizen petition from emery pharma on behalf of najafi pharma, inc.",0,0
0900006484e374e3,Supporting & Related Material,FDA-2021-P-1211-0003,FDA-2021-P-1211,exhibit a re: citizen petition from axinn on behalf of par sterile products llc,0,0
0900006484e374e4,Supporting & Related Material,FDA-2021-P-1211-0004,FDA-2021-P-1211,exhibit b re: citizen petition from axinn on behalf of par sterile products llc,0,0
0900006484e374e5,Supporting & Related Material,FDA-2021-P-1211-0005,FDA-2021-P-1211,exhibit c re: citizen petition from axinn on behalf of par sterile products llc,0,0
0900006484e3817e,Other,FDA-2021-P-1211-0001,FDA-2021-P-1211,citizen petition from axinn on behalf of par sterile products llc,0,0
0900006484e374e6,Supporting & Related Material,FDA-2021-P-1211-0006,FDA-2021-P-1211,exhibit d re: citizen petition from axinn on behalf of par sterile products llc,0,0
0900006484e368f5,Other,FDA-2021-P-1211-0002,FDA-2021-P-1211,acknowledgment letter from fda dms to axinn on behalf of par sterile products llc,0,0
0900006483e73ca4,Notice,FDA-2019-P-0466-0004,FDA-2019-P-0466,"determination that dextrose, 20 grams/100 milliliters, and dextrose, 50
grams/100 milliliters, in plastic containers, were not withdrawn from
sale for reasons of safety or effectiveness",0,0
0900006483a28e12,Other,FDA-2019-P-0466-0002,FDA-2019-P-0466,"acknowledgment letter from fda ddm to fresenius kabi usa, llc",0,0
0900006483a28e10,Other,FDA-2019-P-0466-0001,FDA-2019-P-0466,"citizen petition from fresenius kabi usa, llc",0,0
0900006483ebeecb,Other,FDA-2019-P-0466-0005,FDA-2019-P-0466,"letter from fda cder to fresenius kabi usa, llc",0,0
0900006483db8d61,Other,FDA-2019-P-0466-0003,FDA-2019-P-0466,"letter from fda cder to fresenius kabi usa, llc",0,0
0900006483c5ebb0,Other,FDA-2019-P-2290-0001,FDA-2019-P-2290,citizen petition from alembic pharmaceuticals limited,0,0
0900006483c74f56,Other,FDA-2019-P-2290-0003,FDA-2019-P-2290,acknowledgment letter from fda ddm to alembic pharmaceuticals limited,0,0
0900006483e2d0b1,Notice,FDA-2019-P-2290-0004,FDA-2019-P-2290,"determination that levitra (vardenafil hydrochloride) tablets, 2.5
milligrams were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483e3599b,Other,FDA-2019-P-2290-0005,FDA-2019-P-2290,letter from fda cder to alembic pharmaceuticals limited,0,0
0900006483c5f049,Supporting & Related Material,FDA-2019-P-2290-0002,FDA-2019-P-2290,"exhibit-1- orange book: approved drug products with
therapeutic equivalence evaluations re: citizen petition from syneos health, llc.",0,0
0900006482d58b5b,Other,FDA-2017-P-6967-0001,FDA-2017-P-6967,citizen petition from bergstrom nutrition,0,0
0900006482d58b5f,Other,FDA-2017-P-6967-0002,FDA-2017-P-6967,acknowledgment letter from fda ddm to bergstrom nutrition,0,0
0900006482d58b61,Supporting & Related Material,FDA-2017-P-6967-0003,FDA-2017-P-6967,appendix for citizen petition from bergstrom nutrition,0,0
09000064838a6958,Other,FDA-2017-P-3950-0004,FDA-2017-P-3950,withdrawal from piramal,0,0
0900006482d35e60,Other,FDA-2017-P-3950-0003,FDA-2017-P-3950,interim response from fda to amin talati upadhye llp,0,0
09000064827976ff,Other,FDA-2017-P-3950-0002,FDA-2017-P-3950,acknowledgment letter citizen petition from  amin talati upadhye llp,0,0
0900006482797669,Other,FDA-2017-P-3950-0001,FDA-2017-P-3950,citizen petition from  amin talati upadhye llp (fera pharmaceuticals llc),0,0
090000648240195d,Other,FDA-2016-P-1363-0006,FDA-2016-P-1363,"letter to gordon johnston regulatory consultants, llc",0,0
09000064823f9857,Notice,FDA-2016-P-1363-0005,FDA-2016-P-1363,"determination that sodium chloride 23.4% in plastic container 
(sodium chloride), injectable, 234 milligrams/milliliter, was not withdrawn from sale for reasons of safety or effectiveness",0,0
09000064823a3c4c,Other,FDA-2016-P-1363-0004,FDA-2016-P-1363,"interim response letter from cder to gordon johnston regulatory consultants, llc",0,0
0900006481ff6f89,Other,FDA-2016-P-1363-0001,FDA-2016-P-1363,"citizen petition from gordon johnston regulatory consultants, llc",0,0
0900006481ff7191,Supporting & Related Material,FDA-2016-P-1363-0003,FDA-2016-P-1363,"attachment 1 product listing from the discontinued section of orange book re gordon johnston regulatory consultants, llc",0,0
0900006481ff6f8b,Other,FDA-2016-P-1363-0002,FDA-2016-P-1363,"acknowledgement letter from fda ddm to gordon johnston regulatory consultants, llc",0,0
090000648260d637,Other,FDA-2016-P-4274-0004,FDA-2016-P-4274,"citizen petition response letter from fda cder to teligent, inc.",0,0
09000064823eeac1,Other,FDA-2016-P-4274-0001,FDA-2016-P-4274,"citizen petition from teligent, inc.",0,0
09000064823eeb0c,Supporting & Related Material,FDA-2016-P-4274-0003,FDA-2016-P-4274,attachment 1 - orange book  listing for mupirocin ointment 2% re,0,0
09000064823eeb0a,Other,FDA-2016-P-4274-0002,FDA-2016-P-4274,"acknowledgment letter from fda ddm to teligent, inc.",0,0
0900006481e841ad,Other,FDA-2016-P-0689-0001,FDA-2016-P-0689,"citizen petition from leana wen, m.d., m.sc., commissioner of health, baltimore city department of health, et al.",0,0
0900006481e84884,Other,FDA-2016-P-0689-0002,FDA-2016-P-0689,"acknowledgement letter from fda ddm to the commissioner of health, baltimore city department of health",0,0
09000064821b8b47,Other,FDA-2016-P-0689-0003,FDA-2016-P-0689,"response letter from fda cder to the commissioner of health, baltimore city department of health",0,0
0900006480e50859,Other,FDA-2011-P-0458-0002,FDA-2011-P-0458,acknowledgement letter to personal care products council,0,0
09000064824a69ef,Other,FDA-2011-P-0458-0005,FDA-2011-P-0458,scanned letter to ms. westine personal care products council no ccs,0,0
0900006480e43d1b,Other,FDA-2011-P-0458-0001,FDA-2011-P-0458,personal care products council - citizen peition,0,0
0900006480f7bda4,Other,FDA-2011-P-0458-0003,FDA-2011-P-0458,interim response to personal care products council  - letter,0,0
0900006481acf2eb,Supporting & Related Material,FDA-2015-P-1553-0006,FDA-2015-P-1553,"attachment 5 teva pharmaceutical industries, ltd. (teva respiratory, l.l.c.) - citizen petition; citizen petition from 3m drug delivery systems",0,0
0900006481acf30f,Supporting & Related Material,FDA-2015-P-1553-0013,FDA-2015-P-1553,attachment 12 correspondence from dr. eli meltzer; citizen petition from 3m drug delivery systems,0,0
0900006481c79ec3,Other,FDA-2015-P-1553-0015,FDA-2015-P-1553,citizen petition denial response letter from fda cder to 3m health care business,0,0
0900006481acf2e8,Supporting & Related Material,FDA-2015-P-1553-0004,FDA-2015-P-1553,attachment 2 combination products; citizen petition from 3m drug delivery systems,0,0
0900006481acf0ae,Other,FDA-2015-P-1553-0001,FDA-2015-P-1553,citizen petition from 3m drug delivery systems,0,0
0900006481acf2ea,Supporting & Related Material,FDA-2015-P-1553-0005,FDA-2015-P-1553,attachment 4 asthma attack action plan; citizen petition from 3m drug delivery systems,0,0
0900006481acf2ed,Supporting & Related Material,FDA-2015-P-1553-0008,FDA-2015-P-1553,"attachment 7 d.k. raynor, p. knapp, do patients see, read and retain the new mandatory medicines information leaflets; citizen petition from 3m drug delivery systems",0,0
0900006481acf30d,Supporting & Related Material,FDA-2015-P-1553-0011,FDA-2015-P-1553,attachment 10 label and labeling review; citizen petition from 3m drug delivery systems,0,0
0900006481acf2ec,Supporting & Related Material,FDA-2015-P-1553-0007,FDA-2015-P-1553,attachment 6 citizen petition partial approval and denial response from fda cder to teva pharmaceuticals; citizen petition from 3m drug delivery systems,0,0
0900006481acf30e,Supporting & Related Material,FDA-2015-P-1553-0012,FDA-2015-P-1553,"attachment 11 a patients guide to aerosol drug delivery, american association for respiratory care; citizen petition from 3m drug delivery systems",0,0
0900006481acf0af,Other,FDA-2015-P-1553-0002,FDA-2015-P-1553,acknowledgement letter from fda ddm to 3m drug delivery systems,0,0
0900006481acf2e7,Supporting & Related Material,FDA-2015-P-1553-0003,FDA-2015-P-1553,attachment 1 guidance for industry metered dose inhaler (mdi) and dry powder inhaler (dpi) drug products; citizen petition from 3m drug delivery system,0,0
0900006481acf2ee,Supporting & Related Material,FDA-2015-P-1553-0009,FDA-2015-P-1553,"attachment 8 s. vinker, v. eliyahu, j. yaphe, the effect of drug information leaflets on patient behavior; citizen petition from 3m drug delivery systems",0,0
0900006481acf2ef,Supporting & Related Material,FDA-2015-P-1553-0010,FDA-2015-P-1553,attachment 9 fda's draft guidance for industry and food and drug administration staff- applying human factors and usability engineering to optimize medical device design; citizen petition from 3m drug delivery systems,1,0
09000064829fbead,Other,FDA-2017-P-4852-0002,FDA-2017-P-4852,acknowledgment letter from fda ddm to eas consulting group ( jubilant generics ltd.),0,0
0900006482f38a5a,Notice,FDA-2017-P-4852-0003,FDA-2017-P-4852,"determination that lotensin hct (benazepril hydrochloride;
hydrochlorothiazide) oral tablets, 5 milligrams and 6.25 milligrams, were
not withdrawn from sale for reasons of safety or effectiveness",0,0
09000064829fbea9,Other,FDA-2017-P-4852-0001,FDA-2017-P-4852,citizen petition from  eas consulting group ( jubilant generics ltd.),0,0
0900006482f5269c,Other,FDA-2017-P-4852-0004,FDA-2017-P-4852,"letter from fda cder to pharmaceutical & device consulting services
eas consulting group, llc",0,0
09000064824b6ea0,Other,FDA-2017-P-0863-0002,FDA-2017-P-0863,"acknowledgment letter from fda ddm to  fresenius kabi usa, llc",0,0
09000064824b7155,Other,FDA-2017-P-0863-0001,FDA-2017-P-0863,"citizen petition from fresenius kabi usa, llc",0,0
09000064835f388e,Other,FDA-2017-P-0863-0004,FDA-2017-P-0863,request for withdrawal sp for pbp,0,0
09000064824b7157,Supporting & Related Material,FDA-2017-P-0863-0003,FDA-2017-P-0863,attachment 1 orange book: approved drug products with therapeutic equivalence evaluations,0,0
0900006481a290b5,Other,FDA-2015-P-0051-0004,FDA-2015-P-0051,inrange trade complaint response letter final,0,0
09000064819a777c,Other,FDA-2015-P-0051-0001,FDA-2015-P-0051,citizen petition request from inrange systems inc,0,0
09000064819aaa1a,Other,FDA-2015-P-0051-0002,FDA-2015-P-0051,acknowledgement letter from fda ddm to inrange systems inc,0,0
09000064819aaa1e,Supporting & Related Material,FDA-2015-P-0051-0003,FDA-2015-P-0051,exhibit a,0,0
090000648375b94d,Supporting & Related Material,FDA-2018-P-3616-0003,FDA-2018-P-3616,chloroquine phosphate 250mg tab 06-2018- ims data re citizen petition from suven life sciences limited,0,0
090000648375b5b9,Other,FDA-2018-P-3616-0001,FDA-2018-P-3616,citizen petition from suven life sciences limited,0,0
090000648375b951,Supporting & Related Material,FDA-2018-P-3616-0007,FDA-2018-P-3616,non-availablity from pharmacy re citizen petition from suven life sciences limited,0,0
090000648438e94c,Other,FDA-2018-P-3616-0011,FDA-2018-P-3616,response letter from fda cder to suven life sciences limited,0,0
090000648375b949,Other,FDA-2018-P-3616-0002,FDA-2018-P-3616,acknowledgment letter from fda ddm to suven life sciences limited,0,0
0900006483b01dc5,Other,FDA-2018-P-3616-0010,FDA-2018-P-3616,letter from fda cder to suven life sciences limited,0,0
090000648377501e,Other,FDA-2018-P-3616-0009,FDA-2018-P-3616,acknowledgment letter from fda ddm to suven life sciences limited,0,0
090000648375b94f,Supporting & Related Material,FDA-2018-P-3616-0005,FDA-2018-P-3616,environmental-assesement re citizen petition from suven life sciences limited,0,0
090000648375b950,Supporting & Related Material,FDA-2018-P-3616-0006,FDA-2018-P-3616,national drug code directory-chloroquine phosphate 250mg-15-09-2018 re citizen petition from suven life sciences limited,0,0
090000648375b94e,Supporting & Related Material,FDA-2018-P-3616-0004,FDA-2018-P-3616,dailymed - rising chloroquine phosphate 250mg - chloroquine phosphate tablet re citizen petition from suven life sciences limited,0,0
090000648375b968,Supporting & Related Material,FDA-2018-P-3616-0008,FDA-2018-P-3616,orange book_ approved drug products with therapeutic equivalence evaluations-250mg-natco re citizen petition from suven life sciences limited,0,0
09000064826c7646,Other,FDA-2017-P-3684-0001,FDA-2017-P-3684,"citizen petition from goodwin procter llp (boehringer ingelheim usa corporation (""biusa""))",0,0
0900006482b4b3e1,Other,FDA-2017-P-3684-0004,FDA-2017-P-3684,final response letter from fda to goodwin procter llp,0,0
09000064826c860b,Supporting & Related Material,FDA-2017-P-3684-0003,FDA-2017-P-3684,"global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2017 report re citizen petition from goodwin procter llp",0,0
09000064826c8609,Other,FDA-2017-P-3684-0002,FDA-2017-P-3684,"acknowledgment letter from fda ddm to goodwin procter llp (boehringer ingelheim usa corporation (""biusa""))",0,0
0900006484817292,Other,FDA-2020-P-1792-0002,FDA-2020-P-1792,acknowledgment letter from fda dms to macleods pharmaceuticals limited,0,0
0900006484817291,Other,FDA-2020-P-1792-0001,FDA-2020-P-1792,citizen petition from macleods pharmaceuticals limited,0,0
090000648481763e,Supporting & Related Material,FDA-2020-P-1792-0003,FDA-2020-P-1792,attachments from citizen petition from macleods pharmaceuticals limited,0,0
090000648496ac0f,Other,FDA-2020-P-1792-0004,FDA-2020-P-1792,withdrawal from macleods pharmaceuticals limited,0,0
09000064846fb322,Supporting & Related Material,FDA-2020-P-1597-0022,FDA-2020-P-1597,appendix 4 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb342,Supporting & Related Material,FDA-2020-P-1597-0019,FDA-2020-P-1597,appendix 7 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb343,Supporting & Related Material,FDA-2020-P-1597-0018,FDA-2020-P-1597,appendix 8 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb346,Supporting & Related Material,FDA-2020-P-1597-0015,FDA-2020-P-1597,appendix 11 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb829,Supporting & Related Material,FDA-2020-P-1597-0012,FDA-2020-P-1597,appendix 14 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb321,Supporting & Related Material,FDA-2020-P-1597-0023,FDA-2020-P-1597,appendix 3 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb323,Supporting & Related Material,FDA-2020-P-1597-0021,FDA-2020-P-1597,appendix 5 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb326,Supporting & Related Material,FDA-2020-P-1597-0020,FDA-2020-P-1597,appendix 6 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb82e,Supporting & Related Material,FDA-2020-P-1597-0007,FDA-2020-P-1597,appendix 19 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb345,Supporting & Related Material,FDA-2020-P-1597-0016,FDA-2020-P-1597,appendix 10 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb82a,Supporting & Related Material,FDA-2020-P-1597-0011,FDA-2020-P-1597,appendix 15 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb344,Supporting & Related Material,FDA-2020-P-1597-0017,FDA-2020-P-1597,appendix  re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb82d,Supporting & Related Material,FDA-2020-P-1597-0008,FDA-2020-P-1597,appendix 18 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb31f,Supporting & Related Material,FDA-2020-P-1597-0005,FDA-2020-P-1597,appendix 1 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb82b,Supporting & Related Material,FDA-2020-P-1597-0010,FDA-2020-P-1597,appendix 16 re: petition for administrative stay of action from informed consent action network,0,0
09000064846faf80,Supporting & Related Material,FDA-2020-P-1597-0003,FDA-2020-P-1597,cover letter re: petition for administrative stay of action from siri & glimstad llp on behalf of informed consent action network,0,0
09000064846fb320,Supporting & Related Material,FDA-2020-P-1597-0006,FDA-2020-P-1597,appendix 2 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb347,Supporting & Related Material,FDA-2020-P-1597-0014,FDA-2020-P-1597,appendix 12 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb348,Supporting & Related Material,FDA-2020-P-1597-0013,FDA-2020-P-1597,appendix 13 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb82c,Supporting & Related Material,FDA-2020-P-1597-0009,FDA-2020-P-1597,appendix 17 re: petition for administrative stay of action from informed consent action network,0,0
09000064846fb0f2,Supporting & Related Material,FDA-2020-P-1597-0004,FDA-2020-P-1597,attachment 1- petition for administrative action to require placebo control group in clinical trials of covid-19 vaccines re: petition for administrative stay of action from siri & glimstad llp on behalf of informed consent action network,0,0
09000064846faf7e,Other,FDA-2020-P-1597-0002,FDA-2020-P-1597,acknowledgment letter from fda dms to informed consent action network,0,0
09000064846fab05,Other,FDA-2020-P-1597-0001,FDA-2020-P-1597,petition for administrative stay of action from informed consent action network,0,0
0900006484dfa7d2,Other,FDA-2021-P-1174-0002,FDA-2021-P-1174,acknowledgment letter from fda dms to felix pharmaceuticals pvt ltd,0,0
0900006484dfa7f6,Other,FDA-2021-P-1174-0001,FDA-2021-P-1174,suitability petition from felix pharmaceuticals pvt ltd,0,0
0900006484dfa6de,Supporting & Related Material,FDA-2021-P-1174-0003,FDA-2021-P-1174,attachment 1 re suitability petition from felix pharmaceuticals pvt ltd,0,0
0900006484dfa6df,Supporting & Related Material,FDA-2021-P-1174-0004,FDA-2021-P-1174,attachment 2 re suitability petition from felix pharmaceuticals pvt ltd,0,0
090000648207fcb3,Other,FDA-2016-P-1875-0002,FDA-2016-P-1875,acknowledgement letter from fda ddm to pacific-link consulting (adapt pharma),0,0
090000648207fcb0,Other,FDA-2016-P-1875-0001,FDA-2016-P-1875,citizen petition from pacific-link consulting (adapt pharma),0,0
090000648213651b,Other,FDA-2016-P-1875-0003,FDA-2016-P-1875,adapt pharma withdrawal 13jul2016,0,0
09000064829509ec,Other,FDA-2016-P-3753-0007,FDA-2016-P-3753,petition response letter from fda cder to macleods pharmaceuticals limited,0,0
09000064823840c0,Supporting & Related Material,FDA-2016-P-3753-0004,FDA-2016-P-3753,attachment 2 horizon pharma plc announces acquisition of u.s. rights to pennsaid® 2% from nuvo research inc. re citizen petition from macleods pharmaceuticals limited,0,0
09000064823840bd,Other,FDA-2016-P-3753-0001,FDA-2016-P-3753,citizen petition from macleods pharmaceuticals limited,0,0
09000064823840c1,Supporting & Related Material,FDA-2016-P-3753-0005,FDA-2016-P-3753,attachment 3 growth dynamics audit from september 2012 to september 2016 re citizen petition from macleods pharmaceuticals limited,0,0
0900006482595541,Other,FDA-2016-P-3753-0006,FDA-2016-P-3753,interim response letter from fda cder to macleods pharmaceuticals limited,0,0
09000064823840bf,Supporting & Related Material,FDA-2016-P-3753-0003,FDA-2016-P-3753,attachment 1 approved drug products with therapeutic equivalence evaluations re citizen petition from macleods pharmaceuticals limited,0,0
09000064823856b2,Other,FDA-2016-P-3753-0002,FDA-2016-P-3753,acknowledgment letter from fda ddm to macleods pharmaceuticals limited,0,0
0900006481a8aa21,Supporting & Related Material,FDA-2015-P-1090-0004,FDA-2015-P-1090,"attachment b, product labeling for cortifoam re citizen petition from baker hostetler, llp",0,0
0900006481a8a325,Other,FDA-2015-P-1090-0001,FDA-2015-P-1090,"citizen petition from baker hostetler, llp",0,0
0900006481c9f521,Other,FDA-2015-P-1090-0005,FDA-2015-P-1090,interim response letter from fda cder to baker hostetler llp,0,0
0900006481a8a327,Other,FDA-2015-P-1090-0002,FDA-2015-P-1090,"acknowledgement letter from fda ddm to baker hostetler, llp",0,0
0900006481a8a329,Supporting & Related Material,FDA-2015-P-1090-0003,FDA-2015-P-1090,"attachment a background materials re citizen petition from baker hostetler, llp",0,0
09000064824b9d45,Other,FDA-2017-P-0899-0001,FDA-2017-P-0899,"citizen petition from  hyman, phelps & mcnamara, p.c.",0,0
09000064824b9d47,Other,FDA-2017-P-0899-0002,FDA-2017-P-0899,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara,
 p. c.",0,0
090000648425184b,Supporting & Related Material,FDA-2019-P-6048-0003,FDA-2019-P-6048,"attachment 1 orange book listing of sodium chloride 0.9% irrigation usp re suitability petition from fresenius kabi usa, llc",0,0
090000648425184d,Supporting & Related Material,FDA-2019-P-6048-0005,FDA-2019-P-6048,"attachment 3 fresenius kabi proposed package insert for sodium chloride 0.9% irrigation usp re suitability petition from fresenius kabi usa, llc",0,0
090000648425197e,Other,FDA-2019-P-6048-0002,FDA-2019-P-6048,"acknowledgment letter from fda dms to fresenius kabi usa, llc",0,0
090000648425197d,Other,FDA-2019-P-6048-0001,FDA-2019-P-6048,"suitability petition from fresenius kabi usa, llc",0,0
090000648425184c,Supporting & Related Material,FDA-2019-P-6048-0004,FDA-2019-P-6048,"attachment 2 reference listed drug labeling sodium chloride 0.9% irrigation usp re suitability petition from fresenius kabi usa, llc",0,0
09000064844721dd,Other,FDA-2020-P-1166-0005,FDA-2020-P-1166,agency response  letter from fda cdrh to eckert seamans cherin & mellott llc,0,0
0900006484461b47,Other,FDA-2020-P-1166-0002,FDA-2020-P-1166,acknowledgment letter from fda dms to eckert seamans cherin & mellott llc,0,0
0900006484461b46,Supporting & Related Material,FDA-2020-P-1166-0004,FDA-2020-P-1166,"petition for stay of action cover letter from eckert seamans cherin & mellott, llc re: petition for stay of action  from eckert seamans cherin & mellott, llc",0,0
0900006484461b49,Supporting & Related Material,FDA-2020-P-1166-0003,FDA-2020-P-1166,"exhibit list re: petition for stay of action  from eckert seamans cherin & mellott, llc",0,0
0900006484461b44,Other,FDA-2020-P-1166-0001,FDA-2020-P-1166,"petition for stay of action  from eckert seamans cherin & mellott, llc",0,0
0900006483ebee56,Other,FDA-2019-P-4003-0002,FDA-2019-P-4003,acknowledgment letter from fda dms to lisa myslinski,0,0
0900006483ebee54,Other,FDA-2019-P-4003-0001,FDA-2019-P-4003,citizen petition from lisa myslinski,0,0
09000064843bc552,Other,FDA-2019-P-4003-0003,FDA-2019-P-4003,letter from fda cder to lisa myslinski,0,0
09000064829e1136,Other,FDA-2017-P-4791-0002,FDA-2017-P-4791,"acknowledgement letter from ddm to hyman, phelps, & mcnamara, p.c. (exela pharma sciences )",0,0
0900006484a6c81c,Other,FDA-2017-P-4791-0005,FDA-2017-P-4791,"withdrawal from hyman, phelps, & mcnamara, p.c. (exela pharma sciences)",0,0
09000064829e0d34,Other,FDA-2017-P-4791-0001,FDA-2017-P-4791,"citizen petition from hyman, phelps, & mcnamara, p.c. (exela pharma sciences )",0,0
0900006482e9d32a,Other,FDA-2017-P-4791-0004,FDA-2017-P-4791,"interim response letter from cder to hyman, phelps, & mcnamara, p.c.",0,0
09000064836ce115,Supporting & Related Material,FDA-2018-P-3422-0004,FDA-2018-P-3422,"attachment 2 regulatory agent appointment letter for the nda #013718, oxandrin®( oxandrolone) tablets, usp 2.5 mg and io mg. re: citizen petition from novitium pharma llc",0,0
09000064836cd6a5,Other,FDA-2018-P-3422-0002,FDA-2018-P-3422,acknowledgment letter from fda ddm to novitum pharma llc,0,0
0900006483abc92d,Other,FDA-2018-P-3422-0005,FDA-2018-P-3422,letter from fda cder to novitium pharma llc,0,0
0900006484a81ee7,Other,FDA-2018-P-3422-0006,FDA-2018-P-3422,withdrawal from novitium pharma llc,0,0
09000064836cb83c,Other,FDA-2018-P-3422-0001,FDA-2018-P-3422,citizen petition from novitium pharma llc.,0,0
09000064836cd83a,Supporting & Related Material,FDA-2018-P-3422-0003,FDA-2018-P-3422,attachment 1- orange book: approved drug products with therapeutic equivalence evaluations  re; citizen petition from novitium pharma llc,0,0
0900006484932182,Other,FDA-2020-P-2130-0002,FDA-2020-P-2130,"acknowledgment letter from fda dms to fresenius kabi usa, llc",0,0
09000064849327de,Supporting & Related Material,FDA-2020-P-2130-0003,FDA-2020-P-2130,"attachment a: product listing from the current (26 october 2020) orange book for bortezomib for injection re citizen petition from fresenius kabi usa, llc",0,0
0900006484b7c3cf,Other,FDA-2020-P-2130-0006,FDA-2020-P-2130,"withdrawal request  from fresenius kabi usa, llc",0,0
0900006484932181,Other,FDA-2020-P-2130-0001,FDA-2020-P-2130,"citizen petition from fresenius kabi usa, llc",0,0
090000648046ff88,Other,FDA-2004-P-0151-0007,FDA-2004-P-0151,mcneil consumer & specialty pharmaceuticals - supplement petition,0,0
090000648046ff68,Other,FDA-2004-P-0151-0003,FDA-2004-P-0151,fda cder interim response to mcneil consumer & specialty pharmaceuticals - letter,0,0
09000064810a5045,Other,FDA-2004-P-0151-0011,FDA-2004-P-0151,"johnson & johnson pharmaceutical research & development, llc - petition partial approval and denial",0,0
090000648046ff50,Other,FDA-2004-P-0151-0002,FDA-2004-P-0151,acknowledgement letter to mcneil consumer & specialty pharmaceuticals,0,0
09000064807cd1af,Other,FDA-2004-P-0151-0009,FDA-2004-P-0151,mcneil pediatrics - amendment petition,0,0
090000648046ff48,Other,FDA-2004-P-0151-0004,FDA-2004-P-0151,mcneil consumer & specialty pharmaceuticals - citizen petition,0,0
09000064807cef24,Supporting & Related Material,FDA-2004-P-0151-0005,FDA-2004-P-0151,reference list (volume 2) - mcneil consumer & specialty pharmaceuticals - citizen petition],0,0
090000648046ff44,Other,FDA-2004-P-0151-0001,FDA-2004-P-0151,acknowledgement letter to mcneil consumer & specialty pharmaceuticals,0,0
09000064807cef33,Supporting & Related Material,FDA-2004-P-0151-0006,FDA-2004-P-0151,"references - ""21 cfr 320.1, 21 cfr 320.24, and 21 cfr 320.26"" - [mcneil consumer & specialty pharmaceuticals - citizen petition]",0,0
090000648046ff69,Supporting & Related Material,FDA-2004-P-0151-0008,FDA-2004-P-0151,reference documents (volume 1) - mcneil consumer & specialty pharmaceuticals - supplement petition],0,0
0900006480af00c6,Other,FDA-2004-P-0151-0010,FDA-2004-P-0151,mcneil consumer & specialty pharmaceuticals - supplement,0,0
090000648039acfd,Notice,FDA-2008-N-0025-0001,FDA-2008-N-0025,agency information collection activities; proposed collection; comment request; orphan drugs; common european medicines agency/food and drug administration application form for orphan medicinal product designation (form fda 3671),1,0
090000648314f332,Supporting & Related Material,FDA-2018-P-1531-0006,FDA-2018-P-1531,"attachment 4 ephedrine sulfate injection, usp re petition from king & spalding llp",0,0
090000648314f316,Other,FDA-2018-P-1531-0002,FDA-2018-P-1531,acknowledgment letter from fda ddm to king & spalding llp,0,0
090000648314f31d,Supporting & Related Material,FDA-2018-P-1531-0003,FDA-2018-P-1531,attachment 1 orange book: approved drug products with therapeutic equivalence evaluations re petition from king & spalding llp,0,0
090000648314f31f,Supporting & Related Material,FDA-2018-P-1531-0004,FDA-2018-P-1531,attachment 2 atropine and ephedrine: a significant waste in the operating theatre re petition from king & spalding llp,0,0
090000648314f331,Supporting & Related Material,FDA-2018-P-1531-0005,FDA-2018-P-1531,attachment 3 akovaz - ephedrine sulfate injection re petition from king & spalding llp,0,0
090000648314f2ba,Other,FDA-2018-P-1531-0001,FDA-2018-P-1531,petition from king & spalding llp,0,0
0900006484e501e3,Other,FDA-2018-P-1531-0008,FDA-2018-P-1531,denial letter from cder to king & spalding llp,0,0
09000064823c9414,Other,FDA-2016-P-4095-0002,FDA-2016-P-4095,"acknowledgment letter from fda ddm to mapi usa, inc.",0,0
0900006483a5ea57,Other,FDA-2016-P-4095-0004,FDA-2016-P-4095,"amendment to citizen petition from mapi usa, inc.  (medunik canada ltd.)",0,0
09000064823c6ed2,Supporting & Related Material,FDA-2016-P-4095-0003,FDA-2016-P-4095,"appendices 1 - highlights of prescribing information  re citizen petition from mapi usa, inc.  (medunik canada ltd.)",0,0
09000064823c6e05,Other,FDA-2016-P-4095-0001,FDA-2016-P-4095,"citizen petition from mapi usa, inc.  (medunik canada ltd.)",0,0
0900006482400770,Supporting & Related Material,FDA-2016-P-4341-0003,FDA-2016-P-4341,"exhitbit 1 physiologically based pharmacokinetic modeling for substitutability analysis of venlafaxine hydrochloride extended-release
formulations using different release mechanisms: osmotic pump
versus openable matrix re citizen petition from osmotica pharmaceutical us llc",0,0
0900006482400773,Supporting & Related Material,FDA-2016-P-4341-0006,FDA-2016-P-4341,"exhitbit 4 in vivo bioequivalence and in vitro similarity factor (f2)
for dissolution profile comparisons of extended release formulations: how and when do they match? re citizen petition from osmotica pharmaceutical us llc",0,0
0900006482400771,Supporting & Related Material,FDA-2016-P-4341-0004,FDA-2016-P-4341,exhitbit 2 brand-generic substitutability analysis of venlafaxine hydrochloride extended-release tablets based on openable matrix and osmotic pump using pbpk modeling and simulation re citizen petition from osmotica pharmaceutical us llc,0,0
0900006482400772,Supporting & Related Material,FDA-2016-P-4341-0005,FDA-2016-P-4341,exhitbit 3 innovative approaches for demonstration of bioequivalence: the us fda perspective re citizen petition from osmotica pharmaceutical us llc,0,0
0900006482526d6f,Other,FDA-2016-P-4341-0007,FDA-2016-P-4341,citizen petition denial letter from fda cder to osmotica pharmaceutical corp.,0,0
090000648240076c,Other,FDA-2016-P-4341-0001,FDA-2016-P-4341,citizen petition from osmotica pharmaceutical us llc,0,0
090000648240076e,Other,FDA-2016-P-4341-0002,FDA-2016-P-4341,acknowledgement letter from fda ddm to osmotica pharmaceutical us llc,0,0
09000064820aa5a9,Other,FDA-2016-P-2072-0001,FDA-2016-P-2072,citizen petition from pacific-link consulting (adapt pharma),0,0
09000064823f568a,Other,FDA-2016-P-2072-0005,FDA-2016-P-2072,partial petition approval and denial letter from cder fda to pacific-link consulting,0,0
09000064820aa76d,Other,FDA-2016-P-2072-0002,FDA-2016-P-2072,acknowledgement letter from fda ddm to pacific link consulting (adapt pharma),0,0
090000648131aee8,Notice,FDA-2013-N-0653-0001,FDA-2013-N-0653,"agency inagency information collection activities; proposed collection; comment request; orphan drugs; common european medicines agency/food and drug administration application form for orphan medicinal product designation (form fda 3671)formation collection activities; proposals, submissions, and approvals: orphan drugs, etc.",1,0
09000064825921af,Other,FDA-2015-P-2820-0073,FDA-2015-P-2820,declaration of michael vokhgelt,0,0
0900006481ecf142,Supporting & Related Material,FDA-2015-P-2820-0059,FDA-2015-P-2820,exhibit 1 advancing regulatory science at fda august 2011 re: amendment from center for responsible science,0,0
0900006481ecf1a0,Supporting & Related Material,FDA-2015-P-2820-0067,FDA-2015-P-2820,"exhibit 14 attarwala, h. tgn1412; from discovery to disaster re: amendment from center for responsible science",0,0
0900006481ecf1a7,Supporting & Related Material,FDA-2015-P-2820-0070,FDA-2015-P-2820,"exhibit 21 lougheed, k. hepatitis c drug trial halted after patient death august 24, 2012 re: amendment from center for responsible science",0,0
09000064828d1db1,Other,FDA-2015-P-2820-0074,FDA-2015-P-2820,amendment (third)  from center for responsible science (crs),0,0
0900006481eceacd,Other,FDA-2015-P-2820-0058,FDA-2015-P-2820,amendment from center for responsible science (crs),0,0
0900006482b8c81c,Other,FDA-2015-P-2820-0075,FDA-2015-P-2820,amendment (fourth)  from center for responsible science (crs),0,0
0900006481bbb056,Supporting & Related Material,FDA-2015-P-2820-0005,FDA-2015-P-2820,exhibit b regulation updates re citizen petition from the center for responsible science,0,0
0900006481bbadf8,Other,FDA-2015-P-2820-0001,FDA-2015-P-2820,citizen petition from alston and bird (the center for responsible science),0,0
0900006481eb5c8b,Supporting & Related Material,FDA-2015-P-2820-0056,FDA-2015-P-2820,"status inquiry re requests that the fda modify existing regulations in title 21 of the code of federal regulations (cfr) that govern requirements for investigational new drug (ind) applications, investigational device exemptions (ide), and new drug applications (ndas).",0,0
0900006481ecf199,Supporting & Related Material,FDA-2015-P-2820-0061,FDA-2015-P-2820,exhibit 7 online news articles from different organizations re: amendment from center for responsible science,0,0
0900006481ecf19f,Supporting & Related Material,FDA-2015-P-2820-0066,FDA-2015-P-2820,"exhibit 13 brennan ema will assess ansm review of botched clinical trial in france, january 19, 2016 re: amendment from center for responsible science",0,0
090000648256fe13,Other,FDA-2015-P-2820-0072,FDA-2015-P-2820,amendment from center for responsible science (crs),0,0
0900006481bbb052,Other,FDA-2015-P-2820-0003,FDA-2015-P-2820,acknowledgement letter from fda ddm to alston and bird llp,0,0
0900006481ed3d8d,Supporting & Related Material,FDA-2015-P-2820-0071,FDA-2015-P-2820,"exhibit 22 o'riordan, m. after patient's death, study shows hcv drug cardiotoxic in 14 of 34 treated patients source: www.medscape.com/viewarticle/832251_print september 24, 2014 re: amendment from center for responsible science",0,0
0900006481ecf143,Supporting & Related Material,FDA-2015-P-2820-0060,FDA-2015-P-2820,"exhibit 2 baker et al how regulatory updates allowing for
more modern test methods, pragmatic validation of preclinical test methods, and fda guidances will lead to advancement of more predictive preclinical testing tools, efficiency, and safer and more effective drugs fdli food and drug policy forum re: amendment from center for responsible science",1,0
0900006481ecf19d,Supporting & Related Material,FDA-2015-P-2820-0064,FDA-2015-P-2820,"exhibit 11 the pharmaletter, ansm continues investigations into bial clinical trial death, march 10, 2016 re: amendment from center for responsible science",0,0
0900006481ecf19e,Supporting & Related Material,FDA-2015-P-2820-0065,FDA-2015-P-2820,"exhibit 12 minutes of the temporary specialist scientific committee (tssc) meeting on ""faah (fatty add amide hydrolase) inhibitors"" of 15 february 2016. re: amendment from center for responsible science",0,0
09000064839bfff8,Other,FDA-2015-P-2820-0077,FDA-2015-P-2820,interim response letter from fda  to  alston and bird (the center for responsible science),0,0
0900006481ecf19a,Supporting & Related Material,FDA-2015-P-2820-0062,FDA-2015-P-2820,"exhibit 8 business insider, feb 5, 2016 authorities are rapping up their investigation of a deadly drug trial that left one dead and several others in hospital re: amendment from center for responsible science",0,0
0900006481ecf19b,Supporting & Related Material,FDA-2015-P-2820-0063,FDA-2015-P-2820,"exhibit 9 the guardian man who died in french drug trial had 'unprecedented' reaction, say experts. march 2016 re: amendment from center for responsible science",0,0
0900006481ecf1a2,Supporting & Related Material,FDA-2015-P-2820-0068,FDA-2015-P-2820,"exhibit 16 scientific bloggging science 2.0 blood test predicts cytokine storm drug reaction in humans march 9, 2015 re: amendment from center for responsible science",0,0
0900006481bbadfb,Other,FDA-2015-P-2820-0002,FDA-2015-P-2820,letter from alston and bird llp to fda ddm,0,0
09000064830072a5,Other,FDA-2015-P-2820-0076,FDA-2015-P-2820,amendment (fifth) from center for responsible science (crs),0,0
0900006481bbb055,Supporting & Related Material,FDA-2015-P-2820-0004,FDA-2015-P-2820,exhibit a list of petitioners re citizen petition from the center for responsible science,0,0
09000064831476a4,Other,FDA-2018-P-0829-0003,FDA-2018-P-0829,petition approval letter from fda cder,0,0
0900006482f53b7d,Other,FDA-2018-P-0829-0002,FDA-2018-P-0829,acknowledgment letter from fda ddm to prinston pharmaceutical inc.,0,0
0900006482f53b75,Other,FDA-2018-P-0829-0001,FDA-2018-P-0829,citizen petition from prinston pharmaceutical inc.,0,0
090000648432d9ba,Other,FDA-2019-P-3809-0003,FDA-2019-P-3809,"final response letter from fda cder to lachman consultant services, inc",0,0
0900006483e3c3d8,Other,FDA-2019-P-3809-0002,FDA-2019-P-3809,"acknowledgment letter from fda dms to lachman consultant services, inc.",0,0
0900006483e3c3d7,Other,FDA-2019-P-3809-0001,FDA-2019-P-3809,"citizen petition from lachman consultant services, inc.",0,0
090000648364bf49,Supporting & Related Material,FDA-2018-P-3266-0003,FDA-2018-P-3266,"exhibit a - citizen petition in docket fda-2018-p-1014 re citizen petition from haynes and boone, llp",0,0
090000648364bf2f,Other,FDA-2018-P-3266-0002,FDA-2018-P-3266,"acknowledgment letter from fda ddm to haynes and boone, llp",0,0
090000648364bf7b,Supporting & Related Material,FDA-2018-P-3266-0005,FDA-2018-P-3266,"exhibit c - confidential excerpts from anda no. 210370 re citizen petition from haynes and boone, llp",0,0
090000648364bc7e,Supporting & Related Material,FDA-2018-P-3266-0004,FDA-2018-P-3266,"exhibit b - fda response to citizen petition in docket fda-2018-p-1014 re citizen petition from haynes and boone, llp",0,0
0900006484197add,Other,FDA-2018-P-3266-0007,FDA-2018-P-3266,"final response letter from fda to haynes and boone, llp",0,0
090000648364be1c,Other,FDA-2018-P-3266-0001,FDA-2018-P-3266,"citizen petition from haynes and boone, llp",0,0
0900006483a96b7a,Other,FDA-2018-P-3266-0006,FDA-2018-P-3266,"interim response letter from fda cder to haynes and boone, llp",0,0
0900006482c25ff0,Other,FDA-2017-P-6307-0001,FDA-2017-P-6307,citizen petition from aurolife pharma llc.,0,0
0900006482c260fc,Other,FDA-2017-P-6307-0002,FDA-2017-P-6307,acknowledgment letter from fda ddm to aurolife pharma llc,0,0
09000064830fe02b,Other,FDA-2017-P-6307-0004,FDA-2017-P-6307,interim response letter from fda cder to aurolife pharma llc,0,0
0900006483ae1176,Other,FDA-2017-P-6307-0007,FDA-2017-P-6307,response letter from fda cder to aurolife pharma llc,0,0
09000064844276d9,Other,FDA-2020-P-1074-0001,FDA-2020-P-1074,citizen petition from akorn animal health inc.,0,0
09000064844276db,Other,FDA-2020-P-1074-0002,FDA-2020-P-1074,acknowledgment letter from fda dms to akorn animal health inc.,0,0
0900006484426f2c,Supporting & Related Material,FDA-2020-P-1074-0004,FDA-2020-P-1074,attachment 2 - rlnad labeling re: citizen petition from akorn animal health inc.,0,0
0900006484426f2d,Supporting & Related Material,FDA-2020-P-1074-0006,FDA-2020-P-1074,attachment 3 - proposed generic labeling re: citizen petition from akorn animal health inc.,0,0
09000064846cbaa2,Other,FDA-2020-P-1074-0008,FDA-2020-P-1074,petition approval letter from fda cvm to akorn animal health inc,0,0
09000064845b9d39,Other,FDA-2020-P-1074-0007,FDA-2020-P-1074,amendment to citizen petition from akorn animal health inc.,0,0
0900006484426f2b,Supporting & Related Material,FDA-2020-P-1074-0003,FDA-2020-P-1074,attachment 1 -fda green book listing re: citizen petition from akorn animal health inc.,0,0
0900006484426f2e,Supporting & Related Material,FDA-2020-P-1074-0005,FDA-2020-P-1074,attachment 4 -labeling for vetropolycin hc ointment re: citizen petition from akorn animal health inc.,0,0
0900006480447a04,Other,FDA-2005-P-0313-0003,FDA-2005-P-0313,hfd-005 to frommer lawrence and haug llp,0,0
0900006480447a06,Other,FDA-2005-P-0313-0004,FDA-2005-P-0313,fda/cder to charles j. raubicheck,0,0
09000064804479e3,Other,FDA-2005-P-0313-0001,FDA-2005-P-0313,hfa-305 to frommer lawrence and haug llp,0,0
0900006480447a03,Other,FDA-2005-P-0313-0002,FDA-2005-P-0313,hfa-305 to frommer lawrence and haug llp,0,0
090000648174c569,Other,FDA-2014-P-0802-0001,FDA-2014-P-0802,citizen petition from moon t. kwon,0,0
0900006481e04e2d,Other,FDA-2014-P-0802-0004,FDA-2014-P-0802,second interim response from fda cdrh to moon t. kwon,0,0
090000648174c7a8,Other,FDA-2014-P-0802-0002,FDA-2014-P-0802,acknowledgement letter from fda ddm to moon t. kwon,0,0
0900006484df9006,Other,FDA-2014-P-0802-0005,FDA-2014-P-0802,final response from fda cdrh to moon t kwon,0,0
09000064817df053,Other,FDA-2014-P-0802-0003,FDA-2014-P-0802,citizen petition interim response from fda cdrh to moon t. kwon  (redacted),0,0
0900006482cbd3d6,Other,FDA-2017-P-6663-0002,FDA-2017-P-6663,acknowledgement letter from fda ddm to dr. edwards,0,0
0900006482cbd421,Supporting & Related Material,FDA-2017-P-6663-0009,FDA-2017-P-6663,exh 04 ireland fda ltr to durbin jul 2010 re citizen petition from dr. edwards,0,0
0900006482cbd41f,Supporting & Related Material,FDA-2017-P-6663-0007,FDA-2017-P-6663,exh 04 chicago trib may 2011 page 12 re citizen petition from dr. edwards,0,0
0900006482cbd428,Supporting & Related Material,FDA-2017-P-6663-0010,FDA-2017-P-6663,exh 05 edwards lifesciences letter jtf april 2013 re citizen petition from dr. edwards,0,0
0900006482cbd3d4,Other,FDA-2017-P-6663-0001,FDA-2017-P-6663,citizen petition from dr. edwards,0,0
0900006482cbd41c,Supporting & Related Material,FDA-2017-P-6663-0004,FDA-2017-P-6663,exh 01 edwa lifesci ltr jan 31 2009 re citizen petition from dr. edwards,0,0
0900006482cbd41d,Supporting & Related Material,FDA-2017-P-6663-0005,FDA-2017-P-6663,exh 02 edwa lifesci fax apr 16 2009 re citizen petition from dr. edwards,0,0
0900006482cbd420,Supporting & Related Material,FDA-2017-P-6663-0008,FDA-2017-P-6663,exh 04 chicago trib may 2011 page 13 re citizen petition from dr. edwards,0,0
0900006482cbd41e,Supporting & Related Material,FDA-2017-P-6663-0006,FDA-2017-P-6663,exh 04 chicago trib may 22 2011 heart rings get a pass pg1 re citizen petition from dr. edwards,0,0
0900006483237b1a,Other,FDA-2017-P-6663-0012,FDA-2017-P-6663,interim response from fda cdrh to dr. s. albert edwards,0,0
0900006482cbd41b,Supporting & Related Material,FDA-2017-P-6663-0003,FDA-2017-P-6663,citizen petition supplement from dr. edwards,0,0
0900006482cbd429,Supporting & Related Material,FDA-2017-P-6663-0011,FDA-2017-P-6663,exh 06 rajamannan ig ltr july 28 2017 re citizen petition from dr. edwards,0,0
09000064846af6f5,Other,FDA-2017-P-6663-0014,FDA-2017-P-6663,letter of denial from fda cdrh to dr.  albert edwards,0,0
09000064819f3d77,Other,FDA-2014-P-1930-0004,FDA-2014-P-1930,apotex inc withdrawal letter 02/03/2015,0,0
090000648192eded,Supporting & Related Material,FDA-2014-P-1930-0003,FDA-2014-P-1930,attachment 1 approval letter for acticlate citizen petition from apotex inc.,0,0
090000648192edeb,Other,FDA-2014-P-1930-0002,FDA-2014-P-1930,acknowledgement letter from fda ddm to apotex inc.,0,0
090000648192ede9,Other,FDA-2014-P-1930-0001,FDA-2014-P-1930,citizen petition from apotex inc.,0,0
0900006484157048,Other,FDA-2019-P-2590-0003,FDA-2019-P-2590,"interim response letter from fda to fresenius kabi usa, llc",0,0
0900006483cd42ee,Other,FDA-2019-P-2590-0001,FDA-2019-P-2590,"citizen petition from fresenius kabi usa, llc",0,0
0900006483cd42f2,Other,FDA-2019-P-2590-0002,FDA-2019-P-2590,"acknowledgment letter from fda ddm to fresenius kabi usa, llc",0,0
09000064824b6dd7,Other,FDA-2017-P-0864-0001,FDA-2017-P-0864,citizen petition from hyman phelps & mcnamara pc,0,0
09000064829cca17,Other,FDA-2017-P-0864-0003,FDA-2017-P-0864,"interim response letter from cder to hyman, phelps & mcnamara p.c.",0,0
09000064824b6e72,Other,FDA-2017-P-0864-0002,FDA-2017-P-0864,acknowledgment letter from fda ddm to hyman phelps & mcnamara pc,0,0
090000648485dd4b,Other,FDA-2017-P-0864-0004,FDA-2017-P-0864,"letter from fda cder to hyman, phelps & mcnamara p.c.",0,0
09000064849144ec,Supporting & Related Material,FDA-2020-P-1769-0007,FDA-2020-P-1769,combined - part 1 re amended citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484913c5e,Other,FDA-2020-P-1769-0006,FDA-2020-P-1769,amended citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
090000648480bd8d,Other,FDA-2020-P-1769-0002,FDA-2020-P-1769,acknowledgment letter from fda dms to siri & glimstad llp on behalf of informed consent action network,0,0
09000064849144ed,Supporting & Related Material,FDA-2020-P-1769-0008,FDA-2020-P-1769,combined - part 2 re amended citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484811b6d,Supporting & Related Material,FDA-2020-P-1769-0005,FDA-2020-P-1769,footnotes 2 - 33 re: administrative stay of action from siri & glimstad llp on behalf of informed consent action network,0,0
09000064849d6b35,Other,FDA-2020-P-1769-0011,FDA-2020-P-1769,response letter to siri & glimstad llp from fda cber,0,0
090000648480bd8c,Other,FDA-2020-P-1769-0001,FDA-2020-P-1769,citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484811b69,Other,FDA-2020-P-1769-0004,FDA-2020-P-1769,administrative stay of action from siri & glimstad llp on behalf of informed consent action network,0,0
090000648480bd90,Supporting & Related Material,FDA-2020-P-1769-0003,FDA-2020-P-1769,footnotes 2 - 30 re citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484ca6f1b,Other,FDA-2021-P-0939-0001,FDA-2021-P-0939,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006484ca728d,Other,FDA-2021-P-0939-0002,FDA-2021-P-0939,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
0900006480a58fc5,Notice,FDA-2009-N-0545-0001,FDA-2009-N-0545,"agency information collection activities; proposed collection; comment request; biological products: reporting of biological product deviations and human cells, tissues, and cellular and tissue-based product deviations in manufacturing; form fda 3486 and addendum 3486a",0,0
0900006480aed928,Notice,FDA-2009-N-0545-0002,FDA-2009-N-0545,"agency information collection activities; proposals, submissions, and approvals",0,0
0900006483d538fa,Other,FDA-2019-P-0076-0006,FDA-2019-P-0076,"letter from fda cder to unichem pharmaceuticals (usa), inc.",0,0
09000064839da85d,Other,FDA-2019-P-0076-0001,FDA-2019-P-0076,"citizen petition from unichem pharmaceuticals (usa), inc.",0,0
0900006483ec15e0,Other,FDA-2019-P-0076-0008,FDA-2019-P-0076,response letter from fda cder to unichem pharmaceuticals usa inc,0,0
0900006483e8c363,Notice,FDA-2019-P-0076-0007,FDA-2019-P-0076,"determination that zonegran (zonisamide) capsules, 50 milligrams, was not withdrawn from sale for reasons of safety or effectiveness",0,0
09000064839db14c,Other,FDA-2019-P-0076-0002,FDA-2019-P-0076,"acknowledgement letter  from fda ddm to unichem pharmaceuticals (usa), inc.",0,0
09000064839db14e,Supporting & Related Material,FDA-2019-P-0076-0004,FDA-2019-P-0076,"attachment 2_package insert_11-2006 re: citizen petition from unichem pharmaceuticals (usa), inc.",0,0
09000064839db14d,Supporting & Related Material,FDA-2019-P-0076-0003,FDA-2019-P-0076,"attachement 1_current_orange book re: citizen petition from unichem pharmaceuticals (usa), inc.",0,0
09000064839db14f,Supporting & Related Material,FDA-2019-P-0076-0005,FDA-2019-P-0076,"attachment 3_package insert_04-2009 re: citizen petition from unichem pharmaceuticals (usa), inc.",0,0
0900006481e66aca,Other,FDA-2015-P-3009-0010,FDA-2015-P-3009,interim response letter from fda cfsan to physicians committee for responsible medicine,0,0
0900006481c23d2c,Other,FDA-2015-P-3009-0001,FDA-2015-P-3009,citizen petition from the physicians committee for responsible medicine,0,0
0900006481c2406b,Supporting & Related Material,FDA-2015-P-3009-0003,FDA-2015-P-3009,attachment 1 effect of animal and industrial trans fatty acids re citizen petition from the physicians committee for responsible medicine,0,0
0900006481c24069,Other,FDA-2015-P-3009-0002,FDA-2015-P-3009,acknowledgement letter from fda ddm to the physicians committee for responsible medicine,0,0
0900006481ea6dda,Other,FDA-2015-P-3009-0011,FDA-2015-P-3009,petition denial letter from fda cfsan to physicians committee for responsible medicine,0,0
0900006481c26ea1,Other,FDA-2015-P-3020-0001,FDA-2015-P-3020,citizen petition from women's voices for the earth,0,0
0900006481c26ea3,Other,FDA-2015-P-3020-0002,FDA-2015-P-3020,acknowledgement letter from fda ddm to women's voices for the earth,0,0
09000064833f0385,Other,FDA-2015-P-3020-0009,FDA-2015-P-3020,petition denial letter from fda cfsan to wve,0,0
09000064833743c5,Other,FDA-2018-P-1351-0006,FDA-2018-P-1351,"agency response letter from fda cvm to schafer veterinary consultants, llc",0,0
090000648308705e,Other,FDA-2018-P-1351-0002,FDA-2018-P-1351,"acknowledgment letter from fda ddm to douglass oeller consulting, inc.",0,0
0900006483087064,Supporting & Related Material,FDA-2018-P-1351-0004,FDA-2018-P-1351,"appendix 3 - a marked up copy of the package insert showing felix's proposed changes re citizen petition from douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd.)",0,0
090000648333525e,Other,FDA-2018-P-1351-0005,FDA-2018-P-1351,"change of us agent,  james h. schafer, d.v.m (schafer veterinary consultants, llc) - 06-04-2018",0,0
0900006483087063,Supporting & Related Material,FDA-2018-P-1351-0003,FDA-2018-P-1351,"appendix 2 - a copy of the zoetis package insert for this product re citizen petition from douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd.)",0,0
090000648308676d,Other,FDA-2018-P-1351-0001,FDA-2018-P-1351,"citizen petition from douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd.)",0,0
09000064847a9a96,Other,FDA-2020-P-1701-0002,FDA-2020-P-1701,acknowledgment letter from harman finochem limited,0,0
09000064847a9a94,Other,FDA-2020-P-1701-0001,FDA-2020-P-1701,citizen petition from harman finochem limited,0,0
09000064847a9dc1,Supporting & Related Material,FDA-2020-P-1701-0003,FDA-2020-P-1701,"attachment 1 - amneal pharmaceuticals llc issues voluntary nationwide
recall of metformin hydrochloride extended release tablets, usp, 500 mg and 750 mg, due to detection of nnitrosodimethylamine (ndma) impurity re citizen petition from harman finochem limited",0,0
09000064847a9dc2,Supporting & Related Material,FDA-2020-P-1701-0004,FDA-2020-P-1701,attachment 2 - email correspondence  re citizen petition from harman finochem limited,0,0
090000648496ff13,Other,FDA-2020-P-1701-0005,FDA-2020-P-1701,withdrawal from harman finochem limited,0,0
09000064834cb6f2,Other,FDA-2018-P-2658-0001,FDA-2018-P-2658,"citizen petiton from hyman, phelps & mcnamara, pc",0,0
09000064839f4c58,Other,FDA-2018-P-2658-0003,FDA-2018-P-2658,"interim response from fda cder to  hyman, phelps & mcnamara",0,0
09000064834cb6f4,Other,FDA-2018-P-2658-0002,FDA-2018-P-2658,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara",0,0
0900006484177fb3,Other,FDA-2018-P-2658-0004,FDA-2018-P-2658,"response letter from fda to hyman, phelps, and mcnamara",0,0
090000648042d777,Notice,FDA-2007-N-0385-0002,FDA-2007-N-0385,fda,0,0
090000648042d77e,Supporting & Related Material,FDA-2007-N-0385-0005,FDA-2007-N-0385,supporting statement,0,0
090000648042d77b,Supporting & Related Material,FDA-2007-N-0385-0004,FDA-2007-N-0385,supporting statement,0,0
090000648042d773,Notice,FDA-2007-N-0385-0001,FDA-2007-N-0385,fda,0,0
090000648042d77f,Notice,FDA-2007-N-0385-0006,FDA-2007-N-0385,fda,0,0
090000648042d779,Supporting & Related Material,FDA-2007-N-0385-0003,FDA-2007-N-0385,supporting statement,0,0
090000648042d780,Notice,FDA-2007-N-0385-0007,FDA-2007-N-0385,fda,0,0
0900006480aef98d,Notice,FDA-2010-N-0229-0001,FDA-2010-N-0229,"agency information collection activities; proposals, submissions, and approvals: pilot program",0,0
0900006481eddccb,Other,FDA-2015-P-1899-0006,FDA-2015-P-1899,"citizen petition approval response from fda cder to lachman consultant services, inc.",0,0
0900006481b090d7,Supporting & Related Material,FDA-2015-P-1899-0002,FDA-2015-P-1899,attachment orange book listing for fluoxetine hydrochloride re citizen petition from lachman consultant services inc,0,0
0900006481b09106,Other,FDA-2015-P-1899-0001,FDA-2015-P-1899,citizen petition from lachman consultant services inc,0,0
0900006481b091c7,Other,FDA-2015-P-1899-0003,FDA-2015-P-1899,acknowledgement letter from fda ddm to lachman consultant services inc,0,0
0900006481d6d850,Other,FDA-2015-P-1899-0004,FDA-2015-P-1899,"interim response letter from fda cder to lachman consultant services, inc.",0,0
0900006482e4a743,Notice,FDA-2017-N-6879-0001,FDA-2017-N-6879,"electronic study data submission; data standards; timetable for updates to the food and drug administration data standards catalog for study data submitted electronically under the federal food, drug, and cosmetic act",1,0
0900006483236d94,Supporting & Related Material,FDA-2018-P-1760-0004,FDA-2018-P-1760,"attachment 1- references part 2 of 2 re citizen petition from serenity pharmaceuticals, llc.",0,0
090000648323716a,Other,FDA-2018-P-1760-0002,FDA-2018-P-1760,"acknowledgment letter from fda ddm to serenity pharmaceuticals, llc",0,0
090000648343b70f,Other,FDA-2018-P-1760-0005,FDA-2018-P-1760,"petition response letter from fda cder to serenity pharmaceuticals, llc",0,0
0900006483236ad2,Supporting & Related Material,FDA-2018-P-1760-0003,FDA-2018-P-1760,"attachment 1- references part 1 of 2 re citizen petition from serenity pharmaceuticals, llc.",0,0
0900006483236ad0,Other,FDA-2018-P-1760-0001,FDA-2018-P-1760,"citizen petition from serenity pharmaceuticals, llc.",0,0
0900006483254733,Other,FDA-2017-P-6750-0008,FDA-2017-P-6750,petition denial letter from fda cder to mylan n.v,0,0
0900006482ce61fd,Supporting & Related Material,FDA-2017-P-6750-0006,FDA-2017-P-6750,exhibit d - sandell - inhalation batch variability dec_ 2017-1 re citizen petition from mylan inc.,0,0
0900006482ce61fb,Supporting & Related Material,FDA-2017-P-6750-0004,FDA-2017-P-6750,exhibit b - getz carroll oriel presentation chest-1 re citizen petition from mylan inc.,0,0
0900006482cebd3b,Other,FDA-2017-P-6750-0002,FDA-2017-P-6750,acknowledgment letter from fda ddm to  mylan inc.,0,0
0900006482ce61fa,Supporting & Related Material,FDA-2017-P-6750-0003,FDA-2017-P-6750,exhibit a - getz carroll oriel abstract-2 re citizen petition from mylan inc.,0,0
0900006482ce61fe,Supporting & Related Material,FDA-2017-P-6750-0007,FDA-2017-P-6750,exhibit e - haidar - highly variable-1 re citizen petition from mylan inc.,0,0
0900006482ce53e4,Other,FDA-2017-P-6750-0001,FDA-2017-P-6750,citizen petition from mylan inc.,0,0
0900006482ce61fc,Supporting & Related Material,FDA-2017-P-6750-0005,FDA-2017-P-6750,exhibit c - usp monograph fp-sx-1 re citizen petition from mylan inc.,0,0
0900006482e4d138,Supporting & Related Material,FDA-2018-P-0327-0003,FDA-2018-P-0327,"reference 1- orange book approved drug products with therapeutic equivalence evaluations re: citizen petition fresenius kabiusa, llc",0,0
09000064833d715a,Notice,FDA-2018-P-0327-0004,FDA-2018-P-0327,"determination that mutamycin (mitomycin) injectable, 5 milligrams/ vial and 20 milligrams/vial, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006482e4cd72,Other,FDA-2018-P-0327-0001,FDA-2018-P-0327,"citizen petition fresenius kabiusa, llc",0,0
0900006482e4d0f7,Other,FDA-2018-P-0327-0002,FDA-2018-P-0327,"acknowledgment letter from fda ddm to fresenius kabiusa, llc",0,0
09000064833dc83b,Other,FDA-2018-P-0327-0005,FDA-2018-P-0327,"letter from fda cder to fresenius kabi usa, llc",0,0
090000648362d72c,Other,FDA-2018-P-2344-0005,FDA-2018-P-2344,amendments to suitability petition from noble pharma llc,0,0
0900006483425da1,Other,FDA-2018-P-2344-0001,FDA-2018-P-2344,suitability petition from noble pharma llc,0,0
09000064834258e6,Supporting & Related Material,FDA-2018-P-2344-0003,FDA-2018-P-2344,appendix 1 - pioneer label re suitability petition from noble pharma llc,0,0
09000064834258e7,Supporting & Related Material,FDA-2018-P-2344-0004,FDA-2018-P-2344,appendix 2 - draft label of the proposed generic soft chewable tablet re suitability petition from noble pharma llc,0,0
09000064836bbf1b,Other,FDA-2018-P-2344-0006,FDA-2018-P-2344,"petition approval letter from fda cvm to noble pharma, llc",0,0
0900006483425da4,Other,FDA-2018-P-2344-0002,FDA-2018-P-2344,acknowledgment letter from fda ddm to noble pharma llc,0,0
0900006483147805,Other,FDA-2018-P-1516-0001,FDA-2018-P-1516,citizen petition from encube ethicals private limited,0,0
090000648327f7c6,Other,FDA-2018-P-1516-0003,FDA-2018-P-1516,letter from fda cder to encube ethicals private limited,0,0
0900006483147808,Other,FDA-2018-P-1516-0002,FDA-2018-P-1516,acknowledgment letter from fda ddm to encube ethicals private limited,0,0
0900006481975327,Other,FDA-2014-P-2193-0001,FDA-2014-P-2193,citizen petition from acorda therapeutics,0,0
090000648197652f,Supporting & Related Material,FDA-2014-P-2193-0008,FDA-2014-P-2193,exhibit_f_-_ema_guideline citizen petition from acorda therapeutics,0,0
090000648197652c,Supporting & Related Material,FDA-2014-P-2193-0005,FDA-2014-P-2193,exhibit_c_-_acorda_mar__4_2014_letter citizen petition from acorda therapeutics,0,0
0900006481976530,Supporting & Related Material,FDA-2014-P-2193-0009,FDA-2014-P-2193,exhibit_g_-_health_canada_guidance citizen petition from acorda therapeutics,0,0
0900006481976533,Supporting & Related Material,FDA-2014-P-2193-0012,FDA-2014-P-2193,exhibit_j_-_lionberger_et_al_citizen petition from acorda therapeutics,0,0
090000648197652a,Supporting & Related Material,FDA-2014-P-2193-0003,FDA-2014-P-2193,exhibit_a_-_ampyra_prescribing_information citizen petition from acorda therapeutics,0,0
090000648197652b,Supporting & Related Material,FDA-2014-P-2193-0004,FDA-2014-P-2193,exhibit_b_-_ampyra_medication_guide citizen petition from acorda therapeutics,0,0
0900006481ae1019,Other,FDA-2014-P-2193-0014,FDA-2014-P-2193,"citizen petition denial response letter from fda cder to acorda therapeutics, inc.",0,0
090000648197652d,Supporting & Related Material,FDA-2014-P-2193-0006,FDA-2014-P-2193,exhibit_d_-_acorda_feb__4_2011_letter citizen petition from acorda therapeutics,0,0
0900006481976532,Supporting & Related Material,FDA-2014-P-2193-0011,FDA-2014-P-2193,exhibit_i_-_zhang_et_al_citizen petition from acorda therapeutics,0,0
090000648197652e,Supporting & Related Material,FDA-2014-P-2193-0007,FDA-2014-P-2193,exhibit_e_-_kelley_and_rodriguez citizen petition from acorda therapeutics,0,0
09000064819769c1,Supporting & Related Material,FDA-2014-P-2193-0013,FDA-2014-P-2193,exhibit_k_-_vollmer_et_al_citizen petition from acorda therapeutics,0,0
09000064819769c2,Other,FDA-2014-P-2193-0002,FDA-2014-P-2193,"acknowledgement letter from fda ddm to acorda therapeutics, inc.",0,0
0900006481976531,Supporting & Related Material,FDA-2014-P-2193-0010,FDA-2014-P-2193,exhibit_h_-_jara_et_al_citizen petition from acorda therapeutics,0,0
09000064818b67f0,Other,FDA-2014-P-1562-0001,FDA-2014-P-1562,citizen petition from the institute for safe medication practices,0,0
0900006482427e7d,Other,FDA-2014-P-1562-0004,FDA-2014-P-1562,petition denial letter from fda cder to the institute for safe medication practices et al,0,0
090000648191b1fd,Other,FDA-2014-P-1562-0002,FDA-2014-P-1562,acknowledgement letter from fda ddm to the institute for safe medication practices,0,0
0900006481a90bbf,Other,FDA-2014-P-1562-0003,FDA-2014-P-1562,interim response from fda cder to the institute for safe medication practices,0,0
0900006483050e1c,Other,FDA-2017-P-5845-0003,FDA-2017-P-5845,"interim response  letter from fda cder to b&h consulting services, inc.",0,0
0900006482b65afb,Other,FDA-2017-P-5845-0002,FDA-2017-P-5845,"acknowledgment  letter from fda ddm to b&h consulting services, inc.",0,0
0900006483b6a0d1,Other,FDA-2017-P-5845-0004,FDA-2017-P-5845,"letter from fda cder to b&h consulting services, inc.",0,0
0900006482b65674,Other,FDA-2017-P-5845-0001,FDA-2017-P-5845,"citizen petition from b&h consulting services, inc.",0,0
0900006481363bbf,Notice,FDA-2013-N-0731-0001,FDA-2013-N-0731,"agency information collection activities; proposals, submissions, and approvals: human cells, tissues, and cellular and tissue-based products, establishment registration and listing; form fda 3356; eligibility determination for donors and current good tissue practice",0,0
09000064841e74ee,Notice,FDA-2013-N-0731-0009,FDA-2013-N-0731,"agency information collection activities; proposed collection; comment request; human cells, tissues, and cellular and tissue-based products: establishment registration and listing; eligibility determination for donors; and current good tissue practice",0,0
09000064844848a1,Notice,FDA-2013-N-0731-0010,FDA-2013-N-0731,"agency information collection activities; submission for office of management and budget review; comment request; human cells, tissues, and cellular and tissue-based products: establishment registration and listing; eligibility determination for donors; and current good tissue practice",0,0
090000648482cc90,Notice,FDA-2013-N-0731-0011,FDA-2013-N-0731,"agency information collection activities; announcement of office of
management and budget approvals",0,0
0900006481681949,Notice,FDA-2013-N-0731-0003,FDA-2013-N-0731,"agency information collection activities; announcement of office of
management and budget approval; eligibility determination for donors of human cells, tissues, and cellular and tissue-based products",0,0
090000648151cf3e,Notice,FDA-2013-N-0731-0002,FDA-2013-N-0731,"agency information collection activities; submission for office of
management and budget review; comment request; human cells,
tissues, and cellular and tissue-based products: establishment
registration and listing; form fda 3356; eligibility determination for
donors; and current good tissue practice",0,0
09000064821db835,Notice,FDA-2013-N-0731-0004,FDA-2013-N-0731,"agency information collection activities; proposed collection; comment request; human cells, tissues, and cellular and tissue-based products: establishment registration and listing; eligibility determination for donors; and current good tissue practice",0,0
0900006482aa02d4,Notice,FDA-2013-N-0731-0008,FDA-2013-N-0731,"agency information collection activities; announcement of office of
management and budget approvals",0,0
0900006482533781,Notice,FDA-2013-N-0731-0007,FDA-2013-N-0731,"agency information collection activities; submission for office of
management and budget review; comment request; human cells,
tissues, and cellular and tissue-based products: establishment  registration and listing; eligibility determination for donors; and current good tissue practice",0,0
09000064849b0718,Other,FDA-2020-P-2318-0001,FDA-2020-P-2318,"suitability citizen petition from lachman consulting services, inc.",0,0
09000064849b1603,Other,FDA-2020-P-2318-0002,FDA-2020-P-2318,"acknowledgement letter from fda dms to lachman consulting services, inc.",0,0
09000064849aefda,Notice,FDA-2020-P-1650-0003,FDA-2020-P-1650,"determination that dobutrex (dobutamine hydrochloride), equivalent 12.5 milligram base/milliliter, was not withdrawn from sale for reasons of safety or effectiveness",0,0
090000648473bc28,Other,FDA-2020-P-1650-0002,FDA-2020-P-1650,acknowledgment letter from fda dms to cardinal health regulatory sciences,0,0
09000064849b0d44,Other,FDA-2020-P-1650-0004,FDA-2020-P-1650,final response to citizen petition from fda cder to cardinal health regulatory sciences,0,0
090000648473bb1d,Other,FDA-2020-P-1650-0001,FDA-2020-P-1650,citizen petition from cardinal health regulatory sciences,0,0
0900006483259a5b,Other,FDA-2018-P-1853-0001,FDA-2018-P-1853,"citizen petition from aurobindo pharma usa, inc.",0,0
0900006483d42e39,Other,FDA-2018-P-1853-0004,FDA-2018-P-1853,"letter from fda cder to aurobindo pharma usa, inc.",0,0
090000648388348f,Other,FDA-2018-P-1853-0003,FDA-2018-P-1853,interim response letter from fda cder to aurobindo pharma usa inc.,0,0
0900006483259a62,Other,FDA-2018-P-1853-0002,FDA-2018-P-1853,"acknowledgment letter from fda ddm to aurobindo pharma usa, inc.",0,0
09000064846ec003,Other,FDA-2020-P-0978-0009,FDA-2020-P-0978,"response letter from fda cder to valisure, llc",0,0
09000064843d1af7,Other,FDA-2020-P-0978-0002,FDA-2020-P-0978,"acknowledgment letter from fda dms to valisure, llc",0,0
09000064843d1afe,Supporting & Related Material,FDA-2020-P-0978-0004,FDA-2020-P-0978,"attachment b - american medical association house of delegates re: citizen petition from valisure, llc",0,0
09000064843d1afa,Supporting & Related Material,FDA-2020-P-0978-0003,FDA-2020-P-0978,"attachment a - valisure lc-hrms method for determination of ndma in metformin re: citizen petition from valisure, llc",0,0
09000064843d191b,Other,FDA-2020-P-0978-0001,FDA-2020-P-0978,"citizen petition from valisure, llc",0,0
09000064846bbcd1,Other,FDA-2020-P-0978-0007,FDA-2020-P-0978,"partial response letter from fda cder to valisure, llc",0,0
0900006481e3b05a,Other,FDA-2016-P-0378-0001,FDA-2016-P-0378,"citizen petition from the weinberg group, inc.",0,0
0900006481e3b788,Other,FDA-2016-P-0378-0002,FDA-2016-P-0378,"acknowledgement letter from fda ddm to the weinberg group, inc.",0,0
0900006482008d15,Notice,FDA-2016-P-0378-0003,FDA-2016-P-0378,"determination that trivaris (triamcinolone acetonide) injectable
suspension, 80 milligrams/milliliters, was not withdrawn from sale for
reasons of safety or effectiveness",0,0
090000648200e27f,Other,FDA-2016-P-0378-0004,FDA-2016-P-0378,final response letter june 2 2016,0,0
090000648480bbd6,Supporting & Related Material,FDA-2020-P-1770-0003,FDA-2020-P-1770,footnotes 3 - 32 re citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484973e73,Supporting & Related Material,FDA-2020-P-1770-0036,FDA-2020-P-1770,footnotes 3 - 32 re citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
090000648491383d,Supporting & Related Material,FDA-2020-P-1770-0015,FDA-2020-P-1770,"footnotes 21 -34 re amendment to citizen petition from siri & glimstad llp,  a phase 1/2/3 study to evaluate the safety, tolerability, immunogenicty, and efficacy of rna vaccine candidates against covid-19 in healthy individuals",0,0
090000648491383c,Supporting & Related Material,FDA-2020-P-1770-0014,FDA-2020-P-1770,"footnotes 1 - 20 re amendment to citizen petition from siri & glimstad llp, a phase 1/2/3 study to evaluate the safety, tolerability, immunogenicty, and efficacy of rna vaccine candidates against covid-19 in healthy individuals",0,0
090000648499c488,Other,FDA-2020-P-1770-0037,FDA-2020-P-1770,denial response letter from fda cber to siri & glimstad llp,0,0
090000648480bbd2,Other,FDA-2020-P-1770-0001,FDA-2020-P-1770,citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484812022,Supporting & Related Material,FDA-2020-P-1770-0005,FDA-2020-P-1770,footnotes 3 - 35 re administrative stay of action from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484913839,Other,FDA-2020-P-1770-0013,FDA-2020-P-1770,amendment to citizen petition from siri & glimstad llp,0,0
0900006484812020,Other,FDA-2020-P-1770-0004,FDA-2020-P-1770,administrative stay of action from siri & glimstad llp on behalf of informed consent action network,0,0
090000648480bbd3,Other,FDA-2020-P-1770-0002,FDA-2020-P-1770,acknowledgment letter from fda dms to siri & glimstad llp on behalf of informed consent action network,0,0
0900006484a5c804,Notice,FDA-2020-N-1411-0003,FDA-2020-N-1411,"agency information collection activities; submission for office of
management and budget review; comment request; generic clearance for data to support cross-center collaboration for social behavioral sciences associated with disease prevention, treatment, and the safety, efficacy, and usage of food and drug administration regulated products",1,0
090000648472b508,Notice,FDA-2020-N-1411-0001,FDA-2020-N-1411,"agency information collection activities; proposed collection; comment request; generic clearance for data to support cross-center collaboration for social behavioral sciences associated with disease prevention, treatment, and the safety, efficacy, and usage of food and drug administration regulated products",1,0
09000064848571b6,Other,FDA-2020-P-1875-0001,FDA-2020-P-1875,citizen petition from grain processing corporation,0,0
0900006484b14aa8,Other,FDA-2020-P-1875-0004,FDA-2020-P-1875,180 day interim response letter from fda cfsan to grain processing corporation,0,0
0900006484c2828b,Supporting & Related Material,FDA-2020-P-1875-0005,FDA-2020-P-1875,support letter re citizen petition from grain processing corporation,0,0
09000064848571b7,Other,FDA-2020-P-1875-0002,FDA-2020-P-1875,acknowledgment letter from fda dms to grain processing corporation,0,0
09000064848572dd,Supporting & Related Material,FDA-2020-P-1875-0003,FDA-2020-P-1875,attachment a re citizen petition from grain processing corporation,0,0
0900006484a6b553,Other,FDA-2021-P-0292-0002,FDA-2021-P-0292,acknowledgment letter from fda dms to arnall golden gregory llp,0,0
0900006484c9e30c,Other,FDA-2021-P-0292-0004,FDA-2021-P-0292,response letter from fda cder to arnall golden gregory llp,0,0
0900006484a6b533,Other,FDA-2021-P-0292-0001,FDA-2021-P-0292,citizen petition from arnall golden gregory llp,0,0
0900006484c9bd6e,Notice,FDA-2021-P-0292-0003,FDA-2021-P-0292,"determination that ortho-cept (desogestrel-ethinyl estradiol) 21- and 28-day oral tablets, 0.15 milligram/ 0.03 milligram, were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006480557f71,Other,FDA-2008-P-0295-0001,FDA-2008-P-0295,"par pharmaceuticals and kali laboratories, inc. - citizen petition",0,0
0900006480557fbe,Other,FDA-2008-P-0295-0002,FDA-2008-P-0295,"acknowledgement letter to arent fox, llp",0,0
090000648079c3c3,Other,FDA-2008-P-0295-0003,FDA-2008-P-0295,"par pharmaceuticals and kali laboratories, inc. - citizen petition withdrawal",0,0
0900006482b137a4,Other,FDA-2017-D-5478-0001,FDA-2017-D-5478,mrct draft fda guidance return of aggregate results,0,0
0900006482b138a8,Other,FDA-2017-D-5478-0002,FDA-2017-D-5478,mrct center cover letter to fda sept 6 2017,0,0
0900006481bc7482,Supporting & Related Material,FDA-2015-P-2867-0005,FDA-2015-P-2867,"attachment 3 prescribing information capecitabine re: citizen petition from lachman consultant services, inc.",0,0
0900006484a99850,Other,FDA-2015-P-2867-0006,FDA-2015-P-2867,"withdrawal from lachman consultant services, inc.",0,0
0900006481bc7867,Supporting & Related Material,FDA-2015-P-2867-0003,FDA-2015-P-2867,"attachment 1 excerpt from orange book capecitabine re: citizen petition from lachman consultant services, inc.",0,0
0900006481bc7868,Supporting & Related Material,FDA-2015-P-2867-0004,FDA-2015-P-2867,"attachment 2  prescribing information xeloda re: citizen petition from lachman consultant services, inc.",0,0
0900006481bc651d,Other,FDA-2015-P-2867-0002,FDA-2015-P-2867,"acknowledgment letter from fda ddm to lachman consultant services, inc.",0,0
0900006481bc5fa4,Other,FDA-2015-P-2867-0001,FDA-2015-P-2867,citizen petition from lachman consultant services inc,0,0
0900006480481f6a,Other,FDA-2003-P-0072-0016,FDA-2003-P-0072,acknowledgement letter to international dairy foods association,0,0
0900006480482076,Other,FDA-2003-P-0072-0007,FDA-2003-P-0072,fda regulations policy & management staff to the division of dockets management - memorandum,0,0
0900006480481ee0,Notice,FDA-2003-P-0072-0001,FDA-2003-P-0072,"frozen desserts; petition to revoke standards for goat’s milk ice cream and mellorine and to amend standards for ice cream and frozen custard, sherbet, and water ices; petition to amend standards for parmesan and reggiano cheese",0,0
09000064805f8543,Other,FDA-2003-P-0072-0017,FDA-2003-P-0072,international dairy foods association - withdrawal of citizen petition,0,0
0900006480481f67,Other,FDA-2003-P-0072-0015,FDA-2003-P-0072,international dairy foods association - citizen petition,0,0
09000064826c7c96,Supporting & Related Material,FDA-2017-P-3672-0005,FDA-2017-P-3672,"tab 3 - actavis notice letter (redacted)-1 re citizen petition from millennium pharmaceuticals, inc",0,0
09000064826c7c9b,Supporting & Related Material,FDA-2017-P-3672-0010,FDA-2017-P-3672,"tab 8 - national cancer institute, surveillance, epidemiology, and end results stat program, cancer stat facts myeloma-1 re citizen petition from millennium pharmaceuticals, inc",0,0
09000064826c7ca4,Supporting & Related Material,FDA-2017-P-3672-0019,FDA-2017-P-3672,"tab 17 - reece et al_-1 re citizen petition from millennium pharmaceuticals, inc",0,0
09000064826c82ff,Other,FDA-2017-P-3672-0002,FDA-2017-P-3672,"acknowledgment letter from fda ddm to millennium pharmaceuticals, inc",0,0
0900006482c53ae8,Other,FDA-2017-P-3672-0022,FDA-2017-P-3672,"response letter from fda to millennium pharmaceuticals, inc.",0,0
09000064826c7c97,Supporting & Related Material,FDA-2017-P-3672-0006,FDA-2017-P-3672,"tab 4 - epa red facts boric acid, epa-738-f-93-006 (sept_ 1993)-1 re citizen petition from millennium pharmaceuticals, inc",0,0
09000064826c7c9d,Supporting & Related Material,FDA-2017-P-3672-0012,FDA-2017-P-3672,"tab 10 - fryar et al_-1 re citizen petition from millennium pharmaceuticals, inc",0,0
09000064826c7ca2,Supporting & Related Material,FDA-2017-P-3672-0017,FDA-2017-P-3672,"tab 15 - report of the food quality protection act (fqpa) tolerance reassessment eligibility decision (tred) for boric acid-sodium-1 re citizen petition from millennium pharmaceuticals, inc",1,0
09000064826c7ca5,Supporting & Related Material,FDA-2017-P-3672-0020,FDA-2017-P-3672,"tab 18 - lu et al_-1 re citizen petition from millennium pharmaceuticals, inc",0,0
09000064826c77fb,Other,FDA-2017-P-3672-0001,FDA-2017-P-3672,"citizen petition from millennium pharmaceuticals, inc.",0,0
09000064826c7c9a,Supporting & Related Material,FDA-2017-P-3672-0009,FDA-2017-P-3672,"tab 7 - u_s_ epa integrated risk information system, boron and compounds_ casrn 7440-42-8 (aug_ 5, 2004)-1 re citizen petition from millennium pharmaceuticals, inc",0,0
09000064826c7c9e,Supporting & Related Material,FDA-2017-P-3672-0013,FDA-2017-P-3672,"tab 11 - mosteller-1 re citizen petition from millennium pharmaceuticals, inc",0,0
09000064826c7ca3,Supporting & Related Material,FDA-2017-P-3672-0018,FDA-2017-P-3672,"tab 16 - moreau et al_-1 re citizen petition from millennium pharmaceuticals, inc",0,0
09000064826c77fd,Supporting & Related Material,FDA-2017-P-3672-0003,FDA-2017-P-3672,"tab 1 - innopharma notice letter (redacted) re citizen petition from millennium pharmaceuticals, inc",0,0
09000064826c7c99,Supporting & Related Material,FDA-2017-P-3672-0008,FDA-2017-P-3672,"tab 6 - fresenius notice letter (redacted)-1 re citizen petition from millennium pharmaceuticals, inc",0,0
09000064826c7c9f,Supporting & Related Material,FDA-2017-P-3672-0014,FDA-2017-P-3672,"tab 12 - dinca et al_-1 re citizen petition from millennium pharmaceuticals, inc",0,0
09000064826c7c95,Supporting & Related Material,FDA-2017-P-3672-0004,FDA-2017-P-3672,"tab 2 - drl notice letter (redacted)-1 re citizen petition from millennium pharmaceuticals, inc",0,0
09000064826c7ca0,Supporting & Related Material,FDA-2017-P-3672-0015,FDA-2017-P-3672,"tab 13 - who, _boron in drinking-water,_ whohsewsh09_012 (2009)-1 re citizen petition from millennium pharmaceuticals, inc",0,0
09000064826c7ca1,Supporting & Related Material,FDA-2017-P-3672-0016,FDA-2017-P-3672,"tab 14 - hasegawa et al_-1 re citizen petition from millennium pharmaceuticals, inc",0,0
09000064826c7c98,Supporting & Related Material,FDA-2017-P-3672-0007,FDA-2017-P-3672,"tab 5 - us patent no_ 8,962,572-1 re citizen petition from millennium pharmaceuticals, inc",0,0
09000064826c7c9c,Supporting & Related Material,FDA-2017-P-3672-0011,FDA-2017-P-3672,"tab 9 - national cancer institute, surveillance, epidemiology, and end results stat program, cancer stat facts, non-hodgkin lympho-1 re citizen petition from millennium pharmaceuticals, inc",0,0
0900006482ef0ec6,Other,FDA-2016-P-3968-0136,FDA-2016-P-3968,interim response from fda to international probiotics association,0,0
09000064823a3248,Other,FDA-2016-P-3968-0001,FDA-2016-P-3968,citizen petition from international probiotics association,0,0
09000064823a3502,Other,FDA-2016-P-3968-0002,FDA-2016-P-3968,acknowledgment letter from fda ddm to international probiotics association,0,0
09000064836b152e,Other,FDA-2016-P-3968-0137,FDA-2016-P-3968,citizen petition response to the international probiotics association (ipa) re probiotic labeling,0,0
0900006482146b68,Other,FDA-2016-P-2337-0002,FDA-2016-P-2337,"acknowledgement letter from fda ddm to lachman consultant services, inc.",0,0
0900006482146b66,Other,FDA-2016-P-2337-0001,FDA-2016-P-2337,"citizen petition from lachman consultant services, inc.",0,0
0900006482147992,Supporting & Related Material,FDA-2016-P-2337-0003,FDA-2016-P-2337,"attachment 1 approved drug products with therapeutic equivalence evaluations, electronic orange book accessed july 13, 2016 re citizen petition from lachman consultant services, inc.",0,0
0900006482147993,Supporting & Related Material,FDA-2016-P-2337-0004,FDA-2016-P-2337,"attachment 2 approved labeling for the rld re citizen petition from lachman consultant services, inc.",0,0
0900006482147994,Supporting & Related Material,FDA-2016-P-2337-0005,FDA-2016-P-2337,"attachment 3 proposed prescribing information for leucovorin calcium injection re citizen petition from lachman consultant services, inc.",0,0
0900006483a98e89,Other,FDA-2018-P-4642-0005,FDA-2018-P-4642,agency response letter from fda cvm to provetica animal health llc,0,0
0900006483950c75,Supporting & Related Material,FDA-2018-P-4642-0004,FDA-2018-P-4642,appendix 2 proposed generic product label insert re citizen petition from provetica animal health llc,0,0
0900006483950c76,Other,FDA-2018-P-4642-0002,FDA-2018-P-4642,acknowledgment letter from fda ddm to provetica animal health llc,0,0
0900006483950747,Other,FDA-2018-P-4642-0001,FDA-2018-P-4642,citizen petition from provetica animal health llc,0,0
0900006483950c74,Supporting & Related Material,FDA-2018-P-4642-0003,FDA-2018-P-4642,appendix 1 reference product label insert re citizen petition from provetica animal health llc,0,0
0900006481a0b7ac,Supporting & Related Material,FDA-2015-P-0543-0004,FDA-2015-P-0543,annex 2 citizen petition from gland pharma ltd.,0,0
0900006481a0b7b0,Supporting & Related Material,FDA-2015-P-0543-0008,FDA-2015-P-0543,annex 6 citizen petition from gland pharma ltd.,0,0
0900006481a0c174,Supporting & Related Material,FDA-2015-P-0543-0009,FDA-2015-P-0543,annex 7 citizen petition from gland pharma ltd.,0,0
0900006481a0b7ad,Supporting & Related Material,FDA-2015-P-0543-0005,FDA-2015-P-0543,annex 3 citizen petition from gland pharma ltd.,0,0
0900006481a0c176,Other,FDA-2015-P-0543-0002,FDA-2015-P-0543,acknowledgement letter from fda ddm to gland pharma ltd.,0,0
0900006481a0b7af,Supporting & Related Material,FDA-2015-P-0543-0007,FDA-2015-P-0543,annex 5 citizen petition from gland pharma ltd.,0,0
0900006481a0c175,Supporting & Related Material,FDA-2015-P-0543-0010,FDA-2015-P-0543,annex 8 citizen petition from gland pharma ltd.,0,0
0900006481a0b7ab,Supporting & Related Material,FDA-2015-P-0543-0003,FDA-2015-P-0543,annex 1 citizen petition from gland pharma ltd.,0,0
09000064825e27c0,Other,FDA-2015-P-0543-0012,FDA-2015-P-0543,final response letter from fda cder to gland pharma ltd.,0,0
0900006481a0b7ae,Supporting & Related Material,FDA-2015-P-0543-0006,FDA-2015-P-0543,annex 4 citizen petition from gland pharma ltd.,0,0
0900006481a0b7a9,Other,FDA-2015-P-0543-0001,FDA-2015-P-0543,citizen petition from gland pharma ltd.,0,0
0900006481c2b603,Other,FDA-2015-P-0543-0011,FDA-2015-P-0543,interim response letter from fda cder to gland pharma ltd.,0,0
0900006483cd4296,Supporting & Related Material,FDA-2019-P-1800-0010,FDA-2019-P-1800,boditech reclassification petition appendix ii - submission of a 'reclassification petition' under section 513(f)(3) of the fd&c act to request the fda commissioner for reclassification of medical devices associated with fda device product code ncd from class iii to class ii,0,0
0900006483ba59e6,Supporting & Related Material,FDA-2019-P-1800-0003,FDA-2019-P-1800,"attachment 1 copyrighted article lewinsohn, et al (2016) official american thoracic society/infectious diseases society of america/centers for disease control and prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children re citizen petition from boditech med inc.",0,0
0900006483ba59e8,Supporting & Related Material,FDA-2019-P-1800-0005,FDA-2019-P-1800,attachment 3 fda guideline for industry class ii special controls guideline: nucleic acid-based in vitro diagnostic devices for the detection of mycobacterium tuberculosis complex in respiratory specimens re citizen petition from boditech med inc.,0,0
0900006483cd3a27,Other,FDA-2019-P-1800-0007,FDA-2019-P-1800,submission of a 'reclassification petition' under section 513(f)(3) of the fd&c act to request the fda commissioner for reclassification of medical devices associated with fda device product code ncd from class iii to class ii,0,0
0900006483cd3a2d,Supporting & Related Material,FDA-2019-P-1800-0008,FDA-2019-P-1800,table of contents - re: submission of a 'reclassification petition' under section 513(f)(3) of the fd&c act to request the fda commissioner for reclassification of medical devices associated with fda device product code ncd from class iii to class ii,0,0
0900006483ba59e9,Other,FDA-2019-P-1800-0002,FDA-2019-P-1800,acknowledgment letter from fda ddm to boditech med inc.,0,0
0900006483ba5eba,Other,FDA-2019-P-1800-0001,FDA-2019-P-1800,citizen petition from boditech med inc.,0,0
0900006483bbb176,Other,FDA-2019-P-1800-0006,FDA-2019-P-1800,denial response from fda cdrh to boditech med inc.,0,0
0900006483cd6f71,Other,FDA-2019-P-1800-0012,FDA-2019-P-1800,reclassification petition acknowledgment letter from fda cdrh to boditech med inc,0,0
0900006483ba59e7,Supporting & Related Material,FDA-2019-P-1800-0004,FDA-2019-P-1800,attachment 2 who latent tuberculosis infection; updated and consolidated guidelines for programmatic management re citizen petition from boditech med inc.,0,0
0900006483cd42cc,Supporting & Related Material,FDA-2019-P-1800-0011,FDA-2019-P-1800,boditech reclassification petition appendix iii - submission of a 'reclassification petition' under section 513(f)(3) of the fd&c act to request the fda commissioner for reclassification of medical devices associated with fda device product code ncd from class iii to class ii,0,0
0900006483cd41f0,Supporting & Related Material,FDA-2019-P-1800-0009,FDA-2019-P-1800,boditech reclassification petition appendix i - re: submission of a 'reclassification petition' under section 513(f)(3) of the fd&c act to request the fda commissioner for reclassification of medical devices associated with fda device product code ncd from class iii to class ii,0,0
09000064848603fa,Other,FDA-2018-P-3382-0005,FDA-2018-P-3382,"letter from fda cder to fresenius kabi usa, llc",0,0
09000064836bc3ea,Supporting & Related Material,FDA-2018-P-3382-0003,FDA-2018-P-3382,"attachment a – current orange book listing of 0.45% sodium chloride re: citizen petition from citizen petition from fresenius kabi usa, llc",0,0
09000064836bb9e7,Other,FDA-2018-P-3382-0001,FDA-2018-P-3382,"citizen petition from fresenius kabi usa, llc",0,0
0900006483ad2c88,Other,FDA-2018-P-3382-0004,FDA-2018-P-3382,"letter from fda cder to fresenius kabi usa, llc",0,0
09000064836bc1a0,Other,FDA-2018-P-3382-0002,FDA-2018-P-3382,"acknowledgment letter from fda ddm to fresenius kabi usa, llc",0,0
0900006483436c8c,Other,FDA-2018-P-2407-0001,FDA-2018-P-2407,"citizen petition from ray law firm, pllc",0,0
0900006483436c8e,Other,FDA-2018-P-2407-0002,FDA-2018-P-2407,"acknowledgment letter from fda ddm to ray law firm, pllc",0,0
090000648380da64,Other,FDA-2018-P-2407-0003,FDA-2018-P-2407,amendment to fda-2018-p-2407 10-19-2018_redacted,0,0
09000064846d9cbc,Other,FDA-2020-P-1523-0001,FDA-2020-P-1523,citizens petition from wineamerica and wine institute,0,0
090000648499d38b,Other,FDA-2020-P-1523-0003,FDA-2020-P-1523,response letter from fda cfsan to wine america,0,0
09000064846d9cbd,Other,FDA-2020-P-1523-0002,FDA-2020-P-1523,acknowledgment letter from fda dms to wineamerica and wine institute,0,0
09000064830875eb,Supporting & Related Material,FDA-2018-P-1352-0003,FDA-2018-P-1352,"appendix 2 - a copy of the zoetis package insert for this product re citizen petition from douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd.)",0,0
09000064833743c7,Other,FDA-2018-P-1352-0006,FDA-2018-P-1352,"agency response letter from fda cvm to schafer veterinary consultants, llc",0,0
0900006483087441,Other,FDA-2018-P-1352-0001,FDA-2018-P-1352,"citizen petition from douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd.)",0,0
0900006483335707,Other,FDA-2018-P-1352-0005,FDA-2018-P-1352,"change of us agent, james h. schafer, d.v.m (schafer veterinary consultants, llc) - 06-04-2018",0,0
0900006483087444,Other,FDA-2018-P-1352-0002,FDA-2018-P-1352,"acknowledgment letter from fda ddm to douglass oeller consulting, inc.",0,0
09000064830875ec,Supporting & Related Material,FDA-2018-P-1352-0004,FDA-2018-P-1352,"appendix 3 - a marked up copy of the package insert showing felix's proposed changes re citizen petition from douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd.)",0,0
09000064849fdf8a,Other,FDA-2019-P-4962-0004,FDA-2019-P-4962,"correspondence from fresenius kabi usa, llc to cder",0,0
0900006484a7ec53,Other,FDA-2019-P-4962-0005,FDA-2019-P-4962,"interim response letter from fda cder to fresenius kabi usa, llc",0,0
09000064840f1fca,Other,FDA-2019-P-4962-0001,FDA-2019-P-4962,"citizen petition for fresenius kabi usa, llc",0,0
09000064840f205f,Other,FDA-2019-P-4962-0002,FDA-2019-P-4962,"acknowledgment letter from fda dms to fresenius kabi usa, llc",0,0
09000064844bed49,Other,FDA-2019-P-4962-0003,FDA-2019-P-4962,"interim response letter from fda cder to fresenius kabi usa, llc",0,0
0900006484980495,Supporting & Related Material,FDA-2020-P-2244-0007,FDA-2020-P-2244,"attachment 4 re: citizen petition from camargo pharmaceutical services, llc on behalf of center laboratories, inc.",0,0
090000648497fe46,Supporting & Related Material,FDA-2020-P-2244-0003,FDA-2020-P-2244,"attachment 1- center labs citizen petition authorization letter re: citizen petition from camargo pharmaceutical services, llc on behalf of center laboratories, inc.",0,0
0900006484b1a72f,Notice,FDA-2020-P-2244-0009,FDA-2020-P-2244,"determination that isoptin (verapamil hydrochloride) tablets 40 milligrams, 80 milligrams, and 120 milligrams, and calan (verapamil hydrochloride) tablets, 40 milligrams, 80 milligrams, 120 milligrams, and 160 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006484b1d0b8,Other,FDA-2020-P-2244-0010,FDA-2020-P-2244,response letter from fda cder to camargo pharmaceutical services llc,0,0
090000648497fe3f,Other,FDA-2020-P-2244-0001,FDA-2020-P-2244,"citizen petition from camargo pharmaceutical services, llc on behalf of center laboratories, inc.",0,0
0900006484980494,Supporting & Related Material,FDA-2020-P-2244-0006,FDA-2020-P-2244,"attachment 3 re: citizen petition from camargo pharmaceutical services, llc on behalf of center laboratories, inc.",0,0
0900006484980493,Supporting & Related Material,FDA-2020-P-2244-0005,FDA-2020-P-2244,"attachment 2 re: citizen petition from camargo pharmaceutical services, llc on behalf of center laboratories, inc.",0,0
0900006484980492,Supporting & Related Material,FDA-2020-P-2244-0004,FDA-2020-P-2244,"attachment 1 re: citizen petition from camargo pharmaceutical services, llc on behalf of center laboratories, inc.",0,0
090000648497fe44,Other,FDA-2020-P-2244-0002,FDA-2020-P-2244,"acknowledgment letter from fda dms to camargo pharmaceutical services, llc. on behalf of center laboratories, inc.",0,0
090000648498080c,Supporting & Related Material,FDA-2020-P-2244-0008,FDA-2020-P-2244,"attachment 5 re: citizen petition from camargo pharmaceutical services, llc on behalf of center laboratories, inc.",0,0
0900006484b1d00b,Supporting & Related Material,FDA-2020-P-2244-0011,FDA-2020-P-2244,isoptincalanfrnotice5.19.21,0,0
0900006480a5b482,Notice,FDA-2009-N-0556-0001,FDA-2009-N-0556,agency information collection activities; proposed collection; comment request; records and reports concerning experience withapproved new animal drugs,0,0
0900006481ad34d2,Other,FDA-2015-P-1595-0001,FDA-2015-P-1595,"citizen petition from cubist pharmaceuticals, inc",0,0
0900006481cf0fd5,Other,FDA-2015-P-1595-0004,FDA-2015-P-1595,"interim response letter from fda cder to cubist pharmaceutical, inc.",0,0
0900006481ad34d6,Supporting & Related Material,FDA-2015-P-1595-0002,FDA-2015-P-1595,"exhibit 1 declaration of dr. herbert l. dupont re citizen petition from cubist pharmaceuticals, inc",0,0
0900006482195b31,Other,FDA-2015-P-1595-0005,FDA-2015-P-1595,"final response letter from fda cder to cubist pharmaceutical, inc.",0,0
0900006481ad34d4,Other,FDA-2015-P-1595-0003,FDA-2015-P-1595,"acknowledgement letter from fda ddm to cubist pharmaceuticals, inc",0,0
0900006482295b64,Supporting & Related Material,FDA-2016-P-0159-0008,FDA-2016-P-0159,reference 1 - guidance - procedures for class ii device exemptions from premarket notification 1998,0,0
0900006481e0efaf,Other,FDA-2016-P-0159-0001,FDA-2016-P-0159,citizen petition from biorex labs llc,0,0
0900006481e10188,Other,FDA-2016-P-0159-0002,FDA-2016-P-0159,acknowledgement letter from fda ddm to biorex labs llc,0,0
0900006481edc6ef,Notice,FDA-2016-P-0159-0003,FDA-2016-P-0159,"medical devices; exemption from premarket notification: method,
metallic reduction, glucose (urinary, non-quantitative) test system in a
reagent tablet format",0,0
0900006481fa8786,Notice,FDA-2016-P-0159-0005,FDA-2016-P-0159,"medical devices; exemption from premarket notification: method, 
metallic reduction, glucose (urinary, non-quantitative) test system in 
a reagent tablet format",0,0
09000064822912df,Rule,FDA-2016-P-0159-0007,FDA-2016-P-0159,"medical devices; exemption from premarket notification; method,
metallic reduction, glucose (urinary, nonquantitative) test system in a
reagent tablet format",0,0
09000064820a44c0,Other,FDA-2016-P-0159-0006,FDA-2016-P-0159,denial letter from the fda cdrh to biorex labs llc,0,0
0900006481edd298,Supporting & Related Material,FDA-2016-P-0159-0004,FDA-2016-P-0159,"procedures for class ii device exemptions from premarket notification, guidance for industry and cdrh staff re medical devices; exemption from premarket notification: method, metallic reduction, glucose (urinary, non-quantitative) test system in a reagent tablet format",0,0
0900006481856fd5,Supporting & Related Material,FDA-2014-P-1102-0002,FDA-2014-P-1102,attachment 1 orange book approved drug products with therapeutic equivalence evaluations,0,0
0900006481857032,Other,FDA-2014-P-1102-0003,FDA-2014-P-1102,acknowledgment letter from fda ddm to lachman consultant services inc,0,0
0900006481856fd3,Other,FDA-2014-P-1102-0001,FDA-2014-P-1102,citizen petition from lachman consultant services inc,0,0
09000064819b10b1,Other,FDA-2014-P-1102-0004,FDA-2014-P-1102,response letter from fda cder to lachman consultant services,0,0
0900006481857030,Other,FDA-2014-P-1101-0002,FDA-2014-P-1101,acknowledgement letter from fda ddm to lachman consultant services inc,0,0
0900006481856fd7,Other,FDA-2014-P-1101-0001,FDA-2014-P-1101,citizen petition from lachman consultant services inc,0,0
09000064819b10af,Other,FDA-2014-P-1101-0004,FDA-2014-P-1101,response letter from fda cder to lachman consultant services,0,0
090000648185702f,Supporting & Related Material,FDA-2014-P-1101-0003,FDA-2014-P-1101,attachment 1 orange book approved drug products with therapeitoc equivalence evaluations,0,0
0900006481bb0757,Other,FDA-2015-P-2736-0001,FDA-2015-P-2736,"suitability petition from comodo health, inc.",0,0
0900006481bb075b,Supporting & Related Material,FDA-2015-P-2736-0003,FDA-2015-P-2736,attachment i package insert for sandoz's argatroban re: suitability petition from comodo health inc.,0,0
0900006481bb0759,Other,FDA-2015-P-2736-0002,FDA-2015-P-2736,acknowledgement letter from fda ddm to comodo health inc.,0,0
0900006482fa9a2a,Supporting & Related Material,FDA-2018-P-1019-0004,FDA-2018-P-1019,"attachment 2- nda 17-558/s-053 robinul injection (glycopyrrolate injection, usp) re: citizen petition from lachman consultant services inc.",0,0
0900006482fa9a2b,Supporting & Related Material,FDA-2018-P-1019-0005,FDA-2018-P-1019,"attachment 3- neostigmine methylsulfate - neos tigmine methylsulfate injection, solution fres enius kabi usa, llc re: citizen petition from lachman consultant services inc.",0,0
0900006482fa9a25,Other,FDA-2018-P-1019-0002,FDA-2018-P-1019,"acknowledgment letter from fda ddm to lachman consultant services, inc",0,0
0900006482fa9a29,Supporting & Related Material,FDA-2018-P-1019-0003,FDA-2018-P-1019,attachment 1- orange book: approved drug products with therapeutic equivalence evaluations re: citizen petition from lachman consultant services inc.,0,0
0900006482fa9a2c,Supporting & Related Material,FDA-2018-P-1019-0006,FDA-2018-P-1019,"attachment 4- glycopyrrolate - glycopyrrolate injection, solution re: citizen petition from lachman consultant services inc.",0,0
0900006482fa8ff7,Other,FDA-2018-P-1019-0001,FDA-2018-P-1019,citizen petition from lachman consultant services inc.,0,0
0900006482317098,Other,FDA-2016-P-3427-0002,FDA-2016-P-3427,"acknowledgement letter from fda ddm to douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd)",0,0
0900006482466d24,Other,FDA-2016-P-3427-0006,FDA-2016-P-3427,"petition approval letter from fda cvm to douglass oeller consulting, inc.",0,0
090000648231709a,Supporting & Related Material,FDA-2016-P-3427-0003,FDA-2016-P-3427,"attachment 1 deramaxx re suitability petition from douglass oeller consulting, inc (felix pharmaceuticals pvt. ltd)",0,0
090000648235effc,Other,FDA-2016-P-3427-0005,FDA-2016-P-3427,"amendment  from douglass oeller consulting, inc .",0,0
090000648231709b,Supporting & Related Material,FDA-2016-P-3427-0004,FDA-2016-P-3427,"attachment 2 chewable tablets re suitability petition from douglass oeller consulting, inc (felix pharmaceuticals pvt. ltd)",0,0
0900006482317094,Other,FDA-2016-P-3427-0001,FDA-2016-P-3427,"suitability petition from  douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd)",0,0
09000064841295d3,Other,FDA-2019-P-5268-0002,FDA-2019-P-5268,acknowledgment letter from fda dms to public citizen’s health research group,0,0
0900006484554b34,Other,FDA-2019-P-5268-0015,FDA-2019-P-5268,"interim response letter from fda cder to public citizen’s health research group and delaram j. taghipour, m.d.",0,0
09000064841295d2,Other,FDA-2019-P-5268-0001,FDA-2019-P-5268,citizen petition from public citizen's health research group,0,0
090000648412960b,Supporting & Related Material,FDA-2019-P-5268-0012,FDA-2019-P-5268,"reference 45, by shah et al re citizen petition from public citizen’s health research group",0,0
090000648412960d,Supporting & Related Material,FDA-2019-P-5268-0014,FDA-2019-P-5268,reference 51 by scholl et al re citizen petition from public citizen’s health research group,0,0
0900006484129605,Supporting & Related Material,FDA-2019-P-5268-0006,FDA-2019-P-5268,"reference 12-13, by gillen et al  re citizen petition from public citizen’s health research group",0,0
0900006484129606,Supporting & Related Material,FDA-2019-P-5268-0007,FDA-2019-P-5268,"reference 16 and 20-21, by vanschaik re citizen petition from public citizen’s health research group",0,0
0900006484129607,Supporting & Related Material,FDA-2019-P-5268-0008,FDA-2019-P-5268,"reference 31, by skipper et al re citizen petition from public citizen’s health research group",0,0
0900006484129608,Supporting & Related Material,FDA-2019-P-5268-0009,FDA-2019-P-5268,"reference 34 and 36-37, by harrison et al re citizen petition from public citizen’s health research group",0,0
090000648412960c,Supporting & Related Material,FDA-2019-P-5268-0013,FDA-2019-P-5268,"reference 46-49, by thiels et al re citizen petition from public citizen’s health research group",0,0
09000064846b96c3,Other,FDA-2019-P-5268-0016,FDA-2019-P-5268,supplement from public citizen,0,0
090000648412afed,Supporting & Related Material,FDA-2019-P-5268-0003,FDA-2019-P-5268,appendix boxed warning for oxycontin re citizen petition from public citizen’s health research group,0,0
09000064841299f9,Supporting & Related Material,FDA-2019-P-5268-0004,FDA-2019-P-5268,"reference 7-9 and 14-15, by grond et al re citizen petition from public citizen’s health research group",0,0
0900006484129609,Supporting & Related Material,FDA-2019-P-5268-0010,FDA-2019-P-5268,"reference 43, by jeong et al re citizen petition from public citizen’s health research group",0,0
090000648412960a,Supporting & Related Material,FDA-2019-P-5268-0011,FDA-2019-P-5268,"reference 44, by zeng et al re citizen petition from public citizen’s health research group",0,0
09000064841299fa,Supporting & Related Material,FDA-2019-P-5268-0005,FDA-2019-P-5268,"reference 11, by raffa et al re citizen petition from public citizen’s health research group",0,0
0900006484a60974,Other,FDA-2020-P-1919-0003,FDA-2020-P-1919,"withdrawal from acella pharmaceuticals, llc",0,0
0900006484861b36,Other,FDA-2020-P-1919-0001,FDA-2020-P-1919,"citizen petition from acella pharmaceuticals, llc",0,0
09000064848620de,Other,FDA-2020-P-1919-0002,FDA-2020-P-1919,"acknowledgment letter from fda dms to acella pharmaceuticals, llc",0,0
0900006484a3a72d,Other,FDA-2021-P-0193-0001,FDA-2021-P-0193,"citizen petition from benjamin ogilvie, et.al.",0,0
0900006484a3a730,Other,FDA-2021-P-0193-0002,FDA-2021-P-0193,acknowledgment letter from fda dms to benjamin ogilvie,0,0
0900006484c28b5e,Other,FDA-2021-P-0193-0009,FDA-2021-P-0193,response letter from fda cder to benjamin ogilvie,0,0
0900006484a3a74c,Supporting & Related Material,FDA-2021-P-0193-0003,FDA-2021-P-0193,appendix a re citizen petition from benjamin ogilvie,0,0
0900006484a60d12,Other,FDA-2021-P-0271-0002,FDA-2021-P-0271,acknowledgment letter from fda dms to hyman phelps mcnamara pc,0,0
0900006484a60d10,Other,FDA-2021-P-0271-0001,FDA-2021-P-0271,citizen petition from hyman phelps mcnamara pc,0,0
0900006484c2c8f0,Other,FDA-2021-P-0271-0004,FDA-2021-P-0271,"response letter from fda cder to hyman, phelps& mcnamara, p.c.",0,0
0900006484c2aa83,Notice,FDA-2021-P-0271-0003,FDA-2021-P-0271,"determination that votrient (pazopanib hydrochloride) tablets, 400 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006484a13124,Supporting & Related Material,FDA-2021-P-0096-0028,FDA-2021-P-0096,affidavit of stein re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a12b1e,Supporting & Related Material,FDA-2021-P-0096-0005,FDA-2021-P-0096,tab 4 - jasmohan s. bajaj et al. - colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a12b23,Supporting & Related Material,FDA-2021-P-0096-0007,FDA-2021-P-0096,tab 8 - patrizia brigidi et al. - effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a12b60,Supporting & Related Material,FDA-2021-P-0096-0010,FDA-2021-P-0096,tab 12 - e. fritz et al. - effects of lactulose and polyethylene glycol on colonic transit re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a12b64,Supporting & Related Material,FDA-2021-P-0096-0014,FDA-2021-P-0096,tab 16 - dae joong kang et al. - rifaximin exerts beneficial effects independent of its ability to alter microbiota composition re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a12b1c,Supporting & Related Material,FDA-2021-P-0096-0004,FDA-2021-P-0096,tab 3 - jasmohan s. bajaj - review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a12bb0,Supporting & Related Material,FDA-2021-P-0096-0020,FDA-2021-P-0096,tab 23 - salix pharm. inc - xifaxan prescribing information re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
09000064849fca5f,Other,FDA-2021-P-0096-0001,FDA-2021-P-0096,citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a12b1a,Supporting & Related Material,FDA-2021-P-0096-0003,FDA-2021-P-0096,index of reference documents re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a12b63,Supporting & Related Material,FDA-2021-P-0096-0013,FDA-2021-P-0096,tab 15 - jamie s. huang et al. - use of rifamycin drugs and development of infection by rifamycin-resistant strains of clostridium difficile re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a12bac,Supporting & Related Material,FDA-2021-P-0096-0016,FDA-2021-P-0096,"tab 18 - david g. levitt & michael d. levitt - a model of blood-ammonia homeostasis based on a quantitative analysis of nitrogen metabolism in the multiple organs involved in the production, catabolism,
and excretion of ammonia in humans re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc)",0,0
0900006484a12bb1,Supporting & Related Material,FDA-2021-P-0096-0021,FDA-2021-P-0096,tab 36 - g. c. viscomi et al. - crystal forms of rifaximin and their effect on pharmaceutical properties re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a12b67,Supporting & Related Material,FDA-2021-P-0096-0015,FDA-2021-P-0096,"tab 17 - vishesh kothary et al. - rifaximin resistance in escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpob, and activity of phearg-β-naphthylamide-inhibitable efflux pumps re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc)",0,0
0900006484a12bae,Supporting & Related Material,FDA-2021-P-0096-0018,FDA-2021-P-0096,tab 21 - deanna m. mudie et al. - quantification of gastrointestinal liquid volumes and distribution following a 240 ml dose of water in the fasted state re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a14316,Supporting & Related Material,FDA-2021-P-0096-0022,FDA-2021-P-0096,tab 37 - world health organization -2019 antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a12bb3,Supporting & Related Material,FDA-2021-P-0096-0024,FDA-2021-P-0096,"tab 39 - alex yu et al. - bioequivalence history, in fda bioequivalence standards re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc)",0,0
0900006484a13122,Supporting & Related Material,FDA-2021-P-0096-0026,FDA-2021-P-0096,affidavit of ciolkowski re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a12b62,Supporting & Related Material,FDA-2021-P-0096-0012,FDA-2021-P-0096,tab 14 - ankur gupta et al. - role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
09000064849fcb2e,Other,FDA-2021-P-0096-0002,FDA-2021-P-0096,acknowledgment letter from fda dms to bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a12bad,Supporting & Related Material,FDA-2021-P-0096-0017,FDA-2021-P-0096,tab 19 - xiaochao ma et al. - rifaximin is a gut-specific human pregnane x receptor activator re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a13121,Supporting & Related Material,FDA-2021-P-0096-0025,FDA-2021-P-0096,affidavit of chasan-taber re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a13123,Supporting & Related Material,FDA-2021-P-0096-0027,FDA-2021-P-0096,affidavit of johnson re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a12b5e,Supporting & Related Material,FDA-2021-P-0096-0008,FDA-2021-P-0096,tab 9 - elizabeth a. campbell et al. - structural mechanism for rifampicin inhibition of bacterial rna  polymerase re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
0900006484a12b22,Supporting & Related Material,FDA-2021-P-0096-0006,FDA-2021-P-0096,"tab 7 - corrado blandizzi et al. - impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc)",0,0
0900006484a12b61,Supporting & Related Material,FDA-2021-P-0096-0011,FDA-2021-P-0096,tab 13 - tawanda gumbo et al. - concentration-dependent mycobacterium tuberculosis killing and prevention of resistance by rifampin re citizen petition from bakerhostetler llp (on behalf of salix pharmaceuticals inc),0,0
09000064822f5966,Other,FDA-2016-P-3313-0001,FDA-2016-P-3313,"citizen petition from kleinfeld, kaplan and becker, llp (purdue pharma l.p.)",0,0
09000064824db694,Other,FDA-2016-P-3313-0003,FDA-2016-P-3313,"supplement from purdue pharma l.p. (kleinfeld, kaplan, & becker llp)",0,0
090000648250047b,Other,FDA-2016-P-3313-0004,FDA-2016-P-3313,"cp response from fda cder to kleinfeld, kaplan and becker, llp",0,0
09000064822f5968,Other,FDA-2016-P-3313-0002,FDA-2016-P-3313,"acknowledgment letter from fda ddm to  kleinfeld, kaplan and becker, llp",0,0
09000064831330bd,Other,FDA-2018-P-1492-0002,FDA-2018-P-1492,"acknowledgment letter from fda ddm to lachman consultant services, inc",0,0
09000064831330ba,Other,FDA-2018-P-1492-0001,FDA-2018-P-1492,"citizen petition from lachman consultant services, inc",0,0
090000648313314f,Supporting & Related Material,FDA-2018-P-1492-0003,FDA-2018-P-1492,"attachment orange book acetaminophen and oxycodone re citizen petition from lachman consultant services, inc",0,0
090000648390d0c6,Other,FDA-2018-P-1492-0005,FDA-2018-P-1492,withdrawal of citizen petition fda-2018-p-1492,0,0
0900006482b26a4d,Other,FDA-2017-P-5592-0001,FDA-2017-P-5592,citizens petition from international isotopes inc,0,0
0900006483258ccc,Notice,FDA-2017-P-5592-0006,FDA-2017-P-5592,"determination that sodium iodide i 123 (sodium iodide i-123), oral
solution, 2 millicuries/milliliter, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006482fd5bf1,Other,FDA-2017-P-5592-0005,FDA-2017-P-5592,interim response from fda to international isotopes inc,0,0
0900006482b26c26,Supporting & Related Material,FDA-2017-P-5592-0004,FDA-2017-P-5592,appendix 2 prescribing information for sodium iodide capsules re citizens petition from international isotopes inc,0,0
090000648326f29a,Other,FDA-2017-P-5592-0007,FDA-2017-P-5592,final response - sodium iodide,0,0
0900006482b26c25,Supporting & Related Material,FDA-2017-P-5592-0003,FDA-2017-P-5592,appendix 1 current orange book listing for sodium iodide i-123 re citizens petition from international isotopes inc,0,0
0900006482b26c23,Other,FDA-2017-P-5592-0002,FDA-2017-P-5592,acknowledgement letter from fda ddm to international isotopes inc,0,0
0900006481c63399,Supporting & Related Material,FDA-2015-P-3299-0003,FDA-2015-P-3299,attachment 1 prescription and over the counter drug product list orange book 33rd edition re citizen petition from clinipace worldwide,0,0
0900006481e8be0b,Other,FDA-2015-P-3299-0005,FDA-2015-P-3299,interim response letter from fda cder to clinipace worldwide,0,0
0900006481f8f701,Other,FDA-2015-P-3299-0007,FDA-2015-P-3299,final agency response: re-listing letter - 4-26-16 81 fr 24107,0,0
0900006481f890ee,Notice,FDA-2015-P-3299-0006,FDA-2015-P-3299,"determination that thalitone (chlorthalidone usp) tablets, 15
milligrams, were not withdrawn from sale for reasons of safety or
effectiveness",0,0
0900006481c6339a,Supporting & Related Material,FDA-2015-P-3299-0004,FDA-2015-P-3299,attachment 2  prescription and over the counter drug product list orange book 35th edition re citizen petition from clinipace worldwide,0,0
0900006481c63396,Other,FDA-2015-P-3299-0002,FDA-2015-P-3299,acknowledgement letter from fda ddm to clinipace worldwide,0,0
0900006481c63395,Other,FDA-2015-P-3299-0001,FDA-2015-P-3299,citizen petition from clinipace worldwide,0,0
0900006481ae2723,Other,FDA-2015-P-1722-0001,FDA-2015-P-1722,citizen petition from hogan lovells us llp (helsinn),0,0
0900006481ae2d08,Supporting & Related Material,FDA-2015-P-1722-0008,FDA-2015-P-1722,tab 9 helsinn exela nda medical review re: citizen petition from hogan lovells,0,0
0900006481ae27a3,Supporting & Related Material,FDA-2015-P-1722-0004,FDA-2015-P-1722,tab 3 helsinn exela denial letter re: citizen petition from hogan lovells,0,0
0900006481cc0653,Other,FDA-2015-P-1722-0014,FDA-2015-P-1722,citizen petition denial response from fda cder to hogan lovells us llp,0,0
0900006481ae2725,Other,FDA-2015-P-1722-0002,FDA-2015-P-1722,acknowledgement letter from fda ddm to hogan lovells us llp,0,0
0900006481ae2d07,Supporting & Related Material,FDA-2015-P-1722-0007,FDA-2015-P-1722,tab 8 helsinn exela nda clinical review re: citizen petition from hogan lovells,0,0
0900006481ae27a5,Supporting & Related Material,FDA-2015-P-1722-0005,FDA-2015-P-1722,tab 5 helsinn exela letter from ogd re: citizen petition from hogan lovells,0,0
0900006481ae2d09,Supporting & Related Material,FDA-2015-P-1722-0009,FDA-2015-P-1722,tab 10 helsinn exela nda summary review re: citizen petition from hogan lovells,0,0
0900006481ae2d0a,Supporting & Related Material,FDA-2015-P-1722-0010,FDA-2015-P-1722,tab 11 helsinn exela petition denial re: citizen petition from hogan lovells,0,0
0900006481ae27a6,Supporting & Related Material,FDA-2015-P-1722-0006,FDA-2015-P-1722,tab 6 helsinn exela label evaluation re: citizen petition from hogan lovells,0,0
0900006481ae27a2,Supporting & Related Material,FDA-2015-P-1722-0003,FDA-2015-P-1722,tab 2 helsinn exela label information re: citizen petition from hogan lovells,0,0
0900006481ae2d0b,Supporting & Related Material,FDA-2015-P-1722-0011,FDA-2015-P-1722,tab 12 helsinn exela petition denial re: citizen petition from hogan lovells,0,0
0900006481ae2d0c,Supporting & Related Material,FDA-2015-P-1722-0012,FDA-2015-P-1722,tab 13 helsinn exela journal letter re: citizen petition from hogan lovells,0,0
0900006481ae28cc,Supporting & Related Material,FDA-2015-P-1722-0013,FDA-2015-P-1722,tab 25 helsinn exela redacted anda rejection re: citizen petition from hogan lovells,0,0
090000648498004d,Supporting & Related Material,FDA-2020-P-2245-0003,FDA-2020-P-2245,"attachment 1- center labs citizen petition authorization letter re: citizen petition from camargo pharmaceutical services, llc on behalf of center laboratories, inc.",0,0
0900006484980812,Supporting & Related Material,FDA-2020-P-2245-0007,FDA-2020-P-2245,"attachment 4 re:  citizen petition from camargo pharmaceutical services, llc on behalf of center laboratories, inc.",0,0
090000648498080f,Supporting & Related Material,FDA-2020-P-2245-0004,FDA-2020-P-2245,"attachment 1 re:  citizen petition from camargo pharmaceutical services, llc on behalf of center laboratories, inc.",0,0
0900006484b1e36b,Other,FDA-2020-P-2245-0011,FDA-2020-P-2245,"letter from fda cder to camargo pharmaceutical services, llc",0,0
0900006484980811,Supporting & Related Material,FDA-2020-P-2245-0006,FDA-2020-P-2245,"attachment 3 re:  citizen petition from camargo pharmaceutical services, llc on behalf of center laboratories, inc.",0,0
090000648497fe47,Other,FDA-2020-P-2245-0001,FDA-2020-P-2245,"citizen petition from camargo pharmaceutical services, llc on behalf of center laboratories, inc.",0,0
090000648498004b,Other,FDA-2020-P-2245-0002,FDA-2020-P-2245,"acknowledgment letter from fda dms to camargo pharmaceutical services, llc on behalf of center laboratories, inc.",0,0
0900006484980813,Supporting & Related Material,FDA-2020-P-2245-0008,FDA-2020-P-2245,"attachment 5 re:  citizen petition from camargo pharmaceutical services, llc on behalf of center laboratories, inc.",0,0
0900006484980810,Supporting & Related Material,FDA-2020-P-2245-0005,FDA-2020-P-2245,"attachment 2 re:  citizen petition from camargo pharmaceutical services, llc on behalf of center laboratories, inc.",0,0
0900006484b1b367,Notice,FDA-2020-P-2245-0010,FDA-2020-P-2245,"determination that isoptin (verapamil hydrochloride) tablets 40 milligrams, 80 milligrams, and 120 milligrams, and calan (verapamil hydrochloride) tablets, 40 milligrams, 80 milligrams, 120 milligrams, and 160 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006484b1dbbe,Supporting & Related Material,FDA-2021-P-0477-0005,FDA-2021-P-0477,"attachment  3 - narcan label - 1986  re citizen petition from bpi labs, llc",0,0
0900006484b1d0d1,Supporting & Related Material,FDA-2021-P-0477-0007,FDA-2021-P-0477,"attachment 5 - narcan label-2004  re citizen petition from bpi labs, llc",0,0
0900006484b1d00c,Other,FDA-2021-P-0477-0001,FDA-2021-P-0477,"citizen petition from bpi labs, llc",0,0
0900006484b1dbbc,Supporting & Related Material,FDA-2021-P-0477-0003,FDA-2021-P-0477,"attachment 1 - orange book approved drug productswith therapeutic equivalenceevaluations re citizen petition from bpi labs, llc",0,0
0900006484b1dbbd,Supporting & Related Material,FDA-2021-P-0477-0004,FDA-2021-P-0477,"attachment 2 - orange book approved drug products with therapeutic equivalence  re citizen petition from bpi labs, llc",0,0
0900006484b1d0c5,Other,FDA-2021-P-0477-0002,FDA-2021-P-0477,"acknowledgment letter from fda dms to bpi labs, llc",0,0
0900006484b1d0d0,Supporting & Related Material,FDA-2021-P-0477-0006,FDA-2021-P-0477,"attachment  4 -sboa_ims anda-072076  re citizen petition from bpi labs, llc",0,0
090000648045c70b,Supporting & Related Material,FDA-2006-N-0309-0005,FDA-2006-N-0309,jeffrey shuren,0,0
090000648045c70e,Supporting & Related Material,FDA-2006-N-0309-0006,FDA-2006-N-0309,jeffrey shuren,0,0
090000648045c708,Notice,FDA-2006-N-0309-0004,FDA-2006-N-0309,fda,0,0
090000648045c706,Notice,FDA-2006-N-0309-0003,FDA-2006-N-0309,fda,0,0
090000648045c6ff,Notice,FDA-2006-N-0309-0002,FDA-2006-N-0309,fda,0,0
090000648045c6e8,Notice,FDA-2006-N-0309-0001,FDA-2006-N-0309,fda,0,0
0900006480afeaaa,Notice,FDA-2010-N-0019-0002,FDA-2010-N-0019,"agency information collection activities; proposals, submissions, and approvals: general licensing provisions; biologics license application, changes to an approved application, etc.",0,0
0900006480a83d3f,Notice,FDA-2010-N-0019-0001,FDA-2010-N-0019,"agency information collection activities; proposed collection; comment request; general licensing provisions: biologics license application, changes toan approved application, labeling, revocation and suspension, postmarketing studies status reports, and forms fda 356h and 2567",0,0
090000648257fe31,Supporting & Related Material,FDA-2017-P-2661-0003,FDA-2017-P-2661,attachment 1 - orange book approved drug products with therapeutic equivalence evaluations re request that the fda to declare that empagliflozlin capsules 10 mg and 25 mg are suitable for submission as an anda and the reference product on which the contents of this petition are based is jardiance (empagliflozlin tablets 10 mg and 25 mg,0,0
090000648257fe35,Supporting & Related Material,FDA-2017-P-2661-0006,FDA-2017-P-2661,attachment 4 - nda approval re request that the fda to declare that empagliflozlin capsules 10 mg and 25 mg are suitable for submission as an anda and the reference product on which the contents of this petition are based is jardiance (empagliflozlin tablets 10 mg and 25 mg,0,0
09000064825801e7,Other,FDA-2017-P-2661-0002,FDA-2017-P-2661,acknowledgment letter from fda ddm to foley & lardner llp,0,0
090000648257fceb,Other,FDA-2017-P-2661-0001,FDA-2017-P-2661,citizen petition from foley & lardner llp,0,0
090000648257fe34,Supporting & Related Material,FDA-2017-P-2661-0005,FDA-2017-P-2661,"attachment 3 - jardiance' (empagliflozin) tablets, for oral use re request that the fda to declare that empagliflozlin capsules 10 mg and 25 mg are suitable for submission as an anda and the reference product on which the contents of this petition are based is jardiance (empagliflozlin tablets 10 mg and 25 mg",0,0
0900006484db4d7e,Other,FDA-2017-P-2661-0007,FDA-2017-P-2661,withdrawal of citizen petition from foley & lardner llp,0,0
090000648257fe33,Supporting & Related Material,FDA-2017-P-2661-0004,FDA-2017-P-2661,attachment 2 - empagliflozlin capsules 10 mg and 25 mg re request that the fda to declare that empagliflozlin capsules 10 mg and 25 mg are suitable for submission as an anda and the reference product on which the contents of this petition are based is jardiance (empagliflozlin tablets 10 mg and 25 mg,0,0
0900006484aa34cd,Other,FDA-2021-P-0375-0001,FDA-2021-P-0375,citizen petition from celerity pharmaceuticals llc,0,0
0900006484dbe91e,Other,FDA-2021-P-0375-0005,FDA-2021-P-0375,"interim response letter from fda cder to celerity pharmaceuticals, llc",0,0
0900006484aa3e35,Other,FDA-2021-P-0375-0002,FDA-2021-P-0375,acknowledgement letter from fda dms to celerity pharmaceuticals llc from fda dms,0,0
0900006484aa3e4e,Supporting & Related Material,FDA-2021-P-0375-0003,FDA-2021-P-0375,attachment 2 re: citizen petition from celerity pharmaceuticals llc.,0,0
0900006484aa3e5e,Supporting & Related Material,FDA-2021-P-0375-0004,FDA-2021-P-0375,attachment 1- orange book re: citizen petition from celerity pharmaceuticals llc.,0,0
09000064847cc220,Other,FDA-2020-P-1725-0002,FDA-2020-P-1725,acknowledgment letter from fda dms to knowledge ecology international,0,0
0900006484a0f7c8,Other,FDA-2020-P-1725-0004,FDA-2020-P-1725,interim response letter from fda cder to knowledge ecology international,0,0
09000064847cc21f,Other,FDA-2020-P-1725-0001,FDA-2020-P-1725,citizen petition from knowledge ecology international,0,0
090000648266979e,Other,FDA-2016-P-4186-0003,FDA-2016-P-4186,"interim response from fda cder to lachman consultant services, inc.",0,0
09000064823dabba,Other,FDA-2016-P-4186-0001,FDA-2016-P-4186,"citizen petition from lachman consultant services, inc.",0,0
09000064823dabbc,Other,FDA-2016-P-4186-0002,FDA-2016-P-4186,"acknowledgment letter from fda ddm to lachman consultant services, inc.",0,0
0900006483f21297,Notice,FDA-2016-P-4186-0005,FDA-2016-P-4186,"determination that calcimar (calcitonin salmon) injection, 200 international units per milliliter, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483f22afa,Other,FDA-2016-P-4186-0004,FDA-2016-P-4186,"response letter from fda cder to lachman consultant services, inc",0,0
0900006483a06ca4,Other,FDA-2019-P-0372-0001,FDA-2019-P-0372,"citizen petition from hyman phelps & mcnamara, p.c.",0,0
0900006483a07625,Other,FDA-2019-P-0372-0002,FDA-2019-P-0372,"acknowledgment letter from fda ddm to  hyman phelps & mcnamara, p.c.",0,0
0900006483d96d32,Other,FDA-2019-P-0372-0004,FDA-2019-P-0372,"letter from fda cder to hyman phelps & mcnamara, p.c.",0,0
0900006483d94332,Notice,FDA-2019-P-0372-0003,FDA-2019-P-0372,"determination that miochol (acetylcholine chloride intraocular solution), 20 milligrams/vial, was not withdrawn from sale for reasons of safety or effectiveness",0,0
09000064823debed,Other,FDA-2011-P-0022-0014,FDA-2011-P-0022,interim response letter from cdrh to waxler regulatory consultancy llc,0,0
0900006480fdb94f,Other,FDA-2011-P-0022-0006,FDA-2011-P-0022,waxler regulatory consultancy llc - letter,0,0
090000648185aee8,Other,FDA-2011-P-0022-0009,FDA-2011-P-0022,"petition for reconsideration from waxler consultancy, llc",0,0
0900006480ebc8f4,Other,FDA-2011-P-0022-0004,FDA-2011-P-0022,fda interim response to waxler regulatory consultancy llc,0,0
0900006480bc6a44,Other,FDA-2011-P-0022-0001,FDA-2011-P-0022,waxler regulatory consultancy llc - citizen petition,0,0
0900006481afb0ad,Supporting & Related Material,FDA-2011-P-0022-0012,FDA-2011-P-0022,exhibit 1 citizen petition from waxler regulatory consultancy llc re comment from paula cofer,0,0
09000064823578aa,Other,FDA-2011-P-0022-0013,FDA-2011-P-0022,reconsideration denial letter from the fda to waxler regulatory consultancy llc,0,0
0900006480fa41b3,Other,FDA-2011-P-0022-0005,FDA-2011-P-0022,waxler regulatory consultancy llc - letter,0,0
09000064819df331,Other,FDA-2011-P-0022-0011,FDA-2011-P-0022,reconsideration petition interim response,0,0
09000064810dcfcf,Supporting & Related Material,FDA-2011-P-0022-0007,FDA-2011-P-0022,"waxler regulatory consultancy llc to the division of dockets management august 14, 2012 - background material",0,0
090000648185aee9,Other,FDA-2011-P-0022-0010,FDA-2011-P-0022,"acknowledgement letter from fda/ddm to waxler consultancy, llc",0,0
0900006480bc6f16,Other,FDA-2011-P-0022-0002,FDA-2011-P-0022,acknowledgement letter to waxler regulatory consultancy llc,0,0
09000064818270ec,Other,FDA-2011-P-0022-0008,FDA-2011-P-0022,citizen petition denial response from fda cdrh to waxler regulatory consultancy llc,0,0
090000648192667a,Supporting & Related Material,FDA-2014-P-1896-0003,FDA-2014-P-1896,attachment 1 citizen petition from tecreg services inc,0,0
0900006481926d58,Supporting & Related Material,FDA-2014-P-1896-0004,FDA-2014-P-1896,attachment 2 citizen petition from techreg services inc,0,0
0900006481ab6699,Other,FDA-2014-P-1896-0006,FDA-2014-P-1896,"letter from fda cder to techreg services, inc.",0,0
0900006481926d59,Other,FDA-2014-P-1896-0002,FDA-2014-P-1896,acknowledgement letter from fda ddm to techreg services,0,0
0900006481926678,Other,FDA-2014-P-1896-0001,FDA-2014-P-1896,citizen petition from techreg services inc,0,0
0900006481ab34b2,Notice,FDA-2014-P-1896-0005,FDA-2014-P-1896,determination that oxytocin in 5% dextrose injection products were not withdrawn from sale for reasons of safety or effectiveness,0,0
0900006481a08f37,Supporting & Related Material,FDA-2015-P-0516-0004,FDA-2015-P-0516,attach b,0,0
0900006481a1a53f,Other,FDA-2015-P-0516-0006,FDA-2015-P-0516,withdrawal request letter from lachman consultants services inc,0,0
0900006481a08a3f,Other,FDA-2015-P-0516-0001,FDA-2015-P-0516,citizen pettion  request from lachman consultant services inc,0,0
0900006481a08f38,Supporting & Related Material,FDA-2015-P-0516-0005,FDA-2015-P-0516,attach c,0,0
0900006481a08f36,Supporting & Related Material,FDA-2015-P-0516-0003,FDA-2015-P-0516,attach a,0,0
0900006481a08f39,Other,FDA-2015-P-0516-0002,FDA-2015-P-0516,acknowledgement letter from fda ddm to lachman consultant services inc,0,0
0900006483aa5347,Supporting & Related Material,FDA-2019-P-0916-0003,FDA-2019-P-0916,"apendix 2 -bayer healthcare llc package insert re: suitability petition from schafer veterinary consultants, llc  on behalf of felix pharmaceuticals pvt. ltd",0,0
0900006483aa52f1,Other,FDA-2019-P-0916-0002,FDA-2019-P-0916,"acknowledgment letter from fda ddm to  schafer veterinary consultants, llc  on behalf of felix pharmaceuticals pvt. ltd",0,0
0900006483aa52ea,Other,FDA-2019-P-0916-0001,FDA-2019-P-0916,"suitability petition from schafer veterinary consultants, llc  on behalf of felix pharmaceuticals pvt. ltd",0,0
09000064841ad5b3,Other,FDA-2019-P-0916-0005,FDA-2019-P-0916,response letter from fda to felix pharmaceuticals pvt ltd,0,0
0900006483aa5349,Supporting & Related Material,FDA-2019-P-0916-0004,FDA-2019-P-0916,"appendix 3 -annotated copy of the package insert showing flex's proposed changes re: suitability petition from schafer veterinary consultants, llc  on behalf of felix pharmaceuticals pvt. ltd",0,0
0900006482912323,Supporting & Related Material,FDA-2017-P-4174-0003,FDA-2017-P-4174,"attachment a transcript of proceedings, anesthesiology and respiratory therapy devices panel re citizen petition from mallinckrodt pharmaceuticals",0,0
090000648291269a,Supporting & Related Material,FDA-2017-P-4174-0010,FDA-2017-P-4174,"attachment h tissue debate raises fairness, transparency questions for combo products re citizen petition from mallinckrodt pharmaceuticals",0,0
090000648294233d,Other,FDA-2017-P-4174-0011,FDA-2017-P-4174,withdrawal from mallinckrodt pharmaceuticals,0,0
0900006482912325,Supporting & Related Material,FDA-2017-P-4174-0005,FDA-2017-P-4174,attachment c detention without physical examination of devices from firms that have not met device quality system requirements re citizen petition from mallinckrodt pharmaceuticals,0,0
0900006482912326,Supporting & Related Material,FDA-2017-P-4174-0006,FDA-2017-P-4174,"attachment d praxair distribution, inc v ino therapeutics, llc transcript of proceedings re citizen petition from mallinckrodt pharmaceuticals",0,0
0900006482912327,Supporting & Related Material,FDA-2017-P-4174-0007,FDA-2017-P-4174,"attachment e praxair distribution, inc v ino therapeutics, llc dba ikaria, inc petition for inter partes review re citizen petition from mallinckrodt pharmaceuticals",0,0
0900006482912324,Supporting & Related Material,FDA-2017-P-4174-0004,FDA-2017-P-4174,attachment b life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure re citizen petition from mallinckrodt pharmaceuticals,0,0
090000648291231f,Other,FDA-2017-P-4174-0001,FDA-2017-P-4174,citizen petition from mallinckrodt pharmaceuticals,0,0
0900006482912321,Other,FDA-2017-P-4174-0002,FDA-2017-P-4174,acknowledgement letter from fda ddm to mallinckrodt pharmaceuticals,0,0
0900006482912698,Supporting & Related Material,FDA-2017-P-4174-0008,FDA-2017-P-4174,"attachment f declaration of robert t stone, phd ipr re citizen petition from mallinckrodt pharmaceuticals",0,0
0900006482912699,Supporting & Related Material,FDA-2017-P-4174-0009,FDA-2017-P-4174,"attachment g praxair distribution, inc vs mallinckrodt hospital products ip ltd re citizen petition from mallinckrodt pharmaceuticals",0,0
09000064849a4940,Other,FDA-2020-P-2304-0002,FDA-2020-P-2304,"acknowledgement letter from fda dms to fresenius kabi usa, llc",0,0
09000064849a493f,Other,FDA-2020-P-2304-0001,FDA-2020-P-2304,"citizens petition from fresenius kabi usa, llc",0,0
0900006484ab6882,Notice,FDA-2020-P-2304-0004,FDA-2020-P-2304,"determination that sodium chloride 14.6% solution for injection, 50  milliequivalent/20 milliliters, in plastic containers, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006484ab769c,Other,FDA-2020-P-2304-0005,FDA-2020-P-2304,"determination from fda cder to fresenius kabi usa, llc",0,0
09000064849a4711,Supporting & Related Material,FDA-2020-P-2304-0003,FDA-2020-P-2304,"attachment a – orange book listing of sodium chloride 14.6% - nda 018897 re citizens petition from fresenius kabi usa, llc",0,0
0900006484b7be1c,Supporting & Related Material,FDA-2021-P-0530-0012,FDA-2021-P-0530,exhibit 10 re citizen petition from optinose us inc,0,0
0900006484b7be4b,Supporting & Related Material,FDA-2021-P-0530-0023,FDA-2021-P-0530,exhibit 21 re citizen petition from optinose us inc,0,0
0900006484b7be74,Supporting & Related Material,FDA-2021-P-0530-0031,FDA-2021-P-0530,exhibit 29 re citizen petition from optinose us inc,0,0
0900006484b7be86,Supporting & Related Material,FDA-2021-P-0530-0036,FDA-2021-P-0530,exhibit 34 re citizen petition from optinose us inc,0,0
0900006484b7beb6,Supporting & Related Material,FDA-2021-P-0530-0052,FDA-2021-P-0530,exhibit 50 re citizen petition from optinose us inc,0,0
0900006484b7becd,Supporting & Related Material,FDA-2021-P-0530-0064,FDA-2021-P-0530,exhibit 62 re citizen petition from optinose us inc,0,0
0900006484b7bed3,Supporting & Related Material,FDA-2021-P-0530-0070,FDA-2021-P-0530,exhibit 66 re citizen petition from optinose us inc,0,0
0900006484b7beee,Supporting & Related Material,FDA-2021-P-0530-0076,FDA-2021-P-0530,exhibit 72 re citizen petition from optinose us inc,0,0
0900006484b7bf0b,Supporting & Related Material,FDA-2021-P-0530-0082,FDA-2021-P-0530,exhibit 78 re citizen petition from optinose us inc,0,0
0900006484b7bf0d,Supporting & Related Material,FDA-2021-P-0530-0084,FDA-2021-P-0530,exhibit 80 re citizen petition from optinose us inc,0,0
0900006484b7be17,Supporting & Related Material,FDA-2021-P-0530-0007,FDA-2021-P-0530,exhibit 5 re citizen petition from optinose us inc,0,0
0900006484b7be1a,Supporting & Related Material,FDA-2021-P-0530-0010,FDA-2021-P-0530,exhibit 8 re citizen petition from optinose us inc,0,0
0900006484b7be1d,Supporting & Related Material,FDA-2021-P-0530-0013,FDA-2021-P-0530,exhibit 11 re citizen petition from optinose us inc,0,0
0900006484b7be70,Supporting & Related Material,FDA-2021-P-0530-0027,FDA-2021-P-0530,exhibit 25 re citizen petition from optinose us inc,0,0
0900006484b7be88,Supporting & Related Material,FDA-2021-P-0530-0038,FDA-2021-P-0530,exhibit 36 re citizen petition from optinose us inc,0,0
0900006484b7be8e,Supporting & Related Material,FDA-2021-P-0530-0044,FDA-2021-P-0530,exhibit 42 re citizen petition from optinose us inc,0,0
0900006484b7beb9,Supporting & Related Material,FDA-2021-P-0530-0055,FDA-2021-P-0530,exhibit 53 re citizen petition from optinose us inc,0,0
0900006484b7bebc,Supporting & Related Material,FDA-2021-P-0530-0058,FDA-2021-P-0530,exhibit 56 re citizen petition from optinose us inc,0,0
0900006484b7beca,Supporting & Related Material,FDA-2021-P-0530-0061,FDA-2021-P-0530,exhibit 59 re citizen petition from optinose us inc,0,0
0900006484b7beea,Supporting & Related Material,FDA-2021-P-0530-0072,FDA-2021-P-0530,exhibit 68 re citizen petition from optinose us inc,0,0
0900006484b7beed,Supporting & Related Material,FDA-2021-P-0530-0075,FDA-2021-P-0530,exhibit 71 re citizen petition from optinose us inc,0,0
0900006484b7be19,Supporting & Related Material,FDA-2021-P-0530-0009,FDA-2021-P-0530,exhibit 7 re citizen petition from optinose us inc,0,0
0900006484b7be4a,Supporting & Related Material,FDA-2021-P-0530-0022,FDA-2021-P-0530,exhibit 20 re citizen petition from optinose us inc,0,0
0900006484b7be75,Supporting & Related Material,FDA-2021-P-0530-0032,FDA-2021-P-0530,exhibit 30 re citizen petition from optinose us inc,0,0
0900006484b7be87,Supporting & Related Material,FDA-2021-P-0530-0037,FDA-2021-P-0530,exhibit 35 re citizen petition from optinose us inc,0,0
0900006484a667b9,Other,FDA-2021-P-0280-0001,FDA-2021-P-0280,citizen petition from harry duty,0,0
0900006484a66fbc,Other,FDA-2021-P-0280-0002,FDA-2021-P-0280,acknowledgment letter from fda dms to harry duty,0,0
0900006484c03b5d,Other,FDA-2021-P-0280-0003,FDA-2021-P-0280,final response to harry duty from fda cvm,0,0
09000064821a5641,Supporting & Related Material,FDA-2016-P-2559-0006,FDA-2016-P-2559,"exhibit 4 kulkarni and melkundi (2012) subdural hematoma: an adverse event of electroconvulsive therapy – case report and literature review. case reports in re citizen petition from emord and associates, p.c.
psychiatry",0,0
09000064821a5644,Supporting & Related Material,FDA-2016-P-2559-0009,FDA-2016-P-2559,"exhibit 5 part 3 mecta submission to fda re citizen petition from emord and associates, p.c.",0,0
09000064821a5647,Supporting & Related Material,FDA-2016-P-2559-0012,FDA-2016-P-2559,"exhibit 8 akkerman- statement of decision on submitted issues, january 5, 2005 re citizen petition from emord and associates, p.c.",0,0
09000064839e7a8e,Other,FDA-2016-P-2559-0029,FDA-2016-P-2559,"letter from fda cdrh emord and associates, p.c.",0,0
0900006483a185a8,Other,FDA-2016-P-2559-0030,FDA-2016-P-2559,meeting regarding citizen petition fda minutes 31 july 2017-fda,0,0
09000064821a5645,Supporting & Related Material,FDA-2016-P-2559-0010,FDA-2016-P-2559,"exhibit 6 manufacturer somatics, inc.’s 2010 submission to the fda re citizen petition from emord and associates, p.c.",0,0
09000064821a564b,Supporting & Related Material,FDA-2016-P-2559-0014,FDA-2016-P-2559,"exhibit 10 kenneth castleman, electroshock therapy and brain damage re citizen petition from emord and associates, p.c.",0,0
09000064821a564c,Supporting & Related Material,FDA-2016-P-2559-0015,FDA-2016-P-2559,"exhibit 11 “optimized and full spectrum© dosing parameters” re citizen petition from emord and associates, p.c.",0,0
09000064821a5656,Supporting & Related Material,FDA-2016-P-2559-0025,FDA-2016-P-2559,"exhibit 21 public comment to the fda regarding the ect proposed ruling on ect, from dr. moira dolan re citizen petition from emord and associates, p.c.",0,0
09000064821a51c5,Other,FDA-2016-P-2559-0001,FDA-2016-P-2559,"citizen petition from emord and associates, p.c.",0,0
09000064824afebf,Other,FDA-2016-P-2559-0026,FDA-2016-P-2559,"interim response letter from cdrh to emord and associates, p.c.",0,0
09000064821a563f,Supporting & Related Material,FDA-2016-P-2559-0004,FDA-2016-P-2559,"exhibit 2 dr. moira dolan, feb. 28, 2012 – re - ect machine safety problems -fda executive summary re citizen petition from emord and associates, p.c.",0,0
09000064821a5640,Supporting & Related Material,FDA-2016-P-2559-0005,FDA-2016-P-2559,"exhibit 3 complaint of misconduct, center for medical devices and radiological health, food and drug administration, february 8, 2012 re citizen petition from emord and associates, p.c.",1,0
09000064821a5643,Supporting & Related Material,FDA-2016-P-2559-0008,FDA-2016-P-2559,"exhibit 5 part 2 mecta submission to fda re citizen petition from emord and associates, p.c.",0,0
09000064821a564d,Supporting & Related Material,FDA-2016-P-2559-0016,FDA-2016-P-2559,"exhibit 12 akkerman v. mecta corp., no. 01-10362, u.s.d.c., cd cal. complaint re citizen petition from emord and associates, p.c.",0,0
09000064821a564f,Supporting & Related Material,FDA-2016-P-2559-0018,FDA-2016-P-2559,"exhibit 14 imogene rohovit v, mecta corp re citizen petition from emord and associates, p.c.",0,0
0900006483a185aa,Other,FDA-2016-P-2559-0031,FDA-2016-P-2559,"second supplement from law office of kendrick l. moxon, p.c.",0,0
09000064821a563e,Supporting & Related Material,FDA-2016-P-2559-0003,FDA-2016-P-2559,"exhibit1 fda executive summary, prepared for the january 27-28, 2011 meeting of the neurological devices panel, meeting to discuss the classification of electroconvulsive therapy devices (ect). page 66 re citizen petition from emord and associates, p.c.",0,0
09000064821a5642,Supporting & Related Material,FDA-2016-P-2559-0007,FDA-2016-P-2559,"exhibit 5 mecta submission to fda re citizen petition from emord and associates, p.c.",0,0
09000064821a5646,Supporting & Related Material,FDA-2016-P-2559-0011,FDA-2016-P-2559,"exhibit 7 sackeim deposition, p. 64-68. re citizen petition from emord and associates, p.c.",0,0
09000064821a5653,Supporting & Related Material,FDA-2016-P-2559-0022,FDA-2016-P-2559,"exhibit 18 public comment to the fda from the cchr re citizen petition from emord and associates, p.c.",0,0
09000064821a5655,Supporting & Related Material,FDA-2016-P-2559-0024,FDA-2016-P-2559,"exhibit 20 response to manufacturers submissions from kendrick moxon re citizen petition from emord and associates, p.c.",0,0
0900006482f957e2,Other,FDA-2016-P-2559-0028,FDA-2016-P-2559,"supplement from law office of kendrick l. moxon, p.c.",0,0
09000064821a5650,Supporting & Related Material,FDA-2016-P-2559-0019,FDA-2016-P-2559,"exhibit 15 heirs of jesus torres v. mecta corp re citizen petition from emord and associates, p.c.",0,0
09000064821a5651,Supporting & Related Material,FDA-2016-P-2559-0020,FDA-2016-P-2559,"exhibit 16 freedom of information act communications fda re mdrs of ect re citizen petition from emord and associates, p.c.",0,0
0900006481fb2c18,Other,FDA-2016-P-0621-0028,FDA-2016-P-0621,withdrawal from hogan lovells us llp,0,0
0900006481e7b5a7,Supporting & Related Material,FDA-2016-P-0621-0005,FDA-2016-P-0621,"tab 3 - letter from fda to olsson, frank and weeda, p.c. re: citizen petition from hogan lovells us llp (helsinn healthcare sa)",0,0
0900006481e7b5a8,Supporting & Related Material,FDA-2016-P-0621-0006,FDA-2016-P-0621,tab 4 - preventing medication errors re: citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
0900006481e7b674,Supporting & Related Material,FDA-2016-P-0621-0008,FDA-2016-P-0621,tab 6 - label and labeling review of docetaxel injection re: citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
0900006481e7b67a,Supporting & Related Material,FDA-2016-P-0621-0014,FDA-2016-P-0621,"tab 12 - letter from fda to lipomed, inc. re: citizen petition from hogan lovells us llp (helsinn healthcare sa)",0,0
0900006481e7b683,Supporting & Related Material,FDA-2016-P-0621-0023,FDA-2016-P-0621,"tab 21 - venous thromboembolism: mechanisms, treatment, and public awareness new insights into cancer-associated thrombosis re: citizen petition from hogan lovells us llp (helsinn healthcare sa)",0,0
0900006481e7b676,Supporting & Related Material,FDA-2016-P-0621-0010,FDA-2016-P-0621,"tab 8 - center for drug evaluation and research clinical review of original nda 202,091 re: citizen petition from hogan lovells us llp (helsinn healthcare sa)",0,0
0900006481e7b680,Supporting & Related Material,FDA-2016-P-0621-0020,FDA-2016-P-0621,tab 18 - factors determining peripheral vein tolerance to amino acid infusions re: citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
0900006481e787b9,Other,FDA-2016-P-0621-0001,FDA-2016-P-0621,citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
0900006481e7b5a5,Supporting & Related Material,FDA-2016-P-0621-0003,FDA-2016-P-0621,tab 1 - palonosetron hydrochloride injection (aloxi® ) - nda 21-372 re: citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
0900006481e7b678,Supporting & Related Material,FDA-2016-P-0621-0012,FDA-2016-P-0621,tab 10 - center for drug evaluation and research cross-discipline team leader review nda 202091 re: citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
0900006481e7b67c,Supporting & Related Material,FDA-2016-P-0621-0016,FDA-2016-P-0621,"tab 14 - effect of mannitol on the pharmacokinetics of amikacin in
wistar rats re: citizen petition from hogan lovells us llp (helsinn healthcare sa)",0,0
0900006481e7b687,Supporting & Related Material,FDA-2016-P-0621-0027,FDA-2016-P-0621,tab 25 - letter from fda re: citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
0900006481e7b673,Supporting & Related Material,FDA-2016-P-0621-0007,FDA-2016-P-0621,tab 5 - letter from fda to venable l.l.p. re: citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
0900006481e7b675,Supporting & Related Material,FDA-2016-P-0621-0009,FDA-2016-P-0621,tab 7 - side effects of drugs annual: classification of immunological reactions re: citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
0900006481e7b67d,Supporting & Related Material,FDA-2016-P-0621-0017,FDA-2016-P-0621,tab 15 - a review of ph and osmolarity re: citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
0900006481e7b682,Supporting & Related Material,FDA-2016-P-0621-0022,FDA-2016-P-0621,tab 20 - venous thromboembolism and cancer: risks and outcomes re: citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
0900006481e7b684,Supporting & Related Material,FDA-2016-P-0621-0024,FDA-2016-P-0621,"tab 22 - evidence for acute vascular toxicity of cisplatin-based
chemotherapy in patients with germ cell tumor re: citizen petition from hogan lovells us llp (helsinn healthcare sa)",0,0
0900006481e7b5a3,Other,FDA-2016-P-0621-0002,FDA-2016-P-0621,acknowledgement from fda ddm to hogan lovells us llp,0,0
0900006481e7b5a6,Supporting & Related Material,FDA-2016-P-0621-0004,FDA-2016-P-0621,tab 2 - prescribing information for aloxi re: citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
0900006481e7b677,Supporting & Related Material,FDA-2016-P-0621-0011,FDA-2016-P-0621,tab 9 - center for drug evaluation and research cross discipline team leader review re: citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
0900006481e7b679,Supporting & Related Material,FDA-2016-P-0621-0013,FDA-2016-P-0621,tab 11 - letter from fda to taro pharmaceuticals u.s.a. re: citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
0900006481e7b67b,Supporting & Related Material,FDA-2016-P-0621-0015,FDA-2016-P-0621,tab 13 - postscript - letters re: citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
0900006481e7b67e,Supporting & Related Material,FDA-2016-P-0621-0018,FDA-2016-P-0621,tab 16 - pain on i.v. injection of some anaesthetic agents is evoked by the unphysiological osmolality or ph of their formulations re: citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
0900006481e7b67f,Supporting & Related Material,FDA-2016-P-0621-0019,FDA-2016-P-0621,tab 17 - the epidemiology of peripheral vein infusion thrombophlebitis: a critical review re: citizen petition from hogan lovells us llp (helsinn healthcare sa),0,0
09000064824041d9,Other,FDA-2016-P-1725-0003,FDA-2016-P-1725,"interim response from fda cder to lachman consultant services, inc.",0,0
09000064824ee6b1,Notice,FDA-2016-P-1725-0004,FDA-2016-P-1725,"determination that flonase (fluticasone propionate) nasal spray,
0.05 milligram, was not withdrawn from sale for reasons of safety or
effectiveness",0,0
0900006482054a1b,Other,FDA-2016-P-1725-0002,FDA-2016-P-1725,"acknowledgement letter from fda ddm to lachman consultant services, inc.",0,0
090000648205449a,Other,FDA-2016-P-1725-0001,FDA-2016-P-1725,"citizen petition from lachman consultant services, inc.",0,0
09000064824f0110,Other,FDA-2016-P-1725-0005,FDA-2016-P-1725,"letter from fda cder to lachman consultant services, inc.",0,0
0900006482281260,Supporting & Related Material,FDA-2016-P-3052-0003,FDA-2016-P-3052,"appendix a, virtus pharmaceuticals, llc drug product recalls re citizen petition from foley & lardner llp (lehigh valley technologies, inc.)",0,0
0900006482281262,Supporting & Related Material,FDA-2016-P-3052-0005,FDA-2016-P-3052,"appendix c, products submitted with a name of virtrate re citizen petition from foley & lardner llp (lehigh valley technologies, inc.)",0,0
0900006482281265,Supporting & Related Material,FDA-2016-P-3052-0008,FDA-2016-P-3052,"appendix f, products submitted with a marketing category of medical food re citizen petition from foley & lardner llp (lehigh valley technologies, inc.)",1,0
0900006482280e74,Other,FDA-2016-P-3052-0001,FDA-2016-P-3052,"citizen petition from foley & lardner llp (lehigh valley technologies, inc.)",0,0
090000648228125e,Other,FDA-2016-P-3052-0002,FDA-2016-P-3052,acknowledgement letter from fda ddm to foley & lardner llp,0,0
0900006482281261,Supporting & Related Material,FDA-2016-P-3052-0004,FDA-2016-P-3052,"appendix b, virtus products submitted with a marketing category of unnapproved drug other re citizen petition from foley & lardner llp  
(lehigh valley technologies, inc.)",0,0
0900006482281264,Supporting & Related Material,FDA-2016-P-3052-0007,FDA-2016-P-3052,"appendix e, products submitted with a marketing category of dietary supplement re citizen petition from foley & lardner llp (lehigh valley technologies, inc.)",0,0
0900006482281263,Supporting & Related Material,FDA-2016-P-3052-0006,FDA-2016-P-3052,"appendix d, list of mischaracterized imports re citizen petition from foley & lardner llp (lehigh valley technologies, inc.)",0,0
09000064823ecfcc,Other,FDA-2016-P-1667-0005,FDA-2016-P-1667,interim response letter from cder to zydus pharmaceutical (usa) inc,0,0
0900006482047855,Supporting & Related Material,FDA-2016-P-1667-0003,FDA-2016-P-1667,"attachment 1 - electronic orange book identifying active approved drug products meclizine hydrochloride tablets, 12.5 mg and 25 mg, accessed may 10, 2016 re citizen petition from zydus pharmaceutical (usa) inc",0,0
0900006482047856,Supporting & Related Material,FDA-2016-P-1667-0004,FDA-2016-P-1667,attachment 2 letter of non-availability re citizen petition from zydus pharmaceutical (usa) inc re citizen petition from zydus pharmaceutical (usa) inc,0,0
0900006482047853,Other,FDA-2016-P-1667-0001,FDA-2016-P-1667,citizen petition from zydus pharmaceutical (usa) inc,0,0
09000064820485ae,Other,FDA-2016-P-1667-0002,FDA-2016-P-1667,acknowledgement letter from fda ddm to zydus pharmaceutical (usa) inc,0,0
09000064839fbddc,Other,FDA-2016-P-1667-0006,FDA-2016-P-1667,response letter from fda cder,0,0
09000064824f2629,Supporting & Related Material,FDA-2017-P-1359-0013,FDA-2017-P-1359,"attachment 11 -labeling for percodan and oxycontin re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f262b,Supporting & Related Material,FDA-2017-P-1359-0015,FDA-2017-P-1359,"attachment 13- purdue frederick ms contin sustained release morphine sulfate marketing without fda approval is justified by agency re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f262c,Supporting & Related Material,FDA-2017-P-1359-0016,FDA-2017-P-1359,"attachment 14 - warning letter to purdue pharma may 11, 2000 re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f26fa,Supporting & Related Material,FDA-2017-P-1359-0022,FDA-2017-P-1359,"attachment 20 -cdc, understanding the epidemic re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f2623,Supporting & Related Material,FDA-2017-P-1359-0007,FDA-2017-P-1359,"attachment 5 -us code 355 2012 re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f2624,Supporting & Related Material,FDA-2017-P-1359-0008,FDA-2017-P-1359,"attachment 6 -physician's desk reference 1999 label for oxycontin re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f0b34,Other,FDA-2017-P-1359-0002,FDA-2017-P-1359,"acknowledgment letter from fda ddm to pharmaceutical  manufacturing research services, inc.",0,0
09000064824f2621,Supporting & Related Material,FDA-2017-P-1359-0005,FDA-2017-P-1359,"attachment 3 -food and drug administration, cder_ oxycontin nda 20553, s022 administrative document regulatory division directors reviewf re citizen petition from pharmaceutical  manufacturing research services, inc.",1,0
09000064824f2622,Supporting & Related Material,FDA-2017-P-1359-0006,FDA-2017-P-1359,"attachment 4 -food and drug administration, guidance for industry analgesic indications developing drug and biological products re citizen petition from pharmaceutical  manufacturing research services, inc.",1,0
09000064824f2626,Supporting & Related Material,FDA-2017-P-1359-0010,FDA-2017-P-1359,"attachment 8 - cdc guideline for prescribing opioids for chronic pain re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f26f9,Supporting & Related Material,FDA-2017-P-1359-0021,FDA-2017-P-1359,"attachment 19 -opioid abuse in chronic pain  misconceptions and mitigation strategies re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f26fb,Supporting & Related Material,FDA-2017-P-1359-0023,FDA-2017-P-1359,"attachment 21 -nida, overdose death rates re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f2620,Supporting & Related Material,FDA-2017-P-1359-0004,FDA-2017-P-1359,"attachment 2 -timeline of selected fda activities and significant events addressing opioid misuse and abuse re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f2627,Supporting & Related Material,FDA-2017-P-1359-0011,FDA-2017-P-1359,"attachment 9 -highlights of prescribing information oxycontin, december 2016 re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f26fc,Supporting & Related Material,FDA-2017-P-1359-0024,FDA-2017-P-1359,"attachment 22 -cdc, opioid data analysis re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824eff10,Other,FDA-2017-P-1359-0001,FDA-2017-P-1359,"citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
0900006482afdc1c,Other,FDA-2017-P-1359-0026,FDA-2017-P-1359,"interim response letter from fda cder to pharmaceutical research services, inc.",0,0
09000064824f261f,Supporting & Related Material,FDA-2017-P-1359-0003,FDA-2017-P-1359,"attachment 1 -administrative document regulatory project manager review re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f2625,Supporting & Related Material,FDA-2017-P-1359-0009,FDA-2017-P-1359,"attachment 7 -reducing the risks of relief the cdc opioid-prescribing guideline re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f2628,Supporting & Related Material,FDA-2017-P-1359-0012,FDA-2017-P-1359,"attachment 10- highlights of prescribing information roxicodone, december 2016 re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f262a,Supporting & Related Material,FDA-2017-P-1359-0014,FDA-2017-P-1359,"attachment 12 -oxycontin nda 022272 approval letter re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f2691,Supporting & Related Material,FDA-2017-P-1359-0018,FDA-2017-P-1359,"attachment 16 - announces safety labeling changes and postmarket study requirements for extended-release and long-acting opioid analgesics re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f2692,Supporting & Related Material,FDA-2017-P-1359-0019,FDA-2017-P-1359,"attachment 17 - history of oxycontin labeling and risk management program, anesthetic and life support drugs and drug safety and risk management re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f2693,Supporting & Related Material,FDA-2017-P-1359-0020,FDA-2017-P-1359,"attachment 18 - division director review oxycontin tablets, reformulated fda reference id 3258740 re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
09000064824f262d,Supporting & Related Material,FDA-2017-P-1359-0017,FDA-2017-P-1359,"attachment 15 -highlights of prescribing information oxycontin, april 2013 re citizen petition from pharmaceutical  manufacturing research services, inc.",0,0
0900006480f57521,Other,FDA-2011-P-0767-0001,FDA-2011-P-0767,"somaxon pharmaceuticals, inc. - citizen petition",0,0
0900006480f58202,Other,FDA-2011-P-0767-0002,FDA-2011-P-0767,"acknowledgement letter to somaxon pharmaceuticals, inc., brian t. dorsey",0,0
0900006480ff249b,Other,FDA-2011-P-0767-0003,FDA-2011-P-0767,"fda/cder to somaxon pharmaceuticals, inc. - petition part approved and denied",0,0
09000064823699d9,Other,FDA-2016-P-1247-0003,FDA-2016-P-1247,"interim response from cder to kvk-tech, inc",0,0
0900006481faf6f1,Other,FDA-2016-P-1247-0001,FDA-2016-P-1247,"citizen petition from abhai, llc",0,0
0900006481faf6f3,Other,FDA-2016-P-1247-0002,FDA-2016-P-1247,"acknowledgement letter from fda ddm to abhai, llc",0,0
0900006482c9331d,Other,FDA-2016-P-1247-0004,FDA-2016-P-1247,withdrawal of citizen petition from kvk-tech inc,0,0
0900006483aabaa6,Other,FDA-2019-P-0941-0001,FDA-2019-P-0941,"suitability petition from schafer veterinary consultants, llc  on behalf of felix pharmaceuticals pvt. ltd",0,0
0900006483aabba5,Supporting & Related Material,FDA-2019-P-0941-0003,FDA-2019-P-0941,"appendix 2- bayer healthcare llc package insert for this product re: suitability petition from schafer veterinary consultants, llc  on behalf of felix pharmaceuticals pvt. ltd",0,0
0900006483c857ca,Other,FDA-2019-P-0941-0005,FDA-2019-P-0941,"letter from fda cvm to schafer veterinary consultants, llc",0,0
0900006483aabba7,Supporting & Related Material,FDA-2019-P-0941-0004,FDA-2019-P-0941,"appendix 3- annotated copy of the package insert showing felix's proposed changes re:  suitability petition from schafer veterinary consultants, llc  on behalf of felix pharmaceuticals pvt. ltd",0,0
0900006483aabaa9,Other,FDA-2019-P-0941-0002,FDA-2019-P-0941,"acknowledgment letter from fda ddm to schafer veterinary consultants, llc  on behalf of felix pharmaceuticals pvt. ltd",0,0
0900006484481b51,Other,FDA-2020-P-0042-0003,FDA-2020-P-0042,response letter from fda cder to emery pharma,0,0
0900006484269106,Other,FDA-2020-P-0042-0002,FDA-2020-P-0042,acknowledgment letter from fda dms to emery pharma on behalf of najafi pharma inc,0,0
0900006484268ecb,Other,FDA-2020-P-0042-0001,FDA-2020-P-0042,citizen petition from emery pharm on behalf of najafi pharma,0,0
0900006484160f71,Supporting & Related Material,FDA-2019-P-5403-0004,FDA-2019-P-5403,attachment 2 - ims data re citizen petition from husch blackwell llp,0,0
09000064849f1809,Other,FDA-2019-P-5403-0008,FDA-2019-P-5403,request to withdraw citizen petition from seth mailhot,0,0
0900006484160f70,Supporting & Related Material,FDA-2019-P-5403-0003,FDA-2019-P-5403,attachment 1 - orange book information (swab dosage form) re citizen petition from husch blackwell llp,0,0
0900006484161669,Supporting & Related Material,FDA-2019-P-5403-0006,FDA-2019-P-5403,attachment 4 - draft fda guidance clindamycin_phosphate_solution re citizen petition from husch blackwell llp,0,0
0900006484161668,Supporting & Related Material,FDA-2019-P-5403-0005,FDA-2019-P-5403,attachment 3 - draft fda guidance clindamycin_phosphate_swab re citizen petition from husch blackwell llp,0,0
090000648456a1f0,Other,FDA-2019-P-5403-0007,FDA-2019-P-5403,interim response from fda cder to husch blackwell llp,0,0
0900006484160f6b,Other,FDA-2019-P-5403-0001,FDA-2019-P-5403,"citizen petition from husch blackwell, llp",0,0
0900006484160f6d,Other,FDA-2019-P-5403-0002,FDA-2019-P-5403,"acknowledgment letter from fda dms to husch blackwell, llp",0,0
0900006484b236aa,Notice,FDA-2021-P-0226-0003,FDA-2021-P-0226,"determination that avaclyr  (acyclovir ophthalmic ointment), 3  percent, was not withdrawn from  sale for reasons of safety or effectiveness",0,0
0900006484b2e7c0,Other,FDA-2021-P-0226-0004,FDA-2021-P-0226,response letter from fda cder to cumulus pharmaceutical llc,0,0
0900006484a49f7a,Other,FDA-2021-P-0226-0002,FDA-2021-P-0226,acknowledgment letter from fda dms to cumulus pharmaceutical llc,0,0
0900006484a49ee9,Other,FDA-2021-P-0226-0001,FDA-2021-P-0226,citizen petition from cumulus pharmaceutical llc,0,0
090000648475750c,Other,FDA-2019-P-3022-0007,FDA-2019-P-3022,amendment from foley & lardner llp,0,0
0900006483d3e5bf,Supporting & Related Material,FDA-2019-P-3022-0004,FDA-2019-P-3022,attachment - 2- highlights of prescribing information re citizen petition from foley & lardner llp,0,0
0900006483d3e5c1,Supporting & Related Material,FDA-2019-P-3022-0006,FDA-2019-P-3022,attachment 4- acknowledgment receipt of submission letter re citizen petition from foley & lardner llp,0,0
0900006483d3a2f8,Other,FDA-2019-P-3022-0002,FDA-2019-P-3022,acknowledgment letter from fda ddm to foley & lardner llp,0,0
0900006483d3a760,Other,FDA-2019-P-3022-0001,FDA-2019-P-3022,citizen petition from foley & lardner llp,0,0
0900006483d3e5c0,Supporting & Related Material,FDA-2019-P-3022-0005,FDA-2019-P-3022,attachment - 3- highlights of prescribing information re citizen petition from foley & lardner llp,0,0
0900006484c95b07,Other,FDA-2019-P-3022-0008,FDA-2019-P-3022,approval letter from fda cder to foley & lardner llp,0,0
0900006483d3e5be,Supporting & Related Material,FDA-2019-P-3022-0003,FDA-2019-P-3022,attachment - 1- orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from foley & lardner llp,0,0
0900006480b67dbb,Other,FDA-2010-P-0531-0002,FDA-2010-P-0531,"acknowledgement letter to peptimmune, inc.",0,0
0900006480b67d48,Other,FDA-2010-P-0531-0001,FDA-2010-P-0531,"peptimmune, inc. - citizen petition",0,0
0900006480c13274,Other,FDA-2010-P-0531-0005,FDA-2010-P-0531,"fda/cder to peptimmune, inc. - petition denial",0,0
090000648236be9c,Supporting & Related Material,FDA-2016-P-3674-0007,FDA-2016-P-3674,attachment 5 determination of methyl mercury in dental-unit wastewater re citizen petition from consumers for dental choice,0,0
090000648236be9d,Supporting & Related Material,FDA-2016-P-3674-0008,FDA-2016-P-3674,attachment 6 environmental costs of mercury pollution re citizen petition from consumers for dental choice,0,0
090000648236bea1,Supporting & Related Material,FDA-2016-P-3674-0012,FDA-2016-P-3674,"attachment 10 health canada, the safety of dental amalgam re citizen petition from consumers for dental choice",0,0
090000648236bea4,Supporting & Related Material,FDA-2016-P-3674-0015,FDA-2016-P-3674,"attachment 13 national health _ medical research council, dental amalgam _ filling you in re citizen petition from consumers for dental choice",0,0
090000648236beab,Supporting & Related Material,FDA-2016-P-3674-0017,FDA-2016-P-3674,"attachment 15 swedish chemicals agency, mercury phase-out, a study of the experience of swedish companies re citizen petition from consumers for dental choice",0,0
090000648236beae,Supporting & Related Material,FDA-2016-P-3674-0020,FDA-2016-P-3674,"attachment 18 united kingdom department of health, letter to dentists re citizen petition from consumers for dental choice",0,0
090000648236beaf,Supporting & Related Material,FDA-2016-P-3674-0021,FDA-2016-P-3674,"attachment 19 who, future use of materials for dental restoration re citizen petition from consumers for dental choice",0,0
090000648236bbcb,Other,FDA-2016-P-3674-0001,FDA-2016-P-3674,citizen petition from consumers for dental choice,0,0
090000648236bbd0,Supporting & Related Material,FDA-2016-P-3674-0004,FDA-2016-P-3674,"attachment 2 changing patterns in the use, recycling, and material substitution of mercury in the united states (2013) re citizen petition from consumers for dental choice",0,0
090000648236be9e,Supporting & Related Material,FDA-2016-P-3674-0009,FDA-2016-P-3674,attachment 7 epa will propose rule to protect waterways by reducing mercury from dental offices re citizen petition from consumers for dental choice,0,0
090000648258185f,Other,FDA-2016-P-3674-0023,FDA-2016-P-3674,interim response letter from cdrh to consumers for dental choice,0,0
090000648236be9f,Supporting & Related Material,FDA-2016-P-3674-0010,FDA-2016-P-3674,"attachment 8 european commission scenihr, final opinion on the safety of dental amalgam and alternative dental restoration materials for patien re citizen petition from consumers for dental choice",0,0
090000648236bea0,Supporting & Related Material,FDA-2016-P-3674-0011,FDA-2016-P-3674,"attachment 9 european commission, final report, review of the community strategy concerning mercury re citizen petition from consumers for dental choice",0,0
090000648236bea2,Supporting & Related Material,FDA-2016-P-3674-0013,FDA-2016-P-3674,"attachment 11 hickel, longevity of occlusally-stressed restorations in posterior primary teeth re citizen petition from consumers for dental choice",0,0
090000648236bea5,Supporting & Related Material,FDA-2016-P-3674-0016,FDA-2016-P-3674,"attachment 14 swedish chemicals agency, dental amalgam, prohibition to use dental amalgam re citizen petition from consumers for dental choice",0,0
090000648236bead,Supporting & Related Material,FDA-2016-P-3674-0019,FDA-2016-P-3674,"attachment 17 unep, lessons from countries phasing down dental amalgam use re citizen petition from consumers for dental choice",0,0
090000648236bbcf,Supporting & Related Material,FDA-2016-P-3674-0003,FDA-2016-P-3674,"attachment 1 bio intelligence service, study on the potential for reducing mercury pollution from dental amalgam re citizen petition from consumers for dental choice",0,0
090000648236bbd3,Supporting & Related Material,FDA-2016-P-3674-0006,FDA-2016-P-3674,"attachment 4 dentsply, annual report per sec form 10-k (31 dec_ 2014) re citizen petition from consumers for dental choice",0,0
090000648236beac,Supporting & Related Material,FDA-2016-P-3674-0018,FDA-2016-P-3674,attachment 16 the real cost of dental mercury re citizen petition from consumers for dental choice,0,0
090000648236bbcd,Other,FDA-2016-P-3674-0002,FDA-2016-P-3674,acknowledgement letter from fda ddm to consumers for dental choice,0,0
090000648236bbd2,Supporting & Related Material,FDA-2016-P-3674-0005,FDA-2016-P-3674,"attachment 3 danish ministry of the environment, fact sheet mercury - re citizen petition from consumers for dental choice",0,0
090000648236bea3,Supporting & Related Material,FDA-2016-P-3674-0014,FDA-2016-P-3674,attachment 12 minamata convention (2013) re citizen petition from consumers for dental choice,0,0
0900006481a0c5b4,Supporting & Related Material,FDA-2015-P-0547-0005,FDA-2015-P-0547,"attachment 3 citizen petition from gland pharma, inc.",0,0
0900006481a0c17c,Supporting & Related Material,FDA-2015-P-0547-0003,FDA-2015-P-0547,"attachment 1 citizen petition from gland pharma, inc.",0,0
0900006481a0c5b5,Other,FDA-2015-P-0547-0002,FDA-2015-P-0547,"acknowledgement letter from fda ddm to gland pharma, ltd.",0,0
0900006481a0c17a,Other,FDA-2015-P-0547-0001,FDA-2015-P-0547,"citizen petition from gland pharma, inc.",0,0
0900006481a0c17d,Supporting & Related Material,FDA-2015-P-0547-0004,FDA-2015-P-0547,"attachment 2 citizen petition from gland pharma, inc.",0,0
0900006481a10dee,Other,FDA-2015-P-0547-0006,FDA-2015-P-0547,"corrected copy of acknowledgement letter from fda ddm to gland pharma, ltd.",0,0
09000064824b6a18,Other,FDA-2017-P-0840-0002,FDA-2017-P-0840,acknowledgment letter from fda ddm to the weinberg group,0,0
0900006482c0224d,Notice,FDA-2017-P-0840-0004,FDA-2017-P-0840,"determination that ovrette (norgestrel) tablet, 0.075 milligrams, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006482c05edd,Other,FDA-2017-P-0840-0005,FDA-2017-P-0840,final response letter from cder to the weinberg group inc,0,0
09000064824b5a95,Other,FDA-2017-P-0840-0001,FDA-2017-P-0840,citizen petition from the weinberg group,0,0
090000648298fd1a,Other,FDA-2017-P-0840-0003,FDA-2017-P-0840,interim response letter from cder to the weinberg group inc,0,0
0900006481e8af59,Other,FDA-2015-P-3319-0004,FDA-2015-P-3319,citizen petition response letter from fda cder to winifred m. begley,0,0
0900006481e25259,Notice,FDA-2015-P-3319-0003,FDA-2015-P-3319,"determination that mevacor (lovastatin) tablets, 20 milligrams and
40 milligrams, were not withdrawn from sale for reasons of safety or
effectiveness",0,0
0900006481c66a69,Other,FDA-2015-P-3319-0001,FDA-2015-P-3319,citizen petition from winifred begley,0,0
0900006481c66a6a,Other,FDA-2015-P-3319-0002,FDA-2015-P-3319,acknowledgement letter from fda ddm to winifred begley,0,0
0900006481c03e22,Other,FDA-2015-P-2962-0001,FDA-2015-P-2962,citizen petition from regcon solutions llc,0,0
0900006481c03e28,Other,FDA-2015-P-2962-0002,FDA-2015-P-2962,acknowledgment letter from fda ddm to regcon solutions llc,0,0
0900006482566e73,Other,FDA-2015-P-2962-0004,FDA-2015-P-2962,citizen petition withdrawal request from regcon solutions,0,0
0900006481c04065,Supporting & Related Material,FDA-2015-P-2962-0003,FDA-2015-P-2962,attachment 1 excerpts from the orange book re citizen petition from regcon solutions llc,0,0
0900006483c2e34a,Supporting & Related Material,FDA-2019-P-2142-0003,FDA-2019-P-2142,appendix a- energy value studies id 1-3  attachment a scientific evidence to support the labeling of the dietary fiber component in fibersol resistant maltodextrin as 1.4 calories per gram re citizen petition from archer daniels midland company,0,0
0900006483c2e34b,Supporting & Related Material,FDA-2019-P-2142-0004,FDA-2019-P-2142,attachment a-scientific evidence to support the dietary fiber component in fibersol resistant maltodextrin as having an energy value of 0.7 calories per gram for labeling purposes re: citizen petition from archer daniels midland company,0,0
0900006483c2dcfe,Other,FDA-2019-P-2142-0001,FDA-2019-P-2142,acknowledgment letter from fda ddm to archer daniels midland company,0,0
0900006484145cec,Other,FDA-2019-P-2142-0006,FDA-2019-P-2142,interim response letter from fda to archer daniels midland company,0,0
0900006483c2dc0c,Other,FDA-2019-P-2142-0002,FDA-2019-P-2142,citizen petition from archer daniels midland company,0,0
09000064842f7e5e,Other,FDA-2020-P-0438-0002,FDA-2020-P-0438,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
0900006484837376,Notice,FDA-2020-P-0438-0004,FDA-2020-P-0438,"determination that micro-k ls (potassium chloride) extended- release liquid suspension, 20 milliequivalents/packet, was not withdrawn from sale for reasons of safety or effectiveness",0,0
09000064847ad098,Other,FDA-2020-P-0438-0003,FDA-2020-P-0438,"interim response letter form fda cder to hyman, phelps & mcnamara, p.c.",0,0
0900006484839106,Other,FDA-2020-P-0438-0005,FDA-2020-P-0438,"letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
09000064842f7e5d,Other,FDA-2020-P-0438-0001,FDA-2020-P-0438,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006480b719f5,Other,FDA-2010-P-0546-0001,FDA-2010-P-0546,beckloff associates - citizen petition,0,0
0900006480b719f7,Supporting & Related Material,FDA-2010-P-0546-0002,FDA-2010-P-0546,orange book - [beckloff associates - citizen petition],0,0
0900006480b72176,Other,FDA-2010-P-0546-0003,FDA-2010-P-0546,acknowledgement letter to beckloff associates,0,0
0900006480b7d721,Other,FDA-2010-P-0546-0004,FDA-2010-P-0546,"azur pharma international iii, ltd., (beckloff associates) - withdrawal",0,0
0900006484dab787,Other,FDA-2021-P-1042-0001,FDA-2021-P-1042,citizen petition from pet schooled,0,0
0900006484dac400,Other,FDA-2021-P-1042-0002,FDA-2021-P-1042,acknowledgment letter from fda dms to petschooled,0,0
090000648327dc09,Other,FDA-2018-P-1310-0044,FDA-2018-P-1310,petition denial letter from fda cder,0,0
0900006483078e28,Supporting & Related Material,FDA-2018-P-1310-0036,FDA-2018-P-1310,exhibit 34 confidential material re citizen petition from vertice pharma management corp,0,0
0900006483063cc8,Supporting & Related Material,FDA-2018-P-1310-0005,FDA-2018-P-1310,exhibit 3 - cholestyramine guidance re citizen petition from vertice pharma management corp,0,0
0900006483063ce4,Supporting & Related Material,FDA-2018-P-1310-0014,FDA-2018-P-1310,exhibit 12 - velphoro nda 205109 summary review re citizen petition from vertice pharma management corp,0,0
0900006483063cca,Supporting & Related Material,FDA-2018-P-1310-0007,FDA-2018-P-1310,exhibit 5 - colesevelam hcl tablets guidance re citizen petition from vertice pharma management corp,0,0
0900006483063cc4,Other,FDA-2018-P-1310-0002,FDA-2018-P-1310,acknowledgment letter from fda ddm to vertice pharma management corp,0,0
0900006483079f3d,Supporting & Related Material,FDA-2018-P-1310-0043,FDA-2018-P-1310,exhibit 41 confidential material re citizen petition from vertice pharma management corp,0,0
0900006483065b3d,Supporting & Related Material,FDA-2018-P-1310-0031,FDA-2018-P-1310,exhibit 29 - graham_dig dis sci_1984 re citizen petition from vertice pharma management corp,0,0
0900006483065b35,Supporting & Related Material,FDA-2018-P-1310-0029,FDA-2018-P-1310,exhibit 27 - nakazawa_digestive diseases and sciences_1981 re citizen petition from vertice pharma management corp,0,0
0900006483065b41,Supporting & Related Material,FDA-2018-P-1310-0035,FDA-2018-P-1310,exhibit 33 - nagashima_j clin gastroenterol_1981_p103 re citizen petition from vertice pharma management corp,0,0
090000648306465d,Supporting & Related Material,FDA-2018-P-1310-0020,FDA-2018-P-1310,exhibit 18 - alhamami_archives pharm res_2007 re citizen petition from vertice pharma management corp,0,0
0900006483065b3f,Supporting & Related Material,FDA-2018-P-1310-0033,FDA-2018-P-1310,exhibit 31 - caspary_duodenal ulcer gastric ulcer - sucralfate a new therapeutic concept_1981 re citizen petition from vertice pharma management corp,0,0
090000648306465e,Supporting & Related Material,FDA-2018-P-1310-0021,FDA-2018-P-1310,exhibit 19 - chen_aaps journal_2013 re citizen petition from vertice pharma management corp,0,0
0900006483065b34,Supporting & Related Material,FDA-2018-P-1310-0028,FDA-2018-P-1310,exhibit 26 - simethicone_handbook of pharmaceutical excipients_2009 re citizen petition from vertice pharma management corp,0,0
0900006483063ce0,Supporting & Related Material,FDA-2018-P-1310-0010,FDA-2018-P-1310,exhibit 8 - omega-3-acid ethyl esters guidance re citizen petition from vertice pharma management corp,0,0
0900006483063cc6,Supporting & Related Material,FDA-2018-P-1310-0003,FDA-2018-P-1310,exhibit 1 - sucralfate oral suspension guidance october 2017 re citizen petition from vertice pharma management corp,0,0
0900006483065b1d,Supporting & Related Material,FDA-2018-P-1310-0022,FDA-2018-P-1310,exhibit 20 - lubiprostone guidance re citizen petition from vertice pharma management corp,0,0
0900006483065b23,Supporting & Related Material,FDA-2018-P-1310-0024,FDA-2018-P-1310,exhibit 22 - scogs opinion no 25 - cellulose and certain cellulose derivatives_1973 re citizen petition from vertice pharma management corp,0,0
0900006483063ba2,Other,FDA-2018-P-1310-0001,FDA-2018-P-1310,citizen petition from vertice pharma management corp,0,0
0900006483063cc9,Supporting & Related Material,FDA-2018-P-1310-0006,FDA-2018-P-1310,exhibit 4 - colesevelam hcl powder guidance re citizen petition from vertice pharma management corp,0,0
0900006483065b20,Supporting & Related Material,FDA-2018-P-1310-0023,FDA-2018-P-1310,exhibit 21 - amitiza pi re citizen petition from vertice pharma management corp,0,0
0900006483065b31,Supporting & Related Material,FDA-2018-P-1310-0027,FDA-2018-P-1310,exhibit 25 - scogs opinion no 61 - silicon dioxides_1979 re citizen petition from vertice pharma management corp,0,0
0900006483065b36,Supporting & Related Material,FDA-2018-P-1310-0030,FDA-2018-P-1310,exhibit 28 - nagashima_j clin gastroenterol_1981_p117 re citizen petition from vertice pharma management corp,0,0
0900006483063ccb,Supporting & Related Material,FDA-2018-P-1310-0008,FDA-2018-P-1310,exhibit 6 - lanthanum carbonate powder guidance re citizen petition from vertice pharma management corp,0,0
0900006483078fec,Supporting & Related Material,FDA-2018-P-1310-0041,FDA-2018-P-1310,exhibit 39 confidential material re citizen petition from vertice pharma management corp,0,0
09000064829401e5,Supporting & Related Material,FDA-2013-P-1374-0044,FDA-2013-P-1374,international and national expert group evaluations: biological/health effects of radiofrequency fields re issue a federal regulation to augment fda citizen's petition for public hearings to establish standards on cellphone radiation adverse health effects that might be caused by specific absorption rates (sar) and radio frequency radiation (rfr)/electromagnetic frequency (emf),0,0
09000064814ae187,Other,FDA-2013-P-1374-0003,FDA-2013-P-1374,"supplement from pharmacists planning service, inc.",0,0
0900006481e406cb,Other,FDA-2013-P-1374-0029,FDA-2013-P-1374,"supplement from fred mayer, ppsi",0,0
0900006481ee8cc3,Other,FDA-2013-P-1374-0030,FDA-2013-P-1374,"supplement from fred mayer, ppsi",0,0
0900006481d9b4de,Other,FDA-2013-P-1374-0024,FDA-2013-P-1374,"supplement from fred mayer, ppsi",0,0
0900006481d8eaa0,Other,FDA-2013-P-1374-0018,FDA-2013-P-1374,"supplement from frederick mayer, ppsi",0,0
09000064821a09f3,Other,FDA-2013-P-1374-0034,FDA-2013-P-1374,"supplement from frederick mayer, ppsi",0,0
0900006481cdd2b5,Other,FDA-2013-P-1374-0014,FDA-2013-P-1374,supplement from ppsi,0,0
090000648220c9ff,Other,FDA-2013-P-1374-0035,FDA-2013-P-1374,"supplement from frederick mayer, ppsi",0,0
0900006481d9b4dd,Other,FDA-2013-P-1374-0023,FDA-2013-P-1374,"supplement from fred mayer, ppsi",0,0
0900006481d9b4e0,Other,FDA-2013-P-1374-0026,FDA-2013-P-1374,"supplement from fred mayer, ppsi",0,0
0900006481d9b536,Other,FDA-2013-P-1374-0027,FDA-2013-P-1374,"supplement from fred mayer, ppsi",0,0
0900006481d392e5,Other,FDA-2013-P-1374-0016,FDA-2013-P-1374,"supplement from frederick mayer, pharmacists planning services, inc.",0,0
090000648252bfb5,Other,FDA-2013-P-1374-0037,FDA-2013-P-1374,"supplement from fred mayer, ppsi",0,0
0900006481d8eaa1,Other,FDA-2013-P-1374-0019,FDA-2013-P-1374,"supplement from frederick mayer, ppsi",0,0
0900006481d8eaa2,Other,FDA-2013-P-1374-0020,FDA-2013-P-1374,"supplement from frederick mayer, ppsi",0,0
0900006481d8eaa3,Other,FDA-2013-P-1374-0021,FDA-2013-P-1374,"supplement from frederick mayer, ppsi",0,0
0900006482605222,Other,FDA-2013-P-1374-0038,FDA-2013-P-1374,"supplement from fred mayer, ppsi",0,0
0900006482016341,Other,FDA-2013-P-1374-0031,FDA-2013-P-1374,"supplement from fred mayer, ppsi",0,0
0900006481d9b4dc,Other,FDA-2013-P-1374-0022,FDA-2013-P-1374,"supplement from fred mayer, ppsi",0,0
0900006481e406c9,Other,FDA-2013-P-1374-0028,FDA-2013-P-1374,"supplement from frederick mayer, ppsi",0,0
0900006482016469,Other,FDA-2013-P-1374-0032,FDA-2013-P-1374,"supplement from fred mayer, ppsi",0,0
090000648293f1c3,Other,FDA-2013-P-1374-0040,FDA-2013-P-1374,"letter (denial) from cdrh to pharmacists planning service, inc.",0,0
0900006482212645,Other,FDA-2013-P-1374-0036,FDA-2013-P-1374,"supplement from frederick mayer, ppsi",0,0
09000064829401e2,Supporting & Related Material,FDA-2013-P-1374-0043,FDA-2013-P-1374,scenihr opinion on potential health effects of exposure to electromagnetic fields (emf) 2015 scenihr_o_041 re issue a federal regulation to augment fda citizen's petition for public hearings to establish standards on cellphone radiation adverse health effects that might be caused by specific absorption rates (sar) and radio frequency radiation (rfr)/electromagnetic frequency (emf),0,0
0900006482d8388f,Other,FDA-2017-P-7031-0002,FDA-2017-P-7031,"acknowledgment letter from fda ddm to jrrapoza associates, inc",0,0
0900006482d8388d,Other,FDA-2017-P-7031-0001,FDA-2017-P-7031,"citizen petition from jrrapoza associates, inc",0,0
0900006482d84574,Supporting & Related Material,FDA-2017-P-7031-0004,FDA-2017-P-7031,"attachment 2 approved drug labeling rld re citizen petition from jrrapoza associates, inc",0,0
0900006482d83891,Supporting & Related Material,FDA-2017-P-7031-0003,FDA-2017-P-7031,"attachment 1 orange book listing re citizen petition from jrrapoza associates, inc",0,0
0900006482b0e6f2,Other,FDA-2017-P-5435-0001,FDA-2017-P-5435,"citizen petition from hyman, phelps & mcnamara pc",0,0
0900006482d72ce0,Other,FDA-2017-P-5435-0003,FDA-2017-P-5435,"withdrawal from hyman, phelps & mcnamara pc",0,0
0900006482b0e6f6,Other,FDA-2017-P-5435-0002,FDA-2017-P-5435,"acknowledgement letter from fda ddm to hyman, phelps & mcnamara pc",0,0
090000648483c8de,Other,FDA-2020-P-1844-0002,FDA-2020-P-1844,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
090000648483c6fe,Other,FDA-2020-P-1844-0001,FDA-2020-P-1844,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
09000064844858d9,Other,FDA-2020-P-1246-0002,FDA-2020-P-1246,"acknowledgment letter from fda dms to fresenius kabi usa, llc",0,0
09000064844857d4,Other,FDA-2020-P-1246-0001,FDA-2020-P-1246,"citizen petition from fresenius kabiusa, llc",0,0
0900006484891190,Other,FDA-2020-P-1246-0003,FDA-2020-P-1246,"interim response letter from fda cder to fresenius kabi usa, llc",0,0
090000648404a46f,Other,FDA-2019-P-4669-0001,FDA-2019-P-4669,citizen petition from rdr solutions on behalf of  fiber research international,0,0
0900006484485a98,Other,FDA-2019-P-4669-0003,FDA-2019-P-4669,interim response letter from fda cfsan to rdr solutions,0,0
090000648404c3ca,Other,FDA-2019-P-4669-0002,FDA-2019-P-4669,acknowledgement letter from fda dms to rdr solutions on behalf of  fiber research international,0,0
0900006484729f7e,Other,FDA-2019-P-4669-0004,FDA-2019-P-4669,final response from fda cfsan to dr. catherine adams hutt,0,0
0900006484020da2,Other,FDA-2019-P-4643-0002,FDA-2019-P-4643,acknowledgment letter from fda dms to physicians committee for responsible medicine,0,0
0900006484020da1,Other,FDA-2019-P-4643-0001,FDA-2019-P-4643,citizen petition from physicians committee for responsible medicine,0,0
0900006484020e64,Supporting & Related Material,FDA-2019-P-4643-0011,FDA-2019-P-4643,"reference 8 ronco et al (2002) dairy foods and risk of breast cancer: a case–control study in montevideo, uruguay re citizen petition from physicians committee for responsible medicine",0,0
0900006484ad9c4b,Other,FDA-2019-P-4643-0014,FDA-2019-P-4643,final response from fda cfsan to physicians committee for responsible medicine,0,0
0900006484020e62,Supporting & Related Material,FDA-2019-P-4643-0009,FDA-2019-P-4643,reference 6 (2002) endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies re citizen petition from physicians committee for responsible medicine,0,0
0900006484020e5e,Supporting & Related Material,FDA-2019-P-4643-0005,FDA-2019-P-4643,reference 2 u.s. cancer statistics working group re citizen petition from physicians committee for responsible medicine,0,0
0900006484020e61,Supporting & Related Material,FDA-2019-P-4643-0008,FDA-2019-P-4643,"reference 5 brinkman et al (2010) consumption of animal products, their nutrient components and postmenopausal circulating steroid hormone concentrations re citizen petition from physicians committee for responsible medicine",0,0
0900006484021147,Supporting & Related Material,FDA-2019-P-4643-0004,FDA-2019-P-4643,"reference 1 cdc, breast cancer statistics (may 28, 2019) re citizen petition from physicians committee for responsible medicine",0,0
0900006484020e5f,Supporting & Related Material,FDA-2019-P-4643-0006,FDA-2019-P-4643,"reference 3 blumen et (2016) comparison of treatment costs for breast cancer, by tumor stage and type of service re citizen petition from  physicians committee for responsible medicine",0,0
0900006484020e60,Supporting & Related Material,FDA-2019-P-4643-0007,FDA-2019-P-4643,reference 4 mccann et al (2017) usual consumption of specific dairy foods is associated with breast cancer in the roswell park cancer institute data bank and biorepository re citizen petition from physicians committee for responsible medicine,0,0
0900006484020e63,Supporting & Related Material,FDA-2019-P-4643-0010,FDA-2019-P-4643,"reference 7 kroenke, et al (2013) high- and low-fat dairy intake, recurrence, and mortality after breast cancer diagnosis re citizen petition from physicians committee for responsible medicine",0,0
0900006484020e65,Supporting & Related Material,FDA-2019-P-4643-0012,FDA-2019-P-4643,"reference 9 prentice et al (2019) low-fat dietary pattern among postmenopausal women influences long-term cancer, cardiovascular disease, and diabetes outcomes re citizen petition from physicians committee for responsible medicine",0,0
0900006484020e66,Supporting & Related Material,FDA-2019-P-4643-0013,FDA-2019-P-4643,reference 10 world cancer research fund/american institute for cancer research re citizen petition from physicians committee for responsible medicine,0,0
0900006484021146,Supporting & Related Material,FDA-2019-P-4643-0003,FDA-2019-P-4643,reference list re citizen petition from physicians committee for responsible medicine,0,0
09000064847ab048,Other,FDA-2020-P-0893-0010,FDA-2020-P-0893,interim response letter from fda cdrh to kelly roman,0,0
09000064843953d0,Supporting & Related Material,FDA-2020-P-0893-0004,FDA-2020-P-0893,"appendix b re: citizen petition from fisher wallace laboratories, inc.",0,0
09000064843953d4,Supporting & Related Material,FDA-2020-P-0893-0008,FDA-2020-P-0893,"appendix f re: citizen petition from fisher wallace laboratories, inc.",0,0
09000064843953d1,Supporting & Related Material,FDA-2020-P-0893-0005,FDA-2020-P-0893,"appendix c re: citizen petition from fisher wallace laboratories, inc.",0,0
09000064843953d3,Supporting & Related Material,FDA-2020-P-0893-0007,FDA-2020-P-0893,"appendix e re: citizen petition from fisher wallace laboratories, inc.",0,0
090000648439530b,Other,FDA-2020-P-0893-0001,FDA-2020-P-0893,"citizen petition from fisher wallace laboratories, inc.",0,0
09000064843953c9,Other,FDA-2020-P-0893-0002,FDA-2020-P-0893,"acknowledgment letter from fda dms to fisher wallace laboratories, inc.",0,0
09000064843956f0,Supporting & Related Material,FDA-2020-P-0893-0009,FDA-2020-P-0893,"appendix g re: citizen petition from fisher wallace laboratories, inc.",0,0
09000064843953d2,Supporting & Related Material,FDA-2020-P-0893-0006,FDA-2020-P-0893,"appendix d re: citizen petition from fisher wallace laboratories, inc.",0,0
0900006484d38132,Other,FDA-2020-P-0893-0011,FDA-2020-P-0893,"final response to citizen petition from fda cdrh to fisher wallace laboratories, inc.",0,0
09000064843953cf,Supporting & Related Material,FDA-2020-P-0893-0003,FDA-2020-P-0893,"appendix a re: citizen petition from fisher wallace laboratories, inc.",0,0
09000064833498ab,Other,FDA-2018-P-2175-0001,FDA-2018-P-2175,"citizen petition from pharmalucence, inc.",0,0
0900006483349c70,Other,FDA-2018-P-2175-0002,FDA-2018-P-2175,"acknowledgment letter from fda ddm  to pharmalucence, inc.",0,0
0900006484dbeb40,Other,FDA-2018-P-2175-0003,FDA-2018-P-2175,"withdrawal from sun pharmaceutical industries, inc.",0,0
09000064821ded4c,Supporting & Related Material,FDA-2016-P-2654-0007,FDA-2016-P-2654,"attachment 5 weiden pj et al. 2016. a randomized trial of iloperidone for prevention of relapse in schizophrenia: the reprieve study. cns drugs 30:735-747 re citizen petition from vanda pharmaceuticals, inc.",0,0
09000064821ded49,Supporting & Related Material,FDA-2016-P-2654-0004,FDA-2016-P-2654,"attachment 2 buchanan rw et al. 2010. the 2009 schizophrenia port psychopharmacological treatment recommendations and summary statements. schizophrenia bulletin re citizen petition from vanda pharmaceuticals, inc.",0,0
09000064821ded4b,Supporting & Related Material,FDA-2016-P-2654-0006,FDA-2016-P-2654,"attachment 4 emsley ret al. 2016. how long should antipsychotic treatment be continued after a single episode of schizophrenia? current opinion psychiatry. 29(3):224-229 re citizen petition from vanda pharmaceuticals, inc.",0,0
09000064821ded46,Other,FDA-2016-P-2654-0001,FDA-2016-P-2654,"citizen petition from vanda pharmaceuticals, inc.",0,0
09000064821ded4d,Other,FDA-2016-P-2654-0002,FDA-2016-P-2654,"acknowledgment letter from fda ddm to vanda pharmaceuticals, inc.",0,0
09000064821ded4a,Supporting & Related Material,FDA-2016-P-2654-0005,FDA-2016-P-2654,"attachment 3 emsley ret al. 2013. the nature of relapse in schizophrenia. bmc psychiatry. 13:50 re citizen petition from vanda pharmaceuticals, inc.",0,0
09000064821ded48,Supporting & Related Material,FDA-2016-P-2654-0003,FDA-2016-P-2654,"attachment 1 am. psychiatric ass'n, diagnostic and statistical manual of mental disorders § 295.90 (schizophrenia) csth ed. 2013) (dsm -5). re citizen petition from vanda pharmaceuticals, inc.",0,0
09000064823d0afe,Other,FDA-2016-P-2654-0008,FDA-2016-P-2654,petition denial letter,0,0
0900006483416b7b,Other,FDA-2018-P-1349-0007,FDA-2018-P-1349,"petition response letter from fda cvm to douglass oeller consulting, inc.",0,0
0900006483085e0c,Supporting & Related Material,FDA-2018-P-1349-0003,FDA-2018-P-1349,"appendix 2 - a copy of the boehringer lngelheim vetmedica inc package insert for this product re citizen petition from douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd.)",0,0
09000064831ee6f8,Other,FDA-2018-P-1349-0005,FDA-2018-P-1349,amendments to suitability petition: revised dosage form of pimobendan tablets.,0,0
0900006483086608,Other,FDA-2018-P-1349-0002,FDA-2018-P-1349,"acknowledgment letter from fda ddm to douglass oeller consulting, inc.",0,0
090000648333525a,Other,FDA-2018-P-1349-0006,FDA-2018-P-1349,"change of us agent, james h. schafer, d.v.m (schafer veterinary consultants, llc) - 06-04-2018",0,0
0900006483085e0a,Other,FDA-2018-P-1349-0001,FDA-2018-P-1349,"citizen petition from douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd.)",0,0
0900006483085e0d,Supporting & Related Material,FDA-2018-P-1349-0004,FDA-2018-P-1349,"appendix 3 - a marked up copy of the package insert showing felix's proposed changes re citizen petition from douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd.)",0,0
090000648135f7b3,Other,FDA-2013-P-0058-0004,FDA-2013-P-0058,fda/cder interim response to hogan lovells us llp - letter,0,0
09000064818b90f0,Other,FDA-2013-P-0058-0009,FDA-2013-P-0058,citizen petition denial response from fda cder to hogan lovells us llp and buchanan ingersoll and rooney pc,0,0
090000648167c394,Other,FDA-2013-P-0058-0007,FDA-2013-P-0058,citizen petition from gilead sciences inc (hogan lovells us llp),0,0
09000064811b5197,Other,FDA-2013-P-0058-0002,FDA-2013-P-0058,"acknowledgement letter to gilead sciences, inc. (hogan lovells us llp)",0,0
09000064811b40e1,Other,FDA-2013-P-0058-0001,FDA-2013-P-0058,"gilead sciences, inc. (hogan lovells us llp) - citizen petition",0,0
090000648159d136,Other,FDA-2013-P-0058-0006,FDA-2013-P-0058,citizen petition denial response from fda cder to hoganlovells us llp,0,0
090000648167c396,Other,FDA-2013-P-0058-0008,FDA-2013-P-0058,acknowledgement letter from fda/ddm to gilead sciences inc. (hogan lovells us llp),0,0
09000064818a0320,Other,FDA-2014-P-1483-0002,FDA-2014-P-1483,acknowledgement letter from fda ddm to sean mahoney upsher-smith laboratories inc,0,0
0900006481a31894,Other,FDA-2014-P-1483-0003,FDA-2014-P-1483,"withdrawal of petition from upsher-smith laboratories, inc.",0,0
090000648189e41d,Other,FDA-2014-P-1483-0001,FDA-2014-P-1483,citizen petition from sean mahoney upsher-smith laboratories inc,0,0
09000064824c880a,Other,FDA-2017-P-1039-0001,FDA-2017-P-1039,citizen petition from beck & thomas,0,0
090000648292435c,Other,FDA-2017-P-1039-0003,FDA-2017-P-1039,"citizen petition decision letter from fda cder to beck & thomas, p.c.",0,0
09000064824c8b4d,Other,FDA-2017-P-1039-0002,FDA-2017-P-1039,"acknowledgement letter from fda ddm to beck & thomas, p.c.",0,0
0900006483c6bb16,Other,FDA-2018-P-2040-0006,FDA-2018-P-2040,withdrawal from jerry reed,0,0
0900006483303366,Supporting & Related Material,FDA-2018-P-2040-0004,FDA-2018-P-2040,"exhibit 2-proposed package insert for atropine sulfate injection, 1.0 mg/ml (1 ml single dose vial) and 0.4 mg/ml (1 ml single dose vial) re: citizen petition from jerry taylor reed",0,0
0900006483303367,Supporting & Related Material,FDA-2018-P-2040-0005,FDA-2018-P-2040,exhibit-3 side by side comparison for the approved rld package insert and the proposed package insert re: citizen petition from jerry taylor reed,0,0
0900006483303365,Supporting & Related Material,FDA-2018-P-2040-0003,FDA-2018-P-2040,exhibit 1- package insert for fresenius kabi usa’s atropine sulfate injection 8 mg/20 ml (0.4 mg/ml) submitted under nda 209260 (approved january 2018) re: citizen petition from jerry taylor reed,0,0
090000648330326b,Other,FDA-2018-P-2040-0002,FDA-2018-P-2040,acknowledgment letter from fda ddm to jerry taylor reed,0,0
09000064833031b6,Other,FDA-2018-P-2040-0001,FDA-2018-P-2040,citizen petition from jerry taylor reed,0,0
0900006484651ca7,Supporting & Related Material,FDA-2020-P-1405-0013,FDA-2020-P-1405,attachment 11 -piehler et al - comparison of lal and rfc assays re: citizen petition for biomerieux,0,0
0900006484651caa,Supporting & Related Material,FDA-2020-P-1405-0016,FDA-2020-P-1405,"attachment 14 - article, improving the lal paradigm re: citizen petition for biomerieux",0,0
0900006484651ca8,Supporting & Related Material,FDA-2020-P-1405-0014,FDA-2020-P-1405,attachment 12 -revive and restore letter to usp re: citizen petition for biomerieux,0,0
0900006484651993,Supporting & Related Material,FDA-2020-P-1405-0003,FDA-2020-P-1405,attachment 1- biomedical bleeding process re: citizen petition for biomerieux,0,0
0900006484651ca1,Supporting & Related Material,FDA-2020-P-1405-0007,FDA-2020-P-1405,attachment 5 -horseshoe crab recovery coalition - letter to asmfc re: citizen petition for biomerieux,0,0
0900006484651994,Supporting & Related Material,FDA-2020-P-1405-0004,FDA-2020-P-1405,"attachment 2 - bruce loverock, pharmacoepial forum - citation and abstract re: citizen petition for biomerieux",0,0
0900006484651996,Supporting & Related Material,FDA-2020-P-1405-0006,FDA-2020-P-1405,attachment 4 -fda guidance for industry - pyrogen and endotoxin testing re: citizen petition for biomerieux,0,0
090000648491849d,Other,FDA-2020-P-1405-0031,FDA-2020-P-1405,interim response letter from fda cder to biomerieux,0,0
0900006484651ca9,Supporting & Related Material,FDA-2020-P-1405-0015,FDA-2020-P-1405,attachment 13 -rspca letter to usp - bacterial endotoxin assay re: citizen petition for biomerieux,0,0
0900006484651ca3,Supporting & Related Material,FDA-2020-P-1405-0009,FDA-2020-P-1405,attachment 7 -kikuchi study re: citizen petition for biomerieux,0,0
0900006484651995,Supporting & Related Material,FDA-2020-P-1405-0005,FDA-2020-P-1405,attachment 3 -congressional letter to usp - horseshoe crab re: citizen petition for biomerieux,0,0
0900006484651ca4,Supporting & Related Material,FDA-2020-P-1405-0010,FDA-2020-P-1405,attachment 8 -krisfalus-gannon et al - role of hsc in biomedical insdustry re: citizen petition for biomerieux,0,0
0900006484651ca6,Supporting & Related Material,FDA-2020-P-1405-0012,FDA-2020-P-1405,"attachment 10 -marius, et al -comparison of lal and rfc vaccine endotoxin testing re: citizen petition for biomerieux",0,0
0900006484a6e3e0,Other,FDA-2020-P-1405-0035,FDA-2020-P-1405,amendment from biomerieux,0,0
0900006484651ca2,Supporting & Related Material,FDA-2020-P-1405-0008,FDA-2020-P-1405,attachment 6 -iucn letter to usp - hsc specialist group re: citizen petition for biomerieux,0,0
0900006484651ca5,Supporting & Related Material,FDA-2020-P-1405-0011,FDA-2020-P-1405,attachment 9 -maloney et al - plos saving the hsc re: citizen petition for biomerieux,0,0
0900006484651991,Other,FDA-2020-P-1405-0002,FDA-2020-P-1405,acknowledgement letter from dms to biomerieux,0,0
090000648464fb62,Other,FDA-2020-P-1405-0001,FDA-2020-P-1405,citizen petition from biomerieux,0,0
0900006481b92b4c,Supporting & Related Material,FDA-2014-P-0159-0009,FDA-2014-P-0159,appendix 1 re: citizen petition from mead killion,0,0
0900006481a92e84,Other,FDA-2014-P-0159-0005,FDA-2014-P-0159,interim response letter from fda cdrh to etymotic research inc,0,0
0900006481a92e85,Other,FDA-2014-P-0159-0006,FDA-2014-P-0159,response letter from etymotic research inc,0,0
0900006481b92b4d,Supporting & Related Material,FDA-2014-P-0159-0010,FDA-2014-P-0159,appendix 2 re: citizen petition from mead killion,0,0
090000648153648f,Other,FDA-2014-P-0159-0002,FDA-2014-P-0159,acknowledgement letter from fda ddm to mead killion,0,0
0900006481536337,Other,FDA-2014-P-0159-0001,FDA-2014-P-0159,citizen petition from mead killion,0,0
0900006481e04b4c,Other,FDA-2014-P-0159-0012,FDA-2014-P-0159,"second interim response from fda cdrh to etymotic research, inc.",0,0
0900006481b92b4e,Supporting & Related Material,FDA-2014-P-0159-0011,FDA-2014-P-0159,letter from fda cder to mead c. killion dated 08/20/2014 re: citizen petition from mead killion,0,0
090000648154ba85,Other,FDA-2014-P-0159-0003,FDA-2014-P-0159,amendment from mead killion to fda-2014-p-0159,0,0
0900006484df8ba0,Other,FDA-2014-P-0159-0014,FDA-2014-P-0159,final response from fda cdrh to etymotic research inc,0,0
0900006481e40ee5,Other,FDA-2016-P-0383-0002,FDA-2016-P-0383,acknowledgement letter from fda ddm to fish & richardson p.c.,0,0
0900006481e40cae,Other,FDA-2016-P-0383-0001,FDA-2016-P-0383,citizen petition from fish & richardson p. c. (depomed inc.),0,0
0900006481f99d39,Other,FDA-2016-P-0383-0004,FDA-2016-P-0383,petition denial letter final response,0,0
09000064838aea6d,Other,FDA-2018-P-1008-0006,FDA-2018-P-1008,"withdrawal from vpci, inc.",0,0
0900006482f9a81a,Other,FDA-2018-P-1008-0001,FDA-2018-P-1008,"suitability petition from vpci, inc.",0,0
0900006482f9afa5,Supporting & Related Material,FDA-2018-P-1008-0004,FDA-2018-P-1008,"attachment 2- comparative labeling rld vs proposed drug product re: citizens petition from vpci, inc.",0,0
0900006482f9aa42,Other,FDA-2018-P-1008-0002,FDA-2018-P-1008,"acknowledgment letter from fda ddm to vpci, inc.",0,0
0900006482f9afa4,Supporting & Related Material,FDA-2018-P-1008-0003,FDA-2018-P-1008,"attachment1-vazculep- phenylephrine hydrochloride injection
avadel legacy pharmaceuticals , llc re: citizens petition from vpci, inc.",0,0
0900006481dd4261,Supporting & Related Material,FDA-2015-P-5022-0005,FDA-2015-P-5022,exhibit d summary of product characteristics re citizen petition from pharmaceutical research and manufacturers of america and biotechnology industry organization,0,0
09000064820aa5a7,Other,FDA-2015-P-5022-0008,FDA-2015-P-5022,petition denial letter,0,0
090000648204f957,Other,FDA-2015-P-5022-0007,FDA-2015-P-5022,interim response from fda cder to prma,0,0
0900006481dd3aae,Other,FDA-2015-P-5022-0002,FDA-2015-P-5022,acknowledgement letter from fda ddm to pharmaceutical research and manufacturers of america and biotechnology industry organization,0,0
0900006481dd3ae9,Supporting & Related Material,FDA-2015-P-5022-0003,FDA-2015-P-5022,"exhibit a fda office of legislation response letter to the honorable lamar alexander, chairman of the senate committee on help re citizen petition from the pharmaceutical research and manufacturers of america (“phrma”) and the biotechnology industry organization (“bio”)",0,0
0900006481dd425a,Supporting & Related Material,FDA-2015-P-5022-0004,FDA-2015-P-5022,exhibit b industry standard research's asbm labeling survey re citizen petition from pharmaceutical research and manufacturers of america and  biotechnology industry organization,0,0
0900006481dd38b8,Other,FDA-2015-P-5022-0001,FDA-2015-P-5022,citizen petition from pharmaceutical research and manufacturers of america and biotechnology industry organization,0,0
09000064839df95b,Other,FDA-2018-P-2720-0003,FDA-2018-P-2720,"interim response from fda cder to hyman, phelps & mcnamara, p. c.",0,0
09000064834e706d,Other,FDA-2018-P-2720-0001,FDA-2018-P-2720,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006483bf31c9,Other,FDA-2018-P-2720-0004,FDA-2018-P-2720,"letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
09000064834e706f,Other,FDA-2018-P-2720-0002,FDA-2018-P-2720,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara, p.c.",0,0
09000064823171d6,Supporting & Related Material,FDA-2016-P-3428-0004,FDA-2016-P-3428,"attachment 2 tbd chewable tablets re suitability petition from douglass oeller consulting, inc (felix pharmaceuticals pvt. ltd)",0,0
09000064823171d5,Supporting & Related Material,FDA-2016-P-3428-0003,FDA-2016-P-3428,"attachment 1 simplicef re suitability petition from douglass oeller consulting, inc (felix pharmaceuticals pvt. ltd)",0,0
09000064823171d3,Other,FDA-2016-P-3428-0002,FDA-2016-P-3428,"acknowledgement letter from fda ddm to douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd)",0,0
09000064823171d1,Other,FDA-2016-P-3428-0001,FDA-2016-P-3428,"suitability petition from douglass oeller consulting, inc (felix pharmaceuticals pvt. ltd)",0,0
09000064823c7644,Other,FDA-2016-P-3428-0005,FDA-2016-P-3428,"amendment to suitability petition from douglass oeller consulting, inc. (felix pharmaceuticals)",0,0
0900006482458c08,Other,FDA-2016-P-3428-0006,FDA-2016-P-3428,letter from cvm to douglass oeller consulting inc,0,0
0900006484116414,Other,FDA-2019-P-1525-0005,FDA-2019-P-1525,interim response letter from fda cder to baxter healthcare corporation,0,0
0900006483b4bb9a,Other,FDA-2019-P-1525-0002,FDA-2019-P-1525,acknowledgment letter from fda ddm to baxter healthcare corporation,0,0
0900006483b4bb99,Supporting & Related Material,FDA-2019-P-1525-0004,FDA-2019-P-1525,attachment 2 controlled correspondence (nicardipine hydrochloride nda019734) letter from fda ogd cder to baxter healthcare corporation re citizen petition from baxter healthcare corporation,0,0
090000648486403b,Other,FDA-2019-P-1525-0008,FDA-2019-P-1525,letter from fda cder to baxter healthcare corporation,0,0
09000064842dfbff,Other,FDA-2019-P-1525-0007,FDA-2019-P-1525,final response letter from fda cder to baxter healthcare corporation,0,0
09000064842de590,Notice,FDA-2019-P-1525-0006,FDA-2019-P-1525,"determination that cardene (nicardipine hydrochloride) injection, 25 milligrams/10 milliliters, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483b4bb96,Supporting & Related Material,FDA-2019-P-1525-0003,FDA-2019-P-1525,attachment 1 orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from baxter healthcare corporation,0,0
0900006483b4be37,Other,FDA-2019-P-1525-0001,FDA-2019-P-1525,citizen petition from baxter healthcare corporation,0,0
090000648491b5e0,Other,FDA-2020-P-2102-0001,FDA-2020-P-2102,"suitability petition from aurora pharmaceutical, inc.",0,0
090000648491c185,Supporting & Related Material,FDA-2020-P-2102-0004,FDA-2020-P-2102,"attachment 1. equioxx (firocoxib) oral paste, labeling by merial, rev 02-2015",0,0
09000064849f4430,Other,FDA-2020-P-2102-0005,FDA-2020-P-2102,"approval letter from fda dms to aurora pharmaceutical, inc.",0,0
090000648491c184,Supporting & Related Material,FDA-2020-P-2102-0003,FDA-2020-P-2102,"cover letter re suitability petition from aurora pharmaceutical, inc.",0,0
090000648491b5e1,Other,FDA-2020-P-2102-0002,FDA-2020-P-2102,"acknowledgment letter from fda dms to aurora pharmaceutical, inc.",0,0
0900006483fc60e0,Supporting & Related Material,FDA-2019-P-4481-0004,FDA-2019-P-4481,attachment 2 national drug code directory re citizen petition from macleods pharmaceuticals limited,0,0
0900006483fc5b55,Other,FDA-2019-P-4481-0001,FDA-2019-P-4481,citizen petition from macleods pharmaceuticals limited,0,0
0900006483fc60e2,Supporting & Related Material,FDA-2019-P-4481-0006,FDA-2019-P-4481,attachment 4 ims data re citizen petition from macleods pharmaceuticals limited,0,0
0900006483fc60e1,Supporting & Related Material,FDA-2019-P-4481-0005,FDA-2019-P-4481,attachment 3 fda approved drug products re citizen petition from macleods pharmaceuticals limited,0,0
0900006483fc5ba9,Other,FDA-2019-P-4481-0002,FDA-2019-P-4481,acknowledgment letter from fda dms to macleods pharmaceuticals limited,0,0
0900006483fc5be1,Supporting & Related Material,FDA-2019-P-4481-0003,FDA-2019-P-4481,attachment 1 orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from macleods pharmaceuticals limited,0,0
090000648496c9e1,Other,FDA-2019-P-4481-0008,FDA-2019-P-4481,withdrawal from macleods pharmaceuticals limited,0,0
090000648450d333,Other,FDA-2019-P-4481-0007,FDA-2019-P-4481,interim response letter from fda cder to macleods pharmaceuticals limited,0,0
0900006484a6052f,Notice,FDA-2020-N-2354-0001,FDA-2020-N-2354,"data standards; requirement begins for the clinical data interchange standards consortium version 1.1 of
the standard for exchange of nonclinical data developmental and reproductive toxicology implementation guide and version 1.6 of the study data tabulation model; clarification to food and drug administration data standards",1,0
0900006484a87f91,Other,FDA-2021-P-0340-0001,FDA-2021-P-0340,suitability petition from drug device consulting llc,0,0
0900006484a8836e,Supporting & Related Material,FDA-2021-P-0340-0005,FDA-2021-P-0340,attachment 3 rld label for naproxen suspension 25mg/ml re suitability petition from drug device consulting llc,0,0
0900006484a8836a,Supporting & Related Material,FDA-2021-P-0340-0004,FDA-2021-P-0340,attachment 2 draft label for naproxen suspension 50mg/ml re suitability petition from drug device consulting llc,0,0
0900006484a88992,Other,FDA-2021-P-0340-0002,FDA-2021-P-0340,acknowledgment letter from fda dms to drug device consulting llc,0,0
0900006484a88368,Supporting & Related Material,FDA-2021-P-0340-0003,FDA-2021-P-0340,attachment 1 orange book rld listing re suitability petition from drug device consulting llc,0,0
0900006481a37edd,Supporting & Related Material,FDA-2015-P-0732-0030,FDA-2015-P-0732,"[tab 27] khan et al., activation of nfkb is a novel mechanism of
pro-survival activity of glucocorticoids in breast cancer cells. cancer letters, 2013; 337:90–95. citizen petition from celgene (arnold and porter)",0,0
0900006481a37f36,Supporting & Related Material,FDA-2015-P-0732-0034,FDA-2015-P-0732,"[tab 31] li et al., pharmacology of paclitaxel sensitive to its delivery vehicles drives distinct clinical outcome of paclitaxel formulations.
molecular pharmaceutics, (accepted for publication); web publication date feb, 25, 2015. doi: 10.1021/acs.molpharmaceut.5b00026. citizen petition from celgene (arnold and porter)",0,0
0900006481a37fc9,Supporting & Related Material,FDA-2015-P-0732-0047,FDA-2015-P-0732,"[tab 44] paal et al., high affinity binding of paclitaxel to human serum
albumin. eur j biochem. 2001;268:2187-91. citizen petition from celgene (arnold and porter)",0,0
0900006481a37fcc,Supporting & Related Material,FDA-2015-P-0732-0050,FDA-2015-P-0732,"[tab 47] quillet et al., anisotropic colloids through non-trivial buckling. eur. phys. j. e 2008 27, 13–20. citizen petition from celgene (arnold and porter)",0,0
0900006481a37d6f,Supporting & Related Material,FDA-2015-P-0732-0022,FDA-2015-P-0732,"[tab 19] green et al., abraxane, a novel cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. ann oncol, 2006; 8:1263-8., citizen petition from celgene (arnold and porter)",0,0
0900006481a38bd0,Supporting & Related Material,FDA-2015-P-0732-0094,FDA-2015-P-0732,"[tab 90] nanotechnology - fdas approach to regulation of nanotechnology products., citizen petition from celgene (arnold and porter)",0,0
0900006481a3856c,Supporting & Related Material,FDA-2015-P-0732-0063,FDA-2015-P-0732,"[tab 59] sui et al., glucocorticoids interfere with therapeutic efficacy
of paclitaxel against human breast and ovarian xenograft tumors. int. j. cancer, 2006; 119, 712–717. citizen petition from celgene (arnold and porter)",0,0
0900006481a373bc,Supporting & Related Material,FDA-2015-P-0732-0008,FDA-2015-P-0732,"[tab 5] chen et al. albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. manuscript submitted, 2015., citizen petition from celgene (arnold and porter)",0,0
0900006481a375e7,Supporting & Related Material,FDA-2015-P-0732-0012,FDA-2015-P-0732,"[tab 9] cortes, and saura c. nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. ejc supplements, 2010; 8:1-10., citizen petition from celgene (arnold and porter)",0,0
0900006481a37700,Supporting & Related Material,FDA-2015-P-0732-0014,FDA-2015-P-0732,"[tab 11] frei, e. albumin binding ligands and albumin conjugate uptake by cancer cells. diabetology & metabolic syndrome, 2011; 3:11. citizen petition from celgene (arnold and porter)",0,0
0900006481a379d4,Supporting & Related Material,FDA-2015-P-0732-0015,FDA-2015-P-0732,"[tab 12] frese et al. nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. cancer. discov, 2012; 2:260-9. citizen petition from celgene (arnold and porter)",0,0
0900006481a38b38,Supporting & Related Material,FDA-2015-P-0732-0090,FDA-2015-P-0732,"[tab 86] taxotere prescribing information (rev. nov. 2014, sanofi-aventis u.s. llc)., citizen petition from celgene (arnold and porter)",0,0
0900006481c3fad8,Other,FDA-2015-P-0732-0110,FDA-2015-P-0732,interim response letter from fda cder to arnold and porter llp,0,0
0900006481a37f34,Supporting & Related Material,FDA-2015-P-0732-0032,FDA-2015-P-0732,"[tab 29] langer et al., phase iii trial comparing paclitaxel poliglumex (ct-2103, ppx) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of ps 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. j thorac
oncol, 2008; 6:623-30. citizen petition from celgene (arnold and porter)",0,0
0900006481a37f35,Supporting & Related Material,FDA-2015-P-0732-0033,FDA-2015-P-0732,"[tab 30] lee et al., multicenter phase ii trial of genexol-pm (cynviloq), a cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. breast cancer res treat, 2008 mar; 108:241-50. citizen petition from celgene (arnold and porter)",0,0
0900006481a37f6f,Supporting & Related Material,FDA-2015-P-0732-0041,FDA-2015-P-0732,"[tab 38] makriyannis et al., albumin enhances the diffusion of lipophilic drugs into the membrane bilayer. life sci, 2005;77:1605-11. citizen petition from celgene (arnold and porter)",0,0
0900006481a37f71,Supporting & Related Material,FDA-2015-P-0732-0043,FDA-2015-P-0732,"[tab 40] merisko-liversidge, et al. formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. pharm res, 1996;13:272-278. citizen petition from celgene (arnold and porter)",0,0
0900006481a37d6c,Supporting & Related Material,FDA-2015-P-0732-0019,FDA-2015-P-0732,"[tab 16] galli, experimental determination of the diffusion boundary layer width of micron and submicron particles. international journal of pharmaceutics, 2006; 313:114-22., citizen petition from celgene (arnold and porter)",0,0
0900006481a37d71,Supporting & Related Material,FDA-2015-P-0732-0024,FDA-2015-P-0732,"[tab 21] herr_debatin, et al. glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. cancer research, 2003; 63: 3112-3120., citizen petition from celgene (arnold and porter)",0,0
0900006481a38568,Supporting & Related Material,FDA-2015-P-0732-0061,FDA-2015-P-0732,"[tab 57] sparreboom et al., preclinical pharmacokinetics
of paclitaxel and docetaxel. anticancer drugs, 1998; 9:1-17. citizen petition from celgene (arnold and porter)",0,0
0900006481a3856e,Supporting & Related Material,FDA-2015-P-0732-0065,FDA-2015-P-0732,"[tab 61] ten tije, et al., pharmacological effects of formulation vehicles implications for cancer chemotherapy, clin pharmacokinet 2003;42 (7): 665-685; citizen petition from celgene (arnold and porter)",0,0
0900006481a38570,Supporting & Related Material,FDA-2015-P-0732-0067,FDA-2015-P-0732,[tab 63] trynda-lemiesz l. paclitaxel-hsa interaction. binding sites on hsa molecule. bioorg med chem. 2004;12:3269-75. citizen petition from celgene (arnold and porter),0,0
0900006481a386d8,Supporting & Related Material,FDA-2015-P-0732-0077,FDA-2015-P-0732,"[tab 73] cder, “guidance agenda: new & revised guidances cder is planning to publish during calendar year 2015” (january 6, 2015). citizen petition from celgene (arnold and porter)",0,0
0900006481a386dc,Supporting & Related Material,FDA-2015-P-0732-0078,FDA-2015-P-0732,"[tab 74] draft version of fda notes (feb. 5, 2001) citizen petition from celgene (arnold and porter)",0,0
0900006481a386dd,Supporting & Related Material,FDA-2015-P-0732-0079,FDA-2015-P-0732,"[tab 75] food and drug administration, pharmacology/toxicology review and evaluation of abraxane (nda number 21,660) (2004). citizen petition from celgene (arnold and porter)",1,0
0900006484c8d400,Supporting & Related Material,FDA-2021-P-0923-0003,FDA-2021-P-0923,attachment - i current orange book status re citizen petition from gland pharma limited,0,0
0900006484c8d3fe,Other,FDA-2021-P-0923-0001,FDA-2021-P-0923,citizen petition from gland pharma limited,0,0
0900006484c8cb24,Other,FDA-2021-P-0923-0002,FDA-2021-P-0923,acknowledgment letter from fda dms to gland pharma limited,0,0
0900006484cca749,Other,FDA-2021-P-0959-0002,FDA-2021-P-0959,"acknowledgment letter from fda dms to hyman, phelps, & mcnamara p.c.",0,0
0900006484cca747,Other,FDA-2021-P-0959-0001,FDA-2021-P-0959,"citizen petition from hyman, phelps, & mcnamara p.c.",0,0
09000064807e9ba8,Other,FDA-2008-P-0365-0003,FDA-2008-P-0365,fda to ista pharmaceuticals - petition denied,0,0
090000648063c1b1,Other,FDA-2008-P-0365-0001,FDA-2008-P-0365,ista pharmaceuticals - citizen petition,0,0
090000648063c20f,Other,FDA-2008-P-0365-0002,FDA-2008-P-0365,acknowledgement letter to ista pharmaceuticals,0,0
0900006484dfa83b,Other,FDA-2021-P-1173-0002,FDA-2021-P-1173,acknowledgment letter from fda dms to felix pharmaceuticals pvt ltd,0,0
0900006484dfa777,Other,FDA-2021-P-1173-0001,FDA-2021-P-1173,suitability petition from felix pharmaceuticals pvt. ltd.,0,0
0900006484e72a6a,Other,FDA-2021-P-1173-0005,FDA-2021-P-1173,letter from fda cvm to felix pharmaceuticals pvt. ltd.,0,0
0900006484dfa6e0,Supporting & Related Material,FDA-2021-P-1173-0004,FDA-2021-P-1173,attachment 2 pimobendan oral suspension re: suitability petition from felix pharmaceuticals pvt. ltd.,0,0
0900006484dfa6e1,Supporting & Related Material,FDA-2021-P-1173-0003,FDA-2021-P-1173,attachment 1 vetmedin® (pimobendan) chewable tablets re: suitability petition from felix pharmaceuticals pvt. ltd.,0,0
0900006482324dc6,Supporting & Related Material,FDA-2016-P-3463-0003,FDA-2016-P-3463,"attachment 1 fda orange book page for eliquis® (apixaban) tablets, 2.5 mg and 5 mg re suitability petition from axinn, veltrop & harkrider llp",0,0
0900006482324df0,Supporting & Related Material,FDA-2016-P-3463-0005,FDA-2016-P-3463,"attachment 3 proposed prescribing information for apixaban tablets re suitability petition from axinn, veltrop & harkrider llp",0,0
0900006482324dc7,Supporting & Related Material,FDA-2016-P-3463-0004,FDA-2016-P-3463,"attachment 2 copy of approved labeling for eliquis® (apixaban) tablets (nda 202155, bristol myers squibb) re suitability petition from axinn, veltrop & harkrider llp",0,0
090000648234a2c0,Other,FDA-2016-P-3463-0006,FDA-2016-P-3463,"attachment 3,  supplement to anda - proposed prescribing information for apixaban tablets re suitability petition from axinn, veltrop & harkrider llp",0,0
0900006482b95205,Other,FDA-2016-P-3463-0007,FDA-2016-P-3463,"withdrawal from axinn, veltrop & harkrider llp",0,0
0900006482324da3,Other,FDA-2016-P-3463-0001,FDA-2016-P-3463,"acknowledgement letter from fda ddm to axinn, veltrop & harkrider llp",0,0
0900006482324d22,Other,FDA-2016-P-3463-0002,FDA-2016-P-3463,"suitability petition from axinn, veltrop & harkrider llp",0,0
09000064823459c1,Supporting & Related Material,FDA-2016-P-3418-0068,FDA-2016-P-3418,"attachment 65 impact of model for end-stage liver disease (meld) scoring system on pathological findings at and after liver transplantation, 12 liver transplantation 958 (2006) re citizen petition from baker & hostetler, llp",0,0
09000064823459c5,Supporting & Related Material,FDA-2016-P-3418-0072,FDA-2016-P-3418,"attachment 69 guidance for industry - non-inferiority clinical trials (20 i 0) (draft guidance) re citizen petition from baker & hostetler, llp",0,0
09000064823167b4,Supporting & Related Material,FDA-2016-P-3418-0004,FDA-2016-P-3418,"attachment 1 xifaxan prescribing information re citizen petition from baker & hostetler, llp",0,0
09000064823167b5,Supporting & Related Material,FDA-2016-P-3418-0005,FDA-2016-P-3418,"attachment 2 waiver ofln vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system: guidance for industry (may 20 15) re citizen petition from baker & hostetler, llp",0,0
0900006482317139,Supporting & Related Material,FDA-2016-P-3418-0017,FDA-2016-P-3418,"attachment 14 guidance for industry, bioavailability and bioequivalence studies submitted in ndas or inds- general considerations 21 (2014) (draft guidance) re citizen petition from baker & hostetler, llp",0,0
090000648234b80d,Supporting & Related Material,FDA-2016-P-3418-0083,FDA-2016-P-3418,"attachment 6 a randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea re citizen petition from baker & hostetler, llp",0,0
090000648234b819,Supporting & Related Material,FDA-2016-P-3418-0095,FDA-2016-P-3418,"attachment 18 rifaximin-induced alteration of virulence of diarrhoea-producing escherichia coli and shigella sonnei re citizen petition from baker & hostetler, llp",0,0
090000648234b822,Supporting & Related Material,FDA-2016-P-3418-0104,FDA-2016-P-3418,"attachment 27 meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth re citizen petition from baker & hostetler, llp",0,0
090000648234b823,Supporting & Related Material,FDA-2016-P-3418-0105,FDA-2016-P-3418,"attachment 28 review article: the antimicrobial effects of rifaximin on the gut microbiota re citizen petition from baker & hostetler, llp",0,0
090000648234b824,Supporting & Related Material,FDA-2016-P-3418-0106,FDA-2016-P-3418,"attachment 29 drug absorption in gastrointestinal disease
and surgery clinical pharmacokinetic and therapeutic implications re citizen petition from baker & hostetler, llp",0,0
0900006482345743,Supporting & Related Material,FDA-2016-P-3418-0031,FDA-2016-P-3418,"attachment 28 physiological pharmaceutics: barriers to drug absorption (2d ed. 2001) re citizen petition from baker & hostetler, llp",0,0
0900006482345755,Supporting & Related Material,FDA-2016-P-3418-0049,FDA-2016-P-3418,"attachment 46 concentration-dependent mycobacterium tuberculosis killing and prevention of resistance by rifampin, 51( 11) antimicrobial agents and chemother. 3781 (2007) re citizen petition from baker & hostetler, llp",0,0
0900006482345757,Supporting & Related Material,FDA-2016-P-3418-0051,FDA-2016-P-3418,"attachment 48 rifaximin: an antibiotic with important biologic effects, 15(1) mini-reviews in medicinal chemistry 1. 4 (2015) re citizen petition from baker & hostetler, llp",0,0
0900006482345758,Supporting & Related Material,FDA-2016-P-3418-0052,FDA-2016-P-3418,"attachment 49 antimicrobial resistance information for health professionals and consumers re citizen petition from baker & hostetler, llp",0,0
090000648234575b,Supporting & Related Material,FDA-2016-P-3418-0055,FDA-2016-P-3418,"attachment 52 colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation, 303 am. j. physiol. gastrointest. liver physiol. g675 (2012) re citizen petition from baker & hostetler, llp",0,0
090000648234575d,Supporting & Related Material,FDA-2016-P-3418-0057,FDA-2016-P-3418,"attachment 54 rifaximin-induced alteration of virulence ofdiarrhoea-producing escherichia coli and shigella sonnei, 35(3) int. j. antimicrob. agents 278 (2010) re citizen petition from baker & hostetler, llp",0,0
090000648234bb85,Supporting & Related Material,FDA-2016-P-3418-0079,FDA-2016-P-3418,"attachment 2 prevention and treatment of traveler's diarrhea re citizen petition from baker & hostetler, llp",0,0
090000648234bc9e,Supporting & Related Material,FDA-2016-P-3418-0113,FDA-2016-P-3418,"attachment 36 rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy re citizen petition from baker & hostetler, llp",0,0
090000648234bca2,Supporting & Related Material,FDA-2016-P-3418-0117,FDA-2016-P-3418,"attachment 40 relevant role of efflux pumps in high levels of rifaximin resistance in escherichia coli clinical isolates re citizen petition from baker & hostetler, llp",0,0
090000648234a29c,Supporting & Related Material,FDA-2016-P-3418-0075,FDA-2016-P-3418,"johnson affidavit re citizen petition from baker & hostetler, llp",0,0
0900006482344a39,Other,FDA-2016-P-3418-0002,FDA-2016-P-3418,acknowledgment letter from fda ddm to baker & hostetler llp,0,0
09000064823459c4,Supporting & Related Material,FDA-2016-P-3418-0071,FDA-2016-P-3418,"attachment 68 guidance for industry, bioavailablity and bioequivalence studies for orally administered drug products- general considerations (2003) re citizen petition from baker & hostetler, llp",0,0
0900006482317132,Supporting & Related Material,FDA-2016-P-3418-0010,FDA-2016-P-3418,"attachment 7 approved drug products with therapeutic equivalence evaluations vii-viii (36th ed. 2016) re citizen petition from baker & hostetler, llp",0,0
0900006482317134,Supporting & Related Material,FDA-2016-P-3418-0012,FDA-2016-P-3418,"attachment 9 abbreviated new drug application regulations, 57 fed. reg. at 17,950 (apr. 28, 1992) re citizen petition from baker & hostetler, llp",0,0
0900006482317135,Supporting & Related Material,FDA-2016-P-3418-0013,FDA-2016-P-3418,"attachment 10 letter from janet woodcock, m.d. to a. peter frank, docket no. 92p-0487, 12 (june 17, 1997) re citizen petition from baker & hostetler, llp",0,0
090000648325863b,Supporting & Related Material,FDA-2018-P-1846-0057,FDA-2018-P-1846,reference 53 eibye - persistent genital arousal disorder confluent patient history (case rep psychiatry 2014) re citizen petition from data based medicine americas ltd,0,0
090000648325832b,Supporting & Related Material,FDA-2018-P-1846-0028,FDA-2018-P-1846,reference 24 akasheh - comparison of the effect of sertraline with behavioral therapy (urology 2014) re citizen petition from data based medicine americas ltd,0,0
090000648325832f,Supporting & Related Material,FDA-2018-P-1846-0032,FDA-2018-P-1846,reference 28 lareb - ssris and persistent sexual dysfunction (2012) re citizen petition from data based medicine americas ltd,0,0
0900006483258333,Supporting & Related Material,FDA-2018-P-1846-0036,FDA-2018-P-1846,reference 32 hogan - 120 cases of enduring sexual dysfunction (int j risk saf med 2014) re citizen petition from data based medicine americas ltd,0,0
09000064832585fc,Supporting & Related Material,FDA-2018-P-1846-0006,FDA-2018-P-1846,reference 2 yilmaz - the effects of fluoxetine on several neurophysiological variables (j urol 1999) re citizen petition from data based medicine americas ltd,0,0
0900006483258606,Supporting & Related Material,FDA-2018-P-1846-0008,FDA-2018-P-1846,reference 4 measom - penile anaesthesia and fluoxetine (am j psychiatry 1992) re citizen petition from data based medicine americas ltd,0,0
0900006483258609,Supporting & Related Material,FDA-2018-P-1846-0011,FDA-2018-P-1846,reference 7 diesenhammer - penile anesthesia associated with sertraline use (j clin psychiatry 1999) re citizen petition from data based medicine americas ltd,0,0
090000648325862b,Supporting & Related Material,FDA-2018-P-1846-0044,FDA-2018-P-1846,reference 40 raap - sustained desensitization of 5-ht1a receptors (j pharmacol exp ther 1999) re citizen petition from data based medicine americas ltd,0,0
090000648325862d,Supporting & Related Material,FDA-2018-P-1846-0046,FDA-2018-P-1846,reference 42 de jong - effects of chronic treatment with fluvoxamine and paroxetine (eur neuropsychopharmacol 2006) re citizen petition from data based medicine americas ltd,0,0
0900006483258634,Supporting & Related Material,FDA-2018-P-1846-0050,FDA-2018-P-1846,reference 46 leiblum - persistent sexual arousal syndrome a newly discovered pattern (j sex marital ther 2001) re citizen petition from data based medicine americas ltd,0,0
09000064832585f5,Other,FDA-2018-P-1846-0001,FDA-2018-P-1846,citizen petition from data based medicine americas ltd,0,0
0900006483258329,Supporting & Related Material,FDA-2018-P-1846-0027,FDA-2018-P-1846,reference 23 koyuncu - escitalopram for premature ejaculation has negative effect on semen (int j impot res 2011) re citizen petition from data based medicine americas ltd,0,0
090000648325860a,Supporting & Related Material,FDA-2018-P-1846-0012,FDA-2018-P-1846,reference 8 michael - fluoxetine-induced anaesthesia of vagina and nipples (br j psychiatry 2000) re citizen petition from data based medicine americas ltd,0,0
090000648325860d,Supporting & Related Material,FDA-2018-P-1846-0015,FDA-2018-P-1846,reference 11 csoka - persistent sexual side effects after ssri discontinuation (psychother psychosom 2006) re citizen petition from data based medicine americas ltd,0,0
090000648325860e,Supporting & Related Material,FDA-2018-P-1846-0016,FDA-2018-P-1846,reference 12 bahrick - post ssri sexual dysfunction (asap tablet 2006) re citizen petition from data based medicine americas ltd,0,0
090000648325860f,Supporting & Related Material,FDA-2018-P-1846-0017,FDA-2018-P-1846,reference 13 montejo - sexual dysfunction with antidepressive agents (actas esp psiquiatr 1999) re citizen petition from data based medicine americas ltd,0,0
0900006483258632,Supporting & Related Material,FDA-2018-P-1846-0048,FDA-2018-P-1846,reference 44 gouvêa - maternal exposure to the antidepressant fluoxetine (pharmacol biochem behav 2008) re citizen petition from data based medicine americas ltd,0,0
090000648325863e,Supporting & Related Material,FDA-2018-P-1846-0058,FDA-2018-P-1846,reference 54 de magalhæes - persistent genital arousal disorder following ssri cessation (j clin psychopharmacol 2015) re citizen petition from data based medicine americas ltd,0,0
0900006483258635,Supporting & Related Material,FDA-2018-P-1846-0051,FDA-2018-P-1846,reference 47 freed - persistent sexual arousal syndrome (j sex med 2005) re citizen petition from data based medicine americas ltd,0,0
0900006483258326,Supporting & Related Material,FDA-2018-P-1846-0024,FDA-2018-P-1846,reference 20 tanrikut - adverse effect of paroxetine on sperm (fertil steril 2010) re citizen petition healy,0,0
0900006483258334,Supporting & Related Material,FDA-2018-P-1846-0037,FDA-2018-P-1846,reference 33 waldinger - penile anesthesia in pssd responds to low-power laser irradiation (eur j pharmacol 2015) re citizen petition from data based medicine americas ltd,0,0
09000064832585fd,Supporting & Related Material,FDA-2018-P-1846-0007,FDA-2018-P-1846,reference 3 neill - penile anesthesia associated with fluoxetine use (am j psychiatry 1991) re citizen petition from data based medicine americas ltd,0,0
0900006483258608,Supporting & Related Material,FDA-2018-P-1846-0010,FDA-2018-P-1846,reference 6 ellison - fluoxetine-induced genital anesthesia relieved by ginkgo biloba extract (j clin psychiatry 1998) re citizen petition from data based medicine americas ltd,0,0
090000648325860c,Supporting & Related Material,FDA-2018-P-1846-0014,FDA-2018-P-1846,reference 10 bolton - genital anaesthesia persisting six years after sertraline (j sex marital ther 2006) re citizen petition from data based medicine americas ltd,0,0
0900006483258625,Supporting & Related Material,FDA-2018-P-1846-0038,FDA-2018-P-1846,reference 34 ben-sheetrit - post-ssri sexual dysfunction clinical characterization (j clin psychopharmacol 2015) re citizen petition from data based medicine americas ltd,0,0
09000064819edd4a,Supporting & Related Material,FDA-2015-P-0335-0003,FDA-2015-P-0335,attach 1,0,0
09000064819edcb7,Other,FDA-2015-P-0335-0002,FDA-2015-P-0335,acknowledgement letter from fda ddm to chrai associates inc.,0,0
09000064819edd4b,Supporting & Related Material,FDA-2015-P-0335-0004,FDA-2015-P-0335,attach 2,0,0
09000064819e6fa5,Other,FDA-2015-P-0335-0001,FDA-2015-P-0335,"citizen petition from chrai associates, inc.",0,0
09000064819edd4c,Supporting & Related Material,FDA-2015-P-0335-0005,FDA-2015-P-0335,attach 3,0,0
090000648314b203,Other,FDA-2015-P-3364-0005,FDA-2015-P-3364,citizen petition response from fda cdrh  to dr. leroy l. hamilton,0,0
0900006481c6dcf6,Other,FDA-2015-P-3364-0002,FDA-2015-P-3364,acknowledgement letter from fda ddm to dr. leroy hamilton,0,0
0900006482071606,Other,FDA-2015-P-3364-0003,FDA-2015-P-3364,interim response letter from cdrh to leory hamilton,0,0
0900006483148f5b,Other,FDA-2015-P-3364-0004,FDA-2015-P-3364,citizen petition denial  response from fda cdrh to  leroy l hamilton phd,0,0
0900006481c6dcf4,Other,FDA-2015-P-3364-0001,FDA-2015-P-3364,citizen petition from dr. leroy hamilton,0,0
0900006482f1a4aa,Supporting & Related Material,FDA-2018-P-0670-0004,FDA-2018-P-0670,"attachment b akorn, inc 505(b)(2) approval letter re citizen petition from lachman consultant services, inc",0,0
0900006482f1a4ab,Supporting & Related Material,FDA-2018-P-0670-0005,FDA-2018-P-0670,"attachment c paragon bioteck, inc 505(b)(2) approval letter citizen petition from lachman consultant services, inc",0,0
0900006483103c15,Other,FDA-2018-P-0670-0006,FDA-2018-P-0670,"supplement from paragon bioteck, inc. (sidley austin llp)",0,0
0900006483aa8e4b,Other,FDA-2018-P-0670-0009,FDA-2018-P-0670,meeting on user fee issue for approved product,0,0
0900006482f1a616,Other,FDA-2018-P-0670-0001,FDA-2018-P-0670,"citizen petition from lachman consultant services, inc",0,0
09000064832c50a7,Other,FDA-2018-P-0670-0007,FDA-2018-P-0670,"supplement to citizen petition from paragon bioteck, inc.",0,0
090000648352e537,Other,FDA-2018-P-0670-0008,FDA-2018-P-0670,interim response letter fda-2018-p-0670,0,0
0900006482f1a4a9,Supporting & Related Material,FDA-2018-P-0670-0003,FDA-2018-P-0670,"attachment a orange book listing for paragon and akorn re citizen petition from lachman consultant services, inc",0,0
0900006482f1a618,Other,FDA-2018-P-0670-0002,FDA-2018-P-0670,"acknowledgment letter from fda ddm to lachman consultant services, inc",0,0
0900006483da707d,Other,FDA-2018-P-0670-0010,FDA-2018-P-0670,withdrawal from sean griffin,0,0
09000064827c17fa,Supporting & Related Material,FDA-2017-P-3989-0003,FDA-2017-P-3989,"attachment 1 orange book nda 204447 re citizen petition from lachman consultant services, inc",0,0
0900006482c98c59,Notice,FDA-2017-P-3989-0006,FDA-2017-P-3989,"determination that trintellix (vortioxetine hydrobromide) oral
tablet, eq 15 milligram base, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006482c9fae3,Other,FDA-2017-P-3989-0007,FDA-2017-P-3989,petition response letter,0,0
09000064827bb43f,Other,FDA-2017-P-3989-0002,FDA-2017-P-3989,"acknowledgement letter from fda ddm to lachman consultant services, inc",0,0
09000064827bb6dd,Other,FDA-2017-P-3989-0001,FDA-2017-P-3989,"citizen petition from lachman consultant services, inc",0,0
09000064827c17fc,Supporting & Related Material,FDA-2017-P-3989-0005,FDA-2017-P-3989,"attachment 3 ppi 3-2017 nda204447 re citizen petition from lachman consultant services, inc",0,0
09000064827c17fb,Supporting & Related Material,FDA-2017-P-3989-0004,FDA-2017-P-3989,"attachment 2 ppi 9-2016 nda204447 re citizen petition from lachman consultant services, inc",0,0
0900006482563db1,Other,FDA-2017-P-2496-0002,FDA-2017-P-2496,"acknowledgement letter from fda ddm to kvk-tech, inc. (abhai, llc)",0,0
0900006482b0f6c8,Notice,FDA-2017-P-2496-0004,FDA-2017-P-2496,"determination that ritalin la (methylphenidate hydrochloride)
extended-release capsules, 60 milligrams, were not withdrawn from
sale for reasons of safety or effectiveness",0,0
0900006482563daf,Other,FDA-2017-P-2496-0001,FDA-2017-P-2496,"citizen petition from kvk-tech, inc. (abhai, llc)",0,0
0900006482b11446,Other,FDA-2017-P-2496-0005,FDA-2017-P-2496,letter from fda to kvk-tech inc,0,0
0900006482563f65,Supporting & Related Material,FDA-2017-P-2496-0003,FDA-2017-P-2496,"attachment 1 orange book approved drug products with therapeutic equivalence evaluations re citizen petition from kvk-tech inc (abhai, llc)",0,0
0900006483d5d8ea,Other,FDA-2019-P-3232-0001,FDA-2019-P-3232,citizen petition from lachman consultants,0,0
09000064842394d5,Other,FDA-2019-P-3232-0004,FDA-2019-P-3232,interim response letter from fda cder to lachman consultants,0,0
0900006483d5de28,Supporting & Related Material,FDA-2019-P-3232-0003,FDA-2019-P-3232,attachment a- orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from lachman consultants,0,0
0900006483d5d8f0,Other,FDA-2019-P-3232-0002,FDA-2019-P-3232,acknowledgment letter from fda ddm to lachman consultants,0,0
0900006484aa50c7,Supporting & Related Material,FDA-2021-P-0339-0003,FDA-2021-P-0339,attachment-i orange book approved drug products with therapeutic equivalence evaluations re citizen petition from gland pharma limited,0,0
0900006484a88294,Other,FDA-2021-P-0339-0001,FDA-2021-P-0339,citizen petition from gland pharma limited,0,0
0900006484ae18cd,Other,FDA-2021-P-0339-0004,FDA-2021-P-0339,withdrawal from gland pharma limited,0,0
0900006484a88297,Other,FDA-2021-P-0339-0002,FDA-2021-P-0339,acknowledgment letter from fda dms to gland pharma limited,0,0
0900006481edb5ec,Supporting & Related Material,FDA-2016-P-1073-0014,FDA-2016-P-1073,"attachment 11- minh-nguyet tran et al., alcohol dehydrogenase and catalase content in perinatal infant and adult livers: potential influence on neonatal alcohol metabolism, 169 toxicology letters 245 (2007) re citizen petition from par pharmaceutical",0,0
0900006481edb367,Supporting & Related Material,FDA-2016-P-1073-0007,FDA-2016-P-1073,"attachment 4 - committee for human medicinal products, questions and answers on ethanol in the context of the revision of the guideline on 'excipients in the label and package leaflet of medicinal products for human use', eur. med. agency (20 14) re citizen petition from par pharmaceutical",0,0
0900006481edb36a,Supporting & Related Material,FDA-2016-P-1073-0011,FDA-2016-P-1073,attachment 8 - famhp position on ethanol content in medicinal products used in children (including herbal medicinal products and homeopathic medicinal re citizen petition from par pharmaceutical,0,0
0900006481eea3b1,Supporting & Related Material,FDA-2016-P-1073-0009,FDA-2016-P-1073,"attachment 6 committee on herbal medicinal products, reflection paper on ethanol content in herbal medicinal products and traditional herbal medicinal products used in children, eur. med. agency (20 1 0) re citizen petition from par pharmaceutical",0,0
0900006481edb5ef,Supporting & Related Material,FDA-2016-P-1073-0017,FDA-2016-P-1073,"attachment 14 - raymond c. rowe et al., handbook of pharmaceutical excipients, (ih ed. 2012) re citizen petition from par pharmaceutical",0,0
0900006481edb5f0,Supporting & Related Material,FDA-2016-P-1073-0018,FDA-2016-P-1073,"attachment 15- sofya pugach & isaac z. pugach, overdose in infant caused by over-thecounter cough medicine, 102 s. med. j. 440, (2009) re citizen petition from par pharmaceutical",0,0
0900006482287007,Other,FDA-2016-P-1073-0020,FDA-2016-P-1073,citizen petition interim response from fda cder to par pharmaceutical,0,0
0900006481edb366,Supporting & Related Material,FDA-2016-P-1073-0006,FDA-2016-P-1073,"attachment 3 - chen-chang yang et al., hypoglycemia following ethanol ingestion in children: report of a case, 94 j formos med. ass'n 267 (1995) re citizen petition from par pharmaceutical",0,0
0900006481edb5ee,Supporting & Related Material,FDA-2016-P-1073-0016,FDA-2016-P-1073,"attachment 13- p.h. pikkarainen & n.c.r. raiha, development of alcohol dehydrogenase activity in the human liver, 1 pediatric res. 165 (1967) re citizen petition from par pharmaceutical",0,0
0900006481edb369,Supporting & Related Material,FDA-2016-P-1073-0010,FDA-2016-P-1073,"attachment 7 - elizabeth marek & walter k. kraft, ethanol pharmacokinetics in neonates and infants re citizen petition from par pharmaceutical",0,0
0900006481edb72e,Other,FDA-2016-P-1073-0002,FDA-2016-P-1073,acknowledgement letter from fda ddm to par pharmaceutical,0,0
0900006481edb36b,Supporting & Related Material,FDA-2016-P-1073-0012,FDA-2016-P-1073,"attachment 9 - francis avery ragan, jr. et al., ethanol ingestion in children, 242 jama 2787 (1979) re citizen petition from par pharmaceutical",0,0
0900006481edb5eb,Supporting & Related Material,FDA-2016-P-1073-0013,FDA-2016-P-1073,"attachment 10 - gian vincenzo zuccotti & valentina fabiano, safety issues with ethanol as an excipient in drugs intended for pediatric use, expert opinion drug safety, 499, (2011) re citizen petition from par pharmaceutical",0,0
0900006481edb5ed,Supporting & Related Material,FDA-2016-P-1073-0015,FDA-2016-P-1073,"attachment 12 - nanna christiansen, ethanol exposure through medicines commonly used in paediatrics, 100 arch dis child educ pract ed 101 (20 15) re citizen petition from par pharmaceutical",0,0
0900006483e7068d,Other,FDA-2016-P-1073-0021,FDA-2016-P-1073,withdrawal from par pharmaceutical,0,0
0900006481edb363,Supporting & Related Material,FDA-2016-P-1073-0003,FDA-2016-P-1073,appendix re citizen petition from par pharmaceutical,0,0
0900006481edb364,Supporting & Related Material,FDA-2016-P-1073-0004,FDA-2016-P-1073,"attachment 1 - a fiocchi et al., ethanol in medicines and other products intended for children: commentary on a medical paradox, 3 nutrition res. 373 (1999) re citizen petition from par pharmaceutical",0,0
0900006481edb368,Supporting & Related Material,FDA-2016-P-1073-0008,FDA-2016-P-1073,"attachment 5 - committee on drugs, ethanol in liquid preparations intendedfor children, 73 official j. am. acad. pediatrics 405 (1984) re citizen petition from par pharmaceutical",0,0
0900006481edb365,Supporting & Related Material,FDA-2016-P-1073-0005,FDA-2016-P-1073,"attachment 2 - a. whittaker et al., toxic additives in medication for preterm infants, 94 arch dis child fetal neonatal ed f236 (2009) re citizen petition from par pharmaceutical",0,0
0900006481edb5f1,Supporting & Related Material,FDA-2016-P-1073-0019,FDA-2016-P-1073,"attachment 16  - the merck index: an encyclopedia of chemicals, drugs, and biologicals (maryadele j. o'neil ed., 15th ed. 2013) re citizen petition from par pharmaceutical",0,0
0900006481edb579,Other,FDA-2016-P-1073-0001,FDA-2016-P-1073,citizen petition from par pharmaceutical,0,0
09000064836530da,Other,FDA-2018-P-1361-0004,FDA-2018-P-1361,agency response letter from fda cder to ajanta pharma usa inc.,0,0
090000648308a188,Other,FDA-2018-P-1361-0001,FDA-2018-P-1361,acknowledgment letter from fda ddm to  ajanta pharma usa inc.,0,0
0900006483642a96,Notice,FDA-2018-P-1361-0003,FDA-2018-P-1361,"determination that ditropan xl (oxybutynin chloride) extended
release tablets, 15 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483088b00,Other,FDA-2018-P-1361-0002,FDA-2018-P-1361,citizen petition from ajanta pharma usa inc.,0,0
0900006484864035,Other,FDA-2017-P-6291-0004,FDA-2017-P-6291,"letter from fda cder to lachman consultants services inc. and teligent pharma, inc. and hyman, phelps & mcnamara, p.c.",0,0
09000064831eb224,Other,FDA-2017-P-6291-0003,FDA-2017-P-6291,interim response letter from fda cder to lachman consultants,0,0
0900006482c155e5,Other,FDA-2017-P-6291-0002,FDA-2017-P-6291,acknowledgement letter from fda ddm to lachman consultants services inc,0,0
0900006482c14cf8,Other,FDA-2017-P-6291-0001,FDA-2017-P-6291,"citizen petition from  lachman consultant services, inc",0,0
0900006483d300fd,Other,FDA-2019-P-2998-0001,FDA-2019-P-2998,citizen petition from sonar,0,0
0900006484829981,Other,FDA-2019-P-2998-0104,FDA-2019-P-2998,final response letter from fda cder to southern network on adverse reactions (sonar),0,0
0900006483d30594,Other,FDA-2019-P-2998-0002,FDA-2019-P-2998,acknowledgment letter from fda ddm to sonar,0,0
0900006483d30596,Supporting & Related Material,FDA-2019-P-2998-0003,FDA-2019-P-2998,attachment 1 highlights of prescribing information for levaquin re citizen petition from sonar,0,0
0900006483d30597,Supporting & Related Material,FDA-2019-P-2998-0004,FDA-2019-P-2998,attachment 2 floxed map summary re citizen petition from sonar,0,0
0900006483d30598,Supporting & Related Material,FDA-2019-P-2998-0005,FDA-2019-P-2998,"attachment 3 fda's safety announcement (july 10, 2008) re citizen petition from sonar",0,0
090000648421fb6c,Other,FDA-2019-P-2998-0006,FDA-2019-P-2998,interim response letter from fda cder to sonar,0,0
0900006484285349,Other,FDA-2020-P-0152-0002,FDA-2020-P-0152,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c. on behalf of coalition to preserve access to pgx information",0,0
09000064846dc096,Other,FDA-2020-P-0152-0006,FDA-2020-P-0152,"petition interim response from cdrh to hyman, phelps & mcnamara, p.c.",0,0
0900006484285295,Other,FDA-2020-P-0152-0001,FDA-2020-P-0152,"citizen petition from hyman, phelps & mcnamara, p.c. on behalf of coalition to preserve access to pgx information",0,0
0900006480afb800,Other,FDA-2009-P-0105-0003,FDA-2009-P-0105,"interim response to williams kherkher hart boundas, llp",0,0
09000064808b7516,Other,FDA-2009-P-0105-0001,FDA-2009-P-0105,"williams kherkher hart boundas, llp - citizen petition",0,0
09000064808b8ec0,Other,FDA-2009-P-0105-0002,FDA-2009-P-0105,"acknowledgement letter to williams kherkher hart boundas, llp",0,0
0900006483d3a493,Supporting & Related Material,FDA-2019-P-3024-0004,FDA-2019-P-3024,attachment 2- highlights of prescribing information re citizen petition from foley & lardner llp,0,0
0900006483d3a917,Other,FDA-2019-P-3024-0001,FDA-2019-P-3024,citizen petition from foley & lardner llp,0,0
0900006483d3ab88,Supporting & Related Material,FDA-2019-P-3024-0005,FDA-2019-P-3024,attachment 3- highlights of prescribing information re citizen petition from foley & lardner llp,0,0
0900006483d3a91e,Other,FDA-2019-P-3024-0002,FDA-2019-P-3024,acknowledgment letter from fda ddm to foley & lardner llp,0,0
0900006484d456a5,Other,FDA-2019-P-3024-0007,FDA-2019-P-3024,withdrawal from foley and lardner llp,0,0
0900006483d3ab8a,Supporting & Related Material,FDA-2019-P-3024-0006,FDA-2019-P-3024,attachment 4- acknowledgment receipt of submission letter re citizen petition from foley & lardner llp,0,0
0900006483d3a492,Supporting & Related Material,FDA-2019-P-3024-0003,FDA-2019-P-3024,attachment 1- approved drug products with therapeutic equivalence evaluations re citizen petition from foley & lardner llp,0,0
09000064821ead1f,Supporting & Related Material,FDA-2016-P-2676-0003,FDA-2016-P-2676,"attachment 1 new england natural bakers inc. issues voluntary allergy
alert on undeclared milk, wheat and tree nuts (pecans) in coconut cranberry granola re citizen petition from joshua schroeder",0,0
09000064821ea4f2,Other,FDA-2016-P-2676-0001,FDA-2016-P-2676,citizen petition from joshua schroeder,0,0
090000648397814f,Other,FDA-2016-P-2676-0005,FDA-2016-P-2676,letter from fda cfsan to joshua schroeder,0,0
09000064824e4907,Other,FDA-2016-P-2676-0004,FDA-2016-P-2676,interim response letter from cfsan to joshua schroeder,0,0
09000064821ead1c,Other,FDA-2016-P-2676-0002,FDA-2016-P-2676,acknowledgment letter from fda ddm to joshua schroeder,0,0
09000064820944d6,Other,FDA-2016-P-1962-0001,FDA-2016-P-1962,"citizen petition from hyman, phelps & mcnamara, pc (allergan plc)",0,0
09000064820944dc,Other,FDA-2016-P-1962-0002,FDA-2016-P-1962,"acknowledgement letter from fda ddm to hyman, phelps & mcnamara, pc",0,0
09000064835019a1,Other,FDA-2016-P-1962-0005,FDA-2016-P-1962,fda-2016-p-1962 response to comments,0,0
0900006482431e45,Other,FDA-2016-P-1962-0003,FDA-2016-P-1962,"interim response letter from fda cder to hyman, phelps & mcnamara, pc",0,0
09000064839d2016,Other,FDA-2016-P-1962-0006,FDA-2016-P-1962,"letter from fda cder to hyman, phelps, and mcnamara, p.c.",0,0
09000064839ac1b9,Other,FDA-2018-P-1720-0005,FDA-2018-P-1720,"letter from fda cder to akorn pharmaceuticals, mylan pharmaceuticals, inc., gland pharma limited, foley & lardner llp",0,0
0900006483221221,Supporting & Related Material,FDA-2018-P-1720-0003,FDA-2018-P-1720,annexure - i orange book_ approved drug products with therapeutic equivalence evaluations re citizen petition from gland pharma limited,0,0
090000648322121f,Other,FDA-2018-P-1720-0002,FDA-2018-P-1720,acknowledgment letter from fda ddm to gland pharma limited,0,0
090000648322121d,Other,FDA-2018-P-1720-0001,FDA-2018-P-1720,citizen petition from gland pharma limited,0,0
09000064838e0bac,Other,FDA-2018-P-1720-0004,FDA-2018-P-1720,letter from fda cder to gland pharma limited,0,0
0900006482b0c581,Notice,FDA-2017-P-1459-0003,FDA-2017-P-1459,"determination that enjuvia (estrogens, conjugated synthetic b) tablets, 0.625 milligrams and 1.25 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006482b119f9,Other,FDA-2017-P-1459-0005,FDA-2017-P-1459,letter from fda to foley & lardner llp,0,0
09000064824fc1b7,Other,FDA-2017-P-1459-0001,FDA-2017-P-1459,citizen petition from foley & lardner llp,0,0
09000064824fc1b9,Other,FDA-2017-P-1459-0002,FDA-2017-P-1459,acknowledgement letter from fda ddm to foley & lardner llp,0,0
0900006482b0f909,Other,FDA-2017-P-1459-0004,FDA-2017-P-1459,letter from fda to foley & lardner llp,0,0
0900006481d09345,Supporting & Related Material,FDA-2015-P-3621-0003,FDA-2015-P-3621,product labeling for vancoled re citizen petition from hospira,0,0
0900006481d09346,Supporting & Related Material,FDA-2015-P-3621-0004,FDA-2015-P-3621,proposed labeling for vancomycin hydrochloride re citizen petition from hospira,0,0
0900006481d09344,Supporting & Related Material,FDA-2015-P-3621-0002,FDA-2015-P-3621,"september 16, 2015 response letter from fda cder to hospira, inc. re citizen petition from hospira",0,0
0900006481cb88a7,Other,FDA-2015-P-3621-0005,FDA-2015-P-3621,acknowledgement letter from fda ddm to hospira,0,0
0900006481dbf833,Other,FDA-2015-P-3621-0006,FDA-2015-P-3621,response letter from fda cder to hospira,0,0
0900006481cb87f5,Other,FDA-2015-P-3621-0001,FDA-2015-P-3621,citizen petition from hospira,0,0
090000648310e459,Other,FDA-2018-P-1469-0001,FDA-2018-P-1469,citizen petition from epstein becker & green p.c. ( on behalf of innovative health solutions inc),0,0
090000648310e8b7,Supporting & Related Material,FDA-2018-P-1469-0003,FDA-2018-P-1469,"attachment a - percutaneous electrical nerve field stimulation modulates central pain pathways and attenuates post- inflammatory visceral and somatic hyperalgesia in rats re citizen petition from epstein becker & green, p.c.",0,0
090000648310ece5,Supporting & Related Material,FDA-2018-P-1469-0004,FDA-2018-P-1469,"attachment b- the american journal of drug and alcohol abuse re citizens petition from epstein becker & green, p.c.",0,0
090000648310ecee,Supporting & Related Material,FDA-2018-P-1469-0005,FDA-2018-P-1469,"attachment c- neurostimulation from abdominal pain- related functional gastrointestinal disorders in adolescents: a randomized, double-blind, shame controlled trial re citizen petition from epstein becker & green, p.c",0,0
090000648310e45d,Other,FDA-2018-P-1469-0002,FDA-2018-P-1469,"acknowledgment letter from fda ddm to epstein becker & green, p.c.",0,0
090000648383d1bd,Other,FDA-2018-P-1469-0006,FDA-2018-P-1469,"nerve stimulators, citizen petition, interim response letter issued",0,0
090000648430f6cf,Supporting & Related Material,FDA-2020-P-0511-0005,FDA-2020-P-0511,"attachment 3 us securities and exchange commission form 20-f (medicure, inc.) re citizen petition from novitium pharma llc",0,0
090000648430f6cd,Supporting & Related Material,FDA-2020-P-0511-0003,FDA-2020-P-0511,"attachment 1 orange book: approved drug products with therapeutic
equivalence evaluations re citizen petition from novitium pharma llc",0,0
090000648430f589,Other,FDA-2020-P-0511-0001,FDA-2020-P-0511,citizen petition from novitium pharma llc,0,0
0900006484873043,Supporting & Related Material,FDA-2020-P-0511-0008,FDA-2020-P-0511,relisting notice_prexxartan (valsartan) oral solution,0,0
0900006484872fe4,Other,FDA-2020-P-0511-0007,FDA-2020-P-0511,response letter from fda cder to novitium pharma llc,0,0
090000648430f58a,Other,FDA-2020-P-0511-0002,FDA-2020-P-0511,acknowledgment letter from fda dms to novitium pharma llc,0,0
09000064847c5866,Other,FDA-2020-P-0511-0006,FDA-2020-P-0511,interim response letter from fda cder to novitium pharma llc,0,0
090000648430f6ce,Supporting & Related Material,FDA-2020-P-0511-0004,FDA-2020-P-0511,attachment 2 fda email from ra office re citizen petition from novitium pharma llc,0,0
09000064848fdf52,Other,FDA-2020-P-2077-0001,FDA-2020-P-2077,suitability petition from the weinberg group llc,0,0
09000064848fd8a4,Supporting & Related Material,FDA-2020-P-2077-0003,FDA-2020-P-2077,"attachment 1 approved drug products with therapeutic equivalence evaluations, electronic orange book accessed on august 13, 2020.
re: suitability petition from the weinberg group llc",0,0
09000064848fd8a6,Supporting & Related Material,FDA-2020-P-2077-0005,FDA-2020-P-2077,"attachment 3 proposed prescribing information for vasopressin injection usp, 50 units/2.5 ml (2.5 ml/vial in a single dose vial) and 100 units/5 ml (5 ml/vial in a single dose vial). :re: suitability petition from the weinberg group llc",0,0
09000064848fd8a5,Supporting & Related Material,FDA-2020-P-2077-0004,FDA-2020-P-2077,"attachment 2  labeling for the rld, vasostrict® (vasopressin injection usp), 20 units/ml (single-dose vial), nda # 204485, approved on april 15, 2020. re: suitability petition from the weinberg group llc,",0,0
09000064848fd833,Other,FDA-2020-P-2077-0002,FDA-2020-P-2077,acknowledgment letter from fda dms to the weinberg group llc,0,0
09000064846ff4f8,Other,FDA-2020-P-1605-0002,FDA-2020-P-1605,"acknowledgment letter from fda dms to novitium pharma, llc",0,0
09000064848f2132,Other,FDA-2020-P-1605-0003,FDA-2020-P-1605,"withdrawal from novitium pharma, llc",0,0
09000064846ff4f7,Other,FDA-2020-P-1605-0001,FDA-2020-P-1605,"citizen petition from novitium pharma, llc",0,0
0900006484c0ac69,Other,FDA-2021-P-0784-0001,FDA-2021-P-0784,suitability citizen petition from lachman consultant services inc.,0,0
0900006484c0acbf,Other,FDA-2021-P-0784-0002,FDA-2021-P-0784,acknowledgement letter from fda dms to lachman consultant services inc,0,0
090000648046fe91,Other,FDA-2004-P-0146-0002,FDA-2004-P-0146,hfa-305 to heller ehrman attorneys,0,0
090000648046fe86,Other,FDA-2004-P-0146-0001,FDA-2004-P-0146,hfa-305 to heller ehrman attorneys,0,0
090000648046fe96,Other,FDA-2004-P-0146-0003,FDA-2004-P-0146,hf-22 to white & mcauliffe llp,0,0
0900006482bc19f9,Other,FDA-2017-P-6116-0001,FDA-2017-P-6116,citizen petition from king & spalding llp,0,0
0900006482bc1abb,Supporting & Related Material,FDA-2017-P-6116-0004,FDA-2017-P-6116,attachment 2- reference listed drug prescribing information for bloxiverz- re citizen petition from king & spalding llp,0,0
0900006482bc1b4e,Supporting & Related Material,FDA-2017-P-6116-0005,FDA-2017-P-6116,attachment 3 -draft  labeling  for proposed  neostigmine  methylsulfate  injection - re citizen petition from king & spalding llp,0,0
0900006482bc1ab6,Supporting & Related Material,FDA-2017-P-6116-0003,FDA-2017-P-6116,"attachment 1- approved  drug products with therapeutic equivalence  evaluations  (electronic orange book) for bloxiverz, accessed 09/28/2017- re citizen petition from king & spalding llp",0,0
0900006482bc1780,Other,FDA-2017-P-6116-0002,FDA-2017-P-6116,acknowledgment letter from fda ddm to king & spalding llp,0,0
0900006483b52832,Supporting & Related Material,FDA-2019-P-1534-0008,FDA-2019-P-1534,other sources group 3 women's health analysis of severe adverse events related to the use of mifepristone as an abortifacient re:  american association of pro-life obstetricians and gynecologists and american college of pediatricians,0,0
0900006483b52834,Supporting & Related Material,FDA-2019-P-1534-0012,FDA-2019-P-1534,other sources group 5 court records in the district court in and for oklahoma county state of oklahoma re: american association of pro-life obstetricians and gynecologists and american college of pediatricians,0,0
0900006483b54fc1,Supporting & Related Material,FDA-2019-P-1534-0005,FDA-2019-P-1534,fda documents mifepristone u.s. post-marketing adverse events summary through 12/31/2017 re: american association of pro-life obstetricians and gynecologists and american college of pediatricians,0,0
0900006483b52833,Supporting & Related Material,FDA-2019-P-1534-0009,FDA-2019-P-1534,"other sources group 4 daniel grossman, md research protocol
alternative provision of medication abortion via pharmacy dispensing re:  american association of pro-life obstetricians and gynecologists and american college of pediatricians",0,0
0900006483b52837,Supporting & Related Material,FDA-2019-P-1534-0013,FDA-2019-P-1534,other sources group 7 which abortion patients have had a prior abortion? findings from the 2014 u.s. abortion patient survey re:  american association of pro-life obstetricians and gynecologists and american college of pediatricians,0,0
0900006483b52836,Supporting & Related Material,FDA-2019-P-1534-0010,FDA-2019-P-1534,other sources group 6 proposed rule arc 0891c to amend iac 653- chapter 13 to establish standards of practice for physicians who prescribe or administer abortion-inducing drugs re: american association of pro-life obstetricians and gynecologists and american college of pediatricians,0,0
0900006483b54819,Supporting & Related Material,FDA-2019-P-1534-0004,FDA-2019-P-1534,"other government documents food and drug administration
information on mifeprex labeling changes and ongoing monitoring
efforts re: american association of pro-life obstetricians and gynecologists and american college of pediatricians",1,0
0900006483b5282f,Supporting & Related Material,FDA-2019-P-1534-0011,FDA-2019-P-1534,exhibit b attached references and sources re: american association of pro-life obstetricians and gynecologists and american college of pediatricians,0,0
0900006483b522b6,Other,FDA-2019-P-1534-0001,FDA-2019-P-1534,citizen petition from american association of pro-life obstetricians and gynecologists and american college of pediatricians,0,0
0900006483b52830,Supporting & Related Material,FDA-2019-P-1534-0006,FDA-2019-P-1534,other sources group 1 the american college of obstetricians and gynecologists women’s health care physicians practice bulletin clinical management guidelines for obstetrician–gynecologists re: american association of pro-life obstetricians and gynecologists and american college of pediatricians,0,0
0900006483b5277b,Other,FDA-2019-P-1534-0002,FDA-2019-P-1534,acknowledgment letter from fda ddm to american association of pro-life obstetricians and gynecologists and american college of pediatricians,0,0
0900006483fcee17,Other,FDA-2019-P-1534-0014,FDA-2019-P-1534,interim response letter from fda cder to american association of pro-life obstetricians and gynecologists and american college of pediatricians,0,0
0900006483b5282e,Supporting & Related Material,FDA-2019-P-1534-0003,FDA-2019-P-1534,exhibit a current and requested language (from mifeprex label and risk evaluation and mitigation strategy) re: american association of pro-life obstetricians and gynecologists and american college of pediatricians,0,0
0900006483b52831,Supporting & Related Material,FDA-2019-P-1534-0007,FDA-2019-P-1534,other sources group 2 familyplanning: review mifepristone with buccal misoprostol for medical abortion re: american association of pro-life obstetricians and gynecologists and american college of pediatricians,0,0
09000064829da752,Supporting & Related Material,FDA-2017-P-4745-0011,FDA-2017-P-4745,tab 9 - molecular pharmaceutics 2014 re citizen petition from allergan,0,0
09000064829da757,Supporting & Related Material,FDA-2017-P-4745-0016,FDA-2017-P-4745,tab 14 - zheng nan_2017 re citizen petition from allergan,0,0
0900006482d91ad2,Other,FDA-2017-P-4745-0026,FDA-2017-P-4745,"petition denial letter from fda cder to allergan, inc",0,0
09000064829da74f,Supporting & Related Material,FDA-2017-P-4745-0008,FDA-2017-P-4745,tab 6 - choi_clinical pharmacokinetic and in vitro studies_2016 (2) re citizen petition from allergan,0,0
09000064829da755,Supporting & Related Material,FDA-2017-P-4745-0014,FDA-2017-P-4745,tab 12 - department of health and human services hhsf223201610105c to physical pharmaceutica llc $281 re citizen petition from allergan,0,0
09000064829da756,Supporting & Related Material,FDA-2017-P-4745-0015,FDA-2017-P-4745,tab 13 - june 2017 notice of intent to award a contract modification to physical pharmaceutica re citizen petition from allergan,0,0
09000064829cb066,Other,FDA-2017-P-4745-0002,FDA-2017-P-4745,acknowledgment letter from fda ddm to  allergan,0,0
0900006482bc933d,Other,FDA-2017-P-4745-0023,FDA-2017-P-4745,supplement from allergan,0,0
09000064829da74e,Supporting & Related Material,FDA-2017-P-4745-0007,FDA-2017-P-4745,tab 5 - ophthalmology management_ nov 2016 re citizen petition from allergan,0,0
09000064829da754,Supporting & Related Material,FDA-2017-P-4745-0013,FDA-2017-P-4745,tab 11 - wu et al fda abstract re globule size and petrochenko et al fda abstract re globule size distribution re citizen petition from allergan,0,0
09000064829da75b,Supporting & Related Material,FDA-2017-P-4745-0019,FDA-2017-P-4745,tab 17 - gottlieb to be more forceful inside health policy re citizen petition from allergan,0,0
09000064829da486,Supporting & Related Material,FDA-2017-P-4745-0004,FDA-2017-P-4745,tab 2 - gottlieb forbes july 7  2014 re citizen petition from allergan,0,0
09000064829da487,Supporting & Related Material,FDA-2017-P-4745-0005,FDA-2017-P-4745,tab 3 - hussaarts_et_al-2017-annals_of_the_new_york_academy_of_sciences re citizen petition from allergan,0,0
09000064829da750,Supporting & Related Material,FDA-2017-P-4745-0009,FDA-2017-P-4745,tab 7 - absar and choi scientific considerations for generic cyclosporine ophthalmic emulsion in vitro be studies re citizen petition from allergan,0,0
09000064829da753,Supporting & Related Material,FDA-2017-P-4745-0012,FDA-2017-P-4745,tab 10 - absar and choi scientific considerations for generic cyclosporine ophthalmic emulsion in vitro be studies re citizen petition from allergan,0,0
09000064829da759,Supporting & Related Material,FDA-2017-P-4745-0017,FDA-2017-P-4745,tab 15 - house ec committee ltr to gao re citizen petition from allergan,0,0
09000064829c8eef,Other,FDA-2017-P-4745-0001,FDA-2017-P-4745,citizen petition from allergan,0,0
09000064829da488,Supporting & Related Material,FDA-2017-P-4745-0006,FDA-2017-P-4745,tab 4 - gore. ocular emulsion gabi review article - 2017 (7) (2) re citizen petition from allergan,0,0
09000064829da75c,Supporting & Related Material,FDA-2017-P-4745-0020,FDA-2017-P-4745,tab 18 - gottlieb tackles speculators fda transparency  endpoints news re citizen petition from allergan re citizen petition from allergan,0,0
0900006482a8d323,Other,FDA-2017-P-4745-0022,FDA-2017-P-4745,acknowledgement letter from fda ddm to allergan,0,0
09000064829da485,Supporting & Related Material,FDA-2017-P-4745-0003,FDA-2017-P-4745,tab 1 - wa chambers ophthalmic generkcs - are they really the same re citizen petition from allergan,0,0
09000064829da751,Supporting & Related Material,FDA-2017-P-4745-0010,FDA-2017-P-4745,tab 8 - lionberger scientific agenda update oct 26 2016 re citizen petition from allergan,0,0
09000064829da75a,Supporting & Related Material,FDA-2017-P-4745-0018,FDA-2017-P-4745,tab 16 - allergan comment to fda regarding october 2016 draft guidance on cyclosporine (with attachments) re citizen petition from allergan,0,0
0900006482f96bf0,Other,FDA-2018-P-0998-0001,FDA-2018-P-0998,citizen petition from hyman phelps & mcnamara p.c.,0,0
0900006482f9e8fa,Other,FDA-2018-P-0998-0002,FDA-2018-P-0998,acknowledgment letter from fda ddm to hyman phelps & mcnamara p.c.,0,0
09000064835fd123,Other,FDA-2018-P-0998-0004,FDA-2018-P-0998,"letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
09000064835f8c45,Notice,FDA-2018-P-0998-0003,FDA-2018-P-0998,"determination that prolixin (fluphenazine hydrochloride) tablets,
1 milligram, 2.5 milligrams, 5 milligrams, and 10 milligrams, was not
withdrawn from sale for reasons of safety or effectiveness",0,0
0900006481a750b1,Supporting & Related Material,FDA-2015-P-1003-0003,FDA-2015-P-1003,attachment b fr determination of safety and effectiveness citizen petition from lachman consultant services inc.,0,0
0900006481a750b2,Supporting & Related Material,FDA-2015-P-1003-0004,FDA-2015-P-1003,attachment c current labeling citizen petition from lachman consultant services inc.,0,0
0900006481a750b3,Supporting & Related Material,FDA-2015-P-1003-0005,FDA-2015-P-1003,attachment d proposed labeling citizen petition from lachman consultant services inc.,0,0
0900006481a7358e,Other,FDA-2015-P-1003-0001,FDA-2015-P-1003,citizen petition from lachman consultant services inc.,0,0
0900006481a74fb6,Supporting & Related Material,FDA-2015-P-1003-0002,FDA-2015-P-1003,attachment a orange book listing citizen petition from lachman consultant services inc.,0,0
0900006481a74fb0,Other,FDA-2015-P-1003-0006,FDA-2015-P-1003,acknowledgement letter from fda ddm to lachman consultant services inc.,0,0
09000064820ab5f9,Supporting & Related Material,FDA-2014-P-0935-0010,FDA-2014-P-0935,supplement from the juice products association (jpa),0,0
090000648178e480,Supporting & Related Material,FDA-2014-P-0935-0007,FDA-2014-P-0935,exhibit 5 juice products association thailand coconut water brix citizen petition from the juice products association,0,0
090000648178e39a,Supporting & Related Material,FDA-2014-P-0935-0003,FDA-2014-P-0935,exhibit 1 juice products association philippines coconut water brix data nov 2011 to july 2012 citizen petition from the juice products association,0,0
09000064819e09c4,Other,FDA-2014-P-0935-0009,FDA-2014-P-0935,interim response from fda cfsan to juice products association,0,0
090000648178e47b,Supporting & Related Material,FDA-2014-P-0935-0005,FDA-2014-P-0935,exhibit 3 juice products association philippines coconut water brix data january 2013 october 2013 citizen petition from the juice products association,0,0
090000648178e398,Other,FDA-2014-P-0935-0002,FDA-2014-P-0935,acknowledgment letter from fda ddm to the juice products association,0,0
09000064820cb3b0,Supporting & Related Material,FDA-2014-P-0935-0011,FDA-2014-P-0935,exhibit a processor a (indonesia) re: supplement from the juice products association (jpa),0,0
090000648178e482,Supporting & Related Material,FDA-2014-P-0935-0008,FDA-2014-P-0935,exhibit 6 juice products association thailand coconut water brix data 2 citizen petition from the juice products association,0,0
09000064820cb3b2,Supporting & Related Material,FDA-2014-P-0935-0013,FDA-2014-P-0935,exhibit c processor c (philippines) re: supplement from the juice products association (jpa),0,0
09000064820cb3b3,Supporting & Related Material,FDA-2014-P-0935-0014,FDA-2014-P-0935,exhibit d processor d (philippines) re: supplement from the juice products association (jpa),0,0
09000064820cb3b1,Supporting & Related Material,FDA-2014-P-0935-0012,FDA-2014-P-0935,exhibit b processor b (indonesia) re: supplement from the juice products association (jpa),0,0
090000648178e199,Other,FDA-2014-P-0935-0001,FDA-2014-P-0935,citizen petition from the juice products association,0,0
090000648178e47e,Supporting & Related Material,FDA-2014-P-0935-0006,FDA-2014-P-0935,exhibit 4 juice products association philippines coconut water data september 2012 february2013 citizen petition from the juice products association,0,0
090000648178e479,Supporting & Related Material,FDA-2014-P-0935-0004,FDA-2014-P-0935,exhibit 2 juice products association brix data indonesia 2009 2012 citizen petition from the juice products association,0,0
090000648365e6c1,Supporting & Related Material,FDA-2018-P-3284-0004,FDA-2018-P-3284,"tab 2 re: citizen petition from keryx biopharmaceuticals, inc.",0,0
090000648365e6c5,Supporting & Related Material,FDA-2018-P-3284-0008,FDA-2018-P-3284,"tab 6 re: citizen petition from keryx biopharmaceuticals, inc.",0,0
090000648365e7d5,Supporting & Related Material,FDA-2018-P-3284-0020,FDA-2018-P-3284,"tab 16 re: citizen petition from keryx biopharmaceuticals, inc.",0,0
090000648365e7cd,Supporting & Related Material,FDA-2018-P-3284-0011,FDA-2018-P-3284,"tab 9 re: citizen petition from keryx biopharmaceuticals, inc.",0,0
0900006483a9181b,Other,FDA-2018-P-3284-0023,FDA-2018-P-3284,petition for reconsideration from hogan lovells us llp,0,0
0900006483a30be5,Other,FDA-2018-P-3284-0022,FDA-2018-P-3284,"response letter from fda cder to  keryx biopharmaceuticals, inc.",0,0
090000648365e6c0,Supporting & Related Material,FDA-2018-P-3284-0003,FDA-2018-P-3284,"tab 1 re: citizen petition from keryx biopharmaceuticals, inc.",0,0
090000648365e6c2,Supporting & Related Material,FDA-2018-P-3284-0005,FDA-2018-P-3284,"tab 3 re: citizen petition from keryx biopharmaceuticals, inc.",0,0
090000648365e7d2,Supporting & Related Material,FDA-2018-P-3284-0017,FDA-2018-P-3284,"tab 14 re: citizen petition from keryx biopharmaceuticals, inc.",0,0
090000648365e7d3,Supporting & Related Material,FDA-2018-P-3284-0019,FDA-2018-P-3284,"tab 15 re: citizen petition from keryx biopharmaceuticals, inc.",0,0
090000648365e6c3,Supporting & Related Material,FDA-2018-P-3284-0006,FDA-2018-P-3284,"tab 4 re: citizen petition from keryx biopharmaceuticals, inc.",0,0
090000648365f3b3,Other,FDA-2018-P-3284-0002,FDA-2018-P-3284,"acknowledgment letter from fda ddm to  keryx biopharmaceuticals, inc.",0,0
090000648365e7ce,Supporting & Related Material,FDA-2018-P-3284-0012,FDA-2018-P-3284,"tab 10 re: citizen petition from keryx biopharmaceuticals, inc.",0,0
090000648365e7d0,Supporting & Related Material,FDA-2018-P-3284-0014,FDA-2018-P-3284,"tab 12 re: citizen petition from keryx biopharmaceuticals, inc.",0,0
090000648365e7d1,Supporting & Related Material,FDA-2018-P-3284-0015,FDA-2018-P-3284,"tab 13 re: citizen petition from keryx biopharmaceuticals, inc.",0,0
090000648365e6c4,Supporting & Related Material,FDA-2018-P-3284-0007,FDA-2018-P-3284,"tab 5 re: citizen petition from keryx biopharmaceuticals, inc.",0,0
090000648365e6c6,Supporting & Related Material,FDA-2018-P-3284-0009,FDA-2018-P-3284,"tab 7 re: citizen petition from keryx biopharmaceuticals, inc.",0,0
090000648365e7cc,Supporting & Related Material,FDA-2018-P-3284-0010,FDA-2018-P-3284,"tab 8 re: citizen petition from keryx biopharmaceuticals, inc.",0,0
090000648365e7cf,Supporting & Related Material,FDA-2018-P-3284-0013,FDA-2018-P-3284,"tab 11 re: citizen petition from keryx biopharmaceuticals, inc.",0,0
0900006483a9181d,Other,FDA-2018-P-3284-0024,FDA-2018-P-3284,acknowledgment letter from fda ddm to hogan lovells us llp,0,0
090000648365dffc,Other,FDA-2018-P-3284-0001,FDA-2018-P-3284,"citizen petition from keryx biopharmaceuticals, inc.",0,0
0900006484861475,Other,FDA-2020-P-1914-0001,FDA-2020-P-1914,"citizen petition from aurolife pharma, llc. - redacted copy",0,0
0900006484958dc8,Other,FDA-2020-P-1914-0003,FDA-2020-P-1914,"withdrawal from aurolife pharma, llc",0,0
09000064848619fa,Other,FDA-2020-P-1914-0002,FDA-2020-P-1914,acknowledgment letter from fda dms to aurolife pharma llc,0,0
0900006484785bf0,Other,FDA-2020-P-1678-0001,FDA-2020-P-1678,citizen petition from cardinal health regulatory sciences,0,0
0900006484785bf1,Other,FDA-2020-P-1678-0002,FDA-2020-P-1678,acknowledgment letter from fda dms to cardinal health regulatory sciences,0,0
0900006484a6c5bf,Notice,FDA-2020-P-1678-0005,FDA-2020-P-1678,"determination that nipride rtu (sodium nitroprusside), 10 milligrams/ 50 milliliters (0.2 milligrams/milliliters), was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006484a70b44,Other,FDA-2020-P-1678-0006,FDA-2020-P-1678,letter to cardinal health regulatory sciences from fda cder,0,0
09000064849fa896,Other,FDA-2020-P-1678-0004,FDA-2020-P-1678,interim response letter from fda to cardinal health regulatory sciences,0,0
09000064847872d5,Supporting & Related Material,FDA-2020-P-1678-0003,FDA-2020-P-1678,attachment a - orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from cardinal health regulatory sciences,0,0
0900006484dfa326,Other,FDA-2021-P-1175-0002,FDA-2021-P-1175,acknowledgment letter from fda dms to felix pharmaceuticals pvt. ltd.,0,0
0900006484dfa853,Other,FDA-2021-P-1175-0001,FDA-2021-P-1175,suitability petition from felix pharmaceuticals pvt. ltd.,0,0
0900006484dfa871,Supporting & Related Material,FDA-2021-P-1175-0003,FDA-2021-P-1175,attachment 1 - rlnad package insert re suitability petition from felix pharmaceuticals pvt. ltd.,0,0
0900006484dfa86a,Supporting & Related Material,FDA-2021-P-1175-0004,FDA-2021-P-1175,attachment 2 - draft proposed package insert re suitability petition from felix pharmaceuticals pvt. ltd.,0,0
0900006484d69889,Other,FDA-2021-P-0984-0004,FDA-2021-P-0984,citizen petition from theo allen,0,0
0900006484d6988c,Other,FDA-2021-P-0984-0005,FDA-2021-P-0984,acknowledgment letter from fda dms to theo allen,0,0
0900006484e051c3,Other,FDA-2021-P-0984-0011,FDA-2021-P-0984,response letter from fda cber to theo allen,0,0
090000648242dda5,Other,FDA-2016-P-1874-0005,FDA-2016-P-1874,interim response letter from cder to public citizen's health research group,0,0
090000648207fc83,Other,FDA-2016-P-1874-0002,FDA-2016-P-1874,acknowledgement letter from fda ddm to public citizen health research group,0,0
090000648207f7f5,Other,FDA-2016-P-1874-0001,FDA-2016-P-1874,citizen petition from public citizen health research group,0,0
090000648207fc86,Supporting & Related Material,FDA-2016-P-1874-0004,FDA-2016-P-1874,appendix b - rcts in parkinson’s disease reporting impulse-control problems and compulsive behaviors for dopamine agonists* re citizen petition from public citizen health research group,0,0
090000648207fc85,Supporting & Related Material,FDA-2016-P-1874-0003,FDA-2016-P-1874,appendix a - current dopamine agonist and partial dopamine agonist drugs available in the us and their labeling regarding impulse-control problems/compulsive behaviors re citizen petition from public citizen health research group,0,0
09000064824e7a97,Other,FDA-2016-P-1874-0006,FDA-2016-P-1874,supplement from public citizen,0,0
09000064838688b1,Other,FDA-2018-P-1734-0003,FDA-2018-P-1734,"letter from fda cder to foley & lardner, llp",0,0
090000648398f4af,Other,FDA-2018-P-1734-0005,FDA-2018-P-1734,"letter from fda cder to foley & lardner, llp",0,0
090000648322793c,Other,FDA-2018-P-1734-0002,FDA-2018-P-1734,acknowledgment letter from fda ddm to foley & lardner llp,0,0
090000648322752c,Other,FDA-2018-P-1734-0001,FDA-2018-P-1734,citizen petition from foley & lardner llp,0,0
090000648398ec98,Notice,FDA-2018-P-1734-0004,FDA-2018-P-1734,"determination that ic–green (indocyanine green for injection), 10
milligrams/vial, 40 milligrams/vial, and 50 milligrams/vial were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006482a8db3c,Other,FDA-2017-P-5090-0001,FDA-2017-P-5090,citizen petition from macleods pharmaceuticals limited,0,0
0900006482e9e843,Other,FDA-2017-P-5090-0003,FDA-2017-P-5090,interim response letter from cder to macleods pharmaceuticals,0,0
0900006483ae17ba,Other,FDA-2017-P-5090-0004,FDA-2017-P-5090,response letter from cder to macleods pharmaceuticals,0,0
0900006482a8e48a,Other,FDA-2017-P-5090-0002,FDA-2017-P-5090,acknowledgment letter from fda ddm to macleods pharmaceuticals limited,0,0
0900006483d5b235,Notice,FDA-2019-P-0692-0003,FDA-2019-P-0692,"determination that tham solution (tromethamine) injectable, 3.6 grams/ 100 milliliters, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483a67d42,Other,FDA-2019-P-0692-0001,FDA-2019-P-0692,citizen petition from arent fox llp,0,0
0900006483a67f23,Other,FDA-2019-P-0692-0002,FDA-2019-P-0692,acknowledgment letter from fda ddm to arent fox llp,0,0
0900006483d5d73d,Other,FDA-2019-P-0692-0004,FDA-2019-P-0692,letter from fda cder to arent fox llp,0,0
09000064838e2208,Other,FDA-2018-P-3211-0004,FDA-2018-P-3211,denial letter for suitability petition  from fda cvm to aurora pharmaceutical llc,0,0
090000648363301e,Other,FDA-2018-P-3211-0002,FDA-2018-P-3211,acknowledgment letter from fda ddm to aurora pharmaceutical llc,0,0
0900006483633543,Supporting & Related Material,FDA-2018-P-3211-0003,FDA-2018-P-3211,"attachment, equioxx paste label-1 re: citizen petition from aurora pharmaceutical llc.",0,0
090000648363287a,Other,FDA-2018-P-3211-0001,FDA-2018-P-3211,citizen petition from aurora pharmaceutical llc.,0,0
090000648045fca2,Notice,FDA-2006-N-0366-0001,FDA-2006-N-0366,fda,0,0
090000648045fca7,Notice,FDA-2006-N-0366-0002,FDA-2006-N-0366,fda,0,0
0900006484dc5d38,Supporting & Related Material,FDA-2021-P-1115-0012,FDA-2021-P-1115,exhibit j re citizen petition from professional compounding centers of america,0,0
0900006484dc5d3b,Supporting & Related Material,FDA-2021-P-1115-0015,FDA-2021-P-1115,exhibit m re citizen petition from professional compounding centers of america,0,0
0900006484dc5d3f,Supporting & Related Material,FDA-2021-P-1115-0019,FDA-2021-P-1115,exhibit q re citizen petition from professional compounding centers of america,0,0
0900006484dc5a61,Supporting & Related Material,FDA-2021-P-1115-0007,FDA-2021-P-1115,exhibit e re citizen petition from professional compounding centers of america,0,0
0900006484dc5a63,Supporting & Related Material,FDA-2021-P-1115-0009,FDA-2021-P-1115,exhibit g re citizen petition from professional compounding centers of america,0,0
0900006484dc5d39,Supporting & Related Material,FDA-2021-P-1115-0013,FDA-2021-P-1115,exhibit k re citizen petition from professional compounding centers of america,0,0
0900006484dc5d4c,Supporting & Related Material,FDA-2021-P-1115-0021,FDA-2021-P-1115,exhibit s re citizen petition from professional compounding centers of america,0,0
0900006484dc5a62,Supporting & Related Material,FDA-2021-P-1115-0008,FDA-2021-P-1115,exhibit f re citizen petition from professional compounding centers of america,0,0
0900006484dc5a5d,Supporting & Related Material,FDA-2021-P-1115-0003,FDA-2021-P-1115,exhibit a re citizen petition from professional compounding centers of america,0,0
0900006484dc5d4d,Supporting & Related Material,FDA-2021-P-1115-0022,FDA-2021-P-1115,exhibit t re citizen petition from professional compounding centers of america,0,0
0900006484dc5d36,Supporting & Related Material,FDA-2021-P-1115-0010,FDA-2021-P-1115,exhibit h re citizen petition from professional compounding centers of america,0,0
0900006484dc5d3c,Supporting & Related Material,FDA-2021-P-1115-0016,FDA-2021-P-1115,exhibit n re citizen petition from professional compounding centers of america,0,0
0900006484dc5a5e,Supporting & Related Material,FDA-2021-P-1115-0004,FDA-2021-P-1115,exhibit b re citizen petition from professional compounding centers of america,0,0
0900006484dc5d37,Supporting & Related Material,FDA-2021-P-1115-0011,FDA-2021-P-1115,exhibit i re citizen petition from professional compounding centers of america,0,0
0900006484dc5d3a,Supporting & Related Material,FDA-2021-P-1115-0014,FDA-2021-P-1115,exhibit l re citizen petition from professional compounding centers of america,0,0
0900006484dc5d3d,Supporting & Related Material,FDA-2021-P-1115-0017,FDA-2021-P-1115,exhibit o re citizen petition from professional compounding centers of america,0,0
0900006484dc5d25,Other,FDA-2021-P-1115-0002,FDA-2021-P-1115,acknowledgment letter from fda dms to professional compounding centers of america,0,0
0900006484dc5d23,Other,FDA-2021-P-1115-0001,FDA-2021-P-1115,citizen petition from professional compounding centers of america,0,0
0900006484dc5d3e,Supporting & Related Material,FDA-2021-P-1115-0018,FDA-2021-P-1115,exhibit p re citizen petition from professional compounding centers of america,0,0
0900006484dc5a5f,Supporting & Related Material,FDA-2021-P-1115-0005,FDA-2021-P-1115,exhibit c re citizen petition from professional compounding centers of america,0,0
0900006484dc5a60,Supporting & Related Material,FDA-2021-P-1115-0006,FDA-2021-P-1115,exhibit d re citizen petition from professional compounding centers of america,0,0
0900006484dc5d4b,Supporting & Related Material,FDA-2021-P-1115-0020,FDA-2021-P-1115,exhibit r re citizen petition from professional compounding centers of america,0,0
0900006484dcb098,Supporting & Related Material,FDA-2021-P-1127-0002,FDA-2021-P-1127,exhibit a re: citizen petition from professional compounding centers of america,0,0
0900006484dcbb4e,Supporting & Related Material,FDA-2021-P-1127-0012,FDA-2021-P-1127,exhibit k re: citizen petition from professional compounding centers of america,0,0
0900006484dcb9d8,Other,FDA-2021-P-1127-0001,FDA-2021-P-1127,citizen petition from professional compounding centers of america,0,0
0900006484dcb7a5,Other,FDA-2021-P-1127-0013,FDA-2021-P-1127,acknowledgment letter from fda dms to professional compounding centers of america,0,0
0900006484dcb099,Supporting & Related Material,FDA-2021-P-1127-0003,FDA-2021-P-1127,exhibit b re: citizen petition from professional compounding centers of america,0,0
0900006484dcbb4a,Supporting & Related Material,FDA-2021-P-1127-0008,FDA-2021-P-1127,exhibit g re: citizen petition from professional compounding centers of america,0,0
0900006484dcbb48,Supporting & Related Material,FDA-2021-P-1127-0006,FDA-2021-P-1127,exhibit e re: citizen petition from professional compounding centers of america,0,0
0900006484dcbb49,Supporting & Related Material,FDA-2021-P-1127-0007,FDA-2021-P-1127,exhibit f re: citizen petition from professional compounding centers of america,0,0
0900006484dcbb4b,Supporting & Related Material,FDA-2021-P-1127-0009,FDA-2021-P-1127,exhibit h re: citizen petition from professional compounding centers of america,0,0
0900006484dcbb47,Supporting & Related Material,FDA-2021-P-1127-0005,FDA-2021-P-1127,exhibit d re: citizen petition from professional compounding centers of america,0,0
0900006484dcbb4c,Supporting & Related Material,FDA-2021-P-1127-0010,FDA-2021-P-1127,exhibit i re: citizen petition from professional compounding centers of america,0,0
0900006484dcbb46,Supporting & Related Material,FDA-2021-P-1127-0004,FDA-2021-P-1127,exhibit c re: citizen petition from professional compounding centers of america,0,0
0900006484dcbb4d,Supporting & Related Material,FDA-2021-P-1127-0011,FDA-2021-P-1127,exhibit j re: citizen petition from professional compounding centers of america,0,0
09000064824fba4a,Other,FDA-2016-P-2713-0003,FDA-2016-P-2713,letter from strides pharma inc.  requesting to withdraw citizen petition,0,0
0900006482205561,Other,FDA-2016-P-2713-0001,FDA-2016-P-2713,"citizen petition from strides pharma, inc.",0,0
0900006482205564,Other,FDA-2016-P-2713-0002,FDA-2016-P-2713,"acknowledgement letter from fda ddm to strides pharma, inc.",0,0
090000648377c5e8,Other,FDA-2018-P-3666-0001,FDA-2018-P-3666,"citizen petition from fresenius kabi usa, llc",0,0
090000648377c91a,Other,FDA-2018-P-3666-0002,FDA-2018-P-3666,"acknowledgment letter from fda ddm to fresenius kabi usa, llc",0,0
0900006483b134d8,Other,FDA-2018-P-3666-0003,FDA-2018-P-3666,"letter from fda cder to fresenius kabi usa, llc",0,0
0900006481b08a16,Other,FDA-2015-P-1898-0001,FDA-2015-P-1898,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006481b09a13,Other,FDA-2015-P-1898-0002,FDA-2015-P-1898,"acknowledgement letter from fda ddm to hyman, phelps & mcnamara, p.c.",0,0
0900006481dd3cba,Notice,FDA-2015-P-1898-0003,FDA-2015-P-1898,"determination that kytril granisetron hydrochloride) tablets, equivalent 1 milligram and 2 milligram base, were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006481ddee16,Other,FDA-2015-P-1898-0004,FDA-2015-P-1898,"letter from fda cder to hyman, phelps & mcnamara pc",0,0
0900006482b8b9d6,Supporting & Related Material,FDA-2017-P-5978-0004,FDA-2017-P-5978,attachment 2 dailymed label: nicardipine hydrochloride- nicardipine hydrochloride injection,0,0
0900006483051b56,Other,FDA-2017-P-5978-0005,FDA-2017-P-5978,interim response letter from fda cder to jr rapoza associates inc.,0,0
090000648497e0e1,Other,FDA-2017-P-5978-0006,FDA-2017-P-5978,"withdrawal from jr rapoza associates, inc.",0,0
0900006482b8b5de,Other,FDA-2017-P-5978-0001,FDA-2017-P-5978,"citizen petition from jr rapoza associates, inc.",0,0
0900006482b8b6ec,Other,FDA-2017-P-5978-0002,FDA-2017-P-5978,acknowledgement letter from fda ddm to jr rapoza associates inc.,0,0
0900006482b8b744,Supporting & Related Material,FDA-2017-P-5978-0003,FDA-2017-P-5978,attachment 1 orange book: approved drug products with therapeutic equivalence evaluations,0,0
0900006483cdd64d,Other,FDA-2018-P-4664-0003,FDA-2018-P-4664,"letter from fda cder to fresenius kabi usa, llc",0,0
0900006483973e3d,Other,FDA-2018-P-4664-0001,FDA-2018-P-4664,"citizen petition from fresenius kabi usa, llc",0,0
0900006483975950,Other,FDA-2018-P-4664-0002,FDA-2018-P-4664,"acknowledgment letter from fda ddm to fresenius kabi usa, llc",0,0
090000648362b5ee,Notice,FDA-2018-N-2970-0001,FDA-2018-N-2970,agency information collection activities; proposed collection; comment request; surveys and interviews with investigational new drug sponsors to assess current communication practices with food and drug administration review staff under the sixth authorization of the prescription drug user fee act,1,0
09000064838ce9cc,Notice,FDA-2018-N-2970-0002,FDA-2018-N-2970,agency information collection activities; submission for office of management and budget review; comment request; surveys and interviews with investigational new drug sponsors to assess current communication practices with food and drug administration review staff under the sixth authorization of the prescription drug user fee act,1,0
0900006483bad4cc,Notice,FDA-2018-N-2970-0003,FDA-2018-N-2970,"agency information collection activities; announcement of office of
management and budget approvals",0,0
090000648478c14a,Supporting & Related Material,FDA-2020-P-1689-0007,FDA-2020-P-1689,exhibit 5  re citizen petition from lassman law + policy,0,0
09000064849fd09b,Other,FDA-2020-P-1689-0012,FDA-2020-P-1689,interim response from fda cber to lassman law + policy,0,0
090000648478c143,Other,FDA-2020-P-1689-0002,FDA-2020-P-1689,acknowledgment letter from fda dms to lassman law + policy,0,0
090000648478bf63,Supporting & Related Material,FDA-2020-P-1689-0010,FDA-2020-P-1689,exhibit 8  re citizen petition from lassman law + policy,0,0
090000648478c142,Other,FDA-2020-P-1689-0001,FDA-2020-P-1689,citizen petition from lassman law + policy,0,0
090000648478bf61,Supporting & Related Material,FDA-2020-P-1689-0008,FDA-2020-P-1689,exhibit 6  re citizen petition from lassman law + policy,0,0
090000648478bf62,Supporting & Related Material,FDA-2020-P-1689-0009,FDA-2020-P-1689,exhibit 7  re citizen petition from lassman law + policy,0,0
090000648478bf64,Supporting & Related Material,FDA-2020-P-1689-0011,FDA-2020-P-1689,exhibit 9  re citizen petition from lassman law + policy,0,0
090000648478c147,Supporting & Related Material,FDA-2020-P-1689-0004,FDA-2020-P-1689,exhibit 2  re citizen petition from lassman law + policy,0,0
090000648478c149,Supporting & Related Material,FDA-2020-P-1689-0006,FDA-2020-P-1689,exhibit 4  re citizen petition from lassman law + policy,0,0
090000648478c146,Supporting & Related Material,FDA-2020-P-1689-0003,FDA-2020-P-1689,exhibit 1 re citizen petition from lassman law + policy,0,0
090000648478c148,Supporting & Related Material,FDA-2020-P-1689-0005,FDA-2020-P-1689,exhibit 3  re citizen petition from lassman law + policy,0,0
0900006484a70c41,Other,FDA-2020-P-1991-0003,FDA-2020-P-1991,"interim response letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
090000648486b878,Other,FDA-2020-P-1991-0002,FDA-2020-P-1991,"acknowledgment letter from fda dms to hyman, phelps & mcnamara, p.c.",0,0
090000648486b876,Other,FDA-2020-P-1991-0001,FDA-2020-P-1991,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
090000648480b45f,Supporting & Related Material,FDA-2020-P-1768-0003,FDA-2020-P-1768,footnotes 2 - 17 re citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484811ac5,Supporting & Related Material,FDA-2020-P-1768-0008,FDA-2020-P-1768,footnotes 18-30 re: administrative stay of action from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484811ac6,Supporting & Related Material,FDA-2020-P-1768-0007,FDA-2020-P-1768,footnotes 31-48 re: administrative stay of action from siri & glimstad llp on behalf of informed consent action network,0,0
090000648480b30a,Other,FDA-2020-P-1768-0001,FDA-2020-P-1768,citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
090000648480b461,Supporting & Related Material,FDA-2020-P-1768-0005,FDA-2020-P-1768,footnotes 31 - 41 re citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484973a31,Supporting & Related Material,FDA-2020-P-1768-0044,FDA-2020-P-1768,footnotes 2 - 17 re citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
090000648480b460,Supporting & Related Material,FDA-2020-P-1768-0004,FDA-2020-P-1768,footnotes 18 - 30 re citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484811ac4,Supporting & Related Material,FDA-2020-P-1768-0009,FDA-2020-P-1768,footnotes 2-17 re: administrative stay of action from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484811e83,Other,FDA-2020-P-1768-0006,FDA-2020-P-1768,administrative stay of action from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484aa3a7d,Other,FDA-2020-P-1768-0048,FDA-2020-P-1768,"interim response letter from fda cber to siri & glimstad, llp",0,0
0900006484913841,Other,FDA-2020-P-1768-0010,FDA-2020-P-1768,amended citizen petition siri & glimstad llp on behalf of informed consent action network,0,0
0900006484973e6c,Supporting & Related Material,FDA-2020-P-1768-0046,FDA-2020-P-1768,footnotes 31-48 re: administrative stay of action from siri & glimstad llp on behalf of informed consent action network,0,0
0900006484973dfa,Supporting & Related Material,FDA-2020-P-1768-0045,FDA-2020-P-1768,footnotes 18 - 30 re citizen petition from siri & glimstad llp on behalf of informed consent action network,0,0
090000648480b45c,Other,FDA-2020-P-1768-0002,FDA-2020-P-1768,acknowledgment letter from fda dms to siri & glimstad llp on behalf of informed consent action network,0,0
090000648487321d,Other,FDA-2020-P-2003-0002,FDA-2020-P-2003,acknowledgment letter from fda dms to environmental defense fund,0,0
0900006484873aba,Supporting & Related Material,FDA-2020-P-2003-0004,FDA-2020-P-2003,appendix c review of gras notifications re: citizen petition from environmental defense fund,0,0
09000064848736fe,Supporting & Related Material,FDA-2020-P-2003-0007,FDA-2020-P-2003,"attachment 1- the healthfulness of the us packaged food and
beverage supply: a cross-sectional study re: citizen petition from environmental defense fund",1,0
0900006484a6b478,Other,FDA-2020-P-2003-0455,FDA-2020-P-2003,180 day interim response letter from fda cfsan to environmental defense fund,0,0
0900006484873ab9,Supporting & Related Material,FDA-2020-P-2003-0005,FDA-2020-P-2003,"appendix b review of fda’s regulations, forms, and associated instructions for industry regarding petitions and notifications re: citizen petition from environmental defense fund",0,0
090000648487321b,Other,FDA-2020-P-2003-0001,FDA-2020-P-2003,citizen petition from environmental defense fund,0,0
0900006484873ab8,Supporting & Related Material,FDA-2020-P-2003-0006,FDA-2020-P-2003,appendix a specific changes requested to fda’s regulations re: citizen petition from environmental defense fund,0,0
0900006484873abb,Supporting & Related Material,FDA-2020-P-2003-0003,FDA-2020-P-2003,appendix d review of fda guidance to industry re: citizen petition from environmental defense fund,0,0
0900006484c4a80f,Other,FDA-2021-P-0895-0002,FDA-2021-P-0895,acknowledgment letter from eagle pharmaceuticals,0,0
0900006484c4a80d,Other,FDA-2021-P-0895-0001,FDA-2021-P-0895,citizen petition from eagle pharmaceuticals,0,0
0900006481991a9b,Other,FDA-2014-P-0919-0004,FDA-2014-P-0919,interim response from cdrh to daniel schumaier,0,0
0900006484df8c43,Other,FDA-2014-P-0919-0006,FDA-2014-P-0919,final response from fda cdrh to daniel schumaier,0,0
090000648177d0e9,Supporting & Related Material,FDA-2014-P-0919-0003,FDA-2014-P-0919,supporting  and related materials citizen petition from daniel schumaier phd,0,0
090000648177d0e7,Other,FDA-2014-P-0919-0002,FDA-2014-P-0919,acknowledgement letter from fda ddm to daniel schumaier,0,0
0900006481e5b351,Other,FDA-2014-P-0919-0005,FDA-2014-P-0919,"interim response letter from fda cdrh to daniel schumaier, phd.",0,0
0900006481779c07,Other,FDA-2014-P-0919-0001,FDA-2014-P-0919,"citizen petition from daniel schumaier, ph.d.",0,0
0900006484acdca5,Other,FDA-2021-P-0433-0001,FDA-2021-P-0433,"citizen petition from siri & glimstad, llp",0,0
0900006484dfc8cf,Other,FDA-2021-P-0433-0042,FDA-2021-P-0433,"interim response letter from fda cber to siri & glimstad, llp",0,0
0900006484acdca8,Other,FDA-2021-P-0433-0002,FDA-2021-P-0433,"acknowledgment letter from fda dms to siri & glimstad, llp",0,0
0900006482afdc20,Other,FDA-2016-P-2738-0004,FDA-2016-P-2738,petition response letter from fda cder to metabolic therapy inc.,0,0
090000648220d2a1,Other,FDA-2016-P-2738-0001,FDA-2016-P-2738,citizen petition from metabolic therapy inc.,0,0
0900006482504d65,Other,FDA-2016-P-2738-0003,FDA-2016-P-2738,interim response letter from fda cder to metabolic therapy inc.,0,0
090000648220d6e7,Other,FDA-2016-P-2738-0002,FDA-2016-P-2738,acknowledgement letter from fda ddm to metabolic therapy inc.,0,0
0900006481a2e9ee,Other,FDA-2014-P-0628-0004,FDA-2014-P-0628,intetim response letter from cfsan to shauce co.,0,0
09000064816f8d6b,Other,FDA-2014-P-0628-0002,FDA-2014-P-0628,acknowledgement letter from fda ddm to shauce co,0,0
09000064816f8d6d,Supporting & Related Material,FDA-2014-P-0628-0003,FDA-2014-P-0628,reference 1 analysis report from shauce co re: citizen petition from shauce company,0,0
09000064816f8d69,Other,FDA-2014-P-0628-0001,FDA-2014-P-0628,citizen petition from shauce company,0,0
09000064824ae716,Other,FDA-2017-P-0757-0002,FDA-2017-P-0757,acknowledgment letter from fda ddm  to beck & thomas,0,0
09000064824ae714,Other,FDA-2017-P-0757-0001,FDA-2017-P-0757,citizen petition from beck & thomas,0,0
09000064824ba38a,Other,FDA-2017-P-0757-0003,FDA-2017-P-0757,withdrawal from vertice pharma (beck & thomas),0,0
0900006484d62771,Supporting & Related Material,FDA-2021-P-0985-0004,FDA-2021-P-0985,attachment 2 re: citizen petition from president island green living association  personal care products toxicologist,0,0
0900006484d624d3,Supporting & Related Material,FDA-2021-P-0985-0005,FDA-2021-P-0985,"attachment 3 benzophenone accumulates over time from the degradation of
octocrylene in commercial sunscreen products re: citizen petition from president island green living association  personal care products toxicologist",0,0
0900006484d624d4,Supporting & Related Material,FDA-2021-P-0985-0003,FDA-2021-P-0985,attachment 1 sunscreen drug products for over-the-counter human use re: citizen petition from president island green living association  personal care products toxicologist,0,0
0900006484d624e4,Other,FDA-2021-P-0985-0001,FDA-2021-P-0985,citizen petition from president island green living association  personal care products toxicologist,0,0
0900006484d624d8,Supporting & Related Material,FDA-2021-P-0985-0009,FDA-2021-P-0985,attachment 7 reproductive toxicity and estrogen activity in japanese medaka (oryzias latipes) exposed to environmentally relevant concentrations of octocrylene re: citizen petition from president island green living association  personal care products toxicologist,0,0
0900006484d624d9,Supporting & Related Material,FDA-2021-P-0985-0015,FDA-2021-P-0985,"attachment 13 unveiling complex responses at the molecular level: transcriptional alterations by mixtures of bisphenol a, octocrylene, and 2'-ethylhexyl 4-(dimethylamino)benzoate on chironomus ripariusre: citizen petition from president island green living association  personal care products toxicologist",0,0
0900006484d6276f,Supporting & Related Material,FDA-2021-P-0985-0011,FDA-2021-P-0985,attachment 9 a unique approach to monitor stress in coral exposed to emerging pollutants re: citizen petition from president island green living association  personal care products toxicologist,0,0
0900006484d62776,Supporting & Related Material,FDA-2021-P-0985-0013,FDA-2021-P-0985,"attachment 11 multiresidue analysis of organic uv filters and uv
stabilizers in fish of common consumption re: citizen petition from president island green living association  personal care products toxicologist",0,0
0900006484d624d2,Supporting & Related Material,FDA-2021-P-0985-0008,FDA-2021-P-0985,"attachment 6 effect of 10 uv filters on the brine shrimp artemia 
3 salina and the marine microalga tetraselmis sp re: citizen petition from president island green living association  personal care products toxicologist",0,0
0900006484d624d7,Supporting & Related Material,FDA-2021-P-0985-0012,FDA-2021-P-0985,"attachment 10 metabolomics reveal that octocrylene accumulates in
pocillopora damicornis tissues as fatty acid conjugates and triggers coral cell mitochondrial dysfunction re: citizen petition from president island green living association  personal care products toxicologist",0,0
0900006484d62778,Supporting & Related Material,FDA-2021-P-0985-0014,FDA-2021-P-0985,"attachment 12 emerging contaminants in aquatic environments and coastal waters affected by urban wastewater discharge in thailand: an ecological 
risk perspective re: citizen petition from president island green living association  personal care products toxicologist",0,0
0900006484d62770,Supporting & Related Material,FDA-2021-P-0985-0006,FDA-2021-P-0985,attachment 4 discontinuation of uvinul n 539t (octocrylene)  re: citizen petition from president island green living association  personal care products toxicologist,0,0
0900006484d624e6,Other,FDA-2021-P-0985-0002,FDA-2021-P-0985,acknowledgment letter from fda dms to president island green living association and personal care products toxicologist,0,0
0900006484d624d6,Supporting & Related Material,FDA-2021-P-0985-0016,FDA-2021-P-0985,attachment 14 biomarker-based assessment of sublethal toxicity of organic uv filters (ensulizole and octocrylene) in a sentinel marine bivalve mytilus edulis re: citizen petition from president island green living association  personal care products toxicologist,0,0
0900006484d62772,Supporting & Related Material,FDA-2021-P-0985-0018,FDA-2021-P-0985,attachment 16 skincare chemicals and coral reefs re: citizen petition from president island green living association  personal care products toxicologist,0,0
0900006484d62775,Supporting & Related Material,FDA-2021-P-0985-0017,FDA-2021-P-0985,"attachment 15 oxybenzone contamination from sunscreen pollution and its ecological threat to hanauma bay, oahu, hawaii, u.s.a. re: citizen petition from president island green living association  personal care products toxicologist",0,0
0900006484d62777,Supporting & Related Material,FDA-2021-P-0985-0010,FDA-2021-P-0985,attachment 8 a burning issue: the effect of organic ultraviolet filter exposure on the behaviour and physiology of daphnia magna re: citizen petition from president island green living association  personal care products toxicologist,0,0
0900006484d624d5,Supporting & Related Material,FDA-2021-P-0985-0007,FDA-2021-P-0985,attachment 5 science of the total environment re: citizen petition from president island green living association  personal care products toxicologist,0,0
0900006483ccc7eb,Other,FDA-2019-P-2559-0002,FDA-2019-P-2559,acknowledgment letter from fda ddm to ajanta pharma usa inc,0,0
0900006483dc2022,Notice,FDA-2019-P-2559-0003,FDA-2019-P-2559,"determination that fortamet (metformin hydrochloride) extended-
release tablets, 500 milligrams and 1 gram, were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483ccc6ae,Other,FDA-2019-P-2559-0001,FDA-2019-P-2559,citizen petition from ajanta pharma usa inc,0,0
0900006483dc63b2,Other,FDA-2019-P-2559-0004,FDA-2019-P-2559,letter from fda cder to ajanta pharma usa inc,0,0
090000648420e91b,Other,FDA-2019-P-1607-0003,FDA-2019-P-1607,"response letter from fda to aurobindo pharma usa, inc",0,0
0900006483b636eb,Other,FDA-2019-P-1607-0002,FDA-2019-P-1607,"acknowledgment letter from fda ddm to aurobindo pharma usa, inc.",0,0
0900006483b634e7,Other,FDA-2019-P-1607-0001,FDA-2019-P-1607,"citizen petition from aurobindo pharma usa, inc.",0,0
0900006484a0ffd1,Supporting & Related Material,FDA-2021-P-0086-0003,FDA-2021-P-0086,"comment from neeraj agrawal, schafer veterinary consultants, llc",0,0
09000064849f8abf,Other,FDA-2021-P-0086-0002,FDA-2021-P-0086,acknowledgement letter from fda dms to  felix pharmaceuticals pvt. ltd,0,0
09000064849f8d0e,Other,FDA-2021-P-0086-0001,FDA-2021-P-0086,suitability citizen petition from felix pharmaceuticals pvt. ltd,0,0
0900006484aa060d,Other,FDA-2021-P-0086-0004,FDA-2021-P-0086,"approval of suitability petition from fda cvm to schafer veterinary consultants, llc",0,0
09000064847b4531,Supporting & Related Material,FDA-2020-P-1718-0008,FDA-2020-P-1718,"attachment f examples of beverages labeled as nutrition drinks, nutritional drinks, nutrition shakes re: citizen petition from public health advocacy institute, inc. on behalf  of 1,000 days, et al.",0,0
09000064847b3ef4,Other,FDA-2020-P-1718-0002,FDA-2020-P-1718,"acknowledgment letter from fda dms to public health advocacy institute, inc. on behalf  of 1,000 days, et al.",0,0
0900006484a15d09,Other,FDA-2020-P-1718-0013,FDA-2020-P-1718,"response letter to citizen petition from fda cfsan to public health advocacy institute, inc. on behalf  of 1,000 days, et al.",0,0
09000064847b452c,Supporting & Related Material,FDA-2020-P-1718-0003,FDA-2020-P-1718,"attachment a transition formula & toddler milk products for sale in november 2019 re: citizen petition from public health advocacy institute, inc. on behalf  of 1,000 days, et al.",0,0
09000064847b452e,Supporting & Related Material,FDA-2020-P-1718-0005,FDA-2020-P-1718,"attachment c side by side comparison of nutrient content of infant formula vs transition formula re:  citizen petition from public health advocacy institute, inc. on behalf  of 1,000 days, et al.",0,0
09000064847b4530,Supporting & Related Material,FDA-2020-P-1718-0007,FDA-2020-P-1718,"attachment e marketing claims & comparisons to plain milk & whole foods re: citizen petition from public health advocacy institute, inc. on behalf  of 1,000 days, et al.",0,0
09000064847b4532,Supporting & Related Material,FDA-2020-P-1718-0009,FDA-2020-P-1718,"attachment g incorrect use of the term toddler to encompass infants less than 12 months old re: citizen petition from public health advocacy institute, inc. on behalf  of 1,000 days, et al.",0,0
09000064847b3ef3,Other,FDA-2020-P-1718-0001,FDA-2020-P-1718,"citizen petition from public health advocacy institute, inc. on behalf  of 1,000 days, et al.",0,0
09000064847b452d,Supporting & Related Material,FDA-2020-P-1718-0004,FDA-2020-P-1718,"attachment b price comparison of cow's milk, transition formula & toddler milk re: citizen petition from public health advocacy institute, inc. on behalf  of 1,000 days, et al.",0,0
09000064847b452f,Supporting & Related Material,FDA-2020-P-1718-0006,FDA-2020-P-1718,"attachment d nutritional composition of toddler milk vs plain milk re: citizen petition from public health advocacy institute, inc. on behalf  of 1,000 days, et al.",0,0
09000064832405ee,Other,FDA-2018-P-1780-0001,FDA-2018-P-1780,"citizen petition from pacira pharmaceuticals, inc",0,0
0900006483240a11,Other,FDA-2018-P-1780-0002,FDA-2018-P-1780,"acknowledgment letter from fda ddm to pacira pharmaceuticals, inc",0,0
0900006483883493,Other,FDA-2018-P-1780-0004,FDA-2018-P-1780,"interim response letter from fda cder to pacira pharmaceuticals, inc.",0,0
0900006484af90f3,Other,FDA-2018-P-1780-0005,FDA-2018-P-1780,"response letter from fda cder to pacira pharmaceuticals, inc.",0,0
0900006483ad2f44,Supporting & Related Material,FDA-2019-P-1130-0003,FDA-2019-P-1130,exhibit a vaccination suspension regulation proposed regulations terms re citizen petition from kent heckenlively et al,0,0
0900006483acf5b4,Other,FDA-2019-P-1130-0002,FDA-2019-P-1130,acknowledgment letter from fda ddm to kent heckenlively,0,0
0900006483acf526,Other,FDA-2019-P-1130-0001,FDA-2019-P-1130,citizen petition from kent heckenlively et al,0,0
0900006481e373bd,Other,FDA-2015-P-3053-0004,FDA-2015-P-3053,citizen petition response letter from fda cder to florek & endres pllc,0,0
0900006481c2eaf6,Other,FDA-2015-P-3053-0002,FDA-2015-P-3053,acknowledgement letter from fda ddm to florek & endres pllc,0,0
0900006481c2ed67,Other,FDA-2015-P-3053-0001,FDA-2015-P-3053,citizen petition from florek & endres pllc,0,0
0900006481e2f692,Notice,FDA-2015-P-3053-0003,FDA-2015-P-3053,"determination that izba (travoprost ophthalmic solution), 0.003 percent, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006481c8c746,Supporting & Related Material,FDA-2015-P-3400-0002,FDA-2015-P-3400,prescription and over-the counter drug product list from the orange book,0,0
0900006481c8c744,Other,FDA-2015-P-3400-0001,FDA-2015-P-3400,"citizen petition from lupin pharmaceuticals, inc.",0,0
09000064839fbdda,Other,FDA-2015-P-3400-0005,FDA-2015-P-3400,response letter from fda cder,0,0
0900006481ecc157,Other,FDA-2015-P-3400-0004,FDA-2015-P-3400,"interim response letter from fda cder to lupin pharmaceuticals, inc.",0,0
0900006481c8c815,Other,FDA-2015-P-3400-0003,FDA-2015-P-3400,"acknowledgement letter from fda ddm to lupin pharmaceuticals, inc.",0,0
0900006481cb82c2,Other,FDA-2015-P-3485-0002,FDA-2015-P-3485,acknowledgement letter from fda ddm to national chicken council,0,0
0900006481cb85da,Other,FDA-2015-P-3485-0001,FDA-2015-P-3485,"citizen petition from the national chicken council, et al.",0,0
0900006484326d04,Other,FDA-2020-P-0598-0001,FDA-2020-P-0598,"citizen petition from lachman consulting services, inc.",0,0
0900006484326dfb,Supporting & Related Material,FDA-2020-P-0598-0004,FDA-2020-P-0598,attachment 2- ims data-prochlorperazine re: citizen petition from lachman consultants,0,0
0900006484326dfa,Supporting & Related Material,FDA-2020-P-0598-0003,FDA-2020-P-0598,attachment 1- orange book_ approved drug products with therapeutic equivalence evaluations re: citizen petition from lachman consultants,0,0
0900006484326d87,Other,FDA-2020-P-0598-0002,FDA-2020-P-0598,"acknowledgment letter from fda dms to lachman consulting services, inc",0,0
0900006484455313,Other,FDA-2020-P-0598-0005,FDA-2020-P-0598,"citizen petition withdrawal request from lachman consulting services, inc. to fda cder",0,0
09000064849b07a7,Other,FDA-2020-P-2317-0001,FDA-2020-P-2317,citizen petition from baxter healthcare corporation,0,0
0900006484b5ca79,Other,FDA-2020-P-2317-0004,FDA-2020-P-2317,response letter from fda cder to baxter healthcare corporation,0,0
09000064849b07aa,Other,FDA-2020-P-2317-0002,FDA-2020-P-2317,acknowledgment letter from fda dms to baxter healthcare corporation,0,0
0900006484b59180,Notice,FDA-2020-P-2317-0003,FDA-2020-P-2317,"determination that quelicin preservative free (succinylcholine chloride) injection, 20 milligrams/milliliter, 50 milligrams/milliliter, and 100 milligrams/milliliter, was not withdrawn from sale for
reasons of safety or effectiveness",0,0
0900006484b81467,Other,FDA-2021-P-0559-0002,FDA-2021-P-0559,acknowledgment letter from fda dms to catalyst pharmaceuticals,0,0
0900006484be5a07,Other,FDA-2021-P-0559-0003,FDA-2021-P-0559,withdrawal of citizens petition from catalyst pharmaceuticals,0,0
0900006484b80a58,Other,FDA-2021-P-0559-0001,FDA-2021-P-0559,citizen petition from catalyst pharmaceuticals,0,0
0900006480450f0d,Other,FDA-2005-A-0476-0001,FDA-2005-A-0476,acknowledgement letter to glaxosmithkline,0,0
09000064846c2558,Other,FDA-2005-A-0476-0006,FDA-2005-A-0476,"response letter from fda cder to glaxosmithkline, wilmer cutler pickering hale and dorr llp,  ropes & gray llp,  novo nordisk inc. and finnegan, henderson, farabow, garrett & dunner, llp",0,0
09000064808d46b5,Other,FDA-2005-A-0476-0004,FDA-2005-A-0476,glaxosmithkline (advisory opinion petition) - supplement,0,0
0900006480450f15,Other,FDA-2005-A-0476-0002,FDA-2005-A-0476,fda/cder interim response to glaxosmithkline - letter,0,0
0900006480450f0f,Other,FDA-2005-A-0476-0003,FDA-2005-A-0476,glaxosmithkline - advisory opinion petition,0,0
0900006480c7a5b4,Other,FDA-2005-A-0476-0005,FDA-2005-A-0476,see fda-2005-a-0476-0003,0,0
0900006484ad47c6,Other,FDA-2021-P-0437-0001,FDA-2021-P-0437,"citizen petition from siri & glimstad, llp (on behalf of informed consent action network)",0,0
0900006484ad47c8,Other,FDA-2021-P-0437-0002,FDA-2021-P-0437,"acknowledgment letter from fda dms to siri & glimstad, llp (on behalf of informed consent action network)",0,0
0900006484ad47ca,Supporting & Related Material,FDA-2021-P-0437-0003,FDA-2021-P-0437,"exhibit a -  the measurement and full statistical analysis including bayesian methods of the aluminium content of infant vaccines re citizen petition from siri & glimstad, llp (on behalf of informed consent action network)",0,0
0900006484dfc8fa,Other,FDA-2021-P-0437-0007,FDA-2021-P-0437,"interim response letter from fda cber to siri & glimstad, llp",0,0
0900006484a5ecdc,Supporting & Related Material,FDA-2021-P-0267-0005,FDA-2021-P-0267,reference 2 - ischemia-triggered glutamate excitotoxicity from the perspective of glial cells re citizen petition from adrienne samuels,0,0
0900006484a5ece0,Supporting & Related Material,FDA-2021-P-0267-0006,FDA-2021-P-0267,reference 3  - statistics: an intuitive approach and reference 4 -  statistical analysis in psychology and education re citizen petition from adrienne samuels,0,0
0900006484a5ece5,Supporting & Related Material,FDA-2021-P-0267-0010,FDA-2021-P-0267,"reference 8, 9, 10 - brain damage in infant mice following oral intake of glutamate, aspartate or cysteine, reference 9 - brain damage in mice from voluntary ingestion of glutamate and aspartate and reference 10  -brain-damaging potential of protein hydrolysates re citizen petition from adrienne samuels",0,0
0900006484a5ecf2,Supporting & Related Material,FDA-2021-P-0267-0016,FDA-2021-P-0267,"reference 16 - brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate re citizen petition from adrienne samuels",0,0
0900006484a5ecda,Supporting & Related Material,FDA-2021-P-0267-0003,FDA-2021-P-0267,cover letter re citizen petition from adrienne samuels,0,0
0900006484a5ece1,Supporting & Related Material,FDA-2021-P-0267-0007,FDA-2021-P-0267,reference 5 - the alleged safety of monosodium glutamate (msg) excerpted from msg: a review of the literature and critique of industry sponsored research. re citizen petition from adrienne samuels,0,0
0900006484a5ecf5,Supporting & Related Material,FDA-2021-P-0267-0018,FDA-2021-P-0267,reference 18 - history of glutamate production re citizen petition from adrienne samuels,0,0
0900006484a5ecee,Supporting & Related Material,FDA-2021-P-0267-0014,FDA-2021-P-0267,reference 14 - memorandum: summary of adverse reactions attributed to aspartame re citizen petition from adrienne samuels,0,0
0900006484a5ecfc,Supporting & Related Material,FDA-2021-P-0267-0021,FDA-2021-P-0267,"reference 21 - global food flavor enhancer market report, history and forecast. 2014-2025,
breakdown data by manufacturers, key regions, types and application re citizen petition from adrienne samuels",1,0
0900006484a5ecd3,Other,FDA-2021-P-0267-0002,FDA-2021-P-0267,acknowledgement letter from fda dms to adrienne samuels,0,0
0900006484a5ecdb,Supporting & Related Material,FDA-2021-P-0267-0004,FDA-2021-P-0267,"reference 1 - excitotoxicity in the pathogenesis of neurological and psychiatric disorders: therapeutic
implications re citizen petition from adrienne samuels",0,0
0900006484a5ece4,Supporting & Related Material,FDA-2021-P-0267-0009,FDA-2021-P-0267,reference 7 - designed for deception: the fail-safe way to ensure that their studies would conclude msg is harmless re citizen petition from adrienne samuels,0,0
0900006484a5ece6,Supporting & Related Material,FDA-2021-P-0267-0011,FDA-2021-P-0267,"reference 11 - data from the 1960s and 1970s demonstrate that monosodium glutamate causes  hypothalamic damage, endocrine disruption, and behavior disorders when given to immature animals after
either subcutaneous or oral doses. re citizen petition from adrienne samuels",0,0
0900006484a5ece8,Supporting & Related Material,FDA-2021-P-0267-0013,FDA-2021-P-0267,reference 13  -  memorandum: summary of adverse reactions attributed to msg re citizen petition from adrienne samuels,0,0
0900006484a5ecf4,Supporting & Related Material,FDA-2021-P-0267-0017,FDA-2021-P-0267,reference 17 - discovery and history of amino acid fermentation re citizen petition from adrienne samuels,0,0
0900006484a5ecbe,Other,FDA-2021-P-0267-0001,FDA-2021-P-0267,citizen petition from adrienne samuels,0,0
0900006484a5ecef,Supporting & Related Material,FDA-2021-P-0267-0015,FDA-2021-P-0267,reference 15 - designed for deception: the fail-safe way to ensure that their studies would conclude msg is harmless re citizen petition from adrienne samuels,0,0
0900006484a5ece2,Supporting & Related Material,FDA-2021-P-0267-0008,FDA-2021-P-0267,reference 6 - the toxicity/safety of processed free glutamic acid (msg): a study in suppression of information re citizen petition from adrienne samuels,0,0
0900006484a5ece7,Supporting & Related Material,FDA-2021-P-0267-0012,FDA-2021-P-0267,reference 12 - letter from international glutamate technical committee re citizen petition from adrienne samuels,0,0
0900006484a5ecfa,Supporting & Related Material,FDA-2021-P-0267-0019,FDA-2021-P-0267,"reference 19 - global monosodium glutamate market poised to surge from usd 4,500.0 million in 2014
to usd 5,850.0 million by 2020 – marketresearchstore.com  re citizen petition from adrienne samuels",0,0
0900006484a5ecfb,Supporting & Related Material,FDA-2021-P-0267-0020,FDA-2021-P-0267,reference 20 - global flavor enhancers market: report highlights re citizen petition from adrienne samuels,0,0
0900006482978c64,Other,FDA-2017-P-3064-0025,FDA-2017-P-3064,"letter from fda cder to  pharmaceutical manufacturing research services, inc.",0,0
09000064825bb998,Supporting & Related Material,FDA-2017-P-3064-0015,FDA-2017-P-3064,"attachment 13 inspirion presentation re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
09000064825bb994,Supporting & Related Material,FDA-2017-P-3064-0011,FDA-2017-P-3064,"attachment 9  generic ad opioid draft guidance re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
09000064825bb993,Supporting & Related Material,FDA-2017-P-3064-0010,FDA-2017-P-3064,"attachment 8 highlights of prescribing information roxybond, april 2017 re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
09000064825bb997,Supporting & Related Material,FDA-2017-P-3064-0014,FDA-2017-P-3064,"attachment 12 ir rems - fda re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
0900006482c2afac,Other,FDA-2017-P-3064-0030,FDA-2017-P-3064,"petition response letter from fda cder to  pharmaceutical manufacturing research services, inc.",0,0
09000064825bb0a4,Supporting & Related Material,FDA-2017-P-3064-0005,FDA-2017-P-3064,"attachment 3 cdc guideline for prescribing opioids for chronic pain re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
09000064825bb995,Supporting & Related Material,FDA-2017-P-3064-0012,FDA-2017-P-3064,"attachment 10 fda briefing information (addendum) re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
09000064825bb992,Supporting & Related Material,FDA-2017-P-3064-0009,FDA-2017-P-3064,"attachment 7 ad opioid evaluation and labeling guidance re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
09000064825bb996,Supporting & Related Material,FDA-2017-P-3064-0013,FDA-2017-P-3064,"attachment 11 inspirion briefing information re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
09000064825bb999,Supporting & Related Material,FDA-2017-P-3064-0016,FDA-2017-P-3064,"attachment 14 pokrovnichka history of oxycontin labeling and risk management program re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
09000064825bb99b,Supporting & Related Material,FDA-2017-P-3064-0018,FDA-2017-P-3064,"attachment 16 fda briefing information re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
09000064825bb0a5,Supporting & Related Material,FDA-2017-P-3064-0006,FDA-2017-P-3064,"attachment 4 inspirion delivery sciences receives fda approval for roxybond (oxycodone hydrochloride) tablets-2 re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
09000064825bb99c,Other,FDA-2017-P-3064-0002,FDA-2017-P-3064,"acknowledgment letter from fda ddm to  pharmaceutical manufacturing research services, inc.",0,0
09000064825bb0a0,Other,FDA-2017-P-3064-0001,FDA-2017-P-3064,"citizen petition from pharmaceutical manufacturing research services, inc.",0,0
09000064825c6db3,Supporting & Related Material,FDA-2017-P-3064-0019,FDA-2017-P-3064,"attachment 17  citizen petition fda-2017-p-1359 (2) re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
09000064825c6db4,Supporting & Related Material,FDA-2017-P-3064-0020,FDA-2017-P-3064,attachment 18  citizen petition fda-2016-p-0645 - redacted,0,0
09000064825bb0a2,Supporting & Related Material,FDA-2017-P-3064-0003,FDA-2017-P-3064,"attachment 1  cder interim response letter re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
09000064825bb991,Supporting & Related Material,FDA-2017-P-3064-0008,FDA-2017-P-3064,"attachment 6 a proactive response to prescription opioid abuse re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
09000064825bb99a,Supporting & Related Material,FDA-2017-P-3064-0017,FDA-2017-P-3064,"attachment 15 letter from janet woodcock, docket 1992-p-0494 re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
09000064825bb990,Supporting & Related Material,FDA-2017-P-3064-0007,FDA-2017-P-3064,"attachment 5 letter from edwin r_ thompson-2  re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
09000064825bb0a3,Supporting & Related Material,FDA-2017-P-3064-0004,FDA-2017-P-3064,"attachment 2 washington post april 5-2 re citizen petition from pharmaceutical manufacturing research services, inc.",0,0
090000648259a6fd,Other,FDA-2017-P-1221-0005,FDA-2017-P-1221,suitability petition amendment from aurora pharmaceutical llc,0,0
09000064824de81c,Supporting & Related Material,FDA-2017-P-1221-0003,FDA-2017-P-1221,"attachment 1 equioxx® oral paste, labeling by merial, rev 06-2015 re suitability petition from aurora pharmaceutical llc",0,0
09000064824de81a,Other,FDA-2017-P-1221-0002,FDA-2017-P-1221,acknowledgement letter from fda ddm to aurora pharmaceutical llc,0,0
09000064824de471,Other,FDA-2017-P-1221-0001,FDA-2017-P-1221,suitability petition from aurora pharmaceutical llc,0,0
09000064825832b2,Other,FDA-2017-P-1221-0004,FDA-2017-P-1221,amendment from aurora pharmaceutical llc,0,0
09000064825f62a9,Other,FDA-2017-P-1221-0006,FDA-2017-P-1221,"letter from cvm to aurora pharmaceutical, llc",0,0
09000064841245ca,Supporting & Related Material,FDA-2019-P-5237-0003,FDA-2019-P-5237,"attachment 1 orange book: approved drug products with
therapeutic equivalence evaluations- redacted re citizen petition from aurobindo pharma usa, inc",0,0
090000648484b516,Other,FDA-2019-P-5237-0005,FDA-2019-P-5237,letter from fda cder to aurobindo pharma limited,0,0
0900006484124585,Other,FDA-2019-P-5237-0001,FDA-2019-P-5237,"citizen petition from aurobindo pharma usa, inc",0,0
0900006484124dba,Other,FDA-2019-P-5237-0002,FDA-2019-P-5237,"acknowledgment letter from dms to aurobindo pharma usa, inc",0,0
09000064844d307f,Other,FDA-2019-P-5237-0004,FDA-2019-P-5237,interim response letter from fda cder to us agent for aurobindo pharma limited,0,0
09000064849999b7,Other,FDA-2020-P-1575-0004,FDA-2020-P-1575,interim response letter from fda cder to  francis e. o'donnell,0,0
09000064846f40a6,Supporting & Related Material,FDA-2020-P-1575-0003,FDA-2020-P-1575,attachment 1 - hhs guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics re: citizen petition from francis e. o'donnell,0,0
09000064846f42ff,Other,FDA-2020-P-1575-0001,FDA-2020-P-1575,citizen petition from francis e. o'donnell,0,0
09000064846f40a3,Other,FDA-2020-P-1575-0002,FDA-2020-P-1575,acknowledgment letter from fda dms to francis e. o'donnell,0,0
0900006484a71c7d,Other,FDA-2021-P-0306-0002,FDA-2021-P-0306,acknowledgment letter from fda dms to encube ethicals private limited,0,0
0900006484affd66,Notice,FDA-2021-P-0306-0004,FDA-2021-P-0306,"determination that ovide (malathion) lotion, 0.5%, was not withdrawn from sale for reasons of safety or
effectiveness",0,0
0900006484a74cb7,Supporting & Related Material,FDA-2021-P-0306-0003,FDA-2021-P-0306,attachment re citizen petition from encube ethicals private limited,0,0
0900006484a71c7a,Other,FDA-2021-P-0306-0001,FDA-2021-P-0306,citizen petition from encube ethicals private limited,0,0
0900006484b077a3,Other,FDA-2021-P-0306-0005,FDA-2021-P-0306,response letter from fda cder to encube ethicals private limited,0,0
0900006484be6030,Other,FDA-2021-P-0705-0002,FDA-2021-P-0705,acknowledgment letter from fda dms to catalyst pharmaceuticals,0,0
0900006484be5a09,Other,FDA-2021-P-0705-0001,FDA-2021-P-0705,citizen petition from catalyst pharmaceuticals,0,0
09000064809f11ad,Other,FDA-2009-P-0325-0001,FDA-2009-P-0325,reckitt benckiser pharmaceuticals inc. - citizen petition,0,0
0900006480a0f90f,Supporting & Related Material,FDA-2009-P-0325-0005,FDA-2009-P-0325,"exhibit 1 - guidance for industry--andas: impurities in drug substances - [reckitt benckiser pharmaceuticals, inc. - supplement citizen petition] re fda-2009-p-0325-0004",0,0
09000064809f1bbd,Supporting & Related Material,FDA-2009-P-0325-0002,FDA-2009-P-0325,"exhibit 1 - labeling - [reckitt benckiser, pharmaceuticals inc. - citizen petition]",0,0
0900006480a3edce,Other,FDA-2009-P-0325-0006,FDA-2009-P-0325,"fda to reckitt benckiser pharmaceuticals, inc. - petition partial approval and denial",0,0
0900006480a0f90d,Other,FDA-2009-P-0325-0004,FDA-2009-P-0325,"reckitt benckiser pharmaceuticals, inc. - supplement citizen petition",0,0
09000064809f11ae,Other,FDA-2009-P-0325-0003,FDA-2009-P-0325,acknowledgement letter to reckitt benckiser pharmaceuticals inc.,0,0
0900006484de516c,Other,FDA-2021-P-0413-0003,FDA-2021-P-0413,interim response from fda cder to radius health inc,0,0
0900006484ab849f,Other,FDA-2021-P-0413-0001,FDA-2021-P-0413,"citizen petition from radius health, inc.",0,0
0900006484ab854a,Other,FDA-2021-P-0413-0002,FDA-2021-P-0413,acknowledgment letter to radius health inc from fda dms,0,0
0900006484de575e,Other,FDA-2021-P-1148-0001,FDA-2021-P-1148,citizen petition from marlene keeling,0,0
0900006484de5760,Other,FDA-2021-P-1148-0002,FDA-2021-P-1148,acknowledgment letter from fda dms to marlene keeling,0,0
0900006483d7a3ce,Other,FDA-2018-P-3102-0069,FDA-2018-P-3102,letter from fda cdrh to richard m. fleming,0,0
090000648393b4c2,Other,FDA-2018-P-3102-0068,FDA-2018-P-3102,supplement from richard fleming,0,0
09000064835f38e4,Supporting & Related Material,FDA-2018-P-3102-0005,FDA-2018-P-3102,gamma gazette march 2011- issue 1re: citizen petition from richard m fleming,0,0
09000064835f38e6,Supporting & Related Material,FDA-2018-P-3102-0007,FDA-2018-P-3102,use of parabolic model in tomographic diagnosis of infarction and stenosis. re: citizen petition from richard m fleming,0,0
09000064835f3c35,Supporting & Related Material,FDA-2018-P-3102-0016,FDA-2018-P-3102,"both percent diameter stenosis (%ds) and coronary flow reserve (cfr)
can be derived directly from myocardial perfusion imaging (mpi) using
fmtvdm©℗ and measurement of isotope redistribution re: citizen petition from richard m fleming",0,0
09000064835f3c4d,Supporting & Related Material,FDA-2018-P-3102-0036,FDA-2018-P-3102,"myoview and sestamibi redistribution, stress once- image twice protocol improves detection of ischemia in addition to improving patient throughput and reducing patient radiation  re: citizen petition from richard m fleming",0,0
09000064835f3c56,Supporting & Related Material,FDA-2018-P-3102-0042,FDA-2018-P-3102,training physicians and healthcare providers to accurately  re: citizen petition from richard m fleming,0,0
09000064835f38e5,Supporting & Related Material,FDA-2018-P-3102-0006,FDA-2018-P-3102,the evolution of nuclear cardiology takes us back to the beginning to develop today’s “new standard of care” for cardiac imaging: how quantifying regional radioactive counts at five and 60 minute post-stress unmasks hidden ischemia re: citizen petition from richard m fleming,0,0
09000064835f3c36,Supporting & Related Material,FDA-2018-P-3102-0017,FDA-2018-P-3102,"fmtvdm©℗ stress-first/stress-only imaging is here! but first we need
to clarify the use of what (1) stress, (2) rest, (3) redistribution and (4)
quantification, really mean re: citizen petition from richard m fleming",0,0
09000064835f3c3a,Supporting & Related Material,FDA-2018-P-3102-0021,FDA-2018-P-3102,"breast cancer genes, breast cancer and fmtvdmbest
©℗ imaging re: citizen petition from richard m fleming",0,0
09000064835f3c4a,Supporting & Related Material,FDA-2018-P-3102-0033,FDA-2018-P-3102,"fmtvdm©℗*** nuclear imaging artificial (ai) intelligence but first we need to clarify the use of (1) stress, (2) rest, (3) redistribution and (4) quantification re: citizen petition from richard m fleming",0,0
09000064835f3c37,Supporting & Related Material,FDA-2018-P-3102-0018,FDA-2018-P-3102,united state senate charles e grassley re: citizen petition from richard m fleming,0,0
09000064835f3c39,Supporting & Related Material,FDA-2018-P-3102-0020,FDA-2018-P-3102,"breast enhanced scintigraphy testing distinguishes between normal, inflammatory breast changes, and breast cancer: a prospective
analysis and comparison with mammographyre: citizen petition from richard m fleming",0,0
09000064835f3c45,Supporting & Related Material,FDA-2018-P-3102-0030,FDA-2018-P-3102,integrative cancer therapies re: citizen petition from richard m fleming,0,0
09000064835f3c4b,Supporting & Related Material,FDA-2018-P-3102-0034,FDA-2018-P-3102,are there differences in breast tissue as a result of hormone replacement therapy? can best imaging distinguish these differences? re: citizen petition from richard m fleming,0,0
09000064836cbc0d,Supporting & Related Material,FDA-2018-P-3102-0045,FDA-2018-P-3102,fludeoxyglucose f 18 pet radiopharmacuticals  lantheus,0,0
09000064835f37ab,Other,FDA-2018-P-3102-0002,FDA-2018-P-3102,acknowledgment letter from fda ddm to richard m fleming,0,0
09000064835f3c33,Supporting & Related Material,FDA-2018-P-3102-0014,FDA-2018-P-3102,"the development of fmtvdm-best imaging©℗: the answer for breast
cancer. breast enhanced scintigraphy test (best©℗): quantifying the
detection of breast cancer and its treatment. re: citizen petition from richard m fleming",0,0
09000064835f3c3e,Supporting & Related Material,FDA-2018-P-3102-0024,FDA-2018-P-3102,fmtvdm©℗ – evolution of nuclear cardiology & nuclear medicine. re: citizen petition from richard m fleming,0,0
09000064835f3c4f,Supporting & Related Material,FDA-2018-P-3102-0038,FDA-2018-P-3102,expert endorsement re: citizen petition from richard m fleming,0,0
09000064835f3c44,Supporting & Related Material,FDA-2018-P-3102-0029,FDA-2018-P-3102,"the evolution of nuclear cardiology takes us back to the
beginning to develop today’s “new standard of care” for cardiac imaging: how quantifying regional radioactive counts at five and 60 minutes post-stress unmasks
hidden ischemia re: citizen petition from richard m fleming",0,0
09000064835f3c46,Supporting & Related Material,FDA-2018-P-3102-0031,FDA-2018-P-3102,"ria-fhrww© analysis of the redistribution properties of tc-99m isotope agents,sestamibi and myoview, enhances the detection of ischemic heart disease re: citizen petition from richard m fleming",0,0
09000064835f3c58,Supporting & Related Material,FDA-2018-P-3102-0043,FDA-2018-P-3102,curriculum vitae  richard maximus fleming re: citizen petition from richard m fleming,0,0
09000064835f3c31,Supporting & Related Material,FDA-2018-P-3102-0012,FDA-2018-P-3102,renewed application of an old method improves detection of coronary lschemia: a higher standard of carere: citizen petition from richard m fleming,0,0
09000064835f3c41,Supporting & Related Material,FDA-2018-P-3102-0026,FDA-2018-P-3102,"fmtvdm-tfm©℗: true quantification requires standardization of the tool
being used to measure, with a known, unchanging standard to produce accurate, consistent and reproducible quantified measurements re: citizen petition from richard m fleming",0,0
0900006483318f95,Other,FDA-2017-P-6805-0003,FDA-2017-P-6805,interim response letter from fda cder to bracco diagnostics inc.,0,0
0900006482cf8411,Other,FDA-2017-P-6805-0002,FDA-2017-P-6805,acknowledgment letter from fda ddm to bracco diagnostics inc.,0,0
0900006482cf8273,Other,FDA-2017-P-6805-0001,FDA-2017-P-6805,citizen petition from bracco diagnostics inc,0,0
09000064821487f2,Supporting & Related Material,FDA-2016-P-2342-0004,FDA-2016-P-2342,"orange book printout of rld re citizen petition from sovereign pharmaceuticals, llc",0,0
09000064821484ce,Other,FDA-2016-P-2342-0002,FDA-2016-P-2342,"acknowledgement letter from fda ddm to sovereign pharmaceuticals, llc",0,0
09000064821484cc,Other,FDA-2016-P-2342-0001,FDA-2016-P-2342,"citizen petition from sovereign pharmaceuticals, llc",0,0
09000064821484d0,Supporting & Related Material,FDA-2016-P-2342-0003,FDA-2016-P-2342,"draft guidance on metaxalone re citizen petition from sovereign pharmaceuticals, llc",0,0
09000064821487f3,Supporting & Related Material,FDA-2016-P-2342-0005,FDA-2016-P-2342,"orange book printout of proposed strengths re citizen petition from sovereign pharmaceuticals, llc",0,0
0900006483857e2f,Other,FDA-2016-P-2342-0006,FDA-2016-P-2342,"withdrawal letter from sovereign pharmaceuticals llc, (xspire pharma, llc)",0,0
0900006482c2addd,Supporting & Related Material,FDA-2017-P-6316-0003,FDA-2017-P-6316,"exhibit a -usp monographs for methylene blue and methylene blue injection re citizen petition from kleinfeld kaplan & becker, llp (provepharm sas)",0,0
09000064831e964d,Other,FDA-2017-P-6316-0009,FDA-2017-P-6316,"interim response from fda cder to provepharm, sas",0,0
0900006482c2adde,Supporting & Related Material,FDA-2017-P-6316-0004,FDA-2017-P-6316,"exhibit b - petzer, a., et al., azure b, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase, toxicol re citizen petition from kleinfeld kaplan & becker, llp (provepharm sas)",0,0
0900006482c2ade2,Supporting & Related Material,FDA-2017-P-6316-0008,FDA-2017-P-6316,"exhibit f - akom package insert (april 2017) re citizen petition from kleinfeld kaplan & becker, llp (provepharm sas)",0,0
0900006482c2addf,Supporting & Related Material,FDA-2017-P-6316-0005,FDA-2017-P-6316,"exhibit c- delport, a. et al., azure b and a synthetic structural analogue of methylene blue, ethylthioninium chloride, present with antidepressant-like properties re citizen petition from kleinfeld kaplan & becker, llp (provepharm sas)",0,0
0900006482c2ade0,Supporting & Related Material,FDA-2017-P-6316-0006,FDA-2017-P-6316,"exhibit d - jacobson-kram, d and mcgovern, t, toxicological overview of impurities in pharmaceutical products, advan drug deliv rev, 59 (2007) 38-42 re citizen petition from kleinfeld kaplan & becker, llp (provepharm sas)",0,0
0900006482c2ade1,Supporting & Related Material,FDA-2017-P-6316-0007,FDA-2017-P-6316,"exhibit e - akom product page for methylene blue injection, usp re citizen petition from kleinfeld kaplan & becker, llp (provepharm sas)",0,0
0900006482c29e92,Other,FDA-2017-P-6316-0001,FDA-2017-P-6316,"citizen petition from kleinfeld kaplan & becker, llp (provepharm sas)",0,0
0900006482c2a39e,Other,FDA-2017-P-6316-0002,FDA-2017-P-6316,"acknowledgement letter from fda ddm to kleinfeld kaplan & becker, llp (provepharm sas)",0,0
0900006481fdb7ff,Supporting & Related Material,FDA-2016-P-1288-0018,FDA-2016-P-1288,exhibits-192-205 re citizen petition from fluoride action network,0,0
0900006481fdb7fd,Supporting & Related Material,FDA-2016-P-1288-0016,FDA-2016-P-1288,exhibits-154-173 re citizen petition from fluoride action network,0,0
0900006481fdbb3f,Supporting & Related Material,FDA-2016-P-1288-0005,FDA-2016-P-1288,exhibit_013 re citizen petition from fluoride action network,0,0
0900006481fdbb39,Other,FDA-2016-P-1288-0002,FDA-2016-P-1288,acknowledgement letter from fda ddm to fluoride action network,0,0
09000064823c8f8c,Other,FDA-2016-P-1288-0020,FDA-2016-P-1288,petition denial letter from fda ddm to fluoride action network,0,0
0900006481fdb7dc,Supporting & Related Material,FDA-2016-P-1288-0007,FDA-2016-P-1288,exhibits_027 re citizen petition from fluoride action network,0,0
0900006481fdb7e1,Supporting & Related Material,FDA-2016-P-1288-0012,FDA-2016-P-1288,exhibits_084-95 re citizen petition from fluoride action network,0,0
0900006481fdb7e2,Supporting & Related Material,FDA-2016-P-1288-0013,FDA-2016-P-1288,exhibits-096-109 re citizen petition from fluoride action network,0,0
0900006481fdbb3c,Supporting & Related Material,FDA-2016-P-1288-0003,FDA-2016-P-1288,exhibits 001-07 re citizen petition from fluoride action network,0,0
0900006481fdb7df,Supporting & Related Material,FDA-2016-P-1288-0010,FDA-2016-P-1288,exhibits_061-72 re citizen petition from fluoride action network,0,0
0900006481fdb7e3,Supporting & Related Material,FDA-2016-P-1288-0014,FDA-2016-P-1288,exhibits-110-128 re citizen petition from fluoride action network,0,0
0900006481fdb7db,Supporting & Related Material,FDA-2016-P-1288-0006,FDA-2016-P-1288,exhibits_014-26 re citizen petition from fluoride action network,0,0
0900006481fdb7fe,Supporting & Related Material,FDA-2016-P-1288-0017,FDA-2016-P-1288,exhibits-174-191 re citizen petition from fluoride action network,0,0
0900006481fdba91,Other,FDA-2016-P-1288-0001,FDA-2016-P-1288,citizen petition from fluoride action network,0,0
0900006481fdbb3d,Supporting & Related Material,FDA-2016-P-1288-0004,FDA-2016-P-1288,exhibits_008-12 re citizen petition from fluoride action network,0,0
0900006481fdb7dd,Supporting & Related Material,FDA-2016-P-1288-0008,FDA-2016-P-1288,exhibits_028-47 re citizen petition from fluoride action network,0,0
0900006481fdb7de,Supporting & Related Material,FDA-2016-P-1288-0009,FDA-2016-P-1288,exhibits_048-60 re citizen petition from fluoride action network,0,0
0900006481fdb7e0,Supporting & Related Material,FDA-2016-P-1288-0011,FDA-2016-P-1288,exhibits_073-83 re citizen petition from fluoride action network,0,0
0900006481fdb7e4,Supporting & Related Material,FDA-2016-P-1288-0015,FDA-2016-P-1288,exhibits-129-153 re citizen petition from fluoride action network,0,0
0900006481fdb801,Supporting & Related Material,FDA-2016-P-1288-0019,FDA-2016-P-1288,exhibits-206-209 re citizen petition from fluoride action network,0,0
0900006481a8e609,Other,FDA-2015-P-1103-0001,FDA-2015-P-1103,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
0900006481d1cb54,Other,FDA-2015-P-1103-0004,FDA-2015-P-1103,"withdrawal letter from hyman, phelps, & mcnamara, p.c.",0,0
0900006481a8e792,Other,FDA-2015-P-1103-0002,FDA-2015-P-1103,"acknowledgement letter from fda ddm to hyman, phelps & mcnamara, p.c.",0,0
0900006481c9f525,Other,FDA-2015-P-1103-0003,FDA-2015-P-1103,"interim response letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
090000648252e93c,Other,FDA-2016-P-2377-0010,FDA-2016-P-2377,interim response letter from cfsan to archer daniels midland company,0,0
090000648214f74d,Supporting & Related Material,FDA-2016-P-2377-0003,FDA-2016-P-2377,appendix a scientific evidence re citizen petition from archer daniels midland company,0,0
090000648214f751,Supporting & Related Material,FDA-2016-P-2377-0007,FDA-2016-P-2377,appendix d re citizen petition from archer daniels midland company,0,0
090000648214f753,Supporting & Related Material,FDA-2016-P-2377-0009,FDA-2016-P-2377,appendix f re citizen petition from archer daniels midland company,0,0
090000648214f497,Other,FDA-2016-P-2377-0001,FDA-2016-P-2377,citizen petition from archer daniels midland company,0,0
090000648214f74f,Supporting & Related Material,FDA-2016-P-2377-0005,FDA-2016-P-2377,appendix b re citizen petition from archer daniels midland company,0,0
090000648214f499,Other,FDA-2016-P-2377-0002,FDA-2016-P-2377,acknowledgement letter from fda ddm to archer daniels midland company,0,0
090000648214f750,Supporting & Related Material,FDA-2016-P-2377-0006,FDA-2016-P-2377,appendix c re citizen petition from archer daniels midland company,0,0
090000648214f752,Supporting & Related Material,FDA-2016-P-2377-0008,FDA-2016-P-2377,appendix e re citizen petition from archer daniels midland company,0,0
090000648214f74e,Supporting & Related Material,FDA-2016-P-2377-0004,FDA-2016-P-2377,appendix a re citizen petition from archer daniels midland company,0,0
090000648341077b,Other,FDA-2016-P-2377-0011,FDA-2016-P-2377,fda-2016-p-2377 - archer daniels midland - granting response,0,0
09000064807b0083,Notice,FDA-2008-N-0571-0001,FDA-2008-N-0571,"agency information collection activities; proposed collection; comment request; guidance for industry and food and drug administration staff; compliance with the medical device user fee and modernization act of 2002, as amended: prominent and conspicous mark of manufacturers on single-use devices (formerly ""reprocessed single-use device labeling"")",1,0
09000064808525d0,Notice,FDA-2008-N-0571-0004,FDA-2008-N-0571,"agency information collection activities; proposals, submissions, and approvals",0,0
09000064846d4cb9,Supporting & Related Material,FDA-2020-P-1510-0015,FDA-2020-P-1510,appendix #1 “operation plan for adding drugs to hpus” re: citizen's petition from americans for homeopathy choice foundation,0,0
09000064846d4cdb,Supporting & Related Material,FDA-2020-P-1510-0005,FDA-2020-P-1510,"appendix #11 69 fed. reg. 227, 68834 (nov. 26, 2004) re: citizen's petition from americans for homeopathy choice foundation",0,0
09000064846d4cdd,Supporting & Related Material,FDA-2020-P-1510-0003,FDA-2020-P-1510,"appendix #13 “the safety of homeopathy,”americans for homeopathy choice, and ronald w. dushkin, md and ronald d. whitmont, md re: citizen's petition from americans for homeopathy choice foundation",0,0
09000064846d4cbc,Supporting & Related Material,FDA-2020-P-1510-0012,FDA-2020-P-1510,"appendix #4  “supplements to the homeopathic pharmacopeia
of the united states” re: citizen's petition from americans for homeopathy choice foundation",0,0
09000064846d4cbb,Supporting & Related Material,FDA-2020-P-1510-0013,FDA-2020-P-1510,appendix #3 a proposal by americans for homeopathy choice for the application of a risk-based policy to homeopathic drugs & drug products labeled as homeopathic re: citizen's petition from americans for homeopathy choice foundation,0,0
09000064846d4cd8,Supporting & Related Material,FDA-2020-P-1510-0008,FDA-2020-P-1510,"appendix #8 “homeopathic monographs added to the homeopathic
pharmacopoeia since 2000” re: citizen's petition from americans for homeopathy choice foundation",0,0
09000064846d4c02,Other,FDA-2020-P-1510-0001,FDA-2020-P-1510,acknowledgment letter from fda dms to americans for homeopathy choice foundation,0,0
09000064849e86af,Other,FDA-2020-P-1510-22552,FDA-2020-P-1510,interim response from fda cder to americans for homeopathy choice foundation,0,0
09000064846d4cd7,Supporting & Related Material,FDA-2020-P-1510-0009,FDA-2020-P-1510,"appendix #7 48 fed. reg. 64, 14004 (april 1, 1983) re: citizen's petition from americans for homeopathy choice foundation",0,0
09000064846d4cd9,Supporting & Related Material,FDA-2020-P-1510-0007,FDA-2020-P-1510,"appendix #9 “over-the-counter drug review,” 21 cfr part 330.1 re: citizen's petition from americans for homeopathy choice foundation",0,0
09000064846d4cda,Supporting & Related Material,FDA-2020-P-1510-0006,FDA-2020-P-1510,"appendix #10 “over-the-counter drug review,” 21 cfr part 330.1 re: citizen's petition from americans for homeopathy choice foundation",0,0
09000064846d4cbd,Supporting & Related Material,FDA-2020-P-1510-0011,FDA-2020-P-1510,appendix #5 limitations of faers data re: citizen's petition from americans for homeopathy choice foundation,0,0
09000064846d4cdc,Supporting & Related Material,FDA-2020-P-1510-0004,FDA-2020-P-1510,"appendix #12 “fda’s statements of general policy or interpretation”
found in 37 fed. reg. 156, 16174 (aug 11, 1972) re: citizen's petition from americans for homeopathy choice foundation",0,0
09000064846d4cba,Supporting & Related Material,FDA-2020-P-1510-0014,FDA-2020-P-1510,appendix #2 80 fed. reg. 16327 “homeopathic product regulation: evaluating the food and drug administration’s regulatory framework after a quarter-century: public hearing” re: citizen's petition from americans for homeopathy choice foundation,1,0
09000064846d4cbe,Supporting & Related Material,FDA-2020-P-1510-0010,FDA-2020-P-1510,"appendix #6 “epidemic infectious diseases, public health and homeopathy,” by andre saine, nd re: citizen's petition from americans for homeopathy choice foundation",0,0
09000064846d1276,Other,FDA-2020-P-1510-0002,FDA-2020-P-1510,citizen's petition from americans for homeopathy choice foundation,0,0
0900006482c0b6ba,Supporting & Related Material,FDA-2017-P-6274-0005,FDA-2017-P-6274,attachment 3-usp official monograph (teriparatide) re citizen petition from amneal pharmaceuticals,0,0
0900006482c0b4f9,Supporting & Related Material,FDA-2017-P-6274-0003,FDA-2017-P-6274,attachment 1-reference listed drug prescribing information for forteo re citizen petition from amneal pharmaceuticals,0,0
0900006482c0b6bb,Supporting & Related Material,FDA-2017-P-6274-0006,FDA-2017-P-6274,attachment 4-fda draft guidance for industry andas for certain highly purified synthetic peptide drug re citizen petition from amneal pharmaceuticals,0,0
0900006482c0b6b9,Supporting & Related Material,FDA-2017-P-6274-0004,FDA-2017-P-6274,attachment 2-chemistry review on potential impurities in synthetic teriparatide re citizen petition from amneal pharmaceuticals,0,0
0900006482c0b478,Other,FDA-2017-P-6274-0001,FDA-2017-P-6274,citizen petition from amneal pharmaceuticals,0,0
0900006482c0b4f7,Other,FDA-2017-P-6274-0002,FDA-2017-P-6274,acknowledgement letter from fda ddm to amneal pharmaceuticals,0,0
0900006482d9e58e,Other,FDA-2017-P-6274-0007,FDA-2017-P-6274,response letter from fda cder to amneal pharmaceuticals,0,0
0900006482486094,Other,FDA-2016-P-2469-0006,FDA-2016-P-2469,"determination letter from cder to hyman, phelps & mcnamara, p.c.",0,0
090000648216266d,Supporting & Related Material,FDA-2016-P-2469-0003,FDA-2016-P-2469,"attachment 1 applicant name changes re citizen petition from hyman, phelps & mcnamara, p. c.",0,0
09000064821620a2,Other,FDA-2016-P-2469-0001,FDA-2016-P-2469,"citizen petition from hyman, phelps & mcnamara, p. c.",0,0
090000648248055b,Notice,FDA-2016-P-2469-0005,FDA-2016-P-2469,"determination that symmetrel (amantadine hydrochloride), syrup, 50
milligrams/5 milliliters, was not withdrawn from sale for reasons of
safety or effectiveness",0,0
0900006482369b24,Other,FDA-2016-P-2469-0004,FDA-2016-P-2469,"correction from hyman, phelps & mcnamara, p.c.",0,0
09000064821620a4,Other,FDA-2016-P-2469-0002,FDA-2016-P-2469,"acknowledgement letter from fda ddm to hyman, phelps & mcnamara, p.  c.",0,0
0900006481b67e4a,Other,FDA-2015-P-2344-0001,FDA-2015-P-2344,citizen petition from lachman consultant services inc,0,0
0900006481b67f51,Supporting & Related Material,FDA-2015-P-2344-0005,FDA-2015-P-2344,attachment 2 rld labeling for oxycodone and acetaminophen tablets re citizen petition from lachman consultant services inc,0,0
0900006481b67ed2,Other,FDA-2015-P-2344-0004,FDA-2015-P-2344,acknowledgement letter from fda ddm to lachman consultant services inc,0,0
0900006481b67f50,Supporting & Related Material,FDA-2015-P-2344-0002,FDA-2015-P-2344,attachment 1 electronic orange book listing re citizen petition from lachman consultant services inc,0,0
0900006481b67f52,Supporting & Related Material,FDA-2015-P-2344-0003,FDA-2015-P-2344,attachment 3 proposed labeling for oxycodone and acetaminophen tablets re citizen petition from lachman consultant services inc,0,0
0900006483780eaa,Other,FDA-2018-P-3691-0002,FDA-2018-P-3691,"acknowledgment letter from fda ddm to avanthi, llc.",0,0
0900006483780af6,Other,FDA-2018-P-3691-0001,FDA-2018-P-3691,"citizen petition from avanthi, llc.",0,0
0900006483b572c6,Notice,FDA-2018-P-3691-0004,FDA-2018-P-3691,"trimeton allergy 12 hour (chlorpheniramine maleate) extended
release tablets, 8 milligrams and 12 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483b59139,Other,FDA-2018-P-3691-0005,FDA-2018-P-3691,"letter from fda cder to kvk-tech, inc.",0,0
0900006483781108,Supporting & Related Material,FDA-2018-P-3691-0003,FDA-2018-P-3691,"attachment 1-orange book: approved drug products with therapeutic equivalence evaluations re: citizen petition from avanthi, llc.",0,0
09000064824e67df,Other,FDA-2017-P-1297-0002,FDA-2017-P-1297,acknowledgement letter from fda ddm to regcon solutions,0,0
09000064824e67dd,Other,FDA-2017-P-1297-0001,FDA-2017-P-1297,citizen petition from regcon solutions,0,0
09000064824e6824,Supporting & Related Material,FDA-2017-P-1297-0005,FDA-2017-P-1297,exhibit iii sincalide for injection proposed package insert re citizen petition from regcon solutions,0,0
0900006482b4ff19,Other,FDA-2017-P-1297-0006,FDA-2017-P-1297,interim response letter from fda cder to regcon solutions,0,0
09000064824e6823,Supporting & Related Material,FDA-2017-P-1297-0004,FDA-2017-P-1297,exhibit ii kinevac for injection current package insert re citizen petiton from regcon solutions,0,0
09000064824e6822,Supporting & Related Material,FDA-2017-P-1297-0003,FDA-2017-P-1297,exhibit i kinevac for injection old formula package insert re citizen petition from regcon solutions,0,0
0900006482cbde3a,Other,FDA-2017-P-1297-0007,FDA-2017-P-1297,response in opposition to citizen petition fda-2017-p-1297,0,0
0900006484954922,Other,FDA-2020-P-1427-0003,FDA-2020-P-1427,"withdrawal from aurobindo pharma usa, inc",0,0
09000064846b3a4f,Other,FDA-2020-P-1427-0001,FDA-2020-P-1427,"citizen petition from aurobindo pharma usa, inc.",0,0
09000064846b3f17,Other,FDA-2020-P-1427-0002,FDA-2020-P-1427,"acknowledgment letter from fda dms to aurobindo pharma usa, inc",0,0
0900006484ca7033,Other,FDA-2021-P-0940-0002,FDA-2021-P-0940,"acknowledgment letter from fda dms to hyman, phelps, & mcnamara, p.c.",0,0
0900006484ca7031,Other,FDA-2021-P-0940-0001,FDA-2021-P-0940,"citizen petition from hyman, phelps, & mcnamara, p.c.",0,0
0900006480447f9b,Other,FDA-2005-P-0321-0003,FDA-2005-P-0321,national institute of oilseed products - citizen petition,0,0
0900006480930b9d,Other,FDA-2005-P-0321-0004,FDA-2005-P-0321,fda to national institute of oilseed products - petition denial,0,0
0900006480447f51,Other,FDA-2005-P-0321-0001,FDA-2005-P-0321,hfa-305 to national institute of oilseed products,0,0
0900006480447f9e,Other,FDA-2005-P-0321-0002,FDA-2005-P-0321,hfa-305 to national institute of oilseed products,0,0
0900006484bdaef6,Other,FDA-2021-P-0680-0001,FDA-2021-P-0680,citizen petition from joe dinardo and craig a downs,0,0
0900006484da7a9c,Other,FDA-2021-P-0680-0020,FDA-2021-P-0680,response letter from fda cder to joe dinardo and craig a downs,0,0
0900006484bd8f44,Supporting & Related Material,FDA-2021-P-0680-0004,FDA-2021-P-0680,reference 2 ntp benzophenone carcinogenicity report re citizen petition from joe dinardo and craig a downs,0,0
0900006484bd8f4a,Supporting & Related Material,FDA-2021-P-0680-0010,FDA-2021-P-0680,reference 8 national drug code directory fda re citizen petition from joe dinardo and craig a downs,0,0
0900006484bdb58f,Supporting & Related Material,FDA-2021-P-0680-0017,FDA-2021-P-0680,reference 15 molins delgado a potential new threat to wild life presence of uv filters in bird eggs from a preserved area re citizen petition from joe dinardo and craig a downs,0,0
0900006484bdb58c,Supporting & Related Material,FDA-2021-P-0680-0014,FDA-2021-P-0680,reference 12 cunha co-occurrence of musk fragrances and uv-filters in seafood and macroalgae collected in european hots re citizen petition from joe dinardo and craig a downs,0,0
0900006484bd8f43,Supporting & Related Material,FDA-2021-P-0680-0003,FDA-2021-P-0680,reference 1 downs octocrylene to bp march 2021 chemical research in toxicology re citizen petition from joe dinardo and craig a downs,0,0
0900006484bdb24f,Supporting & Related Material,FDA-2021-P-0680-0018,FDA-2021-P-0680,reference 16 alonso toxic heritage maternal transfer of pyrethroid insecticides and sunscreen agents in dolphins from b re citizen petition from joe dinardo and craig a downs,0,0
0900006484bdb58e,Supporting & Related Material,FDA-2021-P-0680-0016,FDA-2021-P-0680,reference 14 zhang assessment of multiple hormone activities of a uv-filter octocrylene in zebrafish danio rerio re citizen petition from joe dinardo and craig a downs,0,0
0900006484bdb58a,Supporting & Related Material,FDA-2021-P-0680-0012,FDA-2021-P-0680,reference 10 zhong comparison of toxicological effects of oxybenzone avobenzone octocrylene and octinoxate sunscreen re citizen petition from joe dinardo and craig a downs,0,0
0900006484bd8f45,Supporting & Related Material,FDA-2021-P-0680-0005,FDA-2021-P-0680,reference 3 bp federal register food additive regulations synthetic flavoring agents and adjuvants re citizen petition from joe dinardo and craig a downs,1,0
0900006484bd8f46,Supporting & Related Material,FDA-2021-P-0680-0006,FDA-2021-P-0680,reference 4 matta effect of sunscreen application on plasma concentration of sunscreen active ingredients a randomized clinical trial re citizen petition from joe dinardo and craig a downs,0,0
0900006484bd8f49,Supporting & Related Material,FDA-2021-P-0680-0009,FDA-2021-P-0680,reference 7 bronaugh in vivo percutaneous absorption of fragrance ingredients in rhesus monkeys and humans re citizen petition from joe dinardo and craig a downs,0,0
0900006484bdaefa,Other,FDA-2021-P-0680-0002,FDA-2021-P-0680,acknowledgement letter from fda dms to joe dinardo and craig a downs,0,0
0900006484bdb589,Supporting & Related Material,FDA-2021-P-0680-0011,FDA-2021-P-0680,reference 9 dinardo comments fda-1978-n-0018-1508_attachment_1 re citizen petition from joe dinardo and craig a downs,0,0
0900006484bdb58b,Supporting & Related Material,FDA-2021-P-0680-0013,FDA-2021-P-0680,reference 11 yan reproductive toxicity and estrogen activity in japanese medaka oryzias latipes exposed to environm re citizen petition from joe dinardo and craig a downs,0,0
0900006484bdb58d,Supporting & Related Material,FDA-2021-P-0680-0015,FDA-2021-P-0680,reference 13 picot-groz diurnal variations in personal care products in seawater and mussels at three mediterranean coastal re citizen petition from joe dinardo and craig a downs,0,0
0900006484bd8f48,Supporting & Related Material,FDA-2021-P-0680-0008,FDA-2021-P-0680,reference 6 dinardo fall from grase re citizen petition from joe dinardo and craig a downs,0,0
0900006484bd8f47,Supporting & Related Material,FDA-2021-P-0680-0007,FDA-2021-P-0680,reference 5 foubert the presence of benzophenone in sunscreens and cosmetics containing the organic uv filter octocrylen re citizen petition from joe dinardo and craig a downs,0,0
0900006484bdb3b7,Supporting & Related Material,FDA-2021-P-0680-0019,FDA-2021-P-0680,reference 17 he toxicological effects of two organic ultraviolet filters and a related commercial sunscreen product re citizen petition from joe dinardo and craig a downs,0,0
090000648263a992,Supporting & Related Material,FDA-2017-P-3352-0003,FDA-2017-P-3352,"exhibit a bpi labs epinephrine package insert free of sulfites re citizen petition from belcher pharmaceuticals, llc",0,0
090000648263a994,Supporting & Related Material,FDA-2017-P-3352-0005,FDA-2017-P-3352,"exhibit c epipen package insert re citizen petition from belcher pharmaceuticals, llc",0,0
090000648263a993,Supporting & Related Material,FDA-2017-P-3352-0004,FDA-2017-P-3352,"exhibit b adrenalin package insert re citizen petition from belcher pharmaceuticals, llc",0,0
090000648263a65b,Other,FDA-2017-P-3352-0002,FDA-2017-P-3352,"acknowledgement letter from fda ddm to belcher pharmaceuticals, llc",0,0
090000648263a658,Other,FDA-2017-P-3352-0001,FDA-2017-P-3352,"citizen petition from belcher pharmaceuticals, llc",0,0
0900006481d8e0c2,Supporting & Related Material,FDA-2015-P-4664-0005,FDA-2015-P-4664,exhibit 3 cdc salmonella risk graph re: citizen petition from richard fife,0,0
0900006481d8e0c5,Supporting & Related Material,FDA-2015-P-4664-0007,FDA-2015-P-4664,exhibit 5 fda consumer health information pet turtles cute but contaminated with salmonella re: citizen petition from richard fife,0,0
0900006481d8db14,Other,FDA-2015-P-4664-0001,FDA-2015-P-4664,citizen petition from richard fife,0,0
0900006481d8dbf6,Other,FDA-2015-P-4664-0002,FDA-2015-P-4664,acknowledgement letter from fda ddm to richard fife,0,0
0900006483ad280f,Other,FDA-2015-P-4664-0039,FDA-2015-P-4664,letter from fda cvm to richard fife,0,0
0900006483ad2c45,Other,FDA-2015-P-4664-0040,FDA-2015-P-4664,"letter from fda cvm to independent turtle farmers of louisiana, inc.",0,0
0900006481d8e0c4,Supporting & Related Material,FDA-2015-P-4664-0006,FDA-2015-P-4664,"exhibit 4 survey demographics for ""how much would you pay for a turtle for a child under 5-years old october 17, 2015"" (surveymonkey©) re: citizen petition from richard fife",0,0
0900006481fdf4c9,Other,FDA-2015-P-4664-0031,FDA-2015-P-4664,interim response 05_19_2016,0,0
0900006483cddea3,Other,FDA-2015-P-4664-0041,FDA-2015-P-4664,citizen petition response_redacted,0,0
0900006481d8dbfb,Supporting & Related Material,FDA-2015-P-4664-0003,FDA-2015-P-4664,exhibit 1 code of federal regulation title 21 part 1240 control of communicable diseases re: citizen petition from richard fife,0,0
0900006481d8dbfc,Supporting & Related Material,FDA-2015-P-4664-0004,FDA-2015-P-4664,exhibit 2 turtles tortoises and terrapins bred in captivity by ttpg members (turtle and tortoise preservation group) re: citizen petition from richard fife,0,0
090000648046f534,Other,FDA-2004-P-0100-0001,FDA-2004-P-0100,hfa-305 to city of arlington texas,0,0
090000648046f53b,Other,FDA-2004-P-0100-0006,FDA-2004-P-0100,city of arlington texas,0,0
090000648046f53d,Other,FDA-2004-P-0100-0007,FDA-2004-P-0100,hfz-001 to city of arlington texas,0,0
090000648046f538,Other,FDA-2004-P-0100-0004,FDA-2004-P-0100,hfa-305 to city of arlington texas,0,0
090000648046f53a,Other,FDA-2004-P-0100-0005,FDA-2004-P-0100,city of arlington texas,0,0
090000648234581c,Other,FDA-2016-P-3510-0001,FDA-2016-P-3510,"citizen petition from aleon pharma international, inc. (zhuhai kinhoo pharmaceutical co., ltd)",0,0
0900006482345dc1,Supporting & Related Material,FDA-2016-P-3510-0003,FDA-2016-P-3510,"attachment 1 approved drug products with therapeutic equivalence evaluations re citizen petition from aleon pharma international, inc.",0,0
0900006482345dc3,Supporting & Related Material,FDA-2016-P-3510-0005,FDA-2016-P-3510,"attachment 3 fda approved labeling for the reference-listed drug cefadroxil tablet re citizen petition from aleon pharma international, inc.",0,0
0900006482345dc5,Supporting & Related Material,FDA-2016-P-3510-0007,FDA-2016-P-3510,"attachment 5 suitability petition approval letter for metformin hci chewable tablet, sp 2011p-0558 re citizen petition from aleon pharma international, inc.",0,0
0900006482345dc4,Supporting & Related Material,FDA-2016-P-3510-0006,FDA-2016-P-3510,"attachment 4 anda approval letter for cefixime chewable tablet, anda 065380 re citizen petition from aleon pharma international, inc.",0,0
0900006482345dc2,Supporting & Related Material,FDA-2016-P-3510-0004,FDA-2016-P-3510,"attachment 2 draft labeling proposed for cefadroxil chewable tablets re citizen petition from aleon pharma international, inc.",0,0
090000648234581e,Other,FDA-2016-P-3510-0002,FDA-2016-P-3510,"acknowledgement letter from fda ddm to aleon pharma international, inc.",0,0
090000648312e72b,Supporting & Related Material,FDA-2018-P-1484-0003,FDA-2018-P-1484,attachment 1- orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from macleods pharmaceuticals limited,0,0
090000648312ea95,Supporting & Related Material,FDA-2018-P-1484-0006,FDA-2018-P-1484,"attachment 4- detailed ims, moving annual total (mat) data re citizen petition from macleods pharmaceuticals limited",0,0
090000648312e1f2,Other,FDA-2018-P-1484-0002,FDA-2018-P-1484,acknowledgment letter from fda ddm macleods pharmaceuticals limited,0,0
09000064837a008c,Other,FDA-2018-P-1484-0007,FDA-2018-P-1484,interim response from fda cder  to macleods pharmaceuticals limited,0,0
090000648312e4ea,Supporting & Related Material,FDA-2018-P-1484-0004,FDA-2018-P-1484,attachment 2- national drug code directory re citizen petition from macleods pharmaceuticals limited,0,0
090000648312e8e7,Supporting & Related Material,FDA-2018-P-1484-0005,FDA-2018-P-1484,attachment 3- drugs@fda: fda approved drug products re citizen petition from macleods pharmaceuticals limited,0,0
0900006483e6057d,Other,FDA-2018-P-1484-0008,FDA-2018-P-1484,response letter  from cder to macleods pharmaceuticals limited,0,0
090000648312dac7,Other,FDA-2018-P-1484-0001,FDA-2018-P-1484,citizen petition from macleods pharmaceuticals limited,0,0
0900006483f20725,Other,FDA-2018-P-1484-0009,FDA-2018-P-1484,updated response letter from cder to macleods pharmaceuticals limited,0,0
090000648301dde7,Other,FDA-2018-P-1173-0002,FDA-2018-P-1173,acknowledgment letter from fda ddm to alliance for natural health usa,0,0
090000648301d303,Other,FDA-2018-P-1173-0001,FDA-2018-P-1173,citizen petition from the alliance for natural health usa,0,0
09000064836dc86f,Other,FDA-2018-P-1173-0034,FDA-2018-P-1173,interim response letter from fda cder to alliance for natural health usa,0,0
0900006483cc4d3d,Supporting & Related Material,FDA-2019-P-2537-0003,FDA-2019-P-2537,attachment 1 hancock and parks (2000) what is the true solubility advantage for amorphous pharmaceuticals? re: citizen petition from allergan holdings unlimited company,0,0
0900006483cc3a54,Other,FDA-2019-P-2537-0001,FDA-2019-P-2537,citizen petition from allergan holdings unlimited company,0,0
0900006483cc4d37,Other,FDA-2019-P-2537-0002,FDA-2019-P-2537,acknowledgment letter from fda ddm to allergan holding company,0,0
0900006483cc4d3e,Supporting & Related Material,FDA-2019-P-2537-0004,FDA-2019-P-2537,attachment 2 murdande et al (2010) solubility advantage of amorphous pharmaceuticals: ii. application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals re: citizen petition from allergan holdings unlimited company,0,0
09000064841780fb,Other,FDA-2019-P-2537-0005,FDA-2019-P-2537,interim response from fda to allergan holdings unlimited company,0,0
0900006482d7f298,Other,FDA-2017-P-4039-0003,FDA-2017-P-4039,interim response letter from fda cder to center for lawful access and abuse deterrence,0,0
09000064827deb78,Other,FDA-2017-P-4039-0001,FDA-2017-P-4039,citizen petition from center for lawful access and abuse deterrance,0,0
09000064827dee8e,Other,FDA-2017-P-4039-0002,FDA-2017-P-4039,acknowledgment letter from fda ddm to center for lawful access and abuse deterrence,0,0
0900006484803520,Other,FDA-2020-P-1766-0001,FDA-2020-P-1766,suitability petition from the weinberg group llc,0,0
0900006484809eb3,Supporting & Related Material,FDA-2020-P-1766-0003,FDA-2020-P-1766,"attachment 1 approved drug products with therapeutic equivalence evaluations, electronic orange book accessed on august 13, 2020  re: suitability petition from the weinberg group llc",0,0
0900006484803522,Other,FDA-2020-P-1766-0002,FDA-2020-P-1766,acknowledgment letter from fda dms to the weinberg group llc,0,0
0900006484809eb7,Supporting & Related Material,FDA-2020-P-1766-0005,FDA-2020-P-1766,"attachment 3 proposed prescribing information for vasopressin injection usp, 50 units/2.5 ml (2.5 ml/vial in a single dose vial) and 100 units/5 ml (5 ml/vial in a single dose vial)  re: suitability petition from the weinberg group llc",0,0
09000064848f5319,Other,FDA-2020-P-1766-0006,FDA-2020-P-1766,withdrawal from the weinberg group,0,0
0900006484809eb6,Supporting & Related Material,FDA-2020-P-1766-0004,FDA-2020-P-1766,"attachment 2 labeling for the rld, vasostrict® (vasopressin injection usp), 20 units/ml (single-dose vial), nda # 204485, approved on april 15, 2020  re: suitability petition from the weinberg group llc",0,0
09000064820723de,Supporting & Related Material,FDA-2016-P-1825-0003,FDA-2016-P-1825,"attachment 1 - fda approved drug products  drug details re citizen petition from lachman consultant services, inc.",0,0
090000648240d84d,Other,FDA-2016-P-1825-0005,FDA-2016-P-1825,"interim response letter from fda cder to lachman consultant services, inc.",0,0
0900006482cfe709,Other,FDA-2016-P-1825-0006,FDA-2016-P-1825,"final response letter from fda to lachman consultant services, inc",0,0
09000064820720fd,Other,FDA-2016-P-1825-0001,FDA-2016-P-1825,"citizen petition from lachman consultant services, inc.",0,0
09000064820723df,Supporting & Related Material,FDA-2016-P-1825-0004,FDA-2016-P-1825,"attachment 2 drugs@fda label and approval history re citizen petition from lachman consultant services, inc.",0,0
09000064820723d6,Other,FDA-2016-P-1825-0002,FDA-2016-P-1825,"acknowledgement letter from fda ddm to lachman consultant services, inc.",0,0
0900006484ba0408,Other,FDA-2021-P-0576-0002,FDA-2021-P-0576,acknowledgment letter to husch blackwell from fda dms,0,0
0900006484c164a4,Other,FDA-2021-P-0576-0003,FDA-2021-P-0576,withdrawal from husch blackwell llp,0,0
0900006484ba018b,Other,FDA-2021-P-0576-0001,FDA-2021-P-0576,citizen petition from husch blackwell llp on behalf of brenntag great lakes llc,0,0
0900006484df3e6d,Other,FDA-2021-P-1154-0001,FDA-2021-P-1154,citizen petition from lachman consultant services inc.,0,0
0900006484df3e6f,Other,FDA-2021-P-1154-0002,FDA-2021-P-1154,acknowledgment letter from fda dms to lachman consultant services inc,0,0
09000064824defa1,Other,FDA-2017-P-1225-0002,FDA-2017-P-1225,acknowledgement letter from fda ddm to aurora pharmaceutical llc 2,0,0
09000064824defa3,Supporting & Related Material,FDA-2017-P-1225-0003,FDA-2017-P-1225,"attachment 1 gastrogard® oral paste, labeling by merial, rev 05-2014 re suitability petition from aurora pharmaceutical llc 2",0,0
09000064824def9f,Other,FDA-2017-P-1225-0001,FDA-2017-P-1225,suitability petition from aurora pharmaceutical llc 2,0,0
09000064825eab0f,Other,FDA-2017-P-1225-0004,FDA-2017-P-1225,letter from fda to aurora pharmaceuticals llc,0,0
0900006483263f59,Supporting & Related Material,FDA-2018-P-1869-0006,FDA-2018-P-1869,"detailed ims, moving annual total (mat) data indicating approved generic product dicyclomine hydrochloride capsules usp, 10 mg (anda # 085082), of watson laboratories inc., as the leading player in the u.s market. re: citizen petition from aurobindo pharma usa inc",0,0
0900006483263e22,Supporting & Related Material,FDA-2018-P-1869-0005,FDA-2018-P-1869,drugs @ fda search results re: citizen petition from aurobindo pharma usa inc.,0,0
090000648388348d,Other,FDA-2018-P-1869-0008,FDA-2018-P-1869,interim response letter from fda cder to aurobindo pharma usa inc.,0,0
090000648326378f,Other,FDA-2018-P-1869-0002,FDA-2018-P-1869,acknowledgment letter from fda ddm to aurobindo pharma usa inc.,0,0
0900006483263e1b,Supporting & Related Material,FDA-2018-P-1869-0003,FDA-2018-P-1869,orange book: approved drug products with therapeutic equivalence evaluations re: citizen petition from aurobindo pharma usa inc.,0,0
0900006483263fde,Supporting & Related Material,FDA-2018-P-1869-0007,FDA-2018-P-1869,non availability of samples statement from pharmacy re: citizen petition from aurobindo pharma usa inc.,0,0
090000648423ca33,Other,FDA-2018-P-1869-0009,FDA-2018-P-1869,petition response letter from fda cder to aurobindo pharma usa inc,0,0
0900006483263e20,Supporting & Related Material,FDA-2018-P-1869-0004,FDA-2018-P-1869,national drug code directory search results re: citizen petition from aurobindo pharma usa inc.,0,0
090000648326326c,Other,FDA-2018-P-1869-0001,FDA-2018-P-1869,citizen petition from aurobindo pharma usa inc,0,0
09000064841160e8,Other,FDA-2019-P-5121-0002,FDA-2019-P-5121,"acknowledgment letter from fda dms to arent fox llp on behalf of aquestive therapeutics, inc",0,0
09000064841e35f0,Other,FDA-2019-P-5121-0009,FDA-2019-P-5121,"supplement from aquestive therapeutics, inc. (arent fox)",0,0
09000064841160f0,Supporting & Related Material,FDA-2019-P-5121-0003,FDA-2019-P-5121,"exhibit 1- a pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers re: citizen petition and petition for stay of action from arent fox llp on behalf of aquestive therapeutics, inc.",0,0
090000648411628a,Supporting & Related Material,FDA-2019-P-5121-0007,FDA-2019-P-5121,"exhibit 5- nasal drug delivery: new developments and strategies re: citizen petition and petition for stay of action from arent fox llp on behalf of aquestive therapeutics, inc.",0,0
0900006484291b6a,Other,FDA-2019-P-5121-0011,FDA-2019-P-5121,petition response letter from fda cder to arent fox llp,0,0
0900006484116288,Supporting & Related Material,FDA-2019-P-5121-0005,FDA-2019-P-5121,"exhibit 3- pharmacokinetic study of valtoco™ (nrl-1; diazepam nasal spray) in patients with epilepsy under ictal and inter-ictal conditions – interim report re: citizen petition and petition for stay of action from arent fox llp on behalf of aquestive therapeutics, inc.",0,0
0900006484116241,Other,FDA-2019-P-5121-0001,FDA-2019-P-5121,"citizen petition and petition for stay of action from arent fox llp on behalf of aquestive therapeutics, inc.",0,0
0900006484116287,Supporting & Related Material,FDA-2019-P-5121-0004,FDA-2019-P-5121,"exhibit 2- bioavailability and safety of valtoco™ (diazepam intranasal solution) compared to oral and rectal diazepam re: citizen petition and petition for stay of action from arent fox llp on behalf of aquestive therapeutics, inc.",0,0
0900006484116289,Supporting & Related Material,FDA-2019-P-5121-0006,FDA-2019-P-5121,"exhibit 4- buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability re: citizen petition and petition for stay of action from arent fox llp on behalf of aquestive therapeutics, inc.",0,0
0900006484e58069,Supporting & Related Material,FDA-2021-P-1227-0003,FDA-2021-P-1227,petition footnote 24 referenece by klein et al re citizen petition from public citizen’s health research group,0,0
0900006484e57f56,Other,FDA-2021-P-1227-0001,FDA-2021-P-1227,citizen petition from public citizen’s health research group,0,0
0900006484e59a07,Other,FDA-2021-P-1227-0002,FDA-2021-P-1227,acknowledgment letter from fda dms to public citizen’s health research group,0,0
090000648243b754,Supporting & Related Material,FDA-2016-P-4584-0006,FDA-2016-P-4584,carilion-prandin label aug 2016 re citizen petition from public citizens health research group,0,0
090000648243b755,Supporting & Related Material,FDA-2016-P-4584-0007,FDA-2016-P-4584,clopidogrel - 2016-09 re citizen petition from public citizens health research group,0,0
090000648243b756,Supporting & Related Material,FDA-2016-P-4584-0008,FDA-2016-P-4584,health canada warning repaglinide jul 2015 re citizen petition from public citizens health research group,0,0
09000064829cacf7,Other,FDA-2016-P-4584-0012,FDA-2016-P-4584,response letter from fda cder to public citizen's health research group,0,0
090000648243b3c5,Supporting & Related Material,FDA-2016-P-4584-0004,FDA-2016-P-4584,canadian drug label - clopidogrel 2016-06 re citizen petition from public citizens health research group,0,0
090000648243b759,Supporting & Related Material,FDA-2016-P-4584-0011,FDA-2016-P-4584,"glucuronidation converts clopidogrel to a strong time-dependent inhibitor of cyp2c8: a phase ii metabolite as a perpetrator of drug–drug
interactions re citizen petition from public citizens health research group",0,0
090000648243b3c0,Other,FDA-2016-P-4584-0001,FDA-2016-P-4584,citizen petition from public citizens health research group,0,0
090000648243b757,Supporting & Related Material,FDA-2016-P-4584-0009,FDA-2016-P-4584,clarification of the mechanism of clopidogrel-mediated drug-drug interaction in a clinical cassette small-dose study and its prediction re citizen petition from public citizens health research group,0,0
090000648243b3c2,Other,FDA-2016-P-4584-0002,FDA-2016-P-4584,acknowledgement letter from fda ddm to public citizens health research group,0,0
090000648243b758,Supporting & Related Material,FDA-2016-P-4584-0010,FDA-2016-P-4584,repaglinide - 2016-08 re citizen petition from public citizens health research group,0,0
090000648243b3c4,Supporting & Related Material,FDA-2016-P-4584-0003,FDA-2016-P-4584,bms-plavix label sept 2016 re citizen petition from public citizens health research group,0,0
090000648243b753,Supporting & Related Material,FDA-2016-P-4584-0005,FDA-2016-P-4584,canadian drug label - repaglinide 2016-04 re citizen petition from public citizens health research group,0,0
0900006482560340,Other,FDA-2017-P-2460-0002,FDA-2017-P-2460,acknowledgement letter from fda ddm to auromedics pharma llc (aurobindo pharma limited),0,0
09000064829ffcbc,Other,FDA-2017-P-2460-0003,FDA-2017-P-2460,withdrawal from auromedics pharma llc,0,0
090000648256033e,Other,FDA-2017-P-2460-0001,FDA-2017-P-2460,citizen petition from auromedics pharma llc (aurobindo pharma limited),0,0
090000648186e47f,Other,FDA-2014-P-1354-0003,FDA-2014-P-1354,"correction re acknowledgement letter from fda/ddm to otsuka pharmaceutical company ltd., (otsuka pharmaceutical development & commercialization, inc.)",0,0
09000064819f20d1,Other,FDA-2014-P-1354-0004,FDA-2014-P-1354,petition denial,0,0
0900006481869eda,Other,FDA-2014-P-1354-0001,FDA-2014-P-1354,"citizen petition from otsuka pharmaceutical company ltd., (otsuka pharmaceutical development & commercialization, inc.)",0,0
0900006481869edc,Other,FDA-2014-P-1354-0002,FDA-2014-P-1354,"acknowledgement letter from fda/ddm to otsuka pharmaceutical company ltd., (otsuka pharmaceutical development & commercialization, inc.)",0,0
09000064818e6f1a,Supporting & Related Material,FDA-2014-P-1656-0003,FDA-2014-P-1656,addendum part 1,0,0
09000064818e6f1b,Supporting & Related Material,FDA-2014-P-1656-0004,FDA-2014-P-1656,addendum part 2,0,0
09000064818e6f1c,Supporting & Related Material,FDA-2014-P-1656-0005,FDA-2014-P-1656,addendum part 3,0,0
09000064818e6f1d,Supporting & Related Material,FDA-2014-P-1656-0006,FDA-2014-P-1656,addendum part 4,0,0
09000064818e6f20,Other,FDA-2014-P-1656-0002,FDA-2014-P-1656,acknowledgement letter from fda ddm to alaska seafood marketing institute and the golden king crab coalition,0,0
0900006482c8383f,Other,FDA-2014-P-1656-0007,FDA-2014-P-1656,final response letter from fda to  alaska seafood marketing institute (golden king crab),0,0
09000064818b70d9,Other,FDA-2014-P-1656-0001,FDA-2014-P-1656,citizen petition from alaska seafood marketing institute and the golden king crab coalition,0,0
0900006482a400af,Other,FDA-2017-P-1096-0003,FDA-2017-P-1096,"interim response letter from cder to hyman, phelps & mcnamara, p.c.",0,0
09000064824d149a,Other,FDA-2017-P-1096-0001,FDA-2017-P-1096,"citizen petition from hyman, phelps & mcnamara, p.c.",0,0
09000064824d1c5a,Other,FDA-2017-P-1096-0002,FDA-2017-P-1096,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara, p.c.",0,0
09000064839fbde0,Other,FDA-2017-P-1096-0004,FDA-2017-P-1096,"response letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
0900006482d43ea2,Other,FDA-2017-P-6851-0002,FDA-2017-P-6851,acknowledgment letter from ddm to shire development llc,0,0
0900006482d44124,Supporting & Related Material,FDA-2017-P-6851-0006,FDA-2017-P-6851,exhibit d- combination pharmacotherapy for adult adhd re citizen petition from shire development llc,0,0
0900006482d44123,Supporting & Related Material,FDA-2017-P-6851-0005,FDA-2017-P-6851,exhibit c- a review of pharmacological management of attention- deficit/ hyperactivity disorder re citizen petition from shire development llc,0,0
0900006482d44122,Supporting & Related Material,FDA-2017-P-6851-0004,FDA-2017-P-6851,exhibit b- atomoxetine versus methylpjemidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized double-blind comparison trail re citizen petition from shire development llc,0,0
0900006482d44126,Supporting & Related Material,FDA-2017-P-6851-0008,FDA-2017-P-6851,exhibit f- attention-deficit/  hyperactivity disorder: medication treatment-dosing and duration of action re citizen petition from shire development llc,0,0
0900006482d43e73,Other,FDA-2017-P-6851-0001,FDA-2017-P-6851,citizen petition from shire development llc,0,0
0900006482d44121,Supporting & Related Material,FDA-2017-P-6851-0003,FDA-2017-P-6851,exhibit a- atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/ hyperactivity disorder re citizen petition from shire development llc,0,0
0900006482d44125,Supporting & Related Material,FDA-2017-P-6851-0007,FDA-2017-P-6851,exhibit e- clinical presentations of adult patients with adhd re citizen petition from shire development llc,0,0
090000648327a81c,Other,FDA-2017-P-6851-0009,FDA-2017-P-6851,letter from fda cder to sascha haverfield,0,0
090000648279743e,Other,FDA-2017-P-1278-0003,FDA-2017-P-1278,petition approval fda-2017-p-1278,0,0
09000064824e522a,Other,FDA-2017-P-1278-0002,FDA-2017-P-1278,"acknowledgment letter from fda ddm to gilead sciences, inc.",0,0
09000064824e51a2,Other,FDA-2017-P-1278-0001,FDA-2017-P-1278,"citizen petition from gilead sciences, inc.",0,0
09000064838fa641,Other,FDA-2018-P-4490-0001,FDA-2018-P-4490,"citizen petition from hyman, phelps & mcnamara, p. c.",0,0
09000064838fa7ad,Other,FDA-2018-P-4490-0002,FDA-2018-P-4490,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara pc .",0,0
0900006483b4904e,Other,FDA-2018-P-4490-0006,FDA-2018-P-4490,"citizen petition denial response letter from fda cder to hyman, phelps & mcnamara",0,0
0900006484100c47,Supporting & Related Material,FDA-2019-P-5008-0003,FDA-2019-P-5008,exhibit 1 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
0900006484100c49,Supporting & Related Material,FDA-2019-P-5008-0005,FDA-2019-P-5008,exhibit 3 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
090000648410120e,Supporting & Related Material,FDA-2019-P-5008-0026,FDA-2019-P-5008,exhibit 25 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
09000064841011fb,Supporting & Related Material,FDA-2019-P-5008-0008,FDA-2019-P-5008,exhibit 6 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
0900006484101209,Supporting & Related Material,FDA-2019-P-5008-0022,FDA-2019-P-5008,exhibit 20 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
090000648410120c,Supporting & Related Material,FDA-2019-P-5008-0024,FDA-2019-P-5008,exhibit 23 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
090000648410120d,Supporting & Related Material,FDA-2019-P-5008-0025,FDA-2019-P-5008,exhibit 24 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
0900006484100c42,Other,FDA-2019-P-5008-0001,FDA-2019-P-5008,citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
09000064841011fa,Supporting & Related Material,FDA-2019-P-5008-0007,FDA-2019-P-5008,exhibit 5 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
0900006484101204,Supporting & Related Material,FDA-2019-P-5008-0017,FDA-2019-P-5008,exhibit 15 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
09000064841014c6,Supporting & Related Material,FDA-2019-P-5008-0030,FDA-2019-P-5008,exhibit 29 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
09000064841011fc,Supporting & Related Material,FDA-2019-P-5008-0009,FDA-2019-P-5008,exhibit 7 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
09000064841011fe,Supporting & Related Material,FDA-2019-P-5008-0011,FDA-2019-P-5008,exhibit 9 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
0900006484101201,Supporting & Related Material,FDA-2019-P-5008-0014,FDA-2019-P-5008,exhibit 12 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
0900006484101203,Supporting & Related Material,FDA-2019-P-5008-0016,FDA-2019-P-5008,exhibit 14 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
0900006484101205,Supporting & Related Material,FDA-2019-P-5008-0018,FDA-2019-P-5008,exhibit 16 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
0900006484101208,Supporting & Related Material,FDA-2019-P-5008-0021,FDA-2019-P-5008,exhibit 19 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
090000648410120a,Supporting & Related Material,FDA-2019-P-5008-0023,FDA-2019-P-5008,exhibit 21 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
09000064841011ff,Supporting & Related Material,FDA-2019-P-5008-0012,FDA-2019-P-5008,exhibit 10 re citizen's petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
0900006484101207,Supporting & Related Material,FDA-2019-P-5008-0020,FDA-2019-P-5008,exhibit 18 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
0900006484100c48,Supporting & Related Material,FDA-2019-P-5008-0004,FDA-2019-P-5008,exhibit 2 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
09000064841011f9,Supporting & Related Material,FDA-2019-P-5008-0006,FDA-2019-P-5008,exhibit 4 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
0900006484101202,Supporting & Related Material,FDA-2019-P-5008-0015,FDA-2019-P-5008,exhibit 13 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
0900006484101206,Supporting & Related Material,FDA-2019-P-5008-0019,FDA-2019-P-5008,exhibit 17 re citizen petition from foley hoag llp on behalf of vifor fresenius medical care renal pharma france,0,0
0900006484100c46,Other,FDA-2019-P-5008-0002,FDA-2019-P-5008,acknowledgment letter from fda dms to foley hoag llp,0,0
0900006482e54e90,Supporting & Related Material,FDA-2018-P-0345-0003,FDA-2018-P-0345,attachment-1 current orange book search results re: citizen petition from macleods pharmaceuticals limited,0,0
090000648495b9db,Other,FDA-2018-P-0345-0008,FDA-2018-P-0345,withdrawal from macleods pharmaceuticals limited,0,0
09000064834da41e,Other,FDA-2018-P-0345-0006,FDA-2018-P-0345,interim response letter from fda cder to macleods pharmaceuticals limited,0,0
0900006482e54fb1,Supporting & Related Material,FDA-2018-P-0345-0005,FDA-2018-P-0345,"attachment-3 detailed ims, moving annual total (mat) data indicating approved generic product anda #a201679 nitrofurantoin oral suspension 25mg/5ml, of amneal pharms as the market leadrer re: citizen petition from macleods pharmaceuticals limited",0,0
0900006482e54e91,Supporting & Related Material,FDA-2018-P-0345-0004,FDA-2018-P-0345,attachment-2 drugs@fda: fda approved drug products search results re: citizen petition from macleods pharmaceuticals limited,0,0
0900006482e54ba2,Other,FDA-2018-P-0345-0001,FDA-2018-P-0345,citizen petition from macleods pharmaceuticals limited,0,0
090000648495cd87,Other,FDA-2018-P-0345-0007,FDA-2018-P-0345,withdrawal of citizen petition,0,0
0900006484964eea,Other,FDA-2018-P-0345-0009,FDA-2018-P-0345,withdrawal of citizen petition macleods pharmaceuticals limited,0,0
0900006482e54892,Other,FDA-2018-P-0345-0002,FDA-2018-P-0345,acknowledgment letter from fda ddm to macleods pharmaceuticals limited,0,0
090000648207688c,Supporting & Related Material,FDA-2016-P-1826-0004,FDA-2016-P-1826,"exhibit a to citizen petition filed by nutek food science, llc june 27, 2016 re citizen petition from nutek food science llc",1,0
09000064820720cc,Other,FDA-2016-P-1826-0001,FDA-2016-P-1826,citizen petition from nutek food science llc,1,0
0900006482076894,Supporting & Related Material,FDA-2016-P-1826-0006,FDA-2016-P-1826,"reference 21 - sodium, chloride, and potassium re citizen petition from nutek food science llc",1,0
09000064820769a0,Supporting & Related Material,FDA-2016-P-1826-0008,FDA-2016-P-1826,"references 38 through 44 - the effect of salt reduction on sensory quality and microbial growth in hotdog sausages, bacon, ham and salami re citizen petition from nutek food science llc",1,0
0900006483d8cca3,Other,FDA-2016-P-1826-0049,FDA-2016-P-1826,"citizen petition withdrawal letter from nutek food science, llc to fda cfsan",1,0
0900006482076893,Supporting & Related Material,FDA-2016-P-1826-0005,FDA-2016-P-1826,references 1 through 20 - sodium reduction re citizen petition from nutek food science llc,1,0
0900006482076895,Supporting & Related Material,FDA-2016-P-1826-0007,FDA-2016-P-1826,references 22 through 37 - potassium chloride re citizen petition from nutek food science llc,1,0
09000064820769a2,Supporting & Related Material,FDA-2016-P-1826-0010,FDA-2016-P-1826,references 53 through 62 - effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses re citizen petition from nutek food science llc,1,0
09000064820769a3,Supporting & Related Material,FDA-2016-P-1826-0011,FDA-2016-P-1826,references 63 through 70 - micronutrient re citizen petition from nutek food science llc,1,0
09000064820720ce,Other,FDA-2016-P-1826-0002,FDA-2016-P-1826,"acknowledgement letter from fda ddm to nutek food science, llc",1,0
09000064820720d0,Supporting & Related Material,FDA-2016-P-1826-0003,FDA-2016-P-1826,attachment 1 - references links re citizen petition from nutek food science llc,1,0
09000064820769a1,Supporting & Related Material,FDA-2016-P-1826-0009,FDA-2016-P-1826,references 45 through 52 - childhood blood pressure trends and risk factors for high blood pressures re citizen petition from nutek food science llc,1,0
0900006484891f24,Other,FDA-2020-P-2017-0001,FDA-2020-P-2017,citizen petition from alston & bird llp,0,0
0900006484891f26,Other,FDA-2020-P-2017-0002,FDA-2020-P-2017,acknowledgment letter from fda dms to alston & bird llp,0,0
090000648496d1cb,Other,FDA-2020-P-2017-0003,FDA-2020-P-2017,citizen petition withdrawal  for alston & bird llp,0,0
0900006483db82a2,Supporting & Related Material,FDA-2019-P-3545-0003,FDA-2019-P-3545,exhibit a- pharmacokinetic comparison of two carbamazepine slow-release formulations re: citizen petition from axinn on behalf of  zydus pharmaceuticals (usa) inc.,0,0
0900006483db82a0,Other,FDA-2019-P-3545-0002,FDA-2019-P-3545,acknowledgment letter from fda ddm to axinn on behalf of  zydus pharmaceuticals (usa) inc.,0,0
0900006483db82a3,Supporting & Related Material,FDA-2019-P-3545-0004,FDA-2019-P-3545,"exhibit b-  therapeutic drug monitoring of antiepileptic
drugs by use of saliva re: citizen petition from axinn on behalf of  zydus pharmaceuticals (usa) inc.",0,0
0900006483db82a4,Supporting & Related Material,FDA-2019-P-3545-0005,FDA-2019-P-3545,exhibit c- draft guidance on carbamazepine re: citizen petition from axinn on behalf of  zydus pharmaceuticals (usa) inc.,0,0
0900006483db7d1f,Other,FDA-2019-P-3545-0001,FDA-2019-P-3545,citizen petition from axinn on behalf of  zydus pharmaceuticals (usa) inc.,0,0
0900006484239993,Other,FDA-2019-P-3545-0008,FDA-2019-P-3545,"response letter from fda cder to axinn, veltrop & harkrider llp",0,0
0900006483db82a5,Supporting & Related Material,FDA-2019-P-3545-0006,FDA-2019-P-3545,exhibit d- switching from brand-name to generic psychotropic medications: a literature review re: citizen petition from axinn on behalf of  zydus pharmaceuticals (usa) inc.,0,0
0900006484b7ac2d,Supporting & Related Material,FDA-2021-P-0550-0037,FDA-2021-P-0550,"reference 48 sam raney, u.s. food & drug admin., strategies to improve patient 
access to high quality topical products, am. ass’n of pharm. scientists workshop on dermatological drug products: developmental & regulatory considerations at 36 (nov. 12, 2017). re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",1,0
0900006484b7fce0,Supporting & Related Material,FDA-2021-P-0550-0040,FDA-2021-P-0550,"affidavit of lorin k. johnson, ph.d. re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484b6700b,Supporting & Related Material,FDA-2021-P-0550-0004,FDA-2021-P-0550,"reference 1 alex yu et al., bioequivalence history, in fda bioequivalence 
standards 3–4 (lawrence x. yu & bing v. li eds., 2014) [hereinafter yu et al.] re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484b6d27a,Supporting & Related Material,FDA-2021-P-0550-0015,FDA-2021-P-0550,"reference 12 emil a. tanghetti et al., optimized formulation for topical 
application of a fixed combination halobetasol/tazarotene lotion 
using polymeric emulsion technology, 4 j. dermatological 
treatment 1, 6 (2019) [hereinafter tanghetti 2019]. re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484b6d2a1,Supporting & Related Material,FDA-2021-P-0550-0017,FDA-2021-P-0550,"reference 17 david m. pariser et al., halobetasol 0.01%/tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: 
maintenance of therapeutic effect after cessation of therapy, 17 j. 
drugs in dermatology 723, 724 (2018) re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484b6d2a7,Supporting & Related Material,FDA-2021-P-0550-0018,FDA-2021-P-0550,"reference 18 emil a. tanghetti et al., tazarotene revisited: safety and efficacy in 
plaque psoriasis and its emerging role in treatment strategy, 17 j. drugs in dermatology 1280, 1283 (2018). re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484b728c7,Supporting & Related Material,FDA-2021-P-0550-0021,FDA-2021-P-0550,"reference 21 benedetta brazzini & nicola pimpinelli, new & established topical 
corticosteroids in dermatology: clinical pharmacology & 
therapeutic use, 3 am. j. clinical dermatology 47, 48 (2002) re:",0,0
0900006484b728c9,Supporting & Related Material,FDA-2021-P-0550-0023,FDA-2021-P-0550,"reference 23 malcom w. greaves, anti-inflammatory action of corticosteroids, 52 postgraduate med. j. 631, 632 (1976). re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484b728cc,Supporting & Related Material,FDA-2021-P-0550-0026,FDA-2021-P-0550,"reference 26 ralph ruhl et al., role of vitamin a elimination or supplementation 
diets during postnatal development on the allergic sensitisation in 
mice, 51 molecular nutrition food res. 1173 (2007). re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",1,0
0900006484b7ac28,Supporting & Related Material,FDA-2021-P-0550-0032,FDA-2021-P-0550,"reference 32 hilde hermansen steineger et al., retinoid x receptor (rxrα) gene 
expression is regulated by fatty acids & dexamethasone in hepatic 
cells, 79 biochimie 107 (1997). re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484b6ccf7,Supporting & Related Material,FDA-2021-P-0550-0013,FDA-2021-P-0550,"reference 10 leon h. kircik et al., assessing the synergistic effect of a fixed 
combination halobetasol propionate 0.01% and tazarotene 0.045% 
lotion in moderate-to-severe plaque psoriasis, 18 j. drugs in 
dermatology 279, 280 (2019) [hereinafter kircik et al.]. re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484b6d26b,Supporting & Related Material,FDA-2021-P-0550-0014,FDA-2021-P-0550,"reference 11 mark g. lebwohl et al., long-term safety and efficacy of a fixed 
combination halobetasol propionate 0.01%/tazarotene 0.045% 
lotion in moderate-to-severe plaque psoriasis: phase 3 open-label 
study, 35 j. european academy of dermatology & venerology, 
1152, 1157 (2021)[hereinafter lebwohl 2021] re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redac",0,0
0900006484b6d2ae,Supporting & Related Material,FDA-2021-P-0550-0019,FDA-2021-P-0550,"reference 19 ronald m. evans & david j. mangelsdorf, nuclear receptors, rxr, 
& the big bang, 157 cell 255, 257(2014). re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484b6d2b3,Supporting & Related Material,FDA-2021-P-0550-0020,FDA-2021-P-0550,"reference 20 peter j. barnes, anti-inflammatory actions of glucocorticoids: 
molecular mechanisms, 94 clinical sci. 557 (1998). re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484b7309e,Supporting & Related Material,FDA-2021-P-0550-0028,FDA-2021-P-0550,"reference 28 thomas c. roos et al., retinoid metabolism in the skin, 50 
pharmacological rev. 315, 316 (1998). re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484b74ef1,Supporting & Related Material,FDA-2021-P-0550-0030,FDA-2021-P-0550,"reference 30 peter m. elias et al., retinoid effects on epidermal structure, 
differentiation, & permeability. 44 laboratory investigation 531 (1981). re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484b7ac2a,Supporting & Related Material,FDA-2021-P-0550-0034,FDA-2021-P-0550,"reference 34 sachiko yamaguchi et al., glucocorticoids increase retinoid-x 
receptor alpha (rxrα) expression & enhance thyroid hormone action in primary cultured rat hepatocytes, 22 j. molecular endocrinology 81 (1992) re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484b66f07,Other,FDA-2021-P-0550-0002,FDA-2021-P-0550,"acknowledgement  letter from fdm dms to baker  hostetler llp on behalf of bausch health companies, inc. _redacted",0,0
0900006484b6ccf0,Supporting & Related Material,FDA-2021-P-0550-0005,FDA-2021-P-0550,"reference 2 sam raney, u.s. food & drug admin., a generic perspective on the 
use of in vitro assessment methods, (july 30, 2019), at slide 6. re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",1,0
0900006484b6ccf2,Supporting & Related Material,FDA-2021-P-0550-0007,FDA-2021-P-0550,"reference 4 katrin i. tiffner et al., a comprehensive approach to qualify and 
validate the essential parameters of an in vitro release test (ivrt) 
method for acyclovir cream, 5%, 535 int’l j. of pharm. 217, 217 
(2018). re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484b728cb,Supporting & Related Material,FDA-2021-P-0550-0025,FDA-2021-P-0550,"reference 25 ralph ruhl, effects of dietary retinoids & carotenoids on immune 
development, 66 proc. nutrition soc’y 458 (2007). re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484b74ef2,Supporting & Related Material,FDA-2021-P-0550-0031,FDA-2021-P-0550,"reference 31 janine gericke et al., regulation of retinoid-mediated signaling 
involved in skin homeostasis by rar and rxr agonists/antagonists in mouse skin, 8 plos one e62643, 6–7 (2013). re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484b88f96,Supporting & Related Material,FDA-2021-P-0550-0010,FDA-2021-P-0550,"reference 7 - linda stein gold md, rapid onset of action in patients with moderateto-severe plaque psoriasis with halobetasol
0.01%/tazarotene 0.045% fixed combination",0,0
0900006484b6ccf5,Supporting & Related Material,FDA-2021-P-0550-0011,FDA-2021-P-0550,"reference 8 vidhatha reddy et al., impact of halobetasol propionate and 
tazarotene lotion 0.01%/0.045% in the management of plaque 
psoriasis in adults, 13 clinical, cosm. & investigational dermatology 
391 (2020) [hereinafter reddy 2020]. re: citizen petition from baker hostetler on behalf of bausch health companies, inc",0,0
0900006484b6d293,Supporting & Related Material,FDA-2021-P-0550-0016,FDA-2021-P-0550,"reference 16 jeffrey l. sugarman et al., safety and efficacy of a fixed 
combination halobetasol and tazarotene lotion in the treatment of 
moderate-to-severe plaque psoriasis: a pooled analysis of two 
phase 3 studies, 17 j. drugs in dermatology 855, 860 (2018). re: citizen petition from baker hostetler on behalf of bausch health companies, inc_ redacted",0,0
0900006484c64124,Other,FDA-2021-P-0910-0002,FDA-2021-P-0910,"acknowledgment letter from fda dms to shilpa pharma, inc.",0,0
0900006484c63c2a,Supporting & Related Material,FDA-2021-P-0910-0003,FDA-2021-P-0910,"attachment 1 - approved drug products with therapeutic equivalence evaluation (electronic orange book) accessed august 12, 2021 re suitability petition from shilpa pharma, inc.",0,0
0900006484c63c2c,Supporting & Related Material,FDA-2021-P-0910-0005,FDA-2021-P-0910,"attachment 3 - labeling of the approved product, azacitidine for injection -100 mg/vial by celgene corporation re suitability petition from shilpa pharma, inc.",0,0
0900006484c63e6a,Other,FDA-2021-P-0910-0001,FDA-2021-P-0910,"suitability petition  from shilpa pharma, inc.",0,0
0900006484c63c2b,Supporting & Related Material,FDA-2021-P-0910-0004,FDA-2021-P-0910,"attachment 2 - draft insert labeling for proposed azacitidine for injection -50 mg/vial & 150mg/vial re suitability petition  from shilpa pharma, inc.",0,0
09000064843455cf,Supporting & Related Material,FDA-2020-P-0698-0010,FDA-2020-P-0698,reference 9 re citizen petition from physicians committee for responsible medicine,0,0
09000064843455cb,Supporting & Related Material,FDA-2020-P-0698-0006,FDA-2020-P-0698,reference 5 re citizen petition from physicians committee for responsible medicine,0,0
09000064843455ce,Supporting & Related Material,FDA-2020-P-0698-0009,FDA-2020-P-0698,reference 8 re citizen petition from physicians committee for responsible medicine,0,0
090000648434559e,Supporting & Related Material,FDA-2020-P-0698-0003,FDA-2020-P-0698,reference 2 re citizen petition from physicians committee for responsible medicine,0,0
09000064843455ca,Supporting & Related Material,FDA-2020-P-0698-0005,FDA-2020-P-0698,reference 4 re citizen petition from physicians committee for responsible medicine,0,0
09000064843455cd,Supporting & Related Material,FDA-2020-P-0698-0008,FDA-2020-P-0698,reference 7 re citizen petition from physicians committee for responsible medicine,0,0
09000064843455d0,Supporting & Related Material,FDA-2020-P-0698-0011,FDA-2020-P-0698,reference 10 re citizen petition from physicians committee for responsible medicine,0,0
090000648434559a,Other,FDA-2020-P-0698-0012,FDA-2020-P-0698,acknowledgment letter from fda dms to physicians committee for responsible medicine,0,0
0900006484345599,Other,FDA-2020-P-0698-0001,FDA-2020-P-0698,citizen petition from physicians committee for responsible medicine,0,0
090000648434559d,Supporting & Related Material,FDA-2020-P-0698-0002,FDA-2020-P-0698,reference 1 re citizen petition from physicians committee for responsible medicine,0,0
090000648434559f,Supporting & Related Material,FDA-2020-P-0698-0004,FDA-2020-P-0698,reference 3 re citizen petition from physicians committee for responsible medicine,0,0
09000064843455cc,Supporting & Related Material,FDA-2020-P-0698-0007,FDA-2020-P-0698,reference 6 re citizen petition from physicians committee for responsible medicine,0,0
0900006482af6154,Other,FDA-2013-P-1377-0004,FDA-2013-P-1377,final response from fda cder to buchanan ingersoll & rooney pc,0,0
0900006481482fe5,Other,FDA-2013-P-1377-0002,FDA-2013-P-1377,acknowledgement letter to covis pharma sarl (buchanan ingersoll & rooney pc),0,0
0900006481482fd0,Other,FDA-2013-P-1377-0001,FDA-2013-P-1377,covis pharma sarl (buchanan ingersoll & rooney pc) - citizen petition,0,0
0900006481674a4c,Other,FDA-2013-P-1377-0003,FDA-2013-P-1377,interim response from fda cder to buchanan ingersoll & rooney pc,0,0
0900006483d5acb3,Notice,FDA-2019-P-1366-0003,FDA-2019-P-1366,"determination that claforan (cefotaxime sodium) for injection, 500
milligrams/vial, 1 gram/vial, 2 grams/vial and 10 grams/vial, was not
withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483b17fc9,Other,FDA-2019-P-1366-0002,FDA-2019-P-1366,acknowledgment letter from fda ddm to  cardinal health regulatory sciences,0,0
0900006483b17dc6,Other,FDA-2019-P-1366-0001,FDA-2019-P-1366,citizen petition from cardinal health regulatory sciences,0,0
0900006483d5bbc5,Other,FDA-2019-P-1366-0004,FDA-2019-P-1366,letter from cder to cardinal health regulatory sciences,0,0
0900006484811ba8,Other,FDA-2020-P-1775-0002,FDA-2020-P-1775,acknowledgment letter from fda dms to novitium pharma llc,0,0
0900006484811ba7,Other,FDA-2020-P-1775-0001,FDA-2020-P-1775,citizen petition from novitium pharma llc,0,0
0900006484828897,Other,FDA-2020-P-1775-0003,FDA-2020-P-1775,citizen petition withdrawal from novitium pharma llc,0,0
09000064843bcfbc,Other,FDA-2020-P-0963-0002,FDA-2020-P-0963,"acknowledgment letter from fda dms to aurora pharmaceutical, inc.",0,0
09000064843bdcca,Other,FDA-2020-P-0963-0001,FDA-2020-P-0963,suitability citizen petition for aurora pharmaceutical inc.,0,0
0900006484606b56,Other,FDA-2020-P-0963-0005,FDA-2020-P-0963,"suitability petition letter from fda cvm to aurora pharmaceutical, inc.",0,0
09000064844706f2,Other,FDA-2020-P-0963-0004,FDA-2020-P-0963,amendment to suitability citizen petition from aurora pharmaceutical inc.,0,0
09000064843bcfe0,Supporting & Related Material,FDA-2020-P-0963-0003,FDA-2020-P-0963,attachment 1-deramaxx chewable tablets re: suitability citizen petition for aurora pharmaceutical inc.,0,0
090000648082975b,Supporting & Related Material,FDA-2008-D-0224-0029,FDA-2008-D-0224,"certifications to accompany drug, biological product, and device applications/ submissions: compliance with section 402(j) of the public health service act, 42 u.s.c. § 282(j), added by title viii of the food and drug administration amendments act of 2007 - final guidance for sponsors, industry, researchers, investigators and fda staff",1,0
0900006480511b12,Notice,FDA-2008-D-0224-0001,FDA-2008-D-0224,"draft guidance for sponsors, industry, researchers, investigators, and food and drug administration staff: certifications to accompany drug, biological product, and device applications/ submissions: compliance with section 402(j) of the public health service act, added by title viii of the food and drug administration amendments act of 2007",1,0
090000648082941b,Notice,FDA-2008-D-0224-0026,FDA-2008-D-0224,"final guidance for sponsors, industry, researchers, investigators, and food and drug administration staff: certifications to accompany drug, biological product, and device applications/submissions; compliance with section 402(j) of the public health service act, 42 u.s.c. § 282(j), added by title viii of the food and drug administration amendments act of 2007",1,0
0900006480511e08,Other,FDA-2008-D-0224-0005,FDA-2008-D-0224,"draft guidance for sponsors, industry, researchers, investigators, and food and drug administration staff: certifications to accompany drug, biological product, and device applications/ submissions: compliance with section 402(j) of the public health service act, added by title viii of the food and drug administration amendments act of 2007 - guidance document",1,0
09000064803af984,Other,FDA-2008-P-0052-0004,FDA-2008-P-0052,url mutual - supplement,0,0
090000648069ea46,Other,FDA-2008-P-0052-0005,FDA-2008-P-0052,"fda center for drug evaluation and research response to mutual pharmaceuticals, inc. - petition denial",0,0
09000064803a1bbc,Other,FDA-2008-P-0052-0002,FDA-2008-P-0052,acknowledgement letter to mutual pharmaceutical united research,0,0
09000064803a6300,Supporting & Related Material,FDA-2008-P-0052-0003,FDA-2008-P-0052,attachment-a-report-vol1.pdf,0,0
09000064803a1a4a,Other,FDA-2008-P-0052-0001,FDA-2008-P-0052,url mutual - citizen petition,0,0
090000648436b864,Other,FDA-2020-P-0813-0002,FDA-2020-P-0813,acknowledgment letter from fda dms to citizen petition from unichem pharmaceuticals (usa) inc.,0,0
09000064847043b8,Notice,FDA-2020-P-0813-0004,FDA-2020-P-0813,"determination that tenex (guanfacine hydrochloride) tablets, 1
milligram, 2 milligrams, and 3 milligrams, was not withdrawn from
sale for reasons of safety or effectiveness",0,0
090000648436b831,Supporting & Related Material,FDA-2020-P-0813-0003,FDA-2020-P-0813,"exhibit-1 orange book: approved drug products with therapeutic equivalence evaluations re: citizen petition from unichem pharmaceuticals (usa), inc.",0,0
0900006484705266,Other,FDA-2020-P-0813-0005,FDA-2020-P-0813,agency response letter from fda cder to unichem pharmaceuticals usa inc,0,0
090000648436ad7d,Other,FDA-2020-P-0813-0001,FDA-2020-P-0813,citizen petition from unichem pharmaceuticals (usa) inc.,0,0
09000064823bcb33,Other,FDA-2016-P-1873-0007,FDA-2016-P-1873,letter from cder to north american specialty medicines,0,0
090000648207f7f1,Supporting & Related Material,FDA-2016-P-1873-0003,FDA-2016-P-1873,tab a - difficult to swallow: patient preferences for alternative valproate pharmaceutical formulations re citizen petition from teva pharmaceuticals,0,0
090000648207f7f2,Supporting & Related Material,FDA-2016-P-1873-0004,FDA-2016-P-1873,tab b -  pill properties that cause dysphagia and treatment failure re citizen petition from teva pharmaceuticals,0,0
090000648207f7f4,Supporting & Related Material,FDA-2016-P-1873-0006,FDA-2016-P-1873,tab d - analysis of bead sizes for mr capsules labeled for sprinkle re citizen petition from teva pharmaceuticals,0,0
090000648207f7ed,Other,FDA-2016-P-1873-0001,FDA-2016-P-1873,citizen petition from teva pharmaceuticals,0,0
090000648207f7ef,Other,FDA-2016-P-1873-0002,FDA-2016-P-1873,acknowledgement letter from fda ddm to  teva pharmaceuticals,0,0
090000648207f7f3,Supporting & Related Material,FDA-2016-P-1873-0005,FDA-2016-P-1873,"tab c - difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms re citizen petition from teva pharmaceuticals",0,0
090000648247f1a0,Other,FDA-2017-P-0290-0001,FDA-2017-P-0290,citizen petition from malaysian rubber export promotion council,0,0
0900006482797171,Other,FDA-2017-P-0290-0003,FDA-2017-P-0290,letter from cdrh to malaysian rubber export promotion council-usa,0,0
090000648247f21e,Other,FDA-2017-P-0290-0002,FDA-2017-P-0290,acknowledgement letter from fda ddm to malaysian rubber export promotion council,0,0
0900006481ec5841,Other,FDA-2015-P-1924-0007,FDA-2015-P-1924,citizen petition denial response letter from fda cdrh to hunton & williams llp,0,0
0900006481b0d74d,Supporting & Related Material,FDA-2015-P-1924-0003,FDA-2015-P-1924,attachment b  zeltiq investor day presentation re citizen petition from hunton and williams llp,0,0
0900006481b0d650,Other,FDA-2015-P-1924-0001,FDA-2015-P-1924,citizen petition from hunton and williams llp,0,0
0900006481b0d74c,Supporting & Related Material,FDA-2015-P-1924-0002,FDA-2015-P-1924,attachment a 510k premarket notifications for zeltiq system re citizen petition from hunton and williams llp,0,0
0900006481b0d651,Other,FDA-2015-P-1924-0005,FDA-2015-P-1924,acknowledgement letter from fda ddm to hunton and williams llp,0,0
0900006481b0d74e,Supporting & Related Material,FDA-2015-P-1924-0004,FDA-2015-P-1924,attachment c zeltiq aesthetics press release re citizen petition from hunton and williams llp,0,0
0900006481cc8f5e,Other,FDA-2015-P-1924-0006,FDA-2015-P-1924,"interim response letter from fda cdrh to hunton & william, llp",0,0
090000648243b95d,Other,FDA-2014-P-1685-0004,FDA-2014-P-1685,petition denial letter,0,0
09000064818ea61e,Other,FDA-2014-P-1685-0001,FDA-2014-P-1685,citizen petition from larry r. pilot,0,0
0900006481a4a207,Other,FDA-2014-P-1685-0003,FDA-2014-P-1685,interim response from cder to larry r. pilot,0,0
09000064818eb7d2,Other,FDA-2014-P-1685-0002,FDA-2014-P-1685,acknowledgement letter from fda ddm to larry r pilot,0,0
0900006484dc9591,Supporting & Related Material,FDA-2021-P-1123-0003,FDA-2021-P-1123,attachment 1 re: citizen petition from melinta therapeutics llc,0,0
0900006484dc98ca,Supporting & Related Material,FDA-2021-P-1123-0007,FDA-2021-P-1123,attachment 5 re: citizen petition from melinta therapeutics llc,0,0
0900006484dc98cc,Supporting & Related Material,FDA-2021-P-1123-0009,FDA-2021-P-1123,attachment 7 re: citizen petition from melinta therapeutics llc,0,0
0900006484dc9a33,Other,FDA-2021-P-1123-0001,FDA-2021-P-1123,citizen petition from melinta therapeutics llc,0,0
0900006484dc9592,Supporting & Related Material,FDA-2021-P-1123-0004,FDA-2021-P-1123,attachment 2 re: citizen petition from melinta therapeutics llc,0,0
0900006484dc9594,Supporting & Related Material,FDA-2021-P-1123-0006,FDA-2021-P-1123,attachment 4 re: citizen petition from melinta therapeutics llc,0,0
0900006484dc9593,Supporting & Related Material,FDA-2021-P-1123-0005,FDA-2021-P-1123,attachment 3 re: citizen petition from melinta therapeutics llc,0,0
0900006484dc98cd,Supporting & Related Material,FDA-2021-P-1123-0010,FDA-2021-P-1123,attachment 8 re: citizen petition from melinta therapeutics llc,0,0
0900006484dc9be8,Other,FDA-2021-P-1123-0002,FDA-2021-P-1123,acknowledgment letter from fdm dms to melinta therapeutics llc,0,0
0900006484dc98cb,Supporting & Related Material,FDA-2021-P-1123-0008,FDA-2021-P-1123,attachment 6 re: citizen petition from melinta therapeutics llc,0,0
0900006484b488df,Supporting & Related Material,FDA-2021-P-0523-0003,FDA-2021-P-0523,attachment a re: citizen petition from the council for responsible nutrition,0,0
0900006484b488dd,Other,FDA-2021-P-0523-0002,FDA-2021-P-0523,acknowledgment letter from fda dms to  the council for responsible nutrition (crn),0,0
0900006484b488db,Other,FDA-2021-P-0523-0001,FDA-2021-P-0523,citizen petition from the council for responsible nutrition (crn),0,0
0900006482b2fa3c,Other,FDA-2017-P-1460-0004,FDA-2017-P-1460,withdrawal letter from covington & burling llp,0,0
0900006482afd785,Other,FDA-2017-P-1460-0003,FDA-2017-P-1460,interim response letter from fda cder to covington & burling llp,0,0
09000064824fc50d,Other,FDA-2017-P-1460-0001,FDA-2017-P-1460,citizen petition from covington & burling llp,0,0
09000064824fc2ff,Other,FDA-2017-P-1460-0002,FDA-2017-P-1460,acknowledgement letter from fda ddm to covington & burling llp,0,0
0900006483aace20,Other,FDA-2018-P-3933-0003,FDA-2018-P-3933,"response letter from fda cder to fresenius kabi usa, llc",0,0
09000064837fe806,Other,FDA-2018-P-3933-0001,FDA-2018-P-3933,citizen petition from fresenius kabi usa llc,0,0
09000064837fe808,Other,FDA-2018-P-3933-0002,FDA-2018-P-3933,"acknowledgment letter from fda ddm to fresenius kabi usa, llc",0,0
0900006481c385a4,Other,FDA-2015-P-3107-0001,FDA-2015-P-3107,citizen petition from ferrosan medical devices (duval & associates),0,0
0900006481e2890e,Other,FDA-2015-P-3107-0003,FDA-2015-P-3107,"interim response letter from fda cdrh to duval & associates, p.a.",0,0
0900006481c385a7,Other,FDA-2015-P-3107-0002,FDA-2015-P-3107,acknowledgement letter from fda ddm to ferrosan medical devices (duval & associates),0,0
0900006481690d32,Other,FDA-2014-P-0367-0002,FDA-2014-P-0367,acknowledgement letter from fda/ddm to hyman phelps and mcnamara p.c.,0,0
0900006481690458,Other,FDA-2014-P-0367-0001,FDA-2014-P-0367,citizen petition from hyman phelps and mcnamara pc,0,0
0900006481875af2,Other,FDA-2014-P-0367-0003,FDA-2014-P-0367,interim response letter from fda/cder to hyman phelps and mcnamara p.c.,0,0
0900006483cea04e,Other,FDA-2014-P-0367-0004,FDA-2014-P-0367,"letter from fda cder to hyman,  phelps & mcnamara, p.c.",0,0
09000064840fa6de,Other,FDA-2019-P-2088-0003,FDA-2019-P-2088,interim response letter from fda cder to summit health pharmacy inc,0,0
0900006483c1f06b,Other,FDA-2019-P-2088-0002,FDA-2019-P-2088,acknowledgment  letter from fda ddm to summit health pharmacy inc.,0,0
0900006483c1ef73,Other,FDA-2019-P-2088-0001,FDA-2019-P-2088,citizen petition from summit health pharmacy inc.,0,0
0900006484a456f1,Notice,FDA-2020-P-1549-0008,FDA-2020-P-1549,"determination that nymalize (nimodipine), oral solution, 3 milligrams/milliliter, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006484a3b67c,Other,FDA-2020-P-1549-0007,FDA-2020-P-1549,"final response letter from fda cder to windels marx lane & mittendorf, llp",0,0
09000064846e3f02,Other,FDA-2020-P-1549-0001,FDA-2020-P-1549,"citizen petition from windels marx lane & mittendorf, llp",0,0
09000064846e46ad,Supporting & Related Material,FDA-2020-P-1549-0003,FDA-2020-P-1549,"exhibit-1 orange book: approved drug products with therapeutic equivalence evaluations re: citizen petition from windels marx lane & mittendorf, llp.",0,0
09000064846e46ab,Other,FDA-2020-P-1549-0002,FDA-2020-P-1549,"acknowledgment letter from fda dms to windels marx lane& mittendorf, llp",0,0
090000648497e03e,Other,FDA-2020-P-1549-0006,FDA-2020-P-1549,"interim response letter from fda cder to windels marx lane & mittendorf, llp",0,0
0900006484a6ddbf,Supporting & Related Material,FDA-2021-P-0299-0003,FDA-2021-P-0299,"attachment 1 - current (march 16, 2021) orange book listing of efudex (fluorouracil) topical solutions, 5%; nda n016831 held by bausch health americas inc. re citizen petition from encube ethicals private limited",0,0
0900006484a6ddbb,Other,FDA-2021-P-0299-0002,FDA-2021-P-0299,acknowledgment letter from fda dms to encube ethicals private limited,0,0
0900006484a6ddb9,Other,FDA-2021-P-0299-0001,FDA-2021-P-0299,citizen petition from encube ethicals private limited,0,0
0900006484c1495b,Notice,FDA-2021-P-0299-0004,FDA-2021-P-0299,"determination that efudex (fluorouracil) topical solution, 5 percent, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006484c178df,Other,FDA-2021-P-0299-0005,FDA-2021-P-0299,response letter to encube ethicals private limited from fda cder,0,0
0900006484dc5605,Other,FDA-2021-P-1111-0001,FDA-2021-P-1111,citizen petition from lachman consultant services inc,0,0
0900006484dc562e,Other,FDA-2021-P-1111-0002,FDA-2021-P-1111,acknowledgment letter from fda dms to lachman consultant services inc.,0,0
09000064841936fe,Other,FDA-2019-P-5535-0001,FDA-2019-P-5535,citizen petition from foley & lardner llp,0,0
0900006484193700,Other,FDA-2019-P-5535-0002,FDA-2019-P-5535,acknowledgment letter from fda ddm to foley & lardner llp,0,0
0900006484193799,Supporting & Related Material,FDA-2019-P-5535-0004,FDA-2019-P-5535,"attachment 2 approved labeling for the rld, protonix re citizen petition from foley & lardner llp",0,0
090000648419379a,Supporting & Related Material,FDA-2019-P-5535-0005,FDA-2019-P-5535,attachment 3 proposed labeling re citizen petition from foley & lardner llp,0,0
0900006484193798,Supporting & Related Material,FDA-2019-P-5535-0003,FDA-2019-P-5535,attachment 1 approved drug products with therapeutic equivalence evaluations orange book excerpt re citizen petition from foley & lardner llp,0,0
0900006482682b80,Other,FDA-2017-P-3468-0002,FDA-2017-P-3468,"acknowledgment letter from fda ddm to teligent pharma, inc.",0,0
090000648323bfcd,Other,FDA-2017-P-3468-0005,FDA-2017-P-3468,"petition denial letter from fda cder to teligent pharma, inc",0,0
09000064826811b3,Other,FDA-2017-P-3468-0001,FDA-2017-P-3468,"citizen petition from teligent pharma, inc.",0,0
0900006482682b82,Supporting & Related Material,FDA-2017-P-3468-0003,FDA-2017-P-3468,"attachment 1 orange book listing for ketoconazole cream 2% accessed on june 1, 2017",0,0
0900006482cb0fe2,Other,FDA-2017-P-3468-0004,FDA-2017-P-3468,"interim response from fda to teligent pharma, inc",0,0
0900006483b63136,Notice,FDA-2018-P-3412-0006,FDA-2018-P-3412,"determination that qvar 40 and qvar 80 (beclomethasone dipropionate hfa) inhalation aerosol, 40 micrograms and 80 micrograms, were not withdrawn from sale for reasons of safety or effectiveness",0,0
09000064836c9ef7,Other,FDA-2018-P-3412-0001,FDA-2018-P-3412,citizen petition from aurolife pharma llc,0,0
0900006483abc997,Other,FDA-2018-P-3412-0005,FDA-2018-P-3412,letter from fda cder to aurolife pharma llc,0,0
09000064836cb06b,Supporting & Related Material,FDA-2018-P-3412-0003,FDA-2018-P-3412,"attachment 2- orange book: approved drug products with
therapeutic equivalence evaluations re: citizen petition from aurolife pharma llc",0,0
0900006483b65731,Other,FDA-2018-P-3412-0007,FDA-2018-P-3412,letter from fda cder to aurolife pharma llc,0,0
09000064836cb066,Other,FDA-2018-P-3412-0002,FDA-2018-P-3412,acknowledgment letter from fda ddm to aurolife pharma llc,0,0
09000064836cacf3,Supporting & Related Material,FDA-2018-P-3412-0004,FDA-2018-P-3412,attachment 1- fda drug shortages re: citizen petition from aurolife pharma llc,0,0
090000648294136c,Supporting & Related Material,FDA-2017-P-4334-0008,FDA-2017-P-4334,tab33 shire development inc - warning letter re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
090000648294136b,Supporting & Related Material,FDA-2017-P-4334-0007,FDA-2017-P-4334,tab 34 watson pharmaceuticals inc - warning letter re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
090000648294136d,Supporting & Related Material,FDA-2017-P-4334-0009,FDA-2017-P-4334,tab 32 nobel laboratories llc - warning letter re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
090000648294149e,Supporting & Related Material,FDA-2017-P-4334-0022,FDA-2017-P-4334,tab19 fibroblast growth factor 23 is elevated before parathyroid hormone re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064829414a9,Supporting & Related Material,FDA-2017-P-4334-0023,FDA-2017-P-4334,tab 18 fibroblast growth factor-23 mitigates hyperphosphatemia re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064829414aa,Supporting & Related Material,FDA-2017-P-4334-0024,FDA-2017-P-4334,tab 17 hyperphosphatemia in renal failure re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064829414c3,Supporting & Related Material,FDA-2017-P-4334-0037,FDA-2017-P-4334,tab 4 time-dependent associations between iron and mortality in hemodialysis patients re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
0900006482940ca5,Other,FDA-2017-P-4334-0002,FDA-2017-P-4334,acknowledgement letter from fda ddm to sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
0900006482a31f32,Supporting & Related Material,FDA-2017-P-4334-0041,FDA-2017-P-4334,withdrawal letter from fda-2017-p-4023 to justify use of june 30th submission date,0,0
090000648294149c,Supporting & Related Material,FDA-2017-P-4334-0020,FDA-2017-P-4334,tab 21 bloomberg transcript jefferies global health care conference re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064829414bf,Supporting & Related Material,FDA-2017-P-4334-0033,FDA-2017-P-4334,tab 8 gastrointestinal blood loss in patients with chronic renal failure re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
0900006482941368,Supporting & Related Material,FDA-2017-P-4334-0004,FDA-2017-P-4334,tab 37 auryxia pharmacodynamics re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
090000648294136a,Supporting & Related Material,FDA-2017-P-4334-0006,FDA-2017-P-4334,tab 35 schein pharmaceutical inc letter re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
090000648294136f,Supporting & Related Material,FDA-2017-P-4334-0011,FDA-2017-P-4334,tab 30 velphoro highlights of prescribing information re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
0900006482c53bb0,Other,FDA-2017-P-4334-0042,FDA-2017-P-4334,response letter from fda to sidley austin llp,0,0
0900006482941498,Supporting & Related Material,FDA-2017-P-4334-0016,FDA-2017-P-4334,tab 25 ferric citrate reduces intravenous iron and erythropoiesis re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064829414ae,Supporting & Related Material,FDA-2017-P-4334-0028,FDA-2017-P-4334,tab 13 effects of phosphate binders in moderate ckd re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064829414b1,Supporting & Related Material,FDA-2017-P-4334-0031,FDA-2017-P-4334,tab 10 a proton pump inhibitor a day keeps the iron away re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064829414c4,Supporting & Related Material,FDA-2017-P-4334-0038,FDA-2017-P-4334,tab 3 kdigo 2017 clinical practice guideline update re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
0900006482941620,Supporting & Related Material,FDA-2017-P-4334-0003,FDA-2017-P-4334,"tab 1 press release investor relations keryx biopharmaceuticals, inc re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd)",0,0
090000648294136e,Supporting & Related Material,FDA-2017-P-4334-0010,FDA-2017-P-4334,tab 31 bayer healthcare llc - warning letter re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
0900006482941495,Supporting & Related Material,FDA-2017-P-4334-0013,FDA-2017-P-4334,tab 28 highlights of prescribing information re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
090000648294149b,Supporting & Related Material,FDA-2017-P-4334-0019,FDA-2017-P-4334,tab 22 ferric citrate hydrate for the treatment of hyperphosphatemia re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
090000648294149d,Supporting & Related Material,FDA-2017-P-4334-0021,FDA-2017-P-4334,tab 20 bloomberg transcript cowen and company global health care conference re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064829414ab,Supporting & Related Material,FDA-2017-P-4334-0025,FDA-2017-P-4334,tab 16 bloomberg transcript management discussion section re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c5301,Supporting & Related Material,FDA-2017-P-4023-0004,FDA-2017-P-4023,attachment 2 effects of ferric citrate in patients with nondialysis-dependent ckd re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c54d6,Supporting & Related Material,FDA-2017-P-4023-0039,FDA-2017-P-4023,attachment 37 auryxia pharmacodynamics re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c552f,Supporting & Related Material,FDA-2017-P-4023-0012,FDA-2017-P-4023,attachment 10 a proton pump inhibitor a day keeps the iron away re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c5532,Supporting & Related Material,FDA-2017-P-4023-0015,FDA-2017-P-4023,attachment 13 effects of phosphate binders in moderate ckd re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c5533,Supporting & Related Material,FDA-2017-P-4023-0016,FDA-2017-P-4023,attachment 14 highlights of prescribing information re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c5549,Supporting & Related Material,FDA-2017-P-4023-0029,FDA-2017-P-4023,attachment 27 ferric citrate (auryxia) for the treatment of hyperphosphatemia re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c554c,Supporting & Related Material,FDA-2017-P-4023-0032,FDA-2017-P-4023,attachment 30 velphoro highlights of prescribing information re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c554f,Supporting & Related Material,FDA-2017-P-4023-0035,FDA-2017-P-4023,attachment 33 shire development inc - warning letter re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c5550,Supporting & Related Material,FDA-2017-P-4023-0036,FDA-2017-P-4023,attachment 34 watson pharmaceuticals inc - warning letter re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c5551,Supporting & Related Material,FDA-2017-P-4023-0037,FDA-2017-P-4023,attachment 35 schein pharmaceutical inc letter re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c552b,Supporting & Related Material,FDA-2017-P-4023-0008,FDA-2017-P-4023,attachment 6 nkf-k doqi clinical practice guidelines for anemia re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c552c,Supporting & Related Material,FDA-2017-P-4023-0009,FDA-2017-P-4023,attachment 7 the prevalence of anemia in patients with chronic kidney disease re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c5539,Supporting & Related Material,FDA-2017-P-4023-0021,FDA-2017-P-4023,attachment 19 fibroblast growth factor 23 is elevated before parathyroid hormone re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c553c,Supporting & Related Material,FDA-2017-P-4023-0024,FDA-2017-P-4023,attachment 22 ferric citrate hydrate for the treatment of hyperphosphatemia re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c553e,Supporting & Related Material,FDA-2017-P-4023-0026,FDA-2017-P-4023,attachment 24 a randomized controlled trial comparing intravenous ferric re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c5548,Supporting & Related Material,FDA-2017-P-4023-0028,FDA-2017-P-4023,attachment 26 ferric citrate controls phosphorus and delivers iron in patients on dialysis re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c5304,Supporting & Related Material,FDA-2017-P-4023-0007,FDA-2017-P-4023,attachment 5 national kidney foundation practice guidelines for chronic kidney disease re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c552e,Supporting & Related Material,FDA-2017-P-4023-0011,FDA-2017-P-4023,attachment 9 iron management in chronic kidney disease re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c5530,Supporting & Related Material,FDA-2017-P-4023-0013,FDA-2017-P-4023,attachment 11 hepcidin - a potential novel biomarker for iron status in chronic kidney disease re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c553d,Supporting & Related Material,FDA-2017-P-4023-0025,FDA-2017-P-4023,attachment 23 find-ckd a randomized trial of intravenous terric carboxymaltose re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c5537,Supporting & Related Material,FDA-2017-P-4023-0019,FDA-2017-P-4023,attachment 17 hyperphosphatemia in renal failure re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c5538,Supporting & Related Material,FDA-2017-P-4023-0020,FDA-2017-P-4023,attachment 18 fibroblast growth factor-23 mitigates hyperphosphatemia re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c553f,Supporting & Related Material,FDA-2017-P-4023-0027,FDA-2017-P-4023,attachment 25 ferric citrate reduces intravenous iron and erythropoiesis re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
09000064827c5300,Supporting & Related Material,FDA-2017-P-4023-0003,FDA-2017-P-4023,"attachment 1 press release investor relations keryx biopharmaceuticals, inc re citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd)",0,0
09000064827c52fc,Other,FDA-2017-P-4023-0001,FDA-2017-P-4023,citizen petition from sidley austin llp (vifor fresenius medical care renal pharma ltd),0,0
0900006482fd5bec,Supporting & Related Material,FDA-2018-P-1068-0016,FDA-2018-P-1068,"attachment14_n - supac 1997 guidance - re citizen petition from spear pharmaceuticals, inc",0,0
0900006482fd5d32,Supporting & Related Material,FDA-2018-P-1068-0004,FDA-2018-P-1068,"attachment2_b - fluorouracil draft guidance - re citizen petition from spear pharmaceuticals, inc",0,0
0900006482fd5d95,Supporting & Related Material,FDA-2018-P-1068-0006,FDA-2018-P-1068,"attachment4_d - vale et al_ - re citizen petition from spear pharmaceuticals, inc",0,0
0900006482fd5bed,Supporting & Related Material,FDA-2018-P-1068-0017,FDA-2018-P-1068,"attachment15_o - usp 1724 ss performance tests - re citizen petition from spear pharmaceuticals, inc",0,0
0900006482fd5d2e,Other,FDA-2018-P-1068-0002,FDA-2018-P-1068,"acknowledgment letter from fda ddm to spear pharmaceuticals, inc",0,0
0900006482fd5bea,Supporting & Related Material,FDA-2018-P-1068-0014,FDA-2018-P-1068,"attachment12_l - luke fda powerpoint - re citizen petition from spear pharmaceuticals, inc",0,0
0900006482fd5d31,Supporting & Related Material,FDA-2018-P-1068-0003,FDA-2018-P-1068,"attachment1_a - raney powerpoint - re citizen petition from spear pharmaceuticals, inc",0,0
0900006482fd5beb,Supporting & Related Material,FDA-2018-P-1068-0015,FDA-2018-P-1068,"attachment13_m - stinchcombe fda powerpoint - re citizen petition from spear pharmaceuticals, inc",0,0
0900006482fd5d9a,Supporting & Related Material,FDA-2018-P-1068-0010,FDA-2018-P-1068,"attachment8_h - zovirax label - re citizen petition from spear pharmaceuticals, inc",0,0
0900006482fd5d9c,Supporting & Related Material,FDA-2018-P-1068-0012,FDA-2018-P-1068,"attachment10_j - soolantra label - re citizen petition from spear pharmaceuticals, inc",0,0
0900006482fd5d96,Supporting & Related Material,FDA-2018-P-1068-0007,FDA-2018-P-1068,"attachment5_e - yanofsky et al_ - re citizen petition from spear pharmaceuticals, inc",0,0
0900006482fd5d9b,Supporting & Related Material,FDA-2018-P-1068-0011,FDA-2018-P-1068,"attachment9_i - aczone label - re citizen petition from spear pharmaceuticals, inc",0,0
09000064830f93c2,Other,FDA-2018-P-1068-0019,FDA-2018-P-1068,"docket no_ fda-2018-p-1068 - request for withdrawal of citizen petition - april 9, 2018-1",0,0
0900006482fd5bee,Supporting & Related Material,FDA-2018-P-1068-0018,FDA-2018-P-1068,"attachment16_p - ims data - re citizen petition from spear pharmaceuticals, inc",0,0
0900006482fd5d94,Supporting & Related Material,FDA-2018-P-1068-0005,FDA-2018-P-1068,"attachment3_c - final welgus decl_ with exhibits - re citizen petition from spear pharmaceuticals, inc",0,0
0900006482fd5d98,Supporting & Related Material,FDA-2018-P-1068-0008,FDA-2018-P-1068,"attachment6_f - sigma 5-fluorouracil - re citizen petition from spear pharmaceuticals, inc",0,0
0900006482fd5d99,Supporting & Related Material,FDA-2018-P-1068-0009,FDA-2018-P-1068,"attachment7_g - msds fluorouracil - re citizen petition from spear pharmaceuticals, inc",0,0
0900006482fd5d9d,Supporting & Related Material,FDA-2018-P-1068-0013,FDA-2018-P-1068,"attachment11_k - acyclovir draft guidance - re citizen petition from spear pharmaceuticals, inc",0,0
0900006482fd5d2b,Other,FDA-2018-P-1068-0001,FDA-2018-P-1068,"citizen petition from spear pharmaceuticals, inc",0,0
09000064825bbb05,Other,FDA-2017-P-3065-0002,FDA-2017-P-3065,acknowledgment letter from fda ddm to njoy et. al.,0,0
0900006482c3bfcf,Other,FDA-2017-P-3065-3519,FDA-2017-P-3065,petition decision letter from fda ctp to njoy llc,0,0
09000064825bb911,Other,FDA-2017-P-3065-0001,FDA-2017-P-3065,citizen petition from njoy et. al.,0,0
09000064840c5bea,Other,FDA-2019-P-4879-0001,FDA-2019-P-4879,"citizen petition from  lachman consultant services, inc.",0,0
09000064840c6f6a,Supporting & Related Material,FDA-2019-P-4879-0003,FDA-2019-P-4879,"attachment 1 -  orange book: approved drug products with therapeutic equivalence evaluations re: citizen petition from  lachman consultant services, inc.",0,0
09000064846bce49,Other,FDA-2019-P-4879-0004,FDA-2019-P-4879,"interim response from fda cder to lachman consultant services, inc",0,0
09000064840c6f6b,Other,FDA-2019-P-4879-0002,FDA-2019-P-4879,"acknowledgment letter from dms to lachman consultant services, inc.",0,0
090000648498aa77,Other,FDA-2019-P-4879-0005,FDA-2019-P-4879,"withdrawal from lachman consultant services, inc.",0,0
090000648463247a,Other,FDA-2020-P-1393-0002,FDA-2020-P-1393,acknowledgment letter from fda dms to nexus pharmaceuticals inc,0,0
0900006484632eb3,Other,FDA-2020-P-1393-0001,FDA-2020-P-1393,suitability petition from nexus pharmaceuticals inc,0,0
09000064847457b1,Other,FDA-2020-P-1653-0002,FDA-2020-P-1653,"acknowledgment letter from fda dms to aurobindo pharma usa, inc.",0,0
09000064847457ae,Other,FDA-2020-P-1653-0001,FDA-2020-P-1653,"citizen petition from aurobindo pharma usa, inc.",0,0
0900006484954485,Other,FDA-2020-P-1653-0004,FDA-2020-P-1653,"withdrawal of aurobindo pharma usa, inc.",0,0
09000064823c8f32,Other,FDA-2016-P-4094-0001,FDA-2016-P-4094,citizen petition from adapt pharma operations lts,0,0
090000648256e980,Other,FDA-2016-P-4094-0003,FDA-2016-P-4094,response letter from fda cder to adapt pharma operations ltd,0,0
09000064823c8f34,Other,FDA-2016-P-4094-0002,FDA-2016-P-4094,acknowledgment letter from fda ddm to adapt pharma operations ltd,0,0
0900006484a20d06,Other,FDA-2021-P-0168-0001,FDA-2021-P-0168,citizen petition from the center for science in the public interest (cspi),0,0
0900006484c005e5,Other,FDA-2021-P-0168-0146,FDA-2021-P-0168,180 day interim response letter from fda cfsan to center for science in the public interest,0,0
0900006484a20d08,Other,FDA-2021-P-0168-0002,FDA-2021-P-0168,acknowledgement letter from fda dms to the center for science in the public interest (cspi),0,0
0900006481e81d4b,Other,FDA-2016-P-0644-0002,FDA-2016-P-0644,"acknowledgement letter from fda ddm to gordon johnston regulatory consultants, llc",0,0
0900006481e81de2,Supporting & Related Material,FDA-2016-P-0644-0003,FDA-2016-P-0644,"attachment 1 - fda electronic orange book: approved drug products with therapeutic equivalence evaluations for olmesartan medoxomil  tablets 20 mg, 40 mg, and 5 mg re citizen petition from gordon johnston regulatory consultants, llc",0,0
0900006481e81de3,Supporting & Related Material,FDA-2016-P-0644-0004,FDA-2016-P-0644,"attachment 2 - benicar (olmesartan medoxomi) tablets 5 mg, 20 mg and 40 mg approved labeling (rld labeling) re citizen petition from gordon johnston regulatory consultants, llc",0,0
0900006481e8074d,Other,FDA-2016-P-0644-0001,FDA-2016-P-0644,"citizen petition from gordon johnston regulatory consultants, llc",0,0
0900006481e81de4,Supporting & Related Material,FDA-2016-P-0644-0005,FDA-2016-P-0644,"attachment 3 -  draft labeling for olmesartan medoxomil tablets 5 mg, 20 mg and 40 mg re citizen petition from gordon johnston regulatory consultants, llc",0,0
09000064836530dc,Other,FDA-2018-P-1335-0004,FDA-2018-P-1335,"agency response letter from fda cder to hyman, phelps & mcnamara, p.c.",0,0
090000648307529b,Other,FDA-2018-P-1335-0001,FDA-2018-P-1335,"citizen petition form hyman, phelps & mcnamara, p.c.",0,0
0900006483643974,Notice,FDA-2018-P-1335-0003,FDA-2018-P-1335,"determination that ditropan xl (oxybutynin chloride) extended
release tablets, 15 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483075a6d,Other,FDA-2018-P-1335-0002,FDA-2018-P-1335,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara, p.c.",0,0
0900006482cf9607,Other,FDA-2017-P-6809-0002,FDA-2017-P-6809,acknowledgement letter from ddm to freyr inc.,0,0
0900006483341cd9,Other,FDA-2017-P-6809-0003,FDA-2017-P-6809,interim response letter from fda cder to freyr inc,0,0
090000648485a4a9,Other,FDA-2017-P-6809-0004,FDA-2017-P-6809,final response letter from fda cder to freyr inc.,0,0
0900006482cf9084,Other,FDA-2017-P-6809-0001,FDA-2017-P-6809,citizen petition from freyr inc.,0,0
09000064838d697a,Supporting & Related Material,FDA-2018-P-4338-0004,FDA-2018-P-4338,attachment 2-oxycontin reference meeting minutes re: citizen petition from pmrs,0,0
09000064838d69b1,Supporting & Related Material,FDA-2018-P-4338-0006,FDA-2018-P-4338,attachment 3-pmrs response to fda notice re: citizen petition from pmrs,0,0
09000064838d69b2,Supporting & Related Material,FDA-2018-P-4338-0007,FDA-2018-P-4338,attachment 4-roxicodone label re: citizen petition from pmrs,0,0
09000064838d69ba,Supporting & Related Material,FDA-2018-P-4338-0011,FDA-2018-P-4338,"attachment 8-cdc, community outbreak of hiv infection linked to injection drug use of oxymorphone - indiana, 2015(1) re: citizen petition from pmrs",0,0
09000064838d69b3,Supporting & Related Material,FDA-2018-P-4338-0008,FDA-2018-P-4338,attachment 5-percodan label re: citizen petition from pmrs,0,0
09000064838d5dca,Other,FDA-2018-P-4338-0001,FDA-2018-P-4338,citizen petition from pmrs,0,0
09000064838d6979,Supporting & Related Material,FDA-2018-P-4338-0003,FDA-2018-P-4338,attachment 1-approval letter of nda 20-553/s-022 from fda cder ode to purdue pharma l.p.  re: citizen petition from pmrs,0,0
09000064838d69b5,Supporting & Related Material,FDA-2018-P-4338-0010,FDA-2018-P-4338,"attachment 7--cdc, thrombotic thrombocytopenic purpura (ttp)-like illness associated with intravenous opana er abuse - tennessee, 2012(2) re: citizen petition from pmrs",0,0
09000064838d69d4,Supporting & Related Material,FDA-2018-P-4338-0013,FDA-2018-P-4338,attachment 10- correct title data summary report of a cutting force method for multiple formulations of cii narcotic drug products re: citizen petition from pmrs,0,0
09000064838d69d6,Supporting & Related Material,FDA-2018-P-4338-0015,FDA-2018-P-4338,"attachment 12-cdc, opioid data analysis re: citizen petition from pmrs",0,0
09000064838d69d8,Supporting & Related Material,FDA-2018-P-4338-0017,FDA-2018-P-4338,"attachment 14-cdc division of vital statistics, mortality datare: citizen petition from pmrs",0,0
09000064838d69d9,Supporting & Related Material,FDA-2018-P-4338-0018,FDA-2018-P-4338,"attachment 15-nida, overdose death rates re: citizen petition from pmrs",0,0
09000064838d69b4,Supporting & Related Material,FDA-2018-P-4338-0009,FDA-2018-P-4338,attachment 6-highlights of prescribing information (oxycontin) re: citizen petition from pmrs,0,0
0900006483b8bb72,Other,FDA-2018-P-4338-0025,FDA-2018-P-4338,agency response letter from fda cder to pmrs,0,0
09000064838d69d5,Supporting & Related Material,FDA-2018-P-4338-0014,FDA-2018-P-4338,"attachment 11-cdc, understanding the epidemic re: citizen petition from pmrs",0,0
09000064838d69d3,Supporting & Related Material,FDA-2018-P-4338-0012,FDA-2018-P-4338,attachment 9-dea quota history re: citizen petition from pmrs,0,0
09000064838d69d7,Supporting & Related Material,FDA-2018-P-4338-0016,FDA-2018-P-4338,"attachment 13-cdc, morbidity and mortality weekly report re: citizen petition from pmrs",0,0
09000064838d6568,Other,FDA-2018-P-4338-0002,FDA-2018-P-4338,acknowledgment letter from fda ddm to pmrs,0,0
0900006482f31437,Other,FDA-2017-P-5081-0004,FDA-2017-P-5081,"interim response letter from fda cder to pfizer, inc.",0,0
09000064846fb8b4,Other,FDA-2017-P-5081-0005,FDA-2017-P-5081,"response from fda cder to pfizer essential health - pfizer, inc.",0,0
0900006482a8c845,Supporting & Related Material,FDA-2017-P-5081-0003,FDA-2017-P-5081,"appendix 1 summary for report (report no.: 20466f) of study t91ie13 titled as pharmacokinetics of estradiol after application of an estradiol releasing vaginal ring. kabi pharmacia, 1992 re citizen petition from pfizer, inc.",0,0
0900006482a8ceb7,Other,FDA-2017-P-5081-0002,FDA-2017-P-5081,"acknowledgment letter from fda ddm to pfizer, inc.",0,0
0900006482a8cb26,Other,FDA-2017-P-5081-0001,FDA-2017-P-5081,"citizen petition from pfizer, inc.",0,0
0900006483c293cc,Other,FDA-2019-P-2122-0002,FDA-2019-P-2122,acknowledgment letter from fda ddm to handcrafted soap & cosmetic guild,0,0
0900006483c29ac3,Other,FDA-2019-P-2122-0001,FDA-2019-P-2122,citizen petition from handcrafted soap & cosmetic guild,0,0
09000064849e7909,Supporting & Related Material,FDA-2021-P-0032-0011,FDA-2021-P-0032,citation 41 - the role of nicotine in the effects of maternal smoking during pregnancy on lung development and childhood respiratory disease,0,0
09000064849e790d,Supporting & Related Material,FDA-2021-P-0032-0015,FDA-2021-P-0032,citation 45  adverse effects of perinatal nicotine exposure on reproductive outcomes,0,0
09000064849e790b,Supporting & Related Material,FDA-2021-P-0032-0013,FDA-2021-P-0032,"citation 43 - relationship between birth weight, maternal smoking during pregnancy, and childhood and adolescent lung function",0,0
09000064849e7915,Supporting & Related Material,FDA-2021-P-0032-0020,FDA-2021-P-0032,"citation 50 - low birthweight, preterm births and intrauterine growth retardation in relation to maternall smoking",0,0
09000064849e7918,Supporting & Related Material,FDA-2021-P-0032-0023,FDA-2021-P-0032,citation 53 -  the influence of gestational age and smoking habits on the risk of subsequent preterm deliveries,0,0
09000064849e7911,Supporting & Related Material,FDA-2021-P-0032-0019,FDA-2021-P-0032,citation 49 - low birth weight of children is positively associated with mother's prenatal tobacco smoke exposure  in shanghi,0,1
09000064849e72ff,Supporting & Related Material,FDA-2021-P-0032-0003,FDA-2021-P-0032,citation 33 - maternal  smoking before and during pregnancy and the risk of sudden unexpected tinfant death,0,0
0900006484acb496,Other,FDA-2021-P-0032-0025,FDA-2021-P-0032,final response from fda ctp to angela bryan,0,0
09000064849e7219,Other,FDA-2021-P-0032-0001,FDA-2021-P-0032,citizen's petition from angela bryan,0,0
09000064849e7302,Supporting & Related Material,FDA-2021-P-0032-0006,FDA-2021-P-0032,citation 36 - the alteration of neonatal raphe neurons by prenatal-perinatal nicotine,0,0
09000064849e7917,Supporting & Related Material,FDA-2021-P-0032-0022,FDA-2021-P-0032,citation 52 - previous preterm and small for gestational age births and the subsequent risk of stillbith,0,0
09000064849e790c,Supporting & Related Material,FDA-2021-P-0032-0014,FDA-2021-P-0032,citation 44 - maternal smoking and the risk of still birth systematic review and meta analysis,0,0
09000064849e7916,Supporting & Related Material,FDA-2021-P-0032-0021,FDA-2021-P-0032,citation 51 - maternal smoking and causes of very preterm birth,0,0
09000064849e7301,Supporting & Related Material,FDA-2021-P-0032-0005,FDA-2021-P-0032,citation 35 - the amount of brainstem gliosis in sudden infant death dyndrome victims correlates with maternal cigarette smoking during pregnancy,0,0
09000064849e7919,Supporting & Related Material,FDA-2021-P-0032-0024,FDA-2021-P-0032,citation 54 - estimates of healthcare spending for preterm and low-birthweight infants in a commercially insured population 2008-2016,0,0
09000064849e7908,Supporting & Related Material,FDA-2021-P-0032-0010,FDA-2021-P-0032,citation 40 - in utero exposures to electronic- cigarette aerosols impair the wnt signaling during mouse lung development,0,0
09000064849e7910,Supporting & Related Material,FDA-2021-P-0032-0018,FDA-2021-P-0032,"citation 48 - parental smoking during pregnancy and its association with low birthweigh, small for gestational age, and pre-term birth",0,0
09000064849e7474,Other,FDA-2021-P-0032-0002,FDA-2021-P-0032,acknowledgment letter from fda dms to angela bryan,0,0
09000064849e7300,Supporting & Related Material,FDA-2021-P-0032-0004,FDA-2021-P-0032,citation 34 - the role of maternal smoking in sudden fetal and infant death pathogenesis,0,0
09000064849e7305,Supporting & Related Material,FDA-2021-P-0032-0009,FDA-2021-P-0032,citation 39 - pulmonary effects of maternal smoking on the fetus and child,0,0
09000064849e7303,Supporting & Related Material,FDA-2021-P-0032-0007,FDA-2021-P-0032,citation 37 - respiratory dysfunction induced by prenatal nicotine exposure,0,0
09000064849e7304,Supporting & Related Material,FDA-2021-P-0032-0008,FDA-2021-P-0032,citation 38 - impact of  tobacco smoke and nicotine exposure on lung development,0,1
09000064849e790a,Supporting & Related Material,FDA-2021-P-0032-0012,FDA-2021-P-0032,citation 42 - the toxicity of e-cigarettes and children's respiratory health,0,0
09000064849e790e,Supporting & Related Material,FDA-2021-P-0032-0016,FDA-2021-P-0032,citation 46 - maternal active smoking during pregnancy and low birth weight in the americas a systematic review and meta-analysis,0,0
09000064849e790f,Supporting & Related Material,FDA-2021-P-0032-0017,FDA-2021-P-0032,citation 47- exposure to tobacco smoke and low birth weight from epidemiology to metabolomics,0,1
09000064809beeff,Other,FDA-2009-P-0253-0001,FDA-2009-P-0253,scott a. tolchin - citizen petition,0,0
09000064809bef02,Other,FDA-2009-P-0253-0002,FDA-2009-P-0253,acknowledgement letter to scott a. tolchin,0,0
0900006480af1697,Other,FDA-2009-P-0253-0004,FDA-2009-P-0253,fda/oc reponse letter to scott a. tolchin  - petition denial,0,0
0900006481c38916,Other,FDA-2015-P-3108-0001,FDA-2015-P-3108,citizen petition from ferrosan medical devices (duval & associates),0,0
0900006484dae700,Other,FDA-2015-P-3108-0003,FDA-2015-P-3108,petition response to ferrosan medical devices (duval & associates) from cdrh,0,0
0900006481c386c5,Other,FDA-2015-P-3108-0002,FDA-2015-P-3108,acknowledgement letter from fda ddm to ferrosan medical devices (duval & associates),0,0
0900006484dc2ae3,Other,FDA-2021-P-1097-0001,FDA-2021-P-1097,citizen petition from ajanta pharma usa inc,0,0
0900006484dc2793,Other,FDA-2021-P-1097-0002,FDA-2021-P-1097,acknowledgment letter from fda dms to ajanta pharma usa inc,0,0
09000064820a6c62,Supporting & Related Material,FDA-2016-P-2030-0007,FDA-2016-P-2030,appendix i - pages 53 - 79 - regulations and scientific papers re citizen petition from the food lawyers,1,0
09000064820a96c1,Other,FDA-2016-P-2030-0002,FDA-2016-P-2030,acknowledgement letter from fda ddm to the food lawyers,1,0
09000064820a6c63,Supporting & Related Material,FDA-2016-P-2030-0008,FDA-2016-P-2030,appendix ii -- gras notices and fda response letters to gras notifications re citizen petition from the food lawyers,1,0
09000064820a6db2,Supporting & Related Material,FDA-2016-P-2030-0005,FDA-2016-P-2030,appendix i - pages 1 - 23 - regulations and scientific papers re citizen petition from the food lawyers,1,0
09000064820a6c61,Supporting & Related Material,FDA-2016-P-2030-0006,FDA-2016-P-2030,appendix i - pages 24 - 52 - regulations and scientific papers re citizen petition from the food lawyers,1,0
09000064820a6db1,Supporting & Related Material,FDA-2016-P-2030-0004,FDA-2016-P-2030,exhibit b composite analysis of kendall (2014) and lee (1998) studies plasma glucose over time following treatment re citizen petition from the food lawyers,1,0
0900006482534cf4,Other,FDA-2016-P-2030-0011,FDA-2016-P-2030,interim response letter from cfsan to the food lawyers,1,0
09000064820a6dab,Other,FDA-2016-P-2030-0001,FDA-2016-P-2030,citizen petition from the food lawyers,1,0
09000064820a6db0,Supporting & Related Material,FDA-2016-P-2030-0003,FDA-2016-P-2030,exhibit a existing regulation 5 and proposed amendment which is §g re citizen petition from the food lawyers,1,0
0900006482344817,Other,FDA-2016-P-3509-0001,FDA-2016-P-3509,citizen petition from metabolic therapy inc,0,0
0900006482556e83,Other,FDA-2016-P-3509-0003,FDA-2016-P-3509,petition denial response from cder,0,0
0900006482344819,Other,FDA-2016-P-3509-0002,FDA-2016-P-3509,acknowledgement letter from fda ddm to metabolic therapy inc,0,0
09000064819fc702,Other,FDA-2015-D-0268-0002,FDA-2015-D-0268,"individual patient expanded access applications: form fda 3926; draft
guidance for industry",0,0
0900006481ebbfe3,Notice,FDA-2015-D-0268-0011,FDA-2015-D-0268,"agency information collection activities; submission for office of
management and budget review; comment request; guidance for
industry on individual patient expanded access applications: form
fda 3926",0,0
09000064819fca41,Rule,FDA-2015-D-0268-0001,FDA-2015-D-0268,"individual patient expanded access applications: form fda 3926; draft
guidance for industry; availability",0,0
090000648200e1ee,Other,FDA-2015-D-0268-0013,FDA-2015-D-0268,guidance for industry on individual patient expanded access applications - form fda 3926,0,0
090000648200d4f8,Notice,FDA-2015-D-0268-0012,FDA-2015-D-0268,"individual patient expanded access applications: form fda 3926; 
guidance for industry; availability",0,0
0900006480bc6e60,Other,FDA-2010-P-0549-0004,FDA-2010-P-0549,lupin limited - reply comment,0,0
0900006480e324c2,Other,FDA-2010-P-0549-0006,FDA-2010-P-0549,"fda/cder to rakoczy molino mazzochi siwik, llp - petition denial",0,0
0900006480c2efd6,Other,FDA-2010-P-0549-0005,FDA-2010-P-0549,"interim response to rakoczy molino mazzochi siwik, llp",0,0
0900006480b7378f,Other,FDA-2010-P-0549-0002,FDA-2010-P-0549,acknowledgement letter to lupin limited,0,0
0900006480b7323f,Other,FDA-2010-P-0549-0001,FDA-2010-P-0549,"lupin limited (rakoczy molino mazzochi siwik, llp) - citizen petition",0,0
0900006481dd73da,Supporting & Related Material,FDA-2015-P-5108-0016,FDA-2015-P-5108,"exhibit 3 published reports of kaplan et al (1998), heiskanen and kalso (1997) and bruera et al (1998) re citizen petition from purdue pharma l.p. (kleinfeld, kaplan and becker, llp)",0,0
0900006481fe4be3,Other,FDA-2015-P-5108-0012,FDA-2015-P-5108,final agency decision petition denial,0,0
0900006481dd7785,Supporting & Related Material,FDA-2015-P-5108-0015,FDA-2015-P-5108,"exhibit 7 kirvela, et al., the pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation re citizen petition from   purdue pharma l.p. (kleinfeld, kaplan and becker, llp)",0,0
0900006481dd778a,Supporting & Related Material,FDA-2015-P-5108-0014,FDA-2015-P-5108,"exhibit 8 physicians desk reference, 53rd ed. 1999 label for roxicodone ir 5 mg re citizen petition from purdue pharma l.p. (kleinfeld, kaplan and becker, llp)",0,0
0900006481dd91ac,Supporting & Related Material,FDA-2015-P-5108-0013,FDA-2015-P-5108,"exhibit 10 gandelman, k et al. single and multiple dose study to evaluate pharmacokinetics safety and tolerability in healthy volunteers re citizen petition from purdue pharma l.p. (kleinfeld, kaplan and becker, llp)",0,0
0900006481ddf501,Other,FDA-2015-P-5108-0002,FDA-2015-P-5108,"acknowledgement letter from fda ddm to kleinfeld, kaplan and becker, llp",0,0
0900006481dd91ad,Supporting & Related Material,FDA-2015-P-5108-0009,FDA-2015-P-5108,"exhibit 11 benziger, cheng, miotto,  and grandy  comparative pharmacokinetics of controlled release oxycodone (oxycontin) in special populations re citizen petition from purdue pharma l.p. (kleinfeld, kaplan and becker, llp)",0,0
0900006481dd73d9,Supporting & Related Material,FDA-2015-P-5108-0004,FDA-2015-P-5108,"exhibit 2 physicians desk reference, 53rd ed. 1999 label for oxycontin re citizen petition from purdue pharma l.p. (kleinfeld, kaplan and becker, llp)",0,0
0900006481dd73db,Supporting & Related Material,FDA-2015-P-5108-0005,FDA-2015-P-5108,"exhibit 4 medical officer review, integrated summary of efficacy, oxycodone controlled release, nda 20553 and medical officer review, oxycontin study 0402b-cancer pain re citizen petition from purdue pharma l.p. (kleinfeld, kaplan and becker, llp)",0,0
0900006481dd73d8,Supporting & Related Material,FDA-2015-P-5108-0003,FDA-2015-P-5108,"exhibit 1 physicians desk reference, 53rd ed. 1999 label for percodan re citizen petition from purdue pharma l.p. (kleinfeld, kaplan and becker, llp)",0,0
0900006481dd91ae,Supporting & Related Material,FDA-2015-P-5108-0010,FDA-2015-P-5108,"exhibit 12 kaiko, grandy, hou, and benziger controlled release oxycodone pharmacokinetics pharmacodynamics in hepatic cirrhosis (abstract) re citizen petition from purdue pharma l.p. (kleinfeld, kaplan and becker, llp)",0,0
0900006481dd7b86,Supporting & Related Material,FDA-2015-P-5108-0006,FDA-2015-P-5108,"exhibit 5 exclusivity summary, nda 20553 re citizen petition from purdue pharma l.p. (kleinfeld, kaplan and becker, llp)",0,0
0900006481e9eae4,Other,FDA-2015-P-5108-0017,FDA-2015-P-5108,supplement from purdue pharma l.p.,0,0
0900006481dd5e86,Other,FDA-2015-P-5108-0001,FDA-2015-P-5108,"citizen petition from purdue pharma l.p. (kleinfeld, kaplan and becker, llp)",0,0
0900006481dd7783,Supporting & Related Material,FDA-2015-P-5108-0007,FDA-2015-P-5108,"exhibit 6 nda review, nda 20-553 e.d. bashaw, pharmd, with excerpts from appendix to review
re citizen petition from purdue pharma l.p. (kleinfeld, kaplan and becker, llp)",0,0
0900006481dd91ab,Supporting & Related Material,FDA-2015-P-5108-0008,FDA-2015-P-5108,"exhibit 9 comments from purdue pharma l.p. docket no. fda-2011-n-0830 (june 8, 2015) re  citizen petition from purdue pharma l.p. (kleinfeld, kaplan and becker, llp)",0,0
0900006482bcf325,Other,FDA-2017-P-2245-0005,FDA-2017-P-2245,petition withdrawal letter from fresenius kabi usa llc,0,0
0900006482549a75,Other,FDA-2017-P-2245-0001,FDA-2017-P-2245,"citizen petiton from fresenius kabi usa, llc",0,0
090000648254a0b8,Other,FDA-2017-P-2245-0002,FDA-2017-P-2245,"acknowledgment letter from fda ddm to fresenius kabi usa, llc",0,0
0900006482b9b496,Other,FDA-2017-P-2245-0004,FDA-2017-P-2245,"interim response letter from cder to fresenius kabi usa, llc",0,0
090000648254a0bc,Supporting & Related Material,FDA-2017-P-2245-0003,FDA-2017-P-2245,"attachment a -  current orange book listing of lactated ringer's and dextrose 5% re for citizen petition from fresenius kabi usa, llc",0,0
090000648355d155,Supporting & Related Material,FDA-2018-P-2851-0011,FDA-2018-P-2851,012-020553_s022_oxycontin_ap,0,0
090000648355d157,Supporting & Related Material,FDA-2018-P-2851-0013,FDA-2018-P-2851,028-percodan label (007337s049lbl),0,0
090000648355d158,Supporting & Related Material,FDA-2018-P-2851-0014,FDA-2018-P-2851,028-pmrs motion for summary judgment,0,0
0900006483547d42,Other,FDA-2018-P-2851-0001,FDA-2018-P-2851,"citizen petition from pharmaceutical manufacturing research services, inc",0,0
09000064835485d6,Supporting & Related Material,FDA-2018-P-2851-0004,FDA-2018-P-2851,combined attachments 2 of 6,0,0
09000064835482dc,Supporting & Related Material,FDA-2018-P-2851-0006,FDA-2018-P-2851,combined attachments 4 of 6,0,0
09000064835482e0,Supporting & Related Material,FDA-2018-P-2851-0008,FDA-2018-P-2851,combined attachments 6 of 6,0,0
09000064835482dd,Supporting & Related Material,FDA-2018-P-2851-0007,FDA-2018-P-2851,combined attachments 5 of 6,0,0
090000648355d156,Supporting & Related Material,FDA-2018-P-2851-0012,FDA-2018-P-2851,025-pmrs_response_to_fda_notice,0,0
090000648355d15a,Supporting & Related Material,FDA-2018-P-2851-0016,FDA-2018-P-2851,036-roxicodone label [12-2016] (021011s006lbl),0,0
090000648355d15c,Supporting & Related Material,FDA-2018-P-2851-0018,FDA-2018-P-2851,084-022272orig1s014lbl,0,0
090000648355d166,Supporting & Related Material,FDA-2018-P-2851-0021,FDA-2018-P-2851,"113-cdc, thrombotic thrombocytopenic purpura (ttp)-like illness associated with intravenous opana er abuse - tennessee, 2012",0,0
090000648355d168,Supporting & Related Material,FDA-2018-P-2851-0023,FDA-2018-P-2851,118-dea quota history,0,0
090000648355d16a,Supporting & Related Material,FDA-2018-P-2851-0025,FDA-2018-P-2851,"130-cdc, opioid data analysis",0,0
0900006483547d44,Other,FDA-2018-P-2851-0002,FDA-2018-P-2851,"acknowledgment letter from fda ddm to pharmaceutical manufacturing research services, inc",0,0
090000648355ae1e,Supporting & Related Material,FDA-2018-P-2851-0009,FDA-2018-P-2851,008-oxycontin_reference_-_020553_original_approval_pkg-oxycontin_-_highlighted,0,0
090000648355d15b,Supporting & Related Material,FDA-2018-P-2851-0017,FDA-2018-P-2851,"060-oxycontin antitrust litigation, purdue v. teva",0,0
090000648355d15d,Supporting & Related Material,FDA-2018-P-2851-0019,FDA-2018-P-2851,092-oxycontin package insert (020553s060lbl),0,0
090000648355d169,Supporting & Related Material,FDA-2018-P-2851-0024,FDA-2018-P-2851,"128-cdc, understanding the epidemic",0,0
090000648355d154,Supporting & Related Material,FDA-2018-P-2851-0010,FDA-2018-P-2851,011-oxycontin_reference_-_meeting_minutes_2001-06-14_-_labeling_and_development_plan_for_reformulation_-_by_fda,0,0
090000648355d165,Supporting & Related Material,FDA-2018-P-2851-0020,FDA-2018-P-2851,093-as0363600 dsr cii drug product cutting force method,0,0
090000648355d16c,Supporting & Related Material,FDA-2018-P-2851-0027,FDA-2018-P-2851,"138-nida, overdose death rates",0,0
090000648355d159,Supporting & Related Material,FDA-2018-P-2851-0015,FDA-2018-P-2851,029-roxicodone label [2009 approval] (021011s003lbl),0,0
090000648355d167,Supporting & Related Material,FDA-2018-P-2851-0022,FDA-2018-P-2851,"117-cdc, community outbreak of hiv infection linked to injection drug use of oxymorphone - indiana, 2015",0,0
090000648355d16b,Supporting & Related Material,FDA-2018-P-2851-0026,FDA-2018-P-2851,"133-cdc, mm6610a1",0,0
09000064841adddf,Supporting & Related Material,FDA-2019-P-5571-0005,FDA-2019-P-5571,"attachment 3 - structure, properties, and function of acopper(i)-copper(ii) complex of d-penicillamine:pentathalli um( i) μ8-chloro-dodeca(d-penicillaminato )octacuprate(i )hexacu prate( ii) n-hydrate re: citizen petition from sheppard, mullin, richter & hampton llp on behalf of apicore pharmaceutical private ltd",0,0
09000064841adddd,Supporting & Related Material,FDA-2019-P-5571-0003,FDA-2019-P-5571,"attachment 1 - clinical pharmacokinetics re citizen petition from sheppard, mullin, richter & hampton llp on behalf of apicore pharmaceutical private ltd",0,0
09000064841addde,Supporting & Related Material,FDA-2019-P-5571-0004,FDA-2019-P-5571,"attachment 2 - identification of factors limiting the accuratemeasurement of plasma d-penicillamine in rheumatoidarthritis patients re: citizen petition from sheppard, mullin, richter & hampton llp on behalf of apicore pharmaceutical private ltd",0,0
09000064841bfbc9,Other,FDA-2019-P-5571-0001,FDA-2019-P-5571,"citizen petition from sheppard, mullin, richter & hampton llp on behalf of apicore pharmaceutical private ltd",0,0
09000064843795be,Other,FDA-2019-P-5571-0007,FDA-2019-P-5571,"withdrawal from sheppard, mullin, richter & hampton llp on behalf of apicore pharmaceutical private ltd",0,0
09000064841adde0,Supporting & Related Material,FDA-2019-P-5571-0006,FDA-2019-P-5571,"attachment 4 - capsulescuprimine® (penicillamine) re: citizen petition from sheppard, mullin, richter & hampton llp on behalf of apicore pharmaceutical private ltd",0,0
09000064841bfc63,Other,FDA-2019-P-5571-0002,FDA-2019-P-5571,"acknowledgment letter from fda ddm to apicore pharmaceutical private, ltd.",0,0
0900006482bec070,Other,FDA-2017-P-2563-0042,FDA-2017-P-2563,interim response from fda to the tatia oden french memorial foundation,0,0
0900006482bfbe89,Other,FDA-2017-P-2563-0053,FDA-2017-P-2563,supplement from tatia oden french memorial foundation,0,0
090000648257a171,Other,FDA-2017-P-2563-0002,FDA-2017-P-2563,acknowledgment letter from fda ddm to the tatia oden french memorial foundation,0,0
09000064825739b9,Other,FDA-2017-P-2563-0001,FDA-2017-P-2563,citizen petition from the tatia oden french memorial foundation,0,0
09000064832f580b,Other,FDA-2017-P-2563-0056,FDA-2017-P-2563,supplement from the tatia oden french memorial foundation,0,0
09000064839ac3c5,Other,FDA-2017-P-2563-0057,FDA-2017-P-2563,letter from fda cder to the tatia oden french memorial foundation,0,0
0900006482358264,Other,FDA-2016-P-3578-0001,FDA-2016-P-3578,citizen petition from association for truthinpetfood.com (atpf),0,0
0900006483d86d1d,Other,FDA-2016-P-3578-0007,FDA-2016-P-3578,petition for reconsideration from association for truth in pet food (atpf),1,0
090000648432d939,Other,FDA-2016-P-3578-0838,FDA-2016-P-3578,final response letter from fda cvm to association for truth in pet food,1,0
0900006483d8737d,Other,FDA-2016-P-3578-0008,FDA-2016-P-3578,acknowledgment letter from fda ddm to association for truth in pet food,1,0
0900006482358266,Other,FDA-2016-P-3578-0002,FDA-2016-P-3578,acknowledgment letter from fda ddm to association for truthinpetfood.com (atpf),0,0
09000064826801eb,Other,FDA-2016-P-3578-0003,FDA-2016-P-3578,interim response letter from cvm to truthinpetfood.com,0,0
0900006483c1f6fa,Other,FDA-2016-P-3578-0006,FDA-2016-P-3578,final response - letter from fda cvm to associationfortruthinpetfood.com,0,0
09000064828ca926,Other,FDA-2016-P-3578-0004,FDA-2016-P-3578,addendum to citizen petition fda-2016-p-3578  from the association for truth in pet food (atpf),1,0
090000648410a39e,Supporting & Related Material,FDA-2019-P-5048-0003,FDA-2019-P-5048,"attachment a- percutaneous electrical nerve field stimulation modulates central pain pathways and attenuates post-inflammatory visceral and somatic hyperalgesia in rats re citizen petition from epstein, becker and green on behalf of  innovative health solutions, inc.",0,0
0900006484502dce,Other,FDA-2019-P-5048-0005,FDA-2019-P-5048,"interim response letter from fda cdrh to epstein becker & green, pc",0,0
090000648410a39f,Supporting & Related Material,FDA-2019-P-5048-0004,FDA-2019-P-5048,"attachment b- neonatal nociceptive somatic stimulation differentially
modifies the activity of spinal neurons in rats and results in altered somatic and visceral sensation re citizen petition from epstein, becker and green on behalf of  innovative health solutions, inc.",0,0
090000648410a260,Other,FDA-2019-P-5048-0001,FDA-2019-P-5048,"citizen petition from epstein, becker and green p.c. on behalf of  innovative health solutions, inc.",0,0
090000648410a39a,Other,FDA-2019-P-5048-0002,FDA-2019-P-5048,"acknowledgment letter from fda dms to epstein becker & green, p.c. on behalf of innovative health solutions, inc.",0,0
090000648327dd93,Other,FDA-2017-P-6923-0003,FDA-2017-P-6923,petition denial letter from fda cder to zydus noveltech inc.,0,0
0900006482d3cf5e,Other,FDA-2017-P-6923-0001,FDA-2017-P-6923,confidential citizen petition from zydus noveltech inc,0,0
09000064832bf2bd,Other,FDA-2017-P-6923-0004,FDA-2017-P-6923,exelon - acknoledgement letter - corrected,0,0
0900006482d3cf60,Other,FDA-2017-P-6923-0002,FDA-2017-P-6923,acknowledgment letter from fda ddm to zydus noveltech inc.,0,0
0900006483009a0f,Other,FDA-2018-P-1110-0002,FDA-2018-P-1110,acknowledgment letter from fda ddm to haynes and boone llp,0,0
0900006483009264,Other,FDA-2018-P-1110-0001,FDA-2018-P-1110,citizen petition from haynes and boone llp,0,0
090000648458605a,Other,FDA-2020-P-1356-0002,FDA-2020-P-1356,"acknowledgment letter from fda dms to qilu pharmaceutical co., ltd.",0,0
0900006484958604,Other,FDA-2020-P-1356-0003,FDA-2020-P-1356,"withdrawal from qilu pharma, inc.",0,0
0900006484586059,Other,FDA-2020-P-1356-0001,FDA-2020-P-1356,"citizen petition  from qilu pharmaceutical co., ltd",0,0
090000648227fb10,Other,FDA-2016-P-3015-0001,FDA-2016-P-3015,"citizen petition from douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd.)",0,0
090000648227fbb5,Supporting & Related Material,FDA-2016-P-3015-0003,FDA-2016-P-3015,"attachment 1 baytril® ( enrofloxacin) taste tabs® antibacterial tablets for dogs and cats re citizen petition from douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd.)",0,0
090000648227fbb6,Supporting & Related Material,FDA-2016-P-3015-0004,FDA-2016-P-3015,"attachment 2 felix pharmaceuticals pvt. ltd; tbd (enrofloxacin)
soft chew tabs® antibacterial tablets for dogs and cats re citizen petition from douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd.)",0,0
0900006482481e47,Other,FDA-2016-P-3015-0005,FDA-2016-P-3015,letter from cvm to douglass oeller consulting inc,0,0
090000648227fbb3,Other,FDA-2016-P-3015-0002,FDA-2016-P-3015,"acknowledgment letter from fda ddm to douglass oeller consulting, inc.",0,0
0900006482575a28,Other,FDA-2016-P-3598-0004,FDA-2016-P-3598,interim response from fda to axinn veltrop & harkrider llp,0,0
0900006482b26502,Other,FDA-2016-P-3598-0005,FDA-2016-P-3598,"final response letter from fda to axinn, veltrop & harkrider llp",0,0
090000648235b5fd,Supporting & Related Material,FDA-2016-P-3598-0003,FDA-2016-P-3598,attachment 1 - fda orange book page for melphalan hydrochloride,0,0
090000648235b5fb,Other,FDA-2016-P-3598-0002,FDA-2016-P-3598,"acknowledgment letter from fda ddm to axinn, veltrop & harkrider llp",0,0
090000648235b5f9,Other,FDA-2016-P-3598-0001,FDA-2016-P-3598,"citizen petition from axinn, veltrop & harkrider llp",0,0
090000648239e99d,Other,FDA-2016-P-3912-0001,FDA-2016-P-3912,citizen petition from adapt pharma operations ltd.,0,0
090000648239ea16,Other,FDA-2016-P-3912-0002,FDA-2016-P-3912,acknowledgment letter from fda ddm to adapt pharma operations ltd,0,0
09000064823be092,Other,FDA-2016-P-3912-0003,FDA-2016-P-3912,withdrawal from pacific-link consulting,0,0
0900006481fdd5d1,Supporting & Related Material,FDA-2016-P-1303-0003,FDA-2016-P-1303,attachment 1 determination of methyl mercury in dental-unit wastewater re citizen petition from consumers for dental choice,0,0
0900006481fdd5d2,Supporting & Related Material,FDA-2016-P-1303-0004,FDA-2016-P-1303,attachment 2 epa will propose rule to protect waterways by reducing mercury from dental offices re citizen petition from consumers for dental choice,0,0
0900006481fdd5d7,Supporting & Related Material,FDA-2016-P-1303-0009,FDA-2016-P-1303,attachment 7 zogby poll (2006) re citizen petition from consumers for dental choice,0,0
0900006481fdd5d6,Supporting & Related Material,FDA-2016-P-1303-0008,FDA-2016-P-1303,attachment 6 the real cost of dental mercury re citizen petition from consumers for dental choice,0,0
0900006481fdd5dd,Supporting & Related Material,FDA-2016-P-1303-0013,FDA-2016-P-1303,"attachment 11 climate and pollution agency, review of norwegian experiences with the phase-out of dental amalgam use re citizen petition from consumers for dental choice",0,0
0900006481fdd201,Other,FDA-2016-P-1303-0002,FDA-2016-P-1303,acknowledgement letter from fda ddm to  consumers for dental choice,0,0
0900006481fdd5d3,Supporting & Related Material,FDA-2016-P-1303-0005,FDA-2016-P-1303,attachment 3 environmental costs of mercury pollution re citizen petition from consumers for dental choice,0,0
0900006481fdd5d5,Supporting & Related Material,FDA-2016-P-1303-0007,FDA-2016-P-1303,attachment 5 minamata convention (2013) re citizen petition from consumers for dental choice,0,0
0900006481fdd5dc,Supporting & Related Material,FDA-2016-P-1303-0012,FDA-2016-P-1303,"attachment 10 swedish chemicals agency, mercury phase-out, a study of the experiences of swedish companies re citizen petition from consumers for dental choice",0,0
0900006481fdd5d8,Supporting & Related Material,FDA-2016-P-1303-0010,FDA-2016-P-1303,"attachment 8 unep, lessons from countries phasing down dental amalgam use re citizen petition from consumers for dental choice",0,0
0900006481fdd5d9,Supporting & Related Material,FDA-2016-P-1303-0011,FDA-2016-P-1303,attachment 9 request for information of mercury in products and processes re citizen petition from consumers for dental choice,0,0
0900006481fdd5de,Supporting & Related Material,FDA-2016-P-1303-0014,FDA-2016-P-1303,attachment 12  measurably misleading re citizen petition from consumers for dental choice,0,0
0900006482795570,Other,FDA-2016-P-1303-0015,FDA-2016-P-1303,interim response letter from cdrh to consumers for dental choice,0,0
0900006481fdd1ff,Other,FDA-2016-P-1303-0001,FDA-2016-P-1303,citizen petition from consumers for dental choice,0,0
0900006481fdd5d4,Supporting & Related Material,FDA-2016-P-1303-0006,FDA-2016-P-1303,"attachment 4 changing patterns in the use, recycling, and material substitution of mercury in the united states (2013) re citizen petition from consumers for dental choice",0,0
09000064824fc6fd,Other,FDA-2017-P-1461-0001,FDA-2017-P-1461,citizen petition from foley & lardner llp,0,0
09000064824fcce5,Other,FDA-2017-P-1461-0002,FDA-2017-P-1461,acknowledgment letter from fda ddm to foley & lardner llp,0,0
0900006482af77a1,Other,FDA-2017-P-1461-0004,FDA-2017-P-1461,response letter from fda cder to foley & lardner llp,0,0
0900006482af3dfb,Notice,FDA-2017-P-1461-0003,FDA-2017-P-1461,"determination that cenestin (estrogens, conjugated synthetic a)  tablets, 0.3 milligrams, 0.45 milligrams, 0.625 milligrams, 0.9 milligrams, and 1.25 milligrams, were not withdrawn from sale for reasons of safety or effectiveness",0,0
090000648185aeee,Other,FDA-2014-P-1302-0001,FDA-2014-P-1302,citizen petition from duchesnay,0,0
090000648185af92,Other,FDA-2014-P-1302-0004,FDA-2014-P-1302,"acknowledgement letter from fda/ddm to duchesnay, fda-2014-p-1302-0001",0,0
09000064818877eb,Other,FDA-2014-P-1302-0005,FDA-2014-P-1302,withdrawal letter from duchesnay,0,0
090000648185af8e,Supporting & Related Material,FDA-2014-P-1302-0003,FDA-2014-P-1302,"attachment 2 koren, et al., sex differences in the pharmacokinetics and bioequivalence of the delayed-release combination of doxylamine succinate-pyridoxine hydrochloride implications for pharmacotherapy the journal of clinical pharmacology in pregnancy re citizen petition from duchesnay, fda-2014-p-1302-0001",0,0
090000648185aeef,Supporting & Related Material,FDA-2014-P-1302-0002,FDA-2014-P-1302,"attachment 1 re citizen petition from duchesnay, fda-2014-p-1302-0001",0,0
090000648417de3b,Other,FDA-2019-P-5463-0001,FDA-2019-P-5463,"citizen petition from sheppard, mullin, richter & hampton llp on behalf of apicore pharmaceutical private, ltd.",0,0
090000648417db52,Supporting & Related Material,FDA-2019-P-5463-0006,FDA-2019-P-5463,"attachment 4 - label prescribing information (rld cuprimine nda) re citizen petition from sheppard, mullin, richter & hampton llp on behalf of apicore pharmaceutical private, ltd.",0,0
090000648417db4f,Supporting & Related Material,FDA-2019-P-5463-0003,FDA-2019-P-5463,"attachment 1 - netter clinical pharmacokinetics (1987) re citizen petition from sheppard, mullin, richter & hampton llp on behalf of apicore pharmaceutical private, ltd.",0,0
090000648417db50,Supporting & Related Material,FDA-2019-P-5463-0004,FDA-2019-P-5463,"attachment 2 - webb et al ann clin biochem (1988) (1) re citizen petition from sheppard, mullin, richter & hampton llp on behalf of apicore pharmaceutical private, ltd.",0,0
090000648417db51,Supporting & Related Material,FDA-2019-P-5463-0005,FDA-2019-P-5463,"attachment 3 - birker journal american chem soc (1977) re citizen petition from sheppard, mullin, richter & hampton llp on behalf of apicore pharmaceutical private, ltd.",0,0
090000648417db4b,Other,FDA-2019-P-5463-0002,FDA-2019-P-5463,"acknowledgment letter from fda dms to sheppard, mullin, richter & hampton llp on behalf of apicore pharmaceutical private, ltd.",0,0
09000064841b150c,Other,FDA-2019-P-5463-0007,FDA-2019-P-5463,"withdrawal from sheppard, mullin, richter & hampton llp",0,0
0900006484e0530a,Other,FDA-2021-P-1184-0002,FDA-2021-P-1184,acknowledgment letter from fda dms to lachman consultant services inc,0,0
0900006484e05d7c,Other,FDA-2021-P-1184-0001,FDA-2021-P-1184,citizen petition from lachman consultant services inc,0,0
0900006482fa58fc,Supporting & Related Material,FDA-2018-P-1014-0007,FDA-2018-P-1014,exhibit e - zhang_plos one_2014 re citizen petition from haynes and boone llp,0,0
0900006482fa58f8,Supporting & Related Material,FDA-2018-P-1014-0003,FDA-2018-P-1014,exhibit a - mycophenolate mofetil oral suspension draft guidance october 2017 re citizen petition from haynes and boone llp,0,0
0900006482fa58f9,Supporting & Related Material,FDA-2018-P-1014-0004,FDA-2018-P-1014,exhibit b - cellcept pi re citizen petition from haynes and boone llp,0,0
0900006482fa5940,Supporting & Related Material,FDA-2018-P-1014-0012,FDA-2018-P-1014,exhibit j - proamatine prescribing information re citizen petition from haynes and boone llp,0,0
0900006482fa58fe,Supporting & Related Material,FDA-2018-P-1014-0009,FDA-2018-P-1014,exhibit g - borrows_american journal of transplantation_2006 re citizen petition from haynes and boone llp,0,0
0900006482fa58ff,Supporting & Related Material,FDA-2018-P-1014-0010,FDA-2018-P-1014,exhibit h - midodrine hcl draft guidance re citizen petition from haynes and boone llp,0,0
0900006482fa5941,Supporting & Related Material,FDA-2018-P-1014-0013,FDA-2018-P-1014,exhibit k - temodar prescribing information re citizen petition from haynes and boone llp,0,0
09000064835c6e89,Other,FDA-2018-P-1014-0014,FDA-2018-P-1014,"petition response letter from fda cder to haynes and boone, llp",0,0
0900006482fa58fa,Supporting & Related Material,FDA-2018-P-1014-0005,FDA-2018-P-1014,exhibit c - partani_j sep sci_2015 re citizen petition from haynes and boone llp,0,0
0900006482fa58fd,Supporting & Related Material,FDA-2018-P-1014-0008,FDA-2018-P-1014,exhibit f - levesque_clinical pharmacology therapeutics_2007 re citizen petition from haynes and boone llp,0,0
0900006482fa58fb,Supporting & Related Material,FDA-2018-P-1014-0006,FDA-2018-P-1014,exhibit d - fujiyama_drug metabolism and disposition_2010 re citizen petition from haynes and boone llp,0,0
0900006482fa5900,Supporting & Related Material,FDA-2018-P-1014-0011,FDA-2018-P-1014,exhibit i - temozolomide draft guidance re citizen petition from haynes and boone llp,0,0
0900006482fa53de,Other,FDA-2018-P-1014-0002,FDA-2018-P-1014,"acknowledgment letter from fda ddm to haynes and boone, llp",0,0
0900006482fa53dc,Other,FDA-2018-P-1014-0001,FDA-2018-P-1014,citizen petition from haynes and boone llp,0,0
09000064823ccd8a,Other,FDA-2015-P-4935-0006,FDA-2015-P-4935,interim response letter from fda cder to abbvie inc,0,0
0900006481dbe473,Other,FDA-2015-P-4935-0001,FDA-2015-P-4935,citizen petition from abbvie inc.,0,0
0900006481dbe47b,Other,FDA-2015-P-4935-0002,FDA-2015-P-4935,acknowledgement letter from fda ddm to abbvie inc,0,0
09000064821533bd,Other,FDA-2015-P-4935-0005,FDA-2015-P-4935,abbvie meeting minutes,0,0
090000648247ef15,Other,FDA-2015-P-4935-0007,FDA-2015-P-4935,"citizen petition denial letter from fda cder to abbvie, inc.",0,0
090000648448bd08,Other,FDA-2019-P-4683-0007,FDA-2019-P-4683,interim response letter from fda cder to public citizen,0,0
09000064848de0e2,Other,FDA-2019-P-4683-0008,FDA-2019-P-4683,response letter from fda  to public citizen's health research group,0,0
090000648405c4d0,Supporting & Related Material,FDA-2019-P-4683-0004,FDA-2019-P-4683,reference 12 prevention of recurrent preterm delivery by 17 alpha hydroxyprogesterone caproate re: citizen petition from public citizen,0,0
090000648405c460,Other,FDA-2019-P-4683-0001,FDA-2019-P-4683,citizen petition from public citizen,0,0
090000648405c4d1,Supporting & Related Material,FDA-2019-P-4683-0003,FDA-2019-P-4683,reference 2 progestin therapy to prevent preterm birth: history and effectiveness of current strategies and development of novel approaches re: citizen petition from public citizen,0,0
090000648405c719,Other,FDA-2019-P-4683-0002,FDA-2019-P-4683,acknowledgment letter from fda dms to public citizen,0,0
090000648450ec2f,Supporting & Related Material,FDA-2020-P-1312-0003,FDA-2020-P-1312,"attachment a - current lonsurf labeling -  re: citizen petition from foley & lardner llp on behalf of taiho oncology, inc.",0,0
090000648450d7e8,Other,FDA-2020-P-1312-0002,FDA-2020-P-1312,"acknowledgment letter from fda dms to foley & lardner llp on behalf of taiho oncology, inc.",0,0
0900006484866c1e,Other,FDA-2020-P-1312-0005,FDA-2020-P-1312,letter from cder to foley & lardner llp,0,0
090000648450cb13,Other,FDA-2020-P-1312-0001,FDA-2020-P-1312,"citizen petition from foley & lardner llp on behalf of taiho oncology, inc.",0,0
090000648447bd27,Other,FDA-2020-P-1239-0002,FDA-2020-P-1239,"acknowledgment letter from fda dms to wiley rein, llp",0,0
090000648447ed29,Other,FDA-2020-P-1239-0003,FDA-2020-P-1239,"letter from wiley rein, llp",0,0
090000648460dd1b,Other,FDA-2020-P-1239-0005,FDA-2020-P-1239,withdrawal from wiley rein llp,0,0
090000648447bd26,Other,FDA-2020-P-1239-0001,FDA-2020-P-1239,"petition for stay of action from wiley rein, llp",0,0
090000648449143f,Other,FDA-2020-P-1239-0004,FDA-2020-P-1239,supplement from wiley rein llp,0,0
09000064823e5a6f,Supporting & Related Material,FDA-2016-P-4233-0006,FDA-2016-P-4233,attachments 4 - 2016 05 15 - kfsu00038 nutrition and mineral analyses - finished product q240-2 re citizen petition from kfsu ltd,0,0
09000064823e5a69,Other,FDA-2016-P-4233-0002,FDA-2016-P-4233,citizen petition from kfsu ltd,0,0
09000064823e5a6d,Supporting & Related Material,FDA-2016-P-4233-0005,FDA-2016-P-4233,attachment 3 - 2015 12 15 - kfsu00036 nutrition and mineral analyses-2 re citizen petition from kfsu ltd,0,0
090000648275d092,Other,FDA-2016-P-4233-0008,FDA-2016-P-4233,cfsan interim response letter to kfsu ltd sugarcane flour,0,0
09000064823e5a6b,Supporting & Related Material,FDA-2016-P-4233-0003,FDA-2016-P-4233,attachment 1 kfsu process flowchart 2 (1) (002)-1 re citizen petition from kfsu ltd,0,0
09000064823e5a6c,Supporting & Related Material,FDA-2016-P-4233-0004,FDA-2016-P-4233,attachment 2 - an analysis of the lignocellulosic diversity of sugarcane-2 re citizen petition from kfsu ltd,0,0
09000064823e7b86,Other,FDA-2016-P-4233-0001,FDA-2016-P-4233,acknowledgment letter from fda ddm to kfsu ltd,0,0
0900006483410f0e,Other,FDA-2016-P-4233-0009,FDA-2016-P-4233,fda-2016-p-4233 - kfsu granting response letter,0,0
09000064823e5a6e,Supporting & Related Material,FDA-2016-P-4233-0007,FDA-2016-P-4233,attachment 5 - 2016 03 23 - kfsu00037 nutrition analyses report-2 re citizen petition from kfsu ltd,0,0
0900006484661843,Supporting & Related Material,FDA-2020-P-1416-0026,FDA-2020-P-1416,"tab 14 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661851,Supporting & Related Material,FDA-2020-P-1416-0020,FDA-2020-P-1416,"tab 20 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661857,Supporting & Related Material,FDA-2020-P-1416-0014,FDA-2020-P-1416,"tab 26 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
090000648465f7fe,Other,FDA-2020-P-1416-0002,FDA-2020-P-1416,"acknowledgment letter from fda dms to sidley austin, llp. on behalf of cell2in, inc.",0,0
0900006484661804,Supporting & Related Material,FDA-2020-P-1416-0033,FDA-2020-P-1416,"tab 7 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661862,Supporting & Related Material,FDA-2020-P-1416-0009,FDA-2020-P-1416,"tab 31 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661803,Supporting & Related Material,FDA-2020-P-1416-0034,FDA-2020-P-1416,"tab 6 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661805,Supporting & Related Material,FDA-2020-P-1416-0032,FDA-2020-P-1416,"tab 8 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
090000648466183f,Supporting & Related Material,FDA-2020-P-1416-0030,FDA-2020-P-1416,"tab 10 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661861,Supporting & Related Material,FDA-2020-P-1416-0010,FDA-2020-P-1416,"tab 30 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661867,Supporting & Related Material,FDA-2020-P-1416-0004,FDA-2020-P-1416,"tab 36 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661855,Supporting & Related Material,FDA-2020-P-1416-0016,FDA-2020-P-1416,"tab 24 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
090000648465f7fd,Other,FDA-2020-P-1416-0001,FDA-2020-P-1416,"citizen petition from sidley austin, llp.  on behalf of cell2in, inc.",0,0
0900006484661864,Supporting & Related Material,FDA-2020-P-1416-0007,FDA-2020-P-1416,"tab 33 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661845,Supporting & Related Material,FDA-2020-P-1416-0024,FDA-2020-P-1416,"tab 16 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661840,Supporting & Related Material,FDA-2020-P-1416-0029,FDA-2020-P-1416,"tab 11 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661842,Supporting & Related Material,FDA-2020-P-1416-0027,FDA-2020-P-1416,"tab 13 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661868,Supporting & Related Material,FDA-2020-P-1416-0003,FDA-2020-P-1416,"tab 37 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
090000648495a084,Other,FDA-2020-P-1416-0040,FDA-2020-P-1416,interim response from cber to peter choi,0,0
0900006484661863,Supporting & Related Material,FDA-2020-P-1416-0008,FDA-2020-P-1416,"tab 32 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661847,Supporting & Related Material,FDA-2020-P-1416-0022,FDA-2020-P-1416,"tab 18 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661806,Supporting & Related Material,FDA-2020-P-1416-0031,FDA-2020-P-1416,"tab 9 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661846,Supporting & Related Material,FDA-2020-P-1416-0023,FDA-2020-P-1416,"tab 17 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661858,Supporting & Related Material,FDA-2020-P-1416-0013,FDA-2020-P-1416,"tab 27 re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484661859,Supporting & Related Material,FDA-2020-P-1416-0012,FDA-2020-P-1416,"tab 28  re citizen petition from sidley austin, llp. (on behalf of cell2in, inc.)",0,0
0900006484ca1d32,Other,FDA-2021-P-0938-0002,FDA-2021-P-0938,acknowledgment letter from fda dms to daniel fabricant,0,0
0900006484ca210b,Other,FDA-2021-P-0938-0001,FDA-2021-P-0938,citizen petition from daniel fabricant,0,0
0900006484ca1d35,Supporting & Related Material,FDA-2021-P-0938-0003,FDA-2021-P-0938,envelope re citizen petition from daniel fabricant,0,0
090000648362dbab,Other,FDA-2017-P-5947-0005,FDA-2017-P-5947,request to withdraw cp,0,0
0900006482b81fea,Supporting & Related Material,FDA-2017-P-5947-0003,FDA-2017-P-5947,attachment a orange book approved drug products re citizen petition from teligent pharma inc,0,0
09000064830409ac,Other,FDA-2017-P-5947-0004,FDA-2017-P-5947,interim response letter from fda cder to teligent pharma inc,0,0
0900006482b81fd8,Other,FDA-2017-P-5947-0001,FDA-2017-P-5947,citizen petition from teligent pharma inc,0,0
0900006482b81fe8,Other,FDA-2017-P-5947-0002,FDA-2017-P-5947,acknowledgement letter from fda ddm to teligent pharma inc,0,0
090000648174307e,Supporting & Related Material,FDA-2014-P-0794-0003,FDA-2014-P-0794,reference 1 label information felimazole citizen petition from e5 pharma llc,0,0
090000648180436e,Other,FDA-2014-P-0794-0004,FDA-2014-P-0794,"amendment from e5 pharma, llc",0,0
0900006481741daa,Other,FDA-2014-P-0794-0001,FDA-2014-P-0794,citizen petition from e5 pharma llc,0,0
0900006481858d9b,Other,FDA-2014-P-0794-0005,FDA-2014-P-0794,"citizen petition approval letter from fda/cvm to e5 pharma, llc",0,0
0900006481742931,Other,FDA-2014-P-0794-0002,FDA-2014-P-0794,acknowledgement letter from fda ddm to e5 pharma llc,0,0
0900006483a88092,Other,FDA-2018-P-3597-0005,FDA-2018-P-3597,letter from fda cder to arent fox llp,0,0
09000064837590db,Supporting & Related Material,FDA-2018-P-3597-0003,FDA-2018-P-3597,attachment 1- growth dynamics audit from june 2014 to june 2018. re: citizen petition from arent fox,0,0
0900006483758ed8,Other,FDA-2018-P-3597-0001,FDA-2018-P-3597,citizen petition from arent fox llp,0,0
0900006483a6c9f4,Notice,FDA-2018-P-3597-0004,FDA-2018-P-3597,"determination that lotrimin (clotrimazole) topical solution, 1%, was not withdrawn from sale for reasons of safety or effectiveness",0,0
09000064837590d9,Other,FDA-2018-P-3597-0002,FDA-2018-P-3597,acknowledgment letter from fda ddm to arent fox llp,0,0
0900006484328604,Other,FDA-2020-P-0599-0002,FDA-2020-P-0599,"acknowledgment letter from fda dms to foley & lardner, llp  on behalf of romark laboratories, l.c.",0,0
0900006484328603,Other,FDA-2020-P-0599-0001,FDA-2020-P-0599,"citizen petition from foley & lardner, llp. on behalf of romark laboratories, l.c.",0,0
0900006484979ca6,Other,FDA-2020-P-0599-0004,FDA-2020-P-0599,"response letter from fda cder to romark laboratories, l.c.",0,0
09000064847b02ed,Other,FDA-2020-P-0599-0003,FDA-2020-P-0599,"interim response letter from fda cder to romark laboratories, l.c.",0,0
0900006483bc55a6,Supporting & Related Material,FDA-2019-P-1893-0004,FDA-2019-P-1893,tab 2 feng et al (2012) lcz696: a dual-acting sodium supramolecular complex re citizen petition from novartis pharmaceuticals corporation,0,0
090000648408ed91,Other,FDA-2019-P-1893-0008,FDA-2019-P-1893,interim response letter from fda cder to novartis pharmaceuticals corporation,0,0
0900006483bc55a7,Supporting & Related Material,FDA-2019-P-1893-0005,FDA-2019-P-1893,"tab 3 gu et al (2010) pharmacokinetics and pharmacodynamics of lcz696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (arni) re citizen petition from novartis pharmaceuticals corporation",0,0
0900006483bc55a8,Supporting & Related Material,FDA-2019-P-1893-0006,FDA-2019-P-1893,tab 4 kobalava et al (2016) pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (lcz696) in patients with heart failure and reduced ejection fraction re citizen petition from novartis pharmaceuticals corporation,0,0
0900006483bc55aa,Other,FDA-2019-P-1893-0002,FDA-2019-P-1893,acknowledgment letter from fda ddm to novartis pharmaceuticals corporation,0,0
0900006483bc55a1,Other,FDA-2019-P-1893-0001,FDA-2019-P-1893,citizen petition from novartis pharmaceuticals corporation,0,0
0900006483bc55a9,Supporting & Related Material,FDA-2019-P-1893-0007,FDA-2019-P-1893,"tab 5 ayalasomayajula et al (2015) assessment of drug interaction potential between lcz696, an angiotensin receptor neprilysin inhibitor, and digoxin or warfarin re citizen petition from novartis pharmaceuticals corporation",0,0
0900006483bc55a5,Supporting & Related Material,FDA-2019-P-1893-0003,FDA-2019-P-1893,tab 1 mcmurray et al (2014) angiotensin–neprilysin inhibition versus enalapril in heart failure re: citizen petition from novartis pharmaceuticals corporation,0,0
0900006481a39c2c,Supporting & Related Material,FDA-2014-P-1065-0009,FDA-2014-P-1065,letter from fda cder to zydus pharmaceuticals,0,0
0900006481a39e02,Other,FDA-2014-P-1065-0008,FDA-2014-P-1065,letter from zydus pharmaceuticals to fda,0,0
0900006481869b16,Supporting & Related Material,FDA-2014-P-1065-0006,FDA-2014-P-1065,shipping label re citizen petition from zydus pharmaceuticals inc fda-2014-p-1065-0001,0,0
09000064817ee192,Supporting & Related Material,FDA-2014-P-1065-0002,FDA-2014-P-1065,attachment 2 orange book re citizen petition from zydus pharmaceuticals inc fda-2014-p-1065-0001,0,0
09000064817ee193,Supporting & Related Material,FDA-2014-P-1065-0003,FDA-2014-P-1065,attachment 3 another response re citizen petition from zydus pharmaceuticals inc fda-2014-p-1065-0001,0,0
0900006481999f0d,Other,FDA-2014-P-1065-0007,FDA-2014-P-1065,citizen petition approval response letter from fda cder to zydus pharmaceuticals inc,0,0
09000064817ed366,Other,FDA-2014-P-1065-0001,FDA-2014-P-1065,citizen petition from zydus pharmaceuticals inc,0,0
09000064817ed47d,Other,FDA-2014-P-1065-0004,FDA-2014-P-1065,acknowledgement letter from fda ddm to zydus oharmaceuticals,0,0
09000064817ee18f,Supporting & Related Material,FDA-2014-P-1065-0005,FDA-2014-P-1065,attachment 1 prescribing information prasco label re citizen petition from zydus pharmaceuticals inc fda-2014-p-1065-0001,0,0
09000064825303d7,Other,FDA-2015-P-1977-0243,FDA-2015-P-1977,supplement from gerald steel,0,0
0900006482974124,Other,FDA-2015-P-1977-0244,FDA-2015-P-1977,testimony from julie simms (gerald steel),0,0
0900006481b15811,Other,FDA-2015-P-1977-0001,FDA-2015-P-1977,citizen petition from gerald steel,0,0
0900006481b1617a,Supporting & Related Material,FDA-2015-P-1977-0009,FDA-2015-P-1977,attachment 7 nsf fact sheet re citizen petition from gerald steel,0,0
0900006481b1617d,Supporting & Related Material,FDA-2015-P-1977-0012,FDA-2015-P-1977,attachment 10 letter from epa to gerald steel re citizen petition from gerald steel,0,0
0900006481b1617c,Supporting & Related Material,FDA-2015-P-1977-0011,FDA-2015-P-1977,attachment 9 sodium flouride analysis re citizen petition from gerald steel,0,0
090000648395ab47,Other,FDA-2015-P-1977-0249,FDA-2015-P-1977,acknowledgment letter from fda ddm to gerald steel,0,0
0900006481b16179,Supporting & Related Material,FDA-2015-P-1977-0008,FDA-2015-P-1977,attachment 6 letter from gerald steel to fda product jurisdiction officer re citizen petition from gerald steel,0,0
0900006481b161ad,Supporting & Related Material,FDA-2015-P-1977-0014,FDA-2015-P-1977,attachment 12 letter from gerald steel to fda office of combination products re citizen petition from gerald steel,0,0
0900006481b16177,Supporting & Related Material,FDA-2015-P-1977-0006,FDA-2015-P-1977,attachment 4 letter from fda cder to gerald steeel re citizen petition from gerald steel,0,0
0900006481b161b0,Supporting & Related Material,FDA-2015-P-1977-0017,FDA-2015-P-1977,attachment 15 flouride and adhd re citizen petition from gerald steel,0,0
09000064842f5b78,Other,FDA-2015-P-1977-0254,FDA-2015-P-1977,response letter from fda cder to gerald steel,0,0
09000064838cfd42,Other,FDA-2015-P-1977-0247,FDA-2015-P-1977,letter from fda cdrh to gerald steel re citizen petition,0,0
0900006481d6db9e,Other,FDA-2015-P-1977-0235,FDA-2015-P-1977,interim response letter from fda cder to gerald steel,0,0
0900006481b16178,Supporting & Related Material,FDA-2015-P-1977-0007,FDA-2015-P-1977,attachment 5 letter from fda cder to ms. mcelheney re citizen petition from gerald steel,0,0
0900006481b161ac,Supporting & Related Material,FDA-2015-P-1977-0013,FDA-2015-P-1977,attachment 11 letter from gerald steel to fda product jurisdiction officer re citizen petition from gerald steel,0,0
0900006481b16174,Supporting & Related Material,FDA-2015-P-1977-0003,FDA-2015-P-1977,attachment 1 nsf fact sheet re citizen petition from gerald steel,0,0
0900006481b15f03,Other,FDA-2015-P-1977-0002,FDA-2015-P-1977,acknowledgement letter from fda ddm to gerald steel,0,0
09000064839eacd1,Other,FDA-2015-P-1977-0253,FDA-2015-P-1977,supplement from gerald steel,0,0
0900006481b161ae,Supporting & Related Material,FDA-2015-P-1977-0015,FDA-2015-P-1977,attachment 13 fda email correspondence re citizen petition from gerald steel,0,0
0900006481b16175,Supporting & Related Material,FDA-2015-P-1977-0004,FDA-2015-P-1977,attachment 2 letter from gerald steel to fda re citizen petition from gerald steel,0,0
0900006481b16176,Supporting & Related Material,FDA-2015-P-1977-0005,FDA-2015-P-1977,attachment 3 letter from fda cder to dr. kailin and gerald steel re citizen petition from gerald steel,0,0
0900006481b161af,Supporting & Related Material,FDA-2015-P-1977-0016,FDA-2015-P-1977,attachment 14 letter from office of combination products to gerald steel re citizen petition from gerald steel,0,0
0900006481b1617b,Supporting & Related Material,FDA-2015-P-1977-0010,FDA-2015-P-1977,attachment 8 federal register notice 44 fr 42775 re citizen petition from gerald steel,0,0
0900006483946e31,Other,FDA-2015-P-1977-0248,FDA-2015-P-1977,citizen petition for reconsideration from gerald steel,0,0
090000648487976e,Other,FDA-2020-P-1251-0003,FDA-2020-P-1251,interim response letter from fda cfsan to varun varada,0,0
090000648448ac4e,Other,FDA-2020-P-1251-0002,FDA-2020-P-1251,acknowledgment letter from fda dms to varun verada,0,0
090000648448ac11,Other,FDA-2020-P-1251-0001,FDA-2020-P-1251,citizen petition from varun verada,0,0
09000064818cdb48,Other,FDA-2014-P-1570-0002,FDA-2014-P-1570,acknowlegement letter from ddm to natural solutions foundation,0,0
09000064818ba6d8,Other,FDA-2014-P-1570-0001,FDA-2014-P-1570,citizen petition from the natural solutions foundation,0,0
09000064806b1ca2,Other,FDA-2008-P-0441-0001,FDA-2008-P-0441,warner chilcott - citizen petiton,0,0
09000064806b1cf6,Other,FDA-2008-P-0441-0002,FDA-2008-P-0441,acknowledgement letter to warner chilcott,0,0
09000064807b6d08,Other,FDA-2008-P-0441-0003,FDA-2008-P-0441,warner chilcott - withdrawal of citizen petition,0,0
0900006484ace3fa,Other,FDA-2021-P-0434-0002,FDA-2021-P-0434,acknowledgment letter from fda dms to braintree,0,0
0900006484dfd494,Other,FDA-2021-P-0434-0003,FDA-2021-P-0434,interim response from fda cder to braintree,0,0
0900006484ace3f8,Other,FDA-2021-P-0434-0001,FDA-2021-P-0434,citizen petition from braintree,0,0
0900006484d4356f,Other,FDA-2021-P-0967-0002,FDA-2021-P-0967,acknowledgment letter from fda dms to labaton sucharow,0,0
0900006484d4356d,Other,FDA-2021-P-0967-0001,FDA-2021-P-0967,citizen petition from labaton sucharow,0,0
0900006484d6783c,Other,FDA-2021-P-0967-0005,FDA-2021-P-0967,supplement from labaton sucharow,0,0
0900006484d4250d,Supporting & Related Material,FDA-2021-P-0967-0004,FDA-2021-P-0967,attachment 2 re citizen petition from labaton sucharow,0,0
0900006484d4250c,Supporting & Related Material,FDA-2021-P-0967-0003,FDA-2021-P-0967,attachment 1 re citizen petition from labaton sucharow,0,0
09000064839b9484,Other,FDA-2018-P-4812-0002,FDA-2018-P-4812,acknowledgment letter from fda ddm to arent fox llp,0,0
0900006483d04c4e,Other,FDA-2018-P-4812-0004,FDA-2018-P-4812,letter from fda cder to arent fox llp,0,0
09000064839b8ccc,Other,FDA-2018-P-4812-0001,FDA-2018-P-4812,citizen petition from arent fox llp,0,0
0900006483d012e6,Notice,FDA-2018-P-4812-0003,FDA-2018-P-4812,"determination that nizoral (ketoconazole) topical cream, 2%, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483a17398,Supporting & Related Material,FDA-2019-P-0417-0004,FDA-2019-P-0417,attachment 2 re citizen petition from scilex pharmaceuticals inc,0,0
0900006483a185a6,Supporting & Related Material,FDA-2019-P-0417-0008,FDA-2019-P-0417,attachment 6 re citizen petition from scilex pharmaceuticals inc,0,0
0900006483a17395,Other,FDA-2019-P-0417-0002,FDA-2019-P-0417,"acknowledgment letter from fda ddm to scilex pharmaceuticals, inc",0,0
0900006483a17397,Supporting & Related Material,FDA-2019-P-0417-0003,FDA-2019-P-0417,attachment 1 re citizen petition from scilex pharmaceuticals inc,0,0
0900006483a28073,Supporting & Related Material,FDA-2019-P-0417-0009,FDA-2019-P-0417,attachment 7 re citizen petition from scilex pharmaceuticals inc,0,0
0900006483a17393,Other,FDA-2019-P-0417-0001,FDA-2019-P-0417,citizen petition from scilex pharmaceuticals inc,0,0
0900006483d5391a,Other,FDA-2019-P-0417-0010,FDA-2019-P-0417,"letter from fda cder to scilex pharmaceuticals, inc.",0,0
0900006483a1739b,Supporting & Related Material,FDA-2019-P-0417-0007,FDA-2019-P-0417,attachment 5 re citizen petition from scilex pharmaceuticals inc,0,0
0900006483a17399,Supporting & Related Material,FDA-2019-P-0417-0005,FDA-2019-P-0417,attachment 3 re citizen petition from scilex pharmaceuticals inc,0,0
0900006483a1739a,Supporting & Related Material,FDA-2019-P-0417-0006,FDA-2019-P-0417,attachment 4 re citizen petition from scilex pharmaceuticals inc,0,0
0900006483e7a714,Other,FDA-2019-P-3934-0002,FDA-2019-P-3934,acknowledgment letter from fda dms to auromedics pharma llc on behalf of aurobindo pharma ltd,0,0
0900006483e7a713,Other,FDA-2019-P-3934-0001,FDA-2019-P-3934,suitability petition from auromedics pharma llc on behalf of aurobindo pharma ltd,0,0
0900006483adcb4e,Other,FDA-2018-P-0664-0004,FDA-2018-P-0664,withdrawal from prinston pharmaceutical inc.,0,0
09000064835e8504,Other,FDA-2018-P-0664-0003,FDA-2018-P-0664,interim response from fda cder to prinston pharmaceutical inc.,0,0
0900006482f176e9,Other,FDA-2018-P-0664-0002,FDA-2018-P-0664,acknowledgment letter from fda ddm to  prinston pharmaceutical inc.,0,0
0900006482f17096,Other,FDA-2018-P-0664-0001,FDA-2018-P-0664,citizen petition from prinston pharmaceutical inc.,0,0
0900006483cd12a3,Supporting & Related Material,FDA-2019-P-2582-0002,FDA-2019-P-2582,"attachment 1- orange book: approved drug products with therapeutic equivalance evaluations re: suitability petition from pharmacore biotech co., ltd.",0,0
0900006483cd108f,Other,FDA-2019-P-2582-0001,FDA-2019-P-2582,"suitability petition from pharmacore biotech co., ltd.",0,0
0900006483cd12fd,Supporting & Related Material,FDA-2019-P-2582-0003,FDA-2019-P-2582,"attachment 2- approved package insert for alimta re:suitability petition from pharmacore biotech co., ltd.",0,0
0900006483cd12fe,Supporting & Related Material,FDA-2019-P-2582-0004,FDA-2019-P-2582,"attachment 3- draft package insert for proposed drug product re: suitability petition from pharmacore biotech co., ltd.",0,0
0900006483cd13bf,Other,FDA-2019-P-2582-0005,FDA-2019-P-2582,"acknowledgment letter from fda ddm to pharmacore biotech co., ltd.",0,0
09000064841cb14a,Other,FDA-2019-P-2687-0003,FDA-2019-P-2687,letter from fda/cder to auromedics pharma llc,0,0
0900006483ce6cc8,Other,FDA-2019-P-2687-0002,FDA-2019-P-2687,acknowledgment letter from fda ddm to auromedics pharma llc,0,0
0900006483ce6290,Other,FDA-2019-P-2687-0001,FDA-2019-P-2687,citizen petition from auromedics pharma llc,0,0
090000648353bd99,Supporting & Related Material,FDA-2018-P-2838-0004,FDA-2018-P-2838,"attachment 2  trends in alternative medicine use in the united state, 1990-1997 re: citizen petition from public citizen’s health research group",0,0
090000648353bd9c,Supporting & Related Material,FDA-2018-P-2838-0007,FDA-2018-P-2838,attachment 5 electrophysiological effects of cesium and  tetraethylammonium in canine cardiac purkinje fibers1 anne re: citizen petition from public citizen’s health research group,0,0
090000648353dbbd,Supporting & Related Material,FDA-2018-P-2838-0008,FDA-2018-P-2838,attachment 6 case reports of adverse events linked to cesium use re: citizen petition from public citizen’s health research group,0,0
090000648353b410,Other,FDA-2018-P-2838-0002,FDA-2018-P-2838,acknowledgment letter from fda ddm to public citizen’s health research group,0,0
090000648353b40c,Other,FDA-2018-P-2838-0001,FDA-2018-P-2838,citizen petition from public citizen's health research group,0,0
0900006483a441be,Other,FDA-2018-P-2838-0010,FDA-2018-P-2838,letter from fda cfsan to public citizen's health research group,0,0
090000648432e340,Other,FDA-2018-P-2838-0011,FDA-2018-P-2838,final response letter from fda cfsan to public citizen's health research group,0,0
090000648353bd9a,Supporting & Related Material,FDA-2018-P-2838-0005,FDA-2018-P-2838,"attachment 3 blood and tissue concentration of cesium after exposure
to cesium chloride re: citizen petition from public citizen’s health research group",0,0
090000648353bd98,Supporting & Related Material,FDA-2018-P-2838-0003,FDA-2018-P-2838,attachment 1  the  high ph therapy for cancer tests on mice and humans re: citizen petition from public citizen’s health research group,0,0
090000648353bd9b,Supporting & Related Material,FDA-2018-P-2838-0006,FDA-2018-P-2838,attachment 4 central depressant action of cesium in mice re: citizen petition from public citizen’s health research group,0,0
09000064834cba49,Supporting & Related Material,FDA-2018-P-2659-0012,FDA-2018-P-2659,"tab 10 - lawrence x yu, quality by design for orally inhaled drug products, re citizen petiton from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
09000064834cbdec,Supporting & Related Material,FDA-2018-P-2659-0004,FDA-2018-P-2659,"tab 2 - food and drug administration respiratory drug delivery devices a cdrh perspective (nov_ 2 2010) re citizen petiton from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",1,0
09000064834cb9c5,Other,FDA-2018-P-2659-0001,FDA-2018-P-2659,"citizen petiton from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
09000064834cbdf3,Supporting & Related Material,FDA-2018-P-2659-0011,FDA-2018-P-2659,"tab 9 - t_ gessler et al ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension, re citizen petiton from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
09000064834cbded,Supporting & Related Material,FDA-2018-P-2659-0005,FDA-2018-P-2659,"tab 3 - andrew m_ wilson et al importance of drug-device interaction in determining systemic re citizen petiton from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
09000064834cbdee,Supporting & Related Material,FDA-2018-P-2659-0006,FDA-2018-P-2659,"tab 4 - ah kendrick et al_, selecting and using nebulizer equipment re citizen petiton from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
09000064834cba4a,Supporting & Related Material,FDA-2018-P-2659-0013,FDA-2018-P-2659,"tab 11 - wallace p_ adams et al demonstrating bioequivalence of locally acting orally inhaled drug products re citizen petiton from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
09000064834cbdef,Supporting & Related Material,FDA-2018-P-2659-0007,FDA-2018-P-2659,"tab 5 - dean hess et al medication nebulizer performance effects of diluent volume, re citizen petiton from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
09000064834cbdf1,Supporting & Related Material,FDA-2018-P-2659-0009,FDA-2018-P-2659,"tab 7 - jg hardy et al_, lung deposition from four nebulizers, 87 respir med 461 (1993) re citizen petiton from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
09000064834cbdf2,Supporting & Related Material,FDA-2018-P-2659-0010,FDA-2018-P-2659,"tab 8 - christopher ocallaghan peter w_ barry the science of nebulised drug delivery 52 suppl 2 thorax s31 s36 (1997) re citizen petiton from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
090000648362bf8d,Other,FDA-2018-P-2659-0014,FDA-2018-P-2659,"withdrawal from hyman, phelps & mcnamara, p.c.",0,0
09000064834cbdf0,Supporting & Related Material,FDA-2018-P-2659-0008,FDA-2018-P-2659,"tab 6 - d_ todd loffert et al_, a comparison of commercial jet nebulizers, 106 chest 1788 (1994) re citizen petiton from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
09000064834cb9c7,Other,FDA-2018-P-2659-0002,FDA-2018-P-2659,"acknowledgment letter from fda ddm to hyman, phelps & mcnamara on behalf of united therapeutics corporation",0,0
09000064834cbdeb,Supporting & Related Material,FDA-2018-P-2659-0003,FDA-2018-P-2659,"tab 1 - iso 27427, anaesthetic and respiratory equipment _ nebulizing systems and components (2010) re citizen petiton from hyman, phelps & mcnamara, pc on behalf of united therapeutics corporation",0,0
090000648209e86b,Supporting & Related Material,FDA-2016-P-1991-0003,FDA-2016-P-1991,"attachment - 1 - rimadyl re citizen petition from douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd)",0,0
090000648209e86c,Other,FDA-2016-P-1991-0002,FDA-2016-P-1991,"acknowledgement letter from fda ddm to douglass oeller consulting, inc.",0,0
0900006482267607,Other,FDA-2016-P-1991-0004,FDA-2016-P-1991,"suitability petition approval letter from fda cvm to douglass oeller consulting, inc.",0,0
090000648209e639,Other,FDA-2016-P-1991-0001,FDA-2016-P-1991,"citizen petition from douglass oeller consulting, inc. (felix pharmaceuticals pvt. ltd)",0,0
0900006484481f91,Other,FDA-2020-P-1243-0002,FDA-2020-P-1243,acknowledgment letter from fda dms to varun varada,0,0
0900006484481f06,Other,FDA-2020-P-1243-0001,FDA-2020-P-1243,citizen petition from varun varada,0,0
090000648487976a,Other,FDA-2020-P-1243-0003,FDA-2020-P-1243,interim response letter from fda cfsan to varun varada,0,0
090000648447b77b,Other,FDA-2020-P-1237-0001,FDA-2020-P-1237,"citizen petition from wiley rein, llp",0,0
090000648460dd06,Other,FDA-2020-P-1237-0006,FDA-2020-P-1237,withdrawal from wiley rein llp,0,0
090000648447b840,Supporting & Related Material,FDA-2020-P-1237-0003,FDA-2020-P-1237,"exhibit a - voltarenrx labeling re citizen petition from wiley rein, llp.",0,0
090000648447b842,Supporting & Related Material,FDA-2020-P-1237-0005,FDA-2020-P-1237,"exhibit b - otc label - 2 of 2 re citizen petition from wiley rein, llp.",0,0
090000648447b841,Supporting & Related Material,FDA-2020-P-1237-0004,FDA-2020-P-1237,"exhibit b - otc label - 1 of 2 re citizen petition from wiley rein, llp.",0,0
090000648447b77d,Other,FDA-2020-P-1237-0002,FDA-2020-P-1237,"acknowledgment letter from fda dms to wiley rein, llp",0,0
09000064847281dd,Supporting & Related Material,FDA-2020-P-1633-0003,FDA-2020-P-1633,"exhibit a - clinical trials for treatment and prevention of c_ difficile disease re citizen petition from foley hoag, llp (on behalf of the microbiome therapeutics innovation group)",0,0
09000064849d0105,Other,FDA-2020-P-1633-0005,FDA-2020-P-1633,"interim response letter from fda cber to foley hoag, llp (on behalf of the microbiome therapeutics innovation group)",0,0
09000064847281d9,Other,FDA-2020-P-1633-0001,FDA-2020-P-1633,"citizen petition from foley hoag, llp (on behalf of the microbiome therapeutics innovation group)",0,0
09000064847281da,Other,FDA-2020-P-1633-0002,FDA-2020-P-1633,"acknowledgment letter from fda dms to foley hoag, llp (on behalf of the microbiome therapeutics innovation group)",0,0
0900006483ec02a1,Supporting & Related Material,FDA-2019-P-4006-0003,FDA-2019-P-4006,attachment a scientific evidence review re citizen petition from tate & lyle ingredients americas llc,0,0
0900006483ec02a3,Supporting & Related Material,FDA-2019-P-4006-0005,FDA-2019-P-4006,attachment c human studies that evaluated energy value re citizen petition from tate & lyle ingredients americas llc,0,0
09000064847e355e,Other,FDA-2019-P-4006-0008,FDA-2019-P-4006,addendum from tate & lyle ingredients americas llc,0,0
09000064843f2046,Other,FDA-2019-P-4006-0007,FDA-2019-P-4006,interim response letter from fda cfsan to tate & lyle ingredients americas llc,0,0
0900006483ec029c,Other,FDA-2019-P-4006-0002,FDA-2019-P-4006,acknowledgment letter from fda dms to tate & lyle ingredients americas llc,0,0
0900006483ec029b,Other,FDA-2019-P-4006-0001,FDA-2019-P-4006,citizen petition from tate & lyle ingredients americas llc,0,0
0900006483ec02a2,Supporting & Related Material,FDA-2019-P-4006-0004,FDA-2019-P-4006,attachment b_ restricted summary of breath hydrogen study re citizen petition from tate & lyle ingredients americas llc,0,0
090000648448c514,Supporting & Related Material,FDA-2020-P-1252-0003,FDA-2020-P-1252,"attachment 1 re suitability petition from foley & lardner, llp",0,0
090000648448c507,Other,FDA-2020-P-1252-0001,FDA-2020-P-1252,"suitability petition from foley & lardner, llp",0,0
090000648448c517,Supporting & Related Material,FDA-2020-P-1252-0006,FDA-2020-P-1252,"attachment 4 re suitability petition from foley & lardner, llp",0,0
090000648448c508,Other,FDA-2020-P-1252-0002,FDA-2020-P-1252,"acknowledgment letter from fda dms to foley & lardner, llp",0,0
090000648448c516,Supporting & Related Material,FDA-2020-P-1252-0005,FDA-2020-P-1252,"attachment 3 re suitability petition from foley & lardner, llp",0,0
090000648448c515,Supporting & Related Material,FDA-2020-P-1252-0004,FDA-2020-P-1252,"attachment 2 re suitability petition from foley & lardner, llp",0,0
0900006484d46020,Other,FDA-2020-P-1252-0007,FDA-2020-P-1252,withdrawal from foley & lardner llp,0,0
0900006482cc4e17,Other,FDA-2017-P-6689-0002,FDA-2017-P-6689,acknowledgement letter from fda ddm to novitium pharma llc,0,0
09000064832cd162,Other,FDA-2017-P-6689-0004,FDA-2017-P-6689,interim response from fda cder to muthusamy shanmugam,0,0
0900006483d0545f,Other,FDA-2017-P-6689-0007,FDA-2017-P-6689,petition for reconsideration and stay from arnall golden gregory llp,0,0
09000064846afe42,Other,FDA-2017-P-6689-0015,FDA-2017-P-6689,"petition response letter from fda cder to arnall golden gregory, llc",0,0
0900006483da6d32,Other,FDA-2017-P-6689-0011,FDA-2017-P-6689,acknowledgment letter from fda ddm to arnall golden gregory llp_signed_revised,0,0
0900006483d85cd8,Other,FDA-2017-P-6689-0010,FDA-2017-P-6689,"letter from fda cder to arnall golden gregory, llp",0,0
0900006483d054af,Supporting & Related Material,FDA-2017-P-6689-0008,FDA-2017-P-6689,attachment to petition for reconsideration and stay from arnall golden gregory llp,0,0
0900006483d0f6e8,Other,FDA-2017-P-6689-0009,FDA-2017-P-6689,acknowledgment letter from fda ddm to arnall golden gregory llp,0,0
0900006482cc4cf4,Other,FDA-2017-P-6689-0001,FDA-2017-P-6689,citizen petition from novitium pharma llc,0,0
0900006483c47d35,Other,FDA-2017-P-6689-0006,FDA-2017-P-6689,"letter from fda cder to novitium pharma, llc",0,0
09000064846afe3c,Other,FDA-2017-P-6689-0013,FDA-2017-P-6689,"petition response letter from fda cder to arnall golden gregory, llc",0,0
0900006482cc4e19,Supporting & Related Material,FDA-2017-P-6689-0003,FDA-2017-P-6689,exhibit 1 orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from novitium pharma llc,0,0
0900006483da8b88,Other,FDA-2017-P-6689-0012,FDA-2017-P-6689,acknowledgment letter from fda ddm to arnall golden gregory llp,0,0
09000064846afe40,Other,FDA-2017-P-6689-0014,FDA-2017-P-6689,"petition response letter from fda cder to arnall golden gregory, llc",0,0
0900006480c08d6e,Notice,FDA-2011-N-0109-0001,FDA-2011-N-0109,"certification requirements for caseins, caseinates, and mixtures thereof exported from ireland to the u.s.",0,0
09000064813c6749,Other,FDA-2013-P-0247-0004,FDA-2013-P-0247,"novartis pharmaceuticals corporation (kleinfeld, kaplan and becker, llp) - petition for reconsideration",0,0
09000064813c5898,Other,FDA-2013-P-0247-0005,FDA-2013-P-0247,"acknowledgement letter to novartis pharmaceuticals corporation (kleinfeld, kaplan and becker, llp)",0,0
0900006481213d56,Other,FDA-2013-P-0247-0002,FDA-2013-P-0247,acknowledgement letter to novartis pharmaceuticals corporation,0,0
09000064814ae31c,Other,FDA-2013-P-0247-0006,FDA-2013-P-0247,"fda/cder denial response letter to novartis pharmaceuticals corporation (kleinfeld, kaplan and becker, llp)",0,0
0900006481212835,Other,FDA-2013-P-0247-0001,FDA-2013-P-0247,novartis pharmaceuticals corporation - citizen petition,0,0
09000064813c0b7d,Other,FDA-2013-P-0247-0003,FDA-2013-P-0247,fda/cder to novartis pharmaceuticals corporation - denial of petition,0,0
0900006481d5e0b2,Notice,FDA-2015-P-3404-0004,FDA-2015-P-3404,"determination that liptruzet (ezetimibe and atorvastatin) tablets,
10 milligrams/10 milligrams, 10 milligrams/20 milligrams, 10
milligrams/40 milligrams, and 10 milligrams/80 milligrams, were not
withdrawn from sale for reasons of safety or effectiveness",0,0
0900006481c8f3b4,Other,FDA-2015-P-3404-0003,FDA-2015-P-3404,"acknowledgement letter from fda ddm to lupin pharmaceuticals, inc.",0,0
0900006481d61232,Other,FDA-2015-P-3404-0005,FDA-2015-P-3404,"letter from fda cder to lupin pharmaceuticals, inc.",0,0
0900006481c8f3b3,Supporting & Related Material,FDA-2015-P-3404-0002,FDA-2015-P-3404,"attachment 1 prescription and over the counter drug product list from the orange book re citizen petition from lupin pharmaceuticals, inc.",0,0
0900006481c8f3b1,Other,FDA-2015-P-3404-0001,FDA-2015-P-3404,"citizen petition from lupin pharmaceuticals, inc.",0,0
0900006481c42b25,Other,FDA-2015-P-0720-0006,FDA-2015-P-0720,"citizen petition approval response from fda cder to zydus pharmaceutical, inc.",0,0
0900006481a30c00,Supporting & Related Material,FDA-2015-P-0720-0004,FDA-2015-P-0720,attach ii citizen petition from zydus pharmaceuticals inc,0,0
0900006481a30bfd,Other,FDA-2015-P-0720-0002,FDA-2015-P-0720,acknowledgement letter from fda ddm to zydus pharmaceuticals inc,0,0
0900006481a30947,Other,FDA-2015-P-0720-0001,FDA-2015-P-0720,citizen petition request from zydus pharmaceuticals inc,0,0
0900006481a30bff,Supporting & Related Material,FDA-2015-P-0720-0003,FDA-2015-P-0720,attach i citizen petition from zydus pharmaceuticals inc,0,0
0900006481a30c01,Supporting & Related Material,FDA-2015-P-0720-0005,FDA-2015-P-0720,attach iii citizen petition from zydus pharmaceuticals inc,0,0
090000648331eb4a,Supporting & Related Material,FDA-2018-P-2104-0003,FDA-2018-P-2104,"attachment 1- orange book: approved drug products with therapeutic equivalence evaluations re citizen petition from nostrum pharmaceuticals, llc.",0,0
090000648331f12b,Other,FDA-2018-P-2104-0002,FDA-2018-P-2104,"acknowledgment letter from fda ddm to nostrum pharmaceuticals, llc.",0,0
09000064842ec9e9,Other,FDA-2018-P-2104-0005,FDA-2018-P-2104,"citizen petition-withdrawal from nostrum pharmaceuticals, llc",0,0
090000648331eb44,Other,FDA-2018-P-2104-0001,FDA-2018-P-2104,"citizen petition from nostrum pharmaceuticals, llc.",0,0
09000064838ff37d,Other,FDA-2018-P-2104-0004,FDA-2018-P-2104,"letter from fda cder to nostrum pharmaceuticals, llc",0,0
09000064849627c2,Supporting & Related Material,FDA-2020-P-1421-0053,FDA-2020-P-1421,tab 40 re citizen petition for reconsideration from encore dermatology inc,0,0
09000064846ad348,Supporting & Related Material,FDA-2020-P-1421-0004,FDA-2020-P-1421,"tab 2 re citizen petition from encore dermatology, inc.",0,0
09000064846ad356,Supporting & Related Material,FDA-2020-P-1421-0008,FDA-2020-P-1421,"tab 6 re citizen petition from encore dermatology, inc.",0,0
09000064846acf2d,Supporting & Related Material,FDA-2020-P-1421-0025,FDA-2020-P-1421,"tab 22 re citizen petition from encore dermatology, inc.",0,0
09000064846ad357,Supporting & Related Material,FDA-2020-P-1421-0009,FDA-2020-P-1421,"tab 7 re citizen petition from encore dermatology, inc.",0,0
09000064846acf38,Supporting & Related Material,FDA-2020-P-1421-0035,FDA-2020-P-1421,"tab 32 re citizen petition from encore dermatology, inc",0,0
09000064846acf3b,Supporting & Related Material,FDA-2020-P-1421-0038,FDA-2020-P-1421,"tab 35 re citizen petition from encore dermatology, inc.",0,0
09000064846acf37,Supporting & Related Material,FDA-2020-P-1421-0034,FDA-2020-P-1421,"tab 31 re citizen petition from encore dermatology, inc.",0,0
09000064846acf3a,Supporting & Related Material,FDA-2020-P-1421-0037,FDA-2020-P-1421,"tab 34 re citizen petition from encore dermatology, inc.",0,0
09000064846ad342,Other,FDA-2020-P-1421-0002,FDA-2020-P-1421,"acknowledgment letter from fda dms to encore dermatology, inc.",0,0
09000064846acf2c,Supporting & Related Material,FDA-2020-P-1421-0024,FDA-2020-P-1421,"tab 21 re citizen petition from encore dermatology, inc.",0,0
09000064846acf33,Supporting & Related Material,FDA-2020-P-1421-0030,FDA-2020-P-1421,"tab 27 re citizen petition from encore dermatology, inc.",0,0
09000064846ad349,Supporting & Related Material,FDA-2020-P-1421-0005,FDA-2020-P-1421,"tab 3 re citizen petition from encore dermatology, inc.",0,0
09000064846ad355,Supporting & Related Material,FDA-2020-P-1421-0007,FDA-2020-P-1421,"tab 5 re citizen petition from encore dermatology, inc.",0,0
09000064846ad358,Supporting & Related Material,FDA-2020-P-1421-0010,FDA-2020-P-1421,"tab 8 re citizen petition from encore dermatology, inc.",0,0
09000064846aceff,Supporting & Related Material,FDA-2020-P-1421-0016,FDA-2020-P-1421,"tab 14 - confidential unredacted  - re citizen petition from encore dermatology, inc.",0,0
09000064846acf29,Supporting & Related Material,FDA-2020-P-1421-0021,FDA-2020-P-1421,"tab 18 re citizen petition from encore dermatology, inc.",0,0
09000064846ad347,Supporting & Related Material,FDA-2020-P-1421-0003,FDA-2020-P-1421,"tab 1 re citizen petition from encore dermatology, inc.",0,0
09000064846ad34a,Supporting & Related Material,FDA-2020-P-1421-0006,FDA-2020-P-1421,"tab 4 re citizen petition from encore dermatology, inc.",0,0
09000064846acf39,Supporting & Related Material,FDA-2020-P-1421-0036,FDA-2020-P-1421,"tab 33 re citizen petition from encore dermatology, inc.",0,0
09000064846ad359,Supporting & Related Material,FDA-2020-P-1421-0011,FDA-2020-P-1421,"tab 9 re citizen petition from encore dermatology, inc.",0,0
09000064846acf00,Supporting & Related Material,FDA-2020-P-1421-0017,FDA-2020-P-1421,"tab 14 redacted re citizen petition from encore dermatology, inc.",0,0
09000064846acf26,Supporting & Related Material,FDA-2020-P-1421-0019,FDA-2020-P-1421,"tab 16 re citizen petition from encore dermatology, inc.",0,0
09000064846ad35d,Supporting & Related Material,FDA-2020-P-1421-0015,FDA-2020-P-1421,"tab 13 re citizen petition from encore dermatology, inc.",0,0
090000648491869e,Other,FDA-2020-P-1421-0041,FDA-2020-P-1421,"final decision from fda cder to encore dermatology, inc.",0,0
0900006483a93d9a,Supporting & Related Material,FDA-2019-P-0837-0014,FDA-2019-P-0837,"exhibit 12 fda late-cycle meeting minutes 8-1-2013 re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a93d94,Supporting & Related Material,FDA-2019-P-0837-0008,FDA-2019-P-0837,"exhibit 6 apa, practice guidelines re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a92f23,Supporting & Related Material,FDA-2019-P-0837-0005,FDA-2019-P-0837,"exhibit 3 fda supplement approval letter 5-2-2016 re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a93d95,Supporting & Related Material,FDA-2019-P-0837-0009,FDA-2019-P-0837,"exhibit 7 fda mem_ of meeting minutes 2-5-2008 re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a93da1,Supporting & Related Material,FDA-2019-P-0837-0021,FDA-2019-P-0837,"exhibit 19 ogle and akkerman guidance for the discontinuation or switching of antidepressant therapies in adults re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a93d9b,Supporting & Related Material,FDA-2019-P-0837-0015,FDA-2019-P-0837,"exhibit 13 trintellix clinical review re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a93d96,Supporting & Related Material,FDA-2019-P-0837-0010,FDA-2019-P-0837,"exhibit 8 khin re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a92ce8,Supporting & Related Material,FDA-2019-P-0837-0003,FDA-2019-P-0837,"exhibit 1 fda approval letter trintellix re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a93d93,Supporting & Related Material,FDA-2019-P-0837-0007,FDA-2019-P-0837,"exhibit 5 dsm-5 re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a93d9c,Supporting & Related Material,FDA-2019-P-0837-0016,FDA-2019-P-0837,"exhibit 14 cymbalta pi (dec_ 2017) re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a93da2,Other,FDA-2019-P-0837-0002,FDA-2019-P-0837,"acknowledgment letter from fda ddm to takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a94ad6,Supporting & Related Material,FDA-2019-P-0837-0023,FDA-2019-P-0837,"exhibit 21 letter from fda to sidley austin re colcrys re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a93d9e,Supporting & Related Material,FDA-2019-P-0837-0018,FDA-2019-P-0837,"exhibit 16 clayton re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a93da0,Supporting & Related Material,FDA-2019-P-0837-0020,FDA-2019-P-0837,"exhibit 18 keks austprescr-39-076 re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483d9cf7f,Other,FDA-2019-P-0837-0026,FDA-2019-P-0837,"letter from fda cder to takeda pharmaceuticals u.s.a., inc.",0,0
0900006483a93d9f,Supporting & Related Material,FDA-2019-P-0837-0019,FDA-2019-P-0837,"exhibit 17 bostwick mayo clin proc 85 538_550 2010 re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a93d9d,Supporting & Related Material,FDA-2019-P-0837-0017,FDA-2019-P-0837,"exhibit 15 hu compressed re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a93d98,Supporting & Related Material,FDA-2019-P-0837-0012,FDA-2019-P-0837,"exhibit 10 orange book re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a93d99,Supporting & Related Material,FDA-2019-P-0837-0013,FDA-2019-P-0837,"exhibit 11 cassano ann clin psychiatry 16 15-25 2004 re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a92ce9,Supporting & Related Material,FDA-2019-P-0837-0004,FDA-2019-P-0837,"exhibit 2 fda approves brand name change for brintellix re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a92f24,Supporting & Related Material,FDA-2019-P-0837-0006,FDA-2019-P-0837,"exhibit 4 label october 2018 re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a94ad7,Supporting & Related Material,FDA-2019-P-0837-0024,FDA-2019-P-0837,"exhibit 22 letter from woodcock to gulino re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a93d97,Supporting & Related Material,FDA-2019-P-0837-0011,FDA-2019-P-0837,"exhibit 9 trintellix pi (sept_ 2013) re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a94ad5,Supporting & Related Material,FDA-2019-P-0837-0022,FDA-2019-P-0837,"exhibit 20 letter from fda to m labson re rapamune re: citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006483a92c0b,Other,FDA-2019-P-0837-0001,FDA-2019-P-0837,"citizen petition from takeda pharmaceuticals u.s.a., inc. and h. lundbeck a/s",0,0
0900006484704e2a,Supporting & Related Material,FDA-2020-P-1611-0008,FDA-2020-P-1611,footnote 34_danne et al re citizen petition from public citizen’s health research group,0,0
0900006484704e30,Supporting & Related Material,FDA-2020-P-1611-0014,FDA-2020-P-1611,footnote 43_hampp et al re citizen petition from public citizen’s health research group,0,0
0900006484704e31,Supporting & Related Material,FDA-2020-P-1611-0015,FDA-2020-P-1611,footnote 44_hampp et al-supplement re citizen petition from public citizen’s health research group,0,0
0900006484704dcf,Supporting & Related Material,FDA-2020-P-1611-0004,FDA-2020-P-1611,footnote 28_dandona et al re citizen petition from public citizen’s health research group,0,0
0900006484704e2c,Supporting & Related Material,FDA-2020-P-1611-0010,FDA-2020-P-1611,footnote 37_lu et al re citizen petition from public citizen’s health research group,0,0
0900006484704dce,Supporting & Related Material,FDA-2020-P-1611-0003,FDA-2020-P-1611,footnote 27_henry et al re citizen petition from public citizen’s health research group,0,0
0900006484704e2e,Supporting & Related Material,FDA-2020-P-1611-0012,FDA-2020-P-1611,footnote 39_baker et al re citizen petition from public citizen’s health research group,0,0
0900006484704dd0,Supporting & Related Material,FDA-2020-P-1611-0005,FDA-2020-P-1611,footnote 29_mathieu et al re citizen petition from public citizen’s health research group,0,0
0900006484704e28,Supporting & Related Material,FDA-2020-P-1611-0006,FDA-2020-P-1611,footnote 31_rosenstock et al re citizen petition from public citizen’s health research group,0,0
0900006484704e2d,Supporting & Related Material,FDA-2020-P-1611-0011,FDA-2020-P-1611,footnote 38_bode et al re citizen petition from public citizen’s health research group,0,0
0900006484704dcb,Other,FDA-2020-P-1611-0002,FDA-2020-P-1611,acknowledgment letter from fda dms to public citizen’s health research group,0,0
0900006484704e2f,Supporting & Related Material,FDA-2020-P-1611-0013,FDA-2020-P-1611,footnote 40_taylor et al re citizen petition from public citizen’s health research group,0,0
0900006484704e29,Supporting & Related Material,FDA-2020-P-1611-0007,FDA-2020-P-1611,footnote 33_buse et al re citizen petition from public citizen’s health research group,0,0
0900006484704dca,Other,FDA-2020-P-1611-0001,FDA-2020-P-1611,citizen petition from public citizen's health research group,0,0
0900006484704e2b,Supporting & Related Material,FDA-2020-P-1611-0009,FDA-2020-P-1611,footnote 35_garg et al re citizen petition from public citizen’s health research group,0,0
09000064849a99ff,Other,FDA-2020-P-1611-0016,FDA-2020-P-1611,interim response letter from fda cder to public citizen's health research group,0,0
0900006481e825fd,Other,FDA-2016-P-0645-0002,FDA-2016-P-0645,"acknowledgement letter from fda ddm to pharmaceutical manufacturing research services, inc.",0,0
0900006481eb5c91,Supporting & Related Material,FDA-2016-P-0645-0008,FDA-2016-P-0645,46. fda-2012-p-0895-0015 fr re request fda uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction,0,0
09000064839bc185,Other,FDA-2016-P-0645-0014,FDA-2016-P-0645,"cder response letter to pharmaceutical manufacturing research services, inc.",0,0
0900006481eb5ebc,Supporting & Related Material,FDA-2016-P-0645-0011,FDA-2016-P-0645,62. oxycontin package insert re request fda uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction,0,0
0900006481e82090,Other,FDA-2016-P-0645-0001,FDA-2016-P-0645,"citizen petition from pharmaceutical manufacturing research services, inc.",0,0
0900006481eb5c8c,Supporting & Related Material,FDA-2016-P-0645-0003,FDA-2016-P-0645,1. a proactive response to prescription opioid abuse re request fda uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction,0,0
0900006481eb5c8f,Supporting & Related Material,FDA-2016-P-0645-0006,FDA-2016-P-0645,23. chemistry review nda 022272s000 re request fda uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction,0,0
090000648219d362,Other,FDA-2016-P-0645-0013,FDA-2016-P-0645,amendment  from pharmaceutical manufacturing research services inc. (pmrs),0,0
0900006481eb5eba,Supporting & Related Material,FDA-2016-P-0645-0009,FDA-2016-P-0645,"51. oxycontin antitrust litigation, purdue v. teva re request fda uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction",0,0
0900006481eb5ebb,Supporting & Related Material,FDA-2016-P-0645-0010,FDA-2016-P-0645,56. fda-2012-p-0895-0014 re request fda uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction,0,0
09000064821858db,Other,FDA-2016-P-0645-0012,FDA-2016-P-0645,"cder interim response letter to pharmaceutical manufacturing research services, inc.",0,0
0900006481eb5c8d,Supporting & Related Material,FDA-2016-P-0645-0004,FDA-2016-P-0645,5. abuse-deterrent opioids evaluation and labeling guidance for industry re request fda uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction,0,0
0900006481eb5c8e,Supporting & Related Material,FDA-2016-P-0645-0005,FDA-2016-P-0645,22. judge fines oxycontin maker and 3 executives re request fda uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction,0,0
0900006481eb5c90,Supporting & Related Material,FDA-2016-P-0645-0007,FDA-2016-P-0645,27. fda-2011-p-0473-0011 fr re request fda uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction,0,0
09000064839c163c,Other,FDA-2016-P-0645-0015,FDA-2016-P-0645,"cder response letter to pharmaceutical manufacturing research services, inc.",0,0
0900006484967260,Supporting & Related Material,FDA-2020-P-2212-0017,FDA-2020-P-2212,tab 11 re citizen petition from encore dermatology inc,0,0
09000064849672b9,Supporting & Related Material,FDA-2020-P-2212-0031,FDA-2020-P-2212,tab 45 re citizen petition from encore dermatology inc,0,0
09000064849675ec,Supporting & Related Material,FDA-2020-P-2212-0027,FDA-2020-P-2212,tab 1 re citizen petition from encore dermatology inc,0,0
0900006484967670,Supporting & Related Material,FDA-2020-P-2212-0041,FDA-2020-P-2212,tab 35 re citizen petition from encore dermatology inc,0,0
0900006484967644,Supporting & Related Material,FDA-2020-P-2212-0004,FDA-2020-P-2212,tab 24 re citizen petition from encore dermatology inc,0,0
090000648496766b,Supporting & Related Material,FDA-2020-P-2212-0046,FDA-2020-P-2212,tab 30 re citizen petition from encore dermatology inc,0,0
09000064849675ee,Supporting & Related Material,FDA-2020-P-2212-0025,FDA-2020-P-2212,tab 3 re citizen petition from encore dermatology inc,0,0
0900006484967668,Supporting & Related Material,FDA-2020-P-2212-0049,FDA-2020-P-2212,tab 27 re citizen petition from encore dermatology inc,0,0
090000648496766d,Supporting & Related Material,FDA-2020-P-2212-0044,FDA-2020-P-2212,tab 32 re citizen petition from encore dermatology inc,0,0
09000064849672b6,Supporting & Related Material,FDA-2020-P-2212-0034,FDA-2020-P-2212,tab 42 re citizen petition from encore dermatology inc,0,0
090000648496719a,Other,FDA-2020-P-2212-0002,FDA-2020-P-2212,"acknowledgment letter from fda dms to encore dermatology, inc.",0,0
0900006484967264,Supporting & Related Material,FDA-2020-P-2212-0014,FDA-2020-P-2212,tab 14 re citizen petition from encore dermatology inc,0,0
0900006484967197,Other,FDA-2020-P-2212-0001,FDA-2020-P-2212,citizen petition from encore dermatology inc,0,0
0900006484967267,Supporting & Related Material,FDA-2020-P-2212-0011,FDA-2020-P-2212,tab 17 re citizen petition from encore dermatology inc,0,0
09000064849672b4,Supporting & Related Material,FDA-2020-P-2212-0036,FDA-2020-P-2212,tab 40 re citizen petition from encore dermatology inc,0,0
0900006484967667,Supporting & Related Material,FDA-2020-P-2212-0050,FDA-2020-P-2212,tab 26 re citizen petition from encore dermatology inc,0,0
090000648496725f,Supporting & Related Material,FDA-2020-P-2212-0018,FDA-2020-P-2212,tab 10 re citizen petition from encore dermatology inc,0,0
0900006484967268,Supporting & Related Material,FDA-2020-P-2212-0010,FDA-2020-P-2212,tab 18 re citizen petition from encore dermatology inc,0,0
09000064849672b1,Supporting & Related Material,FDA-2020-P-2212-0039,FDA-2020-P-2212,tab 37 re citizen petition from encore dermatology inc,0,0
09000064849672b3,Supporting & Related Material,FDA-2020-P-2212-0037,FDA-2020-P-2212,"tab 39 fy2018 gdufa science and research report topical dermatological drug products re citizen petition from encore dermatology, inc.",0,0
09000064849675f0,Supporting & Related Material,FDA-2020-P-2212-0023,FDA-2020-P-2212,tab 5 re citizen petition from encore dermatology inc,0,0
09000064849675f1,Supporting & Related Material,FDA-2020-P-2212-0022,FDA-2020-P-2212,tab 6 re citizen petition from encore dermatology inc,0,0
09000064849675f3,Supporting & Related Material,FDA-2020-P-2212-0020,FDA-2020-P-2212,"tab 8 labe re citizen petition from encore dermatology, inc.",0,0
0900006484af212e,Other,FDA-2020-P-2212-0051,FDA-2020-P-2212,"interim response from fda cder to encore dermatology, inc.",0,0
09000064849672b0,Supporting & Related Material,FDA-2020-P-2212-0040,FDA-2020-P-2212,tab 36 re citizen petition from encore dermatology inc,0,0
0900006484e57e59,Other,FDA-2021-P-0930-0161,FDA-2021-P-0930,third supplement from labaton sucharow to citizens petition associated with cassava sciences inc,0,0
0900006484c9d396,Other,FDA-2021-P-0930-0001,FDA-2021-P-0930,citizen petition from labaton sucharow,0,0
0900006484c9d303,Supporting & Related Material,FDA-2021-P-0930-0004,FDA-2021-P-0930,"attachment 2  statement of concern regarding the accuracy and integrity of clinical and preclinical data supporting the ongoing clinical evaluation of 
compound pti-125, also known as simufilam re citizen petition from labaton sucharow",0,0
0900006484c9d302,Supporting & Related Material,FDA-2021-P-0930-0003,FDA-2021-P-0930,attachment 1 cassava science vs whistleblower submission re citizen petition from labaton sucharow,0,0
0900006484c9d398,Other,FDA-2021-P-0930-0002,FDA-2021-P-0930,acknowledgment letter from fda dms to labaton sucharow,0,0
0900006484d67805,Other,FDA-2021-P-0930-0113,FDA-2021-P-0930,supplement from labaton sucharow,0,0
0900006484cb4d42,Other,FDA-2021-P-0930-0023,FDA-2021-P-0930,supplement from labaton sucharow,0,0
0900006482548469,Other,FDA-2017-P-2231-0001,FDA-2017-P-2231,"citizen petition from qilu pharma, inc. as the us agent of qilu pharmaceutical co., ltd",0,0
090000648254846f,Other,FDA-2017-P-2231-0002,FDA-2017-P-2231,acknowledgment letter from fda ddm to qilu pharma inc,0,0
090000648267e055,Other,FDA-2017-P-2231-0003,FDA-2017-P-2231,"withdrawal from qilu pharma, inc.",0,0
0900006481a9e6d0,Other,FDA-2015-P-1187-0002,FDA-2015-P-1187,acknowledgement letter from fda ddm to u.s. right to know,0,0
0900006481a9e5de,Other,FDA-2015-P-1187-0001,FDA-2015-P-1187,citizen petition from u.s. right to know (us rtk),0,0
0900006482c7bf05,Other,FDA-2015-P-1187-0004,FDA-2015-P-1187,final response letter from fda to u.s. right to know,0,0
0900006481cafbca,Other,FDA-2015-P-1187-0003,FDA-2015-P-1187,interim response from fda cfsan to u.s. right to know,0,0
09000064842f7be1,Other,FDA-2020-P-0436-0002,FDA-2020-P-0436,"acknowledgment letter to   foley and lardner llp on behalf of romark laboratories, l.c.",0,0
09000064842f7a1b,Other,FDA-2020-P-0436-0001,FDA-2020-P-0436,"citizen petition from foley and lardner llp on behalf of romark laboratories, l.c.",0,0
0900006484307af4,Other,FDA-2020-P-0436-0003,FDA-2020-P-0436,withdrawal from foley & lardner llp,0,0
0900006484450c78,Other,FDA-2019-P-4523-0005,FDA-2019-P-4523,"citizen petition response letter from fda cder to fresenius kabi usa, llc",0,0
0900006483fddeca,Other,FDA-2019-P-4523-0002,FDA-2019-P-4523,"acknowledgment letter from fda dms to fresenius kabi usa, llc",0,0
090000648444c03e,Notice,FDA-2019-P-4523-0004,FDA-2019-P-4523,"determination that potassium chloride in 5% dextrose and 0.225%
sodium chloride injection, 5 milliequivalents, 10 milliequivalents, 15
milliequivalents, 20 milliequivalents, 30 milliequivalents, and 40
milliequivalents, in plastic containers, were not withdrawn from sale for
reasons of safety or effectiveness",0,0
0900006483fddecb,Supporting & Related Material,FDA-2019-P-4523-0003,FDA-2019-P-4523,"attachment a orange book listing of potassium chloride in dextrose 5% and sodium chloride 0.225% - nda 018365 (september 26, 2019) re citizen petition from fresenius kabi usa, llc",0,0
0900006483fddec9,Other,FDA-2019-P-4523-0001,FDA-2019-P-4523,"citizen petition from fresenius kabi usa, llc",0,0
0900006484470c5f,Supporting & Related Material,FDA-2020-P-1220-0004,FDA-2020-P-1220,attachment 2 fda e-mail confirmation-removal from class iii re petition for reconsideration from c laser inc,0,0
0900006484470c5e,Supporting & Related Material,FDA-2020-P-1220-0003,FDA-2020-P-1220,attachment 1 reference figures and tables referred to in the petition re petition for reconsideration from c laser inc,0,0
0900006484470c11,Other,FDA-2020-P-1220-0001,FDA-2020-P-1220,petition for reconsideration from c laser inc,0,0
0900006484798280,Other,FDA-2020-P-1220-0006,FDA-2020-P-1220,denial letter for petition for reconsideration from fda cdrh to c laser inc.,0,0
0900006484470c60,Supporting & Related Material,FDA-2020-P-1220-0005,FDA-2020-P-1220,attachment 3 updated supporting document list with video links re petition for reconsideration from c laser inc,0,0
0900006484470c12,Other,FDA-2020-P-1220-0002,FDA-2020-P-1220,acknowledgment letter from fda dms to c laser inc,0,0
0900006484b4c4ce,Notice,FDA-2021-P-0163-0003,FDA-2021-P-0163,"determination that sandostatin (octreotide acetate) injection, equal to 0.2 milligrams base/milliliter and equal to 1 milligrams base/milliliter, was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006484a1e626,Other,FDA-2021-P-0163-0002,FDA-2021-P-0163,acknowledgment letter from fda dms to caplin steriles limited,0,0
0900006484b56dee,Other,FDA-2021-P-0163-0004,FDA-2021-P-0163,response letter from fda cder to caplin steriles limited,0,0
0900006484a1e624,Other,FDA-2021-P-0163-0001,FDA-2021-P-0163,citizen petition from caplin steriles limited,0,0
0900006484a1e56b,Other,FDA-2021-P-0162-0001,FDA-2021-P-0162,citizen petition from nexsen pruet llc,0,0
0900006484a1e622,Other,FDA-2021-P-0162-0002,FDA-2021-P-0162,acknowledgment letter from fda dms to nexsen pruet llc,0,0
0900006484b236e6,Notice,FDA-2021-P-0162-0003,FDA-2021-P-0162,"determination that normodyne (labetalol hydrochloride) injection, 5 milligrams per milliliter, was not 
withdrawn from sale for reasons of safety or effectiveness",0,0
0900006484b2e963,Other,FDA-2021-P-0162-0004,FDA-2021-P-0162,"response letter from fda cder to nexsen pruet, llc",0,0
0900006484c3dec0,Supporting & Related Material,FDA-2021-P-0885-0004,FDA-2021-P-0885,envelope re citizen petition from zydus pharmaceuticals (usa) inc.,0,0
0900006484c3dadd,Other,FDA-2021-P-0885-0002,FDA-2021-P-0885,acknowledgment letter from fda dms to zydus pharmaceuticals (usa) inc.,0,0
0900006484c3debd,Other,FDA-2021-P-0885-0001,FDA-2021-P-0885,citizen petition from zydus pharmaceuticals (usa) inc.,0,0
0900006484c3debf,Supporting & Related Material,FDA-2021-P-0885-0003,FDA-2021-P-0885,"attachment 1 - current (august 03, 2021) orange book listing of pepcid® (famotidine) tablets, 20 mg and 40 mg, nda # n019462, held by valeant pharmaceuticals north america llc re citizen petition from zydus pharmaceuticals (usa) inc.",0,0
09000064804960bb,Other,FDA-2003-P-0335-0004,FDA-2003-P-0335,hfd-240 to fulcrum inc.,0,0
09000064804960b5,Other,FDA-2003-P-0335-0003,FDA-2003-P-0335,hfd-001 to james o. maloy,0,0
090000648049605e,Other,FDA-2003-P-0335-0001,FDA-2003-P-0335,hfa-305 to fulcrum inc.,0,0
09000064804960ad,Other,FDA-2003-P-0335-0002,FDA-2003-P-0335,"hfd-005 to fulcrum, inc.",0,0
0900006482e414d9,Other,FDA-2017-P-5954-0004,FDA-2017-P-5954,"supplement from elite laboratories, inc.",0,0
09000064837b5410,Other,FDA-2017-P-5954-0006,FDA-2017-P-5954,petition denial letter from fda cder to elite laboratories inc,0,0
0900006482b82e71,Other,FDA-2017-P-5954-0001,FDA-2017-P-5954,citizen petition from elite laboratories inc,0,0
0900006482b82e73,Other,FDA-2017-P-5954-0002,FDA-2017-P-5954,acknowledgement letter from fda ddm to elite laboratories inc,0,0
0900006482b82e76,Supporting & Related Material,FDA-2017-P-5954-0003,FDA-2017-P-5954,attachment a orange book - dantrium re citizen petition from elite laboratories inc,0,0
0900006483050b38,Other,FDA-2017-P-5954-0005,FDA-2017-P-5954,"interim response  letter from fda cder to elite laboratories, inc.",0,0
09000064824f8019,Supporting & Related Material,FDA-2017-P-1392-0004,FDA-2017-P-1392,"attachment 2 - october 3, 2016 citizen petition re citizen petition from latham & watkins, llp",0,0
09000064824fa142,Other,FDA-2017-P-1392-0002,FDA-2017-P-1392,"acknowledgment letter from fda ddm to latham & watkins, llp",0,0
09000064824f801a,Supporting & Related Material,FDA-2017-P-1392-0005,FDA-2017-P-1392,"attachment 3 - fda denial letter re citizen petition from latham & watkins, llp",0,0
09000064829e047b,Other,FDA-2017-P-1392-0006,FDA-2017-P-1392,"citizen petition response letter from fda cder to latham & watkins, llp",0,0
09000064824f8018,Supporting & Related Material,FDA-2017-P-1392-0003,FDA-2017-P-1392,"attachment 1 - august 1 2016 citizen petition re citizen petition from latham & watkins, llp",0,0
09000064824f8016,Other,FDA-2017-P-1392-0001,FDA-2017-P-1392,"citizen petition from latham & watkins, llp (par sterile products, llc)",0,0
0900006482f88128,Supporting & Related Material,FDA-2018-P-0964-0003,FDA-2018-P-0964,"attachment a – current orange book listing of plasma-lyte m and dextrose 5% re :citizen petition from fresenius kabi usa, llc",0,0
090000648365b9d5,Other,FDA-2018-P-0964-0005,FDA-2018-P-0964,"agency response letter from fda cder to fresenius kabi usa, llc",0,0
0900006482f87988,Other,FDA-2018-P-0964-0001,FDA-2018-P-0964,"citizen petition from fresenius kabi usa, llc",0,0
090000648364fa80,Notice,FDA-2018-P-0964-0004,FDA-2018-P-0964,"determination that plasma–lyte m and dextrose 5% and plasma
lyte 148 and dextrose 5% were not withdrawn from sale for reasons
of safety or effectiveness",0,0
0900006482f8798c,Other,FDA-2018-P-0964-0002,FDA-2018-P-0964,"acknowledgment letter from fda ddm to fresenius kabi usa, llc",0,0
09000064835198b0,Supporting & Related Material,FDA-2018-P-2755-0006,FDA-2018-P-2755,"attachment iv - non availability letter-metadate re citizen petition from ascend laboratories, llc",0,0
09000064839f4c56,Other,FDA-2018-P-2755-0007,FDA-2018-P-2755,"interim response from fda cder to ascend laboratories, llc",0,0
0900006483519ae6,Supporting & Related Material,FDA-2018-P-2755-0003,FDA-2018-P-2755,"attachment i - orange book search re citizen petition from ascend laboratories, llc",0,0
0900006483519ae2,Other,FDA-2018-P-2755-0002,FDA-2018-P-2755,"acknowledgment letter from fda ddm to ascend laboratories, llc",0,0
0900006483519ae0,Other,FDA-2018-P-2755-0001,FDA-2018-P-2755,"citizen petition from ascend laboratories, llc",0,0
0900006483519ae8,Supporting & Related Material,FDA-2018-P-2755-0005,FDA-2018-P-2755,"attachment iii - trade customer notification letter from ucb re citizen petition from ascend laboratories, llc",0,0
0900006484177fba,Other,FDA-2018-P-2755-0008,FDA-2018-P-2755,"response letter from fda to hyman, phelps, and mcnamara",0,0
0900006483519ae7,Supporting & Related Material,FDA-2018-P-2755-0004,FDA-2018-P-2755,"attachment ii - approval letter re citizen petition from ascend laboratories, llc",0,0
0900006481ae2bde,Other,FDA-2015-P-1721-0002,FDA-2015-P-1721,acknowledgement letter from fda ddm to hogan lovells us llp,0,0
0900006481ae2be1,Supporting & Related Material,FDA-2015-P-1721-0004,FDA-2015-P-1721,tab 2 helsinn cipla redacted cipla application re: citizen petition from hogan lovells us llp,0,0
0900006481ae2be6,Supporting & Related Material,FDA-2015-P-1721-0005,FDA-2015-P-1721,tab 7 helsinn cipla redacted anda rejection re: citizen petition from hogan lovells us llp,0,0
0900006481ae26ca,Supporting & Related Material,FDA-2015-P-1721-0006,FDA-2015-P-1721,tab 14 helsinn cipla letter from ogd re: itizen petition from hogan lovells us llp,0,0
0900006481ae2be0,Supporting & Related Material,FDA-2015-P-1721-0003,FDA-2015-P-1721,tab 1 helsinn cipla label information re: citizen petition from hogan lovells us llp,0,0
0900006481ae2b15,Other,FDA-2015-P-1721-0001,FDA-2015-P-1721,citizen petition from hogan lovells us llp (helsinn),0,0
0900006481cc0613,Other,FDA-2015-P-1721-0007,FDA-2015-P-1721,citizen petition denial response from fda cder to hogan lovells us llp,0,0
0900006482476cb7,Other,FDA-2016-P-2955-0032,FDA-2016-P-2955,supplement from nicholas isel,0,0
0900006483a315e1,Other,FDA-2016-P-2955-0116,FDA-2016-P-2955,supplement from nicholas isel,0,0
0900006483a31315,Other,FDA-2016-P-2955-0115,FDA-2016-P-2955,supplement from nicholas isel,0,0
0900006482527f70,Other,FDA-2016-P-2955-0078,FDA-2016-P-2955,supplement from nicholas isel,0,0
0900006483a31571,Other,FDA-2016-P-2955-0113,FDA-2016-P-2955,supplement from nicholas isel,0,0
09000064847a3b51,Other,FDA-2016-P-2955-0339,FDA-2016-P-2955,"denial letter on petition and petition for reconsideration from fda oc to michelle j. rozovics, esq.",0,0
0900006482272d4d,Other,FDA-2016-P-2955-0001,FDA-2016-P-2955,citizen petition from nicholas isel,0,0
09000064843c7d83,Other,FDA-2016-P-2955-0330,FDA-2016-P-2955,signed petitioner response,0,0
09000064824787f9,Other,FDA-2016-P-2955-0034,FDA-2016-P-2955,supplement from nicholas isel,0,0
09000064836e2d88,Other,FDA-2016-P-2955-0085,FDA-2016-P-2955,petition to reconsider from rozovics law firm llc on behalf of nicholas isel,0,0
09000064824f1ff2,Other,FDA-2016-P-2955-0053,FDA-2016-P-2955,interim response from cber to nicholas isel,0,0
09000064836e7eda,Other,FDA-2016-P-2955-0087,FDA-2016-P-2955,petition to reconsider from rozovics law firm llc on behalf of nicholas isel_redacted,0,0
09000064836e7f5c,Other,FDA-2016-P-2955-0088,FDA-2016-P-2955,response from fda cber to nicholas isel_redacted,0,0
090000648361e6e0,Supporting & Related Material,FDA-2016-P-2955-0081,FDA-2016-P-2955,list of references re: response  from fda cber to nicholas isel,0,0
0900006483604ef2,Other,FDA-2016-P-2955-0080,FDA-2016-P-2955,response  from fda cber to nicholas isel,0,0
090000648361eb07,Supporting & Related Material,FDA-2016-P-2955-0083,FDA-2016-P-2955,reference 2 - recent advances in the genetics of schizophrenia re: response  from fda cber to nicholas isel,0,0
0900006483aa7142,Other,FDA-2016-P-2955-0136,FDA-2016-P-2955,interim response letter from fda cber to rozovics law firm llc,0,0
0900006483aa2f2d,Other,FDA-2016-P-2955-0134,FDA-2016-P-2955,"letter from fda cber to rozovics law firm, llc",0,0
0900006482529c68,Other,FDA-2016-P-2955-0338,FDA-2016-P-2955,supplement from nicholas isel,0,0
0900006483a31607,Other,FDA-2016-P-2955-0117,FDA-2016-P-2955,supplement from nicholas isel,0,0
0900006482476ff0,Other,FDA-2016-P-2955-0031,FDA-2016-P-2955,comment from nicholas isel,0,0
0900006483a315b3,Other,FDA-2016-P-2955-0114,FDA-2016-P-2955,supplement from nicholas isel,0,0
0900006482272bdb,Other,FDA-2016-P-2955-0002,FDA-2016-P-2955,acknowledgment letter from fda ddm to nicholas isel,0,0
090000648361eb08,Supporting & Related Material,FDA-2016-P-2955-0084,FDA-2016-P-2955,reference 3 - sequencing-based diagnostics for pediatric genetic diseases progress and potential re: response  from fda cber to nicholas isel,0,0
090000648361eb06,Supporting & Related Material,FDA-2016-P-2955-0082,FDA-2016-P-2955,"reference 1 - the genetic basis of complex traits rare variants or common gene, common disease re:   response  from fda cber to nicholas isel",0,0
0900006482287d93,Supporting & Related Material,FDA-2016-P-3089-0006,FDA-2016-P-3089,"attachment 4 anda approval letter for cefixime chewable tablet, anda 065380 re citizen petition from aleon pharma international, inc",0,0
0900006482287d91,Supporting & Related Material,FDA-2016-P-3089-0004,FDA-2016-P-3089,"attachment 2 draft labeling proposed for cefixime tablets for oral suspension re citizen petition from aleon pharma international, inc",0,0
0900006482287d92,Supporting & Related Material,FDA-2016-P-3089-0005,FDA-2016-P-3089,"attachment 3 fda approved labeling for the reference-listed drug suprax re citizen petition from aleon pharma international, inc",0,0
0900006482287d94,Supporting & Related Material,FDA-2016-P-3089-0007,FDA-2016-P-3089,"attachment 5 suitability petition approval letter for amoxicillin and clavulanate potassium tablet re citizen petition from aleon pharma international, inc",0,0
0900006482287844,Supporting & Related Material,FDA-2016-P-3089-0003,FDA-2016-P-3089,"attachment 1 approved drug products with therapeutic equivalence re citizen petition from aleon pharma international, inc",0,0
0900006482287842,Other,FDA-2016-P-3089-0002,FDA-2016-P-3089,"acknowledgement letter from fda ddm to aleon pharma international, inc",0,0
0900006482287840,Other,FDA-2016-P-3089-0001,FDA-2016-P-3089,"citizen petition from aleon pharma international, inc",0,0
0900006484936fcb,Other,FDA-2020-P-2133-0002,FDA-2020-P-2133,acknowledgment letter from fda dms to fresenius kabi usa llc,0,0
0900006484936ab5,Other,FDA-2020-P-2133-0001,FDA-2020-P-2133,"citizen petition from fresenius kabi usa, llc",0,0
0900006484ab4d28,Other,FDA-2020-P-2133-0003,FDA-2020-P-2133,interim response letter from fda cder to fresenius kabi usa llc,0,0
0900006484b14c70,Other,FDA-2020-P-2133-0004,FDA-2020-P-2133,response letter from fda cder to fresenius kabi usa llc,0,0
0900006484aa3abe,Other,FDA-2021-P-0376-0002,FDA-2021-P-0376,acknowledgement letter from fda dms to braintree sebela pharmaceuticals,0,0
0900006484acb787,Other,FDA-2021-P-0376-0003,FDA-2021-P-0376,withdrawal from braintree,0,0
0900006484aa3a45,Other,FDA-2021-P-0376-0001,FDA-2021-P-0376,citizen petition from braintree sebela pharmaceuticals,0,0
0900006481f72251,Supporting & Related Material,FDA-2016-P-1163-0024,FDA-2016-P-1163,"exhibit 21 apr. 3, 2013 general advice letter re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france)",0,0
0900006481f72254,Supporting & Related Material,FDA-2016-P-1163-0026,FDA-2016-P-1163,"exhibit 23 aug. 11 , 2014 meeting request re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france)",0,0
0900006481f72259,Supporting & Related Material,FDA-2016-P-1163-0031,FDA-2016-P-1163,exhibit 28 e-mail correspondence re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france),0,0
0900006481f72565,Supporting & Related Material,FDA-2016-P-1163-0033,FDA-2016-P-1163,"exhibit 30 center for drug evaluation and research, application no. 21-135, chemical reviews re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france)",0,0
0900006481f72568,Supporting & Related Material,FDA-2016-P-1163-0036,FDA-2016-P-1163,exhibit 33 fda draft guidance on sodium fenic gluconate complex (june 2013)  re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france),0,0
0900006481f7256e,Supporting & Related Material,FDA-2016-P-1163-0041,FDA-2016-P-1163,exhibit 38 d vanwyck et al. labile iron in parenteral iron formulations: a quantitative and comparative study. nephrol dial transplant. 2004;19:561-556 re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france),0,0
0900006481f72571,Supporting & Related Material,FDA-2016-P-1163-0044,FDA-2016-P-1163,"exhibit 41 hh popper. etiology, pathogenesis and differential diagnosis of lung grnulomatosis. an update. patologia. 1999; 32(3):395-39 re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france)",0,0
0900006481f74b5e,Supporting & Related Material,FDA-2016-P-1163-0058,FDA-2016-P-1163,"exhibit 10 bg danielson. structure, chemistty, and pharmacokinetics of intravenous iron agents. j am soc nephrol. 2004;15:s93-s98 re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france)",0,0
0900006481f74b66,Supporting & Related Material,FDA-2016-P-1163-0065,FDA-2016-P-1163,"exhibit 18 feb. 13 , 2013 general advice letter re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france)",0,0
0900006481f74b68,Supporting & Related Material,FDA-2016-P-1163-0067,FDA-2016-P-1163,"exhibit 20 mar. 11 , 2013 response to fda's general advice re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france)",0,0
0900006481f74b69,Supporting & Related Material,FDA-2016-P-1163-0068,FDA-2016-P-1163,"exhibit 21 apr. 3, 2013 general advice letter re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france)",0,0
0900006481f74b7b,Supporting & Related Material,FDA-2016-P-1163-0083,FDA-2016-P-1163,exhibit 34 european medicines agency. reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. 2011 re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france),0,0
0900006481f74b7c,Supporting & Related Material,FDA-2016-P-1163-0084,FDA-2016-P-1163,exhibit 35 n desai. challenges in development ofnanoparticle-based therapeutics. aaps j. 20 12; 14(2):282-295 re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france),0,0
0900006481f74b7f,Supporting & Related Material,FDA-2016-P-1163-0087,FDA-2016-P-1163,exhibit 38 d vanwyck et al. labile iron in parenteral iron formulations: a quantitative and comparative study. nephrol dial transplant. 2004;19:561-556 re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france),0,0
0900006481f74b86,Supporting & Related Material,FDA-2016-P-1163-0094,FDA-2016-P-1163,"exhibit 45 amarin v. apotex, 14-cv-02550 (d.n.j.), dkt. no. 100-3 re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france)",0,0
0900006481f74b55,Supporting & Related Material,FDA-2016-P-1163-0056,FDA-2016-P-1163,exhibit 7 ferrlecit label re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france) re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france),0,0
0900006481f74b60,Supporting & Related Material,FDA-2016-P-1163-0059,FDA-2016-P-1163,exhibit 12 je tobbli eta!. comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. inflammation & allergy - drug targets. 2012;11 :66-78 re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france),0,0
0900006481f74b64,Supporting & Related Material,FDA-2016-P-1163-0063,FDA-2016-P-1163,"exhibit 16 s muhlebach, b fluhma1m. iron carbohydrate complexes: characteristics and regulatory challenges. in: dja crommelin, jsb de vlieger, editors. non-biological complex drugs. switzerland: springer international publishing; 2015 re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france)",0,0
0900006481f74b6d,Supporting & Related Material,FDA-2016-P-1163-0074,FDA-2016-P-1163,"exhibit 25 sept. 24, 2014 background/briefing materials re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france)",0,0
0900006481f74b6f,Supporting & Related Material,FDA-2016-P-1163-0076,FDA-2016-P-1163,"exhibit 27 apr. 30, 2015 letter re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france)",0,0
0900006481f74b70,Supporting & Related Material,FDA-2016-P-1163-0077,FDA-2016-P-1163,exhibit 28 e-mail correspondence re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france),0,0
0900006481f74b71,Supporting & Related Material,FDA-2016-P-1163-0078,FDA-2016-P-1163,"exhibit 29 feb.15, 2016letter re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france)",0,0
0900006481f74b87,Supporting & Related Material,FDA-2016-P-1163-0095,FDA-2016-P-1163,exhibit 46 european medicines agency. velphoro assessment report. 2014 re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france),0,0
0900006481f72253,Supporting & Related Material,FDA-2016-P-1163-0025,FDA-2016-P-1163,"exhibit 22 dec. 5, 2013 exclusivity summary re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france)",0,0
0900006481f72569,Supporting & Related Material,FDA-2016-P-1163-0037,FDA-2016-P-1163,exhibit 34 european medicines agency. reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. 2011 re citizen petition from foley hoag llp (vifor fresenius medical care renal pharma france),0,0
0900006483bfd8a2,Supporting & Related Material,FDA-2019-P-2038-0005,FDA-2019-P-2038,exhibits 21-31 re: citizen petition from american dental association,0,0
0900006483bfd9b6,Other,FDA-2019-P-2038-0001,FDA-2019-P-2038,citizen petition from american dental association,0,0
0900006483cd8ded,Other,FDA-2019-P-2038-0063,FDA-2019-P-2038,petition denial letter from fda cdrh to american dental association,0,0
0900006483c1320a,Supporting & Related Material,FDA-2019-P-2038-0006,FDA-2019-P-2038,exhibit 2: re: citizen petition from american dental association,0,0
0900006483c1320b,Supporting & Related Material,FDA-2019-P-2038-0007,FDA-2019-P-2038,exhibit 13-14 re: citizen petition from american dental association,0,0
0900006483bfd8a1,Supporting & Related Material,FDA-2019-P-2038-0004,FDA-2019-P-2038,exhibits 11-12 and 15-20 re: citizen petition from american dental association,0,0
0900006483bfe1ad,Other,FDA-2019-P-2038-0002,FDA-2019-P-2038,acknowledgment letter from fda ddm to american dental association,0,0
0900006483bfd8a0,Supporting & Related Material,FDA-2019-P-2038-0003,FDA-2019-P-2038,exhibits 1 and 3-10 re: citizen petition from american dental association,0,0
090000648229807d,Supporting & Related Material,FDA-2016-P-2860-0003,FDA-2016-P-2860,e-mail from maha tahiri,0,0
090000648252f12a,Other,FDA-2016-P-2860-0005,FDA-2016-P-2860,"interim response letter from cfsan to general mills, inc.",0,0
090000648223ffe0,Other,FDA-2016-P-2860-0001,FDA-2016-P-2860,"citizen petition from general mills, inc.",0,0
0900006483410813,Other,FDA-2016-P-2860-0006,FDA-2016-P-2860,fda-2016p-2860  and fda-2016-2863 general mills - denying part and granting part response,0,0
0900006482246f1e,Other,FDA-2016-P-2860-0002,FDA-2016-P-2860,"acknowledgment letter from fda ddm general mills, inc.",0,0
09000064822f8e01,Other,FDA-2016-P-3356-0001,FDA-2016-P-3356,citizen petition from sandoz inc,0,0
090000648230490a,Supporting & Related Material,FDA-2016-P-3356-0017,FDA-2016-P-3356,"attachment o covance, inc., analytical methods for bioanalysis (2015) re citizen petition from sandoz inc",0,0
0900006482304495,Supporting & Related Material,FDA-2016-P-3356-0004,FDA-2016-P-3356,"attachment b robert lionberger, interpreting pharmacokinetics for inhalation bioequivalence, presentation at the international pharmaceutical aerosol consortium on regulatory science / university of florida orlando inhalation conference (mar. 19, 2014) re citizen petition from sandoz inc",0,0
09000064822f93b5,Supporting & Related Material,FDA-2016-P-3356-0003,FDA-2016-P-3356,"attachment a  günther hochhaus, et al., generics for oral inhaled drugs: knowledge gaps for streamlining bioequivalence approval, presentation at the fda generic drug user fee amendments of 2012 regulatory science initiatives part 15 public hearing (june 21, 2013) re citizen petition from sandoz inc",0,0
0900006482304497,Supporting & Related Material,FDA-2016-P-3356-0006,FDA-2016-P-3356,"attachment d donald j. schuirmann, a comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability, 15 j. pharmacokinetics & biopharmaceutics 657 (1987) re citizen petition from sandoz inc",0,0
0900006482304499,Supporting & Related Material,FDA-2016-P-3356-0008,FDA-2016-P-3356,"attachment f fda, background for advisory committee for pharmaceutical science: concept and criteria of bioinequivalence (oct. 20, 2004) re citizen petition from sandoz inc",0,0
09000064822f921d,Other,FDA-2016-P-3356-0002,FDA-2016-P-3356,acknowledgement letter from fda ddm to sandoz inc,0,0
0900006482304908,Supporting & Related Material,FDA-2016-P-3356-0015,FDA-2016-P-3356,"attachment m gsk, comments submitted to docket no. fda-2007-d-0369 (nov. 12, 2013) re citizen petition from sandoz inc",0,0
0900006482304498,Supporting & Related Material,FDA-2016-P-3356-0007,FDA-2016-P-3356,"attachment e günther hochhaus, et al., meeting report: pharmacokinetics of orally inhaled drug products, 17 am. ass’n of pharmaceutical scientists j. 769, 773 (2015) re citizen petition from sandoz inc",0,0
090000648250047e,Other,FDA-2016-P-3356-0018,FDA-2016-P-3356,cp response from fda cder to sandoz inc.,0,0
090000648230449b,Supporting & Related Material,FDA-2016-P-3356-0010,FDA-2016-P-3356,"attachment h h. möllmann, et al., pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration, 53 european j. clinical pharmacology 459 (1998) re citizen petition from sandoz inc",0,0
0900006482304909,Supporting & Related Material,FDA-2016-P-3356-0016,FDA-2016-P-3356,"attachment n rashmi mehta, et al., comparison of the pharmacokinetics of salmeterol and fluticasone propionate 50/100 ug delivered in combination as a dry powder via a capsule-based inhaler and a multi-dose inhaler, 35 clinical drug investigation 319 (2015) re citizen petition from sandoz inc",0,0
090000648230449d,Supporting & Related Material,FDA-2016-P-3356-0012,FDA-2016-P-3356,"attachment j lars thorsson, et al., pharmacokinetics and systemic activity of fluticasone via diskus® and pmdi, and of budesonide via thurbuhaler®, 52 british j. clinical pharmacology 529 (2001) re citizen petition from sandoz inc",0,0
0900006482304906,Supporting & Related Material,FDA-2016-P-3356-0013,FDA-2016-P-3356,"attachment k charles brindley, et al., absorption kintetics after inhalation of fluticasone propionate via the diskahler®, diskus®, and metered-dose inhaler in healthy volunteers, 39 supp. 1 clinical pharmacokinetics 1 (2000) re citizen petition from sandoz inc",0,0
0900006482304907,Supporting & Related Material,FDA-2016-P-3356-0014,FDA-2016-P-3356,"attachment l s. kirby, et al., salmeterol and fluticasone propionate given as a combination: lack of systemic pharmacodynamic and pharmacokinetic interactions, 56 european j. clinical pharmacology 781 (2001) re citizen petition from sandoz inc",0,0
090000648230449c,Supporting & Related Material,FDA-2016-P-3356-0011,FDA-2016-P-3356,"attachment i r. kunka, et al., dose proportionality of fluticasone propionate from hydrofluoroalkane pressurized petered dose inhalers (pmdis) and comparability with chlorofluorocarbon pmdis, 94 supp. b respiratory medicine s-10 (2000) re citizen petition from sandoz inc",0,0
0900006482304496,Supporting & Related Material,FDA-2016-P-3356-0005,FDA-2016-P-3356,attachment c advair diskus prescribing information & medication guide (rev. apr. 2016) re citizen petition from sandoz inc,0,0
090000648230449a,Supporting & Related Material,FDA-2016-P-3356-0009,FDA-2016-P-3356,"attachment g elise burmeister getz, et al., batch-to-batch pharmacokinetic variability confounds current bioequivalence regulations: a dry powder inhaler randomized clinical trial, clinical pharmacology & therapeutics (advance online publication 2016) re citizen petition from sandoz inc",0,0
0900006482ceaec6,Other,FDA-2017-P-6758-0002,FDA-2017-P-6758,acknowledgement letter from fda ddm to public citizen’s health research group,0,0
0900006483533f90,Other,FDA-2017-P-6758-0004,FDA-2017-P-6758,partial approval and partial denial of petition for fda-2017-p-6758,0,0
0900006482ceaec3,Other,FDA-2017-P-6758-0001,FDA-2017-P-6758,citizen petition from public citizen's health research group,0,0
0900006483337165,Other,FDA-2017-P-6758-0003,FDA-2017-P-6758,interim response from fda cder to public citizen,0,0
090000648373b44d,Other,FDA-2018-P-1099-0005,FDA-2018-P-1099,withdrawal letter from lachman consultants services inc.,0,0
09000064830066ee,Supporting & Related Material,FDA-2018-P-1099-0003,FDA-2018-P-1099,attachment 1~ product listing from the approved drug products with therapeutic equivalence evaluations,0,0
090000648300660c,Other,FDA-2018-P-1099-0002,FDA-2018-P-1099,"acknowledgment letter from fda ddm to lachman consultant services, inc.",0,0
090000648374217e,Other,FDA-2018-P-1099-0006,FDA-2018-P-1099,"correction from lachman consultants services, inc.",0,0
09000064836c36ce,Other,FDA-2018-P-1099-0004,FDA-2018-P-1099,"letter from fda cder to lachman consultant services, inc.",0,0
0900006483006605,Other,FDA-2018-P-1099-0001,FDA-2018-P-1099,"citizen petition from lachman consultant services, inc.",0,0
09000064836b33ba,Other,FDA-2018-P-1453-0019,FDA-2018-P-1453,"response from fda cder to spear pharmaceuticals, inc.",0,0
09000064830fd2ec,Supporting & Related Material,FDA-2018-P-1453-0008,FDA-2018-P-1453,"attachment6_f - sigma 5-fluorouracil re citizen petition from spear pharmaceuticals, inc",0,0
09000064830fd30d,Supporting & Related Material,FDA-2018-P-1453-0018,FDA-2018-P-1453,"attachment16_p - ims data re citizen petition from spear pharmaceuticals, inc",0,0
09000064830fd1fa,Other,FDA-2018-P-1453-0002,FDA-2018-P-1453,"acknowledgment letter from fda ddm to spear pharmaceuticals, inc",0,0
09000064830fd2ea,Supporting & Related Material,FDA-2018-P-1453-0006,FDA-2018-P-1453,"attachment4_d - vale et al re citizen petition from spear pharmaceuticals, inc",0,0
09000064830fd2ee,Supporting & Related Material,FDA-2018-P-1453-0010,FDA-2018-P-1453,"attachment8_h - zovirax label re citizen petition from spear pharmaceuticals, inc",0,0
09000064830fd2e8,Supporting & Related Material,FDA-2018-P-1453-0004,FDA-2018-P-1453,"attachment2_b - fluorouracil draft guidance re citizen petition from spear pharmaceuticals, inc",0,0
09000064830fd2e9,Supporting & Related Material,FDA-2018-P-1453-0005,FDA-2018-P-1453,"attachment3_c - final welgus decl_ with exhibits re citizen petition from spear pharmaceuticals, inc",0,0
09000064830fd1f8,Other,FDA-2018-P-1453-0001,FDA-2018-P-1453,"citizen petition from spear pharmaceuticals, inc",0,0
09000064830fd2e7,Supporting & Related Material,FDA-2018-P-1453-0003,FDA-2018-P-1453,"attachment1_a - raney powerpoint re citizen petition from spear pharmaceuticals, inc",0,0
09000064830fd30a,Supporting & Related Material,FDA-2018-P-1453-0015,FDA-2018-P-1453,"attachment13_m - stinchcombe fda powerpoint re citizen petition from spear pharmaceuticals, inc",0,0
09000064830fd2eb,Supporting & Related Material,FDA-2018-P-1453-0007,FDA-2018-P-1453,"attachment5_e - yanofsky et al re citizen petition from spear pharmaceuticals, inc",0,0
09000064830fd2ef,Supporting & Related Material,FDA-2018-P-1453-0011,FDA-2018-P-1453,"attachment9_i - aczone label re citizen petition from spear pharmaceuticals, inc",0,0
09000064830fd30b,Supporting & Related Material,FDA-2018-P-1453-0016,FDA-2018-P-1453,"attachment14_n - supac 1997 guidance re citizen petition from spear pharmaceuticals, inc",0,0
09000064830fd2ed,Supporting & Related Material,FDA-2018-P-1453-0009,FDA-2018-P-1453,"attachment7_g - msds fluorouracil re citizen petition from spear pharmaceuticals, inc",0,0
09000064830fd309,Supporting & Related Material,FDA-2018-P-1453-0014,FDA-2018-P-1453,"attachment12_l - luke fda powerpoint re citizen petition from spear pharmaceuticals, inc",0,0
09000064830fd2f0,Supporting & Related Material,FDA-2018-P-1453-0012,FDA-2018-P-1453,"attachment10_j - soolantra label re citizen petition from spear pharmaceuticals, inc",0,0
09000064830fd30c,Supporting & Related Material,FDA-2018-P-1453-0017,FDA-2018-P-1453,"attachment15_o - usp 1724 ss performance tests re citizen petition from spear pharmaceuticals, inc",0,0
09000064830fd308,Supporting & Related Material,FDA-2018-P-1453-0013,FDA-2018-P-1453,"attachment11_k - acyclovir draft guidance re citizen petition from spear pharmaceuticals, inc",0,0
09000064825c7b8a,Supporting & Related Material,FDA-2017-P-3092-0006,FDA-2017-P-3092,exhibits 16-25-1 re citizen petition from astrazeneca pharmaceuticals lp,0,0
0900006482bc15d8,Other,FDA-2017-P-3092-0010,FDA-2017-P-3092,response letter from fda to astrazeneca global medicines development,0,0
09000064825c7725,Supporting & Related Material,FDA-2017-P-3092-0004,FDA-2017-P-3092,exhibits 3-9 re citizen petition from astrazeneca pharmaceuticals lp,0,0
09000064825c7726,Supporting & Related Material,FDA-2017-P-3092-0005,FDA-2017-P-3092,exhibits 10-15-1 re citizen petition from astrazeneca pharmaceuticals lp,0,0
09000064825c7b8b,Supporting & Related Material,FDA-2017-P-3092-0007,FDA-2017-P-3092,exhibit 26-1 re citizen petition from astrazeneca pharmaceuticals lp,0,0
09000064825ca158,Other,FDA-2017-P-3092-0002,FDA-2017-P-3092,acknowledgment letter from fda ddm to astrazeneca pharmaceuticals lp,0,0
09000064825c7722,Other,FDA-2017-P-3092-0001,FDA-2017-P-3092,citizen petition from astrazeneca pharmaceuticals lp,0,0
09000064825c7b8c,Supporting & Related Material,FDA-2017-P-3092-0008,FDA-2017-P-3092,exhibits 27-29-1 re citizen petition from astrazeneca pharmaceuticals lp,0,0
09000064825c7b8d,Supporting & Related Material,FDA-2017-P-3092-0009,FDA-2017-P-3092,exhibit 30 re citizen petition from astrazeneca pharmaceuticals lp,0,0
09000064825c7724,Supporting & Related Material,FDA-2017-P-3092-0003,FDA-2017-P-3092,exhibits 1-2 re citizen petition from astrazeneca pharmaceuticals lp,0,0
0900006483ebf790,Other,FDA-2019-P-4002-0002,FDA-2019-P-4002,acknowledgment letter from fda dms to otsuka pharmaceutical development & commercialization inc.,0,0
09000064842b0baf,Other,FDA-2019-P-4002-0003,FDA-2019-P-4002,"letter from fda cder to  otsuka pharmaceutical development & commercialization, inc.",0,0
0900006483ebe4b5,Other,FDA-2019-P-4002-0001,FDA-2019-P-4002,"citizen petition from otsuka pharmaceutical development & commercialization, inc.",0,0
09000064820a6d7f,Supporting & Related Material,FDA-2016-P-2029-0004,FDA-2016-P-2029,"attachment 2 the dispensatory of the united states of america - the 20th edition re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6bf7,Supporting & Related Material,FDA-2016-P-2029-0011,FDA-2016-P-2029,"attachment 9 pharma research software solutions re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6c01,Supporting & Related Material,FDA-2016-P-2029-0016,FDA-2016-P-2029,"attachment 16 order business documents re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6bfa,Supporting & Related Material,FDA-2016-P-2029-0019,FDA-2016-P-2029,"attachment 12 re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6d7c,Other,FDA-2016-P-2029-0001,FDA-2016-P-2029,"citizen petition from buchanan ingersoll & rooney pc  (virtus pharmaceuticals opco, llc)",0,0
09000064820a96bf,Other,FDA-2016-P-2029-0002,FDA-2016-P-2029,"acknowledgement letter from fda ddm to buchanan ingersoll & rooney pc  (virtus pharmaceuticals opco, llc)",0,0
09000064820a6bf8,Supporting & Related Material,FDA-2016-P-2029-0012,FDA-2016-P-2029,"attachment 10 pharma research software solutions, llc re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6d7e,Supporting & Related Material,FDA-2016-P-2029-0003,FDA-2016-P-2029,"attachment 1 current concepts hypokalemia re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6bf5,Supporting & Related Material,FDA-2016-P-2029-0009,FDA-2016-P-2029,"attachment 7 pharma research software solutions re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6d80,Supporting & Related Material,FDA-2016-P-2029-0005,FDA-2016-P-2029,"attachment 3 the dispensatory of the united states of america - the 23rd edition re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6d81,Supporting & Related Material,FDA-2016-P-2029-0006,FDA-2016-P-2029,"attachment 4 physicians' desk reference to pharmaceutical specialties and biologicals in five sections re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064823887c8,Other,FDA-2016-P-2029-0027,FDA-2016-P-2029,petition denial letter,0,0
09000064820a6c04,Supporting & Related Material,FDA-2016-P-2029-0022,FDA-2016-P-2029,"attachment 19 re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6c00,Supporting & Related Material,FDA-2016-P-2029-0015,FDA-2016-P-2029,"attachment 15 identify and dev innovative oral delivery technolo re  citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6c02,Supporting & Related Material,FDA-2016-P-2029-0017,FDA-2016-P-2029,"attachment 17 formulation development re  citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6c03,Supporting & Related Material,FDA-2016-P-2029-0021,FDA-2016-P-2029,"attachment 18 re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6c05,Supporting & Related Material,FDA-2016-P-2029-0018,FDA-2016-P-2029,"attachment 20 united states securities and exchange commission form 10-q re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6bfc,Supporting & Related Material,FDA-2016-P-2029-0014,FDA-2016-P-2029,"attachment 14 united states district court for the district of new jersey complaint and demand for jury trial re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6bfb,Supporting & Related Material,FDA-2016-P-2029-0020,FDA-2016-P-2029,"attachment 13 re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6bf3,Supporting & Related Material,FDA-2016-P-2029-0007,FDA-2016-P-2029,"attachment 5 physicians' desk reference to pharmaceutical specialties and biologicals - 10th edition re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6bf4,Supporting & Related Material,FDA-2016-P-2029-0008,FDA-2016-P-2029,"attachment 6 order business documents re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6bf6,Supporting & Related Material,FDA-2016-P-2029-0010,FDA-2016-P-2029,"attachment 8 pharma research software solutions re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
09000064820a6bf9,Supporting & Related Material,FDA-2016-P-2029-0013,FDA-2016-P-2029,"attachment 11 izbinsky dmitriy re citizen petition from buchanan ingersoll & rooney pc (virtus pharmaceuticals opco, llc)",0,0
0900006482582596,Supporting & Related Material,FDA-2017-P-2674-0003,FDA-2017-P-2674,"attachment 1 - orange book approved drug products with therapeutic equivalence evaluations re request that the fda declare that empagliflozin and linagliptin capsules 10 mg; 5 mg , 25 mg: 5 mg are suitable for submission as an abbreviated new drug application (anda)",0,0
09000064825829fe,Supporting & Related Material,FDA-2017-P-2674-0005,FDA-2017-P-2674,"attachment 3 - glyxambi (empagliflozin and linagliptin) tablets re request that the fda declare that empagliflozin and linagliptin capsules 10 mg; 5 mg , 25 mg: 5 mg are suitable for submission as an abbreviated new drug application (anda)",0,0
0900006482582a51,Supporting & Related Material,FDA-2017-P-2674-0006,FDA-2017-P-2674,"attachment 4 - nda approval re request that the fda declare that empagliflozin and linagliptin capsules 10 mg; 5 mg , 25 mg: 5 mg are suitable for submission as an abbreviated new drug application (anda)",0,0
09000064825820a3,Other,FDA-2017-P-2674-0002,FDA-2017-P-2674,acknowledgment letter from fda ddm to foley & lardner llp,0,0
0900006482582646,Supporting & Related Material,FDA-2017-P-2674-0004,FDA-2017-P-2674,"attachment 2 - empagliflozin and linagliptin capsules re request that the fda declare that empagliflozin and linagliptin capsules 10 mg; 5 mg , 25 mg: 5 mg are suitable for submission as an abbreviated new drug application (anda)",0,0
090000648258234e,Other,FDA-2017-P-2674-0001,FDA-2017-P-2674,citizen petition from foley & lardner llp,0,0
0900006484d4570e,Other,FDA-2017-P-2674-0007,FDA-2017-P-2674,citizen petition withdrawal from foley and lardner llp,0,0
09000064849ea08d,Supporting & Related Material,FDA-2021-P-0035-0008,FDA-2021-P-0035,reference 3 re: citizen petition from adrienne samuels,0,0
09000064849ea0aa,Supporting & Related Material,FDA-2021-P-0035-0014,FDA-2021-P-0035,reference 9 re: citizen petition from adrienne samuels,0,0
09000064849ea090,Supporting & Related Material,FDA-2021-P-0035-0011,FDA-2021-P-0035,reference 6 re: citizen petition from adrienne samuels,0,0
09000064849ea0ae,Supporting & Related Material,FDA-2021-P-0035-0018,FDA-2021-P-0035,reference 13 re: citizen petition from adrienne samuels,0,0
09000064849ea0ac,Supporting & Related Material,FDA-2021-P-0035-0016,FDA-2021-P-0035,reference 11 re: citizen petition from adrienne samuels,0,0
09000064849ea0a9,Supporting & Related Material,FDA-2021-P-0035-0013,FDA-2021-P-0035,reference 8 re: citizen petition from adrienne samuels,0,0
09000064849ea0af,Supporting & Related Material,FDA-2021-P-0035-0019,FDA-2021-P-0035,reference 14 re: citizen petition from adrienne samuels,0,0
09000064849e9e4b,Other,FDA-2021-P-0035-0001,FDA-2021-P-0035,citizen petition from adrienne samuels,0,0
09000064849ea0ab,Supporting & Related Material,FDA-2021-P-0035-0015,FDA-2021-P-0035,reference 10 re: citizen petition from adrienne samuels,0,0
09000064849ea08f,Supporting & Related Material,FDA-2021-P-0035-0010,FDA-2021-P-0035,reference 5 re: citizen petition from adrienne samuels,0,0
0900006484bd235b,Other,FDA-2021-P-0035-0097,FDA-2021-P-0035,180 day response letter from fda cfsan to adrienne samuels,0,0
09000064849ea0b0,Supporting & Related Material,FDA-2021-P-0035-0020,FDA-2021-P-0035,reference 15  re: citizen petition from adrienne samuels,0,0
09000064849ea08e,Supporting & Related Material,FDA-2021-P-0035-0009,FDA-2021-P-0035,reference 4 re: citizen petition from adrienne samuels,0,0
09000064849ea088,Other,FDA-2021-P-0035-0002,FDA-2021-P-0035,acknowledgment letter from fda dms to adrienne samuels,0,0
09000064849ea08c,Supporting & Related Material,FDA-2021-P-0035-0007,FDA-2021-P-0035,reference 2 re: citizen petition from adrienne samuels,0,0
09000064849ea0ad,Supporting & Related Material,FDA-2021-P-0035-0017,FDA-2021-P-0035,reference 12 re: citizen petition from adrienne samuels,0,0
09000064849ea08b,Supporting & Related Material,FDA-2021-P-0035-0006,FDA-2021-P-0035,reference 1 re: citizen petition from adrienne samuels,0,0
09000064849ea091,Supporting & Related Material,FDA-2021-P-0035-0012,FDA-2021-P-0035,reference 7 re: citizen petition from adrienne samuels,0,0
0900006484e1b66b,Other,FDA-2021-P-1193-0001,FDA-2021-P-1193,"citizen petition from valisure, llc",0,0
0900006484e1a32d,Supporting & Related Material,FDA-2021-P-1193-0003,FDA-2021-P-1193,"attachment a - acc resolution - chemical variability in pharmaceutical products re citizen petition from valisure, llc",0,0
0900006484e1b66d,Other,FDA-2021-P-1193-0002,FDA-2021-P-1193,"acknowledgment letter from fda dms to valisure, llc",0,0
090000648119e750,Other,FDA-2012-P-1265-0001,FDA-2012-P-1265,indicus pharma llc - citzen petition,0,0
090000648119e753,Other,FDA-2012-P-1265-0002,FDA-2012-P-1265,acknowledgement letter to indicus pharma llc,0,0
090000648132ec6d,Other,FDA-2012-P-1265-0003,FDA-2012-P-1265,interim response to indicus pharma llc,0,0
09000064839fbdd8,Other,FDA-2012-P-1265-0004,FDA-2012-P-1265,response letter from fda cder,0,0
0900006482f90110,Other,FDA-2018-P-0967-0002,FDA-2018-P-0967,"acknowledgment letter from fda ddm to fresenius kabi usa, llc",0,0
090000648365befa,Other,FDA-2018-P-0967-0005,FDA-2018-P-0967,"agency response letter from fda cder to fresenius kabi usa, llc",0,0
0900006482f901c3,Supporting & Related Material,FDA-2018-P-0967-0003,FDA-2018-P-0967,"attachment a-current orange book listing of plasma-lyte m and dextrose 5% re: citizen petition from fresenius kabi usa, llc",0,0
090000648364f66c,Notice,FDA-2018-P-0967-0004,FDA-2018-P-0967,"determination that plasma–lyte m and dextrose 5% and plasma
lyte 148 and dextrose 5% were not withdrawn from sale for reasons
of safety or effectiveness",0,0
0900006482f8fd47,Other,FDA-2018-P-0967-0001,FDA-2018-P-0967,"citizen petition from fresenius kabi usa, llc",0,0
0900006482190e6d,Supporting & Related Material,FDA-2016-P-2515-0007,FDA-2016-P-2515,exhibit -5 usp commentary usp 39–nf 34  re citizen petition from eli lilly and company,0,0
0900006482190e70,Supporting & Related Material,FDA-2016-P-2515-0010,FDA-2016-P-2515,exhibit -8 the fda’s assessment of follow-on protein products: a historical perspective re citizen petition from eli lilly and company,0,0
0900006482190e79,Supporting & Related Material,FDA-2016-P-2515-0019,FDA-2016-P-2515,"exhibit -17 engineering of therapeutic polypeptides through chemical
synthesis: early lessons from human parathyroid hormone and
analogues re citizen petition from eli lilly and company",0,0
0900006482190e7a,Supporting & Related Material,FDA-2016-P-2515-0020,FDA-2016-P-2515,exhibit -18 precision and robustness of 2d-nmr for structure assessment of filgrastim biosimilars re citizen petition from eli lilly and company,0,0
0900006482190e72,Supporting & Related Material,FDA-2016-P-2515-0012,FDA-2016-P-2515,exhibit -10 structure-activity relation of nh2-terminal human parathyroid hormone fragments re citizen petition from eli lilly and company,0,0
0900006482190e75,Supporting & Related Material,FDA-2016-P-2515-0015,FDA-2016-P-2515,exhibit -13 generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy re citizen petition from eli lilly and company,0,0
0900006482190e7c,Supporting & Related Material,FDA-2016-P-2515-0022,FDA-2016-P-2515,"exhibit -20 effect of transdermal teriparatide administration on
bone mineral density in postmenopausal women re citizen petition from eli lilly and company",0,0
0900006482190e7d,Supporting & Related Material,FDA-2016-P-2515-0023,FDA-2016-P-2515,exhibit -21 sa393 re citizen petition from eli lilly and company,0,0
0900006482190e8f,Other,FDA-2016-P-2515-0002,FDA-2016-P-2515,acknowledgment letter from fda ddm to eli lilly and company,0,0
0900006482190e78,Supporting & Related Material,FDA-2016-P-2515-0018,FDA-2016-P-2515,exhibit -16 scientific considerations for generic synthetic salmon calcitonin nasal spray products re citizen petition from eli lilly and company,0,0
0900006482190e7b,Supporting & Related Material,FDA-2016-P-2515-0021,FDA-2016-P-2515,exhibit -19 contributions of parathyroid hormone (pth)/pth-related peptide receptor signaling pathways to the anabolic effect of pth on bone re citizen petition from eli lilly and company,0,0
0900006482190a57,Supporting & Related Material,FDA-2016-P-2515-0004,FDA-2016-P-2515,exhibit -2 oxidation of therapeutic proteins and peptides: structural and biological consequences re citizen petition from eli lilly and company,0,0
0900006482190e6b,Supporting & Related Material,FDA-2016-P-2515-0005,FDA-2016-P-2515,"exhibit -3 investigation of the solution structure of the human parathyroid hormone fragment (1-34) by 1h nmr spectroscopy, distance geometry, and molecular dynamics calculations re citizen petition from eli lilly and company",0,0
0900006482190e6c,Supporting & Related Material,FDA-2016-P-2515-0006,FDA-2016-P-2515,exhibit -4 structure of human parathyroid hormone 1-37 in solution  re citizen petition from eli lilly and company,0,0
0900006482190e6e,Supporting & Related Material,FDA-2016-P-2515-0008,FDA-2016-P-2515,exhibit -6 terconazole i official monographs re citizen petition from eli lilly and company,0,0
0900006482190e6f,Supporting & Related Material,FDA-2016-P-2515-0009,FDA-2016-P-2515,"exhibit -7 notice of anda no. 208569 concerning teriparatide injection 600 p.g/2.4 ml (250 p.g/ml), with paragraph iv certification concerning u.s. patent nos. 6,770,623; 6,977,077; 7,144,861; 7,163,684; 7,351,414; 7,517,334; and 7,550,434 re citizen petition from eli lilly and company",0,0
0900006482190e71,Supporting & Related Material,FDA-2016-P-2515-0011,FDA-2016-P-2515,exhibit -9 solution structure and adenylyl cyclase stimulating activities of c-terminal truncated human parathyroid hormone analogues re citizen petition from eli lilly and company,0,0
0900006482190e77,Supporting & Related Material,FDA-2016-P-2515-0017,FDA-2016-P-2515,"exhibit -15 measuring parathyroid hormone (pth) in patients with
oxidative stress - do we need a fourth generation parathyroid hormone assay? re citizen petition from eli lilly and company",0,0
0900006482190e8a,Supporting & Related Material,FDA-2016-P-2515-0025,FDA-2016-P-2515,exhibit -23 combination therapy for osteoporosis: a reappraisal re citizen petition from eli lilly and company,0,0
0900006482190e8c,Supporting & Related Material,FDA-2016-P-2515-0026,FDA-2016-P-2515,"exhibit -24 randomlsed controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among
postmenopausal women on oestrogen with osteoporosis re citizen petition from eli lilly and company",0,0
0900006482190a54,Other,FDA-2016-P-2515-0001,FDA-2016-P-2515,citizen petition from eli lilly and company,0,0
0900006482190e73,Supporting & Related Material,FDA-2016-P-2515-0013,FDA-2016-P-2515,exhibit -11 addressing the tertiary structure of human parathyroid hormone-(1–34)* re citizen petition from eli lilly and company,0,0
0900006482190e76,Supporting & Related Material,FDA-2016-P-2515-0016,FDA-2016-P-2515,"exhibit -14 effects of oxidation of human parathyroid hormone on its
biological activity in continuously infused, thyroparathyroidectomized rats re citizen petition from eli lilly and company",0,0
0900006482190a56,Supporting & Related Material,FDA-2016-P-2515-0003,FDA-2016-P-2515,exhibit -1 § 600.3 definitions re citizen petition from eli lilly and company,0,0
0900006482190e74,Supporting & Related Material,FDA-2016-P-2515-0014,FDA-2016-P-2515,exhibit -12 pharmaceutical salts: a formulation trick or a clinical conundrum  re citizen petition from eli lilly and company,0,0
0900006481f9a0a6,Other,FDA-2015-P-4224-0005,FDA-2015-P-4224,interim response letter,0,0
0900006481d39860,Other,FDA-2015-P-4224-0004,FDA-2015-P-4224,acknowledgement letter from fda ddm to flamingo pharmaceuticals ltd,0,0
09000064820ac90a,Notice,FDA-2015-P-4224-0006,FDA-2015-P-4224,"determination that parafon forte dsc (chlorzoxazone) tablets, 500
milligrams, was not withdrawn from sale for reasons of safety or
effectiveness",0,0
09000064820b35a3,Other,FDA-2015-P-4224-0007,FDA-2015-P-4224,petition approval letter,0,0
0900006481d42a1d,Supporting & Related Material,FDA-2015-P-4224-0003,FDA-2015-P-4224,attachment 2 electronic orange book identifying active approved chlorzoxazone tablets 500 mg products re citizen petition from flamingo pharmaceuticals ltd,0,0
0900006481d39467,Other,FDA-2015-P-4224-0001,FDA-2015-P-4224,citizen petition from flamingo pharmaceuticals ltd,0,0
0900006481d42a1c,Supporting & Related Material,FDA-2015-P-4224-0002,FDA-2015-P-4224,attachment 1 fda drug shortages current and resolved drug shortages and discontinuations reported to fda re citizen petition from flamingo pharmaceuticals ltd,0,0
09000064840fa89d,Supporting & Related Material,FDA-2019-P-4979-0005,FDA-2019-P-4979,"attachment-3 draft labeling for proposed magnesium sulfate in dextrose 5% injection usp, 1 gm/50 ml re citizen application from andersen pharma llc",0,0
09000064840fa89b,Supporting & Related Material,FDA-2019-P-4979-0003,FDA-2019-P-4979,attachment-1 approved drug products with therapeutic equivalence evaluations (electronic orange book) for rld re citizen application from andersen pharma llc,0,0
09000064840fa89c,Supporting & Related Material,FDA-2019-P-4979-0004,FDA-2019-P-4979,attachment-2 reference listed drug prescribing information re citizen application from andersen pharma llc,0,0
09000064840fa7f2,Other,FDA-2019-P-4979-0001,FDA-2019-P-4979,citizen petition from andersen pharma llc,0,0
09000064840faae2,Other,FDA-2019-P-4979-0002,FDA-2019-P-4979,acknowledgment letter from fda dms to andersen pharma llc,0,0
09000064849373fb,Other,FDA-2020-P-2134-0001,FDA-2020-P-2134,citizen petition from natural products association,0,0
0900006484ab33c6,Other,FDA-2020-P-2134-0003,FDA-2020-P-2134,interim response letter from fda cfsan to natural products association,0,0
09000064849373fc,Other,FDA-2020-P-2134-0002,FDA-2020-P-2134,acknowledgment letter from fda dms to natural products association,0,0
0900006484b2654d,Other,FDA-2020-P-2289-0004,FDA-2020-P-2289,"interim response to loeb & loeb, llp from fda cdrh",0,0
09000064849987ab,Other,FDA-2020-P-2289-0001,FDA-2020-P-2289,"citizen petition from loeb & loeb, llp",0,0
09000064849987ac,Other,FDA-2020-P-2289-0002,FDA-2020-P-2289,"acknowledgment letter from fda dms to loeb & loeb, llp",0,0
090000648253b389,Supporting & Related Material,FDA-2017-P-2092-0016,FDA-2017-P-2092,"appendix n - effect  of the artificial sweetener, sucralose , on gastric
emptying and incretin hormone release in health y subjects re citizen petition from wilson sonsini goodrich & rosati",0,0
090000648253b383,Supporting & Related Material,FDA-2017-P-2092-0010,FDA-2017-P-2092,appendix h - absorption of drugs re citizen petition from wilson sonsini goodrich & rosati,0,0
090000648253b384,Supporting & Related Material,FDA-2017-P-2092-0011,FDA-2017-P-2092,appendix i - splenda alters gut microflora and increases intestinal p-glycoprotein and cytochrome p-450 in male rats re citizen petition from wilson sonsini goodrich & rosati,0,0
090000648253b388,Supporting & Related Material,FDA-2017-P-2092-0015,FDA-2017-P-2092,appendix m - sucralose revisited: rebuttal of two papers about splenda safety re citizen petition from wilson sonsini goodrich & rosati,0,0
090000648253b381,Supporting & Related Material,FDA-2017-P-2092-0008,FDA-2017-P-2092,appendix f - molecular and physicochemical properties impacting oral absorption of drugs re citizen petition from wilson sonsini goodrich & rosati,0,0
090000648253b386,Supporting & Related Material,FDA-2017-P-2092-0013,FDA-2017-P-2092,appendix k - clinical pharmacology and biopharmaceutics review (s) re citizen petition from wilson sonsini goodrich & rosati,0,0
090000648253aef6,Supporting & Related Material,FDA-2017-P-2092-0003,FDA-2017-P-2092,"appendix a - characterization of the expression and activity of carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human re citizen petition from wilson sonsini goodrich & rosati",0,0
090000648253b387,Supporting & Related Material,FDA-2017-P-2092-0014,FDA-2017-P-2092,appendix l -  regulatory toxicology and pharmacology re citizen petition from wilson sonsini goodrich & rosati,0,0
09000064840ff737,Other,FDA-2017-P-2092-0019,FDA-2017-P-2092,response letter from fda cder to wilson sonsini goodrich & rosati,0,0
090000648253a540,Other,FDA-2017-P-2092-0001,FDA-2017-P-2092,"citizen petition from wilson sonsini goodrich & rosati (silvergate pharmaceuticals, inc.)",0,0
090000648253aef4,Other,FDA-2017-P-2092-0002,FDA-2017-P-2092,acknowledgment letter from fda ddm to wilson sonsini goodrich & rosati,0,0
090000648253aef9,Supporting & Related Material,FDA-2017-P-2092-0006,FDA-2017-P-2092,appendix d - surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir re citizen petition from wilson sonsini goodrich & rosati,0,0
090000648253aefa,Supporting & Related Material,FDA-2017-P-2092-0007,FDA-2017-P-2092,appendix e - modelling and simulation in bioequivalence re citizen petition from wilson sonsini goodrich & rosati,0,0
090000648253aef7,Supporting & Related Material,FDA-2017-P-2092-0004,FDA-2017-P-2092,appendix b - the role of intestinal carboxylesterase in the oral absorption of prodrugs re citizen petition from wilson sonsini goodrich & rosati,0,0
090000648253aef8,Supporting & Related Material,FDA-2017-P-2092-0005,FDA-2017-P-2092,"appendix c - absorption and cleavage of enalapril, a carboxyl ester prodrug, in the rat intestine: in vitro, in situ intestinal perfusion and
portal vein cannulation models re citizen petition from wilson sonsini goodrich & rosati",0,0
090000648253b382,Supporting & Related Material,FDA-2017-P-2092-0009,FDA-2017-P-2092,appendix g -  open circles=enalaprilat re citizen petition from wilson sonsini goodrich & rosati,0,0
090000648253b385,Supporting & Related Material,FDA-2017-P-2092-0012,FDA-2017-P-2092,appendix j - enalapril re citizen petition from wilson sonsini goodrich & rosati,0,0
0900006482b6318c,Other,FDA-2017-P-2092-0018,FDA-2017-P-2092,interim response letter from cder to wilson sonsini goodrich & rosati,0,0
09000064824a56aa,Other,FDA-2017-P-0662-0001,FDA-2017-P-0662,"citizen petition from impax laboratories, inc.",0,0
09000064827c3352,Other,FDA-2017-P-0662-0004,FDA-2017-P-0662,"letter from fda cder to impax laboratories, inc.",0,0
09000064824a7e37,Other,FDA-2017-P-0662-0003,FDA-2017-P-0662,"supplement from impax laboratories, inc.",0,0
09000064824a579c,Other,FDA-2017-P-0662-0002,FDA-2017-P-0662,"acknowledgment letter from fda ddm to impax laboratories, inc.",0,0
090000648448eb5e,Other,FDA-2020-P-1260-0002,FDA-2020-P-1260,acknowledgment letter from fda dms to foley & lardner llp,0,0
090000648448eb61,Supporting & Related Material,FDA-2020-P-1260-0003,FDA-2020-P-1260,annex i - orange book approved drug products re citizen petition from foley & lardner llp,0,0
090000648448eb62,Supporting & Related Material,FDA-2020-P-1260-0004,FDA-2020-P-1260,annex ii - additions/deletions for prescription drug product list re citizen petition from foley & lardner llp,0,0
09000064848d15ed,Other,FDA-2020-P-1260-0006,FDA-2020-P-1260,interim response letter from fda cder to foley & lardner llp,0,0
09000064849747f3,Other,FDA-2020-P-1260-0007,FDA-2020-P-1260,withdrawal from foley & lardner llp,0,0
090000648448ef2a,Supporting & Related Material,FDA-2020-P-1260-0005,FDA-2020-P-1260,annex iii - additions/deletions for prescription drug product list re citizen petition from foley & lardner llp,0,0
090000648448eb5d,Other,FDA-2020-P-1260-0001,FDA-2020-P-1260,citizen petition from foley & lardner llp,0,0
090000648494dcee,Other,FDA-2020-P-2175-0002,FDA-2020-P-2175,"acknowledgment letter from fda dms to lachman consulting services, inc",0,0
090000648494dced,Other,FDA-2020-P-2175-0001,FDA-2020-P-2175,"citizen petition from lachman consulting services, inc",0,0
0900006484957fb2,Other,FDA-2020-P-1016-0010,FDA-2020-P-1016,"withdrawal from celltrion, inc.",0,0
09000064843dcae7,Supporting & Related Material,FDA-2020-P-1016-0002,FDA-2020-P-1016,"appendix 1 orange book: approved drug products with therapeutic equivalence evaluations (ropinrole hydrochloride) re citizen petition from celltrion, inc.",0,0
09000064843dab2c,Other,FDA-2020-P-1016-0001,FDA-2020-P-1016,"citizen petition from celltrion, inc.",0,0
09000064843dc73c,Other,FDA-2020-P-1016-0008,FDA-2020-P-1016,"acknowledgment letter from fda dms to celltrion, inc.",0,0
09000064843dc739,Supporting & Related Material,FDA-2020-P-1016-0005,FDA-2020-P-1016,"appendix 4 highlights of prescribing information (requip xl) re citizen petition from celltrion, inc.",0,0
09000064843dc73a,Supporting & Related Material,FDA-2020-P-1016-0006,FDA-2020-P-1016,"appendix 5 principal display panel ndc 0007-4887-13 requip xl® re citizen petition from celltrion, inc.",0,0
09000064843dcae9,Supporting & Related Material,FDA-2020-P-1016-0004,FDA-2020-P-1016,"appendix 3 email communication between globyz and celltrion re citizen petition from celltrion, inc.",0,0
09000064848219a6,Other,FDA-2020-P-1016-0009,FDA-2020-P-1016,"interim response from fda cder to celltrion, inc.",0,0
09000064843dcae8,Supporting & Related Material,FDA-2020-P-1016-0003,FDA-2020-P-1016,"appendix 2 orange book: approved drug products with therapeutic equivalence evaluations (nda 022008) re citizen petition from celltrion, inc.",0,0
09000064843dc73b,Supporting & Related Material,FDA-2020-P-1016-0007,FDA-2020-P-1016,"appendix 6 national drug code directory re citizen petition from celltrion, inc.",0,0
0900006483626d99,Other,FDA-2018-P-3176-0001,FDA-2018-P-3176,citizen petition from medefil inc,0,0
0900006483627dd0,Supporting & Related Material,FDA-2018-P-3176-0003,FDA-2018-P-3176,attachment 1- orange book: approved drug products with therapeutic equivalence evaluations re: citizen petition from medefil inc,0,0
0900006483627914,Other,FDA-2018-P-3176-0002,FDA-2018-P-3176,acknowledgment letter from fda ddm to medefil inc,0,0
0900006483a535c0,Other,FDA-2018-P-3176-0004,FDA-2018-P-3176,agency interim response letter from fda cdrh to medefil inc,0,0
0900006482567428,Supporting & Related Material,FDA-2017-P-2528-0009,FDA-2017-P-2528,exhibit f - neutropenia in cancer patients - mayor re citizen petition from apotex inc,0,0
09000064825676b9,Supporting & Related Material,FDA-2017-P-2528-0013,FDA-2017-P-2528,exhibit j - first and subsequent cycle use of pegfilgrastim - vogel re citizen petition from apotex inc,0,0
0900006482567426,Supporting & Related Material,FDA-2017-P-2528-0007,FDA-2017-P-2528,exhibit d - predicting individual risk of neutropenic complications - lyman ii re citizen petition from apotex inc,0,0
0900006482567429,Supporting & Related Material,FDA-2017-P-2528-0010,FDA-2017-P-2528,exhibit g - optimizing adjuvant chemotherapy in early-stage breast cancer - perez re citizen petition from apotex inc,0,0
090000648256742a,Supporting & Related Material,FDA-2017-P-2528-0011,FDA-2017-P-2528,exhibit h - pharmacokinetic pharmacodynamic modeling - roskos re citizen petition from apotex inc,0,0
09000064825676b8,Supporting & Related Material,FDA-2017-P-2528-0012,FDA-2017-P-2528,exhibit i - granulocyte-colony stimulating factor administration - tigue re citizen petition from apotex inc,0,0
09000064825676ba,Supporting & Related Material,FDA-2017-P-2528-0014,FDA-2017-P-2528,exhibit k - pharmacokinetics and pharmacodynamics of pegfilgrastim - yang re citizen petition from apotex inc,0,0
0900006482567427,Supporting & Related Material,FDA-2017-P-2528-0008,FDA-2017-P-2528,exhibit e - risk models for predicting chemotherapy-induced newtropenia - lyman i re citizen petition from apotex inc,0,0
0900006482567638,Supporting & Related Material,FDA-2017-P-2528-0003,FDA-2017-P-2528,declaration of dr scadden re citizen petition from apotex inc,0,0
0900006482567636,Other,FDA-2017-P-2528-0002,FDA-2017-P-2528,acknowledgement letter from fda ddm to apotex inc,0,0
0900006482567634,Other,FDA-2017-P-2528-0001,FDA-2017-P-2528,citizen petition from apotex inc,0,0
0900006482567423,Supporting & Related Material,FDA-2017-P-2528-0004,FDA-2017-P-2528,exhibit a - confirmation of biosimilarity - desai re citizen petition from apotex inc,0,0
0900006482567424,Supporting & Related Material,FDA-2017-P-2528-0005,FDA-2017-P-2528,exhibit b - chemotherapy for breast cancer - hassan re citizen petition from apotex inc,0,0
09000064825676bb,Supporting & Related Material,FDA-2017-P-2528-0015,FDA-2017-P-2528,exhibit l - neutrophil dynamics in response to chemotherapy and g-csf - zhuge re citizen petition from apotex inc,0,0
0900006482567425,Supporting & Related Material,FDA-2017-P-2528-0006,FDA-2017-P-2528,exhibit c - pegylation of therapeutic proteins - jevsevar re citizen petition from apotex inc,0,0
0900006483fbffbf,Other,FDA-2019-P-2123-0004,FDA-2019-P-2123,agency response letter from fda cder to lachman consultants,0,0
0900006483fbbeab,Notice,FDA-2019-P-2123-0003,FDA-2019-P-2123,"determination that atropine sulfate ansyr plastic syringe
(atropine sulfate solution) intravenous, intramuscular, subcutaneous, and endotracheal, 0.5 milligram/5 milliliters (0.1 milligram/ milliliter), was not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006483c2a1d0,Other,FDA-2019-P-2123-0002,FDA-2019-P-2123,acknowledgment letter from fda ddm to lachman consultants,0,0
0900006483c294d6,Other,FDA-2019-P-2123-0001,FDA-2019-P-2123,citizen petition from lachman consultants,0,0
0900006481c1a677,Other,FDA-2015-P-0403-0005,FDA-2015-P-0403,"interim response letter from fda cder to lachman consultant services, inc.",0,0
0900006481fff842,Notice,FDA-2015-P-0403-0007,FDA-2015-P-0403,"determination that levothroid (levothyroxine sodium) tablets, 0.025
milligram, 0.05 milligram, 0.075 milligram, 0.088 milligram, 0.112
milligram, 0.125 milligram, 0.137 milligram, 0.15 milligram, 0.175
milligram, 0.1 milligram, 0.2 milligram, and 0.3 milligram, were not withdrawn from sale for reasons of safety or effectiveness",0,0
0900006481ffb2e0,Other,FDA-2015-P-0403-0006,FDA-2015-P-0403,final petition approval response,0,0
09000064819f8ea5,Other,FDA-2015-P-0403-0002,FDA-2015-P-0403,acknowledgement letter from  fda ddm to lachman consultant services inc,0,0
09000064819f8b6c,Supporting & Related Material,FDA-2015-P-0403-0004,FDA-2015-P-0403,attach 2,0,0
09000064819f8b6a,Supporting & Related Material,FDA-2015-P-0403-0003,FDA-2015-P-0403,attach 1,0,0
09000064819f8510,Other,FDA-2015-P-0403-0001,FDA-2015-P-0403,citizen petition request from lachman consultant services inc,0,0
09000064838edeee,Supporting & Related Material,FDA-2018-P-4454-0005,FDA-2018-P-4454,attachment 3_bonumose_d-tagatose as fiber citizen petition_appendix 1 part 3 re citizen petition from bonumose llc,0,0
09000064838edeef,Supporting & Related Material,FDA-2018-P-4454-0006,FDA-2018-P-4454,attachment 4_bonumose_d-tagatose as fiber citizen petition_appendix 1 part 4 re citizen petition from bonumose llc,0,0
09000064838edeed,Supporting & Related Material,FDA-2018-P-4454-0004,FDA-2018-P-4454,attachment 2_bonumose_d-tagatose as fiber citizen petition_appendix 1 part 2 re citizen petition from bonumose llc,0,0
09000064838edeec,Supporting & Related Material,FDA-2018-P-4454-0003,FDA-2018-P-4454,attachment 1_bonumose_d-tagatose as fiber citizen petition_appendix 1 part 1 re citizen petition from bonumose llc,0,0
09000064838ede7a,Other,FDA-2018-P-4454-0001,FDA-2018-P-4454,citizen petition from bonumose llc,0,0
0900006483d3f85c,Other,FDA-2018-P-4454-0009,FDA-2018-P-4454,letter from fda cfsan to bonumose llc,0,0
0900006484b8203e,Other,FDA-2018-P-4454-0011,FDA-2018-P-4454,final response letter from fda cfsan to bonumose llc,0,0
09000064838ede7c,Other,FDA-2018-P-4454-0002,FDA-2018-P-4454,acknowledgment letter from fda ddm to bonumose llc,0,0
0900006483cb608a,Other,FDA-2018-P-4454-0008,FDA-2018-P-4454,letter from fda cfsan to bonumose llc,0,0
09000064838edef0,Supporting & Related Material,FDA-2018-P-4454-0007,FDA-2018-P-4454,attachment 5_bonumose_d-tagatose as fiber citizen petition_appendix 1 part 5 re citizen petition from bonumose llc,0,0
0900006484b64ea0,Supporting & Related Material,FDA-2020-P-2174-0006,FDA-2020-P-2174,fr notice re agency response from fda cder to lachman consulting services inc,0,0
0900006484b5927d,Notice,FDA-2020-P-2174-0004,FDA-2020-P-2174,"determination that atrovent (ipratropium bromide) metered spray, 0.021 micrograms/spray and 0.042
micrograms/spray, were not withdrawn from sale for reasons of safety or effectiveness",0,0
090000648494d979,Other,FDA-2020-P-2174-0001,FDA-2020-P-2174,"citizen petition from lachman consulting services, inc",0,0
0900006484acb34f,Other,FDA-2020-P-2174-0003,FDA-2020-P-2174,"interim response from fda cder to lachman consulting services, inc.",0,0
090000648494d97a,Other,FDA-2020-P-2174-0002,FDA-2020-P-2174,"acknowledgment letter from fda dms to lachman consulting services, inc",0,0
0900006484b64c7b,Other,FDA-2020-P-2174-0005,FDA-2020-P-2174,agency response from fda cder to lachman consulting services inc,0,0
0900006482991246,Other,FDA-2017-P-4586-0001,FDA-2017-P-4586,citizen petition from jubilant draximage inc.,0,0
0900006482992465,Other,FDA-2017-P-4586-0002,FDA-2017-P-4586,acknowledgment letter from fda ddm to jubilant draximage inc.,0,0
0900006482d51faf,Other,FDA-2017-P-4586-0004,FDA-2017-P-4586,petition response letter from fda cder to jubilant draximage inc.,0,0
0900006481df4d1b,Supporting & Related Material,FDA-2016-P-0040-0004,FDA-2016-P-0040,attachment 3 ashp aminocaproic acid oral presentations re citizen petition from troutman sanders llp,0,0
0900006481de9859,Other,FDA-2016-P-0040-0002,FDA-2016-P-0040,acknowledgement letter from fda ddm to troutman sanders llp,0,0
0900006481de9a3d,Supporting & Related Material,FDA-2016-P-0040-0003,FDA-2016-P-0040,attachment 1 orange book approved drug products with therapeutic equivalence evaluations re citizen petition from troutman sanders llp,0,0
0900006481ed9aac,Other,FDA-2016-P-0040-0005,FDA-2016-P-0040,withdrawal letter from troutman sanders llp,0,0
0900006481de97cc,Other,FDA-2016-P-0040-0001,FDA-2016-P-0040,citizen petition from troutman sanders llp,0,0
0900006484841330,Other,FDA-2020-P-1849-0002,FDA-2020-P-1849,acknowledgment letter from fda dms to foley & lardner llp,0,0
0900006484841332,Supporting & Related Material,FDA-2020-P-1849-0003,FDA-2020-P-1849,attachment 1_ approved drug products with therapeutic equivalence evaluations_orange book re: citizen petition from foley & lardner llp,0,0
0900006484973a08,Other,FDA-2020-P-1849-0004,FDA-2020-P-1849,withdrawal from foley & lardner llp,0,0
090000648484132c,Other,FDA-2020-P-1849-0001,FDA-2020-P-1849,citizen petition from foley & lardner llp,0,0
0900006484a01e53,Other,FDA-2020-P-2028-0007,FDA-2020-P-2028,response letter from fda cder to outsourcing facilities association (ofa),0,0
09000064848a5396,Supporting & Related Material,FDA-2020-P-2028-0003,FDA-2020-P-2028,attachment 1_confidential_ofa cp sources relied upon that are not readily available to the fda re; citizen petition from outsourcing facilities association,0,0
09000064848a5394,Other,FDA-2020-P-2028-0002,FDA-2020-P-2028,acknowledgment letter from fda dms to outsourcing facilities association,0,0
09000064848a4e34,Other,FDA-2020-P-2028-0001,FDA-2020-P-2028,citizen petition from outsourcing facilities association,0,0
0900006484dc4727,Supporting & Related Material,FDA-2021-P-1109-0008,FDA-2021-P-1109,exhibit f re citizen petition from pccca,0,0
0900006484dc472b,Supporting & Related Material,FDA-2021-P-1109-0011,FDA-2021-P-1109,exhibit i re citizen petition from pccca,0,0
0900006484dc46f6,Other,FDA-2021-P-1109-0002,FDA-2021-P-1109,acknowledgment letter from fda dms to pcca,0,0
0900006484dc4dbb,Supporting & Related Material,FDA-2021-P-1109-0014,FDA-2021-P-1109,exhibit l re citizen petition from pccca,0,0
0900006484dc471b,Supporting & Related Material,FDA-2021-P-1109-0012,FDA-2021-P-1109,exhibit j re citizen petition from pccca,0,0
0900006484dc4728,Supporting & Related Material,FDA-2021-P-1109-0009,FDA-2021-P-1109,exhibit g re citizen petition from pccca,0,0
0900006484dc4719,Supporting & Related Material,FDA-2021-P-1109-0007,FDA-2021-P-1109,exhibit e re citizen petition from pccca,0,0
0900006484dc472c,Supporting & Related Material,FDA-2021-P-1109-0013,FDA-2021-P-1109,exhibit k re citizen petition from pccca,0,0
0900006484dc471a,Supporting & Related Material,FDA-2021-P-1109-0010,FDA-2021-P-1109,exhibit h re citizen petition from pccca,0,0
0900006484dc4715,Supporting & Related Material,FDA-2021-P-1109-0003,FDA-2021-P-1109,exhibit a re citizen petition from pccca,0,0
0900006484dc4716,Supporting & Related Material,FDA-2021-P-1109-0004,FDA-2021-P-1109,exhibit b re citizen petition from pccca,0,0
0900006484dc4717,Supporting & Related Material,FDA-2021-P-1109-0005,FDA-2021-P-1109,exhibit c re citizen petition from pccca,0,0
0900006484dc4718,Supporting & Related Material,FDA-2021-P-1109-0006,FDA-2021-P-1109,exhibit d re citizen petition from pccca,0,0
0900006484dc4365,Other,FDA-2021-P-1109-0001,FDA-2021-P-1109,citizen petition from pccca,0,0
0900006484dc4dbc,Supporting & Related Material,FDA-2021-P-1109-0016,FDA-2021-P-1109,exhibit n re citizen petition from pccca,0,0
0900006484dc4dbd,Supporting & Related Material,FDA-2021-P-1109-0018,FDA-2021-P-1109,exhibit p re citizen petition from pccca,0,0
0900006484dc4dc6,Supporting & Related Material,FDA-2021-P-1109-0015,FDA-2021-P-1109,exhibit m re citizen petition from pccca,0,0
0900006484dc4dc7,Supporting & Related Material,FDA-2021-P-1109-0017,FDA-2021-P-1109,exhibit o re citizen petition from pccca,0,0
090000648352aeea,Other,FDA-2015-N-3469-0100,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
090000648352b185,Other,FDA-2015-N-3469-0101,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
090000648353cb75,Other,FDA-2015-N-3469-0121,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
090000648353c7ed,Other,FDA-2015-N-3469-0110,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
090000648353c98e,Other,FDA-2015-N-3469-0112,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
090000648353c74c,Other,FDA-2015-N-3469-0109,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
090000648353d17c,Other,FDA-2015-N-3469-0117,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
090000648347f09e,Other,FDA-2015-N-3469-0094,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
09000064833a6525,Other,FDA-2015-N-3469-0078,FDA-2015-N-3469,nomination from outsourcing facilities association (ofa),0,0
090000648353db6f,Other,FDA-2015-N-3469-0131,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
0900006483abcec7,Other,FDA-2015-N-3469-0255,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
090000648387825b,Other,FDA-2015-N-3469-0238,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
09000064838781cf,Other,FDA-2015-N-3469-0233,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
0900006483859ba7,Other,FDA-2015-N-3469-0225,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
090000648390f6bf,Other,FDA-2015-N-3469-0245,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
0900006483859895,Other,FDA-2015-N-3469-0222,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
09000064838596d3,Other,FDA-2015-N-3469-0220,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
0900006483786e3d,Other,FDA-2015-N-3469-0202,FDA-2015-N-3469,nomination from aspcares,0,0
0900006482923e1c,Other,FDA-2015-N-3469-0019,FDA-2015-N-3469,"nomination from sincerus florida, llc",0,0
0900006482923d9f,Other,FDA-2015-N-3469-0016,FDA-2015-N-3469,"nomination from sincerus florida, llc",0,0
090000648295af69,Other,FDA-2015-N-3469-0021,FDA-2015-N-3469,nomination from imprimis pharmaceuticals,0,0
0900006483b9fa5d,Other,FDA-2015-N-3469-0267,FDA-2015-N-3469,nomination from pentec health,0,0
0900006483baa522,Other,FDA-2015-N-3469-0268,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
090000648353d410,Other,FDA-2015-N-3469-0126,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
090000648353f3d1,Other,FDA-2015-N-3469-0154,FDA-2015-N-3469,nomination from outsourcing facilities association,0,0
0900006482353ce0,Other,FDA-2016-P-3560-0001,FDA-2016-P-3560,citizen petition from orchid healthcare  (a division of orchid pharma ltd.),0,0
09000064823540cc,Supporting & Related Material,FDA-2016-P-3560-0003,FDA-2016-P-3560,attachment 1 copies of the relevant pages of the orange book re citizen petition from orchid healthcare,0,0
0900006482353ce2,Other,FDA-2016-P-3560-0002,FDA-2016-P-3560,acknowledgment letter from fda ddm to orchid healthcare  (a division of orchid pharma ltd.),0,0
090000648253db21,Other,FDA-2016-P-3560-0005,FDA-2016-P-3560,letter from fda to orchid healthcare  (a division of orchid pharma ltd.),0,0
090000648253c0de,Notice,FDA-2016-P-3560-0004,FDA-2016-P-3560,"determinations that products were not withdrawn from sale for reasons of safety or effectiveness: cedax (ceftibuten dihydrate) for oral suspension, 90 milligrams/5 milliliters and 180 milligrams/5 milliliters",0,0
090000648228e6e0,Other,FDA-2016-P-2376-0003,FDA-2016-P-2376,supplement from latham & watkins llp,0,0
090000648252ea2a,Other,FDA-2016-P-2376-0005,FDA-2016-P-2376,"interim response letter from cfsan to hyman, phelps & mcnamara, p.c.",0,0
090000648214f179,Other,FDA-2016-P-2376-0001,FDA-2016-P-2376,citizen petition from latham & watkins llp,0,0
090000648214f5e1,Other,FDA-2016-P-2376-0002,FDA-2016-P-2376,"acknowledgement letter from fda ddm to latham & watkins, llp",0,0
0900006482433cb5,Other,FDA-2016-P-2376-0004,FDA-2016-P-2376,petition denial letter from fda cder to latham & watkins llp,0,0
09000064818b8db8,Other,FDA-2014-P-1576-0001,FDA-2014-P-1576,citizen petition from gordon johnston regulatory consultants llc,0,0
09000064818b8f6b,Supporting & Related Material,FDA-2014-P-1576-0004,FDA-2014-P-1576,attachment 2,0,0
09000064818b8f66,Other,FDA-2014-P-1576-0002,FDA-2014-P-1576,acknowledgment letter from fda ddm to gordon johnston regulatory consultants llc,0,0
0900006483db04ab,Other,FDA-2014-P-1576-0006,FDA-2014-P-1576,"letter from fda cder to gordon johnston regulatory consultants, llc",0,0
09000064818b8f6a,Supporting & Related Material,FDA-2014-P-1576-0003,FDA-2014-P-1576,attachment 1,0,0
0900006481a84f76,Other,FDA-2014-P-1576-0005,FDA-2014-P-1576,"interim response from cder to gordon johnston regulatory consultants, llc",0,0
0900006483c45460,Other,FDA-2019-P-2240-0001,FDA-2019-P-2240,citizen petition from axinn on behalf of zydus pharmaceuticals (usa) inc.,0,0
0900006483c45990,Supporting & Related Material,FDA-2019-P-2240-0002,FDA-2019-P-2240,exhibit a iarc monograph (vitamin k substances) re citizen petition from axinn on behalf of zydus pharmaceuticals (usa) inc.,0,0
0900006483c45992,Supporting & Related Material,FDA-2019-P-2240-0004,FDA-2019-P-2240,exhibit c merck index 15th ed. (2013) re citizen petition from axinn on behalf of zydus pharmaceuticals (usa) inc.,0,0
0900006483c45994,Supporting & Related Material,FDA-2019-P-2240-0006,FDA-2019-P-2240,exhibit e usp monograph re citizen petition from axinn on behalf of zydus pharmaceuticals (usa) inc.,0,0
0900006483c45991,Supporting & Related Material,FDA-2019-P-2240-0003,FDA-2019-P-2240,exhibit b golubkina et al methods of synthesis and production technology of drugs re citizen petition from axinn on behalf of zydus pharmaceuticals (usa) inc.,0,0
0900006483c45993,Supporting & Related Material,FDA-2019-P-2240-0005,FDA-2019-P-2240,exhibit d knaeur et al metabolism and biological activity of cis- and trans-phylloquinone in the rat article re citizen petition from axinn on behalf of zydus pharmaceuticals (usa) inc.,0,0
0900006483c459c3,Supporting & Related Material,FDA-2019-P-2240-0008,FDA-2019-P-2240,"exhibit g schmid et al 126. synthesis of all four stereoisomers of (e)-vitamin k, (phylloquinone), analysis of their diastereoisomeric and enantiomeric purities and determination of their biopotencies1 re citizen petition from axinn on behalf of zydus pharmaceuticals (usa) inc.",0,0
0900006483c459c9,Other,FDA-2019-P-2240-0009,FDA-2019-P-2240,acknowledgment letter from fda ddm to axinn,0,0
09000064840195b7,Other,FDA-2019-P-2240-0010,FDA-2019-P-2240,response letter from fda cder to axinn,0,0
0900006483c459c2,Supporting & Related Material,FDA-2019-P-2240-0007,FDA-2019-P-2240,exhibit f smith review chiral toxicology: it’s the same thing. . .only different re citizen petition from axinn on behalf of zydus pharmaceuticals (usa) inc.,0,0
09000064836b3867,Other,FDA-2018-D-3130-0002,FDA-2018-D-3130,"consideration of uncertainty in 1 making benefit-risk 2 determinations in medical device 3 premarket approvals, de novo 4 classifications, and humanitarian 5 device exemptions; draft guidance for industry and
7food and drug administration staff",0,0
0900006483ed972c,Other,FDA-2018-D-3130-0009,FDA-2018-D-3130,"consideration of uncertainty in making benefit-risk determinations in medical device premarket approvals, de novo classifications, and humanitarian device exemptions; guidance for industry and food and drug administration staff",1,0
09000064836af5f9,Notice,FDA-2018-D-3130-0001,FDA-2018-D-3130,"consideration of uncertainty in making benefit-risk determinations in medical device premarket approvals, de novo classifications, and humanitarian device exemptions; draft guidance for industry and food and drug administration staff; availability",1,0
0900006483edc73d,Notice,FDA-2018-D-3130-0008,FDA-2018-D-3130,"consideration of uncertainty in making benefit-risk determinations in medical device premarket approvals, de novo classifications, and humanitarian device exemptions; guidance for industry and food and drug administration staff; availability",1,0
09000064818e0b89,Supporting & Related Material,FDA-2014-P-1657-0003,FDA-2014-P-1657,attachment 1,0,0
09000064818e02ea,Other,FDA-2014-P-1657-0001,FDA-2014-P-1657,citizen petition from gordon johnston regulatory consultants llc,0,0
090000648192c197,Other,FDA-2014-P-1657-0004,FDA-2014-P-1657,citizens petition approval letter to robert dormer and gordon johnston,0,0
09000064818e0b87,Other,FDA-2014-P-1657-0002,FDA-2014-P-1657,acknowledgement letter from fda ddm to gordon johnston regulatory consultants llc,0,0
09000064816b7e8f,Notice,FDA-2014-D-0331-0001,FDA-2014-D-0331,"live case presentations during investigational device exemption
clinical trials; draft guidance for institutional review boards, industry,
investigators, and food and drug administration staff; availability",1,0
09000064816b8001,Other,FDA-2014-D-0331-0002,FDA-2014-D-0331,"live case presentations during investigational device exemption
clinical trials; draft guidance for institutional review boards, industry,
investigators, and food and drug administration staff",1,0
0900006483d7d25a,Notice,FDA-2014-D-0331-0006,FDA-2014-D-0331,"live case presentations during investigational device exemption clinical trials; guidance for institutional review boards, industry, clinical investigators, and food and drug administration staff; availability",1,0
0900006483d7d49d,Other,FDA-2014-D-0331-0008,FDA-2014-D-0331,"live case presentations during investigational device exemption (ide) clinical trials; guidance for institutional review boards, industry, clinical investigators, and food and drug administration staff",1,0
0900006481119914,Other,FDA-2012-P-0984-0001,FDA-2012-P-0984,sheppard mullin richter & hampton llp - citizen petition,0,0
0900006481169939,Other,FDA-2012-P-0984-0003,FDA-2012-P-0984,"sheppard, mullin, richter & hampton llp - withdrawal",0,0
090000648111991c,Other,FDA-2012-P-0984-0002,FDA-2012-P-0984,acknowledgement letter to sheppard mullin richter & hampton llp,0,0
090000648225c932,Other,FDA-2012-P-1259-0003,FDA-2012-P-1259,"citizen petition approval letter from fda cder to hyman, phelps, & mcnamara, p.c.",0,0
090000648119d635,Other,FDA-2012-P-1259-0001,FDA-2012-P-1259,hyman phelps mcnamara pc - citizen petition,0,0
090000648119d736,Other,FDA-2012-P-1259-0002,FDA-2012-P-1259,"acknowledgement letter to hyman, phelps & mcnamara, pc",0,0
090000648405b43b,Supporting & Related Material,FDA-2019-P-4644-0036,FDA-2019-P-4644,"appendix zzz redacted re citizen petition from clarus therapeutics, inc.",0,0
090000648404be07,Supporting & Related Material,FDA-2019-P-4644-0038,FDA-2019-P-4644,"appendix r redacted re citizen petition from clarus therapeutics, inc.",0,0
090000648404be09,Supporting & Related Material,FDA-2019-P-4644-0022,FDA-2019-P-4644,"appendix s wang et al (2008) validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: interference and comparison with established methods re citizen petition from clarus therapeutics, inc.",0,0
090000648404c457,Supporting & Related Material,FDA-2019-P-4644-0024,FDA-2019-P-4644,"appendix u ceponis et al (2008) accurate measurement of androgen after androgen esters: problems created by ex vivo esterase effects and lc-ms/ms interference re citizen petition from clarus therapeutics, inc.",0,0
090000648404c45b,Supporting & Related Material,FDA-2019-P-4644-0028,FDA-2019-P-4644,"appendix w confidential re citizen petition from clarus therapeutics, inc.",0,0
090000648405b3ba,Supporting & Related Material,FDA-2019-P-4644-0031,FDA-2019-P-4644,"appendix y redacted re citizen petition from clarus therapeutics, inc.",0,0
09000064840266ef,Supporting & Related Material,FDA-2019-P-4644-0003,FDA-2019-P-4644,"appendix a cdc laboratory/manufacturer hormone standardization (host) program total testosterone - participant protocol re citizen petition from clarus therapeutics, inc.",0,0
090000648402675d,Supporting & Related Material,FDA-2019-P-4644-0011,FDA-2019-P-4644,"appendix h fda cder approval package for application number 204399orig1s000 re citizen petition from clarus therapeutics, inc.",0,0
09000064840266f3,Supporting & Related Material,FDA-2019-P-4644-0007,FDA-2019-P-4644,"appendix d fda briefing document nda 206089 testosterone undecanoate (proposed trade name jatenzo) re citizen petition from clarus therapeutics, inc.",0,0
090000648402675c,Supporting & Related Material,FDA-2019-P-4644-0010,FDA-2019-P-4644,"appendix g fda cder application number 205488orig1s000 medical review(s) re citizen petition from clarus therapeutics, inc.",0,0
09000064840266f2,Supporting & Related Material,FDA-2019-P-4644-0006,FDA-2019-P-4644,"appendix c fda briefing document nda 208088 testosterone undecanoate (proposed trade name tlando) re citizen petition from clarus therapeutics, inc.",0,0
09000064840266ee,Other,FDA-2019-P-4644-0002,FDA-2019-P-4644,"acknowledgment letter from fda dms to clarus therapeutics, inc.",0,0
090000648404c45a,Supporting & Related Material,FDA-2019-P-4644-0027,FDA-2019-P-4644,"appendix w redacted re citizen petition from clarus therapeutics, inc.",0,0
09000064840266f5,Supporting & Related Material,FDA-2019-P-4644-0009,FDA-2019-P-4644,"appendix f fda cder application number 022219orig1s000 medical review(s) re citizen petition from clarus therapeutics, inc.",0,0
0900006484026761,Supporting & Related Material,FDA-2019-P-4644-0015,FDA-2019-P-4644,"appendix l transcripts re citizen petition from clarus therapeutics, inc.",0,0
090000648404be04,Supporting & Related Material,FDA-2019-P-4644-0018,FDA-2019-P-4644,"appendix o bagus et al (2003) important effect of food on the bioavailability of oral testosterone undecanoate re citizen petition from clarus therapeutics, inc.",1,0
090000648404c45d,Supporting & Related Material,FDA-2019-P-4644-0030,FDA-2019-P-4644,"appendix x confidential re citizen petition from clarus therapeutics, inc.",0,0
09000064843fdf00,Other,FDA-2019-P-4644-0039,FDA-2019-P-4644,"citizen petition denial response letter from fda cder to clams therapeutics, inc.",0,0
090000648404be03,Supporting & Related Material,FDA-2019-P-4644-0017,FDA-2019-P-4644,"appendix n transcripts re citizen petition from clarus therapeutics, inc.",0,0
090000648404be08,Supporting & Related Material,FDA-2019-P-4644-0021,FDA-2019-P-4644,"appendix r confidential re citizen petition from clarus therapeutics, inc.",0,0
090000648404c458,Supporting & Related Material,FDA-2019-P-4644-0025,FDA-2019-P-4644,"appendix v redacted re citizen petition from clarus therapeutics, inc.",0,0
090000648405b439,Supporting & Related Material,FDA-2019-P-4644-0034,FDA-2019-P-4644,"appendix zz redacted re citizen petition from clarus therapeutics, inc.",0,0
090000648405b43a,Supporting & Related Material,FDA-2019-P-4644-0035,FDA-2019-P-4644,"appendix zz confidential re citizen petition from clarus therapeutics, inc.",0,0
090000648405b43c,Supporting & Related Material,FDA-2019-P-4644-0037,FDA-2019-P-4644,"appendix zzz confidential re citizen petition from clarus therapeutics, inc.",0,0
09000064840266f0,Supporting & Related Material,FDA-2019-P-4644-0004,FDA-2019-P-4644,"appendix b confidential re citizen petition from clarus therapeutics, inc.",0,0
0900006483d458cb,Supporting & Related Material,FDA-2019-P-2289-0108,FDA-2019-P-2289,updated background material re citizen petition from contraceptive study group,0,0
0900006483ca5470,Supporting & Related Material,FDA-2019-P-2289-0014,FDA-2019-P-2289,references for impact of contraceptives on body mass re citizen petition from contraceptive study group,0,0
0900006483ca4cd0,Supporting & Related Material,FDA-2019-P-2289-0017,FDA-2019-P-2289,references for atherosclerosis and cardiovascular events re citizen petition from contraceptive study group,0,0
0900006484112611,Other,FDA-2019-P-2289-0164,FDA-2019-P-2289,letter from fda cder to contraceptive study group,0,0
0900006483c59d3b,Other,FDA-2019-P-2289-0002,FDA-2019-P-2289,acknowledgment letter from fda ddm to contraceptive study group,0,0
0900006483ca3cb4,Supporting & Related Material,FDA-2019-P-2289-0011,FDA-2019-P-2289,references for multiple sclerosis references re citizen petition from contraceptive study group,0,0
0900006483ca46e5,Supporting & Related Material,FDA-2019-P-2289-0012,FDA-2019-P-2289,references for interstitial cystitis references re citizen petition from contraceptive study group,0,0
0900006484ad694e,Other,FDA-2019-P-2289-0181,FDA-2019-P-2289,supplement from contraceptive study group,0,0
0900006483ca2aa9,Supporting & Related Material,FDA-2019-P-2289-0010,FDA-2019-P-2289,references for depression mood disorders and suicide re citizen petition from contraceptive study group,0,0
0900006483cb9ba4,Supporting & Related Material,FDA-2019-P-2289-0019,FDA-2019-P-2289,references for economic costs re citizen petition from contraceptive study group,0,0
0900006483ca4a19,Supporting & Related Material,FDA-2019-P-2289-0013,FDA-2019-P-2289,references for osteoporotic fracture re citizen petition from contraceptive study group,0,0
0900006483d458ea,Supporting & Related Material,FDA-2019-P-2289-0109,FDA-2019-P-2289,updated background material re  re citizen petition from contraceptive study group,0,0
0900006483c94e5d,Supporting & Related Material,FDA-2019-P-2289-0006,FDA-2019-P-2289,references for cervical cancer re citizen petition from contraceptive study group,0,0
0900006483c943af,Supporting & Related Material,FDA-2019-P-2289-0007,FDA-2019-P-2289,references for crohn's disease re citizen petition from contraceptive study group,0,0
0900006483c92160,Supporting & Related Material,FDA-2019-P-2289-0005,FDA-2019-P-2289,references for breast cancer (m-z) re citizen petition from contraceptive study group,0,0
0900006483ca4c08,Supporting & Related Material,FDA-2019-P-2289-0015,FDA-2019-P-2289,references for urogenital effects re citizen petition from contraceptive study group,0,0
0900006483cb7cf1,Supporting & Related Material,FDA-2019-P-2289-0018,FDA-2019-P-2289,references for environmental impact re citizen petition from contraceptive study group,0,0
0900006483ca29d7,Supporting & Related Material,FDA-2019-P-2289-0008,FDA-2019-P-2289,references for ulcerative colitis re citizen petition from contraceptive study group,0,0
0900006483c91609,Supporting & Related Material,FDA-2019-P-2289-0003,FDA-2019-P-2289,references for risk of hiv transmission re citizen petition from contraceptive study group,0,0
0900006483c91e4d,Supporting & Related Material,FDA-2019-P-2289-0004,FDA-2019-P-2289,references for breast cancer (a-l) re citizen petition from contraceptive study group,0,0
0900006483ca2a33,Supporting & Related Material,FDA-2019-P-2289-0009,FDA-2019-P-2289,references for systemic lupus erythematosus re citizen petition from contraceptive study group,0,0
0900006483ca4c53,Supporting & Related Material,FDA-2019-P-2289-0016,FDA-2019-P-2289,references for venous thromboembolism re citizen petition from contraceptive study group,0,0
0900006483c596f0,Other,FDA-2019-P-2289-0001,FDA-2019-P-2289,citizen petition from contraceptive study group,0,0
0900006481debe18,Other,FDA-2016-P-0031-0001,FDA-2016-P-0031,citizen petition from indoco remedies limited,0,0
0900006482071491,Other,FDA-2016-P-0031-0004,FDA-2016-P-0031,interim response,0,0
0900006481debe19,Other,FDA-2016-P-0031-0002,FDA-2016-P-0031,acknowledgement letter from fda ddm to indoco remedies limited,0,0
0900006481decb18,Supporting & Related Material,FDA-2016-P-0031-0003,FDA-2016-P-0031,attachment 1 orange book approved drug products with therapeutic equivalence evaluations (furosemide) re: citizen petition from indoco remedies limited,0,0
0900006483a653a5,Other,FDA-2016-P-0031-0005,FDA-2016-P-0031,withdrawal from indoco remedies limited,0,0
0900006481f8f70a,Other,FDA-2015-P-3942-0004,FDA-2015-P-3942,petition approval letter,0,0
0900006481cef433,Other,FDA-2015-P-3942-0001,FDA-2015-P-3942,citizen petition from regcon solutions,0,0
0900006481cef4f7,Supporting & Related Material,FDA-2015-P-3942-0002,FDA-2015-P-3942,fda's orange book approved drug products with therapeutic equivalence evaluation for chlorzoxazone re: citizen petition from regcon solutions,0,0
0900006481cef4f5,Other,FDA-2015-P-3942-0003,FDA-2015-P-3942,acknowledgement letter from fda ddm to regcon solutions,0,0
0900006484763918,Notice,FDA-2019-D-3769-0009,FDA-2019-D-3769,"providing regulatory submissions for medical devices in electronic format—submissions under section 745a(b) of the federal food, drug, and cosmetic act; guidance for industry and food and drug administration staff; availability",1,0
0900006483fcb532,Other,FDA-2019-D-3769-0002,FDA-2019-D-3769,"providing regulatory submissions for medical devices in electronic format-submissions under section 745a(b) of the federal food, drug, and cosmetic act; draft guidance for industry and food and drug administration staff; draft guidance",1,0
0900006483fcae92,Notice,FDA-2019-D-3769-0001,FDA-2019-D-3769,"providing regulatory submissions for medical devices in electronic format—submissions under section 745a(b) of the federal food, drug, and cosmetic act; draft guidance for industry and food and drug administration staff; availability",1,0
09000064847664ca,Other,FDA-2019-D-3769-0010,FDA-2019-D-3769,"providing regulatory submissions for medical devices in electronic format — submissions under section 745a(b) of the federal food, drug, and cosmetic act guidance for industry and food and drug administration staff",1,0
09000064814413c1,Other,FDA-2013-P-0163-0003,FDA-2013-P-0163,"fda/cder response to teva women's health, inc. (teva) - letter",0,0
09000064811f5732,Other,FDA-2013-P-0163-0002,FDA-2013-P-0163,"acknowledgement letter to teva women's health, inc. (teva)",0,0
09000064839f145c,Other,FDA-2013-P-0163-0004,FDA-2013-P-0163,"withdrawal from teva pharmaceutical industries ltd., teva women's health, inc.",0,0
09000064811f56f3,Other,FDA-2013-P-0163-0001,FDA-2013-P-0163,teva pharmaceutical industries ltd. (teva) - citizen petition,0,0
0900006482cbbc77,Notice,FDA-2017-D-5570-0001,FDA-2017-D-5570,select updates for recommendations for clinical laboratory  improvement amendments of 1988 waiver applications for  manufacturers of in vitro diagnostic devices; draft guidance for industry and food and drug administration staff; availability,1,0
09000064843b60b4,Other,FDA-2017-D-5570-0020,FDA-2017-D-5570,recommendations for clinical laboratory improvement amendments of 1988 (clia) waiver applications for manufacturers of in vitro diagnostic devices guidance for industry and food and drug administration staff,1,0
0900006482d9d48d,Other,FDA-2017-D-5570-0005,FDA-2017-D-5570,"request for extension from coalition for clia waiver reform (epstein becker & green, p.c.)",0,0
0900006482e6be59,Notice,FDA-2017-D-5570-0006,FDA-2017-D-5570,select updates for recommendations for clinical laboratory improvement amendments of 1988 waiver applications for  manufacturers of in vitro diagnostic devices; draft guidance for industry and food and drug administration staff; availability; extension of comment period,1,0
0900006482cbce4e,Other,FDA-2017-D-5570-0002,FDA-2017-D-5570,select updates for recommendations for clinical laboratory  improvement amendments of 1988 (clia) waiver applications for manufacturers of in vitro diagnostic devices draft guidance for industry and food and drug administration staff,1,0
090000648390cc70,Other,FDA-2017-D-5570-0013,FDA-2017-D-5570,draft guidance for industry and fda_select updates for clia of 1988 waiver applications for manufacturers of ivd devices_11-29-2018,0,0
090000648390c0fa,Notice,FDA-2017-D-5570-0012,FDA-2017-D-5570,select updates for recommendations for clinical laboratory improvement amendments of 1988 waiver applications for manufacturers of in vitro diagnostic devices; draft guidance for industry and food and drug administration staff; availability,1,0
09000064843b4ec1,Notice,FDA-2017-D-5570-0019,FDA-2017-D-5570,recommendations for clinical laboratory improvement amendments of 1988 waiver applications for manufacturers of in vitro diagnostic devices; guidance for industry and food and drug administration staff; availability,1,0
0900006484a64752,Other,FDA-2021-P-0277-0001,FDA-2021-P-0277,suitability petition from lachman consulting services inc,0,0
0900006484a64754,Other,FDA-2021-P-0277-0002,FDA-2021-P-0277,acknowledgment letter from fda dms to lachman consulting services inc,0,0
09000064820ae5c8,Other,FDA-2016-D-1233-0002,FDA-2016-D-1233,"use of public human genetic variant databases to support clinical  validity for next generation sequencing (ngs)-based in vitro diagnostics  
draft guidance for stakeholders and food and drug administration staff",1,0
090000648313aebc,Other,FDA-2016-D-1233-0040,FDA-2016-D-1233,use of public human genetic variant 1 databases to support clinical validity 2 for next generation sequencing 3 (ngs)-based in vitro diagnostics,0,0
0900006482095b9c,Notice,FDA-2016-D-1233-0001,FDA-2016-D-1233,use of public human genetic variant databases to support clinical validity for next generation sequencing-based in vitro diagnostics; draft guidance for stakeholders and food and drug administration staff; availability,1,0
090000648314e9bb,Other,FDA-2016-D-1233-0041,FDA-2016-D-1233,use of public human genetic variant databases to support clinical validity for genetic and genomic-based in vitro diagnostics guidance for stakeholders and food and drug administration staff,1,0
090000648313a776,Notice,FDA-2016-D-1233-0039,FDA-2016-D-1233,use of public human genetic variant databases to support clinical validity for genetic and genomic-based in vitro diagnostics; guidance for stakeholders and food and drug administration staff; availability,1,0
09000064842df06b,Other,FDA-2020-P-0368-0002,FDA-2020-P-0368,"acknowledgment letter from fda dms to crowell & moring, llp",0,0
09000064842de8c1,Other,FDA-2020-P-0368-0001,FDA-2020-P-0368,"citizen petition from crowell & moring, llp",0,0
09000064845ee523,Other,FDA-2020-P-0368-0004,FDA-2020-P-0368,final response letter from fda cder to crowell moring llp,0,0
09000064842df06a,Supporting & Related Material,FDA-2020-P-0368-0003,FDA-2020-P-0368,"attachment 1 interstate distribution under section 503a of the federal food, drug, and cosmetic act—the five percent limit draft guidance for industry re citizen petition from crowell & moring, llp",1,0
0900006482908ccc,Notice,FDA-2017-N-2166-0001,FDA-2017-N-2166,"draft standardization of pharmaceutical quality/chemistry
manufacturing and control data elements and terminologies; request
for comments",0,0
090000648290d955,Supporting & Related Material,FDA-2017-N-2166-0002,FDA-2017-N-2166,pharmaceutical quality/chemistry manufacturing and controls (pq/cmc) data elements and terminologies,0,0
090000648430fe9f,Other,FDA-2020-P-0513-0002,FDA-2020-P-0513,acknowledgment letter from fda dms to foley and lardner llp,0,0
090000648430faa1,Other,FDA-2020-P-0513-0001,FDA-2020-P-0513,"citizen petition from foley and lardner llp on behalf of romark laboratories, l.c.",0,0
09000064843274f5,Other,FDA-2020-P-0513-0003,FDA-2020-P-0513,withdrawal from foley & lardner llp,0,0
090000648425e54b,Supporting & Related Material,FDA-2019-P-6100-0008,FDA-2019-P-6100,attachment g- sterile decellularized dermis - instructions for use re: citizen petition from american association of tissue banks,0,0
090000648425e4dd,Supporting & Related Material,FDA-2019-P-6100-0004,FDA-2019-P-6100,attachment c- the classic reprint: the use and uses of large split skin grafts of intermediate thickness re: citizen petition from american association of tissue banks,0,0
090000648425e4de,Supporting & Related Material,FDA-2019-P-6100-0005,FDA-2019-P-6100,"attachment d- 50 years of burn care at shriners hospitals for children, galveston re: citizen petition from american association of tissue banks",0,0
090000648425e54c,Supporting & Related Material,FDA-2019-P-6100-0009,FDA-2019-P-6100,"attachment h- pelvic, abdominal, and chest wall reconstruction with allo derm in patients at increased risk for mesh-related complications re: citizen petition from american association of tissue banks",0,0
090000648425e4db,Supporting & Related Material,FDA-2019-P-6100-0002,FDA-2019-P-6100,attachment a- the classic reprint re: citizen petition from american association of tissue banks,0,0
090000648425e552,Supporting & Related Material,FDA-2019-P-6100-0015,FDA-2019-P-6100,"attachment r- the use of a cellular dermal matrix in breast reconstruction
evolution of techniques over 2 decades re: citizen petition from american association of tissue banks",0,0
090000648425e4dc,Supporting & Related Material,FDA-2019-P-6100-0003,FDA-2019-P-6100,attachment b- early care of burns re: citizen petition from american association of tissue banks,0,0
090000648425e4f4,Supporting & Related Material,FDA-2019-P-6100-0018,FDA-2019-P-6100,attachment u part 1- the use of acellular dermal matrix in breast reconstruction: evolution of techniques over 2 decades re: citizen petition from american association of tissue banks,0,0
090000648425e54e,Supporting & Related Material,FDA-2019-P-6100-0011,FDA-2019-P-6100,attachments j through n re: citizen petition from american association of tissue banks,0,0
090000648425e4e0,Supporting & Related Material,FDA-2019-P-6100-0007,FDA-2019-P-6100,"attachment f- decellularization strategies for regenerative medicine:
from processing techniques to applications re: citizen petition from american association of tissue banks",0,0
090000648425e54d,Supporting & Related Material,FDA-2019-P-6100-0010,FDA-2019-P-6100,attachment i- efficacy and safety of acellular dermal matrix in diabetic foot ulcer treatment: a systematic review and meta-analysis re: citizen petition from american association of tissue banks,0,0
090000648425e54f,Supporting & Related Material,FDA-2019-P-6100-0012,FDA-2019-P-6100,attachment o- achilles tendon augmented repair using human acellular dermal matrix: a case series re: citizen petition from american association of tissue banks,0,0
090000648425e553,Supporting & Related Material,FDA-2019-P-6100-0016,FDA-2019-P-6100,attachment s- market recap: q418/fy18 market recap: us surgical matrices re: citizen petition from american association of tissue banks,0,0
09000064846dbb88,Other,FDA-2019-P-6100-0034,FDA-2019-P-6100,response letter from cber to american association of tissue banks,0,0
09000064846dbb87,Other,FDA-2019-P-6100-0033,FDA-2019-P-6100,letter from american association of tissue banks to cber,0,0
090000648425e332,Other,FDA-2019-P-6100-0001,FDA-2019-P-6100,citizen petition from american association of tissue banks,0,0
090000648425e4df,Supporting & Related Material,FDA-2019-P-6100-0006,FDA-2019-P-6100,attachment e- the us navy tissue bank: 50 years on the cutting edge re: citizen petition from american association of tissue banks,0,0
090000648425e4f6,Supporting & Related Material,FDA-2019-P-6100-0020,FDA-2019-P-6100,attachment v shuren letter re: citizen petition from american association of tissue banks,0,0
090000648425e4f5,Supporting & Related Material,FDA-2019-P-6100-0019,FDA-2019-P-6100,"attachment u part 2- prepectoral breast reconstruction with fenestrated
acellular dermal matrix: a novel design re: citizen petition from american association of tissue banks",0,0
0900006484568fde,Other,FDA-2019-P-6100-0031,FDA-2019-P-6100,interim response letter from fda cber to american association of tissue banks (aatb),0,0
090000648425dfef,Other,FDA-2019-P-6100-0021,FDA-2019-P-6100,acknowledgment letter from fda dms to american association of tissue banks,0,0
090000648425e550,Supporting & Related Material,FDA-2019-P-6100-0013,FDA-2019-P-6100,attachment p- a randomized controlled trial comparing a human acellular dermal matrix versus conventional care for the treatment of venous leg ulcers  re: citizen petition from american association of tissue banks,0,0
090000648425e551,Supporting & Related Material,FDA-2019-P-6100-0014,FDA-2019-P-6100,attachment q- clinical evaluation of acellular allograft dermis for the treatment of human gingival recession re: citizen petition from american association of tissue banks,0,0
090000648425e554,Supporting & Related Material,FDA-2019-P-6100-0017,FDA-2019-P-6100,attachment t aatb letter re: citizen petition from american association of tissue banks,0,0
090000648044429b,Other,FDA-2005-P-0253-0001,FDA-2005-P-0253,"hfa-305 to antibody systems, inc.",0,0
09000064804442d9,Other,FDA-2005-P-0253-0005,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442e7,Other,FDA-2005-P-0253-0019,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442da,Other,FDA-2005-P-0253-0006,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442e5,Other,FDA-2005-P-0253-0017,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442e2,Other,FDA-2005-P-0253-0014,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442e1,Other,FDA-2005-P-0253-0013,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442de,Other,FDA-2005-P-0253-0010,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442dc,Other,FDA-2005-P-0253-0008,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442d5,Other,FDA-2005-P-0253-0004,FDA-2005-P-0253,"hfm-1 to simpson woolley mcconacnie, llp",0,0
09000064804442d0,Other,FDA-2005-P-0253-0002,FDA-2005-P-0253,"hfa-305 to antibody systems, inc.",0,0
09000064804442e4,Other,FDA-2005-P-0253-0016,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442e0,Other,FDA-2005-P-0253-0012,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442dd,Other,FDA-2005-P-0253-0009,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442e9,Other,FDA-2005-P-0253-0021,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442e3,Other,FDA-2005-P-0253-0015,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442db,Other,FDA-2005-P-0253-0007,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442d1,Other,FDA-2005-P-0253-0003,FDA-2005-P-0253,hfm-1 to simpson woolley mcconachie l.l.p.,0,0
09000064804442ea,Other,FDA-2005-P-0253-0022,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442e6,Other,FDA-2005-P-0253-0018,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442e8,Other,FDA-2005-P-0253-0020,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
09000064804442df,Other,FDA-2005-P-0253-0011,FDA-2005-P-0253,"j. shuren, assistant commissioner for policy",0,0
090000648103ca35,Other,FDA-2012-P-0589-0002,FDA-2012-P-0589,"onco therapies limited (strides, inc.) - citizen petition",0,0
090000648116cd94,Other,FDA-2012-P-0589-0003,FDA-2012-P-0589,oncotherapies limited - withdrawal,0,0
090000648103cb1c,Other,FDA-2012-P-0589-0001,FDA-2012-P-0589,acknowledgement letter to onco therapies limited,0,0
0900006481172df1,Other,FDA-2011-P-0580-0005,FDA-2011-P-0580,fda/cder response to charles watson - partial petition approval and denial,0,0
0900006480fa9aba,Other,FDA-2011-P-0580-0004,FDA-2011-P-0580,interim response to charles watson - letter,0,0
0900006480f146e0,Other,FDA-2011-P-0580-0003,FDA-2011-P-0580,charles watson - supplement,0,0
0900006480ed6a9a,Other,FDA-2011-P-0580-0001,FDA-2011-P-0580,charles watson - citizen petition,0,0
0900006480ed6abf,Other,FDA-2011-P-0580-0002,FDA-2011-P-0580,acknowledgement letter to charles watson,0,0
09000064820b6b8b,Supporting & Related Material,FDA-2016-P-2091-0004,FDA-2016-P-2091,"attachment ii prescription and over-the-counter drug product list
36th edition cumulative supplement number 02: february 2016
additions/deletions for prescription drug product list re citizen petition from anda consultants furosemide inj (luitpold)",0,0
09000064820b69d4,Other,FDA-2016-P-2091-0001,FDA-2016-P-2091,citizen petition from anda consultants,0,0
09000064820b69d6,Other,FDA-2016-P-2091-0002,FDA-2016-P-2091,acknowledgement letter from fda ddm to anda consultants,0,0
09000064820b6b8a,Supporting & Related Material,FDA-2016-P-2091-0003,FDA-2016-P-2091,attachment i orange book discontinued drug products listing re citizen petition from anda consultants furosemide inj (luitpold),0,0
09000064821c4d75,Other,FDA-2016-P-2091-0005,FDA-2016-P-2091,response letter from fda cder to anda consultants,0,0
0900006481cf9674,Supporting & Related Material,FDA-2015-P-3980-0004,FDA-2015-P-3980,"approval letter nda 022249 (mar 20, 2008) re citizen petition from teva pharmaceutical industries, ltd.",0,0
0900006481cf9b2f,Supporting & Related Material,FDA-2015-P-3980-0005,FDA-2015-P-3980,"approval letter nda 022303 (oct 31, 2008) re citizen petition from teva pharmaceutical industries, ltd.",0,0
0900006481cf9b33,Supporting & Related Material,FDA-2015-P-3980-0009,FDA-2015-P-3980,"approval letter nda 50708 (mar 29, 2006) re citizen petition from teva pharmaceutical industries, ltd.",0,0
0900006481cf9b35,Supporting & Related Material,FDA-2015-P-3980-0011,FDA-2015-P-3980,"package insert nda 50708 (apr 27, 2006) re citizen petition from teva pharmaceutical industries, ltd.",0,0
0900006481cf9b3c,Supporting & Related Material,FDA-2015-P-3980-0016,FDA-2015-P-3980,"h r report no 97-840 part 1 (sept 17, 1982) re citizen petition from teva pharmaceutical industries, ltd.",0,0
0900006481cf9672,Supporting & Related Material,FDA-2015-P-3980-0003,FDA-2015-P-3980,"clinical review nda 022249 (feb 26 2008) (excerpts) re citizen petition from teva pharmaceutical industries, ltd.",0,0
0900006481cf9b30,Supporting & Related Material,FDA-2015-P-3980-0006,FDA-2015-P-3980,"package insert nda 022249 (sept 2, 2015) re citizen petition from teva pharmaceutical industries, ltd.",0,0
0900006481cf9b3d,Supporting & Related Material,FDA-2015-P-3980-0017,FDA-2015-P-3980,"bla 103705 prescribing information (rituxan pi) (aug 12, 2014) re citizen petition from teva pharmaceutical industries, ltd.",0,0
0900006481cf937b,Other,FDA-2015-P-3980-0001,FDA-2015-P-3980,"citizen petition from teva pharmaceutical industries, ltd.",0,0
0900006481cf9b36,Supporting & Related Material,FDA-2015-P-3980-0012,FDA-2015-P-3980,"package insert anda 065461 (aug 10, 2009) re citizen petition from teva pharmaceutical industries, ltd.",0,0
0900006481cfa652,Supporting & Related Material,FDA-2015-P-3980-0018,FDA-2015-P-3980,(copyrighted material) -- nccn clinical practice guidelines in oncology non-hodgkins lymphoma version 2 2015 (march 3 2015) re citizen petition from teva pharmaceuticals,0,0
0900006481cf94ca,Other,FDA-2015-P-3980-0002,FDA-2015-P-3980,"acknowledgement letter from fda ddm to teva pharmaceutical industries, ltd.",0,0
0900006481cf9b31,Supporting & Related Material,FDA-2015-P-3980-0007,FDA-2015-P-3980,"package insert nda 22303 (oct 31, 2008) re citizen petition from teva pharmaceutical industries, ltd.",0,0
0900006481cf9b32,Supporting & Related Material,FDA-2015-P-3980-0008,FDA-2015-P-3980,"clinical review nda 022303 (july 30, 2008) re citizen petition from teva pharmaceutical industries, ltd.",0,0
0900006481cf9b34,Supporting & Related Material,FDA-2015-P-3980-0010,FDA-2015-P-3980,"anda 065461 approval summary #1 labeling review branch (mar 5, 2009) re citizen petition from teva pharmaceutical industries, ltd.",0,0
0900006481cf9b38,Supporting & Related Material,FDA-2015-P-3980-0014,FDA-2015-P-3980,"package insert anda 200882 (jan 2014) re citizen petition from teva pharmaceutical industries, ltd.",0,0
0900006481ede141,Other,FDA-2015-P-3980-0021,FDA-2015-P-3980,citizen petition denial response from fda cder to teva pharmaceuticals,0,0
0900006481cf9b37,Supporting & Related Material,FDA-2015-P-3980-0013,FDA-2015-P-3980,"package insert nda 021689 (dec 19, 2014) re citizen petition from teva pharmaceutical industries, ltd.",0,0
0900006481cf9b3b,Supporting & Related Material,FDA-2015-P-3980-0015,FDA-2015-P-3980,"pub l no 97-414 96 stat 2049 (1983) re citizen petition from teva pharmaceutical industries, ltd.",0,0
0900006484a34a5f,Other,FDA-2020-P-1797-9319,FDA-2020-P-1797,final response from fda  ctp to keller and heckman llp on behalf of cream vapor llc et al.,0,0
090000648481ea74,Other,FDA-2020-P-1797-0001,FDA-2020-P-1797,petition for extension of premarket tobacco product application filing deadline from keller and heckman llp on behalf of cream vapor llc et al.,0,1
090000648481ee32,Other,FDA-2020-P-1797-0002,FDA-2020-P-1797,acknowledgement letter from fda dms to keller and heckman llp,0,0
0900006481cb2a31,Supporting & Related Material,FDA-2015-P-3540-0003,FDA-2015-P-3540,"attachment 1 excerpt from electronic orange book metolazonc tablets,10 mg re citizen petition from  lachman consultant services",0,0
0900006481cb10a7,Other,FDA-2015-P-3540-0001,FDA-2015-P-3540,citizen petition from lachman consultant services,0,0
0900006481cb2a2f,Other,FDA-2015-P-3540-0002,FDA-2015-P-3540,"acknowledgment letter from fda ddm to lachman consultant services, inc",0,0
0900006481f99d35,Other,FDA-2015-P-3540-0005,FDA-2015-P-3540,petition withdrawal notice from lachman consultants inc.,0,0
0900006481cb2b68,Supporting & Related Material,FDA-2015-P-3540-0004,FDA-2015-P-3540,attachment 2 label information zaroxolyn - metolazone tablet re citizen petition from  lachman consultant services,0,0
0900006480e50abc,Other,FDA-2011-P-0473-0001,FDA-2011-P-0473,"acknowledgement letter to varam, inc.",0,0
0900006480f81c54,Other,FDA-2011-P-0473-0004,FDA-2011-P-0473,"interim response to varam, inc. c/o: kvk-tech, inc. - letter",0,0
09000064812984b4,Other,FDA-2011-P-0473-0010,FDA-2011-P-0473,"fda/cder to varam, inc. c/o: kvk-tech, inc. -  agency response",0,0
0900006480e50991,Other,FDA-2011-P-0473-0002,FDA-2011-P-0473,"varam, inc. - citizen petition",0,0
0900006481299dce,Notice,FDA-2011-P-0473-0011,FDA-2011-P-0473,determination that the oxycontin (oxycodone hydrochloride) drug products covered by new drug application 20-553 were withdrawn from sale for reasons of safety or effectiveness,0,0
